id,pubMedId,title,url
1,23344264,DNA-Mutation Inventory to Refine and Enhance Cancer Treatment (DIRECT): a catalog of clinically relevant cancer mutations to enable genome-directed anticancer therapy.,http://www.ncbi.nlm.nih.gov/pubmed/23344264
2,22843421,Mechanisms of BRCA1 tumor suppression.,http://www.ncbi.nlm.nih.gov/pubmed/22843421
3,22798288,BRAF(L597) mutations in melanoma are associated with sensitivity to MEK inhibitors.,http://www.ncbi.nlm.nih.gov/pubmed/22798288
4,22193408,BRCA1 and BRCA2: different roles in a common pathway of genome protection.,http://www.ncbi.nlm.nih.gov/pubmed/22193408
5,21731065,Unraveling the mechanism of BRCA2 in homologous recombination.,http://www.ncbi.nlm.nih.gov/pubmed/21731065
6,20547991,Gene expression profile of BRCAness that correlates with responsiveness to chemotherapy and with outcome in patients with epithelial ovarian cancer.,http://www.ncbi.nlm.nih.gov/pubmed/20547991
7,18794803,CRAF inhibition induces apoptosis in melanoma cells with non-V600E BRAF mutations.,http://www.ncbi.nlm.nih.gov/pubmed/18794803
8,18172190,"CHEK2*1100delC genotyping for clinical assessment of breast cancer risk: meta-analyses of 26,000 patient cases and 27,000 controls.",http://www.ncbi.nlm.nih.gov/pubmed/18172190
9,16998506,The CHEK2 gene and inherited breast cancer susceptibility.,http://www.ncbi.nlm.nih.gov/pubmed/16998506
10,9836640,Linkage of ATM to cell cycle regulation by the Chk2 protein kinase.,http://www.ncbi.nlm.nih.gov/pubmed/9836640
11,24091716,Current status of targeted therapy for anaplastic lymphoma kinase-rearranged non-small cell lung cancer.,http://www.ncbi.nlm.nih.gov/pubmed/24091716
12,10065147,Introduction: p53--the first twenty years.,http://www.ncbi.nlm.nih.gov/pubmed/10065147
13,16243804,p53 Codon 72 polymorphism predicts the pathologic response to neoadjuvant chemotherapy in patients with breast cancer.,http://www.ncbi.nlm.nih.gov/pubmed/16243804
14,20948295,Differential basal levels of MDM-2 transcription induced by p53-P72 and p53-R72.,http://www.ncbi.nlm.nih.gov/pubmed/20948295
15,22864622,Aurora A kinase (AURKA) in normal and pathological cell division.,http://www.ncbi.nlm.nih.gov/pubmed/22864622
16,12881723,Identification of Stk6/STK15 as a candidate low-penetrance tumor-susceptibility gene in mouse and human.,http://www.ncbi.nlm.nih.gov/pubmed/12881723
17,23403721,Exploring mechanisms of FGF signalling through the lens of structural biology.,http://www.ncbi.nlm.nih.gov/pubmed/23403721
18,21622724,FGFR-4 Arg³⁸⁸ enhances prostate cancer progression via extracellular signal-related kinase and serum response factor signaling.,http://www.ncbi.nlm.nih.gov/pubmed/21622724
19,20606037,Vascular endothelial growth factor receptors VEGFR-2 and VEGFR-3 are localized primarily to the vasculature in human primary solid cancers.,http://www.ncbi.nlm.nih.gov/pubmed/20606037
20,21712447,Novel functional germline variants in the VEGF receptor 2 gene and their effect on gene expression and microvessel density in lung cancer.,http://www.ncbi.nlm.nih.gov/pubmed/21712447
21,16912195,"Kinetic analysis of epidermal growth factor receptor somatic mutant proteins shows increased sensitivity to the epidermal growth factor receptor tyrosine kinase inhibitor, erlotinib.",http://www.ncbi.nlm.nih.gov/pubmed/16912195
22,17495523,Allele-dependent variation in the relative cellular potency of distinct EGFR inhibitors.,http://www.ncbi.nlm.nih.gov/pubmed/17495523
23,23251911,G protein-coupled receptors--recent advances.,http://www.ncbi.nlm.nih.gov/pubmed/23251911
24,2549426,GTPase inhibiting mutations activate the alpha chain of Gs and stimulate adenylyl cyclase in human pituitary tumours.,http://www.ncbi.nlm.nih.gov/pubmed/2549426
25,2362213,Nursing shortage. Catalyst for administrative/educational partnership.,http://www.ncbi.nlm.nih.gov/pubmed/2362213
26,23455880,KRAS allel-specific activity of sunitinib in an isogenic disease model of colorectal cancer.,http://www.ncbi.nlm.nih.gov/pubmed/23455880
27,21810517,Predictive molecular classifiers in colorectal cancer.,http://www.ncbi.nlm.nih.gov/pubmed/21810517
28,19629070,"Targeting PI3K signalling in cancer: opportunities, challenges and limitations.",http://www.ncbi.nlm.nih.gov/pubmed/19629070
29,239483,[Effect of the characteristics of various alimentary stimuli and changes in the pH of the duodenal content on the acid-forming function of the stomach].,http://www.ncbi.nlm.nih.gov/pubmed/239483
30,2283317,Histochemical response of mice to mistletoe lectin I (ML I).,http://www.ncbi.nlm.nih.gov/pubmed/2283317
31,2327506,Diagnostic criteria for epilepsy-related mental changes.,http://www.ncbi.nlm.nih.gov/pubmed/2327506
32,10473107,The Trk tyrosine kinase inhibitor CEP-701 (KT-5555) exhibits significant antitumor efficacy in preclinical xenograft models of human pancreatic ductal adenocarcinoma.,http://www.ncbi.nlm.nih.gov/pubmed/10473107
33,12082455,A phase I/II trial of rAd/p53 (SCH 58500) gene replacement in recurrent ovarian cancer.,http://www.ncbi.nlm.nih.gov/pubmed/12082455
34,12082456,Long term follow-up of patients with recurrent ovarian cancer after Ad p53 gene replacement with SCH 58500.,http://www.ncbi.nlm.nih.gov/pubmed/12082456
35,15297186,A phase I study of Adp53 (INGN 201; ADVEXIN) for patients with platinum- and paclitaxel-resistant epithelial ovarian cancer.,http://www.ncbi.nlm.nih.gov/pubmed/15297186
36,16820176,Methylnaltrexone inhibits opiate and VEGF-induced angiogenesis: role of receptor transactivation.,http://www.ncbi.nlm.nih.gov/pubmed/16820176
37,17243944,Vandetanib (ZD6474): an orally available receptor tyrosine kinase inhibitor that selectively targets pathways critical for tumor growth and angiogenesis.,http://www.ncbi.nlm.nih.gov/pubmed/17243944
38,18528634,Phase 1 study of TAS-102 administered once daily on a 5-day-per-week schedule in patients with solid tumors.,http://www.ncbi.nlm.nih.gov/pubmed/18528634
39,19621448,"Immunization with a P53 synthetic long peptide vaccine induces P53-specific immune responses in ovarian cancer patients, a phase II trial.",http://www.ncbi.nlm.nih.gov/pubmed/19621448
40,19661297,"Methylnaltrexone, a peripherally acting opioid receptor antagonist, enhances tumoricidal effects of 5-Fu on human carcinoma cells.",http://www.ncbi.nlm.nih.gov/pubmed/19661297
41,19832844,E7050: a dual c-Met and VEGFR-2 tyrosine kinase inhibitor promotes tumor regression and prolongs survival in mouse xenograft models.,http://www.ncbi.nlm.nih.gov/pubmed/19832844
42,20145185,"AZD8931, an equipotent, reversible inhibitor of signaling by epidermal growth factor receptor, ERBB2 (HER2), and ERBB3: a unique agent for simultaneous ERBB receptor blockade in cancer.",http://www.ncbi.nlm.nih.gov/pubmed/20145185
43,20388807,"CUDC-101, a multitargeted inhibitor of histone deacetylase, epidermal growth factor receptor, and human epidermal growth factor receptor 2, exerts potent anticancer activity.",http://www.ncbi.nlm.nih.gov/pubmed/20388807
44,20573926,Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR.,http://www.ncbi.nlm.nih.gov/pubmed/20573926
45,20823884,Phase I and pharmacological study of the broad-spectrum tyrosine kinase inhibitor JNJ-26483327 in patients with advanced solid tumours.,http://www.ncbi.nlm.nih.gov/pubmed/20823884
46,20935223,"Preclinical evaluation of AMG 900, a novel potent and highly selective pan-aurora kinase inhibitor with activity in taxane-resistant tumor cell lines.",http://www.ncbi.nlm.nih.gov/pubmed/20935223
47,21177375,ENMD-2076 is an orally active kinase inhibitor with antiangiogenic and antiproliferative mechanisms of action.,http://www.ncbi.nlm.nih.gov/pubmed/21177375
48,21328579,Long-term clinical and immunological effects of p53-SLP® vaccine in patients with ovarian cancer.,http://www.ncbi.nlm.nih.gov/pubmed/21328579
49,21378200,"Phase I evaluation of telatinib, a VEGF receptor tyrosine kinase inhibitor, in combination with bevacizumab in subjects with advanced solid tumors.",http://www.ncbi.nlm.nih.gov/pubmed/21378200
50,21389100,"MK-1775, a potent Wee1 inhibitor, synergizes with gemcitabine to achieve tumor regressions, selectively in p53-deficient pancreatic cancer xenografts.",http://www.ncbi.nlm.nih.gov/pubmed/21389100
51,21463133,Chimeric antigen receptor (CAR)-engineered lymphocytes for cancer therapy.,http://www.ncbi.nlm.nih.gov/pubmed/21463133
52,21490702,Effects of brain-derived neurotrophic factor on local inflammation in experimental stroke of rat.,http://www.ncbi.nlm.nih.gov/pubmed/21490702
53,21576284,"Phase I safety, pharmacokinetic and pharmacodynamic trial of BMS-599626 (AC480), an oral pan-HER receptor tyrosine kinase inhibitor, in patients with advanced solid tumors.",http://www.ncbi.nlm.nih.gov/pubmed/21576284
54,21613405,VEGF and c-Met blockade amplify angiogenesis inhibition in pancreatic islet cancer.,http://www.ncbi.nlm.nih.gov/pubmed/21613405
55,21622725,"Brivanib, a dual FGF/VEGF inhibitor, is active both first and second line against mouse pancreatic neuroendocrine tumors developing adaptive/evasive resistance to VEGF inhibition.",http://www.ncbi.nlm.nih.gov/pubmed/21622725
56,21843052,Recombinant modified vaccinia virus ankara (MVA) expressing wild-type human p53 induces specific antitumor CTL expansion.,http://www.ncbi.nlm.nih.gov/pubmed/21843052
57,21921616,"The pathogenesis of acute kidney injury and the toxic triangle of oxygen, reactive oxygen species and nitric oxide.",http://www.ncbi.nlm.nih.gov/pubmed/21921616
58,21927947,A gynecologic oncology group phase II trial of two p53 peptide vaccine approaches: subcutaneous injection and intravenous pulsed dendritic cells in high recurrence risk ovarian cancer patients.,http://www.ncbi.nlm.nih.gov/pubmed/21927947
59,22146228,Multi-targeted tyrosine kinase inhibitors in clinical development: focus on XL-184 (cabozantinib).,http://www.ncbi.nlm.nih.gov/pubmed/22146228
60,22302096,The aurora kinase A inhibitor MLN8237 enhances cisplatin-induced cell death in esophageal adenocarcinoma cells.,http://www.ncbi.nlm.nih.gov/pubmed/22302096
61,22351689,RAF265 inhibits the growth of advanced human melanoma tumors.,http://www.ncbi.nlm.nih.gov/pubmed/22351689
62,22516948,"A phase I study of E7080, a multitargeted tyrosine kinase inhibitor, in patients with advanced solid tumours.",http://www.ncbi.nlm.nih.gov/pubmed/22516948
63,22753918,"Randomized phase II study of dacomitinib (PF-00299804), an irreversible pan-human epidermal growth factor receptor inhibitor, versus erlotinib in patients with advanced non-small-cell lung cancer.",http://www.ncbi.nlm.nih.gov/pubmed/22753918
64,22833179,Phase 2 trial of linifanib (ABT-869) in patients with unresectable or metastatic hepatocellular carcinoma.,http://www.ncbi.nlm.nih.gov/pubmed/22833179
65,22869872,Targeting the hepatocyte growth factor-cMET axis in cancer therapy.,http://www.ncbi.nlm.nih.gov/pubmed/22869872
66,22878519,A phase I study of BMS-690514 in Japanese patients with advanced or metastatic solid tumors.,http://www.ncbi.nlm.nih.gov/pubmed/22878519
67,22903472,Analysis of functional germline polymorphisms for prediction of response to anthracycline-based neoadjuvant chemotherapy in breast cancer.,http://www.ncbi.nlm.nih.gov/pubmed/22903472
68,22921155,"ENMD-2076, an oral inhibitor of angiogenic and proliferation kinases, has activity in recurrent, platinum resistant ovarian cancer.",http://www.ncbi.nlm.nih.gov/pubmed/22921155
69,22928785,Randomized phase II study of danusertib in patients with metastatic castration-resistant prostate cancer after docetaxel failure.,http://www.ncbi.nlm.nih.gov/pubmed/22928785
70,22935731,"Preclinical characterization of ABT-348, a kinase inhibitor targeting the aurora, vascular endothelial growth factor receptor/platelet-derived growth factor receptor, and Src kinase families.",http://www.ncbi.nlm.nih.gov/pubmed/22935731
71,22972611,"The combination of alisertib, an investigational Aurora kinase A inhibitor, and docetaxel promotes cell death and reduces tumor growth in preclinical cell models of upper gastrointestinal adenocarcinomas.",http://www.ncbi.nlm.nih.gov/pubmed/22972611
72,22997455,"Metastatic non-small-cell lung cancer (NSCLC): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.",http://www.ncbi.nlm.nih.gov/pubmed/22997455
73,23292795,Cabozantinib as a novel therapy for renal cell carcinoma.,http://www.ncbi.nlm.nih.gov/pubmed/23292795
74,23294134,"Dacomitinib, a new therapy for the treatment of non-small cell lung cancer.",http://www.ncbi.nlm.nih.gov/pubmed/23294134
75,23372346,Efficacy and safety evaluation of icotinib in patients with advanced non-small cell lung cancer.,http://www.ncbi.nlm.nih.gov/pubmed/23372346
76,23411383,Second-generation epidermal growth factor receptor tyrosine kinase inhibitors in lung cancers.,http://www.ncbi.nlm.nih.gov/pubmed/23411383
77,23443805,Activity of the fibroblast growth factor receptor inhibitors dovitinib (TKI258) and NVP-BGJ398 in human endometrial cancer cells.,http://www.ncbi.nlm.nih.gov/pubmed/23443805
78,23490650,"Phase I-IIa study of BMS-690514, an EGFR, HER-2 and -4 and VEGFR-1 to -3 oral tyrosine kinase inhibitor, in patients with advanced or metastatic solid tumours.",http://www.ncbi.nlm.nih.gov/pubmed/23490650
79,23670029,"P53 mutations in advanced cancers: clinical characteristics, outcomes, and correlation between progression-free survival and bevacizumab-containing therapy.",http://www.ncbi.nlm.nih.gov/pubmed/23670029
80,23699655,Preclinical evaluation of the WEE1 inhibitor MK-1775 as single-agent anticancer therapy.,http://www.ncbi.nlm.nih.gov/pubmed/23699655
81,23729403,"BIBF 1120 (nintedanib), a triple angiokinase inhibitor, induces hypoxia but not EMT and blocks progression of preclinical models of lung and pancreatic cancer.",http://www.ncbi.nlm.nih.gov/pubmed/23729403
82,23896512,Combination therapy with anti-ErbB3 monoclonal antibodies and EGFR TKIs potently inhibits non-small cell lung cancer.,http://www.ncbi.nlm.nih.gov/pubmed/23896512
83,23918952,"Apatinib for chemotherapy-refractory advanced metastatic gastric cancer: results from a randomized, placebo-controlled, parallel-arm, phase II trial.",http://www.ncbi.nlm.nih.gov/pubmed/23918952
84,24009732,The conformational control inhibitor of tyrosine kinases DCC-2036 is effective for imatinib-resistant cells expressing T674I FIP1L1-PDGFRα.,http://www.ncbi.nlm.nih.gov/pubmed/24009732
85,24019543,Preserving the sanctity of overall survival for drugs approved on the basis of progression-free survival: tivozanib as a case study.,http://www.ncbi.nlm.nih.gov/pubmed/24019543
86,24019545,Tivozanib versus sorafenib as initial targeted therapy for patients with metastatic renal cell carcinoma: results from a phase III trial.,http://www.ncbi.nlm.nih.gov/pubmed/24019545
87,24043137,"Phase I study of the safety, pharmacokinetics and antitumor activity of famitinib.",http://www.ncbi.nlm.nih.gov/pubmed/24043137
88,24124571,Targeting wild-type and mutationally activated FGFR4 in rhabdomyosarcoma with the inhibitor ponatinib (AP24534).,http://www.ncbi.nlm.nih.gov/pubmed/24124571
89,24166903,"Phase I safety, pharmacokinetic, and pharmacodynamic study of SAR245408 (XL147), an oral pan-class I PI3K inhibitor, in patients with advanced solid tumors.",http://www.ncbi.nlm.nih.gov/pubmed/24166903
90,24190702,A phase 1b clinical trial of the multi-targeted tyrosine kinase inhibitor lenvatinib (E7080) in combination with everolimus for treatment of metastatic renal cell carcinoma (RCC).,http://www.ncbi.nlm.nih.gov/pubmed/24190702
91,24238512,Famitinib in metastatic renal cell carcinoma: a single center study.,http://www.ncbi.nlm.nih.gov/pubmed/24238512
92,24305878,Dramatic antitumor effects of the dual MET/RON small-molecule inhibitor LY2801653 in non-small cell lung cancer.,http://www.ncbi.nlm.nih.gov/pubmed/24305878
93,24312144,"Molecular Targeted Drugs and Biomarkers in NSCLC, the Evolving Role of Individualized Therapy.",http://www.ncbi.nlm.nih.gov/pubmed/24312144
94,24323026,Phase I study of neratinib in combination with temsirolimus in patients with human epidermal growth factor receptor 2-dependent and other solid tumors.,http://www.ncbi.nlm.nih.gov/pubmed/24323026
95,24360368,"Randomised, double-blind trial of carboplatin and paclitaxel with daily oral cediranib or placebo in patients with advanced non-small cell lung cancer: NCIC Clinical Trials Group study BR29.",http://www.ncbi.nlm.nih.gov/pubmed/24360368
96,24367159,New approaches in the management of advanced breast cancer - role of combination treatment with liposomal doxorubicin.,http://www.ncbi.nlm.nih.gov/pubmed/24367159
97,24419239,Phase III study (MONET1) of motesanib plus carboplatin/paclitaxel in patients with advanced nonsquamous nonsmall-cell lung cancer (NSCLC): Asian subgroup analysis.,http://www.ncbi.nlm.nih.gov/pubmed/24419239
98,24438614,Efficacy and safety of icotinib in Chinese patients with advanced non-small cell lung cancer after failure of chemotherapy.,http://www.ncbi.nlm.nih.gov/pubmed/24438614
99,24556040,"Dovitinib versus sorafenib for third-line targeted treatment of patients with metastatic renal cell carcinoma: an open-label, randomised phase 3 trial.",http://www.ncbi.nlm.nih.gov/pubmed/24556040
100,24583798,"Phase I safety, pharmacokinetic, and pharmacodynamic study of SAR245409 (XL765), a novel, orally administered PI3K/mTOR inhibitor in patients with advanced solid tumors.",http://www.ncbi.nlm.nih.gov/pubmed/24583798
101,17376864,Rare cancer-specific mutations in PIK3CA show gain of function.,http://www.ncbi.nlm.nih.gov/pubmed/17376864
102,16533766,PIK3CA mutations in head and neck squamous cell carcinoma.,http://www.ncbi.nlm.nih.gov/pubmed/16533766
103,23134728,Disruption of PH-kinase domain interactions leads to oncogenic activation of AKT in human cancers.,http://www.ncbi.nlm.nih.gov/pubmed/23134728
104,18504432,AKT1(E17K) in human solid tumours.,http://www.ncbi.nlm.nih.gov/pubmed/18504432
105,21502284,Anaplastic lymphoma kinase in human cancer.,http://www.ncbi.nlm.nih.gov/pubmed/21502284
106,22079189,The ATM protein kinase and cellular redox signaling: beyond the DNA damage response.,http://www.ncbi.nlm.nih.gov/pubmed/22079189
107,22649787,ALK Signaling and Target Therapy in Anaplastic Large Cell Lymphoma.,http://www.ncbi.nlm.nih.gov/pubmed/22649787
108,16598769,Androgen axis in prostate cancer.,http://www.ncbi.nlm.nih.gov/pubmed/16598769
109,15170388,Two related ARID family proteins are alternative subunits of human SWI/SNF complexes.,http://www.ncbi.nlm.nih.gov/pubmed/15170388
110,22079198,Validation of the Chinese version of the Pelvic Organ Prolapse/Urinary Incontinence Sexual Questionnaire short form (PISQ-12).,http://www.ncbi.nlm.nih.gov/pubmed/22079198
111,23583268,Targeting ATR in DNA damage response and cancer therapeutics.,http://www.ncbi.nlm.nih.gov/pubmed/23583268
112,23249563,ATRX: the case of a peculiar chromatin remodeler.,http://www.ncbi.nlm.nih.gov/pubmed/23249563
113,22940834,Aurora kinases in childhood acute leukemia: the promise of aurora B as therapeutic target.,http://www.ncbi.nlm.nih.gov/pubmed/22940834
114,23364291,BRCA1 and BRCA2 mutations in the ovarian cancer population across race and ethnicity: special reference to Asia.,http://www.ncbi.nlm.nih.gov/pubmed/23364291
115,0,,http://www.ncbi.nlm.nih.gov/pubmed
116,24077403,Melanoma mutagenesis and aberrant cell signaling.,http://www.ncbi.nlm.nih.gov/pubmed/24077403
117,21779504,Ras in cancer and developmental diseases.,http://www.ncbi.nlm.nih.gov/pubmed/21779504
118,22891276,Whole-genome sequencing identifies recurrent somatic NOTCH2 mutations in splenic marginal zone lymphoma.,http://www.ncbi.nlm.nih.gov/pubmed/22891276
119,18632602,Novel MEK1 mutation identified by mutational analysis of epidermal growth factor receptor signaling pathway genes in lung adenocarcinoma.,http://www.ncbi.nlm.nih.gov/pubmed/18632602
120,18851712,Cytoplasmic signalling by the c-Abl tyrosine kinase in normal and cancer cells.,http://www.ncbi.nlm.nih.gov/pubmed/18851712
121,11248065,"ACVR1B (ALK4, activin receptor type 1B) gene mutations in pancreatic carcinoma.",http://www.ncbi.nlm.nih.gov/pubmed/11248065
122,7657393,Molecular alterations of the AKT2 oncogene in ovarian and breast carcinomas.,http://www.ncbi.nlm.nih.gov/pubmed/7657393
123,12783884,Protein kinase B alpha/Akt1 regulates placental development and fetal growth.,http://www.ncbi.nlm.nih.gov/pubmed/12783884
124,24618703,The emerging roles of ARID1A in tumor suppression.,http://www.ncbi.nlm.nih.gov/pubmed/24618703
125,22095441,ARID2: a new tumor suppressor gene in hepatocellular carcinoma.,http://www.ncbi.nlm.nih.gov/pubmed/22095441
126,21710690,Aberrantly expressed AURKC enhances the transformation and tumourigenicity of epithelial cells.,http://www.ncbi.nlm.nih.gov/pubmed/21710690
127,10700176,"AXIN1 mutations in hepatocellular carcinomas, and growth suppression in cancer cells by virus-mediated transfer of AXIN1.",http://www.ncbi.nlm.nih.gov/pubmed/10700176
128,23479507,AXL mediates TRAIL resistance in esophageal adenocarcinoma.,http://www.ncbi.nlm.nih.gov/pubmed/23479507
129,20619739,"Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis.",http://www.ncbi.nlm.nih.gov/pubmed/20619739
130,19064407,Understanding the predictive role of K-ras for epidermal growth factor receptor-targeted therapies in colorectal cancer.,http://www.ncbi.nlm.nih.gov/pubmed/19064407
131,24737949,BRAF and beyond: Tailoring strategies for the individual melanoma patient.,http://www.ncbi.nlm.nih.gov/pubmed/24737949
132,21285145,Genetic modifiers of cancer risk for BRCA1 and BRCA2 mutation carriers.,http://www.ncbi.nlm.nih.gov/pubmed/21285145
133,23085373,Protein tyrosine kinase regulation by ubiquitination: critical roles of Cbl-family ubiquitin ligases.,http://www.ncbi.nlm.nih.gov/pubmed/23085373
134,19915144,MEK1 mutations confer resistance to MEK and B-RAF inhibition.,http://www.ncbi.nlm.nih.gov/pubmed/19915144
135,22327936,Oncogenic MAP2K1 mutations in human epithelial tumors.,http://www.ncbi.nlm.nih.gov/pubmed/22327936
136,12969974,Identification and characterization of polymorphic variations of the ataxia telangiectasia mutated (ATM) gene in childhood Hodgkin disease.,http://www.ncbi.nlm.nih.gov/pubmed/12969974
137,20739657,The PARP inhibitor olaparib induces significant killing of ATM-deficient lymphoid tumor cells in vitro and in vivo.,http://www.ncbi.nlm.nih.gov/pubmed/20739657
138,23875803,The genetics of melanoma: recent advances.,http://www.ncbi.nlm.nih.gov/pubmed/23875803
139,22186992,Therapeutic applications of macrophage colony-stimulating factor-1 (CSF-1) and antagonists of CSF-1 receptor (CSF-1R) signaling.,http://www.ncbi.nlm.nih.gov/pubmed/22186992
140,22617422,The many faces and functions of β-catenin.,http://www.ncbi.nlm.nih.gov/pubmed/22617422
141,22328973,Mutations in the DDR2 kinase gene identify a novel therapeutic target in squamous cell lung cancer.,http://www.ncbi.nlm.nih.gov/pubmed/22328973
142,24649006,DNMT3A -448A>G polymorphism and the risk for hepatocellular carcinoma.,http://www.ncbi.nlm.nih.gov/pubmed/24649006
143,24497509,DNMT3A Arg882 mutation drives chronic myelomonocytic leukemia through disturbing gene expression/DNA methylation in hematopoietic cells.,http://www.ncbi.nlm.nih.gov/pubmed/24497509
144,23738943,EphA4 is a prognostic factor in gastric cancer.,http://www.ncbi.nlm.nih.gov/pubmed/23738943
145,17471238,The oncogene HER2: its signaling and transforming functions and its role in human cancer pathogenesis.,http://www.ncbi.nlm.nih.gov/pubmed/17471238
146,15035987,Mechanism of activation of the RAF-ERK signaling pathway by oncogenic mutations of B-RAF.,http://www.ncbi.nlm.nih.gov/pubmed/15035987
147,15150094,Different effects of point mutations within the B-Raf glycine-rich loop in colorectal tumors on mitogen-activated protein/extracellular signal-regulated kinase kinase/extracellular signal-regulated kinase and nuclear factor kappaB pathway and cellular transformation.,http://www.ncbi.nlm.nih.gov/pubmed/15150094
148,23542176,Pin1 modulates ERα levels in breast cancer through inhibition of phosphorylation-dependent ubiquitination and degradation.,http://www.ncbi.nlm.nih.gov/pubmed/23542176
149,24362326,"EZH2: biology, disease, and structure-based drug discovery.",http://www.ncbi.nlm.nih.gov/pubmed/24362326
150,24114654,Somatic alterations as the basis for resistance to targeted therapies.,http://www.ncbi.nlm.nih.gov/pubmed/24114654
151,24768039,Standardized decision support in next generation sequencing reports of somatic cancer variants.,http://www.ncbi.nlm.nih.gov/pubmed/24768039
152,22673505,Tumor suppressor functions of FBW7 in cancer development and progression.,http://www.ncbi.nlm.nih.gov/pubmed/22673505
153,22508544,"Fibroblast growth factor receptors in breast cancer: expression, downstream effects, and possible drug targets.",http://www.ncbi.nlm.nih.gov/pubmed/22508544
154,19467916,FLT3 inhibition and mechanisms of drug resistance in mutant FLT3-positive AML.,http://www.ncbi.nlm.nih.gov/pubmed/19467916
155,23172303,Vascular endothelial growth factor and its receptor system: physiological functions in angiogenesis and pathological roles in various diseases.,http://www.ncbi.nlm.nih.gov/pubmed/23172303
156,22188813,"Identification and characterization of NVP-BKM120, an orally available pan-class I PI3-kinase inhibitor.",http://www.ncbi.nlm.nih.gov/pubmed/22188813
157,24065731,Discovery of a mutant-selective covalent inhibitor of EGFR that overcomes T790M-mediated resistance in NSCLC.,http://www.ncbi.nlm.nih.gov/pubmed/24065731
158,2343836,"Travel, time zones, and sudden cardiac death. Emporiatric pathology.",http://www.ncbi.nlm.nih.gov/pubmed/2343836
159,9815717,A pilot clinical/pharmacological study of the protein kinase C-specific inhibitor safingol alone and in combination with doxorubicin.,http://www.ncbi.nlm.nih.gov/pubmed/9815717
160,10964608,A novel neuroprotective mechanism of riluzole: direct inhibition of protein kinase C.,http://www.ncbi.nlm.nih.gov/pubmed/10964608
161,11742498,Association of c-Raf expression with survival and its targeting with antisense oligonucleotides in ovarian cancer.,http://www.ncbi.nlm.nih.gov/pubmed/11742498
162,15608394,In vivo recombinant adenovirus-mediated p53 gene therapy in a syngeneic rat model for colorectal cancer.,http://www.ncbi.nlm.nih.gov/pubmed/15608394
163,16184551,Comparison of strategies targeting Raf-1 mRNA in ovarian cancer.,http://www.ncbi.nlm.nih.gov/pubmed/16184551
164,19738417,A phase I study of paclitaxel and continuous daily CAI in patients with refractory solid tumors.,http://www.ncbi.nlm.nih.gov/pubmed/19738417
165,20023657,Chimeric mouse tumor models reveal differences in pathway activation between ERBB family- and KRAS-dependent lung adenocarcinomas.,http://www.ncbi.nlm.nih.gov/pubmed/20023657
166,20176935,Cholesterol trafficking is required for mTOR activation in endothelial cells.,http://www.ncbi.nlm.nih.gov/pubmed/20176935
167,20947488,Metformin and cancer risk in diabetic patients: a systematic review and meta-analysis.,http://www.ncbi.nlm.nih.gov/pubmed/20947488
168,21185843,Antroquinonol inhibits NSCLC proliferation by altering PI3K/mTOR proteins and miRNA expression profiles.,http://www.ncbi.nlm.nih.gov/pubmed/21185843
169,21386633,"Novel agents in the management of pancreatic adenocarcinoma: phase I studies. Highlights from the ""2011 ASCO Gastrointestinal Cancers Symposium"". San Francisco, CA, USA. January 20-22, 2011.",http://www.ncbi.nlm.nih.gov/pubmed/21386633
170,21516509,"Pilot study of PD-0325901 in previously treated patients with advanced melanoma, breast cancer, and colon cancer.",http://www.ncbi.nlm.nih.gov/pubmed/21516509
171,21670972,Phase I study of axitinib (AG-013736) in combination with gemcitabine in patients with advanced pancreatic cancer.,http://www.ncbi.nlm.nih.gov/pubmed/21670972
172,21725213,Quinacrine synergizes with 5-fluorouracil and other therapies in colorectal cancer.,http://www.ncbi.nlm.nih.gov/pubmed/21725213
173,22015452,"A phase I dose escalation study of AT9283, a small molecule inhibitor of aurora kinases, in patients with advanced solid malignancies.",http://www.ncbi.nlm.nih.gov/pubmed/22015452
174,22016509,"Characterization of Alisertib (MLN8237), an investigational small-molecule inhibitor of aurora A kinase using novel in vivo pharmacodynamic assays.",http://www.ncbi.nlm.nih.gov/pubmed/22016509
175,22025163,First-in-man clinical trial of the oral pan-AKT inhibitor MK-2206 in patients with advanced solid tumors.,http://www.ncbi.nlm.nih.gov/pubmed/22025163
176,22242557,"Danusertib, an aurora kinase inhibitor.",http://www.ncbi.nlm.nih.gov/pubmed/22242557
177,22679111,Phase I study of pazopanib in combination with paclitaxel and carboplatin given every 21 days in patients with advanced solid tumors.,http://www.ncbi.nlm.nih.gov/pubmed/22679111
178,22781393,The combination of RAD001 and NVP-BKM120 synergistically inhibits the growth of lung cancer in vitro and in vivo.,http://www.ncbi.nlm.nih.gov/pubmed/22781393
179,23085766,"Investigational drug MLN0128, a novel TORC1/2 inhibitor, demonstrates potent oral antitumor activity in human breast cancer xenograft models.",http://www.ncbi.nlm.nih.gov/pubmed/23085766
180,23414587,"MEK162 for patients with advanced melanoma harbouring NRAS or Val600 BRAF mutations: a non-randomised, open-label phase 2 study.",http://www.ncbi.nlm.nih.gov/pubmed/23414587
181,23438367,Novel MEK inhibitor trametinib and other retinoblastoma gene (RB)-reactivating agents enhance efficacy of 5-fluorouracil on human colon cancer cells.,http://www.ncbi.nlm.nih.gov/pubmed/23438367
182,23546045,Phase 2 study of pemetrexed and itraconazole as second-line therapy for metastatic nonsquamous non-small-cell lung cancer.,http://www.ncbi.nlm.nih.gov/pubmed/23546045
183,23661005,The novel c-Met inhibitor cabozantinib overcomes gemcitabine resistance and stem cell signaling in pancreatic cancer.,http://www.ncbi.nlm.nih.gov/pubmed/23661005
184,23795919,Characterization of a chemical affinity probe targeting Akt kinases.,http://www.ncbi.nlm.nih.gov/pubmed/23795919
185,23841031,"Phase 1 study of intravenous rigosertib (ON 01910.Na), a novel benzyl styryl sulfone structure producing G2/M arrest and apoptosis, in adult patients with advanced cancer.",http://www.ncbi.nlm.nih.gov/pubmed/23841031
186,23846936,Novel agents and future prospects in the treatment of pancreatic adenocarcinoma.,http://www.ncbi.nlm.nih.gov/pubmed/23846936
187,23934108,Mechanism of MEK inhibition determines efficacy in mutant KRAS- versus BRAF-driven cancers.,http://www.ncbi.nlm.nih.gov/pubmed/23934108
188,24013662,A novel selective small-molecule PI3K inhibitor is effective against human multiple myeloma in vitro and in vivo.,http://www.ncbi.nlm.nih.gov/pubmed/24013662
189,24051929,"Afatinib, erlotinib and gefitinib in the first-line therapy of EGFR mutation-positive lung adenocarcinoma: a review.",http://www.ncbi.nlm.nih.gov/pubmed/24051929
190,24084771,Phase II study of dovitinib in patients with metastatic and/or unresectable gastrointestinal stromal tumours after failure of imatinib and sunitinib.,http://www.ncbi.nlm.nih.gov/pubmed/24084771
191,24141624,Evaluation and clinical analyses of downstream targets of the Akt inhibitor GDC-0068.,http://www.ncbi.nlm.nih.gov/pubmed/24141624
192,24309100,Dramatic suppression of colorectal cancer cell growth by the dual mTORC1 and mTORC2 inhibitor AZD-2014.,http://www.ncbi.nlm.nih.gov/pubmed/24309100
193,24372276,GI-4000 in KRAS mutant cancers.,http://www.ncbi.nlm.nih.gov/pubmed/24372276
194,24410791,Novel agents and strategies for overcoming EGFR TKIs resistance.,http://www.ncbi.nlm.nih.gov/pubmed/24410791
195,24422853,"Inhibition of mutant BRAF splice variant signaling by next-generation, selective RAF inhibitors.",http://www.ncbi.nlm.nih.gov/pubmed/24422853
196,24470511,Phase Ib study of Buparlisib plus Trastuzumab in patients with HER2-positive advanced or metastatic breast cancer that has progressed on Trastuzumab-based therapy.,http://www.ncbi.nlm.nih.gov/pubmed/24470511
197,24493623,Temsirolimus enhances the efficacy of cetuximab in colon cancer through a CIP2A-dependent mechanism.,http://www.ncbi.nlm.nih.gov/pubmed/24493623
198,24615777,"Idelalisib, an inhibitor of phosphatidylinositol 3-kinase p110δ, for relapsed/refractory chronic lymphocytic leukemia.",http://www.ncbi.nlm.nih.gov/pubmed/24615777
199,24696502,Quantitative chemical proteomics identifies novel targets of the anti-cancer multi-kinase inhibitor E-3810.,http://www.ncbi.nlm.nih.gov/pubmed/24696502
200,24706672,Ramucirumab extends gastric cancer survival.,http://www.ncbi.nlm.nih.gov/pubmed/24706672
201,20023658,Genome-wide association study identifies two susceptibility loci for nonsyndromic cleft lip with or without cleft palate.,http://www.ncbi.nlm.nih.gov/pubmed/20023658
202,20818376,Allosteric inhibition of lysyl oxidase-like-2 impedes the development of a pathologic microenvironment.,http://www.ncbi.nlm.nih.gov/pubmed/20818376
203,22319199,CEP-32496: a novel orally active BRAF(V600E) inhibitor with selective cellular and in vivo antitumor activity.,http://www.ncbi.nlm.nih.gov/pubmed/22319199
204,22781553,"AT13148 is a novel, oral multi-AGC kinase inhibitor with potent pharmacodynamic and antitumor activity.",http://www.ncbi.nlm.nih.gov/pubmed/22781553
205,23178755,Increased anti-leukemic activity of decitabine via AR-42-induced upregulation of miR-29b: a novel epigenetic-targeting approach in acute myeloid leukemia.,http://www.ncbi.nlm.nih.gov/pubmed/23178755
206,23662903,"Discovery of 2-{3-[2-(1-isopropyl-3-methyl-1H-1,2-4-triazol-5-yl)-5,6-dihydrobenzo[f]imidazo[1,2-d][1,4]oxazepin-9-yl]-1H-pyrazol-1-yl}-2-methylpropanamide (GDC-0032): a β-sparing phosphoinositide 3-kinase inhibitor with high unbound exposure and robust in vivo antitumor activity.",http://www.ncbi.nlm.nih.gov/pubmed/23662903
207,23736028,Functional and cancer genomics of ASXL family members.,http://www.ncbi.nlm.nih.gov/pubmed/23736028
208,23622131,Roles for KRAS in pancreatic tumor development and progression.,http://www.ncbi.nlm.nih.gov/pubmed/23622131
209,11719452,"Radiosensitization of p53 mutant cells by PD0166285, a novel G(2) checkpoint abrogator.",http://www.ncbi.nlm.nih.gov/pubmed/11719452
210,15483017,"Multicenter phase II study of the oral MEK inhibitor, CI-1040, in patients with advanced non-small-cell lung, breast, colon, and pancreatic cancer.",http://www.ncbi.nlm.nih.gov/pubmed/15483017
211,15696205,KRAS mutations and primary resistance of lung adenocarcinomas to gefitinib or erlotinib.,http://www.ncbi.nlm.nih.gov/pubmed/15696205
212,16774045,Drug evaluation: Reolysin--wild-type reovirus as a cancer therapeutic.,http://www.ncbi.nlm.nih.gov/pubmed/16774045
213,17936563,A functional genetic approach identifies the PI3K pathway as a major determinant of trastuzumab resistance in breast cancer.,http://www.ncbi.nlm.nih.gov/pubmed/17936563
214,18056456,Targeting protein translation in human non small cell lung cancer via combined MEK and mammalian target of rapamycin suppression.,http://www.ncbi.nlm.nih.gov/pubmed/18056456
215,18959794,"First-in-class, first-in-human phase I results of targeted agents: highlights of the 2008 American society of clinical oncology meeting.",http://www.ncbi.nlm.nih.gov/pubmed/18959794
216,19029981,Effective use of PI3K and MEK inhibitors to treat mutant Kras G12D and PIK3CA H1047R murine lung cancers.,http://www.ncbi.nlm.nih.gov/pubmed/19029981
217,19723655,KDR activating mutations in human angiosarcomas are sensitive to specific kinase inhibitors.,http://www.ncbi.nlm.nih.gov/pubmed/19723655
218,20332327,"A phase II study of PD-0325901, an oral MEK inhibitor, in previously treated patients with advanced non-small cell lung cancer.",http://www.ncbi.nlm.nih.gov/pubmed/20332327
219,20664174,PIK3CA and KRAS mutations predict for response to everolimus therapy: now that's RAD001.,http://www.ncbi.nlm.nih.gov/pubmed/20664174
220,21325073,"Antitumor efficacy of PKI-587, a highly potent dual PI3K/mTOR kinase inhibitor.",http://www.ncbi.nlm.nih.gov/pubmed/21325073
221,21594665,Evaluation of the association of PIK3CA mutations and PTEN loss with efficacy of trastuzumab therapy in metastatic breast cancer.,http://www.ncbi.nlm.nih.gov/pubmed/21594665
222,21639808,Improved survival with vemurafenib in melanoma with BRAF V600E mutation.,http://www.ncbi.nlm.nih.gov/pubmed/21639808
223,21668414,A drug targeting only p110α can block phosphoinositide 3-kinase signalling and tumour growth in certain cell types.,http://www.ncbi.nlm.nih.gov/pubmed/21668414
224,21676217,PI3K pathway activation results in low efficacy of both trastuzumab and lapatinib.,http://www.ncbi.nlm.nih.gov/pubmed/21676217
225,21679088,Necitumumab in the treatment of advanced non-small cell lung cancer: translation from preclinical to clinical development.,http://www.ncbi.nlm.nih.gov/pubmed/21679088
226,21750219,"PF-04691502, a potent and selective oral inhibitor of PI3K and mTOR kinases with antitumor activity.",http://www.ncbi.nlm.nih.gov/pubmed/21750219
227,21847063,A phase II trial of Salirasib in patients with lung adenocarcinomas with KRAS mutations.,http://www.ncbi.nlm.nih.gov/pubmed/21847063
228,22048237,"Phase II, open-label, randomized trial of the MEK1/2 inhibitor selumetinib as monotherapy versus temozolomide in patients with advanced melanoma.",http://www.ncbi.nlm.nih.gov/pubmed/22048237
229,22357447,"Phase I safety, pharmacokinetic, and pharmacodynamic study of the oral phosphatidylinositol-3-kinase and mTOR inhibitor BGT226 in patients with advanced solid tumors.",http://www.ncbi.nlm.nih.gov/pubmed/22357447
230,22534815,Phase-I/II study of bortezomib in combination with carboplatin and bevacizumab as first-line therapy in patients with advanced non-small-cell lung cancer.,http://www.ncbi.nlm.nih.gov/pubmed/22534815
231,22693357,"A multicenter phase I trial of PX-866, an oral irreversible phosphatidylinositol 3-kinase inhibitor, in patients with advanced solid tumors.",http://www.ncbi.nlm.nih.gov/pubmed/22693357
232,22735384,"Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial.",http://www.ncbi.nlm.nih.gov/pubmed/22735384
233,22805292,Activity of the oral MEK inhibitor trametinib in patients with advanced melanoma: a phase 1 dose-escalation trial.,http://www.ncbi.nlm.nih.gov/pubmed/22805292
234,23136191,Phosphoinositide 3-kinase (PI3K) pathway alterations are associated with histologic subtypes and are predictive of sensitivity to PI3K inhibitors in lung cancer preclinical models.,http://www.ncbi.nlm.nih.gov/pubmed/23136191
235,23172311,Dual targeting of EGFR and HER3 with MEHD7945A overcomes acquired resistance to EGFR inhibitors and radiation.,http://www.ncbi.nlm.nih.gov/pubmed/23172311
236,23726034,Discovery of NVP-BYL719 a potent and selective phosphatidylinositol-3 kinase alpha inhibitor selected for clinical evaluation.,http://www.ncbi.nlm.nih.gov/pubmed/23726034
237,23728919,Vorinostat and bortezomib as third-line therapy in patients with advanced non-small cell lung cancer: a Wisconsin Oncology Network Phase II study.,http://www.ncbi.nlm.nih.gov/pubmed/23728919
238,23846731,Trametinib: first global approval.,http://www.ncbi.nlm.nih.gov/pubmed/23846731
239,23861835,Efficacy and safety profile of combining vandetanib with chemotherapy in patients with advanced non-small cell lung cancer: a meta-analysis.,http://www.ncbi.nlm.nih.gov/pubmed/23861835
240,23940356,Mutant PIK3CA accelerates HER2-driven transgenic mammary tumors and induces resistance to combinations of anti-HER2 therapies.,http://www.ncbi.nlm.nih.gov/pubmed/23940356
241,23980091,Gefitinib versus placebo in completely resected non-small-cell lung cancer: results of the NCIC CTG BR19 study.,http://www.ncbi.nlm.nih.gov/pubmed/23980091
242,24063423,Selumetinib in advanced non small cell lung cancer (NSCLC) harbouring KRAS mutation: endless clinical challenge to KRAS-mutant NSCLC.,http://www.ncbi.nlm.nih.gov/pubmed/24063423
243,24130052,"Sym004, a novel anti-EGFR antibody mixture, augments radiation response in human lung and head and neck cancers.",http://www.ncbi.nlm.nih.gov/pubmed/24130052
244,24166906,Comprehensive biomarker analysis and final efficacy results of sorafenib in the BATTLE trial.,http://www.ncbi.nlm.nih.gov/pubmed/24166906
245,24170767,BAY 80-6946 is a highly selective intravenous PI3K inhibitor with potent p110α and p110δ activities in tumor cell lines and xenograft models.,http://www.ncbi.nlm.nih.gov/pubmed/24170767
246,24204198,"Sym004, a novel EGFR antibody mixture, can overcome acquired resistance to cetuximab.",http://www.ncbi.nlm.nih.gov/pubmed/24204198
247,24304820,Acquired drug resistance conferred by a KRAS gene mutation following the administration of cetuximab: a case report.,http://www.ncbi.nlm.nih.gov/pubmed/24304820
248,24373609,A phase I study of temsirolimus and thoracic radiation in non--small-cell lung cancer.,http://www.ncbi.nlm.nih.gov/pubmed/24373609
249,24398428,Overcoming acquired BRAF inhibitor resistance in melanoma via targeted inhibition of Hsp90 with ganetespib.,http://www.ncbi.nlm.nih.gov/pubmed/24398428
250,24451154,Direct inhibition of PI3K in combination with dual HER2 inhibitors is required for optimal antitumor activity in HER2+ breast cancer cells.,http://www.ncbi.nlm.nih.gov/pubmed/24451154
251,24569458,Oncogenic and sorafenib-sensitive ARAF mutations in lung adenocarcinoma.,http://www.ncbi.nlm.nih.gov/pubmed/24569458
252,18552176,Drug-sensitive FGFR2 mutations in endometrial carcinoma.,http://www.ncbi.nlm.nih.gov/pubmed/18552176
253,23640210,The emerging mutational landscape of G proteins and G-protein-coupled receptors in cancer.,http://www.ncbi.nlm.nih.gov/pubmed/23640210
254,23999440,HIF-1 mediates metabolic responses to intratumoral hypoxia and oncogenic mutations.,http://www.ncbi.nlm.nih.gov/pubmed/23999440
255,23999441,Isocitrate dehydrogenase mutations in leukemia.,http://www.ncbi.nlm.nih.gov/pubmed/23999441
256,22520978,Targeting the insulin growth factor receptor 1.,http://www.ncbi.nlm.nih.gov/pubmed/22520978
257,15575979,The Janus kinases (Jaks).,http://www.ncbi.nlm.nih.gov/pubmed/15575979
258,23181448,"Advanced systemic mastocytosis: the impact of KIT mutations in diagnosis, treatment, and progression.",http://www.ncbi.nlm.nih.gov/pubmed/23181448
259,22753777,MEK genomics in development and disease.,http://www.ncbi.nlm.nih.gov/pubmed/22753777
260,7651428,RAS signalling is abnormal in a c-raf1 MEK1 double mutant.,http://www.ncbi.nlm.nih.gov/pubmed/7651428
261,22450690,"Monomeric and dimeric models of ERK2 in conjunction with studies on cellular localization, nuclear translocation, and in vitro analysis.",http://www.ncbi.nlm.nih.gov/pubmed/22450690
262,22128285,c-MET as a potential therapeutic target and biomarker in cancer.,http://www.ncbi.nlm.nih.gov/pubmed/22128285
263,16834459,MPLW515L is a novel somatic activating mutation in myelofibrosis with myeloid metaplasia.,http://www.ncbi.nlm.nih.gov/pubmed/16834459
264,24385746,MPL W515L/K Mutations in Chronic Myeloproliferative Neoplasms.,http://www.ncbi.nlm.nih.gov/pubmed/24385746
265,24764656,Targeting mTOR network in colorectal cancer therapy.,http://www.ncbi.nlm.nih.gov/pubmed/24764656
266,19506249,Structural basis for the multiple interactions of the MyD88 TIR domain in TLR4 signaling.,http://www.ncbi.nlm.nih.gov/pubmed/19506249
267,19380279,Neurofibromatosis.,http://www.ncbi.nlm.nih.gov/pubmed/19380279
268,24535670,Reduced NF1 expression confers resistance to EGFR inhibition in lung cancer.,http://www.ncbi.nlm.nih.gov/pubmed/24535670
269,22006338,Loss-of-function mutations in Notch receptors in cutaneous and lung squamous cell carcinoma.,http://www.ncbi.nlm.nih.gov/pubmed/22006338
270,20001801,Pathogenesis of ovarian cancer: clues from selected overexpressed genes.,http://www.ncbi.nlm.nih.gov/pubmed/20001801
271,21605429,The role of mutational analysis of KIT and PDGFRA in gastrointestinal stromal tumors in a clinical setting.,http://www.ncbi.nlm.nih.gov/pubmed/21605429
272,15928335,"PDGFRA mutations in gastrointestinal stromal tumors: frequency, spectrum and in vitro sensitivity to imatinib.",http://www.ncbi.nlm.nih.gov/pubmed/15928335
273,23411347,Novel approaches to inhibitor design for the p110β phosphoinositide 3-kinase.,http://www.ncbi.nlm.nih.gov/pubmed/23411347
274,16881963,Hedgehog signalling in skin development and cancer.,http://www.ncbi.nlm.nih.gov/pubmed/16881963
275,10,,http://www.ncbi.nlm.nih.gov/pubmed/10
276,24656806,PTEN function: the long and the short of it.,http://www.ncbi.nlm.nih.gov/pubmed/24656806
277,20337577,Targeting protein tyrosine phosphatases for anticancer drug discovery.,http://www.ncbi.nlm.nih.gov/pubmed/20337577
278,21577205,Raf kinases in cancer-roles and therapeutic opportunities.,http://www.ncbi.nlm.nih.gov/pubmed/21577205
279,20930041,Targeting RET receptor tyrosine kinase activation in cancer.,http://www.ncbi.nlm.nih.gov/pubmed/20930041
280,23719267,Molecular pathways: ROS1 fusion proteins in cancer.,http://www.ncbi.nlm.nih.gov/pubmed/23719267
281,22150309,"RUNX1 mutations in clonal myeloid disorders: from conventional cytogenetics to next generation sequencing, a story 40 years in the making.",http://www.ncbi.nlm.nih.gov/pubmed/22150309
282,20087440,Smad4-mediated TGF-beta signaling in tumorigenesis.,http://www.ncbi.nlm.nih.gov/pubmed/20087440
283,23095836,Molecular markers in pediatric neuro-oncology.,http://www.ncbi.nlm.nih.gov/pubmed/23095836
284,24788409,c-Src drives intestinal regeneration and transformation.,http://www.ncbi.nlm.nih.gov/pubmed/24788409
285,,,http://www.ncbi.nlm.nih.gov/pubmed
286,,FDA.gov,http://www.fda.gov/
287,,(NCI Drug Dictionary),http://www.cancer.gov/drugdictionary
288,17599048,A role for LKB1 gene in human cancer beyond the Peutz-Jeghers syndrome.,http://www.ncbi.nlm.nih.gov/pubmed/17599048
289,18466115,The TSC1-TSC2 complex: a molecular switchboard controlling cell growth.,http://www.ncbi.nlm.nih.gov/pubmed/18466115
290,24583008,The multifaceted von Hippel-Lindau tumour suppressor protein.,http://www.ncbi.nlm.nih.gov/pubmed/24583008
291,18287029,Discovery of a selective inhibitor of oncogenic B-Raf kinase with potent antimelanoma activity.,http://www.ncbi.nlm.nih.gov/pubmed/18287029
292,12060641,"The in vitro and in vivo effects of 2-(4-morpholinyl)-8-phenyl-chromone (LY294002), a specific inhibitor of phosphatidylinositol 3'-kinase, in human colon cancer cells.",http://www.ncbi.nlm.nih.gov/pubmed/12060641
293,22767670,"Phase I study of aurora A kinase inhibitor MLN8237 in advanced solid tumors: safety, pharmacokinetics, pharmacodynamics, and bioavailability of two oral formulations.",http://www.ncbi.nlm.nih.gov/pubmed/22767670
294,22394203,Sorafenib in melanoma.,http://www.ncbi.nlm.nih.gov/pubmed/22394203
295,,,www.uniprot.org
296,18923525,Activating mutations in ALK provide a therapeutic target in neuroblastoma.,http://www.ncbi.nlm.nih.gov/pubmed/18923525
297,12917204,The relationship between twenty missense ATM variants and breast cancer risk: the Multiethnic Cohort.,http://www.ncbi.nlm.nih.gov/pubmed/12917204
298,17308087,Determination of cancer risk associated with germ line BRCA1 missense variants by functional analysis.,http://www.ncbi.nlm.nih.gov/pubmed/17308087
299,16357163,The G691S RET polymorphism increases glial cell line-derived neurotrophic factor-induced pancreatic cancer cell invasion by amplifying mitogen-activated protein kinase signaling.,http://www.ncbi.nlm.nih.gov/pubmed/16357163
300,8187068,Frequent detection of codon 877 mutation in the androgen receptor gene in advanced prostate cancers.,http://www.ncbi.nlm.nih.gov/pubmed/8187068
301,19002384,Open-label phase I trial of vandetanib in combination with mFOLFOX6 in patients with advanced colorectal cancer.,http://www.ncbi.nlm.nih.gov/pubmed/19002384
302,18381943,Single-nucleotide polymorphisms of DNA damage response genes are associated with overall survival in patients with pancreatic cancer.,http://www.ncbi.nlm.nih.gov/pubmed/18381943
303,,,https://clinicaltrials.gov/
304,19801554,A cancer-associated aurora A mutant is mislocalized and misregulated due to loss of interaction with TPX2.,http://www.ncbi.nlm.nih.gov/pubmed/19801554
305,22232731,Phase I trial of sorafenib in combination with 5-fluorouracil/leucovorin in advanced solid tumors.,http://www.ncbi.nlm.nih.gov/pubmed/22232731
306,22912816,The multi-targeted kinase inhibitor sunitinib induces apoptosis in colon cancer cells via PUMA.,http://www.ncbi.nlm.nih.gov/pubmed/22912816
307,21781317,"E7080, a multi-targeted tyrosine kinase inhibitor suppresses tumor cell migration and invasion.",http://www.ncbi.nlm.nih.gov/pubmed/21781317
308,23180582,Targeting aurora kinases limits tumour growth through DNA damage-mediated senescence and blockade of NF-κB impairs this drug-induced senescence.,http://www.ncbi.nlm.nih.gov/pubmed/23180582
309,18347145,Dual inhibition of VEGFR and EGFR signaling reduces the incidence and size of intestinal adenomas in Apc(Min/+) mice.,http://www.ncbi.nlm.nih.gov/pubmed/18347145
310,24674871,An open-label phase II study evaluating the safety and efficacy of ramucirumab combined with mFOLFOX-6 as first-line therapy for metastatic colorectal cancer.,http://www.ncbi.nlm.nih.gov/pubmed/24674871
311,22238366,"Ponatinib (AP24534), a multitargeted pan-FGFR inhibitor with activity in multiple FGFR-amplified or mutated cancer models.",http://www.ncbi.nlm.nih.gov/pubmed/22238366
312,23526464,Ponatinib (AP24534) is a novel potent inhibitor of oncogenic RET mutants associated with thyroid cancer.,http://www.ncbi.nlm.nih.gov/pubmed/23526464
313,24423921,Intermittent dosing of axitinib combined with chemotherapy is supported by (18)FLT-PET in gastrointestinal tumours.,http://www.ncbi.nlm.nih.gov/pubmed/24423921
314,,Activity of cabozantinib (XL184) in soft tissue and bone: Results of a phase II randomized discontinuation trial (RDT) in patients (pts) with advanced solid tumors.,http://meetinglibrary.asco.org/content/80906-102
315,,A phase II randomized study of ramucirumab (IMC-1121B) with or without dacarbazine (DTIC) in patients (pts) with metastatic melanoma (MM).,http://meetinglibrary.asco.org/content/50441-74
316,21976544,"Multicenter, phase II study of axitinib, a selective second-generation inhibitor of vascular endothelial growth factor receptors 1, 2, and 3, in patients with metastatic melanoma.",http://www.ncbi.nlm.nih.gov/pubmed/21976544
317,22223528,Phase I study of the combination of sorafenib and temsirolimus in patients with metastatic melanoma.,http://www.ncbi.nlm.nih.gov/pubmed/22223528
318,21170960,"Regorafenib (BAY 73-4506): a new oral multikinase inhibitor of angiogenic, stromal and oncogenic receptor tyrosine kinases with potent preclinical antitumor activity.",http://www.ncbi.nlm.nih.gov/pubmed/21170960
319,23064954,A Phase I study of pazopanib in combination with gemcitabine in patients with advanced solid tumors.,http://www.ncbi.nlm.nih.gov/pubmed/23064954
320,20923544,Safety and pharmacokinetics of novel selective vascular endothelial growth factor receptor-2 inhibitor YN968D1 in patients with advanced malignancies.,http://www.ncbi.nlm.nih.gov/pubmed/20923544
322,21976540,"Phase I/II and pharmacodynamic study of dovitinib (TKI258), an inhibitor of fibroblast growth factor receptors and VEGF receptors, in patients with advanced melanoma.",http://www.ncbi.nlm.nih.gov/pubmed/21976540
323,23680147,Oncogenic ERBB3 mutations in human cancers.,http://www.ncbi.nlm.nih.gov/pubmed/23680147
324,23437064,Computational analysis of KRAS mutations: implications for different effects on the KRAS p.G12D and p.G13D mutations.,http://www.ncbi.nlm.nih.gov/pubmed/23437064
325,21984976,High frequency of PIK3R1 and PIK3R2 mutations in endometrial cancer elucidates a novel mechanism for regulation of PTEN protein stability.,http://www.ncbi.nlm.nih.gov/pubmed/21984976
326,9598803,Inactivation of the PTEN/MMAC1/TEP1 gene in human lung cancers.,http://www.ncbi.nlm.nih.gov/pubmed/9598803
327,20823850,Clinical efficacy of a RAF inhibitor needs broad target blockade in BRAF-mutant melanoma.,http://www.ncbi.nlm.nih.gov/pubmed/20823850
328,20980437,CDK9 regulates AR promoter selectivity and cell growth through serine 81 phosphorylation.,http://www.ncbi.nlm.nih.gov/pubmed/20980437
329,18273901,Activating NOTCH3 mutation in a patient with small-vessel-disease of the brain.,http://www.ncbi.nlm.nih.gov/pubmed/18273901
330,23134362,Characterization of therapeutic antibodies and related products.,http://www.ncbi.nlm.nih.gov/pubmed/23134362
331,23275061,"LY2801653 is an orally bioavailable multi-kinase inhibitor with potent activity against MET, MST1R, and other oncoproteins, and displays anti-tumor activities in mouse xenograft models.",http://www.ncbi.nlm.nih.gov/pubmed/23275061
332,14559814,c-MET mutational analysis in small cell lung cancer: novel juxtamembrane domain mutations regulating cytoskeletal functions.,http://www.ncbi.nlm.nih.gov/pubmed/14559814
333,17483355,"An orally available small-molecule inhibitor of c-Met, PF-2341066, exhibits cytoreductive antitumor efficacy through antiproliferative and antiangiogenic mechanisms.",http://www.ncbi.nlm.nih.gov/pubmed/17483355
334,24337769,A phase II trial of a selective c-Met inhibitor tivantinib (ARQ 197) monotherapy as a second- or third-line therapy in the patients with metastatic gastric cancer.,http://www.ncbi.nlm.nih.gov/pubmed/24337769
335,24617631,"Population pharmacokinetics and pharmacodynamics of BYL719, a phosphoinositide 3-kinase antagonist, in adult patients with advanced solid malignancies.",http://www.ncbi.nlm.nih.gov/pubmed/24617631
336,23553846,EMD 1214063 and EMD 1204831 constitute a new class of potent and highly selective c-Met inhibitors.,http://www.ncbi.nlm.nih.gov/pubmed/23553846
337,23629727,"Antitumor activity of pimasertib, a selective MEK 1/2 inhibitor, in combination with PI3K/mTOR inhibitors or with multi-targeted kinase inhibitors in pimasertib-resistant human lung and colorectal cancer cells.",http://www.ncbi.nlm.nih.gov/pubmed/23629727
338,22886613,REO-001: A phase I trial of percutaneous intralesional administration of reovirus type 3 dearing (Reolysin®) in patients with advanced solid tumors.,http://www.ncbi.nlm.nih.gov/pubmed/22886613
339,18202412,KRAS mutations as an independent prognostic factor in patients with advanced colorectal cancer treated with cetuximab.,http://www.ncbi.nlm.nih.gov/pubmed/18202412
340,18316791,Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer.,http://www.ncbi.nlm.nih.gov/pubmed/18316791
341,23612453,"Everolimus as second- or third-line treatment of advanced endometrial cancer: ENDORAD, a phase II trial of GINECO.",http://www.ncbi.nlm.nih.gov/pubmed/23612453
342,23877793,K‑ras gene mutation as a predictor of cancer cell responsiveness to metformin.,http://www.ncbi.nlm.nih.gov/pubmed/23877793
343,24269517,Metformin is associated with improved survival in endometrial cancer.,http://www.ncbi.nlm.nih.gov/pubmed/24269517
344,23463670,Sorafenib induces endometrial carcinoma apoptosis by inhibiting Elk-1-dependent Mcl-1 transcription and inducing Akt/GSK3β-dependent protein degradation.,http://www.ncbi.nlm.nih.gov/pubmed/23463670
345,15136596,"Safety and pharmacokinetics of escalated doses of weekly intravenous infusion of CCI-779, a novel mTOR inhibitor, in patients with cancer.",http://www.ncbi.nlm.nih.gov/pubmed/15136596
346,23877009,Sorafenib/regorafenib and phosphatidyl inositol 3 kinase/thymoma viral proto-oncogene inhibition interact to kill tumor cells.,http://www.ncbi.nlm.nih.gov/pubmed/23877009
347,24577626,"Temsirolimus and pegylated liposomal doxorubicin (PLD) combination therapy in breast, endometrial, and ovarian cancer: phase Ib results and prediction of clinical outcome with FDG-PET/CT.",http://www.ncbi.nlm.nih.gov/pubmed/24577626
348,22662154,"Genotype-dependent efficacy of a dual PI3K/mTOR inhibitor, NVP-BEZ235, and an mTOR inhibitor, RAD001, in endometrial carcinomas.",http://www.ncbi.nlm.nih.gov/pubmed/22662154
349,24405565,"Phase I dose-escalation study of buparlisib (BKM120), an oral pan-class I PI3K inhibitor, in Japanese patients with advanced solid tumors.",http://www.ncbi.nlm.nih.gov/pubmed/24405565
350,24322983,A genetic mouse model of invasive endometrial cancer driven by concurrent loss of Pten and Lkb1 Is highly responsive to mTOR inhibition.,http://www.ncbi.nlm.nih.gov/pubmed/24322983
351,23270925,"VS-5584, a novel and highly selective PI3K/mTOR kinase inhibitor for the treatment of cancer.",http://www.ncbi.nlm.nih.gov/pubmed/23270925
352,20890178,"Evaluation of the mTOR inhibitor, everolimus, in combination with cytotoxic antitumor agents using human tumor models in vitro and in vivo.",http://www.ncbi.nlm.nih.gov/pubmed/20890178
353,22084396,Intermittent administration of MEK inhibitor GDC-0973 plus PI3K inhibitor GDC-0941 triggers robust apoptosis and tumor growth inhibition.,http://www.ncbi.nlm.nih.gov/pubmed/22084396
354,24339963,The enhanced in vivo activity of the combination of a MEK and a PI3K inhibitor correlates with [18F]-FLT PET in human colorectal cancer xenograft tumour-bearing mice.,http://www.ncbi.nlm.nih.gov/pubmed/24339963
356,24387334,Therapeutic targeting of cancers with loss of PTEN function.,http://www.ncbi.nlm.nih.gov/pubmed/24387334
359,22238365,(212)Pb-radioimmunotherapy induces G(2) cell-cycle arrest and delays DNA damage repair in tumor xenografts in a model for disseminated intraperitoneal disease.,http://www.ncbi.nlm.nih.gov/pubmed/22238365
360,24634416,ERBB3/HER2 signaling promotes resistance to EGFR blockade in head and neck and colorectal cancer models.,http://www.ncbi.nlm.nih.gov/pubmed/24634416
361,22543857,Selective PI3K inhibition by BKM120 and BEZ235 alone or in combination with chemotherapy in wild-type and mutated human gastrointestinal cancer cell lines.,http://www.ncbi.nlm.nih.gov/pubmed/22543857
362,24576621,"Combination PI3K/MEK inhibition promotes tumor apoptosis and regression in PIK3CA wild-type, KRAS mutant colorectal cancer.",http://www.ncbi.nlm.nih.gov/pubmed/24576621
363,,supp,
364,,Phase I expansion trial of an oral TORC1/TORC2 inhibitor (CC-223) in advanced solid tumors.,
365,21649578,Progress in the preclinical discovery and clinical development of class I and dual class I/IV phosphoinositide 3-kinase (PI3K) inhibitors.,http://www.ncbi.nlm.nih.gov/pubmed/21649578
366,23461471,From bench to bedside: promising colon cancer clinical trials.,http://www.ncbi.nlm.nih.gov/pubmed/23461471
367,23002019,"Initial testing (stage 1) of the phosphatidylinositol 3' kinase inhibitor, SAR245408 (XL147) by the pediatric preclinical testing program.",http://www.ncbi.nlm.nih.gov/pubmed/23002019
368,23814482,Multimodal microvascular imaging reveals that selective inhibition of class I PI3K is sufficient to induce an antivascular response.,http://www.ncbi.nlm.nih.gov/pubmed/23814482
369,22481432,Antiangiogenic agents in the management of non-small cell lung cancer: where do we stand now and where are we headed?,http://www.ncbi.nlm.nih.gov/pubmed/22481432
370,24862536,Axitinib Improves Radiotherapy in Murine Xenograft Lung Tumors.,http://www.ncbi.nlm.nih.gov/pubmed/24862536
371,23246812,Functional characterisation of p53 mutants identified in breast cancers with suboptimal responses to anthracyclines or mitomycin.,http://www.ncbi.nlm.nih.gov/pubmed/23246812
372,23660168,NRAS mutant melanoma--undrugable?,http://www.ncbi.nlm.nih.gov/pubmed/23660168
373,19749790,Mutant fibroblast growth factor receptor 3 induces intracellular signaling and cellular transformation in a cell type- and mutation-specific manner.,http://www.ncbi.nlm.nih.gov/pubmed/19749790
374,20190810,Single amino-acid changes that confer constitutive activation of mTOR are discovered in human cancer.,http://www.ncbi.nlm.nih.gov/pubmed/20190810
375,8665528,Suppression of a human colon cancer cell line by introduction of an exogenous NF1 gene.,http://www.ncbi.nlm.nih.gov/pubmed/8665528
376,19451225,"NF2/merlin is a novel negative regulator of mTOR complex 1, and activation of mTORC1 is associated with meningioma and schwannoma growth.",http://www.ncbi.nlm.nih.gov/pubmed/19451225
377,15598747,Neurofibromatosis 2 (NF2) tumor suppressor merlin inhibits phosphatidylinositol 3-kinase through binding to PIKE-L.,http://www.ncbi.nlm.nih.gov/pubmed/15598747
378,22114072,Gain-of-function mutant p53 upregulates CXC chemokines and enhances cell migration.,http://www.ncbi.nlm.nih.gov/pubmed/22114072
379,17646409,FBW7 mutations in leukemic cells mediate NOTCH pathway activation and resistance to gamma-secretase inhibitors.,http://www.ncbi.nlm.nih.gov/pubmed/17646409
380,17024798,Synergistic effects of valproic acid and mitomycin C in adenocarcinoma cell lines and fresh tumor cells of patients with colon cancer.,http://www.ncbi.nlm.nih.gov/pubmed/17024798
381,22161747,Chemoprevention of mouse lung and colon tumors by suberoylanilide hydroxamic acid and atorvastatin.,http://www.ncbi.nlm.nih.gov/pubmed/22161747
382,21046105,The histone deacetylase inhibitor PXD101 increases the efficacy of irinotecan in in vitro and in vivo colon cancer models.,http://www.ncbi.nlm.nih.gov/pubmed/21046105
383,21965751,Low-dose combinations of LBH589 and TRAIL can overcome TRAIL-resistance in colon cancer cell lines.,http://www.ncbi.nlm.nih.gov/pubmed/21965751
384,24463458,BRAF inhibitor resistance mechanisms in metastatic melanoma: spectrum and clinical impact.,http://www.ncbi.nlm.nih.gov/pubmed/24463458
385,10389768,Functional reassessment of P16 variants using a transfection-based assay.,http://www.ncbi.nlm.nih.gov/pubmed/10389768
386,22543158,Metronomic oral topotecan prolongs survival and reduces liver metastasis in improved preclinical orthotopic and adjuvant therapy colon cancer models.,http://www.ncbi.nlm.nih.gov/pubmed/22543158
387,17311302,Impact of mutant p53 functional properties on TP53 mutation patterns and tumor phenotype: lessons from recent developments in the IARC TP53 database.,http://www.ncbi.nlm.nih.gov/pubmed/17311302
388,24255582,Effects of tyrosine kinase inhibitor E7080 and eNOS inhibitor L-NIO on colorectal cancer alone and in combination.,http://www.ncbi.nlm.nih.gov/pubmed/24255582
389,23292912,ErbBs inhibition by lapatinib blocks tumor growth in an orthotopic model of human testicular germ cell tumor.,http://www.ncbi.nlm.nih.gov/pubmed/23292912
390,16462496,Phase II study of imatinib mesylate in chemotherapy refractory germ cell tumors expressing KIT.,http://www.ncbi.nlm.nih.gov/pubmed/16462496
391,18751412,Complete response after imatinib mesylate administration in a patient with chemoresistant stage IV seminoma.,http://www.ncbi.nlm.nih.gov/pubmed/18751412
392,17535970,"DA-Raf1, a competent intrinsic dominant-negative antagonist of the Ras-ERK pathway, is required for myogenic differentiation.",http://www.ncbi.nlm.nih.gov/pubmed/17535970
393,15084261,Cyclin C/cdk3 promotes Rb-dependent G0 exit.,http://www.ncbi.nlm.nih.gov/pubmed/15084261
394,22713237,Combined inhibition of Chk1 and Wee1: in vitro synergistic effect translates to tumor growth inhibition in vivo.,http://www.ncbi.nlm.nih.gov/pubmed/22713237
395,17456055,Loss-of-function JAK3 mutations in TMD and AMKL of Down syndrome.,http://www.ncbi.nlm.nih.gov/pubmed/17456055
396,22718859,Outcome of patients with platelet-derived growth factor receptor alpha-mutated gastrointestinal stromal tumors in the tyrosine kinase inhibitor era.,http://www.ncbi.nlm.nih.gov/pubmed/22718859
397,18971950,Imatinib sensitivity as a consequence of a CSF1R-Y571D mutation and CSF1/CSF1R signaling abnormalities in the cell line GDM1.,http://www.ncbi.nlm.nih.gov/pubmed/18971950
398,23895135,Comprehensive characterization of malignant phyllodes tumor by whole genomic and proteomic analysis: biological implications for targeted therapy opportunities.,http://www.ncbi.nlm.nih.gov/pubmed/23895135
399,24367637,Structural context of disease-associated mutations and putative mechanism of autoinhibition revealed by X-ray crystallographic analysis of the EZH2-SET domain.,http://www.ncbi.nlm.nih.gov/pubmed/24367637
400,,Abstract 2249: Mutations to the GSK3-beta regulatory region of CTNNB1 increase TCF transcription activity and are resistant to degradation by GSK3-beta,http://cancerres.aacrjournals.org/content/72/8_Supplement/2249.short
401,18282277,Correlation between beta-catenin mutations and expression of Wnt-signaling target genes in hepatocellular carcinoma.,http://www.ncbi.nlm.nih.gov/pubmed/18282277
402,9065403,Stabilization of beta-catenin by genetic defects in melanoma cell lines.,http://www.ncbi.nlm.nih.gov/pubmed/9065403
403,15133491,Genetic and epigenetic alterations of the APC gene in malignant melanoma.,http://www.ncbi.nlm.nih.gov/pubmed/15133491
404,21901162,Molecular genetic analysis of 103 sporadic colorectal tumours in Czech patients.,http://www.ncbi.nlm.nih.gov/pubmed/21901162
405,1338764,Screening for germ-line mutations in familial adenomatous polyposis patients: 61 new patients and a summary of 150 unrelated patients.,http://www.ncbi.nlm.nih.gov/pubmed/1338764
406,21599579,Description of a novel Janus kinase 3 P132A mutation in acute megakaryoblastic leukemia and demonstration of previously reported Janus kinase 3 mutations in normal subjects.,http://www.ncbi.nlm.nih.gov/pubmed/21599579
407,24944698,Effect of tumor suppressor gene cyclin-dependent kinase inhibitor 2A wild-type and A148T mutant on the cell cycle of human ovarian cancer cells.,http://www.ncbi.nlm.nih.gov/pubmed/24944698
408,15064718,Phosphorylation and ubiquitination of oncogenic mutants of beta-catenin containing substitutions at Asp32.,http://www.ncbi.nlm.nih.gov/pubmed/15064718
409,11781295,Functional analysis of hMLH1 variants and HNPCC-related mutations using a human expression system.,http://www.ncbi.nlm.nih.gov/pubmed/11781295
410,16187797,Oncogenic transformation by inhibitor-sensitive and -resistant EGFR mutants.,http://www.ncbi.nlm.nih.gov/pubmed/16187797
411,16861262,Inactive full-length p53 mutants lacking dominant wild-type p53 inhibition highlight loss of heterozygosity as an important aspect of p53 status in human cancers.,http://www.ncbi.nlm.nih.gov/pubmed/16861262
412,20594292,Identification and characterization of retinoblastoma gene mutations disturbing apoptosis in human breast cancers.,http://www.ncbi.nlm.nih.gov/pubmed/20594292
413,23092099,"Involvement of KRAS G12A mutation in the IL-2-independent growth of a human T-LGL leukemia cell line, PLT-2.",http://www.ncbi.nlm.nih.gov/pubmed/23092099
414,10871851,Tumorigenesis mediated by MET mutant M1268T is inhibited by dominant-negative Src.,http://www.ncbi.nlm.nih.gov/pubmed/10871851
415,9065402,Activation of beta-catenin-Tcf signaling in colon cancer by mutations in beta-catenin or APC.,http://www.ncbi.nlm.nih.gov/pubmed/9065402
416,22075979,Vascular endothelial growth factor receptor 2 inhibition in-vivo affects tumor vasculature in a tumor type-dependent way and downregulates vascular endothelial growth factor receptor 2 protein without a prominent role for miR-296.,http://www.ncbi.nlm.nih.gov/pubmed/22075979
417,,Abstract 3790: Preclinical profile of LGX818: A potent and selective RAF kinase inhibitor,http://cancerres.aacrjournals.org/cgi/content/short/72/8_MeetingAbstracts/3790
418,21224473,Novel imatinib-sensitive PDGFRA-activating point mutations in hypereosinophilic syndrome induce growth factor independence and leukemia-like disease.,http://www.ncbi.nlm.nih.gov/pubmed/21224473
419,23981578,Two co-existing germline mutations P53 V157D and PMS2 R20Q promote tumorigenesis in a familial cancer syndrome.,http://www.ncbi.nlm.nih.gov/pubmed/23981578
420,18768816,Apoptotic function of human PMS2 compromised by the nonsynonymous single-nucleotide polymorphic variant R20Q.,http://www.ncbi.nlm.nih.gov/pubmed/18768816
421,,Abstract C146: Combination treatment with the investigational RAF kinase inhibitor MLN2480 and the investigational MEK kinase inhibitor TAK-733 inhibits the growth of BRAF mutant and RAS mutant preclinical models of melanoma and CRC.,
422,24791855,Identification of Wee1 as a novel therapeutic target for mutant RAS-driven acute leukemia and other malignancies.,http://www.ncbi.nlm.nih.gov/pubmed/24791855
423,22649091,Kinase-impaired BRAF mutations in lung cancer confer sensitivity to dasatinib.,http://www.ncbi.nlm.nih.gov/pubmed/22649091
424,20141835,Kinase-dead BRAF and oncogenic RAS cooperate to drive tumor progression through CRAF.,http://www.ncbi.nlm.nih.gov/pubmed/20141835
425,15790786,Activation mutations of human c-KIT resistant to imatinib mesylate are sensitive to the tyrosine kinase inhibitor PKC412.,http://www.ncbi.nlm.nih.gov/pubmed/15790786
426,24406863,Retinoblastoma gene mutations detected by whole exome sequencing of Merkel cell carcinoma.,http://www.ncbi.nlm.nih.gov/pubmed/24406863
427,22743296,A patient with BRAF V600E lung adenocarcinoma responding to vemurafenib.,http://www.ncbi.nlm.nih.gov/pubmed/22743296
428,,Interim results of phase II study BRF113928 of dabrafenib in BRAF V600E mutation–positive non-small cell lung cancer (NSCLC) patients.,http://meetinglibrary.asco.org//content/112427-132
429,22197931,Exome sequencing identifies recurrent somatic MAP2K1 and MAP2K2 mutations in melanoma.,http://www.ncbi.nlm.nih.gov/pubmed/22197931
430,9506724,A new hot spot for mutations in the ret protooncogene causing familial medullary thyroid carcinoma and multiple endocrine neoplasia type 2A.,http://www.ncbi.nlm.nih.gov/pubmed/9506724
431,22923433,Genome sequencing identifies a basis for everolimus sensitivity.,http://www.ncbi.nlm.nih.gov/pubmed/22923433
432,9242375,Oncogenic activation of RET by two distinct FMTC mutations affecting the tyrosine kinase domain.,http://www.ncbi.nlm.nih.gov/pubmed/9242375
433,9422511,Activating Smoothened mutations in sporadic basal-cell carcinoma.,http://www.ncbi.nlm.nih.gov/pubmed/9422511
434,9342358,Incomplete penetrance of familial retinoblastoma linked to germ-line mutations that result in partial loss of RB function.,http://www.ncbi.nlm.nih.gov/pubmed/9342358
435,18813315,A novel AKT3 mutation in melanoma tumours and cell lines.,http://www.ncbi.nlm.nih.gov/pubmed/18813315
436,16051643,Conditional expression of the mutant Ki-rasG12C allele results in formation of benign lung adenomas: development of a novel mouse lung tumor model.,http://www.ncbi.nlm.nih.gov/pubmed/16051643
437,7732013,"A simple p53 functional assay for screening cell lines, blood, and tumors.",http://www.ncbi.nlm.nih.gov/pubmed/7732013
438,17349580,Structures of lung cancer-derived EGFR mutants and inhibitor complexes: mechanism of activation and insights into differential inhibitor sensitivity.,http://www.ncbi.nlm.nih.gov/pubmed/17349580
439,22190593,EGFR exon 19 insertions: a new family of sensitizing EGFR mutations in lung adenocarcinoma.,http://www.ncbi.nlm.nih.gov/pubmed/22190593
440,24353160,"Structural, biochemical, and clinical characterization of epidermal growth factor receptor (EGFR) exon 20 insertion mutations in lung cancer.",http://www.ncbi.nlm.nih.gov/pubmed/24353160
441,23387505,Sensitivity and kinase activity of epidermal growth factor receptor (EGFR) exon 19 and others to EGFR-tyrosine kinase inhibitors.,http://www.ncbi.nlm.nih.gov/pubmed/23387505
442,18227510,The T790M mutation in EGFR kinase causes drug resistance by increasing the affinity for ATP.,http://www.ncbi.nlm.nih.gov/pubmed/18227510
443,20026433,Structural and mechanistic underpinnings of the differential drug sensitivity of EGFR mutations in non-small cell lung cancer.,http://www.ncbi.nlm.nih.gov/pubmed/20026433
444,22986737,The FGFR4-G388R single-nucleotide polymorphism alters pancreatic neuroendocrine tumor progression and response to mTOR inhibition therapy.,http://www.ncbi.nlm.nih.gov/pubmed/22986737
445,22805291,"Safety, pharmacokinetic, pharmacodynamic, and efficacy data for the oral MEK inhibitor trametinib: a phase 1 dose-escalation trial.",http://www.ncbi.nlm.nih.gov/pubmed/22805291
446,17388661,Exquisite sensitivity of TP53 mutant and basal breast cancers to a dose-dense epirubicin-cyclophosphamide regimen.,http://www.ncbi.nlm.nih.gov/pubmed/17388661
447,24857124,Management and future directions in non-small cell lung cancer with known activating mutations.,http://www.ncbi.nlm.nih.gov/pubmed/24857124
448,,"First-line dacomitinib (PF-00299804), an irreversible pan-HER tyrosine kinase inhibitor, for patients with EGFR-mutant lung cancers",http://meetinglibrary.asco.org/content/99805-114
449,24736073,Comparison of clinical outcomes following gefitinib and erlotinib treatment in non-small-cell lung cancer patients harboring an epidermal growth factor receptor mutation in either exon 19 or 21.,http://www.ncbi.nlm.nih.gov/pubmed/24736073
450,24533047,"Network meta-analysis of erlotinib, gefitinib, afatinib and icotinib in patients with advanced non-small-cell lung cancer harboring EGFR mutations.",http://www.ncbi.nlm.nih.gov/pubmed/24533047
451,12118367,"K252a inhibits the oncogenic properties of Met, the HGF receptor.",http://www.ncbi.nlm.nih.gov/pubmed/12118367
452,15064724,The Met kinase inhibitor SU11274 exhibits a selective inhibition pattern toward different receptor mutated variants.,http://www.ncbi.nlm.nih.gov/pubmed/15064724
453,22307269,GNAQ and GNA11 mutations in melanocytomas of the central nervous system.,http://www.ncbi.nlm.nih.gov/pubmed/22307269
454,23828442,KRAS as prognostic biomarker in metastatic colorectal cancer patients treated with bevacizumab: a pooled analysis of 12 published trials.,http://www.ncbi.nlm.nih.gov/pubmed/23828442
455,19783361,Differential inhibition sensitivities of MET mutants to the small molecule inhibitor SU11274.,http://www.ncbi.nlm.nih.gov/pubmed/19783361
456,15731909,"Peutz-Jeghers LKB1 mutants fail to activate GSK-3beta, preventing it from inhibiting Wnt signaling.",http://www.ncbi.nlm.nih.gov/pubmed/15731909
457,9837816,"Loss of LKB1 kinase activity in Peutz-Jeghers syndrome, and evidence for allelic and locus heterogeneity.",http://www.ncbi.nlm.nih.gov/pubmed/9837816
458,15611064,Inactivation of VHL by tumorigenic mutations that disrupt dynamic coupling of the pVHL.hypoxia-inducible transcription factor-1alpha complex.,http://www.ncbi.nlm.nih.gov/pubmed/15611064
459,23689514,JAK3 deregulation by activating mutations confers invasive growth advantage in extranodal nasal-type natural killer cell lymphoma.,http://www.ncbi.nlm.nih.gov/pubmed/23689514
460,18795925,Association of paediatric mastocytosis with a polymorphism resulting in an amino acid substitution (M541L) in the transmembrane domain of c-KIT.,http://www.ncbi.nlm.nih.gov/pubmed/18795925
461,15829978,Functional correlates of mutation of the Asp32 and Gly34 residues of beta-catenin.,http://www.ncbi.nlm.nih.gov/pubmed/15829978
462,25015329,"Identification of kit(M541L) somatic mutation in chronic eosinophilic leukemia, not otherwise specified and its implication in low-dose imatinib response.",http://www.ncbi.nlm.nih.gov/pubmed/25015329
463,22926515,ARAF acts as a scaffold to stabilize BRAF:CRAF heterodimers.,http://www.ncbi.nlm.nih.gov/pubmed/22926515
464,17637569,Aurora-C-T191D is a hyperactive Aurora-C mutant.,http://www.ncbi.nlm.nih.gov/pubmed/17637569
465,15938719,Aurora C is directly associated with Survivin and required for cytokinesis.,http://www.ncbi.nlm.nih.gov/pubmed/15938719
466,11427728,Raf-1 promotes cell survival by antagonizing apoptosis signal-regulating kinase 1 through a MEK-ERK independent mechanism.,http://www.ncbi.nlm.nih.gov/pubmed/11427728
467,22608338,"Dabrafenib in patients with melanoma, untreated brain metastases, and other solid tumours: a phase 1 dose-escalation trial.",http://www.ncbi.nlm.nih.gov/pubmed/22608338
468,22663011,Improved survival with MEK inhibition in BRAF-mutated melanoma.,http://www.ncbi.nlm.nih.gov/pubmed/22663011
469,22356324,Survival in BRAF V600-mutant advanced melanoma treated with vemurafenib.,http://www.ncbi.nlm.nih.gov/pubmed/22356324
470,23237741,BRAF inhibitor activity in V600R metastatic melanoma.,http://www.ncbi.nlm.nih.gov/pubmed/23237741
471,23463675,The somatic affairs of BRAF: tailored therapies for advanced malignant melanoma and orphan non-V600E (V600R-M) mutations.,http://www.ncbi.nlm.nih.gov/pubmed/23463675
472,20551065,"RG7204 (PLX4032), a selective BRAFV600E inhibitor, displays potent antitumor activity in preclinical melanoma models.",http://www.ncbi.nlm.nih.gov/pubmed/20551065
473,23288408,A genome-scale RNA interference screen implicates NF1 loss in resistance to RAF inhibition.,http://www.ncbi.nlm.nih.gov/pubmed/23288408
474,23932362,Response to dasatinib in a patient with SQCC of the lung harboring a discoid-receptor-2 and synchronous chronic myelogenous leukemia.,http://www.ncbi.nlm.nih.gov/pubmed/23932362
475,18060073,"Mutation analysis of BRAF, MEK1 and MEK2 in 15 ovarian cancer cell lines: implications for therapy.",http://www.ncbi.nlm.nih.gov/pubmed/18060073
476,23752188,PDGFRA alterations in cancer: characterization of a gain-of-function V536E transmembrane mutant as well as loss-of-function and passenger mutations.,http://www.ncbi.nlm.nih.gov/pubmed/23752188
477,22327175,"MEDI3617, a human anti-angiopoietin 2 monoclonal antibody, inhibits angiogenesis and tumor growth in human tumor xenograft models.",http://www.ncbi.nlm.nih.gov/pubmed/22327175
478,22128301,Iniparib nonselectively modifies cysteine-containing proteins in tumor cells and is not a bona fide PARP inhibitor.,http://www.ncbi.nlm.nih.gov/pubmed/22128301
479,22186789,"Phase I trial of ""bi-shRNAi(furin)/GMCSF DNA/autologous tumor cell"" vaccine (FANG) in advanced cancer.",http://www.ncbi.nlm.nih.gov/pubmed/22186789
480,21959046,Chloroquine enhances the cytotoxicity of topotecan by inhibiting autophagy in lung cancer cells.,http://www.ncbi.nlm.nih.gov/pubmed/21959046
481,,A phase I trial of pazopanib and vorinostat: The role of TP53 mutations.,http://meetinglibrary.asco.org/content/132490-144
483,23838316,A dendritic cell vaccine pulsed with autologous hypochlorous acid-oxidized ovarian cancer lysate primes effective broad antitumor immunity: from bench to bedside.,http://www.ncbi.nlm.nih.gov/pubmed/23838316
484,23520471,Wee1 inhibition by MK-1775 leads to tumor inhibition and enhances efficacy of gemcitabine in human sarcomas.,http://www.ncbi.nlm.nih.gov/pubmed/23520471
485,23165797,Correlation of TP53 and MDM2 genotypes with response to therapy in sarcoma.,http://www.ncbi.nlm.nih.gov/pubmed/23165797
486,19228619,IDH1 and IDH2 mutations in gliomas.,http://www.ncbi.nlm.nih.gov/pubmed/19228619
487,19935646,Cancer-associated IDH1 mutations produce 2-hydroxyglutarate.,http://www.ncbi.nlm.nih.gov/pubmed/19935646
488,20171147,The common feature of leukemia-associated IDH1 and IDH2 mutations is a neomorphic enzyme activity converting alpha-ketoglutarate to 2-hydroxyglutarate.,http://www.ncbi.nlm.nih.gov/pubmed/20171147
489,22309944,Glioma derived isocitrate dehydrogenase-2 mutations induced up-regulation of HIF-1α and β-catenin signaling: possible impact on glioma cell metastasis and chemo-resistance.,http://www.ncbi.nlm.nih.gov/pubmed/22309944
490,24077826,Efficient induction of differentiation and growth inhibition in IDH1 mutant glioma cells by the DNMT Inhibitor Decitabine.,http://www.ncbi.nlm.nih.gov/pubmed/24077826
491,24470557,Phase I/II study of erlotinib and temsirolimus for patients with recurrent malignant gliomas: North American Brain Tumor Consortium trial 04-02.,http://www.ncbi.nlm.nih.gov/pubmed/24470557
492,24162827,PTEN status mediates 2ME2 anti-tumor efficacy in preclinical glioblastoma models: role of HIF1α suppression.,http://www.ncbi.nlm.nih.gov/pubmed/24162827
493,24077805,"5-azacytidine reduces methylation, promotes differentiation and induces tumor regression in a patient-derived IDH1 mutant glioma xenograft.",http://www.ncbi.nlm.nih.gov/pubmed/24077805
494,17603482,Germline gain-of-function mutations in RAF1 cause Noonan syndrome.,http://www.ncbi.nlm.nih.gov/pubmed/17603482
495,24882554,"A phase II trial of sunitinib in women with metastatic or recurrent endometrial carcinoma: a study of the Princess Margaret, Chicago and California Consortia.",http://www.ncbi.nlm.nih.gov/pubmed/24882554
496,24735922,Genomic profiling of hepatocellular adenomas reveals recurrent FRK-activating mutations and the mechanisms of malignant transformation.,http://www.ncbi.nlm.nih.gov/pubmed/24735922
497,7937865,A variant epidermal growth factor receptor exhibits altered type alpha transforming growth factor binding and transmembrane signaling.,http://www.ncbi.nlm.nih.gov/pubmed/7937865
498,20978130,Cancer-associated p53 tetramerization domain mutants: quantitative analysis reveals a low threshold for tumor suppressor inactivation.,http://www.ncbi.nlm.nih.gov/pubmed/20978130
499,19454241,Evaluation of transcriptional activity of p53 in individual living mammalian cells.,http://www.ncbi.nlm.nih.gov/pubmed/19454241
500,16007150,"The relationship among p53 oligomer formation, structure and transcriptional activity using a comprehensive missense mutation library.",http://www.ncbi.nlm.nih.gov/pubmed/16007150
501,11420669,Functional analysis and intracellular localization of p53 modified by SUMO-1.,http://www.ncbi.nlm.nih.gov/pubmed/11420669
502,15781620,Lack of correlation between p53-dependent transcriptional activity and the ability to induce apoptosis among 179 mutant p53s.,http://www.ncbi.nlm.nih.gov/pubmed/15781620
503,24052547,EZH2 mutations are frequent and represent an early event in follicular lymphoma.,http://www.ncbi.nlm.nih.gov/pubmed/24052547
504,24381593,Strategies for Molecularly Enhanced Chemotherapy to Achieve Synthetic Lethality in Endometrial Tumors with Mutant p53.,http://www.ncbi.nlm.nih.gov/pubmed/24381593
505,21190999,"Somatic mutations at EZH2 Y641 act dominantly through a mechanism of selectively altered PRC2 catalytic activity, to increase H3K27 trimethylation.",http://www.ncbi.nlm.nih.gov/pubmed/21190999
506,22323599,Mutation of A677 in histone methyltransferase EZH2 in human B-cell lymphoma promotes hypertrimethylation of histone H3 on lysine 27 (H3K27).,http://www.ncbi.nlm.nih.gov/pubmed/22323599
507,19448675,"RUNX1 and its fusion oncoprotein derivative, RUNX1-ETO, induce senescence-like growth arrest independently of replicative stress.",http://www.ncbi.nlm.nih.gov/pubmed/19448675
508,24098673,Functionally deregulated AML1/RUNX1 cooperates with BCR-ABL to induce a blastic phase-like phenotype of chronic myelogenous leukemia in mice.,http://www.ncbi.nlm.nih.gov/pubmed/24098673
509,10068652,Biallelic and heterozygous point mutations in the runt domain of the AML1/PEBP2alphaB gene associated with myeloblastic leukemias.,http://www.ncbi.nlm.nih.gov/pubmed/10068652
510,21821475,The underlying mechanism for the PARP and BRCA synthetic lethality: clearing up the misunderstandings.,http://www.ncbi.nlm.nih.gov/pubmed/21821475
511,22318203,Functional features of RUNX1 mutants in acute transformation of chronic myeloid leukemia and their contribution to inducing murine full-blown leukemia.,http://www.ncbi.nlm.nih.gov/pubmed/22318203
512,20979469,Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer.,http://www.ncbi.nlm.nih.gov/pubmed/20979469
513,20952506,"Inhibition of ALK, PI3K/MEK, and HSP90 in murine lung adenocarcinoma induced by EML4-ALK fusion oncogene.",http://www.ncbi.nlm.nih.gov/pubmed/20952506
514,16556909,Inhibition of poly (ADP-ribose) polymerase activates ATM which is required for subsequent homologous recombination repair.,http://www.ncbi.nlm.nih.gov/pubmed/16556909
515,20404560,Romidepsin (FK228/depsipeptide) controls growth and induces apoptosis in neuroblastoma tumor cells.,http://www.ncbi.nlm.nih.gov/pubmed/20404560
516,22167207,"Anticancer agent ellipticine combined with histone deacetylase inhibitors, valproic acid and trichostatin A, is an effective DNA damage strategy in human neuroblastoma.",http://www.ncbi.nlm.nih.gov/pubmed/22167207
517,23019217,Mithramycin A inhibits myeloid cell leukemia-1 to induce apoptosis in oral squamous cell carcinomas and tumor xenograft through activation of Bax and oligomerization.,http://www.ncbi.nlm.nih.gov/pubmed/23019217
518,20556479,Therapeutic effects of the Sp1 inhibitor mithramycin A in glioblastoma.,http://www.ncbi.nlm.nih.gov/pubmed/20556479
519,17973266,Therapeutic inhibition of Sp1 expression in growing tumors by mithramycin a correlates directly with potent antiangiogenic effects on human pancreatic cancer.,http://www.ncbi.nlm.nih.gov/pubmed/17973266
520,23881923,"BMN 673, a novel and highly potent PARP1/2 inhibitor for the treatment of human cancers with DNA repair deficiency.",http://www.ncbi.nlm.nih.gov/pubmed/23881923
521,22703804,Efficacy of class I and II vs class III histone deacetylase inhibitors in neuroblastoma.,http://www.ncbi.nlm.nih.gov/pubmed/22703804
522,11276260,The leukemia-associated AML1 (Runx1)--CBF beta complex functions as a DNA-induced molecular clamp.,http://www.ncbi.nlm.nih.gov/pubmed/11276260
523,11830488,In vitro analyses of known and novel RUNX1/AML1 mutations in dominant familial platelet disorder with predisposition to acute myelogenous leukemia: implications for mechanisms of pathogenesis.,http://www.ncbi.nlm.nih.gov/pubmed/11830488
524,12529654,New mechanisms of AML1 gene alteration in hematological malignancies.,http://www.ncbi.nlm.nih.gov/pubmed/12529654
525,11435891,Various forms of mutant p53 confer sensitivity to cisplatin and doxorubicin in bladder cancer cells.,http://www.ncbi.nlm.nih.gov/pubmed/11435891
526,15279807,"Ataxia-telangiectasia, an evolving phenotype.",http://www.ncbi.nlm.nih.gov/pubmed/15279807
527,21838707,Activating ALK mutations found in neuroblastoma are inhibited by Crizotinib and NVP-TAE684.,http://www.ncbi.nlm.nih.gov/pubmed/21838707
528,20233444,"A rapid, sensitive, reproducible and cost-effective method for mutation profiling of colon cancer and metastatic lymph nodes.",http://www.ncbi.nlm.nih.gov/pubmed/20233444
529,,Abstract 925: The c-Met inhibitor MSC2156119J effectively inhibits growth of liver cancer models.,
530,21881915,Phase I study of temsirolimus in combination with EKB-569 in patients with advanced solid tumors.,http://www.ncbi.nlm.nih.gov/pubmed/21881915
531,23359171,An update on molecularly targeted therapies in second- and third-line treatment in non-small cell lung cancer: focus on EGFR inhibitors and anti-angiogenic agents.,http://www.ncbi.nlm.nih.gov/pubmed/23359171
532,19917254,Suppression of cancer cell growth by promoting cyclin D1 degradation.,http://www.ncbi.nlm.nih.gov/pubmed/19917254
533,14965268,A dual role of cyclin E in cell proliferation and apoptosis may provide a target for cancer therapy.,http://www.ncbi.nlm.nih.gov/pubmed/14965268
534,24089445,The cell-cycle regulator CDK4: an emerging therapeutic target in melanoma.,http://www.ncbi.nlm.nih.gov/pubmed/24089445
535,23303139,"MDM2, MDMX and p53 in oncogenesis and cancer therapy.",http://www.ncbi.nlm.nih.gov/pubmed/23303139
536,25038584,Impact of MYC in regulation of tumor cell metabolism.,http://www.ncbi.nlm.nih.gov/pubmed/25038584
537,24893891,"AZD9291, an irreversible EGFR TKI, overcomes T790M-mediated resistance to EGFR inhibitors in lung cancer.",http://www.ncbi.nlm.nih.gov/pubmed/24893891
538,23136197,Predictive biomarkers of sensitivity to the aurora and angiogenic kinase inhibitor ENMD-2076 in preclinical breast cancer models.,http://www.ncbi.nlm.nih.gov/pubmed/23136197
539,20589168,"VX680/MK-0457, a potent and selective Aurora kinase inhibitor, targets both tumor and endothelial cells in clear cell renal cell carcinoma.",http://www.ncbi.nlm.nih.gov/pubmed/20589168
540,23403633,The investigational Aurora kinase A inhibitor MLN8237 induces defects in cell viability and cell-cycle progression in malignant bladder cancer cells in vitro and in vivo.,http://www.ncbi.nlm.nih.gov/pubmed/23403633
541,,,http://meetinglibrary.asco.org/content/105634-133
542,23200175,"Selumetinib plus docetaxel for KRAS-mutant advanced non-small-cell lung cancer: a randomised, multicentre, placebo-controlled, phase 2 study.",http://www.ncbi.nlm.nih.gov/pubmed/23200175
543,22586319,The BATTLE trial: personalizing therapy for lung cancer.,http://www.ncbi.nlm.nih.gov/pubmed/22586319
544,18176934,Activated K-RAS increases polyamine uptake in human colon cancer cells through modulation of caveolar endocytosis.,http://www.ncbi.nlm.nih.gov/pubmed/18176934
545,21228365,KRAS gene mutation in colorectal cancer is correlated with increased proliferation and spontaneous apoptosis.,http://www.ncbi.nlm.nih.gov/pubmed/21228365
546,21079152,Somatic KRAS mutations associated with a human nonmalignant syndrome of autoimmunity and abnormal leukocyte homeostasis.,http://www.ncbi.nlm.nih.gov/pubmed/21079152
547,19075190,"High-throughput sequencing screen reveals novel, transforming RAS mutations in myeloid leukemia patients.",http://www.ncbi.nlm.nih.gov/pubmed/19075190
548,,,http://abstracts.hematologylibrary.org/cgi/content/abstract/114/22/3468
549,19808697,AML1/RUNX1 mutations in 470 adult patients with de novo acute myeloid leukemia: prognostic implication and interaction with other gene alterations.,http://www.ncbi.nlm.nih.gov/pubmed/19808697
550,17150185,Characterization of a novel oncogenic K-ras mutation in colon cancer.,http://www.ncbi.nlm.nih.gov/pubmed/17150185
551,23471304,RUNX1/AML1 mutant collaborates with BMI1 overexpression in the development of human and murine myelodysplastic syndromes.,http://www.ncbi.nlm.nih.gov/pubmed/23471304
552,19850737,AML1/RUNX1 point mutation possibly promotes leukemic transformation in myeloproliferative neoplasms.,http://www.ncbi.nlm.nih.gov/pubmed/19850737
553,22888167,Identification of a new recurrent aurora kinase C mutation in both European and African men with macrozoospermia.,http://www.ncbi.nlm.nih.gov/pubmed/22888167
554,22710932,Transactivation and reactivation capabilities of temperature-dependent p53 mutants in yeast and human cells.,http://www.ncbi.nlm.nih.gov/pubmed/22710932
555,10435620,p53 compound heterozygosity in a severely affected child with Li-Fraumeni syndrome.,http://www.ncbi.nlm.nih.gov/pubmed/10435620
556,21232794,A comprehensive study of TP53 mutations in chronic lymphocytic leukemia: Analysis of 1287 diagnostic and 1148 follow-up CLL samples.,http://www.ncbi.nlm.nih.gov/pubmed/21232794
557,,"TAS-119, a selective Aurora A inhibitor, enhanced the antitumor efficacy of taxanes in multiple human tumor cell lines including paclitaxel-resistant cells.",http://mct.aacrjournals.org/content/12/11_Supplement/A268
558,,"Antitumor activity of alisertib (MLN8237), an investigational small molecule Aurora A kinase inhibitor, as a single agent and in combination with paclitaxel, in experimental models of small cell lung cancer",http://mct.aacrjournals.org/content/12/11_Supplement/A282
559,23328556,Non-small-cell lung cancer with HER2 exon 20 mutation: regression with dual HER2 inhibition and anti-VEGF combination treatment.,http://www.ncbi.nlm.nih.gov/pubmed/23328556
560,23610105,Lung cancer that harbors an HER2 mutation: epidemiologic characteristics and therapeutic perspectives.,http://www.ncbi.nlm.nih.gov/pubmed/23610105
561,22649146,HER2 mutations in non-small-cell lung cancer can be continually targeted.,http://www.ncbi.nlm.nih.gov/pubmed/22649146
562,,"NCCN guidelines, Breast cancer version 3.2014",
563,21991949,Adjuvant trastuzumab in HER2-positive breast cancer.,http://www.ncbi.nlm.nih.gov/pubmed/21991949
564,23801166,First FDA approval of dual anti-HER2 regimen: pertuzumab in combination with trastuzumab and docetaxel for HER2-positive metastatic breast cancer.,http://www.ncbi.nlm.nih.gov/pubmed/23801166
565,23227212,Systemic analysis of gene expression profiles identifies ErbB3 as a potential drug target in pediatric alveolar rhabdomyosarcoma.,http://www.ncbi.nlm.nih.gov/pubmed/23227212
566,19718025,Analysis of the tyrosine kinome in melanoma reveals recurrent mutations in ERBB4.,http://www.ncbi.nlm.nih.gov/pubmed/19718025
567,9856504,Functional characterisation of mutations in the ligand-binding domain of the androgen receptor gene in patients with androgen insensitivity syndrome.,http://www.ncbi.nlm.nih.gov/pubmed/9856504
568,18006781,"Relationship of EGFR mutations, expression, amplification, and polymorphisms to epidermal growth factor receptor inhibitors in the NCI60 cell lines.",http://www.ncbi.nlm.nih.gov/pubmed/18006781
569,24165483,FBXW7 mediates chemotherapeutic sensitivity and prognosis in NSCLCs.,http://www.ncbi.nlm.nih.gov/pubmed/24165483
570,23274910,Mcl-1 and FBW7 control a dominant survival pathway underlying HDAC and Bcl-2 inhibitor synergy in squamous cell carcinoma.,http://www.ncbi.nlm.nih.gov/pubmed/23274910
571,18787170,FBXW7 targets mTOR for degradation and cooperates with PTEN in tumor suppression.,http://www.ncbi.nlm.nih.gov/pubmed/18787170
572,23558291,Rapamycin inhibits FBXW7 loss-induced epithelial-mesenchymal transition and cancer stem cell-like characteristics in colorectal cancer cells.,http://www.ncbi.nlm.nih.gov/pubmed/23558291
573,23483975,A kinome screen identifies checkpoint kinase 1 (CHK1) as a sensitizer for RRM1-dependent gemcitabine efficacy.,http://www.ncbi.nlm.nih.gov/pubmed/23483975
574,21763698,Structural and functional impact of cancer-related missense somatic mutations.,http://www.ncbi.nlm.nih.gov/pubmed/21763698
575,15683227,In the quest for stable rescuing mutants of p53: computational mutagenesis of flexible loop L1.,http://www.ncbi.nlm.nih.gov/pubmed/15683227
576,22898678,"Vandetanib in locally advanced or metastatic differentiated thyroid cancer: a randomised, double-blind, phase 2 trial.",http://www.ncbi.nlm.nih.gov/pubmed/22898678
577,20048182,"Phase I pharmacologic and biologic study of ramucirumab (IMC-1121B), a fully human immunoglobulin G1 monoclonal antibody targeting the vascular endothelial growth factor receptor-2.",http://www.ncbi.nlm.nih.gov/pubmed/20048182
578,20694064,Axitinib: The evidence of its potential in the treatment of advanced thyroid cancer.,http://www.ncbi.nlm.nih.gov/pubmed/20694064
579,23489023,Clinical responses to vemurafenib in patients with metastatic papillary thyroid cancer harboring BRAF(V600E) mutation.,http://www.ncbi.nlm.nih.gov/pubmed/23489023
580,24658273,Targeting Bruton's tyrosine kinase in B cell malignancies.,http://www.ncbi.nlm.nih.gov/pubmed/24658273
581,23953056,A phase two randomised trial of neratinib monotherapy versus lapatinib plus capecitabine combination therapy in patients with HER2+ advanced breast cancer.,http://www.ncbi.nlm.nih.gov/pubmed/23953056
582,,"Phase I study of margetuximab (MGAH22), an FC-modified chimeric monoclonal antibody (MAb), in patients (pts) with advanced solid tumors expressing the HER2 oncoprotein.",http://meetinglibrary.asco.org/content/115290-132
583,,"A Phase I Study of MM-302, a HER2-targeted Liposomal Doxorubicin, in Patients with Advanced, HER2- Positive Breast Cancer",http://cancerres.aacrjournals.org/cgi/content/meeting_abstract/72/24_MeetingAbstracts/P5-18-09
584,10976406,[Functional restoration of tumor suppressor p53 alters susceptibility of glioblastoma cells to irradiation--analysis using a cell line containing a temperature-sensitive mutant].,http://www.ncbi.nlm.nih.gov/pubmed/10976406
585,21643018,Acquisition of p53 mutations in response to the non-genotoxic p53 activator Nutlin-3.,http://www.ncbi.nlm.nih.gov/pubmed/21643018
586,15579438,CTNNB1 mutations and overexpression of Wnt/beta-catenin target genes in WT1-mutant Wilms' tumors.,http://www.ncbi.nlm.nih.gov/pubmed/15579438
587,21926191,"Cabozantinib (XL184), a novel MET and VEGFR2 inhibitor, simultaneously suppresses metastasis, angiogenesis, and tumor growth.",http://www.ncbi.nlm.nih.gov/pubmed/21926191
588,23775486,"Phase 2 trial of afatinib, an ErbB family blocker, in solid tumors genetically screened for target activation.",http://www.ncbi.nlm.nih.gov/pubmed/23775486
589,17664273,Sorafenib functions to potently suppress RET tyrosine kinase activity by direct enzymatic inhibition and promoting RET lysosomal degradation independent of proteasomal targeting.,http://www.ncbi.nlm.nih.gov/pubmed/17664273
590,25085632,Next generation sequencing analysis of platinum refractory advanced germ cell tumor sensitive to Sunitinib (Sutent®) a VEGFR2/PDGFRβ/c-kit/ FLT3/RET/CSF1R inhibitor in a phase II trial.,http://www.ncbi.nlm.nih.gov/pubmed/25085632
591,24606768,Sunitinib in combination with trastuzumab for the treatment of advanced breast cancer: activity and safety results from a phase II study.,http://www.ncbi.nlm.nih.gov/pubmed/24606768
592,21443688,YN968D1 is a novel and selective inhibitor of vascular endothelial growth factor receptor-2 tyrosine kinase with potent activity in vitro and in vivo.,http://www.ncbi.nlm.nih.gov/pubmed/21443688
593,22761403,"Dacomitinib (PF-00299804), an irreversible Pan-HER inhibitor, inhibits proliferation of HER2-amplified breast cancer cell lines resistant to trastuzumab and lapatinib.",http://www.ncbi.nlm.nih.gov/pubmed/22761403
594,21799033,"MK-1775, a novel Wee1 kinase inhibitor, radiosensitizes p53-defective human tumor cells.",http://www.ncbi.nlm.nih.gov/pubmed/21799033
595,23585514,Active immunotherapy in HER2 overexpressing breast cancer: current status and future perspectives.,http://www.ncbi.nlm.nih.gov/pubmed/23585514
596,22304225,"AL3810, a multi-tyrosine kinase inhibitor, exhibits potent anti-angiogenic and anti-tumour activity via targeting VEGFR, FGFR and PDGFR.",http://www.ncbi.nlm.nih.gov/pubmed/22304225
597,17591827,Lapatinib in breast cancer.,http://www.ncbi.nlm.nih.gov/pubmed/17591827
598,18451145,"Nutlin-3a activates p53 to both down-regulate inhibitor of growth 2 and up-regulate mir-34a, mir-34b, and mir-34c expression, and induce senescence.",http://www.ncbi.nlm.nih.gov/pubmed/18451145
599,17145525,Bevacizumab in combination with chemotherapy: first-line treatment of patients with metastatic colorectal cancer.,http://www.ncbi.nlm.nih.gov/pubmed/17145525
600,,"Abstract LB-302: Potent antitumor activity of XL184 (cabozantinib), a c-MET and VEGFR2 inhibitor, in colorectal cancer patient-derived tumor explant models.",
601,21617858,"Growth response of human colorectal tumour cell lines to treatment with afatinib (BIBW2992), an irreversible erbB family blocker, and its association with expression of HER family members.",http://www.ncbi.nlm.nih.gov/pubmed/21617858
602,23811235,Ponatinib is a potent inhibitor of wild-type and drug-resistant gatekeeper mutant RET kinase.,http://www.ncbi.nlm.nih.gov/pubmed/23811235
603,18618574,Association of p53 codon 72 polymorphism and MDM2 SNP309 with clinical outcome of advanced nonsmall cell lung cancer.,http://www.ncbi.nlm.nih.gov/pubmed/18618574
604,20179222,"Lapatinib, a dual EGFR and HER2 kinase inhibitor, selectively inhibits HER2-amplified human gastric cancer cells and is synergistic with trastuzumab in vitro and in vivo.",http://www.ncbi.nlm.nih.gov/pubmed/20179222
605,9754653,Identification of HER2/neu-derived peptide epitopes recognized by gastric cancer-specific cytotoxic T lymphocytes.,http://www.ncbi.nlm.nih.gov/pubmed/9754653
606,18606718,"Antitumor activity and pharmacokinetic properties of PF-00299804, a second-generation irreversible pan-erbB receptor tyrosine kinase inhibitor.",http://www.ncbi.nlm.nih.gov/pubmed/18606718
608,,,www.biooncology.com
609,22862161,Roscovitine-induced apoptosis of H1299 cells depends on functional status of p53.,http://www.ncbi.nlm.nih.gov/pubmed/22862161
610,19681600,Effect of thioredoxin deletion and p53 cysteine replacement on human p53 activity in wild-type and thioredoxin reductase null yeast.,http://www.ncbi.nlm.nih.gov/pubmed/19681600
611,12066214,Oral fluoropyrimidine anticancer drug TS-1 for gastric cancer patients with peritoneal dissemination.,http://www.ncbi.nlm.nih.gov/pubmed/12066214
612,10473078,"Pharmacokinetic study of S-1, a novel oral fluorouracil antitumor drug.",http://www.ncbi.nlm.nih.gov/pubmed/10473078
613,17679724,Capecitabine and trastuzumab in heavily pretreated metastatic breast cancer.,http://www.ncbi.nlm.nih.gov/pubmed/17679724
614,24868024,"Lapatinib plus paclitaxel versus paclitaxel alone in the second-line treatment of HER2-amplified advanced gastric cancer in Asian populations: TyTAN--a randomized, phase III study.",http://www.ncbi.nlm.nih.gov/pubmed/24868024
615,21278246,Expression of p16 and retinoblastoma determines response to CDK4/6 inhibition in ovarian cancer.,http://www.ncbi.nlm.nih.gov/pubmed/21278246
616,25122067,The CDK4/6 inhibitor LY2835219 overcomes vemurafenib resistance resulting from MAPK reactivation and cyclin D1 upregulation.,http://www.ncbi.nlm.nih.gov/pubmed/25122067
617,24657911,miR-34: from bench to bedside.,http://www.ncbi.nlm.nih.gov/pubmed/24657911
618,18406353,Downregulation of CCND1 and CDK6 by miR-34a induces cell cycle arrest.,http://www.ncbi.nlm.nih.gov/pubmed/18406353
619,24742739,"Everolimus for women with trastuzumab-resistant, HER2-positive, advanced breast cancer (BOLERO-3): a randomised, double-blind, placebo-controlled phase 3 trial.",http://www.ncbi.nlm.nih.gov/pubmed/24742739
620,24300914,Trastuzumab and oxaliplatin exhibit a synergistic antitumor effect in HER2-postive gastric cancer cells.,http://www.ncbi.nlm.nih.gov/pubmed/24300914
621,22046346,Differential sensitivity of ERBB2 kinase domain mutations towards lapatinib.,http://www.ncbi.nlm.nih.gov/pubmed/22046346
622,19287305,Multiple hepatic arterial injections of recombinant adenovirus p53 and 5-fluorouracil after transcatheter arterial chemoembolization for unresectable hepatocellular carcinoma: a pilot phase II trial.,http://www.ncbi.nlm.nih.gov/pubmed/19287305
623,14654539,TP53 gene mutations predict the response to neoadjuvant treatment with 5-fluorouracil and mitomycin in locally advanced breast cancer.,http://www.ncbi.nlm.nih.gov/pubmed/14654539
624,23948973,Human breast cancer cells harboring a gatekeeper T798M mutation in HER2 overexpress EGFR ligands and are sensitive to dual inhibition of EGFR and HER2.,http://www.ncbi.nlm.nih.gov/pubmed/23948973
625,24886365,"AZD8931, an equipotent, reversible inhibitor of signaling by epidermal growth factor receptor (EGFR), HER2, and HER3: preclinical activity in HER2 non-amplified inflammatory breast cancer models.",http://www.ncbi.nlm.nih.gov/pubmed/24886365
626,21454469,Dysregulation of the HIF pathway due to VHL mutation causing severe erythrocytosis and pulmonary arterial hypertension.,http://www.ncbi.nlm.nih.gov/pubmed/21454469
627,,The FLT3-D324N Variant Is a Functionally Silent Polymorphism in the FLT3 Gene and May Be Associated with a Higher Risk for AML.,http://abstracts.hematologylibrary.org/cgi/content/short/104/11/3373
628,12909720,Functional mutants of the sequence-specific transcription factor p53 and implications for master genes of diversity.,http://www.ncbi.nlm.nih.gov/pubmed/12909720
629,16687402,Mutational analysis of the p53 core domain L1 loop.,http://www.ncbi.nlm.nih.gov/pubmed/16687402
630,12402348,Loss of heterozygosity and mutations are the major mechanisms of RB1 gene inactivation in Chinese with sporadic retinoblastoma.,http://www.ncbi.nlm.nih.gov/pubmed/12402348
631,11358831,TP53 mutations in breast cancer associated with BRCA1 or BRCA2 germ-line mutations: distinctive spectrum and structural distribution.,http://www.ncbi.nlm.nih.gov/pubmed/11358831
632,18719709,A complex barcode underlies the heterogeneous response of p53 to stress.,http://www.ncbi.nlm.nih.gov/pubmed/18719709
633,18439086,Mutations of KRAS and TP53 in a minor proportion of Opisthorchis viverrini-associated cholangiocarcinomas in a hamster model.,http://www.ncbi.nlm.nih.gov/pubmed/18439086
634,2415468,Human T-cell leukemia virus type I: pseudotype neutralization of Japanese and American isolates with human and rabbit sera.,http://www.ncbi.nlm.nih.gov/pubmed/2415468
635,20142593,Phase II study of sunitinib in patients with metastatic urothelial cancer.,http://www.ncbi.nlm.nih.gov/pubmed/20142593
636,19010912,Genetic predictors of MEK dependence in non-small cell lung cancer.,http://www.ncbi.nlm.nih.gov/pubmed/19010912
637,12068308,Mutations of the BRAF gene in human cancer.,http://www.ncbi.nlm.nih.gov/pubmed/12068308
638,8755984,Control of an outbreak of salmonellosis caused by drug-resistant Salmonella anatum in horses at a veterinary hospital and measures to prevent future infections.,http://www.ncbi.nlm.nih.gov/pubmed/8755984
639,18755984,Activating mutations in human acute megakaryoblastic leukemia.,http://www.ncbi.nlm.nih.gov/pubmed/18755984
640,23990666,"Pleiotropic effects of the trichloroethylene-associated P81S VHL mutation on metabolism, apoptosis, and ATM-mediated DNA damage response.",http://www.ncbi.nlm.nih.gov/pubmed/23990666
641,18493606,Phosphatidylinositol 3-kinase mediates bronchioalveolar stem cell expansion in mouse models of oncogenic K-ras-induced lung cancer.,http://www.ncbi.nlm.nih.gov/pubmed/18493606
642,24939055,Antitumor activity of selective MEK1/2 inhibitor AZD6244 in combination with PI3K/mTOR inhibitor BEZ235 in gefitinib-resistant NSCLC xenograft models.,http://www.ncbi.nlm.nih.gov/pubmed/24939055
643,20407015,Altered-function p53 missense mutations identified in breast cancers can have subtle effects on transactivation.,http://www.ncbi.nlm.nih.gov/pubmed/20407015
644,18794843,Activation of tyrosine kinases by mutation of the gatekeeper threonine.,http://www.ncbi.nlm.nih.gov/pubmed/18794843
645,11377682,Classes of c-KIT activating mutations: proposed mechanisms of action and implications for disease classification and therapy.,http://www.ncbi.nlm.nih.gov/pubmed/11377682
646,19865100,Pediatric mastocytosis is a clonal disease associated with D816V and other activating c-KIT mutations.,http://www.ncbi.nlm.nih.gov/pubmed/19865100
647,23567324,Are two better than one? A novel double-mutant KIT in GIST that responds to Imatinib.,http://www.ncbi.nlm.nih.gov/pubmed/23567324
648,16226710,Structure and regulation of Kit protein-tyrosine kinase--the stem cell factor receptor.,http://www.ncbi.nlm.nih.gov/pubmed/16226710
649,15837988,Familial gastrointestinal stromal tumor syndrome: phenotypic and molecular features in a kindred.,http://www.ncbi.nlm.nih.gov/pubmed/15837988
650,9438854,Gain-of-function mutations of c-kit in human gastrointestinal stromal tumors.,http://www.ncbi.nlm.nih.gov/pubmed/9438854
651,24317392,"A new KIT mutation (N505I) in acral melanoma confers constitutive signaling, favors tumorigenic properties, and is sensitive to imatinib.",http://www.ncbi.nlm.nih.gov/pubmed/24317392
652,18390729,"Unique effects of KIT D816V in BaF3 cells: induction of cluster formation, histamine synthesis, and early mast cell differentiation antigens.",http://www.ncbi.nlm.nih.gov/pubmed/18390729
653,10362788,Activating c-kit gene mutations in human germ cell tumors.,http://www.ncbi.nlm.nih.gov/pubmed/10362788
654,11494148,STAT3 activation is required for Asp(816) mutant c-Kit induced tumorigenicity.,http://www.ncbi.nlm.nih.gov/pubmed/11494148
655,19164557,KIT kinase mutants show unique mechanisms of drug resistance to imatinib and sunitinib in gastrointestinal stromal tumor patients.,http://www.ncbi.nlm.nih.gov/pubmed/19164557
656,15625120,Normal and oncogenic forms of the receptor tyrosine kinase kit.,http://www.ncbi.nlm.nih.gov/pubmed/15625120
657,16397263,"Dasatinib (BMS-354825), a dual SRC/ABL kinase inhibitor, inhibits the kinase activity of wild-type, juxtamembrane, and activation loop mutant KIT isoforms associated with human malignancies.",http://www.ncbi.nlm.nih.gov/pubmed/16397263
658,21399868,"p53, HER2 and tumor cell apoptosis correlate with clinical outcome after neoadjuvant bevacizumab plus chemotherapy in breast cancer.",http://www.ncbi.nlm.nih.gov/pubmed/21399868
659,21640708,Mechanism of activation of human c-KIT kinase by internal tandem duplications of the juxtamembrane domain and point mutations at aspartic acid 816.,http://www.ncbi.nlm.nih.gov/pubmed/21640708
660,11984533,Familial gastrointestinal stromal tumors associated with dysphagia and novel type germline mutation of KIT gene.,http://www.ncbi.nlm.nih.gov/pubmed/11984533
661,19035443,Pathological activation of KIT in metastatic tumors of acral and mucosal melanomas.,http://www.ncbi.nlm.nih.gov/pubmed/19035443
662,21689725,"Novel, activating KIT-N822I mutation in familial cutaneous mastocytosis.",http://www.ncbi.nlm.nih.gov/pubmed/21689725
663,24205792,"Flumatinib, a selective inhibitor of BCR-ABL/PDGFR/KIT, effectively overcomes drug resistance of certain KIT mutants.",http://www.ncbi.nlm.nih.gov/pubmed/24205792
664,23001754,"Combination antiangiogenic therapy in advanced breast cancer: a phase 1 trial of vandetanib, a VEGFR inhibitor, and metronomic chemotherapy, with correlative platelet proteomics.",http://www.ncbi.nlm.nih.gov/pubmed/23001754
665,25185099,"Primary results of ROSE/TRIO-12, a randomized placebo-controlled phase III trial evaluating the addition of ramucirumab to first-line docetaxel chemotherapy in metastatic breast cancer.",http://www.ncbi.nlm.nih.gov/pubmed/25185099
666,14695343,KIT mutations are common in testicular seminomas.,http://www.ncbi.nlm.nih.gov/pubmed/14695343
667,9990072,Activating and dominant inactivating c-KIT catalytic domain mutations in distinct clinical forms of human mastocytosis.,http://www.ncbi.nlm.nih.gov/pubmed/9990072
668,20824047,Mutations in the c-Kit gene disrupt mitogen-activated protein kinase signaling during tumor development in adenoid cystic carcinoma of the salivary glands.,http://www.ncbi.nlm.nih.gov/pubmed/20824047
669,10213492,Dominant negative effect of the APC1309 mutation: a possible explanation for genotype-phenotype correlations in familial adenomatous polyposis.,http://www.ncbi.nlm.nih.gov/pubmed/10213492
670,19861435,Comprehensive genomic analysis reveals clinically relevant molecular distinctions between thymic carcinomas and thymomas.,http://www.ncbi.nlm.nih.gov/pubmed/19861435
671,21148330,"Mast cell hyperplasia, B-cell malignancy, and intestinal inflammation in mice with conditional expression of a constitutively active kit.",http://www.ncbi.nlm.nih.gov/pubmed/21148330
672,11888926,Functional analysis of 44 mutant androgen receptors from human prostate cancer.,http://www.ncbi.nlm.nih.gov/pubmed/11888926
673,22403669,The impact of point mutations in the human androgen receptor: classification of mutations on the basis of transcriptional activity.,http://www.ncbi.nlm.nih.gov/pubmed/22403669
674,22355224,"Study of the role of ""gatekeeper"" mutations V654A and T670I of c-kit kinase in the interaction with inhibitors by means mixed molecular dynamics/docking approach.",http://www.ncbi.nlm.nih.gov/pubmed/22355224
675,15236194,A new mutation in the KIT ATP pocket causes acquired resistance to imatinib in a gastrointestinal stromal tumor patient.,http://www.ncbi.nlm.nih.gov/pubmed/15236194
676,17699867,Sorafenib inhibits the imatinib-resistant KITT670I gatekeeper mutation in gastrointestinal stromal tumor.,http://www.ncbi.nlm.nih.gov/pubmed/17699867
677,19718013,Correlation between KIT expression and KIT mutation in melanoma: a study of 173 cases with emphasis on the acral-lentiginous/mucosal type.,http://www.ncbi.nlm.nih.gov/pubmed/19718013
678,17363509,Resistance to c-KIT kinase inhibitors conferred by V654A mutation.,http://www.ncbi.nlm.nih.gov/pubmed/17363509
679,11073817,Germline-activating mutation in the kinase domain of KIT gene in familial gastrointestinal stromal tumors.,http://www.ncbi.nlm.nih.gov/pubmed/11073817
680,15990278,Differences in signaling pathways and expression level of the phosphoinositide phosphatase SHIP1 between two oncogenic mutants of the receptor tyrosine kinase KIT.,http://www.ncbi.nlm.nih.gov/pubmed/15990278
681,19802003,c-Kit mutants require hypoxia-inducible factor 1alpha to transform melanocytes.,http://www.ncbi.nlm.nih.gov/pubmed/19802003
682,20695522,Crystal structures of anaplastic lymphoma kinase in complex with ATP competitive inhibitors.,http://www.ncbi.nlm.nih.gov/pubmed/20695522
683,22277784,Mechanisms of acquired crizotinib resistance in ALK-rearranged lung Cancers.,http://www.ncbi.nlm.nih.gov/pubmed/22277784
684,8589721,Growth retardation and tumour inhibition by BRCA1.,http://www.ncbi.nlm.nih.gov/pubmed/8589721
685,7925293,Tumour induction by activated abl involves tyrosine phosphorylation of the product of the cbl oncogene.,http://www.ncbi.nlm.nih.gov/pubmed/7925293
686,11239464,RING finger mutations that abolish c-Cbl-directed polyubiquitination and downregulation of the EGF receptor are insufficient for cell transformation.,http://www.ncbi.nlm.nih.gov/pubmed/11239464
687,19260062,"Functional, structural, and genetic evaluation of 20 CDKN2A germ line mutations identified in melanoma-prone families or patients.",http://www.ncbi.nlm.nih.gov/pubmed/19260062
688,19712690,Functional impairment of p16(INK4A) due to CDKN2A p.Gly23Asp missense mutation.,http://www.ncbi.nlm.nih.gov/pubmed/19712690
689,2157180,Transforming activities of human CSF-1 receptors with different point mutations at codon 301 in their extracellular domains.,http://www.ncbi.nlm.nih.gov/pubmed/2157180
690,2974321,A point mutation in the extracellular domain of the human CSF-1 receptor (c-fms proto-oncogene product) activates its transforming potential.,http://www.ncbi.nlm.nih.gov/pubmed/2974321
691,23935925,"NVP-LDE225, a potent and selective SMOOTHENED antagonist reduces melanoma growth in vitro and in vivo.",http://www.ncbi.nlm.nih.gov/pubmed/23935925
692,21191045,"Preclinical pharmacology, antitumor activity, and development of pharmacodynamic markers for the novel, potent AKT inhibitor CCT128930.",http://www.ncbi.nlm.nih.gov/pubmed/21191045
693,22294718,"Preclinical pharmacology of AZD5363, an inhibitor of AKT: pharmacodynamics, antitumor activity, and correlation of monotherapy activity with genetic background.",http://www.ncbi.nlm.nih.gov/pubmed/22294718
694,9545503,"Comparison of the human and murine ATRX gene identifies highly conserved, functionally important domains.",http://www.ncbi.nlm.nih.gov/pubmed/9545503
695,17372901,L576P KIT mutation in anal melanomas correlates with KIT protein expression and is sensitive to specific kinase inhibition.,http://www.ncbi.nlm.nih.gov/pubmed/17372901
696,7691885,Identification of mutations in the coding sequence of the proto-oncogene c-kit in a human mast cell leukemia cell line causing ligand-independent activation of c-kit product.,http://www.ncbi.nlm.nih.gov/pubmed/7691885
697,20551067,Essential requirement for PP2A inhibition by the oncogenic receptor c-KIT suggests PP2A reactivation as a strategy to treat c-KIT+ cancers.,http://www.ncbi.nlm.nih.gov/pubmed/20551067
698,24456472,"Discovery of AMG 232, a potent, selective, and orally bioavailable MDM2-p53 inhibitor in clinical development.",http://www.ncbi.nlm.nih.gov/pubmed/24456472
699,15858187,A gain-of-function mutation of JAK2 in myeloproliferative disorders.,http://www.ncbi.nlm.nih.gov/pubmed/15858187
700,18166348,Functional characterization of the novel APC N1026S variant associated with attenuated familial adenomatous polyposis.,http://www.ncbi.nlm.nih.gov/pubmed/18166348
701,25193989,High protein expression of EZH2 is related to unfavorable outcome to tamoxifen in metastatic breast cancer.,http://www.ncbi.nlm.nih.gov/pubmed/25193989
702,17525745,Frequent activating FGFR2 mutations in endometrial carcinomas parallel germline mutations associated with craniosynostosis and skeletal dysplasia syndromes.,http://www.ncbi.nlm.nih.gov/pubmed/17525745
703,22850114,A687V EZH2 is a gain-of-function mutation found in lymphoma patients.,http://www.ncbi.nlm.nih.gov/pubmed/22850114
704,1301010,Long-range correlations in nucleotide sequences.,http://www.ncbi.nlm.nih.gov/pubmed/1301010
705,11756186,FLT3 internal tandem duplication mutations associated with human acute myeloid leukemias induce myeloproliferative disease in a murine bone marrow transplant model.,http://www.ncbi.nlm.nih.gov/pubmed/11756186
706,21853109,Frequent alteration of MLL3 frameshift mutations in microsatellite deficient colorectal cancer.,http://www.ncbi.nlm.nih.gov/pubmed/21853109
707,14983014,The BRCA1-associated protein BACH1 is a DNA helicase targeted by clinically relevant inactivating mutations.,http://www.ncbi.nlm.nih.gov/pubmed/14983014
708,20234167,Pancreatic cancer DNMT1 expression and sensitivity to DNMT1 inhibitors.,http://www.ncbi.nlm.nih.gov/pubmed/20234167
709,23410976,EphA3 maintains tumorigenicity and is a therapeutic target in glioblastoma multiforme.,http://www.ncbi.nlm.nih.gov/pubmed/23410976
710,19326470,Distribution of EphA5 receptor protein in the developing and adult mouse nervous system.,http://www.ncbi.nlm.nih.gov/pubmed/19326470
711,17489795,Characterization of tyrosine kinase I domain c-kit gene mutation Asn655Lys newly found in primary jejunal gastrointestinal stromal tumor.,http://www.ncbi.nlm.nih.gov/pubmed/17489795
712,17259998,Juxtamembrane-type c-kit gene mutation found in aggressive systemic mastocytosis induces imatinib-resistant constitutive KIT activation.,http://www.ncbi.nlm.nih.gov/pubmed/17259998
713,16954519,Molecular correlates of imatinib resistance in gastrointestinal stromal tumors.,http://www.ncbi.nlm.nih.gov/pubmed/16954519
714,9797363,A novel gain-of-function mutation of c-kit gene in gastrointestinal stromal tumors.,http://www.ncbi.nlm.nih.gov/pubmed/9797363
715,17371720,"AG-013736, a novel inhibitor of VEGF receptor tyrosine kinases, inhibits breast cancer growth and decreases vascular permeability as detected by dynamic contrast-enhanced magnetic resonance imaging.",http://www.ncbi.nlm.nih.gov/pubmed/17371720
716,24940450,Sorafenib-based therapy in HER2-negative advanced breast cancer: Results from a retrospective pooled analysis of randomized controlled trials.,http://www.ncbi.nlm.nih.gov/pubmed/24940450
717,20682606,A phase II study of pazopanib in patients with recurrent or metastatic invasive breast carcinoma: a trial of the Princess Margaret Hospital phase II consortium.,http://www.ncbi.nlm.nih.gov/pubmed/20682606
718,24604288,"Multicenter phase II study of apatinib, a novel VEGFR inhibitor in heavily pretreated patients with metastatic triple-negative breast cancer.",http://www.ncbi.nlm.nih.gov/pubmed/24604288
719,20978347,Gene therapy using genetically modified lymphocytes targeting VEGFR-2 inhibits the growth of vascularized syngenic tumors in mice.,http://www.ncbi.nlm.nih.gov/pubmed/20978347
720,9243759,Triplet repeat polymorphism in the NOTCH4 gene with the human major histocompatibility complex in a healthy population and patients with a salivary gland tumor in Japan.,http://www.ncbi.nlm.nih.gov/pubmed/9243759
721,15824741,A mutation-created novel intra-exonic pre-mRNA splice site causes constitutive activation of KIT in human gastrointestinal stromal tumors.,http://www.ncbi.nlm.nih.gov/pubmed/15824741
722,9458119,Triplet repeat polymorphism within the NOTCH4 gene located near the junction of the HLA class II and class III regions in narcolepsy.,http://www.ncbi.nlm.nih.gov/pubmed/9458119
723,20713702,Cancer-derived mutations in the regulatory subunit p85alpha of phosphoinositide 3-kinase function through the catalytic subunit p110alpha.,http://www.ncbi.nlm.nih.gov/pubmed/20713702
724,10090408,Comparative significance of p53 and WAF/1-p21 expression on the efficacy of adjuvant chemotherapy for resectable invasive ductal carcinoma of the pancreas.,http://www.ncbi.nlm.nih.gov/pubmed/10090408
725,24091768,"AMG 900, pan-Aurora kinase inhibitor, preferentially inhibits the proliferation of breast cancer cell lines with dysfunctional p53.",http://www.ncbi.nlm.nih.gov/pubmed/24091768
726,12918066,Deletion of Trp-557 and Lys-558 in the juxtamembrane domain of the c-kit protooncogene is associated with metastatic behavior of gastrointestinal stromal tumors.,http://www.ncbi.nlm.nih.gov/pubmed/12918066
727,23990115,"AMG 900, a small-molecule inhibitor of aurora kinases, potentiates the activity of microtubule-targeting agents in human metastatic breast cancer models.",http://www.ncbi.nlm.nih.gov/pubmed/23990115
728,15897563,Analysis of KIT mutations in sporadic and familial gastrointestinal stromal tumors: therapeutic implications through protein modeling.,http://www.ncbi.nlm.nih.gov/pubmed/15897563
729,,"LY2801653, an orally available small molecule inhibitor of c-Met, demonstrated broad antitumor efficacy in patient derived xenograft models",http://cancerres.aacrjournals.org/cgi/content/meeting_abstract/70/8_MeetingAbstracts/3611
730,11206059,Stability and peptide binding specificity of Btk SH2 domain: molecular basis for X-linked agammaglobulinemia.,http://www.ncbi.nlm.nih.gov/pubmed/11206059
731,8164701,Brief report: a point mutation in the SH2 domain of Bruton's tyrosine kinase in atypical X-linked agammaglobulinemia.,http://www.ncbi.nlm.nih.gov/pubmed/8164701
732,8885720,X-linked agammaglobulinemia (XLA): a genetic tyrosine kinase (Btk) disease.,http://www.ncbi.nlm.nih.gov/pubmed/8885720
733,16951917,Four novel and three recurrent mutations of the BTK gene and pathogenic effects of putative splice mutations.,http://www.ncbi.nlm.nih.gov/pubmed/16951917
734,9268346,A comparative analysis of the phosphoinositide binding specificity of pleckstrin homology domains.,http://www.ncbi.nlm.nih.gov/pubmed/9268346
735,9391111,Phosphatidylinositol 3-kinase-gamma activates Bruton's tyrosine kinase in concert with Src family kinases.,http://www.ncbi.nlm.nih.gov/pubmed/9391111
736,20607586,Cediranib in combination with various anticancer regimens: results of a phase I multi-cohort study.,http://www.ncbi.nlm.nih.gov/pubmed/20607586
737,18768809,Inhibition of the mTORC1 pathway suppresses intestinal polyp formation and reduces mortality in ApcDelta716 mice.,http://www.ncbi.nlm.nih.gov/pubmed/18768809
738,20080688,Development of a mouse model for sporadic and metastatic colon tumors and its use in assessing drug treatment.,http://www.ncbi.nlm.nih.gov/pubmed/20080688
739,25193991,"Phase I/IIa study evaluating the safety, efficacy, pharmacokinetics, and pharmacodynamics of lucitanib in advanced solid tumors.",http://www.ncbi.nlm.nih.gov/pubmed/25193991
740,22399804,The microtubule poison vinorelbine kills cells independently of mitotic arrest and targets cells lacking the APC tumour suppressor more effectively.,http://www.ncbi.nlm.nih.gov/pubmed/22399804
741,23657946,Fibroblast growth factor receptor 3 is a rational therapeutic target in bladder cancer.,http://www.ncbi.nlm.nih.gov/pubmed/23657946
742,19381019,Antibody-based targeting of FGFR3 in bladder carcinoma and t(4;14)-positive multiple myeloma in mice.,http://www.ncbi.nlm.nih.gov/pubmed/19381019
743,,"Preliminary results from a phase Ib/II, open-label, dose-escalation study of the oral BRAF inhibitor LGX818 in combination with the oral MEK1/2 inhibitor MEK162 in BRAF V600-dependent advanced solid tumors.",
744,23406027,Selumetinib-enhanced radioiodine uptake in advanced thyroid cancer.,http://www.ncbi.nlm.nih.gov/pubmed/23406027
745,20811697,Effects of vandetanib on adenoma formation in a dextran sodium sulphate enhanced Apc(MIN/+) mouse model.,http://www.ncbi.nlm.nih.gov/pubmed/20811697
746,16841094,Mosaicism of activating FGFR3 mutations in human skin causes epidermal nevi.,http://www.ncbi.nlm.nih.gov/pubmed/16841094
747,22351438,"Differential induction of apoptosis in human breast cancer cell lines by phenethyl isothiocyanate, a glutathione depleting agent.",http://www.ncbi.nlm.nih.gov/pubmed/22351438
748,24486569,"PM060184, a new tubulin binding agent with potent antitumor activity including P-glycoprotein over-expressing tumors.",http://www.ncbi.nlm.nih.gov/pubmed/24486569
749,12124172,"CT53518, a novel selective FLT3 antagonist for the treatment of acute myelogenous leukemia (AML).",http://www.ncbi.nlm.nih.gov/pubmed/12124172
750,20615965,The Bruton tyrosine kinase inhibitor PCI-32765 blocks B-cell activation and is efficacious in models of autoimmune disease and B-cell malignancy.,http://www.ncbi.nlm.nih.gov/pubmed/20615965
751,21422473,Bruton tyrosine kinase represents a promising therapeutic target for treatment of chronic lymphocytic leukemia and is effectively targeted by PCI-32765.,http://www.ncbi.nlm.nih.gov/pubmed/21422473
752,24154688,JAK1 truncating mutations in gynecologic cancer define new role of cancer-associated protein tyrosine kinase aberrations.,http://www.ncbi.nlm.nih.gov/pubmed/24154688
753,24166501,Aurora-A is a determinant of tamoxifen sensitivity through phosphorylation of ERα in breast cancer.,http://www.ncbi.nlm.nih.gov/pubmed/24166501
754,23658459,Targeting FGFR with dovitinib (TKI258): preclinical and clinical data in breast cancer.,http://www.ncbi.nlm.nih.gov/pubmed/23658459
755,21199802,Novel synthetic antagonists of canonical Wnt signaling inhibit colorectal cancer cell growth.,http://www.ncbi.nlm.nih.gov/pubmed/21199802
756,19378335,Selective inhibition of proliferation in colorectal carcinoma cell lines expressing mutant APC or activated B-Raf.,http://www.ncbi.nlm.nih.gov/pubmed/19378335
757,9067281,"LY231514, a pyrrolo[2,3-d]pyrimidine-based antifolate that inhibits multiple folate-requiring enzymes.",http://www.ncbi.nlm.nih.gov/pubmed/9067281
758,17553957,Inhibition of VEGF-A prevents the angiogenic switch and results in increased survival of Apc+/min mice.,http://www.ncbi.nlm.nih.gov/pubmed/17553957
759,15542782,Specific inhibition of cyclin-dependent kinase 4/6 by PD 0332991 and associated antitumor activity in human tumor xenografts.,http://www.ncbi.nlm.nih.gov/pubmed/15542782
760,19206169,"Germline BRAF mutations in Noonan, LEOPARD, and cardiofaciocutaneous syndromes: molecular diversity and associated phenotypic spectrum.",http://www.ncbi.nlm.nih.gov/pubmed/19206169
761,,NCCN Guidelines Version 2.2014 Prostate Cancer,
762,19956657,The specificity of the FOXL2 c.402C>G somatic mutation: a survey of solid tumors.,http://www.ncbi.nlm.nih.gov/pubmed/19956657
763,23842682,An F876L mutation in androgen receptor confers genetic and phenotypic resistance to MDV3100 (enzalutamide).,http://www.ncbi.nlm.nih.gov/pubmed/23842682
764,23708653,Targeting cell cycle and hormone receptor pathways in cancer.,http://www.ncbi.nlm.nih.gov/pubmed/23708653
765,24916770,"A phase I clinical trial of navitoclax, a targeted high-affinity Bcl-2 family inhibitor, in combination with gemcitabine in patients with solid tumors.",http://www.ncbi.nlm.nih.gov/pubmed/24916770
766,23259599,ABT-737 reverses the acquired radioresistance of breast cancer cells by targeting Bcl-2 and Bcl-xL.,http://www.ncbi.nlm.nih.gov/pubmed/23259599
767,21760983,Small molecule inhibitors of bcl-2 family proteins for pancreatic cancer therapy.,http://www.ncbi.nlm.nih.gov/pubmed/21760983
768,21135055,An aCGH classifier derived from BRCA1-mutated breast cancer and benefit of high-dose platinum-based chemotherapy in HER2-negative breast cancer patients.,http://www.ncbi.nlm.nih.gov/pubmed/21135055
769,18649131,Response to neoadjuvant therapy with cisplatin in BRCA1-positive breast cancer patients.,http://www.ncbi.nlm.nih.gov/pubmed/18649131
770,20609467,Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and advanced breast cancer: a proof-of-concept trial.,http://www.ncbi.nlm.nih.gov/pubmed/20609467
771,22406760,BRCA1/2 mutations and expression: response to platinum chemotherapy in patients with advanced stage epithelial ovarian cancer.,http://www.ncbi.nlm.nih.gov/pubmed/22406760
772,24141786,Combined PKC and MEK inhibition in uveal melanoma with GNAQ and GNA11 mutations.,http://www.ncbi.nlm.nih.gov/pubmed/24141786
773,16879967,Emerging roles of pseudokinases.,http://www.ncbi.nlm.nih.gov/pubmed/16879967
774,12351625,The pseudokinase domain is required for suppression of basal activity of Jak2 and Jak3 tyrosine kinases and for cytokine-inducible activation of signal transduction.,http://www.ncbi.nlm.nih.gov/pubmed/12351625
775,17373727,Effects of steroidal and non-steroidal antiandrogens on wild-type and mutant androgen receptors.,http://www.ncbi.nlm.nih.gov/pubmed/17373727
776,9815822,Functional characterization of mutant androgen receptors from androgen-independent prostate cancer.,http://www.ncbi.nlm.nih.gov/pubmed/9815822
777,10363963,Selection for androgen receptor mutations in prostate cancers treated with androgen antagonist.,http://www.ncbi.nlm.nih.gov/pubmed/10363963
778,24874833,Galeterone prevents androgen receptor binding to chromatin and enhances degradation of mutant androgen receptor.,http://www.ncbi.nlm.nih.gov/pubmed/24874833
779,19462533,Dissection of the sequence-specific DNA binding and exonuclease activities reveals a superactive yet apoptotically impaired mutant p53 protein.,http://www.ncbi.nlm.nih.gov/pubmed/19462533
780,25156567,CDK4/6 inhibitors have potent activity in combination with pathway selective therapeutic agents in models of pancreatic cancer.,http://www.ncbi.nlm.nih.gov/pubmed/25156567
781,24980948,Translational exposure-efficacy modeling to optimize the dose and schedule of taxanes combined with the investigational Aurora A kinase inhibitor MLN8237 (alisertib).,http://www.ncbi.nlm.nih.gov/pubmed/24980948
782,23270924,The tyrosine kinase inhibitor E-3810 combined with paclitaxel inhibits the growth of advanced-stage triple-negative breast cancer xenografts.,http://www.ncbi.nlm.nih.gov/pubmed/23270924
783,10196129,"Structure of the PH domain from Bruton's tyrosine kinase in complex with inositol 1,3,4,5-tetrakisphosphate.",http://www.ncbi.nlm.nih.gov/pubmed/10196129
784,8898377,A novel mutation (Cys145-->Stop) in Bruton's tyrosine kinase is associated with newly diagnosed X-linked agammaglobulinemia in a 51-year-old male.,http://www.ncbi.nlm.nih.gov/pubmed/8898377
785,10785355,Mitogen-activated protein kinase kinase 4 (MKK4).,http://www.ncbi.nlm.nih.gov/pubmed/10785355
786,,P1-17-10: Cabozantinib (XL184) in Patients with Metastatic Breast Cancer: Results from a Phase 2 Randomized Discontinuation Trial.,http://cancerres.aacrjournals.org/cgi/content/meeting_abstract/71/24_MeetingAbstracts/P1-17-10
787,9486400,Bruton's tyrosine kinase expression and activity in X-linked agammaglobulinaemia (XLA): the use of protein analysis as a diagnostic indicator of XLA.,http://www.ncbi.nlm.nih.gov/pubmed/9486400
788,7657668,An SH3-binding site conserved in Bruton's tyrosine kinase and related tyrosine kinases mediates specific protein interactions in vitro and in vivo.,http://www.ncbi.nlm.nih.gov/pubmed/7657668
789,11877742,Interaction between Btk TH and SH3 domain.,http://www.ncbi.nlm.nih.gov/pubmed/11877742
790,8629002,Activation of BTK by a phosphorylation mechanism initiated by SRC family kinases.,http://www.ncbi.nlm.nih.gov/pubmed/8629002
791,24403446,NOTCH4 is a potential therapeutic target for triple-negative breast cancer.,http://www.ncbi.nlm.nih.gov/pubmed/24403446
792,25054037,Investigation of neurotrophic tyrosine kinase receptor 1 fusions and neurotrophic tyrosine kinase receptor family expression in non-small-cell lung cancer and sensitivity to AZD7451 in vitro.,http://www.ncbi.nlm.nih.gov/pubmed/25054037
793,8630736,Regulation of Btk function by a major autophosphorylation site within the SH3 domain.,http://www.ncbi.nlm.nih.gov/pubmed/8630736
794,9012831,"BAP-135, a target for Bruton's tyrosine kinase in response to B cell receptor engagement.",http://www.ncbi.nlm.nih.gov/pubmed/9012831
795,9524119,"Phosphatidylinositol-3,4,5-trisphosphate (PtdIns-3,4,5-P3)/Tec kinase-dependent calcium signaling pathway: a target for SHIP-mediated inhibitory signals.",http://www.ncbi.nlm.nih.gov/pubmed/9524119
796,17932028,Signaling by Toll-like receptors 8 and 9 requires Bruton's tyrosine kinase.,http://www.ncbi.nlm.nih.gov/pubmed/17932028
797,15849198,Bruton's tyrosine kinase is involved in p65-mediated transactivation and phosphorylation of p65 on serine 536 during NFkappaB activation by lipopolysaccharide.,http://www.ncbi.nlm.nih.gov/pubmed/15849198
798,7538439,Activation of Bruton's tyrosine kinase (BTK) by a point mutation in its pleckstrin homology (PH) domain.,http://www.ncbi.nlm.nih.gov/pubmed/7538439
799,9525870,The cancer-predisposing mutation C61G disrupts homodimer formation in the NH2-terminal BRCA1 RING finger domain.,http://www.ncbi.nlm.nih.gov/pubmed/9525870
800,20949621,Germline KRAS mutations cause aberrant biochemical and physical properties leading to developmental disorders.,http://www.ncbi.nlm.nih.gov/pubmed/20949621
801,19855393,Activating mutations in FGFR3 and HRAS reveal a shared genetic origin for congenital disorders and testicular tumors.,http://www.ncbi.nlm.nih.gov/pubmed/19855393
802,7554468,"Structural basis for X-linked agammaglobulinemia (XLA): mutations at interacting Btk residues R562, W563, and A582.",http://www.ncbi.nlm.nih.gov/pubmed/7554468
803,11527964,Crystal structure of Bruton's tyrosine kinase domain suggests a novel pathway for activation and provides insights into the molecular basis of X-linked agammaglobulinemia.,http://www.ncbi.nlm.nih.gov/pubmed/11527964
804,12727838,Overexpression of high mobility group box 1 in gastrointestinal stromal tumors with KIT mutation.,http://www.ncbi.nlm.nih.gov/pubmed/12727838
805,19874578,"PD 0332991, a selective cyclin D kinase 4/6 inhibitor, preferentially inhibits proliferation of luminal estrogen receptor-positive human breast cancer cell lines in vitro.",http://www.ncbi.nlm.nih.gov/pubmed/19874578
806,16159644,A genotype-phenotype correlation study in a group of 54 patients with X-linked agammaglobulinemia.,http://www.ncbi.nlm.nih.gov/pubmed/16159644
807,21760703,TP53 status and response to treatment in breast cancers.,http://www.ncbi.nlm.nih.gov/pubmed/21760703
808,10754312,Six X-linked agammaglobulinemia-causing missense mutations in the Src homology 2 domain of Bruton's tyrosine kinase: phosphotyrosine-binding and circular dichroism analysis.,http://www.ncbi.nlm.nih.gov/pubmed/10754312
809,16291652,Mutational analysis of the SH2-kinase linker region of Bruton's tyrosine kinase defines alternative modes of regulation for cytoplasmic tyrosine kinase families.,http://www.ncbi.nlm.nih.gov/pubmed/16291652
810,10373551,Regulation of nuclear localization and transcriptional activity of TFII-I by Bruton's tyrosine kinase.,http://www.ncbi.nlm.nih.gov/pubmed/10373551
811,11726500,Wide spectrum of tumors in knock-in mice carrying a Cdk4 protein insensitive to INK4 inhibitors.,http://www.ncbi.nlm.nih.gov/pubmed/11726500
812,24692729,Pediatric patients with refractory central nervous system tumors: experiences of a clinical trial combining bevacizumab and temsirolimus.,http://www.ncbi.nlm.nih.gov/pubmed/24692729
813,23536435,"Phase I trial, pharmacokinetics, and pharmacodynamics of vandetanib and dasatinib in children with newly diagnosed diffuse intrinsic pontine glioma.",http://www.ncbi.nlm.nih.gov/pubmed/23536435
814,25123598,RIST: a potent new combination therapy for glioblastoma.,http://www.ncbi.nlm.nih.gov/pubmed/25123598
815,23857966,Phase I pharmacokinetic and pharmacodynamic study of pazopanib in children with soft tissue sarcoma and other refractory solid tumors: a children's oncology group phase I consortium report.,http://www.ncbi.nlm.nih.gov/pubmed/23857966
816,24305702,Targeting Wee1 for the treatment of pediatric high-grade gliomas.,http://www.ncbi.nlm.nih.gov/pubmed/24305702
817,9168133,Gene organization of human NOTCH4 and (CTG)n polymorphism in this human counterpart gene of mouse proto-oncogene Int3.,http://www.ncbi.nlm.nih.gov/pubmed/9168133
818,18362173,Somatically acquired JAK1 mutations in adult acute lymphoblastic leukemia.,http://www.ncbi.nlm.nih.gov/pubmed/18362173
819,19139102,Acute lymphoblastic leukemia-associated JAK1 mutants activate the Janus kinase/STAT pathway via interleukin-9 receptor alpha homodimers.,http://www.ncbi.nlm.nih.gov/pubmed/19139102
820,25043171,The future of JAK inhibition in myelofibrosis and beyond.,http://www.ncbi.nlm.nih.gov/pubmed/25043171
821,22705984,Janus kinase 3-activating mutations identified in natural killer/T-cell lymphoma.,http://www.ncbi.nlm.nih.gov/pubmed/22705984
822,24874286,Combination of gefitinib and DNA methylation inhibitor decitabine exerts synergistic anti-cancer activity in colon cancer cells.,http://www.ncbi.nlm.nih.gov/pubmed/24874286
823,19417133,A new class of quinoline-based DNA hypomethylating agents reactivates tumor suppressor genes by blocking DNA methyltransferase 1 activity and inducing its degradation.,http://www.ncbi.nlm.nih.gov/pubmed/19417133
824,23319303,Proteomic analysis of novel targets associated with TrkA-mediated tyrosine phosphorylation signaling pathways in SK-N-MC neuroblastoma cells.,http://www.ncbi.nlm.nih.gov/pubmed/23319303
825,19726763,Inhibition of the hedgehog pathway in advanced basal-cell carcinoma.,http://www.ncbi.nlm.nih.gov/pubmed/19726763
826,24293458,Inhibition of BET bromodomain proteins as a therapeutic approach in prostate cancer.,http://www.ncbi.nlm.nih.gov/pubmed/24293458
827,24335499,Potent antimyeloma activity of the novel bromodomain inhibitors I-BET151 and I-BET762.,http://www.ncbi.nlm.nih.gov/pubmed/24335499
828,24045179,Dual CDK4/CDK6 inhibition induces cell-cycle arrest and senescence in neuroblastoma.,http://www.ncbi.nlm.nih.gov/pubmed/24045179
829,11095964,A novel activating mutation of the K-ras gene in human primary colon adenocarcinoma.,http://www.ncbi.nlm.nih.gov/pubmed/11095964
830,17875937,Biochemical and functional characterization of germ line KRAS mutations.,http://www.ncbi.nlm.nih.gov/pubmed/17875937
831,19638505,"MEK4 function, genistein treatment, and invasion of human prostate cancer cells.",http://www.ncbi.nlm.nih.gov/pubmed/19638505
832,17577251,"Up-regulation of MKK4, MKK6 and MKK7 during prostate cancer progression: an important role for SAPK signalling in prostatic neoplasia.",http://www.ncbi.nlm.nih.gov/pubmed/17577251
833,18948577,"SNX-2112, a selective Hsp90 inhibitor, potently inhibits tumor cell growth, angiogenesis, and osteoclastogenesis in multiple myeloma and other hematologic tumors by abrogating signaling via Akt and ERK.",http://www.ncbi.nlm.nih.gov/pubmed/18948577
834,21349995,A novel HSP90 inhibitor delays castrate-resistant prostate cancer without altering serum PSA levels and inhibits osteoclastogenesis.,http://www.ncbi.nlm.nih.gov/pubmed/21349995
835,24967612,Discovery of a small molecule MDM2 inhibitor (AMG 232) for treating cancer.,http://www.ncbi.nlm.nih.gov/pubmed/24967612
836,17541402,"TG101209, a small molecule JAK2-selective kinase inhibitor potently inhibits myeloproliferative disorder-associated JAK2V617F and MPLW515L/K mutations.",http://www.ncbi.nlm.nih.gov/pubmed/17541402
837,18354492,"TG101348, a JAK2-selective antagonist, inhibits primary hematopoietic cells derived from myeloproliferative disorder patients with JAK2V617F, MPLW515K or JAK2 exon 12 mutations as well as mutation negative patients.",http://www.ncbi.nlm.nih.gov/pubmed/18354492
838,21725052,"Safety and efficacy of everolimus, a mTOR inhibitor, as single agent in a phase 1/2 study in patients with myelofibrosis.",http://www.ncbi.nlm.nih.gov/pubmed/21725052
839,23748344,AKT is a therapeutic target in myeloproliferative neoplasms.,http://www.ncbi.nlm.nih.gov/pubmed/23748344
840,16474405,Germline KRAS mutations cause Noonan syndrome.,http://www.ncbi.nlm.nih.gov/pubmed/16474405
841,20147967,Activating K-Ras mutations outwith 'hotspot' codons in sporadic colorectal tumours - implications for personalised cancer medicine.,http://www.ncbi.nlm.nih.gov/pubmed/20147967
842,22302539,Characterization of a novel KRAS mutation identified in Noonan syndrome.,http://www.ncbi.nlm.nih.gov/pubmed/22302539
843,20570890,Genomic and biological characterization of exon 4 KRAS mutations in human cancer.,http://www.ncbi.nlm.nih.gov/pubmed/20570890
844,22139128,Biological mechanism and clinical effect of protein-bound polysaccharide K (KRESTIN(®)): review of development and future perspectives.,http://www.ncbi.nlm.nih.gov/pubmed/22139128
845,19098899,Bead-based profiling of tyrosine kinase phosphorylation identifies SRC as a potential target for glioblastoma therapy.,http://www.ncbi.nlm.nih.gov/pubmed/19098899
846,17290220,The deubiquitinating enzyme USP2a regulates the p53 pathway by targeting Mdm2.,http://www.ncbi.nlm.nih.gov/pubmed/17290220
847,9131587,A genetic approach to mapping the p53 binding site in the MDM2 protein.,http://www.ncbi.nlm.nih.gov/pubmed/9131587
848,23653682,In vitro selection of mutant HDM2 resistant to Nutlin inhibition.,http://www.ncbi.nlm.nih.gov/pubmed/23653682
849,12552135,Flexible lid to the p53-binding domain of human Mdm2: implications for p53 regulation.,http://www.ncbi.nlm.nih.gov/pubmed/12552135
850,20303977,The effects of phosphomimetic lid mutation on the thermostability of the N-terminal domain of MDM2.,http://www.ncbi.nlm.nih.gov/pubmed/20303977
851,19568783,Regulation of the E3 ubiquitin ligase activity of MDM2 by an N-terminal pseudo-substrate motif.,http://www.ncbi.nlm.nih.gov/pubmed/19568783
852,14707282,"MDM2, an introduction.",http://www.ncbi.nlm.nih.gov/pubmed/14707282
853,18006825,Metformin inhibits mammalian target of rapamycin-dependent translation initiation in breast cancer cells.,http://www.ncbi.nlm.nih.gov/pubmed/18006825
854,17062558,Metformin is an AMP kinase-dependent growth inhibitor for breast cancer cells.,http://www.ncbi.nlm.nih.gov/pubmed/17062558
855,17116689,Cancer-associated mutations in the MDM2 zinc finger domain disrupt ribosomal protein interaction and attenuate MDM2-induced p53 degradation.,http://www.ncbi.nlm.nih.gov/pubmed/17116689
856,18769110,Targeted therapy for the loss of von Hippel-Lindau in renal cell carcinoma: a novel molecule that induces autophagic cell death.,http://www.ncbi.nlm.nih.gov/pubmed/18769110
857,18598947,A molecule targeting VHL-deficient renal cell carcinoma that induces autophagy.,http://www.ncbi.nlm.nih.gov/pubmed/18598947
858,21903592,Hydrophilic residues are crucial for ribosomal protein L11 (RPL11) interaction with zinc finger domain of MDM2 and p53 protein activation.,http://www.ncbi.nlm.nih.gov/pubmed/21903592
859,23291630,"ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing platelets.",http://www.ncbi.nlm.nih.gov/pubmed/23291630
860,17548806,Pivotal Advance: Inhibition of MyD88 dimerization and recruitment of IRAK1 and IRAK4 by a novel peptidomimetic compound.,http://www.ncbi.nlm.nih.gov/pubmed/17548806
861,,Emerging targets in human lymphoma: targeting the MYD88 mutation,
862,24864047,Transient MEK inhibitor-associated retinopathy in metastatic melanoma.,http://www.ncbi.nlm.nih.gov/pubmed/24864047
863,24204195,Allosteric MEK1/2 inhibitor refametinib (BAY 86-9766) in combination with sorafenib exhibits antitumor activity in preclinical murine and rat models of hepatocellular carcinoma.,http://www.ncbi.nlm.nih.gov/pubmed/24204195
864,19143567,"Fragment-based discovery of the pyrazol-4-yl urea (AT9283), a multitargeted kinase inhibitor with potent aurora kinase activity.",http://www.ncbi.nlm.nih.gov/pubmed/19143567
865,20072840,Danusertib (formerly PHA-739358)--a novel combined pan-Aurora kinases and third generation Bcr-Abl tyrosine kinase inhibitor.,http://www.ncbi.nlm.nih.gov/pubmed/20072840
866,19609559,Preclinical characterization of Aurora kinase inhibitor R763/AS703569 identified through an image-based phenotypic screen.,http://www.ncbi.nlm.nih.gov/pubmed/19609559
867,23358665,"Biological characterization of TAK-901, an investigational, novel, multitargeted Aurora B kinase inhibitor.",http://www.ncbi.nlm.nih.gov/pubmed/23358665
868,20354118,"PF-03814735, an orally bioavailable small molecule aurora kinase inhibitor for cancer therapy.",http://www.ncbi.nlm.nih.gov/pubmed/20354118
869,18678489,Discovery of a potent and selective aurora kinase inhibitor.,http://www.ncbi.nlm.nih.gov/pubmed/18678489
870,22242939,Cancer somatic mutations disrupt functions of the EphA3 receptor tyrosine kinase through multiple mechanisms.,http://www.ncbi.nlm.nih.gov/pubmed/22242939
871,22829656,Effects of cancer-associated EPHA3 mutations on lung cancer.,http://www.ncbi.nlm.nih.gov/pubmed/22829656
872,23002168,"FGFR genetic alterations predict for sensitivity to NVP-BGJ398, a selective pan-FGFR inhibitor.",http://www.ncbi.nlm.nih.gov/pubmed/23002168
873,,"Phase 1 study of JNJ-42756493, a pan-fibroblast growth factor receptor (FGFR) inhibitor, in patients with advanced solid tumors.",http://meetinglibrary.asco.org/content/126428-144
874,19887545,Small-molecule inhibition of Wee1 kinase by MK-1775 selectively sensitizes p53-deficient tumor cells to DNA-damaging agents.,http://www.ncbi.nlm.nih.gov/pubmed/19887545
875,18723486,"Breaching the DNA damage checkpoint via PF-00477736, a novel small-molecule inhibitor of checkpoint kinase 1.",http://www.ncbi.nlm.nih.gov/pubmed/18723486
876,,Use of combination treatment with the investigational RAF kinase inhibitor MLN2480 and the investigational MEK kinase inhibitor TAK-733 on the growth of BRAF-mutant and RAS-mutant preclinical models of melanoma and CRC.,http://meetinglibrary.asco.org/content/114757-132
877,19706763,"RDEA119/BAY 869766: a potent, selective, allosteric inhibitor of MEK1/2 for the treatment of cancer.",http://www.ncbi.nlm.nih.gov/pubmed/19706763
878,24231268,BET bromodomain protein inhibition is a therapeutic option for medulloblastoma.,http://www.ncbi.nlm.nih.gov/pubmed/24231268
879,19707204,MI-63: a novel small-molecule inhibitor targets MDM2 and induces apoptosis in embryonal and alveolar rhabdomyosarcoma cells with wild-type p53.,http://www.ncbi.nlm.nih.gov/pubmed/19707204
880,24934408,Synthetic lethality in ATM-deficient RAD50-mutant tumors underlies outlier response to cancer therapy.,http://www.ncbi.nlm.nih.gov/pubmed/24934408
881,23558173,Targeted inhibition of mutant IDH2 in leukemia cells induces cellular differentiation.,http://www.ncbi.nlm.nih.gov/pubmed/23558173
882,,,http://cancerres.aacrjournals.org/content/73/8_Supplement/919.abstract
883,,,http://cancerres.aacrjournals.org/cgi/content/meeting_abstract/71/8_MeetingAbstracts/2819?si
884,24097868,"Ang-2-VEGF-A CrossMab, a novel bispecific human IgG1 antibody blocking VEGF-A and Ang-2 functions simultaneously, mediates potent antitumor, antiangiogenic, and antimetastatic efficacy.",http://www.ncbi.nlm.nih.gov/pubmed/24097868
885,19726788,Smoothened mutation confers resistance to a Hedgehog pathway inhibitor in medulloblastoma.,http://www.ncbi.nlm.nih.gov/pubmed/19726788
886,19443052,Mechanisms of Hedgehog pathway activation in cancer and implications for therapy.,http://www.ncbi.nlm.nih.gov/pubmed/19443052
887,21425998,Discovery of OSI-906: a selective and orally efficacious dual inhibitor of the IGF-1 receptor and insulin receptor.,http://www.ncbi.nlm.nih.gov/pubmed/21425998
888,9228064,Identification of CDK4 sequences involved in cyclin D1 and p16 binding.,http://www.ncbi.nlm.nih.gov/pubmed/9228064
889,23952683,Insight into crizotinib resistance mechanisms caused by three mutations in ALK tyrosine kinase using free energy calculation approaches.,http://www.ncbi.nlm.nih.gov/pubmed/23952683
890,22659414,A molecular dynamics investigation on the crizotinib resistance mechanism of C1156Y mutation in ALK.,http://www.ncbi.nlm.nih.gov/pubmed/22659414
891,,"A phase I study of S-222611 an oral reversible dual inhibitor of EGFR and HER2, in patients with solid tumors.",http://meetinglibrary.asco.org/content/93825-114
892,24691421,Impact of HER2 copy number in IHC2+/FISH-amplified breast cancer on outcome of adjuvant trastuzumab treatment in a large UK cancer network.,http://www.ncbi.nlm.nih.gov/pubmed/24691421
893,20728210,"Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial.",http://www.ncbi.nlm.nih.gov/pubmed/20728210
894,24998779,PALB2: the hub of a network of tumor suppressors involved in DNA damage responses.,http://www.ncbi.nlm.nih.gov/pubmed/24998779
895,25135369,Breast cancer: PALB2--a new player in hereditary breast cancer.,http://www.ncbi.nlm.nih.gov/pubmed/25135369
896,21035407,"Mre11-Rad50-Nbs1 conformations and the control of sensing, signaling, and effector responses at DNA double-strand breaks.",http://www.ncbi.nlm.nih.gov/pubmed/21035407
897,22240200,"TET2, a tumor suppressor in hematological disorders.",http://www.ncbi.nlm.nih.gov/pubmed/22240200
898,21992793,Targeting radiation-induced G(2) checkpoint activation with the Wee-1 inhibitor MK-1775 in glioblastoma cell lines.,http://www.ncbi.nlm.nih.gov/pubmed/21992793
899,24716986,Efficacy and safety of selumetinib compared with current therapies for advanced cancer: a meta-analysis.,http://www.ncbi.nlm.nih.gov/pubmed/24716986
900,,"NEMO: A PHASE 3 TRIALOF BINIMETINIB (MEK162)
VERSUS DACARBAZINE IN PATIENTS WITH ADVANCED
NRAS-MUTANT MELANOMAWHOARE UNTREATED OR
HAVE PROGRESSED AFTER ANY NUMBER OF
IMMUNOTHERAPY REGIMENS",http://annonc.oxfordjournals.org/content/25/suppl_4/iv392.1.full.pdf
901,23724914,Acquired resistance to crizotinib from a mutation in CD74-ROS1.,http://www.ncbi.nlm.nih.gov/pubmed/23724914
902,25033171,P-loop conformation governed crizotinib resistance in G2032R-mutated ROS1 tyrosine kinase: clues from free energy landscape.,http://www.ncbi.nlm.nih.gov/pubmed/25033171
903,23454836,Rapamycin extends life span of Rb1+/- mice by inhibiting neuroendocrine tumors.,http://www.ncbi.nlm.nih.gov/pubmed/23454836
904,21468343,Advanced retinoblastoma treatment: targeting hypoxia by inhibition of the mammalian target of rapamycin (mTOR) in LH(BETA)T(AG) retinal tumors.,http://www.ncbi.nlm.nih.gov/pubmed/21468343
905,1689463,Retinoblastoma in transgenic mice.,http://www.ncbi.nlm.nih.gov/pubmed/1689463
906,24013208,Structure of a pseudokinase-domain switch that controls oncogenic activation of Jak kinases.,http://www.ncbi.nlm.nih.gov/pubmed/24013208
907,24348920,Attenuation of eph receptor kinase activation in cancer cells by coexpressed ephrin ligands.,http://www.ncbi.nlm.nih.gov/pubmed/24348920
908,21393331,Oncogenic JAK1 and JAK2-activating mutations resistant to ATP-competitive inhibitors.,http://www.ncbi.nlm.nih.gov/pubmed/21393331
909,19936769,Activating mutations of the GNAQ gene: a frequent event in primary melanocytic neoplasms of the central nervous system.,http://www.ncbi.nlm.nih.gov/pubmed/19936769
910,23324396,"A high-content cellular senescence screen identifies candidate tumor suppressors, including EPHA3.",http://www.ncbi.nlm.nih.gov/pubmed/23324396
911,22007748,Investigational Notch and Hedgehog inhibitors--therapies for cardiovascular disease.,http://www.ncbi.nlm.nih.gov/pubmed/22007748
912,20979473,EML4-ALK mutations in lung cancer that confer resistance to ALK inhibitors.,http://www.ncbi.nlm.nih.gov/pubmed/20979473
913,25175806,Drugging MYCN through an allosteric transition in Aurora kinase A.,http://www.ncbi.nlm.nih.gov/pubmed/25175806
914,23430699,Targeting MYCN in neuroblastoma by BET bromodomain inhibition.,http://www.ncbi.nlm.nih.gov/pubmed/23430699
915,20565112,"Imidazo[4,5-b]pyridine derivatives as inhibitors of Aurora kinases: lead optimization studies toward the identification of an orally bioavailable preclinical development candidate.",http://www.ncbi.nlm.nih.gov/pubmed/20565112
916,21885865,The aurora kinase inhibitor CCT137690 downregulates MYCN and sensitizes MYCN-amplified neuroblastoma in vivo.,http://www.ncbi.nlm.nih.gov/pubmed/21885865
917,22753594,Genetically defined subsets of human pancreatic cancer show unique in vitro chemosensitivity.,http://www.ncbi.nlm.nih.gov/pubmed/22753594
918,21791641,A novel ALK secondary mutation and EGFR signaling cause resistance to ALK kinase inhibitors.,http://www.ncbi.nlm.nih.gov/pubmed/21791641
919,25263539,Initial testing (stage 1) of the PARP inhibitor BMN 673 by the pediatric preclinical testing program: PALB2 mutation predicts exceptional in vivo response to BMN 673.,http://www.ncbi.nlm.nih.gov/pubmed/25263539
920,19074898,Mutational inactivation of PTPRD in glioblastoma multiforme and malignant melanoma.,http://www.ncbi.nlm.nih.gov/pubmed/19074898
921,8674031,Flavopiridol induces G1 arrest with inhibition of cyclin-dependent kinase (CDK) 2 and CDK4 in human breast carcinoma cells.,http://www.ncbi.nlm.nih.gov/pubmed/8674031
922,12165651,The cell cycle as a target for cancer therapy: basic and clinical findings with the small molecule inhibitors flavopiridol and UCN-01.,http://www.ncbi.nlm.nih.gov/pubmed/12165651
923,18223228,Rhabdoid tumor growth is inhibited by flavopiridol.,http://www.ncbi.nlm.nih.gov/pubmed/18223228
924,22624716,ATM phosphorylation of Mdm2 Ser394 regulates the amplitude and duration of the DNA damage response in mice.,http://www.ncbi.nlm.nih.gov/pubmed/22624716
925,22624708,What a difference a phosphate makes: life or death decided by a single amino acid in MDM2.,http://www.ncbi.nlm.nih.gov/pubmed/22624708
926,11053450,Characterization of tumor-associated Chk2 mutations.,http://www.ncbi.nlm.nih.gov/pubmed/11053450
927,12049740,Structural and functional versatility of the FHA domain in DNA-damage signaling by the tumor suppressor kinase Chk2.,http://www.ncbi.nlm.nih.gov/pubmed/12049740
928,19591900,"JNK1, a potential therapeutic target for hepatocellular carcinoma.",http://www.ncbi.nlm.nih.gov/pubmed/19591900
929,10811620,Transcriptional repression by Pax5 (BSAP) through interaction with corepressors of the Groucho family.,http://www.ncbi.nlm.nih.gov/pubmed/10811620
930,24013638,A recurrent germline PAX5 mutation confers susceptibility to pre-B cell acute lymphoblastic leukemia.,http://www.ncbi.nlm.nih.gov/pubmed/24013638
931,11055896,Distinct missense mutations of the FGFR3 lys650 codon modulate receptor kinase activation and the severity of the skeletal dysplasia phenotype.,http://www.ncbi.nlm.nih.gov/pubmed/11055896
932,18397343,Functional analysis of JAK3 mutations in transient myeloproliferative disorder and acute megakaryoblastic leukaemia accompanying Down syndrome.,http://www.ncbi.nlm.nih.gov/pubmed/18397343
933,16790275,Identification of a constitutively active mutant of JAK3 by retroviral expression screening.,http://www.ncbi.nlm.nih.gov/pubmed/16790275
934,,2709 Pre-Donor Evaluation of an HLA Matched Sibling Identifies a Novel Inherited RUNX1 Mutation Encoding a Missense Mutation Found Outside of the RUNT Domain in Familial Platelet Disorder,https://ash.confex.com/ash/2010/webprogram/Paper29502.html
935,15178581,Identifying and characterizing a novel activating mutation of the FLT3 tyrosine kinase in AML.,http://www.ncbi.nlm.nih.gov/pubmed/15178581
936,17429874,Concurrent cetuximab and bevacizumab therapy in a murine orthotopic model of anaplastic thyroid carcinoma.,http://www.ncbi.nlm.nih.gov/pubmed/17429874
937,22194861,EZH2 codon 641 mutations are common in BCL2-rearranged germinal center B cell lymphomas.,http://www.ncbi.nlm.nih.gov/pubmed/22194861
938,23177514,"Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): an international, multicentre, randomised, placebo-controlled, phase 3 trial.",http://www.ncbi.nlm.nih.gov/pubmed/23177514
939,19528456,Impact of tumor cell VEGF expression on the in vivo efficacy of vandetanib (ZACTIMA; ZD6474).,http://www.ncbi.nlm.nih.gov/pubmed/19528456
940,25242168,"Potent antitumor activity of cabozantinib, a c-MET and VEGFR2 inhibitor, in a colorectal cancer patient-derived tumor explant model.",http://www.ncbi.nlm.nih.gov/pubmed/25242168
941,25103625,Selective activity over a constitutively active RET-variant of the oral multikinase inhibitor dovitinib: results of the CNIO-BR002 phase I-trial.,http://www.ncbi.nlm.nih.gov/pubmed/25103625
942,25265494,Combined vemurafenib and cobimetinib in BRAF-mutated melanoma.,http://www.ncbi.nlm.nih.gov/pubmed/25265494
943,25302162,Review of the current targeted therapies for non-small-cell lung cancer.,http://www.ncbi.nlm.nih.gov/pubmed/25302162
945,25189416,Functional characterization of BTK(C481S) mutation that confers ibrutinib resistance: exploration of alternative kinase inhibitors.,http://www.ncbi.nlm.nih.gov/pubmed/25189416
946,23940282,Egress of CD19(+)CD5(+) cells into peripheral blood following treatment with the Bruton tyrosine kinase inhibitor ibrutinib in mantle cell lymphoma patients.,http://www.ncbi.nlm.nih.gov/pubmed/23940282
947,,Disease progression on ibrutinib therapy is uncommon and is associated with the acquisition of resistance mutations: a single center experience of 267 patients,http://www.haematologica.org/content/haematol/99/supplement_1/1.full.pdf
948,24869597,Ibrutinib resistance in chronic lymphocytic leukemia.,http://www.ncbi.nlm.nih.gov/pubmed/24869597
949,19505147,Regulation of process retraction and cell migration by EphA3 is mediated by the adaptor protein Nck1.,http://www.ncbi.nlm.nih.gov/pubmed/19505147
950,12116240,Novel de novo mutation of MADH4/SMAD4 in a patient with juvenile polyposis.,http://www.ncbi.nlm.nih.gov/pubmed/12116240
951,15031030,A combined syndrome of juvenile polyposis and hereditary haemorrhagic telangiectasia associated with mutations in MADH4 (SMAD4).,http://www.ncbi.nlm.nih.gov/pubmed/15031030
952,20101697,Overlapping spectra of SMAD4 mutations in juvenile polyposis (JP) and JP-HHT syndrome.,http://www.ncbi.nlm.nih.gov/pubmed/20101697
953,9887333,Characterization of ATM gene mutations in 66 ataxia telangiectasia families.,http://www.ncbi.nlm.nih.gov/pubmed/9887333
954,23139211,"SMAD2, SMAD3 and SMAD4 mutations in colorectal cancer.",http://www.ncbi.nlm.nih.gov/pubmed/23139211
955,14647410,Tumor-derived C-terminal mutations of Smad4 with decreased DNA binding activity and enhanced intramolecular interaction.,http://www.ncbi.nlm.nih.gov/pubmed/14647410
956,25261231,"A single-arm, multicenter, safety-monitoring, phase IV study of icotinib in treating advanced non-small cell lung cancer (NSCLC).",http://www.ncbi.nlm.nih.gov/pubmed/25261231
957,2394835,Ascitic fluid from human ovarian cancer patients contains growth factors necessary for intraperitoneal growth of human ovarian adenocarcinoma cells.,http://www.ncbi.nlm.nih.gov/pubmed/2394835
958,24697238,"The bruton tyrosine kinase inhibitor ibrutinib (PCI-32765) blocks hairy cell leukaemia survival, proliferation and B cell receptor signalling: a new therapeutic approach.",http://www.ncbi.nlm.nih.gov/pubmed/24697238
959,,Efficacy of cabozantinib (Cabo) in medullary thyroid cancer (MTC) patients with RAS or RET mutations: Results from a phase III study.,http://meetinglibrary.asco.org/content/113710-132
960,11871661,Identification of domains in apobec-1 complementation factor required for RNA binding and apolipoprotein-B mRNA editing.,http://www.ncbi.nlm.nih.gov/pubmed/11871661
961,24289319,Adenosine-to-inosine RNA editing and human disease.,http://www.ncbi.nlm.nih.gov/pubmed/24289319
962,24978597,Discovery of novel AKT inhibitors with enhanced anti-tumor effects in combination with the MEK inhibitor.,http://www.ncbi.nlm.nih.gov/pubmed/24978597
963,24315485,Crystal structure of TET2-DNA complex: insight into TET-mediated 5mC oxidation.,http://www.ncbi.nlm.nih.gov/pubmed/24315485
964,24869598,Resistance mechanisms for the Bruton's tyrosine kinase inhibitor ibrutinib.,http://www.ncbi.nlm.nih.gov/pubmed/24869598
965,19010870,Acquired resistance to epidermal growth factor receptor kinase inhibitors associated with a novel T854A mutation in a patient with EGFR-mutant lung adenocarcinoma.,http://www.ncbi.nlm.nih.gov/pubmed/19010870
966,23696637,CBL linker region and RING finger mutations lead to enhanced granulocyte-macrophage colony-stimulating factor (GM-CSF) signaling via elevated levels of JAK2 and LYN.,http://www.ncbi.nlm.nih.gov/pubmed/23696637
967,22470475,E-cadherin destabilization accounts for the pathogenicity of missense mutations in hereditary diffuse gastric cancer.,http://www.ncbi.nlm.nih.gov/pubmed/22470475
968,14617781,Potent and selective inhibitors of the Met [hepatocyte growth factor/scatter factor (HGF/SF) receptor] tyrosine kinase block HGF/SF-induced tumor cell growth and invasion.,http://www.ncbi.nlm.nih.gov/pubmed/14617781
969,17221870,Identification of seven novel germline mutations in the human E-cadherin (CDH1) gene.,http://www.ncbi.nlm.nih.gov/pubmed/17221870
970,15603957,A novel series of potent gamma-secretase inhibitors based on a benzobicyclo[4.2.1]nonane core.,http://www.ncbi.nlm.nih.gov/pubmed/15603957
971,19904829,NOTCH pathway blockade depletes CD133-positive glioblastoma cells and inhibits growth of tumor neurospheres and xenografts.,http://www.ncbi.nlm.nih.gov/pubmed/19904829
972,16648571,"Preclinical activity of ABT-869, a multitargeted receptor tyrosine kinase inhibitor.",http://www.ncbi.nlm.nih.gov/pubmed/16648571
973,24141978,A subset of gastric cancers with EGFR amplification and overexpression respond to cetuximab therapy.,http://www.ncbi.nlm.nih.gov/pubmed/24141978
974,15070706,A novel form of mastocytosis associated with a transmembrane c-kit mutation and response to imatinib.,http://www.ncbi.nlm.nih.gov/pubmed/15070706
975,21753906,Ellipticine cytotoxicity to cancer cell lines - a comparative study.,http://www.ncbi.nlm.nih.gov/pubmed/21753906
976,,"First-in-human evaluation of CO-1686, an irreversible, selective, and potent tyrosine kinase inhibitor of EGFR T790M.",http://meetinglibrary.asco.org/content/117319-132
977,23583440,"A phase 1b study of trametinib, an oral Mitogen-activated protein kinase kinase (MEK) inhibitor, in combination with gemcitabine in advanced solid tumours.",http://www.ncbi.nlm.nih.gov/pubmed/23583440
978,23868008,"Tumours with elevated levels of the Notch and Wnt pathways exhibit efficacy to PF-03084014, a γ-secretase inhibitor, in a preclinical colorectal explant model.",http://www.ncbi.nlm.nih.gov/pubmed/23868008
979,17804716,Gamma-secretase inhibitor prevents Notch3 activation and reduces proliferation in human lung cancers.,http://www.ncbi.nlm.nih.gov/pubmed/17804716
980,10913280,"L-685,458, an aspartyl protease transition state mimic, is a potent inhibitor of amyloid beta-protein precursor gamma-secretase activity.",http://www.ncbi.nlm.nih.gov/pubmed/10913280
981,16007227,Notch4 intracellular domain binding to Smad3 and inhibition of the TGF-beta signaling.,http://www.ncbi.nlm.nih.gov/pubmed/16007227
982,22253748,The protein kinase C inhibitor enzastaurin exhibits antitumor activity against uveal melanoma.,http://www.ncbi.nlm.nih.gov/pubmed/22253748
983,22144665,"Ganetespib, a unique triazolone-containing Hsp90 inhibitor, exhibits potent antitumor activity and a superior safety profile for cancer therapy.",http://www.ncbi.nlm.nih.gov/pubmed/22144665
984,24982373,Phase II study of S-1 in combination with trastuzumab for HER2-positive metastatic breast cancer.,http://www.ncbi.nlm.nih.gov/pubmed/24982373
985,12124173,Inhibition of mutant FLT3 receptors in leukemia cells by the small molecule tyrosine kinase inhibitor PKC412.,http://www.ncbi.nlm.nih.gov/pubmed/12124173
986,24077915,Another surprise from Metformin: novel mechanism of action via K-Ras influences endometrial cancer response to therapy.,http://www.ncbi.nlm.nih.gov/pubmed/24077915
987,21057493,Impaired hydroxylation of 5-methylcytosine in myeloid cancers with mutant TET2.,http://www.ncbi.nlm.nih.gov/pubmed/21057493
988,24697267,Evaluation of allelic strength of human TET2 mutations and cooperation between Tet2 knockdown and oncogenic Nras mutation.,http://www.ncbi.nlm.nih.gov/pubmed/24697267
989,23390247,"Dual inactivation of Akt and ERK by TIC10 signals Foxo3a nuclear translocation, TRAIL gene induction, and potent antitumor effects.",http://www.ncbi.nlm.nih.gov/pubmed/23390247
990,24634471,The Nedd8-activating enzyme inhibitor MLN4924 thwarts microenvironment-driven NF-κB activation and induces apoptosis in chronic lymphocytic leukemia B cells.,http://www.ncbi.nlm.nih.gov/pubmed/24634471
991,11298456,The ATM-Chk2-Cdc25A checkpoint pathway guards against radioresistant DNA synthesis.,http://www.ncbi.nlm.nih.gov/pubmed/11298456
992,20547222,"Analysis of TSC1 truncations defines regions involved in TSC1 stability, aggregation and interaction.",http://www.ncbi.nlm.nih.gov/pubmed/20547222
993,23401075,TSC1 involvement in bladder cancer: diverse effects and therapeutic implications.,http://www.ncbi.nlm.nih.gov/pubmed/23401075
994,21921646,Phase I dose-finding study of vandetanib in combination with gemcitabine in locally advanced unresectable or metastatic pancreatic adenocarcinoma.,http://www.ncbi.nlm.nih.gov/pubmed/21921646
995,16951187,"AMG 706, an oral, multikinase inhibitor that selectively targets vascular endothelial growth factor, platelet-derived growth factor, and kit receptors, potently inhibits angiogenesis and induces regression in tumor xenografts.",http://www.ncbi.nlm.nih.gov/pubmed/16951187
996,21422803,Anti-tumor activity of motesanib in a medullary thyroid cancer model.,http://www.ncbi.nlm.nih.gov/pubmed/21422803
997,24037486,Small molecule targeted therapies for the second-line treatment for metastatic renal cell carcinoma: a systematic review and indirect comparison of safety and efficacy.,http://www.ncbi.nlm.nih.gov/pubmed/24037486
998,,"Abstract B281: Phase I study of two dosing schedules of BI 847325, an orally administered dual inhibitor of MEK and aurora kinase B, in patients with advanced solid tumors.",http://mct.aacrjournals.org/content/12/11_Supplement/B281.meeting_abstract
999,,"Abstract 1919: Pharmacological characterization of BI 847325, a dual inhibitor of MEK and Aurora kinases",http://cancerres.aacrjournals.org/cgi/content/meeting_abstract/72/8_MeetingAbstracts/1919
1000,21976531,"Novel phosphoinositide 3-kinase/mTOR dual inhibitor, NVP-BGT226, displays potent growth-inhibitory activity against human head and neck cancer cells in vitro and in vivo.",http://www.ncbi.nlm.nih.gov/pubmed/21976531
1001,23443802,Inhibition of mutant GNAQ signaling in uveal melanoma induces AMPK-dependent autophagic cell death.,http://www.ncbi.nlm.nih.gov/pubmed/23443802
1002,24413085,Combined PKC and MEK inhibition for treating metastatic uveal melanoma.,http://www.ncbi.nlm.nih.gov/pubmed/24413085
1003,24900569,Discovery and Biological Profiling of Potent and Selective mTOR Inhibitor GDC-0349.,http://www.ncbi.nlm.nih.gov/pubmed/24900569
1004,25077176,"A-TWinnipeg: Pathogenesis of rare ATM missense mutation c.6200C>A with decreased protein expression and downstream signaling, early-onset dystonia, cancer, and life-threatening radiotoxicity.",http://www.ncbi.nlm.nih.gov/pubmed/25077176
1005,11830610,Dominant negative ATM mutations in breast cancer families.,http://www.ncbi.nlm.nih.gov/pubmed/11830610
1006,7592920,Ras CAAX peptidomimetic FTI-277 selectively blocks oncogenic Ras signaling by inducing cytoplasmic accumulation of inactive Ras-Raf complexes.,http://www.ncbi.nlm.nih.gov/pubmed/7592920
1007,23166678,Somatic mutations of PIK3R1 promote gliomagenesis.,http://www.ncbi.nlm.nih.gov/pubmed/23166678
1008,8620483,The farnesyltransferase inhibitor FTI-277 radiosensitizes H-ras-transformed rat embryo fibroblasts.,http://www.ncbi.nlm.nih.gov/pubmed/8620483
1009,,Phase I and IIa studies of simtuzumab alone and in combination with FOLFIRI in patients with advanced solid tumors.,http://meetinglibrary.asco.org/content/123214-143
1010,,"A phase 1 study to assess the safety, tolerability and pharmacokinetics of the ErbB?family inhibitor ARRY?334543 in patients with advanced solid tumors",http://mct.aacrjournals.org/content/8/12_Supplement/B54.short
1011,23733758,Dramatic response induced by vemurafenib in a BRAF V600E-mutated lung adenocarcinoma.,http://www.ncbi.nlm.nih.gov/pubmed/23733758
1012,24888229,BRAF V600E-mutated lung adenocarcinoma with metastases to the brain responding to treatment with vemurafenib.,http://www.ncbi.nlm.nih.gov/pubmed/24888229
1013,,Abstract A162: Identification of brain penetrant p70S6K/Akt inhibitor MSC2363318A.,http://mct.aacrjournals.org/content/12/11_Supplement/A162.short
1014,,A phase I study of an MVA vaccine targeting p53 in cancer.,meetinglibrary.asco.org/content/111188-132
1015,22722787,Phase II study of the multitargeted tyrosine kinase inhibitor XL647 in patients with non-small-cell lung cancer.,http://www.ncbi.nlm.nih.gov/pubmed/22722787
1016,21154125,"Necitumumab, a fully human IgG1 mAb directed against the EGFR for the potential treatment of cancer.",http://www.ncbi.nlm.nih.gov/pubmed/21154125
1017,24947258,Targeting multiple angiogenic pathways simultaneously: experience with nintedanib in non-small-cell lung cancer.,http://www.ncbi.nlm.nih.gov/pubmed/24947258
1018,22693356,Cancer network disruption by a single molecule inhibitor targeting both histone deacetylase activity and phosphatidylinositol 3-kinase signaling.,http://www.ncbi.nlm.nih.gov/pubmed/22693356
1019,,"Abstract B136: CAL?120, a novel dual p110beta/p110delta phosphatidylinositol?3?kinase (PI3K) inhibitor, attenuates PI3K signaling and demonstrates potent in vivo antitumor activity against solid tumors",http://mct.aacrjournals.org/content/8/12_Supplement/B136.short
1021,19474163,Polo-like kinase (PLK) inhibitors in preclinical and early clinical development in oncology.,http://www.ncbi.nlm.nih.gov/pubmed/19474163
1022,19770380,Phase I pharmacokinetic and pharmacodynamic study of the aurora kinase inhibitor danusertib in patients with advanced or metastatic solid tumors.,http://www.ncbi.nlm.nih.gov/pubmed/19770380
1023,,"Phase II study of danusertib (D) in advanced/metastatic colorectal and pancreatic cancers (CRC, PC).",
1024,25028150,Inhibition of PARP1-dependent end-joining contributes to Olaparib-mediated radiosensitization in tumor cells.,http://www.ncbi.nlm.nih.gov/pubmed/25028150
1025,25309914,Biological and molecular effects of small molecule kinase inhibitors on low-passage human colorectal cancer cell lines.,http://www.ncbi.nlm.nih.gov/pubmed/25309914
1026,17367541,Tyrosine kinase inhibitor SU6668 represses chondrosarcoma growth via antiangiogenesis in vivo.,http://www.ncbi.nlm.nih.gov/pubmed/17367541
1027,23633494,Simultaneous targeting of tumor antigens and the tumor vasculature using T lymphocyte transfer synergize to induce regression of established tumors in mice.,http://www.ncbi.nlm.nih.gov/pubmed/23633494
1028,24885690,Genetic targeting of B-RafV600E affects survival and proliferation and identifies selective agents against BRAF-mutant colorectal cancer cells.,http://www.ncbi.nlm.nih.gov/pubmed/24885690
1029,23365119,Relief of feedback inhibition of HER3 transcription by RAF and MEK inhibitors attenuates their antitumor effects in BRAF-mutant thyroid carcinomas.,http://www.ncbi.nlm.nih.gov/pubmed/23365119
1030,16397041,Anti-CD3 x anti-epidermal growth factor receptor (EGFR) bispecific antibody redirects T-cell cytolytic activity to EGFR-positive cancers in vitro and in an animal model.,http://www.ncbi.nlm.nih.gov/pubmed/16397041
1031,21464044,The dual EGFR/HER2 inhibitor lapatinib synergistically enhances the antitumor activity of the histone deacetylase inhibitor panobinostat in colorectal cancer models.,http://www.ncbi.nlm.nih.gov/pubmed/21464044
1032,22448344,EGFR-mediated re-activation of MAPK signaling contributes to insensitivity of BRAF mutant colorectal cancers to RAF inhibition with vemurafenib.,http://www.ncbi.nlm.nih.gov/pubmed/22448344
1033,24523613,Anticancer activity of combination targeted therapy using cetuximab plus vemurafenib for refractory BRAF (V600E)-mutant metastatic colorectal carcinoma.,http://www.ncbi.nlm.nih.gov/pubmed/24523613
1034,21404105,"A phase I trial of vandetanib combined with capecitabine, oxaliplatin and bevacizumab for the first-line treatment of metastatic colorectal cancer.",http://www.ncbi.nlm.nih.gov/pubmed/21404105
1035,22811876,A phase II study of capecitabine and lapatinib in advanced refractory colorectal adenocarcinoma: A Wisconsin Oncology Network study.,http://www.ncbi.nlm.nih.gov/pubmed/22811876
1036,17767136,H-Ras mutation modulates the expression of major cell cycle regulatory proteins and disease prognosis in oral carcinoma.,http://www.ncbi.nlm.nih.gov/pubmed/17767136
1037,19147536,Loss-of-function fibroblast growth factor receptor-2 mutations in melanoma.,http://www.ncbi.nlm.nih.gov/pubmed/19147536
1038,23248156,PIK3CA mutations in advanced cancers: characteristics and outcomes.,http://www.ncbi.nlm.nih.gov/pubmed/23248156
1039,21529352,WEE1 inhibition sensitizes osteosarcoma to radiotherapy.,http://www.ncbi.nlm.nih.gov/pubmed/21529352
1040,20797855,PKI-179: an orally efficacious dual phosphatidylinositol-3-kinase (PI3K)/mammalian target of rapamycin (mTOR) inhibitor.,http://www.ncbi.nlm.nih.gov/pubmed/20797855
1041,10415871,The novel Trk receptor tyrosine kinase inhibitor CEP-701 (KT-5555) exhibits antitumor efficacy against human pancreatic carcinoma (Panc1) xenograft growth and in vivo invasiveness.,http://www.ncbi.nlm.nih.gov/pubmed/10415871
1042,17442779,Effect of FLT3 inhibition on normal hematopoietic progenitor cells.,http://www.ncbi.nlm.nih.gov/pubmed/17442779
1043,17984313,Lestaurtinib (CEP701) is a JAK2 inhibitor that suppresses JAK2/STAT5 signaling and the proliferation of primary erythroid cells from patients with myeloproliferative disorders.,http://www.ncbi.nlm.nih.gov/pubmed/17984313
1044,24501284,IPI-145 shows promise in CLL patients.,http://www.ncbi.nlm.nih.gov/pubmed/24501284
1045,22014573,A two-in-one antibody against HER3 and EGFR has superior inhibitory activity compared with monospecific antibodies.,http://www.ncbi.nlm.nih.gov/pubmed/22014573
1046,,Abstract 3020,
1047,12560429,Phase II trial of systemic continuous fluorouracil and subcutaneous recombinant interferon Alfa-2b for treatment of hepatocellular carcinoma.,http://www.ncbi.nlm.nih.gov/pubmed/12560429
1048,11148999,Preoperative main portal branch transection combined with liver locoregional transarterial neo and adjuvant immunochemotherapy for patients with hepatocellular carcinoma.,http://www.ncbi.nlm.nih.gov/pubmed/11148999
1049,,459P A Phase I study to assess the safety and tolerability of the selective Akt inhibitor AZD5363 in Japanese patients with advanced solid tumours,http://annonc.oxfordjournals.org/content/25/suppl_4/iv153.1.full.pdf
1050,,"53P Encorafenib (LGX818), an oral BRAF inhibitor, in patients (PTS) WITH BRAF V600E metastatic colorectal cancer (MCRC): results of dose expansion in an open-label, phase I study.",
1051,,"Efficacy and tolerability in an open-label phase I/II study of MEK inhibitor trametinib (T), BRAF inhibitor dabrafenib (D), and anti-EGFR antibody panitumumab (P) in combination in patients (pts) with BRAF V600E mutated colorectal cancer (CRC).",http://meetinglibrary.asco.org/content/131642-144
1052,19268661,E-cadherin mutations and cell motility: a genotype-phenotype correlation.,http://www.ncbi.nlm.nih.gov/pubmed/19268661
1053,16469774,A novel activating mutation in the RET tyrosine kinase domain mediates neoplastic transformation.,http://www.ncbi.nlm.nih.gov/pubmed/16469774
1054,,"BAY 1125976, a highly selective and potent allosteric AKT1/2 inhibitor, for the treatment of cancers with aberrations in the PI3K-AKT-mTOR pathway",http://cancerres.aacrjournals.org/content/73/8_Supplement/2050
1055,22154054,c-kit gene mutation and CD117 expression in human anorectal melanomas.,http://www.ncbi.nlm.nih.gov/pubmed/22154054
1056,22083669,"Characterization of novel germline c-kit gene mutation, KIT-Tyr553Cys, observed in a family with multiple gastrointestinal stromal tumors.",http://www.ncbi.nlm.nih.gov/pubmed/22083669
1057,24503538,Fibroblast growth factor receptor 4 (FGFR4): a targetable regulator of drug resistance in colorectal cancer.,http://www.ncbi.nlm.nih.gov/pubmed/24503538
1058,21478295,PIK3R1 (p85α) is somatically mutated at high frequency in primary endometrial cancer.,http://www.ncbi.nlm.nih.gov/pubmed/21478295
1059,,TKI258 Is Efficacious as a Multitargeted TKI in Head and Neck Squamous Cell Carcinoma Models,http://oto.sagepub.com/content/145/2_suppl/P77.1.abstract
1060,19735675,Insights into the molecular function of the inactivating mutations of B-Raf involving the DFG motif.,http://www.ncbi.nlm.nih.gov/pubmed/19735675
1061,,"Abstract C252: A phase 1, dose-escalation study of MLN0128, an investigational oral mammalian target of rapamycin complex 1/2 (mTORC1/2) catalytic inhibitor, in patients (pts) with advanced non-hematologic malignancies.",http://mct.aacrjournals.org/content/12/11_Supplement/C252.short
1062,24282274,"MM-141, an IGF-IR- and ErbB3-directed bispecific antibody, overcomes network adaptations that limit activity of IGF-IR inhibitors.",http://www.ncbi.nlm.nih.gov/pubmed/24282274
1063,,ONC201 Exerts p53-Independent Cytotoxicity Through TRAIL and DR5 Induction In Mantle Cell Lymphomas,http://www.bloodjournal.org/content/122/21/3822.abstract
1064,20215549,Phase I pharmacokinetic and pharmacodynamic study of the oral MAPK/ERK kinase inhibitor PD-0325901 in patients with advanced cancers.,http://www.ncbi.nlm.nih.gov/pubmed/20215549
1065,24823695,The dual PI3K/mTOR inhibitor PKI-587 enhances sensitivity to cetuximab in EGFR-resistant human head and neck cancer models.,http://www.ncbi.nlm.nih.gov/pubmed/24823695
1066,23434733,Multicenter phase I trial of the mitogen-activated protein kinase 1/2 inhibitor BAY 86-9766 in patients with advanced cancer.,http://www.ncbi.nlm.nih.gov/pubmed/23434733
1067,20664172,Deregulation of the PI3K and KRAS signaling pathways in human cancer cells determines their response to everolimus.,http://www.ncbi.nlm.nih.gov/pubmed/20664172
1068,24801563,Effect of metformin on the incidence of head and neck cancer in diabetics.,http://www.ncbi.nlm.nih.gov/pubmed/24801563
1069,23815869,Anti-lymphangiogenic properties of mTOR inhibitors in head and neck squamous cell carcinoma experimental models.,http://www.ncbi.nlm.nih.gov/pubmed/23815869
1070,20222045,Pharmacodynamic evaluation of temsirolimus in patients with newly diagnosed advanced-stage head and neck squamous cell carcinoma.,http://www.ncbi.nlm.nih.gov/pubmed/20222045
1071,25085003,The RNA editing enzyme APOBEC1 induces somatic mutations and a compatible mutational signature is present in esophageal adenocarcinomas.,http://www.ncbi.nlm.nih.gov/pubmed/25085003
1072,22001110,Functions and regulation of the APOBEC family of proteins.,http://www.ncbi.nlm.nih.gov/pubmed/22001110
1073,20022958,"Deficiency in APOBEC2 leads to a shift in muscle fiber type, diminished body mass, and myopathy.",http://www.ncbi.nlm.nih.gov/pubmed/20022958
1074,21469143,Excessive activity of apolipoprotein B mRNA editing enzyme catalytic polypeptide 2 (APOBEC2) contributes to liver and lung tumorigenesis.,http://www.ncbi.nlm.nih.gov/pubmed/21469143
1075,15252137,"Molecular pharmacology and antitumor activity of PX-866, a novel inhibitor of phosphoinositide-3-kinase signaling.",http://www.ncbi.nlm.nih.gov/pubmed/15252137
1076,17766839,"The phosphatidylinositol 3-kinase inhibitor, PX-866, is a potent inhibitor of cancer cell motility and growth in three-dimensional cultures.",http://www.ncbi.nlm.nih.gov/pubmed/17766839
1077,15647370,Phosphatidylinositol 3-kinase mutations identified in human cancer are oncogenic.,http://www.ncbi.nlm.nih.gov/pubmed/15647370
1078,20858724,Antitumor effect of temsirolimus against oral squamous cell carcinoma associated with bone destruction.,http://www.ncbi.nlm.nih.gov/pubmed/20858724
1079,19458050,A phase 0 trial of riluzole in patients with resectable stage III and IV melanoma.,http://www.ncbi.nlm.nih.gov/pubmed/19458050
1080,,"First-in-human study with ARQ 092, a novel pan AKT-inhibitor: Results from the advanced solid tumors cohorts",http://www.abstractsonline.com/Plan/ViewAbstract.aspx?sKey=d4332bf8-005b-4cb2-a378-921ae4782081&cKey=4d4b15a2-4923-4f10-8182-7bf41054c560&mKey={9B2D28E7-24A0-466F-A3C9-07C21F6E9BC9}
1081,24088382,"The AKT inhibitor AZD5363 is selectively active in PI3KCA mutant gastric cancer, and sensitizes a patient-derived gastric cancer xenograft model with PTEN loss to Taxotere.",http://www.ncbi.nlm.nih.gov/pubmed/24088382
1082,,A phase I study of carboxyamidotriazole orotate (CTO) in of advanced solid tumors.,http://meetinglibrary.asco.org/content/115114-132
1083,21914794,"ATP9B, a P4-ATPase (a putative aminophospholipid translocase), localizes to the trans-Golgi network in a CDC50 protein-independent manner.",http://www.ncbi.nlm.nih.gov/pubmed/21914794
1084,,Abstract CT328: Clinical results of a phase Ib dose-escalation study of the Mek inhibitor cobimetinib (GDC-0973) and the Akt inhibitor ipatasertib (GDC-0068) in patients (pts) with solid tumors,http://cancerres.aacrjournals.org/content/74/19_Supplement/CT328.short
1085,,"Abstract 1136: MK-1775, a selective wee1 kinase inhibitor, overcomes cisplatin resistance associated with high risk TP53 mutations in squamous cell carcinoma of the head and neck.",http://cancerres.aacrjournals.org/cgi/content/meeting_abstract/73/8_MeetingAbstracts/1136
1086,23986086,Dietary restriction-resistant human tumors harboring the PIK3CA-activating mutation H1047R are sensitive to metformin.,http://www.ncbi.nlm.nih.gov/pubmed/23986086
1087,,"Abstract 3759: P7170, a novel inhibitor of phosphoinositide 3-kinase (PI3K)-mammalian target of Rapamycin (mTOR) and activin receptor-like kinase 1 (ALK1) as a new therapeutic option for Kras mutated non small cell lung cancer (NSCLC)",http://cancerres.aacrjournals.org/cgi/content/meeting_abstract/72/8_MeetingAbstracts/3759
1088,16364494,"EKB-569, a new irreversible epidermal growth factor receptor tyrosine kinase inhibitor, with clinical activity in patients with non-small cell lung cancer with acquired resistance to gefitinib.",http://www.ncbi.nlm.nih.gov/pubmed/16364494
1089,16710023,"Phase I study of EKB-569, an irreversible inhibitor of the epidermal growth factor receptor, in patients with advanced solid tumors.",http://www.ncbi.nlm.nih.gov/pubmed/16710023
1090,,PR610: A novel hypoxia-selective tyrosine kinase inhibitor in phase I clinical trial.,http://mct.aacrjournals.org/content/12/11_Supplement/B278.short
1091,23977391,Human APOBEC3A isoforms translocate to the nucleus and induce DNA double strand breaks leading to cell stress and death.,http://www.ncbi.nlm.nih.gov/pubmed/23977391
1092,20062055,APOBEC3 proteins mediate the clearance of foreign DNA from human cells.,http://www.ncbi.nlm.nih.gov/pubmed/20062055
1093,21632763,Genetic editing of herpes simplex virus 1 and Epstein-Barr herpesvirus genomes by human APOBEC3 cytidine deaminases in culture and in vivo.,http://www.ncbi.nlm.nih.gov/pubmed/21632763
1094,23388464,Subcellular localization of the APOBEC3 proteins during mitosis and implications for genomic DNA deamination.,http://www.ncbi.nlm.nih.gov/pubmed/23388464
1095,24753761,APOBEC3G expression is correlated with poor prognosis in colon carcinoma patients with hepatic metastasis.,http://www.ncbi.nlm.nih.gov/pubmed/24753761
1096,10860993,"huASH1 protein, a putative transcription factor encoded by a human homologue of the Drosophila ash1 gene, localizes to both nuclei and cell-cell tight junctions.",http://www.ncbi.nlm.nih.gov/pubmed/10860993
1097,21239497,Crystal structure of the human histone methyltransferase ASH1L catalytic domain and its implications for the regulatory mechanism.,http://www.ncbi.nlm.nih.gov/pubmed/21239497
1098,23033341,Genome and transcriptome sequencing of lung cancers reveal diverse mutational and splicing events.,http://www.ncbi.nlm.nih.gov/pubmed/23033341
1099,24670651,Identification of genomic alterations in oesophageal squamous cell cancer.,http://www.ncbi.nlm.nih.gov/pubmed/24670651
1100,23098991,MicroRNA profiling predicts survival in anti-EGFR treated chemorefractory metastatic colorectal cancer patients with wild-type KRAS and BRAF.,http://www.ncbi.nlm.nih.gov/pubmed/23098991
1101,10973986,"Atrophin-1, the dentato-rubral and pallido-luysian atrophy gene product, interacts with ETO/MTG8 in the nuclear matrix and represses transcription.",http://www.ncbi.nlm.nih.gov/pubmed/10973986
1102,9501202,Monocyte chemoattractant protein-1-induced CCR2B receptor desensitization mediated by the G protein-coupled receptor kinase 2.,http://www.ncbi.nlm.nih.gov/pubmed/9501202
1103,23408426,Tyrosine sulfation of chemokine receptor CCR2 enhances interactions with both monomeric and dimeric forms of the chemokine monocyte chemoattractant protein-1 (MCP-1).,http://www.ncbi.nlm.nih.gov/pubmed/23408426
1104,15956248,"ZM336372, a Raf-1 activator, suppresses growth and neuroendocrine hormone levels in carcinoid tumor cells.",http://www.ncbi.nlm.nih.gov/pubmed/15956248
1105,12192431,Structural analysis of human CCR2b and primate CCR2b by molecular modeling and molecular dynamics simulation.,http://www.ncbi.nlm.nih.gov/pubmed/12192431
1106,17417627,p53 gain-of-function cancer mutants induce genetic instability by inactivating ATM.,http://www.ncbi.nlm.nih.gov/pubmed/17417627
1107,16432179,Cancer-specific mutations in PIK3CA are oncogenic in vivo.,http://www.ncbi.nlm.nih.gov/pubmed/16432179
1108,15156179,Core-binding factors in hematopoiesis and immune function.,http://www.ncbi.nlm.nih.gov/pubmed/15156179
1109,8351518,Fusion between transcription factor CBF beta/PEBP2 beta and a myosin heavy chain in acute myeloid leukemia.,http://www.ncbi.nlm.nih.gov/pubmed/8351518
1110,17888033,"Pharmacological characterization of MP-412 (AV-412), a dual epidermal growth factor receptor and ErbB2 tyrosine kinase inhibitor.",http://www.ncbi.nlm.nih.gov/pubmed/17888033
1111,17189293,Truncated APC regulates the transcriptional activity of beta-catenin in a cell cycle dependent manner.,http://www.ncbi.nlm.nih.gov/pubmed/17189293
1112,23355941,Contribution of BCR-ABL kinase domain mutations to imatinib mesylate resistance in Philadelphia chromosome positive Malaysian chronic myeloid leukemia patients.,http://www.ncbi.nlm.nih.gov/pubmed/23355941
1113,22683265,Stoichiometry of the CD95 death-inducing signaling complex: experimental and modeling evidence for a death effector domain chain model.,http://www.ncbi.nlm.nih.gov/pubmed/22683265
1114,24921003,Role of PRMTs in cancer: Could minor isoforms be leaving a mark?,http://www.ncbi.nlm.nih.gov/pubmed/24921003
1115,21243720,Xenoestrogens regulate the activity of arginine methyltransferases.,http://www.ncbi.nlm.nih.gov/pubmed/21243720
1116,,,http://rgd.mcw.edu/wg/home/pathway2
1117,15221992,"Aberrant expression of CARM1, a transcriptional coactivator of androgen receptor, in the development of prostate carcinoma and androgen-independent status.",http://www.ncbi.nlm.nih.gov/pubmed/15221992
1118,8918887,BID: a novel BH3 domain-only death agonist.,http://www.ncbi.nlm.nih.gov/pubmed/8918887
1119,20482490,Bid stands at the crossroad of stress-response pathways.,http://www.ncbi.nlm.nih.gov/pubmed/20482490
1120,10898795,"BCoR, a novel corepressor involved in BCL-6 repression.",http://www.ncbi.nlm.nih.gov/pubmed/10898795
1121,12776190,The mixed lineage leukemia fusion partner AF9 binds specific isoforms of the BCL-6 corepressor.,http://www.ncbi.nlm.nih.gov/pubmed/12776190
1122,16943429,Polycomb group and SCF ubiquitin ligases are found in a novel BCOR complex that is recruited to BCL6 targets.,http://www.ncbi.nlm.nih.gov/pubmed/16943429
1123,3312414,The human beta 2-microglobulin gene. Primary structure and definition of the transcriptional unit.,http://www.ncbi.nlm.nih.gov/pubmed/3312414
1124,16204070,Epidermal growth factor-independent transformation of Ba/F3 cells with cancer-derived epidermal growth factor receptor mutants induces gefitinib-sensitive cell cycle progression.,http://www.ncbi.nlm.nih.gov/pubmed/16204070
1125,24894453,Colon cancer-derived oncogenic EGFR G724S mutant identified by whole genome sequence analysis is dependent on asymmetric dimerization and sensitive to cetuximab.,http://www.ncbi.nlm.nih.gov/pubmed/24894453
1126,22228403,Characteristics of translocation (16;16)(p13;q22) acute myeloid leukemia.,http://www.ncbi.nlm.nih.gov/pubmed/22228403
1127,18648004,Clinical significance of the most common chromosome translocations in adult acute myeloid leukemia.,http://www.ncbi.nlm.nih.gov/pubmed/18648004
1128,16504290,Granulocytic sarcoma of mesentery in acute myeloid leukemia with CBFB/MYH11 fusion gene but not inv(16) chromosome: case report and review of literature.,http://www.ncbi.nlm.nih.gov/pubmed/16504290
1129,15976757,Specific detection of Flt3 point mutations by highly sensitive real-time polymerase chain reaction in acute myeloid leukemia.,http://www.ncbi.nlm.nih.gov/pubmed/15976757
1130,,"Abstract LB-122: A phase I dose escalation study of NVP-BGJ398, a selective pan FGFR inhibitor in genetically preselected advanced solid tumors",http://cancerres.aacrjournals.org/cgi/content/short/72/8_MeetingAbstracts/LB-122
1131,24434212,Widespread genetic heterogeneity in multiple myeloma: implications for targeted therapy.,http://www.ncbi.nlm.nih.gov/pubmed/24434212
1132,10862053,"Sequence variants of the axin gene in breast, colon, and other cancers: an analysis of mutations that interfere with GSK3 binding.",http://www.ncbi.nlm.nih.gov/pubmed/10862053
1133,23836671,"Targeted genetic dependency screen facilitates identification of actionable mutations in FGFR4, MAP3K9, and PAK5 in lung cancer.",http://www.ncbi.nlm.nih.gov/pubmed/23836671
1134,19139135,"Genomics screen in transformed stem cells reveals RNASEH2A, PPAP2C, and ADARB1 as putative anticancer drug targets.",http://www.ncbi.nlm.nih.gov/pubmed/19139135
1135,23737728,RNA editing and drug discovery for cancer therapy.,http://www.ncbi.nlm.nih.gov/pubmed/23737728
1136,9299237,"Gene structure and subcellular localization of FMR2, a member of a new family of putative transcription activators.",http://www.ncbi.nlm.nih.gov/pubmed/9299237
1137,16289642,Identification of novel argonaute-associated proteins.,http://www.ncbi.nlm.nih.gov/pubmed/16289642
1138,24086155,Ago1 Interacts with RNA polymerase II and binds to the promoters of actively transcribed genes in human cancer cells.,http://www.ncbi.nlm.nih.gov/pubmed/24086155
1139,22025453,"Expression levels of the microRNA maturing microprocessor complex component DGCR8 and the RNA-induced silencing complex (RISC) components argonaute-1, argonaute-2, PACT, TARBP1, and TARBP2 in epithelial skin cancer.",http://www.ncbi.nlm.nih.gov/pubmed/22025453
1140,24169347,Strong reduction of AGO2 expression in melanoma and cellular consequences.,http://www.ncbi.nlm.nih.gov/pubmed/24169347
1141,18771919,Importance of translation and nonnucleolytic ago proteins for on-target RNA interference.,http://www.ncbi.nlm.nih.gov/pubmed/18771919
1142,23398123,Downregulation of the microRNA biogenesis components and its association with poor prognosis in hepatocellular carcinoma.,http://www.ncbi.nlm.nih.gov/pubmed/23398123
1143,21966435,The dual PI3K/mTOR inhibitor NVP-BEZ235 induces tumor regression in a genetically engineered mouse model of PIK3CA wild-type colorectal cancer.,http://www.ncbi.nlm.nih.gov/pubmed/21966435
1144,22116303,Preclinical evaluation of dual PI3K-mTOR inhibitors and histone deacetylase inhibitors in head and neck squamous cell carcinoma.,http://www.ncbi.nlm.nih.gov/pubmed/22116303
1145,24608574,Characterization of the novel and specific PI3Kα inhibitor NVP-BYL719 and development of the patient stratification strategy for clinical trials.,http://www.ncbi.nlm.nih.gov/pubmed/24608574
1146,,446PD - Phase Ib dose-escalation study of the Akt inhibitor ipatasertib (Ipat) with paclitaxel (P) in patients (pts) with advanced solid tumors,http://oncologypro.esmo.org/Meeting-Resources/ESMO-2014/Developmental-Therapeutics/Phase-Ib-dose-escalation-study-of-the-Akt-inhibitor-ipatasertib-Ipat-with-paclitaxel-P-in-patients-pts-with-advanced-
1147,19759537,Tankyrase inhibition stabilizes axin and antagonizes Wnt signalling.,http://www.ncbi.nlm.nih.gov/pubmed/19759537
1148,22932669,Biomarkers of response to Akt inhibitor MK-2206 in breast cancer.,http://www.ncbi.nlm.nih.gov/pubmed/22932669
1149,16648140,Defective human leukocyte antigen class I-associated antigen presentation caused by a novel beta2-microglobulin loss-of-function in melanoma cells.,http://www.ncbi.nlm.nih.gov/pubmed/16648140
1150,14525967,"Interferon-gamma: an overview of signals, mechanisms and functions.",http://www.ncbi.nlm.nih.gov/pubmed/14525967
1151,23873848,The dual pathway inhibitor rigosertib is effective in direct patient tumor xenografts of head and neck squamous cell carcinomas.,http://www.ncbi.nlm.nih.gov/pubmed/23873848
1152,23149938,A quantitative signaling screen identifies CARD11 mutations in the CARD and LATCH domains that induce Bcl10 ubiquitination and human lymphoma cell survival.,http://www.ncbi.nlm.nih.gov/pubmed/23149938
1153,22219178,"MHC class I molecules act as tumor suppressor genes regulating the cell cycle gene expression, invasion and intrinsic tumorigenicity of melanoma cells.",http://www.ncbi.nlm.nih.gov/pubmed/22219178
1154,22012066,Whole-exome sequencing identifies somatic mutations of BCOR in acute myeloid leukemia with normal karyotype.,http://www.ncbi.nlm.nih.gov/pubmed/22012066
1155,23659359,Cancer-associated missense mutations of caspase-8 activate nuclear factor-κB signaling.,http://www.ncbi.nlm.nih.gov/pubmed/23659359
1156,22789541,Endothelial CCR2 signaling induced by colon carcinoma cells enables extravasation via the JAK2-Stat5 and p38MAPK pathway.,http://www.ncbi.nlm.nih.gov/pubmed/22789541
1157,,NCI Thesaurus,http://nciterms.nci.nih.gov
1158,9257915,Dissociation of the effects of the antitumour ether lipid ET-18-OCH3 on cytosolic calcium and on apoptosis.,http://www.ncbi.nlm.nih.gov/pubmed/9257915
1159,24413065,"Synergistic cytotoxicity of gemcitabine, clofarabine and edelfosine in lymphoma cell lines.",http://www.ncbi.nlm.nih.gov/pubmed/24413065
1160,23181381,Regulation of Aicda expression and AID activity.,http://www.ncbi.nlm.nih.gov/pubmed/23181381
1161,21498506,Structural and functional characterization of the Wnt inhibitor APC membrane recruitment 1 (Amer1).,http://www.ncbi.nlm.nih.gov/pubmed/21498506
1162,9196022,The adenomatous polyposis coli (APC) tumor suppressor.,http://www.ncbi.nlm.nih.gov/pubmed/9196022
1163,16339184,Dysregulation of the Hedgehog pathway in human hepatocarcinogenesis.,http://www.ncbi.nlm.nih.gov/pubmed/16339184
1164,22324351,"Mast cell leukemia: identification of a new c-Kit mutation, dup(501-502), and response to masitinib, a c-Kit tyrosine kinase inhibitor.",http://www.ncbi.nlm.nih.gov/pubmed/22324351
1165,21478825,KIT mutations in ocular melanoma: frequency and anatomic distribution.,http://www.ncbi.nlm.nih.gov/pubmed/21478825
1166,15046639,Constitutive activation of the Ras-Raf signaling pathway in metastatic melanoma is associated with poor prognosis.,http://www.ncbi.nlm.nih.gov/pubmed/15046639
1167,14681681,Activating BRAF and N-Ras mutations in sporadic primary melanomas: an inverse association with allelic loss on chromosome 9.,http://www.ncbi.nlm.nih.gov/pubmed/14681681
1168,24822169,DNA methyltransferases: a novel target for prevention and therapy.,http://www.ncbi.nlm.nih.gov/pubmed/24822169
1169,24854991,The emerging roles of DOT1L in leukemia and normal development.,http://www.ncbi.nlm.nih.gov/pubmed/24854991
1170,21741596,Selective killing of mixed lineage leukemia cells by a potent small-molecule DOT1L inhibitor.,http://www.ncbi.nlm.nih.gov/pubmed/21741596
1171,24416237,Colorectal tumors from APC*I1307K carriers principally harbor somatic APC mutations outside the A8 tract.,http://www.ncbi.nlm.nih.gov/pubmed/24416237
1172,20592068,Moderate influence of human APOBEC3F on HIV-1 replication in primary lymphocytes.,http://www.ncbi.nlm.nih.gov/pubmed/20592068
1173,21993670,ATM gene alterations in chronic lymphocytic leukemia patients induce a distinct gene expression profile and predict disease progression.,http://www.ncbi.nlm.nih.gov/pubmed/21993670
1174,24909261,Recurrent somatic mutation in DROSHA induces microRNA profile changes in Wilms tumour.,http://www.ncbi.nlm.nih.gov/pubmed/24909261
1176,25351346,Hypoxia-mediated downregulation of miRNA biogenesis promotes tumour progression.,http://www.ncbi.nlm.nih.gov/pubmed/25351346
1177,25027649,Regulation of microRNA biogenesis.,http://www.ncbi.nlm.nih.gov/pubmed/25027649
1178,18292776,Small integrin-binding ligand N-linked glycoproteins (SIBLINGs): multifunctional proteins in cancer.,http://www.ncbi.nlm.nih.gov/pubmed/18292776
1179,21103065,"Dentin sialophosphoprotein (DSPP) gene-silencing inhibits key tumorigenic activities in human oral cancer cell line, OSC2.",http://www.ncbi.nlm.nih.gov/pubmed/21103065
1180,16108038,Expression of dentin sialophosphoprotein in human prostate cancer and its correlation with tumor aggressiveness.,http://www.ncbi.nlm.nih.gov/pubmed/16108038
1181,23466651,"Histone-lysine methyltransferase EHMT2 is involved in proliferation, apoptosis, cell invasion, and DNA methylation of human neuroblastoma cells.",http://www.ncbi.nlm.nih.gov/pubmed/23466651
1182,24832370,"Euchromatic histone methyltransferase 2 inhibitor, BIX-01294, sensitizes human promyelocytic leukemia HL-60 and NB4 cells to growth inhibition and differentiation.",http://www.ncbi.nlm.nih.gov/pubmed/24832370
1183,21743462,A chemical probe selectively inhibits G9a and GLP methyltransferase activity in cells.,http://www.ncbi.nlm.nih.gov/pubmed/21743462
1184,2536950,Pharmacological studies of lappaconitine. Occurrence of analgesic effect without opioid receptor.,http://www.ncbi.nlm.nih.gov/pubmed/2536950
1185,24622842,Driver mutations of cancer epigenomes.,http://www.ncbi.nlm.nih.gov/pubmed/24622842
1186,25111821,Somatic alterations and dysregulation of epigenetic modifiers in cancers.,http://www.ncbi.nlm.nih.gov/pubmed/25111821
1187,16516143,Potential clinical relevance of Eph receptors and ephrin ligands expressed in prostate carcinoma cell lines.,http://www.ncbi.nlm.nih.gov/pubmed/16516143
1188,24403271,Expression of Eph receptor A10 is correlated with lymph node metastasis and stage progression in breast cancer patients.,http://www.ncbi.nlm.nih.gov/pubmed/24403271
1189,25152371,Ligand stimulation induces clathrin- and Rab5-dependent downregulation of the kinase-dead EphB6 receptor preceded by the disruption of EphB6-Hsp90 interaction.,http://www.ncbi.nlm.nih.gov/pubmed/25152371
1190,24924629,Eph receptor A10 has a potential as a target for a prostate cancer therapy.,http://www.ncbi.nlm.nih.gov/pubmed/24924629
1191,15955811,Biphasic functions of the kinase-defective Ephb6 receptor in cell adhesion and migration.,http://www.ncbi.nlm.nih.gov/pubmed/15955811
1192,25239188,EphB6 promotes anoikis by modulating EphA2 signaling.,http://www.ncbi.nlm.nih.gov/pubmed/25239188
1193,22685175,Aberrant STAT5 and PI3K/mTOR pathway signaling occurs in human CRLF2-rearranged B-precursor acute lymphoblastic leukemia.,http://www.ncbi.nlm.nih.gov/pubmed/22685175
1194,12906867,Identification of two new members of the CSMD gene family.,http://www.ncbi.nlm.nih.gov/pubmed/12906867
1195,21351276,Somatic mutations and germline sequence variants in patients with familial colorectal cancer.,http://www.ncbi.nlm.nih.gov/pubmed/21351276
1196,19528667,Association of chromosome 8q variants with prostate cancer risk in Caucasian and Hispanic men.,http://www.ncbi.nlm.nih.gov/pubmed/19528667
1197,24554720,"Ovarian cancer-associated mutations disable catalytic activity of CDK12, a kinase that promotes homologous recombination repair and resistance to cisplatin and poly(ADP-ribose) polymerase inhibitors.",http://www.ncbi.nlm.nih.gov/pubmed/24554720
1198,22012619,The Cyclin K/Cdk12 complex maintains genomic stability via regulation of expression of DNA damage response genes.,http://www.ncbi.nlm.nih.gov/pubmed/22012619
1199,22987117,CDC73 mutations and parafibromin immunohistochemistry in parathyroid tumors: clinical correlations in a single-centre patient cohort.,http://www.ncbi.nlm.nih.gov/pubmed/22987117
1200,23029104,Novel HRPT2/CDC73 gene mutations and loss of expression of parafibromin in Chinese patients with clinically sporadic parathyroid carcinomas.,http://www.ncbi.nlm.nih.gov/pubmed/23029104
1201,23555276,A novel mutation in the upstream open reading frame of the CDKN1B gene causes a MEN4 phenotype.,http://www.ncbi.nlm.nih.gov/pubmed/23555276
1202,18354415,The Cdk inhibitor p27 in human cancer: prognostic potential and relevance to anticancer therapy.,http://www.ncbi.nlm.nih.gov/pubmed/18354415
1203,16828711,TEL/ETV6 induces apoptosis in 32D cells through p53-dependent pathways.,http://www.ncbi.nlm.nih.gov/pubmed/16828711
1204,22528774,Matrix metalloproteinase-9 and the Cu/Zn ratio as ancillary diagnostic tools in distinguishing between the classical and follicular variants of papillary thyroid carcinoma.,http://www.ncbi.nlm.nih.gov/pubmed/22528774
1205,21351264,p27Kip1 is a predictive factor for tamoxifen treatment response but not a prognostic marker in premenopausal breast cancer patients.,http://www.ncbi.nlm.nih.gov/pubmed/21351264
1206,19147556,p18Ink4c and p53 Act as tumor suppressors in cyclin D1-driven primitive neuroectodermal tumor.,http://www.ncbi.nlm.nih.gov/pubmed/19147556
1207,18942719,P18 is a tumor suppressor gene involved in human medullary thyroid carcinoma and pheochromocytoma development.,http://www.ncbi.nlm.nih.gov/pubmed/18942719
1208,24880342,Rare variants of large effect in BRCA2 and CHEK2 affect risk of lung cancer.,http://www.ncbi.nlm.nih.gov/pubmed/24880342
1209,24713400,"A risk of breast cancer in women - carriers of constitutional CHEK2 gene mutations, originating from the North - Central Poland.",http://www.ncbi.nlm.nih.gov/pubmed/24713400
1210,18790776,"AZD7762, a novel checkpoint kinase inhibitor, drives checkpoint abrogation and potentiates DNA-targeted therapies.",http://www.ncbi.nlm.nih.gov/pubmed/18790776
1211,23839309,Chk1/2 inhibition overcomes the cisplatin resistance of head and neck cancer cells secondary to the loss of functional p53.,http://www.ncbi.nlm.nih.gov/pubmed/23839309
1212,21817013,Mutations in CIC and FUBP1 contribute to human oligodendroglioma.,http://www.ncbi.nlm.nih.gov/pubmed/21817013
1213,22588899,"CIC and FUBP1 mutations in oligodendrogliomas, oligoastrocytomas and astrocytomas.",http://www.ncbi.nlm.nih.gov/pubmed/22588899
1214,19277990,Down-regulating cold shock protein genes impairs cancer cell survival and enhances chemosensitivity.,http://www.ncbi.nlm.nih.gov/pubmed/19277990
1215,12819390,"Expression of cold-inducible RNA-binding protein in the normal endometrium, endometrial hyperplasia, and endometrial carcinoma.",http://www.ncbi.nlm.nih.gov/pubmed/12819390
1216,20361288,Prognostic relevance of collagen XVIII expression in metastatic gastric carcinoma.,http://www.ncbi.nlm.nih.gov/pubmed/20361288
1217,21815140,Serum endostatin levels correlate with enhanced extracellular matrix degradation and poor patients' prognosis in bladder cancer.,http://www.ncbi.nlm.nih.gov/pubmed/21815140
1218,23839013,Expressional and mutational analysis of CREBBP gene in gastric and colorectal cancers with microsatellite instability.,http://www.ncbi.nlm.nih.gov/pubmed/23839013
1219,21390130,CREBBP mutations in relapsed acute lymphoblastic leukaemia.,http://www.ncbi.nlm.nih.gov/pubmed/21390130
1220,23022987,Acute myeloid leukemia with translocation (8;16)(p11;p13) and MYST3-CREBBP rearrangement harbors a distinctive microRNA signature targeting RET proto-oncogene.,http://www.ncbi.nlm.nih.gov/pubmed/23022987
1221,9290955,Novel MLL-CBP fusion transcript in therapy-related chronic myelomonocytic leukemia with a t(11;16)(q23;p13) chromosome translocation.,http://www.ncbi.nlm.nih.gov/pubmed/9290955
1222,21465478,The tumor suppressor role of CTCF.,http://www.ncbi.nlm.nih.gov/pubmed/21465478
1223,8649389,"An exceptionally conserved transcriptional repressor, CTCF, employs different combinations of zinc fingers to bind diverged promoter sequences of avian and mammalian c-myc oncogenes.",http://www.ncbi.nlm.nih.gov/pubmed/8649389
1224,20228059,CXC chemokine receptor 4 is a cell surface receptor for extracellular ubiquitin.,http://www.ncbi.nlm.nih.gov/pubmed/20228059
1225,15339043,"CXCR4-SDF-1 signalling, locomotion, chemotaxis and adhesion.",http://www.ncbi.nlm.nih.gov/pubmed/15339043
1226,19641136,Elucidation of CXCR7-mediated signaling events and inhibition of CXCR4-mediated tumor cell transendothelial migration by CXCR7 ligands.,http://www.ncbi.nlm.nih.gov/pubmed/19641136
1227,16815309,"Characterization of the molecular pharmacology of AMD3100: a specific antagonist of the G-protein coupled chemokine receptor, CXCR4.",http://www.ncbi.nlm.nih.gov/pubmed/16815309
1228,25363530,CXCR4 expression affects overall survival of HCC patients whereas CXCR7 expression does not.,http://www.ncbi.nlm.nih.gov/pubmed/25363530
1229,20347313,Ubiquitin chain cleavage: CYLD at work.,http://www.ncbi.nlm.nih.gov/pubmed/20347313
1230,25342597,CYLD-mediated signaling and diseases.,http://www.ncbi.nlm.nih.gov/pubmed/25342597
1231,23505378,Estrogen mediated-activation of miR-191/425 cluster modulates tumorigenicity of breast cancer cells depending on estrogen receptor status.,http://www.ncbi.nlm.nih.gov/pubmed/23505378
1232,19906709,"Integrative analysis of the human cis-antisense gene pairs, miRNAs and their transcription regulation patterns.",http://www.ncbi.nlm.nih.gov/pubmed/19906709
1233,23539629,Death domain-associated protein DAXX promotes ovarian cancer development and chemoresistance.,http://www.ncbi.nlm.nih.gov/pubmed/23539629
1234,20166753,Structural analysis and functional implications of the negative mTORC1 regulator REDD1.,http://www.ncbi.nlm.nih.gov/pubmed/20166753
1235,18198340,Hypoxia regulates TSC1/2-mTOR signaling and tumor suppression through REDD1-mediated 14-3-3 shuttling.,http://www.ncbi.nlm.nih.gov/pubmed/18198340
1236,19026780,EZH1 mediates methylation on histone H3 lysine 27 and complements EZH2 in maintaining stem cell identity and executing pluripotency.,http://www.ncbi.nlm.nih.gov/pubmed/19026780
1237,24183969,Identification of EZH2 and EZH1 small molecule inhibitors with selective impact on diffuse large B cell lymphoma cell growth.,http://www.ncbi.nlm.nih.gov/pubmed/24183969
1238,25176334,"DICER1: mutations, microRNAs and mechanisms.",http://www.ncbi.nlm.nih.gov/pubmed/25176334
1239,20677351,Metastasis: It's nicer with DICER.,http://www.ncbi.nlm.nih.gov/pubmed/20677351
1240,22192845,"GATA-2 mediated regulation of normal hematopoietic stem/progenitor cell function, myelodysplasia and myeloid leukemia.",http://www.ncbi.nlm.nih.gov/pubmed/22192845
1241,14633602,Alterations of beta-catenin pathway in non-melanoma skin tumors: loss of alpha-ABC nuclear reactivity correlates with the presence of beta-catenin gene mutation.,http://www.ncbi.nlm.nih.gov/pubmed/14633602
1242,11950921,Loss of membranous expression of beta-catenin is associated with tumor progression in cutaneous melanoma and rarely caused by exon 3 mutations.,http://www.ncbi.nlm.nih.gov/pubmed/11950921
1243,19293793,An investigation of WNT pathway activation and association with survival in central nervous system primitive neuroectodermal tumours (CNS PNET).,http://www.ncbi.nlm.nih.gov/pubmed/19293793
1244,10213482,Frequent mutation and nuclear localization of beta-catenin in anaplastic thyroid carcinoma.,http://www.ncbi.nlm.nih.gov/pubmed/10213482
1245,11559529,Accumulation of beta-catenin protein and mutations in exon 3 of beta-catenin gene in gastrointestinal carcinoid tumor.,http://www.ncbi.nlm.nih.gov/pubmed/11559529
1246,12781449,Expression of HIF-1 and ubiquitin in conventional renal cell carcinoma: relationship to mutations of the von Hippel-Lindau tumor suppressor gene.,http://www.ncbi.nlm.nih.gov/pubmed/12781449
1247,14556007,"Tat-binding protein-1, a component of the 26S proteasome, contributes to the E3 ubiquitin ligase function of the von Hippel-Lindau protein.",http://www.ncbi.nlm.nih.gov/pubmed/14556007
1248,2827888,Molecular heterogeneity of adult Philadelphia chromosome-positive acute lymphoblastic leukemia.,http://www.ncbi.nlm.nih.gov/pubmed/2827888
1249,10702799,The ETV6-NTRK3 gene fusion encodes a chimeric protein tyrosine kinase that transforms NIH3T3 cells.,http://www.ncbi.nlm.nih.gov/pubmed/10702799
1250,23811600,Chaperones as thermodynamic sensors of drug-target interactions reveal kinase inhibitor specificities in living cells.,http://www.ncbi.nlm.nih.gov/pubmed/23811600
1251,24882558,Proteomic identification of target proteins in normal but nonfertilizing sperm.,http://www.ncbi.nlm.nih.gov/pubmed/24882558
1252,25151357,Genetic landscape of esophageal squamous cell carcinoma.,http://www.ncbi.nlm.nih.gov/pubmed/25151357
1253,24951259,Novel recurrently mutated genes and a prognostic mutation signature in colorectal cancer.,http://www.ncbi.nlm.nih.gov/pubmed/24951259
1254,24744582,An updated review of gastric cancer in the next-generation sequencing era: insights from bench to bedside and vice versa.,http://www.ncbi.nlm.nih.gov/pubmed/24744582
1255,18598945,Mutations in Fbx4 inhibit dimerization of the SCF(Fbx4) ligase and contribute to cyclin D1 overexpression in human cancer.,http://www.ncbi.nlm.nih.gov/pubmed/18598945
1256,21177873,Endocytic recycling proteins EHD1 and EHD2 interact with fer-1-like-5 (Fer1L5) and mediate myoblast fusion.,http://www.ncbi.nlm.nih.gov/pubmed/21177873
1257,22202072,The contrasting oncogenic and tumor suppressor roles of FES.,http://www.ncbi.nlm.nih.gov/pubmed/22202072
1258,24625025,Vasculature analysis of patient derived tumor xenografts using species-specific PCR assays: evidence of tumor endothelial cells and atypical VEGFA-VEGFR1/2 signalings.,http://www.ncbi.nlm.nih.gov/pubmed/24625025
1259,24909162,Targeted resequencing of the microRNAome and 3'UTRome reveals functional germline DNA variants with altered prevalence in epithelial ovarian cancer.,http://www.ncbi.nlm.nih.gov/pubmed/24909162
1260,11114740,Vascular endothelial growth factor receptors in the regulation of angiogenesis and lymphangiogenesis.,http://www.ncbi.nlm.nih.gov/pubmed/11114740
1261,11718224,Vascular endothelial growth factor C promotes human gastric carcinoma lymph node metastasis in mice.,http://www.ncbi.nlm.nih.gov/pubmed/11718224
1262,24948874,Modulation of androgen receptor by FOXA1 and FOXO1 factors in prostate cancer.,http://www.ncbi.nlm.nih.gov/pubmed/24948874
1263,24596370,Overexpression of androgen receptor and forkhead-box A1 protein in apocrine breast carcinoma.,http://www.ncbi.nlm.nih.gov/pubmed/24596370
1264,24528009,FOXA1: a promising prognostic marker in breast cancer.,http://www.ncbi.nlm.nih.gov/pubmed/24528009
1265,24415069,Impact of GATA-3 and FOXA1 expression in patients with hormone receptor-positive/HER2-negative breast cancer.,http://www.ncbi.nlm.nih.gov/pubmed/24415069
1266,23614352,An orally bioavailable chemical probe of the Lysine Methyltransferases EZH2 and EZH1.,http://www.ncbi.nlm.nih.gov/pubmed/23614352
1267,7550312,Targeted disruption of the GATA3 gene causes severe abnormalities in the nervous system and in fetal liver haematopoiesis.,http://www.ncbi.nlm.nih.gov/pubmed/7550312
1268,21924928,An essential role of the transcription factor GATA-3 for the function of regulatory T cells.,http://www.ncbi.nlm.nih.gov/pubmed/21924928
1269,20189993,GATA3 inhibits breast cancer metastasis through the reversal of epithelial-mesenchymal transition.,http://www.ncbi.nlm.nih.gov/pubmed/20189993
1270,25232488,GATA3 in the urinary bladder: suppression of neoplastic transformation and down-regulation by androgens.,http://www.ncbi.nlm.nih.gov/pubmed/25232488
1271,11001584,The sonic hedgehog-patched-gli pathway in human development and disease.,http://www.ncbi.nlm.nih.gov/pubmed/11001584
1272,1825351,The zinc finger protein GLI transforms primary cells in cooperation with adenovirus E1A.,http://www.ncbi.nlm.nih.gov/pubmed/1825351
1273,21862631,TGF-β/SMAD/GLI2 signaling axis in cancer progression and metastasis.,http://www.ncbi.nlm.nih.gov/pubmed/21862631
1274,25422910,Low FOXA1 expression predicts good response to neo-adjuvant chemotherapy resulting in good outcomes for luminal HER2-negative breast cancer cases.,http://www.ncbi.nlm.nih.gov/pubmed/25422910
1275,22926519,"Far upstream element binding protein 1: a commander of transcription, translation and beyond.",http://www.ncbi.nlm.nih.gov/pubmed/22926519
1276,25435116,Down syndrome preleukemia and leukemia.,http://www.ncbi.nlm.nih.gov/pubmed/25435116
1277,24880866,Are GATA1 mutations occurring at random in Down syndrome transient leukemia?,http://www.ncbi.nlm.nih.gov/pubmed/24880866
1278,23874683,Overexpression of GATA1 confers resistance to chemotherapy in acute megakaryocytic Leukemia.,http://www.ncbi.nlm.nih.gov/pubmed/23874683
1279,24946055,Discovery and optimization of small-molecule ligands for the CBP/p300 bromodomains.,http://www.ncbi.nlm.nih.gov/pubmed/24946055
1280,,Abstract 2084: Ponatinib is a highly potent inhibitor of activated variants of RET found in MTC and NSCLC .,http://cancerres.aacrjournals.org/content/73/8_Supplement/2084.short
1281,,"Use of axitinib, a new-generation tyrosine kinase inhibitor, to decrease glioblastoma growth despite primary resistance to the VEGF-antibody bevacizumab.",http://meeting.ascopubs.org/cgi/content/abstract/31/15_suppl/2077
1282,23209813,KRAS mutation is a predictor of oxaliplatin sensitivity in colon cancer cells.,http://www.ncbi.nlm.nih.gov/pubmed/23209813
1283,25338318,Phase II trial of triple tyrosine kinase receptor inhibitor nintedanib in recurrent high-grade gliomas.,http://www.ncbi.nlm.nih.gov/pubmed/25338318
1284,24424564,Sunitinib administered prior to radiotherapy in patients with non-resectable glioblastoma: results of a phase II study.,http://www.ncbi.nlm.nih.gov/pubmed/24424564
1285,23086433,Continuous daily sunitinib for recurrent glioblastoma.,http://www.ncbi.nlm.nih.gov/pubmed/23086433
1286,24206133,Can γH2AX be used to personalise cancer treatment?,http://www.ncbi.nlm.nih.gov/pubmed/24206133
1287,24164298,H2AX a promising biomarker for lung cancer: a review.,http://www.ncbi.nlm.nih.gov/pubmed/24164298
1288,19427217,"HAUS, the 8-subunit human Augmin complex, regulates centrosome and spindle integrity.",http://www.ncbi.nlm.nih.gov/pubmed/19427217
1289,12235138,Interaction of HCF-1 with a cellular nuclear export factor.,http://www.ncbi.nlm.nih.gov/pubmed/12235138
1290,25234168,Hes1 suppresses acute myeloid leukemia development through FLT3 repression.,http://www.ncbi.nlm.nih.gov/pubmed/25234168
1291,25139105,HES1 as an independent prognostic marker in esophageal squamous cell carcinoma.,http://www.ncbi.nlm.nih.gov/pubmed/25139105
1292,24492635,Hes1 is involved in the self-renewal and tumourigenicity of stem-like cancer cells in colon cancer.,http://www.ncbi.nlm.nih.gov/pubmed/24492635
1293,21468686,Synergistic killing of colorectal cancer cells by oxaliplatin and ABT-737.,http://www.ncbi.nlm.nih.gov/pubmed/21468686
1294,25167228,KRAS mutational subtype and copy number predict in vitro response of human pancreatic cancer cell lines to MEK inhibition.,http://www.ncbi.nlm.nih.gov/pubmed/25167228
1295,23637910,Epigenetic inactivation of Notch-Hes pathway in human B-cell acute lymphoblastic leukemia.,http://www.ncbi.nlm.nih.gov/pubmed/23637910
1296,20091184,The expressions of bHLH gene HES1 and HES5 in advanced ovarian serous adenocarcinomas and their prognostic significance: a retrospective clinical study.,http://www.ncbi.nlm.nih.gov/pubmed/20091184
1297,20212049,Characterization of functional domains necessary for mutant p53 gain of function.,http://www.ncbi.nlm.nih.gov/pubmed/20212049
1298,23538418,Two hot spot mutant p53 mouse models display differential gain of function in tumorigenesis.,http://www.ncbi.nlm.nih.gov/pubmed/23538418
1299,23900217,Notch-induced transcription factors are predictive of survival and 5-fluorouracil response in colorectal cancer patients.,http://www.ncbi.nlm.nih.gov/pubmed/23900217
1300,20814245,Gli3 mediates cell survival and sensitivity to cyclopamine in pancreatic cancer.,http://www.ncbi.nlm.nih.gov/pubmed/20814245
1301,10984056,Effects of oncogenic mutations in Smoothened and Patched can be reversed by cyclopamine.,http://www.ncbi.nlm.nih.gov/pubmed/10984056
1302,22806875,Biomarker and pharmacologic evaluation of the γ-secretase inhibitor PF-03084014 in breast cancer models.,http://www.ncbi.nlm.nih.gov/pubmed/22806875
1303,24403239,Thiocoraline alters neuroendocrine phenotype and activates the Notch pathway in MTC-TT cell line.,http://www.ncbi.nlm.nih.gov/pubmed/24403239
1304,24930887,HGF/MET-directed therapeutics in gastroesophageal cancer: a review of clinical and biomarker development.,http://www.ncbi.nlm.nih.gov/pubmed/24930887
1305,24865428,Four individually druggable MET hotspots mediate HGF-driven tumor progression.,http://www.ncbi.nlm.nih.gov/pubmed/24865428
1306,20126411,CBL is frequently altered in lung cancers: its relationship to mutations in MET and EGFR tyrosine kinases.,http://www.ncbi.nlm.nih.gov/pubmed/20126411
1307,19649990,"Rilotumumab, a mAb against human hepatocyte growth factor for the treatment of cancer.",http://www.ncbi.nlm.nih.gov/pubmed/19649990
1308,24919569,Randomized phase Ib/II trial of rilotumumab or ganitumab with panitumumab versus panitumumab alone in patients with wild-type KRAS metastatic colorectal cancer.,http://www.ncbi.nlm.nih.gov/pubmed/24919569
1309,24289130,A review of epigenetic and gene expression alterations associated with intracranial meningiomas.,http://www.ncbi.nlm.nih.gov/pubmed/24289130
1310,18852131,"Antitumor activity and molecular effects of the novel heat shock protein 90 inhibitor, IPI-504, in pancreatic cancer.",http://www.ncbi.nlm.nih.gov/pubmed/18852131
1311,25009658,Metformin inhibits histone H2B monoubiquitination and downstream gene transcription in human breast cancer cells.,http://www.ncbi.nlm.nih.gov/pubmed/25009658
1312,24891457,Histone H2B monoubiquitination: roles to play in human malignancy.,http://www.ncbi.nlm.nih.gov/pubmed/24891457
1313,24242757,Molecular analysis of diffuse intrinsic brainstem gliomas in adults.,http://www.ncbi.nlm.nih.gov/pubmed/24242757
1314,22286216,Somatic histone H3 alterations in pediatric diffuse intrinsic pontine gliomas and non-brainstem glioblastomas.,http://www.ncbi.nlm.nih.gov/pubmed/22286216
1315,20388056,Human leukocyte antigen class I alleles and the risk of chronic myelogenous leukemia: a meta-analysis.,http://www.ncbi.nlm.nih.gov/pubmed/20388056
1316,22880099,"Evaluation of human leukocyte antigen-A (HLA-A), other non-HLA markers on chromosome 6p21 and risk of nasopharyngeal carcinoma.",http://www.ncbi.nlm.nih.gov/pubmed/22880099
1317,22814293,Risk of developing chronic lymphocytic leukemia is influenced by HLA-A class I variation.,http://www.ncbi.nlm.nih.gov/pubmed/22814293
1318,20080636,Resolvin D1 binds human phagocytes with evidence for proresolving receptors.,http://www.ncbi.nlm.nih.gov/pubmed/20080636
1319,24120851,Resolvin D1 inhibits TGF-β1-induced epithelial mesenchymal transition of A549 lung cancer cells via lipoxin A4 receptor/formyl peptide receptor 2 and GPR32.,http://www.ncbi.nlm.nih.gov/pubmed/24120851
1320,10480904,A candidate target for G protein action in brain.,http://www.ncbi.nlm.nih.gov/pubmed/10480904
1321,15488195,Identification and biochemical analysis of GRIN1 and GRIN2.,http://www.ncbi.nlm.nih.gov/pubmed/15488195
1322,17877814,Functional analysis of cancer-associated EGFR mutants using a cellular assay with YFP-tagged EGFR intracellular domain.,http://www.ncbi.nlm.nih.gov/pubmed/17877814
1323,22172337,Notch signaling modulates hypoxia-induced neuroendocrine differentiation of human prostate cancer cells.,http://www.ncbi.nlm.nih.gov/pubmed/22172337
1324,22056382,Crosstalk between the canonical NF-κB and Notch signaling pathways inhibits Pparγ expression and promotes pancreatic cancer progression in mice.,http://www.ncbi.nlm.nih.gov/pubmed/22056382
1325,20386868,Gene expression profiling of the hedgehog signaling pathway in human meningiomas.,http://www.ncbi.nlm.nih.gov/pubmed/20386868
1326,25326334,Controlled delivery of BID protein fused with TAT peptide sensitizes cancer cells to apoptosis.,http://www.ncbi.nlm.nih.gov/pubmed/25326334
1327,21943176,A MCP1 fusokine with CCR2-specific tumoricidal activity.,http://www.ncbi.nlm.nih.gov/pubmed/21943176
1328,24908363,The Rho-kinase inhibitor HA-1077 suppresses proliferation/migration and induces apoptosis of urothelial cancer cells.,http://www.ncbi.nlm.nih.gov/pubmed/24908363
1329,22541434,The GATA2 transcriptional network is requisite for RAS oncogene-driven non-small cell lung cancer.,http://www.ncbi.nlm.nih.gov/pubmed/22541434
1330,16357129,Identification of GATA3 as a breast cancer prognostic marker by global gene expression meta-analysis.,http://www.ncbi.nlm.nih.gov/pubmed/16357129
1331,23354167,GATA3 suppresses metastasis and modulates the tumour microenvironment by regulating microRNA-29b expression.,http://www.ncbi.nlm.nih.gov/pubmed/23354167
1332,25374920,"Nuclear receptor corepressor complexes in cancer: mechanism, function and regulation.",http://www.ncbi.nlm.nih.gov/pubmed/25374920
1333,21499247,Exome sequencing identifies GRIN2A as frequently mutated in melanoma.,http://www.ncbi.nlm.nih.gov/pubmed/21499247
1334,22291485,NMDA receptors are expressed by small-cell lung cancer and are potential targets for effective treatment.,http://www.ncbi.nlm.nih.gov/pubmed/22291485
1335,21183792,Arsenic trioxide inhibits human cancer cell growth and tumor development in mice by blocking Hedgehog/GLI pathway.,http://www.ncbi.nlm.nih.gov/pubmed/21183792
1336,17494766,Inhibition of GLI-mediated transcription and tumor cell growth by small-molecule antagonists.,http://www.ncbi.nlm.nih.gov/pubmed/17494766
1337,21135115,Hedgehog signaling drives cellular survival in human colon carcinoma cells.,http://www.ncbi.nlm.nih.gov/pubmed/21135115
1338,3529096,The anticonvulsant MK-801 is a potent N-methyl-D-aspartate antagonist.,http://www.ncbi.nlm.nih.gov/pubmed/3529096
1339,16230611,NMDA antagonist inhibits the extracellular signal-regulated kinase pathway and suppresses cancer growth.,http://www.ncbi.nlm.nih.gov/pubmed/16230611
1340,24240127,The combination of glutamate receptor antagonist MK-801 with tamoxifen and its active metabolites potentiates their antiproliferative activity in mouse melanoma K1735-M2 cells.,http://www.ncbi.nlm.nih.gov/pubmed/24240127
1341,23171453,Blocking glutamate-mediated signalling inhibits human melanoma growth and migration.,http://www.ncbi.nlm.nih.gov/pubmed/23171453
1342,25338956,Genome-wide linkage and exome analyses identify variants of HMCN1 for splenic epidermoid cyst.,http://www.ncbi.nlm.nih.gov/pubmed/25338956
1343,17031392,Hemicentins: what have we learned from worms?,http://www.ncbi.nlm.nih.gov/pubmed/17031392
1344,25233928,Transcriptome analysis of pancreatic cancer reveals a tumor suppressor function for HNF1A.,http://www.ncbi.nlm.nih.gov/pubmed/25233928
1345,25119106,The DNA binding property of PML/RARA but not the integrity of PML nuclear bodies is indispensable for leukemic transformation.,http://www.ncbi.nlm.nih.gov/pubmed/25119106
1346,21704618,A neuronal transmembrane protein LRFN4 induces monocyte/macrophage migration via actin cytoskeleton reorganization.,http://www.ncbi.nlm.nih.gov/pubmed/21704618
1347,22347506,ALK-activating homologous mutations in LTK induce cellular transformation.,http://www.ncbi.nlm.nih.gov/pubmed/22347506
1348,19471318,A novel microdeletion syndrome involving 5q14.3-q15: clinical and molecular cytogenetic characterization of three patients.,http://www.ncbi.nlm.nih.gov/pubmed/19471318
1349,11384978,"The putative tumor suppressor LRP1B, a novel member of the low density lipoprotein (LDL) receptor family, exhibits both overlapping and distinct properties with the LDL receptor-related protein.",http://www.ncbi.nlm.nih.gov/pubmed/11384978
1350,12194987,Low density lipoprotein (LDL) receptor-related protein 1B impairs urokinase receptor regeneration on the cell surface and inhibits cell migration.,http://www.ncbi.nlm.nih.gov/pubmed/12194987
1351,20095042,Aberrant methylation impairs low density lipoprotein receptor-related protein 1B tumor suppressor function in gastric cancer.,http://www.ncbi.nlm.nih.gov/pubmed/20095042
1352,22896685,LRP1B deletion in high-grade serous ovarian cancers is associated with acquired chemotherapy resistance to liposomal doxorubicin.,http://www.ncbi.nlm.nih.gov/pubmed/22896685
1353,21333379,The bottleneck of JNK signaling: molecular and functional characteristics of MKK4 and MKK7.,http://www.ncbi.nlm.nih.gov/pubmed/21333379
1354,23207916,The INO80 chromatin remodeling complex prevents polyploidy and maintains normal chromatin structure at centromeres.,http://www.ncbi.nlm.nih.gov/pubmed/23207916
1355,22749148,The RSC and INO80 chromatin-remodeling complexes in DNA double-strand break repair.,http://www.ncbi.nlm.nih.gov/pubmed/22749148
1356,21148483,"Human inositol 1,4,5-trisphosphate 3-kinase isoform B (IP3KB) is a nucleocytoplasmic shuttling protein specifically enriched at cortical actin filaments and at invaginations of the nuclear envelope.",http://www.ncbi.nlm.nih.gov/pubmed/21148483
1357,16946712,A Web-based data warehouse on gene expression in human malignant melanoma.,http://www.ncbi.nlm.nih.gov/pubmed/16946712
1358,17549425,Comparative integromics on JMJD1C gene encoding histone demethylase: conserved POU5F1 binding site elucidating mechanism of JMJD1C expression in undifferentiated ES cells and diffuse-type gastric cancer.,http://www.ncbi.nlm.nih.gov/pubmed/17549425
1359,24501218,shRNA screening identifies JMJD1C as being required for leukemia maintenance.,http://www.ncbi.nlm.nih.gov/pubmed/24501218
1360,24896186,Novel somatic and germline mutations in intracranial germ cell tumours.,http://www.ncbi.nlm.nih.gov/pubmed/24896186
1361,17947579,JMJD6 is a histone arginine demethylase.,http://www.ncbi.nlm.nih.gov/pubmed/17947579
1362,19574390,"Jmjd6 catalyses lysyl-hydroxylation of U2AF65, a protein associated with RNA splicing.",http://www.ncbi.nlm.nih.gov/pubmed/19574390
1363,22621393,JMJD6 is a driver of cellular proliferation and motility and a marker of poor prognosis in breast cancer.,http://www.ncbi.nlm.nih.gov/pubmed/22621393
1364,23595221,High expression of JMJD6 predicts unfavorable survival in lung adenocarcinoma.,http://www.ncbi.nlm.nih.gov/pubmed/23595221
1365,24667498,JMJD6 promotes colon carcinogenesis through negative regulation of p53 by hydroxylation.,http://www.ncbi.nlm.nih.gov/pubmed/24667498
1366,9836639,KCNQ2 and KCNQ3 potassium channel subunits: molecular correlates of the M-channel.,http://www.ncbi.nlm.nih.gov/pubmed/9836639
1367,11160379,Differential expression of kcnq2 splice variants: implications to m current function during neuronal development.,http://www.ncbi.nlm.nih.gov/pubmed/11160379
1368,10455268,Separation of M-like current and ERG current in NG108-15 cells.,http://www.ncbi.nlm.nih.gov/pubmed/10455268
1369,14764898,Scaffolding of Keap1 to the actin cytoskeleton controls the function of Nrf2 as key regulator of cytoprotective phase 2 genes.,http://www.ncbi.nlm.nih.gov/pubmed/14764898
1370,24142871,The emerging role of the Nrf2-Keap1 signaling pathway in cancer.,http://www.ncbi.nlm.nih.gov/pubmed/24142871
1371,24283590,Identification of PLX4032-resistance mechanisms and implications for novel RAF inhibitors.,http://www.ncbi.nlm.nih.gov/pubmed/24283590
1372,18485478,FBXW7 mutation in adult T-cell and B-cell acute lymphocytic leukemias.,http://www.ncbi.nlm.nih.gov/pubmed/18485478
1373,20962861,A nonsense mutation of IDH1 in myelodysplastic syndromes and related disorders.,http://www.ncbi.nlm.nih.gov/pubmed/20962861
1374,18685719,Oncomirs: the potential role of non-coding microRNAs in understanding cancer.,http://www.ncbi.nlm.nih.gov/pubmed/18685719
1375,18787018,Argonaute-2 expression is regulated by epidermal growth factor receptor and mitogen-activated protein kinase signaling and correlates with a transformed phenotype in breast cancer cells.,http://www.ncbi.nlm.nih.gov/pubmed/18787018
1376,25375928,Ubiquitination in disease pathogenesis and treatment.,http://www.ncbi.nlm.nih.gov/pubmed/25375928
1377,23748107,CTLA-4 blockade and the renaissance of cancer immunotherapy.,http://www.ncbi.nlm.nih.gov/pubmed/23748107
1378,22658126,Tumor immunotherapy directed at PD-1.,http://www.ncbi.nlm.nih.gov/pubmed/22658126
1379,15620353,Histone demethylation mediated by the nuclear amine oxidase homolog LSD1.,http://www.ncbi.nlm.nih.gov/pubmed/15620353
1380,22464800,The histone demethylase KDM1A sustains the oncogenic potential of MLL-AF9 leukemia stem cells.,http://www.ncbi.nlm.nih.gov/pubmed/22464800
1381,24625776,Activating mTOR mutations in a patient with an extraordinary response on a phase I trial of everolimus and pazopanib.,http://www.ncbi.nlm.nih.gov/pubmed/24625776
1382,18987994,HspBP1 levels are elevated in breast tumor tissue and inversely related to tumor aggressiveness.,http://www.ncbi.nlm.nih.gov/pubmed/18987994
1383,24380799,An essential role for heat shock transcription factor binding protein 1 (HSBP1) during early embryonic development.,http://www.ncbi.nlm.nih.gov/pubmed/24380799
1384,9649501,Negative regulation of the heat shock transcriptional response by HSBP1.,http://www.ncbi.nlm.nih.gov/pubmed/9649501
1385,20101233,Heat shock protein 27 confers resistance to androgen ablation and chemotherapy in prostate cancer cells through eIF4E.,http://www.ncbi.nlm.nih.gov/pubmed/20101233
1386,22012255,OGX-427 inhibits tumor progression and enhances gemcitabine chemotherapy in pancreatic cancer.,http://www.ncbi.nlm.nih.gov/pubmed/22012255
1387,25465722,Transcription factors Hsf1 and Nrf2 engage in crosstalk for cytoprotection.,http://www.ncbi.nlm.nih.gov/pubmed/25465722
1388,25199534,Upregulation of heat shock factor 1 transcription activity is associated with hepatocellular carcinoma progression.,http://www.ncbi.nlm.nih.gov/pubmed/25199534
1389,25202032,Expression of HSF2 decreases in mitosis to enable stress-inducible transcription and cell survival.,http://www.ncbi.nlm.nih.gov/pubmed/25202032
1390,10488131,The mammalian HSF4 gene generates both an activator and a repressor of heat shock genes by alternative splicing.,http://www.ncbi.nlm.nih.gov/pubmed/10488131
1391,22528049,Zebrafish HSF4: a novel protein that shares features of both HSF1 and HSF4 of mammals.,http://www.ncbi.nlm.nih.gov/pubmed/22528049
1392,25248477,"Id proteins: small molecules, mighty regulators.",http://www.ncbi.nlm.nih.gov/pubmed/25248477
1393,16034366,Id family of helix-loop-helix proteins in cancer.,http://www.ncbi.nlm.nih.gov/pubmed/16034366
1394,12842081,Id proteins in cell growth and tumorigenesis.,http://www.ncbi.nlm.nih.gov/pubmed/12842081
1395,20842217,Increased inhibitor of differentiation 4 (id4) expression in glioblastoma: a tissue microarray study.,http://www.ncbi.nlm.nih.gov/pubmed/20842217
1396,25364233,Bardoxolone methyl (CDDO-Me) as a therapeutic agent: an update on its pharmacokinetic and pharmacodynamic properties.,http://www.ncbi.nlm.nih.gov/pubmed/25364233
1397,25341045,HDAC1 and Klf4 interplay critically regulates human myeloid leukemia cell proliferation.,http://www.ncbi.nlm.nih.gov/pubmed/25341045
1398,24551169,Promoter hypermethylation of KLF4 inactivates its tumor suppressor function in cervical carcinogenesis.,http://www.ncbi.nlm.nih.gov/pubmed/24551169
1399,23722653,Epigenetic alterations of Krüppel-like factor 4 and its tumor suppressor function in renal cell carcinoma.,http://www.ncbi.nlm.nih.gov/pubmed/23722653
1400,17143534,"Apigenin and cancer chemoprevention: progress, potential and promise (review).",http://www.ncbi.nlm.nih.gov/pubmed/17143534
1401,22084167,Apigenin induces apoptosis in human leukemia cells and exhibits anti-leukemic activity in vivo.,http://www.ncbi.nlm.nih.gov/pubmed/22084167
1402,23317647,KLF4 overexpression and apigenin treatment down regulated anti-apoptotic Bcl-2 proteins and matrix metalloproteinases to control growth of human malignant neuroblastoma SK-N-DZ and IMR-32 cells.,http://www.ncbi.nlm.nih.gov/pubmed/23317647
1403,16166635,The BTB-kelch protein KLHL6 is involved in B-lymphocyte antigen receptor signaling and germinal center formation.,http://www.ncbi.nlm.nih.gov/pubmed/16166635
1404,21642962,Whole-genome sequencing identifies recurrent mutations in chronic lymphocytic leukaemia.,http://www.ncbi.nlm.nih.gov/pubmed/21642962
1405,20945404,Fine-mapping of prostate cancer aggressiveness loci on chromosome 7q22-35.,http://www.ncbi.nlm.nih.gov/pubmed/20945404
1406,23787160,The therapeutic potential of blocking the activin signalling pathway.,http://www.ncbi.nlm.nih.gov/pubmed/23787160
1407,24085226,Significance of INHBA expression in human colorectal cancer.,http://www.ncbi.nlm.nih.gov/pubmed/24085226
1408,19308293,Upregulated INHBA expression may promote cell proliferation and is associated with poor survival in lung adenocarcinoma.,http://www.ncbi.nlm.nih.gov/pubmed/19308293
1409,24292625,Lenalidomide causes selective degradation of IKZF1 and IKZF3 in multiple myeloma cells.,http://www.ncbi.nlm.nih.gov/pubmed/24292625
1410,24965397,A missense mutation (S3660L) in MLL3 gene influences risk of gastric cancer.,http://www.ncbi.nlm.nih.gov/pubmed/24965397
1411,23429989,Exome sequencing identifies an MLL3 gene germ line mutation in a pedigree of colorectal cancer and acute myeloid leukemia.,http://www.ncbi.nlm.nih.gov/pubmed/23429989
1412,21116761,Somatic mutations of the mixed-lineage leukemia 3 (MLL3) gene in primary breast cancers.,http://www.ncbi.nlm.nih.gov/pubmed/21116761
1413,21531766,ID4 imparts chemoresistance and cancer stemness to glioma cells by derepressing miR-9*-mediated suppression of SOX2.,http://www.ncbi.nlm.nih.gov/pubmed/21531766
1414,24122992,Id4 promotes senescence and sensitivity to doxorubicin-induced apoptosis in DU145 prostate cancer cells.,http://www.ncbi.nlm.nih.gov/pubmed/24122992
1415,25344919,"High Id1 expression, a generally negative prognostic factor, paradoxically predicts a favorable prognosis for adjuvant paclitaxel plus cisplatin therapy in surgically treated lung cancer patients.",http://www.ncbi.nlm.nih.gov/pubmed/25344919
1416,24362818,Integrated genomic analysis identifies recurrent mutations and evolution patterns driving the initiation and progression of follicular lymphoma.,http://www.ncbi.nlm.nih.gov/pubmed/24362818
1417,24240169,KMT2D maintains neoplastic cell proliferation and global histone H3 lysine 4 monomethylation.,http://www.ncbi.nlm.nih.gov/pubmed/24240169
1418,23386620,Heat shock factor 1 (HSF1) controls chemoresistance and autophagy through transcriptional regulation of autophagy-related protein 7 (ATG7).,http://www.ncbi.nlm.nih.gov/pubmed/23386620
1419,23403953,Susceptibility of hepatoma-derived cells to histone deacetylase inhibitors is associated with ID2 expression.,http://www.ncbi.nlm.nih.gov/pubmed/23403953
1420,24026096,Evidence for a tumor suppressor role for the large tumor suppressor genes LATS1 and LATS2 in human cancer.,http://www.ncbi.nlm.nih.gov/pubmed/24026096
1421,19601813,17 AAG for HSP90 inhibition in cancer--from bench to bedside.,http://www.ncbi.nlm.nih.gov/pubmed/19601813
1422,20841485,"Heat shock protein 90 inhibition depletes LATS1 and LATS2, two regulators of the mammalian hippo tumor suppressor pathway.",http://www.ncbi.nlm.nih.gov/pubmed/20841485
1423,22580609,"The human Lgl polarity gene, Hugl-2, induces MET and suppresses Snail tumorigenesis.",http://www.ncbi.nlm.nih.gov/pubmed/22580609
1424,23110097,"Hugl1 and Hugl2 in mammary epithelial cells: polarity, proliferation, and differentiation.",http://www.ncbi.nlm.nih.gov/pubmed/23110097
1425,23303138,LIM-domain-only proteins in cancer.,http://www.ncbi.nlm.nih.gov/pubmed/23303138
1426,20664928,Inhibition of tumourigenicity of small cell lung cancer cells by suppressing Id3 expression.,http://www.ncbi.nlm.nih.gov/pubmed/20664928
1427,22355043,Inactivation of heat shock factor Hsf4 induces cellular senescence and suppresses tumorigenesis in vivo.,http://www.ncbi.nlm.nih.gov/pubmed/22355043
1428,25314077,Cancer-selective targeting of the NF-κB survival pathway with GADD45β/MKK7 inhibitors.,http://www.ncbi.nlm.nih.gov/pubmed/25314077
1429,11713530,Induction of gadd45beta by NF-kappaB downregulates pro-apoptotic JNK signalling.,http://www.ncbi.nlm.nih.gov/pubmed/11713530
1430,20670891,Human LSD2/KDM1b/AOF1 regulates gene transcription by modulating intragenic H3K4me2 methylation.,http://www.ncbi.nlm.nih.gov/pubmed/20670891
1431,24386504,MAP3K1: Genomic Alterations in Cancer and Function in Promoting Cell Survival or Apoptosis.,http://www.ncbi.nlm.nih.gov/pubmed/24386504
1432,24924415,"Inhibition of histone demethylase, LSD2 (KDM1B), attenuates DNA methylation and increases sensitivity to DNMT inhibitor-induced apoptosis in breast cancer cells.",http://www.ncbi.nlm.nih.gov/pubmed/24924415
1433,19001877,KDM2A represses transcription of centromeric satellite repeats and maintains the heterochromatic state.,http://www.ncbi.nlm.nih.gov/pubmed/19001877
1434,24659638,Pathogenesis and regulation of cellular proliferation in acute lymphoblastic leukemia - the role of Ikaros.,http://www.ncbi.nlm.nih.gov/pubmed/24659638
1435,22150303,Ikaros and tumor suppression in acute lymphoblastic leukemia.,http://www.ncbi.nlm.nih.gov/pubmed/22150303
1436,18445656,Medullary thyroid cancer: targeting the RET kinase pathway with sorafenib/tipifarnib.,http://www.ncbi.nlm.nih.gov/pubmed/18445656
1437,,,http://www.accessdata.fda.gov/drugsatfda_docs/label/2014/202806s002lbl.pdf
1438,24253898,Silencing MAP3K1 expression through RNA interference enhances paclitaxel-induced cell cycle arrest in human breast cancer cells.,http://www.ncbi.nlm.nih.gov/pubmed/24253898
1439,20395419,Self-association mediated by the Ras association 1 domain of AF6 activates the oncogenic potential of MLL-AF6.,http://www.ncbi.nlm.nih.gov/pubmed/20395419
1440,23481206,Afadin/AF-6 and canoe: roles in cell adhesion and beyond.,http://www.ncbi.nlm.nih.gov/pubmed/23481206
1441,21478912,"Loss of AF6/afadin, a marker of poor outcome in breast cancer, induces cell migration, invasiveness and tumor growth.",http://www.ncbi.nlm.nih.gov/pubmed/21478912
1442,,NCCN Guidelines Melanoma version 3.2015,http://www.nccn.org/professionals/physician_gls/pdf/melanoma.pdf
1443,15077147,Mitogen-activated protein kinases in apoptosis regulation.,http://www.ncbi.nlm.nih.gov/pubmed/15077147
1444,,,http://www.accessdata.fda.gov/drugsatfda_docs/label/2014/202429s006lbl.pdf
1445,,,http://www.accessdata.fda.gov/drugsatfda_docs/label/2014/204114s001lbl.pdf
1446,19883086,"Structure-activity relationship studies of chalcone leading to 3-hydroxy-4,3',4',5'-tetramethoxychalcone and its analogues as potent nuclear factor kappaB inhibitors and their anticancer activities.",http://www.ncbi.nlm.nih.gov/pubmed/19883086
1447,23831571,A JNK-mediated autophagy pathway that triggers c-IAP degradation and necroptosis for anticancer chemotherapy.,http://www.ncbi.nlm.nih.gov/pubmed/23831571
1448,,NCCN Guidelines Version 1.2017 Colon Cancer,https://www.nccn.org/professionals/physician_gls/pdf/colon.pdf
1449,,Erbitux label,http://www.accessdata.fda.gov/drugsatfda_docs/label/2013/125084s242lbl.pdf
1450,,Vectibix label,http://www.accessdata.fda.gov/drugsatfda_docs/label/2014/125147s194lbl.pdf
1451,23361057,Cytosine-based nucleoside analogs are selectively lethal to DNA mismatch repair-deficient tumour cells by enhancing levels of intracellular oxidative stress.,http://www.ncbi.nlm.nih.gov/pubmed/23361057
1452,21075307,A stapled p53 helix overcomes HDMX-mediated suppression of p53.,http://www.ncbi.nlm.nih.gov/pubmed/21075307
1453,22820643,MDM4 is a key therapeutic target in cutaneous melanoma.,http://www.ncbi.nlm.nih.gov/pubmed/22820643
1454,24123922,MED12 related disorders.,http://www.ncbi.nlm.nih.gov/pubmed/24123922
1455,23178117,MED12 controls the response to multiple cancer drugs through regulation of TGF-β receptor signaling.,http://www.ncbi.nlm.nih.gov/pubmed/23178117
1456,22988093,Selective requirement for Mediator MED23 in Ras-active lung cancer.,http://www.ncbi.nlm.nih.gov/pubmed/22988093
1457,25273169,"Upregulation of mediator MED23 in non-small-cell lung cancer promotes the growth, migration, and metastasis of cancer cells.",http://www.ncbi.nlm.nih.gov/pubmed/25273169
1458,23625751,Downregulation of MED23 promoted the tumorigenecity of esophageal squamous cell carcinoma.,http://www.ncbi.nlm.nih.gov/pubmed/23625751
1459,23850066,Menin: a scaffold protein that controls gene expression and cell signaling.,http://www.ncbi.nlm.nih.gov/pubmed/23850066
1460,22915754,MEN1 gene replacement therapy reduces proliferation rates in a mouse model of pituitary adenomas.,http://www.ncbi.nlm.nih.gov/pubmed/22915754
1461,21829508,PIK3CA mutations frequently coexist with RAS and BRAF mutations in patients with advanced cancers.,http://www.ncbi.nlm.nih.gov/pubmed/21829508
1462,24559118,A functional proteogenomic analysis of endometrioid and clear cell carcinomas using reverse phase protein array and mutation analysis: protein expression is histotype-specific and loss of ARID1A/BAF250a is associated with AKT phosphorylation.,http://www.ncbi.nlm.nih.gov/pubmed/24559118
1463,17942903,In vivo functional analysis of the counterbalance of hyperactive phosphatidylinositol 3-kinase p110 catalytic oncoproteins by the tumor suppressor PTEN.,http://www.ncbi.nlm.nih.gov/pubmed/17942903
1464,22277660,Biochemical analysis of the human mismatch repair proteins hMutSα MSH2(G674A)-MSH6 and MSH2-MSH6(T1219D).,http://www.ncbi.nlm.nih.gov/pubmed/22277660
1465,19584161,MSH6 mutations arise in glioblastomas during temozolomide therapy and mediate temozolomide resistance.,http://www.ncbi.nlm.nih.gov/pubmed/19584161
1466,23985272,Mst1 and Mst2 kinases: regulations and diseases.,http://www.ncbi.nlm.nih.gov/pubmed/23985272
1467,20951342,The hippo signaling pathway in development and cancer.,http://www.ncbi.nlm.nih.gov/pubmed/20951342
1468,23419720,Effect of Mst1 overexpression on the growth of human hepatocellular carcinoma HepG2 cells and the sensitivity to cisplatin in vitro.,http://www.ncbi.nlm.nih.gov/pubmed/23419720
1469,25002120,MUC16: molecular analysis and its functional implications in benign and malignant conditions.,http://www.ncbi.nlm.nih.gov/pubmed/25002120
1470,,Abstract LB-290: Targeting MUC16 with the antibody-drug conjugate (ADC) DMUC5754A in patients with platinum-resistant ovarian cancer: A phase I study of safety and pharmacokinetics.,http://cancerres.aacrjournals.org/content/73/8_Supplement/LB-290.abstract?sid=11b83865-6391-490b-86ad-c4b93e1afa58
1471,,Targeting MUC16 with the antibody-drug conjugate (ADC) DMUC5754A in patients with platinum-resistant ovarian cancer: A phase I study of safety and pharmacokinetics.,http://cancerres.aacrjournals.org/content/73/8_Supplement/LB-290.abstract?sid=11b83865-6391-490b-86ad-c4b93e1afa58
1472,16737958,Characterization of human mucin MUC17. Complete coding sequence and organization.,http://www.ncbi.nlm.nih.gov/pubmed/16737958
1473,20702471,Expression of intestinal MUC17 membrane-bound mucin in inflammatory and neoplastic diseases of the colon.,http://www.ncbi.nlm.nih.gov/pubmed/20702471
1474,19817750,Molecular markers associated with lymph node metastasis in pancreatic ductal adenocarcinoma by genome-wide expression profiling.,http://www.ncbi.nlm.nih.gov/pubmed/19817750
1475,20001800,Muc4/MUC4 functions and regulation in cancer.,http://www.ncbi.nlm.nih.gov/pubmed/20001800
1476,18024835,"Structure, evolution, and biology of the MUC4 mucin.",http://www.ncbi.nlm.nih.gov/pubmed/18024835
1477,9729478,"MUC5B is a major gel-forming, oligomeric mucin from human salivary gland, respiratory tract and endocervix: identification of glycoforms and C-terminal cleavage.",http://www.ncbi.nlm.nih.gov/pubmed/9729478
1478,19783639,Unpacking a gel-forming mucin: a view of MUC5B organization after granular release.,http://www.ncbi.nlm.nih.gov/pubmed/19783639
1479,23056409,MUC5B leads to aggressive behavior of breast cancer MCF7 cells.,http://www.ncbi.nlm.nih.gov/pubmed/23056409
1480,21196221,Myb proteins: angels and demons in normal and transformed cells.,http://www.ncbi.nlm.nih.gov/pubmed/21196221
1481,1851123,Identification and characterization of a novel repressor of beta-interferon gene expression.,http://www.ncbi.nlm.nih.gov/pubmed/1851123
1482,22143801,PRDM1 is a tumor suppressor gene in natural killer cell malignancies.,http://www.ncbi.nlm.nih.gov/pubmed/22143801
1483,20047096,Blimp-1 is a tumor suppressor gene in lymphoid malignancies.,http://www.ncbi.nlm.nih.gov/pubmed/20047096
1484,9373037,"Myelin transcription factor 1 (Myt1) of the oligodendrocyte lineage, along with a closely related CCHC zinc finger, is expressed in developing neurons in the mammalian central nervous system.",http://www.ncbi.nlm.nih.gov/pubmed/9373037
1485,24015200,Clinical significance of MYT1L gene polymorphisms in Chinese patients with gastric cancer.,http://www.ncbi.nlm.nih.gov/pubmed/24015200
1486,24252690,Identification of a neuronal transcription factor network involved in medulloblastoma development.,http://www.ncbi.nlm.nih.gov/pubmed/24252690
1487,20530581,PRDM1 is required for mantle cell lymphoma response to bortezomib.,http://www.ncbi.nlm.nih.gov/pubmed/20530581
1488,21647249,SRC-3 has a role in cancer other than as a nuclear receptor coactivator.,http://www.ncbi.nlm.nih.gov/pubmed/21647249
1489,24390736,Bufalin is a potent small-molecule inhibitor of the steroid receptor coactivators SRC-3 and SRC-1.,http://www.ncbi.nlm.nih.gov/pubmed/24390736
1490,19738614,Pancreatic cancer cells resistance to gemcitabine: the role of MUC4 mucin.,http://www.ncbi.nlm.nih.gov/pubmed/19738614
1491,22580602,The MUC4 mucin mediates gemcitabine resistance of human pancreatic cancer cells via the Concentrative Nucleoside Transporter family.,http://www.ncbi.nlm.nih.gov/pubmed/22580602
1492,20825420,Mechanisms of resistance to anti-human epidermal growth factor receptor 2 agents in breast cancer.,http://www.ncbi.nlm.nih.gov/pubmed/20825420
1493,20953172,A genome-wide RNAi screen reveals determinants of human embryonic stem cell identity.,http://www.ncbi.nlm.nih.gov/pubmed/20953172
1494,23690269,High expression of PRDM14 correlates with cell differentiation and is a novel prognostic marker in resected non-small cell lung cancer.,http://www.ncbi.nlm.nih.gov/pubmed/23690269
1495,17942894,Gene amplification and overexpression of PRDM14 in breast cancers.,http://www.ncbi.nlm.nih.gov/pubmed/17942894
1496,24249158,Genome-wide analysis of DNA copy number alterations and loss of heterozygosity in intracranial germ cell tumors.,http://www.ncbi.nlm.nih.gov/pubmed/24249158
1497,21369371,Anticancer activity of the PR domain of tumor suppressor RIZ1.,http://www.ncbi.nlm.nih.gov/pubmed/21369371
1498,20159667,DNA methylation of the RIZ1 tumor suppressor gene plays an important role in the tumorigenesis of cervical cancer.,http://www.ncbi.nlm.nih.gov/pubmed/20159667
1499,18712668,Hyper-methylation of RIZ1 tumor suppressor gene is involved in the early tumorigenesis of hepatocellular carcinoma.,http://www.ncbi.nlm.nih.gov/pubmed/18712668
1500,11280725,Adenovirus expressing RIZ1 in tumor suppressor gene therapy of microsatellite-unstable colorectal cancers.,http://www.ncbi.nlm.nih.gov/pubmed/11280725
1501,24634223,Trimethylation of histone H3 lysine 36 by human methyltransferase PRDM9 protein.,http://www.ncbi.nlm.nih.gov/pubmed/24634223
1502,24754746,Allelic variants of PRDM9 associated with high hyperdiploid childhood acute lymphoblastic leukaemia.,http://www.ncbi.nlm.nih.gov/pubmed/24754746
1503,23222848,Rare allelic forms of PRDM9 associated with childhood leukemogenesis.,http://www.ncbi.nlm.nih.gov/pubmed/23222848
1504,24895169,Gene of the month. AMP kinase (PRKAA1).,http://www.ncbi.nlm.nih.gov/pubmed/24895169
1505,24419061,The AMPK inhibitor compound C is a potent AMPK-independent antiglioma agent.,http://www.ncbi.nlm.nih.gov/pubmed/24419061
1506,23630073,Emerging roles of the corepressors NCoR1 and SMRT in homeostasis.,http://www.ncbi.nlm.nih.gov/pubmed/23630073
1507,20091860,Transcription factor co-repressors in cancer biology: roles and targeting.,http://www.ncbi.nlm.nih.gov/pubmed/20091860
1508,23132929,Cell cycle regulation by the NEK family of protein kinases.,http://www.ncbi.nlm.nih.gov/pubmed/23132929
1509,17606467,"A novel family of transmembrane proteins interacting with beta subunits of the Na,K-ATPase.",http://www.ncbi.nlm.nih.gov/pubmed/17606467
1510,17429401,Synthetic lethal screen identification of chemosensitizer loci in cancer cells.,http://www.ncbi.nlm.nih.gov/pubmed/17429401
1511,23763999,NKX2-1/TTF-1: an enigmatic oncogene that functions as a double-edged sword for cancer cell survival and progression.,http://www.ncbi.nlm.nih.gov/pubmed/23763999
1512,25408701,Genetic polymorphism in the NRF2 gene as a prognosis marker for cancer chemotherapy.,http://www.ncbi.nlm.nih.gov/pubmed/25408701
1513,23507558,"MicroRNA-365 regulates NKX2-1, a key mediator of lung cancer.",http://www.ncbi.nlm.nih.gov/pubmed/23507558
1514,22185756,MiR-365 regulates lung cancer and developmental gene thyroid transcription factor 1.,http://www.ncbi.nlm.nih.gov/pubmed/22185756
1515,11713805,"Technology evaluation: leukemia therapy, University of Pennsylvania.",http://www.ncbi.nlm.nih.gov/pubmed/11713805
1516,9024626,MutS homologs in mammalian cells.,http://www.ncbi.nlm.nih.gov/pubmed/9024626
1517,18157157,Mechanisms and functions of DNA mismatch repair.,http://www.ncbi.nlm.nih.gov/pubmed/18157157
1518,23255516,Cancer risks for MLH1 and MSH2 mutation carriers.,http://www.ncbi.nlm.nih.gov/pubmed/23255516
1519,23391514,"Structural, molecular and cellular functions of MSH2 and MSH6 during DNA mismatch repair, damage signaling and other noncanonical activities.",http://www.ncbi.nlm.nih.gov/pubmed/23391514
1520,20028993,Risks of Lynch syndrome cancers for MSH6 mutation carriers.,http://www.ncbi.nlm.nih.gov/pubmed/20028993
1521,23436734,Nucleophosmin mutations in acute myeloid leukemia: a tale of protein unfolding and mislocalization.,http://www.ncbi.nlm.nih.gov/pubmed/23436734
1522,15659725,Cytoplasmic nucleophosmin in acute myelogenous leukemia with a normal karyotype.,http://www.ncbi.nlm.nih.gov/pubmed/15659725
1523,16076867,Nucleophosmin gene mutations are predictors of favorable prognosis in acute myelogenous leukemia with a normal karyotype.,http://www.ncbi.nlm.nih.gov/pubmed/16076867
1524,12591985,Effects of deguelin on the phosphatidylinositol 3-kinase/Akt pathway and apoptosis in premalignant human bronchial epithelial cells.,http://www.ncbi.nlm.nih.gov/pubmed/12591985
1525,15579801,A germline variation in the progesterone receptor gene increases transcriptional activity and may modify ovarian cancer risk.,http://www.ncbi.nlm.nih.gov/pubmed/15579801
1526,25242579,"Deguelin, a selective silencer of the NPM1 mutant, potentiates apoptosis and induces differentiation in AML cells carrying the NPM1 mutation.",http://www.ncbi.nlm.nih.gov/pubmed/25242579
1527,25348016,Nontoxic-dose of deguelin induce NPMc+ AML cell differentiation by selectively targeting Mt NPM1/SIRT1 instead of HDAC1/3.,http://www.ncbi.nlm.nih.gov/pubmed/25348016
1528,24796332,NPM1 silencing reduces tumour growth and MAPK signalling in prostate cancer cells.,http://www.ncbi.nlm.nih.gov/pubmed/24796332
1529,23187807,Alternatively spliced protein arginine methyltransferase 1 isoform PRMT1v2 promotes the survival and invasiveness of breast cancer cells.,http://www.ncbi.nlm.nih.gov/pubmed/23187807
1530,19414388,Colon cancer and protein arginine methyltransferase 1 gene expression.,http://www.ncbi.nlm.nih.gov/pubmed/19414388
1531,22839530,Correlation of SRSF1 and PRMT1 expression with clinical status of pediatric acute lymphoblastic leukemia.,http://www.ncbi.nlm.nih.gov/pubmed/22839530
1532,17891136,Protein arginine-methyltransferase-dependent oncogenesis.,http://www.ncbi.nlm.nih.gov/pubmed/17891136
1533,19085993,Virtual screening and biological characterization of novel histone arginine methyltransferase PRMT1 inhibitors.,http://www.ncbi.nlm.nih.gov/pubmed/19085993
1534,11509567,Identification and characterization of a novel androgen receptor coregulator ARA267-alpha in prostate cancer cells.,http://www.ncbi.nlm.nih.gov/pubmed/11509567
1535,11733144,"Molecular characterization of NSD1, a human homologue of the mouse Nsd1 gene.",http://www.ncbi.nlm.nih.gov/pubmed/11733144
1536,21196496,The structure of NSD1 reveals an autoregulatory mechanism underlying histone H3K36 methylation.,http://www.ncbi.nlm.nih.gov/pubmed/21196496
1537,21922056,An open and shut case for the role of NSD proteins as oncogenes.,http://www.ncbi.nlm.nih.gov/pubmed/21922056
1538,21664949,Cancers and the NSD family of histone lysine methyltransferases.,http://www.ncbi.nlm.nih.gov/pubmed/21664949
1539,17008023,Neurotrophic receptor TrkB: Is it a predictor of poor prognosis for carcinoma patients?,http://www.ncbi.nlm.nih.gov/pubmed/17008023
1540,24900443,"Discovery of GNF-5837, a Selective TRK Inhibitor with Efficacy in Rodent Cancer Tumor Models.",http://www.ncbi.nlm.nih.gov/pubmed/24900443
1541,22006983,Genetic variants of the NOTCH3 gene in the elderly and magnetic resonance imaging correlates of age-related cerebral small vessel disease.,http://www.ncbi.nlm.nih.gov/pubmed/22006983
1542,23396845,Context is everything for dependence receptors in colorectal cancer.,http://www.ncbi.nlm.nih.gov/pubmed/23396845
1543,23131561,ETV6-NTRK3 as a therapeutic target of small molecule inhibitor PKC412.,http://www.ncbi.nlm.nih.gov/pubmed/23131561
1544,18639460,UnPAKing the class differences among p21-activated kinases.,http://www.ncbi.nlm.nih.gov/pubmed/18639460
1545,23818969,p21-activated kinase 3 (PAK3) is an AP-1 regulated gene contributing to actin organisation and migration of transformed fibroblasts.,http://www.ncbi.nlm.nih.gov/pubmed/23818969
1546,22968184,Everolimus and erlotinib as second- or third-line therapy in patients with advanced non-small-cell lung cancer.,http://www.ncbi.nlm.nih.gov/pubmed/22968184
1547,24658085,Rapamycin downregulates thymidylate synthase and potentiates the activity of pemetrexed in non-small cell lung cancer.,http://www.ncbi.nlm.nih.gov/pubmed/24658085
1548,23860537,Phase 1 study of lenvatinib combined with carboplatin and paclitaxel in patients with non-small-cell lung cancer.,http://www.ncbi.nlm.nih.gov/pubmed/23860537
1549,24795392,Molecular pathways: CDK4 inhibitors for cancer therapy.,http://www.ncbi.nlm.nih.gov/pubmed/24795392
1550,24287036,The putative roles of nuclear and membrane-bound progesterone receptors in the female reproductive tract.,http://www.ncbi.nlm.nih.gov/pubmed/24287036
1551,20436503,"Issues and updates: evaluating estrogen receptor-alpha, progesterone receptor, and HER2 in breast cancer.",http://www.ncbi.nlm.nih.gov/pubmed/20436503
1552,23280579,Biomarkers for the clinical management of breast cancer: international perspective.,http://www.ncbi.nlm.nih.gov/pubmed/23280579
1553,22996918,Concise review: The Piwi-piRNA axis: pivotal beyond transposon silencing.,http://www.ncbi.nlm.nih.gov/pubmed/22996918
1554,21928326,Piwis and piwi-interacting RNAs in the epigenetics of cancer.,http://www.ncbi.nlm.nih.gov/pubmed/21928326
1555,23087701,PIWI Expression and Function in Cancer.,http://www.ncbi.nlm.nih.gov/pubmed/23087701
1556,24932571,Overexpression of piRNA pathway genes in epithelial ovarian cancer.,http://www.ncbi.nlm.nih.gov/pubmed/24932571
1557,24667170,Polo-like kinase-1 in DNA damage response.,http://www.ncbi.nlm.nih.gov/pubmed/24667170
1558,23227884,Polo-like kinase 1 as target for cancer therapy.,http://www.ncbi.nlm.nih.gov/pubmed/23227884
1559,24019381,Personalizing the treatment of pediatric medulloblastoma: Polo-like kinase 1 as a molecular target in high-risk children.,http://www.ncbi.nlm.nih.gov/pubmed/24019381
1560,19757494,Distribution and neuronal expression of phosphatidylinositol phosphate kinase IIgamma in the mouse brain.,http://www.ncbi.nlm.nih.gov/pubmed/19757494
1561,18753295,Localization of phosphatidylinositol phosphate kinase IIgamma in kidney to a membrane trafficking compartment within specialized cells of the nephron.,http://www.ncbi.nlm.nih.gov/pubmed/18753295
1562,11920679,DNA mismatch repair and mutation avoidance pathways.,http://www.ncbi.nlm.nih.gov/pubmed/11920679
1563,24333356,Mismatch repair deficiency in ovarian cancer -- molecular characteristics and clinical implications.,http://www.ncbi.nlm.nih.gov/pubmed/24333356
1564,24978665,Lynch syndrome: an updated review.,http://www.ncbi.nlm.nih.gov/pubmed/24978665
1565,22577134,Human POLB gene is mutated in high percentage of colorectal tumors.,http://www.ncbi.nlm.nih.gov/pubmed/22577134
1566,23922701,Overexpressed DNA polymerase iota regulated by JNK/c-Jun contributes to hypermutagenesis in bladder cancer.,http://www.ncbi.nlm.nih.gov/pubmed/23922701
1567,23955086,The error-prone DNA polymerase ι provides quantitative resistance to lung tumorigenesis and mutagenesis in mice.,http://www.ncbi.nlm.nih.gov/pubmed/23955086
1568,19662497,PPEF/PP7 protein Ser/Thr phosphatases.,http://www.ncbi.nlm.nih.gov/pubmed/19662497
1569,23454242,"Phosphatase: PP2A structural importance, regulation and its aberrant expression in cancer.",http://www.ncbi.nlm.nih.gov/pubmed/23454242
1570,22888282,The genomics and genetics of endometrial cancer.,http://www.ncbi.nlm.nih.gov/pubmed/22888282
1571,23169667,Heptahelical protein PQLC2 is a lysosomal cationic amino acid exporter underlying the action of cysteamine in cystinosis therapy.,http://www.ncbi.nlm.nih.gov/pubmed/23169667
1572,22822152,LAAT-1 is the lysosomal lysine/arginine transporter that maintains amino acid homeostasis.,http://www.ncbi.nlm.nih.gov/pubmed/22822152
1573,22573322,Colon cancer-associated DNA polymerase β variant induces genomic instability and cellular transformation.,http://www.ncbi.nlm.nih.gov/pubmed/22573322
1574,21310926,"KDM2b/JHDM1b, an H3K36me2-specific demethylase, is required for initiation and maintenance of acute myeloid leukemia.",http://www.ncbi.nlm.nih.gov/pubmed/21310926
1575,21596573,Inhibitors of histone demethylases.,http://www.ncbi.nlm.nih.gov/pubmed/21596573
1576,18984585,The histone demethylases JMJD1A and JMJD2B are transcriptional targets of hypoxia-inducible factor HIF.,http://www.ncbi.nlm.nih.gov/pubmed/18984585
1577,22020899,The JmjC domain-containing histone demethylase KDM3A is a positive regulator of the G1/S transition in cancer cells via transcriptional regulation of the HOXA1 gene.,http://www.ncbi.nlm.nih.gov/pubmed/22020899
1578,22581778,The histone demethylase Kdm3a is essential to progression through differentiation.,http://www.ncbi.nlm.nih.gov/pubmed/22581778
1579,25488809,The histone demethylase enzyme KDM3A is a key estrogen receptor regulator in breast cancer.,http://www.ncbi.nlm.nih.gov/pubmed/25488809
1580,23780887,Inhibition of protein phosphatase 2A radiosensitizes pancreatic cancers by modulating CDC25C/CDK1 and homologous recombination repair.,http://www.ncbi.nlm.nih.gov/pubmed/23780887
1581,24770870,Base excision repair defects invoke hypersensitivity to PARP inhibition.,http://www.ncbi.nlm.nih.gov/pubmed/24770870
1582,23621188,Hiwi knockdown inhibits the growth of lung cancer in nude mice.,http://www.ncbi.nlm.nih.gov/pubmed/23621188
1583,23792809,A small molecule modulates Jumonji histone demethylase activity and selectively inhibits cancer growth.,http://www.ncbi.nlm.nih.gov/pubmed/23792809
1584,24349617,"Histone lysine demethylase (KDM) subfamily 4: structures, functions and therapeutic potential.",http://www.ncbi.nlm.nih.gov/pubmed/24349617
1585,22937203,Genomic amplification and a role in drug-resistance for the KDM5A histone demethylase in breast cancer.,http://www.ncbi.nlm.nih.gov/pubmed/22937203
1586,25275298,The head and neck cancer cell oncogenome: a platform for the development of precision molecular therapies.,http://www.ncbi.nlm.nih.gov/pubmed/25275298
1587,24947179,Loss of histone demethylase KDM6B enhances aggressiveness of pancreatic cancer through downregulation of C/EBPα.,http://www.ncbi.nlm.nih.gov/pubmed/24947179
1588,23266085,Histone lysine demethylases in breast cancer.,http://www.ncbi.nlm.nih.gov/pubmed/23266085
1589,24937458,JARID1B is a luminal lineage-driving oncogene in breast cancer.,http://www.ncbi.nlm.nih.gov/pubmed/24937458
1590,25016185,KDM5C is overexpressed in prostate cancer and is a prognostic marker for prostate-specific antigen-relapse following radical prostatectomy.,http://www.ncbi.nlm.nih.gov/pubmed/25016185
1591,15788663,Association of NCOA3 polymorphisms with breast cancer risk.,http://www.ncbi.nlm.nih.gov/pubmed/15788663
1592,17351630,The trithorax-group gene in Drosophila little imaginal discs encodes a trimethylated histone H3 Lys4 demethylase.,http://www.ncbi.nlm.nih.gov/pubmed/17351630
1593,25225064,"Concurrent alterations in TERT, KDM6A, and the BRCA pathway in bladder cancer.",http://www.ncbi.nlm.nih.gov/pubmed/25225064
1594,19084573,Polybromo-1: the chromatin targeting subunit of the PBAF complex.,http://www.ncbi.nlm.nih.gov/pubmed/19084573
1595,23867514,PBRM1 and BAP1 as novel targets for renal cell carcinoma.,http://www.ncbi.nlm.nih.gov/pubmed/23867514
1596,19074595,Mutation profile of JAK2 transcripts in patients with chronic myeloproliferative neoplasias.,http://www.ncbi.nlm.nih.gov/pubmed/19074595
1597,23892662,A new player SETs in myeloid malignancy.,http://www.ncbi.nlm.nih.gov/pubmed/23892662
1598,11231286,"Identification and characterization of SEB, a novel protein that binds to the acute undifferentiated leukemia-associated protein SET.",http://www.ncbi.nlm.nih.gov/pubmed/11231286
1599,23832012,Somatic SETBP1 mutations in myeloid malignancies.,http://www.ncbi.nlm.nih.gov/pubmed/23832012
1600,20501857,Histone methyltransferase gene SETD2 is a novel tumor suppressor gene in clear cell renal cell carcinoma.,http://www.ncbi.nlm.nih.gov/pubmed/20501857
1601,25136132,(R)-PFI-2 is a potent and selective inhibitor of SETD7 methyltransferase activity in cells.,http://www.ncbi.nlm.nih.gov/pubmed/25136132
1602,21826189,Regulation of p53 function by lysine methylation.,http://www.ncbi.nlm.nih.gov/pubmed/21826189
1603,18471979,Regulation of estrogen receptor alpha by the SET7 lysine methyltransferase.,http://www.ncbi.nlm.nih.gov/pubmed/18471979
1604,12435635,The pRb-related protein p130 is regulated by phosphorylation-dependent proteolysis via the protein-ubiquitin ligase SCF(Skp2).,http://www.ncbi.nlm.nih.gov/pubmed/12435635
1605,23911321,Pharmacological inactivation of Skp2 SCF ubiquitin ligase restricts cancer stem cell traits and cancer progression.,http://www.ncbi.nlm.nih.gov/pubmed/23911321
1606,10823827,"Primary structure, genomic organization, and functional and electrogenic characteristics of human system N 1, a Na+- and H+-coupled glutamine transporter.",http://www.ncbi.nlm.nih.gov/pubmed/10823827
1607,16432833,"Down regulation of 3p genes, LTF, SLC38A3 and DRR1, upon growth of human chromosome 3-mouse fibrosarcoma hybrids in severe combined immunodeficiency mice.",http://www.ncbi.nlm.nih.gov/pubmed/16432833
1608,18437052,Involvement of the chromatin-remodeling factor BRG1/SMARCA4 in human cancer.,http://www.ncbi.nlm.nih.gov/pubmed/18437052
1609,24145903,The SWI/SNF tumor suppressor complex: Regulation of promoter nucleosomes and beyond.,http://www.ncbi.nlm.nih.gov/pubmed/24145903
1610,19234488,The SWI/SNF complex and cancer.,http://www.ncbi.nlm.nih.gov/pubmed/19234488
1611,22795084,An allosteric inhibitor of protein arginine methyltransferase 3.,http://www.ncbi.nlm.nih.gov/pubmed/22795084
1612,22904088,The arginine methyltransferase PRMT6 regulates cell proliferation and senescence through transcriptional repression of tumor suppressor genes.,http://www.ncbi.nlm.nih.gov/pubmed/22904088
1613,25263650,Protein arginine methyltransferases (PRMTs): role in chromatin organization.,http://www.ncbi.nlm.nih.gov/pubmed/25263650
1614,20473859,"Dysregulation of PRMT1 and PRMT6, Type I arginine methyltransferases, is involved in various types of human cancers.",http://www.ncbi.nlm.nih.gov/pubmed/20473859
1615,22987071,p53-Independent regulation of p21Waf1/Cip1 expression and senescence by PRMT6.,http://www.ncbi.nlm.nih.gov/pubmed/22987071
1616,15056663,Small molecule regulators of protein arginine methyltransferases.,http://www.ncbi.nlm.nih.gov/pubmed/15056663
1617,21975038,Versatility of PRMT5-induced methylation in growth control and development.,http://www.ncbi.nlm.nih.gov/pubmed/21975038
1618,21966347,Targets in epigenetics: inhibiting the methyl writers of the histone code.,http://www.ncbi.nlm.nih.gov/pubmed/21966347
1619,24453002,Genetic validation of the protein arginine methyltransferase PRMT5 as a candidate therapeutic target in glioblastoma.,http://www.ncbi.nlm.nih.gov/pubmed/24453002
1620,18483217,Role of platelet-derived growth factors in physiology and medicine.,http://www.ncbi.nlm.nih.gov/pubmed/18483217
1621,24359404,Targeting the PDGF signaling pathway in tumor treatment.,http://www.ncbi.nlm.nih.gov/pubmed/24359404
1622,22133064,Targeting PDGFR-β in Cholangiocarcinoma.,http://www.ncbi.nlm.nih.gov/pubmed/22133064
1623,21059412,Tyrosine 87 is vital for the activity of human protein arginine methyltransferase 3 (PRMT3).,http://www.ncbi.nlm.nih.gov/pubmed/21059412
1624,25278565,The SOX11-PDGFA axis in mantle cell lymphoma.,http://www.ncbi.nlm.nih.gov/pubmed/25278565
1625,25092176,SOX11 promotes tumor angiogenesis through transcriptional regulation of PDGFA in mantle cell lymphoma.,http://www.ncbi.nlm.nih.gov/pubmed/25092176
1626,23201163,Metastatic colonization requires the repression of the epithelial-mesenchymal transition inducer Prrx1.,http://www.ncbi.nlm.nih.gov/pubmed/23201163
1627,23807160,"Paired related homoeobox 1, a new EMT inducer, is involved in metastasis and poor prognosis in colorectal cancer.",http://www.ncbi.nlm.nih.gov/pubmed/23807160
1628,25404478,Downregulation of PRRX1 Confers Cancer Stem Cell-Like Properties and Predicts Poor Prognosis in Hepatocellular Carcinoma.,http://www.ncbi.nlm.nih.gov/pubmed/25404478
1629,21482413,Focal adhesion kinase: exploring Fak structure to gain insight into function.,http://www.ncbi.nlm.nih.gov/pubmed/21482413
1630,20001213,Targeting Pyk2 for therapeutic intervention.,http://www.ncbi.nlm.nih.gov/pubmed/20001213
1631,25217697,Pyk2 promotes tumor progression in multiple myeloma.,http://www.ncbi.nlm.nih.gov/pubmed/25217697
1632,23024808,Functional specialization in proline biosynthesis of melanoma.,http://www.ncbi.nlm.nih.gov/pubmed/23024808
1633,15235609,SMYD3 encodes a histone methyltransferase involved in the proliferation of cancer cells.,http://www.ncbi.nlm.nih.gov/pubmed/15235609
1634,25382779,Lysine methylation in cancer: SMYD3-MAP3K2 teaches us new lessons in the Ras-ERK pathway.,http://www.ncbi.nlm.nih.gov/pubmed/25382779
1635,24847881,SMYD3 links lysine methylation of MAP3K2 to Ras-driven cancer.,http://www.ncbi.nlm.nih.gov/pubmed/24847881
1636,24856061,Targeting the homologous recombination pathway by small molecule modulators.,http://www.ncbi.nlm.nih.gov/pubmed/24856061
1637,22467216,Homologous recombination and its regulation.,http://www.ncbi.nlm.nih.gov/pubmed/22467216
1638,23615915,Prx1 modulates the chemosensitivity of lung cancer to docetaxel through suppression of FOXO1-induced apoptosis.,http://www.ncbi.nlm.nih.gov/pubmed/23615915
1639,24705396,MiR-124 Radiosensitizes human colorectal cancer cells by targeting PRRX1.,http://www.ncbi.nlm.nih.gov/pubmed/24705396
1640,22573178,RI-1: a chemical inhibitor of RAD51 that disrupts homologous recombination in human cells.,http://www.ncbi.nlm.nih.gov/pubmed/22573178
1641,24757565,The role of suppressors of cytokine signalling in human neoplasms.,http://www.ncbi.nlm.nih.gov/pubmed/24757565
1642,21084693,Suppressor of cytokine signaling 1 (SOCS1) limits NFkappaB signaling by decreasing p65 stability within the cell nucleus.,http://www.ncbi.nlm.nih.gov/pubmed/21084693
1643,21779500,Mammalian son of sevenless Guanine nucleotide exchange factors: old concepts and new perspectives.,http://www.ncbi.nlm.nih.gov/pubmed/21779500
1644,25455859,"Rational design of small molecule inhibitors targeting the Ras GEF, SOS1.",http://www.ncbi.nlm.nih.gov/pubmed/25455859
1645,,"Abstract LB-10: Rational design of small molecules targeting the Ras GEF, SOS1",http://cancerres.aacrjournals.org/content/74/19_Supplement/LB-10.short
1646,21821141,"RAD51 paralogs: roles in DNA damage signalling, recombinational repair and tumorigenesis.",http://www.ncbi.nlm.nih.gov/pubmed/21821141
1647,24139550,Germline mutation in the RAD51B gene confers predisposition to breast cancer.,http://www.ncbi.nlm.nih.gov/pubmed/24139550
1648,25368520,RAD51B Activity and Cell Cycle Regulation in Response to DNA Damage in Breast Cancer Cell Lines.,http://www.ncbi.nlm.nih.gov/pubmed/25368520
1649,22246670,Oncogenicity of the developmental transcription factor Sox9.,http://www.ncbi.nlm.nih.gov/pubmed/22246670
1650,24563616,SPOP mutations in prostate cancer across demographically diverse patient cohorts.,http://www.ncbi.nlm.nih.gov/pubmed/24563616
1651,19818708,Structures of SPOP-substrate complexes: insights into molecular architectures of BTB-Cul3 ubiquitin ligases.,http://www.ncbi.nlm.nih.gov/pubmed/19818708
1652,23512992,RAD51C-deficient cancer cells are highly sensitive to the PARP inhibitor olaparib.,http://www.ncbi.nlm.nih.gov/pubmed/23512992
1653,23108668,The RAD51 paralogs ensure cellular protection against mitotic defects and aneuploidy.,http://www.ncbi.nlm.nih.gov/pubmed/23108668
1654,23372765,Analysis of RAD51D in ovarian cancer patients and families with a history of ovarian or breast cancer.,http://www.ncbi.nlm.nih.gov/pubmed/23372765
1655,21822267,Germline mutations in RAD51D confer susceptibility to ovarian cancer.,http://www.ncbi.nlm.nih.gov/pubmed/21822267
1657,23335386,"Spliceosome mutations involving SRSF2, SF3B1, and U2AF35 in chronic myelomonocytic leukemia: prevalence, clinical correlates, and prognostic relevance.",http://www.ncbi.nlm.nih.gov/pubmed/23335386
1658,24523246,Splicing factor mutations and cancer.,http://www.ncbi.nlm.nih.gov/pubmed/24523246
1659,22668012,Mutational and expressional analyses of STAG2 gene in solid cancers.,http://www.ncbi.nlm.nih.gov/pubmed/22668012
1660,12034751,STAG2 and Rad21 mammalian mitotic cohesins are implicated in meiosis.,http://www.ncbi.nlm.nih.gov/pubmed/12034751
1661,23071261,Molecular pathways: understanding the role of Rad52 in homologous recombination for therapeutic advancement.,http://www.ncbi.nlm.nih.gov/pubmed/23071261
1662,22964643,RAD52 inactivation is synthetically lethal with deficiencies in BRCA1 and PALB2 in addition to BRCA2 through RAD51-mediated homologous recombination.,http://www.ncbi.nlm.nih.gov/pubmed/22964643
1663,15994916,Mammalian sterile 20-like kinases in tumor suppression: an emerging pathway.,http://www.ncbi.nlm.nih.gov/pubmed/15994916
1664,24336504,The two faces of Hippo: targeting the Hippo pathway for regenerative medicine and cancer treatment.,http://www.ncbi.nlm.nih.gov/pubmed/24336504
1665,12723694,SU(VAR)3-9 is a conserved key function in heterochromatic gene silencing.,http://www.ncbi.nlm.nih.gov/pubmed/12723694
1666,23836560,Personalized synthetic lethality induced by targeting RAD52 in leukemias identified by gene mutation and expression profile.,http://www.ncbi.nlm.nih.gov/pubmed/23836560
1667,22194015,Targeting protein lysine methylation and demethylation in cancers.,http://www.ncbi.nlm.nih.gov/pubmed/22194015
1668,24844570,Histone lysine methyltransferase SUV39H1 is a potent target for epigenetic therapy of hepatocellular carcinoma.,http://www.ncbi.nlm.nih.gov/pubmed/24844570
1669,25063769,A role for SUV39H1-mediated H3K9 trimethylation in the control of genome stability and senescence in WI38 human diploid lung fibroblasts.,http://www.ncbi.nlm.nih.gov/pubmed/25063769
1670,17452327,Human TRBP and PACT directly interact with each other and associate with dicer to facilitate the production of small interfering RNA.,http://www.ncbi.nlm.nih.gov/pubmed/17452327
1671,22719182,Interrelationship between microsatellite instability and microRNA in gastrointestinal cancer.,http://www.ncbi.nlm.nih.gov/pubmed/22719182
1672,25437560,Deletion of human tarbp2 reveals cellular microRNA targets and cell-cycle function of TRBP.,http://www.ncbi.nlm.nih.gov/pubmed/25437560
1673,24563327,Up-regulation and worse prognostic marker of cytoplasmic TARBP2 expression in obstinate breast cancer.,http://www.ncbi.nlm.nih.gov/pubmed/24563327
1674,11782437,A role for RAD54B in homologous recombination in human cells.,http://www.ncbi.nlm.nih.gov/pubmed/11782437
1675,25384516,Rad54B serves as a scaffold in the DNA damage response that limits checkpoint strength.,http://www.ncbi.nlm.nih.gov/pubmed/25384516
1676,20089461,"Rad54, the motor of homologous recombination.",http://www.ncbi.nlm.nih.gov/pubmed/20089461
1677,21704205,Functions of the Snf2/Swi2 family Rad54 motor protein in homologous recombination.,http://www.ncbi.nlm.nih.gov/pubmed/21704205
1678,21412013,Gene expression profiles of non-small cell lung cancer: survival prediction and new biomarkers.,http://www.ncbi.nlm.nih.gov/pubmed/21412013
1679,16893456,TBLR1 regulates the expression of nuclear hormone receptor co-repressors.,http://www.ncbi.nlm.nih.gov/pubmed/16893456
1680,24667177,TBL1XR1 promotes lymphangiogenesis and lymphatic metastasis in esophageal squamous cell carcinoma.,http://www.ncbi.nlm.nih.gov/pubmed/24667177
1681,22837180,Recurrent mutations of MYD88 and TBL1XR1 in primary central nervous system lymphomas.,http://www.ncbi.nlm.nih.gov/pubmed/22837180
1682,17374848,"An adenosine triphosphatase of the sucrose nonfermenting 2 family, androgen receptor-interacting protein 4, is essential for mouse embryonic development and cell proliferation.",http://www.ncbi.nlm.nih.gov/pubmed/17374848
1683,15970593,TBP-TAF complex SL1 directs RNA polymerase I pre-initiation complex formation and stabilizes upstream binding factor at the rDNA promoter.,http://www.ncbi.nlm.nih.gov/pubmed/15970593
1684,22002537,Physical and functional interaction between PML and TBX2 in the establishment of cellular senescence.,http://www.ncbi.nlm.nih.gov/pubmed/22002537
1685,24025717,The oncogenic TBX3 is a downstream target and mediator of the TGF-β1 signaling pathway.,http://www.ncbi.nlm.nih.gov/pubmed/24025717
1686,25294679,The Ras/Rap GTPase activating protein RASA3: from gene structure to in vivo functions.,http://www.ncbi.nlm.nih.gov/pubmed/25294679
1687,21111786,The RasGrf family of mammalian guanine nucleotide exchange factors.,http://www.ncbi.nlm.nih.gov/pubmed/21111786
1688,25460271,Extracellular modulators of Wnt signalling.,http://www.ncbi.nlm.nih.gov/pubmed/25460271
1689,25344691,RNF43 is frequently mutated in colorectal and endometrial cancers.,http://www.ncbi.nlm.nih.gov/pubmed/25344691
1690,23847203,Inactivating mutations of RNF43 confer Wnt dependency in pancreatic ductal adenocarcinoma.,http://www.ncbi.nlm.nih.gov/pubmed/23847203
1691,21385388,"The cytokine-driven regulation of secretoglobins in normal human upper airway and their expression, particularly that of uteroglobin-related protein 1, in chronic rhinosinusitis.",http://www.ncbi.nlm.nih.gov/pubmed/21385388
1692,23819652,Secretoglobin expression in ovarian carcinoma: lipophilin B gene upregulation as an independent marker of better prognosis.,http://www.ncbi.nlm.nih.gov/pubmed/23819652
1693,25394791,Patient-derived models of acquired resistance can identify effective drug combinations for cancer.,http://www.ncbi.nlm.nih.gov/pubmed/25394791
1694,22127701,"Overexpression of SPACIA1/SAAL1, a newly identified gene that is involved in synoviocyte proliferation, accelerates the progression of synovitis in mice and humans.",http://www.ncbi.nlm.nih.gov/pubmed/22127701
1695,23233346,"The dual role of the novel Wnt receptor tyrosine kinase, ROR2, in human carcinogenesis.",http://www.ncbi.nlm.nih.gov/pubmed/23233346
1697,18177486,Wnt signaling inside the nucleus.,http://www.ncbi.nlm.nih.gov/pubmed/18177486
1698,9727977,Identification of c-MYC as a target of the APC pathway.,http://www.ncbi.nlm.nih.gov/pubmed/9727977
1699,10919662,"The human T-cell transcription factor-4 gene: structure, extensive characterization of alternative splicings, and mutational analysis in colorectal cancer cell lines.",http://www.ncbi.nlm.nih.gov/pubmed/10919662
1700,18579750,TEAD mediates YAP-dependent gene induction and growth control.,http://www.ncbi.nlm.nih.gov/pubmed/18579750
1701,23029054,Alteration of TEAD1 expression levels confers apoptotic resistance through the transcriptional up-regulation of Livin.,http://www.ncbi.nlm.nih.gov/pubmed/23029054
1702,25384421,Targeting Hippo pathway by specific interruption of YAP-TEAD interaction using cyclic YAP-like peptides.,http://www.ncbi.nlm.nih.gov/pubmed/25384421
1703,25557945,"TEAD2, a Hippo pathway gene, is somatically mutated in gastric and colorectal cancers with high microsatellite instability.",http://www.ncbi.nlm.nih.gov/pubmed/25557945
1704,20945341,The Hippo pathway in biological control and cancer development.,http://www.ncbi.nlm.nih.gov/pubmed/20945341
1705,15256431,Transforming growth factor beta receptor type II inactivation promotes the establishment and progression of colon cancer.,http://www.ncbi.nlm.nih.gov/pubmed/15256431
1706,25060520,Neutralizing murine TGFβR2 promotes a differentiated tumor cell phenotype and inhibits pancreatic cancer metastasis.,http://www.ncbi.nlm.nih.gov/pubmed/25060520
1707,16167060,"Relation between genetic variants of the ataxia telangiectasia-mutated (ATM) gene, drug resistance, clinical outcome and predisposition to childhood T-lineage acute lymphoblastic leukaemia.",http://www.ncbi.nlm.nih.gov/pubmed/16167060
1708,17000706,Search for low penetrance alleles for colorectal cancer through a scan of 1467 non-synonymous SNPs in 2575 cases and 2707 controls with validation by kin-cohort analysis of 14 704 first-degree relatives.,http://www.ncbi.nlm.nih.gov/pubmed/17000706
1709,18573109,Pathogenic ATM mutations occur rarely in a subset of multiple myeloma patients.,http://www.ncbi.nlm.nih.gov/pubmed/18573109
1710,22563985,Ciliary transition zone (TZ) proteins RPGR and CEP290: role in photoreceptor cilia and degenerative diseases.,http://www.ncbi.nlm.nih.gov/pubmed/22563985
1711,24501176,Transducin-like enhancer of split-6 (TLE6) is a substrate of protein kinase A activity during mouse oocyte maturation.,http://www.ncbi.nlm.nih.gov/pubmed/24501176
1712,24141781,Identification of latent biomarkers in hepatocellular carcinoma by ultra-deep whole-transcriptome sequencing.,http://www.ncbi.nlm.nih.gov/pubmed/24141781
1713,23059429,A20: linking a complex regulator of ubiquitylation to immunity and human disease.,http://www.ncbi.nlm.nih.gov/pubmed/23059429
1714,23128672,Downregulation of ubiquitin E3 ligase TNF receptor-associated factor 7 leads to stabilization of p53 in breast cancer.,http://www.ncbi.nlm.nih.gov/pubmed/23128672
1715,22105767,The seventh ring: exploring TRAF7 functions.,http://www.ncbi.nlm.nih.gov/pubmed/22105767
1716,23348505,"Genomic analysis of non-NF2 meningiomas reveals mutations in TRAF7, KLF4, AKT1, and SMO.",http://www.ncbi.nlm.nih.gov/pubmed/23348505
1717,21511239,Small molecule TSHR agonists and antagonists.,http://www.ncbi.nlm.nih.gov/pubmed/21511239
1718,25333622,New small molecule agonists to the thyrotropin receptor.,http://www.ncbi.nlm.nih.gov/pubmed/25333622
1719,18719389,Strap: a versatile transcription co-factor.,http://www.ncbi.nlm.nih.gov/pubmed/18719389
1720,23559008,TTC5 is required to prevent apoptosis of acute myeloid leukemia stem cells.,http://www.ncbi.nlm.nih.gov/pubmed/23559008
1721,21257761,The giant protein titin: a regulatory node that integrates myocyte signaling pathways.,http://www.ncbi.nlm.nih.gov/pubmed/21257761
1722,18085994,Genomic landscapes of cancers: prospects for targeted therapies.,http://www.ncbi.nlm.nih.gov/pubmed/18085994
1723,17344846,Patterns of somatic mutation in human cancer genomes.,http://www.ncbi.nlm.nih.gov/pubmed/17344846
1724,23645565,The changing mutational landscape of acute myeloid leukemia and myelodysplastic syndrome.,http://www.ncbi.nlm.nih.gov/pubmed/23645565
1725,22678168,Emerging roles of the spliceosomal machinery in myelodysplastic syndromes and other hematological disorders.,http://www.ncbi.nlm.nih.gov/pubmed/22678168
1726,22980975,Mapping the hallmarks of lung adenocarcinoma with massively parallel sequencing.,http://www.ncbi.nlm.nih.gov/pubmed/22980975
1727,24498085,A pan-cancer analysis of transcriptome changes associated with somatic mutations in U2AF1 reveals commonly altered splicing events.,http://www.ncbi.nlm.nih.gov/pubmed/24498085
1728,23669039,Disruption of polyubiquitin gene Ubc leads to defective proliferation of hepatocytes and bipotent fetal liver epithelial progenitor cells.,http://www.ncbi.nlm.nih.gov/pubmed/23669039
1729,17491588,"The mouse polyubiquitin gene UbC is essential for fetal liver development, cell-cycle progression and stress tolerance.",http://www.ncbi.nlm.nih.gov/pubmed/17491588
1730,1660345,Changes in expressions of proteasome and ubiquitin genes in human renal cancer cells.,http://www.ncbi.nlm.nih.gov/pubmed/1660345
1731,11788194,Localization and expression of usherin: a novel basement membrane protein defective in people with Usher's syndrome type IIa.,http://www.ncbi.nlm.nih.gov/pubmed/11788194
1732,,Abstract 3959: COSMIC: Mining the world's knowledge on somatic cancer mutations,
1733,18172012,Multiple-myeloma-related WHSC1/MMSET isoform RE-IIBP is a histone methyltransferase with transcriptional repression activity.,http://www.ncbi.nlm.nih.gov/pubmed/18172012
1734,23011637,The histone methyltransferase Wolf-Hirschhorn syndrome candidate 1-like 1 (WHSC1L1) is involved in human carcinogenesis.,http://www.ncbi.nlm.nih.gov/pubmed/23011637
1735,24488880,How the TP53 family proteins TP63 and TP73 contribute to tumorigenesis: regulators and effectors.,http://www.ncbi.nlm.nih.gov/pubmed/24488880
1736,21760596,p63 is a suppressor of tumorigenesis and metastasis interacting with mutant p53.,http://www.ncbi.nlm.nih.gov/pubmed/21760596
1737,22232518,WNT7A regulates tumor growth and progression in ovarian cancer through the WNT/β-catenin pathway.,http://www.ncbi.nlm.nih.gov/pubmed/22232518
1738,18227151,TAZ promotes cell proliferation and epithelial-mesenchymal transition and is inhibited by the hippo pathway.,http://www.ncbi.nlm.nih.gov/pubmed/18227151
1739,10541549,XRCC3 promotes homology-directed repair of DNA damage in mammalian cells.,http://www.ncbi.nlm.nih.gov/pubmed/10541549
1740,17974916,Inactivation of YAP oncoprotein by the Hippo pathway is involved in cell contact inhibition and tissue growth control.,http://www.ncbi.nlm.nih.gov/pubmed/17974916
1741,22609812,Structures of YAP protein domains reveal promising targets for development of new cancer drugs.,http://www.ncbi.nlm.nih.gov/pubmed/22609812
1742,21586534,A cell-based assay to screen stimulators of the Hippo pathway reveals the inhibitory effect of dobutamine on the YAP-dependent gene transcription.,http://www.ncbi.nlm.nih.gov/pubmed/21586534
1743,20818419,PRIMA-1(MET)/APR-246 targets mutant forms of p53 family members p63 and p73.,http://www.ncbi.nlm.nih.gov/pubmed/20818419
1744,23913810,The TP73 complex network: ready for clinical translation in cancer?,http://www.ncbi.nlm.nih.gov/pubmed/23913810
1745,21566460,Clues for c-Yes involvement in the cell cycle and cytokinesis.,http://www.ncbi.nlm.nih.gov/pubmed/21566460
1746,21779430,Identification of the YES1 Kinase as a Therapeutic Target in Basal-Like Breast Cancers.,http://www.ncbi.nlm.nih.gov/pubmed/21779430
1747,25106868,ZFP36L1 and ZFP36L2 control LDLR mRNA stability via the ERK-RSK pathway.,http://www.ncbi.nlm.nih.gov/pubmed/25106868
1749,20802528,A novel concept in antiangiogenic and antitumoral therapy: multitarget destabilization of short-lived mRNAs by the zinc finger protein ZFP36L1.,http://www.ncbi.nlm.nih.gov/pubmed/20802528
1750,16039987,MYND domain specific interaction of the melanin-concentrating hormone receptor 1 interacting zinc-finger protein with alpha- and beta-tubulin.,http://www.ncbi.nlm.nih.gov/pubmed/16039987
1751,20186265,Targeting A20 decreases glioma stem cell survival and tumor growth.,http://www.ncbi.nlm.nih.gov/pubmed/20186265
1752,24448638,"Phase I dose-escalation study of AZD7762, a checkpoint kinase inhibitor, in combination with gemcitabine in US patients with advanced solid tumors.",http://www.ncbi.nlm.nih.gov/pubmed/24448638
1753,25411085,"Phase 1, open-label, dose escalation, safety, and pharmacokinetics study of ME-344 as a single agent in patients with refractory solid tumors.",http://www.ncbi.nlm.nih.gov/pubmed/25411085
1754,25146434,Identification of mutant alleles of JAK3 in pediatric patients with acute lymphoblastic leukemia.,http://www.ncbi.nlm.nih.gov/pubmed/25146434
1755,21976535,A phase I dose-escalation study of Tivantinib (ARQ 197) in adult patients with metastatic solid tumors.,http://www.ncbi.nlm.nih.gov/pubmed/21976535
1756,22271473,PI3K/AKT/mTOR inhibitors in patients with breast and gynecologic malignancies harboring PIK3CA mutations.,http://www.ncbi.nlm.nih.gov/pubmed/22271473
1757,24362531,"Effective inhibition of c-MET-mediated signaling, growth and migration of ovarian cancer cells is influenced by the ovarian tissue microenvironment.",http://www.ncbi.nlm.nih.gov/pubmed/24362531
1758,19889612,A phase I open-label dose-escalation study of oral BIBF 1120 combined with standard paclitaxel and carboplatin in patients with advanced gynecological malignancies.,http://www.ncbi.nlm.nih.gov/pubmed/19889612
1759,,Novel AKT Pathway Inhibitor ARQ 092 Safe in Phase 1 Trial,"In: Proceedings of the 104th Annual Meeting of the American Association for Cancer Research; 2013 Apr 6-10; Washington, DC. Philadelphia (PA): AACR; 2013"
1760,25331402,[Surgical treatment of internal fixation failure after clavicular fracture operation].,http://www.ncbi.nlm.nih.gov/pubmed/25331402
1761,,"Results of two Phase 1 multicenter trials of AZD5363, an inhibitor of AKT1, 2 and 3: biomarker and early clinical evaluation in Western and Japanese patients with advanced solid tumors.",https://www.escholar.manchester.ac.uk/uk-ac-man-scw:194446
1762,25231402,"LY2875358, a neutralizing and internalizing anti-MET bivalent antibody, inhibits HGF-dependent and HGF-independent MET activation and tumor growth.",http://www.ncbi.nlm.nih.gov/pubmed/25231402
1763,24927217,The PI3K/mTOR dual inhibitor NVP-BEZ235 reduces the growth of ovarian clear cell carcinoma.,http://www.ncbi.nlm.nih.gov/pubmed/24927217
1764,22421192,"A phase I dose-escalation study of regorafenib (BAY 73-4506), an inhibitor of oncogenic, angiogenic, and stromal kinases, in patients with advanced solid tumors.",http://www.ncbi.nlm.nih.gov/pubmed/22421192
1765,,A phase 1b dose-escalation study of BYL719 plus binimetinib (MEK162) in patients with selected advanced solid tumors.,http://meetinglibrary.asco.org/content/129278-144
1766,,"Abstract A17: ME-344, a novel mitochondrial oxygenase inhibitor: Results from a first-in-human Phase I study.",http://mct.aacrjournals.org/content/12/11_Supplement/A17.short
1767,23939375,Overcoming platinum resistance in preclinical models of ovarian cancer using the neddylation inhibitor MLN4924.,http://www.ncbi.nlm.nih.gov/pubmed/23939375
1768,,"Biologic and Clinical Activity of Tivozanib (AV-951, KRN-951), a Selective Inhibitor of VEGF Receptor-1, -2, and -3 Tyrosine Kinases, in a 4-Week-On, 2-Week-Off Schedule in Patients with Advanced Solid Tumors",http://clincancerres.aacrjournals.org/content/17/22/7156.short
1769,,A randomized phase 2 trial comparing efficacy of the combination of the PARP inhibitor olaparib and the antiangiogenic cediranib against olaparib alone in recurrent platinum-sensitive ovarian cancer.,http://meetinglibrary.asco.org/content/130933-144
1770,24709487,"Randomised phase II study of docetaxel plus vandetanib versus docetaxel followed by vandetanib in patients with persistent or recurrent epithelial ovarian, fallopian tube or primary peritoneal carcinoma: SWOG S0904.",http://www.ncbi.nlm.nih.gov/pubmed/24709487
1771,20068097,"Vandetanib, designed to inhibit VEGFR2 and EGFR signaling, had no clinical activity as monotherapy for recurrent ovarian cancer and no detectable modulation of VEGFR2.",http://www.ncbi.nlm.nih.gov/pubmed/20068097
1772,20967300,Vandetanib: An overview of its clinical development in NSCLC and other tumors.,http://www.ncbi.nlm.nih.gov/pubmed/20967300
1773,,Activity of cabozantinib (XL184) in advanced ovarian cancer patients (pts): Results from a phase II randomized discontinuation trial (RDT).,http://meetinglibrary.asco.org/content/82365-102
1774,22990652,Phase I trial of axitinib combined with platinum doublets in patients with advanced non-small cell lung cancer and other solid tumours.,http://www.ncbi.nlm.nih.gov/pubmed/22990652
1775,24778064,Impact of combination chemotherapy with itraconazole on survival of patients with refractory ovarian cancer.,http://www.ncbi.nlm.nih.gov/pubmed/24778064
1776,,Abstract 931: The combination of the dual mTORC1/mTORC2 inhibitor AZD2014 and paclitaxel in human ovarian cancer models,http://cancerres.aacrjournals.org/content/72/8_Supplement/931.short
1777,22162589,"Phase I, dose-escalation study of BKM120, an oral pan-Class I PI3K inhibitor, in patients with advanced solid tumors.",http://www.ncbi.nlm.nih.gov/pubmed/22162589
1778,,"Abstract CT-01: BYL719, a next generation PI3K alpha specific inhibitor: Preliminary safety, PK, and efficacy results from the first-in-human study",http://cancerres.aacrjournals.org/content/72/8_Supplement/CT-01
1779,,"Abstract A171: A potent and selective PI3K inhibitor, INK1117, targets human cancers harboring oncogenic PIK3CA mutations.",http://mct.aacrjournals.org/content/10/11_Supplement/A171.short
1780,24070205,The potential of sunitinib as a therapy in ovarian cancer.,http://www.ncbi.nlm.nih.gov/pubmed/24070205
1781,,A phase I study of the single-agent CDK4/6 inhibitor LEE011 in pts with advanced solid tumors and lymphomas.,http://meeting.ascopubs.org/cgi/content/abstract/32/15_suppl/2528
1782,,"Abstract LB-122: LY2835219, a selective inhibitor of CDK4 and CDK6, inhibits growth in preclinical models of human cancer.",http://cancerres.aacrjournals.org/content/73/8_Supplement/LB-122
1783,21850009,HRAS mutants identified in Costello syndrome patients can induce cellular senescence: possible implications for the pathogenesis of Costello syndrome.,http://www.ncbi.nlm.nih.gov/pubmed/21850009
1784,6330729,Analysis of the transforming potential of the human H-ras gene by random mutagenesis.,http://www.ncbi.nlm.nih.gov/pubmed/6330729
1786,24919854,Preclinical characterization of the CDK4/6 inhibitor LY2835219: in-vivo cell cycle-dependent/independent anti-tumor activities alone/in combination with gemcitabine.,http://www.ncbi.nlm.nih.gov/pubmed/24919854
1787,23569312,Phase II trial of the CDK4 inhibitor PD0332991 in patients with advanced CDK4-amplified well-differentiated or dedifferentiated liposarcoma.,http://www.ncbi.nlm.nih.gov/pubmed/23569312
1788,,"Discovery and characterization of SAR260301, a novel PI3K?-selective inhibitor in clinical development for the treatment of PTEN-deficient tumors",http://www.abstractsonline.com/Plan/ViewAbstract.aspx?mID=3086&sKey=baf1d502-5e79-4f22-a1ac-1645d0d388ca&cKey=c0b15ace-d738-4283-82a9-33fb6b20024e&mKey=9b2d28e7-24a0-466f-a3c9-07c21f6e9bc9
1789,,Abstract 4501: INK1117: A potent and orally efficacious PI3K?-selective inhibitor for the treatment of cancer,http://cancerres.aacrjournals.org/content/71/8_Supplement/4501.short
1790,21831957,Synergistic action of a RAF inhibitor and a dual PI3K/mTOR inhibitor in thyroid cancer.,http://www.ncbi.nlm.nih.gov/pubmed/21831957
1791,25432176,PI3K/mTOR dual inhibitor VS-5584 preferentially targets cancer stem cells.,http://www.ncbi.nlm.nih.gov/pubmed/25432176
1793,22797062,Oncogenic RAS simultaneously protects against anti-EGFR antibody-dependent cellular cytotoxicity and EGFR signaling blockade.,http://www.ncbi.nlm.nih.gov/pubmed/22797062
1794,25500057,A phase Ib dose-escalation study of the oral pan-PI3K inhibitor buparlisib (BKM120) in combination with the oral MEK1/2 inhibitor trametinib (GSK1120212) in patients with selected advanced solid tumors.,http://www.ncbi.nlm.nih.gov/pubmed/25500057
1795,21757432,"The prevalence of the c-kit exon 10 variant, M541L, in aggressive fibromatosis does not differ from the general population.",http://www.ncbi.nlm.nih.gov/pubmed/21757432
1796,16307017,"The c-kit (CD117) sequence variation M541L, but not N564K, is frequent in the general population, and is not associated with CML in Caucasians.",http://www.ncbi.nlm.nih.gov/pubmed/16307017
1797,24668667,Whole exome sequencing implicates PTCH1 and COL17A1 genes in ossification of the posterior longitudinal ligament of the cervical spine in Chinese patients.,http://www.ncbi.nlm.nih.gov/pubmed/24668667
1798,11090615,"Sequence-specific transcriptional corepressor function for BRCA1 through a novel zinc finger protein, ZBRK1.",http://www.ncbi.nlm.nih.gov/pubmed/11090615
1799,11493692,BRCA1 mediates ligand-independent transcriptional repression of the estrogen receptor.,http://www.ncbi.nlm.nih.gov/pubmed/11493692
1800,17406639,Mutation analysis of candidate genes within the 2q33.3 linkage area for familial early-onset generalised osteoarthritis.,http://www.ncbi.nlm.nih.gov/pubmed/17406639
1801,19567821,"GSK1070916, a potent Aurora B/C kinase inhibitor with broad antitumor activity in tissue culture cells and human tumor xenograft models.",http://www.ncbi.nlm.nih.gov/pubmed/19567821
1802,22829080,"Pacritinib (SB1518), a JAK2/FLT3 inhibitor for the treatment of acute myeloid leukemia.",http://www.ncbi.nlm.nih.gov/pubmed/22829080
1803,21691275,"SB1518, a novel macrocyclic pyrimidine-based JAK2 inhibitor for the treatment of myeloid and lymphoid malignancies.",http://www.ncbi.nlm.nih.gov/pubmed/21691275
1804,16373402,Dimerization and the signal transduction pathway of a small in-frame deletion in the epidermal growth factor receptor.,http://www.ncbi.nlm.nih.gov/pubmed/16373402
1805,20617134,Clinical relevance of KRAS in human cancers.,http://www.ncbi.nlm.nih.gov/pubmed/20617134
1806,12009017,Differential activation of cysteine-substitution mutants of fibroblast growth factor receptor 3 is determined by cysteine localization.,http://www.ncbi.nlm.nih.gov/pubmed/12009017
1807,23239810,Crizotinib-resistant NPM-ALK mutants confer differential sensitivity to unrelated Alk inhibitors.,http://www.ncbi.nlm.nih.gov/pubmed/23239810
1808,24882516,Mutant Gq/11 promote uveal melanoma tumorigenesis by activating YAP.,http://www.ncbi.nlm.nih.gov/pubmed/24882516
1809,15075507,A CCR2-V64I polymorphism affects stability of CCR2A isoform.,http://www.ncbi.nlm.nih.gov/pubmed/15075507
1810,22722839,The mutational landscape of lethal castration-resistant prostate cancer.,http://www.ncbi.nlm.nih.gov/pubmed/22722839
1811,,"Phase 1, open-label, dose-escalation, and expansion study of ABT-700, an anti-C-met antibody, in patients (pts) with advanced solid tumors.",http://meetinglibrary.asco.org/content/134301-144
1812,23617957,B-Raf and the inhibitors: from bench to bedside.,http://www.ncbi.nlm.nih.gov/pubmed/23617957
1813,24434059,MEK1/2 inhibitors in the treatment of gynecologic malignancies.,http://www.ncbi.nlm.nih.gov/pubmed/24434059
1814,25422890,The dual RAF/MEK inhibitor CH5126766/RO5126766 may be a potential therapy for RAS-mutated tumor cells.,http://www.ncbi.nlm.nih.gov/pubmed/25422890
1815,21316218,Design and synthesis of novel allosteric MEK inhibitor CH4987655 as an orally available anticancer agent.,http://www.ncbi.nlm.nih.gov/pubmed/21316218
1816,21154127,"Bafetinib, a dual Bcr-Abl/Lyn tyrosine kinase inhibitor for the potential treatment of leukemia.",http://www.ncbi.nlm.nih.gov/pubmed/21154127
1817,21575866,"CH5424802, a selective ALK inhibitor capable of blocking the resistant gatekeeper mutant.",http://www.ncbi.nlm.nih.gov/pubmed/21575866
1818,22619466,Current clinical development of PI3K pathway inhibitors in glioblastoma.,http://www.ncbi.nlm.nih.gov/pubmed/22619466
1819,24900173,"Discovery of GSK2126458, a Highly Potent Inhibitor of PI3K and the Mammalian Target of Rapamycin.",http://www.ncbi.nlm.nih.gov/pubmed/24900173
1820,24777753,Clinical activity and safety of the dual pathway inhibitor rigosertib for higher risk myelodysplastic syndromes following DNA methyltransferase inhibitor therapy.,http://www.ncbi.nlm.nih.gov/pubmed/24777753
1821,,"Activity of TGR-1202, a novel once-daily PI3K? inhibitor, in patients with relapsed or refractory hematologic malignancies.",http://meetinglibrary.asco.org/content/134240-144
1822,25476894,"Phase I study of XL281 (BMS-908662), a potent oral RAF kinase inhibitor, in patients with advanced solid tumors.",http://www.ncbi.nlm.nih.gov/pubmed/25476894
1823,16622124,"Antitumor activity of ZSTK474, a new phosphatidylinositol 3-kinase inhibitor.",http://www.ncbi.nlm.nih.gov/pubmed/16622124
1824,23473235,"Pyrimidoaminotropanes as potent, selective, and efficacious small molecule kinase inhibitors of the mammalian target of rapamycin (mTOR).",http://www.ncbi.nlm.nih.gov/pubmed/23473235
1825,21531814,"Antitumor and antiangiogenic activities of BMS-690514, an inhibitor of human EGF and VEGF receptor kinase families.",http://www.ncbi.nlm.nih.gov/pubmed/21531814
1826,17616683,A novel epidermal growth factor receptor inhibitor promotes apoptosis in non-small cell lung cancer cells resistant to erlotinib.,http://www.ncbi.nlm.nih.gov/pubmed/17616683
1827,23808545,"Discovery of RG7388, a potent and selective p53-MDM2 inhibitor in clinical development.",http://www.ncbi.nlm.nih.gov/pubmed/23808545
1828,23594139,"Structure-based design, discovery and development of checkpoint kinase inhibitors as potential anticancer therapies.",http://www.ncbi.nlm.nih.gov/pubmed/23594139
1829,20024691,"A novel Chk inhibitor, XL-844, increases human cancer cell radiosensitivity through promotion of mitotic catastrophe.",http://www.ncbi.nlm.nih.gov/pubmed/20024691
1830,23536719,"Potential advantages of CUDC-101, a multitargeted HDAC, EGFR, and HER2 inhibitor, in treating drug resistance and preventing cancer cell migration and invasion.",http://www.ncbi.nlm.nih.gov/pubmed/23536719
1831,22112293,"Icotinib (BPI-2009H), a novel EGFR tyrosine kinase inhibitor, displays potent efficacy in preclinical studies.",http://www.ncbi.nlm.nih.gov/pubmed/22112293
1832,24265351,Genomic aberrations in the FGFR pathway: opportunities for targeted therapies in solid tumors.,http://www.ncbi.nlm.nih.gov/pubmed/24265351
1833,17575237,Inhibition of the T790M gatekeeper mutant of the epidermal growth factor receptor by EXEL-7647.,http://www.ncbi.nlm.nih.gov/pubmed/17575237
1834,19809159,Identification of FGFR4-activating mutations in human rhabdomyosarcomas that promote metastasis in xenotransplanted models.,http://www.ncbi.nlm.nih.gov/pubmed/19809159
1835,24837299,"Preclinical antitumor activity of S-222611, an oral reversible tyrosine kinase inhibitor of epidermal growth factor receptor and human epidermal growth factor receptor 2.",http://www.ncbi.nlm.nih.gov/pubmed/24837299
1836,15916691,"Deguelin, A PI3K/AKT inhibitor, enhances chemosensitivity of leukaemia cells with an active PI3K/AKT pathway.",http://www.ncbi.nlm.nih.gov/pubmed/15916691
1837,,Abstract 1739: Preclinical profile of BAY 1163877 - a selective pan-FGFR inhibitor in phase 1 clinical trial,http://cancerres.aacrjournals.org/content/74/19_Supplement/1739
1838,23587417,MEK and the inhibitors: from bench to bedside.,http://www.ncbi.nlm.nih.gov/pubmed/23587417
1839,24419498,The role of MEK inhibitors in the treatment of metastatic melanoma.,http://www.ncbi.nlm.nih.gov/pubmed/24419498
1840,23039341,Sensitivity to the MEK inhibitor E6201 in melanoma cells is associated with mutant BRAF and wildtype PTEN status.,http://www.ncbi.nlm.nih.gov/pubmed/23039341
1841,,"Abstract 1738: JNJ-42756493 is an inhibitor of FGFR-1, 2, 3 and 4 with nanomolar affinity for targeted therapy",http://cancerres.aacrjournals.org/content/74/19_Supplement/1738.short
1842,21900693,"A novel, selective inhibitor of fibroblast growth factor receptors that shows a potent broad spectrum of antitumor activity in several tumor xenograft models.",http://www.ncbi.nlm.nih.gov/pubmed/21900693
1843,25302168,Epidermal growth factor receptor tyrosine kinase inhibitors for non-small cell lung cancer.,http://www.ncbi.nlm.nih.gov/pubmed/25302168
1844,22369928,"AZD4547: an orally bioavailable, potent, and selective inhibitor of the fibroblast growth factor receptor tyrosine kinase family.",http://www.ncbi.nlm.nih.gov/pubmed/22369928
1845,25521095,The next generation of epidermal growth factor receptor tyrosine kinase inhibitors in the treatment of lung cancer.,http://www.ncbi.nlm.nih.gov/pubmed/25521095
1846,24063894,Cetuximab response of lung cancer-derived EGF receptor mutants is associated with asymmetric dimerization.,http://www.ncbi.nlm.nih.gov/pubmed/24063894
1847,25568876,Clinical advances in the development of novel VEGFR2 inhibitors.,http://www.ncbi.nlm.nih.gov/pubmed/25568876
1848,,Abstract C244: Development of the BET bromodomain inhibitor OTX015.,http://mct.aacrjournals.org/content/12/11_Supplement/C244.short
1849,25277525,BET protein inhibitor JQ1 attenuates Myc-amplified MCC tumor growth in vivo.,http://www.ncbi.nlm.nih.gov/pubmed/25277525
1850,24297863,BET bromodomain inhibition of MYC-amplified medulloblastoma.,http://www.ncbi.nlm.nih.gov/pubmed/24297863
1851,21889194,BET bromodomain inhibition as a therapeutic strategy to target c-Myc.,http://www.ncbi.nlm.nih.gov/pubmed/21889194
1852,25144241,A functional polymorphism in CSF1R gene is a novel susceptibility marker for lung cancer among never-smoking females.,http://www.ncbi.nlm.nih.gov/pubmed/25144241
1853,18178548,Spatial structure of the dimeric transmembrane domain of the growth factor receptor ErbB2 presumably corresponding to the receptor active state.,http://www.ncbi.nlm.nih.gov/pubmed/18178548
1854,24019069,The FBXO4 tumor suppressor functions as a barrier to BRAFV600E-dependent metastatic melanoma.,http://www.ncbi.nlm.nih.gov/pubmed/24019069
1855,16507368,Autophosphorylation of FGFR1 kinase is mediated by a sequential and precisely ordered reaction.,http://www.ncbi.nlm.nih.gov/pubmed/16507368
1856,18829493,"Brivanib alaninate, a dual inhibitor of vascular endothelial growth factor receptor and fibroblast growth factor receptor tyrosine kinases, induces growth inhibition in mouse models of human hepatocellular carcinoma.",http://www.ncbi.nlm.nih.gov/pubmed/18829493
1857,16570908,"Discovery and preclinical studies of (R)-1-(4-(4-fluoro-2-methyl-1H-indol-5-yloxy)-5- methylpyrrolo[2,1-f][1,2,4]triazin-6-yloxy)propan- 2-ol (BMS-540215), an in vivo active potent VEGFR-2 inhibitor.",http://www.ncbi.nlm.nih.gov/pubmed/16570908
1858,15899831,"AZD2171: a highly potent, orally bioavailable, vascular endothelial growth factor receptor-2 tyrosine kinase inhibitor for the treatment of cancer.",http://www.ncbi.nlm.nih.gov/pubmed/15899831
1859,23928993,An antibody that locks HER3 in the inactive conformation inhibits tumor growth driven by HER2 or neuregulin.,http://www.ncbi.nlm.nih.gov/pubmed/23928993
1860,23126373,"Metabolism and bioactivation of famitinib, a novel inhibitor of receptor tyrosine kinase, in cancer patients.",http://www.ncbi.nlm.nih.gov/pubmed/23126373
1861,25482937,"Discovery of fruquintinib, a potent and highly selective small molecule inhibitor of VEGFR 1, 2, 3 tyrosine kinases for cancer therapy.",http://www.ncbi.nlm.nih.gov/pubmed/25482937
1862,,Abstract 3741: Inhibition of PI3K? kinase by a selective small molecule inhibitor suppresses B-cell proliferation and leukemic cell growth,"http://cancerres.aacrjournals.org/content/72/8_Supplement/3741.short

http://www.tgtherapeutics.com/AACR2012Poster3741.pdf"
1863,20530683,Correlating phosphatidylinositol 3-kinase inhibitor efficacy with signaling pathway status: in silico and biological evaluations.,http://www.ncbi.nlm.nih.gov/pubmed/20530683
1864,24520092,Molecular pathways: HER3 targeted therapy.,http://www.ncbi.nlm.nih.gov/pubmed/24520092
1865,21481795,"Conformational control inhibition of the BCR-ABL1 tyrosine kinase, including the gatekeeper T315I mutant, by the switch-control inhibitor DCC-2036.",http://www.ncbi.nlm.nih.gov/pubmed/21481795
1866,24838835,FBXW7 mutations in melanoma and a new therapeutic paradigm.,http://www.ncbi.nlm.nih.gov/pubmed/24838835
1867,25605917,Suppression of cancer relapse and metastasis by inhibiting cancer stemness.,http://www.ncbi.nlm.nih.gov/pubmed/25605917
1868,25252692,Mutation-specific RAS oncogenicity explains NRAS codon 61 selection in melanoma.,http://www.ncbi.nlm.nih.gov/pubmed/25252692
1869,24705026,Mechanisms of RET signaling in cancer: current and future implications for targeted therapy.,http://www.ncbi.nlm.nih.gov/pubmed/24705026
1870,21551259,"In vitro transforming potential, intracellular signaling properties, and sensitivity to a kinase inhibitor (sorafenib) of RET proto-oncogene variants Glu511Lys, Ser649Leu, and Arg886Trp.",http://www.ncbi.nlm.nih.gov/pubmed/21551259
1871,15753368,"RET-familial medullary thyroid carcinoma mutants Y791F and S891A activate a Src/JAK/STAT3 pathway, independent of glial cell line-derived neurotrophic factor.",http://www.ncbi.nlm.nih.gov/pubmed/15753368
1872,17823240,Runx1 protects hematopoietic stem/progenitor cells from oncogenic insult.,http://www.ncbi.nlm.nih.gov/pubmed/17823240
1873,18951408,PIK3CA somatic mutations in breast cancer: Mechanistic insights from Langevin dynamics simulations.,http://www.ncbi.nlm.nih.gov/pubmed/18951408
1874,20132997,Three novel mutations in MODY and its phenotype in three different Czech families.,http://www.ncbi.nlm.nih.gov/pubmed/20132997
1875,16188233,KIT (c-kit oncogene product) pathway is constitutively activated in human testicular germ cell tumors.,http://www.ncbi.nlm.nih.gov/pubmed/16188233
1876,24817905,Structure-functional prediction and analysis of cancer mutation effects in protein kinases.,http://www.ncbi.nlm.nih.gov/pubmed/24817905
1877,17177598,Epidermal growth factor receptor activation in glioblastoma through novel missense mutations in the extracellular domain.,http://www.ncbi.nlm.nih.gov/pubmed/17177598
1878,19671738,Double EGFR mutants containing rare EGFR mutant types show reduced in vitro response to gefitinib compared with common activating missense mutations.,http://www.ncbi.nlm.nih.gov/pubmed/19671738
1879,15737014,Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain.,http://www.ncbi.nlm.nih.gov/pubmed/15737014
1880,17020982,Analysis of epidermal growth factor receptor gene mutation in patients with non-small cell lung cancer and acquired resistance to gefitinib.,http://www.ncbi.nlm.nih.gov/pubmed/17020982
1881,17318210,Epidermal growth factor receptor mutations in lung cancer.,http://www.ncbi.nlm.nih.gov/pubmed/17318210
1882,19561646,Functional RET G691S polymorphism in cutaneous malignant melanoma.,http://www.ncbi.nlm.nih.gov/pubmed/19561646
1883,24900694,Discovery of RG7112: A Small-Molecule MDM2 Inhibitor in Clinical Development.,http://www.ncbi.nlm.nih.gov/pubmed/24900694
1884,,A phase I study of MDM2 antagonist RG7112 in patients (pts) with relapsed/refractory solid tumors.,http://meetinglibrary.asco.org/content/99973-114
1885,,Abstract 4638: NVP-CGM097: a novel p53-Mdm2 inhibitor exhibiting potent antitumor activity in mouse models of human cancer,http://cancerres.aacrjournals.org/content/74/19_Supplement/4638.short
1886,25145672,SAR405838: an optimized inhibitor of MDM2-p53 interaction that induces complete and durable tumor regression.,http://www.ncbi.nlm.nih.gov/pubmed/25145672
1887,22588883,Differential sensitivity of glioma- versus lung cancer-specific EGFR mutations to EGFR kinase inhibitors.,http://www.ncbi.nlm.nih.gov/pubmed/22588883
1888,19284481,Epidermal growth factor receptor extracellular domain mutations in primary glioblastoma.,http://www.ncbi.nlm.nih.gov/pubmed/19284481
1889,19625781,"BB, a new EGFR inhibitor, exhibits prominent anti-angiogenesis and antitumor activities.",http://www.ncbi.nlm.nih.gov/pubmed/19625781
1890,19147750,Functional analysis of epidermal growth factor receptor (EGFR) mutations and potential implications for EGFR targeted therapy.,http://www.ncbi.nlm.nih.gov/pubmed/19147750
1891,23360111,Targeting the RAS oncogene.,http://www.ncbi.nlm.nih.gov/pubmed/23360111
1892,16501605,Biochemical and molecular characterization of the novel BRAF(V599Ins) mutation detected in a classic papillary thyroid carcinoma.,http://www.ncbi.nlm.nih.gov/pubmed/16501605
1893,19802009,AKT1 mutations in bladder cancer: identification of a novel oncogenic mutation that can co-operate with E17K.,http://www.ncbi.nlm.nih.gov/pubmed/19802009
1894,19200582,Detection and molecular characterization of a novel BRAF activated domain mutation in follicular variant of papillary thyroid carcinoma.,http://www.ncbi.nlm.nih.gov/pubmed/19200582
1895,7774014,The protein kinase encoded by the Akt proto-oncogene is a target of the PDGF-activated phosphatidylinositol 3-kinase.,http://www.ncbi.nlm.nih.gov/pubmed/7774014
1896,9005851,Regulation of neuronal survival by the serine-threonine protein kinase Akt.,http://www.ncbi.nlm.nih.gov/pubmed/9005851
1897,16362038,Novel roles of Akt and mTOR in suppressing TGF-beta/ALK5-mediated Smad3 activation.,http://www.ncbi.nlm.nih.gov/pubmed/16362038
1898,24509625,Activating mutations in ALK kinase domain confer resistance to structurally unrelated ALK inhibitors in NPM-ALK-positive anaplastic large-cell lymphoma.,http://www.ncbi.nlm.nih.gov/pubmed/24509625
1899,23104988,Cell culture and Drosophila model systems define three classes of anaplastic lymphoma kinase mutations in neuroblastoma.,http://www.ncbi.nlm.nih.gov/pubmed/23104988
1900,9331080,Inactivation of Smad4 in gastric carcinomas.,http://www.ncbi.nlm.nih.gov/pubmed/9331080
1901,24980830,Discovery of novel non-ATP competitive FGFR1 inhibitors and evaluation of their anti-tumor activity in non-small cell lung cancer in vitro and in vivo.,http://www.ncbi.nlm.nih.gov/pubmed/24980830
1902,23817572,Recurrent somatic alterations of FGFR1 and NTRK2 in pilocytic astrocytoma.,http://www.ncbi.nlm.nih.gov/pubmed/23817572
1903,19212647,FGFR2-related pathogenesis and FGFR2-targeted therapeutics (Review).,http://www.ncbi.nlm.nih.gov/pubmed/19212647
1904,24993163,Activating FGFR2-RAS-BRAF mutations in ameloblastoma.,http://www.ncbi.nlm.nih.gov/pubmed/24993163
1905,17803937,A molecular brake in the kinase hinge region regulates the activity of receptor tyrosine kinases.,http://www.ncbi.nlm.nih.gov/pubmed/17803937
1906,,Early detection of a metabolic tumor response to p70S6 kinase/AKT inhibition by LYS6KAKT1 using in vivo choline proton magnetic resonance spectroscopy.,http://mct.aacrjournals.org/content/10/11_Supplement/B117.short
1907,20439987,NF449 is a novel inhibitor of fibroblast growth factor receptor 3 (FGFR3) signaling active in chondrocytes and multiple myeloma cells.,http://www.ncbi.nlm.nih.gov/pubmed/20439987
1908,11032810,Activation of B-Raf kinase requires phosphorylation of the conserved residues Thr598 and Ser601.,http://www.ncbi.nlm.nih.gov/pubmed/11032810
1909,23237847,Functional analysis of non-hotspot AKT1 mutants found in human breast cancers identifies novel driver mutations: implications for personalized medicine.,http://www.ncbi.nlm.nih.gov/pubmed/23237847
1910,21190184,Functional characterization of a BRAF insertion mutant associated with pilocytic astrocytoma.,http://www.ncbi.nlm.nih.gov/pubmed/21190184
1911,25348715,Kinase regulation by hydrophobic spine assembly in cancer.,http://www.ncbi.nlm.nih.gov/pubmed/25348715
1912,22752848,"Functional characterization of the novel BRAF complex mutation, BRAF(V600delinsYM) , identified in papillary thyroid carcinoma.",http://www.ncbi.nlm.nih.gov/pubmed/22752848
1913,20360943,Small molecule inhibitors of Wnt/beta-catenin/lef-1 signaling induces apoptosis in chronic lymphocytic leukemia cells in vitro and in vivo.,http://www.ncbi.nlm.nih.gov/pubmed/20360943
1914,18347139,A small-molecule inhibitor of Tcf/beta-catenin signaling down-regulates PPARgamma and PPARdelta activities.,http://www.ncbi.nlm.nih.gov/pubmed/18347139
1915,15314234,A small molecule inhibitor of beta-catenin/CREB-binding protein transcription [corrected].,http://www.ncbi.nlm.nih.gov/pubmed/15314234
1916,23071338,Inhibition of oncogenic Wnt signaling through direct targeting of β-catenin.,http://www.ncbi.nlm.nih.gov/pubmed/23071338
1917,12543790,"SKI-606, a 4-anilino-3-quinolinecarbonitrile dual inhibitor of Src and Abl kinases, is a potent antiproliferative agent against chronic myelogenous leukemia cells in culture and causes regression of K562 xenografts in nude mice.",http://www.ncbi.nlm.nih.gov/pubmed/12543790
1918,17431114,Inhibition of both focal adhesion kinase and insulin-like growth factor-I receptor kinase suppresses glioma proliferation in vitro and in vivo.,http://www.ncbi.nlm.nih.gov/pubmed/17431114
1919,18339875,"Antitumor activity and pharmacology of a selective focal adhesion kinase inhibitor, PF-562,271.",http://www.ncbi.nlm.nih.gov/pubmed/18339875
1920,19571674,A novel small molecule inhibitor of FAK decreases growth of human pancreatic cancer.,http://www.ncbi.nlm.nih.gov/pubmed/19571674
1921,17881494,Adenomatous polyposis coli (APC): a multi-functional tumor suppressor gene.,http://www.ncbi.nlm.nih.gov/pubmed/17881494
1922,16003752,MF tricyclic and sulindac retard tumor formation in an animal model.,http://www.ncbi.nlm.nih.gov/pubmed/16003752
1923,17213821,COX-2 involvement in breast cancer metastasis to bone.,http://www.ncbi.nlm.nih.gov/pubmed/17213821
1924,17909047,Targeting cyclooxygenase-2 and the epidermal growth factor receptor for the prevention and treatment of intestinal cancer.,http://www.ncbi.nlm.nih.gov/pubmed/17909047
1925,11250728,Estrogen receptor transcription and transactivation: Structure-function relationship in DNA- and ligand-binding domains of estrogen receptors.,http://www.ncbi.nlm.nih.gov/pubmed/11250728
1926,17157789,Disruption of estrogen receptor DNA-binding domain and related intramolecular communication restores tamoxifen sensitivity in resistant breast cancer.,http://www.ncbi.nlm.nih.gov/pubmed/17157789
1927,19755659,Sulindac effects on inflammation and tumorigenesis in the intestine of mice with Apc and Mlh1 mutations.,http://www.ncbi.nlm.nih.gov/pubmed/19755659
1928,18669636,Use of Akt inhibitor and a drug-resistant mutant validates a critical role for protein kinase B/Akt in the insulin-dependent regulation of glucose and system A amino acid uptake.,http://www.ncbi.nlm.nih.gov/pubmed/18669636
1929,24185512,ESR1 ligand-binding domain mutations in hormone-resistant breast cancer.,http://www.ncbi.nlm.nih.gov/pubmed/24185512
1930,24185510,Activating ESR1 mutations in hormone-resistant metastatic breast cancer.,http://www.ncbi.nlm.nih.gov/pubmed/24185510
1931,10733896,Estrogen receptors: how do they control reproductive and nonreproductive functions?,http://www.ncbi.nlm.nih.gov/pubmed/10733896
1932,8114756,Identification of charged residues in an N-terminal portion of the hormone-binding domain of the human estrogen receptor important in transcriptional activity of the receptor.,http://www.ncbi.nlm.nih.gov/pubmed/8114756
1933,18829572,PIK3CA cooperates with other phosphatidylinositol 3'-kinase pathway mutations to effect oncogenic transformation.,http://www.ncbi.nlm.nih.gov/pubmed/18829572
1934,16081693,"Extracellular KIT receptor mutants, commonly found in core binding factor AML, are constitutively active and respond to imatinib mesylate.",http://www.ncbi.nlm.nih.gov/pubmed/16081693
1935,18814281,Oncogenic NRAS has multiple effects on the malignant phenotype of human melanoma cells cultured in vitro.,http://www.ncbi.nlm.nih.gov/pubmed/18814281
1936,20538734,Effects of the TP53 p.R249S mutant on proliferation and clonogenic properties in human hepatocellular carcinoma cell lines: interaction with hepatitis B virus X protein.,http://www.ncbi.nlm.nih.gov/pubmed/20538734
1937,20951801,NOTCH1 missense alleles associated with left ventricular outflow tract defects exhibit impaired receptor processing and defective EMT.,http://www.ncbi.nlm.nih.gov/pubmed/20951801
1938,24055055,Endocrine-therapy-resistant ESR1 variants revealed by genomic characterization of breast-cancer-derived xenografts.,http://www.ncbi.nlm.nih.gov/pubmed/24055055
1939,10713666,Quantitative analysis of residual folding and DNA binding in mutant p53 core domain: definition of mutant states for rescue in cancer therapy.,http://www.ncbi.nlm.nih.gov/pubmed/10713666
1940,9581815,Missense mutations in SMOH in sporadic basal cell carcinomas of the skin and primitive neuroectodermal tumors of the central nervous system.,http://www.ncbi.nlm.nih.gov/pubmed/9581815
1941,17108110,Molecular mechanisms of RET receptor-mediated oncogenesis in multiple endocrine neoplasia 2B.,http://www.ncbi.nlm.nih.gov/pubmed/17108110
1942,17102091,Molecular implications of RET mutations for pheochromocytoma risk in multiple endocrine neoplasia 2.,http://www.ncbi.nlm.nih.gov/pubmed/17102091
1943,20049516,Investigating the function of three non-synonymous SNPs in EGFR gene: structural modelling and association with breast cancer.,http://www.ncbi.nlm.nih.gov/pubmed/20049516
1944,15623594,High frequency of epidermal growth factor receptor mutations with complex patterns in non-small cell lung cancers related to gefitinib responsiveness in Taiwan.,http://www.ncbi.nlm.nih.gov/pubmed/15623594
1945,16205628,Distinctive activation patterns in constitutively active and gefitinib-sensitive EGFR mutants.,http://www.ncbi.nlm.nih.gov/pubmed/16205628
1946,19726454,Prognostic significance of epidermal growth factor receptor phosphorylation and mutation in head and neck squamous cell carcinoma.,http://www.ncbi.nlm.nih.gov/pubmed/19726454
1947,21242967,The constitutive activity of the ALK mutated at positions F1174 or R1275 impairs receptor trafficking.,http://www.ncbi.nlm.nih.gov/pubmed/21242967
1948,22179664,"Phase I study of bosutinib, a src/abl tyrosine kinase inhibitor, administered to patients with advanced solid tumors.",http://www.ncbi.nlm.nih.gov/pubmed/22179664
1949,20473900,Curcumin enhances dasatinib-induced inhibition of growth and transformation of colon cancer cells.,http://www.ncbi.nlm.nih.gov/pubmed/20473900
1950,14749129,Small-molecule antagonists of the oncogenic Tcf/beta-catenin protein complex.,http://www.ncbi.nlm.nih.gov/pubmed/14749129
1951,8923465,Constitutively active human estrogen receptors containing amino acid substitutions for tyrosine 537 in the receptor protein.,http://www.ncbi.nlm.nih.gov/pubmed/8923465
1952,24940873,Targeting the Wnt/β-catenin signaling pathway in liver cancer stem cells and hepatocellular carcinoma cell lines with FH535.,http://www.ncbi.nlm.nih.gov/pubmed/24940873
1953,24631838,A diverse array of cancer-associated MTOR mutations are hyperactivating and can predict rapamycin sensitivity.,http://www.ncbi.nlm.nih.gov/pubmed/24631838
1954,23843721,Recent progress in mouse models for tumor suppressor genes and its implications in human cancer.,http://www.ncbi.nlm.nih.gov/pubmed/23843721
1955,21400081,A phase II trial of the Src kinase inhibitor saracatinib (AZD0530) in patients with metastatic or locally advanced gastric or gastro esophageal junction (GEJ) adenocarcinoma: a trial of the PMH phase II consortium.,http://www.ncbi.nlm.nih.gov/pubmed/21400081
1956,20942962,Clinical implications of novel activating EGFR mutations in malignant peritoneal mesothelioma.,http://www.ncbi.nlm.nih.gov/pubmed/20942962
1957,15256466,AEE788: a dual family epidermal growth factor receptor/ErbB2 and vascular endothelial growth factor receptor tyrosine kinase inhibitor with antitumor and antiangiogenic activity.,http://www.ncbi.nlm.nih.gov/pubmed/15256466
1958,22766511,Anti-tumor effect of a novel FAK inhibitor TAE226 against human oral squamous cell carcinoma.,http://www.ncbi.nlm.nih.gov/pubmed/22766511
1959,23792569,Focal adhesion kinase autophosphorylation inhibition decreases colon cancer cell growth and enhances the efficacy of chemotherapy.,http://www.ncbi.nlm.nih.gov/pubmed/23792569
1960,23983820,"Antitumor Activity of TAK-285, an Investigational, Non-Pgp Substrate HER2/EGFR Kinase Inhibitor, in Cultured Tumor Cells, Mouse and Rat Xenograft Tumors, and in an HER2-Positive Brain Metastasis Model.",http://www.ncbi.nlm.nih.gov/pubmed/23983820
1961,11706399,"CI-1033, a pan-erbB tyrosine kinase inhibitor.",http://www.ncbi.nlm.nih.gov/pubmed/11706399
1962,17342332,The pan-erbB tyrosine kinase inhibitor CI-1033 inhibits human esophageal cancer cells in vitro and in vivo.,http://www.ncbi.nlm.nih.gov/pubmed/17342332
1963,25027951,Oral epidermal growth factor receptor tyrosine kinase inhibitors for the treatment of non-small cell lung cancer: comparative pharmacokinetics and drug-drug interactions.,http://www.ncbi.nlm.nih.gov/pubmed/25027951
1964,23127174,Therapeutic targeting of c-KIT in cancer.,http://www.ncbi.nlm.nih.gov/pubmed/23127174
1965,23775962,"Imatinib for melanomas harboring mutationally activated or amplified KIT arising on mucosal, acral, and chronically sun-damaged skin.",http://www.ncbi.nlm.nih.gov/pubmed/23775962
1966,19789626,"Masitinib (AB1010), a potent and selective tyrosine kinase inhibitor targeting KIT.",http://www.ncbi.nlm.nih.gov/pubmed/19789626
1967,16424037,OSI-930: a novel selective inhibitor of Kit and kinase insert domain receptor tyrosine kinases with antitumor activity in mouse xenograft models.,http://www.ncbi.nlm.nih.gov/pubmed/16424037
1968,25653539,"BRAF-mutant melanoma: treatment approaches, resistance mechanisms, and diagnostic strategies.",http://www.ncbi.nlm.nih.gov/pubmed/25653539
1969,7954456,Selective platelet-derived growth factor receptor kinase blockers reverse sis-transformation.,http://www.ncbi.nlm.nih.gov/pubmed/7954456
1970,15150607,Co-targeting IGF-1R and c-kit: synergistic inhibition of proliferation and induction of apoptosis in H 209 small cell lung cancer cells.,http://www.ncbi.nlm.nih.gov/pubmed/15150607
1971,25204436,Therapy response monitoring of the early effects of a new BRAF inhibitor on melanoma xenograft in mice: evaluation of (18) F-FDG-PET and (18) F-FLT-PET.,http://www.ncbi.nlm.nih.gov/pubmed/25204436
1972,25079552,Comprehensive molecular profiling of lung adenocarcinoma.,http://www.ncbi.nlm.nih.gov/pubmed/25079552
1973,15123609,A conserved DpYR motif in the juxtamembrane domain of the Met receptor family forms an atypical c-Cbl/Cbl-b tyrosine kinase binding domain binding site required for suppression of oncogenic activation.,http://www.ncbi.nlm.nih.gov/pubmed/15123609
1974,16397241,Somatic mutations lead to an oncogenic deletion of met in lung cancer.,http://www.ncbi.nlm.nih.gov/pubmed/16397241
1975,25531467,Transcriptome meta-analysis of lung cancer reveals recurrent aberrations in NRG1 and Hippo pathway genes.,http://www.ncbi.nlm.nih.gov/pubmed/25531467
1976,,489P: FUNCTIONAL SIMILARITY ASSESSMENT RESULTS COMPARING BEVACIZUMAB TO BIOSIMILAR CANDIDATE ABP 215,http://annonc.oxfordjournals.org/content/25/suppl_4/iv163.2.short
1977,16891470,The proteasome inhibitor NPI-0052 is a more effective inducer of apoptosis than bortezomib in lymphocytes from patients with chronic lymphocytic leukemia.,http://www.ncbi.nlm.nih.gov/pubmed/16891470
1978,22072639,Differential inhibitor sensitivity of anaplastic lymphoma kinase variants found in neuroblastoma.,http://www.ncbi.nlm.nih.gov/pubmed/22072639
1979,22908275,Functional analysis of receptor tyrosine kinase mutations in lung cancer identifies oncogenic extracellular domain mutations of ERBB2.,http://www.ncbi.nlm.nih.gov/pubmed/22908275
1980,23220880,Activating HER2 mutations in HER2 gene amplification negative breast cancer.,http://www.ncbi.nlm.nih.gov/pubmed/23220880
1982,,The Mdm2 inhibitor NVP-CGM097 enhances the anti-tumor activity of NVP-LDK378 in ALK mutant neuroblastoma models,http://cancerres.aacrjournals.org/content/74/19_Supplement/2929
1983,,"Abstract DDT02-03: Discovery of GDC-0994, a potent and selective ERK1/2 inhibitor in early clinical development",http://cancerres.aacrjournals.org/content/74/19_Supplement/DDT02-03.short
1984,,Abstract 922: ABTL0812: A new drug class with oral antitumor action inhibiting mTOR activity and DHFR expression,http://cancerres.aacrjournals.org/content/72/8_Supplement/922.short
1985,21558396,The selective class I PI3K inhibitor CH5132799 targets human cancers harboring oncogenic PIK3CA mutations.,http://www.ncbi.nlm.nih.gov/pubmed/21558396
1986,23810788,The poly(ADP-ribose) polymerase inhibitor niraparib (MK4827) in BRCA mutation carriers and patients with sporadic cancer: a phase 1 dose-escalation trial.,http://www.ncbi.nlm.nih.gov/pubmed/23810788
1987,17363489,Preclinical selection of a novel poly(ADP-ribose) polymerase inhibitor for clinical trial.,http://www.ncbi.nlm.nih.gov/pubmed/17363489
1988,,Abstract B184: In vitro and in vivo profiling of novel mTORC1/2 inhibitor DS-3078a.,http://mct.aacrjournals.org/content/12/11_Supplement/B184.short
1989,,Abstract B117: Early detection of a metabolic tumor response to p70S6 kinase/AKT inhibition by LYS6KAKT1 using in vivo choline proton magnetic resonance spectroscopy.,http://mct.aacrjournals.org/content/10/11_Supplement/B117.short
1990,9563489,Two North American families with hereditary papillary renal carcinoma and identical novel mutations in the MET proto-oncogene.,http://www.ncbi.nlm.nih.gov/pubmed/9563489
1991,10327054,Novel mutations of the MET proto-oncogene in papillary renal carcinomas.,http://www.ncbi.nlm.nih.gov/pubmed/10327054
1992,12460923,Novel somatic mutations of the MET oncogene in human carcinoma metastases activating cell motility and invasion.,http://www.ncbi.nlm.nih.gov/pubmed/12460923
1993,22430491,MYC pathway activation in triple-negative breast cancer is synthetic lethal with CDK inhibition.,http://www.ncbi.nlm.nih.gov/pubmed/22430491
1994,24045150,Met as a therapeutic target in HCC: facts and hopes.,http://www.ncbi.nlm.nih.gov/pubmed/24045150
1995,24317512,CDK/CK1 inhibitors roscovitine and CR8 downregulate amplified MYCN in neuroblastoma cells.,http://www.ncbi.nlm.nih.gov/pubmed/24317512
1996,18039657,Mutational activation of ErbB2 reveals a new protein kinase autoinhibition mechanism.,http://www.ncbi.nlm.nih.gov/pubmed/18039657
1997,9030781,"Biochemical and cellular effects of roscovitine, a potent and selective inhibitor of the cyclin-dependent kinases cdc2, cdk2 and cdk5.",http://www.ncbi.nlm.nih.gov/pubmed/9030781
1998,9366565,"Direct in vivo inhibition of the nuclear cell cycle cascade in experimental mesangial proliferative glomerulonephritis with Roscovitine, a novel cyclin-dependent kinase antagonist.",http://www.ncbi.nlm.nih.gov/pubmed/9366565
2000,20515943,"BMS-777607, a small-molecule met kinase inhibitor, suppresses hepatocyte growth factor-stimulated prostate cancer metastatic phenotype in vitro.",http://www.ncbi.nlm.nih.gov/pubmed/20515943
2002,17311002,The major lung cancer-derived mutants of ERBB2 are oncogenic and are associated with sensitivity to the irreversible EGFR/ERBB2 inhibitor HKI-272.,http://www.ncbi.nlm.nih.gov/pubmed/17311002
2003,23493885,Focus on the potential role of ficlatuzumab in the treatment of non-small cell lung cancer.,http://www.ncbi.nlm.nih.gov/pubmed/23493885
2004,16843263,HER2 kinase domain mutation results in constitutive phosphorylation and activation of HER2 and EGFR and resistance to EGFR tyrosine kinase inhibitors.,http://www.ncbi.nlm.nih.gov/pubmed/16843263
2005,,"Phase I study of PF-03446962, a fully human mAb against ALK 1, a TGF-beta receptor involved in tumor angiogenesis",http://meetinglibrary.asco.org/content/78762-102
2006,23882082,"Monovalent antibody design and mechanism of action of onartuzumab, a MET antagonist with anti-tumor activity as a therapeutic agent.",http://www.ncbi.nlm.nih.gov/pubmed/23882082
2007,23804704,"S49076 is a novel kinase inhibitor of MET, AXL, and FGFR with strong preclinical activity alone and in association with bevacizumab.",http://www.ncbi.nlm.nih.gov/pubmed/23804704
2008,24566706,"PF-03446962, a fully-human monoclonal antibody against transforming growth-factor β (TGFβ) receptor ALK1, in pre-treated patients with urothelial cancer: an open label, single-group, phase 2 trial.",http://www.ncbi.nlm.nih.gov/pubmed/24566706
2009,25504634,The selective intravenous inhibitor of the MET tyrosine kinase SAR125844 inhibits tumor growth in MET-amplified cancer.,http://www.ncbi.nlm.nih.gov/pubmed/25504634
2010,25248999,"Volitinib, a potent and highly selective c-Met inhibitor, effectively blocks c-Met signaling and growth in c-MET amplified gastric cancer patient-derived tumor xenograft models.",http://www.ncbi.nlm.nih.gov/pubmed/25248999
2011,11290608,Activating mutation of D835 within the activation loop of FLT3 in human hematologic malignancies.,http://www.ncbi.nlm.nih.gov/pubmed/11290608
2012,14612533,A selective small molecule inhibitor of c-Met kinase inhibits c-Met-dependent phenotypes in vitro and exhibits cytoreductive antitumor activity in vivo.,http://www.ncbi.nlm.nih.gov/pubmed/14612533
2013,11230495,"Phase I and pharmacokinetic study of PKC412, an inhibitor of protein kinase C.",http://www.ncbi.nlm.nih.gov/pubmed/11230495
2014,20145145,"MK-2461, a novel multitargeted kinase inhibitor, preferentially inhibits the activated c-Met receptor.",http://www.ncbi.nlm.nih.gov/pubmed/20145145
2015,20015007,Discovery of small molecule c-Met inhibitors: Evolution and profiles of clinical candidates.,http://www.ncbi.nlm.nih.gov/pubmed/20015007
2016,22937135,Prevalence of c-KIT mutations in gonadoblastoma and dysgerminomas of patients with disorders of sex development (DSD) and ovarian dysgerminomas.,http://www.ncbi.nlm.nih.gov/pubmed/22937135
2017,9029028,A new c-kit mutation in a case of aggressive mast cell disease.,http://www.ncbi.nlm.nih.gov/pubmed/9029028
2018,16741525,Detection of c-kit exons 11- and 17-activating mutations in testicular seminomas by high-resolution melting amplicon analysis.,http://www.ncbi.nlm.nih.gov/pubmed/16741525
2019,15796538,Characterization of the FKBP.rapamycin.FRB ternary complex.,http://www.ncbi.nlm.nih.gov/pubmed/15796538
2020,19723643,Ethnic differences and functional analysis of MET mutations in lung cancer.,http://www.ncbi.nlm.nih.gov/pubmed/19723643
2021,19459657,Enzymatic characterization of c-Met receptor tyrosine kinase oncogenic mutants and kinetic studies with aminopyridine and triazolopyrazine inhibitors.,http://www.ncbi.nlm.nih.gov/pubmed/19459657
2022,16245927,Regulation of the wild-type and Y1235D mutant Met kinase activation.,http://www.ncbi.nlm.nih.gov/pubmed/16245927
2023,,"First-in-human study of AMG 208, an oral MET inhibitor, in adult patients (pts) with advanced solid tumors.",http://meetinglibrary.asco.org/content/106477-134
2024,24849582,Phase 1B study of amuvatinib in combination with five standard cancer therapies in adults with advanced solid tumors.,http://www.ncbi.nlm.nih.gov/pubmed/24849582
2025,24326130,Targeting MET kinase with the small-molecule inhibitor amuvatinib induces cytotoxicity in primary myeloma cells and cell lines.,http://www.ncbi.nlm.nih.gov/pubmed/24326130
2026,22286523,Impact of the small molecule Met inhibitor BMS-777607 on the metastatic process in a rodent tumor model with constitutive c-Met activation.,http://www.ncbi.nlm.nih.gov/pubmed/22286523
2027,,"Phase I study of SCH 900105 (SC), an anti-hepatocyte growth factor (HGF) monoclonal antibody (MAb), as a single agent and in combination with erlotinib (E) in patients (pts) with advanced solid tumors.",http://hwmaint.meeting.ascopubs.org/cgi/content/abstract/28/15_suppl/2525
2028,,"Phase Ib study of ficlatuzumab (formerly AV-299), an anti-hepatocyte growth factor (HGF) monoclonal antibody (MAb) in combination with gefitinib (G) in Asian patients (pts) with NSCLC.",
2029,,"Abstract C173: Anti?tumor activity of SCH 900105 (AV299), an anti?HGF antibody, in non?small cell lung cancer models",http://mct.aacrjournals.org/content/8/12_Supplement/C173.short
2030,24101053,Randomized phase II trial of Onartuzumab in combination with erlotinib in patients with advanced non-small-cell lung cancer.,http://www.ncbi.nlm.nih.gov/pubmed/24101053
2031,,"Onartuzumab plus erlotinib versus erlotinib in previously treated stage IIIb or IV NSCLC: Results from the pivotal phase III randomized, multicenter, placebo-controlled METLung (OAM4971g) global trial.",http://meetinglibrary.asco.org/content/128045-144
2032,17684489,Structural characterization of the interaction of mTOR with phosphatidic acid and a novel class of inhibitor: compelling evidence for a central role of the FRB domain in small molecule-mediated regulation of mTOR.,http://www.ncbi.nlm.nih.gov/pubmed/17684489
2033,19680293,Activating and resistance mutations of EGFR in non-small-cell lung cancer: role in clinical response to EGFR tyrosine kinase inhibitors.,http://www.ncbi.nlm.nih.gov/pubmed/19680293
2034,,"Abstract 845: In vitro and in vivo pharmacology of SAR125844, a potent and selective intravenous MET kinase inhibitor undergoing Phase I clinical trial",
2035,,"A first-in-human (FIH) phase I study of SAR125844, a novel selective MET kinase inhibitor, in patients (pts) with advanced solid tumors: Dose escalation results.",http://meetinglibrary.asco.org/content/126762-144
2036,20716641,"TAK-701, a humanized monoclonal antibody to hepatocyte growth factor, reverses gefitinib resistance induced by tumor-derived HGF in non-small cell lung cancer with an EGFR mutation.",http://www.ncbi.nlm.nih.gov/pubmed/20716641
2037,23416972,KIT-D816V oncogenic activity is controlled by the juxtamembrane docking site Y568-Y570.,http://www.ncbi.nlm.nih.gov/pubmed/23416972
2038,23588081,Protein modelling of a novel KIT mutation (N567Y) in the gastrointestinal stromal tumour.,http://www.ncbi.nlm.nih.gov/pubmed/23588081
2039,23705946,"In vitro and in vivo activity of cabozantinib (XL184), an inhibitor of RET, MET, and VEGFR2, in a model of medullary thyroid cancer.",http://www.ncbi.nlm.nih.gov/pubmed/23705946
2040,21994418,"Phase I trial of ALT-801, an interleukin-2/T-cell receptor fusion protein targeting p53 (aa264-272)/HLA-A*0201 complex, in patients with advanced malignancies.",http://www.ncbi.nlm.nih.gov/pubmed/21994418
2041,11815602,Fibroblast growth factor-2 induces translational regulation of Bcl-XL and Bcl-2 via a MEK-dependent pathway: correlation with resistance to etoposide-induced apoptosis.,http://www.ncbi.nlm.nih.gov/pubmed/11815602
2042,17785202,FGFR3 activates RSK2 to mediate hematopoietic transformation through tyrosine phosphorylation of RSK2 and activation of the MEK/ERK pathway.,http://www.ncbi.nlm.nih.gov/pubmed/17785202
2043,23242278,To BRAF or not to BRAF: is that even a question anymore?,http://www.ncbi.nlm.nih.gov/pubmed/23242278
2044,18974108,Tandem duplication producing a novel oncogenic BRAF fusion gene defines the majority of pilocytic astrocytomas.,http://www.ncbi.nlm.nih.gov/pubmed/18974108
2045,24889603,"In situ selectivity profiling and crystal structure of SML-8-73-1, an active site inhibitor of oncogenic K-Ras G12C.",http://www.ncbi.nlm.nih.gov/pubmed/24889603
2046,24259466,Therapeutic targeting of oncogenic K-Ras by a covalent catalytic site inhibitor.,http://www.ncbi.nlm.nih.gov/pubmed/24259466
2047,20528225,Salirasib in the treatment of pancreatic cancer.,http://www.ncbi.nlm.nih.gov/pubmed/20528225
2048,25323927,Drugging the undruggable RAS: Mission possible?,http://www.ncbi.nlm.nih.gov/pubmed/25323927
2049,21363918,"Reduced VEGF production, angiogenesis, and vascular regrowth contribute to the antitumor properties of dual mTORC1/mTORC2 inhibitors.",http://www.ncbi.nlm.nih.gov/pubmed/21363918
2050,23152448,Pediatric glioma-associated KIAA1549:BRAF expression regulates neuroglial cell growth in a cell type-specific and mTOR-dependent manner.,http://www.ncbi.nlm.nih.gov/pubmed/23152448
2051,11042681,A novel germ line juxtamembrane Met mutation in human gastric cancer.,http://www.ncbi.nlm.nih.gov/pubmed/11042681
2052,17322284,Activation of HGF/c-Met pathway contributes to the reactive oxygen species generation and motility of small cell lung cancer cells.,http://www.ncbi.nlm.nih.gov/pubmed/17322284
2053,22973954,Detection and therapeutic implications of c-Met mutations in small cell lung cancer and neuroendocrine tumors.,http://www.ncbi.nlm.nih.gov/pubmed/22973954
2054,15365079,Biology of gastrointestinal stromal tumors.,http://www.ncbi.nlm.nih.gov/pubmed/15365079
2055,12879016,Signal transduction by several KIT juxtamembrane domain mutations.,http://www.ncbi.nlm.nih.gov/pubmed/12879016
2056,22282465,KRAS and BRAF mutations predict primary resistance to imatinib in gastrointestinal stromal tumors.,http://www.ncbi.nlm.nih.gov/pubmed/22282465
2057,21482695,"Ridaforolimus (AP23573; MK-8669), a potent mTOR inhibitor, has broad antitumor activity and can be optimally administered using intermittent dosing regimens.",http://www.ncbi.nlm.nih.gov/pubmed/21482695
2058,25215588,Inhibition of the PI3K/Akt/mTOR signaling pathway in diffuse large B-cell lymphoma: current knowledge and clinical significance.,http://www.ncbi.nlm.nih.gov/pubmed/25215588
2059,19402821,Ku-0063794 is a specific inhibitor of the mammalian target of rapamycin (mTOR).,http://www.ncbi.nlm.nih.gov/pubmed/19402821
2060,19075588,mTOR pathway and mTOR inhibitors as agents for cancer therapy.,http://www.ncbi.nlm.nih.gov/pubmed/19075588
2061,12815052,"Selective cytotoxic mechanism of GTP-14564, a novel tyrosine kinase inhibitor in leukemia cells expressing a constitutively active Fms-like tyrosine kinase 3 (FLT3).",http://www.ncbi.nlm.nih.gov/pubmed/12815052
2062,12091352,Inhibition of constitutively active forms of mutant kit by multitargeted indolinone tyrosine kinase inhibitors.,http://www.ncbi.nlm.nih.gov/pubmed/12091352
2063,23216927,SU11652 Inhibits tyrosine kinase activity of FLT3 and growth of MV-4-11 cells.,http://www.ncbi.nlm.nih.gov/pubmed/23216927
2064,19209957,Active-site inhibitors of mTOR target rapamycin-resistant outputs of mTORC1 and mTORC2.,http://www.ncbi.nlm.nih.gov/pubmed/19209957
2065,20068177,"Beyond rapalog therapy: preclinical pharmacology and antitumor activity of WYE-125132, an ATP-competitive and specific inhibitor of mTORC1 and mTORC2.",http://www.ncbi.nlm.nih.gov/pubmed/20068177
2066,19584280,"Biochemical, cellular, and in vivo activity of novel ATP-competitive and selective inhibitors of the mammalian target of rapamycin.",http://www.ncbi.nlm.nih.gov/pubmed/19584280
2067,16697955,A dual PI3 kinase/mTOR inhibitor reveals emergent efficacy in glioma.,http://www.ncbi.nlm.nih.gov/pubmed/16697955
2068,19940012,A phase I study of axitinib (AG-013736) in combination with bevacizumab plus chemotherapy or chemotherapy alone in patients with metastatic colorectal cancer and other solid tumors.,http://www.ncbi.nlm.nih.gov/pubmed/19940012
2069,25012508,"Vascular effects, efficacy and safety of nintedanib in patients with advanced, refractory colorectal cancer: a prospective phase I subanalysis.",http://www.ncbi.nlm.nih.gov/pubmed/25012508
2070,21322566,"Discovery of 9-(6-aminopyridin-3-yl)-1-(3-(trifluoromethyl)phenyl)benzo[h][1,6]naphthyridin-2(1H)-one (Torin2) as a potent, selective, and orally available mammalian target of rapamycin (mTOR) inhibitor for treatment of cancer.",http://www.ncbi.nlm.nih.gov/pubmed/21322566
2071,19010932,"Palomid 529, a novel small-molecule drug, is a TORC1/TORC2 inhibitor that reduces tumor growth, tumor angiogenesis, and vascular permeability.",http://www.ncbi.nlm.nih.gov/pubmed/19010932
2072,24867098,"PP121, a dual inhibitor of tyrosine and phosphoinositide kinases, inhibits anaplastic thyroid carcinoma cell proliferation and migration.",http://www.ncbi.nlm.nih.gov/pubmed/24867098
2073,20484085,Pediatric mastocytosis-associated KIT extracellular domain mutations exhibit different functional and signaling properties compared with KIT-phosphotransferase domain mutations.,http://www.ncbi.nlm.nih.gov/pubmed/20484085
2074,16273091,BRAF mutation predicts sensitivity to MEK inhibition.,http://www.ncbi.nlm.nih.gov/pubmed/16273091
2075,22701765,"Antitumor Activity of VB-111, a Novel Antiangiogenic Virotherapeutic, in Thyroid Cancer Xenograft Mouse Models.",http://www.ncbi.nlm.nih.gov/pubmed/22701765
2076,11900252,"APC, signal transduction and genetic instability in colorectal cancer.",http://www.ncbi.nlm.nih.gov/pubmed/11900252
2077,7753829,Loss of Apc heterozygosity and abnormal tissue building in nascent intestinal polyps in mice carrying a truncated Apc gene.,http://www.ncbi.nlm.nih.gov/pubmed/7753829
2078,19390622,Anti-EGFR Therapy: Mechanism and Advances in Clinical Efficacy in Breast Cancer.,http://www.ncbi.nlm.nih.gov/pubmed/19390622
2079,18193092,Epidermal growth factor receptor activation in prostate cancer by three novel missense mutations.,http://www.ncbi.nlm.nih.gov/pubmed/18193092
2080,23358982,Activating germline R776H mutation in the epidermal growth factor receptor associated with lung cancer with squamous differentiation.,http://www.ncbi.nlm.nih.gov/pubmed/23358982
2081,,"A phase I trial of X-396, a novel ALK inhibitor, in patients with advanced solid tumors.",http://meetinglibrary.asco.org/content/134110-144
2082,25567130,The MDM2 Inhibitor AMG 232 Demonstrates Robust Antitumor Efficacy and Potentiates the Activity of p53-Inducing Cytotoxic Agents.,http://www.ncbi.nlm.nih.gov/pubmed/25567130
2084,16103100,"The protein kinase Cbeta-selective inhibitor, Enzastaurin (LY317615.HCl), suppresses signaling through the AKT pathway, induces apoptosis, and suppresses growth of human colon cancer and glioblastoma xenografts.",http://www.ncbi.nlm.nih.gov/pubmed/16103100
2085,16869740,Detection of oncogenic mutations in the EGFR gene in lung adenocarcinoma with differential sensitivity to EGFR tyrosine kinase inhibitors.,http://www.ncbi.nlm.nih.gov/pubmed/16869740
2086,3457562,"Staurosporine, a potent inhibitor of phospholipid/Ca++dependent protein kinase.",http://www.ncbi.nlm.nih.gov/pubmed/3457562
2087,8772178,Inhibition of protein kinase C mu by various inhibitors. Differentiation from protein kinase c isoenzymes.,http://www.ncbi.nlm.nih.gov/pubmed/8772178
2088,23562764,Upregulation of PKCη by PKCε and PDK1 involves two distinct mechanisms and promotes breast cancer cell survival.,http://www.ncbi.nlm.nih.gov/pubmed/23562764
2089,16252018,Gö 6983: a fast acting protein kinase C inhibitor that attenuates myocardial ischemia/reperfusion injury.,http://www.ncbi.nlm.nih.gov/pubmed/16252018
2090,1874734,The bisindolylmaleimide GF 109203X is a potent and selective inhibitor of protein kinase C.,http://www.ncbi.nlm.nih.gov/pubmed/1874734
2091,8826855,Effects of the selective bisindolylmaleimide protein kinase C inhibitor GF 109203X on P-glycoprotein-mediated multidrug resistance.,http://www.ncbi.nlm.nih.gov/pubmed/8826855
2092,22389471,"Combinations of BRAF, MEK, and PI3K/mTOR inhibitors overcome acquired resistance to the BRAF inhibitor GSK2118436 dabrafenib, mediated by NRAS or MEK mutations.",http://www.ncbi.nlm.nih.gov/pubmed/22389471
2093,16969076,Recurrent KRAS codon 146 mutations in human colorectal cancer.,http://www.ncbi.nlm.nih.gov/pubmed/16969076
2094,15772072,The solution structure of the FATC domain of the protein kinase target of rapamycin suggests a role for redox-dependent structural and cellular stability.,http://www.ncbi.nlm.nih.gov/pubmed/15772072
2095,11406571,A novel N-ras mutation in malignant melanoma is associated with excellent prognosis.,http://www.ncbi.nlm.nih.gov/pubmed/11406571
2096,16679305,"K-ras Asp12 mutant neither interacts with Raf, nor signals through Erk and is less tumorigenic than K-ras Val12.",http://www.ncbi.nlm.nih.gov/pubmed/16679305
2097,22589270,A comprehensive survey of Ras mutations in cancer.,http://www.ncbi.nlm.nih.gov/pubmed/22589270
2098,6092966,Biological properties of human c-Ha-ras1 genes mutated at codon 12.,http://www.ncbi.nlm.nih.gov/pubmed/6092966
2099,21478863,ERK and PDE4 cooperate to induce RAF isoform switching in melanoma.,http://www.ncbi.nlm.nih.gov/pubmed/21478863
2100,19966803,A restricted spectrum of NRAS mutations causes Noonan syndrome.,http://www.ncbi.nlm.nih.gov/pubmed/19966803
2101,17517660,NRAS mutation causes a human autoimmune lymphoproliferative syndrome.,http://www.ncbi.nlm.nih.gov/pubmed/17517660
2102,21993244,RAS oncogenes: weaving a tumorigenic web.,http://www.ncbi.nlm.nih.gov/pubmed/21993244
2103,23103856,Oncogenic and wild-type Ras play divergent roles in the regulation of mitogen-activated protein kinase signaling.,http://www.ncbi.nlm.nih.gov/pubmed/23103856
2104,19492075,Combined targeting of BRAF and CRAF or BRAF and PI3K effector pathways is required for efficacy in NRAS mutant tumors.,http://www.ncbi.nlm.nih.gov/pubmed/19492075
2105,18073111,Transformation efficiency of RasQ61 mutants linked to structural features of the switch regions in the presence of Raf.,http://www.ncbi.nlm.nih.gov/pubmed/18073111
2106,24897507,Activating c-KIT mutations confer oncogenic cooperativity and rescue RUNX1/ETO-induced DNA damage and apoptosis in human primary CD34+ hematopoietic progenitors.,http://www.ncbi.nlm.nih.gov/pubmed/24897507
2107,23820125,The novel anticancer agent JNJ-26854165 induces cell death through inhibition of cholesterol transport and degradation of ABCA1.,http://www.ncbi.nlm.nih.gov/pubmed/23820125
2108,25455730,p53 as a target for the treatment of cancer.,http://www.ncbi.nlm.nih.gov/pubmed/25455730
2109,18056464,Genetic alterations in the tyrosine kinase transcriptome of human cancer cell lines.,http://www.ncbi.nlm.nih.gov/pubmed/18056464
2110,23276709,Comparative functional analysis of two fibroblast growth factor receptor 1 (FGFR1) mutations affecting the same residue (R254W and R254Q) in isolated hypogonadotropic hypogonadism (IHH).,http://www.ncbi.nlm.nih.gov/pubmed/23276709
2111,25559798,Randomized phase II study of carboplatin and paclitaxel with either linifanib or placebo for advanced nonsquamous non-small-cell lung cancer.,http://www.ncbi.nlm.nih.gov/pubmed/25559798
2112,17297294,Functional characterization of the T1799-1801del and A1799-1816ins BRAF mutations in papillary thyroid cancer.,http://www.ncbi.nlm.nih.gov/pubmed/17297294
2113,22563563,Identification of a rare 3 bp BRAF gene deletion in a thyroid nodule by mutant enrichment with 3'-modified oligonucleotides polymerase chain reaction.,http://www.ncbi.nlm.nih.gov/pubmed/22563563
2114,9136983,Activation of FGF receptors by mutations in the transmembrane domain.,http://www.ncbi.nlm.nih.gov/pubmed/9136983
2115,14981513,"VX-680, a potent and selective small-molecule inhibitor of the Aurora kinases, suppresses tumor growth in vivo.",http://www.ncbi.nlm.nih.gov/pubmed/14981513
2116,14719906,Dedifferentiation of lineage-committed cells by a small molecule.,http://www.ncbi.nlm.nih.gov/pubmed/14719906
2117,18483302,"Reversine, a novel Aurora kinases inhibitor, inhibits colony formation of human acute myeloid leukemia cells.",http://www.ncbi.nlm.nih.gov/pubmed/18483302
2118,21879811,A novel Aurora kinase A inhibitor MK-8745 predicts TPX2 as a therapeutic biomarker in non-Hodgkin lymphoma cell lines.,http://www.ncbi.nlm.nih.gov/pubmed/21879811
2119,16204078,The in vitro and in vivo effects of JNJ-7706621: a dual inhibitor of cyclin-dependent kinases and aurora kinases.,http://www.ncbi.nlm.nih.gov/pubmed/16204078
2120,16818708,"PHA-680632, a novel Aurora kinase inhibitor with potent antitumoral activity.",http://www.ncbi.nlm.nih.gov/pubmed/16818708
2121,20053775,"MK-5108, a highly selective Aurora-A kinase inhibitor, shows antitumor activity alone and in combination with docetaxel.",http://www.ncbi.nlm.nih.gov/pubmed/20053775
2122,20462263,Discovery of N-phenyl-4-(thiazol-5-yl)pyrimidin-2-amine aurora kinase inhibitors.,http://www.ncbi.nlm.nih.gov/pubmed/20462263
2123,18089709,Mechanism of action of the Aurora kinase inhibitor CCT129202 and in vivo quantification of biological activity.,http://www.ncbi.nlm.nih.gov/pubmed/18089709
2124,17360485,"Antitumor activity of MLN8054, an orally active small-molecule inhibitor of Aurora A kinase.",http://www.ncbi.nlm.nih.gov/pubmed/17360485
2125,17495131,"AZD1152, a novel and selective aurora B kinase inhibitor, induces growth arrest, apoptosis, and sensitization for tubulin depolymerizing agent or topoisomerase II inhibitor in human acute leukemia cells in vitro and in vivo.",http://www.ncbi.nlm.nih.gov/pubmed/17495131
2126,12719470,"Aurora B couples chromosome alignment with anaphase by targeting BubR1, Mad2, and Cenp-E to kinetochores.",http://www.ncbi.nlm.nih.gov/pubmed/12719470
2127,24642870,Characterization of rare transforming KRAS mutations in sporadic colorectal cancer.,http://www.ncbi.nlm.nih.gov/pubmed/24642870
2128,19490892,Synthetic lethal interaction between oncogenic KRAS dependency and STK33 suppression in human cancer cells.,http://www.ncbi.nlm.nih.gov/pubmed/19490892
2129,25705018,"Comparative analysis of KRAS codon 12, 13, 18, 61, and 117 mutations using human MCF10A isogenic cell lines.",http://www.ncbi.nlm.nih.gov/pubmed/25705018
2130,19064915,A mouse model for EML4-ALK-positive lung cancer.,http://www.ncbi.nlm.nih.gov/pubmed/19064915
2131,17625570,Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer.,http://www.ncbi.nlm.nih.gov/pubmed/17625570
2132,23786770,Inhibitor-sensitive FGFR2 and FGFR3 mutations in lung squamous cell carcinoma.,http://www.ncbi.nlm.nih.gov/pubmed/23786770
2133,23913723,"A novel FGFR2 mutation in tyrosine kinase II domain, L617F, in Crouzon syndrome.",http://www.ncbi.nlm.nih.gov/pubmed/23913723
2134,24227820,Crenolanib is a potent inhibitor of FLT3 with activity against resistance-conferring point mutants.,http://www.ncbi.nlm.nih.gov/pubmed/24227820
2135,15705896,"Antiangiogenic and antitumor activity of a selective PDGFR tyrosine kinase inhibitor, CP-673,451.",http://www.ncbi.nlm.nih.gov/pubmed/15705896
2136,12213964,The structural basis for the transition from Ras-GTP to Ras-GDP.,http://www.ncbi.nlm.nih.gov/pubmed/12213964
2137,11103938,Oncogenic insertional mutations in the P-loop of Ras are overactive in MAP kinase signaling.,http://www.ncbi.nlm.nih.gov/pubmed/11103938
2138,23908597,"The N550K/H mutations in FGFR2 confer differential resistance to PD173074, dovitinib, and ponatinib ATP-competitive inhibitors.",http://www.ncbi.nlm.nih.gov/pubmed/23908597
2139,11121055,Loss of fibroblast growth factor receptor 2 ligand-binding specificity in Apert syndrome.,http://www.ncbi.nlm.nih.gov/pubmed/11121055
2140,20175913,Activation of p38 MAPK pathway in the skull abnormalities of Apert syndrome Fgfr2(+P253R) mice.,http://www.ncbi.nlm.nih.gov/pubmed/20175913
2141,18938156,"Inhibition of collagen-induced discoidin domain receptor 1 and 2 activation by imatinib, nilotinib and dasatinib.",http://www.ncbi.nlm.nih.gov/pubmed/18938156
2142,24768818,Structural mechanisms determining inhibition of the collagen receptor DDR1 by selective and multi-targeted type II kinase inhibitors.,http://www.ncbi.nlm.nih.gov/pubmed/24768818
2143,24930769,Dual Aurora A and JAK2 kinase blockade effectively suppresses malignant transformation.,http://www.ncbi.nlm.nih.gov/pubmed/24930769
2144,8373348,"Isoenzyme specificity of bisindolylmaleimides, selective inhibitors of protein kinase C.",http://www.ncbi.nlm.nih.gov/pubmed/8373348
2145,18281471,Growth suppression of lung cancer cells by targeting cyclic AMP response element-binding protein.,http://www.ncbi.nlm.nih.gov/pubmed/18281471
2146,23341890,Clinical significance of EML4-ALK fusion gene and association with EGFR and KRAS gene mutations in 208 Chinese patients with non-small cell lung cancer.,http://www.ncbi.nlm.nih.gov/pubmed/23341890
2147,8486620,Selective inhibition of protein kinase C isozymes by the indolocarbazole Gö 6976.,http://www.ncbi.nlm.nih.gov/pubmed/8486620
2148,16956345,Gö6976 is a potent inhibitor of the JAK 2 and FLT3 tyrosine kinases with significant activity in primary acute myeloid leukaemia cells.,http://www.ncbi.nlm.nih.gov/pubmed/16956345
2149,24296828,Acquired resistance to dasatinib in lung cancer cell lines conferred by DDR2 gatekeeper mutation and NF1 loss.,http://www.ncbi.nlm.nih.gov/pubmed/24296828
2150,15914319,Effects of the kinase inhibitor CGP41251 (PKC 412) on lymphocyte activation and TNF-alpha production.,http://www.ncbi.nlm.nih.gov/pubmed/15914319
2151,17585335,Targeting the protein kinase C family: are we there yet?,http://www.ncbi.nlm.nih.gov/pubmed/17585335
2152,20509775,Platelet-derived growth factor receptor tyrosine kinase inhibitors: a review of the recent patent literature.,http://www.ncbi.nlm.nih.gov/pubmed/20509775
2153,14743206,Mutant p53 exerts a dominant negative effect by preventing wild-type p53 from binding to the promoter of its target genes.,http://www.ncbi.nlm.nih.gov/pubmed/14743206
2154,18701504,"Suppression of inhibitor of differentiation 2, a target of mutant p53, is required for gain-of-function mutations.",http://www.ncbi.nlm.nih.gov/pubmed/18701504
2155,21561095,"Structural effects of the L145Q, V157F, and R282W cancer-associated mutations in the p53 DNA-binding core domain.",http://www.ncbi.nlm.nih.gov/pubmed/21561095
2156,15077194,Tumor-derived p53 mutants induce oncogenesis by transactivating growth-promoting genes.,http://www.ncbi.nlm.nih.gov/pubmed/15077194
2157,16778209,"Mutant p53 induces the GEF-H1 oncogene, a guanine nucleotide exchange factor-H1 for RhoA, resulting in accelerated cell proliferation in tumor cells.",http://www.ncbi.nlm.nih.gov/pubmed/16778209
2158,22460902,Systematic identification of genomic markers of drug sensitivity in cancer cells.,http://www.ncbi.nlm.nih.gov/pubmed/22460902
2159,11668624,Oncogenic levels of mitogen-activated protein kinase (MAPK) signaling of the dinucleotide KRAS2 mutations G12F and GG12-13VC.,http://www.ncbi.nlm.nih.gov/pubmed/11668624
2160,23527311,Activating somatic FGFR2 mutations in breast cancer.,http://www.ncbi.nlm.nih.gov/pubmed/23527311
2161,12949711,Gain-of-function mutations of platelet-derived growth factor receptor alpha gene in gastrointestinal stromal tumors.,http://www.ncbi.nlm.nih.gov/pubmed/12949711
2162,8062826,Analysis of the most representative tumour-derived p53 mutants reveals that changes in protein conformation are not correlated with loss of transactivation or inhibition of cell proliferation.,http://www.ncbi.nlm.nih.gov/pubmed/8062826
2163,17401432,Structure-function-rescue: the diverse nature of common p53 cancer mutants.,http://www.ncbi.nlm.nih.gov/pubmed/17401432
2164,7972137,Inhibition of protein kinase C-alpha expression in mice after systemic administration of phosphorothioate antisense oligodeoxynucleotides.,http://www.ncbi.nlm.nih.gov/pubmed/7972137
2165,15701280,Efficacy and toxicity of the antisense oligonucleotide aprinocarsen directed against protein kinase C-alpha delivered as a 21-day continuous intravenous infusion in patients with recurrent high-grade astrocytomas.,http://www.ncbi.nlm.nih.gov/pubmed/15701280
2166,8022414,"Differential inhibition of protein kinase C isozymes by UCN-01, a staurosporine analogue.",http://www.ncbi.nlm.nih.gov/pubmed/8022414
2167,22745105,Crenolanib inhibits the drug-resistant PDGFRA D842V mutation associated with imatinib-resistant gastrointestinal stromal tumors.,http://www.ncbi.nlm.nih.gov/pubmed/22745105
2168,,CC-122 Degrades the Lymphoid Transcription Factor Aiolos (IKZF3) By Modulating Cereblon and Shows Clinical Activity in a Phase Ib Study of Subjects with Relapsed or Refractory Non-Hodgkin’s Lymphoma and Multiple Myeloma,http://www.bloodjournal.org/content/124/21/3500?sso-checked=true
2169,24518207,A novel Bruton's tyrosine kinase inhibitor CC-292 in combination with the proteasome inhibitor carfilzomib impacts the bone microenvironment in a multiple myeloma model with resultant antimyeloma activity.,http://www.ncbi.nlm.nih.gov/pubmed/24518207
2170,24151975,Palifermin for the protection and regeneration of epithelial tissues following injury: new findings in basic research and pre-clinical models.,http://www.ncbi.nlm.nih.gov/pubmed/24151975
2171,16531227,Structure of a transient intermediate for GTP hydrolysis by ras.,http://www.ncbi.nlm.nih.gov/pubmed/16531227
2172,15878843,Structure of the G60A mutant of Ras: implications for the dominant negative effect.,http://www.ncbi.nlm.nih.gov/pubmed/15878843
2173,23802516,Mutations affecting G-protein subunit α11 in hypercalcemia and hypocalcemia.,http://www.ncbi.nlm.nih.gov/pubmed/23802516
2174,10571700,"A novel GNAS1 mutation, R201G, in McCune-albright syndrome.",http://www.ncbi.nlm.nih.gov/pubmed/10571700
2175,11429702,"Deregulated FGFR3 mutants in multiple myeloma cell lines with t(4;14): comparative analysis of Y373C, K650E and the novel G384D mutations.",http://www.ncbi.nlm.nih.gov/pubmed/11429702
2176,19423757,"Extralarge XL(alpha)s (XXL(alpha)s), a variant of stimulatory G protein alpha-subunit (Gs(alpha)), is a distinct, membrane-anchored GNAS product that can mimic Gs(alpha).",http://www.ncbi.nlm.nih.gov/pubmed/19423757
2177,16912704,Novel FGFR3 mutations creating cysteine residues in the extracellular domain of the receptor cause achondroplasia or severe forms of hypochondroplasia.,http://www.ncbi.nlm.nih.gov/pubmed/16912704
2178,8468064,Assignment of the cysteinyl-tRNA synthetase gene (CARS) to 11p15.5.,http://www.ncbi.nlm.nih.gov/pubmed/8468064
2179,12112524,"Identification of novel fusion partners of ALK, the anaplastic lymphoma kinase, in anaplastic large-cell lymphoma and inflammatory myofibroblastic tumor.",http://www.ncbi.nlm.nih.gov/pubmed/12112524
2180,13679433,Identification of CARS-ALK fusion in primary and metastatic lesions of an inflammatory myofibroblastic tumor.,http://www.ncbi.nlm.nih.gov/pubmed/13679433
2181,1765375,"Human clathrin heavy chain (CLTC): partial molecular cloning, expression, and mapping of the gene to human chromosome 17q11-qter.",http://www.ncbi.nlm.nih.gov/pubmed/1765375
2182,12750159,ALK activation by the CLTC-ALK fusion is a recurrent event in large B-cell lymphoma.,http://www.ncbi.nlm.nih.gov/pubmed/12750159
2183,24142740,CLTC-ALK fusion as a primary event in congenital blastic plasmacytoid dendritic cell neoplasm.,http://www.ncbi.nlm.nih.gov/pubmed/24142740
2184,23437153,Multiple consequences of a single amino acid pathogenic RTK mutation: the A391E mutation in FGFR3.,http://www.ncbi.nlm.nih.gov/pubmed/23437153
2185,21536014,The A391E mutation enhances FGFR3 activation in the absence of ligand.,http://www.ncbi.nlm.nih.gov/pubmed/21536014
2186,19287463,FGFR3 and TP53 mutation analysis in inverted urothelial papilloma: incidence and etiological considerations.,http://www.ncbi.nlm.nih.gov/pubmed/19287463
2187,11485898,"Fusion of the ALK gene to the clathrin heavy chain gene, CLTC, in inflammatory myofibroblastic tumor.",http://www.ncbi.nlm.nih.gov/pubmed/11485898
2188,17185414,"Identification of NVP-TAE684, a potent, selective, and efficacious inhibitor of NPM-ALK.",http://www.ncbi.nlm.nih.gov/pubmed/17185414
2189,11157491,Activated fibroblast growth factor receptor 3 is an oncogene that contributes to tumor progression in multiple myeloma.,http://www.ncbi.nlm.nih.gov/pubmed/11157491
2190,21494621,Inhibition of anaplastic lymphoma kinase (ALK) activity provides a therapeutic approach for CLTC-ALK-positive human diffuse large B cell lymphomas.,http://www.ncbi.nlm.nih.gov/pubmed/21494621
2191,20624921,"Physical basis behind achondroplasia, the most common form of human dwarfism.",http://www.ncbi.nlm.nih.gov/pubmed/20624921
2192,10611230,The transmembrane mutation G380R in fibroblast growth factor receptor 3 uncouples ligand-mediated receptor activation from down-regulation.,http://www.ncbi.nlm.nih.gov/pubmed/10611230
2193,23582185,Secondary c-Kit mutations confer acquired resistance to RTK inhibitors in c-Kit mutant melanoma cells.,http://www.ncbi.nlm.nih.gov/pubmed/23582185
2194,25594040,Resistance to c-Kit inhibitors in melanoma: insights for future therapies.,http://www.ncbi.nlm.nih.gov/pubmed/25594040
2195,15880580,Constitutive activating mutation of the FGFR3b in oral squamous cell carcinomas.,http://www.ncbi.nlm.nih.gov/pubmed/15880580
2196,24061647,The novel ATP-competitive inhibitor of the MET hepatocyte growth factor receptor EMD1214063 displays inhibitory activity against selected MET-mutated variants.,http://www.ncbi.nlm.nih.gov/pubmed/24061647
2197,,A first-in-human Phase 1 study of anti-cancer stem cell (CSC) agent OMP-54F28 (FZD8-Fc) targeting the WNT pathway in patients with advanced solid tumors,http://mct.aacrjournals.org/content/12/11_Supplement/B79.short
2198,20670955,MET receptor sequence variants R970C and T992I lack transforming capacity.,http://www.ncbi.nlm.nih.gov/pubmed/20670955
2199,9326629,Activating mutations for the met tyrosine kinase receptor in human cancer.,http://www.ncbi.nlm.nih.gov/pubmed/9326629
2200,21779495,Functional specificity of ras isoforms: so similar but so different.,http://www.ncbi.nlm.nih.gov/pubmed/21779495
2201,3283542,The ras gene family and human carcinogenesis.,http://www.ncbi.nlm.nih.gov/pubmed/3283542
2202,22683711,Postzygotic HRAS and KRAS mutations cause nevus sebaceous and Schimmelpenning syndrome.,http://www.ncbi.nlm.nih.gov/pubmed/22683711
2203,19035362,Oncogenic HRAS mutations cause prolonged PI3K signaling in response to epidermal growth factor in fibroblasts of patients with Costello syndrome.,http://www.ncbi.nlm.nih.gov/pubmed/19035362
2204,3510078,Biological and biochemical properties of human rasH genes mutated at codon 61.,http://www.ncbi.nlm.nih.gov/pubmed/3510078
2205,18089710,"PHA-739358, a potent inhibitor of Aurora kinases with a selective target inhibition profile relevant to cancer.",http://www.ncbi.nlm.nih.gov/pubmed/18089710
2206,22585574,p38 Inhibition ameliorates skin and skull abnormalities in Fgfr2 Beare-Stevenson mice.,http://www.ncbi.nlm.nih.gov/pubmed/22585574
2207,25295214,Antitumor activity of lenvatinib (e7080): an angiogenesis inhibitor that targets multiple receptor tyrosine kinases in preclinical human thyroid cancer models.,http://www.ncbi.nlm.nih.gov/pubmed/25295214
2208,19662654,Small molecule antagonists of Tcf4/beta-catenin complex inhibit the growth of HCC cells in vitro and in vivo.,http://www.ncbi.nlm.nih.gov/pubmed/19662654
2209,18242697,Tailoring tyrosine kinase inhibitor therapy to tackle specific BCR-ABL1 mutant clones.,http://www.ncbi.nlm.nih.gov/pubmed/18242697
2210,23086624,Characteristics and outcomes of patients with V299L BCR-ABL kinase domain mutation after therapy with tyrosine kinase inhibitors.,http://www.ncbi.nlm.nih.gov/pubmed/23086624
2211,21266528,A unique spectrum of somatic PIK3CA (p110alpha) mutations within primary endometrial carcinomas.,http://www.ncbi.nlm.nih.gov/pubmed/21266528
2212,15930273,Functional analysis of PIK3CA gene mutations in human colorectal cancer.,http://www.ncbi.nlm.nih.gov/pubmed/15930273
2213,20610623,A useful approach to identify novel small-molecule inhibitors of Wnt-dependent transcription.,http://www.ncbi.nlm.nih.gov/pubmed/20610623
2214,19075254,"Activity of bosutinib, dasatinib, and nilotinib against 18 imatinib-resistant BCR/ABL mutants.",http://www.ncbi.nlm.nih.gov/pubmed/19075254
2215,24474669,Pan-PIM kinase inhibition provides a novel therapy for treating hematologic cancers.,http://www.ncbi.nlm.nih.gov/pubmed/24474669
2216,25605813,Impact on creatinine renal clearance by the interplay of multiple renal transporters: a case study with INCB039110.,http://www.ncbi.nlm.nih.gov/pubmed/25605813
2217,24188694,"Wnt signaling blockage inhibits cell proliferation and migration, and induces apoptosis in triple-negative breast cancer cells.",http://www.ncbi.nlm.nih.gov/pubmed/24188694
2218,21321609,A diterpenoid derivative 15-oxospiramilactone inhibits Wnt/β-catenin signaling and colon cancer cell tumorigenesis.,http://www.ncbi.nlm.nih.gov/pubmed/21321609
2219,20605905,B-cell depletion in vitro and in vivo with an afucosylated anti-CD19 antibody.,http://www.ncbi.nlm.nih.gov/pubmed/20605905
2220,20028853,Small-molecule inhibitors of phosphatidylinositol 3-kinase/Akt signaling inhibit Wnt/beta-catenin pathway cross-talk and suppress medulloblastoma growth.,http://www.ncbi.nlm.nih.gov/pubmed/20028853
2221,18039567,"Semi-mechanistic modelling of the tumour growth inhibitory effects of LY2157299, a new type I receptor TGF-beta kinase antagonist, in mice.",http://www.ncbi.nlm.nih.gov/pubmed/18039567
2222,22224445,Structure-based discovery of a novel inhibitor targeting the β-catenin/Tcf4 interaction.,http://www.ncbi.nlm.nih.gov/pubmed/22224445
2223,22440753,A novel tankyrase inhibitor decreases canonical Wnt signaling in colon carcinoma cells and reduces tumor growth in conditional APC mutant mice.,http://www.ncbi.nlm.nih.gov/pubmed/22440753
2224,23612969,A novel p53 mutant found in iatrogenic urothelial cancers is dysfunctional and can be rescued by a second-site global suppressor mutation.,http://www.ncbi.nlm.nih.gov/pubmed/23612969
2225,23264849,Gain-of-Function Activity of Mutant p53 in Lung Cancer through Up-Regulation of Receptor Protein Tyrosine Kinase Axl.,http://www.ncbi.nlm.nih.gov/pubmed/23264849
2226,20890287,Small-molecule inhibition of Wnt signaling through activation of casein kinase 1α.,http://www.ncbi.nlm.nih.gov/pubmed/20890287
2227,8336941,Heterogeneity of transcriptional activity of mutant p53 proteins and p53 DNA target sequences.,http://www.ncbi.nlm.nih.gov/pubmed/8336941
2228,10787423,The phosphotyrosyl phosphatase activator gene is a novel p53 target gene.,http://www.ncbi.nlm.nih.gov/pubmed/10787423
2229,18566217,Potent synergy of dual antitumor peptides for growth suppression of human glioblastoma cell lines.,http://www.ncbi.nlm.nih.gov/pubmed/18566217
2230,20570896,Dysregulation of p53/Sp1 control leads to DNA methyltransferase-1 overexpression in lung cancer.,http://www.ncbi.nlm.nih.gov/pubmed/20570896
2231,19522463,Discovery of a potent and orally active hedgehog pathway antagonist (IPI-926).,http://www.ncbi.nlm.nih.gov/pubmed/19522463
2232,24608250,"Impact of the Smoothened inhibitor, IPI-926, on smoothened ciliary localization and Hedgehog pathway activity.",http://www.ncbi.nlm.nih.gov/pubmed/24608250
2233,21876152,PI3K-targeted therapy can be evaded by gene amplification along the MYC-eukaryotic translation initiation factor 4E (eIF4E) axis.,http://www.ncbi.nlm.nih.gov/pubmed/21876152
2234,19716296,GDC-0449-a potent inhibitor of the hedgehog pathway.,http://www.ncbi.nlm.nih.gov/pubmed/19716296
2235,24259609,Vismodegib: an inhibitor of the Hedgehog signaling pathway in the treatment of basal cell carcinoma.,http://www.ncbi.nlm.nih.gov/pubmed/24259609
2236,21097693,Tumor growth inhibition by olaparib in BRCA2 germline-mutated patient-derived ovarian cancer tissue xenografts.,http://www.ncbi.nlm.nih.gov/pubmed/21097693
2237,24900436,"Discovery of PF-04449913, a Potent and Orally Bioavailable Inhibitor of Smoothened.",http://www.ncbi.nlm.nih.gov/pubmed/24900436
2238,25388167,"A phase I study of PF-04449913, an oral hedgehog inhibitor, in patients with advanced solid tumors.",http://www.ncbi.nlm.nih.gov/pubmed/25388167
2239,22084163,"Effective targeting of Hedgehog signaling in a medulloblastoma model with PF-5274857, a potent and selective Smoothened antagonist that penetrates the blood-brain barrier.",http://www.ncbi.nlm.nih.gov/pubmed/22084163
2240,25636740,MRT-92 inhibits Hedgehog signaling by blocking overlapping binding sites in the transmembrane domain of the Smoothened receptor.,http://www.ncbi.nlm.nih.gov/pubmed/25636740
2241,24202394,Unraveling the therapeutic potential of the Hedgehog pathway in cancer.,http://www.ncbi.nlm.nih.gov/pubmed/24202394
2242,24132921,Large-scale analysis of PDGFRA mutations in melanomas and evaluation of their sensitivity to tyrosine kinase inhibitors imatinib and crenolanib.,http://www.ncbi.nlm.nih.gov/pubmed/24132921
2243,22929803,Carfilzomib and ONX 0912 inhibit cell survival and tumor growth of head and neck cancer and their activities are enhanced by suppression of Mcl-1 or autophagy.,http://www.ncbi.nlm.nih.gov/pubmed/22929803
2244,24115092,Preclinical safety and activity of recombinant VSV-IFN-β in an immunocompetent model of squamous cell carcinoma of the head and neck.,http://www.ncbi.nlm.nih.gov/pubmed/24115092
2245,22864522,Phase I/II study of pegylated arginine deiminase (ADI-PEG 20) in patients with advanced melanoma.,http://www.ncbi.nlm.nih.gov/pubmed/22864522
2246,19394761,Oncogenic mutation of PIK3CA in small cell lung carcinoma: a potential therapeutic target pathway for chemotherapy-resistant lung cancer.,http://www.ncbi.nlm.nih.gov/pubmed/19394761
2247,24141787,"Breast cancer-associated missense mutants of the PALB2 WD40 domain, which directly binds RAD51C, RAD51 and BRCA2, disrupt DNA repair.",http://www.ncbi.nlm.nih.gov/pubmed/24141787
2248,22949682,Oncogenic mutations mimic and enhance dynamic events in the natural activation of phosphoinositide 3-kinase p110α (PIK3CA).,http://www.ncbi.nlm.nih.gov/pubmed/22949682
2249,23246288,Germline PIK3CA and AKT1 mutations in Cowden and Cowden-like syndromes.,http://www.ncbi.nlm.nih.gov/pubmed/23246288
2250,23564295,"TAK-441, a novel investigational smoothened antagonist, delays castration-resistant progression in prostate cancer by disrupting paracrine hedgehog signaling.",http://www.ncbi.nlm.nih.gov/pubmed/23564295
2251,23258168,WNT signalling pathways as therapeutic targets in cancer.,http://www.ncbi.nlm.nih.gov/pubmed/23258168
2252,,"Abstract CT326: Phase I study of BGJ398, a selective pan-FGFR inhibitor in genetically preselected advanced solid tumors",http://cancerres.aacrjournals.org/content/74/19_Supplement/CT326.short
2253,18223206,Advances in targeting the Ras/Raf/MEK/Erk mitogen-activated protein kinase cascade with MEK inhibitors for cancer therapy.,http://www.ncbi.nlm.nih.gov/pubmed/18223206
2254,12522257,PDGFRA activating mutations in gastrointestinal stromal tumors.,http://www.ncbi.nlm.nih.gov/pubmed/12522257
2255,14645423,Kinase mutations and imatinib response in patients with metastatic gastrointestinal stromal tumor.,http://www.ncbi.nlm.nih.gov/pubmed/14645423
2256,23533272,Paradoxical activation and RAF inhibitor resistance of BRAF protein kinase fusions characterizing pediatric astrocytomas.,http://www.ncbi.nlm.nih.gov/pubmed/23533272
2257,,"TAS-120, a highly potent and selective irreversible FGFR inhibitor, is effective in tumors harboring various FGFR gene abnormalities",http://mct.aacrjournals.org/content/12/11_Supplement/A270.short
2258,21703185,Altered composition of fatty acids exacerbates hepatotumorigenesis during activation of the phosphatidylinositol 3-kinase pathway.,http://www.ncbi.nlm.nih.gov/pubmed/21703185
2259,9873633,"MEK inhibitors: the chemistry and biological activity of U0126, its analogs, and cyclization products.",http://www.ncbi.nlm.nih.gov/pubmed/9873633
2260,14613031,"CI-1040 (PD184352), a targeted signal transduction inhibitor of MEK (MAPKK).",http://www.ncbi.nlm.nih.gov/pubmed/14613031
2261,19014680,Activation of MEK1 or MEK2 isoform is sufficient to fully transform intestinal epithelial cells and induce the formation of metastatic tumors.,http://www.ncbi.nlm.nih.gov/pubmed/19014680
2262,,Abstract 4716: A first-in-human phase 1 study to evaluate the MEK1/2 inhibitor GDC-0973 administered daily in patients with advanced solid tumors,http://cancerres.aacrjournals.org/content/71/8_Supplement/4716.short
2263,23619167,Frequent mutation of the PI3K pathway in head and neck cancer defines predictive biomarkers.,http://www.ncbi.nlm.nih.gov/pubmed/23619167
2264,21810974,In silico and in vitro analysis of rare germline allelic variants of RET oncogene associated with medullary thyroid cancer.,http://www.ncbi.nlm.nih.gov/pubmed/21810974
2265,24442130,Patient-derived xenografts reveal limits to PI3K/mTOR- and MEK-mediated inhibition of bladder cancer.,http://www.ncbi.nlm.nih.gov/pubmed/24442130
2266,11438491,Functional analysis of RET with Hirschsprung mutations affecting its kinase domain.,http://www.ncbi.nlm.nih.gov/pubmed/11438491
2267,16715139,Evaluation of potential mechanisms underlying genotype-phenotype correlations in multiple endocrine neoplasia type 2.,http://www.ncbi.nlm.nih.gov/pubmed/16715139
2268,10445857,Biological and biochemical properties of Ret with kinase domain mutations identified in multiple endocrine neoplasia type 2B and familial medullary thyroid carcinoma.,http://www.ncbi.nlm.nih.gov/pubmed/10445857
2269,19186126,"Computational modeling of structurally conserved cancer mutations in the RET and MET kinases: the impact on protein structure, dynamics, and stability.",http://www.ncbi.nlm.nih.gov/pubmed/19186126
2270,22487539,Perifosine plus docetaxel in patients with platinum and taxane resistant or refractory high-grade epithelial ovarian cancer.,http://www.ncbi.nlm.nih.gov/pubmed/22487539
2271,9879991,Dual effect on the RET receptor of MEN 2 mutations affecting specific extracytoplasmic cysteines.,http://www.ncbi.nlm.nih.gov/pubmed/9879991
2272,9230192,"Biological properties of Ret with cysteine mutations correlate with multiple endocrine neoplasia type 2A, familial medullary thyroid carcinoma, and Hirschsprung's disease phenotype.",http://www.ncbi.nlm.nih.gov/pubmed/9230192
2274,,"Abstract A230: Discovery and characterization of ARQ 092, an ATP-independent, potent and selective inhibitor of AKT kinases.",
2275,,"Abstract 3685: BAY 1125976, is a selective allosteric AKT1/2 inhibitor with high efficacy in AKT1-mutated cancers",http://cancerres.aacrjournals.org/content/74/19_Supplement/3685
2276,18952427,The discovery of the benzhydroxamate MEK inhibitors CI-1040 and PD 0325901.,http://www.ncbi.nlm.nih.gov/pubmed/18952427
2277,25589621,Pilot trial of combined BRAF and EGFR inhibition in BRAF-mutant metastatic colorectal cancer patients.,http://www.ncbi.nlm.nih.gov/pubmed/25589621
2278,20085938,The PI3K pathway as drug target in human cancer.,http://www.ncbi.nlm.nih.gov/pubmed/20085938
2279,19491325,The potent protein kinase C-selective inhibitor AEB071 (sotrastaurin) represents a new class of immunosuppressive agents affecting early T-cell activation.,http://www.ncbi.nlm.nih.gov/pubmed/19491325
2280,15016963,High frequency of mutations of the PIK3CA gene in human cancers.,http://www.ncbi.nlm.nih.gov/pubmed/15016963
2281,18606717,"Identification and characterization of NVP-BEZ235, a new orally available dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor with potent in vivo antitumor activity.",http://www.ncbi.nlm.nih.gov/pubmed/18606717
2282,22934575,Discovery and preclinical pharmacology of a selective ATP-competitive Akt inhibitor (GDC-0068) for the treatment of human tumors.,http://www.ncbi.nlm.nih.gov/pubmed/22934575
2283,20571069,"MK-2206, an allosteric Akt inhibitor, enhances antitumor efficacy by standard chemotherapeutic agents or molecular targeted drugs in vitro and in vivo.",http://www.ncbi.nlm.nih.gov/pubmed/20571069
2284,20166697,"Bis(morpholino-1,3,5-triazine) derivatives: potent adenosine 5'-triphosphate competitive phosphatidylinositol-3-kinase/mammalian target of rapamycin inhibitors: discovery of compound 26 (PKI-587), a highly efficacious dual inhibitor.",http://www.ncbi.nlm.nih.gov/pubmed/20166697
2285,20846000,Akt inhibitors in clinical development for the treatment of cancer.,http://www.ncbi.nlm.nih.gov/pubmed/20846000
2286,21636709,Control of proliferation in astrocytoma cells by the receptor tyrosine kinase/PI3K/AKT signaling axis and the use of PI-103 and TCN as potential anti-astrocytoma therapies.,http://www.ncbi.nlm.nih.gov/pubmed/21636709
2287,17163846,Mutations and nuclear accumulation of beta-catenin correlate with intestinal phenotypic expression in human gastric cancer.,http://www.ncbi.nlm.nih.gov/pubmed/17163846
2288,20028854,"AZD8055 is a potent, selective, and orally bioavailable ATP-competitive mammalian target of rapamycin kinase inhibitor with in vitro and in vivo antitumor activity.",http://www.ncbi.nlm.nih.gov/pubmed/20028854
2289,22821149,"BAY 1000394, a novel cyclin-dependent kinase inhibitor, with potent antitumor activity in mono- and in combination treatment upon oral application.",http://www.ncbi.nlm.nih.gov/pubmed/22821149
2290,20423992,AT7867 is a potent and oral inhibitor of AKT and p70 S6 kinase that induces pharmacodynamic changes and inhibits human tumor xenograft growth.,http://www.ncbi.nlm.nih.gov/pubmed/20423992
2291,19208828,Inhibition of Akt inhibits growth of glioblastoma and glioblastoma stem-like cells.,http://www.ncbi.nlm.nih.gov/pubmed/19208828
2292,10597262,Close correlation between beta-catenin gene alterations and nuclear accumulation of the protein in human hepatocellular carcinomas.,http://www.ncbi.nlm.nih.gov/pubmed/10597262
2293,25431235,Nuclear expression and gain-of-function β-catenin mutation in glomangiopericytoma (sinonasal-type hemangiopericytoma): insight into pathogenesis and a diagnostic marker.,http://www.ncbi.nlm.nih.gov/pubmed/25431235
2294,14612392,Requirement for a nuclear function of beta-catenin in Wnt signaling.,http://www.ncbi.nlm.nih.gov/pubmed/14612392
2295,10671680,Mutational analysis of the CTNNB1 (beta-catenin) gene in human endometrial cancer: frequent mutations at codon 34 that cause nuclear accumulation.,http://www.ncbi.nlm.nih.gov/pubmed/10671680
2296,9671767,Somatic mutations of the beta-catenin gene are frequent in mouse and human hepatocellular carcinomas.,http://www.ncbi.nlm.nih.gov/pubmed/9671767
2297,23155232,Antagonistic effect of small-molecule inhibitors of Wnt/β-catenin in multiple myeloma.,http://www.ncbi.nlm.nih.gov/pubmed/23155232
2298,21565795,Characterization of differential gene expression in adrenocortical tumors harboring beta-catenin (CTNNB1) mutations.,http://www.ncbi.nlm.nih.gov/pubmed/21565795
2299,23621985,Evidence for tankyrases as antineoplastic targets in lung cancer.,http://www.ncbi.nlm.nih.gov/pubmed/23621985
2300,24442032,"Phase 1 and dose-finding study of patritumab (U3-1287), a human monoclonal antibody targeting HER3, in Japanese patients with advanced solid tumors.",http://www.ncbi.nlm.nih.gov/pubmed/24442032
2301,9233789,beta-catenin is a target for the ubiquitin-proteasome pathway.,http://www.ncbi.nlm.nih.gov/pubmed/9233789
2302,11276007,Nuclear localization of beta-catenin is an important prognostic factor in hepatoblastoma.,http://www.ncbi.nlm.nih.gov/pubmed/11276007
2303,21828076,A comprehensive functional analysis of PTEN mutations: implications in tumor- and autism-related syndromes.,http://www.ncbi.nlm.nih.gov/pubmed/21828076
2304,10866302,Functional evaluation of PTEN missense mutations using in vitro phosphoinositide phosphatase assay.,http://www.ncbi.nlm.nih.gov/pubmed/10866302
2305,9823298,The phosphoinositol phosphatase activity of PTEN mediates a serum-sensitive G1 growth arrest in glioma cells.,http://www.ncbi.nlm.nih.gov/pubmed/9823298
2306,20194734,Allele-specific tumor spectrum in pten knockin mice.,http://www.ncbi.nlm.nih.gov/pubmed/20194734
2307,9811831,The lipid phosphatase activity of PTEN is critical for its tumor supressor function.,http://www.ncbi.nlm.nih.gov/pubmed/9811831
2308,23475934,Cowden syndrome-related mutations in PTEN associate with enhanced proteasome activity.,http://www.ncbi.nlm.nih.gov/pubmed/23475934
2309,17062696,"Preclinical antitumor activity of BMS-599626, a pan-HER kinase inhibitor that inhibits HER1/HER2 homodimer and heterodimer signaling.",http://www.ncbi.nlm.nih.gov/pubmed/17062696
2310,,"Abstract A143: ARRY-380, a selective HER2 inhibitor: From drug design to clinical evaluation.",http://mct.aacrjournals.org/content/10/11_Supplement/A143.short
2311,22129105,"Anti-tumor activity and toxicokinetics analysis of MGAH22, an anti-HER2 monoclonal antibody with enhanced Fcγ receptor binding properties.",http://www.ncbi.nlm.nih.gov/pubmed/22129105
2312,22248472,Antitumor activity of a novel bispecific antibody that targets the ErbB2/ErbB3 oncogenic unit and inhibits heregulin-induced activation of ErbB3.,http://www.ncbi.nlm.nih.gov/pubmed/22248472
2313,15173008,"Antitumor activity of HKI-272, an orally active, irreversible inhibitor of the HER-2 tyrosine kinase.",http://www.ncbi.nlm.nih.gov/pubmed/15173008
2314,21306821,"Antitumor activity of HM781-36B, an irreversible Pan-HER inhibitor, alone or in combination with cytotoxic chemotherapeutic agents in gastric cancer.",http://www.ncbi.nlm.nih.gov/pubmed/21306821
2315,22298898,Activation of β-catenin signaling in androgen receptor-negative prostate cancer cells.,http://www.ncbi.nlm.nih.gov/pubmed/22298898
2316,11955436,Control of beta-catenin phosphorylation/degradation by a dual-kinase mechanism.,http://www.ncbi.nlm.nih.gov/pubmed/11955436
2317,10987273,Beta-catenin affects androgen receptor transcriptional activity and ligand specificity.,http://www.ncbi.nlm.nih.gov/pubmed/10987273
2318,15943036,"Expression of beta-catenin, E-cadherin and cyclin D1 in adenoid cystic carcinoma of the salivary gland.",http://www.ncbi.nlm.nih.gov/pubmed/15943036
2319,21188138,Aromatase is a direct target of FOXL2: C134W in granulosa cell tumors via a single highly conserved binding site in the ovarian specific promoter.,http://www.ncbi.nlm.nih.gov/pubmed/21188138
2320,12051714,Characterisation of the phosphorylation of beta-catenin at the GSK-3 priming site Ser45.,http://www.ncbi.nlm.nih.gov/pubmed/12051714
2321,18074223,Comprehensive analysis of oncogenic effects of PIK3CA mutations in human mammary epithelial cells.,http://www.ncbi.nlm.nih.gov/pubmed/18074223
2322,11051241,Functional evaluation of p53 and PTEN gene mutations in gliomas.,http://www.ncbi.nlm.nih.gov/pubmed/11051241
2323,25527629,Functionally distinct groups of inherited PTEN mutations in autism and tumour syndromes.,http://www.ncbi.nlm.nih.gov/pubmed/25527629
2324,11156408,Stabilization and productive positioning roles of the C2 domain of PTEN tumor suppressor.,http://www.ncbi.nlm.nih.gov/pubmed/11156408
2325,24241536,High prevalence of MAP2K1 mutations in variant and IGHV4-34-expressing hairy-cell leukemias.,http://www.ncbi.nlm.nih.gov/pubmed/24241536
2326,18372316,"Missense mutations in the forkhead domain of FOXL2 lead to subcellular mislocalization, protein aggregation and impaired transactivation.",http://www.ncbi.nlm.nih.gov/pubmed/18372316
2327,11309340,Frequent deletions and mutations of the beta-catenin gene are associated with overexpression of cyclin D1 and fibronectin and poorly differentiated histology in childhood hepatoblastoma.,http://www.ncbi.nlm.nih.gov/pubmed/11309340
2328,12027456,Identification of two novel regulated serines in the N terminus of beta-catenin.,http://www.ncbi.nlm.nih.gov/pubmed/12027456
2329,21881488,β-catenin (CTNNB1) S33C mutation in ovarian microcystic stromal tumors.,http://www.ncbi.nlm.nih.gov/pubmed/21881488
2330,19582367,CTNNB1 (beta-catenin) mutation is rare in brain tumours but involved as a sporadic event in a brain metastasis.,http://www.ncbi.nlm.nih.gov/pubmed/19582367
2331,10076565,Mutations of the beta-catenin gene in endometrial carcinomas.,http://www.ncbi.nlm.nih.gov/pubmed/10076565
2332,18757411,Illegitimate WNT pathway activation by beta-catenin mutation or autocrine stimulation in T-cell malignancies.,http://www.ncbi.nlm.nih.gov/pubmed/18757411
2333,11731417,Frequent beta-catenin mutation and cytoplasmic/nuclear accumulation in pancreatic solid-pseudopapillary neoplasm.,http://www.ncbi.nlm.nih.gov/pubmed/11731417
2334,24868098,U.S. Food and Drug Administration approval summary: Erlotinib for the first-line treatment of metastatic non-small cell lung cancer with epidermal growth factor receptor exon 19 deletions or exon 21 (L858R) substitution mutations.,http://www.ncbi.nlm.nih.gov/pubmed/24868098
2335,24398047,Emergence of constitutively active estrogen receptor-α mutations in pretreated advanced estrogen receptor-positive breast cancer.,http://www.ncbi.nlm.nih.gov/pubmed/24398047
2336,10347231,The ubiquitin-proteasome pathway and serine kinase activity modulate adenomatous polyposis coli protein-mediated regulation of beta-catenin-lymphocyte enhancer-binding factor signaling.,http://www.ncbi.nlm.nih.gov/pubmed/10347231
2337,12754743,Beta-catenin mutations in pulmonary blastomas: association with morule formation.,http://www.ncbi.nlm.nih.gov/pubmed/12754743
2338,10433945,"beta-catenin expression pattern in stage I and II ovarian carcinomas : relationship with beta-catenin gene mutations, clinicopathological features, and clinical outcome.",http://www.ncbi.nlm.nih.gov/pubmed/10433945
2339,11196159,More frequent beta-catenin exon 3 mutations in gallbladder adenomas than in carcinomas indicate different lineages.,http://www.ncbi.nlm.nih.gov/pubmed/11196159
2340,11943721,Solid-pseudopapillary tumors of the pancreas are genetically distinct from pancreatic ductal adenocarcinomas and almost always harbor beta-catenin mutations.,http://www.ncbi.nlm.nih.gov/pubmed/11943721
2341,19321622,Characterization of the interaction between latency-associated nuclear antigen and glycogen synthase kinase 3beta.,http://www.ncbi.nlm.nih.gov/pubmed/19321622
2342,10487827,Nuclear accumulation of mutated beta-catenin in hepatocellular carcinoma is associated with increased cell proliferation.,http://www.ncbi.nlm.nih.gov/pubmed/10487827
2343,17096730,Gene mutation analysis and immunohistochemical study of beta-catenin in odontogenic tumors.,http://www.ncbi.nlm.nih.gov/pubmed/17096730
2344,10698519,Activation of beta-catenin in epithelial and mesenchymal hepatoblastomas.,http://www.ncbi.nlm.nih.gov/pubmed/10698519
2345,12200448,Transcriptional activation of interleukin-8 by beta-catenin-Tcf4.,http://www.ncbi.nlm.nih.gov/pubmed/12200448
2346,12101426,"Mutational spectrum of beta-catenin, AXIN1, and AXIN2 in hepatocellular carcinomas and hepatoblastomas.",http://www.ncbi.nlm.nih.gov/pubmed/12101426
2347,12474227,Cribriform-morular variant of papillary thyroid carcinoma: a pathological and molecular genetic study with evidence of frequent somatic mutations in exon 3 of the beta-catenin gene.,http://www.ncbi.nlm.nih.gov/pubmed/12474227
2348,25559287,Afatinib efficacy against squamous cell carcinoma of the head and neck cell lines in vitro and in vivo.,http://www.ncbi.nlm.nih.gov/pubmed/25559287
2349,23828214,Cetuximab promotes anticancer drug toxicity in rhabdomyosarcomas with EGFR amplification in vitro.,http://www.ncbi.nlm.nih.gov/pubmed/23828214
2350,22897982,EGFR gene copy number as a predictive biomarker for the treatment of metastatic colorectal cancer with anti-EGFR monoclonal antibodies: a meta-analysis.,http://www.ncbi.nlm.nih.gov/pubmed/22897982
2351,,Abstract A250: ABT-414: An anti-EGFR antibody-drug conjugate as a potential therapeutic for the treatment of patients with squamous cell tumors.,http://mct.aacrjournals.org/content/12/11_Supplement/A250.short?rss=1
2352,22323597,Intratumoral heterogeneity of receptor tyrosine kinases EGFR and PDGFRA amplification in glioblastoma defines subpopulations with distinct growth factor response.,http://www.ncbi.nlm.nih.gov/pubmed/22323597
2353,10919641,Tyrosine 1062 of RET-MEN2A mediates activation of Akt (protein kinase B) and mitogen-activated protein kinase pathways leading to PC12 cell survival.,http://www.ncbi.nlm.nih.gov/pubmed/10919641
2354,25448479,Engineering PTEN function: membrane association and activity.,http://www.ncbi.nlm.nih.gov/pubmed/25448479
2355,19654296,Cancer-specific high-throughput annotation of somatic mutations: computational prediction of driver missense mutations.,http://www.ncbi.nlm.nih.gov/pubmed/19654296
2356,11448956,The tumor suppressor gene PTEN can regulate cardiac hypertrophy and survival.,http://www.ncbi.nlm.nih.gov/pubmed/11448956
2357,19457929,Germline and somatic cancer-associated mutations in the ATP-binding motifs of PTEN influence its subcellular localization and tumor suppressive function.,http://www.ncbi.nlm.nih.gov/pubmed/19457929
2358,20926450,Naturally occurring germline and tumor-associated mutations within the ATP-binding motifs of PTEN lead to oxidative damage of DNA associated with decreased nuclear p53.,http://www.ncbi.nlm.nih.gov/pubmed/20926450
2359,14711368,The tumour-suppressor function of PTEN requires an N-terminal lipid-binding motif.,http://www.ncbi.nlm.nih.gov/pubmed/14711368
2360,17213812,A short N-terminal sequence of PTEN controls cytoplasmic localization and is required for suppression of cell growth.,http://www.ncbi.nlm.nih.gov/pubmed/17213812
2361,,"ABL001, a Potent Allosteric Inhibitor of BCR-ABL, Prevents Emergence of Resistant Disease When Administered in Combination with Nilotinib in an in Vivo Murine Model of Chronic Myeloid Leukemia",http://www.bloodjournal.org/content/124/21/398.abstract?sso-checked=true
2362,22684302,Brentuximab vedotin.,http://www.ncbi.nlm.nih.gov/pubmed/22684302
2363,9356475,Growth suppression of glioma cells by PTEN requires a functional phosphatase catalytic domain.,http://www.ncbi.nlm.nih.gov/pubmed/9356475
2364,16673816,Inhibitory effect of isoflavones on prostate cancer cells and PTEN gene.,http://www.ncbi.nlm.nih.gov/pubmed/16673816
2365,21536651,"Mechanistic analysis of a DNA damage-induced, PTEN-dependent size checkpoint in human cells.",http://www.ncbi.nlm.nih.gov/pubmed/21536651
2366,24790411,Clinical and comparative utility of afatinib in non-small cell lung cancer.,http://www.ncbi.nlm.nih.gov/pubmed/24790411
2367,23991291,Afatinib as first-line treatment for patients with advanced non-small-cell lung cancer harboring EGFR mutations: focus on LUX-Lung 3 and LUX-Lung 6 phase III trials.,http://www.ncbi.nlm.nih.gov/pubmed/23991291
2368,23816960,Phase III study of afatinib or cisplatin plus pemetrexed in patients with metastatic lung adenocarcinoma with EGFR mutations.,http://www.ncbi.nlm.nih.gov/pubmed/23816960
2369,12374669,Approval summary: imatinib mesylate in the treatment of metastatic and/or unresectable malignant gastrointestinal stromal tumors.,http://www.ncbi.nlm.nih.gov/pubmed/12374669
2370,20100962,Pazopanib in locally advanced or metastatic renal cell carcinoma: results of a randomized phase III trial.,http://www.ncbi.nlm.nih.gov/pubmed/20100962
2371,10468583,The tumor-suppressor activity of PTEN is regulated by its carboxyl-terminal region.,http://www.ncbi.nlm.nih.gov/pubmed/10468583
2372,24721394,Combined PTEN Mutation and Protein Expression Associate with Overall and Disease-Free Survival of Glioblastoma Patients.,http://www.ncbi.nlm.nih.gov/pubmed/24721394
2373,22595799,"Pazopanib for metastatic soft-tissue sarcoma (PALETTE): a randomised, double-blind, placebo-controlled phase 3 trial.",http://www.ncbi.nlm.nih.gov/pubmed/22595799
2374,23935038,Ponatinib--a step forward in overcoming resistance in chronic myeloid leukemia.,http://www.ncbi.nlm.nih.gov/pubmed/23935038
2375,19692680,Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma.,http://www.ncbi.nlm.nih.gov/pubmed/19692680
2376,25671254,Lenvatinib versus placebo in radioiodine-refractory thyroid cancer.,http://www.ncbi.nlm.nih.gov/pubmed/25671254
2377,12637609,Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia.,http://www.ncbi.nlm.nih.gov/pubmed/12637609
2378,12200353,A phase 2 study of imatinib in patients with relapsed or refractory Philadelphia chromosome-positive acute lymphoid leukemias.,http://www.ncbi.nlm.nih.gov/pubmed/12200353
2379,11423618,Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification.,http://www.ncbi.nlm.nih.gov/pubmed/11423618
2380,25261369,Catalytic mTOR inhibitors can overcome intrinsic and acquired resistance to allosteric mTOR inhibitors.,http://www.ncbi.nlm.nih.gov/pubmed/25261369
2381,24979808,"Engineering ePTEN, an enhanced PTEN with increased tumor suppressor activities.",http://www.ncbi.nlm.nih.gov/pubmed/24979808
2382,23436801,"Characterization of Torin2, an ATP-competitive inhibitor of mTOR, ATM, and ATR.",http://www.ncbi.nlm.nih.gov/pubmed/23436801
2383,23319867,Profile of cabozantinib and its potential in the treatment of advanced medullary thyroid cancer.,http://www.ncbi.nlm.nih.gov/pubmed/23319867
2384,16357008,"Mutation and expression of PDGFRA and KIT in malignant peripheral nerve sheath tumors, and its implications for imatinib sensitivity.",http://www.ncbi.nlm.nih.gov/pubmed/16357008
2385,19366796,Ligand-dependent platelet-derived growth factor receptor (PDGFR)-alpha activation sensitizes rare lung cancer and sarcoma cells to PDGFR kinase inhibitors.,http://www.ncbi.nlm.nih.gov/pubmed/19366796
2386,18316547,"U.S. Food and Drug Administration approval: panitumumab for epidermal growth factor receptor-expressing metastatic colorectal carcinoma with progression following fluoropyrimidine-, oxaliplatin-, and irinotecan-containing chemotherapy regimens.",http://www.ncbi.nlm.nih.gov/pubmed/18316547
2387,16707451,Regulation of microtubule-dependent protein transport by the TSC2/mammalian target of rapamycin pathway.,http://www.ncbi.nlm.nih.gov/pubmed/16707451
2388,25295501,Response and acquired resistance to everolimus in anaplastic thyroid cancer.,http://www.ncbi.nlm.nih.gov/pubmed/25295501
2389,24200292,Exploiting APC function as a novel cancer therapy.,http://www.ncbi.nlm.nih.gov/pubmed/24200292
2390,,"COMBI-d: A randomized, double-blinded, Phase III study comparing the combination of dabrafenib and trametinib to dabrafenib and trametinib placebo as first-line therapy in patients (pts) with unresectable or metastatic BRAF V600E/K mutation-positive cutan",http://meetinglibrary.asco.org/content/128598-144
2391,22825030,Co-treatment with vorinostat synergistically enhances activity of Aurora kinase inhibitor against human breast cancer cells.,http://www.ncbi.nlm.nih.gov/pubmed/22825030
2392,14672538,Role of APC and DNA mismatch repair genes in the development of colorectal cancers.,http://www.ncbi.nlm.nih.gov/pubmed/14672538
2393,10984057,The APC tumour suppressor has a nuclear export function.,http://www.ncbi.nlm.nih.gov/pubmed/10984057
2394,14633595,Reconstructed beta-catenin/TCF4 signaling in yeast applicable to functional evaluation of APC mutations.,http://www.ncbi.nlm.nih.gov/pubmed/14633595
2395,18199528,Multiple rare nonsynonymous variants in the adenomatous polyposis coli gene predispose to colorectal adenomas.,http://www.ncbi.nlm.nih.gov/pubmed/18199528
2396,25265492,Combined BRAF and MEK inhibition versus BRAF inhibition alone in melanoma.,http://www.ncbi.nlm.nih.gov/pubmed/25265492
2397,22713868,"Mutant p53: one name, many proteins.",http://www.ncbi.nlm.nih.gov/pubmed/22713868
2398,25560485,CYP17A1 inhibitors in castration-resistant prostate cancer.,http://www.ncbi.nlm.nih.gov/pubmed/25560485
2399,22406983,Targeting of 4-1BB by monoclonal antibody PF-05082566 enhances T-cell function and promotes anti-tumor activity.,http://www.ncbi.nlm.nih.gov/pubmed/22406983
2400,23177515,"Efficacy and safety of regorafenib for advanced gastrointestinal stromal tumours after failure of imatinib and sunitinib (GRID): an international, multicentre, randomised, placebo-controlled, phase 3 trial.",http://www.ncbi.nlm.nih.gov/pubmed/23177515
2401,21306237,Sunitinib malate for the treatment of pancreatic neuroendocrine tumors.,http://www.ncbi.nlm.nih.gov/pubmed/21306237
2402,22723734,Vandetanib for the treatment of metastatic medullary thyroid cancer.,http://www.ncbi.nlm.nih.gov/pubmed/22723734
2403,22025146,"Vandetanib in patients with locally advanced or metastatic medullary thyroid cancer: a randomized, double-blind phase III trial.",http://www.ncbi.nlm.nih.gov/pubmed/22025146
2404,19707433,Sunitinib for advanced renal cell cancer.,http://www.ncbi.nlm.nih.gov/pubmed/19707433
2405,17332278,Approval summary: sunitinib for the treatment of imatinib refractory or intolerant gastrointestinal stromal tumors and advanced renal cell carcinoma.,http://www.ncbi.nlm.nih.gov/pubmed/17332278
2406,22679179,Vismodegib.,http://www.ncbi.nlm.nih.gov/pubmed/22679179
2407,22670903,Efficacy and safety of vismodegib in advanced basal-cell carcinoma.,http://www.ncbi.nlm.nih.gov/pubmed/22670903
2408,24573551,U.S. Food and Drug Administration approval: crizotinib for treatment of advanced or metastatic non-small cell lung cancer that is anaplastic lymphoma kinase positive.,http://www.ncbi.nlm.nih.gov/pubmed/24573551
2409,10346819,Apc1638T: a mouse model delineating critical domains of the adenomatous polyposis coli protein involved in tumorigenesis and development.,http://www.ncbi.nlm.nih.gov/pubmed/10346819
2410,20338520,A structure-guided approach to creating covalent FGFR inhibitors.,http://www.ncbi.nlm.nih.gov/pubmed/20338520
2411,15136787,"Discovery and development of bevacizumab, an anti-VEGF antibody for treating cancer.",http://www.ncbi.nlm.nih.gov/pubmed/15136787
2412,23597563,"Molecular mechanism of SSR128129E, an extracellularly acting, small-molecule, allosteric inhibitor of FGF receptor signaling.",http://www.ncbi.nlm.nih.gov/pubmed/23597563
2413,24760775,"Tumor vasculature is regulated by FGF/FGFR signaling-mediated angiogenesis and bone marrow-derived cell recruitment: this mechanism is inhibited by SSR128129E, the first allosteric antagonist of FGFRs.",http://www.ncbi.nlm.nih.gov/pubmed/24760775
2414,23597562,Inhibition of tumor angiogenesis and growth by a small-molecule multi-FGF receptor blocker with allosteric properties.,http://www.ncbi.nlm.nih.gov/pubmed/23597562
2415,25776529,First Selective Small Molecule Inhibitor of FGFR4 for the Treatment of Hepatocellular Carcinomas with an Activated FGFR4 Signaling Pathway.,http://www.ncbi.nlm.nih.gov/pubmed/25776529
2416,15175435,"Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.",http://www.ncbi.nlm.nih.gov/pubmed/15175435
2417,22477726,Bevacizumab-based therapies in the first-line treatment of metastatic colorectal cancer.,http://www.ncbi.nlm.nih.gov/pubmed/22477726
2418,20061402,FDA drug approval summary: bevacizumab plus interferon for advanced renal cell carcinoma.,http://www.ncbi.nlm.nih.gov/pubmed/20061402
2419,17189398,Sorafenib for the treatment of advanced renal cell carcinoma.,http://www.ncbi.nlm.nih.gov/pubmed/17189398
2420,17602060,FDA drug approval summary: bevacizumab (Avastin) plus Carboplatin and Paclitaxel as first-line treatment of advanced/metastatic recurrent nonsquamous non-small cell lung cancer.,http://www.ncbi.nlm.nih.gov/pubmed/17602060
2421,19897538,FDA drug approval summary: bevacizumab (Avastin) as treatment of recurrent glioblastoma multiforme.,http://www.ncbi.nlm.nih.gov/pubmed/19897538
2422,25281440,Bevacizumab and treatment of cervical cancer.,http://www.ncbi.nlm.nih.gov/pubmed/25281440
2423,24552320,Improved survival with bevacizumab in advanced cervical cancer.,http://www.ncbi.nlm.nih.gov/pubmed/24552320
2424,23734178,Characterization of a tumor-associated activating mutation of the p110β PI 3-kinase.,http://www.ncbi.nlm.nih.gov/pubmed/23734178
2425,15834429,PI 3-kinase p110beta: a new target for antithrombotic therapy.,http://www.ncbi.nlm.nih.gov/pubmed/15834429
2426,25473181,Phosphatidylinositol 3-kinase CB association with preoperative radiotherapy response in rectal adenocarcinoma.,http://www.ncbi.nlm.nih.gov/pubmed/25473181
2427,18076711,The selective Aurora B kinase inhibitor AZD1152 is a potential new treatment for multiple myeloma.,http://www.ncbi.nlm.nih.gov/pubmed/18076711
2428,19684075,Clinical experience with aurora kinase inhibitors: a review.,http://www.ncbi.nlm.nih.gov/pubmed/19684075
2429,21415220,PRIMA-1Met/APR-246 induces apoptosis and tumor growth delay in small cell lung cancer expressing mutant p53.,http://www.ncbi.nlm.nih.gov/pubmed/21415220
2430,21910042,Tanibirumab (TTAC-0001): a fully human monoclonal antibody targets vascular endothelial growth factor receptor 2 (VEGFR-2).,http://www.ncbi.nlm.nih.gov/pubmed/21910042
2431,19644473,Targeting the phosphoinositide 3-kinase pathway in cancer.,http://www.ncbi.nlm.nih.gov/pubmed/19644473
2432,19200708,Should individual PI3 kinase isoforms be targeted in cancer?,http://www.ncbi.nlm.nih.gov/pubmed/19200708
2433,25712626,Idelalisib- a PI3Kδ targeting agent for B-cell malignancies.,http://www.ncbi.nlm.nih.gov/pubmed/25712626
2434,21665146,"Receptor tyrosine kinases and TLR/IL1Rs unexpectedly activate myeloid cell PI3kγ, a single convergent point promoting tumor inflammation and progression.",http://www.ncbi.nlm.nih.gov/pubmed/21665146
2435,17172449,Phosphoinositide 3-kinase gamma/delta inhibition limits infarct size after myocardial ischemia/reperfusion injury.,http://www.ncbi.nlm.nih.gov/pubmed/17172449
2436,16127437,Blockade of PI3Kgamma suppresses joint inflammation and damage in mouse models of rheumatoid arthritis.,http://www.ncbi.nlm.nih.gov/pubmed/16127437
2437,20224967,Targeting PI3K in neuroblastoma.,http://www.ncbi.nlm.nih.gov/pubmed/20224967
2438,24768112,"Sorafenib in radioactive iodine-refractory, locally advanced or metastatic differentiated thyroid cancer: a randomised, double-blind, phase 3 trial.",http://www.ncbi.nlm.nih.gov/pubmed/24768112
2439,19144678,Sorafenib for the treatment of unresectable hepatocellular carcinoma.,http://www.ncbi.nlm.nih.gov/pubmed/19144678
2440,23470564,Transferrin receptor targeting nanomedicine delivering wild-type p53 gene sensitizes pancreatic cancer to gemcitabine therapy.,http://www.ncbi.nlm.nih.gov/pubmed/23470564
2441,22203728,"CEP-28122, a highly potent and selective orally active inhibitor of anaplastic lymphoma kinase with antitumor activity in experimental models of human cancers.",http://www.ncbi.nlm.nih.gov/pubmed/22203728
2442,21613408,Insights into ALK-driven cancers revealed through development of novel ALK tyrosine kinase inhibitors.,http://www.ncbi.nlm.nih.gov/pubmed/21613408
2443,,"Safety, activity, and pharmacokinetics of an oral anaplastic lymphoma kinase (ALK) inhibitor, ASP3026, observed in a “fast follower” phase 1 trial design.",http://meetinglibrary.asco.org/content/132526-144
2444,25623213,The BET Bromodomain Inhibitor OTX015 Affects Pathogenetic Pathways in Preclinical B-cell Tumor Models and Synergizes with Targeted Drugs.,http://www.ncbi.nlm.nih.gov/pubmed/25623213
2445,24779514,"Discovery of GS-9973, a selective and orally efficacious inhibitor of spleen tyrosine kinase.",http://www.ncbi.nlm.nih.gov/pubmed/24779514
2446,16397056,"CG0070, a conditionally replicating granulocyte macrophage colony-stimulating factor--armed oncolytic adenovirus for the treatment of bladder cancer.",http://www.ncbi.nlm.nih.gov/pubmed/16397056
2447,24933332,"Ramucirumab plus docetaxel versus placebo plus docetaxel for second-line treatment of stage IV non-small-cell lung cancer after disease progression on platinum-based therapy (REVEL): a multicentre, double-blind, randomised phase 3 trial.",http://www.ncbi.nlm.nih.gov/pubmed/24933332
2448,22589397,Development of a human monoclonal antibody for potential therapy of CD27-expressing lymphoma and leukemia.,http://www.ncbi.nlm.nih.gov/pubmed/22589397
2449,24094768,"Ramucirumab monotherapy for previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (REGARD): an international, randomised, multicentre, placebo-controlled, phase 3 trial.",http://www.ncbi.nlm.nih.gov/pubmed/24094768
2450,25253883,The novel kinase inhibitor PRT062070 (Cerdulatinib) demonstrates efficacy in models of autoimmunity and B-cell cancer.,http://www.ncbi.nlm.nih.gov/pubmed/25253883
2451,21091142,Nilotinib is superior to imatinib as first-line therapy of chronic myeloid leukemia: the ENESTnd study.,http://www.ncbi.nlm.nih.gov/pubmed/21091142
2452,19741151,Cellular inhibition of checkpoint kinase 2 (Chk2) and potentiation of camptothecins and radiation by the novel Chk2 inhibitor PV1019 [7-nitro-1H-indole-2-carboxylic acid {4-[1-(guanidinohydrazone)-ethyl]-phenyl}-amide].,http://www.ncbi.nlm.nih.gov/pubmed/19741151
2453,17363488,"Biochemical and cellular characterization of VRX0466617, a novel and selective inhibitor for the checkpoint kinase Chk2.",http://www.ncbi.nlm.nih.gov/pubmed/17363488
2454,,NCCN Guidelines Version 5.2015 Non-Small Cell Lung Cancer,
2455,24681808,"SLC25A1, or CIC, is a novel transcriptional target of mutant p53 and a negative tumor prognostic marker.",http://www.ncbi.nlm.nih.gov/pubmed/24681808
2456,24857548,Gain-of-function mutant p53 promotes cell growth and cancer cell metabolism via inhibition of AMPK activation.,http://www.ncbi.nlm.nih.gov/pubmed/24857548
2457,22214764,Interaction between ZBP-89 and p53 mutants and its contribution to effects of HDACi on hepatocellular carcinoma.,http://www.ncbi.nlm.nih.gov/pubmed/22214764
2458,24651012,Mutant p53 in cancer: new functions and therapeutic opportunities.,http://www.ncbi.nlm.nih.gov/pubmed/24651012
2459,9632751,Characterization of structural p53 mutants which show selective defects in apoptosis but not cell cycle arrest.,http://www.ncbi.nlm.nih.gov/pubmed/9632751
2460,15037740,A global suppressor motif for p53 cancer mutants.,http://www.ncbi.nlm.nih.gov/pubmed/15037740
2461,22484423,p53 modulates homologous recombination at I-SceI-induced double-strand breaks through cell-cycle regulation.,http://www.ncbi.nlm.nih.gov/pubmed/22484423
2462,16707427,Identification of a novel germ line variant hotspot mutant p53-R175L in pediatric adrenal cortical carcinoma.,http://www.ncbi.nlm.nih.gov/pubmed/16707427
2463,24136356,Phosphoinositide 3-kinase δ gene mutation predisposes to respiratory infection and airway damage.,http://www.ncbi.nlm.nih.gov/pubmed/24136356
2464,24165795,Dominant-activating germline mutations in the gene encoding the PI(3)K catalytic subunit p110δ result in T cell senescence and human immunodeficiency.,http://www.ncbi.nlm.nih.gov/pubmed/24165795
2465,14690015,A novel dysfunctional p53 mutation in the human neuroblastoma cell line TGW.,http://www.ncbi.nlm.nih.gov/pubmed/14690015
2466,11920959,Complex functions of mutant p53 alleles from human prostate cancer.,http://www.ncbi.nlm.nih.gov/pubmed/11920959
2467,12782597,Cooperation of two mutant p53 alleles contributes to Fas resistance of prostate carcinoma cells.,http://www.ncbi.nlm.nih.gov/pubmed/12782597
2468,10871862,Identification of a tumor-derived p53 mutant with novel transactivating selectivity.,http://www.ncbi.nlm.nih.gov/pubmed/10871862
2469,23339124,"Phase I study of dovitinib (TKI258), an oral FGFR, VEGFR, and PDGFR inhibitor, in advanced or metastatic renal cell carcinoma.",http://www.ncbi.nlm.nih.gov/pubmed/23339124
2470,20581473,Prioritization of driver mutations in pancreatic cancer using cancer-specific high-throughput annotation of somatic mutations (CHASM).,http://www.ncbi.nlm.nih.gov/pubmed/20581473
2471,20207148,Evaluating Smoothened as a G-protein-coupled receptor for Hedgehog signalling.,http://www.ncbi.nlm.nih.gov/pubmed/20207148
2472,15550452,The rare ERBB2 variant Ile654Val is associated with an increased familial breast cancer risk.,http://www.ncbi.nlm.nih.gov/pubmed/15550452
2473,25787766,Exploiting selective BCL-2 family inhibitors to dissect cell survival dependencies and define improved strategies for cancer therapy.,http://www.ncbi.nlm.nih.gov/pubmed/25787766
2474,23922646,Peripheral reduction of FGFR4 with antisense oligonucleotides increases metabolic rate and lowers adiposity in diet-induced obese mice.,http://www.ncbi.nlm.nih.gov/pubmed/23922646
2475,19581523,The role of Src in solid tumors.,http://www.ncbi.nlm.nih.gov/pubmed/19581523
2476,,"Integrated report of the phase 2 experience with XL999 administered IV to patients (pts) with NSCLC, renal cell CA (RCC), metastatic colorectal CA (CRC), recurrent ovarian CA, acute myelogenous leaukemia (AML), and multiple myeloma (MM)",http://meeting.ascopubs.org/cgi/content/short/25/18_suppl/3591
2477,25662515,"Src protein-tyrosine kinase structure, mechanism, and small molecule inhibitors.",http://www.ncbi.nlm.nih.gov/pubmed/25662515
2478,21776389,Regulation of SRC family kinases in human cancers.,http://www.ncbi.nlm.nih.gov/pubmed/21776389
2479,21521831,Current status of SRC inhibitors in solid tumor malignancies.,http://www.ncbi.nlm.nih.gov/pubmed/21521831
2480,11931842,BGP-15 - a novel poly(ADP-ribose) polymerase inhibitor - protects against nephrotoxicity of cisplatin without compromising its antitumor activity.,http://www.ncbi.nlm.nih.gov/pubmed/11931842
2481,22661288,"Inhibition of cancer growth and induction of apoptosis by BGP-13 and BGP-15, new calcipotriene-derived vitamin D3 analogs, in-vitro and in-vivo studies.",http://www.ncbi.nlm.nih.gov/pubmed/22661288
2482,24880570,Phase 1 dose-escalation study of the PARP inhibitor CEP-9722 as monotherapy or in combination with temozolomide in patients with solid tumors.,http://www.ncbi.nlm.nih.gov/pubmed/24880570
2483,24714082,"Activity of CEP-9722, a poly (ADP-ribose) polymerase inhibitor, in urothelial carcinoma correlates inversely with homologous recombination repair response to DNA damage.",http://www.ncbi.nlm.nih.gov/pubmed/24714082
2484,25868125,"Chromosomal damage and micronucleus induction by MP-124, a novel poly(ADP-ribose) polymerase-1 (PARP-1) inhibitor: Evidence for a non-DNA-reactive mode of action.",http://www.ncbi.nlm.nih.gov/pubmed/25868125
2485,25531448,PARP inhibition restores extrinsic apoptotic sensitivity in glioblastoma.,http://www.ncbi.nlm.nih.gov/pubmed/25531448
2486,9724739,MEKK1/JNK signaling stabilizes and activates p53.,http://www.ncbi.nlm.nih.gov/pubmed/9724739
2487,8208536,Transactivational and DNA binding abilities of endogenous p53 in p53 mutant cell lines.,http://www.ncbi.nlm.nih.gov/pubmed/8208536
2488,16236433,Localization of a mutant p53 response element on the tissue inhibitor of metalloproteinase-3 promoter: mutant p53 activities are distinct from wild-type.,http://www.ncbi.nlm.nih.gov/pubmed/16236433
2489,23103855,Loss of 53BP1 causes PARP inhibitor resistance in Brca1-mutated mouse mammary tumors.,http://www.ncbi.nlm.nih.gov/pubmed/23103855
2490,9927431,Destruction of Myc by ubiquitin-mediated proteolysis: cancer-associated and transforming mutations stabilize Myc.,http://www.ncbi.nlm.nih.gov/pubmed/9927431
2491,24013231,Burkitt's lymphoma-associated c-Myc mutations converge on a dramatically altered target gene response and implicate Nol5a/Nop56 in oncogenesis.,http://www.ncbi.nlm.nih.gov/pubmed/24013231
2492,10706881,c-Myc hot spot mutations in lymphomas result in inefficient ubiquitination and decreased proteasome-mediated turnover.,http://www.ncbi.nlm.nih.gov/pubmed/10706881
2493,25668228,EGFR T790M resistance mutation in non small-cell lung carcinoma.,http://www.ncbi.nlm.nih.gov/pubmed/25668228
2494,25614115,"Discovery of 1-substituted benzyl-quinazoline-2,4(1H,3H)-dione derivatives as novel poly(ADP-ribose)polymerase-1 inhibitors.",http://www.ncbi.nlm.nih.gov/pubmed/25614115
2495,24263190,VEGF targets the tumour cell.,http://www.ncbi.nlm.nih.gov/pubmed/24263190
2496,18596824,VEGF-targeted therapy: mechanisms of anti-tumour activity.,http://www.ncbi.nlm.nih.gov/pubmed/18596824
2497,22172724,BRCA1 RING function is essential for tumor suppression but dispensable for therapy resistance.,http://www.ncbi.nlm.nih.gov/pubmed/22172724
2498,24781550,Therapeutic modulation of Notch signalling--are we there yet?,http://www.ncbi.nlm.nih.gov/pubmed/24781550
2499,24879797,FDA approval: ado-trastuzumab emtansine for the treatment of patients with HER2-positive metastatic breast cancer.,http://www.ncbi.nlm.nih.gov/pubmed/24879797
2500,19786658,Lapatinib combined with letrozole versus letrozole and placebo as first-line therapy for postmenopausal hormone receptor-positive metastatic breast cancer.,http://www.ncbi.nlm.nih.gov/pubmed/19786658
2501,8220424,Point mutations in the c-Myc transactivation domain are common in Burkitt's lymphoma and mouse plasmacytomas.,http://www.ncbi.nlm.nih.gov/pubmed/8220424
2502,,NCCN Guidelines Version 2.2015 Breast Cancer,
2503,,"The Safety and Activity of BMS-906024, a Gamma Secretase Inhibitor (GSI) with Anti-Notch Activity, in Patients with Relapsed T-Cell Acute Lymphoblastic Leukemia (T-ALL): Initial Results of a Phase 1 Trial",https://ash.confex.com/ash/2014/webprogram/Paper70285.html
2504,22679110,MEDI0639: a novel therapeutic antibody targeting Dll4 modulates endothelial cell function and angiogenesis in vivo.,http://www.ncbi.nlm.nih.gov/pubmed/22679110
2505,21831306,"Anti-DLL4, a cancer therapeutic with multiple mechanisms of action.",http://www.ncbi.nlm.nih.gov/pubmed/21831306
2506,23774673,Therapeutic antibody targeting of Notch1 in T-acute lymphoblastic leukemia xenografts.,http://www.ncbi.nlm.nih.gov/pubmed/23774673
2507,,688P FINAL RESULTS OF A PHASE 1B OF OMP-59R5 (ANTI-NOTCH2/3/STEM CELL ANTIBODY) IN COMBINATION WITH NAB-PACLITAXEL AND GEMCITABINE (NAB-P + GEM) IN PATIENTS (PTS) WITH UNTREATED METASTATIC PANCREATIC CANCER (MPC): ALPINE STUDY,http://annonc.oxfordjournals.org/content/25/suppl_4/iv233.3
2508,20463236,Acute gamma-secretase inhibition of nonhuman primate CNS shifts amyloid precursor protein (APP) metabolism from amyloid-beta production to alternative APP fragments without amyloid-beta rebound.,http://www.ncbi.nlm.nih.gov/pubmed/20463236
2509,23340294,Preclinical and clinical studies of gamma secretase inhibitors with docetaxel on human breast tumors.,http://www.ncbi.nlm.nih.gov/pubmed/23340294
2510,19773430,Preclinical profile of a potent gamma-secretase inhibitor targeting notch signaling with in vivo efficacy and pharmacodynamic properties.,http://www.ncbi.nlm.nih.gov/pubmed/19773430
2511,22323718,Differential effects between γ-secretase inhibitors and modulators on cognitive function in amyloid precursor protein-transgenic and nontransgenic mice.,http://www.ncbi.nlm.nih.gov/pubmed/22323718
2512,14709552,"Chronic treatment with the gamma-secretase inhibitor LY-411,575 inhibits beta-amyloid peptide production and alters lymphopoiesis and intestinal cell differentiation.",http://www.ncbi.nlm.nih.gov/pubmed/14709552
2513,20064975,Pharmacological analysis of Drosophila melanogaster gamma-secretase with respect to differential proteolysis of Notch and APP.,http://www.ncbi.nlm.nih.gov/pubmed/20064975
2514,24900185,"Discovery and Evaluation of BMS-708163, a Potent, Selective and Orally Bioavailable γ-Secretase Inhibitor.",http://www.ncbi.nlm.nih.gov/pubmed/24900185
2515,11145990,Functional gamma-secretase inhibitors reduce beta-amyloid peptide levels in brain.,http://www.ncbi.nlm.nih.gov/pubmed/11145990
2516,15103331,Phosphorylation-dependent degradation of c-Myc is mediated by the F-box protein Fbw7.,http://www.ncbi.nlm.nih.gov/pubmed/15103331
2517,20978199,BRAF inactivation drives aneuploidy by deregulating CRAF.,http://www.ncbi.nlm.nih.gov/pubmed/20978199
2518,24642617,Mechanism and consequences of RAF kinase activation by small-molecule inhibitors.,http://www.ncbi.nlm.nih.gov/pubmed/24642617
2519,16088943,PTEN enters the nucleus by diffusion.,http://www.ncbi.nlm.nih.gov/pubmed/16088943
2520,21059859,Appearance of the novel activating F1174S ALK mutation in neuroblastoma correlates with aggressive tumor progression and unresponsiveness to therapy.,http://www.ncbi.nlm.nih.gov/pubmed/21059859
2521,18923523,Somatic and germline activating mutations of the ALK kinase receptor in neuroblastoma.,http://www.ncbi.nlm.nih.gov/pubmed/18923523
2522,17317574,Apoptosis in T cell acute lymphoblastic leukemia cells after cell cycle arrest induced by pharmacological inhibition of notch signaling.,http://www.ncbi.nlm.nih.gov/pubmed/17317574
2523,23344087,Heterogeneity of genetic changes associated with acquired crizotinib resistance in ALK-rearranged lung cancer.,http://www.ncbi.nlm.nih.gov/pubmed/23344087
2524,22235099,Mechanisms of resistance to crizotinib in patients with ALK gene rearranged non-small cell lung cancer.,http://www.ncbi.nlm.nih.gov/pubmed/22235099
2525,24675041,The ALK inhibitor ceritinib overcomes crizotinib resistance in non-small cell lung cancer.,http://www.ncbi.nlm.nih.gov/pubmed/24675041
2526,25501949,Linking tumor mutations to drug responses via a quantitative chemical-genetic interaction map.,http://www.ncbi.nlm.nih.gov/pubmed/25501949
2527,24781551,"Design and synthesis of 3,3'-biscoumarin-based c-Met inhibitors.",http://www.ncbi.nlm.nih.gov/pubmed/24781551
2528,11443619,beta-Catenin mutation and overexpression in hepatocellular carcinoma: clinicopathologic and prognostic significance.,http://www.ncbi.nlm.nih.gov/pubmed/11443619
2529,18628470,Therapeutic consequences from molecular biology for gastrointestinal stromal tumor patients affected by neurofibromatosis type 1.,http://www.ncbi.nlm.nih.gov/pubmed/18628470
2530,23169527,The β-catenin destruction complex.,http://www.ncbi.nlm.nih.gov/pubmed/23169527
2531,9191060,Somatic in frame deletions not involving juxtamembranous cysteine residues strongly activate the RET proto-oncogene.,http://www.ncbi.nlm.nih.gov/pubmed/9191060
2532,15277225,The oncogenic activity of RET point mutants for follicular thyroid cells may account for the occurrence of papillary thyroid carcinoma in patients affected by familial medullary thyroid carcinoma.,http://www.ncbi.nlm.nih.gov/pubmed/15277225
2533,24716929,Characterization of wild-type and mutated RET proto- oncogene associated with familial medullary thyroid cancer.,http://www.ncbi.nlm.nih.gov/pubmed/24716929
2534,10224103,Inhibition of spontaneous receptor phosphorylation by residues in a putative alpha-helix in the KIT intracellular juxtamembrane region.,http://www.ncbi.nlm.nih.gov/pubmed/10224103
2535,9815757,O6-benzylguanine and its role in chemotherapy.,http://www.ncbi.nlm.nih.gov/pubmed/9815757
2536,19560417,The juxtamembrane region of the EGF receptor functions as an activation domain.,http://www.ncbi.nlm.nih.gov/pubmed/19560417
2537,24687871,Using a rhabdomyosarcoma patient-derived xenograft to examine precision medicine approaches and model acquired resistance.,http://www.ncbi.nlm.nih.gov/pubmed/24687871
2538,23918606,Dual blockade of the PI3K/AKT/mTOR (AZD8055) and RAS/MEK/ERK (AZD6244) pathways synergistically inhibits rhabdomyosarcoma cell growth in vitro and in vivo.,http://www.ncbi.nlm.nih.gov/pubmed/23918606
2539,25795637,Phase I study of nintedanib incorporating dynamic contrast-enhanced magnetic resonance imaging in patients with advanced solid tumors.,http://www.ncbi.nlm.nih.gov/pubmed/25795637
2540,20531296,The activating mutation R201C in GNAS promotes intestinal tumourigenesis in Apc(Min/+) mice through activation of Wnt and ERK1/2 MAPK pathways.,http://www.ncbi.nlm.nih.gov/pubmed/20531296
2541,24498230,"GNAS mutations identify a set of right-sided, RAS mutant, villous colon cancers.",http://www.ncbi.nlm.nih.gov/pubmed/24498230
2542,3498122,Requirement for intrinsic protein tyrosine kinase in the immediate and late actions of the EGF receptor.,http://www.ncbi.nlm.nih.gov/pubmed/3498122
2543,24023066,EGFR lung cancer mutants get specialized.,http://www.ncbi.nlm.nih.gov/pubmed/24023066
2544,15118073,Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib.,http://www.ncbi.nlm.nih.gov/pubmed/15118073
2545,17172848,FGFR3 mutations in benign skin tumors.,http://www.ncbi.nlm.nih.gov/pubmed/17172848
2546,25868854,Powerful anti-tumor and anti-angiogenic activity of a new anti-vascular endothelial growth factor receptor 1 peptide in colorectal cancer models.,http://www.ncbi.nlm.nih.gov/pubmed/25868854
2547,17124058,FLT3 mutations: biology and treatment.,http://www.ncbi.nlm.nih.gov/pubmed/17124058
2548,25231999,Targeting FLT3 to treat leukemia.,http://www.ncbi.nlm.nih.gov/pubmed/25231999
2549,17145802,Pathways targeting tumor lymphangiogenesis.,http://www.ncbi.nlm.nih.gov/pubmed/17145802
2550,24009722,BET inhibition silences expression of MYCN and BCL2 and induces cytotoxicity in neuroblastoma tumor models.,http://www.ncbi.nlm.nih.gov/pubmed/24009722
2551,25678837,New developments in the pathogenesis and therapeutic targeting of the IDH1 mutation in glioma.,http://www.ncbi.nlm.nih.gov/pubmed/25678837
2552,23558169,An inhibitor of mutant IDH1 delays growth and promotes differentiation of glioma cells.,http://www.ncbi.nlm.nih.gov/pubmed/23558169
2553,21132006,Characterization of epidermal growth factor receptor mutations in non-small-cell lung cancer patients of African-American ancestry.,http://www.ncbi.nlm.nih.gov/pubmed/21132006
2554,25558173,Disease progression in iridocorneal angle tissues of BMP2-induced ocular hypertensive mice with optical coherence tomography.,http://www.ncbi.nlm.nih.gov/pubmed/25558173
2555,25251602,Metabolomic comparison between cells over-expressing isocitrate dehydrogenase 1 and 2 mutants and the effects of an inhibitor on the metabolism.,http://www.ncbi.nlm.nih.gov/pubmed/25251602
2556,11468194,A FLT3 tyrosine kinase inhibitor is selectively cytotoxic to acute myeloid leukemia blasts harboring FLT3 internal tandem duplication mutations.,http://www.ncbi.nlm.nih.gov/pubmed/11468194
2557,12670652,"Tricyclic quinoxalines as potent kinase inhibitors of PDGFR kinase, Flt3 and Kit.",http://www.ncbi.nlm.nih.gov/pubmed/12670652
2558,24586741,FBXW7 mutations in patients with advanced cancers: clinical and molecular characteristics and outcomes with mTOR inhibitors.,http://www.ncbi.nlm.nih.gov/pubmed/24586741
2559,9892193,"SU5416 is a potent and selective inhibitor of the vascular endothelial growth factor receptor (Flk-1/KDR) that inhibits tyrosine kinase catalysis, tumor vascularization, and growth of multiple tumor types.",http://www.ncbi.nlm.nih.gov/pubmed/9892193
2560,12351406,SU5416 and SU5614 inhibit kinase activity of wild-type and mutant FLT3 receptor tyrosine kinase.,http://www.ncbi.nlm.nih.gov/pubmed/12351406
2561,20197554,Selective inhibition of IDO1 effectively regulates mediators of antitumor immunity.,http://www.ncbi.nlm.nih.gov/pubmed/20197554
2562,23444216,Aflibercept.,http://www.ncbi.nlm.nih.gov/pubmed/23444216
2563,20443627,"BI-97C1, an optically pure Apogossypol derivative as pan-active inhibitor of antiapoptotic B-cell lymphoma/leukemia-2 (Bcl-2) family proteins.",http://www.ncbi.nlm.nih.gov/pubmed/20443627
2564,17332241,Preclinical studies of the pan-Bcl inhibitor obatoclax (GX015-070) in multiple myeloma.,http://www.ncbi.nlm.nih.gov/pubmed/17332241
2565,18040043,Small molecule obatoclax (GX15-070) antagonizes MCL-1 and overcomes MCL-1-mediated resistance to apoptosis.,http://www.ncbi.nlm.nih.gov/pubmed/18040043
2566,21358717,The novel antisense Bcl-2 inhibitor SPC2996 causes rapid leukemic cell clearance and immune activation in chronic lymphocytic leukemia.,http://www.ncbi.nlm.nih.gov/pubmed/21358717
2567,24832107,Development and antitumor activity of a BCL-2 targeted single-stranded DNA oligonucleotide.,http://www.ncbi.nlm.nih.gov/pubmed/24832107
2568,23064957,Oblimersen in combination with temozolomide and albumin-bound paclitaxel in patients with advanced melanoma: a phase I trial.,http://www.ncbi.nlm.nih.gov/pubmed/23064957
2569,22273505,Mechanisms of FGFR-mediated carcinogenesis.,http://www.ncbi.nlm.nih.gov/pubmed/22273505
2570,24326534,Anti-KIR antibody enhancement of anti-lymphoma activity of natural killer cells as monotherapy and in combination with anti-CD20 antibodies.,http://www.ncbi.nlm.nih.gov/pubmed/24326534
2571,25551293,A kinase-independent function of AKT promotes cancer cell survival.,http://www.ncbi.nlm.nih.gov/pubmed/25551293
2572,24736079,Next-generation sequencing reveals a Novel NSCLC ALK F1174V mutation and confirms ALK G1202R mutation confers high-level resistance to alectinib (CH5424802/RO5424802) in ALK-rearranged NSCLC patients who progressed on crizotinib.,http://www.ncbi.nlm.nih.gov/pubmed/24736079
2573,25727400,Activity of second-generation ALK inhibitors against crizotinib-resistant mutants in an NPM-ALK model compared to EML4-ALK.,http://www.ncbi.nlm.nih.gov/pubmed/25727400
2574,22737296,Structure-Function Of The Tumor Suppressor BRCA1.,http://www.ncbi.nlm.nih.gov/pubmed/22737296
2575,16618730,Identification of domains of BRCA1 critical for the ubiquitin-dependent inhibition of centrosome function.,http://www.ncbi.nlm.nih.gov/pubmed/16618730
2576,25823446,Massively Parallel Functional Analysis of BRCA1 RING Domain Variants.,http://www.ncbi.nlm.nih.gov/pubmed/25823446
2578,24845084,Probing structure-function relationships in missense variants in the carboxy-terminal region of BRCA1.,http://www.ncbi.nlm.nih.gov/pubmed/24845084
2579,11157798,Functional analysis of BRCA1 C-terminal missense mutations identified in breast and ovarian cancer families.,http://www.ncbi.nlm.nih.gov/pubmed/11157798
2580,12619154,"Deletion of Brca2 exon 27 causes hypersensitivity to DNA crosslinks, chromosomal instability, and reduced life span in mice.",http://www.ncbi.nlm.nih.gov/pubmed/12619154
2581,9699678,Cells deleted for Brca2 COOH terminus exhibit hypersensitivity to gamma-radiation and premature senescence.,http://www.ncbi.nlm.nih.gov/pubmed/9699678
2582,15695382,Functional evaluation and cancer risk assessment of BRCA2 unclassified variants.,http://www.ncbi.nlm.nih.gov/pubmed/15695382
2583,18724707,Computational and structural investigation of deleterious functional SNPs in breast cancer BRCA2 gene.,http://www.ncbi.nlm.nih.gov/pubmed/18724707
2584,23704879,Missense variants of uncertain significance (VUS) altering the phosphorylation patterns of BRCA1 and BRCA2.,http://www.ncbi.nlm.nih.gov/pubmed/23704879
2585,23108138,A classification model for BRCA2 DNA binding domain missense variants based on homology-directed repair activity.,http://www.ncbi.nlm.nih.gov/pubmed/23108138
2586,25523067,"Germline activating AKT3 mutation associated with megalencephaly, polymicrogyria, epilepsy and hypoglycemia.",http://www.ncbi.nlm.nih.gov/pubmed/25523067
2587,12228710,BRCA2 function in DNA binding and recombination from a BRCA2-DSS1-ssDNA structure.,http://www.ncbi.nlm.nih.gov/pubmed/12228710
2588,22678057,Functional evaluation of BRCA2 variants mapping to the PALB2-binding and C-terminal DNA-binding domains using a mouse ES cell-based assay.,http://www.ncbi.nlm.nih.gov/pubmed/22678057
2589,19946327,The FGFR4 Y367C mutant is a dominant oncogene in MDA-MB453 breast cancer cells.,http://www.ncbi.nlm.nih.gov/pubmed/19946327
2590,14534301,Detection of protein folding defects caused by BRCA1-BRCT truncation and missense mutations.,http://www.ncbi.nlm.nih.gov/pubmed/14534301
2591,15256422,"Inhibition of wild-type and mutant Bcr-Abl by AP23464, a potent ATP-based oncogenic protein kinase inhibitor: implications for CML.",http://www.ncbi.nlm.nih.gov/pubmed/15256422
2592,15657179,"PD166326, a novel tyrosine kinase inhibitor, has greater antileukemic activity than imatinib mesylate in a murine model of chronic myeloid leukemia.",http://www.ncbi.nlm.nih.gov/pubmed/15657179
2593,12684394,A novel pyridopyrimidine inhibitor of abl kinase is a picomolar inhibitor of Bcr-abl-driven K562 cells and is effective against STI571-resistant Bcr-abl mutants.,http://www.ncbi.nlm.nih.gov/pubmed/12684394
2594,16492148,Structural basis of Src tyrosine kinase inhibition with a new class of potent and selective trisubstituted purine-based compounds.,http://www.ncbi.nlm.nih.gov/pubmed/16492148
2595,22126373,Dendritic cell-targeted protein vaccines: a novel approach to induce T-cell immunity.,http://www.ncbi.nlm.nih.gov/pubmed/22126373
2596,21790611,"Emerging evidence of the health benefits of S-equol, an estrogen receptor β agonist.",http://www.ncbi.nlm.nih.gov/pubmed/21790611
2597,,"BAY 1238097, a novel BET inhibitor with strong efficacy in hematological tumor models",http://www.abstractsonline.com/plan/ViewAbstract.aspx?mID=3682&sKey=b4807182-6a38-470a-b895-86207d0fe55a&cKey=83e86e35-c100-4b31-9794-2db7bdbb4faf&mKey=19573a54-ae8f-4e00-9c23-bd6d62268424
2598,14507635,"BRAF and FBXW7 (CDC4, FBW7, AGO, SEL10) mutations in distinct subsets of pancreatic cancer: potential therapeutic targets.",http://www.ncbi.nlm.nih.gov/pubmed/14507635
2599,8122112,"Fusion of a kinase gene, ALK, to a nucleolar protein gene, NPM, in non-Hodgkin's lymphoma.",http://www.ncbi.nlm.nih.gov/pubmed/8122112
2600,9121481,Role of the nucleophosmin (NPM) portion of the non-Hodgkin's lymphoma-associated NPM-anaplastic lymphoma kinase fusion protein in oncogenesis.,http://www.ncbi.nlm.nih.gov/pubmed/9121481
2601,24495176,Oclacitinib (APOQUEL(®)) is a novel Janus kinase inhibitor with activity against cytokines involved in allergy.,http://www.ncbi.nlm.nih.gov/pubmed/24495176
2602,12154026,Characterization of potent inhibitors of the Bcr-Abl and the c-kit receptor tyrosine kinases.,http://www.ncbi.nlm.nih.gov/pubmed/12154026
2603,10626805,Inhibition of Src kinases by a selective tyrosine kinase inhibitor causes mitotic arrest.,http://www.ncbi.nlm.nih.gov/pubmed/10626805
2604,21750655,A small-molecule p53 activator induces apoptosis through inhibiting MDMX expression in breast cancer cells.,http://www.ncbi.nlm.nih.gov/pubmed/21750655
2605,22957303,High levels of Hdmx promote cell growth in a subset of uveal melanomas.,http://www.ncbi.nlm.nih.gov/pubmed/22957303
2606,21075910,A small-molecule inhibitor of MDMX activates p53 and induces apoptosis.,http://www.ncbi.nlm.nih.gov/pubmed/21075910
2607,15815726,"Identification of Ki23819, a highly potent inhibitor of kinase activity of mutant FLT3 receptor tyrosine kinase.",http://www.ncbi.nlm.nih.gov/pubmed/15815726
2608,20080970,Identification and characterization of the first small molecule inhibitor of MDMX.,http://www.ncbi.nlm.nih.gov/pubmed/20080970
2609,10974196,"Biochemical and cellular effects of c-Src kinase-selective pyrido[2, 3-d]pyrimidine tyrosine kinase inhibitors.",http://www.ncbi.nlm.nih.gov/pubmed/10974196
2610,12499247,"Activity of the Bcr-Abl kinase inhibitor PD180970 against clinically relevant Bcr-Abl isoforms that cause resistance to imatinib mesylate (Gleevec, STI571).",http://www.ncbi.nlm.nih.gov/pubmed/12499247
2611,23946421,Stapled α-helical peptide drug development: a potent dual inhibitor of MDM2 and MDMX for p53-dependent cancer therapy.,http://www.ncbi.nlm.nih.gov/pubmed/23946421
2612,19541823,"KW-2449, a novel multikinase inhibitor, suppresses the growth of leukemia cells with FLT3 mutations or T315I-mutated BCR/ABL translocation.",http://www.ncbi.nlm.nih.gov/pubmed/19541823
2613,19654408,AC220 is a uniquely potent and selective inhibitor of FLT3 for the treatment of acute myeloid leukemia (AML).,http://www.ncbi.nlm.nih.gov/pubmed/19654408
2614,24258348,Ever-advancing chronic myeloid leukemia treatment.,http://www.ncbi.nlm.nih.gov/pubmed/24258348
2615,20537386,BCR-ABL tyrosine kinase inhibitors in the treatment of Philadelphia chromosome positive chronic myeloid leukemia: a review.,http://www.ncbi.nlm.nih.gov/pubmed/20537386
2616,16580199,Identification of 2-acylaminothiophene-3-carboxamides as potent inhibitors of FLT3.,http://www.ncbi.nlm.nih.gov/pubmed/16580199
2617,24532805,"G-749, a novel FLT3 kinase inhibitor, can overcome drug resistance for the treatment of acute myeloid leukemia.",http://www.ncbi.nlm.nih.gov/pubmed/24532805
2618,21505103,The ABL switch control inhibitor DCC-2036 is active against the chronic myeloid leukemia mutant BCR-ABLT315I and exhibits a narrow resistance profile.,http://www.ncbi.nlm.nih.gov/pubmed/21505103
2619,19878872,"AP24534, a pan-BCR-ABL inhibitor for chronic myeloid leukemia, potently inhibits the T315I mutant and overcomes mutation-based resistance.",http://www.ncbi.nlm.nih.gov/pubmed/19878872
2620,22160483,Dasatinib or imatinib in newly diagnosed chronic-phase chronic myeloid leukemia: 2-year follow-up from a randomized phase 3 trial (DASISION).,http://www.ncbi.nlm.nih.gov/pubmed/22160483
2621,21703324,Effects of S-equol and natural S-equol supplement (SE5-OH) on the growth of MCF-7 in vitro and as tumors implanted into ovariectomized athymic mice.,http://www.ncbi.nlm.nih.gov/pubmed/21703324
2622,24487643,Equol induces apoptosis in human hepatocellular carcinoma SMMC-7721 cells through the intrinsic pathway and the endoplasmic reticulum stress pathway.,http://www.ncbi.nlm.nih.gov/pubmed/24487643
2623,21081186,"The interactome of a PTB domain-containing adapter protein, Odin, revealed by SILAC.",http://www.ncbi.nlm.nih.gov/pubmed/21081186
2624,20495563,Post-translational modifications in signal integration.,http://www.ncbi.nlm.nih.gov/pubmed/20495563
2625,21865346,Safety and efficacy of bosutinib (SKI-606) in chronic phase Philadelphia chromosome-positive chronic myeloid leukemia patients with resistance or intolerance to imatinib.,http://www.ncbi.nlm.nih.gov/pubmed/21865346
2626,15194504,The two major imatinib resistance mutations E255K and T315I enhance the activity of BCR/ABL fusion kinase.,http://www.ncbi.nlm.nih.gov/pubmed/15194504
2627,24959084,The potential roles of hepatocyte growth factor (HGF)-MET pathway inhibitors in cancer treatment.,http://www.ncbi.nlm.nih.gov/pubmed/24959084
2628,16105974,"NS-187, a potent and selective dual Bcr-Abl/Lyn tyrosine kinase inhibitor, is a novel agent for imatinib-resistant leukemia.",http://www.ncbi.nlm.nih.gov/pubmed/16105974
2629,20730632,Inhibition of cancer cell invasion and metastasis by genistein.,http://www.ncbi.nlm.nih.gov/pubmed/20730632
2630,23226579,Activation of abl family kinases in solid tumors.,http://www.ncbi.nlm.nih.gov/pubmed/23226579
2631,17161815,PD98059 triggers G1 arrest and apoptosis in human leukemic U937 cells through downregulation of Akt signal pathway.,http://www.ncbi.nlm.nih.gov/pubmed/17161815
2632,7644477,A synthetic inhibitor of the mitogen-activated protein kinase cascade.,http://www.ncbi.nlm.nih.gov/pubmed/7644477
2633,23614898,Discovery of a novel ERK inhibitor with activity in models of acquired resistance to BRAF and MEK inhibitors.,http://www.ncbi.nlm.nih.gov/pubmed/23614898
2634,19340001,"The impact of NOTCH1, FBW7 and PTEN mutations on prognosis and downstream signaling in pediatric T-cell acute lymphoblastic leukemia: a report from the Children's Oncology Group.",http://www.ncbi.nlm.nih.gov/pubmed/19340001
2635,17909001,FBXW7/hCDC4 is a general tumor suppressor in human cancer.,http://www.ncbi.nlm.nih.gov/pubmed/17909001
2636,25126421,A melanoma helper peptide vaccine increases Th1 cytokine production by leukocytes in peripheral blood and immunized lymph nodes.,http://www.ncbi.nlm.nih.gov/pubmed/25126421
2637,17575125,The tumor suppressor gene hCDC4 is frequently mutated in human T-cell acute lymphoblastic leukemia with functional consequences for Notch signaling.,http://www.ncbi.nlm.nih.gov/pubmed/17575125
2638,22608923,Negative regulation of the stability and tumor suppressor function of Fbw7 by the Pin1 prolyl isomerase.,http://www.ncbi.nlm.nih.gov/pubmed/22608923
2639,16014569,Mutations in the ATM gene lead to impaired overall and treatment-free survival that is independent of IGVH mutation status in patients with B-CLL.,http://www.ncbi.nlm.nih.gov/pubmed/16014569
2640,20589832,Restoration of DNA-binding and growth-suppressive activity of mutant forms of p53 via a PCAF-mediated acetylation pathway.,http://www.ncbi.nlm.nih.gov/pubmed/20589832
2641,22170099,Adaptation of cancer cells from different entities to the MDM2 inhibitor nutlin-3 results in the emergence of p53-mutated multi-drug-resistant cancer cells.,http://www.ncbi.nlm.nih.gov/pubmed/22170099
2642,19393585,"Preclinical anticancer activity of the potent, oral Src inhibitor AZD0530.",http://www.ncbi.nlm.nih.gov/pubmed/19393585
2643,15630097,tp53 mutant zebrafish develop malignant peripheral nerve sheath tumors.,http://www.ncbi.nlm.nih.gov/pubmed/15630097
2644,25366685,Olaparib monotherapy in patients with advanced cancer and a germline BRCA1/2 mutation.,http://www.ncbi.nlm.nih.gov/pubmed/25366685
2645,21671020,Effect of the overexpression of BRCA2 unclassified missense variants on spontaneous homologous recombination in human cells.,http://www.ncbi.nlm.nih.gov/pubmed/21671020
2646,7592628,Characterization of two activated mutants of human pp60c-src that escape c-Src kinase regulation by distinct mechanisms.,http://www.ncbi.nlm.nih.gov/pubmed/7592628
2647,25292412,Idiopathic basal ganglia calcification-associated PDGFRB mutations impair the receptor signalling.,http://www.ncbi.nlm.nih.gov/pubmed/25292412
2648,24796542,Genetic screening and functional characterization of PDGFRB mutations associated with basal ganglia calcification of unknown etiology.,http://www.ncbi.nlm.nih.gov/pubmed/24796542
2649,21084400,"Wnt/β-catenin pathway activation in adrenocortical adenomas is frequently due to somatic CTNNB1-activating mutations, which are associated with larger and nonsecreting tumors: a study in cortisol-secreting and -nonsecreting tumors.",http://www.ncbi.nlm.nih.gov/pubmed/21084400
2650,20702649,Identification of several novel non-p.R132 IDH1 variants in thyroid carcinomas.,http://www.ncbi.nlm.nih.gov/pubmed/20702649
2651,21996744,Identification of additional IDH mutations associated with oncometabolite R(-)-2-hydroxyglutarate production.,http://www.ncbi.nlm.nih.gov/pubmed/21996744
2652,20171178,Identification and functional characterization of isocitrate dehydrogenase 1 (IDH1) mutations in thyroid cancer.,http://www.ncbi.nlm.nih.gov/pubmed/20171178
2653,23585524,ATM mutations uniformly lead to ATM dysfunction in chronic lymphocytic leukemia: application of functional test using doxorubicin.,http://www.ncbi.nlm.nih.gov/pubmed/23585524
2654,22673234,The human TLR innate immune gene family is differentially influenced by DNA stress and p53 status in cancer cells.,http://www.ncbi.nlm.nih.gov/pubmed/22673234
2655,25401086,A Small-Molecule Inhibitor of RAD51 Reduces Homologous Recombination and Sensitizes Multiple Myeloma Cells to Doxorubicin.,http://www.ncbi.nlm.nih.gov/pubmed/25401086
2656,24741445,Human interferon alpha-2b: a therapeutic protein for cancer treatment.,http://www.ncbi.nlm.nih.gov/pubmed/24741445
2657,25581613,Biodegradable polymeric micelles encapsulated JK184 suppress tumor growth through inhibiting Hedgehog signaling pathway.,http://www.ncbi.nlm.nih.gov/pubmed/25581613
2658,24394624,Inhibition of hedgehog signaling by GANT58 induces apoptosis and shows synergistic antitumor activity with AKT inhibitor in acute T cell leukemia cells.,http://www.ncbi.nlm.nih.gov/pubmed/24394624
2659,25292178,Enhanced non-homologous end joining contributes toward synthetic lethality of pathological RAD51C mutants with poly (ADP-ribose) polymerase.,http://www.ncbi.nlm.nih.gov/pubmed/25292178
2660,23420418,FOXA1 mutations in hormone-dependent cancers.,http://www.ncbi.nlm.nih.gov/pubmed/23420418
2661,22115363,FOXA1: a transcription factor with parallel functions in development and cancer.,http://www.ncbi.nlm.nih.gov/pubmed/22115363
2662,25284480,"Naturally occurring neomorphic PIK3R1 mutations activate the MAPK pathway, dictating therapeutic response to MAPK pathway inhibitors.",http://www.ncbi.nlm.nih.gov/pubmed/25284480
2663,25913680,"A phase 2 trial of lenvatinib (E7080) in advanced, progressive, radioiodine-refractory, differentiated thyroid cancer: A clinical outcomes and biomarker assessment.",http://www.ncbi.nlm.nih.gov/pubmed/25913680
2664,22506672,Cannabidiol as potential anticancer drug.,http://www.ncbi.nlm.nih.gov/pubmed/22506672
2665,23243024,Id-1 is a key transcriptional regulator of glioblastoma aggressiveness and a novel therapeutic target.,http://www.ncbi.nlm.nih.gov/pubmed/23243024
2666,25923549,AZD9291 in EGFR inhibitor-resistant non-small-cell lung cancer.,http://www.ncbi.nlm.nih.gov/pubmed/25923549
2667,25877855,"Ramucirumab versus placebo in combination with second-line FOLFIRI in patients with metastatic colorectal carcinoma that progressed during or after first-line therapy with bevacizumab, oxaliplatin, and a fluoropyrimidine (RAISE): a randomised, double-blind, multicentre, phase 3 study.",http://www.ncbi.nlm.nih.gov/pubmed/25877855
2668,18634022,Functional and computational assessment of missense variants in the ataxia-telangiectasia mutated (ATM) gene: mutations with increased cancer risk.,http://www.ncbi.nlm.nih.gov/pubmed/18634022
2669,16603769,The FATC domains of PIKK proteins are functionally equivalent and participate in the Tip60-dependent activation of DNA-PKcs and ATM.,http://www.ncbi.nlm.nih.gov/pubmed/16603769
2670,10706620,Mantle cell lymphoma is characterized by inactivation of the ATM gene.,http://www.ncbi.nlm.nih.gov/pubmed/10706620
2671,22147941,A live-attenuated Listeria vaccine (ANZ-100) and a live-attenuated Listeria vaccine expressing mesothelin (CRS-207) for advanced cancers: phase I studies of safety and immune induction.,http://www.ncbi.nlm.nih.gov/pubmed/22147941
2672,21217520,"A lethally irradiated allogeneic granulocyte-macrophage colony stimulating factor-secreting tumor vaccine for pancreatic adenocarcinoma. A Phase II trial of safety, efficacy, and immune activation.",http://www.ncbi.nlm.nih.gov/pubmed/21217520
2673,24563541,"Birinapant (TL32711), a bivalent SMAC mimetic, targets TRAF2-associated cIAPs, abrogates TNF-induced NF-κB activation, and is active in patient-derived xenograft models.",http://www.ncbi.nlm.nih.gov/pubmed/24563541
2674,25708576,Immunotherapy: Sipuleucel-T induces humoral antigen spread in patients with mCRPC.,http://www.ncbi.nlm.nih.gov/pubmed/25708576
2675,24127596,Structural basis for KIT receptor tyrosine kinase inhibition by antibodies targeting the D4 membrane-proximal region.,http://www.ncbi.nlm.nih.gov/pubmed/24127596
2676,25652454,"First-in-Human Study of PF-05212384 (PKI-587), a Small-Molecule, Intravenous, Dual Inhibitor of PI3K and mTOR in Patients with Advanced Cancer.",http://www.ncbi.nlm.nih.gov/pubmed/25652454
2677,25759020,Smoothened variants explain the majority of drug resistance in basal cell carcinoma.,http://www.ncbi.nlm.nih.gov/pubmed/25759020
2678,24367658,Identification of mutations in distinct regions of p85 alpha in urothelial cancer.,http://www.ncbi.nlm.nih.gov/pubmed/24367658
2679,19962665,Somatic mutations in p85alpha promote tumorigenesis through class IA PI3K activation.,http://www.ncbi.nlm.nih.gov/pubmed/19962665
2680,23810379,SHORT syndrome with partial lipodystrophy due to impaired phosphatidylinositol 3 kinase signaling.,http://www.ncbi.nlm.nih.gov/pubmed/23810379
2681,20404484,A growing family: adding mutated Erbb4 as a novel cancer target.,http://www.ncbi.nlm.nih.gov/pubmed/20404484
2682,25476449,Gli1/DNA interaction is a druggable target for Hedgehog-dependent tumors.,http://www.ncbi.nlm.nih.gov/pubmed/25476449
2683,25700942,Trk inhibitor attenuates the BDNF/TrkB-induced protection of neuroblastoma cells from etoposide in vitro and in vivo.,http://www.ncbi.nlm.nih.gov/pubmed/25700942
2684,25394774,TrkB inhibition by GNF-4256 slows growth and enhances chemotherapeutic efficacy in neuroblastoma xenografts.,http://www.ncbi.nlm.nih.gov/pubmed/25394774
2685,22160853,"Phase I study of the safety, tolerability and pharmacokinetics of PHA-848125AC, a dual tropomyosin receptor kinase A and cyclin-dependent kinase inhibitor, in patients with advanced solid malignancies.",http://www.ncbi.nlm.nih.gov/pubmed/22160853
2686,23810382,Mutations in PIK3R1 cause SHORT syndrome.,http://www.ncbi.nlm.nih.gov/pubmed/23810382
2687,18455128,"Discovery, in vivo activity, and mechanism of action of a small-molecule p53 activator.",http://www.ncbi.nlm.nih.gov/pubmed/18455128
2688,24648290,Pleiotropic antitumor effects of the pan-HDAC inhibitor ITF2357 against c-Myc-overexpressing human B-cell non-Hodgkin lymphomas.,http://www.ncbi.nlm.nih.gov/pubmed/24648290
2689,25669976,"Novel oral histone deacetylase inhibitor, MPT0E028, displays potent growth-inhibitory activity against human B-cell lymphoma in vitro and in vivo.",http://www.ncbi.nlm.nih.gov/pubmed/25669976
2690,,"Abstract 1747: BGB324, a selective small molecule Axl kinase inhibitor to overcome EMT-associated drug resistance in carcinomas: Therapeutic rationale and early clinical studies",http://cancerres.aacrjournals.org/content/74/19_Supplement/1747.short
2691,25674538,The Potential of panHER Inhibition in Cancer.,http://www.ncbi.nlm.nih.gov/pubmed/25674538
2692,23855452,Inhibition of checkpoint kinase 2 (CHK2) enhances sensitivity of pancreatic adenocarcinoma cells to gemcitabine.,http://www.ncbi.nlm.nih.gov/pubmed/23855452
2693,24130053,Small-molecule inhibitors of USP1 target ID1 degradation in leukemic cells.,http://www.ncbi.nlm.nih.gov/pubmed/24130053
2694,21925315,USP1 deubiquitinates ID proteins to preserve a mesenchymal stem cell program in osteosarcoma.,http://www.ncbi.nlm.nih.gov/pubmed/21925315
2695,24362713,Checkpoint kinase inhibitor AZD7762 overcomes cisplatin resistance in clear cell carcinoma of the ovary.,http://www.ncbi.nlm.nih.gov/pubmed/24362713
2696,16912188,Deficiency in the repair of DNA damage by homologous recombination and sensitivity to poly(ADP-ribose) polymerase inhibition.,http://www.ncbi.nlm.nih.gov/pubmed/16912188
2697,23145321,A novel tumor suppressor network in squamous malignancies.,http://www.ncbi.nlm.nih.gov/pubmed/23145321
2698,24531842,A selective USP1-UAF1 inhibitor links deubiquitination to DNA damage responses.,http://www.ncbi.nlm.nih.gov/pubmed/24531842
2699,23023262,A selective inhibitor of EZH2 blocks H3K27 methylation and kills mutant lymphoma cells.,http://www.ncbi.nlm.nih.gov/pubmed/23023262
2700,25774336,Immunohistochemical analysis in ethinylestradiol-treated breast cancers after prior long-term estrogen-deprivation therapy.,http://www.ncbi.nlm.nih.gov/pubmed/25774336
2701,1590276,Fluoxymesterone as third line endocrine therapy for advanced breast cancer. A phase II trial of the Piedmont Oncology Association.,http://www.ncbi.nlm.nih.gov/pubmed/1590276
2702,16538529,Randomized trial of tamoxifen alone or combined with fluoxymesterone as adjuvant therapy in postmenopausal women with resected estrogen receptor positive breast cancer. North Central Cancer Treatment Group Trial 89-30-52.,http://www.ncbi.nlm.nih.gov/pubmed/16538529
2703,21078963,Coordinated activities of wild-type plus mutant EZH2 drive tumor-associated hypertrimethylation of lysine 27 on histone H3 (H3K27) in human B-cell lymphomas.,http://www.ncbi.nlm.nih.gov/pubmed/21078963
2704,22237022,A novel retinoblastoma therapy from genomic and epigenetic analyses.,http://www.ncbi.nlm.nih.gov/pubmed/22237022
2705,21515735,Targeting the p53 pathway in retinoblastoma with subconjunctival Nutlin-3a.,http://www.ncbi.nlm.nih.gov/pubmed/21515735
2706,15256420,Variable sensitivity of FLT3 activation loop mutations to the small molecule tyrosine kinase inhibitor MLN518.,http://www.ncbi.nlm.nih.gov/pubmed/15256420
2707,24608088,Activating FLT3 mutants show distinct gain-of-function phenotypes in vitro and a characteristic signaling pathway profile associated with prognosis in acute myeloid leukemia.,http://www.ncbi.nlm.nih.gov/pubmed/24608088
2708,18387942,Disrupted RabGAP function of the p85 subunit of phosphatidylinositol 3-kinase results in cell transformation.,http://www.ncbi.nlm.nih.gov/pubmed/18387942
2709,24799061,Orteronel for the treatment of prostate cancer.,http://www.ncbi.nlm.nih.gov/pubmed/24799061
2710,23858101,NF1 deletion generates multiple subtypes of soft-tissue sarcoma that respond to MEK inhibition.,http://www.ncbi.nlm.nih.gov/pubmed/23858101
2711,23221341,MEK inhibition exhibits efficacy in human and mouse neurofibromatosis tumors.,http://www.ncbi.nlm.nih.gov/pubmed/23221341
2712,23171796,Elucidating distinct roles for NF1 in melanomagenesis.,http://www.ncbi.nlm.nih.gov/pubmed/23171796
2713,19509272,"Identification and preclinical characterization of AZ-23, a novel, selective, and orally bioavailable inhibitor of the Trk kinase pathway.",http://www.ncbi.nlm.nih.gov/pubmed/19509272
2714,21236475,Tyrosine kinase A receptor (trkA): a potential marker in epithelial ovarian cancer.,http://www.ncbi.nlm.nih.gov/pubmed/21236475
2715,22623209,AZ64 inhibits TrkB and enhances the efficacy of chemotherapy and local radiation in neuroblastoma xenografts.,http://www.ncbi.nlm.nih.gov/pubmed/22623209
2716,20179224,Lestaurtinib enhances the antitumor efficacy of chemotherapy in murine xenograft models of neuroblastoma.,http://www.ncbi.nlm.nih.gov/pubmed/20179224
2717,25748921,A high-throughput in vitro drug screen in a genetically engineered mouse model of diffuse intrinsic pontine glioma identifies BMS-754807 as a promising therapeutic agent.,http://www.ncbi.nlm.nih.gov/pubmed/25748921
2718,24386191,Discovery and preclinical characterization of novel small molecule TRK and ROS1 tyrosine kinase inhibitors for the treatment of cancer and inflammation.,http://www.ncbi.nlm.nih.gov/pubmed/24386191
2719,23587795,"Anti-cancer effect of HS-345, a new tropomyosin-related kinase A inhibitor, on human pancreatic cancer.",http://www.ncbi.nlm.nih.gov/pubmed/23587795
2720,21216928,Interpreting mammalian target of rapamycin and cell growth inhibition in a genetically engineered mouse model of Nf1-deficient astrocytes.,http://www.ncbi.nlm.nih.gov/pubmed/21216928
2721,23209032,Prognostic significance of AKT/mTOR and MAPK pathways and antitumor effect of mTOR inhibitor in NF1-related and sporadic malignant peripheral nerve sheath tumors.,http://www.ncbi.nlm.nih.gov/pubmed/23209032
2722,21748792,Hyperactivation of mTOR critically regulates abnormal osteoclastogenesis in neurofibromatosis Type 1.,http://www.ncbi.nlm.nih.gov/pubmed/21748792
2723,22312557,The Role of Wild-Type p53 in Cisplatin-Induced Chk2 Phosphorylation and the Inhibition of Platinum Resistance with a Chk2 Inhibitor.,http://www.ncbi.nlm.nih.gov/pubmed/22312557
2724,23620515,Durable tumor regression in genetically altered malignant rhabdoid tumors by inhibition of methyltransferase EZH2.,http://www.ncbi.nlm.nih.gov/pubmed/23620515
2725,24563539,Selective inhibition of EZH2 by EPZ-6438 leads to potent antitumor activity in EZH2-mutant non-Hodgkin lymphoma.,http://www.ncbi.nlm.nih.gov/pubmed/24563539
2726,17098432,"Anti-breast cancer activity of LFM-A13, a potent inhibitor of Polo-like kinase (PLK).",http://www.ncbi.nlm.nih.gov/pubmed/17098432
2727,15196000,The Btk inhibitor LFM-A13 is a potent inhibitor of Jak2 kinase activity.,http://www.ncbi.nlm.nih.gov/pubmed/15196000
2728,10092645,"Rational design and synthesis of a novel anti-leukemic agent targeting Bruton's tyrosine kinase (BTK), LFM-A13 [alpha-cyano-beta-hydroxy-beta-methyl-N-(2, 5-dibromophenyl)propenamide].",http://www.ncbi.nlm.nih.gov/pubmed/10092645
2729,22228807,"RN486, a selective Bruton's tyrosine kinase inhibitor, abrogates immune hypersensitivity responses and arthritis in rodents.",http://www.ncbi.nlm.nih.gov/pubmed/22228807
2730,25934888,Targeting Notch signaling with a Notch2/Notch3 antagonist (tarextumab) inhibits tumor growth and decreases tumor-initiating cell frequency.,http://www.ncbi.nlm.nih.gov/pubmed/25934888
2731,23958373,Ibrutinib and novel BTK inhibitors in clinical development.,http://www.ncbi.nlm.nih.gov/pubmed/23958373
2732,25701252,Potent and selective Bruton's tyrosine kinase inhibitors: discovery of GDC-0834.,http://www.ncbi.nlm.nih.gov/pubmed/25701252
2733,25944695,Irreversible dual inhibitory mode: the novel Btk inhibitor PLS-123 demonstrates promising anti-tumor activity in human B-cell lymphoma.,http://www.ncbi.nlm.nih.gov/pubmed/25944695
2734,21113169,Specific Btk inhibition suppresses B cell- and myeloid cell-mediated arthritis.,http://www.ncbi.nlm.nih.gov/pubmed/21113169
2735,25673697,"A Translational, Pharmacodynamic, and Pharmacokinetic Phase IB Clinical Study of Everolimus in Resectable Non-Small Cell Lung Cancer.",http://www.ncbi.nlm.nih.gov/pubmed/25673697
2736,16507829,BAY 43-9006 inhibition of oncogenic RET mutants.,http://www.ncbi.nlm.nih.gov/pubmed/16507829
2737,25777572,Oncolytic virus immunotherapy for melanoma.,http://www.ncbi.nlm.nih.gov/pubmed/25777572
2738,17652518,Vaccination with an NY-ESO-1 peptide of HLA class I/II specificities induces integrated humoral and T cell responses in ovarian cancer.,http://www.ncbi.nlm.nih.gov/pubmed/17652518
2739,22293180,Understanding pRb: toward the necessary development of targeted treatments for retinoblastoma.,http://www.ncbi.nlm.nih.gov/pubmed/22293180
2740,17102977,Plasmid DNA vaccine encoding prostatic acid phosphatase is effective in eliciting autologous antigen-specific CD8+ T cells.,http://www.ncbi.nlm.nih.gov/pubmed/17102977
2741,24162378,Mechanisms of action of tasquinimod on the tumour microenvironment.,http://www.ncbi.nlm.nih.gov/pubmed/24162378
2742,24435321,Afatinib: a review of its use in the treatment of advanced non-small cell lung cancer.,http://www.ncbi.nlm.nih.gov/pubmed/24435321
2743,25505694,Second generation tyrosine kinase inhibitors for the treatment of metastatic non-small-cell lung cancer.,http://www.ncbi.nlm.nih.gov/pubmed/25505694
2744,3790170,3-Deazaneplanocin A: a new inhibitor of S-adenosylhomocysteine synthesis and its effects in human colon carcinoma cells.,http://www.ncbi.nlm.nih.gov/pubmed/3790170
2745,19638619,Combined epigenetic therapy with the histone methyltransferase EZH2 inhibitor 3-deazaneplanocin A and the histone deacetylase inhibitor panobinostat against human AML cells.,http://www.ncbi.nlm.nih.gov/pubmed/19638619
2746,25806203,Irreversible EGFR-TKIs: dreaming perfection.,http://www.ncbi.nlm.nih.gov/pubmed/25806203
2747,23236167,Selective inhibition of Ezh2 by a small molecule inhibitor blocks tumor cells proliferation.,http://www.ncbi.nlm.nih.gov/pubmed/23236167
2748,10921887,A repressor sequence in the juxtamembrane domain of Flt-1 (VEGFR-1) constitutively inhibits vascular endothelial growth factor-dependent phosphatidylinositol 3'-kinase activation and endothelial cell migration.,http://www.ncbi.nlm.nih.gov/pubmed/10921887
2749,23071358,IDH1 and IDH2 mutations in tumorigenesis: mechanistic insights and clinical perspectives.,http://www.ncbi.nlm.nih.gov/pubmed/23071358
2750,21356389,Mutant IDH1 confers an in vivo growth in a melanoma cell line with BRAF mutation.,http://www.ncbi.nlm.nih.gov/pubmed/21356389
2751,21596855,The prognostic significance of IDH2 mutations in AML depends on the location of the mutation.,http://www.ncbi.nlm.nih.gov/pubmed/21596855
2752,16738328,Leukemia-associated mutations within the NOTCH1 heterodimerization domain fall into at least two distinct mechanistic classes.,http://www.ncbi.nlm.nih.gov/pubmed/16738328
2753,25824335,Efficacy of Carboplatin Alone and in Combination with ABT888 in Intracranial Murine Models of BRCA-Mutated and BRCA-Wild-Type Triple-Negative Breast Cancer.,http://www.ncbi.nlm.nih.gov/pubmed/25824335
2754,23264629,The potential for isocitrate dehydrogenase mutations to produce 2-hydroxyglutarate depends on allele specificity and subcellular compartmentalization.,http://www.ncbi.nlm.nih.gov/pubmed/23264629
2755,21326614,"2-hydroxyglutarate production, but not dominant negative function, is conferred by glioma-derived NADP-dependent isocitrate dehydrogenase mutations.",http://www.ncbi.nlm.nih.gov/pubmed/21326614
2756,21366804,Transforming growth factor-beta 2 gene silencing with trabedersen (AP 12009) in pancreatic cancer.,http://www.ncbi.nlm.nih.gov/pubmed/21366804
2757,,"The TGF-beta1 antisense oligonucleotide AP 11014 for the treatment of non-small cell lung, colorectal and prostate cancer: Preclinical studies",http://meeting.ascopubs.org/cgi/content/short/22/14_suppl/3132
2758,3861940,Human transforming growth factor-beta complementary DNA sequence and expression in normal and transformed cells.,http://www.ncbi.nlm.nih.gov/pubmed/3861940
2759,24618589,Phase I study of GC1008 (fresolimumab): a human anti-transforming growth factor-beta (TGFβ) monoclonal antibody in patients with advanced malignant melanoma or renal cell carcinoma.,http://www.ncbi.nlm.nih.gov/pubmed/24618589
2760,20001556,Targeting the transforming growth factor-beta signaling pathway in human cancer.,http://www.ncbi.nlm.nih.gov/pubmed/20001556
2761,,1104. Phase II Study of Lucanix|[trade]| a Transforming Growth Factor |[beta]|2 (TGF-|[beta]|2) Antisense Gene Modified Allogeneic Tumor Cell Vaccine in Non Small Cell Lung Cancer (NSCLC),http://www.nature.com/mt/journal/v13/n1s/full/mt20061245a.html
2762,16539403,Dihydropyrrolopyrazole transforming growth factor-beta type I receptor kinase domain inhibitors: a novel benzimidazole series with selectivity versus transforming growth factor-beta type II receptor kinase and mixed lineage kinase-7.,http://www.ncbi.nlm.nih.gov/pubmed/16539403
2763,15709742,Kinetic characterization of novel pyrazole TGF-beta receptor I kinase inhibitors and their blockade of the epithelial-mesenchymal transition.,http://www.ncbi.nlm.nih.gov/pubmed/15709742
2764,15177479,"Synthesis and activity of new aryl- and heteroaryl-substituted 5,6-dihydro-4H-pyrrolo[1,2-b]pyrazole inhibitors of the transforming growth factor-beta type I receptor kinase domain.",http://www.ncbi.nlm.nih.gov/pubmed/15177479
2765,15573100,Development of TGF-beta signalling inhibitors for cancer therapy.,http://www.ncbi.nlm.nih.gov/pubmed/15573100
2766,18413796,"LY2109761, a novel transforming growth factor beta receptor type I and type II dual inhibitor, as a therapeutic approach to suppressing pancreatic cancer metastasis.",http://www.ncbi.nlm.nih.gov/pubmed/18413796
2767,18339844,Cancer-associated transforming growth factor beta type II receptor gene mutant causes activation of bone morphogenic protein-Smads and invasive phenotype.,http://www.ncbi.nlm.nih.gov/pubmed/18339844
2768,15967103,"A specific inhibitor of TGF-beta receptor kinase, SB-431542, as a potent antitumor agent for human cancers.",http://www.ncbi.nlm.nih.gov/pubmed/15967103
2769,25609063,The Efficacy of the Wee1 Inhibitor MK-1775 Combined with Temozolomide Is Limited by Heterogeneous Distribution across the Blood-Brain Barrier in Glioblastoma.,http://www.ncbi.nlm.nih.gov/pubmed/25609063
2770,17129361,"Ki26894, a novel transforming growth factor-beta type I receptor kinase inhibitor, inhibits in vitro invasion and in vivo bone metastasis of a human breast cancer cell line.",http://www.ncbi.nlm.nih.gov/pubmed/17129361
2771,15866172,Conserved docking site is essential for activation of mammalian MAP kinase kinases by specific MAP kinase kinase kinases.,http://www.ncbi.nlm.nih.gov/pubmed/15866172
2772,21896780,Map2k4 functions as a tumor suppressor in lung adenocarcinoma and inhibits tumor cell invasion by decreasing peroxisome proliferator-activated receptor γ2 expression.,http://www.ncbi.nlm.nih.gov/pubmed/21896780
2773,9331070,Human mitogen-activated protein kinase kinase 4 as a candidate tumor suppressor.,http://www.ncbi.nlm.nih.gov/pubmed/9331070
2774,22924430,Steroid receptor coactivator-3 as a potential molecular target for cancer therapy.,http://www.ncbi.nlm.nih.gov/pubmed/22924430
2775,24743578,Identification of verrucarin a as a potent and selective steroid receptor coactivator-3 small molecule inhibitor.,http://www.ncbi.nlm.nih.gov/pubmed/24743578
2776,25914884,Targeting cell cycle regulators in hematologic malignancies.,http://www.ncbi.nlm.nih.gov/pubmed/25914884
2777,23634254,"CDK4: A Key Player in the Cell Cycle, Development, and Cancer.",http://www.ncbi.nlm.nih.gov/pubmed/23634254
2778,21311763,DNA polymerase β as a novel target for chemotherapeutic intervention of colorectal cancer.,http://www.ncbi.nlm.nih.gov/pubmed/21311763
2779,25933036,"NSC666715 and Its Analogs Inhibit Strand-Displacement Activity of DNA Polymerase β and Potentiate Temozolomide-Induced DNA Damage, Senescence and Apoptosis in Colorectal Cancer Cells.",http://www.ncbi.nlm.nih.gov/pubmed/25933036
2780,22401667,Advances in using PARP inhibitors to treat cancer.,http://www.ncbi.nlm.nih.gov/pubmed/22401667
2781,25779564,Poly (ADP-ribose) polymerase inhibitors: recent advances and future development.,http://www.ncbi.nlm.nih.gov/pubmed/25779564
2782,15828833,3-Aminopyrazole inhibitors of CDK2/cyclin A as antitumor agents. 2. Lead optimization.,http://www.ncbi.nlm.nih.gov/pubmed/15828833
2783,24004674,Resistance to CDK2 inhibitors is associated with selection of polyploid cells in CCNE1-amplified ovarian cancer.,http://www.ncbi.nlm.nih.gov/pubmed/24004674
2784,24294592,PARP Inhibitors in Cancer Therapy: Magic Bullets but Moving Targets.,http://www.ncbi.nlm.nih.gov/pubmed/24294592
2785,21968702,PARP-1 and PARP-2: New players in tumour development.,http://www.ncbi.nlm.nih.gov/pubmed/21968702
2786,25671128,Therapeutic DNA vaccination against colorectal cancer by targeting the MYB oncoprotein.,http://www.ncbi.nlm.nih.gov/pubmed/25671128
2788,15001837,Antisense oligodeoxynucleotide directed against c-myb has anticancer activity and potentiates the antiproliferative effect of conventional anticancer drugs acting by different mechanisms in human colorectal cancer cells.,http://www.ncbi.nlm.nih.gov/pubmed/15001837
2789,,Investigation of PARP1 as a therapeutic target in small cell lung cancer,http://meetinglibrary.asco.org/content/98896-114
2790,9677190,"Exploiting chemical libraries, structure, and genomics in the search for kinase inhibitors.",http://www.ncbi.nlm.nih.gov/pubmed/9677190
2791,24190492,Purvalanol A is a strong apoptotic inducer via activating polyamine catabolic pathway in MCF-7 estrogen receptor positive breast cancer cells.,http://www.ncbi.nlm.nih.gov/pubmed/24190492
2792,19169685,"SNS-032 is a potent and selective CDK 2, 7 and 9 inhibitor that drives target modulation in patient samples.",http://www.ncbi.nlm.nih.gov/pubmed/19169685
2793,11507069,"A novel cdk2-selective inhibitor, SU9516, induces apoptosis in colon carcinoma cells.",http://www.ncbi.nlm.nih.gov/pubmed/11507069
2794,19174555,"Biological characterization of AT7519, a small-molecule inhibitor of cyclin-dependent kinases, in human tumor cell lines.",http://www.ncbi.nlm.nih.gov/pubmed/19174555
2795,19509270,"AZD5438, a potent oral inhibitor of cyclin-dependent kinases 1, 2, and 9, leads to pharmacodynamic changes and potent antitumor effects in human tumor xenografts.",http://www.ncbi.nlm.nih.gov/pubmed/19509270
2796,25763356,OX40 Agonists and Combination Immunotherapy: Putting the Pedal to the Metal.,http://www.ncbi.nlm.nih.gov/pubmed/25763356
2797,18411416,NOTCH1 extracellular juxtamembrane expansion mutations in T-ALL.,http://www.ncbi.nlm.nih.gov/pubmed/18411416
2798,17085664,Novel D761Y and common secondary T790M mutations in epidermal growth factor receptor-mutant lung adenocarcinomas with acquired resistance to kinase inhibitors.,http://www.ncbi.nlm.nih.gov/pubmed/17085664
2799,22687603,Antineoplastic activity of the DNA methyltransferase inhibitor 5-aza-2'-deoxycytidine in anaplastic large cell lymphoma.,http://www.ncbi.nlm.nih.gov/pubmed/22687603
2800,25583779,IDH1 inhibitor shows promising early results.,http://www.ncbi.nlm.nih.gov/pubmed/25583779
2801,25962717,Safety and Activity of the First-in-Class Sym004 Anti-EGFR Antibody Mixture in Patients with Refractory Colorectal Cancer.,http://www.ncbi.nlm.nih.gov/pubmed/25962717
2802,23759589,Three-dimensional culture sensitizes epithelial ovarian cancer cells to EZH2 methyltransferase inhibition.,http://www.ncbi.nlm.nih.gov/pubmed/23759589
2803,18068628,Identification of driver and passenger mutations of FLT3 by high-throughput DNA sequence analysis and functional assessment of candidate alleles.,http://www.ncbi.nlm.nih.gov/pubmed/18068628
2805,16614245,Activating NOTCH1 mutations predict favorable early treatment response and long-term outcome in childhood precursor T-cell lymphoblastic leukemia.,http://www.ncbi.nlm.nih.gov/pubmed/16614245
2806,15897231,Functional conservation of Notch1 and Notch2 intracellular domains.,http://www.ncbi.nlm.nih.gov/pubmed/15897231
2807,25394726,Truncating mutations in the last exon of NOTCH3 cause lateral meningocele syndrome.,http://www.ncbi.nlm.nih.gov/pubmed/25394726
2808,23836557,A mutation in MYD88 (L265P) supports the survival of lymphoplasmacytic cells by activation of Bruton tyrosine kinase in Waldenström macroglobulinemia.,http://www.ncbi.nlm.nih.gov/pubmed/23836557
2809,21179087,Oncogenically active MYD88 mutations in human lymphoma.,http://www.ncbi.nlm.nih.gov/pubmed/21179087
2810,25853747,Ibrutinib in previously treated Waldenström's macroglobulinemia.,http://www.ncbi.nlm.nih.gov/pubmed/25853747
2811,8797864,Reduced messenger RNA expression level of p21 CIP1 in human colorectal carcinoma tissues and its association with p53 gene mutation.,http://www.ncbi.nlm.nih.gov/pubmed/8797864
2812,15831478,Direct p53 transcriptional repression: in vivo analysis of CCAAT-containing G2/M promoters.,http://www.ncbi.nlm.nih.gov/pubmed/15831478
2813,19582488,Schwannomatosis associated with multiple meningiomas due to a familial SMARCB1 mutation.,http://www.ncbi.nlm.nih.gov/pubmed/19582488
2814,15472075,Activating mutations of NOTCH1 in human T cell acute lymphoblastic leukemia.,http://www.ncbi.nlm.nih.gov/pubmed/15472075
2815,21173237,Therapeutically targeting cyclin D1 in primary tumors arising from loss of Ini1.,http://www.ncbi.nlm.nih.gov/pubmed/21173237
2816,21778190,"AR42, a novel histone deacetylase inhibitor, as a potential therapy for vestibular schwannomas and meningiomas.",http://www.ncbi.nlm.nih.gov/pubmed/21778190
2817,10835628,Missense mutations interfere with VEGFR-3 signalling in primary lymphoedema.,http://www.ncbi.nlm.nih.gov/pubmed/10835628
2818,15102829,Activation of vascular endothelial growth factor receptor-3 and its downstream signaling promote cell survival under oxidative stress.,http://www.ncbi.nlm.nih.gov/pubmed/15102829
2819,19773441,MicroRNA-34a inhibits glioblastoma growth by targeting multiple oncogenes.,http://www.ncbi.nlm.nih.gov/pubmed/19773441
2820,17548515,Contact-dependent inhibition of EGFR signaling by Nf2/Merlin.,http://www.ncbi.nlm.nih.gov/pubmed/17548515
2821,18593924,Dissecting and targeting the growth factor-dependent and growth factor-independent extracellular signal-regulated kinase pathway in human schwannoma.,http://www.ncbi.nlm.nih.gov/pubmed/18593924
2822,16302003,"Targeting cyclin D1, a downstream effector of INI1/hSNF5, in rhabdoid tumors.",http://www.ncbi.nlm.nih.gov/pubmed/16302003
2823,23016851,"Modulation of epigenetic targets for anticancer therapy: clinicopathological relevance, structural data and drug discovery perspectives.",http://www.ncbi.nlm.nih.gov/pubmed/23016851
2824,22805104,Bevacizumab for progressive vestibular schwannoma in neurofibromatosis type 2: a retrospective review of 31 patients.,http://www.ncbi.nlm.nih.gov/pubmed/22805104
2825,20406973,Anti-vascular endothelial growth factor therapies as a novel therapeutic approach to treating neurofibromatosis-related tumors.,http://www.ncbi.nlm.nih.gov/pubmed/20406973
2826,20736812,Erlotinib for progressive vestibular schwannoma in neurofibromatosis 2 patients.,http://www.ncbi.nlm.nih.gov/pubmed/20736812
2827,22745749,Investigation of the in vitro therapeutic efficacy of nilotinib in immortalized human NF2-null vestibular schwannoma cells.,http://www.ncbi.nlm.nih.gov/pubmed/22745749
2828,22844108,Phase II trial of lapatinib in adult and pediatric patients with neurofibromatosis type 2 and progressive vestibular schwannomas.,http://www.ncbi.nlm.nih.gov/pubmed/22844108
2829,18223225,Dose and schedule study of panitumumab monotherapy in patients with advanced solid malignancies.,http://www.ncbi.nlm.nih.gov/pubmed/18223225
2830,25504632,A multicenter phase I study of pazopanib in combination with paclitaxel in first-line treatment of patients with advanced solid tumors.,http://www.ncbi.nlm.nih.gov/pubmed/25504632
2831,19509233,Human schwannomas express activated platelet-derived growth factor receptors and c-kit and are growth inhibited by Gleevec (Imatinib Mesylate).,http://www.ncbi.nlm.nih.gov/pubmed/19509233
2832,20028764,Phase 1 study of aflibercept administered subcutaneously to patients with advanced solid tumors.,http://www.ncbi.nlm.nih.gov/pubmed/20028764
2833,25458015,Sunitinib impedes brain tumor progression and reduces tumor-induced neurodegeneration in the microenvironment.,http://www.ncbi.nlm.nih.gov/pubmed/25458015
2834,22996612,"Phase I study of axitinib combined with paclitaxel, docetaxel or capecitabine in patients with advanced solid tumours.",http://www.ncbi.nlm.nih.gov/pubmed/22996612
2835,24495407,Loss of CDKN2A expression is a frequent event in primary invasive melanoma and correlates with sensitivity to the CDK4/6 inhibitor PD0332991 in melanoma cell lines.,http://www.ncbi.nlm.nih.gov/pubmed/24495407
2836,25378936,"The effects of ponatinib, a multi-targeted tyrosine kinase inhibitor, against human U87 malignant glioblastoma cells.",http://www.ncbi.nlm.nih.gov/pubmed/25378936
2837,25421643,The effect of bevacizumab on vestibular schwannoma tumour size and hearing in patients with neurofibromatosis type 2.,http://www.ncbi.nlm.nih.gov/pubmed/25421643
2838,12777976,The effect of flavopiridol on the growth of p16+ and p16- melanoma cell lines.,http://www.ncbi.nlm.nih.gov/pubmed/12777976
2839,21727212,Nilotinib alone or in combination with selumetinib is a drug candidate for neurofibromatosis type 2.,http://www.ncbi.nlm.nih.gov/pubmed/21727212
2840,23347136,"Anti-tumour efficacy on glioma models of PHA-848125, a multi-kinase inhibitor able to cross the blood-brain barrier.",http://www.ncbi.nlm.nih.gov/pubmed/23347136
2841,21800959,The molecular biology and novel treatments of vestibular schwannomas.,http://www.ncbi.nlm.nih.gov/pubmed/21800959
2842,18653327,"Open-label, non-randomised, inter-individual dose escalation of ZK 304709 with the evaluation of safety, tolerability, pharmacokinetics, oral bioavailability and orientating efficacy after daily administration in patients with advanced cancer (7 d treatment and 14 d recovery).",http://www.ncbi.nlm.nih.gov/pubmed/18653327
2843,18692501,Genetic alteration of Keap1 confers constitutive Nrf2 activation and resistance to chemotherapy in gallbladder cancer.,http://www.ncbi.nlm.nih.gov/pubmed/18692501
2844,21810918,"A phase I pharmacokinetic and pharmacodynamic study of dalotuzumab (MK-0646), an anti-insulin-like growth factor-1 receptor monoclonal antibody, in patients with advanced solid tumors.",http://www.ncbi.nlm.nih.gov/pubmed/21810918
2845,24246155,Bazedoxifene/conjugated estrogens for managing the burden of estrogen deficiency symptoms.,http://www.ncbi.nlm.nih.gov/pubmed/24246155
2846,25486082,A simplified strategy for studying the etiology of viral diseases: Apple stem grooving virus as a case study.,http://www.ncbi.nlm.nih.gov/pubmed/25486082
2847,25684082,Perspective on prescribing conjugated estrogens/bazedoxifene for estrogen-deficiency symptoms of menopause: a practical guide.,http://www.ncbi.nlm.nih.gov/pubmed/25684082
2848,15961563,Bazedoxifene acetate: a selective estrogen receptor modulator with improved selectivity.,http://www.ncbi.nlm.nih.gov/pubmed/15961563
2849,25926740,"GSK1838705A, an insulin-like growth factor-1 receptor/insulin receptor inhibitor, induces apoptosis and reduces viability of docetaxel-resistant prostate cancer cells both in vitro and in vivo.",http://www.ncbi.nlm.nih.gov/pubmed/25926740
2850,21875414,Insulin-like growth factor: current concepts and new developments in cancer therapy.,http://www.ncbi.nlm.nih.gov/pubmed/21875414
2851,20591650,Anti-insulin-like growth factor 1 receptor antibody EM164 (murine AVE1642) exhibits anti-tumour activity alone and in combination with temozolomide against neuroblastoma.,http://www.ncbi.nlm.nih.gov/pubmed/20591650
2852,23104723,"Phase I study of humanized monoclonal antibody AVE1642 directed against the type 1 insulin-like growth factor receptor (IGF-1R), administered in combination with anticancer therapies to patients with advanced solid tumors.",http://www.ncbi.nlm.nih.gov/pubmed/23104723
2853,21141739,"The insulin-like growth factor-1 receptor kinase inhibitor, NVP-ADW742, suppresses survival and resistance to chemotherapy in acute myeloid leukemia cells.",http://www.ncbi.nlm.nih.gov/pubmed/21141739
2854,16740780,"Insulin-like growth factor I receptor pathway inhibition by ADW742, alone or in combination with imatinib, doxorubicin, or vincristine, is a novel therapeutic approach in Ewing tumor.",http://www.ncbi.nlm.nih.gov/pubmed/16740780
2855,21295335,Insulin-like growth factor-I receptor inhibition by specific tyrosine kinase inhibitor NVP-AEW541 in endometrioid and serous papillary endometrial cancer cell lines.,http://www.ncbi.nlm.nih.gov/pubmed/21295335
2856,25897243,"BMS-536924, an ATP-competitive IGF-1R/IR inhibitor, decreases viability and migration of temozolomide-resistant glioma cells in vitro and suppresses tumor growth in vivo.",http://www.ncbi.nlm.nih.gov/pubmed/25897243
2857,19383820,"Antitumor activity of GSK1904529A, a small-molecule inhibitor of the insulin-like growth factor-I receptor tyrosine kinase.",http://www.ncbi.nlm.nih.gov/pubmed/19383820
2858,16648580,Diarylureas are small-molecule inhibitors of insulin-like growth factor I receptor signaling and breast cancer cell growth.,http://www.ncbi.nlm.nih.gov/pubmed/16648580
2859,20124453,A fully human insulin-like growth factor-I receptor antibody SCH 717454 (Robatumumab) has antitumor activity as a single agent and in combination with cytotoxics in pediatric tumor xenografts.,http://www.ncbi.nlm.nih.gov/pubmed/20124453
2860,24458261,"A phase 1, open-label, dose-escalation study of BIIB022 (anti-IGF-1R monoclonal antibody) in subjects with relapsed or refractory solid tumors.",http://www.ncbi.nlm.nih.gov/pubmed/24458261
2861,21659463,Enhanced efficacy of IGF1R inhibition in pediatric glioblastoma by combinatorial targeting of PDGFRα/β.,http://www.ncbi.nlm.nih.gov/pubmed/21659463
2862,24900195,Discovery of Dinaciclib (SCH 727965): A Potent and Selective Inhibitor of Cyclin-Dependent Kinases.,http://www.ncbi.nlm.nih.gov/pubmed/24900195
2863,12663439,Sensitivity toward tyrosine kinase inhibitors varies between different activating mutations of the FLT3 receptor.,http://www.ncbi.nlm.nih.gov/pubmed/12663439
2864,24717435,Copper is required for oncogenic BRAF signalling and tumorigenesis.,http://www.ncbi.nlm.nih.gov/pubmed/24717435
2865,8626452,"The mitogen-activated protein kinase phosphatases PAC1, MKP-1, and MKP-2 have unique substrate specificities and reduced activity in vivo toward the ERK2 sevenmaker mutation.",http://www.ncbi.nlm.nih.gov/pubmed/8626452
2866,20385094,ERK2 but not ERK1 induces epithelial-to-mesenchymal transformation via DEF motif-dependent signaling events.,http://www.ncbi.nlm.nih.gov/pubmed/20385094
2867,16273204,"A mutation in the common docking domain of ERK2 in a human cancer cell line, which was associated with its constitutive phosphorylation.",http://www.ncbi.nlm.nih.gov/pubmed/16273204
2868,25320010,ERK mutations confer resistance to mitogen-activated protein kinase pathway inhibitors.,http://www.ncbi.nlm.nih.gov/pubmed/25320010
2869,9604935,Phosphorylation of the MAP kinase ERK2 promotes its homodimerization and nuclear translocation.,http://www.ncbi.nlm.nih.gov/pubmed/9604935
2870,11113199,"Biochemical and biological functions of the N-terminal, noncatalytic domain of extracellular signal-regulated kinase 2.",http://www.ncbi.nlm.nih.gov/pubmed/11113199
2871,15520202,"SD-208, a novel transforming growth factor beta receptor I kinase inhibitor, inhibits growth and invasiveness and enhances immunogenicity of murine and human glioma cells in vitro and in vivo.",http://www.ncbi.nlm.nih.gov/pubmed/15520202
2872,15183116,Selective inhibitors of type I receptor kinase block cellular transforming growth factor-beta signaling.,http://www.ncbi.nlm.nih.gov/pubmed/15183116
2873,15289325,Targeting endogenous transforming growth factor beta receptor signaling in SMAD4-deficient human pancreatic carcinoma cells inhibits their invasive phenotype1.,http://www.ncbi.nlm.nih.gov/pubmed/15289325
2874,20363976,Selective inhibition of JAK1 and JAK2 is efficacious in rodent models of arthritis: preclinical characterization of INCB028050.,http://www.ncbi.nlm.nih.gov/pubmed/20363976
2875,19295546,"CYT387, a selective JAK1/JAK2 inhibitor: in vitro assessment of kinase selectivity and preclinical studies using cell lines and primary cells from polycythemia vera patients.",http://www.ncbi.nlm.nih.gov/pubmed/19295546
2876,24006460,"Preclinical characterization of GLPG0634, a selective inhibitor of JAK1, for the treatment of inflammatory diseases.",http://www.ncbi.nlm.nih.gov/pubmed/24006460
2877,17332368,A novel small-molecule inhibitor of transforming growth factor beta type I receptor kinase (SM16) inhibits murine mesothelioma tumor growth in vivo and prevents tumor recurrence after surgical resection.,http://www.ncbi.nlm.nih.gov/pubmed/17332368
2878,25704750,"A phase 2a randomized, double-blind, placebo-controlled, sequential dose-escalation study to evaluate the efficacy and safety of ASP015K, a novel Janus kinase inhibitor, in patients with moderate-to-severe psoriasis.",http://www.ncbi.nlm.nih.gov/pubmed/25704750
2879,,BRAIN TUMOUR INITIATING CELLS AND TARGETING STAT3 ONCOGENIC SIGNALLING IN GBM,http://neuro-oncology.oxfordjournals.org/content/16/suppl_3/iii35.2.abstract
2880,16271073,The ALK-5 inhibitor A-83-01 inhibits Smad signaling and epithelial-to-mesenchymal transition by transforming growth factor-beta.,http://www.ncbi.nlm.nih.gov/pubmed/16271073
2881,17522330,Inhibiting TGF-beta signaling restores immune surveillance in the SMA-560 glioma model.,http://www.ncbi.nlm.nih.gov/pubmed/17522330
2882,18951571,"Effect of IN-1130, a small molecule inhibitor of transforming growth factor-beta type I receptor/activin receptor-like kinase-5, on prostate cancer cells.",http://www.ncbi.nlm.nih.gov/pubmed/18951571
2883,24887560,"An novel inhibitor of TGF-β type I receptor, IN-1130, blocks breast cancer lung metastasis through inhibition of epithelial-mesenchymal transition.",http://www.ncbi.nlm.nih.gov/pubmed/24887560
2884,16024632,Epigenetic reactivation of tumor suppressor genes by a novel small-molecule inhibitor of human DNA methyltransferases.,http://www.ncbi.nlm.nih.gov/pubmed/16024632
2885,19138966,Long-term epigenetic therapy with oral zebularine has minimal side effects and prevents intestinal tumors in mice.,http://www.ncbi.nlm.nih.gov/pubmed/19138966
2886,25123819,Can we unlock the potential of IGF-1R inhibition in cancer therapy?,http://www.ncbi.nlm.nih.gov/pubmed/25123819
2887,22722925,Mutations in DNA methyltransferase (DNMT3A) observed in acute myeloid leukemia patients disrupt processive methylation.,http://www.ncbi.nlm.nih.gov/pubmed/22722925
2888,21549127,ICF syndrome mutations cause a broad spectrum of biochemical defects in DNMT3B-mediated de novo DNA methylation.,http://www.ncbi.nlm.nih.gov/pubmed/21549127
2889,7652577,A p16INK4a-insensitive CDK4 mutant targeted by cytolytic T lymphocytes in a human melanoma.,http://www.ncbi.nlm.nih.gov/pubmed/7652577
2890,10617466,Pharmacological rescue of mutant p53 conformation and function.,http://www.ncbi.nlm.nih.gov/pubmed/10617466
2891,25028469,Antiproliferative effects of CDK4/6 inhibition in CDK4-amplified human liposarcoma in vitro and in vivo.,http://www.ncbi.nlm.nih.gov/pubmed/25028469
2892,22374332,The cyclin-dependent kinase inhibitor flavopiridol potentiates doxorubicin efficacy in advanced sarcomas: preclinical investigations and results of a phase I dose-escalation clinical trial.,http://www.ncbi.nlm.nih.gov/pubmed/22374332
2893,19238148,"Cell cycle, CDKs and cancer: a changing paradigm.",http://www.ncbi.nlm.nih.gov/pubmed/19238148
2894,24529257,D-2-Hydroxyglutarate producing neo-enzymatic activity inversely correlates with frequency of the type of isocitrate dehydrogenase 1 mutations found in glioma.,http://www.ncbi.nlm.nih.gov/pubmed/24529257
2895,15345593,Identification of a novel activating mutation (Y842C) within the activation loop of FLT3 in patients with acute myeloid leukemia (AML).,http://www.ncbi.nlm.nih.gov/pubmed/15345593
2896,12970773,FLT3: ITDoes matter in leukemia.,http://www.ncbi.nlm.nih.gov/pubmed/12970773
2897,9737679,Internal tandem duplication of the FLT3 gene is a novel modality of elongation mutation which causes constitutive activation of the product.,http://www.ncbi.nlm.nih.gov/pubmed/9737679
2898,11090077,Flt3 mutations from patients with acute myeloid leukemia induce transformation of 32D cells mediated by the Ras and STAT5 pathways.,http://www.ncbi.nlm.nih.gov/pubmed/11090077
2899,16684964,Identification of Y589 and Y599 in the juxtamembrane domain of Flt3 as ligand-induced autophosphorylation sites involved in binding of Src family kinases and the protein tyrosine phosphatase SHP2.,http://www.ncbi.nlm.nih.gov/pubmed/16684964
2900,25533676,"VHL, the story of a tumour suppressor gene.",http://www.ncbi.nlm.nih.gov/pubmed/25533676
2901,22105611,Pilot trial of sunitinib therapy in patients with von Hippel-Lindau disease.,http://www.ncbi.nlm.nih.gov/pubmed/22105611
2902,22931246,Tumor microvasculature with endothelial fenestrations in VHL null clear cell renal cell carcinomas as a potent target of anti-angiogenic therapy.,http://www.ncbi.nlm.nih.gov/pubmed/22931246
2903,16410449,Point mutations in the juxtamembrane domain of FLT3 define a new class of activating mutations in AML.,http://www.ncbi.nlm.nih.gov/pubmed/16410449
2904,24814347,The DNA-binding domain mediates both nuclear and cytosolic functions of p53.,http://www.ncbi.nlm.nih.gov/pubmed/24814347
2905,23674492,"NMS-E973, a novel synthetic inhibitor of Hsp90 with activity against multiple models of drug resistance to targeted agents, including intracranial metastases.",http://www.ncbi.nlm.nih.gov/pubmed/23674492
2906,22181674,"The heat shock protein 90 inhibitor, AT13387, displays a long duration of action in vitro and in vivo in non-small cell lung cancer.",http://www.ncbi.nlm.nih.gov/pubmed/22181674
2907,22714264,"The HSP90 inhibitor, AT13387, is effective against imatinib-sensitive and -resistant gastrointestinal stromal tumor models.",http://www.ncbi.nlm.nih.gov/pubmed/22714264
2908,20406843,"New molecular and biological mechanism of antitumor activities of KW-2478, a novel nonansamycin heat shock protein 90 inhibitor, in multiple myeloma cells.",http://www.ncbi.nlm.nih.gov/pubmed/20406843
2909,17363486,"In vitro antitumor properties of a novel cyclin-dependent kinase inhibitor, P276-00.",http://www.ncbi.nlm.nih.gov/pubmed/17363486
2910,15791458,"In vivo antitumor efficacy of 17-DMAG (17-dimethylaminoethylamino-17-demethoxygeldanamycin hydrochloride), a water-soluble geldanamycin derivative.",http://www.ncbi.nlm.nih.gov/pubmed/15791458
2911,21821931,"SNX-2112, a novel Hsp90 inhibitor, induces G2/M cell cycle arrest and apoptosis in MCF-7 cells.",http://www.ncbi.nlm.nih.gov/pubmed/21821931
2912,22447251,The heat shock protein 90 inhibitor SNX-2112 inhibits B16 melanoma cell growth in vitro and in vivo.,http://www.ncbi.nlm.nih.gov/pubmed/22447251
2913,24369839,"Design and synthesis of 2-amino-6-(1H,3H-benzo[de]isochromen-6-yl)-1,3,5-triazines as novel Hsp90 inhibitors.",http://www.ncbi.nlm.nih.gov/pubmed/24369839
2914,19372565,"BIIB021, an orally available, fully synthetic small-molecule inhibitor of the heat shock protein Hsp90.",http://www.ncbi.nlm.nih.gov/pubmed/19372565
2915,25955495,Role of the novel HSP90 inhibitor AUY922 in hepatocellular carcinoma: Potential for therapy.,http://www.ncbi.nlm.nih.gov/pubmed/25955495
2916,18413753,"NVP-AUY922: a novel heat shock protein 90 inhibitor active against xenograft tumor growth, angiogenesis, and metastasis.",http://www.ncbi.nlm.nih.gov/pubmed/18413753
2917,25501124,Dual inhibition of Bcr-Abl and Hsp90 by C086 potently inhibits the proliferation of imatinib-resistant CML cells.,http://www.ncbi.nlm.nih.gov/pubmed/25501124
2918,25416789,"TAS-116, a highly selective inhibitor of heat shock protein 90α and β, demonstrates potent antitumor activity and minimal ocular toxicity in preclinical models.",http://www.ncbi.nlm.nih.gov/pubmed/25416789
2919,25117641,"Anti-tumor activity of WK88-1, a novel geldanamycin derivative, in gefitinib-resistant non-small cell lung cancers with Met amplification.",http://www.ncbi.nlm.nih.gov/pubmed/25117641
2920,23714726,Therapeutic potential of HSP90 inhibition for neurofibromatosis type 2.,http://www.ncbi.nlm.nih.gov/pubmed/23714726
2921,20643786,The novel Hsp90 inhibitor NXD30001 induces tumor regression in a genetically engineered mouse model of glioblastoma multiforme.,http://www.ncbi.nlm.nih.gov/pubmed/20643786
2922,21715568,"Effective targeting of triple-negative breast cancer cells by PF-4942847, a novel oral inhibitor of Hsp 90.",http://www.ncbi.nlm.nih.gov/pubmed/21715568
2923,21737509,"The Novel HSP90 inhibitor, IPI-493, is highly effective in human gastrostrointestinal stromal tumor xenografts carrying heterogeneous KIT mutations.",http://www.ncbi.nlm.nih.gov/pubmed/21737509
2924,23538902,"Inhibition of Wee1, AKT, and CDK4 underlies the efficacy of the HSP90 inhibitor XL888 in an in vivo model of NRAS-mutant melanoma.",http://www.ncbi.nlm.nih.gov/pubmed/23538902
2925,22877636,Discovery of XL888: a novel tropane-derived small molecule inhibitor of HSP90.,http://www.ncbi.nlm.nih.gov/pubmed/22877636
2926,22246440,The novel oral Hsp90 inhibitor NVP-HSP990 exhibits potent and broad-spectrum antitumor activities in vitro and in vivo.,http://www.ncbi.nlm.nih.gov/pubmed/22246440
2927,23002124,U.S. Food and Drug Administration Approval: peginterferon-alfa-2b for the adjuvant treatment of patients with melanoma.,http://www.ncbi.nlm.nih.gov/pubmed/23002124
2928,25587654,The JAK-STAT pathway: impact on human disease and therapeutic intervention.,http://www.ncbi.nlm.nih.gov/pubmed/25587654
2929,16953837,Growth inhibitory effects of pegylated IFN alpha-2b on human liver cancer cells in vitro and in vivo.,http://www.ncbi.nlm.nih.gov/pubmed/16953837
2930,25762693,VX-509 (decernotinib) is a potent and selective janus kinase 3 inhibitor that attenuates inflammation in animal models of autoimmune disease.,http://www.ncbi.nlm.nih.gov/pubmed/25762693
2931,23584399,"Discovery and characterization of LY2784544, a small-molecule tyrosine kinase inhibitor of JAK2V617F.",http://www.ncbi.nlm.nih.gov/pubmed/23584399
2932,22027691,Therapeutic potential of AZD1480 for the treatment of human glioblastoma.,http://www.ncbi.nlm.nih.gov/pubmed/22027691
2933,23127890,SAR and in vivo evaluation of 4-aryl-2-aminoalkylpyrimidines as potent and selective Janus kinase 2 (JAK2) inhibitors.,http://www.ncbi.nlm.nih.gov/pubmed/23127890
2934,22015772,"Characterization of BMS-911543, a functionally selective small-molecule inhibitor of JAK2.",http://www.ncbi.nlm.nih.gov/pubmed/22015772
2935,24413068,"Effect of NS-018, a selective JAK2V617F inhibitor, in a murine model of myelofibrosis.",http://www.ncbi.nlm.nih.gov/pubmed/24413068
2936,22829185,"Efficacy of NS-018, a potent and selective JAK2/Src inhibitor, in primary cells and mouse models of myeloproliferative neoplasms.",http://www.ncbi.nlm.nih.gov/pubmed/22829185
2937,11687575,Mitogen-activated protein kinase phosphorylates and negatively regulates basic helix-loop-helix-PAS transcription factor BMAL1.,http://www.ncbi.nlm.nih.gov/pubmed/11687575
2938,9201297,"The SH3 domain of Bruton's tyrosine kinase interacts with Vav, Sam68 and EWS.",http://www.ncbi.nlm.nih.gov/pubmed/9201297
2939,1676428,Tyrphostins. 2. Heterocyclic and alpha-substituted benzylidenemalononitrile tyrphostins as potent inhibitors of EGF receptor and ErbB2/neu tyrosine kinases.,http://www.ncbi.nlm.nih.gov/pubmed/1676428
2940,8628398,Inhibition of acute lymphoblastic leukaemia by a Jak-2 inhibitor.,http://www.ncbi.nlm.nih.gov/pubmed/8628398
2941,18245540,"WP1066, a novel JAK2 inhibitor, suppresses proliferation and induces apoptosis in erythroid human cells carrying the JAK2 V617F mutation.",http://www.ncbi.nlm.nih.gov/pubmed/18245540
2942,21792892,The tumor microenvironment expression of p-STAT3 influences the efficacy of cyclophosphamide with WP1066 in murine melanoma models.,http://www.ncbi.nlm.nih.gov/pubmed/21792892
2943,20587663,Potent and selective inhibition of polycythemia by the quinoxaline JAK2 inhibitor NVP-BSK805.,http://www.ncbi.nlm.nih.gov/pubmed/20587663
2944,21207414,Expression of p-JAK2 predicts clinical outcome and is a potential molecular target of acute myelogenous leukemia.,http://www.ncbi.nlm.nih.gov/pubmed/21207414
2945,22334590,"Therapeutic efficacy of CEP-33779, a novel selective JAK2 inhibitor, in a mouse model of colitis-induced colorectal cancer.",http://www.ncbi.nlm.nih.gov/pubmed/22334590
2946,,A phase 1b/2 study of LEE011 in combination with binimetinib (MEK162) in patients with NRAS-mutant melanoma: Early encouraging clinical activity,http://meetinglibrary.asco.org/content/130034-144
2947,,"A first-in-human phase I study of the CDK4/6 inhibitor, LY2835219, for patients with advanced cancer",http://meetinglibrary.asco.org/content/111069-132
2948,23898052,"PD-0332991, a potent and selective inhibitor of cyclin-dependent kinase 4/6, demonstrates inhibition of proliferation in renal cell carcinoma at nanomolar concentrations and molecular markers predict for sensitivity.",http://www.ncbi.nlm.nih.gov/pubmed/23898052
2949,18829975,"The oral multitarget tumour growth inhibitor, ZK 304709, inhibits growth of pancreatic neuroendocrine tumours in an orthotopic mouse model.",http://www.ncbi.nlm.nih.gov/pubmed/18829975
2950,22031796,Heat shock protein as molecular targets for breast cancer therapeutics.,http://www.ncbi.nlm.nih.gov/pubmed/22031796
2951,25583084,Dehydrocrenatidine is a novel janus kinase inhibitor.,http://www.ncbi.nlm.nih.gov/pubmed/25583084
2952,25387665,Pharmacological properties of JTE-052: a novel potent JAK inhibitor that suppresses various inflammatory responses in vitro and in vivo.,http://www.ncbi.nlm.nih.gov/pubmed/25387665
2953,22295124,ELR510444 inhibits tumor growth and angiogenesis by abrogating HIF activity and disrupting microtubules in renal cell carcinoma.,http://www.ncbi.nlm.nih.gov/pubmed/22295124
2954,20717479,A Non-ATP-Competitive Dual Inhibitor of JAK2 and BCR-ABL Kinases: Elucidation of a Novel Therapeutic Spectrum Based on Substrate Competitive Inhibition.,http://www.ncbi.nlm.nih.gov/pubmed/20717479
2955,17145886,Protein kinase C beta enhances growth and expression of cyclin D1 in human breast cancer cells.,http://www.ncbi.nlm.nih.gov/pubmed/17145886
2956,22351686,The HSP90 inhibitor XL888 overcomes BRAF inhibitor resistance mediated through diverse mechanisms.,http://www.ncbi.nlm.nih.gov/pubmed/22351686
2957,18483305,"LS104, a non-ATP-competitive small-molecule inhibitor of JAK2, is potently inducing apoptosis in JAK2V617F-positive cells.",http://www.ncbi.nlm.nih.gov/pubmed/18483305
2958,18094329,The specificity of JAK3 kinase inhibitors.,http://www.ncbi.nlm.nih.gov/pubmed/18094329
2959,21107323,Melanomas acquire resistance to B-RAF(V600E) inhibition by RTK or N-RAS upregulation.,http://www.ncbi.nlm.nih.gov/pubmed/21107323
2960,18804034,Identification of chemical inhibitors to human tissue transglutaminase by screening existing drug libraries.,http://www.ncbi.nlm.nih.gov/pubmed/18804034
2961,10741557,Naphthyl ketones: a new class of Janus kinase 3 inhibitors.,http://www.ncbi.nlm.nih.gov/pubmed/10741557
2962,,A randomized phase II study of GDC-0980 versus everolimus in metastatic renal cell carcinoma (mRCC) patients (pts) after VEGF-targeted therapy (VEGF-TT),http://meetinglibrary.asco.org/content/132562-144
2963,20072651,"INCB16562, a JAK1/2 selective inhibitor, is efficacious against multiple myeloma cells and reverses the protective effects of cytokine and stromal cell support.",http://www.ncbi.nlm.nih.gov/pubmed/20072651
2964,25336693,"First-in-human phase I dose escalation study of a second-generation non-ansamycin HSP90 inhibitor, AT13387, in patients with advanced solid tumors.",http://www.ncbi.nlm.nih.gov/pubmed/25336693
2965,17018630,"Pyridone 6, a pan-Janus-activated kinase inhibitor, induces growth inhibition of multiple myeloma cells.",http://www.ncbi.nlm.nih.gov/pubmed/17018630
2966,19139110,Janus kinase inhibitor INCB20 has antiproliferative and apoptotic effects on human myeloma cells in vitro and in vivo.,http://www.ncbi.nlm.nih.gov/pubmed/19139110
2967,23569315,Multicenter phase II study of neoadjuvant lapatinib and trastuzumab with hormonal therapy and without chemotherapy in patients with human epidermal growth factor receptor 2-overexpressing breast cancer: TBCRC 006.,http://www.ncbi.nlm.nih.gov/pubmed/23569315
2968,21553822,Engineering an antibiotic to fight cancer: optimization of the novobiocin scaffold to produce anti-proliferative agents.,http://www.ncbi.nlm.nih.gov/pubmed/21553822
2969,10945979,The heat shock protein 90 antagonist novobiocin interacts with a previously unrecognized ATP-binding domain in the carboxyl terminus of the chaperone.,http://www.ncbi.nlm.nih.gov/pubmed/10945979
2970,15867383,Cooperation between Cdk4 and p27kip1 in tumor development: a preclinical model to evaluate cell cycle inhibitors with therapeutic activity.,http://www.ncbi.nlm.nih.gov/pubmed/15867383
2971,25077897,The HSP90 inhibitor ganetespib potentiates the antitumor activity of EGFR tyrosine kinase inhibition in mutant and wild-type non-small cell lung cancer.,http://www.ncbi.nlm.nih.gov/pubmed/25077897
2972,24623852,Crenolanib is a selective type I pan-FLT3 inhibitor.,http://www.ncbi.nlm.nih.gov/pubmed/24623852
2973,17300186,Flipped out: structure-guided design of selective pyrazolylpyrrole ERK inhibitors.,http://www.ncbi.nlm.nih.gov/pubmed/17300186
2974,19827834,Structure-guided design of potent and selective pyrimidylpyrrole inhibitors of extracellular signal-regulated kinase (ERK) using conformational control.,http://www.ncbi.nlm.nih.gov/pubmed/19827834
2975,12955092,Cyclin D1 gene (CCND1) mutations in endometrial cancer.,http://www.ncbi.nlm.nih.gov/pubmed/12955092
2976,23733133,Cyclin D1 harboring the T286I mutation promotes oncogenic activation in endometrial cancer.,http://www.ncbi.nlm.nih.gov/pubmed/23733133
2977,16247460,Expression of constitutively nuclear cyclin D1 in murine lymphocytes induces B-cell lymphoma.,http://www.ncbi.nlm.nih.gov/pubmed/16247460
2978,21637161,An in-vitro evaluation of the polo-like kinase inhibitor GW843682X against paediatric malignancies.,http://www.ncbi.nlm.nih.gov/pubmed/21637161
2979,22319201,"NMS-P937, an orally available, specific small-molecule polo-like kinase 1 inhibitor with antitumor activity in solid and hematologic malignancies.",http://www.ncbi.nlm.nih.gov/pubmed/22319201
2980,15766665,"ON01910, a non-ATP-competitive small molecule inhibitor of Plk1, is a potent anticancer agent.",http://www.ncbi.nlm.nih.gov/pubmed/15766665
2981,23670175,Sensitivity and resistance of JAK2 inhibitors to myeloproliferative neoplasms.,http://www.ncbi.nlm.nih.gov/pubmed/23670175
2982,20486473,"Prevention of UVB-induced skin inflammation, genotoxicity, and photocarcinogenesis in mice by WHI-P131, a dual-function inhibitor of Janus kinase 3 and EGF receptor kinase.",http://www.ncbi.nlm.nih.gov/pubmed/20486473
2983,20924972,Chemoprevention of colorectal cancer by targeting Janus kinase 3 with a rationally designed small molecule inhibitor.,http://www.ncbi.nlm.nih.gov/pubmed/20924972
2984,11290504,Transcription factors in mouse lung development and function.,http://www.ncbi.nlm.nih.gov/pubmed/11290504
2985,22819198,Jakinibs: a new class of kinase inhibitors in cancer and autoimmune disease.,http://www.ncbi.nlm.nih.gov/pubmed/22819198
2986,23539448,Androgen receptor-independent function of FoxA1 in prostate cancer metastasis.,http://www.ncbi.nlm.nih.gov/pubmed/23539448
2987,12781364,PKC412 overcomes resistance to imatinib in a murine model of FIP1L1-PDGFRα-induced myeloproliferative disease.,http://www.ncbi.nlm.nih.gov/pubmed/12781364
2988,12660384,A tyrosine kinase created by fusion of the PDGFRA and FIP1L1 genes as a therapeutic target of imatinib in idiopathic hypereosinophilic syndrome.,http://www.ncbi.nlm.nih.gov/pubmed/12660384
2989,19071955,Analysis of germline GLI1 variation implicates hedgehog signalling in the regulation of intestinal inflammatory pathways.,http://www.ncbi.nlm.nih.gov/pubmed/19071955
2990,18843283,Five years since the discovery of FIP1L1-PDGFRA: what we have learned about the fusion and other molecularly defined eosinophilias.,http://www.ncbi.nlm.nih.gov/pubmed/18843283
2991,25217444,Selective inhibitors of the Janus kinase Jak3--Are they effective?,http://www.ncbi.nlm.nih.gov/pubmed/25217444
2992,16341243,Hypoxia-inducible factor determines sensitivity to inhibitors of mTOR in kidney cancer.,http://www.ncbi.nlm.nih.gov/pubmed/16341243
2993,15994174,A previously unidentified amino-terminal domain regulates transcriptional activity of wild-type and disease-associated human GLI2.,http://www.ncbi.nlm.nih.gov/pubmed/15994174
2994,10441342,Point mutations throughout the GLI3 gene cause Greig cephalopolysyndactyly syndrome.,http://www.ncbi.nlm.nih.gov/pubmed/10441342
2996,25045626,"Androgen receptor gene mutation, rearrangement, polymorphism.",http://www.ncbi.nlm.nih.gov/pubmed/25045626
2997,25945058,Enzalutamide for patients with metastatic castration-resistant prostate cancer.,http://www.ncbi.nlm.nih.gov/pubmed/25945058
2998,24881730,Enzalutamide in metastatic prostate cancer before chemotherapy.,http://www.ncbi.nlm.nih.gov/pubmed/24881730
2999,,"Abstract 2799: BAY 1082439, a highly selective and balanced PI3K?/? inhibitor demonstrated potent activity in tumors with activated PI3K? and loss-of-function of PTEN",http://cancerres.aacrjournals.org/content/72/8_Supplement/2799.short
3000,25805799,First-in-Human Pharmacokinetic and Pharmacodynamic Study of the Dual m-TORC 1/2 Inhibitor AZD2014.,http://www.ncbi.nlm.nih.gov/pubmed/25805799
3001,24601221,More antitumor efficacy of the PI3K inhibitor GDC-0941 in breast cancer with PIK3CA mutation or HER2 amplification status in vitro.,http://www.ncbi.nlm.nih.gov/pubmed/24601221
3002,25252916,Plk1 inhibition enhances the efficacy of androgen signaling blockade in castration-resistant prostate cancer.,http://www.ncbi.nlm.nih.gov/pubmed/25252916
3003,25609585,The epigenetic modifier EZH2 controls melanoma growth and metastasis through silencing of distinct tumour suppressors.,http://www.ncbi.nlm.nih.gov/pubmed/25609585
3004,25634071,"CH5137291, an androgen receptor nuclear translocation-inhibiting compound, inhibits the growth of castration-resistant prostate cancer cells.",http://www.ncbi.nlm.nih.gov/pubmed/25634071
3005,21050768,Design and synthesis of an androgen receptor pure antagonist (CH5137291) for the treatment of castration-resistant prostate cancer.,http://www.ncbi.nlm.nih.gov/pubmed/21050768
3006,23779130,A clinically relevant androgen receptor mutation confers resistance to second-generation antiandrogens enzalutamide and ARN-509.,http://www.ncbi.nlm.nih.gov/pubmed/23779130
3007,22378068,Therapeutic metformin/AMPK activation blocked lymphoma cell growth via inhibition of mTOR pathway and induction of autophagy.,http://www.ncbi.nlm.nih.gov/pubmed/22378068
3008,22558078,Characterization of cyclin E expression in multiple myeloma and its functional role in seliciclib-induced apoptotic cell death.,http://www.ncbi.nlm.nih.gov/pubmed/22558078
3009,15231645,"Akt/protein kinase B signaling inhibitor-2, a selective small molecule inhibitor of Akt signaling with antitumor activity in cancer cells overexpressing Akt.",http://www.ncbi.nlm.nih.gov/pubmed/15231645
3010,22245973,Phase II trial of temsirolimus in patients with metastatic breast cancer.,http://www.ncbi.nlm.nih.gov/pubmed/22245973
3011,16266977,Antiandrogen bicalutamide promotes tumor growth in a novel androgen-dependent prostate cancer xenograft model derived from a bicalutamide-treated patient.,http://www.ncbi.nlm.nih.gov/pubmed/16266977
3012,19790238,Antiandrogen withdrawal syndrome and alternative antiandrogen therapy associated with the W741C mutant androgen receptor in a novel prostate cancer xenograft.,http://www.ncbi.nlm.nih.gov/pubmed/19790238
3013,20878136,The antiandrogen bicalutamide activates the androgen receptor (AR) with a mutation in codon 741 through the mitogen activated protein kinase (MARK) pathway in human prostate cancer PC3 cells.,http://www.ncbi.nlm.nih.gov/pubmed/20878136
3014,25563847,Switching and withdrawing hormonal agents for castration-resistant prostate cancer.,http://www.ncbi.nlm.nih.gov/pubmed/25563847
3015,12517791,Novel mutations of androgen receptor: a possible mechanism of bicalutamide withdrawal syndrome.,http://www.ncbi.nlm.nih.gov/pubmed/12517791
3016,21138753,The antiprogestin Lonaprisan inhibits breast cancer cell proliferation by inducing p21 expression.,http://www.ncbi.nlm.nih.gov/pubmed/21138753
3017,23180967,A study of mifepristone/IFN-γ-induced apoptosis of human cholangiocarcinoma cell line FRH-0201 in vitro.,http://www.ncbi.nlm.nih.gov/pubmed/23180967
3018,19654297,"Discovery of BMS-641988, a novel and potent inhibitor of androgen receptor signaling for the treatment of prostate cancer.",http://www.ncbi.nlm.nih.gov/pubmed/19654297
3019,21119048,"CDB-4124, a progesterone receptor modulator, inhibits mammary carcinogenesis by suppressing cell proliferation and inducing apoptosis.",http://www.ncbi.nlm.nih.gov/pubmed/21119048
3020,20043998,In vitro characterization of ZK 230211--A type III progesterone receptor antagonist with enhanced antiproliferative properties.,http://www.ncbi.nlm.nih.gov/pubmed/20043998
3021,19223503,Phospho-p70S6K/p85S6K and cdc2/cdk1 are novel targets for diffuse large B-cell lymphoma combination therapy.,http://www.ncbi.nlm.nih.gov/pubmed/19223503
3022,23861347,AZD3514: a small molecule that modulates androgen receptor signaling and function in vitro and in vivo.,http://www.ncbi.nlm.nih.gov/pubmed/23861347
3023,21092758,CYP17 inhibitors for prostate cancer therapy.,http://www.ncbi.nlm.nih.gov/pubmed/21092758
3024,24044547,Is mTOR inhibition a systemic treatment for tuberous sclerosis?,http://www.ncbi.nlm.nih.gov/pubmed/24044547
3025,22294205,Microglial stimulation of glioblastoma invasion involves epidermal growth factor receptor (EGFR) and colony stimulating factor 1 receptor (CSF-1R) signaling.,http://www.ncbi.nlm.nih.gov/pubmed/22294205
3026,25993548,Targeting cells of the myeloid lineage attenuates pain and disease progression in a prostate model of bone cancer.,http://www.ncbi.nlm.nih.gov/pubmed/25993548
3027,25847190,"Characterizing and Overriding the Structural Mechanism of the Quizartinib-Resistant FLT3 ""Gatekeeper"" F691L Mutation with PLX3397.",http://www.ncbi.nlm.nih.gov/pubmed/25847190
3028,23430109,Activity of ponatinib against clinically-relevant AC220-resistant kinase domain mutants of FLT3-ITD.,http://www.ncbi.nlm.nih.gov/pubmed/23430109
3029,19318574,FMS-like tyrosine kinase 3-internal tandem duplication tyrosine kinase inhibitors display a nonoverlapping profile of resistance mutations in vitro.,http://www.ncbi.nlm.nih.gov/pubmed/19318574
3030,22271575,Genetic resistance to JAK2 enzymatic inhibitors is overcome by HSP90 inhibition.,http://www.ncbi.nlm.nih.gov/pubmed/22271575
3031,22916261,Random mutagenesis reveals residues of JAK2 critical in evading inhibition by a tyrosine kinase inhibitor.,http://www.ncbi.nlm.nih.gov/pubmed/22916261
3032,22019729,Attention induces conservative subjective biases in visual perception.,http://www.ncbi.nlm.nih.gov/pubmed/22019729
3033,11108884,Preclinical experience with two selective progesterone receptor modulators on breast and endometrium.,http://www.ncbi.nlm.nih.gov/pubmed/11108884
3034,17604001,Suppression of cytokine response by GATA inhibitor K-7174 via unfolded protein response.,http://www.ncbi.nlm.nih.gov/pubmed/17604001
3035,10833420,"A novel cell adhesion inhibitor, K-7174, reduces the endothelial VCAM-1 induction by inflammatory cytokines, acting through the regulation of GATA.",http://www.ncbi.nlm.nih.gov/pubmed/10833420
3036,24565895,"Preclinical pharmacology of FL442, a novel nonsteroidal androgen receptor modulator.",http://www.ncbi.nlm.nih.gov/pubmed/24565895
3037,9736611,Transformation of hematopoietic cell lines to growth-factor independence and induction of a fatal myelo- and lymphoproliferative disease in mice by retrovirally transduced TEL/JAK2 fusion genes.,http://www.ncbi.nlm.nih.gov/pubmed/9736611
3038,21926964,Kinase domain mutations confer resistance to novel inhibitors targeting JAK2V617F in myeloproliferative neoplasms.,http://www.ncbi.nlm.nih.gov/pubmed/21926964
3039,23748007,"The effects of R683S (G) genetic mutations on the JAK2 activity, structure and stability.",http://www.ncbi.nlm.nih.gov/pubmed/23748007
3040,23009939,Therapy with JAK2 inhibitors for myeloproliferative neoplasms.,http://www.ncbi.nlm.nih.gov/pubmed/23009939
3041,23823659,Specificity and mechanism-of-action of the JAK2 tyrosine kinase inhibitors ruxolitinib and SAR302503 (TG101348).,http://www.ncbi.nlm.nih.gov/pubmed/23823659
3042,25193870,"JAK3 mutants transform hematopoietic cells through JAK1 activation, causing T-cell acute lymphoblastic leukemia in a mouse model.",http://www.ncbi.nlm.nih.gov/pubmed/25193870
3043,15143194,Jak3-independent trafficking of the common gamma chain receptor subunit: chaperone function of Jaks revisited.,http://www.ncbi.nlm.nih.gov/pubmed/15143194
3044,10330181,DIX domains of Dvl and axin are necessary for protein interactions and their ability to regulate beta-catenin stability.,http://www.ncbi.nlm.nih.gov/pubmed/10330181
3045,20215545,Randomized phase II multicenter trial of two schedules of lapatinib as first- or second-line monotherapy in patients with advanced or metastatic non-small cell lung cancer.,http://www.ncbi.nlm.nih.gov/pubmed/20215545
3046,25456362,"Dacomitinib as first-line treatment in patients with clinically or molecularly selected advanced non-small-cell lung cancer: a multicentre, open-label, phase 2 trial.",http://www.ncbi.nlm.nih.gov/pubmed/25456362
3047,,"Abstract 1733: EGF816, a novel covalent inhibitor of mutant-selective epidermal growth factor receptor, overcomes T790M-mediated resistance in NSCLC",http://cancerres.aacrjournals.org/content/74/19_Supplement/1733.short
3048,,"ASP8273, a mutant-selective irreversible EGFR inhibitor in patients (pts) with NSCLC harboring EGFR activating mutations: Preliminary results of first-in-human phase I study in Japan.",http://meetinglibrary.asco.org/content/147772-156
3049,25322874,"Phase II study of selumetinib (AZD6244, ARRY-142886) plus irinotecan as second-line therapy in patients with K-RAS mutated colorectal cancer.",http://www.ncbi.nlm.nih.gov/pubmed/25322874
3050,25294897,A phase II study of the efficacy and safety of the combination therapy of the MEK inhibitor refametinib (BAY 86-9766) plus sorafenib for Asian patients with unresectable hepatocellular carcinoma.,http://www.ncbi.nlm.nih.gov/pubmed/25294897
3051,24652201,"Phase I dose-escalation and -expansion study of buparlisib (BKM120), an oral pan-Class I PI3K inhibitor, in patients with advanced solid tumors.",http://www.ncbi.nlm.nih.gov/pubmed/24652201
3052,26037647,Biochemical and Structural Analysis of Common Cancer-Associated KRAS Mutations.,http://www.ncbi.nlm.nih.gov/pubmed/26037647
3053,10629052,Complex effects of naturally occurring mutations in the JAK3 pseudokinase domain: evidence for interactions between the kinase and pseudokinase domains.,http://www.ncbi.nlm.nih.gov/pubmed/10629052
3054,10075926,Autosomal SCID caused by a point mutation in the N-terminus of Jak3: mapping of the Jak3-receptor interaction domain.,http://www.ncbi.nlm.nih.gov/pubmed/10075926
3055,9391116,Distinct tyrosine phosphorylation sites in JAK3 kinase domain positively and negatively regulate its enzymatic activity.,http://www.ncbi.nlm.nih.gov/pubmed/9391116
3056,22512864,Cyclin K goes with Cdk12 and Cdk13.,http://www.ncbi.nlm.nih.gov/pubmed/22512864
3057,25712099,Ovarian carcinoma CDK12 mutations misregulate expression of DNA repair genes via deficient formation and function of the Cdk12/CycK complex.,http://www.ncbi.nlm.nih.gov/pubmed/25712099
3058,16201750,Dissection of CDK4-binding and transactivation activities of p34(SEI-1) and comparison between functions of p34(SEI-1) and p16(INK4A).,http://www.ncbi.nlm.nih.gov/pubmed/16201750
3059,19110720,Expression of the p16INK4A/Cdkn2a gene is prevalently downregulated in human pheochromocytoma tumor specimens.,http://www.ncbi.nlm.nih.gov/pubmed/19110720
3060,21900389,Ipilimumab: an anti-CTLA-4 antibody for metastatic melanoma.,http://www.ncbi.nlm.nih.gov/pubmed/21900389
3061,20525992,Improved survival with ipilimumab in patients with metastatic melanoma.,http://www.ncbi.nlm.nih.gov/pubmed/20525992
3062,23190892,Familial melanoma-associated mutations in p16 uncouple its tumor-suppressor functions.,http://www.ncbi.nlm.nih.gov/pubmed/23190892
3063,9053859,Point mutations can inactivate in vitro and in vivo activities of p16(INK4a)/CDKN2A in human glioma.,http://www.ncbi.nlm.nih.gov/pubmed/9053859
3064,11719428,Destabilization of CHK2 by a missense mutation associated with Li-Fraumeni Syndrome.,http://www.ncbi.nlm.nih.gov/pubmed/11719428
3065,12606942,Detailed computational study of p53 and p16: using evolutionary sequence analysis and disease-associated mutations to predict the functional consequences of allelic variants.,http://www.ncbi.nlm.nih.gov/pubmed/12606942
3066,25724527,"A Phase I First-in-Human Study of Enoticumab (REGN421), a Fully Human Delta-like Ligand 4 (Dll4) Monoclonal Antibody in Patients with Advanced Solid Tumors.",http://www.ncbi.nlm.nih.gov/pubmed/25724527
3067,10491434,Biologic and biochemical analyses of p16(INK4a) mutations from primary tumors.,http://www.ncbi.nlm.nih.gov/pubmed/10491434
3068,21419934,"Nilotinib: a novel, selective tyrosine kinase inhibitor.",http://www.ncbi.nlm.nih.gov/pubmed/21419934
3069,16249345,Inhibition of colony-stimulating-factor-1 signaling in vivo with the orally bioavailable cFMS kinase inhibitor GW2580.,http://www.ncbi.nlm.nih.gov/pubmed/16249345
3070,23372702,Genetic and pharmacological targeting of CSF-1/CSF-1R inhibits tumor-associated macrophages and impairs BRAF-induced thyroid cancer progression.,http://www.ncbi.nlm.nih.gov/pubmed/23372702
3071,21517818,BAY 43-9006/Sorafenib blocks CSF1R activity and induces apoptosis in various classical Hodgkin lymphoma cell lines.,http://www.ncbi.nlm.nih.gov/pubmed/21517818
3072,17121910,"A c-fms tyrosine kinase inhibitor, Ki20227, suppresses osteoclast differentiation and osteolytic bone destruction in a bone metastasis model.",http://www.ncbi.nlm.nih.gov/pubmed/17121910
3073,19158277,Cold-inducible RNA-binding protein bypasses replicative senescence in primary cells through extracellular signal-regulated kinase 1 and 2 activation.,http://www.ncbi.nlm.nih.gov/pubmed/19158277
3074,20871615,Cooperation of breast cancer proteins PALB2 and piccolo BRCA2 in stimulating homologous recombination.,http://www.ncbi.nlm.nih.gov/pubmed/20871615
3075,,Abstract #DDT02-2: MCS110: a monoclonal antibody with potent neutralizing activity against macrophage colony-stimulating factor for the treatment of tumor-induced osteolysis,http://cancerres.aacrjournals.org/content/69/9_Supplement/DDT02-2.abstract
3076,25628399,"An Open-Label, Multicenter, Phase I/II Study of JNJ-40346527, a CSF-1R Inhibitor, in Patients with Relapsed or Refractory Hodgkin Lymphoma.",http://www.ncbi.nlm.nih.gov/pubmed/25628399
3077,26051995,CSF-1/CSF-1R targeting agents in clinical development for cancer therapy.,http://www.ncbi.nlm.nih.gov/pubmed/26051995
3078,20227038,DNA polymerases as potential therapeutic targets for cancers deficient in the DNA mismatch repair proteins MSH2 or MLH1.,http://www.ncbi.nlm.nih.gov/pubmed/20227038
3079,,"Abstract #2077: Antagonistic antibodies to c-fms block c-fms-mediated activities, reduce tumor-associated macrophages and decrease tumor growth in preclinical models",http://cancerres.aacrjournals.org/content/69/9_Supplement/2077.short
3080,24898549,Targeting tumor-associated macrophages with anti-CSF-1R antibody reveals a strategy for cancer therapy.,http://www.ncbi.nlm.nih.gov/pubmed/24898549
3081,24498562,CSF1R inhibition delays cervical and mammary tumor growth in murine models by attenuating the turnover of tumor-associated macrophages and enhancing infiltration by CD8(+) T cells.,http://www.ncbi.nlm.nih.gov/pubmed/24498562
3082,,Abstract 903: AC708 is a potent and selective inhibitor of CSF1R and reduces tumor associated macrophage infiltration in a breast tumor model.,http://cancerres.aacrjournals.org/content/73/8_Supplement/903.short
3083,25504752,"Identification of LY2510924, a novel cyclic peptide CXCR4 antagonist that exhibits antitumor activities in solid tumor and breast cancer metastatic models.",http://www.ncbi.nlm.nih.gov/pubmed/25504752
3084,23213054,BMS-936564/MDX-1338: a fully human anti-CXCR4 antibody induces apoptosis in vitro and shows antitumor activity in vivo in hematologic malignancies.,http://www.ncbi.nlm.nih.gov/pubmed/23213054
3085,22485156,Development of a unique small molecule modulator of CXCR4.,http://www.ncbi.nlm.nih.gov/pubmed/22485156
3086,21138752,CXCR4 antagonist 4F-benzoyl-TN14003 inhibits leukemia and multiple myeloma tumor growth.,http://www.ncbi.nlm.nih.gov/pubmed/21138752
3087,25775124,IL-24 inhibits lung cancer cell migration and invasion by disrupting the SDF-1/CXCR4 signaling axis.,http://www.ncbi.nlm.nih.gov/pubmed/25775124
3088,23538388,Inhibition of CXCR4-CXCL12 chemotaxis in melanoma by AMD11070.,http://www.ncbi.nlm.nih.gov/pubmed/23538388
3089,23211868,Halting metastasis through CXCR4 inhibition.,http://www.ncbi.nlm.nih.gov/pubmed/23211868
3090,23801631,Potent inhibition of DOT1L as treatment of MLL-fusion leukemia.,http://www.ncbi.nlm.nih.gov/pubmed/23801631
3091,10498896,Functional evaluation of tumour-specific variants of p16INK4a/CDKN2A: correlation with protein structure information.,http://www.ncbi.nlm.nih.gov/pubmed/10498896
3092,23250418,Catalytic site remodelling of the DOT1L methyltransferase by selective inhibitors.,http://www.ncbi.nlm.nih.gov/pubmed/23250418
3093,14759363,The structural basis for autoinhibition of FLT3 by the juxtamembrane domain.,http://www.ncbi.nlm.nih.gov/pubmed/14759363
3094,11518711,Mutations in the INK4a/ARF melanoma susceptibility locus functionally impair p14ARF.,http://www.ncbi.nlm.nih.gov/pubmed/11518711
3095,20340136,Predicting functional significance of cancer-associated p16(INK4a) mutations in CDKN2A.,http://www.ncbi.nlm.nih.gov/pubmed/20340136
3096,11108894,Progesterone antagonists and progesterone receptor modulators in the treatment of breast cancer.,http://www.ncbi.nlm.nih.gov/pubmed/11108894
3097,21242281,Parallel high-throughput RNA interference screens identify PINK1 as a potential therapeutic target for the treatment of DNA mismatch repair-deficient cancers.,http://www.ncbi.nlm.nih.gov/pubmed/21242281
3098,16595706,Human androgen receptor gene ligand-binding-domain mutations leading to disrupted interaction between the N- and C-terminal domains.,http://www.ncbi.nlm.nih.gov/pubmed/16595706
3099,22645304,Evidence for DNA-binding domain--ligand-binding domain communications in the androgen receptor.,http://www.ncbi.nlm.nih.gov/pubmed/22645304
3100,25678665,Chemical biology. A small-molecule inhibitor of the aberrant transcription factor CBFβ-SMMHC delays leukemia in mice.,http://www.ncbi.nlm.nih.gov/pubmed/25678665
3101,18697867,A novel mutation in the human androgen receptor suggests a regulatory role for the hinge region in amino-terminal and carboxy-terminal interactions.,http://www.ncbi.nlm.nih.gov/pubmed/18697867
3102,20007693,Systematic structure-function analysis of androgen receptor Leu701 mutants explains the properties of the prostate cancer mutant L701H.,http://www.ncbi.nlm.nih.gov/pubmed/20007693
3103,15531547,Residual activity of mutant androgen receptors explains wolffian duct development in the complete androgen insensitivity syndrome.,http://www.ncbi.nlm.nih.gov/pubmed/15531547
3104,17356134,"NPI-0052, a novel proteasome inhibitor, induces caspase-8 and ROS-dependent apoptosis alone and in combination with HDAC inhibitors in leukemia cells.",http://www.ncbi.nlm.nih.gov/pubmed/17356134
3105,12115546,Broadened ligand responsiveness of androgen receptor mutants obtained by random amino acid substitution of H874 and mutation hot spot T877 in prostate cancer.,http://www.ncbi.nlm.nih.gov/pubmed/12115546
3106,25779944,"The MET Inhibitor AZD6094 (Savolitinib, HMPL-504) Induces Regression in Papillary Renal Cell Carcinoma Patient-Derived Xenograft Models.",http://www.ncbi.nlm.nih.gov/pubmed/25779944
3107,24912431,"The WHIM-like CXCR4(S338X) somatic mutation activates AKT and ERK, and promotes resistance to ibrutinib and other agents used in the treatment of Waldenstrom's Macroglobulinemia.",http://www.ncbi.nlm.nih.gov/pubmed/24912431
3108,8668202,Temperature-sensitive mutants of p16CDKN2 associated with familial melanoma.,http://www.ncbi.nlm.nih.gov/pubmed/8668202
3109,22556427,N- and C-terminal transactivation domains of GATA1 protein coordinate hematopoietic program.,http://www.ncbi.nlm.nih.gov/pubmed/22556427
3110,22786876,High GATA2 expression is a poor prognostic marker in pediatric acute myeloid leukemia.,http://www.ncbi.nlm.nih.gov/pubmed/22786876
3111,21892162,Heritable GATA2 mutations associated with familial myelodysplastic syndrome and acute myeloid leukemia.,http://www.ncbi.nlm.nih.gov/pubmed/21892162
3112,24322982,Cancer-derived mutations in KEAP1 impair NRF2 degradation but not ubiquitination.,http://www.ncbi.nlm.nih.gov/pubmed/24322982
3113,17020408,Dysfunctional KEAP1-NRF2 interaction in non-small-cell lung cancer.,http://www.ncbi.nlm.nih.gov/pubmed/17020408
3114,25825487,Combined rational design and a high throughput screening platform for identifying chemical inhibitors of a Ras-activating enzyme.,http://www.ncbi.nlm.nih.gov/pubmed/25825487
3115,16109840,Regulation of aromatase expression in estrogen-responsive breast and uterine disease: from bench to treatment.,http://www.ncbi.nlm.nih.gov/pubmed/16109840
3116,10731124,"Aromatase overexpression and breast hyperplasia, an in vivo model--continued overexpression of aromatase is sufficient to maintain hyperplasia without circulating estrogens, and aromatase inhibitors abrogate these preneoplastic changes in mammary glands.",http://www.ncbi.nlm.nih.gov/pubmed/10731124
3117,25685062,EHMT2 inhibitor BIX-01294 induces apoptosis through PMAIP1-USP9X-MCL1 axis in human bladder cancer cells.,http://www.ncbi.nlm.nih.gov/pubmed/25685062
3118,22615450,Development of an Fc-enhanced anti-B7-H3 monoclonal antibody with potent antitumor activity.,http://www.ncbi.nlm.nih.gov/pubmed/22615450
3119,25349307,Alectinib shows potent antitumor activity against RET-rearranged non-small cell lung cancer.,http://www.ncbi.nlm.nih.gov/pubmed/25349307
3120,22810810,The rationale for targeting the LOX family in cancer.,http://www.ncbi.nlm.nih.gov/pubmed/22810810
3121,25891481,Perspectives for therapeutic targeting of gene mutations in acute myeloid leukaemia with normal cytogenetics.,http://www.ncbi.nlm.nih.gov/pubmed/25891481
3122,,"ASP2215, a novel FLT3/AXL inhibitor: Preclinical evaluation in acute myeloid leukemia (AML)",http://meetinglibrary.asco.org/content/131170-144
3123,21847359,Enhanced expression of EHMT2 is involved in the proliferation of cancer cells through negative regulation of SIAH1.,http://www.ncbi.nlm.nih.gov/pubmed/21847359
3124,,"Results from a phase 2 study of enzalutamide (ENZA), an androgen receptor (AR) inhibitor, in advanced AR+ triple-negative breast cancer (TNBC).",http://meetinglibrary.asco.org/content/150040-156
3125,,"Abstract 2570: IMO-8400, a selective antagonist of TLRs 7, 8 and 9, inhibits MYD88 L265P mutation-driven signaling and cell survival: A potential novel approach for treatment of B-cell lymphomas harboring MYD88 L265P mutation",http://cancerres.aacrjournals.org/content/74/19_Supplement/2570.short
3126,11309348,Trichostatin A is a histone deacetylase inhibitor with potent antitumor activity against breast cancer in vivo.,http://www.ncbi.nlm.nih.gov/pubmed/11309348
3127,22931316,MYD88 L265P somatic mutation in Waldenström's macroglobulinemia.,http://www.ncbi.nlm.nih.gov/pubmed/22931316
3128,21454220,"Histone deacetylase inhibitors demonstrate significant preclinical activity as single agents, and in combination with bortezomib in Waldenström's macroglobulinemia.",http://www.ncbi.nlm.nih.gov/pubmed/21454220
3129,19826124,Histone deacetylase inhibitors in cancer therapy.,http://www.ncbi.nlm.nih.gov/pubmed/19826124
3130,,Synergistic Blockade Of Activated B Cell-Like DLBCL Proliferation With a Selective Inhibitor Of IRAK4 In Combination With Inhibition Of The B-Cell Receptor Signaling Network,http://www.bloodjournal.org/content/122/21/3833?sso-checked=true
3131,,Effect Of MYD88 Mutation In CLL On IRAK4 and BTK Inhibition In Vitro,http://www.bloodjournal.org/content/122/21/4132?sso-checked=true
3132,25290089,IRAK signalling in cancer.,http://www.ncbi.nlm.nih.gov/pubmed/25290089
3133,23352126,LKB1 inactivation dictates therapeutic response of non-small cell lung cancer to the metabolism drug phenformin.,http://www.ncbi.nlm.nih.gov/pubmed/23352126
3134,24387336,Targeting the LKB1 tumor suppressor.,http://www.ncbi.nlm.nih.gov/pubmed/24387336
3135,15480979,Suppression of Peutz-Jeghers polyposis by inhibition of cyclooxygenase-2.,http://www.ncbi.nlm.nih.gov/pubmed/15480979
3136,23355676,APR-246/PRIMA-1(MET) rescues epidermal differentiation in skin keratinocytes derived from EEC syndrome patients with p63 mutations.,http://www.ncbi.nlm.nih.gov/pubmed/23355676
3137,24526126,Skp2: a dream target in the coming age of cancer therapy.,http://www.ncbi.nlm.nih.gov/pubmed/24526126
3138,17696825,Immunotherapy for prostate cancer using antigen-loaded antigen-presenting cells: APC8015 (Provenge).,http://www.ncbi.nlm.nih.gov/pubmed/17696825
3139,25565923,Sipuleucel-T in the treatment of prostate cancer: an evidence-based review of its place in therapy.,http://www.ncbi.nlm.nih.gov/pubmed/25565923
3140,22778948,Effects of somatic mutations in the C-terminus of insulin-like growth factor 1 receptor on activity and signaling.,http://www.ncbi.nlm.nih.gov/pubmed/22778948
3141,25895124,Anti-β₂-microglobulin monoclonal antibodies overcome bortezomib resistance in multiple myeloma by inhibiting autophagy.,http://www.ncbi.nlm.nih.gov/pubmed/25895124
3142,11902578,Assessing TP53 status in human tumours to evaluate clinical outcome.,http://www.ncbi.nlm.nih.gov/pubmed/11902578
3143,17724467,Analysis of transactivation capability and conformation of p53 temperature-dependent mutants and their reactivation by amifostine in yeast.,http://www.ncbi.nlm.nih.gov/pubmed/17724467
3144,11896595,Tumour p53 mutations exhibit promoter selective dominance over wild type p53.,http://www.ncbi.nlm.nih.gov/pubmed/11896595
3145,17463250,MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling.,http://www.ncbi.nlm.nih.gov/pubmed/17463250
3146,23659703,"Development of everolimus, a novel oral mTOR inhibitor, across a spectrum of diseases.",http://www.ncbi.nlm.nih.gov/pubmed/23659703
3147,18470917,Uncertain pathogenicity of MSH2 variants N127S and G322D challenges their classification.,http://www.ncbi.nlm.nih.gov/pubmed/18470917
3148,21379385,Functional characterization of human cancer-derived TRKB mutations.,http://www.ncbi.nlm.nih.gov/pubmed/21379385
3149,23073384,Transcriptome correlation analysis identifies two unique craniosynostosis subtypes associated with IRS1 activation.,http://www.ncbi.nlm.nih.gov/pubmed/23073384
3150,11159935,Congenital insensitivity to pain with anhidrosis (CIPA): effect of TRKA (NTRK1) missense mutations on autophosphorylation of the receptor tyrosine kinase for nerve growth factor.,http://www.ncbi.nlm.nih.gov/pubmed/11159935
3151,25682238,Anti-tumor effect of the mammalian target of rapamycin inhibitor everolimus in oral squamous cell carcinoma.,http://www.ncbi.nlm.nih.gov/pubmed/25682238
3152,25636350,Effects of metformin on head and neck cancer: a systematic review.,http://www.ncbi.nlm.nih.gov/pubmed/25636350
3153,21520111,Efficacy and comparative effectiveness of sirolimus as an anticancer drug.,http://www.ncbi.nlm.nih.gov/pubmed/21520111
3154,1568247,Somatic mutations in the neurofibromatosis 1 gene in human tumors.,http://www.ncbi.nlm.nih.gov/pubmed/1568247
3155,26084990,Multicenter phase II study of the AKT inhibitor MK-2206 in recurrent or metastatic nasopharyngeal carcinoma from patients in the mayo phase II consortium and the cancer therapeutics research group (MC1079).,http://www.ncbi.nlm.nih.gov/pubmed/26084990
3156,16880785,Sorafenib in advanced melanoma: a Phase II randomised discontinuation trial analysis.,http://www.ncbi.nlm.nih.gov/pubmed/16880785
3157,25016924,"A phase II study of ramucirumab (IMC-1121B) in the treatment of persistent or recurrent epithelial ovarian, fallopian tube or primary peritoneal carcinoma.",http://www.ncbi.nlm.nih.gov/pubmed/25016924
3158,,"Abstract 3560: Ponatinib (AP24534), a potent pan-FGFR inhibitor with activity in multiple FGFR-driven cancer models",http://cancerres.aacrjournals.org/content/71/8_Supplement/3560.short
3159,25527417,TEMHEAD: a single-arm multicentre phase II study of temsirolimus in platin- and cetuximab refractory recurrent and/or metastatic squamous cell carcinoma of the head and neck (SCCHN) of the German SCCHN Group (AIO).,http://www.ncbi.nlm.nih.gov/pubmed/25527417
3160,,Phase I study of MEDI0639 in patients with advanced solid tumors.,http://meetinglibrary.asco.org/content/150624-156
3161,23143779,Preclinical evaluation of the AKT inhibitor MK-2206 in nasopharyngeal carcinoma cell lines.,http://www.ncbi.nlm.nih.gov/pubmed/23143779
3162,,Abstract B48: A first-in-human Phase I study of the novel cancer stem cell (CSC) targeting antibody OMP-52M51 (anti-Notch1) administered intravenously to patients with certain advanced solid tumors.,http://mct.aacrjournals.org/content/12/11_Supplement/B48.short
3163,25049390,Next-generation sequencing identifies rare variants associated with Noonan syndrome.,http://www.ncbi.nlm.nih.gov/pubmed/25049390
3164,23224737,"A phase II study of sorafenib in patients with platinum-pretreated, advanced (Stage IIIb or IV) non-small cell lung cancer with a KRAS mutation.",http://www.ncbi.nlm.nih.gov/pubmed/23224737
3165,,Abstract 4708: Short-term romidepsin treatment combined with mitogen-activated protein kinase and phosphatidylinositol 3-kinase inhibition causes increased Bim expression and cell death in KRAS mutant cell lines,http://cancerres.aacrjournals.org/content/72/8_Supplement/4708.short
3166,22711703,Molecular pathways: targeting the TGF-β pathway for cancer therapy.,http://www.ncbi.nlm.nih.gov/pubmed/22711703
3167,20332142,FDA approval summary: temsirolimus as treatment for advanced renal cell carcinoma.,http://www.ncbi.nlm.nih.gov/pubmed/20332142
3168,,"Final overall survival analysis of EXAM, an international, double-blind, randomized, placebo-controlled phase III trial of cabozantinib (Cabo) in medullary thyroid carcinoma (MTC) patients with documented RECIST progression at baseline.",http://meetinglibrary.asco.org/content/147994-156
3169,22825331,The novel ATR inhibitor VE-821 increases sensitivity of pancreatic cancer cells to radiation and chemotherapy.,http://www.ncbi.nlm.nih.gov/pubmed/22825331
3170,25468710,"Untangling the ATR-CHEK1 network for prognostication, prediction and therapeutic target validation in breast cancer.",http://www.ncbi.nlm.nih.gov/pubmed/25468710
3171,21730979,"Identification and evaluation of a potent novel ATR inhibitor, NU6027, in breast and ovarian cancer cell lines.",http://www.ncbi.nlm.nih.gov/pubmed/21730979
3172,25269479,ATR inhibitors VE-821 and VX-970 sensitize cancer cells to topoisomerase i inhibitors by disabling DNA replication initiation and fork elongation responses.,http://www.ncbi.nlm.nih.gov/pubmed/25269479
3173,,"AZ20, a novel potent and selective inhibitor of ATR kinase with in vivo antitumour activity",http://cancerres.aacrjournals.org/content/72/8_Supplement/1823
3174,,The pre-clinical in vitro and in vivo activity of AZD6738: A potent and selective inhibitor of ATR kinase,http://cancerres.aacrjournals.org/content/73/8_Supplement/3343.short
3175,17340614,A tale of two proteins: differential roles and regulation of Smad2 and Smad3 in TGF-beta signaling.,http://www.ncbi.nlm.nih.gov/pubmed/17340614
3176,10822381,Heterogeneities in the biological and biochemical functions of Smad2 and Smad4 mutants naturally occurring in human lung cancers.,http://www.ncbi.nlm.nih.gov/pubmed/10822381
3177,22204491,Roles of TGFβ signaling Smads in squamous cell carcinoma.,http://www.ncbi.nlm.nih.gov/pubmed/22204491
3178,22586678,Anti-MET targeted therapy has come of age: the first durable complete response with MetMAb in metastatic gastric cancer.,http://www.ncbi.nlm.nih.gov/pubmed/22586678
3179,23345546,The role of MET receptor tyrosine kinase in non-small cell lung cancer and clinical development of targeted anti-MET agents.,http://www.ncbi.nlm.nih.gov/pubmed/23345546
3180,18077431,Assessing the significance of chromosomal aberrations in cancer: methodology and application to glioma.,http://www.ncbi.nlm.nih.gov/pubmed/18077431
3181,26045340,"Necitumumab plus gemcitabine and cisplatin versus gemcitabine and cisplatin alone as first-line therapy in patients with stage IV squamous non-small-cell lung cancer (SQUIRE): an open-label, randomised, controlled phase 3 trial.",http://www.ncbi.nlm.nih.gov/pubmed/26045340
3182,23872584,A synthetic lethality-based strategy to treat cancers harboring a genetic deficiency in the chromatin remodeling factor BRG1.,http://www.ncbi.nlm.nih.gov/pubmed/23872584
3183,21148487,ETV6-NTRK3-mediated breast epithelial cell transformation is blocked by targeting the IGF1R signaling pathway.,http://www.ncbi.nlm.nih.gov/pubmed/21148487
3184,20534551,Pattern of retinoblastoma pathway inactivation dictates response to CDK4/6 inhibition in GBM.,http://www.ncbi.nlm.nih.gov/pubmed/20534551
3185,,Abstract 5485: Induction of proliferation sensitizes chronic lymphocytic leukemia cells to apoptosis mediated by the ATR inhibitor AZD6738,http://cancerres.aacrjournals.org/content/74/19_Supplement/5485.short
3186,23737487,C-RAF mutations confer resistance to RAF inhibitors.,http://www.ncbi.nlm.nih.gov/pubmed/23737487
3187,17603483,Gain-of-function RAF1 mutations cause Noonan and LEOPARD syndromes with hypertrophic cardiomyopathy.,http://www.ncbi.nlm.nih.gov/pubmed/17603483
3188,16266992,Mutations of C-RAF are rare in human cancer because C-RAF has a low basal kinase activity compared with B-RAF.,http://www.ncbi.nlm.nih.gov/pubmed/16266992
3189,22650412,The E288K colon tumor variant of DNA polymerase β is a sequence specific mutator.,http://www.ncbi.nlm.nih.gov/pubmed/22650412
3190,23144635,A germline polymorphism of DNA polymerase beta induces genomic instability and cellular transformation.,http://www.ncbi.nlm.nih.gov/pubmed/23144635
3191,24360397,Temsirolimus therapy in a patient with lung adenocarcinoma harboring an FBXW7 mutation.,http://www.ncbi.nlm.nih.gov/pubmed/24360397
3192,25450031,A phase I study of everolimus and docetaxel in patients with castration-resistant prostate cancer.,http://www.ncbi.nlm.nih.gov/pubmed/25450031
3193,24412228,Metformin in chemotherapy-naive castration-resistant prostate cancer: a multicenter phase 2 trial (SAKK 08/09).,http://www.ncbi.nlm.nih.gov/pubmed/24412228
3194,22367541,The translational landscape of mTOR signalling steers cancer initiation and metastasis.,http://www.ncbi.nlm.nih.gov/pubmed/22367541
3195,21138868,Combination therapy targeting both tumor-initiating and differentiated cell populations in prostate carcinoma.,http://www.ncbi.nlm.nih.gov/pubmed/21138868
3196,2168563,A single amino acid substitution results in a retinoblastoma protein defective in phosphorylation and oncoprotein binding.,http://www.ncbi.nlm.nih.gov/pubmed/2168563
3197,16505003,Mitotic defects in XRCC3 variants T241M and D213N and their relation to cancer susceptibility.,http://www.ncbi.nlm.nih.gov/pubmed/16505003
3198,12629044,Essential and dispensable roles of ATR in cell cycle arrest and genome maintenance.,http://www.ncbi.nlm.nih.gov/pubmed/12629044
3199,25512053,ATM and ATR as therapeutic targets in cancer.,http://www.ncbi.nlm.nih.gov/pubmed/25512053
3200,26069190,ARID1A Deficiency Impairs the DNA Damage Checkpoint and Sensitizes Cells to PARP Inhibitors.,http://www.ncbi.nlm.nih.gov/pubmed/26069190
3201,16585161,Two transforming C-RAF germ-line mutations identified in patients with therapy-related acute myeloid leukemia.,http://www.ncbi.nlm.nih.gov/pubmed/16585161
3202,,"ITOC2 – 037. CEA TCB, A novel T-cell bispecific antibody with potent in vitro and in vivo antitumour activity against solid tumours",(http://www.sciencedirect.com/science/article/pii/S0959804915000817)
3203,25054064,"The indoleamine 2,3-dioxygenase pathway controls complement-dependent enhancement of chemo-radiation therapy against murine glioblastoma.",http://www.ncbi.nlm.nih.gov/pubmed/25054064
3204,20679480,Impaired binding of 14-3-3 to C-RAF in Noonan syndrome suggests new approaches in diseases with increased Ras signaling.,http://www.ncbi.nlm.nih.gov/pubmed/20679480
3205,21285983,"PG545, a dual heparanase and angiogenesis inhibitor, induces potent anti-tumour and anti-metastatic efficacy in preclinical models.",http://www.ncbi.nlm.nih.gov/pubmed/21285983
3206,25669977,The heparan sulfate mimetic PG545 interferes with Wnt/β-catenin signaling and significantly suppresses pancreatic tumorigenesis alone and in combination with gemcitabine.,http://www.ncbi.nlm.nih.gov/pubmed/25669977
3207,20154217,Efficacy of the JAK2 inhibitor INCB16562 in a murine model of MPLW515L-induced thrombocytosis and myelofibrosis.,http://www.ncbi.nlm.nih.gov/pubmed/20154217
3208,23478059,"Abagovomab as maintenance therapy in patients with epithelial ovarian cancer: a phase III trial of the AGO OVAR, COGI, GINECO, and GEICO--the MIMOSA study.",http://www.ncbi.nlm.nih.gov/pubmed/23478059
3209,22826437,Increased BRAF heterodimerization is the common pathogenic mechanism for noonan syndrome-associated RAF1 mutants.,http://www.ncbi.nlm.nih.gov/pubmed/22826437
3210,25699052,Review of the Results of WT1 Peptide Vaccination Strategies for Myelodysplastic Syndromes and Acute Myeloid Leukemia from Nine Different Studies.,http://www.ncbi.nlm.nih.gov/pubmed/25699052
3211,26078430,Targeting FGFR Signaling in Cancer.,http://www.ncbi.nlm.nih.gov/pubmed/26078430
3212,21611109,HN125: A Novel Immunoadhesin Targeting MUC16 with Potential for Cancer Therapy.,http://www.ncbi.nlm.nih.gov/pubmed/21611109
3213,20537908,Adoptive transfer of unselected or leukemia-reactive T-cells in the treatment of relapse following allogeneic hematopoietic cell transplantation.,http://www.ncbi.nlm.nih.gov/pubmed/20537908
3214,24447304,Novel treatment option for MUC16-positive malignancies with the targeted TRAIL-based fusion protein Meso-TR3.,http://www.ncbi.nlm.nih.gov/pubmed/24447304
3215,17960112,Ten novel RB1 gene mutations in patients with retinoblastoma.,http://www.ncbi.nlm.nih.gov/pubmed/17960112
3216,15605413,"Identification of 26 new constitutional RB1 gene mutations in Spanish, Colombian, and Cuban retinoblastoma patients.",http://www.ncbi.nlm.nih.gov/pubmed/15605413
3217,24791139,Screening of RB1 gene mutations in Chinese patients with retinoblastoma and preliminary exploration of genotype-phenotype correlations.,http://www.ncbi.nlm.nih.gov/pubmed/24791139
3218,24886523,"MUC16 (CA125): tumor biomarker to cancer therapy, a work in progress.",http://www.ncbi.nlm.nih.gov/pubmed/24886523
3219,25890361,A phase I clinical trial of adoptive T cell therapy using IL-12 secreting MUC-16(ecto) directed chimeric antigen receptors for recurrent ovarian cancer.,http://www.ncbi.nlm.nih.gov/pubmed/25890361
3220,15337799,"Randomized, placebo-controlled study of oregovomab for consolidation of clinical remission in patients with advanced ovarian cancer.",http://www.ncbi.nlm.nih.gov/pubmed/15337799
3221,21615945,Low penetrance of retinoblastoma for p.V654L mutation of the RB1 gene.,http://www.ncbi.nlm.nih.gov/pubmed/21615945
3222,10882758,"Two novel germline mutations of the retinoblastoma gene (RB1) that show incomplete penetrance, one splice site and one missense.",http://www.ncbi.nlm.nih.gov/pubmed/10882758
3223,9447969,Regulation of hypoxia-inducible mRNAs by the von Hippel-Lindau tumor suppressor protein requires binding to complexes containing elongins B/C and Cul2.,http://www.ncbi.nlm.nih.gov/pubmed/9447969
3224,11331612,von Hippel-Lindau protein mutants linked to type 2C VHL disease preserve the ability to downregulate HIF.,http://www.ncbi.nlm.nih.gov/pubmed/11331612
3225,18836774,Computational detection of deleterious SNPs and their effect on sequence and structural level of the VHL gene.,http://www.ncbi.nlm.nih.gov/pubmed/18836774
3226,14636579,Tumorigenic mutations in VHL disrupt folding in vivo by interfering with chaperonin binding.,http://www.ncbi.nlm.nih.gov/pubmed/14636579
3227,10973499,Activation of HIF1alpha ubiquitination by a reconstituted von Hippel-Lindau (VHL) tumor suppressor complex.,http://www.ncbi.nlm.nih.gov/pubmed/10973499
3228,24225019,PARP Inhibitors for BRCA1/2 mutation-associated and BRCA-like malignancies.,http://www.ncbi.nlm.nih.gov/pubmed/24225019
3229,18345031,"NSC348884, a nucleophosmin inhibitor disrupts oligomer formation and induces apoptosis in human cancer cells.",http://www.ncbi.nlm.nih.gov/pubmed/18345031
3230,21719597,Targeting levels or oligomerization of nucleophosmin 1 induces differentiation and loss of survival of human AML cells with mutant NPM1.,http://www.ncbi.nlm.nih.gov/pubmed/21719597
3231,18292931,"YM753, a novel histone deacetylase inhibitor, exhibits antitumor activity with selective, sustained accumulation of acetylated histones in tumors in the WiDr xenograft model.",http://www.ncbi.nlm.nih.gov/pubmed/18292931
3232,23900601,A novel HDAC inhibitor OBP-801 and a PI3K inhibitor LY294002 synergistically induce apoptosis via the suppression of survivin and XIAP in renal cell carcinoma.,http://www.ncbi.nlm.nih.gov/pubmed/23900601
3233,24908436,"Novel DNA methyltransferase-1 (DNMT1) depleting anticancer nucleosides, 4'-thio-2'-deoxycytidine and 5-aza-4'-thio-2'-deoxycytidine.",http://www.ncbi.nlm.nih.gov/pubmed/24908436
3234,11331613,Contrasting effects on HIF-1alpha regulation by disease-causing pVHL mutations correlate with patterns of tumourigenesis in von Hippel-Lindau disease.,http://www.ncbi.nlm.nih.gov/pubmed/11331613
3235,10823831,Hypoxia inducible factor-alpha binding and ubiquitylation by the von Hippel-Lindau tumor suppressor protein.,http://www.ncbi.nlm.nih.gov/pubmed/10823831
3236,15574766,In vitro and in vivo models analyzing von Hippel-Lindau disease-specific mutations.,http://www.ncbi.nlm.nih.gov/pubmed/15574766
3237,9122164,"The von Hippel-Lindau tumor-suppressor gene product forms a stable complex with human CUL-2, a member of the Cdc53 family of proteins.",http://www.ncbi.nlm.nih.gov/pubmed/9122164
3238,11739384,Ubiquitination of a novel deubiquitinating enzyme requires direct binding to von Hippel-Lindau tumor suppressor protein.,http://www.ncbi.nlm.nih.gov/pubmed/11739384
3239,10878807,Ubiquitination of hypoxia-inducible factor requires direct binding to the beta-domain of the von Hippel-Lindau protein.,http://www.ncbi.nlm.nih.gov/pubmed/10878807
3240,22071692,Phosphorylation of von Hippel-Lindau protein by checkpoint kinase 2 regulates p53 transactivation.,http://www.ncbi.nlm.nih.gov/pubmed/22071692
3241,11818567,Importance of epidermal growth factor receptor signaling in establishment of adenomas and maintenance of carcinomas during intestinal tumorigenesis.,http://www.ncbi.nlm.nih.gov/pubmed/11818567
3242,10086326,"Irreversible inhibition of epidermal growth factor receptor tyrosine kinase with in vivo activity by N-[4-[(3-bromophenyl)amino]-6-quinazolinyl]-2-butynamide (CL-387,785).",http://www.ncbi.nlm.nih.gov/pubmed/10086326
3243,19408289,Local recurrences and second primary tumors from squamous cell carcinoma of the oral cavity: a retrospective analytic study of 500 patients.,http://www.ncbi.nlm.nih.gov/pubmed/19408289
3244,23633926,Cellular immunotherapy for carcinoma using genetically modified EGFR-specific T lymphocytes.,http://www.ncbi.nlm.nih.gov/pubmed/23633926
3245,19020081,Non-DNA-binding platinum anticancer agents: Cytotoxic activities of platinum-phosphato complexes towards human ovarian cancer cells.,http://www.ncbi.nlm.nih.gov/pubmed/19020081
3246,26100274,"Palbociclib for the Treatment of Estrogen Receptor-Positive, HER2-Negative Metastatic Breast Cancer.",http://www.ncbi.nlm.nih.gov/pubmed/26100274
3247,22585997,Suppression of tumor invasion and metastasis by concurrent inhibition of c-Met and VEGF signaling in pancreatic neuroendocrine tumors.,http://www.ncbi.nlm.nih.gov/pubmed/22585997
3248,25539919,Tumor-associated mutations in a conserved structural motif alter physical and biochemical properties of human RAD51 recombinase.,http://www.ncbi.nlm.nih.gov/pubmed/25539919
3249,20628007,TGFBR2 mutations alter smooth muscle cell phenotype and predispose to thoracic aortic aneurysms and dissections.,http://www.ncbi.nlm.nih.gov/pubmed/20628007
3250,,Phase 1-2 trial of the BRAF inhibitor dabrafenib (D) plus MEK inhibitor trametinib (T) in BRAF V600 mutant colorectal cancer (CRC): Updated efficacy and biomarker analysis.,http://meetinglibrary.asco.org/content/131743-144
3252,,"Abstract CT237: Interim results of a first-in-human phase 1 study of the oral MET kinase inhibitor, LY2801653, in patients with advanced cancer",http://cancerres.aacrjournals.org/content/74/19_Supplement/CT237.short
3253,23942066,"Acute tumour response to the MEK1/2 inhibitor selumetinib (AZD6244, ARRY-142886) evaluated by non-invasive diffusion-weighted MRI.",http://www.ncbi.nlm.nih.gov/pubmed/23942066
3254,16717057,Fusion between CIC and DUX4 up-regulates PEA3 family genes in Ewing-like sarcomas with t(4;19)(q35;q13) translocation.,http://www.ncbi.nlm.nih.gov/pubmed/16717057
3255,21482694,Potent activity of ponatinib (AP24534) in models of FLT3-driven acute myeloid leukemia and other hematologic malignancies.,http://www.ncbi.nlm.nih.gov/pubmed/21482694
3256,25818407,A phase I/II study of sunitinib and intensive chemotherapy in patients over 60 years of age with acute myeloid leukaemia and activating FLT3 mutations.,http://www.ncbi.nlm.nih.gov/pubmed/25818407
3257,,The Novel Inhibitor PLX3397 Effectively Inhibits FLT3-Mutant AML,http://abstracts.hematologylibrary.org/cgi/content/abstract/118/21/3632?maxtoshow=&hits=10&RESULTFORMAT=&fulltext=PLX3397&searchid=1&FIRSTINDEX=0&volume=118&issue=21&resourcetype=HWCIT
3258,22665524,Sorafenib inhibits many kinase mutations associated with drug-resistant gastrointestinal stromal tumors.,http://www.ncbi.nlm.nih.gov/pubmed/22665524
3259,25836719,Pharmacological Inhibition of KIT Activates MET Signaling in Gastrointestinal Stromal Tumors.,http://www.ncbi.nlm.nih.gov/pubmed/25836719
3260,20442311,Preclinical evaluation of nilotinib efficacy in an imatinib-resistant KIT-driven tumor model.,http://www.ncbi.nlm.nih.gov/pubmed/20442311
3261,,Final results of the multicenter randomized phase II PAZOGIST trial evaluating the efficacy of pazopanib (P) plus best supportive care (BSC) vs BSC alone in resistant unresectable metastatic and/or locally advanced gastrointestinal stromal tumors (GIST).,http://meetinglibrary.asco.org/content/149452-156
3262,24583793,Increased KIT inhibition enhances therapeutic efficacy in gastrointestinal stromal tumor.,http://www.ncbi.nlm.nih.gov/pubmed/24583793
3263,25686104,Synthetic lethality by targeting EZH2 methyltransferase activity in ARID1A-mutated cancers.,http://www.ncbi.nlm.nih.gov/pubmed/25686104
3264,26125128,Potential therapeutic targets in ARID1A-mutated cancers.,http://www.ncbi.nlm.nih.gov/pubmed/26125128
3265,26005520,"EPZ011989, A Potent, Orally-Available EZH2 Inhibitor with Robust in Vivo Activity.",http://www.ncbi.nlm.nih.gov/pubmed/26005520
3266,20201988,Enhancement of humoral and cellular immunity with an anti-glucocorticoid-induced tumour necrosis factor receptor monoclonal antibody.,http://www.ncbi.nlm.nih.gov/pubmed/20201988
3267,26124204,SMO Gene Amplification and Activation of the Hedgehog Pathway as Novel Mechanisms of Resistance to Anti-Epidermal Growth Factor Receptor Drugs in Human Lung Cancer.,http://www.ncbi.nlm.nih.gov/pubmed/26124204
3268,15870435,Epidermal growth factor receptor gene and protein and gefitinib sensitivity in non-small-cell lung cancer.,http://www.ncbi.nlm.nih.gov/pubmed/15870435
3269,12958308,Amyloid fibril formation in the context of full-length protein: effects of proline mutations on the amyloid fibril formation of beta2-microglobulin.,http://www.ncbi.nlm.nih.gov/pubmed/12958308
3270,15661905,"Immune selection of hot-spot beta 2-microglobulin gene mutations, HLA-A2 allospecificity loss, and antigen-processing machinery component down-regulation in melanoma cells derived from recurrent metastases following immunotherapy.",http://www.ncbi.nlm.nih.gov/pubmed/15661905
3271,21606950,Histone tails regulate DNA methylation by allosterically activating de novo methyltransferase.,http://www.ncbi.nlm.nih.gov/pubmed/21606950
3272,20051626,CXCR1 blockade selectively targets human breast cancer stem cells in vitro and in xenografts.,http://www.ncbi.nlm.nih.gov/pubmed/20051626
3273,11943769,Conformation of beta 2-microglobulin amyloid fibrils analyzed by reduction of the disulfide bond.,http://www.ncbi.nlm.nih.gov/pubmed/11943769
3274,10570174,Truncated BRCA2 is cytoplasmic: implications for cancer-linked mutations.,http://www.ncbi.nlm.nih.gov/pubmed/10570174
3275,19206206,Activation loop phosphorylation modulates Bruton's tyrosine kinase (Btk) kinase domain activity.,http://www.ncbi.nlm.nih.gov/pubmed/19206206
3276,,Abstract B243: A phase I dose-escalation study of MEK inhibitor MEK162 (ARRY-438162) in patients with advanced solid tumors.,http://mct.aacrjournals.org/content/10/11_Supplement/B243.abstract
3277,,Abstract 4766: Pharmacodynamic and stratification biomarker for the anti-FGFR2 antibody (BAY1179470) and the FGFR2-ADC,http://cancerres.aacrjournals.org/content/74/19_Supplement/4766.abstract
3278,,"FPA144, a humanized monoclonal antibody for both FGFR2-amplified and nonamplified, FGFR2b-overexpressing gastric cancer patients.",http://meetinglibrary.asco.org/content/133812-144
3279,25057173,EGFR biomarkers predict benefit from vandetanib in combination with docetaxel in a randomized phase III study of second-line treatment of patients with advanced non-small cell lung cancer.,http://www.ncbi.nlm.nih.gov/pubmed/25057173
3280,,"A Phase I Study of the Safety and Pharmacokinetics of Escalating Doses of MFGR1877S, a Fibroblast Growth Factor Receptor 3 (FGFR3) Antibody, in Patients with Relapsed or Refractory t(4;14)-Positive",http://abstracts.hematologylibrary.org/cgi/content/abstract/120/21/4029
3281,,"TH-4000, a hypoxia-activated EGFR/Her2 inhibitor to treat EGFR-TKI resistant T790M-negative NSCLC.",http://meetinglibrary.asco.org/content/153293-156
3282,25911688,"Enhanced Targeting of the EGFR Network with MM-151, an Oligoclonal Anti-EGFR Antibody Therapeutic.",http://www.ncbi.nlm.nih.gov/pubmed/25911688
3283,19509246,Activity of panitumumab alone or with chemotherapy in non-small cell lung carcinoma cell lines expressing mutant epidermal growth factor receptor.,http://www.ncbi.nlm.nih.gov/pubmed/19509246
3284,17664472,Epidermal growth factor receptor gene copy number and clinical outcome of metastatic colorectal cancer treated with panitumumab.,http://www.ncbi.nlm.nih.gov/pubmed/17664472
3285,19930156,Phase I clinical trial using peptide vaccine for human vascular endothelial growth factor receptor 2 in combination with gemcitabine for patients with advanced pancreatic cancer.,http://www.ncbi.nlm.nih.gov/pubmed/19930156
3286,,First-in-human dose-finding study of the ALK/EGFR inhibitor AP26113 in patients with advanced malignancies: Updated results.,http://meetinglibrary.asco.org/content/114967-132
3287,24162107,HER-2/neu vaccine-primed autologous T-cell infusions for the treatment of advanced stage HER-2/neu expressing cancers.,http://www.ncbi.nlm.nih.gov/pubmed/24162107
3288,20068073,HER2-specific T cells target primary glioblastoma stem cells and induce regression of autologous experimental tumors.,http://www.ncbi.nlm.nih.gov/pubmed/20068073
3289,,"BLU-285, the first selective inhibitor of PDGFR? D842V and KIT Exon 17 mutants",http://www.abstractsonline.com/plan/ViewAbstract.aspx?mID=3682&sKey=d5b048e4-c58d-4458-b1d2-1d174261752c&cKey=6e17d4b2-c0e3-4430-a953-05575feec816&mKey=19573a54-ae8f-4e00-9c23-bd6d62268424
3290,25623065,Receptor tyrosine kinase EphA5 is a functional molecular target in human lung cancer.,http://www.ncbi.nlm.nih.gov/pubmed/25623065
3291,,Activity of AUY922 in NSCLC patients with EGFR exon 20 insertions.,http://meetinglibrary.asco.org/content/148352-156
3292,,"Abstract 1697: CPI-169, a novel and potent EZH2 inhibitor, synergizes with CHOP in vivo and achieves complete regression in lymphoma xenograft models",http://cancerres.aacrjournals.org/content/74/19_Supplement/1697
3293,14709739,Anticancer chemosensitization and radiosensitization by the novel poly(ADP-ribose) polymerase-1 inhibitor AG14361.,http://www.ncbi.nlm.nih.gov/pubmed/14709739
3294,14871963,"Novel poly(ADP-ribose) polymerase-1 inhibitor, AG14361, restores sensitivity to temozolomide in mismatch repair-deficient cells.",http://www.ncbi.nlm.nih.gov/pubmed/14871963
3295,15036647,"Radiosensitization of human and rodent cell lines by INO-1001, a novel inhibitor of poly(ADP-ribose) polymerase.",http://www.ncbi.nlm.nih.gov/pubmed/15036647
3296,17628743,"INO-1001, a novel inhibitor of poly(ADP-ribose) polymerase, enhances tumor response to doxorubicin.",http://www.ncbi.nlm.nih.gov/pubmed/17628743
3297,20337371,"Optimization of phenyl-substituted benzimidazole carboxamide poly(ADP-ribose) polymerase inhibitors: identification of (S)-2-(2-fluoro-4-(pyrrolidin-2-yl)phenyl)-1H-benzimidazole-4-carboxamide (A-966492), a highly potent and efficacious inhibitor.",http://www.ncbi.nlm.nih.gov/pubmed/20337371
3298,25981734,Differential Potential of Pharmacological PARP Inhibitors for Inhibiting Cell Proliferation and Inducing Apoptosis in Human Breast Cancer Cells.,http://www.ncbi.nlm.nih.gov/pubmed/25981734
3299,,"BGB-290, a novel PARP inhibitor with unique brain penetration ability, demonstrated strong synergism with temozolomide in subcutaneous and intracranial xenograft models",http://www.abstractsonline.com/Plan/ViewAbstract.aspx?sKey=1fa5c23e-9775-40a7-9008-02f75c55446d&cKey=46922991-5337-4928-a46c-5a7af33b209d&mKey={19573A54-AE8F-4E00-9C23-BD6D62268424}
3300,17446348,Flt3-dependent transformation by inactivating c-Cbl mutations in AML.,http://www.ncbi.nlm.nih.gov/pubmed/17446348
3301,25477533,Molecular pathways: cbl proteins in tumorigenesis and antitumor immunity-opportunities for cancer treatment.,http://www.ncbi.nlm.nih.gov/pubmed/25477533
3302,22990016,Flt3 inhibitor AC220 is a potent therapy in a mouse model of myeloproliferative disease driven by enhanced wild-type Flt3 signaling.,http://www.ncbi.nlm.nih.gov/pubmed/22990016
3303,9774334,Crystal structure of an angiogenesis inhibitor bound to the FGF receptor tyrosine kinase domain.,http://www.ncbi.nlm.nih.gov/pubmed/9774334
3304,20951944,Myeloid leukemia development in c-Cbl RING finger mutant mice is dependent on FLT3 signaling.,http://www.ncbi.nlm.nih.gov/pubmed/20951944
3305,26043365,Fragment-Based Design of Selective Nanomolar Ligands of the CREBBP Bromodomain.,http://www.ncbi.nlm.nih.gov/pubmed/26043365
3306,25409876,Selective inhibition of RET mediated cell proliferation in vitro by the kinase inhibitor SPP86.,http://www.ncbi.nlm.nih.gov/pubmed/25409876
3307,20622007,Novel oncogenic mutations of CBL in human acute myeloid leukemia that activate growth and survival pathways depend on increased metabolism.,http://www.ncbi.nlm.nih.gov/pubmed/20622007
3308,21188110,Efficacy and safety of amrubicin hydrochloride for treatment of relapsed small cell lung cancer.,http://www.ncbi.nlm.nih.gov/pubmed/21188110
3309,21988782,A meta-analysis of the prevalence of somatic mutations in the hMLH1 and hMSH2 genes in colorectal cancer.,http://www.ncbi.nlm.nih.gov/pubmed/21988782
3310,23555617,MLH1 promoter methylation frequency in colorectal cancer patients and related clinicopathological and molecular features.,http://www.ncbi.nlm.nih.gov/pubmed/23555617
3311,16873062,Endonucleolytic function of MutLalpha in human mismatch repair.,http://www.ncbi.nlm.nih.gov/pubmed/16873062
3312,10597277,"ATR is a caffeine-sensitive, DNA-activated protein kinase with a substrate specificity distinct from DNA-PK.",http://www.ncbi.nlm.nih.gov/pubmed/10597277
3313,18089823,"PF00299804, an irreversible pan-ERBB inhibitor, is effective in lung cancer models with EGFR and ERBB2 mutations that are resistant to gefitinib.",http://www.ncbi.nlm.nih.gov/pubmed/18089823
3314,21764376,EGFR exon 20 insertion mutations in non-small-cell lung cancer: preclinical data and clinical implications.,http://www.ncbi.nlm.nih.gov/pubmed/21764376
3315,20479403,"Neratinib, an irreversible pan-ErbB receptor tyrosine kinase inhibitor: results of a phase II trial in patients with advanced non-small-cell lung cancer.",http://www.ncbi.nlm.nih.gov/pubmed/20479403
3316,26179511,Deep Sequencing in Conjunction with Expression and Functional Analyses Reveals Activation of FGFR1 in Ewing Sarcoma.,http://www.ncbi.nlm.nih.gov/pubmed/26179511
3317,26175911,Let's be pragmatic about clinical data.,http://www.ncbi.nlm.nih.gov/pubmed/26175911
3318,,A Recombinant Antibody to EphA3 with Pro-Apoptotic and Enhanced ADCC Activity Against Various Hematologic Malignancies Shows Selective Inhibition of Colony Formation From Long-Term Culture-Initiating Cells (LTC-ICs) In Primary Leukemia Samples,http://www.bloodjournal.org/content/116/21/2897
3319,22869148,Tumour cell responses to new fibroblast growth factor receptor tyrosine kinase inhibitors and identification of a gatekeeper mutation in FGFR3 as a mechanism of acquired resistance.,http://www.ncbi.nlm.nih.gov/pubmed/22869148
3320,23371856,"EGFR exon 20 insertion mutations in lung adenocarcinomas: prevalence, molecular heterogeneity, and clinicopathologic characteristics.",http://www.ncbi.nlm.nih.gov/pubmed/23371856
3321,12569357,An unusual H-Ras mutant isolated from a human multiple myeloma line leads to transformation and factor-independent cell growth.,http://www.ncbi.nlm.nih.gov/pubmed/12569357
3322,,"Abstract 2509: AV-203, a humanized ERBB3 inhibitory antibody inhibits ligand-dependent and ligand-independent ERBB3 signaling in vitro and in vivo",http://cancerres.aacrjournals.org/content/72/8_Supplement/2509
3323,,"An ErbB3 Antibody, MM-121, Is Active in Cancers with Ligand-Dependent Activation",http://cancerres.aacrjournals.org/content/70/6/2485.short
3324,25857941,BMS-871: a novel orally active pan-Notch inhibitor as an anticancer agent.,http://www.ncbi.nlm.nih.gov/pubmed/25857941
3325,,Abstract 1131: Novel inhibitor of Notch signaling for the treatment of cancer.,http://cancerres.aacrjournals.org/content/73/8_Supplement/1131.short
3326,,Abstract DDT02-01: In vitro and in vivo characterization of a novel anti-fibroblast growth factor receptor (FGFR) 2 antibody (BAY 1179470) for the treatment of gastric cancer,http://cancerres.aacrjournals.org/content/74/19_Supplement/DDT02-01.short
3327,25728526,"Safety and activity of alisertib, an investigational aurora kinase A inhibitor, in patients with breast cancer, small-cell lung cancer, non-small-cell lung cancer, head and neck squamous-cell carcinoma, and gastro-oesophageal adenocarcinoma: a five-arm phase 2 study.",http://www.ncbi.nlm.nih.gov/pubmed/25728526
3328,26051236,"Clinical activity of afatinib in patients with advanced non-small-cell lung cancer harbouring uncommon EGFR mutations: a combined post-hoc analysis of LUX-Lung 2, LUX-Lung 3, and LUX-Lung 6.",http://www.ncbi.nlm.nih.gov/pubmed/26051236
3329,25981810,"Treatment with two different doses of sonidegib in patients with locally advanced or metastatic basal cell carcinoma (BOLT): a multicentre, randomised, double-blind phase 2 trial.",http://www.ncbi.nlm.nih.gov/pubmed/25981810
3330,23097632,Functional analysis of in-frame indel ARID1A mutations reveals new regulatory mechanisms of its tumor suppressor functions.,http://www.ncbi.nlm.nih.gov/pubmed/23097632
3331,22127921,The Pax-5 gene: a pluripotent regulator of B-cell differentiation and cancer disease.,http://www.ncbi.nlm.nih.gov/pubmed/22127921
3332,20601953,Inactivating mutations of the histone methyltransferase gene EZH2 in myeloid disorders.,http://www.ncbi.nlm.nih.gov/pubmed/20601953
3333,25840971,Biological Activities of RUNX1 Mutants Predict Secondary Acute Leukemia Transformation from Chronic Myelomonocytic Leukemia and Myelodysplastic Syndromes.,http://www.ncbi.nlm.nih.gov/pubmed/25840971
3334,24983357,Clinical profiling of BCL-2 family members in the setting of BRAF inhibition offers a rationale for targeting de novo resistance using BH3 mimetics.,http://www.ncbi.nlm.nih.gov/pubmed/24983357
3335,23208470,ARID1A mutations in cancer: another epigenetic tumor suppressor?,http://www.ncbi.nlm.nih.gov/pubmed/23208470
3336,21390126,Inactivating mutations of acetyltransferase genes in B-cell lymphoma.,http://www.ncbi.nlm.nih.gov/pubmed/21390126
3337,22659450,The oncogenic lung cancer fusion kinase CD74-ROS activates a novel invasiveness pathway through E-Syt1 phosphorylation.,http://www.ncbi.nlm.nih.gov/pubmed/22659450
3338,22215748,ROS1 rearrangements define a unique molecular class of lung cancers.,http://www.ncbi.nlm.nih.gov/pubmed/22215748
3339,25351743,Cabozantinib overcomes crizotinib resistance in ROS1 fusion-positive cancer.,http://www.ncbi.nlm.nih.gov/pubmed/25351743
3340,25113440,Mutational and functional analysis of the tumor-suppressor PTPRD in human melanoma.,http://www.ncbi.nlm.nih.gov/pubmed/25113440
3341,19478061,The tyrosine phosphatase PTPRD is a tumor suppressor that is frequently inactivated and mutated in glioblastoma and other human cancers.,http://www.ncbi.nlm.nih.gov/pubmed/19478061
3342,24709888,Rare SF3B1 R625 mutations in cutaneous melanoma.,http://www.ncbi.nlm.nih.gov/pubmed/24709888
3343,26125448,Impact of KRAS codon subtypes from a randomised phase II trial of selumetinib plus docetaxel in KRAS mutant advanced non-small-cell lung cancer.,http://www.ncbi.nlm.nih.gov/pubmed/26125448
3344,,Genetic Characterization of Ten-Eleven-Translocation Methylcytosine Dioxygenase Alterations in Human Glioma,http://www.jcancer.org/v06p0832.htm
3345,23674493,PI3K pathway dependencies in endometrioid endometrial cancer cell lines.,http://www.ncbi.nlm.nih.gov/pubmed/23674493
3346,19033389,Distinct roles of class IA PI3K isoforms in primary and immortalised macrophages.,http://www.ncbi.nlm.nih.gov/pubmed/19033389
3347,16647110,A pharmacological map of the PI3-K family defines a role for p110alpha in insulin signaling.,http://www.ncbi.nlm.nih.gov/pubmed/16647110
3348,20170098,Salicylic acid based small molecule inhibitor for the oncogenic Src homology-2 domain containing protein tyrosine phosphatase-2 (SHP2).,http://www.ncbi.nlm.nih.gov/pubmed/20170098
3349,16789742,"Furan-2-ylmethylene thiazolidinediones as novel, potent, and selective inhibitors of phosphoinositide 3-kinase gamma.",http://www.ncbi.nlm.nih.gov/pubmed/16789742
3350,24919154,Inactivation of PI(3)K p110δ breaks regulatory T-cell-mediated immune tolerance to cancer.,http://www.ncbi.nlm.nih.gov/pubmed/24919154
3352,19815551,Non-redundant roles of phosphoinositide 3-kinase isoforms alpha and beta in glycoprotein VI-induced platelet signaling and thrombus formation.,http://www.ncbi.nlm.nih.gov/pubmed/19815551
3353,16717135,Discovery of a novel shp2 protein tyrosine phosphatase inhibitor.,http://www.ncbi.nlm.nih.gov/pubmed/16717135
3354,25371371,CXCR4 WHIM-like frameshift and nonsense mutations promote ibrutinib resistance but do not supplant MYD88(L265P) -directed survival signalling in Waldenström macroglobulinaemia cells.,http://www.ncbi.nlm.nih.gov/pubmed/25371371
3355,25496334,Mogamulizumab and the treatment of CCR4-positive T-cell lymphomas.,http://www.ncbi.nlm.nih.gov/pubmed/25496334
3356,11727524,HSPPC-96: a personalised cancer vaccine.,http://www.ncbi.nlm.nih.gov/pubmed/11727524
3357,17391493,Oncolytic Coxsackievirus A21 as a novel therapy for multiple myeloma.,http://www.ncbi.nlm.nih.gov/pubmed/17391493
3358,24130706,Regression of fibrosis and reversal of cirrhosis in rats by galectin inhibitors in thioacetamide-induced liver disease.,http://www.ncbi.nlm.nih.gov/pubmed/24130706
3359,26033215,"Inhibition of indoleamine 2,3-dioxygenase 1 expression alters immune response in colon tumor microenvironment in mice.",http://www.ncbi.nlm.nih.gov/pubmed/26033215
3360,24832153,Development of thyroglobulin antibodies after GVAX immunotherapy is associated with prolonged survival.,http://www.ncbi.nlm.nih.gov/pubmed/24832153
3361,17085673,Anti-vascular endothelial growth factor receptor-1 antagonist antibody as a therapeutic agent for cancer.,http://www.ncbi.nlm.nih.gov/pubmed/17085673
3362,23903897,"Icrucumab, a fully human monoclonal antibody against the vascular endothelial growth factor receptor-1, in the treatment of patients with advanced solid malignancies: a Phase 1 study.",http://www.ncbi.nlm.nih.gov/pubmed/23903897
3363,,Protein tyrosine phosphatase non receptor 11 (PTPN11/Shp2) as a driver oncogene and a novel therapeutic target in non-small cell lung cancer (NSCLC),http://meetinglibrary.asco.org/content/147146-156
3364,20510203,Inhibition of cellular Shp2 activity by a methyl ester analog of SPI-112.,http://www.ncbi.nlm.nih.gov/pubmed/20510203
3365,17942397,Shp2E76K mutant confers cytokine-independent survival of TF-1 myeloid cells by up-regulating Bcl-XL.,http://www.ncbi.nlm.nih.gov/pubmed/17942397
3366,25931518,Combined Inhibition of Cyclin-Dependent Kinases (Dinaciclib) and AKT (MK-2206) Blocks Pancreatic Tumor Growth and Metastases in Patient-Derived Xenograft Models.,http://www.ncbi.nlm.nih.gov/pubmed/25931518
3367,26144315,"PF-06463922, an ALK/ROS1 Inhibitor, Overcomes Resistance to First and Second Generation ALK Inhibitors in Preclinical Models.",http://www.ncbi.nlm.nih.gov/pubmed/26144315
3369,26168818,Antiangiogenic and antitumor activities of berberine derivative NAX014 compound in a transgenic murine model of HER2/neu-positive mammary carcinoma.,http://www.ncbi.nlm.nih.gov/pubmed/26168818
3370,24000115,Antitumor effect of novel berberine derivatives in breast cancer cells.,http://www.ncbi.nlm.nih.gov/pubmed/24000115
3371,25228534,Two novel ALK mutations mediate acquired resistance to the next-generation ALK inhibitor alectinib.,http://www.ncbi.nlm.nih.gov/pubmed/25228534
3372,25724523,Radiation Enhancement of Head and Neck Squamous Cell Carcinoma by the Dual PI3K/mTOR Inhibitor PF-05212384.,http://www.ncbi.nlm.nih.gov/pubmed/25724523
3373,25370464,Phase I Study to Assess the Combination of Afatinib with Trastuzumab in Patients with Advanced or Metastatic HER2-Positive Breast Cancer.,http://www.ncbi.nlm.nih.gov/pubmed/25370464
3374,25975632,"Efficacy of neoadjuvant bevacizumab added to docetaxel followed by fluorouracil, epirubicin, and cyclophosphamide, for women with HER2-negative early breast cancer (ARTemis): an open-label, randomised, phase 3 trial.",http://www.ncbi.nlm.nih.gov/pubmed/25975632
3375,25559818,PIK3CA mutations are associated with decreased benefit to neoadjuvant human epidermal growth factor receptor 2-targeted therapies in breast cancer.,http://www.ncbi.nlm.nih.gov/pubmed/25559818
3376,21632823,Methylation specifies distinct estrogen-induced binding site repertoires of CBP to chromatin.,http://www.ncbi.nlm.nih.gov/pubmed/21632823
3377,24739903,Somatic mutation of GRIN2A in malignant melanoma results in loss of tumor suppressor activity via aberrant NMDAR complex formation.,http://www.ncbi.nlm.nih.gov/pubmed/24739903
3378,12461170,A putative molecular-activation switch in the transmembrane domain of erbB2.,http://www.ncbi.nlm.nih.gov/pubmed/12461170
3379,14715624,Inhibition of fibroblast growth factor receptor 3 induces differentiation and apoptosis in t(4;14) myeloma.,http://www.ncbi.nlm.nih.gov/pubmed/14715624
3380,26048680,Identification of Oncogenic and Drug-Sensitizing Mutations in the Extracellular Domain of FGFR2.,http://www.ncbi.nlm.nih.gov/pubmed/26048680
3381,17208434,KIT mutations in GIST.,http://www.ncbi.nlm.nih.gov/pubmed/17208434
3382,7687267,Novel mutations of the KIT (mast/stem cell growth factor receptor) proto-oncogene in human piebaldism.,http://www.ncbi.nlm.nih.gov/pubmed/7687267
3383,18955458,Primary and secondary kinase genotypes correlate with the biological and clinical activity of sunitinib in imatinib-resistant gastrointestinal stromal tumor.,http://www.ncbi.nlm.nih.gov/pubmed/18955458
3384,22898329,Understanding sensitivity to BH3 mimetics: ABT-737 as a case study to foresee the complexities of personalized medicine.,http://www.ncbi.nlm.nih.gov/pubmed/22898329
3385,20576107,Chemotherapeutic drugs sensitize human renal cell carcinoma cells to ABT-737 by a mechanism involving the Noxa-dependent inactivation of Mcl-1 or A1.,http://www.ncbi.nlm.nih.gov/pubmed/20576107
3386,25806224,Targeting EML4-ALK driven non-small cell lung cancer (NSCLC).,http://www.ncbi.nlm.nih.gov/pubmed/25806224
3387,23539443,A novel tankyrase small-molecule inhibitor suppresses APC mutation-driven colorectal tumor growth.,http://www.ncbi.nlm.nih.gov/pubmed/23539443
3388,18922926,Pleiotropic biological activities of alternatively spliced TMPRSS2/ERG fusion gene transcripts.,http://www.ncbi.nlm.nih.gov/pubmed/18922926
3389,24589464,Poly (ADP-ribose) polymerase inhibitor: an evolving paradigm in the treatment of prostate cancer.,http://www.ncbi.nlm.nih.gov/pubmed/24589464
3390,21575865,Mechanistic rationale for inhibition of poly(ADP-ribose) polymerase in ETS gene fusion-positive prostate cancer.,http://www.ncbi.nlm.nih.gov/pubmed/21575865
3391,25535896,Recurrent FGFR3-TACC3 fusion gene in nasopharyngeal carcinoma.,http://www.ncbi.nlm.nih.gov/pubmed/25535896
3392,25294908,Identification of recurrent FGFR3-TACC3 fusion oncogenes from lung adenocarcinoma.,http://www.ncbi.nlm.nih.gov/pubmed/25294908
3393,23298836,The tumorigenic FGFR3-TACC3 gene fusion escapes miR-99a regulation in glioblastoma.,http://www.ncbi.nlm.nih.gov/pubmed/23298836
3394,23578175,Identification of a lung adenocarcinoma cell line with CCDC6-RET fusion gene and the effect of RET inhibitors in vitro and in vivo.,http://www.ncbi.nlm.nih.gov/pubmed/23578175
3395,23856031,Antitumor activities of the targeted multi-tyrosine kinase inhibitor lenvatinib (E7080) against RET gene fusion-driven tumor models.,http://www.ncbi.nlm.nih.gov/pubmed/23856031
3396,22617245,Preclinical rationale for use of the clinically available multitargeted tyrosine kinase inhibitor crizotinib in ROS1-translocated lung cancer.,http://www.ncbi.nlm.nih.gov/pubmed/22617245
3397,25667280,Crizotinib therapy for advanced lung adenocarcinoma and a ROS1 rearrangement: results from the EUROS1 cohort.,http://www.ncbi.nlm.nih.gov/pubmed/25667280
3398,18451166,Genomic alterations of anaplastic lymphoma kinase may sensitize tumors to anaplastic lymphoma kinase inhibitors.,http://www.ncbi.nlm.nih.gov/pubmed/18451166
3399,18757741,Cancer related mutations in NRF2 impair its recognition by Keap1-Cul3 E3 ligase and promote malignancy.,http://www.ncbi.nlm.nih.gov/pubmed/18757741
3400,21062981,Global downstream pathway analysis reveals a dependence of oncogenic NF-E2-related factor 2 mutation on the mTOR growth signaling pathway.,http://www.ncbi.nlm.nih.gov/pubmed/21062981
3401,24455489,Evidence That GRIN2A Mutations in Melanoma Correlate with Decreased Survival.,http://www.ncbi.nlm.nih.gov/pubmed/24455489
3402,24277854,Targeting Wnt-driven cancer through the inhibition of Porcupine by LGK974.,http://www.ncbi.nlm.nih.gov/pubmed/24277854
3403,24713927,"MLN4924, an NAE inhibitor, suppresses AKT and mTOR signaling via upregulation of REDD1 in human myeloma cells.",http://www.ncbi.nlm.nih.gov/pubmed/24713927
3404,25151963,Fatty acid synthase inhibition engages a novel caspase-2 regulatory mechanism to induce ovarian cancer cell death.,http://www.ncbi.nlm.nih.gov/pubmed/25151963
3405,24515947,Methylseleninic acid elevates REDD1 and inhibits prostate cancer cell growth despite AKT activation and mTOR dysregulation in hypoxia.,http://www.ncbi.nlm.nih.gov/pubmed/24515947
3406,25543165,Baicalein upregulates DDIT4 expression which mediates mTOR inhibition and growth inhibition in cancer cells.,http://www.ncbi.nlm.nih.gov/pubmed/25543165
3407,11250899,p300/CBP-mediated p53 acetylation is commonly induced by p53-activating agents and inhibited by MDM2.,http://www.ncbi.nlm.nih.gov/pubmed/11250899
3408,22645312,"Histone methyltransferase NSD2/MMSET mediates constitutive NF-κB signaling for cancer cell proliferation, survival, and tumor growth via a feed-forward loop.",http://www.ncbi.nlm.nih.gov/pubmed/22645312
3409,22683710,BAP1 loss defines a new class of renal cell carcinoma.,http://www.ncbi.nlm.nih.gov/pubmed/22683710
3410,22038994,Histone deacetylase inhibitors induce growth arrest and differentiation in uveal melanoma.,http://www.ncbi.nlm.nih.gov/pubmed/22038994
3411,21642991,The nuclear deubiquitinase BAP1 is commonly inactivated by somatic mutations and 3p21.1 losses in malignant pleural mesothelioma.,http://www.ncbi.nlm.nih.gov/pubmed/21642991
3412,24135138,Identification of kinase fusion oncogenes in post-Chernobyl radiation-induced thyroid cancers.,http://www.ncbi.nlm.nih.gov/pubmed/24135138
3413,23890088,Recurrent BRAF kinase fusions in melanocytic tumors offer an opportunity for targeted therapy.,http://www.ncbi.nlm.nih.gov/pubmed/23890088
3414,17283122,"TFE3 fusions activate MET signaling by transcriptional up-regulation, defining another class of tumors as candidates for therapeutic MET inhibition.",http://www.ncbi.nlm.nih.gov/pubmed/17283122
3415,26187510,(90)Y-clivatuzumab tetraxetan with or without low-dose gemcitabine: A phase Ib study in patients with metastatic pancreatic cancer after two or more prior therapies.,http://www.ncbi.nlm.nih.gov/pubmed/26187510
3416,21317455,The class I HDAC inhibitor MGCD0103 induces cell cycle arrest and apoptosis in colon cancer initiating cells by upregulating Dickkopf-1 and non-canonical Wnt signaling.,http://www.ncbi.nlm.nih.gov/pubmed/21317455
3417,20538840,The histone deacetylase inhibitor MGCD0103 has both deacetylase and microtubule inhibitory activity.,http://www.ncbi.nlm.nih.gov/pubmed/20538840
3418,25384499,"Chidamide, a histone deacetylase inhibitor, functions as a tumor inhibitor by modulating the ratio of Bax/Bcl-2 and P21 in pancreatic cancer.",http://www.ncbi.nlm.nih.gov/pubmed/25384499
3419,24038993,"Initial testing (stage 1) of the histone deacetylase inhibitor, quisinostat (JNJ-26481585), by the Pediatric Preclinical Testing Program.",http://www.ncbi.nlm.nih.gov/pubmed/24038993
3420,19861438,"JNJ-26481585, a novel ""second-generation"" oral histone deacetylase inhibitor, shows broad-spectrum preclinical antitumoral activity.",http://www.ncbi.nlm.nih.gov/pubmed/19861438
3421,22553374,"A phase I pharmacokinetic and pharmacodynamic study of CHR-3996, an oral class I selective histone deacetylase inhibitor in refractory solid tumors.",http://www.ncbi.nlm.nih.gov/pubmed/22553374
3422,21051595,Frequent mutation of BAP1 in metastasizing uveal melanomas.,http://www.ncbi.nlm.nih.gov/pubmed/21051595
3423,18757409,BRCA1-associated protein-1 is a tumor suppressor that requires deubiquitinating activity and nuclear localization.,http://www.ncbi.nlm.nih.gov/pubmed/18757409
3424,18628483,A novel breast cancer-associated BRIP1 (FANCJ/BACH1) germ-line mutation impairs protein stability and function.,http://www.ncbi.nlm.nih.gov/pubmed/18628483
3425,23565244,PARP inhibition sensitizes to low dose-rate radiation TMPRSS2-ERG fusion gene-expressing and PTEN-deficient prostate cancer cells.,http://www.ncbi.nlm.nih.gov/pubmed/23565244
3426,22837387,Transforming fusions of FGFR and TACC genes in human glioblastoma.,http://www.ncbi.nlm.nih.gov/pubmed/22837387
3427,25915810,"Efficacy and safety of CDX-301, recombinant human Flt3L, at expanding dendritic cells and hematopoietic stem cells in healthy human volunteers.",http://www.ncbi.nlm.nih.gov/pubmed/25915810
3428,23777306,A Phase I vaccine trial using dendritic cells pulsed with autologous oxidized lysate for recurrent ovarian cancer.,http://www.ncbi.nlm.nih.gov/pubmed/23777306
3429,23721559,EphB4 as a therapeutic target in mesothelioma.,http://www.ncbi.nlm.nih.gov/pubmed/23721559
3430,26175415,A DNA Hypomethylation Signature Predicts Antitumor Activity of LSD1 Inhibitors in SCLC.,http://www.ncbi.nlm.nih.gov/pubmed/26175415
3431,,"First-In-Human Study Of AMG 319, a Highly Selective, Small Molecule Inhibitor Of PI3K?, In Adult Patients With Relapsed Or Refractory Lymphoid Malignancies",http://www.bloodjournal.org/content/122/21/678.full?sso-checked=true
3432,20196086,Integrated genomic profiling identifies candidate genes implicated in glioma-genesis and a novel LEO1-SLC12A1 fusion gene.,http://www.ncbi.nlm.nih.gov/pubmed/20196086
3433,23433846,"A phase I dose-finding, safety and tolerability study of AZD8330 in patients with advanced malignancies.",http://www.ncbi.nlm.nih.gov/pubmed/23433846
3434,,"High dose intermittent scheduling of AZD8835, a novel potent and selective inhibitor of PI3K-alpha and PI3K-delta, identifies potential treatment strategies for PIK3CA-dependent cancers",http://www.abstractsonline.com/plan/ViewAbstract.aspx?mID=3682&sKey=14323955-7e99-4856-aec7-b2f95e96b99b&cKey=7627fe75-d2b2-4175-8cd6-98aaeb2524e2&mKey=19573a54-ae8f-4e00-9c23-bd6d62268424
3435,,"Activity of BAY1082439, a balanced PI3Kalpha/beta inhibitor, in gastric cancer",http://www.abstractsonline.com/plan/ViewAbstract.aspx?mID=3682&sKey=14323955-7e99-4856-aec7-b2f95e96b99b&cKey=5384c5ef-c9a4-49da-a50c-67bf77ceef19&mKey=19573a54-ae8f-4e00-9c23-bd6d62268424
3436,,Abstract 869: Potent in vitro and in vivo anti-tumor activity of PI3K inhibitor BAY 80-6946 and MEK inhibitor BAY 86-9766 in preclinical biliary tract cancer models,http://cancerres.aacrjournals.org/content/72/8_Supplement/869.short
3437,23475782,"Coexistent mutations of KRAS and PIK3CA affect the efficacy of NVP-BEZ235, a dual PI3K/MTOR inhibitor, in regulating the PI3K/MTOR pathway in colorectal cancer.",http://www.ncbi.nlm.nih.gov/pubmed/23475782
3439,22327624,KIF5B-RET fusions in lung adenocarcinoma.,http://www.ncbi.nlm.nih.gov/pubmed/22327624
3440,9850089,The RET/PTC3 oncogene: metastatic solid-type papillary carcinomas in murine thyroids.,http://www.ncbi.nlm.nih.gov/pubmed/9850089
3441,23150706,RET fusions define a unique molecular and clinicopathologic subtype of non-small-cell lung cancer.,http://www.ncbi.nlm.nih.gov/pubmed/23150706
3442,22871572,KRAS(G12D)- and BRAF(V600E)-induced transformation of murine pancreatic epithelial cells requires MEK/ERK-stimulated IGF1R signaling.,http://www.ncbi.nlm.nih.gov/pubmed/22871572
3443,22684718,Combination of a MEK inhibitor at sub-MTD with a PI3K/mTOR inhibitor significantly suppresses growth of lung adenocarcinoma tumors in Kras(G12D-LSL) mice.,http://www.ncbi.nlm.nih.gov/pubmed/22684718
3444,20876794,Key role of phosphoinositide 3-kinase class IB in pancreatic cancer.,http://www.ncbi.nlm.nih.gov/pubmed/20876794
3445,24395457,"Phase I study of PF-04691502, a small-molecule, oral, dual inhibitor of PI3K and mTOR, in patients with advanced cancer.",http://www.ncbi.nlm.nih.gov/pubmed/24395457
3446,24416348,Promotion of cancer cell invasiveness and metastasis emergence caused by olfactory receptor stimulation.,http://www.ncbi.nlm.nih.gov/pubmed/24416348
3447,22159814,"NVP-BKM120, a novel PI3K inhibitor, shows synergism with a STAT3 inhibitor in human gastric cancer cells harboring KRAS mutations.",http://www.ncbi.nlm.nih.gov/pubmed/22159814
3448,19018267,KRAS or BRAF mutation status is a useful predictor of sensitivity to MEK inhibition in ovarian cancer.,http://www.ncbi.nlm.nih.gov/pubmed/19018267
3449,19372556,KRAS/BRAF mutation status and ERK1/2 activation as biomarkers for MEK1/2 inhibitor therapy in colorectal cancer.,http://www.ncbi.nlm.nih.gov/pubmed/19372556
3450,,"Preclinical characterization of PWT33597, a dual inhibitor of PI3-kinase alpha and mTOR",http://cancerres.aacrjournals.org/content/71/8_Supplement/4485.short
3451,26156229,The combination of intravenous Reolysin and gemcitabine induces reovirus replication and endoplasmic reticular stress in a patient with KRAS-activated pancreatic cancer.,http://www.ncbi.nlm.nih.gov/pubmed/26156229
3452,26091808,A phase II/III randomized study to compare the efficacy and safety of rigosertib plus gemcitabine versus gemcitabine alone in patients with previously untreated metastatic pancreatic cancer.,http://www.ncbi.nlm.nih.gov/pubmed/26091808
3453,,"Abstract C270: In vitro and in vivo antitumor activity of DCBCI0901, a potent PI3K/mTORC1/mTORC2 inhibitor.",http://mct.aacrjournals.org/content/12/11_Supplement/C270.short
3454,24947927,Phase I expansion and pharmacodynamic study of the oral MEK inhibitor RO4987655 (CH4987655) in selected patients with advanced cancer with RAS-RAF mutations.,http://www.ncbi.nlm.nih.gov/pubmed/24947927
3455,16952909,"The Akt inhibitor deguelin, is an angiopreventive agent also acting on the NF-kappaB pathway.",http://www.ncbi.nlm.nih.gov/pubmed/16952909
3456,25202376,Synergistic antitumor effects of combined deguelin and cisplatin treatment in gastric cancer cells.,http://www.ncbi.nlm.nih.gov/pubmed/25202376
3457,22761467,"First-in-human, phase I dose-escalation study of the safety, pharmacokinetics, and pharmacodynamics of RO5126766, a first-in-class dual MEK/RAF inhibitor in patients with solid tumors.",http://www.ncbi.nlm.nih.gov/pubmed/22761467
3458,,"460P PHASE I CLINICAL TRIAL OF DS-7423, AN ORAL PI3K/MTOR DUAL INHIBITOR, IN JAPANESE PATIENTS WITH ADVANCED SOLID TUMORS",http://annonc.oxfordjournals.org/content/25/suppl_4/iv153.2
3459,,"Combination of the MEK inhibitor, pimasertib (MSC1936369B), and the PI3K/mTOR inhibitor, SAR245409, in patients with advanced solid tumors: Results of a phase Ib dose-escalation trial.",http://cancerres.aacrjournals.org/content/73/8_Supplement/LB-147.short
3460,,The PI3K Inhibitor GDC-0941 Attenuates Disease in a KrasG12D Mouse Model of CMML and JMML.,http://abstracts.hematologylibrary.org/cgi/content/abstract/120/21/2862?maxtoshow=&hits=10&RESULTFORMAT=&fulltext=GDC-0941&searchid=1&FIRSTINDEX=0&volume=120&issue=21&resourcetype=HWCIT
3461,25193512,Dual targeting of hypoxia and homologous recombination repair dysfunction in triple-negative breast cancer.,http://www.ncbi.nlm.nih.gov/pubmed/25193512
3462,22952903,K-RAS mutant pancreatic tumors show higher sensitivity to MEK than to PI3K inhibition in vivo.,http://www.ncbi.nlm.nih.gov/pubmed/22952903
3463,25673820,Dual PI3K/mTOR Inhibitors Induce Rapid Overactivation of the MEK/ERK Pathway in Human Pancreatic Cancer Cells through Suppression of mTORC2.,http://www.ncbi.nlm.nih.gov/pubmed/25673820
3464,,Phase I first-in-human study of the PI3 kinase inhibitor GSK2126458 (GSK458) in patients with advanced solid tumors (study P3K112826).,http://hwmaint.meeting.ascopubs.org/cgi/content/abstract/29/15_suppl/3018
3465,24935174,Whole genome gene copy number profiling of gastric cancer identifies PAK1 and KRAS gene amplification as therapy targets.,http://www.ncbi.nlm.nih.gov/pubmed/24935174
3466,22921184,Phase I pharmacokinetic and pharmacodynamic study of the pan-PI3K/mTORC vascular targeted pro-drug SF1126 in patients with advanced solid tumours and B-cell malignancies.,http://www.ncbi.nlm.nih.gov/pubmed/22921184
3467,,"BRAF is not the only predictor of sensitivity in vitro and in vivo for TAK-733, a selective potent inhibitor of MEK1/2",http://cancerres.aacrjournals.org/content/70/8_Supplement/2523.short
3468,25620467,Nanomicellar TGX221 blocks xenograft tumor growth of prostate cancer in nude mice.,http://www.ncbi.nlm.nih.gov/pubmed/25620467
3469,18666379,Tirapazamine: from bench to clinical trials.,http://www.ncbi.nlm.nih.gov/pubmed/18666379
3470,17606726,Mechanism of action and preclinical antitumor activity of the novel hypoxia-activated DNA cross-linking agent PR-104.,http://www.ncbi.nlm.nih.gov/pubmed/17606726
3471,20732963,Pharmacokinetic/pharmacodynamic modeling identifies SN30000 and SN29751 as tirapazamine analogues with improved tissue penetration and hypoxic cell killing in tumors.,http://www.ncbi.nlm.nih.gov/pubmed/20732963
3472,,"Dose-escalation of the first-in human phase I/Ib study of ABTL0812, a novel antitumor drug inhibiting the Akt/mTOR pathway in patients with advanced solid tumors.",http://meeting.ascopubs.org/cgi/content/short/33/15_suppl/2585?rss=1
3473,25902900,"A first-in-human phase I trial of LY2780301, a dual p70 S6 kinase and Akt Inhibitor, in patients with advanced or metastatic cancer.",http://www.ncbi.nlm.nih.gov/pubmed/25902900
3474,24952432,A polymorphism in JMJD2C alters the cleavage by caspase-3 and the prognosis of human breast cancer.,http://www.ncbi.nlm.nih.gov/pubmed/24952432
3475,22327623,"RET, ROS1 and ALK fusions in lung cancer.",http://www.ncbi.nlm.nih.gov/pubmed/22327623
3476,24218589,Foretinib is a potent inhibitor of oncogenic ROS1 fusion proteins.,http://www.ncbi.nlm.nih.gov/pubmed/24218589
3477,24999209,Lack of GOPC-ROS1 (FIG-ROS1) rearrangement in adult human gliomas.,http://www.ncbi.nlm.nih.gov/pubmed/24999209
3478,18262558,PIK3CA mutation status in Japanese esophageal squamous cell carcinoma.,http://www.ncbi.nlm.nih.gov/pubmed/18262558
3479,25827820,"Phase 2 study of MK-2206, an allosteric inhibitor of AKT, as second-line therapy for advanced gastric and gastroesophageal junction cancer: A SWOG cooperative group trial (S1005).",http://www.ncbi.nlm.nih.gov/pubmed/25827820
3480,26222558,Structure-Guided Blockade of CSF1R Kinase in Tenosynovial Giant-Cell Tumor.,http://www.ncbi.nlm.nih.gov/pubmed/26222558
3481,,"First-in-human, phase I, dose-escalation study of selective PI3K? isoform inhibitor MLN1117 in patients (pts) with advanced solid malignancies.",http://hwmaint.meeting.ascopubs.org/cgi/content/abstract/33/15_suppl/2501
3482,22271687,Enhanced apoptosis and tumor growth suppression elicited by combination of MEK (selumetinib) and mTOR kinase inhibitors (AZD8055).,http://www.ncbi.nlm.nih.gov/pubmed/22271687
3483,21673091,"Preclinical characterization of OSI-027, a potent and selective inhibitor of mTORC1 and mTORC2: distinct from rapamycin.",http://www.ncbi.nlm.nih.gov/pubmed/21673091
3484,25183650,A phase I and pharmacokinetic study of oral perifosine with different loading schedules in patients with refractory neoplasms.,http://www.ncbi.nlm.nih.gov/pubmed/25183650
3485,24962792,The TPM3-NTRK1 rearrangement is a recurring event in colorectal carcinoma and is associated with tumor sensitivity to TRKA kinase inhibition.,http://www.ncbi.nlm.nih.gov/pubmed/24962792
3486,26029667,Downregulation of MYCN through PI3K Inhibition in Mouse Models of Pediatric Neural Cancer.,http://www.ncbi.nlm.nih.gov/pubmed/26029667
3487,25700704,P7170: A Novel Molecule with Unique Profile of mTORC1/C2 and Activin Receptor-like Kinase 1 Inhibition Leading to Antitumor and Antiangiogenic Activity.,http://www.ncbi.nlm.nih.gov/pubmed/25700704
3488,22336586,Pharmacologic synergy between dual phosphoinositide-3-kinase and mammalian target of rapamycin inhibition and 5-fluorouracil in PIK3CA mutant gastric cancer cells.,http://www.ncbi.nlm.nih.gov/pubmed/22336586
3489,26235881,The anti-esophageal cancer cell activity by a novel tyrosine/phosphoinositide kinase inhibitor PP121.,http://www.ncbi.nlm.nih.gov/pubmed/26235881
3490,25035961,"PP242 suppresses cell proliferation, metastasis, and angiogenesis of gastric cancer through inhibition of the PI3K/AKT/mTOR pathway.",http://www.ncbi.nlm.nih.gov/pubmed/25035961
3491,,First-in-man (FIM) pharmacodynamic (PD) and pharmacokinetic (PK) phase I trial of PQR309 in advanced solid tumors,http://cancerres.aacrjournals.org/content/75/15_Supplement/CT310.short
3492,22391131,"High levels of p110δ PI3K expression in solid tumor cells suppress PTEN activity, generating cellular sensitivity to p110δ inhibitors through PTEN activation.",http://www.ncbi.nlm.nih.gov/pubmed/22391131
3493,26177599,"A phase I dose-escalation study to assess safety, tolerability, pharmacokinetics, and preliminary efficacy of the dual mTORC1/mTORC2 kinase inhibitor CC-223 in patients with advanced solid tumors or multiple myeloma.",http://www.ncbi.nlm.nih.gov/pubmed/26177599
3494,19901013,Phase Ib study of weekly mammalian target of rapamycin inhibitor ridaforolimus (AP23573; MK-8669) with weekly paclitaxel.,http://www.ncbi.nlm.nih.gov/pubmed/19901013
3495,,Phase I study of RX-0201 in patients with advanced or metastatic solid tumors,http://meeting.ascopubs.org/cgi/content/abstract/24/18_suppl/13102
3496,25107918,"Phase I first-in-human study of CUDC-101, a multitargeted inhibitor of HDACs, EGFR, and HER2 in patients with advanced solid tumors.",http://www.ncbi.nlm.nih.gov/pubmed/25107918
3497,19584230,Response prediction to a multitargeted kinase inhibitor in cancer cell lines and xenograft tumors using high-content tyrosine peptide arrays with a kinetic readout.,http://www.ncbi.nlm.nih.gov/pubmed/19584230
3498,25231405,"First-in-human study of CH5132799, an oral class I PI3K inhibitor, studying toxicity, pharmacokinetics, and pharmacodynamics, in patients with metastatic cancer.",http://www.ncbi.nlm.nih.gov/pubmed/25231405
3499,25701378,Celecoxib sensitizes gastric cancer to rapamycin via inhibition of the Cbl-b-regulated PI3K/Akt pathway.,http://www.ncbi.nlm.nih.gov/pubmed/25701378
3500,20811676,Deguelin promotes apoptosis and inhibits angiogenesis of gastric cancer.,http://www.ncbi.nlm.nih.gov/pubmed/20811676
3501,,"Abstract C173: A first-in-human Phase I study of DS-3078a, an oral TORC1/2 inhibitor, in patients with advanced solid tumors: Preliminary results.",http://mct.aacrjournals.org/content/12/11_Supplement/C173.abstract
3502,,"Phase I expansion of S-222611, a reversible inhibitor of EGFR and HER2, in advanced solid tumors, including patients with brain metastases",http://meetinglibrary.asco.org/content/148414-156
3503,24185040,Selective targeting of human colon cancer stem-like cells by the mTOR inhibitor Torin-1.,http://www.ncbi.nlm.nih.gov/pubmed/24185040
3504,26239364,The novel mTOR inhibitor Torin-2 induces autophagy and downregulates the expression of UHRF1 to suppress hepatocarcinoma cell growth.,http://www.ncbi.nlm.nih.gov/pubmed/26239364
3505,25172762,"Taselisib, a selective inhibitor of PIK3CA, is highly effective on PIK3CA-mutated and HER2/neu amplified uterine serous carcinoma in vitro and in vivo.",http://www.ncbi.nlm.nih.gov/pubmed/25172762
3506,,"In vivo activity of ARRY-543, a potent, small molecule inhibitor of EGFR/ErbB-2 in combination with trastuzumab or docetaxel",http://cancerres.aacrjournals.org/content/69/2_Supplement/2150
3507,,"Abstract 915: Expanded biomarker results from a phase I dose escalation study of GDC-0032, a beta isoform-sparing PI3K inhibitor",http://cancerres.aacrjournals.org/content/74/19_Supplement/915.short
3508,21998291,GDC-0980 is a novel class I PI3K/mTOR kinase inhibitor with robust activity in cancer models driven by the PI3K pathway.,http://www.ncbi.nlm.nih.gov/pubmed/21998291
3509,,Phase I dose-escalation of the oral MEK1/2 inhibitor GSK1120212 (GSK212) dosed in combination with the oral AKT inhibitor GSK2141795 (GSK795).,http://hwmaint.meeting.ascopubs.org/cgi/content/abstract/29/15_suppl/3085
3510,19755509,Combination of EGFR and MEK1/2 inhibitor shows synergistic effects by suppressing EGFR/HER3-dependent AKT activation in human gastric cancer cells.,http://www.ncbi.nlm.nih.gov/pubmed/19755509
3511,10556217,TRK-fused gene (TFG) is a new partner of ALK in anaplastic large cell lymphoma producing two structurally different TFG-ALK translocations.,http://www.ncbi.nlm.nih.gov/pubmed/10556217
3512,24569089,Context-dependent antagonism between Akt inhibitors and topoisomerase poisons.,http://www.ncbi.nlm.nih.gov/pubmed/24569089
3513,25855786,"CC-223, a Potent and Selective Inhibitor of mTOR Kinase: In Vitro and In Vivo Characterization.",http://www.ncbi.nlm.nih.gov/pubmed/25855786
3514,22325357,Clinical activity of afatinib (BIBW 2992) in patients with lung adenocarcinoma with mutations in the kinase domain of HER2/neu.,http://www.ncbi.nlm.nih.gov/pubmed/22325357
3515,,Abstract 3610: Pan-ErbB inhibition by ARRY-334543 is superior to selective ErbB inhibition in a preclinical model that signals through multiple ErbB receptors,http://cancerres.aacrjournals.org/content/70/8_Supplement/3610.short
3516,20644979,"Phase I pharmacokinetic and pharmacodynamic study of triciribine phosphate monohydrate, a small-molecule inhibitor of AKT phosphorylation, in adult subjects with solid tumors containing activated AKT.",http://www.ncbi.nlm.nih.gov/pubmed/20644979
3517,25483727,Basal expression of insulin-like growth factor 1 receptor determines intrinsic resistance of cancer cells to a phosphatidylinositol 3-kinase inhibitor ZSTK474.,http://www.ncbi.nlm.nih.gov/pubmed/25483727
3518,,Abstract #3603: ARRY-334543 in ErbB2 positive metastatic breast cancer and other ErbB expressing-cancers: experience from expansion cohorts on a phase I study,http://cancerres.aacrjournals.org/content/69/9_Supplement/3603
3519,19459856,Antitumor activity of a dual epidermal growth factor receptor and ErbB2 kinase inhibitor MP-412 (AV-412) in mouse xenograft models.,http://www.ncbi.nlm.nih.gov/pubmed/19459856
3520,,"Targeting HER family signaling in gastric cancer: The selective and equipotent EGFR, HER2 and HER3 signaling inhibitor, AZD8931, is efficacious in primary models of HER family driven disease",http://cancerres.aacrjournals.org/content/73/8_Supplement/2090.short
3521,18774637,"The growth inhibitory effect of lapatinib, a dual inhibitor of EGFR and HER2 tyrosine kinase, in gastric cancer cell lines.",http://www.ncbi.nlm.nih.gov/pubmed/18774637
3522,23578997,Monitoring afatinib treatment in HER2-positive gastric cancer with 18F-FDG and 89Zr-trastuzumab PET.,http://www.ncbi.nlm.nih.gov/pubmed/23578997
3523,20885895,Dual Inhibitor AEE788 Reduces Tumor Growth in Preclinical Models of Medulloblastoma.,http://www.ncbi.nlm.nih.gov/pubmed/20885895
3524,,"Abstract A050: ARRY-380, an oral HER2 inhibitor: Final phase 1 results and conclusions",http://mcr.aacrjournals.org/content/11/10_Supplement/A050.abstract
3525,,"Abstract 852: ARRY-380, a potent, small molecule inhibitor of ErbB2, increases survival in intracranial ErbB2+ xenograft models in mice",http://cancerres.aacrjournals.org/content/72/8_Supplement/852
3526,,A phase II open-label trial of dacomitinib monotherapy in patients with HER2-positive advanced gastric cancer after failure of at least one prior chemotherapy regimen,http://meetinglibrary.asco.org/content/88180-115
3527,12019211,Functional analysis of MSH6 mutations linked to kindreds with putative hereditary non-polyposis colorectal cancer syndrome.,http://www.ncbi.nlm.nih.gov/pubmed/12019211
3528,22983396,Oncogenic NRAS signaling differentially regulates survival and proliferation in melanoma.,http://www.ncbi.nlm.nih.gov/pubmed/22983396
3529,21620836,PI3K-dependent phosphorylation of Fbw7 modulates substrate degradation and activity.,http://www.ncbi.nlm.nih.gov/pubmed/21620836
3530,,"Preclinical activity of MM-111, a bispecific ErbB2/ErbB3 antibody in previously treated ErbB2-positive gastric and gastroesophageal junction cancer",http://meetinglibrary.asco.org/content/106018-133
3531,18441328,HER2 in gastric cancer: a new prognostic factor and a novel therapeutic target.,http://www.ncbi.nlm.nih.gov/pubmed/18441328
3532,,Association of ErbB/HER biomarkers with antitumor activity of the anti-ErbB3/HER3 monoclonal antibody KTN3379 in SCCHN,http://www.abstractsonline.com/Plan/ViewAbstract.aspx?mID=3682&sKey=8ef53702-fa4b-4bcd-959a-adc80c411249&cKey=8eef59f4-1b14-46a5-933b-b20bbb91a185&mKey=19573a54-ae8f-4e00-9c23-bd6d62268424
3533,21458915,Trastuzumab-DM1 is highly effective in preclinical models of HER2-positive gastric cancer.,http://www.ncbi.nlm.nih.gov/pubmed/21458915
3534,,"Abstract P3-14-09: Preclinical Safety and Activity of MM-302, a HER2-Targeted Liposomal Doxorubicin Designed To Have an Improved Safety and Efficacy Profile over Approved Anthracyclines",http://cancerres.aacrjournals.org/content/70/24_Supplement/P3-14-09
3535,25852058,CDKN2A/p16 Loss Implicates CDK4 as a Therapeutic Target in Imatinib-Resistant Dermatofibrosarcoma Protuberans.,http://www.ncbi.nlm.nih.gov/pubmed/25852058
3536,,Association of HER2 and ErbB3 molecular alterations with afatinib sensitivity in platinum-refractory metastatic urothelial carcinoma (UC) in a phase II trial,http://meetinglibrary.asco.org/content/141495-159
3537,,A first-in-human phase I study of oral pan-CDK inhibitor BAY 1000394 in patients with advanced solid tumors: Dose escalation with an intermittent 3 days on/4 days off schedule.,http://meetinglibrary.asco.org/content/95610-114
3538,,Abstract 3419: Frequency and function of ERBB3 mutations in bladder cancer,http://cancerres.aacrjournals.org/content/74/19_Supplement/3419.abstract
3539,22135232,"Evaluation of the antitumor effects and mechanisms of PF00299804, a pan-HER inhibitor, alone or in combination with chemotherapy or targeted agents in gastric cancer.",http://www.ncbi.nlm.nih.gov/pubmed/22135232
3540,,"A phase II clinical trial of the CDK 4/6 inhibitor palbociclib (PD 0332991) in previously treated, advanced non-small cell lung cancer (NSCLC) patients with inactivated CDKN2A.",http://meetinglibrary.asco.org/content/135087-144
3541,15831461,"Inhibition of human Chk1 causes increased initiation of DNA replication, phosphorylation of ATR targets, and DNA breakage.",http://www.ncbi.nlm.nih.gov/pubmed/15831461
3542,15150122,UCN-01-induced cell cycle arrest requires the transcriptional induction of p21(waf1/cip1) by activation of mitogen-activated protein/extracellular signal-regulated kinase kinase/extracellular signal-regulated kinase pathway.,http://www.ncbi.nlm.nih.gov/pubmed/15150122
3543,25393368,"A Phase I study of cyclin-dependent kinase inhibitor, AT7519, in patients with advanced cancer: NCIC Clinical Trials Group IND 177.",http://www.ncbi.nlm.nih.gov/pubmed/25393368
3544,20822897,"Phase I evaluation of seliciclib (R-roscovitine), a novel oral cyclin-dependent kinase inhibitor, in patients with advanced malignancies.",http://www.ncbi.nlm.nih.gov/pubmed/20822897
3545,,A phase 1 study of the selective cyclin dependent kinase inhibitor P276–00 in patients with advanced refractory neoplasms,http://meeting.ascopubs.org/cgi/content/short/25/18_suppl/14117
3546,25594012,HER2 and HER3 cooperatively regulate cancer cell growth and determine sensitivity to the novel investigational EGFR/HER2 kinase inhibitor TAK-285.,http://www.ncbi.nlm.nih.gov/pubmed/25594012
3547,25221644,CDK4/6 inhibition provides a potent adjunct to Her2-targeted therapies in preclinical breast cancer models.,http://www.ncbi.nlm.nih.gov/pubmed/25221644
3548,25000258,ERBB3 is required for metastasis formation of melanoma cells.,http://www.ncbi.nlm.nih.gov/pubmed/25000258
3549,24670165,Ceritinib in ALK-rearranged non-small-cell lung cancer.,http://www.ncbi.nlm.nih.gov/pubmed/24670165
3550,25104330,Discovery of biomarkers predictive of GSI response in triple-negative breast cancer and adenoid cystic carcinoma.,http://www.ncbi.nlm.nih.gov/pubmed/25104330
3551,25234595,Frequent mutations in NOTCH1 ligand-binding regions in Japanese oral squamous cell carcinoma.,http://www.ncbi.nlm.nih.gov/pubmed/25234595
3552,24162815,Oncogenic and drug-sensitive NTRK1 rearrangements in lung cancer.,http://www.ncbi.nlm.nih.gov/pubmed/24162815
3553,21502504,Therapeutic strategies to overcome crizotinib resistance in non-small cell lung cancers harboring the fusion oncogene EML4-ALK.,http://www.ncbi.nlm.nih.gov/pubmed/21502504
3554,,"Efficacy and safety of the ALK inhibitor alectinib in ALK+ non-small-cell lung cancer (NSCLC) patients who have failed prior crizotinib: an open-label, single-arm, global phase 2 study (NP28673).",http://meetinglibrary.asco.org/content/149578-156
3555,25122427,RET mutation and expression in small-cell lung cancer.,http://www.ncbi.nlm.nih.gov/pubmed/25122427
3556,21725357,MYCN sensitizes neuroblastoma to the MDM2-p53 antagonists Nutlin-3 and MI-63.,http://www.ncbi.nlm.nih.gov/pubmed/21725357
3557,26259918,High ROR2 expression in tumor cells and stroma is correlated with poor prognosis in pancreatic ductal adenocarcinoma.,http://www.ncbi.nlm.nih.gov/pubmed/26259918
3558,22644735,Combined immunotherapy with Listeria monocytogenes-based PSA vaccine and radiation therapy leads to a therapeutic response in a murine model of prostate cancer.,http://www.ncbi.nlm.nih.gov/pubmed/22644735
3559,20844743,Single nucleotide polymorphisms in the Wnt and BMP pathways and colorectal cancer risk in a Spanish cohort.,http://www.ncbi.nlm.nih.gov/pubmed/20844743
3560,24788099,SWI/SNF factors required for cellular resistance to DNA damage include ARID1A and ARID1B and show interdependent protein stability.,http://www.ncbi.nlm.nih.gov/pubmed/24788099
3561,22711607,p16-Cdk4-Rb axis controls sensitivity to a cyclin-dependent kinase inhibitor PD0332991 in glioblastoma xenograft cells.,http://www.ncbi.nlm.nih.gov/pubmed/22711607
3562,24404427,The IL-15-based superagonist ALT-803 promotes the antigen-independent conversion of memory CD8(+) T cells into innate-like effector cells with antitumor activity.,http://www.ncbi.nlm.nih.gov/pubmed/24404427
3563,25897966,"RTA 408, A Novel Synthetic Triterpenoid with Broad Anticancer and Anti-Inflammatory Activity.",http://www.ncbi.nlm.nih.gov/pubmed/25897966
3564,12879008,The oncogenic fusion protein nucleophosmin-anaplastic lymphoma kinase (NPM-ALK) induces two distinct malignant phenotypes in a murine retroviral transplantation model.,http://www.ncbi.nlm.nih.gov/pubmed/12879008
3565,24496003,"HIP1-ALK, a novel ALK fusion variant that responds to crizotinib.",http://www.ncbi.nlm.nih.gov/pubmed/24496003
3566,26101715,Genetic alterations of KDM4 subfamily and therapeutic effect of novel demethylase inhibitor in breast cancer.,http://www.ncbi.nlm.nih.gov/pubmed/26101715
3567,16390546,"A phase I trial of pox PSA vaccines (PROSTVAC-VF) with B7-1, ICAM-1, and LFA-3 co-stimulatory molecules (TRICOM) in patients with prostate cancer.",http://www.ncbi.nlm.nih.gov/pubmed/16390546
3568,19165201,LKB1/KRAS mutant lung cancers constitute a genetic subset of NSCLC with increased sensitivity to MAPK and mTOR signalling inhibition.,http://www.ncbi.nlm.nih.gov/pubmed/19165201
3569,9661880,Frequent inactivation of PTEN in prostate cancer cell lines and xenografts.,http://www.ncbi.nlm.nih.gov/pubmed/9661880
3570,23936606,Genomic structure and variation of nuclear factor (erythroid-derived 2)-like 2.,http://www.ncbi.nlm.nih.gov/pubmed/23936606
3571,19321346,NRF2 and KEAP1 mutations: permanent activation of an adaptive response in cancer.,http://www.ncbi.nlm.nih.gov/pubmed/19321346
3572,24366543,"Kinetic, thermodynamic, and structural characterizations of the association between Nrf2-DLGex degron and Keap1.",http://www.ncbi.nlm.nih.gov/pubmed/24366543
3573,15743501,Common ERBB2 polymorphisms and risk of breast cancer in a white British population: a case-control study.,http://www.ncbi.nlm.nih.gov/pubmed/15743501
3574,16818618,Non-small-cell lung cancer and Ba/F3 transformed cells harboring the ERBB2 G776insV_G/C mutation are sensitive to the dual-specific epidermal growth factor receptor and ERBB2 inhibitor HKI-272.,http://www.ncbi.nlm.nih.gov/pubmed/16818618
3575,21969819,NRF2 mutation confers malignant potential and resistance to chemoradiation therapy in advanced esophageal squamous cancer.,http://www.ncbi.nlm.nih.gov/pubmed/21969819
3576,18381444,Characterization of an Akt kinase inhibitor with potent pharmacodynamic and antitumor activity.,http://www.ncbi.nlm.nih.gov/pubmed/18381444
3577,22109972,A novel human Smad4 mutation is involved in papillary thyroid carcinoma progression.,http://www.ncbi.nlm.nih.gov/pubmed/22109972
3578,25581430,Germline ETV6 mutations in familial thrombocytopenia and hematologic malignancy.,http://www.ncbi.nlm.nih.gov/pubmed/25581430
3579,25807284,"Germline mutations in ETV6 are associated with thrombocytopenia, red cell macrocytosis and predisposition to lymphoblastic leukemia.",http://www.ncbi.nlm.nih.gov/pubmed/25807284
3580,23365135,CUL3 and NRF2 mutations confer an NRF2 activation phenotype in a sporadic form of papillary renal cell carcinoma.,http://www.ncbi.nlm.nih.gov/pubmed/23365135
3581,22275377,Impaired transforming growth factor-β (TGF-β) transcriptional activity and cell proliferation control of a menin in-frame deletion mutant associated with multiple endocrine neoplasia type 1 (MEN1).,http://www.ncbi.nlm.nih.gov/pubmed/22275377
3582,,"A phase 1, open-label, dose escalation study of AMG 337 in Asian patients (pts) with advanced solid tumors.",http://meetinglibrary.asco.org/content/145698-156
3583,,"Onapristone in patients (pts) with progesterone receptor (PR)-expressing cancers: PK results from part 1 of a randomized, parallel-dose phase 1 study",http://cancerres.aacrjournals.org/content/75/15_Supplement/4512.short
3584,,"Abstract 941: G1T28-1, a novel CDK4/6 inhibitor, protects murine hematopoietic stem and progenitor cells from cytotoxic chemotherapy",
3585,21656749,A novel KIF5B-ALK variant in nonsmall cell lung cancer.,http://www.ncbi.nlm.nih.gov/pubmed/21656749
3586,21757704,Crystal structure of menin reveals binding site for mixed lineage leukemia (MLL) protein.,http://www.ncbi.nlm.nih.gov/pubmed/21757704
3587,20033049,Novel mutant-selective EGFR kinase inhibitors against EGFR T790M.,http://www.ncbi.nlm.nih.gov/pubmed/20033049
3588,16888629,Structure of the Keap1:Nrf2 interface provides mechanistic insight into Nrf2 signaling.,http://www.ncbi.nlm.nih.gov/pubmed/16888629
3589,16489002,ErbB2 increases vascular endothelial growth factor protein synthesis via activation of mammalian target of rapamycin/p70S6K leading to increased angiogenesis and spontaneous metastasis of human breast cancer cells.,http://www.ncbi.nlm.nih.gov/pubmed/16489002
3590,15753384,ErbB2 promotes Src synthesis and stability: novel mechanisms of Src activation that confer breast cancer metastasis.,http://www.ncbi.nlm.nih.gov/pubmed/15753384
3591,18981003,Effects of erlotinib in EGFR mutated non-small cell lung cancers with resistance to gefitinib.,http://www.ncbi.nlm.nih.gov/pubmed/18981003
3592,18199554,Impact of common epidermal growth factor receptor and HER2 variants on receptor activity and inhibition by lapatinib.,http://www.ncbi.nlm.nih.gov/pubmed/18199554
3593,10706082,A new variant anaplastic lymphoma kinase (ALK)-fusion protein (ATIC-ALK) in a case of ALK-positive anaplastic large cell lymphoma.,http://www.ncbi.nlm.nih.gov/pubmed/10706082
3594,22347464,KLC1-ALK: a novel fusion in lung cancer identified using a formalin-fixed paraffin-embedded tissue only.,http://www.ncbi.nlm.nih.gov/pubmed/22347464
3595,24850290,Reduction of leukemia cell burden and restoration of normal hematopoiesis at 3 months of crizotinib treatment in RAN-binding protein 2 (RANBP2)-anaplastic lymphoma kinase (ALK) acute myeloid leukemia.,http://www.ncbi.nlm.nih.gov/pubmed/24850290
3596,24613930,Identification of the transforming STRN-ALK fusion as a potential therapeutic target in the aggressive forms of thyroid cancer.,http://www.ncbi.nlm.nih.gov/pubmed/24613930
3597,10934142,TPM3-ALK and TPM4-ALK oncogenes in inflammatory myofibroblastic tumors.,http://www.ncbi.nlm.nih.gov/pubmed/10934142
3598,21474455,Targeting oncogenic ALK: a promising strategy for cancer treatment.,http://www.ncbi.nlm.nih.gov/pubmed/21474455
3599,17535915,"Sumoylation of nucleophosmin/B23 regulates its subcellular localization, mediating cell proliferation and survival.",http://www.ncbi.nlm.nih.gov/pubmed/17535915
3600,16501600,Cytoplasmic localization of NPM in myeloid leukemias is dictated by gain-of-function mutations that create a functional nuclear export signal.,http://www.ncbi.nlm.nih.gov/pubmed/16501600
3601,16720834,Immunohistochemistry predicts nucleophosmin (NPM) mutations in acute myeloid leukemia.,http://www.ncbi.nlm.nih.gov/pubmed/16720834
3602,25538044,The thrombopoietin receptor P106L mutation functionally separates receptor signaling activity from thrombopoietin homeostasis.,http://www.ncbi.nlm.nih.gov/pubmed/25538044
3603,26232141,Limited predictive value of achieving beneficial plasma (Z)-endoxifen threshold level by CYP2D6 genotyping in tamoxifen-treated Polish women with breast cancer.,http://www.ncbi.nlm.nih.gov/pubmed/26232141
3604,21787277,Clinical importance and potential use of small molecule inhibitors of focal adhesion kinase.,http://www.ncbi.nlm.nih.gov/pubmed/21787277
3605,17715146,Physical and functional interactions between Werner syndrome helicase and mismatch-repair initiation factors.,http://www.ncbi.nlm.nih.gov/pubmed/17715146
3606,23341610,Dependence receptor TrkC is a putative colon cancer tumor suppressor.,http://www.ncbi.nlm.nih.gov/pubmed/23341610
3607,24040339,Functional analysis in mouse embryonic stem cells reveals wild-type activity for three MSH6 variants found in suspected Lynch syndrome patients.,http://www.ncbi.nlm.nih.gov/pubmed/24040339
3608,18790734,Hereditary cancer-associated missense mutations in hMSH6 uncouple ATP hydrolysis from DNA mismatch binding.,http://www.ncbi.nlm.nih.gov/pubmed/18790734
3609,17546043,TrkC binds to the type II TGF-beta receptor to suppress TGF-beta signaling.,http://www.ncbi.nlm.nih.gov/pubmed/17546043
3610,24130096,Development of a steady-state FRET-based assay to identify inhibitors of the Keap1-Nrf2 protein-protein interaction.,http://www.ncbi.nlm.nih.gov/pubmed/24130096
3611,24817629,"EW-7197, a novel ALK-5 kinase inhibitor, potently inhibits breast to lung metastasis.",http://www.ncbi.nlm.nih.gov/pubmed/24817629
3612,16214425,Contribution of Msh2 and Msh6 subunits to the asymmetric ATPase and DNA mismatch binding activities of Saccharomyces cerevisiae Msh2-Msh6 mismatch repair protein.,http://www.ncbi.nlm.nih.gov/pubmed/16214425
3613,18822302,Functional analysis of HNPCC-related missense mutations in MSH2.,http://www.ncbi.nlm.nih.gov/pubmed/18822302
3614,17934517,BRD-NUT oncoproteins: a family of closely related nuclear proteins that block epithelial differentiation and maintain the growth of carcinoma cells.,http://www.ncbi.nlm.nih.gov/pubmed/17934517
3615,20871596,Selective inhibition of BET bromodomains.,http://www.ncbi.nlm.nih.gov/pubmed/20871596
3616,21447744,Differentiation of NUT midline carcinoma by epigenomic reprogramming.,http://www.ncbi.nlm.nih.gov/pubmed/21447744
3617,17325341,The identification of (ETV6)/RUNX1-regulated genes in lymphopoiesis using histone deacetylase inhibitors in ETV6/RUNX1-positive lymphoid leukemic cells.,http://www.ncbi.nlm.nih.gov/pubmed/17325341
3618,25948633,EGFR Mutations and Resistance to Irreversible Pyrimidine-Based EGFR Inhibitors.,http://www.ncbi.nlm.nih.gov/pubmed/25948633
3619,9333014,"Gamma-heregulin: a novel heregulin isoform that is an autocrine growth factor for the human breast cancer cell line, MDA-MB-175.",http://www.ncbi.nlm.nih.gov/pubmed/9333014
3620,25964297,The Allelic Context of the C797S Mutation Acquired upon Treatment with Third-Generation EGFR Inhibitors Impacts Sensitivity to Subsequent Treatment Strategies.,http://www.ncbi.nlm.nih.gov/pubmed/25964297
3621,8552387,"The EWS-ATF-1 gene involved in malignant melanoma of soft parts with t(12;22) chromosome translocation, encodes a constitutive transcriptional activator.",http://www.ncbi.nlm.nih.gov/pubmed/8552387
3622,,"Preliminary clinical pharmacokinetics and pharmacodynamics of Debio 1347 (CH5183284), a novel FGFR inhibitor.",http://meeting.ascopubs.org/cgi/content/abstract/33/15_suppl/2540
3623,22411527,Biophysical characterization and stabilization of the recombinant albumin fusion protein sEphB4-HSA.,http://www.ncbi.nlm.nih.gov/pubmed/22411527
3624,25148033,The differential expression of EphB2 and EphB4 receptor kinases in normal bladder and in transitional cell carcinoma of the bladder.,http://www.ncbi.nlm.nih.gov/pubmed/25148033
3625,8516324,Ewing sarcoma 11;22 translocation produces a chimeric transcription factor that requires the DNA-binding domain encoded by FLI1 for transformation.,http://www.ncbi.nlm.nih.gov/pubmed/8516324
3626,8164678,DNA-binding and transcriptional activation properties of the EWS-FLI-1 fusion protein resulting from the t(11;22) translocation in Ewing sarcoma.,http://www.ncbi.nlm.nih.gov/pubmed/8164678
3627,23630200,Cediranib for metastatic alveolar soft part sarcoma.,http://www.ncbi.nlm.nih.gov/pubmed/23630200
3628,19188185,Response to sunitinib malate in advanced alveolar soft part sarcoma.,http://www.ncbi.nlm.nih.gov/pubmed/19188185
3629,22605650,"Tivantinib (ARQ 197), a selective inhibitor of MET, in patients with microphthalmia transcription factor-associated tumors: results of a multicenter phase 2 trial.",http://www.ncbi.nlm.nih.gov/pubmed/22605650
3630,17361230,A tumor suppressor and oncogene: the WT1 story.,http://www.ncbi.nlm.nih.gov/pubmed/17361230
3631,18089725,"Cytoreductive antitumor activity of PF-2341066, a novel inhibitor of anaplastic lymphoma kinase and c-Met, in experimental models of anaplastic large-cell lymphoma.",http://www.ncbi.nlm.nih.gov/pubmed/18089725
3632,20207848,ALK-positive large B-cell lymphomas with cryptic SEC31A-ALK and NPM1-ALK fusions.,http://www.ncbi.nlm.nih.gov/pubmed/20207848
3633,25923550,Rociletinib in EGFR-mutated non-small-cell lung cancer.,http://www.ncbi.nlm.nih.gov/pubmed/25923550
3634,22218692,Paracrine signaling through MYCN enhances tumor-vascular interactions in neuroblastoma.,http://www.ncbi.nlm.nih.gov/pubmed/22218692
3635,,"A phase Ib dose-escalation study of PRI-724, a CBP/beta-catenin modulator, plus gemcitabine (GEM) in patients with advanced pancreatic adenocarcinoma (APC) as second-line therapy after FOLFIRINOX or FOLFOX.",http://meetinglibrary.asco.org/content/148137-156
3636,17314276,Phosphatidylinositol-3-OH kinase or RAS pathway mutations in human breast cancer cell lines.,http://www.ncbi.nlm.nih.gov/pubmed/17314276
3637,26050618,Activating ERBB4 mutations in non-small cell lung cancer.,http://www.ncbi.nlm.nih.gov/pubmed/26050618
3638,21358673,"PIK3CA mutation, but not PTEN loss of function, determines the sensitivity of breast cancer cells to mTOR inhibitory drugs.",http://www.ncbi.nlm.nih.gov/pubmed/21358673
3639,24042735,Epigenetic and genetic features of 24 colon cancer cell lines.,http://www.ncbi.nlm.nih.gov/pubmed/24042735
3640,23012248,Targeting KRAS-mutant non-small cell lung cancer with the Hsp90 inhibitor ganetespib.,http://www.ncbi.nlm.nih.gov/pubmed/23012248
3641,19238632,Dual MET-EGFR combinatorial inhibition against T790M-EGFR-mediated erlotinib-resistant lung cancer.,http://www.ncbi.nlm.nih.gov/pubmed/19238632
3642,16731747,Chemotherapy-induced epidermal growth factor receptor activation determines response to combined gefitinib/chemotherapy treatment in non-small cell lung cancer cells.,http://www.ncbi.nlm.nih.gov/pubmed/16731747
3643,20418756,Phenotype and genotype of pancreatic cancer cell lines.,http://www.ncbi.nlm.nih.gov/pubmed/20418756
3644,14737113,PTEN inhibits cell proliferation and induces apoptosis by downregulating cell surface IGF-IR expression in prostate cancer cells.,http://www.ncbi.nlm.nih.gov/pubmed/14737113
3645,23980093,Integrative radiogenomic profiling of squamous cell lung cancer.,http://www.ncbi.nlm.nih.gov/pubmed/23980093
3646,,Targeting the Wnt pathway in human cancers: Therapeutic targeting with a focus on OMP-54F28,http://meetinglibrary.asco.org/content/131996-144
3647,21393571,An RNAi-based chemical genetic screen identifies three small-molecule inhibitors of the Wnt/wingless signaling pathway.,http://www.ncbi.nlm.nih.gov/pubmed/21393571
3648,23533264,Response to Cabozantinib in patients with RET fusion-positive lung adenocarcinomas.,http://www.ncbi.nlm.nih.gov/pubmed/23533264
3649,,Characterization of three recurring STK11/LKB1 mutants in lung adenocarcinoma,http://cancerres.aacrjournals.org/content/74/19_Supplement/4159.abstract
3650,23823660,Point mutation E1099K in MMSET/NSD2 enhances its methyltranferase activity and leads to altered global chromatin methylation in lymphoid malignancies.,http://www.ncbi.nlm.nih.gov/pubmed/23823660
3651,17200672,Fanconi anemia is associated with a defect in the BRCA2 partner PALB2.,http://www.ncbi.nlm.nih.gov/pubmed/17200672
3652,25625428,Progress in Discovery of KIF5B-RET Kinase Inhibitors for the Treatment of Non-Small-Cell Lung Cancer.,http://www.ncbi.nlm.nih.gov/pubmed/25625428
3653,22912387,Differential protein stability and ALK inhibitor sensitivity of EML4-ALK fusion variants.,http://www.ncbi.nlm.nih.gov/pubmed/22912387
3654,21531761,Antihelminth compound niclosamide downregulates Wnt signaling and elicits antitumor responses in tumors with activating APC mutations.,http://www.ncbi.nlm.nih.gov/pubmed/21531761
3655,26296355,Sustained Inhibition of HER3 and EGFR Is Necessary to Induce Regression of HER2-Amplified Gastrointestinal Carcinomas.,http://www.ncbi.nlm.nih.gov/pubmed/26296355
3656,21317452,Drug discovery approaches to target Wnt signaling in cancer stem cells.,http://www.ncbi.nlm.nih.gov/pubmed/21317452
3657,,Phase 1 study of CWP232291 in relapsed/refractory acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS).,http://hwmaint.meeting.ascopubs.org/cgi/content/abstract/33/15_suppl/7044
3658,20223922,Conditional TPM3-ALK and NPM-ALK transgenic mice develop reversible ALK-positive early B-cell lymphoma/leukemia.,http://www.ncbi.nlm.nih.gov/pubmed/20223922
3659,25028698,"A case report of epithelioid inflammatory myofibroblastic sarcoma with RANBP2-ALK fusion gene treated with the ALK inhibitor, crizotinib.",http://www.ncbi.nlm.nih.gov/pubmed/25028698
3660,21030459,The neuroblastoma-associated F1174L ALK mutation causes resistance to an ALK kinase inhibitor in ALK-translocated cancers.,http://www.ncbi.nlm.nih.gov/pubmed/21030459
3661,18519687,"Inhibition of gastric cancer invasion and metastasis by PLA2G2A, a novel beta-catenin/TCF target gene.",http://www.ncbi.nlm.nih.gov/pubmed/18519687
3662,19892943,Structure of the LKB1-STRAD-MO25 complex reveals an allosteric mechanism of kinase activation.,http://www.ncbi.nlm.nih.gov/pubmed/19892943
3663,12049819,"Differential expression of Wnt genes, beta-catenin and E-cadherin in human brain tumors.",http://www.ncbi.nlm.nih.gov/pubmed/12049819
3664,23684459,Phosphorylation of EZH2 activates STAT3 signaling via STAT3 methylation and promotes tumorigenicity of glioblastoma stem-like cells.,http://www.ncbi.nlm.nih.gov/pubmed/23684459
3665,25701171,"Necitumumab plus pemetrexed and cisplatin as first-line therapy in patients with stage IV non-squamous non-small-cell lung cancer (INSPIRE): an open-label, randomised, controlled phase 3 study.",http://www.ncbi.nlm.nih.gov/pubmed/25701171
3666,,"Efficacy, safety, biomarkers, and phase II dose modeling in a phase I trial of the oral selective c-Met inhibitor tepotinib (MSC2156119J).",http://hwmaint.meeting.ascopubs.org/cgi/content/abstract/33/15_suppl/2591
3667,23698369,BAF complexes facilitate decatenation of DNA by topoisomerase IIα.,http://www.ncbi.nlm.nih.gov/pubmed/23698369
3668,11553622,Loss of Smad4 function in pancreatic tumors: C-terminal truncation leads to decreased stability.,http://www.ncbi.nlm.nih.gov/pubmed/11553622
3669,22316667,Germline mutations in SMAD4 disrupt bone morphogenetic protein signaling.,http://www.ncbi.nlm.nih.gov/pubmed/22316667
3670,15350224,Structural basis of heteromeric smad protein assembly in TGF-beta signaling.,http://www.ncbi.nlm.nih.gov/pubmed/15350224
3671,9214508,A structural basis for mutational inactivation of the tumour suppressor Smad4.,http://www.ncbi.nlm.nih.gov/pubmed/9214508
3672,11265759,Regulation of intracellular dynamics of Smad4 by its leucine-rich nuclear export signal.,http://www.ncbi.nlm.nih.gov/pubmed/11265759
3673,11274206,Formation of a stable heterodimer between Smad2 and Smad4.,http://www.ncbi.nlm.nih.gov/pubmed/11274206
3674,14715079,Molecular and functional consequences of Smad4 C-terminal missense mutations in colorectal tumour cells.,http://www.ncbi.nlm.nih.gov/pubmed/14715079
3675,11003650,BRG-1 is recruited to estrogen-responsive promoters and cooperates with factors involved in histone acetylation.,http://www.ncbi.nlm.nih.gov/pubmed/11003650
3676,7777061,Tumour-derived p16 alleles encoding proteins defective in cell-cycle inhibition.,http://www.ncbi.nlm.nih.gov/pubmed/7777061
3677,22407764,The tumour suppressor and chromatin-remodelling factor BRG1 antagonizes Myc activity and promotes cell differentiation in human cancer.,http://www.ncbi.nlm.nih.gov/pubmed/22407764
3678,25485619,A comprehensive transcriptional portrait of human cancer cell lines.,http://www.ncbi.nlm.nih.gov/pubmed/25485619
3679,17143285,Germline gain-of-function mutations in SOS1 cause Noonan syndrome.,http://www.ncbi.nlm.nih.gov/pubmed/17143285
3680,,,http://cancerres.aacrjournals.org/content/75/15_Supplement/285.abstract
3681,26005526,Discovery of Clinical Candidate BMS-906024: A Potent Pan-Notch Inhibitor for the Treatment of Leukemia and Solid Tumors.,http://www.ncbi.nlm.nih.gov/pubmed/26005526
3682,22270724,Identification of a mutation in the extracellular domain of the Epidermal Growth Factor Receptor conferring cetuximab resistance in colorectal cancer.,http://www.ncbi.nlm.nih.gov/pubmed/22270724
3683,25483687,ADXS-HPV: a therapeutic Listeria vaccination targeting cervical cancers expressing the HPV E7 antigen.,http://www.ncbi.nlm.nih.gov/pubmed/25483687
3684,22128302,VTX-2337 is a novel TLR8 agonist that activates NK cells and augments ADCC.,http://www.ncbi.nlm.nih.gov/pubmed/22128302
3685,25736418,"Pharmacological characterization of AZD5069, a slowly reversible CXC chemokine receptor 2 antagonist.",http://www.ncbi.nlm.nih.gov/pubmed/25736418
3686,24561444,RET revisited: expanding the oncogenic portfolio.,http://www.ncbi.nlm.nih.gov/pubmed/24561444
3687,15184865,Disease associated mutations at valine 804 in the RET receptor tyrosine kinase confer resistance to selective kinase inhibitors.,http://www.ncbi.nlm.nih.gov/pubmed/15184865
3688,25910950,"A Multicenter, Phase II, Randomized, Noncomparative Clinical Trial of Radiation and Temozolomide with or without Vandetanib in Newly Diagnosed Glioblastoma Patients.",http://www.ncbi.nlm.nih.gov/pubmed/25910950
3689,26216294,An Oncogenic NTRK Fusion in a Patient with Soft-Tissue Sarcoma with Response to the Tropomyosin-Related Kinase Inhibitor LOXO-101.,http://www.ncbi.nlm.nih.gov/pubmed/26216294
3690,16377799,"PTPN11 (Shp2) mutations in LEOPARD syndrome have dominant negative, not activating, effects.",http://www.ncbi.nlm.nih.gov/pubmed/16377799
3691,16358218,Diversity and functional consequences of germline and somatic PTPN11 mutations in human disease.,http://www.ncbi.nlm.nih.gov/pubmed/16358218
3692,15604238,Activating mutations of the noonan syndrome-associated SHP2/PTPN11 gene in human solid tumors and adult acute myelogenous leukemia.,http://www.ncbi.nlm.nih.gov/pubmed/15604238
3693,12717436,"Somatic mutations in PTPN11 in juvenile myelomonocytic leukemia, myelodysplastic syndromes and acute myeloid leukemia.",http://www.ncbi.nlm.nih.gov/pubmed/12717436
3694,21339643,Rapamycin reverses hypertrophic cardiomyopathy in a mouse model of LEOPARD syndrome-associated PTPN11 mutation.,http://www.ncbi.nlm.nih.gov/pubmed/21339643
3695,25207766,Targetable kinase-activating lesions in Ph-like acute lymphoblastic leukemia.,http://www.ncbi.nlm.nih.gov/pubmed/25207766
3696,26015511,FGFR1 Expression Levels Predict BGJ398 Sensitivity of FGFR1-Dependent Head and Neck Squamous Cell Cancers.,http://www.ncbi.nlm.nih.gov/pubmed/26015511
3697,11858826,Sry and sex determination: how lazy can it be?,http://www.ncbi.nlm.nih.gov/pubmed/11858826
3698,25931286,High-Frequency Targetable EGFR Mutations in Sinonasal Squamous Cell Carcinomas Arising from Inverted Sinonasal Papilloma.,http://www.ncbi.nlm.nih.gov/pubmed/25931286
3699,25377158,"Population pharmacokinetics of HM781-36 (poziotinib), pan-human EGF receptor (HER) inhibitor, and its two metabolites in patients with advanced solid malignancies.",http://www.ncbi.nlm.nih.gov/pubmed/25377158
3700,,"A phase II, single-arm, efficacy and safety study of poziotinib (NOV120101) in Korean patients with advanced or metastatic lung adenocarcinoma who have acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors.",http://meetinglibrary.asco.org/content/153342-156
3701,26026677,The novel HDAC inhibitor AR-42-induced anti-colon cancer cell activity is associated with ceramide production.,http://www.ncbi.nlm.nih.gov/pubmed/26026677
3702,25870087,Phase I/II Study of HSP90 Inhibitor AUY922 and Erlotinib for EGFR-Mutant Lung Cancer With Acquired Resistance to Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors.,http://www.ncbi.nlm.nih.gov/pubmed/25870087
3703,26341920,Analysis of KRAS/NRAS Mutations in a Phase III Study of Panitumumab with FOLFIRI Compared with FOLFIRI Alone as Second-line Treatment for Metastatic Colorectal Cancer.,http://www.ncbi.nlm.nih.gov/pubmed/26341920
3704,22327622,Identification of new ALK and RET gene fusions from colorectal and lung cancer biopsies.,http://www.ncbi.nlm.nih.gov/pubmed/22327622
3705,22570254,Identification of anaplastic lymphoma kinase as a potential therapeutic target in ovarian cancer.,http://www.ncbi.nlm.nih.gov/pubmed/22570254
3706,11310834,Molecular characterization of a new ALK translocation involving moesin (MSN-ALK) in anaplastic large cell lymphoma.,http://www.ncbi.nlm.nih.gov/pubmed/11310834
3707,21430068,"Pulmonary inflammatory myofibroblastic tumor expressing a novel fusion, PPFIBP1-ALK: reappraisal of anti-ALK immunohistochemistry as a tool for novel ALK fusion identification.",http://www.ncbi.nlm.nih.gov/pubmed/21430068
3708,21213368,ALK rearrangement in sickle cell trait-associated renal medullary carcinoma.,http://www.ncbi.nlm.nih.gov/pubmed/21213368
3709,23216836,VEGFA and tumour angiogenesis.,http://www.ncbi.nlm.nih.gov/pubmed/23216836
3710,18243099,Mps1 phosphorylates Borealin to control Aurora B activity and chromosome alignment.,http://www.ncbi.nlm.nih.gov/pubmed/18243099
3711,26202014,Naturally Occurring Mutations in the MPS1 Gene Predispose Cells to Kinase Inhibitor Drug Resistance.,http://www.ncbi.nlm.nih.gov/pubmed/26202014
3712,,"DNA repair defects and antitumor activity with PARP inhibition: TOPARP, a phase II trial of olaparib in metastatic castration resistant prostate cancer",http://cancerres.aacrjournals.org/content/75/15_Supplement/CT322.short
3713,26392102,Combined BRAF and MEK Inhibition With Dabrafenib and Trametinib in BRAF V600-Mutant Colorectal Cancer.,http://www.ncbi.nlm.nih.gov/pubmed/26392102
3714,25500121,Paradox-breaking RAF inhibitors that also target SRC are effective in drug-resistant BRAF mutant melanoma.,http://www.ncbi.nlm.nih.gov/pubmed/25500121
3715,25695691,Phase I Study of Vorinostat as a Radiation Sensitizer with 131I-Metaiodobenzylguanidine (131I-MIBG) for Patients with Relapsed or Refractory Neuroblastoma.,http://www.ncbi.nlm.nih.gov/pubmed/25695691
3716,21159646,"Targeting the mitotic checkpoint for cancer therapy with NMS-P715, an inhibitor of MPS1 kinase.",http://www.ncbi.nlm.nih.gov/pubmed/21159646
3717,26215950,Paclitaxel Given Once Per Week With or Without Bevacizumab in Patients With Advanced Angiosarcoma: A Randomized Phase II Trial.,http://www.ncbi.nlm.nih.gov/pubmed/26215950
3718,25724526,Progression-Free and Overall Survival in ALK-Positive NSCLC Patients Treated with Sequential Crizotinib and Ceritinib.,http://www.ncbi.nlm.nih.gov/pubmed/25724526
3719,26106072,Phase II Study of the AKT Inhibitor MK-2206 plus Erlotinib in Patients with Advanced Non-Small Cell Lung Cancer Who Previously Progressed on Erlotinib.,http://www.ncbi.nlm.nih.gov/pubmed/26106072
3720,26287849,Vemurafenib in Multiple Nonmelanoma Cancers with BRAF V600 Mutations.,http://www.ncbi.nlm.nih.gov/pubmed/26287849
3721,19747374,Identification of a region required for TSC1 stability by functional analysis of TSC1 missense mutations found in individuals with tuberous sclerosis complex.,http://www.ncbi.nlm.nih.gov/pubmed/19747374
3722,25660951,Wnt/β-Catenin Small-Molecule Inhibitor CWP232228 Preferentially Inhibits the Growth of Breast Cancer Stem-like Cells.,http://www.ncbi.nlm.nih.gov/pubmed/25660951
3723,15604286,Identification and characterization of a novel and specific inhibitor of the ataxia-telangiectasia mutated kinase ATM.,http://www.ncbi.nlm.nih.gov/pubmed/15604286
3724,20624899,Sustained Mps1 activity is required in mitosis to recruit O-Mad2 to the Mad1-C-Mad2 core complex.,http://www.ncbi.nlm.nih.gov/pubmed/20624899
3725,25695690,Phase II Study of Nilotinib in Melanoma Harboring KIT Alterations Following Progression to Prior KIT Inhibition.,http://www.ncbi.nlm.nih.gov/pubmed/25695690
3726,21216929,PIK3CA mutations in patients with advanced cancers treated with PI3K/AKT/mTOR axis inhibitors.,http://www.ncbi.nlm.nih.gov/pubmed/21216929
3727,21134980,"Identification of a novel fusion, SQSTM1-ALK, in ALK-positive large B-cell lymphoma.",http://www.ncbi.nlm.nih.gov/pubmed/21134980
3728,23431193,Combined targeting of MEK and PI3K/mTOR effector pathways is necessary to effectively inhibit NRAS mutant melanoma in vitro and in vivo.,http://www.ncbi.nlm.nih.gov/pubmed/23431193
3729,15294323,Real-time allele-specific amplification for sensitive detection of the BRAF mutation V600E.,http://www.ncbi.nlm.nih.gov/pubmed/15294323
3730,17210691,Tumor necrosis factor-alpha blocks apoptosis in melanoma cells when BRAF signaling is inhibited.,http://www.ncbi.nlm.nih.gov/pubmed/17210691
3731,20880116,ASXL1 mutation is associated with poor prognosis and acute transformation in chronic myelomonocytic leukaemia.,http://www.ncbi.nlm.nih.gov/pubmed/20880116
3732,22897849,ASXL1 mutations promote myeloid transformation through loss of PRC2-mediated gene repression.,http://www.ncbi.nlm.nih.gov/pubmed/22897849
3733,24216483,Myelodysplastic syndromes are induced by histone methylation–altering ASXL1 mutations.,http://www.ncbi.nlm.nih.gov/pubmed/24216483
3734,26325365,"Anticancer activity of TTAC-0001, a fully human anti-vascular endothelial growth factor receptor 2 (VEGFR-2/KDR) monoclonal antibody, is associated with inhibition of tumor angiogenesis.",http://www.ncbi.nlm.nih.gov/pubmed/26325365
3735,26230957,An international data set for CMML validates prognostic scoring systems and demonstrates a need for novel prognostication strategies.,http://www.ncbi.nlm.nih.gov/pubmed/26230957
3736,26354527,Afatinib in Non-Small Cell Lung Cancer Harboring Uncommon EGFR Mutations Pretreated With Reversible EGFR Inhibitors.,http://www.ncbi.nlm.nih.gov/pubmed/26354527
3737,21494260,Impact of TET2 mutations on response rate to azacitidine in myelodysplastic syndromes and low blast count acute myeloid leukemias.,http://www.ncbi.nlm.nih.gov/pubmed/21494260
3738,22315494,CBL mutations in myeloproliferative neoplasms are also found in the gene's proline-rich domain and in patients with the V617FJAK2.,http://www.ncbi.nlm.nih.gov/pubmed/22315494
3739,26095772,Cancer-associated ASXL1 mutations may act as gain-of-function mutations of the ASXL1-BAP1 complex.,http://www.ncbi.nlm.nih.gov/pubmed/26095772
3740,25224413,TET2 mutations predict response to hypomethylating agents in myelodysplastic syndrome patients.,http://www.ncbi.nlm.nih.gov/pubmed/25224413
3741,26452166,Occurrence of Neuroblastoma among TP53 p.R337H Carriers.,http://www.ncbi.nlm.nih.gov/pubmed/26452166
3742,20929407,Subclinical nonautoimmune hyperthyroidism in a family segregates with a thyrotropin receptor mutation with weakly increased constitutive activity.,http://www.ncbi.nlm.nih.gov/pubmed/20929407
3743,17079233,Contacts between extracellular loop two and transmembrane helix six determine basal activity of the thyroid-stimulating hormone receptor.,http://www.ncbi.nlm.nih.gov/pubmed/17079233
3744,17122103,Biological effects of thyrotropin receptor activation on human orbital preadipocytes.,http://www.ncbi.nlm.nih.gov/pubmed/17122103
3745,21677043,Nonclassic TSH resistance: TSHR mutation carriers with discrepantly high thyroidal iodine uptake.,http://www.ncbi.nlm.nih.gov/pubmed/21677043
3746,18162522,"An intracellular loop (IL2) residue confers different basal constitutive activities to the human lutropin receptor and human thyrotropin receptor through structural communication between IL2 and helix 6, via helix 3.",http://www.ncbi.nlm.nih.gov/pubmed/18162522
3747,22049173,Frequent TSH receptor genetic alterations with variable signaling impairment in a large series of children with nonautoimmune isolated hyperthyrotropinemia.,http://www.ncbi.nlm.nih.gov/pubmed/22049173
3748,12902333,The expression of the thyroid-stimulating hormone (TSH) receptor and the cAMP-dependent protein kinase RII beta regulatory subunit confers TSH-cAMP-dependent growth to mouse fibroblasts.,http://www.ncbi.nlm.nih.gov/pubmed/12902333
3749,15630448,Oncogenic AKAP9-BRAF fusion is a novel mechanism of MAPK pathway activation in thyroid cancer.,http://www.ncbi.nlm.nih.gov/pubmed/15630448
3750,25985019,Common Oncogene Mutations and Novel SND1-BRAF Transcript Fusion in Lung Adenocarcinoma from Never Smokers.,http://www.ncbi.nlm.nih.gov/pubmed/25985019
3751,22745804,A novel SND1-BRAF fusion confers resistance to c-Met inhibitor PF-04217903 in GTL16 cells through [corrected] MAPK activation.,http://www.ncbi.nlm.nih.gov/pubmed/22745804
3752,21424530,Oncogenic FAM131B-BRAF fusion resulting from 7q34 deletion comprises an alternative mechanism of MAPK pathway activation in pilocytic astrocytoma.,http://www.ncbi.nlm.nih.gov/pubmed/21424530
3753,20526349,"Rearrangements of the RAF kinase pathway in prostate cancer, gastric cancer and melanoma.",http://www.ncbi.nlm.nih.gov/pubmed/20526349
3754,11468294,Mapping of a region within the N terminus of Jak1 involved in cytokine receptor interaction.,http://www.ncbi.nlm.nih.gov/pubmed/11468294
3755,23242808,Inhibiting EGF receptor or SRC family kinase signaling overcomes BRAF inhibitor resistance in melanoma.,http://www.ncbi.nlm.nih.gov/pubmed/23242808
3756,17463090,"Selective chemical probe inhibitor of Stat3, identified through structure-based virtual screening, induces antitumor activity.",http://www.ncbi.nlm.nih.gov/pubmed/17463090
3757,25950519,Mutation of androgen receptor N-terminal phosphorylation site Tyr-267 leads to inhibition of nuclear translocation and DNA binding.,http://www.ncbi.nlm.nih.gov/pubmed/25950519
3758,,"Preclinical characterization and first-in-human study of MM-141, a dual antibody inhibitor of IGF-1R and ErbB3",http://cancerres.aacrjournals.org/content/75/15_Supplement/CT237?cited-by=yes&legid=canres;75/15_Supplement/CT237
3759,,"A phase I, dose-escalation, safety, pharmacokinetic, pharmacodynamic study of thioureidobutyronitrile, a novel p53 targeted therapy, in patients with advanced solid tumors.",http://meetinglibrary.asco.org/content/113150-132
3760,25605843,"Fluorouracil, leucovorin, and irinotecan plus cetuximab treatment and RAS mutations in colorectal cancer.",http://www.ncbi.nlm.nih.gov/pubmed/25605843
3761,26245675,Prospective Biomarker Analysis of the Randomized CHER-LOB Study Evaluating the Dual Anti-HER2 Treatment With Trastuzumab and Lapatinib Plus Chemotherapy as Neoadjuvant Therapy for HER2-Positive Breast Cancer.,http://www.ncbi.nlm.nih.gov/pubmed/26245675
3762,18372921,EGFR somatic doublets in lung cancer are frequent and generally arise from a pair of driver mutations uncommonly seen as singlet mutations: one-third of doublets occur at five pairs of amino acids.,http://www.ncbi.nlm.nih.gov/pubmed/18372921
3763,19626115,Modulation of microRNA processing by p53.,http://www.ncbi.nlm.nih.gov/pubmed/19626115
3764,26294908,Beneficial Effects of the mTOR Inhibitor Everolimus in Patients with Advanced Medullary Thyroid Carcinoma: Subgroup Results of a Phase II Trial.,http://www.ncbi.nlm.nih.gov/pubmed/26294908
3765,15077183,The PAX8/PPARgamma fusion oncoprotein transforms immortalized human thyrocytes through a mechanism probably involving wild-type PPARgamma inhibition.,http://www.ncbi.nlm.nih.gov/pubmed/15077183
3766,24382387,New and emerging HDAC inhibitors for cancer treatment.,http://www.ncbi.nlm.nih.gov/pubmed/24382387
3767,15374944,Prediction of resistance to small molecule FLT3 inhibitors: implications for molecularly targeted therapy of acute leukemia.,http://www.ncbi.nlm.nih.gov/pubmed/15374944
3768,17594689,Moesin expression is a marker of basal breast carcinomas.,http://www.ncbi.nlm.nih.gov/pubmed/17594689
3769,25319834,Identification of a novel FN1-FGFR1 genetic fusion as a frequent event in phosphaturic mesenchymal tumour.,http://www.ncbi.nlm.nih.gov/pubmed/25319834
3770,22627678,Phase IB study of the FLT3 kinase inhibitor midostaurin with chemotherapy in younger newly diagnosed adult patients with acute myeloid leukemia.,http://www.ncbi.nlm.nih.gov/pubmed/22627678
3772,23792191,Small molecule inhibitors of aurora-a induce proteasomal degradation of N-myc in childhood neuroblastoma.,http://www.ncbi.nlm.nih.gov/pubmed/23792191
3773,24965569,"Rilotumumab in combination with epirubicin, cisplatin, and capecitabine as first-line treatment for gastric or oesophagogastric junction adenocarcinoma: an open-label, dose de-escalation phase 1b study and a double-blind, randomised phase 2 study.",http://www.ncbi.nlm.nih.gov/pubmed/24965569
3774,25669829,Phase I study of pazopanib and vorinostat: a therapeutic approach for inhibiting mutant p53-mediated angiogenesis and facilitating mutant p53 degradation.,http://www.ncbi.nlm.nih.gov/pubmed/25669829
3775,26014098,Antibody-Dependent Cellular Cytotoxicity Activity of a Novel Anti-PD-L1 Antibody Avelumab (MSB0010718C) on Human Tumor Cells.,http://www.ncbi.nlm.nih.gov/pubmed/26014098
3776,,,http://meetinglibrary.asco.org/content/134551-144
3777,26160923,BIOMEDICINE. Targeting copper to treat breast cancer.,http://www.ncbi.nlm.nih.gov/pubmed/26160923
3778,26308386,Minireview: Roles of Fibroblast Growth Factors 19 and 21 in Metabolic Regulation and Chronic Diseases.,http://www.ncbi.nlm.nih.gov/pubmed/26308386
3779,23842646,Role of ABL family kinases in cancer: from leukaemia to solid tumours.,http://www.ncbi.nlm.nih.gov/pubmed/23842646
3780,19955487,"1-tert-butyl-3-[6-(3,5-dimethoxy-phenyl)-2-(4-diethylamino-butylamino)-pyrido[2,3-d]pyrimidin-7-yl]-urea (PD173074), a selective tyrosine kinase inhibitor of fibroblast growth factor receptor-3 (FGFR3), inhibits cell proliferation of bladder cancer carrying the FGFR3 gene mutation along with up-regulation of p27/Kip1 and G1/G0 arrest.",http://www.ncbi.nlm.nih.gov/pubmed/19955487
3781,26107252,Inflammasome-independent role of AIM2 in suppressing colon tumorigenesis via DNA-PK and Akt.,http://www.ncbi.nlm.nih.gov/pubmed/26107252
3782,21804607,Absent in Melanoma 2 (AIM2) is an important mediator of interferon-dependent and -independent HLA-DRA and HLA-DRB gene expression in colorectal cancers.,http://www.ncbi.nlm.nih.gov/pubmed/21804607
3783,26450751,Increased Expression of FGF19 Contributes to Tumor Progression and Cell Motility of Human Thyroid Cancer.,http://www.ncbi.nlm.nih.gov/pubmed/26450751
3784,24728076,Separating Tumorigenicity from Bile Acid Regulatory Activity for Endocrine Hormone FGF19.,http://www.ncbi.nlm.nih.gov/pubmed/24728076
3785,25950492,Fibroblast growth factor family aberrations in cancers: clinical and molecular characteristics.,http://www.ncbi.nlm.nih.gov/pubmed/25950492
3786,25847957,Paralog-Specific Kinase Inhibition of FGFR4: Adding to the Arsenal of Anti-FGFR Agents.,http://www.ncbi.nlm.nih.gov/pubmed/25847957
3787,15897558,"In vivo target modulation and biological activity of CHIR-258, a multitargeted growth factor receptor kinase inhibitor, in colon cancer models.",http://www.ncbi.nlm.nih.gov/pubmed/15897558
3788,25219510,Structural analysis of the human fibroblast growth factor receptor 4 kinase.,http://www.ncbi.nlm.nih.gov/pubmed/25219510
3789,15598814,"CHIR-258, a novel, multitargeted tyrosine kinase inhibitor for the potential treatment of t(4;14) multiple myeloma.",http://www.ncbi.nlm.nih.gov/pubmed/15598814
3790,21596819,Anaplastic thyroid cancers harbor novel oncogenic mutations of the ALK gene.,http://www.ncbi.nlm.nih.gov/pubmed/21596819
3791,25421750,Treatment Efficacy and Resistance Mechanisms Using the Second-Generation ALK Inhibitor AP26113 in Human NPM-ALK-Positive Anaplastic Large Cell Lymphoma.,http://www.ncbi.nlm.nih.gov/pubmed/25421750
3792,22914783,"Role of MRE11 in cell proliferation, tumor invasion, and DNA repair in breast cancer.",http://www.ncbi.nlm.nih.gov/pubmed/22914783
3793,26436112,Multigene panel analysis identified germline mutations of DNA repair genes in breast and ovarian cancer.,http://www.ncbi.nlm.nih.gov/pubmed/26436112
3794,19491272,In vitro and in vivo activity of novel small-molecule inhibitors targeting the pleckstrin homology domain of protein kinase B/AKT.,http://www.ncbi.nlm.nih.gov/pubmed/19491272
3795,25447316,The MRE11 complex: an important source of stress relief.,http://www.ncbi.nlm.nih.gov/pubmed/25447316
3796,15279809,Nijmegen breakage syndrome: clinical manifestation of defective response to DNA double-strand breaks.,http://www.ncbi.nlm.nih.gov/pubmed/15279809
3797,24396275,NBN Gene Polymorphisms and Cancer Susceptibility: A Systemic Review.,http://www.ncbi.nlm.nih.gov/pubmed/24396275
3798,8944023,Identification of a RING protein that can interact in vivo with the BRCA1 gene product.,http://www.ncbi.nlm.nih.gov/pubmed/8944023
3799,21344236,Cancer predisposing BARD1 mutations in breast-ovarian cancer families.,http://www.ncbi.nlm.nih.gov/pubmed/21344236
3800,16263090,"Fibroblast growth factor 3, a protein with a dual subcellular fate, is interacting with human ribosomal protein S2.",http://www.ncbi.nlm.nih.gov/pubmed/16263090
3801,17601531,"Differential requirements for FGF3, FGF8 and FGF10 during inner ear development.",http://www.ncbi.nlm.nih.gov/pubmed/17601531
3802,12429977,WNT and FGF gene clusters (review).,http://www.ncbi.nlm.nih.gov/pubmed/12429977
3803,17804712,"YM155, a novel small-molecule survivin suppressant, induces regression of established human hormone-refractory prostate tumor xenografts.",http://www.ncbi.nlm.nih.gov/pubmed/17804712
3804,23874397,Human folliculin delays cell cycle progression through late S and G2/M-phases: effect of phosphorylation and tumor associated mutations.,http://www.ncbi.nlm.nih.gov/pubmed/23874397
3805,26418749,Flcn-deficient renal cells are tumorigenic and sensitive to mTOR suppression.,http://www.ncbi.nlm.nih.gov/pubmed/26418749
3806,15956655,High frequency of somatic frameshift BHD gene mutations in Birt-Hogg-Dubé-associated renal tumors.,http://www.ncbi.nlm.nih.gov/pubmed/15956655
3807,19764794,Selective inhibitors of the mutant B-Raf pathway: discovery of a potent and orally bioavailable aminoisoquinoline.,http://www.ncbi.nlm.nih.gov/pubmed/19764794
3808,21658003,Binding affinities of vascular endothelial growth factor (VEGF) for heparin-derived oligosaccharides.,http://www.ncbi.nlm.nih.gov/pubmed/21658003
3809,25266736,Comprehensive genomic profiling of pancreatic acinar cell carcinomas identifies recurrent RAF fusions and frequent inactivation of DNA repair genes.,http://www.ncbi.nlm.nih.gov/pubmed/25266736
3810,26380006,CDK4/6 inhibitor suppresses gastric cancer with CDKN2A mutation.,http://www.ncbi.nlm.nih.gov/pubmed/26380006
3811,20952405,COSMIC: mining complete cancer genomes in the Catalogue of Somatic Mutations in Cancer.,http://www.ncbi.nlm.nih.gov/pubmed/20952405
3812,24743239,Prediction and prioritization of rare oncogenic mutations in the cancer Kinome using novel features and multiple classifiers.,http://www.ncbi.nlm.nih.gov/pubmed/24743239
3813,20633017,"Analysis of TSC cortical tubers by deep sequencing of TSC1, TSC2 and KRAS demonstrates that small second-hit mutations in these genes are rare events.",http://www.ncbi.nlm.nih.gov/pubmed/20633017
3814,23209031,"GA201 (RG7160): a novel, humanized, glycoengineered anti-EGFR antibody with enhanced ADCC and superior in vivo efficacy compared with cetuximab.",http://www.ncbi.nlm.nih.gov/pubmed/23209031
3815,19909247,The heparin-binding domain confers diverse functions of VEGF-A in development and disease: a structure-function study.,http://www.ncbi.nlm.nih.gov/pubmed/19909247
3816,21245303,Dishevelled interacts with the DIX domain polymerization interface of Axin to interfere with its function in down-regulating β-catenin.,http://www.ncbi.nlm.nih.gov/pubmed/21245303
3817,15538750,Mutations and elevated transcriptional activity of conductin (AXIN2) in hepatoblastomas.,http://www.ncbi.nlm.nih.gov/pubmed/15538750
3818,17301836,Chromosomal translocations as a mechanism of BRAF activation in two cases of large congenital melanocytic nevi.,http://www.ncbi.nlm.nih.gov/pubmed/17301836
3819,24445538,Kinase fusions are frequent in Spitz tumours and spitzoid melanomas.,http://www.ncbi.nlm.nih.gov/pubmed/24445538
3820,22301675,"Ponatinib is active against imatinib-resistant mutants of FIP1L1-PDGFRA and KIT, and against FGFR1-derived fusion kinases.",http://www.ncbi.nlm.nih.gov/pubmed/22301675
3821,17229632,The ability of sorafenib to inhibit oncogenic PDGFRbeta and FLT3 mutants and overcome resistance to other small molecule inhibitors.,http://www.ncbi.nlm.nih.gov/pubmed/17229632
3822,18024392,"Synergistic growth-inhibitory effects of two tyrosine kinase inhibitors, dasatinib and PKC412, on neoplastic mast cells expressing the D816V-mutated oncogenic variant of KIT.",http://www.ncbi.nlm.nih.gov/pubmed/18024392
3823,,677 Phase I/II Trial of the MEK1/2 Inhibitor Trametinib (GSK1120212) in Relapsed/Refractory Myeloid Malignancies: Evidence of Activity in Patients with RAS Mutation-Positive Disease,https://ash.confex.com/ash/2012/webprogram/Paper51144.html
3824,20033038,Complex landscapes of somatic rearrangement in human breast cancer genomes.,http://www.ncbi.nlm.nih.gov/pubmed/20033038
3825,25515853,Detailed imaging and genetic analysis reveal a secondary BRAF(L505H) resistance mutation and extensive intrapatient heterogeneity in metastatic BRAF mutant melanoma patients treated with vemurafenib.,http://www.ncbi.nlm.nih.gov/pubmed/25515853
3826,26437915,A novel dual EGFR/HER2 inhibitor KU004 induces cell cycle arrest and apoptosis in HER2-overexpressing cancer cells.,http://www.ncbi.nlm.nih.gov/pubmed/26437915
3827,15510211,Evidence for D276G and L364I Bcr-Abl mutations in Ph+ leukaemic cells obtained from patients resistant to Imatinib.,http://www.ncbi.nlm.nih.gov/pubmed/15510211
3828,21562040,BCR-ABL kinase domain mutation analysis in chronic myeloid leukemia patients treated with tyrosine kinase inhibitors: recommendations from an expert panel on behalf of European LeukemiaNet.,http://www.ncbi.nlm.nih.gov/pubmed/21562040
3829,10749119,"EWS-FLI1, EWS-ERG, and EWS-ETV1 oncoproteins of Ewing tumor family all suppress transcription of transforming growth factor beta type II receptor gene.",http://www.ncbi.nlm.nih.gov/pubmed/10749119
3830,16424036,Structure of the kinase domain of an imatinib-resistant Abl mutant in complex with the Aurora kinase inhibitor VX-680.,http://www.ncbi.nlm.nih.gov/pubmed/16424036
3831,9591781,The desmoplastic small round cell tumor t(11;22) translocation produces EWS/WT1 isoforms with differing oncogenic properties.,http://www.ncbi.nlm.nih.gov/pubmed/9591781
3832,15826834,The EWS-WT1 gene fusion in desmoplastic small round cell tumor.,http://www.ncbi.nlm.nih.gov/pubmed/15826834
3833,24365090,Rapid identification of compound mutations in patients with Philadelphia-positive leukaemias by long-range next generation sequencing.,http://www.ncbi.nlm.nih.gov/pubmed/24365090
3834,16880519,"Kinase domain mutants of Bcr-Abl exhibit altered transformation potency, kinase activity, and substrate utilization, irrespective of sensitivity to imatinib.",http://www.ncbi.nlm.nih.gov/pubmed/16880519
3835,16482207,The Bcr-Abl mutations T315I and Y253H do not confer a growth advantage in the absence of imatinib.,http://www.ncbi.nlm.nih.gov/pubmed/16482207
3836,25838395,Eribulin mesylate: mechanism of action of a unique microtubule-targeting agent.,http://www.ncbi.nlm.nih.gov/pubmed/25838395
3837,26247207,A Pan-GTPase Inhibitor as a Molecular Probe.,http://www.ncbi.nlm.nih.gov/pubmed/26247207
3838,,"Study Of Activity Of E6201, a Dual FLT3 and MEK Inhibitor, In Acute Myelogenous Leukemia With FLT3 Or RAS Mutation",http://www.bloodjournal.org/content/122/21/2683?sso-checked=true
3839,11301010,"BACH1, a novel helicase-like protein, interacts directly with BRCA1 and contributes to its DNA repair function.",http://www.ncbi.nlm.nih.gov/pubmed/11301010
3840,17420723,Involvement of H4(D10S170) protein in ATM-dependent response to DNA damage.,http://www.ncbi.nlm.nih.gov/pubmed/17420723
3841,23154560,"Identification of CCDC6-RET fusion in the human lung adenocarcinoma cell line, LC-2/ad.",http://www.ncbi.nlm.nih.gov/pubmed/23154560
3842,26078337,Identification and characterization of RET fusions in advanced colorectal cancer.,http://www.ncbi.nlm.nih.gov/pubmed/26078337
3843,25035671,Wilms tumor 1 gene mutations in patients with cytogenetically normal acute myeloid leukemia.,http://www.ncbi.nlm.nih.gov/pubmed/25035671
3844,24398328,Germ-line JAK2 mutations in the kinase domain are responsible for hereditary thrombocytosis and are resistant to JAK2 and HSP90 inhibitors.,http://www.ncbi.nlm.nih.gov/pubmed/24398328
3845,21343560,RUNX1 mutations in acute myeloid leukemia: results from a comprehensive genetic and clinical analysis from the AML study group.,http://www.ncbi.nlm.nih.gov/pubmed/21343560
3846,16987884,"The many facets of the Wilms' tumour gene, WT1.",http://www.ncbi.nlm.nih.gov/pubmed/16987884
3847,25964253,Simpson's Paradox and the Impact of Different DNMT3A Mutations on Outcome in Younger Adults With Acute Myeloid Leukemia.,http://www.ncbi.nlm.nih.gov/pubmed/25964253
3848,16434492,Implications of NRAS mutations in AML: a study of 2502 patients.,http://www.ncbi.nlm.nih.gov/pubmed/16434492
3849,25281355,"Clinical features of de novo acute myeloid leukemia with concurrent DNMT3A, FLT3 and NPM1 mutations.",http://www.ncbi.nlm.nih.gov/pubmed/25281355
3850,16189265,"PKC412 inhibits in vitro growth of neoplastic human mast cells expressing the D816V-mutated variant of KIT: comparison with AMN107, imatinib, and cladribine (2CdA) and evaluation of cooperative drug effects.",http://www.ncbi.nlm.nih.gov/pubmed/16189265
3851,23691988,Ponatinib in patients with refractory acute myeloid leukaemia: findings from a phase 1 study.,http://www.ncbi.nlm.nih.gov/pubmed/23691988
3852,23613521,Phase 2 study of azacytidine plus sorafenib in patients with acute myeloid leukemia and FLT-3 internal tandem duplication mutation.,http://www.ncbi.nlm.nih.gov/pubmed/23613521
3853,12481435,Juxtamembrane mutant V560GKit is more sensitive to Imatinib (STI571) compared with wild-type c-kit whereas the kinase domain mutant D816VKit is resistant.,http://www.ncbi.nlm.nih.gov/pubmed/12481435
3854,,"AG-221, an Oral, Selective, First-in-Class, Potent Inhibitor of the IDH2 Mutant Metabolic Enzyme, Induces Durable Remissions in a Phase I Study in Patients with IDH2 Mutation Positive Advanced Hematologic Malignancies",https://ash.confex.com/ash/2014/webprogram/Paper70721.html
3855,,"Results of a first-in-human, phase I/II trial of ASP2215, a selective, potent inhibitor of FLT3/Axl in patients with relapsed or refractory (R/R) acute myeloid leukemia (AML)",http://meetinglibrary.asco.org/content/146239-156
3856,,Results of a Phase II Study of Crenolanib in Relapsed/Refractory Acute Myeloid Leukemia Patients (Pts) with Activating FLT3 Mutations,https://ash.confex.com/ash/2014/webprogram/Paper74499.html
3857,24736545,Activation of SOX2 expression by BRD4-NUT oncogenic fusion drives neoplastic transformation in NUT midline carcinoma.,http://www.ncbi.nlm.nih.gov/pubmed/24736545
3858,12543779,BRD4-NUT fusion oncogene: a novel mechanism in aggressive carcinoma.,http://www.ncbi.nlm.nih.gov/pubmed/12543779
3860,25239608,Ponatinib inhibits polyclonal drug-resistant KIT oncoproteins and shows therapeutic potential in heavily pretreated gastrointestinal stromal tumor (GIST) patients.,http://www.ncbi.nlm.nih.gov/pubmed/25239608
3861,16144927,Dose-finding study of the multitargeted tyrosine kinase inhibitor SU6668 in patients with advanced malignancies.,http://www.ncbi.nlm.nih.gov/pubmed/16144927
3862,23497317,"Quizartinib (AC220) is a potent second generation class III tyrosine kinase inhibitor that displays a distinct inhibition profile against mutant-FLT3, -PDGFRA and -KIT isoforms.",http://www.ncbi.nlm.nih.gov/pubmed/23497317
3863,24714778,Phase II study of cediranib in patients with advanced gastrointestinal stromal tumors or soft-tissue sarcoma.,http://www.ncbi.nlm.nih.gov/pubmed/24714778
3864,,"Abstract 787: FLX925 (AMG 925) is a rationally designed FLT3, CDK4/6 inhibitor that retains potency against clinically relevant secondary resistance mutations in FLT3",http://cancerres.aacrjournals.org/content/75/15_Supplement/787.short
3865,17943726,"E7080, a novel inhibitor that targets multiple kinases, has potent antitumor activities against stem cell factor producing human small cell lung cancer H146, based on angiogenesis inhibition.",http://www.ncbi.nlm.nih.gov/pubmed/17943726
3866,23788831,Tivozanib in the treatment of renal cell carcinoma.,http://www.ncbi.nlm.nih.gov/pubmed/23788831
3867,23700288,A phase II study of the oral VEGF receptor tyrosine kinase inhibitor vatalanib (PTK787/ZK222584) in myelodysplastic syndrome: Cancer and Leukemia Group B study 10105 (Alliance).,http://www.ncbi.nlm.nih.gov/pubmed/23700288
3868,12124335,"PTK787/ZK 222584, a specific vascular endothelial growth factor-receptor tyrosine kinase inhibitor, affects the anatomy of the tumor vascular bed and the functional vascular properties as detected by dynamic enhanced magnetic resonance imaging.",http://www.ncbi.nlm.nih.gov/pubmed/12124335
3869,25530214,Phase I/II trial of the combination of midostaurin (PKC412) and 5-azacytidine for patients with acute myeloid leukemia and myelodysplastic syndrome.,http://www.ncbi.nlm.nih.gov/pubmed/25530214
3870,24552773,Ponatinib induces apoptosis in imatinib-resistant human mast cells by dephosphorylating mutant D816V KIT and silencing β-catenin signaling.,http://www.ncbi.nlm.nih.gov/pubmed/24552773
3871,,"AG-221, a Small Molecule Mutant IDH2 Inhibitor, Remodels the Epigenetic State of IDH2-Mutant Cells and Induces Alterations in Self-Renewal/Differentiation in IDH2-Mutant AML Model in Vivo",http://www.bloodjournal.org/content/124/21/437?sso-checked=true
3872,24569456,Hematopoiesis and RAS-driven myeloid leukemia differentially require PI3K isoform p110α.,http://www.ncbi.nlm.nih.gov/pubmed/24569456
3873,11238126,Cell-cycle-dependent activation of mitogen-activated protein kinase kinase (MEK-1/2) in myeloid leukemia cell lines and induction of growth inhibition and apoptosis by inhibitors of RAS signaling.,http://www.ncbi.nlm.nih.gov/pubmed/11238126
3874,24002496,Phase I study of quizartinib administered daily to patients with relapsed or refractory acute myeloid leukemia irrespective of FMS-like tyrosine kinase 3-internal tandem duplication status.,http://www.ncbi.nlm.nih.gov/pubmed/24002496
3875,,"Clinical activity and safety profile of TGR-1202, a novel once daily PI3K{delta} inhibitor, in patients with CLL and B-cell lymphoma.",http://hwmaint.meeting.ascopubs.org/cgi/content/abstract/33/15_suppl/7069
3876,25608663,Massive parallel sequencing uncovers actionable FGFR2-PPHLN1 fusion and ARAF mutations in intrahepatic cholangiocarcinoma.,http://www.ncbi.nlm.nih.gov/pubmed/25608663
3877,26101246,Belinostat in Patients With Relapsed or Refractory Peripheral T-Cell Lymphoma: Results of the Pivotal Phase II BELIEF (CLN-19) Study.,http://www.ncbi.nlm.nih.gov/pubmed/26101246
3878,18245542,A phase 1 pharmacokinetic and pharmacodynamic study of the histone deacetylase inhibitor belinostat in patients with advanced solid tumors.,http://www.ncbi.nlm.nih.gov/pubmed/18245542
3879,24854104,The novel HDAC inhibitor OBP-801/YM753 enhances the effects of 5-fluorouracil with radiation on esophageal squamous carcinoma cells.,http://www.ncbi.nlm.nih.gov/pubmed/24854104
3880,26362997,Panobinostat for the Treatment of Multiple Myeloma.,http://www.ncbi.nlm.nih.gov/pubmed/26362997
3881,20697094,"Final results from a multicenter, international, pivotal study of romidepsin in refractory cutaneous T-cell lymphoma.",http://www.ncbi.nlm.nih.gov/pubmed/20697094
3882,22748449,Phase II trial of the histone deacetylase inhibitor romidepsin in patients with recurrent/metastatic head and neck cancer.,http://www.ncbi.nlm.nih.gov/pubmed/22748449
3883,22814295,GATA2 mutations are frequent in intermediate-risk karyotype AML with biallelic CEBPA mutations and are associated with favorable prognosis.,http://www.ncbi.nlm.nih.gov/pubmed/22814295
3884,25709401,The role of dasatinib in the management of chronic myeloid leukemia.,http://www.ncbi.nlm.nih.gov/pubmed/25709401
3885,23942795,The development of dasatinib as a treatment for chronic myeloid leukemia (CML): from initial studies to application in newly diagnosed patients.,http://www.ncbi.nlm.nih.gov/pubmed/23942795
3886,22214462,Sorafenib (BAY 43-9006) in hepatocellular carcinoma patients: from discovery to clinical development.,http://www.ncbi.nlm.nih.gov/pubmed/22214462
3887,18986703,Chemotherapy and dasatinib induce long-term hematologic and molecular remission in systemic mastocytosis with acute myeloid leukemia with KIT D816V.,http://www.ncbi.nlm.nih.gov/pubmed/18986703
3888,25714871,AKT1 E17K in Colorectal Carcinoma Is Associated with BRAF V600E but Not MSI-H Status: A Clinicopathologic Comparison to PIK3CA Helical and Kinase Domain Mutants.,http://www.ncbi.nlm.nih.gov/pubmed/25714871
3889,24883179,The evolving role of FLT3 inhibitors in acute myeloid leukemia: quizartinib and beyond.,http://www.ncbi.nlm.nih.gov/pubmed/24883179
3890,26135807,Inhibitory effects of valproic acid in DNA double-strand break repair after irradiation in esophageal squamous carcinoma cells.,http://www.ncbi.nlm.nih.gov/pubmed/26135807
3891,24389139,Inotuzumab ozogamicin in the treatment of acute lymphoblastic leukemia.,http://www.ncbi.nlm.nih.gov/pubmed/24389139
3892,16061562,Identification and characterization of missense alterations in the BRCA1 associated RING domain (BARD1) gene in breast and ovarian cancer.,http://www.ncbi.nlm.nih.gov/pubmed/16061562
3893,22167183,Distinct roles of FANCO/RAD51C protein in DNA damage signaling and repair: implications for Fanconi anemia and breast cancer susceptibility.,http://www.ncbi.nlm.nih.gov/pubmed/22167183
3894,21980511,RAD51C germline mutations in breast and ovarian cancer cases from high-risk families.,http://www.ncbi.nlm.nih.gov/pubmed/21980511
3895,10441570,The phenotypic spectrum of GLI3 morphopathies includes autosomal dominant preaxial polydactyly type-IV and postaxial polydactyly type-A/B; No phenotype prediction from the position of GLI3 mutations.,http://www.ncbi.nlm.nih.gov/pubmed/10441570
3896,25527561,Hedgehog pathway mutations in T-cell acute lymphoblastic leukemia.,http://www.ncbi.nlm.nih.gov/pubmed/25527561
3897,21816343,The Ewing sarcoma protein regulates DNA damage-induced alternative splicing.,http://www.ncbi.nlm.nih.gov/pubmed/21816343
3898,18390968,"Phase I pharmacokinetic and pharmacodynamic study of the oral, small-molecule mitogen-activated protein kinase kinase 1/2 inhibitor AZD6244 (ARRY-142886) in patients with advanced cancers.",http://www.ncbi.nlm.nih.gov/pubmed/18390968
3899,23329308,Molecular detection and targeting of EWSR1 fusion transcripts in soft tissue tumors.,http://www.ncbi.nlm.nih.gov/pubmed/23329308
3900,11175359,Expression and function of Ets transcription factors in mammalian development: a regulatory network.,http://www.ncbi.nlm.nih.gov/pubmed/11175359
3901,19417137,Ewing sarcoma fusion protein EWSR1/FLI1 interacts with EWSR1 leading to mitotic defects in zebrafish embryos and human cell lines.,http://www.ncbi.nlm.nih.gov/pubmed/19417137
3902,14764528,"Familial essential thrombocythemia associated with a dominant-positive activating mutation of the c-MPL gene, which encodes for the receptor for thrombopoietin.",http://www.ncbi.nlm.nih.gov/pubmed/14764528
3903,,Update of progression-free survival (PFS) and correlative biomarker analysis from coBRIM: Phase III study of cobimetinib (cobi) plus vemurafenib (vem) in advanced BRAF-mutated melanoma,http://meetinglibrary.asco.org/content/144759-156
3904,20478527,"An integrated network of androgen receptor, polycomb, and TMPRSS2-ERG gene fusions in prostate cancer progression.",http://www.ncbi.nlm.nih.gov/pubmed/20478527
3905,18094413,EWSR1-CREB1 and EWSR1-ATF1 fusion genes in angiomatoid fibrous histiocytoma.,http://www.ncbi.nlm.nih.gov/pubmed/18094413
3906,22570737,Myxoid liposarcoma-associated EWSR1-DDIT3 selectively represses osteoblastic and chondrocytic transcription in multipotent mesenchymal cells.,http://www.ncbi.nlm.nih.gov/pubmed/22570737
3907,18855877,The EWSR1/NR4A3 fusion protein of extraskeletal myxoid chondrosarcoma activates the PPARG nuclear receptor gene.,http://www.ncbi.nlm.nih.gov/pubmed/18855877
3908,18383210,Detection of a t(1;22)(q23;q12) translocation leading to an EWSR1-PBX1 fusion gene in a myoepithelioma.,http://www.ncbi.nlm.nih.gov/pubmed/18383210
3909,15729702,EWSR1 is fused to POU5F1 in a bone tumor with translocation t(6;22)(p21;q12).,http://www.ncbi.nlm.nih.gov/pubmed/15729702
3910,18338330,"POU5F1, encoding a key regulator of stem cell pluripotency, is fused to EWSR1 in hidradenoma of the skin and mucoepidermoid carcinoma of the salivary glands.",http://www.ncbi.nlm.nih.gov/pubmed/18338330
3911,26352686,Targeting Mutant BRAF in Relapsed or Refractory Hairy-Cell Leukemia.,http://www.ncbi.nlm.nih.gov/pubmed/26352686
3912,26351323,Tumors with AKT1E17K Mutations Are Rational Targets for Single Agent or Combination Therapy with AKT Inhibitors.,http://www.ncbi.nlm.nih.gov/pubmed/26351323
3913,,AZD9291 in Pre-Treated T790M Positive Advanced NSCLC: AURA Study Phase II Extension Cohort.,http://library.iaslc.org/virtual-library-search?product_id=1&author=Yang&category=&date=&session_type=&session=&presentation=&keyword=AURA
3914,21056992,Mage-A cancer/testis antigens inhibit p53 function by blocking its interaction with chromatin.,http://www.ncbi.nlm.nih.gov/pubmed/21056992
3915,22822097,The rebel angel: mutant p53 as the driving oncogene in breast cancer.,http://www.ncbi.nlm.nih.gov/pubmed/22822097
3916,18524770,Oligomerization of BAK by p53 utilizes conserved residues of the p53 DNA binding domain.,http://www.ncbi.nlm.nih.gov/pubmed/18524770
3917,22851205,A phase I trial of oral administration of panobinostat in combination with paclitaxel and carboplatin in patients with solid tumors.,http://www.ncbi.nlm.nih.gov/pubmed/22851205
3918,,A phase I trial of romidepsin in combination with gemcitabine in patients with pancreatic and other advanced solid tumors,http://meeting.ascopubs.org/cgi/content/short/26/15_suppl/2567
3919,17513804,Phase I trial of histone deacetylase inhibition by valproic acid followed by the topoisomerase II inhibitor epirubicin in advanced solid tumors: a clinical and translational study.,http://www.ncbi.nlm.nih.gov/pubmed/17513804
3920,25417902,Phase I study of the MEK inhibitor trametinib in combination with the AKT inhibitor afuresertib in patients with solid tumors and multiple myeloma.,http://www.ncbi.nlm.nih.gov/pubmed/25417902
3921,26510020,DNA-Repair Defects and Olaparib in Metastatic Prostate Cancer.,http://www.ncbi.nlm.nih.gov/pubmed/26510020
3922,26202950,Cyclin-Dependent Kinase Inhibitor AT7519 as a Potential Drug for MYCN-Dependent Neuroblastoma.,http://www.ncbi.nlm.nih.gov/pubmed/26202950
3923,11595711,"A new antiestrogen, 2-(4-hydroxy-phenyl)-3-methyl-1-[4-(2-piperidin-1-yl-ethoxy)-benzyl]-1H-indol-5-ol hydrochloride (ERA-923), inhibits the growth of tamoxifen-sensitive and -resistant tumors and is devoid of uterotropic effects in mice and rats.",http://www.ncbi.nlm.nih.gov/pubmed/11595711
3924,25991817,Efficacy of SERD/SERM Hybrid-CDK4/6 Inhibitor Combinations in Models of Endocrine Therapy-Resistant Breast Cancer.,http://www.ncbi.nlm.nih.gov/pubmed/25991817
3925,25132561,Connections between TET proteins and aberrant DNA modification in cancer.,http://www.ncbi.nlm.nih.gov/pubmed/25132561
3926,22547150,Design and selection of Toca 511 for clinical use: modified retroviral replicating vector with improved stability and gene expression.,http://www.ncbi.nlm.nih.gov/pubmed/22547150
3927,19878677,Adding structural information to the von Hippel-Lindau (VHL) tumor suppressor interaction network.,http://www.ncbi.nlm.nih.gov/pubmed/19878677
3928,23408573,Functional characterization of a heterozygous GLI2 missense mutation in patients with multiple pituitary hormone deficiency.,http://www.ncbi.nlm.nih.gov/pubmed/23408573
3929,20420527,INGN-225: a dendritic cell-based p53 vaccine (Ad.p53-DC) in small cell lung cancer: observed association between immune response and enhanced chemotherapy effect.,http://www.ncbi.nlm.nih.gov/pubmed/20420527
3930,18075512,"Survivin, cancer networks and pathway-directed drug discovery.",http://www.ncbi.nlm.nih.gov/pubmed/18075512
3931,22088485,Targeted BIRC5 silencing using YM155 causes cell death in neuroblastoma cells with low ABCB1 expression.,http://www.ncbi.nlm.nih.gov/pubmed/22088485
3932,24162670,Oncogenic rearrangements driving ionizing radiation-associated human cancer.,http://www.ncbi.nlm.nih.gov/pubmed/24162670
3933,25082432,Lipid metabolism in mitochondrial membranes.,http://www.ncbi.nlm.nih.gov/pubmed/25082432
3934,26441649,Targeting protein-protein interactions in complexes organized by A kinase anchoring proteins.,http://www.ncbi.nlm.nih.gov/pubmed/26441649
3935,25078495,"Human ASPL/TUG interacts with p97 and complements the proteasome mislocalization of a yeast ubx4 mutant, but not the ER-associated degradation defect.",http://www.ncbi.nlm.nih.gov/pubmed/25078495
3936,11438465,Primary renal neoplasms with the ASPL-TFE3 gene fusion of alveolar soft part sarcoma: a distinctive tumor entity previously included among renal cell carcinomas of children and adolescents.,http://www.ncbi.nlm.nih.gov/pubmed/11438465
3937,1655749,The cAMP-regulated enhancer-binding protein ATF-1 activates transcription in response to cAMP-dependent protein kinase A.,http://www.ncbi.nlm.nih.gov/pubmed/1655749
3938,21484932,EWSR1-ATF1 fusion is a novel and consistent finding in hyalinizing clear-cell carcinoma of salivary gland.,http://www.ncbi.nlm.nih.gov/pubmed/21484932
3939,23575228,CEP89 is required for mitochondrial metabolism and neuronal function in man and fly.,http://www.ncbi.nlm.nih.gov/pubmed/23575228
3940,23416275,"Modulation of p53 C-terminal acetylation by mdm2, p14ARF, and cytoplasmic SirT2.",http://www.ncbi.nlm.nih.gov/pubmed/23416275
3941,26438117,Extended Survival and Prognostic Factors for Patients With ALK-Rearranged Non-Small-Cell Lung Cancer and Brain Metastasis.,http://www.ncbi.nlm.nih.gov/pubmed/26438117
3942,25564152,PEST domain mutations in Notch receptors comprise an oncogenic driver segment in triple-negative breast cancer sensitive to a γ-secretase inhibitor.,http://www.ncbi.nlm.nih.gov/pubmed/25564152
3943,20940169,"Fibroblast growth factors: from molecular evolution to roles in development, metabolism and disease.",http://www.ncbi.nlm.nih.gov/pubmed/20940169
3944,23967228,Fibroblast growth factor-4 enhances proliferation of mouse embryonic stem cells via activation of c-Jun signaling.,http://www.ncbi.nlm.nih.gov/pubmed/23967228
3945,22890726,FGF3/FGF4 amplification and multiple lung metastases in responders to sorafenib in hepatocellular carcinoma.,http://www.ncbi.nlm.nih.gov/pubmed/22890726
3946,8962718,"Aberrant FGF-2, FGF-3, FGF-4 and C-erb-B2 gene copy number in human ovarian, breast and endometrial tumours.",http://www.ncbi.nlm.nih.gov/pubmed/8962718
3947,25505174,Inhibition of polo-like kinase 1 (Plk1) enhances the antineoplastic activity of metformin in prostate cancer.,http://www.ncbi.nlm.nih.gov/pubmed/25505174
3948,26358790,"HER2-Mutated Breast Cancer Responds to Treatment With Single-Agent Neratinib, a Second-Generation HER2/EGFR Tyrosine Kinase Inhibitor.",http://www.ncbi.nlm.nih.gov/pubmed/26358790
3949,26358791,Prolonged Response to Trastuzumab in a Patient With HER2-Nonamplified Breast Cancer With Elevated HER2 Dimerization Harboring an ERBB2 S310F Mutation.,http://www.ncbi.nlm.nih.gov/pubmed/26358791
3950,23896413,The new genetics of chronic neutrophilic leukemia and atypical CML: implications for diagnosis and treatment.,http://www.ncbi.nlm.nih.gov/pubmed/23896413
3951,23656643,Oncogenic CSF3R mutations in chronic neutrophilic leukemia and atypical CML.,http://www.ncbi.nlm.nih.gov/pubmed/23656643
3952,24365789,Calreticulin gene exon 9 frameshift mutations in patients with thrombocytosis.,http://www.ncbi.nlm.nih.gov/pubmed/24365789
3953,24325356,Somatic mutations of calreticulin in myeloproliferative neoplasms.,http://www.ncbi.nlm.nih.gov/pubmed/24325356
3954,24645956,JAK inhibitor in CALR-mutant myelofibrosis.,http://www.ncbi.nlm.nih.gov/pubmed/24645956
3955,20529858,Stimulation of platelet-derived growth factor receptor beta (PDGFRbeta) activates ADAM17 and promotes metalloproteinase-dependent cross-talk between the PDGFRbeta and epidermal growth factor receptor (EGFR) signaling pathways.,http://www.ncbi.nlm.nih.gov/pubmed/20529858
3956,24703957,PDGF receptor signaling networks in normal and cancer cells.,http://www.ncbi.nlm.nih.gov/pubmed/24703957
3957,26455322,PDGFRB mutants found in patients with familial infantile myofibromatosis or overgrowth syndrome are oncogenic and sensitive to imatinib.,http://www.ncbi.nlm.nih.gov/pubmed/26455322
3958,22197930,Frequent somatic mutations in MAP3K5 and MAP3K9 in metastatic melanoma identified by exome sequencing.,http://www.ncbi.nlm.nih.gov/pubmed/22197930
3959,23792360,MSP-RON signalling in cancer: pathogenesis and therapeutic potential.,http://www.ncbi.nlm.nih.gov/pubmed/23792360
3960,26392073,Breast Cancer Tumor Suppressors: A Special Emphasis on Novel Protein Nischarin.,http://www.ncbi.nlm.nih.gov/pubmed/26392073
3961,21917605,Molecular characterization of the tumor-suppressive function of nischarin in breast cancer.,http://www.ncbi.nlm.nih.gov/pubmed/21917605
3962,18686028,Down-regulation of tumor suppressor gene FEZ1/LZTS1 in breast carcinoma involves promoter methylation and associates with metastasis.,http://www.ncbi.nlm.nih.gov/pubmed/18686028
3963,23917401,The integrated landscape of driver genomic alterations in glioblastoma.,http://www.ncbi.nlm.nih.gov/pubmed/23917401
3964,24362817,Germline loss-of-function mutations in LZTR1 predispose to an inherited disorder of multiple schwannomas.,http://www.ncbi.nlm.nih.gov/pubmed/24362817
3965,23393200,Amplification of FRS2 and activation of FGFR/FRS2 signaling pathway in high-grade liposarcoma.,http://www.ncbi.nlm.nih.gov/pubmed/23393200
3966,25368431,The Tyrosine Kinase Adaptor Protein FRS2 Is Oncogenic and Amplified in High-Grade Serous Ovarian Cancer.,http://www.ncbi.nlm.nih.gov/pubmed/25368431
3967,10416984,"Amplification and expression of cyclin D genes (CCND1, CCND2 and CCND3) in human malignant gliomas.",http://www.ncbi.nlm.nih.gov/pubmed/10416984
3968,,"Abstract 3104: Molecular features that determine the sensitivity of cancer cells to abemaciclib, an inhibitor of CDK4 and CDK6",http://cancerres.aacrjournals.org/content/75/15_Supplement/3104.abstract
3969,21734724,Cyclin D as a therapeutic target in cancer.,http://www.ncbi.nlm.nih.gov/pubmed/21734724
3970,25031937,Vandetanib.,http://www.ncbi.nlm.nih.gov/pubmed/25031937
3971,25490448,Targeting ABL1-mediated oxidative stress adaptation in fumarate hydratase-deficient cancer.,http://www.ncbi.nlm.nih.gov/pubmed/25490448
3972,25864878,Oncometabolites: tailoring our genes.,http://www.ncbi.nlm.nih.gov/pubmed/25864878
3973,25105836,The Succinated Proteome of FH-Mutant Tumours.,http://www.ncbi.nlm.nih.gov/pubmed/25105836
3974,16453285,"The role of folate receptor alpha in cancer development, progression and treatment: cause, consequence or innocent bystander?",http://www.ncbi.nlm.nih.gov/pubmed/16453285
3975,24146823,Expression of the B-cell receptor component CD79a on immature myeloid cells contributes to their tumor promoting effects.,http://www.ncbi.nlm.nih.gov/pubmed/24146823
3976,21324920,Protein kinase C inhibitor sotrastaurin selectively inhibits the growth of CD79 mutant diffuse large B-cell lymphomas.,http://www.ncbi.nlm.nih.gov/pubmed/21324920
3977,25499268,"The type 2 inositol 1,4,5-trisphosphate receptor, emerging functions for an intriguing Ca²⁺-release channel.",http://www.ncbi.nlm.nih.gov/pubmed/25499268
3978,18723115,RAP55: insights into an evolutionarily conserved protein family.,http://www.ncbi.nlm.nih.gov/pubmed/18723115
3979,23104211,Acceleration of gastric tumorigenesis through MKRN1-mediated posttranslational regulation of p14ARF.,http://www.ncbi.nlm.nih.gov/pubmed/23104211
3980,23176491,Roles for myosin Va in RNA transport and turnover.,http://www.ncbi.nlm.nih.gov/pubmed/23176491
3981,22926524,"RBB, a novel transcription repressor, represses the transcription of HDM2 oncogene.",http://www.ncbi.nlm.nih.gov/pubmed/22926524
3982,21376385,Eribulin monotherapy versus treatment of physician's choice in patients with metastatic breast cancer (EMBRACE): a phase 3 open-label randomised study.,http://www.ncbi.nlm.nih.gov/pubmed/21376385
3983,25505253,PIM kinase inhibitor AZD1208 for treatment of MYC-driven prostate cancer.,http://www.ncbi.nlm.nih.gov/pubmed/25505253
3984,15800014,Functional analysis of Peutz-Jeghers mutations reveals that the LKB1 C-terminal region exerts a crucial role in regulating both the AMPK pathway and the cell polarity.,http://www.ncbi.nlm.nih.gov/pubmed/15800014
3985,10901165,Identification of p53 gene mutations in breast cancers and their effects on transcriptional activation function.,http://www.ncbi.nlm.nih.gov/pubmed/10901165
3986,19640899,The Ste20-like kinase SLK promotes p53 transactivation and apoptosis.,http://www.ncbi.nlm.nih.gov/pubmed/19640899
3987,21470995,The effects of four different tyrosine kinase inhibitors on medullary and papillary thyroid cancer cells.,http://www.ncbi.nlm.nih.gov/pubmed/21470995
3988,24411639,"Docetaxel plus nintedanib versus docetaxel plus placebo in patients with previously treated non-small-cell lung cancer (LUME-Lung 1): a phase 3, double-blind, randomised controlled trial.",http://www.ncbi.nlm.nih.gov/pubmed/24411639
3989,22885699,Burkitt lymphoma pathogenesis and therapeutic targets from structural and functional genomics.,http://www.ncbi.nlm.nih.gov/pubmed/22885699
3990,24913233,Frequent disruption of the RB pathway in indolent follicular lymphoma suggests a new combination therapy.,http://www.ncbi.nlm.nih.gov/pubmed/24913233
3991,26333381,A Phase I Study of the SMAC-Mimetic Birinapant in Adults with Refractory Solid Tumors or Lymphoma.,http://www.ncbi.nlm.nih.gov/pubmed/26333381
3992,26540314,Panitumumab in combination with gemcitabine and oxaliplatin does not prolong survival in wild-type KRAS advanced biliary tract cancer: A randomized phase 2 trial (Vecti-BIL study).,http://www.ncbi.nlm.nih.gov/pubmed/26540314
3993,26541586,"Sacituzumab Govitecan, a Novel Antibody--Drug Conjugate, in Patients With Metastatic Platinum-Resistant Urothelial Carcinoma.",http://www.ncbi.nlm.nih.gov/pubmed/26541586
3994,26169970,Phase I Dose-Escalation Study of the Multikinase Inhibitor Lenvatinib in Patients with Advanced Solid Tumors and in an Expanded Cohort of Patients with Melanoma.,http://www.ncbi.nlm.nih.gov/pubmed/26169970
3995,,RXDX-105 demonstrates potent RET inhibitory activity with therapeutic potential in multiple preclinical models of RET-rearrangement driven cancer,http://www.abstractsonline.com/Plan/ViewAbstract.aspx?mID=3651&sKey=d1d66231-4f10-424a-9688-19c32dbd515e&cKey=607ffde8-32be-4583-942d-d16b7b31e194&mKey=c69f0c7b-cff2-4010-ac6c-deae12e60491
3996,25939061,Acquired EGFR C797S mutation mediates resistance to AZD9291 in non-small cell lung cancer harboring EGFR T790M.,http://www.ncbi.nlm.nih.gov/pubmed/25939061
3997,,Abstract C176: The combination of mTORC1/2 and PI3K? inhibition alleviates PI3K pathway reactivation and leads to significant antitumor activity in multiple preclinical xenograft models.,http://mct.aacrjournals.org/content/12/11_Supplement/C176.short
3998,19091548,"A phase I and pharmacokinetic study of daily oral cediranib, an inhibitor of vascular endothelial growth factor tyrosine kinases, in combination with cisplatin and gemcitabine in patients with advanced non-small cell lung cancer: a study of the National Cancer Institute of Canada Clinical Trials Group.",http://www.ncbi.nlm.nih.gov/pubmed/19091548
3999,20061136,"Phase I evaluation of cediranib, a selective VEGFR signalling inhibitor, in combination with gefitinib in patients with advanced tumours.",http://www.ncbi.nlm.nih.gov/pubmed/20061136
4000,26598747,Alectinib in Crizotinib-Refractory ALK-Rearranged Non-Small-Cell Lung Cancer: A Phase II Global Study.,http://www.ncbi.nlm.nih.gov/pubmed/26598747
4001,20182602,"TP53 mutations in human cancers: origins, consequences, and clinical use.",http://www.ncbi.nlm.nih.gov/pubmed/20182602
4002,19165225,p53 polymorphisms: cancer implications.,http://www.ncbi.nlm.nih.gov/pubmed/19165225
4003,26366092,Chronic neutrophilic leukemia: a clinical perspective.,http://www.ncbi.nlm.nih.gov/pubmed/26366092
4004,21074287,Mutation analysis of the FRK gene in non-small cell lung cancers.,http://www.ncbi.nlm.nih.gov/pubmed/21074287
4005,23318459,The Rak/Frk tyrosine kinase associates with and internalizes the epidermal growth factor receptor.,http://www.ncbi.nlm.nih.gov/pubmed/23318459
4006,19652529,RAKing in AKT: a tumor suppressor function for the intracellular tyrosine kinase FRK.,http://www.ncbi.nlm.nih.gov/pubmed/19652529
4007,26063635,Targeting the folate receptor: diagnostic and therapeutic approaches to personalize cancer treatments.,http://www.ncbi.nlm.nih.gov/pubmed/26063635
4008,26136852,Vintafolide: a novel targeted therapy for the treatment of folate receptor expressing tumors.,http://www.ncbi.nlm.nih.gov/pubmed/26136852
4009,25904506,"IMGN853, a Folate Receptor-α (FRα)-Targeting Antibody-Drug Conjugate, Exhibits Potent Targeted Antitumor Activity against FRα-Expressing Tumors.",http://www.ncbi.nlm.nih.gov/pubmed/25904506
4010,16357184,"BGC 945, a novel tumor-selective thymidylate synthase inhibitor targeted to alpha-folate receptor-overexpressing tumors.",http://www.ncbi.nlm.nih.gov/pubmed/16357184
4011,22446329,In vitro binding properties of tumor suppressor p53 with PUMA and NOXA.,http://www.ncbi.nlm.nih.gov/pubmed/22446329
4012,26590673,"Standard first-line chemotherapy with or without nintedanib for advanced ovarian cancer (AGO-OVAR 12): a randomised, double-blind, placebo-controlled phase 3 trial.",http://www.ncbi.nlm.nih.gov/pubmed/26590673
4013,,Biomarker Predictive Ibrutinib Response Using Profiled ABC-DLBCL Patient Derived Xenografts,https://ash.confex.com/ash/2015/webprogram/Paper81154.html
4014,26312875,Potential for monocyte recruitment by IgE immunotherapy for cancer in a rat model of tumour metastasis.,http://www.ncbi.nlm.nih.gov/pubmed/26312875
4015,9815766,"Cellular pharmacology and in vivo activity of a new anticancer agent, ZD9331: a water-soluble, nonpolyglutamatable, quinazoline-based inhibitor of thymidylate synthase.",http://www.ncbi.nlm.nih.gov/pubmed/9815766
4016,15094210,Antifolates targeted specifically to the folate receptor.,http://www.ncbi.nlm.nih.gov/pubmed/15094210
4017,24249723,Enhanced receptor-mediated endocytosis and cytotoxicity of a folic acid-desacetylvinblastine monohydrazide conjugate in a pemetrexed-resistant cell line lacking folate-specific facilitative carriers but with increased folate receptor expression.,http://www.ncbi.nlm.nih.gov/pubmed/24249723
4018,14871988,The role of alpha-folate receptor-mediated transport in the antitumor activity of antifolate drugs.,http://www.ncbi.nlm.nih.gov/pubmed/14871988
4019,25457975,The folate receptor as a rational therapeutic target for personalized cancer treatment.,http://www.ncbi.nlm.nih.gov/pubmed/25457975
4020,24233399,Synergistic activities of MET/RON inhibitor BMS-777607 and mTOR inhibitor AZD8055 to polyploid cells derived from pancreatic cancer and cancer stem cells.,http://www.ncbi.nlm.nih.gov/pubmed/24233399
4021,21543897,RON (MST1R) is a novel prognostic marker and therapeutic target for gastroesophageal adenocarcinoma.,http://www.ncbi.nlm.nih.gov/pubmed/21543897
4022,26372962,Structural insight into selectivity and resistance profiles of ROS1 tyrosine kinase inhibitors.,http://www.ncbi.nlm.nih.gov/pubmed/26372962
4023,19808973,"Inhibition of tumor cell growth, invasion, and metastasis by EXEL-2880 (XL880, GSK1363089), a novel inhibitor of HGF and VEGF receptor tyrosine kinases.",http://www.ncbi.nlm.nih.gov/pubmed/19808973
4024,23379595,"Discovery of 1-[3-(1-methyl-1H-pyrazol-4-yl)-5-oxo-5H-benzo[4,5]cyclohepta[1,2-b]pyridin-7-yl]-N-(pyridin-2-ylmethyl)methanesulfonamide (MK-8033): A Specific c-Met/Ron dual kinase inhibitor with preferential affinity for the activated state of c-Met.",http://www.ncbi.nlm.nih.gov/pubmed/23379595
4025,23467907,"A novel c-Met inhibitor, MK8033, synergizes with carboplatin plus paclitaxel to inhibit ovarian cancer cell growth.",http://www.ncbi.nlm.nih.gov/pubmed/23467907
4026,16982759,"Therapeutic implications of a human neutralizing antibody to the macrophage-stimulating protein receptor tyrosine kinase (RON), a c-MET family member.",http://www.ncbi.nlm.nih.gov/pubmed/16982759
4027,21749705,The monoclonal antibody Zt/f2 targeting RON receptor tyrosine kinase as potential therapeutics against tumor growth-mediated by colon cancer cells.,http://www.ncbi.nlm.nih.gov/pubmed/21749705
4028,25294907,Efficacy of anti-RON antibody Zt/g4-drug maytansinoid conjugation (Anti-RON ADC) as a novel therapeutics for targeted colorectal cancer therapy.,http://www.ncbi.nlm.nih.gov/pubmed/25294907
4029,20596675,Monoclonal antibody (mAb)-induced down-regulation of RON receptor tyrosine kinase diminishes tumorigenic activities of colon cancer cells.,http://www.ncbi.nlm.nih.gov/pubmed/20596675
4030,25953155,"Design and synthesis of close analogs of LCRF-0004, a potent and selective RON receptor tyrosine kinase inhibitor.",http://www.ncbi.nlm.nih.gov/pubmed/25953155
4031,26206867,EGFR Exon 18 Mutations in Lung Cancer: Molecular Predictors of Augmented Sensitivity to Afatinib or Neratinib as Compared with First- or Third-Generation TKIs.,http://www.ncbi.nlm.nih.gov/pubmed/26206867
4032,,Phase I study of daily administration of MGCD265 to patients with advanced malignancies (Study 265-101).,http://meetinglibrary.asco.org/content/33739-65
4033,26479923,High-throughput screening using patient-derived tumor xenografts to predict clinical trial drug response.,http://www.ncbi.nlm.nih.gov/pubmed/26479923
4034,,Phase I study of the safety and efficacy of INC280 in patients with advanced MET-dependent solid tumors.,http://meetinglibrary.asco.org/content/128427-144
4035,,"A phase I, first-in-human dose study of the dual PI3K/mTOR inhibitor LY3023414 (LY) in patients (pts) with advanced cancer.",http://meetinglibrary.asco.org/content/144556-156
4036,26117819,Drugging PI3K in cancer: refining targets and therapeutic strategies.,http://www.ncbi.nlm.nih.gov/pubmed/26117819
4037,,Exploratory genetic analysis of tumors from a phase I/II dose escalation study of GSK2636771 in patients (pts) with PTEN deficient advanced tumors,http://cancerres.aacrjournals.org/content/75/15_Supplement/CT328.short
4038,,"Safety, pharmacology, and preliminary clinical activity of MM-151: An oligocolnal anti-EGFR theraputic in patients with cetuximab-resistant CRC and other refractory solid tumors.",http://meetinglibrary.asco.org/content/140146-158
4039,15166229,Functional domain and motif analyses of androgen receptor coregulator ARA70 and its differential expression in prostate cancer.,http://www.ncbi.nlm.nih.gov/pubmed/15166229
4040,25731779,The RET oncogene in papillary thyroid carcinoma.,http://www.ncbi.nlm.nih.gov/pubmed/25731779
4041,25492964,"Neuregulin 1-activated ERBB4 as a ""dedicated"" receptor for the Hippo-YAP pathway.",http://www.ncbi.nlm.nih.gov/pubmed/25492964
4042,25870798,"Beyond ALK-RET, ROS1 and other oncogene fusions in lung cancer.",http://www.ncbi.nlm.nih.gov/pubmed/25870798
4043,21962892,Molecular characterization of an EWSR1-POU5F1 fusion associated with a t(6;22) in an undifferentiated soft tissue sarcoma.,http://www.ncbi.nlm.nih.gov/pubmed/21962892
4044,9209705,PPAR gamma and the control of adipogenesis.,http://www.ncbi.nlm.nih.gov/pubmed/9209705
4045,25069464,Pax-8-PPAR-γ fusion protein in thyroid carcinoma.,http://www.ncbi.nlm.nih.gov/pubmed/25069464
4046,10412986,Mechanisms controlling mitochondrial biogenesis and respiration through the thermogenic coactivator PGC-1.,http://www.ncbi.nlm.nih.gov/pubmed/10412986
4047,25490445,"Is reliance on mitochondrial respiration a ""chink in the armor"" of therapy-resistant cancer?",http://www.ncbi.nlm.nih.gov/pubmed/25490445
4048,23175443,Oncogenic FGFR3 gene fusions in bladder cancer.,http://www.ncbi.nlm.nih.gov/pubmed/23175443
4049,24469108,CD74-NRG1 fusions in lung adenocarcinoma.,http://www.ncbi.nlm.nih.gov/pubmed/24469108
4050,7565764,The DNA rearrangement that generates the TRK-T3 oncogene involves a novel gene on chromosome 3 whose product has a potential coiled-coil domain.,http://www.ncbi.nlm.nih.gov/pubmed/7565764
4051,25281618,Inhibition of monocarboxylate transporter-1 (MCT1) by AZD3965 enhances radiosensitivity by reducing lactate transport.,http://www.ncbi.nlm.nih.gov/pubmed/25281618
4052,24798403,The reversible P2Y12 inhibitor ticagrelor inhibits metastasis and improves survival in mouse models of cancer.,http://www.ncbi.nlm.nih.gov/pubmed/24798403
4053,19890374,A comprehensive target selectivity survey of the BCR-ABL kinase inhibitor INNO-406 by kinase profiling and chemical proteomics in chronic myeloid leukemia cells.,http://www.ncbi.nlm.nih.gov/pubmed/19890374
4054,25284748,Discoidin domain receptor 1 (DDR1) kinase as target for structure-based drug discovery.,http://www.ncbi.nlm.nih.gov/pubmed/25284748
4055,24671415,"Normal activation of discoidin domain receptor 1 mutants with disulfide cross-links, insertions, or deletions in the extracellular juxtamembrane region: mechanistic implications.",http://www.ncbi.nlm.nih.gov/pubmed/24671415
4056,21398698,DDR1 receptor tyrosine kinase promotes prosurvival pathway through Notch1 activation.,http://www.ncbi.nlm.nih.gov/pubmed/21398698
4057,16417579,Alternative splicing of human metabotropic glutamate receptor 3.,http://www.ncbi.nlm.nih.gov/pubmed/16417579
4058,22564439,mGlu3 receptor and astrocytes: partners in neuroprotection.,http://www.ncbi.nlm.nih.gov/pubmed/22564439
4059,21946352,Exon capture analysis of G protein-coupled receptors identifies activating mutations in GRM3 in melanoma.,http://www.ncbi.nlm.nih.gov/pubmed/21946352
4060,15102433,IkappaB kinases: key regulators of the NF-kappaB pathway.,http://www.ncbi.nlm.nih.gov/pubmed/15102433
4061,26025939,IKBKE Upregulation is Positively Associated with Squamous Cell Carcinoma of the Lung In Vivo and Malignant Transformation of Human Bronchial Epithelial Cells In Vitro.,http://www.ncbi.nlm.nih.gov/pubmed/26025939
4062,25365225,Targeting an IKBKE cytokine network impairs triple-negative breast cancer growth.,http://www.ncbi.nlm.nih.gov/pubmed/25365225
4063,23724064,"Synergistic inhibition of survival, proliferation, and migration of U87 cells with a combination of LY341495 and Iressa.",http://www.ncbi.nlm.nih.gov/pubmed/23724064
4064,16053698,Pharmacological blockade of group II metabotropic glutamate receptors reduces the growth of glioma cells in vivo.,http://www.ncbi.nlm.nih.gov/pubmed/16053698
4065,,Abstract LB-310: Small molecule inhibitors of IKBKE with antitumor activity in cancer cells overexpressing IKBKE,http://cancerres.aacrjournals.org/content/73/8_Supplement/LB-310.short
4066,18065762,Identification of disulfide-linked dimers of the receptor tyrosine kinase DDR1.,http://www.ncbi.nlm.nih.gov/pubmed/18065762
4067,21892159,Oncogenic IL7R gain-of-function mutations in childhood T-cell acute lymphoblastic leukemia.,http://www.ncbi.nlm.nih.gov/pubmed/21892159
4068,21536738,Gain-of-function mutations in interleukin-7 receptor-α (IL7R) in childhood acute lymphoblastic leukemias.,http://www.ncbi.nlm.nih.gov/pubmed/21536738
4069,17030631,Mammary tumorigenesis and metastasis caused by overexpression of insulin receptor substrate 1 (IRS-1) or IRS-2.,http://www.ncbi.nlm.nih.gov/pubmed/17030631
4070,25200290,"IRS2 integrates insulin/IGF1 signalling with metabolism, neurodegeneration and longevity.",http://www.ncbi.nlm.nih.gov/pubmed/25200290
4071,23594372,IRS2 is a candidate driver oncogene on 13q34 in colorectal cancer.,http://www.ncbi.nlm.nih.gov/pubmed/23594372
4072,23562473,"IRS1 is highly expressed in localized breast tumors and regulates the sensitivity of breast cancer cells to chemotherapy, while IRS2 is highly expressed in invasive breast tumors.",http://www.ncbi.nlm.nih.gov/pubmed/23562473
4073,24107449,"Molecular predictors of sensitivity to the insulin-like growth factor 1 receptor inhibitor Figitumumab (CP-751,871).",http://www.ncbi.nlm.nih.gov/pubmed/24107449
4074,25527633,"IRS2 copy number gain, KRAS and BRAF mutation status as predictive biomarkers for response to the IGF-1R/IR inhibitor BMS-754807 in colorectal cancer cell lines.",http://www.ncbi.nlm.nih.gov/pubmed/25527633
4075,25724667,Frequent Loss of NISCH Promotes Tumor Proliferation and Invasion in Ovarian Cancer via Inhibiting the FAK Signal Pathway.,http://www.ncbi.nlm.nih.gov/pubmed/25724667
4076,19363522,Oncogenic RAF1 rearrangement and a novel BRAF mutation as alternatives to KIAA1549:BRAF fusion in activating the MAPK pathway in pilocytic astrocytoma.,http://www.ncbi.nlm.nih.gov/pubmed/19363522
4077,22201794,RUNX1 and RUNX1-ETO: roles in hematopoiesis and leukemogenesis.,http://www.ncbi.nlm.nih.gov/pubmed/22201794
4078,26050648,The leukemia-associated RUNX1/ETO oncoprotein confers a mutator phenotype.,http://www.ncbi.nlm.nih.gov/pubmed/26050648
4079,,,http://www.immunedesign.com/wp-content/uploads/2015/05/G305-ASCO-poster-2015.pdf
4080,24315690,AP-1/c-Jun transcription factors: regulation and function in malignant melanoma.,http://www.ncbi.nlm.nih.gov/pubmed/24315690
4081,20044606,Infrequent amplification of JUN in hepatocellular carcinoma.,http://www.ncbi.nlm.nih.gov/pubmed/20044606
4082,24713656,Genetic and pharmacologic inhibition of EPHA2 promotes apoptosis in NSCLC.,http://www.ncbi.nlm.nih.gov/pubmed/24713656
4083,20360610,"EphA2 mutation in lung squamous cell carcinoma promotes increased cell survival, cell invasion, focal adhesions, and mammalian target of rapamycin activation.",http://www.ncbi.nlm.nih.gov/pubmed/20360610
4084,26089640,Small-molecule BH3 mimetic and pan-Bcl-2 inhibitor AT-101 enhances the antitumor efficacy of cisplatin through inhibition of APE1 repair and redox activity in non-small-cell lung cancer.,http://www.ncbi.nlm.nih.gov/pubmed/26089640
4085,16611409,(-)-gossypol inhibits growth and promotes apoptosis of human head and neck squamous cell carcinoma in vivo.,http://www.ncbi.nlm.nih.gov/pubmed/16611409
4086,26004684,Small-Molecule Bcl2 BH4 Antagonist for Lung Cancer Therapy.,http://www.ncbi.nlm.nih.gov/pubmed/26004684
4087,25590800,Potent and selective small-molecule MCL-1 inhibitors demonstrate on-target cancer cell killing activity as single agents and in combination with ABT-263 (navitoclax).,http://www.ncbi.nlm.nih.gov/pubmed/25590800
4088,24813888,Acquired resistance of EGFR-mutant lung adenocarcinomas to afatinib plus cetuximab is associated with activation of mTORC1.,http://www.ncbi.nlm.nih.gov/pubmed/24813888
4089,,Phase I study of ABT-414 mono- or combination therapy with temozolomide (TMZ) in recurrent glioblastoma (GBM).,http://hwmaint.meeting.ascopubs.org/cgi/content/abstract/33/15_suppl/2016
4090,,ABT-414 in patients with advanced solid tumors likely to overexpress the epidermal growth factor receptor (EGFR),http://meetinglibrary.asco.org/content/146940-156
4091,,Dose escalation stage of a first-in-class phase I study of the novel oral ERK 1/2 kinase inhibitor BVD-523 (ulixertinib) in patients with advanced solid tumors,http://meetinglibrary.asco.org/content/145666-156
4092,26045609,Inhibition of Mcl-1 with the pan-Bcl-2 family inhibitor (-)BI97D6 overcomes ABT-737 resistance in acute myeloid leukemia.,http://www.ncbi.nlm.nih.gov/pubmed/26045609
4093,24901320,BM-1197: a novel and specific Bcl-2/Bcl-xL inhibitor inducing complete and long-lasting tumor regression in vivo.,http://www.ncbi.nlm.nih.gov/pubmed/24901320
4094,25289887,MCL1 and BCL-xL levels in solid tumors are predictive of dinaciclib-induced apoptosis.,http://www.ncbi.nlm.nih.gov/pubmed/25289887
4095,17097561,The BH3 mimetic ABT-737 targets selective Bcl-2 proteins and efficiently induces apoptosis via Bak/Bax if Mcl-1 is neutralized.,http://www.ncbi.nlm.nih.gov/pubmed/17097561
4096,24019208,A novel small-molecule inhibitor of mcl-1 blocks pancreatic cancer growth in vitro and in vivo.,http://www.ncbi.nlm.nih.gov/pubmed/24019208
4097,17404107,"Preclinical studies of TW-37, a new nonpeptidic small-molecule inhibitor of Bcl-2, in diffuse large cell lymphoma xenograft model reveal drug action on both Bcl-2 and Mcl-1.",http://www.ncbi.nlm.nih.gov/pubmed/17404107
4098,16510597,The small organic compound HA14-1 prevents Bcl-2 interaction with Bax to sensitize malignant glioma cells to induction of cell death.,http://www.ncbi.nlm.nih.gov/pubmed/16510597
4099,16213584,"HA14-1, a small molecule Bcl-2 antagonist, induces apoptosis and modulates action of selected anticancer drugs in follicular lymphoma B cells.",http://www.ncbi.nlm.nih.gov/pubmed/16213584
4100,26556430,Targeting BCL2-Proteins for the Treatment of Solid Tumours.,http://www.ncbi.nlm.nih.gov/pubmed/26556430
4101,23478333,Programming cancer cells for high expression levels of Mcl1.,http://www.ncbi.nlm.nih.gov/pubmed/23478333
4102,26645404,"Metabolism and disposition of the DOT1L inhibitor, pinometostat (EPZ-5676), in rat, dog and human.",http://www.ncbi.nlm.nih.gov/pubmed/26645404
4103,19477428,"A gene expression signature associated with ""K-Ras addiction"" reveals regulators of EMT and tumor cell survival.",http://www.ncbi.nlm.nih.gov/pubmed/19477428
4104,25068800,"UNC2025, a potent and orally bioavailable MER/FLT3 dual inhibitor.",http://www.ncbi.nlm.nih.gov/pubmed/25068800
4105,,"Discovery of AZD8835, a potent and selective inhibitor of PI3K? and PI3K? for the treatment of PIK3CA-dependent cancers",http://cancerres.aacrjournals.org/content/75/15_Supplement/2830.short
4106,,"High dose intermittent scheduling of AZD8835, a novel potent and selective inhibitor of PI3K? and PI3K?, identifies potential treatment strategies for PIK3CA-dependent cancers",http://cancerres.aacrjournals.org/content/75/15_Supplement/2665.short
4107,12203787,Differential expression of multiple isoforms of the ELKS mRNAs involved in a papillary thyroid carcinoma.,http://www.ncbi.nlm.nih.gov/pubmed/12203787
4108,24296167,Central role of RET in thyroid cancer.,http://www.ncbi.nlm.nih.gov/pubmed/24296167
4109,17639057,HOOK3-RET: a novel type of RET/PTC rearrangement in papillary thyroid carcinoma.,http://www.ncbi.nlm.nih.gov/pubmed/17639057
4110,26483203,JX06 Selectively Inhibits Pyruvate Dehydrogenase Kinase PDK1 by a Covalent Cysteine Modification.,http://www.ncbi.nlm.nih.gov/pubmed/26483203
4111,22677547,Genetic and pharmacological disruption of the TEAD-YAP complex suppresses the oncogenic activity of YAP.,http://www.ncbi.nlm.nih.gov/pubmed/22677547
4112,24694946,"Identification, mechanism of action, and antitumor activity of a small molecule inhibitor of hippo, TGF-β, and Wnt signaling pathways.",http://www.ncbi.nlm.nih.gov/pubmed/24694946
4113,,TORK/DNA-PK inhibitor CC-115 is effective as a single agent in a subset of glioblastoma patient-derived cancer stem cells and xenografts and potentiates temozolomide therapy,http://cancerres.aacrjournals.org/content/75/15_Supplement/1755.short
4114,26443806,Antitumor Activity of KW-2450 against Triple-Negative Breast Cancer by Inhibiting Aurora A and B Kinases.,http://www.ncbi.nlm.nih.gov/pubmed/26443806
4115,26581242,"A First-in-Human Phase I Study of the Oral p38 MAPK Inhibitor, Ralimetinib (LY2228820 Dimesylate), in Patients with Advanced Cancer.",http://www.ncbi.nlm.nih.gov/pubmed/26581242
4116,24356814,"Characterization of LY2228820 dimesylate, a potent and selective inhibitor of p38 MAPK with antitumor activity.",http://www.ncbi.nlm.nih.gov/pubmed/24356814
4117,25514658,"Discovery of (R)-8-(1-(3,5-difluorophenylamino)ethyl)-N,N-dimethyl-2-morpholino-4-oxo-4H-chromene-6-carboxamide (AZD8186): a potent and selective inhibitor of PI3Kβ and PI3Kδ for the treatment of PTEN-deficient cancers.",http://www.ncbi.nlm.nih.gov/pubmed/25514658
4118,,"Phase I study of the PI3K?/? inhibitor AZD8186 in patients with advanced castration resistant prostate cancer, triple negative breast cancer, squamous non-small cell lung cancer or PTEN deficient solid tumors: update from dose-finding",http://cancerres.aacrjournals.org/content/75/15_Supplement/CT329.short
4119,25528022,A preclinical evaluation of the PI3K alpha/delta dominant inhibitor BAY 80-6946 in HER2-positive breast cancer models with acquired resistance to the HER2-targeted therapies trastuzumab and lapatinib.,http://www.ncbi.nlm.nih.gov/pubmed/25528022
4120,26552700,Generation of a Selective Small Molecule Inhibitor of the CBP/p300 Bromodomain for Leukemia Therapy.,http://www.ncbi.nlm.nih.gov/pubmed/26552700
4121,26513298,E7449: A dual inhibitor of PARP1/2 and tankyrase1/2 inhibits growth of DNA repair deficient tumors and antagonizes Wnt signaling.,http://www.ncbi.nlm.nih.gov/pubmed/26513298
4122,10882136,IKKepsilon is part of a novel PMA-inducible IkappaB kinase complex.,http://www.ncbi.nlm.nih.gov/pubmed/10882136
4123,15753290,"Genome-wide analysis of cAMP-response element binding protein occupancy, phosphorylation, and target gene activation in human tissues.",http://www.ncbi.nlm.nih.gov/pubmed/15753290
4124,25134518,Primary pulmonary myxoid sarcomas with EWSR1-CREB1 translocation might originate from primitive peribronchial mesenchymal cells undergoing (myo)fibroblastic differentiation.,http://www.ncbi.nlm.nih.gov/pubmed/25134518
4125,22279422,Oncogenic activation of ERG: A predominant mechanism in prostate cancer.,http://www.ncbi.nlm.nih.gov/pubmed/22279422
4126,24121489,Antitumor activity of the selective pan-RAF inhibitor TAK-632 in BRAF inhibitor-resistant melanoma.,http://www.ncbi.nlm.nih.gov/pubmed/24121489
4127,26271487,Downregulation of Critical Oncogenes by the Selective SK2 Inhibitor ABC294640 Hinders Prostate Cancer Progression.,http://www.ncbi.nlm.nih.gov/pubmed/26271487
4128,25142146,"Antitumor activity of the ERK inhibitor SCH772984 [corrected] against BRAF mutant, NRAS mutant and wild-type melanoma.",http://www.ncbi.nlm.nih.gov/pubmed/25142146
4129,,Abstract 3563: A highly selective Erk1/2 Inhibitor with in-vivo anti tumor potency,http://cancerres.aacrjournals.org/content/71/8_Supplement/3563.short
4130,25143136,Evaluation of the antitumor effects of c-Myc-Max heterodimerization inhibitor 100258-F4 in ovarian cancer cells.,http://www.ncbi.nlm.nih.gov/pubmed/25143136
4131,17876039,Improved low molecular weight Myc-Max inhibitors.,http://www.ncbi.nlm.nih.gov/pubmed/17876039
4132,18509642,"Efficacy, pharmacokinetics, tisssue distribution, and metabolism of the Myc-Max disruptor, 10058-F4 [Z,E]-5-[4-ethylbenzylidine]-2-thioxothiazolidin-4-one, in mice.",http://www.ncbi.nlm.nih.gov/pubmed/18509642
4133,21119661,Small molecule FGF receptor inhibitors block FGFR-dependent urothelial carcinoma growth in vitro and in vivo.,http://www.ncbi.nlm.nih.gov/pubmed/21119661
4134,23420874,Grb2 controls phosphorylation of FGFR2 by inhibiting receptor kinase and Shp2 phosphatase activity.,http://www.ncbi.nlm.nih.gov/pubmed/23420874
4135,18852144,Fibroblast growth factor receptor-mediated signals contribute to the malignant phenotype of non-small cell lung cancer cells: therapeutic implications and synergism with epidermal growth factor receptor inhibition.,http://www.ncbi.nlm.nih.gov/pubmed/18852144
4136,26187616,A Phase I Trial of Combined Ridaforolimus and MK-2206 in Patients with Advanced Malignancies.,http://www.ncbi.nlm.nih.gov/pubmed/26187616
4137,26603897,SBI-0640756 Attenuates the Growth of Clinically Unresponsive Melanomas by Disrupting the eIF4F Translation Initiation Complex.,http://www.ncbi.nlm.nih.gov/pubmed/26603897
4138,19175524,BI-69A11-mediated inhibition of AKT leads to effective regression of xenograft melanoma.,http://www.ncbi.nlm.nih.gov/pubmed/19175524
4139,20531415,Recovery of phospho-ERK activity allows melanoma cells to escape from BRAF inhibitor therapy.,http://www.ncbi.nlm.nih.gov/pubmed/20531415
4140,,,https://ash.confex.com/ash/2015/webprogram/Paper84941.html
4141,25961845,Selective Allosteric Inhibition of MMP9 Is Efficacious in Preclinical Models of Ulcerative Colitis and Colorectal Cancer.,http://www.ncbi.nlm.nih.gov/pubmed/25961845
4142,20167603,DYRK1A and DYRK3 promote cell survival through phosphorylation and activation of SIRT1.,http://www.ncbi.nlm.nih.gov/pubmed/20167603
4143,25795597,DYRK1A in neurodegeneration and cancer: Molecular basis and clinical implications.,http://www.ncbi.nlm.nih.gov/pubmed/25795597
4144,23635774,Inhibition of DYRK1A destabilizes EGFR and reduces EGFR-dependent glioblastoma growth.,http://www.ncbi.nlm.nih.gov/pubmed/23635774
4145,17382885,Programmed anuclear cell death delimits platelet life span.,http://www.ncbi.nlm.nih.gov/pubmed/17382885
4146,22407831,Survivin is a viable target for the treatment of malignant peripheral nerve sheath tumors.,http://www.ncbi.nlm.nih.gov/pubmed/22407831
4147,23125950,Untangling the complexity of PAK1 dynamics: The future challenge.,http://www.ncbi.nlm.nih.gov/pubmed/23125950
4148,23162742,PAK signaling in cancer.,http://www.ncbi.nlm.nih.gov/pubmed/23162742
4149,24529727,Role of p-21-activated kinases in cancer progression.,http://www.ncbi.nlm.nih.gov/pubmed/24529727
4150,23535073,P21-activated kinase 1 (PAK1) as a therapeutic target in BRAF wild-type melanoma.,http://www.ncbi.nlm.nih.gov/pubmed/23535073
4151,20439741,Small-molecule p21-activated kinase inhibitor PF-3758309 is a potent inhibitor of oncogenic signaling and tumor growth.,http://www.ncbi.nlm.nih.gov/pubmed/20439741
4152,23543898,"Association of the epithelial-to-mesenchymal transition phenotype with responsiveness to the p21-activated kinase inhibitor, PF-3758309, in colon cancer models.",http://www.ncbi.nlm.nih.gov/pubmed/23543898
4153,18420139,"An isoform-selective, small-molecule inhibitor targets the autoregulatory mechanism of p21-activated kinase.",http://www.ncbi.nlm.nih.gov/pubmed/18420139
4154,23894351,IPA-3 inhibits the growth of liver cancer cells by suppressing PAK1 and NF-κB activation.,http://www.ncbi.nlm.nih.gov/pubmed/23894351
4155,25902869,Small molecule inhibition of group I p21-activated kinases in breast cancer induces apoptosis and potentiates the activity of microtubule stabilizing agents.,http://www.ncbi.nlm.nih.gov/pubmed/25902869
4156,22354171,Increased dosage of the chromosome 21 ortholog Dyrk1a promotes megakaryoblastic leukemia in a murine model of Down syndrome.,http://www.ncbi.nlm.nih.gov/pubmed/22354171
4157,11023514,A partial deficiency of interleukin-7R alpha is sufficient to abrogate T-cell development and cause severe combined immunodeficiency.,http://www.ncbi.nlm.nih.gov/pubmed/11023514
4158,24955215,The normal function of the cancer kinase Mirk/dyrk1B is to reduce reactive oxygen species.,http://www.ncbi.nlm.nih.gov/pubmed/24955215
4159,17583556,Mirk/Dyrk1B in cancer.,http://www.ncbi.nlm.nih.gov/pubmed/17583556
4160,25352950,Mirk kinase inhibition blocks the in vivo growth of pancreatic cancer cells.,http://www.ncbi.nlm.nih.gov/pubmed/25352950
4161,25556849,A novel DYRK1A (dual specificity tyrosine phosphorylation-regulated kinase 1A) inhibitor for the treatment of Alzheimer's disease: effect on Tau and amyloid pathologies in vitro.,http://www.ncbi.nlm.nih.gov/pubmed/25556849
4162,24134204,"A novel DYRK1B inhibitor AZ191 demonstrates that DYRK1B acts independently of GSK3β to phosphorylate cyclin D1 at Thr(286), not Thr(288).",http://www.ncbi.nlm.nih.gov/pubmed/24134204
4163,23114871,"Ovarian cancer cells, not normal cells, are damaged by Mirk/Dyrk1B kinase inhibition.",http://www.ncbi.nlm.nih.gov/pubmed/23114871
4164,21911917,NUAK2: an emerging acral melanoma oncogene.,http://www.ncbi.nlm.nih.gov/pubmed/21911917
4165,25832654,NUAK2 Amplification Coupled with PTEN Deficiency Promotes Melanoma Development via CDK Activation.,http://www.ncbi.nlm.nih.gov/pubmed/25832654
4166,17660817,Interleukin 7 receptor alpha chain (IL7R) shows allelic and functional association with multiple sclerosis.,http://www.ncbi.nlm.nih.gov/pubmed/17660817
4167,26628478,"Lapatinib in Combination With Capecitabine Plus Oxaliplatin in Human Epidermal Growth Factor Receptor 2-Positive Advanced or Metastatic Gastric, Esophageal, or Gastroesophageal Adenocarcinoma: TRIO-013/LOGiC--A Randomized Phase III Trial.",http://www.ncbi.nlm.nih.gov/pubmed/26628478
4168,26487760,"Lenvatinib in Advanced, Radioactive Iodine-Refractory, Differentiated Thyroid Carcinoma.",http://www.ncbi.nlm.nih.gov/pubmed/26487760
4169,17363507,Colon carcinoma cells harboring PIK3CA mutations display resistance to growth factor deprivation induced apoptosis.,http://www.ncbi.nlm.nih.gov/pubmed/17363507
4170,24265155,Acquired resistance and clonal evolution in melanoma during BRAF inhibitor therapy.,http://www.ncbi.nlm.nih.gov/pubmed/24265155
4171,26222500,Regulation of the PI3K pathway through a p85α monomer-homodimer equilibrium.,http://www.ncbi.nlm.nih.gov/pubmed/26222500
4172,23950209,BRD4 sustains melanoma proliferation and represents a new target for epigenetic therapy.,http://www.ncbi.nlm.nih.gov/pubmed/23950209
4173,22645123,Down-regulation of NF-κB transcriptional activity in HIV-associated kidney disease by BRD4 inhibition.,http://www.ncbi.nlm.nih.gov/pubmed/22645123
4174,24144283,Structure-guided design of potent diazobenzene inhibitors for the BET bromodomains.,http://www.ncbi.nlm.nih.gov/pubmed/24144283
4175,22658128,Safety and activity of anti-PD-L1 antibody in patients with advanced cancer.,http://www.ncbi.nlm.nih.gov/pubmed/22658128
4176,24551119,PD-L1 expression is increased in a subset of basal type breast cancer cells.,http://www.ncbi.nlm.nih.gov/pubmed/24551119
4177,20628145,"Integrative analysis reveals selective 9p24.1 amplification, increased PD-1 ligand expression, and further induction via JAK2 in nodular sclerosing Hodgkin lymphoma and primary mediastinal large B-cell lymphoma.",http://www.ncbi.nlm.nih.gov/pubmed/20628145
4178,25482239,PD-1 blockade with nivolumab in relapsed or refractory Hodgkin's lymphoma.,http://www.ncbi.nlm.nih.gov/pubmed/25482239
4179,,"[P4-14-20] A phase 1b study of ONT 380, an oral HER2-specific inhibitor, combined with ado trastuzumab emtansine (T DM1), in HER2+ metastatic breast cancer (MBC)",http://www.abstracts2view.com/sabcs15/view.php?nu=SABCS15L_1338&terms=
4180,,[P4-14-19] ONT-380 in the treatment of HER2+ breast cancer central nervous system (CNS) metastases (mets),http://www.abstracts2view.com/sabcs15/view.php?nu=SABCS15L_1267&terms=
4181,22186794,The oncolytic poxvirus JX-594 selectively replicates in and destroys cancer cells driven by genetic pathways commonly activated in cancers.,http://www.ncbi.nlm.nih.gov/pubmed/22186794
4182,26005365,Profile of elotuzumab and its potential in the treatment of multiple myeloma.,http://www.ncbi.nlm.nih.gov/pubmed/26005365
4183,24905006,The mechanisms behind the therapeutic activity of BET bromodomain inhibition.,http://www.ncbi.nlm.nih.gov/pubmed/24905006
4184,22222631,An integrated genomic approach to identify predictive biomarkers of response to the aurora kinase inhibitor PF-03814735.,http://www.ncbi.nlm.nih.gov/pubmed/22222631
4185,16116477,Combined microarray analysis of small cell lung cancer reveals altered apoptotic balance and distinct expression signatures of MYC family gene amplification.,http://www.ncbi.nlm.nih.gov/pubmed/16116477
4186,19387008,Frequent CBL mutations associated with 11q acquired uniparental disomy in myeloproliferative neoplasms.,http://www.ncbi.nlm.nih.gov/pubmed/19387008
4187,22961667,Reactivation of ERK signaling causes resistance to EGFR kinase inhibitors.,http://www.ncbi.nlm.nih.gov/pubmed/22961667
4188,26181029,Genomic Correlate of Exceptional Erlotinib Response in Head and Neck Squamous Cell Carcinoma.,http://www.ncbi.nlm.nih.gov/pubmed/26181029
4189,8805275,Human Ste20 homologue hPAK1 links GTPases to the JNK MAP kinase pathway.,http://www.ncbi.nlm.nih.gov/pubmed/8805275
4190,23960073,"FRAX597, a small molecule inhibitor of the p21-activated kinases, inhibits tumorigenesis of neurofibromatosis type 2 (NF2)-associated Schwannomas.",http://www.ncbi.nlm.nih.gov/pubmed/23960073
4191,19047918,Correlation of clinical features with the mutational status of GM-CSF signaling pathway-related genes in juvenile myelomonocytic leukemia.,http://www.ncbi.nlm.nih.gov/pubmed/19047918
4192,26674224,CDH1/E-cadherin and solid tumors. An updated gene-disease association analysis using bioinformatics tools.,http://www.ncbi.nlm.nih.gov/pubmed/26674224
4193,18726070,The cell-cell adhesion molecule E-cadherin.,http://www.ncbi.nlm.nih.gov/pubmed/18726070
4194,25184143,"E-cadherin and gastric cancer: cause, consequence, and applications.",http://www.ncbi.nlm.nih.gov/pubmed/25184143
4195,21170474,Differential effects of HNF-1α mutations associated with familial young-onset diabetes on target gene regulation.,http://www.ncbi.nlm.nih.gov/pubmed/21170474
4196,25076298,"Update on the new classification of hepatic adenomas: clinical, molecular, and pathologic characteristics.",http://www.ncbi.nlm.nih.gov/pubmed/25076298
4197,26182300,Hereditary Diffuse Gastric Cancer Syndrome: CDH1 Mutations and Beyond.,http://www.ncbi.nlm.nih.gov/pubmed/26182300
4198,10980597,RET/PCM-1: a novel fusion gene in papillary thyroid carcinoma.,http://www.ncbi.nlm.nih.gov/pubmed/10980597
4199,12787916,"Novel tumorigenic rearrangement, Delta rfp/ret, in a papillary thyroid carcinoma from externally irradiated patient.",http://www.ncbi.nlm.nih.gov/pubmed/12787916
4200,26251290,"A Multicenter, Open-Label Phase II Clinical Trial of Combined MEK plus EGFR Inhibition for Chemotherapy-Refractory Advanced Pancreatic Adenocarcinoma.",http://www.ncbi.nlm.nih.gov/pubmed/26251290
4201,16129687,The elongated first fibronectin type III domain of collagen XIV is an inducer of quiescence and differentiation in fibroblasts and preadipocytes.,http://www.ncbi.nlm.nih.gov/pubmed/16129687
4202,24122810,Fibroblast growth factor receptor 2 tyrosine kinase fusions define a unique molecular subtype of cholangiocarcinoma.,http://www.ncbi.nlm.nih.gov/pubmed/24122810
4203,24043446,Structural flexibility and functional interaction of Mediator Cdk8 module.,http://www.ncbi.nlm.nih.gov/pubmed/24043446
4204,18794900,CDK8 is a colorectal cancer oncogene that regulates beta-catenin activity.,http://www.ncbi.nlm.nih.gov/pubmed/18794900
4205,25401474,LYN-activating mutations mediate antiestrogen resistance in estrogen receptor-positive breast cancer.,http://www.ncbi.nlm.nih.gov/pubmed/25401474
4206,20393564,Therapeutic antibody targeting of individual Notch receptors.,http://www.ncbi.nlm.nih.gov/pubmed/20393564
4207,18677410,Leukemia-associated NOTCH1 alleles are weak tumor initiators but accelerate K-ras-initiated leukemia.,http://www.ncbi.nlm.nih.gov/pubmed/18677410
4208,11313942,"PRCC, the commonest TFE3 fusion partner in papillary renal carcinoma is associated with pre-mRNA splicing factors.",http://www.ncbi.nlm.nih.gov/pubmed/11313942
4209,22869755,Cyclin-dependent kinase 8 mediates chemotherapy-induced tumor-promoting paracrine activities.,http://www.ncbi.nlm.nih.gov/pubmed/22869755
4210,,,http://cancerimmunolres.aacrjournals.org/content/4/1_Supplement/B029.abstract?sid=af20e2c0-b945-4273-b2ee-f353d1973d72
4211,,Targeting tumor microenvironment with selective small-molecule inhibitors of CDK8/19,http://cancerres.aacrjournals.org/content/75/1_Supplement/PR08.abstract
4212,19478553,"JNK inhibitor SP600125 promotes the formation of polymerized tubulin, leading to G2/M phase arrest, endoreduplication, and delayed apoptosis.",http://www.ncbi.nlm.nih.gov/pubmed/19478553
4213,11717429,"SP600125, an anthrapyrazolone inhibitor of Jun N-terminal kinase.",http://www.ncbi.nlm.nih.gov/pubmed/11717429
4214,18406326,The double bromodomain proteins Brd2 and Brd3 couple histone acetylation to transcription.,http://www.ncbi.nlm.nih.gov/pubmed/18406326
4215,14563639,E mu-BRD2 transgenic mice develop B-cell lymphoma and leukemia.,http://www.ncbi.nlm.nih.gov/pubmed/14563639
4216,22619672,"AS601245, an Anti-Inflammatory JNK Inhibitor, and Clofibrate Have a Synergistic Effect in Inducing Cell Responses and in Affecting the Gene Expression Profile in CaCo-2 Colon Cancer Cells.",http://www.ncbi.nlm.nih.gov/pubmed/22619672
4217,15210584,Inhibition of c-Jun N-terminal kinase decreases cardiomyocyte apoptosis and infarct size after myocardial ischemia and reperfusion in anaesthetized rats.,http://www.ncbi.nlm.nih.gov/pubmed/15210584
4218,26023085,Inhibition of JNK Sensitizes Hypoxic Colon Cancer Cells to DNA-Damaging Agents.,http://www.ncbi.nlm.nih.gov/pubmed/26023085
4219,17202416,A pathogenic role for c-Jun amino-terminal kinase signaling in renal fibrosis and tubular cell apoptosis.,http://www.ncbi.nlm.nih.gov/pubmed/17202416
4220,22284361,Discovery of potent and selective covalent inhibitors of JNK.,http://www.ncbi.nlm.nih.gov/pubmed/22284361
4221,26565999,"BET Protein BRDT Complexes With HDAC1, PRMT5, and TRIM28 and Functions in Transcriptional Repression During Spermatogenesis.",http://www.ncbi.nlm.nih.gov/pubmed/26565999
4222,10704737,"Expression of cancer-testis antigens in lung cancer: definition of bromodomain testis-specific gene (BRDT) as a new CT gene, CT9.",http://www.ncbi.nlm.nih.gov/pubmed/10704737
4223,21536911,Bromodomain protein Brd3 associates with acetylated GATA1 to promote its chromatin occupancy at erythroid target genes.,http://www.ncbi.nlm.nih.gov/pubmed/21536911
4224,25688404,NUT midline carcinoma.,http://www.ncbi.nlm.nih.gov/pubmed/25688404
4225,26286024,The transcription cofactor c-JUN mediates phenotype switching and BRAF inhibitor resistance in melanoma.,http://www.ncbi.nlm.nih.gov/pubmed/26286024
4226,24852265,c-Jun promotes cell migration and drives expression of the motility factor ENPP2 in soft tissue sarcomas.,http://www.ncbi.nlm.nih.gov/pubmed/24852265
4227,18003757,The type and the position of HNF1A mutation modulate age at diagnosis of diabetes in patients with maturity-onset diabetes of the young (MODY)-3.,http://www.ncbi.nlm.nih.gov/pubmed/18003757
4228,12574234,Hepatocyte nuclear factor-1 alpha gene mutations and diabetes in Norway.,http://www.ncbi.nlm.nih.gov/pubmed/12574234
4229,19809274,Melanotic Xp11 translocation renal cancer: a case with PSF-TFE3 gene fusion and up-regulation of melanogenetic transcripts.,http://www.ncbi.nlm.nih.gov/pubmed/19809274
4230,12917640,A novel CLTC-TFE3 gene fusion in pediatric renal adenocarcinoma with t(X;17)(p11.2;q23).,http://www.ncbi.nlm.nih.gov/pubmed/12917640
4231,16585160,TMPRSS2:ETV4 gene fusions define a third molecular subtype of prostate cancer.,http://www.ncbi.nlm.nih.gov/pubmed/16585160
4232,24819961,Identification and characterization of a novel small-molecule inhibitor of β-catenin signaling.,http://www.ncbi.nlm.nih.gov/pubmed/24819961
4233,23630077,Structure-function studies of STAR family Quaking proteins bound to their in vivo RNA target sites.,http://www.ncbi.nlm.nih.gov/pubmed/23630077
4234,23583981,Whole-genome sequencing identifies genetic alterations in pediatric low-grade gliomas.,http://www.ncbi.nlm.nih.gov/pubmed/23583981
4235,,A phase I first-in-human study of PRI-724 in patients (pts) with advanced solid tumors.,http://meetinglibrary.asco.org/content/115980-132
4236,,"BAY 1125976, is a selective allosteric AKT1/2 inhibitor with high efficacy in AKT1-mutated cancers",http://cancerres.aacrjournals.org/content/74/19_Supplement/3685.short
4237,26311725,A Phase II Trial of the Multitargeted Tyrosine Kinase Inhibitor Lenvatinib (E7080) in Advanced Medullary Thyroid Cancer.,http://www.ncbi.nlm.nih.gov/pubmed/26311725
4238,21722318,Dz13: c-Jun downregulation and tumour cell death.,http://www.ncbi.nlm.nih.gov/pubmed/21722318
4239,23660123,"Safety and tolerability of an intratumorally injected DNAzyme, Dz13, in patients with nodular basal-cell carcinoma: a phase 1 first-in-human trial (DISCOVER).",http://www.ncbi.nlm.nih.gov/pubmed/23660123
4240,18497564,Involvement of c-jun in human liposarcoma growth: supporting data from clinical immunohistochemistry and DNAzyme efficacy.,http://www.ncbi.nlm.nih.gov/pubmed/18497564
4241,25749173,A Meta-Analysis of SMAD4 Immunohistochemistry as a Prognostic Marker in Colorectal Cancer.,http://www.ncbi.nlm.nih.gov/pubmed/25749173
4242,25333693,Meta-analysis of the prognostic value of smad4 immunohistochemistry in various cancers.,http://www.ncbi.nlm.nih.gov/pubmed/25333693
4243,22850631,The importance of E-cadherin binding partners to evaluate the pathogenicity of E-cadherin missense mutations associated to HDGC.,http://www.ncbi.nlm.nih.gov/pubmed/22850631
4244,26641137,Acalabrutinib (ACP-196) in Relapsed Chronic Lymphocytic Leukemia.,http://www.ncbi.nlm.nih.gov/pubmed/26641137
4245,26639149,Ibrutinib as Initial Therapy for Patients with Chronic Lymphocytic Leukemia.,http://www.ncbi.nlm.nih.gov/pubmed/26639149
4246,17994767,Novel mutations in Smad proteins that inhibit signaling by the transforming growth factor beta in mammalian cells.,http://www.ncbi.nlm.nih.gov/pubmed/17994767
4247,18990760,Frequent alterations of p16INK4a and p14ARF in oral proliferative verrucous leukoplakia.,http://www.ncbi.nlm.nih.gov/pubmed/18990760
4248,26351344,"Randomized, Double-Blind, Phase II Study of Ruxolitinib or Placebo in Combination With Capecitabine in Patients With Metastatic Pancreatic Cancer for Whom Therapy With Gemcitabine Has Failed.",http://www.ncbi.nlm.nih.gov/pubmed/26351344
4249,20118910,Prevalence of TMPRSS2-ERG and SLC45A3-ERG gene fusions in a large prostatectomy cohort.,http://www.ncbi.nlm.nih.gov/pubmed/20118910
4250,16258068,The ETV6-NTRK3 chimeric tyrosine kinase suppresses TGF-beta signaling by inactivating the TGF-beta type II receptor.,http://www.ncbi.nlm.nih.gov/pubmed/16258068
4251,25724520,PIK3CA Pathway Mutations Predictive of Poor Response Following Standard Radiochemotherapy ± Cetuximab in Cervical Cancer Patients.,http://www.ncbi.nlm.nih.gov/pubmed/25724520
4252,17143529,Tyrosine kinase inhibitor CEP-701 blocks the NTRK1/NGF receptor and limits the invasive capability of prostate cancer cells in vitro.,http://www.ncbi.nlm.nih.gov/pubmed/17143529
4253,,"Safety, pharmacokinetics (PK), pharmacodynamics (PD), and clinical activity of the oral AKT inhibitor GSK2141795 (GSK795) in a phase I first-in-human study.",http://meetinglibrary.asco.org/content/80659-102
4254,26497682,"A putative biomarker signature for clinically effective AKT inhibition: correlation of in vitro, in vivo and clinical data identifies the importance of modulation of the mTORC1 pathway.",http://www.ncbi.nlm.nih.gov/pubmed/26497682
4255,26627007,Identification of Variant-Specific Functions of PIK3CA by Rapid Phenotyping of Rare Mutations.,http://www.ncbi.nlm.nih.gov/pubmed/26627007
4256,21804605,"A tripartite complex composed of ETV6-NTRK3, IRS1 and IGF1R is required for ETV6-NTRK3-mediated membrane localization and transformation.",http://www.ncbi.nlm.nih.gov/pubmed/21804605
4257,16546979,Combined inhibition of the phosphatidylinositol 3-kinase/Akt and Ras/mitogen-activated protein kinase pathways results in synergistic effects in glioblastoma cells.,http://www.ncbi.nlm.nih.gov/pubmed/16546979
4258,19737955,C-Raf is associated with disease progression and cell proliferation in a subset of melanomas.,http://www.ncbi.nlm.nih.gov/pubmed/19737955
4259,26100670,Novel Cancer Therapeutics with Allosteric Modulation of the Mitochondrial C-Raf-DAPK Complex by Raf Inhibitor Combination Therapy.,http://www.ncbi.nlm.nih.gov/pubmed/26100670
4260,10523652,Dual transforming activities of the FUS (TLS)-ERG leukemia fusion protein conferred by two N-terminal domains of FUS (TLS).,http://www.ncbi.nlm.nih.gov/pubmed/10523652
4261,19649210,N-myc downstream regulated gene 1 (NDRG1) is fused to ERG in prostate cancer.,http://www.ncbi.nlm.nih.gov/pubmed/19649210
4262,17671502,Distinct classes of chromosomal rearrangements create oncogenic ETS gene fusions in prostate cancer.,http://www.ncbi.nlm.nih.gov/pubmed/17671502
4263,26488212,Clinicopathological and genetic differences between low-grade and high-grade colorectal mucinous adenocarcinomas.,http://www.ncbi.nlm.nih.gov/pubmed/26488212
4264,11481457,"SMAD4 mutations in colorectal cancer probably occur before chromosomal instability, but after divergence of the microsatellite instability pathway.",http://www.ncbi.nlm.nih.gov/pubmed/11481457
4265,25688157,Molecular Changes Associated with Acquired Resistance to Crizotinib in ROS1-Rearranged Non-Small Cell Lung Cancer.,http://www.ncbi.nlm.nih.gov/pubmed/25688157
4266,24089446,Weekly nab-Rapamycin in patients with advanced nonhematologic malignancies: final results of a phase I trial.,http://www.ncbi.nlm.nih.gov/pubmed/24089446
4267,25536954,"Phase 1 study of oral abexinostat, a histone deacetylase inhibitor, in combination with doxorubicin in patients with metastatic sarcoma.",http://www.ncbi.nlm.nih.gov/pubmed/25536954
4268,25709080,Ricolinostat (ACY-1215) induced inhibition of aggresome formation accelerates carfilzomib-induced multiple myeloma cell death.,http://www.ncbi.nlm.nih.gov/pubmed/25709080
4269,15688068,"RNA polymerases I and III, growth control and cancer.",http://www.ncbi.nlm.nih.gov/pubmed/15688068
4270,26160835,RB1 dual role in proliferation and apoptosis: cell fate control and implications for cancer therapy.,http://www.ncbi.nlm.nih.gov/pubmed/26160835
4271,16990856,Topoisomerase I inhibitors: camptothecins and beyond.,http://www.ncbi.nlm.nih.gov/pubmed/16990856
4272,16707468,KRAS(D13) Promotes apoptosis of human colorectal tumor cells by ReovirusT3D and oxaliplatin but not by tumor necrosis factor-related apoptosis-inducing ligand.,http://www.ncbi.nlm.nih.gov/pubmed/16707468
4273,21284948,"Role of the androgen receptor CAG repeat polymorphism in prostate cancer, and spinal and bulbar muscular atrophy.",http://www.ncbi.nlm.nih.gov/pubmed/21284948
4274,25607836,Fighting polyglutamine disease by wrestling with SUMO.,http://www.ncbi.nlm.nih.gov/pubmed/25607836
4275,19833203,Involvement of three glutamine tracts in human androgen receptor transactivation.,http://www.ncbi.nlm.nih.gov/pubmed/19833203
4276,26649278,CDK4/6 Inhibitor PD0332991 in Glioblastoma Treatment: Does It Have a Future?,http://www.ncbi.nlm.nih.gov/pubmed/26649278
4277,,Selective HDAC inhibition by ricolinostat (ACY-1215) or ACY-241 synergizes with IMiD® immunomodulatory drugs in Multiple Myeloma (MM) and Mantle Cell Lymphoma (MCL) cells,http://cancerres.aacrjournals.org/content/75/15_Supplement/5380.short?rss=1
4278,25085664,"Precision medicine and precision therapeutics: hedgehog signaling pathway, basal cell carcinoma and beyond.",http://www.ncbi.nlm.nih.gov/pubmed/25085664
4279,,Protein tyrosine phosphatase non receptor 11 (PTPN11/Shp2) as a driver oncogene and a novel therapeutic target in non-small cell lung cancer (NSCLC),http://meeting.ascopubs.org/cgi/content/short/33/15_suppl/11077?rss=1
4280,18559669,Regulation of RhoA-dependent ROCKII activation by Shp2.,http://www.ncbi.nlm.nih.gov/pubmed/18559669
4281,26080084,Digging a hole under Hedgehog: downstream inhibition as an emerging anticancer strategy.,http://www.ncbi.nlm.nih.gov/pubmed/26080084
4282,26161618,A novel oral insulin-like growth factor-1 receptor pathway modulator and its implications for patients with non-small cell lung carcinoma: A phase I clinical trial.,http://www.ncbi.nlm.nih.gov/pubmed/26161618
4283,25208878,Phase I study of intermittent oral dosing of the insulin-like growth factor-1 and insulin receptors inhibitor OSI-906 in patients with advanced solid tumors.,http://www.ncbi.nlm.nih.gov/pubmed/25208878
4284,19825801,GSK1838705A inhibits the insulin-like growth factor-1 receptor and anaplastic lymphoma kinase and shows antitumor activity in experimental models of human cancers.,http://www.ncbi.nlm.nih.gov/pubmed/19825801
4285,26238593,"GSK1838705A, an IGF-1R inhibitor, inhibits glioma cell proliferation and suppresses tumor growth in vivo.",http://www.ncbi.nlm.nih.gov/pubmed/26238593
4286,25971682,"PQ401, an IGF-1R inhibitor, induces apoptosis and inhibits growth, proliferation and migration of glioma cells.",http://www.ncbi.nlm.nih.gov/pubmed/25971682
4287,12067995,beta-Catenin mutation is a frequent cause of Wnt pathway activation in gastric cancer.,http://www.ncbi.nlm.nih.gov/pubmed/12067995
4288,11592102,beta-catenin nuclear expression correlates with cyclin D1 overexpression in sporadic desmoid tumours.,http://www.ncbi.nlm.nih.gov/pubmed/11592102
4289,11148558,Frequent nuclear accumulation of beta-catenin in pituitary adenoma.,http://www.ncbi.nlm.nih.gov/pubmed/11148558
4290,25748177,Synergy of Histone-Deacetylase Inhibitor AR-42 with Cisplatin in Bladder Cancer.,http://www.ncbi.nlm.nih.gov/pubmed/25748177
4291,26589432,"Taselisib (GDC-0032), a Potent β-Sparing Small Molecule Inhibitor of PI3K, Radiosensitizes Head and Neck Squamous Carcinomas Containing Activating PIK3CA Alterations.",http://www.ncbi.nlm.nih.gov/pubmed/26589432
4292,15834506,Functional analysis of PTPN11/SHP-2 mutants identified in Noonan syndrome and childhood leukemia.,http://www.ncbi.nlm.nih.gov/pubmed/15834506
4293,,"A phase I study of XL228, a potent IGF1R/AURORA/SRC inhibitor, in patients with solid tumors or hematologic malignancies",http://meetinglibrary.asco.org/content/35000-65
4294,,"A phase I study of XL228, a multitargeted protein kinase inhibitor, in patients (pts) with solid tumors or multiple myeloma",http://meetinglibrary.asco.org/content/53431-74
4295,24816908,"Anticancer activity of the type I insulin-like growth factor receptor antagonist, ganitumab, in combination with the death receptor 5 agonist, conatumumab.",http://www.ncbi.nlm.nih.gov/pubmed/24816908
4296,22508822,"Phase II study of ganitumab, a fully human anti-type-1 insulin-like growth factor receptor antibody, in patients with metastatic Ewing family tumors or desmoplastic small round cell tumors.",http://www.ncbi.nlm.nih.gov/pubmed/22508822
4297,26563355,Sensitivity to Entrectinib Associated With a Novel LMNA-NTRK1 Gene Fusion in Metastatic Colorectal Cancer.,http://www.ncbi.nlm.nih.gov/pubmed/26563355
4298,26546295,Acquired Resistance to the TRK Inhibitor Entrectinib in Colorectal Cancer.,http://www.ncbi.nlm.nih.gov/pubmed/26546295
4299,23825065,Targeting protein tyrosine phosphatase SHP2 for the treatment of PTPN11-associated malignancies.,http://www.ncbi.nlm.nih.gov/pubmed/23825065
4300,23957426,Identification of cryptotanshinone as an inhibitor of oncogenic protein tyrosine phosphatase SHP2 (PTPN11).,http://www.ncbi.nlm.nih.gov/pubmed/23957426
4301,26090892,"TAE226, a Bis-Anilino Pyrimidine Compound, Inhibits the EGFR-Mutant Kinase Including T790M Mutant to Show Anti-Tumor Effect on EGFR-Mutant Non-Small Cell Lung Cancer Cells.",http://www.ncbi.nlm.nih.gov/pubmed/26090892
4302,21298745,Initial testing (stage 1) of the IGF-1 receptor inhibitor BMS-754807 by the pediatric preclinical testing program.,http://www.ncbi.nlm.nih.gov/pubmed/21298745
4303,26294215,Small-Molecule NSC59984 Restores p53 Pathway Signaling and Antitumor Effects against Colorectal Cancer via p73 Activation and Degradation of Mutant p53.,http://www.ncbi.nlm.nih.gov/pubmed/26294215
4304,26565381,Durable Clinical Response to Entrectinib in NTRK1-Rearranged Non-Small Cell Lung Cancer.,http://www.ncbi.nlm.nih.gov/pubmed/26565381
4305,26633560,Novel CAD-ALK gene rearrangement is drugable by entrectinib in colorectal cancer.,http://www.ncbi.nlm.nih.gov/pubmed/26633560
4306,14614447,"CP-31398, a novel p53-stabilizing agent, induces p53-dependent and p53-independent glioma cell death.",http://www.ncbi.nlm.nih.gov/pubmed/14614447
4307,15746061,"The insulin-like growth factor-I receptor kinase inhibitor, NVP-ADW742, sensitizes small cell lung cancer cell lines to the effects of chemotherapy.",http://www.ncbi.nlm.nih.gov/pubmed/15746061
4308,22624712,Allele-specific p53 mutant reactivation.,http://www.ncbi.nlm.nih.gov/pubmed/22624712
4309,26748848,A Designed Inhibitor of p53 Aggregation Rescues p53 Tumor Suppression in Ovarian Carcinomas.,http://www.ncbi.nlm.nih.gov/pubmed/26748848
4310,,"Phase (Ph) 1/2 study of TSR-011, a potent inhibitor of ALK and TRK, including crizotinib-resistant ALK mutations",http://meetinglibrary.asco.org/content/134653-144
4311,26675259,"Significant blockade of multiple receptor tyrosine kinases by MGCD516 (Sitravatinib), a novel small molecule inhibitor, shows potent anti-tumor activity in preclinical models of sarcoma.",http://www.ncbi.nlm.nih.gov/pubmed/26675259
4312,21242122,Role and relevance of TrkB mutations and expression in non-small cell lung cancer.,http://www.ncbi.nlm.nih.gov/pubmed/21242122
4313,26105599,"Results from a multicenter, open-label, pivotal phase II study of chidamide in relapsed or refractory peripheral T-cell lymphoma.",http://www.ncbi.nlm.nih.gov/pubmed/26105599
4314,12761039,"Genetic and functional analyses of FH mutations in multiple cutaneous and uterine leiomyomatosis, hereditary leiomyomatosis and renal cancer, and fumarate hydratase deficiency.",http://www.ncbi.nlm.nih.gov/pubmed/12761039
4315,26230596,Significance of MYD88 L265P Mutation Status in the Subclassification of Low-Grade B-Cell Lymphoma/Leukemia.,http://www.ncbi.nlm.nih.gov/pubmed/26230596
4316,25729899,Template for Reporting Results of Biomarker Testing of Specimens From Patients With Gastrointestinal Stromal Tumors.,http://www.ncbi.nlm.nih.gov/pubmed/25729899
4317,26346493,Identification of DYRK1B as a substrate of ERK1/2 and characterisation of the kinase activity of DYRK1B mutants from cancer and metabolic syndrome.,http://www.ncbi.nlm.nih.gov/pubmed/26346493
4318,25140973,The metabolic syndrome and DYRK1B.,http://www.ncbi.nlm.nih.gov/pubmed/25140973
4319,24827035,A form of the metabolic syndrome associated with mutations in DYRK1B.,http://www.ncbi.nlm.nih.gov/pubmed/24827035
4320,21056685,Co-localization of mutant p53 and amyloid-like protein aggregates in breast tumors.,http://www.ncbi.nlm.nih.gov/pubmed/21056685
4321,12094214,Mechanisms and functions of Eph and ephrin signalling.,http://www.ncbi.nlm.nih.gov/pubmed/12094214
4322,16816380,Receptor tyrosine kinase EphB4 is a survival factor in breast cancer.,http://www.ncbi.nlm.nih.gov/pubmed/16816380
4323,9472631,Effects of p53 mutants derived from lung carcinomas on the p53-responsive element (p53RE) of the MDM2 gene.,http://www.ncbi.nlm.nih.gov/pubmed/9472631
4324,16294026,Activating mutations in c-KIT and PDGFRalpha are exclusively found in gastrointestinal stromal tumors and not in other tumors overexpressing these imatinib mesylate target genes.,http://www.ncbi.nlm.nih.gov/pubmed/16294026
4325,19861442,Mechanisms of sunitinib resistance in gastrointestinal stromal tumors harboring KITAY502-3ins mutation: an in vitro mutagenesis screen for drug resistance.,http://www.ncbi.nlm.nih.gov/pubmed/19861442
4326,25877780,Selective inhibitors of the protein tyrosine phosphatase SHP2 block cellular motility and growth of cancer cells in vitro and in vivo.,http://www.ncbi.nlm.nih.gov/pubmed/25877780
4327,21903770,Disruptive TP53 mutation is associated with aggressive disease characteristics in an orthotopic murine model of oral tongue cancer.,http://www.ncbi.nlm.nih.gov/pubmed/21903770
4328,23625637,Serine substitution of proline at codon 151 of TP53 confers gain of function activity leading to anoikis resistance and tumor progression of head and neck cancer cells.,http://www.ncbi.nlm.nih.gov/pubmed/23625637
4329,20803239,The small molecule specific EphB4 kinase inhibitor NVP-BHG712 inhibits VEGF driven angiogenesis.,http://www.ncbi.nlm.nih.gov/pubmed/20803239
4330,22989750,Allele specific gain-of-function activity of p53 mutants in lung cancer cells.,http://www.ncbi.nlm.nih.gov/pubmed/22989750
4331,23018556,p53 regulates epithelial-mesenchymal transition induced by transforming growth factor β.,http://www.ncbi.nlm.nih.gov/pubmed/23018556
4332,16835297,Small-molecule modulators of p53 family signaling and antitumor effects in p53-deficient human colon tumor xenografts.,http://www.ncbi.nlm.nih.gov/pubmed/16835297
4333,19225112,A panel of isogenic human cancer cells suggests a therapeutic approach for cancers with inactivated p53.,http://www.ncbi.nlm.nih.gov/pubmed/19225112
4334,21383700,p53 inhibits mRNA 3' processing through its interaction with the CstF/BARD1 complex.,http://www.ncbi.nlm.nih.gov/pubmed/21383700
4335,11870884,Restoration of wild-type conformation and activity of a temperature-sensitive mutant of p53 (p53(V272M)) by the cytoprotective aminothiol WR1065 in the esophageal cancer cell line TE-1.,http://www.ncbi.nlm.nih.gov/pubmed/11870884
4336,15613472,Hsp90 is essential for restoring cellular functions of temperature-sensitive p53 mutant protein but not for stabilization and activation of wild-type p53: implications for cancer therapy.,http://www.ncbi.nlm.nih.gov/pubmed/15613472
4337,25458359,Multitargeting strategy using lenvatinib and golvatinib: maximizing anti-angiogenesis activity in a preclinical cancer model.,http://www.ncbi.nlm.nih.gov/pubmed/25458359
4338,9331090,Characterization of the p53 tumor suppressor pathway in cell lines of the National Cancer Institute anticancer drug screen and correlations with the growth-inhibitory potency of 123 anticancer agents.,http://www.ncbi.nlm.nih.gov/pubmed/9331090
4339,16969106,Oligomerization of p53 precedes its association with dynein and nuclear accumulation.,http://www.ncbi.nlm.nih.gov/pubmed/16969106
4340,10778859,Drosophila p53 is a structural and functional homolog of the tumor suppressor p53.,http://www.ncbi.nlm.nih.gov/pubmed/10778859
4341,23844053,The EphB4 receptor tyrosine kinase promotes lung cancer growth: a potential novel therapeutic target.,http://www.ncbi.nlm.nih.gov/pubmed/23844053
4342,22540896,A prognostic signature of defective p53-dependent G1 checkpoint function in melanoma cell lines.,http://www.ncbi.nlm.nih.gov/pubmed/22540896
4343,16209708,Telomerase expression is sufficient for chromosomal integrity in cells lacking p53 dependent G1 checkpoint function.,http://www.ncbi.nlm.nih.gov/pubmed/16209708
4344,22591714,"The CRKL gene encoding an adaptor protein is amplified, overexpressed, and a possible therapeutic target in gastric cancer.",http://www.ncbi.nlm.nih.gov/pubmed/22591714
4345,9627118,Human tumor-derived p53 proteins exhibit binding site selectivity and temperature sensitivity for transactivation in a yeast-based assay.,http://www.ncbi.nlm.nih.gov/pubmed/9627118
4346,16492679,Specific TP53 mutation pattern in radiation-induced sarcomas.,http://www.ncbi.nlm.nih.gov/pubmed/16492679
4347,7700648,A variant Ewing's sarcoma translocation (7;22) fuses the EWS gene to the ETS gene ETV1.,http://www.ncbi.nlm.nih.gov/pubmed/7700648
4348,1944289,The transactivating domain of the c-Jun proto-oncoprotein is required for cotransformation of rat embryo cells.,http://www.ncbi.nlm.nih.gov/pubmed/1944289
4349,15831482,Selective regulation of c-jun gene expression by mitogen-activated protein kinases via the 12-o-tetradecanoylphorbol-13-acetate- responsive element and myocyte enhancer factor 2 binding sites.,http://www.ncbi.nlm.nih.gov/pubmed/15831482
4350,19863445,Cushing's syndrome in an infant secondary to malignant adrenocortical tumors with somatic mutation of beta-catenin.,http://www.ncbi.nlm.nih.gov/pubmed/19863445
4352,16469872,Dasatinib (BMS-354825) targets an earlier progenitor population than imatinib in primary CML but does not eliminate the quiescent fraction.,http://www.ncbi.nlm.nih.gov/pubmed/16469872
4353,23624299,Transforming acidic coiled-coil proteins (TACCs) in human cancer.,http://www.ncbi.nlm.nih.gov/pubmed/23624299
4354,26425723,FGFR3-TACC3: A novel gene fusion in cervical cancer.,http://www.ncbi.nlm.nih.gov/pubmed/26425723
4355,26606880,Transcriptome sequencing identifies ETV6-NTRK3 as a gene fusion involved in GIST.,http://www.ncbi.nlm.nih.gov/pubmed/26606880
4356,17620431,"Pharmacokinetic-pharmacodynamic correlation from mouse to human with pazopanib, a multikinase angiogenesis inhibitor with potent antitumor and antiangiogenic activity.",http://www.ncbi.nlm.nih.gov/pubmed/17620431
4357,21559405,YK-4-279 inhibits ERG and ETV1 mediated prostate cancer cell invasion.,http://www.ncbi.nlm.nih.gov/pubmed/21559405
4359,,"Phase 1, first-in-human study of ARQ 087, an oral pan-Fibroblast Growth Factor Receptor (FGFR) inhibitor, in patients (pts) with advanced solid tumors.",http://meetinglibrary.asco.org/content/149025-156
4360,24755674,Focal adhesion kinase: an alternative focus for anti-angiogenesis therapy in ovarian cancer.,http://www.ncbi.nlm.nih.gov/pubmed/24755674
4361,24899686,FAK Inhibition disrupts a β5 integrin signaling axis controlling anchorage-independent ovarian carcinoma growth.,http://www.ncbi.nlm.nih.gov/pubmed/24899686
4362,14534538,The phosphotyrosine phosphatase SHP2 is a critical mediator of transformation induced by the oncogenic fibroblast growth factor receptor 3.,http://www.ncbi.nlm.nih.gov/pubmed/14534538
4363,26324363,"Phase I Dose-Escalation Study of JNJ-42756493, an Oral Pan-Fibroblast Growth Factor Receptor Inhibitor, in Patients With Advanced Solid Tumors.",http://www.ncbi.nlm.nih.gov/pubmed/26324363
4364,25609060,"Detection, Characterization, and Inhibition of FGFR-TACC Fusions in IDH Wild-type Glioma.",http://www.ncbi.nlm.nih.gov/pubmed/25609060
4365,25326231,MMP-1 and Pro-MMP-10 as potential urinary pharmacodynamic biomarkers of FGFR3-targeted therapy in patients with bladder cancer.,http://www.ncbi.nlm.nih.gov/pubmed/25326231
4366,22767668,"Phase I dose-escalation study of the safety, pharmacokinetics, and pharmacodynamics of the MEK inhibitor RO4987655 (CH4987655) in patients with advanced solid tumors.",http://www.ncbi.nlm.nih.gov/pubmed/22767668
4367,,A first in-human phase I study to evaluate the MEK1/2 inhibitor GDC-0623 in patients with advanced solid tumors.,http://mct.aacrjournals.org/content/12/11_Supplement/B75.short
4368,10210316,"A patient-derived mutant form of the Fanconi anemia protein, FANCA, is defective in nuclear accumulation.",http://www.ncbi.nlm.nih.gov/pubmed/10210316
4369,,"Phase I, dose-escalation study of the investigational drug TAK-733, an oral MEK inhibitor, in patients (pts) with advanced solid tumors.",http://meetinglibrary.asco.org/content/112399-132
4370,12354784,BRCA1 interacts directly with the Fanconi anemia protein FANCA.,http://www.ncbi.nlm.nih.gov/pubmed/12354784
4371,22343915,FAAP20: a novel ubiquitin-binding FA nuclear core-complex protein required for functional integrity of the FA-BRCA DNA repair pathway.,http://www.ncbi.nlm.nih.gov/pubmed/22343915
4372,24920063,Acquired initiating mutations in early hematopoietic cells of CLL patients.,http://www.ncbi.nlm.nih.gov/pubmed/24920063
4373,23239736,EZH2 oncogenic activity in castration-resistant prostate cancer cells is Polycomb-independent.,http://www.ncbi.nlm.nih.gov/pubmed/23239736
4374,16224021,Akt-mediated phosphorylation of EZH2 suppresses methylation of lysine 27 in histone H3.,http://www.ncbi.nlm.nih.gov/pubmed/16224021
4375,15157880,Characterization of a conserved structural determinant controlling protein kinase sensitivity to selective inhibitors.,http://www.ncbi.nlm.nih.gov/pubmed/15157880
4376,25686244,Illuminating the molecular mechanisms of tyrosine kinase inhibitor resistance for the FGFR1 gatekeeper mutation: the Achilles' heel of targeted therapy.,http://www.ncbi.nlm.nih.gov/pubmed/25686244
4378,21383288,Dissecting therapeutic resistance to RAF inhibition in melanoma by tumor genomic profiling.,http://www.ncbi.nlm.nih.gov/pubmed/21383288
4379,26304929,Targeting activating mutations of EZH2 leads to potent cell growth inhibition in human melanoma by derepression of tumor suppressor genes.,http://www.ncbi.nlm.nih.gov/pubmed/26304929
4380,24448821,Novel ATP-competitive MEK inhibitor E6201 is effective against vemurafenib-resistant melanoma harboring the MEK1-C121S mutation in a preclinical model.,http://www.ncbi.nlm.nih.gov/pubmed/24448821
4381,24755886,"Trabectedin, a drug acting on both cancer cells and the tumour microenvironment.",http://www.ncbi.nlm.nih.gov/pubmed/24755886
4382,26438159,"ERK Signal Suppression and Sensitivity to CH5183284/Debio 1347, a Selective FGFR Inhibitor.",http://www.ncbi.nlm.nih.gov/pubmed/26438159
4383,26036639,FGFR2 is overexpressed in myxoid liposarcoma and inhibition of FGFR signaling impairs tumor growth in vitro.,http://www.ncbi.nlm.nih.gov/pubmed/26036639
4384,17698633,Activity of TKI258 against primary cells and cell lines with FGFR1 fusion genes associated with the 8p11 myeloproliferative syndrome.,http://www.ncbi.nlm.nih.gov/pubmed/17698633
4385,,"First-in-human phase I safety, pharmacokinetic (PK), and pharmacodynamic (PD) analysis of the oral MEK-inhibitor AS703026 (two regimens [R]) in patients (pts) with advanced solid tumors",http://meetinglibrary.asco.org/content/43866-74
4386,26370156,RICTOR Amplification Defines a Novel Subset of Patients with Lung Cancer Who May Benefit from Treatment with mTORC1/2 Inhibitors.,http://www.ncbi.nlm.nih.gov/pubmed/26370156
4387,23558953,Identification of targetable FGFR gene fusions in diverse cancers.,http://www.ncbi.nlm.nih.gov/pubmed/23558953
4388,25169980,"The fibroblast growth factor receptor genetic status as a potential predictor of the sensitivity to CH5183284/Debio 1347, a novel selective FGFR inhibitor.",http://www.ncbi.nlm.nih.gov/pubmed/25169980
4389,26650227,A phase I study of two dosing schedules of oral BI 847325 in patients with advanced solid tumors.,http://www.ncbi.nlm.nih.gov/pubmed/26650227
4390,16009947,Phase I and pharmacodynamic study of the oral MEK inhibitor CI-1040 in patients with advanced malignancies.,http://www.ncbi.nlm.nih.gov/pubmed/16009947
4391,24349332,Human Fanconi anemia complementation group a protein stimulates the 5' flap endonuclease activity of FEN1.,http://www.ncbi.nlm.nih.gov/pubmed/24349332
4392,24325461,Epithelial mesenchymal transition status is associated with anti-cancer responses towards receptor tyrosine-kinase inhibition by dovitinib in human bladder cancer cells.,http://www.ncbi.nlm.nih.gov/pubmed/24325461
4393,,Abstract 772: Anti-tumor efficacy of the selective pan-FGFR Inhibitor BAY 1163877 in preclinical squamous cell carcinoma models of different origin,http://cancerres.aacrjournals.org/content/75/15_Supplement/772.short
4394,20826828,"Missense variants in ATM in 26,101 breast cancer cases and 29,842 controls.",http://www.ncbi.nlm.nih.gov/pubmed/20826828
4395,11429700,Amifostine (WR2721) restores transcriptional activity of specific p53 mutant proteins in a yeast functional assay.,http://www.ncbi.nlm.nih.gov/pubmed/11429700
4396,21552262,A cell-based screen identifies ATR inhibitors with synthetic lethal properties for cancer-associated mutations.,http://www.ncbi.nlm.nih.gov/pubmed/21552262
4397,26432108,Molecular Heterogeneity and Receptor Coamplification Drive Resistance to Targeted Therapy in MET-Amplified Esophagogastric Cancer.,http://www.ncbi.nlm.nih.gov/pubmed/26432108
4398,16113653,Ablation of the spindle assembly checkpoint by a compound targeting Mps1.,http://www.ncbi.nlm.nih.gov/pubmed/16113653
4399,22438244,Selective killing of p53-deficient cancer cells by SP600125.,http://www.ncbi.nlm.nih.gov/pubmed/22438244
4400,20383151,Small-molecule kinase inhibitors provide insight into Mps1 cell cycle function.,http://www.ncbi.nlm.nih.gov/pubmed/20383151
4401,26564006,"Concomitant loss of SMARCA2 and SMARCA4 expression in small cell carcinoma of the ovary, hypercalcemic type.",http://www.ncbi.nlm.nih.gov/pubmed/26564006
4402,26267657,Characterization of the MUC1-C Cytoplasmic Domain as a Cancer Target.,http://www.ncbi.nlm.nih.gov/pubmed/26267657
4403,26307133,"Copy Number Changes Are Associated with Response to Treatment with Carboplatin, Paclitaxel, and Sorafenib in Melanoma.",http://www.ncbi.nlm.nih.gov/pubmed/26307133
4404,16717128,Distinct p53 acetylation cassettes differentially influence gene-expression patterns and cell fate.,http://www.ncbi.nlm.nih.gov/pubmed/16717128
4405,14695212,Induction of PIG3 and NOXA through acetylation of p53 at 320 and 373 lysine residues as a mechanism for apoptotic cell death by histone deacetylase inhibitors.,http://www.ncbi.nlm.nih.gov/pubmed/14695212
4406,22171973,TOP1 gene copy numbers in colorectal cancer samples and cell lines and their association to in vitro drug sensitivity.,http://www.ncbi.nlm.nih.gov/pubmed/22171973
4407,26086967,APR-246 overcomes resistance to cisplatin and doxorubicin in ovarian cancer cells.,http://www.ncbi.nlm.nih.gov/pubmed/26086967
4408,26710211,"SARC009: Phase 2 study of dasatinib in patients with previously treated, high-grade, advanced sarcoma.",http://www.ncbi.nlm.nih.gov/pubmed/26710211
4409,22380534,Direct induction of apoptosis using an optimal mitochondrially targeted p53.,http://www.ncbi.nlm.nih.gov/pubmed/22380534
4410,23630318,Small molecule induced reactivation of mutant p53 in cancer cells.,http://www.ncbi.nlm.nih.gov/pubmed/23630318
4411,8605035,"A novel chimera gene between EWS and E1A-F, encoding the adenovirus E1A enhancer-binding protein, in extraosseous Ewing's sarcoma.",http://www.ncbi.nlm.nih.gov/pubmed/8605035
4412,19318479,The NFATc2 gene is involved in a novel cloned translocation in a Ewing sarcoma variant that couples its function in immunology to oncology.,http://www.ncbi.nlm.nih.gov/pubmed/19318479
4413,10949935,A novel zinc finger gene is fused to EWS in small round cell tumor.,http://www.ncbi.nlm.nih.gov/pubmed/10949935
4414,21872822,Promiscuous partnerships in Ewing's sarcoma.,http://www.ncbi.nlm.nih.gov/pubmed/21872822
4415,,Novel Mps1 kinase inhibitors with potent anti-tumor activity,http://cancerres.aacrjournals.org/content/75/15_Supplement/3090.abstract?cited-by=yes&legid=canres;75/15_Supplement/3090
4416,23480895,A benign vascular tumor with a new fusion gene: EWSR1-NFATC1 in hemangioma of the bone.,http://www.ncbi.nlm.nih.gov/pubmed/23480895
4417,23933817,Characterization of novel MPS1 inhibitors with preclinical anticancer activity.,http://www.ncbi.nlm.nih.gov/pubmed/23933817
4418,9121764,A new member of the ETS family fused to EWS in Ewing tumors.,http://www.ncbi.nlm.nih.gov/pubmed/9121764
4419,17172842,Expression of EWS-ETS fusions in NIH3T3 cells reveals significant differences to Ewing's sarcoma.,http://www.ncbi.nlm.nih.gov/pubmed/17172842
4420,23940287,Effects of the selective MPS1 inhibitor MPS1-IN-3 on glioblastoma sensitivity to antimitotic drugs.,http://www.ncbi.nlm.nih.gov/pubmed/23940287
4421,19403560,The role of senescence and prosurvival signaling in controlling the oncogenic activity of FGFR2 mutants associated with cancer and birth defects.,http://www.ncbi.nlm.nih.gov/pubmed/19403560
4422,20505364,Transactivation by temperature-dependent p53 mutants in yeast and human cells.,http://www.ncbi.nlm.nih.gov/pubmed/20505364
4423,12917626,Characterization of the p53 mutants ability to inhibit p73 beta transactivation using a yeast-based functional assay.,http://www.ncbi.nlm.nih.gov/pubmed/12917626
4424,25584008,Prevalence and functional consequence of TP53 mutations in pediatric adrenocortical carcinoma: a children's oncology group study.,http://www.ncbi.nlm.nih.gov/pubmed/25584008
4425,26478211,Recent Advances and New Strategies in Targeting Plk1 for Anticancer Therapy.,http://www.ncbi.nlm.nih.gov/pubmed/26478211
4426,19004025,Overexpression of PLK1 is associated with poor survival by inhibiting apoptosis via enhancement of survivin level in esophageal squamous cell carcinoma.,http://www.ncbi.nlm.nih.gov/pubmed/19004025
4427,21993851,Clinical and therapeutic relevance of PIM1 kinase in gastric cancer.,http://www.ncbi.nlm.nih.gov/pubmed/21993851
4428,24124229,New connections between old pathways: PDK1 signaling promotes cellular transformation through PLK1-dependent MYC stabilization.,http://www.ncbi.nlm.nih.gov/pubmed/24124229
4429,10229196,Novel p53 mutants selected in BRCA-associated tumours which dissociate transformation suppression from other wild-type p53 functions.,http://www.ncbi.nlm.nih.gov/pubmed/10229196
4430,19602588,3-Phosphoinositide-dependent kinase 1 potentiates upstream lesions on the phosphatidylinositol 3-kinase pathway in breast carcinoma.,http://www.ncbi.nlm.nih.gov/pubmed/19602588
4431,25901683,TP53 loss creates therapeutic vulnerability in colorectal cancer.,http://www.ncbi.nlm.nih.gov/pubmed/25901683
4432,9150393,Two functional assays employed to detect an unusual mutation in the oligomerisation domain of p53 in a Li-Fraumeni like family.,http://www.ncbi.nlm.nih.gov/pubmed/9150393
4433,18593716,NOTCH1 mutations in individuals with left ventricular outflow tract malformations reduce ligand-induced signaling.,http://www.ncbi.nlm.nih.gov/pubmed/18593716
4434,9766574,Characterization of p53 mutants identified in human tumors with a missense mutation in the tetramerization domain.,http://www.ncbi.nlm.nih.gov/pubmed/9766574
4435,21980130,"Characterization of the cellular and antitumor effects of MPI-0479605, a small-molecule inhibitor of the mitotic kinase Mps1.",http://www.ncbi.nlm.nih.gov/pubmed/21980130
4436,11313981,"p53 mutants exhibiting enhanced transcriptional activation and altered promoter selectivity are revealed using a sensitive, yeast-based functional assay.",http://www.ncbi.nlm.nih.gov/pubmed/11313981
4437,12509279,A novel p53 mutant retained functional activity in lung carcinomas.,http://www.ncbi.nlm.nih.gov/pubmed/12509279
4438,26398286,Mitotic Checkpoint Kinase Mps1 Has a Role in Normal Physiology which Impacts Clinical Utility.,http://www.ncbi.nlm.nih.gov/pubmed/26398286
4439,26153498,Inhibition of the spindle assembly checkpoint kinase TTK enhances the efficacy of docetaxel in a triple-negative breast cancer model.,http://www.ncbi.nlm.nih.gov/pubmed/26153498
4440,10949925,Activation of the insulin-like growth factor II transcription by aflatoxin B1 induced p53 mutant 249 is caused by activation of transcription complexes; implications for a gain-of-function during the formation of hepatocellular carcinoma.,http://www.ncbi.nlm.nih.gov/pubmed/10949925
4441,11668476,Restoration of endogenous wild-type p53 activity in a glioblastoma cell line with intrinsic temperature-sensitive p53 induces growth arrest but not apoptosis.,http://www.ncbi.nlm.nih.gov/pubmed/11668476
4442,21113140,A novel t(4;22)(q31;q12) produces an EWSR1-SMARCA5 fusion in extraskeletal Ewing sarcoma/primitive neuroectodermal tumor.,http://www.ncbi.nlm.nih.gov/pubmed/21113140
4443,17690209,Undifferentiated small round cell sarcomas with rare EWS gene fusions: identification of a novel EWS-SP3 fusion and of additional cases with the EWS-ETV1 and EWS-FEV fusions.,http://www.ncbi.nlm.nih.gov/pubmed/17690209
4444,23630070,RNA sequencing identifies fusion of the EWSR1 and YY1 genes in mesothelioma with t(14;22)(q32;q12).,http://www.ncbi.nlm.nih.gov/pubmed/23630070
4445,12359745,"Recurrent rearrangement of the Ewing's sarcoma gene, EWSR1, or its homologue, TAF15, with the transcription factor CIZ/NMP4 in acute leukemia.",http://www.ncbi.nlm.nih.gov/pubmed/12359745
4446,19760602,t(19;22)(q13;q12) Translocation leading to the novel fusion gene EWSR1-ZNF444 in soft tissue myoepithelial carcinoma.,http://www.ncbi.nlm.nih.gov/pubmed/19760602
4447,25043312,Discovery of inhibitors of the mitotic kinase TTK based on N-(3-(3-sulfamoylphenyl)-1H-indazol-5-yl)-acetamides and carboxamides.,http://www.ncbi.nlm.nih.gov/pubmed/25043312
4448,25763473,The Discovery of Orally Bioavailable Tyrosine Threonine Kinase (TTK) Inhibitors: 3-(4-(heterocyclyl)phenyl)-1H-indazole-5-carboxamides as Anticancer Agents.,http://www.ncbi.nlm.nih.gov/pubmed/25763473
4449,26364596,Molecular basis underlying resistance to Mps1/TTK inhibitors.,http://www.ncbi.nlm.nih.gov/pubmed/26364596
4450,24633157,Recurrent PTPRB and PLCG1 mutations in angiosarcoma.,http://www.ncbi.nlm.nih.gov/pubmed/24633157
4451,26026053,Structure-Based Screen Identifies a Potent Small Molecule Inhibitor of Stat5a/b with Therapeutic Potential for Prostate Cancer and Chronic Myeloid Leukemia.,http://www.ncbi.nlm.nih.gov/pubmed/26026053
4452,23660011,STAT5A/B gene locus undergoes amplification during human prostate cancer progression.,http://www.ncbi.nlm.nih.gov/pubmed/23660011
4453,21745565,"The driver of malignancy in KG-1a leukemic cells, FGFR1OP2-FGFR1, encodes an HSP90 addicted oncoprotein.",http://www.ncbi.nlm.nih.gov/pubmed/21745565
4454,18172298,Characterization of TMPRSS2:ETV5 and SLC45A3:ETV5 gene fusions in prostate cancer.,http://www.ncbi.nlm.nih.gov/pubmed/18172298
4455,26677978,Identification and Characterization of Tyrosine Kinase Nonreceptor 2 Mutations in Leukemia through Integration of Kinase Inhibitor Screening and Genomic Analysis.,http://www.ncbi.nlm.nih.gov/pubmed/26677978
4456,21527531,Constitutive Notch pathway activation in murine ZMYM2-FGFR1-induced T-cell lymphomas associated with atypical myeloproliferative disease.,http://www.ncbi.nlm.nih.gov/pubmed/21527531
4457,15448205,PKC412 inhibits the zinc finger 198-fibroblast growth factor receptor 1 fusion tyrosine kinase and is active in treatment of stem cell myeloproliferative disorder.,http://www.ncbi.nlm.nih.gov/pubmed/15448205
4458,25873899,A method to control phosphoinositides and to analyze PTEN function in living cells using voltage sensitive phosphatases.,http://www.ncbi.nlm.nih.gov/pubmed/25873899
4459,11739186,The t(8;22) in chronic myeloid leukemia fuses BCR to FGFR1: transforming activity and specific inhibition of FGFR1 fusion proteins.,http://www.ncbi.nlm.nih.gov/pubmed/11739186
4460,10582703,PTEN suppresses breast cancer cell growth by phosphatase activity-dependent G1 arrest followed by cell death.,http://www.ncbi.nlm.nih.gov/pubmed/10582703
4461,9256433,"P-TEN, the tumor suppressor from human chromosome 10q23, is a dual-specificity phosphatase.",http://www.ncbi.nlm.nih.gov/pubmed/9256433
4462,22090360,TP53 disruptive mutations lead to head and neck cancer treatment failure through inhibition of radiation-induced senescence.,http://www.ncbi.nlm.nih.gov/pubmed/22090360
4463,25294809,Small molecule restoration of wildtype structure and function of mutant p53 using a novel zinc-metallochaperone based mechanism.,http://www.ncbi.nlm.nih.gov/pubmed/25294809
4464,19035295,Variations in sensitivity to ionizing radiation in relation to p53 mutation point.,http://www.ncbi.nlm.nih.gov/pubmed/19035295
4465,14587098,Elevated levels of prostate-specific antigen (PSA) in prostate cancer cells expressing mutant p53 is associated with tumor metastasis.,http://www.ncbi.nlm.nih.gov/pubmed/14587098
4466,19808868,Therapy-induced PML/RARA proteolysis and acute promyelocytic leukemia cure.,http://www.ncbi.nlm.nih.gov/pubmed/19808868
4467,20388784,Mammalian target of rapamycin activator RHEB is frequently overexpressed in human carcinomas and is critical and sufficient for skin epithelial carcinogenesis.,http://www.ncbi.nlm.nih.gov/pubmed/20388784
4468,26255626,Point mutations of the mTOR-RHEB pathway in renal cell carcinoma.,http://www.ncbi.nlm.nih.gov/pubmed/26255626
4469,24469055,Oncogenic RIT1 mutations in lung adenocarcinoma.,http://www.ncbi.nlm.nih.gov/pubmed/24469055
4470,25825523,Molecular Role of RNF43 in Canonical and Noncanonical Wnt Signaling.,http://www.ncbi.nlm.nih.gov/pubmed/25825523
4471,25349305,Combined CDKN1A/TP53 mutation in bladder cancer is a therapeutic target.,http://www.ncbi.nlm.nih.gov/pubmed/25349305
4472,26744526,EPHA2 Blockade Overcomes Acquired Resistance to EGFR Kinase Inhibitors in Lung Cancer.,http://www.ncbi.nlm.nih.gov/pubmed/26744526
4473,26324738,"Clinical and Translational Results of a Phase II, Randomized Trial of an Anti-IGF-1R (Cixutumumab) in Women with Breast Cancer That Progressed on Endocrine Therapy.",http://www.ncbi.nlm.nih.gov/pubmed/26324738
4474,22427690,Various p53 mutant proteins differently regulate the Ras circuit to induce a cancer-related gene signature.,http://www.ncbi.nlm.nih.gov/pubmed/22427690
4475,16409295,Genomic and expression profiling identifies the B-cell associated tyrosine kinase Syk as a possible therapeutic target in mantle cell lymphoma.,http://www.ncbi.nlm.nih.gov/pubmed/16409295
4476,24763051,A gain-of-function mutant p53-HSF1 feed forward circuit governs adaptation of cancer cells to proteotoxic stress.,http://www.ncbi.nlm.nih.gov/pubmed/24763051
4477,26546616,An Investigator-Initiated Open-Label Trial of Sonidegib in Advanced Basal Cell Carcinoma Patients Resistant to Vismodegib.,http://www.ncbi.nlm.nih.gov/pubmed/26546616
4478,26582900,"AZD9150, a next-generation antisense oligonucleotide inhibitor of STAT3 with early evidence of clinical activity in lymphoma and lung cancer.",http://www.ncbi.nlm.nih.gov/pubmed/26582900
4479,23887393,"PDK1 signaling toward PLK1-MYC activation confers oncogenic transformation, tumor-initiating cell activation, and resistance to mTOR-targeted therapy.",http://www.ncbi.nlm.nih.gov/pubmed/23887393
4480,,Single agent vanucizumab (RO5520985) for platinum (Pt)-resistant recurrent ovarian cancer (OC): Results from a single arm extension phase of the phase I FIH study.,http://meetinglibrary.asco.org/content/149637-156
4481,26692561,Tankyrase Inhibition Causes Reversible Intestinal Toxicity in Mice with a Therapeutic Index < 1.,http://www.ncbi.nlm.nih.gov/pubmed/26692561
4482,10867031,"Selenomethionine: a review of its nutritional significance, metabolism and toxicity.",http://www.ncbi.nlm.nih.gov/pubmed/10867031
4483,21242312,An association between NUAK2 and MRIP reveals a novel mechanism for regulation of actin stress fibers.,http://www.ncbi.nlm.nih.gov/pubmed/21242312
4484,26690705,The AMPK-related kinase SNARK regulates muscle mass and myocyte survival.,http://www.ncbi.nlm.nih.gov/pubmed/26690705
4485,18797457,Effects of dasatinib on EphA2 receptor tyrosine kinase activity and downstream signalling in pancreatic cancer.,http://www.ncbi.nlm.nih.gov/pubmed/18797457
4486,22591662,Pharmacological activation of the p53 pathway by nutlin-3 exerts anti-tumoral effects in medulloblastomas.,http://www.ncbi.nlm.nih.gov/pubmed/22591662
4487,25583207,DNA helicases FANCM and DDX11 are determinants of PARP inhibitor sensitivity.,http://www.ncbi.nlm.nih.gov/pubmed/25583207
4488,26812910,"The Dual Inhibition of Met and EGFR by ME22S, a Novel Met/EGFR Bispecific Monoclonal Antibody, Suppresses the Proliferation and Invasion of Laryngeal Cancer.",http://www.ncbi.nlm.nih.gov/pubmed/26812910
4489,23383239,"Protective effects of SKF-96365, a non-specific inhibitor of SOCE, against MPP+-induced cytotoxicity in PC12 cells: potential role of Homer1.",http://www.ncbi.nlm.nih.gov/pubmed/23383239
4490,20590636,The transient receptor potential channel antagonist SKF96365 is a potent blocker of low-voltage-activated T-type calcium channels.,http://www.ncbi.nlm.nih.gov/pubmed/20590636
4491,26744529,A Novel IL6 Antibody Sensitizes Multiple Tumor Types to Chemotherapy Including Trastuzumab-Resistant Tumors.,http://www.ncbi.nlm.nih.gov/pubmed/26744529
4492,26170629,Siltuximab (CNTO 328): a promising option for human malignancies.,http://www.ncbi.nlm.nih.gov/pubmed/26170629
4493,16111488,Phosphorylation states of cell cycle and DNA repair proteins can be altered by the nsSNPs.,http://www.ncbi.nlm.nih.gov/pubmed/16111488
4494,17974985,Resistance to an irreversible epidermal growth factor receptor (EGFR) inhibitor in EGFR-mutant lung cancer reveals novel treatment strategies.,http://www.ncbi.nlm.nih.gov/pubmed/17974985
4495,26339441,EGFR mutation L747P led to gefitinib resistance and accelerated liver metastases in a Chinese patient with lung adenocarcinoma.,http://www.ncbi.nlm.nih.gov/pubmed/26339441
4496,21531810,"Effectiveness of tyrosine kinase inhibitors on ""uncommon"" epidermal growth factor receptor mutations of unknown clinical significance in non-small cell lung cancer.",http://www.ncbi.nlm.nih.gov/pubmed/21531810
4497,25434923,"Phase 1 dose-escalation study of S-222611, an oral reversible dual tyrosine kinase inhibitor of EGFR and HER2, in patients with solid tumours.",http://www.ncbi.nlm.nih.gov/pubmed/25434923
4498,26762204,Identification of Patients with Recurrent Glioblastoma Who May Benefit from Combined Bevacizumab and CCNU Therapy: A Report from the BELOB Trial.,http://www.ncbi.nlm.nih.gov/pubmed/26762204
4499,26088127,Hydroxamic Acid and Benzoic Acid-Based STAT3 Inhibitors Suppress Human Glioma and Breast Cancer Phenotypes In Vitro and In Vivo.,http://www.ncbi.nlm.nih.gov/pubmed/26088127
4500,22889873,The promise of anti-ErbB3 monoclonals as new cancer therapeutics.,http://www.ncbi.nlm.nih.gov/pubmed/22889873
4501,22213458,Novel anti-ErbB3 monoclonal antibodies show therapeutic efficacy in xenografted and spontaneous mouse tumors.,http://www.ncbi.nlm.nih.gov/pubmed/22213458
4502,19332730,"Vandetanib versus gefitinib in patients with advanced non-small-cell lung cancer: results from a two-part, double-blind, randomized phase ii study.",http://www.ncbi.nlm.nih.gov/pubmed/19332730
4503,17121911,In vitro and in vivo activity of R547: a potent and selective cyclin-dependent kinase inhibitor currently in phase I clinical trials.,http://www.ncbi.nlm.nih.gov/pubmed/17121911
4504,25466181,Inhibition of C-terminal truncated PPM1D enhances the effect of doxorubicin on cell viability in human colorectal carcinoma cell line.,http://www.ncbi.nlm.nih.gov/pubmed/25466181
4505,26358280,Novel inhibitors targeting PPM1D phosphatase potently suppress cancer cell proliferation.,http://www.ncbi.nlm.nih.gov/pubmed/26358280
4506,25875300,A functional dissection of PTEN N-terminus: implications in PTEN subcellular targeting and tumor suppressor activity.,http://www.ncbi.nlm.nih.gov/pubmed/25875300
4507,20197484,"A phase I pharmacologic study of necitumumab (IMC-11F8), a fully human IgG1 monoclonal antibody directed against EGFR in patients with advanced solid malignancies.",http://www.ncbi.nlm.nih.gov/pubmed/20197484
4508,26766738,Phase II study of necitumumab plus modified FOLFOX6 as first-line treatment in patients with locally advanced or metastatic colorectal cancer.,http://www.ncbi.nlm.nih.gov/pubmed/26766738
4509,26759240,Activating Mutations in PIK3CB Confer Resistance to PI3K Inhibition and Define a Novel Oncogenic Role for p110β.,http://www.ncbi.nlm.nih.gov/pubmed/26759240
4510,18950453,Safety and efficacy of imatinib in chronic eosinophilic leukaemia and hypereosinophilic syndrome: a phase-II study.,http://www.ncbi.nlm.nih.gov/pubmed/18950453
4511,8291820,All-trans retinoic acid for acute promyelocytic leukemia. Results of the New York Study.,http://www.ncbi.nlm.nih.gov/pubmed/8291820
4512,1850498,Differentiation therapy of acute promyelocytic leukemia with tretinoin (all-trans-retinoic acid).,http://www.ncbi.nlm.nih.gov/pubmed/1850498
4513,23264850,The STAT5 Inhibitor Pimozide Displays Efficacy in Models of Acute Myelogenous Leukemia Driven by FLT3 Mutations.,http://www.ncbi.nlm.nih.gov/pubmed/23264850
4514,,Abstract 2702: Therapeutic potentials of STAT5 inhibitors in overcoming bortezomib resistance in human T-cell leukemia,http://cancerres.aacrjournals.org.ezproxy.jax.org/content/75/15_Supplement/2702.abstract
4515,24880341,Exome sequencing identifies somatic gain-of-function PPM1D mutations in brainstem gliomas.,http://www.ncbi.nlm.nih.gov/pubmed/24880341
4516,23649806,Gain-of-function mutations of PPM1D/Wip1 impair the p53-dependent G1 checkpoint.,http://www.ncbi.nlm.nih.gov/pubmed/23649806
4517,25388163,Molecular pathways: translational and therapeutic implications of the Notch signaling pathway in cancer.,http://www.ncbi.nlm.nih.gov/pubmed/25388163
4518,25250858,"Phase 2 study of RO4929097, a gamma-secretase inhibitor, in metastatic melanoma: SWOG 0933.",http://www.ncbi.nlm.nih.gov/pubmed/25250858
4519,26676746,Balancing Protein Stability and Activity in Cancer: A New Approach for Identifying Driver Mutations Affecting CBL Ubiquitin Ligase Activation.,http://www.ncbi.nlm.nih.gov/pubmed/26676746
4520,20354191,Pharmacologic inhibition of cyclin-dependent kinases 4 and 6 arrests the growth of glioblastoma multiforme intracranial xenografts.,http://www.ncbi.nlm.nih.gov/pubmed/20354191
4521,22474318,Ruxolitinib: the first FDA approved therapy for the treatment of myelofibrosis.,http://www.ncbi.nlm.nih.gov/pubmed/22474318
4522,24240700,Genome-wide profiling of genetic synthetic lethality identifies CDK12 as a novel determinant of PARP1/2 inhibitor sensitivity.,http://www.ncbi.nlm.nih.gov/pubmed/24240700
4523,26053182,Targeting the Hedgehog signaling pathway in cancer: beyond Smoothened.,http://www.ncbi.nlm.nih.gov/pubmed/26053182
4524,26759175,Inhibition of KDM6 activity during murine ESC differentiation induces DNA damage.,http://www.ncbi.nlm.nih.gov/pubmed/26759175
4525,22591685,Casitas B-cell lymphoma mutation in childhood T-cell acute lymphoblastic leukemia.,http://www.ncbi.nlm.nih.gov/pubmed/22591685
4526,11777909,c-Cbl binding and ubiquitin-dependent lysosomal degradation of membrane-associated Notch1.,http://www.ncbi.nlm.nih.gov/pubmed/11777909
4527,24423321,"CLM3, a multitarget tyrosine kinase inhibitor with antiangiogenic properties, is active against primary anaplastic thyroid cancer in vitro and in vivo.",http://www.ncbi.nlm.nih.gov/pubmed/24423321
4528,24754906,"All-atomic molecular dynamic studies of human CDK8: insight into the A-loop, point mutations and binding with its partner CycC.",http://www.ncbi.nlm.nih.gov/pubmed/24754906
4529,23454913,Tumor-suppressive effects of CDK8 in endometrial cancer cells.,http://www.ncbi.nlm.nih.gov/pubmed/23454913
4530,26198850,Cell death induction by the BH3 mimetic GX15-070 in thyroid carcinoma cells.,http://www.ncbi.nlm.nih.gov/pubmed/26198850
4531,26644315,Tumor Heterogeneity and Lesion-Specific Response to Targeted Therapy in Colorectal Cancer.,http://www.ncbi.nlm.nih.gov/pubmed/26644315
4532,19841262,Recurrent fusion of MYB and NFIB transcription factor genes in carcinomas of the breast and head and neck.,http://www.ncbi.nlm.nih.gov/pubmed/19841262
4533,26631609,Novel MYBL1 Gene Rearrangements with Recurrent MYBL1-NFIB Fusions in Salivary Adenoid Cystic Carcinomas Lacking t(6;9) Translocations.,http://www.ncbi.nlm.nih.gov/pubmed/26631609
4534,26631070,"Recurrent Fusions in MYB and MYBL1 Define a Common, Transcription Factor-Driven Oncogenic Pathway in Salivary Gland Adenoid Cystic Carcinoma.",http://www.ncbi.nlm.nih.gov/pubmed/26631070
4535,25517749,ALK mutations confer differential oncogenic activation and sensitivity to ALK inhibition therapy in neuroblastoma.,http://www.ncbi.nlm.nih.gov/pubmed/25517749
4536,18472962,Different mutant/wild-type p53 combinations cause a spectrum of increased invasive potential in nonmalignant immortalized human mammary epithelial cells.,http://www.ncbi.nlm.nih.gov/pubmed/18472962
4537,22510516,Amplification and high-level expression of heat shock protein 90 marks aggressive phenotypes of human epidermal growth factor receptor 2 negative breast cancer.,http://www.ncbi.nlm.nih.gov/pubmed/22510516
4538,25982393,Targeting of multiple oncogenic signaling pathways by Hsp90 inhibitor alone or in combination with berberine for treatment of colorectal cancer.,http://www.ncbi.nlm.nih.gov/pubmed/25982393
4539,21459081,"Antiproliferative and proapoptotic activity of CLM3, a novel multiple tyrosine kinase inhibitor, alone and in combination with SN-38 on endothelial and cancer cells.",http://www.ncbi.nlm.nih.gov/pubmed/21459081
4540,23275335,Selective inhibition of phosphoinositide 3-kinase p110α preserves lymphocyte function.,http://www.ncbi.nlm.nih.gov/pubmed/23275335
4541,15199141,Functional interaction of monoubiquitinated FANCD2 and BRCA2/FANCD1 in chromatin.,http://www.ncbi.nlm.nih.gov/pubmed/15199141
4542,15454491,"Regulated interaction of the Fanconi anemia protein, FANCD2, with chromatin.",http://www.ncbi.nlm.nih.gov/pubmed/15454491
4543,12086603,Convergence of the fanconi anemia and ataxia telangiectasia signaling pathways.,http://www.ncbi.nlm.nih.gov/pubmed/12086603
4544,9988270,Activating SRC mutation in a subset of advanced human colon cancers.,http://www.ncbi.nlm.nih.gov/pubmed/9988270
4545,26744521,Effective Targeting of the Survivin Dimerization Interface with Small-Molecule Inhibitors.,http://www.ncbi.nlm.nih.gov/pubmed/26744521
4546,26324372,"Adjuvant Erlotinib Versus Placebo in Patients With Stage IB-IIIA Non-Small-Cell Lung Cancer (RADIANT): A Randomized, Double-Blind, Phase III Trial.",http://www.ncbi.nlm.nih.gov/pubmed/26324372
4547,10676634,No evidence of Peutz-Jeghers syndrome gene LKB1 involvement in left-sided colorectal carcinomas.,http://www.ncbi.nlm.nih.gov/pubmed/10676634
4548,25306215,Therapeutic effects of an anti-Myc drug on mouse pancreatic cancer.,http://www.ncbi.nlm.nih.gov/pubmed/25306215
4549,25332683,Small molecules targeting c-Myc oncogene: promising anti-cancer therapeutics.,http://www.ncbi.nlm.nih.gov/pubmed/25332683
4550,25584002,Safety and survival with GVAX pancreas prime and Listeria Monocytogenes-expressing mesothelin (CRS-207) boost vaccines for metastatic pancreatic cancer.,http://www.ncbi.nlm.nih.gov/pubmed/25584002
4551,25502863,"Phase I study of amatuximab, a novel monoclonal antibody to mesothelin, in Japanese patients with advanced solid tumors.",http://www.ncbi.nlm.nih.gov/pubmed/25502863
4552,25231400,"Phase II clinical trial of amatuximab, a chimeric antimesothelin antibody with pemetrexed and cisplatin in advanced unresectable pleural mesothelioma.",http://www.ncbi.nlm.nih.gov/pubmed/25231400
4553,25376608,The protein phosphatase 2A inhibitor LB100 sensitizes ovarian carcinoma cells to cisplatin-mediated cytotoxicity.,http://www.ncbi.nlm.nih.gov/pubmed/25376608
4554,26602448,"Tumor-selective use of DNA base excision repair inhibition in pancreatic cancer using the NQO1 bioactivatable drug, β-lapachone.",http://www.ncbi.nlm.nih.gov/pubmed/26602448
4555,26462257,Targeting glutamine metabolism sensitizes pancreatic cancer to PARP-driven metabolic catastrophe induced by ß-lapachone.,http://www.ncbi.nlm.nih.gov/pubmed/26462257
4556,26645196,Loss of PTEN Promotes Resistance to T Cell-Mediated Immunotherapy.,http://www.ncbi.nlm.nih.gov/pubmed/26645196
4557,26268924,"Phase 1 study of APTO-253 HCl, an inducer of KLF4, in patients with advanced or metastatic solid tumors.",http://www.ncbi.nlm.nih.gov/pubmed/26268924
4558,21037025,Phase I clinical trial of the chimeric anti-mesothelin monoclonal antibody MORAb-009 in patients with mesothelin-expressing cancers.,http://www.ncbi.nlm.nih.gov/pubmed/21037025
4559,23136186,"A recombinant immunotoxin against the tumor-associated antigen mesothelin reengineered for high activity, low off-target toxicity, and reduced antigenicity.",http://www.ncbi.nlm.nih.gov/pubmed/23136186
4560,24989332,"Phase 1 study of the antimesothelin immunotoxin SS1P in combination with pemetrexed and cisplatin for front-line therapy of pleural mesothelioma and correlation of tumor response with serum mesothelin, megakaryocyte potentiating factor, and cancer antigen 125.",http://www.ncbi.nlm.nih.gov/pubmed/24989332
4561,17785569,"Phase I study of SS1P, a recombinant anti-mesothelin immunotoxin given as a bolus I.V. infusion to patients with mesothelin-expressing mesothelioma, ovarian, and pancreatic cancers.",http://www.ncbi.nlm.nih.gov/pubmed/17785569
4562,26849637,"Antitumor activity of alectinib, a selective ALK inhibitor, in an ALK-positive NSCLC cell line harboring G1269A mutation: Efficacy of alectinib against ALK G1269A mutated cells.",http://www.ncbi.nlm.nih.gov/pubmed/26849637
4563,24845231,Targeting the disordered C terminus of PTP1B with an allosteric inhibitor.,http://www.ncbi.nlm.nih.gov/pubmed/24845231
4564,21831956,"A phase 1 dose escalation, pharmacokinetic, and pharmacodynamic evaluation of eIF-4E antisense oligonucleotide LY2275796 in patients with advanced cancer.",http://www.ncbi.nlm.nih.gov/pubmed/21831956
4565,17786246,Therapeutic suppression of translation initiation factor eIF4E expression reduces tumor growth without toxicity.,http://www.ncbi.nlm.nih.gov/pubmed/17786246
4566,26732741,A Cell Biologist's Field Guide to Aurora Kinase Inhibitors.,http://www.ncbi.nlm.nih.gov/pubmed/26732741
4567,24152827,The dual Aurora kinase inhibitor ZM447439 prevents anaplastic thyroid cancer cell growth and tumorigenicity.,http://www.ncbi.nlm.nih.gov/pubmed/24152827
4568,26751478,Preclinical Activity of the Vascular Disrupting Agent OXi4503 against Head and Neck Cancer.,http://www.ncbi.nlm.nih.gov/pubmed/26751478
4569,20974154,Support of a free radical mechanism for enhanced antitumor efficacy of the microtubule disruptor OXi4503.,http://www.ncbi.nlm.nih.gov/pubmed/20974154
4570,22842901,A selective jumonji H3K27 demethylase inhibitor modulates the proinflammatory macrophage response.,http://www.ncbi.nlm.nih.gov/pubmed/22842901
4571,26228206,The MEK1/2 Inhibitor Pimasertib Enhances Gemcitabine Efficacy in Pancreatic Cancer Models by Altering Ribonucleotide Reductase Subunit-1 (RRM1).,http://www.ncbi.nlm.nih.gov/pubmed/26228206
4572,25646015,Targeted Blockade of JAK/STAT3 Signaling Inhibits Ovarian Carcinoma Growth.,http://www.ncbi.nlm.nih.gov/pubmed/25646015
4573,26803057,SKF-96365 activates cytoprotective autophagy to delay apoptosis in colorectal cancer cells through inhibition of the calcium/CaMKIIγ/AKT-mediated pathway.,http://www.ncbi.nlm.nih.gov/pubmed/26803057
4574,18676821,The Arf/p53 pathway in cancer and aging.,http://www.ncbi.nlm.nih.gov/pubmed/18676821
4575,17055429,The regulation of INK4/ARF in cancer and aging.,http://www.ncbi.nlm.nih.gov/pubmed/17055429
4576,25587024,A unifying gene signature for adenoid cystic cancer identifies parallel MYB-dependent and MYB-independent therapeutic targets.,http://www.ncbi.nlm.nih.gov/pubmed/25587024
4577,26719531,Therapeutic Targeting of Tumor-Derived R-Spondin Attenuates β-Catenin Signaling and Tumorigenesis in Multiple Cancer Types.,http://www.ncbi.nlm.nih.gov/pubmed/26719531
4578,26183925,Preclinical Characterization of Novel Chordoma Cell Systems and Their Targeting by Pharmocological Inhibitors of the CDK4/6 Cell-Cycle Pathway.,http://www.ncbi.nlm.nih.gov/pubmed/26183925
4579,10632371,The p16 status of tumor cell lines identifies small molecule inhibitors specific for cyclin-dependent kinase 4.,http://www.ncbi.nlm.nih.gov/pubmed/10632371
4580,25870145,Acquired Resistance to the Mutant-Selective EGFR Inhibitor AZD9291 Is Associated with Increased Dependence on RAS Signaling in Preclinical Models.,http://www.ncbi.nlm.nih.gov/pubmed/25870145
4581,16618762,Antitumor activity of a small-molecule inhibitor of human silent information regulator 2 enzymes.,http://www.ncbi.nlm.nih.gov/pubmed/16618762
4582,25665005,The Hippo effector YAP promotes resistance to RAF- and MEK-targeted cancer therapies.,http://www.ncbi.nlm.nih.gov/pubmed/25665005
4583,18212739,"FANCG promotes formation of a newly identified protein complex containing BRCA2, FANCD2 and XRCC3.",http://www.ncbi.nlm.nih.gov/pubmed/18212739
4584,22586091,Gene regulation via excitation and BDNF is mediated by induction and phosphorylation of the Etv1 transcription factor in cerebellar granule cells.,http://www.ncbi.nlm.nih.gov/pubmed/22586091
4585,11593430,HER2/Neu-mediated activation of the ETS transcription factor ER81 and its target gene MMP-1.,http://www.ncbi.nlm.nih.gov/pubmed/11593430
4586,12036890,"The Tel-Abl (ETV6-Abl) tyrosine kinase, product of complex (9;12) translocations in human leukemia, induces distinct myeloproliferative disease in mice.",http://www.ncbi.nlm.nih.gov/pubmed/12036890
4587,15299017,"Phosphorylation of fanconi anemia (FA) complementation group G protein, FANCG, at serine 7 is important for function of the FA pathway.",http://www.ncbi.nlm.nih.gov/pubmed/15299017
4588,15005341,The TEL/ARG leukemia oncogene promotes viability and hyperresponsiveness to hematopoietic growth factors.,http://www.ncbi.nlm.nih.gov/pubmed/15005341
4589,22271894,ETV6-PDGFRB and FIP1L1-PDGFRA stimulate human hematopoietic progenitor cell proliferation and differentiation into eosinophils: the role of nuclear factor-κB.,http://www.ncbi.nlm.nih.gov/pubmed/22271894
4590,16572202,t(5;12)(q23-31;p13) with ETV6-ACSL6 gene fusion in polycythemia vera.,http://www.ncbi.nlm.nih.gov/pubmed/16572202
4591,21987447,A novel EWSR1-CREB3L1 fusion transcript in a case of small cell osteosarcoma.,http://www.ncbi.nlm.nih.gov/pubmed/21987447
4592,23116066,"The DEAD/DEAH box helicase, DDX11, is essential for the survival of advanced melanomas.",http://www.ncbi.nlm.nih.gov/pubmed/23116066
4593,24487782,Molecular functions and cellular roles of the ChlR1 (DDX11) helicase defective in the rare cohesinopathy Warsaw breakage syndrome.,http://www.ncbi.nlm.nih.gov/pubmed/24487782
4594,26681738,ESR1 Mutations Prevalent in Some Breast Cancers.,http://www.ncbi.nlm.nih.gov/pubmed/26681738
4595,21937691,PIM2 inhibition as a rational therapeutic approach in B-cell lymphoma.,http://www.ncbi.nlm.nih.gov/pubmed/21937691
4596,21628411,"Mechanisms of cytotoxicity to Pim kinase inhibitor, SGI-1776, in acute myeloid leukemia.",http://www.ncbi.nlm.nih.gov/pubmed/21628411
4597,22895193,Recurrent R-spondin fusions in colon cancer.,http://www.ncbi.nlm.nih.gov/pubmed/22895193
4598,26257057,Wnt addiction of genetically defined cancers reversed by PORCN inhibition.,http://www.ncbi.nlm.nih.gov/pubmed/26257057
4599,23033317,Identification and biochemical characterization of a novel mutation in DDX11 causing Warsaw breakage syndrome.,http://www.ncbi.nlm.nih.gov/pubmed/23033317
4600,15897554,Approval summary: azacitidine for treatment of myelodysplastic syndrome subtypes.,http://www.ncbi.nlm.nih.gov/pubmed/15897554
4601,10064595,Autophosphorylation of p110delta phosphoinositide 3-kinase: a new paradigm for the regulation of lipid kinases in vitro and in vivo.,http://www.ncbi.nlm.nih.gov/pubmed/10064595
4602,11607838,Crk family adaptors-signalling complex formation and biological roles.,http://www.ncbi.nlm.nih.gov/pubmed/11607838
4603,15829966,Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase.,http://www.ncbi.nlm.nih.gov/pubmed/15829966
4604,24439051,Poly(ADP-ribose) polymerase inhibitor CEP-8983 synergizes with bendamustine in chronic lymphocytic leukemia cells in vitro.,http://www.ncbi.nlm.nih.gov/pubmed/24439051
4605,23428903,Synergistic interaction between cisplatin and PARP inhibitors in non-small cell lung cancer.,http://www.ncbi.nlm.nih.gov/pubmed/23428903
4606,19422384,Selective PARP-2 inhibitors increase apoptosis in hippocampal slices but protect cortical cells in models of post-ischaemic brain damage.,http://www.ncbi.nlm.nih.gov/pubmed/19422384
4607,19808866,"Oral poly(ADP-ribose) polymerase-1 inhibitor BSI-401 has antitumor activity and synergizes with oxaliplatin against pancreatic cancer, preventing acute neurotoxicity.",http://www.ncbi.nlm.nih.gov/pubmed/19808866
4608,12371144,Focal adhesion kinase: protein interactions and cellular functions.,http://www.ncbi.nlm.nih.gov/pubmed/12371144
4609,20137776,"Warsaw breakage syndrome, a cohesinopathy associated with mutations in the XPD helicase family member DDX11/ChlR1.",http://www.ncbi.nlm.nih.gov/pubmed/20137776
4610,22102414,Biochemical characterization of Warsaw breakage syndrome helicase.,http://www.ncbi.nlm.nih.gov/pubmed/22102414
4611,24100870,Molecular and clinical characteristics of MSH6 germline variants detected in colorectal cancer patients.,http://www.ncbi.nlm.nih.gov/pubmed/24100870
4612,16116422,A human ortholog of archaeal DNA repair protein Hef is defective in Fanconi anemia complementation group M.,http://www.ncbi.nlm.nih.gov/pubmed/16116422
4613,14974087,Eight novel MSH6 germline mutations in patients with familial and nonfamilial colorectal cancer selected by loss of protein expression in tumor tissue.,http://www.ncbi.nlm.nih.gov/pubmed/14974087
4614,22510687,The structure of the FANCM-MHF complex reveals physical features for functional assembly.,http://www.ncbi.nlm.nih.gov/pubmed/22510687
4615,26311731,A DLL3-targeted antibody-drug conjugate eradicates high-grade pulmonary neuroendocrine tumor-initiating cells in vivo.,http://www.ncbi.nlm.nih.gov/pubmed/26311731
4616,26550540,"Tumor-specific targeting by Bavituximab, a phosphatidylserine-targeting monoclonal antibody with vascular targeting and immune modulating properties, in lung cancer xenografts.",http://www.ncbi.nlm.nih.gov/pubmed/26550540
4617,26463709,"First-in-Human Phase I Study of Lumretuzumab, a Glycoengineered Humanized Anti-HER3 Monoclonal Antibody, in Patients with Metastatic or Advanced HER3-Positive Solid Tumors.",http://www.ncbi.nlm.nih.gov/pubmed/26463709
4618,26865565,Aurora kinase inhibitor nanoparticles target tumors with favorable therapeutic index in vivo.,http://www.ncbi.nlm.nih.gov/pubmed/26865565
4619,26715098,Targeting the PI3K signaling pathway in KRAS mutant colon cancer.,http://www.ncbi.nlm.nih.gov/pubmed/26715098
4620,26681740,PI3K Inhibitor Improves PFS in BELLE-2 Trial.,http://www.ncbi.nlm.nih.gov/pubmed/26681740
4621,26472029,The PIM inhibitor AZD1208 synergizes with ruxolitinib to induce apoptosis of ruxolitinib sensitive and resistant JAK2-V617F-driven cells and inhibit colony formation of primary MPN cells.,http://www.ncbi.nlm.nih.gov/pubmed/26472029
4622,26744524,Characterization of a c-Rel Inhibitor That Mediates Anticancer Properties in Hematologic Malignancies by Blocking NF-κB-Controlled Oxidative Stress Responses.,http://www.ncbi.nlm.nih.gov/pubmed/26744524
4623,26490311,Analysis of mTOR Gene Aberrations in Melanoma Patients and Evaluation of Their Sensitivity to PI3K-AKT-mTOR Pathway Inhibitors.,http://www.ncbi.nlm.nih.gov/pubmed/26490311
4624,26850678,"Preclinical and first-in-human phase I studies of KW-2450, an oral tyrosine kinase inhibitor with insulin-like growth factor receptor-1/insulin receptor selectivity.",http://www.ncbi.nlm.nih.gov/pubmed/26850678
4625,18559266,Molecular basis of drug resistance in aurora kinases.,http://www.ncbi.nlm.nih.gov/pubmed/18559266
4626,10446987,The dermatofibrosarcoma protuberans-associated collagen type Ialpha1/platelet-derived growth factor (PDGF) B-chain fusion gene generates a transforming protein that is processed to functional PDGF-BB.,http://www.ncbi.nlm.nih.gov/pubmed/10446987
4627,26645561,Deguelin Analogue SH-1242 Inhibits Hsp90 Activity and Exerts Potent Anticancer Efficacy with Limited Neurotoxicity.,http://www.ncbi.nlm.nih.gov/pubmed/26645561
4628,26739882,Selective Inhibition of Oncogenic KRAS Output with Small Molecules Targeting the Inactive State.,http://www.ncbi.nlm.nih.gov/pubmed/26739882
4629,25001079,Comparative nonclinical assessments of the proposed biosimilar PF-05280014 and trastuzumab (Herceptin(®)).,http://www.ncbi.nlm.nih.gov/pubmed/25001079
4630,25041377,A randomized phase 1 pharmacokinetic trial comparing the potential biosimilar PF-05280014 with trastuzumab in healthy volunteers (REFLECTIONS B327-01).,http://www.ncbi.nlm.nih.gov/pubmed/25041377
4631,22616006,Tetrahydrouridine inhibits cell proliferation through cell cycle regulation regardless of cytidine deaminase expression levels.,http://www.ncbi.nlm.nih.gov/pubmed/22616006
4632,21701703,Analysis of Somatic Mutations in Cancer: Molecular Mechanisms of Activation in the ErbB Family of Receptor Tyrosine Kinases.,http://www.ncbi.nlm.nih.gov/pubmed/21701703
4633,22147791,"GLA-SE, a synthetic toll-like receptor 4 agonist, enhances T-cell responses to influenza vaccine in older adults.",http://www.ncbi.nlm.nih.gov/pubmed/22147791
4634,14743203,Identification and validation of an ERBB2 gene expression signature in breast cancers.,http://www.ncbi.nlm.nih.gov/pubmed/14743203
4635,26261104,Efficacy and Biological Activity of Imatinib in Metastatic Dermatofibrosarcoma Protuberans (DFSP).,http://www.ncbi.nlm.nih.gov/pubmed/26261104
4636,23955071,RAF inhibition overcomes resistance to TRAIL-induced apoptosis in melanoma cells.,http://www.ncbi.nlm.nih.gov/pubmed/23955071
4637,12970777,Differential effects of kinase cascade inhibitors on neoplastic and cytokine-mediated cell proliferation.,http://www.ncbi.nlm.nih.gov/pubmed/12970777
4638,,Irreversible Covalent Pan-FGFR Inhibitors are Highly Efficacious Against FGFR-dependent Cancers,http://www.ejcancer.com/article/S0959-8049%2814%2970609-4/pdf
4639,,"Preclinical antitumor activity of ASP5878, a novel inhibitor of FGFR1, 2, 3 and 4, in bladder cancer harboring FGFR3-fusion or -mutation",http://mct.aacrjournals.org/content/14/12_Supplement_2/A170.short
4640,25999455,CD19-targeted chimeric antigen receptor T-cell therapy for acute lymphoblastic leukemia.,http://www.ncbi.nlm.nih.gov/pubmed/25999455
4641,26503962,Mesothelin-Targeted CARs: Driving T Cells to Solid Tumors.,http://www.ncbi.nlm.nih.gov/pubmed/26503962
4642,23788110,Combining CAR T cells and the Bcl-2 family apoptosis inhibitor ABT-737 for treating B-cell malignancy.,http://www.ncbi.nlm.nih.gov/pubmed/23788110
4643,26286086,EGFR Kinase Domain Duplication (EGFR-KDD) Is a Novel Oncogenic Driver in Lung Cancer That Is Clinically Responsive to Afatinib.,http://www.ncbi.nlm.nih.gov/pubmed/26286086
4644,24798740,"Concomitant RAS, RET/PTC, or BRAF mutations in advanced stage of papillary thyroid carcinoma.",http://www.ncbi.nlm.nih.gov/pubmed/24798740
4645,24360952,Somatic mutational analysis of FAK in breast cancer: a novel gain-of-function mutation due to deletion of exon 33.,http://www.ncbi.nlm.nih.gov/pubmed/24360952
4646,9044825,Fusion of ETV6 to MDS1/EVI1 as a result of t(3;12)(q26;p13) in myeloproliferative disorders.,http://www.ncbi.nlm.nih.gov/pubmed/9044825
4647,15514005,Transforming property of TEL-FGFR3 mediated through PI3-K in a T-cell lymphoma that subsequently progressed to AML.,http://www.ncbi.nlm.nih.gov/pubmed/15514005
4648,16757412,Fusion of ETV6 to GOT1 in a case with myelodysplastic syndrome and t(10;12)(q24;p13).,http://www.ncbi.nlm.nih.gov/pubmed/16757412
4649,17555450,Two novel imatinib-responsive PDGFRA fusion genes in chronic eosinophilic leukaemia.,http://www.ncbi.nlm.nih.gov/pubmed/17555450
4650,20804916,ETV6-ARNT fusion in a patient with childhood T lymphoblastic leukemia.,http://www.ncbi.nlm.nih.gov/pubmed/20804916
4651,26829751,MYB-QKI rearrangements in angiocentric glioma drive tumorigenicity through a tripartite mechanism.,http://www.ncbi.nlm.nih.gov/pubmed/26829751
4652,16651630,The myxoid/round cell liposarcoma fusion oncogene FUS-DDIT3 and the normal DDIT3 induce a liposarcoma phenotype in transfected human fibrosarcoma cells.,http://www.ncbi.nlm.nih.gov/pubmed/16651630
4653,18850010,The myxoid liposarcoma FUS-DDIT3 fusion oncoprotein deregulates NF-kappaB target genes by interaction with NFKBIZ.,http://www.ncbi.nlm.nih.gov/pubmed/18850010
4654,17395594,Cellular characterization of a novel focal adhesion kinase inhibitor.,http://www.ncbi.nlm.nih.gov/pubmed/17395594
4655,,"Abstract 683: DEBIO0932, an Hsp90 inhibitor downregulates key signaling pathways and sensitizes glioma cells to temozolomide",http://cancerres.aacrjournals.org/content/75/15_Supplement/683.short
4656,26334219,"A phase I study of VS-6063, a second-generation focal adhesion kinase inhibitor, in patients with advanced solid tumors.",http://www.ncbi.nlm.nih.gov/pubmed/26334219
4657,26743233,"CPUY201112, a novel synthetic small-molecule compound and inhibitor of heat shock protein Hsp90, induces p53-mediated apoptosis in MCF-7 cells.",http://www.ncbi.nlm.nih.gov/pubmed/26743233
4658,25684663,"Restoration of TRAIL-induced apoptosis in resistant human pancreatic cancer cells by a novel FAK inhibitor, PH11.",http://www.ncbi.nlm.nih.gov/pubmed/25684663
4659,20738310,"The novel Hsp-90 inhibitor SNX7081 is significantly more potent than 17-AAG against primary CLL cells and a range of haematological cell lines, irrespective of lesions in the TP53 pathway.",http://www.ncbi.nlm.nih.gov/pubmed/20738310
4660,19829694,Point mutations in GLI3 lead to misregulation of its subcellular localization.,http://www.ncbi.nlm.nih.gov/pubmed/19829694
4661,8357792,Three-dimensional structures and properties of a transforming and a nontransforming glycine-12 mutant of p21H-ras.,http://www.ncbi.nlm.nih.gov/pubmed/8357792
4662,23222540,TET2 promotes histone O-GlcNAcylation during gene transcription.,http://www.ncbi.nlm.nih.gov/pubmed/23222540
4663,26475333,"The Colony-Stimulating Factor 3 Receptor T640N Mutation Is Oncogenic, Sensitive to JAK Inhibition, and Mimics T618I.",http://www.ncbi.nlm.nih.gov/pubmed/26475333
4664,25883212,"LLL12, a novel small inhibitor targeting STAT3 for hepatocellular carcinoma therapy.",http://www.ncbi.nlm.nih.gov/pubmed/25883212
4665,,NCCN Guidelines Version 2.2016 CLL/SLL,
4666,24900510,Diaminopyridine-based potent and selective mps1 kinase inhibitors binding to an unusual flipped-Peptide conformation.,http://www.ncbi.nlm.nih.gov/pubmed/24900510
4667,24657306,Inhibition of both focal adhesion kinase and fibroblast growth factor receptor 2 pathways induces anti-tumor and anti-angiogenic activities.,http://www.ncbi.nlm.nih.gov/pubmed/24657306
4668,26882569,A synthetic-lethality RNAi screen reveals an ERK-mTOR co-targeting pro-apoptotic switch in PIK3CA+ oral cancers.,http://www.ncbi.nlm.nih.gov/pubmed/26882569
4669,25833835,PTEN Expression as a Predictor of Response to Focal Adhesion Kinase Inhibition in Uterine Cancer.,http://www.ncbi.nlm.nih.gov/pubmed/25833835
4670,25847941,EMERGE: A Randomized Phase II Study of the Antibody-Drug Conjugate Glembatumumab Vedotin in Advanced Glycoprotein NMB-Expressing Breast Cancer.,http://www.ncbi.nlm.nih.gov/pubmed/25847941
4671,24194567,Phosphoproteomic profiling identifies focal adhesion kinase as a mediator of docetaxel resistance in castrate-resistant prostate cancer.,http://www.ncbi.nlm.nih.gov/pubmed/24194567
4672,,"BI 853520, a potent and highly selective inhibitor of protein tyrosine kinase 2 (focal adhesion kinase), shows efficacy in multiple xenograft models of human cancer.",http://mct.aacrjournals.org/content/10/11_Supplement/A249.short
4673,,"A phase I study of BI 853520, an inhibitor of focal adhesion kinase (FAK), in patients with advanced or metastatic solid tumors",http://meetinglibrary.asco.org/content/146958-156
4674,25519148,Preclinical Efficacy for AKT Targeting in Clear Cell Carcinoma of the Ovary.,http://www.ncbi.nlm.nih.gov/pubmed/25519148
4675,26891329,Targeting the Sonic Hedgehog Signaling Pathway: Review of Smoothened and GLI Inhibitors.,http://www.ncbi.nlm.nih.gov/pubmed/26891329
4676,12886236,Opportunities for Trisenox (arsenic trioxide) in the treatment of myelodysplastic syndromes.,http://www.ncbi.nlm.nih.gov/pubmed/12886236
4677,22454420,"Safety, pharmacokinetic, and pharmacodynamic phase I dose-escalation trial of PF-00562271, an inhibitor of focal adhesion kinase, in advanced solid tumors.",http://www.ncbi.nlm.nih.gov/pubmed/22454420
4678,18996393,Structural basis of restoring sequence-specific DNA binding and transactivation to mutant p53 by suppressor mutations.,http://www.ncbi.nlm.nih.gov/pubmed/18996393
4679,25096516,Preclinical antitumor activity of SST0116CL1: a novel heat shock protein 90 inhibitor.,http://www.ncbi.nlm.nih.gov/pubmed/25096516
4680,26695442,"Phase I study of KW-2478, a novel Hsp90 inhibitor, in patients with B-cell malignancies.",http://www.ncbi.nlm.nih.gov/pubmed/26695442
4681,26438783,Crizotinib Synergizes with Chemotherapy in Preclinical Models of Neuroblastoma.,http://www.ncbi.nlm.nih.gov/pubmed/26438783
4682,26071189,Regulation and function of the human HSP90AA1 gene.,http://www.ncbi.nlm.nih.gov/pubmed/26071189
4683,23770287,Rit subfamily small GTPases: regulators in neuronal differentiation and survival.,http://www.ncbi.nlm.nih.gov/pubmed/23770287
4684,23791108,"Gain-of-function mutations in RIT1 cause Noonan syndrome, a RAS/MAPK pathway syndrome.",http://www.ncbi.nlm.nih.gov/pubmed/23791108
4685,23755147,Effect of single amino acid substitution observed in cancer on Pim-1 kinase thermodynamic stability and structure.,http://www.ncbi.nlm.nih.gov/pubmed/23755147
4686,10364160,A PDK1 homolog is necessary and sufficient to transduce AGE-1 PI3 kinase signals that regulate diapause in Caenorhabditis elegans.,http://www.ncbi.nlm.nih.gov/pubmed/10364160
4687,20978239,Regulation of 3-phosphoinositide-dependent protein kinase 1 activity by homodimerization in live cells.,http://www.ncbi.nlm.nih.gov/pubmed/20978239
4688,11481331,Identification of tyrosine phosphorylation sites on 3-phosphoinositide-dependent protein kinase-1 and their role in regulating kinase activity.,http://www.ncbi.nlm.nih.gov/pubmed/11481331
4689,24843152,Structure of the pseudokinase-kinase domains from protein kinase TYK2 reveals a mechanism for Janus kinase (JAK) autoinhibition.,http://www.ncbi.nlm.nih.gov/pubmed/24843152
4690,20148280,Polo-box domain: a versatile mediator of polo-like kinase function.,http://www.ncbi.nlm.nih.gov/pubmed/20148280
4691,10607393,The seven-transmembrane receptor smoothened cell-autonomously induces multiple ventral cell types.,http://www.ncbi.nlm.nih.gov/pubmed/10607393
4692,24025258,Targeting inhibitor 2 of protein phosphatase 2A as a therapeutic strategy for prostate cancer treatment.,http://www.ncbi.nlm.nih.gov/pubmed/24025258
4693,22453599,Carnosic acid modulates Akt/IKK/NF-κB signaling by PP2A and induces intrinsic and extrinsic pathway mediated apoptosis in human prostate carcinoma PC-3 cells.,http://www.ncbi.nlm.nih.gov/pubmed/22453599
4694,21233840,PP2A impaired activity is a common event in acute myeloid leukemia and its activation by forskolin has a potent anti-leukemic effect.,http://www.ncbi.nlm.nih.gov/pubmed/21233840
4695,26023836,Activation of the Tumor Suppressor PP2A Emerges as a Potential Therapeutic Strategy for Treating Prostate Cancer.,http://www.ncbi.nlm.nih.gov/pubmed/26023836
4696,24448818,PP2A inhibition is a common event in colorectal cancer and its restoration using FTY720 shows promising therapeutic potential.,http://www.ncbi.nlm.nih.gov/pubmed/24448818
4697,26563471,Inhibition of Pten deficient Castration Resistant Prostate Cancer by Targeting of the SET - PP2A Signaling axis.,http://www.ncbi.nlm.nih.gov/pubmed/26563471
4698,21297667,Targeting SET/I(2)PP2A oncoprotein functions as a multi-pathway strategy for cancer therapy.,http://www.ncbi.nlm.nih.gov/pubmed/21297667
4699,25939762,Protein Phosphatase 2A Inhibition with LB100 Enhances Radiation-Induced Mitotic Catastrophe and Tumor Growth Delay in Glioblastoma.,http://www.ncbi.nlm.nih.gov/pubmed/25939762
4700,19564615,Inhibition of serine/threonine phosphatase PP2A enhances cancer chemotherapy by blocking DNA damage induced defense mechanisms.,http://www.ncbi.nlm.nih.gov/pubmed/19564615
4701,16884327,VHL P25L is not a pathogenic von Hippel-Lindau mutation: a family study.,http://www.ncbi.nlm.nih.gov/pubmed/16884327
4702,26519059,Molecular Pathways: Fatty Acid Synthase.,http://www.ncbi.nlm.nih.gov/pubmed/26519059
4703,18974394,"A RNA antagonist of hypoxia-inducible factor-1alpha, EZN-2968, inhibits tumor cell growth.",http://www.ncbi.nlm.nih.gov/pubmed/18974394
4704,24292632,"Pilot trial of EZN-2968, an antisense oligonucleotide inhibitor of hypoxia-inducible factor-1 alpha (HIF-1α), in patients with refractory solid tumors.",http://www.ncbi.nlm.nih.gov/pubmed/24292632
4705,25253783,SGN-LIV1A: a novel antibody-drug conjugate targeting LIV-1 for the treatment of metastatic breast cancer.,http://www.ncbi.nlm.nih.gov/pubmed/25253783
4706,26708004,Actin-resistant DNAse I Expression From Oncolytic Adenovirus Enadenotucirev Enhances Its Intratumoral Spread and Reduces Tumor Growth.,http://www.ncbi.nlm.nih.gov/pubmed/26708004
4707,,"A PHASE 1 STUDY OF ENADENOTUCIREV, AN ONCOLYTIC AD11/AD3 CHIMERIC GROUP B ADENOVIRUS, ADMINISTERED INTRAVENOUSLY - ANALYSIS OF DOSE EXPANSION AND REPEAT CYCLE COHORTS IN PATIENTS WITH METASTATIC COLORECTAL CANCER (MCRC)",http://annonc.oxfordjournals.org/content/25/suppl_4/iv367.1.abstract
4708,23456430,Targeting the PI3K/Akt/mTOR pathway in castration-resistant prostate cancer.,http://www.ncbi.nlm.nih.gov/pubmed/23456430
4709,23215354,"Identification, synthesis, and biological evaluation of metabolites of the experimental cancer treatment drugs indotecan (LMP400) and indimitecan (LMP776) and investigation of isomerically hydroxylated indenoisoquinoline analogues as topoisomerase I poisons.",http://www.ncbi.nlm.nih.gov/pubmed/23215354
4710,21907711,X-ray structures of checkpoint kinase 2 in complex with inhibitors that target its gatekeeper-dependent hydrophobic pocket.,http://www.ncbi.nlm.nih.gov/pubmed/21907711
4711,26837770,Effects of Anticancer Drugs on Chromosome Instability and New Clinical Implications for Tumor-Suppressing Therapies.,http://www.ncbi.nlm.nih.gov/pubmed/26837770
4712,19417149,"Radiosensitization of solid tumors by Z-VAD, a pan-caspase inhibitor.",http://www.ncbi.nlm.nih.gov/pubmed/19417149
4713,25957812,Targeting histone deacetylase 6 mediates a dual anti-melanoma effect: Enhanced antitumor immunity and impaired cell proliferation.,http://www.ncbi.nlm.nih.gov/pubmed/25957812
4714,24041744,"Learning and confirming with preclinical studies: modeling and simulation in the discovery of GDC-0917, an inhibitor of apoptosis proteins antagonist.",http://www.ncbi.nlm.nih.gov/pubmed/24041744
4715,,"Phase I study of safety and pharmacokinetics (PK) of GDC-0917, an antagonist of inhibitor of apoptosis (IAP) proteins in patients (Pts) with refractory solid tumors or lymphoma.",http://meetinglibrary.asco.org/content/114861-132
4716,26847057,Phase I Study of PSMA-Targeted Docetaxel-Containing Nanoparticle BIND-014 in Patients with Advanced Solid Tumors.,http://www.ncbi.nlm.nih.gov/pubmed/26847057
4717,21681929,"Initial testing (stage 1) of LCL161, a SMAC mimetic, by the Pediatric Preclinical Testing Program.",http://www.ncbi.nlm.nih.gov/pubmed/21681929
4718,24976294,Synergistic effects of IAP inhibitor LCL161 and paclitaxel on hepatocellular carcinoma cells.,http://www.ncbi.nlm.nih.gov/pubmed/24976294
4719,23130925,Custirsen (OGX-011): a second-generation antisense inhibitor of clusterin in development for the treatment of prostate cancer.,http://www.ncbi.nlm.nih.gov/pubmed/23130925
4720,19147778,Phase II trial of OGX-011 in combination with docetaxel in metastatic breast cancer.,http://www.ncbi.nlm.nih.gov/pubmed/19147778
4721,21443232,A potent and orally active antagonist (SM-406/AT-406) of multiple inhibitor of apoptosis proteins (IAPs) in clinical development for cancer treatment.,http://www.ncbi.nlm.nih.gov/pubmed/21443232
4722,25842225,"Oral Debio1143 (AT406), an antagonist of inhibitor of apoptosis proteins, combined with daunorubicin and cytarabine in patients with poor-risk acute myeloid leukemia--results of a phase I dose-escalation study.",http://www.ncbi.nlm.nih.gov/pubmed/25842225
4723,,"Safety, pharmacokinetics (PK), and pharmacodynamics (PD) of HGS1029, an inhibitor of apoptosis protein (IAP) inhibitor, in patients (Pts) with advanced solid tumors: Results of a phase I study.",http://meetinglibrary.asco.org/content/77596-102
4724,20733135,Randomized phase II study of docetaxel and prednisone with or without OGX-011 in patients with metastatic castration-resistant prostate cancer.,http://www.ncbi.nlm.nih.gov/pubmed/20733135
4725,21788353,Randomized phase II trial of Custirsen (OGX-011) in combination with docetaxel or mitoxantrone as second-line therapy in patients with metastatic castrate-resistant prostate cancer progressing after first-line docetaxel: CUOG trial P-06c.,http://www.ncbi.nlm.nih.gov/pubmed/21788353
4726,22198426,"Phase I/II trial of custirsen (OGX-011), an inhibitor of clusterin, in combination with a gemcitabine and platinum regimen in patients with previously untreated advanced non-small cell lung cancer.",http://www.ncbi.nlm.nih.gov/pubmed/22198426
4727,25573954,Differential Effects of Tyrosine Kinase Inhibitors on Normal and Oncogenic EGFR Signaling and Downstream Effectors.,http://www.ncbi.nlm.nih.gov/pubmed/25573954
4728,24746821,Uterine leiomyoma-linked MED12 mutations disrupt mediator-associated CDK activity.,http://www.ncbi.nlm.nih.gov/pubmed/24746821
4729,25593300,Next-Gen Sequencing Exposes Frequent MED12 Mutations and Actionable Therapeutic Targets in Phyllodes Tumors.,http://www.ncbi.nlm.nih.gov/pubmed/25593300
4730,18174154,Inhibitory role of Plk1 in the regulation of p73-dependent apoptosis through physical interaction and phosphorylation.,http://www.ncbi.nlm.nih.gov/pubmed/18174154
4731,18615013,Polo-like kinase-1 is activated by aurora A to promote checkpoint recovery.,http://www.ncbi.nlm.nih.gov/pubmed/18615013
4732,12207013,Phosphorylation of threonine 210 and the role of serine 137 in the regulation of mammalian polo-like kinase.,http://www.ncbi.nlm.nih.gov/pubmed/12207013
4733,17461553,Structure of the catalytic domain of human polo-like kinase 1.,http://www.ncbi.nlm.nih.gov/pubmed/17461553
4734,17307877,Molecular and structural basis of polo-like kinase 1 substrate recognition: Implications in centrosomal localization.,http://www.ncbi.nlm.nih.gov/pubmed/17307877
4735,25712683,Androgen Receptor Gene Aberrations in Circulating Cell-Free DNA: Biomarkers of Therapeutic Resistance in Castration-Resistant Prostate Cancer.,http://www.ncbi.nlm.nih.gov/pubmed/25712683
4736,25870146,Mechanistic Rationale to Target PTEN-Deficient Tumor Cells with Inhibitors of the DNA Damage Response Kinase ATM.,http://www.ncbi.nlm.nih.gov/pubmed/25870146
4737,19808981,"Improved ATM kinase inhibitor KU-60019 radiosensitizes glioma cells, compromises insulin, AKT and ERK prosurvival signaling, and inhibits migration and invasion.",http://www.ncbi.nlm.nih.gov/pubmed/19808981
4738,25840982,Rho kinase inhibitors block melanoma cell migration and inhibit metastasis.,http://www.ncbi.nlm.nih.gov/pubmed/25840982
4739,23907125,Genetic variants and mutations of PPM1D control the response to DNA damage.,http://www.ncbi.nlm.nih.gov/pubmed/23907125
4740,26891877,Leukemogenic potency of the novel FLT3-N676K mutant.,http://www.ncbi.nlm.nih.gov/pubmed/26891877
4741,24214971,Cancerous inhibitor of protein phosphatase 2A (CIP2A) protein is involved in centrosome separation through the regulation of NIMA (never in mitosis gene A)-related kinase 2 (NEK2) protein activity.,http://www.ncbi.nlm.nih.gov/pubmed/24214971
4742,25015035,Oncogenic nexus of cancerous inhibitor of protein phosphatase 2A (CIP2A): an oncoprotein with many hands.,http://www.ncbi.nlm.nih.gov/pubmed/25015035
4743,26507691,All roads lead to PP2A: exploiting the therapeutic potential of this phosphatase.,http://www.ncbi.nlm.nih.gov/pubmed/26507691
4744,17889719,Cytotoxicity of NF-kappaB inhibitors Bay 11-7085 and caffeic acid phenethyl ester to Ramos and other human B-lymphoma cell lines.,http://www.ncbi.nlm.nih.gov/pubmed/17889719
4745,15772071,Novel small molecule inhibitors of 3-phosphoinositide-dependent kinase-1.,http://www.ncbi.nlm.nih.gov/pubmed/15772071
4746,,"High Efficiency Of the PDPK1-Inhibitor, BX912, In MCL",http://www.bloodjournal.org/content/122/21/3077?sso-checked=true
4747,25269480,Phosphoinositide protein kinase PDPK1 is a crucial cell signaling mediator in multiple myeloma.,http://www.ncbi.nlm.nih.gov/pubmed/25269480
4748,17932254,The genomic landscapes of human breast and colorectal cancers.,http://www.ncbi.nlm.nih.gov/pubmed/17932254
4749,22491800,Antitumor mechanisms of targeting the PDK1 pathway in head and neck cancer.,http://www.ncbi.nlm.nih.gov/pubmed/22491800
4750,15340059,Biochemical and functional characterizations of small GTPase Rheb and TSC2 GAP activity.,http://www.ncbi.nlm.nih.gov/pubmed/15340059
4751,12869586,Rheb GTPase is a direct target of TSC2 GAP activity and regulates mTOR signaling.,http://www.ncbi.nlm.nih.gov/pubmed/12869586
4752,,"A first-in-human phase I trial of AR-12, a PDK-1 inhibitor, in patients with advanced solid tumors",http://meetinglibrary.asco.org/content/115148-132
4753,,Abstract LB-116: GSK2334470: A potent and highly selective inhibitor of PDK1,http://cancerres.aacrjournals.org/content/70/8_Supplement/LB-116.short
4754,20197390,"Molecular pharmacology and antitumor activity of PHT-427, a novel Akt/phosphatidylinositide-dependent protein kinase 1 pleckstrin homology domain inhibitor.",http://www.ncbi.nlm.nih.gov/pubmed/20197390
4755,23996484,Farnesyltransferase inhibitor tipifarnib inhibits Rheb prenylation and stabilizes Bax in acute myelogenous leukemia cells.,http://www.ncbi.nlm.nih.gov/pubmed/23996484
4756,22560091,A human homeotic transformation resulting from mutations in PLCB4 and GNAI3 causes auriculocondylar syndrome.,http://www.ncbi.nlm.nih.gov/pubmed/22560091
4757,26683228,Deep sequencing of uveal melanoma identifies a recurrent mutation in PLCB4.,http://www.ncbi.nlm.nih.gov/pubmed/26683228
4758,18708578,Tumorigenic activity and therapeutic inhibition of Rheb GTPase.,http://www.ncbi.nlm.nih.gov/pubmed/18708578
4759,24039447,3-Phosphoinositide-dependent protein kinase-1 as an emerging target in the management of breast cancer.,http://www.ncbi.nlm.nih.gov/pubmed/24039447
4760,19299511,Specific activation of mTORC1 by Rheb G-protein in vitro involves enhanced recruitment of its substrate protein.,http://www.ncbi.nlm.nih.gov/pubmed/19299511
4761,26861905,Correlation of CTNNB1 Mutation Status with Progression Arrest Rate in RECIST Progressive Desmoid-Type Fibromatosis Treated with Imatinib: Translational Research Results from a Phase 2 Study of the German Interdisciplinary Sarcoma Group (GISG-01).,http://www.ncbi.nlm.nih.gov/pubmed/26861905
4762,16006564,The farnesyl transferase inhibitor (FTI) SCH66336 (lonafarnib) inhibits Rheb farnesylation and mTOR signaling. Role in FTI enhancement of taxane and tamoxifen anti-tumor activity.,http://www.ncbi.nlm.nih.gov/pubmed/16006564
4763,25157153,Rare variants in PPARG with decreased activity in adipocyte differentiation are associated with increased risk of type 2 diabetes.,http://www.ncbi.nlm.nih.gov/pubmed/25157153
4764,,First-in-human phase I study of a selective VEGFR/FGFR dual inhibitor sulfatinib in patients with advanced solid tumors,http://mct.aacrjournals.org/content/14/12_Supplement_2/A1.short
4765,,"Phase I study of the safety and pharmacokinetics of epitinib, an oral EGFR tyrosine kinase inhibitor, in patients with advanced solid tumors.",http://meetinglibrary.asco.org/content/114269-132
4766,20686120,Targeting TORC2 in multiple myeloma with a new mTOR kinase inhibitor.,http://www.ncbi.nlm.nih.gov/pubmed/20686120
4767,20839315,Activation of the phosphoinositide-3-kinase and mammalian target of rapamycin signaling pathways are associated with shortened survival in patients with malignant peritoneal mesothelioma.,http://www.ncbi.nlm.nih.gov/pubmed/20839315
4768,23555046,Combined RNAi-mediated suppression of Rictor and EGFR resulted in complete tumor regression in an orthotopic glioblastoma tumor model.,http://www.ncbi.nlm.nih.gov/pubmed/23555046
4769,24953177,A small-molecule inhibitor of PIM kinases as a potential treatment for urothelial carcinomas.,http://www.ncbi.nlm.nih.gov/pubmed/24953177
4770,25921059,The mTORC1 inhibitor everolimus has antitumor activity in vitro and produces tumor responses in patients with relapsed T-cell lymphoma.,http://www.ncbi.nlm.nih.gov/pubmed/25921059
4771,19965690,A small molecule inhibitor of Pim protein kinases blocks the growth of precursor T-cell lymphoblastic leukemia/lymphoma.,http://www.ncbi.nlm.nih.gov/pubmed/19965690
4772,26186558,Targeting the Pim kinases in multiple myeloma.,http://www.ncbi.nlm.nih.gov/pubmed/26186558
4773,25450580,mTOR signaling in tumorigenesis.,http://www.ncbi.nlm.nih.gov/pubmed/25450580
4774,24900437,"Discovery of CX-6258. A Potent, Selective, and Orally Efficacious pan-Pim Kinases Inhibitor.",http://www.ncbi.nlm.nih.gov/pubmed/24900437
4775,16317287,NPI-2358 is a tubulin-depolymerizing agent: in-vitro evidence for activity as a tumor vascular-disrupting agent.,http://www.ncbi.nlm.nih.gov/pubmed/16317287
4776,21327495,Phase 1 study of the novel vascular disrupting agent plinabulin (NPI-2358) and docetaxel.,http://www.ncbi.nlm.nih.gov/pubmed/21327495
4777,26164533,"NO to cancer: The complex and multifaceted role of nitric oxide and the epigenetic nitric oxide donor, RRx-001.",http://www.ncbi.nlm.nih.gov/pubmed/26164533
4778,,JAK2 E846D Germline Mutation Associated with Erythrocytosis Causes Increased and Prolonged Epo-Induced Activation of STAT5,http://www.bloodjournal.org/content/124/21/4008
4779,26419724,Targeting substrate-site in Jak2 kinase prevents emergence of genetic resistance.,http://www.ncbi.nlm.nih.gov/pubmed/26419724
4780,,,https://ash.confex.com/ash/2008/webprogram/Paper3729.html
4781,26459175,"(Ir)relevance of Metformin Treatment in Patients with Metastatic Pancreatic Cancer: An Open-Label, Randomized Phase II Trial.",http://www.ncbi.nlm.nih.gov/pubmed/26459175
4782,26903311,A phase I trial of panobinostat and epirubicin in solid tumors with a dose expansion in patients with sarcoma.,http://www.ncbi.nlm.nih.gov/pubmed/26903311
4783,24975213,PIM and AKT kinase inhibitors show synergistic cytotoxicity in acute myeloid leukaemia that is associated with convergence on mTOR and MCL1 pathways.,http://www.ncbi.nlm.nih.gov/pubmed/24975213
4784,19720745,Characterization of Rictor phosphorylation sites reveals direct regulation of mTOR complex 2 by S6K1.,http://www.ncbi.nlm.nih.gov/pubmed/19720745
4785,26504226,Discovery and functional characterization of a neomorphic PTEN mutation.,http://www.ncbi.nlm.nih.gov/pubmed/26504226
4786,26446942,"A Phase II Trial of AZD6244 (Selumetinib, ARRY-142886), an Oral MEK1/2 Inhibitor, in Relapsed/Refractory Multiple Myeloma.",http://www.ncbi.nlm.nih.gov/pubmed/26446942
4787,26482040,"A Phase I/II Multicenter, Open-Label Study of the Oral Histone Deacetylase Inhibitor Abexinostat in Relapsed/Refractory Lymphoma.",http://www.ncbi.nlm.nih.gov/pubmed/26482040
4788,,"A Novel Pan-PIM Kinase Inhibitor, SEL24-B489, Induces Apoptosis and Inhibits Proliferation of Diffuse Large B-Cell Lymphoma Cells through Inhibition of Protein Translation and Attenuation of Myc and NFkB Activity",https://ash.confex.com/ash/2015/webprogram/Paper84427.html
4789,26862733,The mechanism of acquired resistance to irreversible EGFR tyrosine kinase inhibitor-afatinib in lung adenocarcinoma patients.,http://www.ncbi.nlm.nih.gov/pubmed/26862733
4790,26224368,Calcipotriol Targets LRP6 to Inhibit Wnt Signaling in Pancreatic Cancer.,http://www.ncbi.nlm.nih.gov/pubmed/26224368
4791,19667145,The relevance of vitamin D receptor (VDR) gene polymorphisms for cancer: a review of the literature.,http://www.ncbi.nlm.nih.gov/pubmed/19667145
4792,,Activity of the pan-PIM kinase inhibitor INCB053914 in models of acute myelogenous leukemia,http://cancerres.aacrjournals.org/content/75/15_Supplement/5416.short
4793,24416653,STAT5 acetylation: Mechanisms and consequences for immunological control and leukemogenesis.,http://www.ncbi.nlm.nih.gov/pubmed/24416653
4794,23541951,"STAT signaling in mammary gland differentiation, cell survival and tumorigenesis.",http://www.ncbi.nlm.nih.gov/pubmed/23541951
4795,21704724,Signal transducer and activator of transcription 5a/b: biomarker and therapeutic target in prostate and breast cancer.,http://www.ncbi.nlm.nih.gov/pubmed/21704724
4796,25333255,Inhibition of STAT5: a therapeutic option in BCR-ABL1-driven leukemia.,http://www.ncbi.nlm.nih.gov/pubmed/25333255
4797,18508994,Signal transducer and activator of transcription 5A/B in prostate and breast cancers.,http://www.ncbi.nlm.nih.gov/pubmed/18508994
4798,24573384,Novel activating STAT5B mutations as putative drivers of T-cell acute lymphoblastic leukemia.,http://www.ncbi.nlm.nih.gov/pubmed/24573384
4799,23495171,Pim1 serine/threonine kinase regulates the number and functions of murine hematopoietic stem cells.,http://www.ncbi.nlm.nih.gov/pubmed/23495171
4800,26703889,"Everolimus for the treatment of advanced, non-functional neuroendocrine tumours of the lung or gastrointestinal tract (RADIANT-4): a randomised, placebo-controlled, phase 3 study.",http://www.ncbi.nlm.nih.gov/pubmed/26703889
4801,26732095,Oncogenic BRAF Deletions That Function as Homodimers and Are Sensitive to Inhibition by RAF Dimer Inhibitor LY3009120.,http://www.ncbi.nlm.nih.gov/pubmed/26732095
4802,24983364,Withacnistin inhibits recruitment of STAT3 and STAT5 to growth factor and cytokine receptors and induces regression of breast tumours.,http://www.ncbi.nlm.nih.gov/pubmed/24983364
4803,26646755,TP53 mutational status is predictive of pazopanib response in advanced sarcomas.,http://www.ncbi.nlm.nih.gov/pubmed/26646755
4804,26811525,Overall Survival and Durable Responses in Patients With BRAF V600-Mutant Metastatic Melanoma Receiving Dabrafenib Combined With Trametinib.,http://www.ncbi.nlm.nih.gov/pubmed/26811525
4805,25838391,Primary and Acquired Resistance of Colorectal Cancer to Anti-EGFR Monoclonal Antibody Can Be Overcome by Combined Treatment of Regorafenib with Cetuximab.,http://www.ncbi.nlm.nih.gov/pubmed/25838391
4806,26947875,Prognostic Value of SMAD4 in Pancreatic Cancer: A Meta-Analysis.,http://www.ncbi.nlm.nih.gov/pubmed/26947875
4807,26461489,Landscape of Targeted Anti-Cancer Drug Synergies in Melanoma Identifies a Novel BRAF-VEGFR/PDGFR Combination Treatment.,http://www.ncbi.nlm.nih.gov/pubmed/26461489
4808,26926681,"Docetaxel As Monotherapy or Combined With Ramucirumab or Icrucumab in Second-Line Treatment for Locally Advanced or Metastatic Urothelial Carcinoma: An Open-Label, Three-Arm, Randomized Controlled Phase II Trial.",http://www.ncbi.nlm.nih.gov/pubmed/26926681
4809,25586472,Activating mutations of STAT5B and STAT3 in lymphomas derived from γδ-T or NK cells.,http://www.ncbi.nlm.nih.gov/pubmed/25586472
4810,24133210,"Effects of isoform-selective phosphatidylinositol 3-kinase inhibitors on osteoclasts: actions on cytoskeletal organization, survival, and resorption.",http://www.ncbi.nlm.nih.gov/pubmed/24133210
4811,24387221,Discovery and optimization of pyrimidone indoline amide PI3Kβ inhibitors for the treatment of phosphatase and tensin homologue (PTEN)-deficient cancers.,http://www.ncbi.nlm.nih.gov/pubmed/24387221
4812,22148584,Small molecule STAT5-SH2 domain inhibitors exhibit potent antileukemia activity.,http://www.ncbi.nlm.nih.gov/pubmed/22148584
4813,26929321,High-throughput small molecule screen identifies inhibitors of aberrant chromatin accessibility.,http://www.ncbi.nlm.nih.gov/pubmed/26929321
4814,15849726,Antitumor effects of histone deacetylase inhibitor on Ewing's family tumors.,http://www.ncbi.nlm.nih.gov/pubmed/15849726
4815,25605252,Functional consequence of the MET-T1010I polymorphism in breast cancer.,http://www.ncbi.nlm.nih.gov/pubmed/25605252
4816,17486365,Histone deacetylase inhibitors induce cell death and enhance the apoptosis-inducing activity of TRAIL in Ewing's sarcoma cells.,http://www.ncbi.nlm.nih.gov/pubmed/17486365
4817,24124617,Ewing sarcoma cells secrete EWS/Fli-1 fusion mRNA via microvesicles.,http://www.ncbi.nlm.nih.gov/pubmed/24124617
4818,26631613,Identification of a Novel Pathogenic Germline KDR Variant in Melanoma.,http://www.ncbi.nlm.nih.gov/pubmed/26631613
4819,,"A phase I/II, first-in-human dose-escalation study of GSK2636771 in patients (pts) with PTEN-deficient advanced tumors.",http://meetinglibrary.asco.org/content/131727-144
4820,26927065,Synergetic Effects of PARP Inhibitor AZD2281 and Cisplatin in Oral Squamous Cell Carcinoma in Vitro and in Vivo.,http://www.ncbi.nlm.nih.gov/pubmed/26927065
4821,24417566,"Discovery of 8-cyclopentyl-2-[4-(4-methyl-piperazin-1-yl)-phenylamino]-7-oxo-7,8-dihydro-pyrido[2,3-d]pyrimidine-6-carbonitrile (7x) as a potent inhibitor of cyclin-dependent kinase 4 (CDK4) and AMPK-related kinase 5 (ARK5).",http://www.ncbi.nlm.nih.gov/pubmed/24417566
4822,26873845,Dual Targeting of CDK4 and ARK5 Using a Novel Kinase Inhibitor ON123300 Exerts Potent Anticancer Activity against Multiple Myeloma.,http://www.ncbi.nlm.nih.gov/pubmed/26873845
4823,26916115,A Novel RAF Kinase Inhibitor with DFG-Out-Binding Mode: High Efficacy in BRAF-Mutant Tumor Xenograft Models in the Absence of Normal Tissue Hyperproliferation.,http://www.ncbi.nlm.nih.gov/pubmed/26916115
4824,24992874,"Discovery of 9-(1-anilinoethyl)-2-morpholino-4-oxo-pyrido[1,2-a]pyrimidine-7-carboxamides as PI3Kβ/δ inhibitors for the treatment of PTEN-deficient tumours.",http://www.ncbi.nlm.nih.gov/pubmed/24992874
4825,20048334,"The telomerase antagonist, imetelstat, efficiently targets glioblastoma tumor-initiating cells leading to decreased proliferation and tumor growth.",http://www.ncbi.nlm.nih.gov/pubmed/20048334
4826,,Loss of PTEN leads to clinical resistance to the PI3K? inhibitor BYL719 and provides evidence of convergent evolution under selective therapeutic pressure,http://cancerres.aacrjournals.org/content/74/19_Supplement/LB-327.short
4827,22949014,Targeting the hedgehog signal transduction pathway at the level of GLI inhibits neuroblastoma cell growth in vitro and in vivo.,http://www.ncbi.nlm.nih.gov/pubmed/22949014
4828,,Co-targeting PTEN-defined TNBC with p110beta-isoform specific inhibitor and PARP inhibitor BMN 673: A predictive context to sensitize PARP inhibitors in TNBC,http://mcr.aacrjournals.org/content/14/2_Supplement/B12.short
4829,26645560,Peptide-Drug Conjugate GnRH-Sunitinib Targets Angiogenesis Selectively at the Site of Action to Inhibit Tumor Growth.,http://www.ncbi.nlm.nih.gov/pubmed/26645560
4830,25976679,Aromatase Inhibitor-Mediated Downregulation of INrf2 (Keap1) Leads to Increased Nrf2 and Resistance in Breast Cancer.,http://www.ncbi.nlm.nih.gov/pubmed/25976679
4831,26009011,Improving survival by exploiting tumour dependence on stabilized mutant p53 for treatment.,http://www.ncbi.nlm.nih.gov/pubmed/26009011
4832,16407837,A novel mutation of STK11/LKB1 gene leads to the loss of cell growth inhibition in head and neck squamous cell carcinoma.,http://www.ncbi.nlm.nih.gov/pubmed/16407837
4833,26772734,Correlation of KIT and PDGFRA mutational status with clinical benefit in patients with gastrointestinal stromal tumor treated with sunitinib in a worldwide treatment-use trial.,http://www.ncbi.nlm.nih.gov/pubmed/26772734
4834,26951079,Second- and third-generation ALK inhibitors for non-small cell lung cancer.,http://www.ncbi.nlm.nih.gov/pubmed/26951079
4835,25264305,Crizotinib in ROS1-rearranged non-small-cell lung cancer.,http://www.ncbi.nlm.nih.gov/pubmed/25264305
4836,16203769,Clinicopathologic significance of the mutations of the epidermal growth factor receptor gene in patients with non-small cell lung cancer.,http://www.ncbi.nlm.nih.gov/pubmed/16203769
4837,15897572,Mutation in the tyrosine kinase domain of epidermal growth factor receptor is a predictive and prognostic factor for gefitinib treatment in patients with non-small cell lung cancer.,http://www.ncbi.nlm.nih.gov/pubmed/15897572
4838,18588508,Comparison of the EGFR resistance mutation profiles generated by EGFR-targeted tyrosine kinase inhibitors and the impact of drug combinations.,http://www.ncbi.nlm.nih.gov/pubmed/18588508
4839,23940421,Profile of vismodegib and its potential in the treatment of advanced basal cell carcinoma.,http://www.ncbi.nlm.nih.gov/pubmed/23940421
4840,26714497,Spectrum of mutations and genotype-phenotype analysis in Noonan syndrome patients with RIT1 mutations.,http://www.ncbi.nlm.nih.gov/pubmed/26714497
4841,24980904,R-spondins: novel matricellular regulators of the skeleton.,http://www.ncbi.nlm.nih.gov/pubmed/24980904
4842,26676867,Reduced proliferation and increased apoptosis of the SGC‑7901 gastric cancer cell line on exposure to GDC‑0449.,http://www.ncbi.nlm.nih.gov/pubmed/26676867
4843,23535903,"Canonical Wnt/β-catenin signaling drives human schwann cell transformation, progression, and tumor maintenance.",http://www.ncbi.nlm.nih.gov/pubmed/23535903
4844,26487584,A clinical case of invasive lobular breast carcinoma with ERBB2 and CDH1 mutations presenting a dramatic response to anti-HER2-directed therapy.,http://www.ncbi.nlm.nih.gov/pubmed/26487584
4845,24390428,Allosteric Wip1 phosphatase inhibition through flap-subdomain interaction.,http://www.ncbi.nlm.nih.gov/pubmed/24390428
4846,15235021,Germline E-cadherin mutations in hereditary diffuse gastric cancer: assessment of 42 new families and review of genetic screening criteria.,http://www.ncbi.nlm.nih.gov/pubmed/15235021
4847,26950094,Genomic analysis identifies new drivers and progression pathways in skin basal cell carcinoma.,http://www.ncbi.nlm.nih.gov/pubmed/26950094
4848,26951660,Oligonucleotide-directed mutagenesis screen to identify pathogenic Lynch syndrome-associated MSH2 DNA mismatch repair gene variants.,http://www.ncbi.nlm.nih.gov/pubmed/26951660
4849,17101317,Pathogenicity of MSH2 missense mutations is typically associated with impaired repair capability of the mutated protein.,http://www.ncbi.nlm.nih.gov/pubmed/17101317
4850,19697156,Functional characterization of rare missense mutations in MLH1 and MSH2 identified in Danish colorectal cancer patients.,http://www.ncbi.nlm.nih.gov/pubmed/19697156
4851,20672385,Lynch syndrome-associated mutations in MSH2 alter DNA repair and checkpoint response functions in vivo.,http://www.ncbi.nlm.nih.gov/pubmed/20672385
4852,22739024,The hMSH2(M688R) Lynch syndrome mutation may function as a dominant negative.,http://www.ncbi.nlm.nih.gov/pubmed/22739024
4853,26832796,Chemical Inhibition of Wild-Type p53-Induced Phosphatase 1 (WIP1/PPM1D) by GSK2830371 Potentiates the Sensitivity to MDM2 Inhibitors in a p53-Dependent Manner.,http://www.ncbi.nlm.nih.gov/pubmed/26832796
4854,26446947,"Safety, Pharmacokinetics, and Pharmacodynamics of a Humanized Anti-Semaphorin 4D Antibody, in a First-In-Human Study of Patients with Advanced Solid Tumors.",http://www.ncbi.nlm.nih.gov/pubmed/26446947
4855,24501230,Functional analysis of MSH2 unclassified variants found in suspected Lynch syndrome patients reveals pathogenicity due to attenuated mismatch repair.,http://www.ncbi.nlm.nih.gov/pubmed/24501230
4856,26423795,Phase I Study of the Investigational NEDD8-Activating Enzyme Inhibitor Pevonedistat (TAK-924/MLN4924) in Patients with Advanced Solid Tumors.,http://www.ncbi.nlm.nih.gov/pubmed/26423795
4857,16145049,"A phase I pharmacokinetic and pharmacodynamic study of OGX-011, a 2'-methoxyethyl antisense oligonucleotide to clusterin, in patients with localized prostate cancer.",http://www.ncbi.nlm.nih.gov/pubmed/16145049
4858,12200596,Impact of microsatellite testing and mismatch repair protein expression on the clinical interpretation of genetic testing in hereditary non-polyposis colorectal cancer.,http://www.ncbi.nlm.nih.gov/pubmed/12200596
4859,18245546,"A phase I study of OGX-011, a 2'-methoxyethyl phosphorothioate antisense to clusterin, in combination with docetaxel in patients with advanced cancer.",http://www.ncbi.nlm.nih.gov/pubmed/18245546
4860,18951462,Mechanisms of pathogenicity in human MSH2 missense mutants.,http://www.ncbi.nlm.nih.gov/pubmed/18951462
4861,17700519,A chemical inhibitor of PPM1D that selectively kills cells overexpressing PPM1D.,http://www.ncbi.nlm.nih.gov/pubmed/17700519
4862,26516583,FTY720 (Fingolimod) sensitizes hepatocellular carcinoma cells to sorafenib-mediated cytotoxicity.,http://www.ncbi.nlm.nih.gov/pubmed/26516583
4863,25086508,A human fatty acid synthase inhibitor binds β-ketoacyl reductase in the keto-substrate site.,http://www.ncbi.nlm.nih.gov/pubmed/25086508
4864,,Design and synthesis of a series highly potent and bioavailable FASN KR domain inhibitors for cancer,http://cancerres.aacrjournals.org/content/74/19_Supplement/4747
4865,,Biomarker and PK/PD analyses of first in class FASN inhibitor TVB-2640 in a first-in-human phase 1 study in solid tumor patients,http://cancerres.aacrjournals.org/content/75/15_Supplement/2675?cited-by=yes&legid=canres;75/15_Supplement/2675
4866,,"Evidence of activity of a new mechanism of action (MoA): A first-in-human study of the first-in-class fatty acid synthase (FASN) inhibitor, TVB-2640, as monotherapy or in combination",https://www.researchgate.net/publication/282785628_Evidence_of_activity_of_a_new_mechanism_of_action_MoA_A_first-in-human_study_of_the_first-in-class_fatty_acid_synthase_FASN_inhibitor_TVB-2640_as_mon
4867,23416332,Inhibitors of Hedgehog acyltransferase block Sonic Hedgehog signaling.,http://www.ncbi.nlm.nih.gov/pubmed/23416332
4868,25889650,"Hedgehog Acyltransferase as a target in estrogen receptor positive, HER2 amplified, and tamoxifen resistant breast cancer cells.",http://www.ncbi.nlm.nih.gov/pubmed/25889650
4869,25561897,Clinical significance of a point mutation in DNA polymerase beta (POLB) gene in gastric cancer.,http://www.ncbi.nlm.nih.gov/pubmed/25561897
4870,24668809,The S229L colon tumor-associated variant of DNA polymerase β induces cellular transformation as a result of decreased polymerization efficiency.,http://www.ncbi.nlm.nih.gov/pubmed/24668809
4871,26459177,"Results of the Phase I Trial of RG7112, a Small-Molecule MDM2 Antagonist in Leukemia.",http://www.ncbi.nlm.nih.gov/pubmed/26459177
4872,,"Interim Analysis Of Dose-Escalation Stage Of a Phase 1b Study Evaluating Safety and Pharmacology Of GS-9820, a Second-Generation, Selective, PI3Kd-Inhibitor in Recurrent Lymphoid Malignancies",http://www.bloodjournal.org/content/122/21/2881?sso-checked=true
4873,,First-in-human phase I trial of the PI3Kb-selective inhibitor SAR260301 in patients with advanced solid tumors (NCT01673737).,http://meetinglibrary.asco.org/content/146302-156
4874,19176369,Inhibition of class I phosphoinositide 3-kinase activity impairs proliferation and triggers apoptosis in acute promyelocytic leukemia without affecting atra-induced differentiation.,http://www.ncbi.nlm.nih.gov/pubmed/19176369
4875,,"Effects of perioperative lapatinib and trastuzumab, alone and in combination, in early HER2+ breast cancer - the UK EPHOS-B trial (CRUK/08/002)",http://www.ecco-org.eu/Events/EBCC10/Abstract-search?abstractid=25368
4876,25544636,Feedback suppression of PI3Kα signaling in PTEN-mutated tumors is relieved by selective inhibition of PI3Kβ.,http://www.ncbi.nlm.nih.gov/pubmed/25544636
4877,26839307,"Intermittent High-Dose Scheduling of AZD8835, a Novel Selective Inhibitor of PI3Kα and PI3Kδ, Demonstrates Treatment Strategies for PIK3CA-Dependent Breast Cancers.",http://www.ncbi.nlm.nih.gov/pubmed/26839307
4878,26924569,Frequent PTPRK-RSPO3 fusions and RNF43 mutations in colorectal traditional serrated adenoma.,http://www.ncbi.nlm.nih.gov/pubmed/26924569
4879,24852792,"Preliminary results of a phase II study of single agent Bay 80-6946, a Novel PI3K inhibitor, in patients with relapsed/refractory, indolent or aggressive lymphoma.",http://www.ncbi.nlm.nih.gov/pubmed/24852792
4880,19359241,Discovery and exploitation of inhibitor-resistant aurora and polo kinase mutants for the analysis of mitotic networks.,http://www.ncbi.nlm.nih.gov/pubmed/19359241
4881,22327403,Using transcriptome sequencing to identify mechanisms of drug action and resistance.,http://www.ncbi.nlm.nih.gov/pubmed/22327403
4882,24450857,Idelalisib and rituximab in relapsed chronic lymphocytic leukemia.,http://www.ncbi.nlm.nih.gov/pubmed/24450857
4883,26968534,Phase 2 study of idelalisib and entospletinib: pneumonitis limits combination therapy in relapsed refractory CLL and NHL.,http://www.ncbi.nlm.nih.gov/pubmed/26968534
4884,18502982,Point mutation of the proteasome beta5 subunit gene is an important mechanism of bortezomib resistance in bortezomib-selected variants of Jurkat T cell lymphoblastic lymphoma/leukemia line.,http://www.ncbi.nlm.nih.gov/pubmed/18502982
4885,,"A phase 1 study of INCB040093, a PI3K? inhibitor, alone or in combination with INCB039110, a selective JAK1 inhibitor: Interim results from patients (pts) with relapsed or refractory (r/r) classical Hodgkin lymphoma (cHL).",http://meetinglibrary.asco.org/content/146209-156
4886,,"INCB050465, a novel PI3K-delta inhibitor, synergizes with PIM protein kinase inhibition to cause tumor regression in a model of DLBCL",http://cancerres.aacrjournals.org/content/75/15_Supplement/2671.short
4887,26046350,Identification of Novel Small Molecule Inhibitors of Oncogenic RET Kinase.,http://www.ncbi.nlm.nih.gov/pubmed/26046350
4888,,"Duvelisib (IPI-145), a PI3K-?,? Inhibitor, Is Clinically Active in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia",http://www.bloodjournal.org/content/124/21/3334.abstract?sso-checked=true
4889,,"a Phase 1 Evaluation of Duvelisib (IPI-145), a PI3K-?,? Inhibitor, in Patients with Relapsed/Refractory iNHL",http://www.bloodjournal.org/content/124/21/802.abstract
4890,,"A Dose Escalation Study of RP6530, a Novel Dual PI3K Delta/Gamma Inhibitor, in Patients with Relapsed/Refractory Hematologic Malignancies",http://www.bloodjournal.org/content/126/23/1495.abstract
4891,26952093,PI3K/AKT/mTOR inhibition in combination with doxorubicin is an effective therapy for leiomyosarcoma.,http://www.ncbi.nlm.nih.gov/pubmed/26952093
4892,,"RP6530, a dual PI3K ?/? inhibitor, potentiates ruxolitinib activity in the JAK2-V617F mutant erythroleukemia cell lines",http://cancerres.aacrjournals.org/content/75/15_Supplement/2704.short
4893,,Dual PI3Kdelta/gamma Inhibition By RP6530 Induces Apoptosis and Cytotoxicity In B-Lymphoma Cells,http://www.bloodjournal.org/content/122/21/4411?sso-checked=true
4894,18536917,The E75 HER2/neu peptide vaccine.,http://www.ncbi.nlm.nih.gov/pubmed/18536917
4895,24907636,Final report of the phase I/II clinical trial of the E75 (nelipepimut-S) vaccine with booster inoculations to prevent disease recurrence in high-risk breast cancer patients.,http://www.ncbi.nlm.nih.gov/pubmed/24907636
4896,19047165,"F14512, a potent antitumor agent targeting topoisomerase II vectored into cancer cells via the polyamine transport system.",http://www.ncbi.nlm.nih.gov/pubmed/19047165
4897,26267534,Small Molecule Inhibition of ERK Dimerization Prevents Tumorigenesis by RAS-ERK Pathway Oncogenes.,http://www.ncbi.nlm.nih.gov/pubmed/26267534
4898,,"Safety and activity of the chemotherapy-free triplet of ublituximab, TGR-1202, and ibrutinib in relapsed B-cell malignancies.",http://meetinglibrary.asco.org/content/152147-156
4899,,Ublituximab plus TGR-1202 activity and safety profile in relapsed/refractory B-cell NHL and high-risk CLL.,http://meetinglibrary.asco.org/content/152562-156
4900,,The PI3K-delta Inhibitor TGR-1202 in Combination with Brentuximab Vedotin (SGN-35) Synergistically Inhibits Tubulin Polymerization and Exerts Potent Antitumor Effects in NOD/SCID Mice with Hodgkin Lymphoma Cell Line Xenografts,http://www.bloodjournal.org/content/124/21/4486.abstract?sso-checked=true
4901,26363012,Radioprotection of IDH1-Mutated Cancer Cells by the IDH1-Mutant Inhibitor AGI-5198.,http://www.ncbi.nlm.nih.gov/pubmed/26363012
4902,24718026,"Targeting class IA PI3K isoforms selectively impairs cell growth, survival, and migration in glioblastoma.",http://www.ncbi.nlm.nih.gov/pubmed/24718026
4903,26137449,Inhibitors of pan-PI3K Signaling Synergize with BRAF or MEK Inhibitors to Prevent BRAF-Mutant Melanoma Cell Growth.,http://www.ncbi.nlm.nih.gov/pubmed/26137449
4904,26389665,Non-canonical NF-κB signalling and ETS1/2 cooperatively drive C250T mutant TERT promoter activation.,http://www.ncbi.nlm.nih.gov/pubmed/26389665
4905,25980501,Wnt-C59 arrests stemness and suppresses growth of nasopharyngeal carcinoma in mice by inhibiting the Wnt pathway in the tumor microenvironment.,http://www.ncbi.nlm.nih.gov/pubmed/25980501
4906,25869207,PI3K inhibition synergizes with glucocorticoids but antagonizes with methotrexate in T-cell acute lymphoblastic leukemia.,http://www.ncbi.nlm.nih.gov/pubmed/25869207
4907,,"The potent and selective phosphoinositide-3-kinase-gamma inhibitor, IPI-549, inhibits tumor growth in murine syngeneic solid tumor models through alterations in the immune suppressive microenvironment",http://mct.aacrjournals.org/content/14/12_Supplement_2/A192.short
4908,23330955,Signaling by the phosphoinositide 3-kinase family in immune cells.,http://www.ncbi.nlm.nih.gov/pubmed/23330955
4909,22609854,"MLN0905, a small-molecule plk1 inhibitor, induces antitumor responses in human models of diffuse large B-cell lymphoma.",http://www.ncbi.nlm.nih.gov/pubmed/22609854
4910,25469863,Discovery and in vivo evaluation of (S)-N-(1-(7-fluoro-2-(pyridin-2-yl)quinolin-3-yl)ethyl)-9H-purin-6-amine (AMG319) and related PI3Kδ inhibitors for inflammation and autoimmune disease.,http://www.ncbi.nlm.nih.gov/pubmed/25469863
4911,22935583,"Safety, tolerability, pharmacokinetics and pharmacodynamics of AZD8055 in advanced solid tumours and lymphoma.",http://www.ncbi.nlm.nih.gov/pubmed/22935583
4912,24504419,Antitumor activity and induction of TP53-dependent apoptosis toward ovarian clear cell adenocarcinoma by the dual PI3K/mTOR inhibitor DS-7423.,http://www.ncbi.nlm.nih.gov/pubmed/24504419
4913,,Phase II trial of GDC-0980 (dual PI3K/mTOR inhibitor) in patients with advanced endometrial carcinoma: Final study results.,http://meetinglibrary.asco.org/content/132500-144
4914,26951309,"Randomized Open-Label Phase II Trial of Apitolisib (GDC-0980), a Novel Inhibitor of the PI3K/Mammalian Target of Rapamycin Pathway, Versus Everolimus in Patients With Metastatic Renal Cell Carcinoma.",http://www.ncbi.nlm.nih.gov/pubmed/26951309
4915,26787751,"Phase I Study of Apitolisib (GDC-0980), Dual Phosphatidylinositol-3-Kinase and Mammalian Target of Rapamycin Kinase Inhibitor, in Patients with Advanced Solid Tumors.",http://www.ncbi.nlm.nih.gov/pubmed/26787751
4916,,In vitro sensitivity data suggests targeting several tumor types and molecular subtypes with the PI3K inhibitor GSK1059615 could maximize response rates in early clinical trials,http://clincancerres.aacrjournals.org/content/14/19_Supplement/B37.short
4917,26145171,Promotion of BRCA2-Dependent Homologous Recombination by DSS1 via RPA Targeting and DNA Mimicry.,http://www.ncbi.nlm.nih.gov/pubmed/26145171
4918,23024267,Identification of the deleted in split hand/split foot 1 protein as a novel biomarker for human cervical cancer.,http://www.ncbi.nlm.nih.gov/pubmed/23024267
4919,24289229,Breast cancers with high DSS1 expression that potentially maintains BRCA2 stability have poor prognosis in the relapse-free survival.,http://www.ncbi.nlm.nih.gov/pubmed/24289229
4920,26968357,"Rigosertib versus best supportive care for patients with high-risk myelodysplastic syndromes after failure of hypomethylating drugs (ONTIME): a randomised, controlled, phase 3 trial.",http://www.ncbi.nlm.nih.gov/pubmed/26968357
4921,25425962,"Anti-tumor effect of a novel PI3-kinase inhibitor, SF1126, in (12) V-Ha-Ras transgenic mouse glioma model.",http://www.ncbi.nlm.nih.gov/pubmed/25425962
4922,25528496,Phase II study of the PI3K inhibitor pilaralisib (SAR245408; XL147) in patients with advanced or recurrent endometrial carcinoma.,http://www.ncbi.nlm.nih.gov/pubmed/25528496
4923,24900269,Highly Selective and Potent Thiophenes as PI3K Inhibitors with Oral Antitumor Activity.,http://www.ncbi.nlm.nih.gov/pubmed/24900269
4924,24240111,Targeting small cell lung cancer harboring PIK3CA mutation with a selective oral PI3K inhibitor PF-4989216.,http://www.ncbi.nlm.nih.gov/pubmed/24240111
4925,25574601,"Molecular targeting of the oncoprotein PLK1 in pediatric acute myeloid leukemia: RO3280, a novel PLK1 inhibitor, induces apoptosis in leukemia cells.",http://www.ncbi.nlm.nih.gov/pubmed/25574601
4926,25447675,Calling in SYK: SYK's dual role as a tumor promoter and tumor suppressor in cancer.,http://www.ncbi.nlm.nih.gov/pubmed/25447675
4927,19473291,"Combination of taxol and Bcl-2 siRNA induces apoptosis in human glioblastoma cells and inhibits invasion, angiogenesis and tumour growth.",http://www.ncbi.nlm.nih.gov/pubmed/19473291
4928,24975478,Getting Syk: spleen tyrosine kinase as a therapeutic target.,http://www.ncbi.nlm.nih.gov/pubmed/24975478
4929,22188812,"TAK-960, a novel, orally available, selective inhibitor of polo-like kinase 1, shows broad-spectrum preclinical antitumor activity in multiple dosing regimens.",http://www.ncbi.nlm.nih.gov/pubmed/22188812
4930,23220742,The selective SYK inhibitor P505-15 (PRT062607) inhibits B cell signaling and function in vitro and in vivo and augments the activity of fludarabine in chronic lymphocytic leukemia.,http://www.ncbi.nlm.nih.gov/pubmed/23220742
4931,26372358,Genomic signatures for paclitaxel and gemcitabine resistance in breast cancer derived by machine learning.,http://www.ncbi.nlm.nih.gov/pubmed/26372358
4932,10432288,Bcl-2-mediated drug resistance: inhibition of apoptosis by blocking nuclear factor of activated T lymphocytes (NFAT)-induced Fas ligand transcription.,http://www.ncbi.nlm.nih.gov/pubmed/10432288
4933,26251761,Analysis of the anti-proliferative and the pro-apoptotic efficacy of Syk inhibition in multiple myeloma.,http://www.ncbi.nlm.nih.gov/pubmed/26251761
4934,16946104,"R406, an orally available spleen tyrosine kinase inhibitor blocks fc receptor signaling and reduces immune complex-mediated inflammation.",http://www.ncbi.nlm.nih.gov/pubmed/16946104
4935,7961959,"Inhibition of mast cell Fc epsilon R1-mediated signaling and effector function by the Syk-selective inhibitor, piceatannol.",http://www.ncbi.nlm.nih.gov/pubmed/7961959
4936,22362000,"Selective, novel spleen tyrosine kinase (Syk) inhibitors suppress chronic lymphocytic leukemia B-cell activation and migration.",http://www.ncbi.nlm.nih.gov/pubmed/22362000
4937,21839059,Polo-box domain inhibitor poloxin activates the spindle assembly checkpoint and inhibits tumor growth in vivo.,http://www.ncbi.nlm.nih.gov/pubmed/21839059
4938,9706977,Expression of melan-A (MART1) in benign melanocytic nevi and primary cutaneous malignant melanoma.,http://www.ncbi.nlm.nih.gov/pubmed/9706977
4939,17899082,Concentrations of the DNA methyltransferase inhibitor 5-fluoro-2'-deoxycytidine (FdCyd) and its cytotoxic metabolites in plasma of patients treated with FdCyd and tetrahydrouridine (THU).,http://www.ncbi.nlm.nih.gov/pubmed/17899082
4940,18978467,Hyper IgE syndrome: an update on clinical aspects and the role of signal transducer and activator of transcription 3.,http://www.ncbi.nlm.nih.gov/pubmed/18978467
4941,22591296,Somatic STAT3 mutations in large granular lymphocytic leukemia.,http://www.ncbi.nlm.nih.gov/pubmed/22591296
4942,23861822,A novel missense (M206K) STAT3 mutation in diffuse large B cell lymphoma deregulates STAT3 signaling.,http://www.ncbi.nlm.nih.gov/pubmed/23861822
4943,26921394,High Sensitivity of an Ha-RAS Transgenic Model of Superficial Bladder Cancer to Metformin Is Associated with ∼240-Fold Higher Drug Concentration in Urine than Serum.,http://www.ncbi.nlm.nih.gov/pubmed/26921394
4944,22581330,STAT3 mutations correlated with hyper-IgE syndrome lead to blockage of IL-6/STAT3 signalling pathway.,http://www.ncbi.nlm.nih.gov/pubmed/22581330
4945,26419508,Activating somatic mutations outside the SH2-domain of STAT3 in LGL leukemia.,http://www.ncbi.nlm.nih.gov/pubmed/26419508
4946,9765152,Alterations of the PPP2R1B gene in human lung and colon cancer.,http://www.ncbi.nlm.nih.gov/pubmed/9765152
4947,10713707,Low frequency of alterations of the alpha (PPP2R1A) and beta (PPP2R1B) isoforms of the subunit A of the serine-threonine phosphatase 2A in human neoplasms.,http://www.ncbi.nlm.nih.gov/pubmed/10713707
4948,,"Abstract LB-289: A phase I dose escalation study of TKM-080301, a RNAi therapeutic directed against PLK1, in patients with advanced solid tumors",http://cancerres.aacrjournals.org/content/73/8_Supplement/LB-289
4949,19421227,A novel treatment strategy targeting polo-like kinase 1 in hematological malignancies.,http://www.ncbi.nlm.nih.gov/pubmed/19421227
4950,18602572,"Novel signal transducer and activator of transcription 3 (STAT3) mutations, reduced T(H)17 cell numbers, and variably defective STAT3 phosphorylation in hyper-IgE syndrome.",http://www.ncbi.nlm.nih.gov/pubmed/18602572
4951,25696919,"An open-label phase 2 trial of entospletinib (GS-9973), a selective spleen tyrosine kinase inhibitor, in chronic lymphocytic leukemia.",http://www.ncbi.nlm.nih.gov/pubmed/25696919
4952,26707592,A phase II trial to evaluate the efficacy of fostamatinib in patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL).,http://www.ncbi.nlm.nih.gov/pubmed/26707592
4953,20139717,Biological impact of freezing Plk1 in its inactive conformation in cancer cells.,http://www.ncbi.nlm.nih.gov/pubmed/20139717
4954,20151979,Targeting SYK kinase-dependent anti-apoptotic resistance pathway in B-lineage acute lymphoblastic leukaemia (ALL) cells with a potent SYK inhibitory pentapeptide mimic.,http://www.ncbi.nlm.nih.gov/pubmed/20151979
4955,16484589,Cell-surface CD74 initiates a signaling cascade leading to cell proliferation and survival.,http://www.ncbi.nlm.nih.gov/pubmed/16484589
4956,21228923,Enhanced expression of CD74 in gastrointestinal cancers and benign tissues.,http://www.ncbi.nlm.nih.gov/pubmed/21228923
4957,23877438,CD74-ROS1 fusion transcripts in resected non-small cell lung carcinoma.,http://www.ncbi.nlm.nih.gov/pubmed/23877438
4958,26657509,Efficacy and toxicity of bevacizumab in recurrent ovarian disease: an update meta-analysis on phase III trials.,http://www.ncbi.nlm.nih.gov/pubmed/26657509
4959,26883202,"A novel small molecule STAT3 inhibitor, LY5, inhibits cell viability, colony formation, and migration of colon and liver cancer cells.",http://www.ncbi.nlm.nih.gov/pubmed/26883202
4960,26534966,Phase I Clinical Trial of Ipilimumab in Pediatric Patients with Advanced Solid Tumors.,http://www.ncbi.nlm.nih.gov/pubmed/26534966
4961,23149917,"Angiopoietin-2 functions as a Tie2 agonist in tumor models, where it limits the effects of VEGF inhibition.",http://www.ncbi.nlm.nih.gov/pubmed/23149917
4962,26490310,"A Phase I First-in-Human Study of Nesvacumab (REGN910), a Fully Human Anti-Angiopoietin-2 (Ang2) Monoclonal Antibody, in Patients with Advanced Solid Tumors.",http://www.ncbi.nlm.nih.gov/pubmed/26490310
4963,,"Targeting p53 mutant ovarian cancer: Phase I results of the WEE1 inhibitor MK-1775 with carboplatin plus paclitaxel in patients (pts) with platinum-sensitive, p53-mutant ovarian cancer (OC).",http://meetinglibrary.asco.org/content/110824-132
4964,19039322,Global target profile of the kinase inhibitor bosutinib in primary chronic myeloid leukemia cells.,http://www.ncbi.nlm.nih.gov/pubmed/19039322
4965,22322295,Ack1 tyrosine kinase activation correlates with pancreatic cancer progression.,http://www.ncbi.nlm.nih.gov/pubmed/22322295
4966,20623637,Effect of Ack1 tyrosine kinase inhibitor on ligand-independent androgen receptor activity.,http://www.ncbi.nlm.nih.gov/pubmed/20623637
4967,22773903,Phosphomannopentaose sulfate (PI-88) suppresses angiogenesis by downregulating heparanase and vascular endothelial growth factor in an oxygen-induced retinal neovascularization animal model.,http://www.ncbi.nlm.nih.gov/pubmed/22773903
4968,25699576,Development of novel ACK1/TNK2 inhibitors using a fragment-based approach.,http://www.ncbi.nlm.nih.gov/pubmed/25699576
4969,25170226,Adjuvant heparanase inhibitor PI-88 therapy for hepatocellular carcinoma recurrence.,http://www.ncbi.nlm.nih.gov/pubmed/25170226
4970,25985938,Colorectal cancer: POLR2A deletion with TP53 opens a window of opportunity for therapy.,http://www.ncbi.nlm.nih.gov/pubmed/25985938
4971,8990153,RNA polymerase II transcription initiation: a structural view.,http://www.ncbi.nlm.nih.gov/pubmed/8990153
4972,26500236,Safety and Pharmacokinetics of Lenvatinib in Patients with Advanced Hepatocellular Carcinoma.,http://www.ncbi.nlm.nih.gov/pubmed/26500236
4973,19293255,PPM1D is a potential therapeutic target in ovarian clear cell carcinomas.,http://www.ncbi.nlm.nih.gov/pubmed/19293255
4974,22379189,HDM2 promotes WIP1-mediated medulloblastoma growth.,http://www.ncbi.nlm.nih.gov/pubmed/22379189
4975,16311512,Regulation of the antioncogenic Chk2 kinase by the oncogenic Wip1 phosphatase.,http://www.ncbi.nlm.nih.gov/pubmed/16311512
4976,26016894,Combined Inhibition of MEK and Plk1 Has Synergistic Antitumor Activity in NRAS Mutant Melanoma.,http://www.ncbi.nlm.nih.gov/pubmed/26016894
4977,20576088,RNA interference (RNAi) screening approach identifies agents that enhance paclitaxel activity in breast cancer cells.,http://www.ncbi.nlm.nih.gov/pubmed/20576088
4978,26804704,Induction of cell death by the novel proteasome inhibitor marizomib in glioblastoma in vitro and in vivo.,http://www.ncbi.nlm.nih.gov/pubmed/26804704
4979,25658463,WIP1 phosphatase as a potential therapeutic target in neuroblastoma.,http://www.ncbi.nlm.nih.gov/pubmed/25658463
4980,20432460,Shepherding AKT and androgen receptor by Ack1 tyrosine kinase.,http://www.ncbi.nlm.nih.gov/pubmed/20432460
4981,23597703,ACK1 tyrosine kinase: targeted inhibition to block cancer cell proliferation.,http://www.ncbi.nlm.nih.gov/pubmed/23597703
4982,25699237,Therapeutic Re-Activation of Protein Phosphatase 2A in Acute Myeloid Leukemia.,http://www.ncbi.nlm.nih.gov/pubmed/25699237
4983,19879149,WIP1 phosphatase at the crossroads of cancer and aging.,http://www.ncbi.nlm.nih.gov/pubmed/19879149
4984,22262169,Mouse model for probing tumor suppressor activity of protein phosphatase 2A in diverse signaling pathways.,http://www.ncbi.nlm.nih.gov/pubmed/22262169
4985,,"First-in-human study of oral S 49076, a MET/AXL/FGFR inhibitor, in advanced solid tumors",http://annonc.oxfordjournals.org/content/26/suppl_9/ix37.1.full
4986,,"A first-in-human phase I/Ib study of receptor tyrosine kinase (RTK) inhibitor, MGCD516, in patients with advanced solid tumors",http://meetinglibrary.asco.org/content/146823-156
4987,,"MGCD265, a multitargeted oral tyrosine kinase receptor inhibitor of Met and VEGFR, in combination with docetaxel.",http://meetinglibrary.asco.org/content/96214-114
4988,,"MGCD265, a multitargeted oral tyrosine kinase receptor inhibitor of Met and VEGFR, in combination with erlotinib in patients with advanced solid tumors.",http://meetinglibrary.asco.org/content/96526-114
4989,22102614,A rapid and cell-free assay to test the activity of lynch syndrome-associated MSH2 and MSH6 missense variants.,http://www.ncbi.nlm.nih.gov/pubmed/22102614
4990,19666565,Small-molecule inhibitors reveal multiple strategies for Hedgehog pathway blockade.,http://www.ncbi.nlm.nih.gov/pubmed/19666565
4991,26683772,Bromodomain and hedgehog pathway targets in small cell lung cancer.,http://www.ncbi.nlm.nih.gov/pubmed/26683772
4992,22027695,A polymeric nanoparticle encapsulated small-molecule inhibitor of Hedgehog signaling (NanoHHI) bypasses secondary mutational resistance to Smoothened antagonists.,http://www.ncbi.nlm.nih.gov/pubmed/22027695
4993,21868763,Polymeric nanoparticle-encapsulated hedgehog pathway inhibitor HPI-1 (NanoHHI) inhibits systemic metastases in an orthotopic model of human hepatocellular carcinoma.,http://www.ncbi.nlm.nih.gov/pubmed/21868763
4994,22072503,In vitro and in vivo characterization of a novel Hedgehog signaling antagonist in human glioblastoma cell lines.,http://www.ncbi.nlm.nih.gov/pubmed/22072503
4995,23825539,Multimodal Treatment Eliminates Cancer Stem Cells and Leads to Long-Term Survival in Primary Human Pancreatic Cancer Tissue Xenografts.,http://www.ncbi.nlm.nih.gov/pubmed/23825539
4996,25528764,The role of AXL and the in vitro activity of the receptor tyrosine kinase inhibitor BGB324 in Ewing sarcoma.,http://www.ncbi.nlm.nih.gov/pubmed/25528764
4997,26036314,Axl receptor tyrosine kinase is up-regulated in metformin resistant prostate cancer cells.,http://www.ncbi.nlm.nih.gov/pubmed/26036314
4998,25767293,AXL Is a Logical Molecular Target in Head and Neck Squamous Cell Carcinoma.,http://www.ncbi.nlm.nih.gov/pubmed/25767293
4999,26720423,First-Line Erlotinib Therapy Until and Beyond Response Evaluation Criteria in Solid Tumors Progression in Asian Patients With Epidermal Growth Factor Receptor Mutation-Positive Non-Small-Cell Lung Cancer: The ASPIRATION Study.,http://www.ncbi.nlm.nih.gov/pubmed/26720423
5000,26206333,NSCLC Driven by DDR2 Mutation Is Sensitive to Dasatinib and JQ1 Combination Therapy.,http://www.ncbi.nlm.nih.gov/pubmed/26206333
5001,24026012,Axl mediates acquired resistance of head and neck cancer cells to the epidermal growth factor receptor inhibitor erlotinib.,http://www.ncbi.nlm.nih.gov/pubmed/24026012
5002,20145120,"R428, a selective small molecule inhibitor of Axl kinase, blocks tumor spread and prolongs survival in models of metastatic breast cancer.",http://www.ncbi.nlm.nih.gov/pubmed/20145120
5003,22247788,"Design, Synthesis and Biological Evaluation of a Series of Novel Axl Kinase Inhibitors.",http://www.ncbi.nlm.nih.gov/pubmed/22247788
5004,11607819,Molecular mechanisms of leukemogenesis mediated by MLL fusion proteins.,http://www.ncbi.nlm.nih.gov/pubmed/11607819
5005,25673699,Targeted Axl Inhibition Primes Chronic Lymphocytic Leukemia B Cells to Apoptosis and Shows Synergistic/Additive Effects in Combination with BTK Inhibitors.,http://www.ncbi.nlm.nih.gov/pubmed/25673699
5006,23704351,Dynamic trafficking of STAT5 depends on an unconventional nuclear localization signal.,http://www.ncbi.nlm.nih.gov/pubmed/23704351
5007,20194896,The AF4.MLL fusion protein is capable of inducing ALL in mice without requirement of MLL.AF4.,http://www.ncbi.nlm.nih.gov/pubmed/20194896
5008,16169901,"The MLL fusion gene, MLL-AF4, regulates cyclin-dependent kinase inhibitor CDKN1B (p27kip1) expression.",http://www.ncbi.nlm.nih.gov/pubmed/16169901
5009,9250666,Immortalization and leukemic transformation of a myelomonocytic precursor by retrovirally transduced HRX-ENL.,http://www.ncbi.nlm.nih.gov/pubmed/9250666
5010,26627013,The CDK9 Inhibitor Dinaciclib Exerts Potent Apoptotic and Antitumor Effects in Preclinical Models of MLL-Rearranged Acute Myeloid Leukemia.,http://www.ncbi.nlm.nih.gov/pubmed/26627013
5011,18785960,"mTOR, cancer and transplantation.",http://www.ncbi.nlm.nih.gov/pubmed/18785960
5012,18790754,SPC3042: a proapoptotic survivin inhibitor.,http://www.ncbi.nlm.nih.gov/pubmed/18790754
5013,26983495,Survivin selective inhibitor YM155 promotes cisplatin‑induced apoptosis in embryonal rhabdomyosarcoma.,http://www.ncbi.nlm.nih.gov/pubmed/26983495
5014,10823841,Constitutive activation of STAT5 by a point mutation in the SH2 domain.,http://www.ncbi.nlm.nih.gov/pubmed/10823841
5015,25486469,Sirtuin deacetylases: a new target for melanoma management.,http://www.ncbi.nlm.nih.gov/pubmed/25486469
5016,11413148,Transcription factor STAT5A is a substrate of Bruton's tyrosine kinase in B cells.,http://www.ncbi.nlm.nih.gov/pubmed/11413148
5017,26901067,Frequent somatic CDH1 loss-of-function mutations in plasmacytoid variant bladder cancer.,http://www.ncbi.nlm.nih.gov/pubmed/26901067
5018,26152429,"Structure-activity relationship studies of QS11, a small molecule Wnt synergistic agonist.",http://www.ncbi.nlm.nih.gov/pubmed/26152429
5019,17460038,Small-molecule synergist of the Wnt/beta-catenin signaling pathway.,http://www.ncbi.nlm.nih.gov/pubmed/17460038
5020,26373572,Activin Receptor-like Kinase 1 Ligand Trap Reduces Microvascular Density and Improves Chemotherapy Efficiency to Various Solid Tumors.,http://www.ncbi.nlm.nih.gov/pubmed/26373572
5021,20124460,ALK1-Fc inhibits multiple mediators of angiogenesis and suppresses tumor growth.,http://www.ncbi.nlm.nih.gov/pubmed/20124460
5022,25708802,Activin receptor inhibitors--dalantercept.,http://www.ncbi.nlm.nih.gov/pubmed/25708802
5023,25888978,"Phase II evaluation of dalantercept, a soluble recombinant activin receptor-like kinase 1 (ALK1) receptor fusion protein, for the treatment of recurrent or persistent endometrial cancer: an NRG Oncology/Gynecologic Oncology Group Study 0229N.",http://www.ncbi.nlm.nih.gov/pubmed/25888978
5024,24247240,Differences in the regulation of K-Ras and H-Ras isoforms by monoubiquitination.,http://www.ncbi.nlm.nih.gov/pubmed/24247240
5025,24531387,ImmTAC-redirected tumour cell killing induces and potentiates antigen cross-presentation by dendritic cells.,http://www.ncbi.nlm.nih.gov/pubmed/24531387
5026,27009859,TKI sensitivity patterns of novel kinase-domain mutations suggest therapeutic opportunities for patients with resistant ALK+ tumors.,http://www.ncbi.nlm.nih.gov/pubmed/27009859
5027,23980167,SIRT1 regulates adaptive response of the growth hormone--insulin-like growth factor-I axis under fasting conditions in liver.,http://www.ncbi.nlm.nih.gov/pubmed/23980167
5028,25393796,Identification of a novel HIP1-ALK fusion variant in Non-Small-Cell Lung Cancer (NSCLC) and discovery of ALK I1171 (I1171N/S) mutations in two ALK-rearranged NSCLC patients with resistance to Alectinib.,http://www.ncbi.nlm.nih.gov/pubmed/25393796
5029,25749034,NPM/ALK mutants resistant to ASP3026 display variable sensitivity to alternative ALK inhibitors but succumb to the novel compound PF-06463922.,http://www.ncbi.nlm.nih.gov/pubmed/25749034
5030,26168268,B56δ-related protein phosphatase 2A dysfunction identified in patients with intellectual disability.,http://www.ncbi.nlm.nih.gov/pubmed/26168268
5031,24451369,Shear stress-induced redistribution of vascular endothelial-protein-tyrosine phosphatase (VE-PTP) in endothelial cells and its role in cell elongation.,http://www.ncbi.nlm.nih.gov/pubmed/24451369
5032,23394126,"Discovery of a novel class of highly potent, selective, ATP-competitive, and orally bioavailable inhibitors of the mammalian target of rapamycin (mTOR).",http://www.ncbi.nlm.nih.gov/pubmed/23394126
5033,,"Abstract 4484: AR-mTOR-26 - A potent, selective mTORC 1/2 kinase inhibitor for the treatment of malignancy",http://cancerres.aacrjournals.org/content/70/8_Supplement/4484.short
5034,,Novel small molecule inhibitors of signal transducer and activator of transcription (STAT3) for cancer treatment.,http://mct.aacrjournals.org/content/12/11_Supplement/C180.short
5035,24030701,"The mTOR kinase inhibitors, CC214-1 and CC214-2, preferentially block the growth of EGFRvIII-activated glioblastomas.",http://www.ncbi.nlm.nih.gov/pubmed/24030701
5036,23414803,"Use of core modification in the discovery of CC214-2, an orally available, selective inhibitor of mTOR kinase.",http://www.ncbi.nlm.nih.gov/pubmed/23414803
5037,22896668,"Antitumor activity of Triolimus: a novel multidrug-loaded micelle containing Paclitaxel, Rapamycin, and 17-AAG.",http://www.ncbi.nlm.nih.gov/pubmed/22896668
5038,25912076,"Phase I study of OPB-51602, an oral inhibitor of signal transducer and activator of transcription 3, in patients with relapsed/refractory hematological malignancies.",http://www.ncbi.nlm.nih.gov/pubmed/25912076
5039,22992516,Targeting the PI3K pathway in the brain--efficacy of a PI3K inhibitor optimized to cross the blood-brain barrier.,http://www.ncbi.nlm.nih.gov/pubmed/22992516
5040,25609248,"Phase I and biomarker study of OPB-51602, a novel signal transducer and activator of transcription (STAT) 3 inhibitor, in patients with refractory solid malignancies.",http://www.ncbi.nlm.nih.gov/pubmed/25609248
5041,20371716,"Antitumor efficacy profile of PKI-402, a dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor.",http://www.ncbi.nlm.nih.gov/pubmed/20371716
5042,23512661,ETV1 directs androgen metabolism and confers aggressive prostate cancer in targeted mice and patients.,http://www.ncbi.nlm.nih.gov/pubmed/23512661
5043,,976 Effects of Dual PI3K and mTOR Inhibition on Incidence and Local Growth of Prostate Cancer Bone Metastases,http://www.sciencedirect.com/science/article/pii/S0959804912715940
5044,,"Extended cohort study of OPB51602, a novel inhibitor of STAT3/5 activation, in non-small cell lung carcinoma.",http://meetinglibrary.asco.org/content/127674-144
5045,23402820,"OPB-31121, a novel small molecular inhibitor, disrupts the JAK2/STAT3 pathway and exhibits an antitumor activity in gastric cancer cells.",http://www.ncbi.nlm.nih.gov/pubmed/23402820
5046,25715763,"Phase I Study of OPB-31121, an Oral STAT3 Inhibitor, in Patients with Advanced Solid Tumors.",http://www.ncbi.nlm.nih.gov/pubmed/25715763
5047,25436981,Pre-clinical study of drug combinations that reduce breast cancer burden due to aberrant mTOR and metabolism promoted by LKB1 loss.,http://www.ncbi.nlm.nih.gov/pubmed/25436981
5048,25676869,"Phase 1 and pharmacological trial of OPB-31121, a signal transducer and activator of transcription-3 inhibitor, in patients with advanced hepatocellular carcinoma.",http://www.ncbi.nlm.nih.gov/pubmed/25676869
5049,21298110,Overexpression of full-length ETV1 transcripts in clinical prostate cancer due to gene translocation.,http://www.ncbi.nlm.nih.gov/pubmed/21298110
5050,17390040,Molecular genetic analyses of the TMPRSS2-ERG and TMPRSS2-ETV1 gene fusions in 50 cases of prostate cancer.,http://www.ncbi.nlm.nih.gov/pubmed/17390040
5051,10523827,Divergent Ewing's sarcoma EWS/ETS fusions confer a common tumorigenic phenotype on NIH3T3 cells.,http://www.ncbi.nlm.nih.gov/pubmed/10523827
5052,,"A phase I extension study of BBI608, a first-in-class cancer stem cell (CSC) inhibitor, in patients with advanced solid tumors.",http://meetinglibrary.asco.org/content/135128-144
5053,26574479,Heightening Energetic Stress Selectively Targets LKB1-Deficient Non-Small Cell Lung Cancers.,http://www.ncbi.nlm.nih.gov/pubmed/26574479
5054,25914136,ALK rearrangement testing and treatment patterns for patients with ALK-positive non-small cell lung cancer.,http://www.ncbi.nlm.nih.gov/pubmed/25914136
5055,,A phase Ib/II study of cancer stem cell inhibitor BBI608 administered with panitumumab in KRAS wild-type (wt) patients (pts) with metastatic colorectal cancer (mCRC) following progression on anti-EGFR therapy.,http://meetinglibrary.asco.org/content/153568-156
5056,26899963,Suppression of prostate cancer progression by cancer cell stemness inhibitor napabucasin.,http://www.ncbi.nlm.nih.gov/pubmed/26899963
5057,21911359,Epigenetic regulation by RARα maintains ligand-independent transcriptional activity.,http://www.ncbi.nlm.nih.gov/pubmed/21911359
5058,15103387,Acute promyelocytic leukemia: PML/RARalpha and the leukemic stem cell.,http://www.ncbi.nlm.nih.gov/pubmed/15103387
5059,21526200,"The small molecule, LLL12, inhibits STAT3 phosphorylation and induces apoptosis in medulloblastoma and glioblastoma cells.",http://www.ncbi.nlm.nih.gov/pubmed/21526200
5060,20142330,Lkb1 inactivation is sufficient to drive endometrial cancers that are aggressive yet highly responsive to mTOR inhibitor monotherapy.,http://www.ncbi.nlm.nih.gov/pubmed/20142330
5061,21737619,LLL12 inhibits endogenous and exogenous interleukin-6-induced STAT3 phosphorylation in human pancreatic cancer cells.,http://www.ncbi.nlm.nih.gov/pubmed/21737619
5062,21520044,"A small molecule, LLL12 inhibits constitutive STAT3 and IL-6-induced STAT3 signaling and exhibits potent growth suppressive activity in human multiple myeloma cells.",http://www.ncbi.nlm.nih.gov/pubmed/21520044
5063,21189378,mTOR inhibitor treatment of pancreatic cancer in a patient With Peutz-Jeghers syndrome.,http://www.ncbi.nlm.nih.gov/pubmed/21189378
5064,21340507,"Small molecules, LLL12 and FLLL32, inhibit STAT3 and exhibit potent growth suppressive activity in osteosarcoma cells and tumor growth in mice.",http://www.ncbi.nlm.nih.gov/pubmed/21340507
5065,21109950,"Two small molecule compounds, LLL12 and FLLL32, exhibit potent inhibitory activity on STAT3 in human rhabdomyosarcoma cells.",http://www.ncbi.nlm.nih.gov/pubmed/21109950
5066,20215512,Novel STAT3 phosphorylation inhibitors exhibit potent growth-suppressive activity in pancreatic and breast cancer cells.,http://www.ncbi.nlm.nih.gov/pubmed/20215512
5067,20576164,The small molecule curcumin analog FLLL32 induces apoptosis in melanoma cells via STAT3 inhibition and retains the cellular response to cytokines with anti-tumor activity.,http://www.ncbi.nlm.nih.gov/pubmed/20576164
5068,22899991,Structurally modified curcumin analogs inhibit STAT3 phosphorylation and promote apoptosis of human renal cell carcinoma and melanoma cell lines.,http://www.ncbi.nlm.nih.gov/pubmed/22899991
5069,26515494,A Novel Bioavailable BH3 Mimetic Efficiently Inhibits Colon Cancer via Cascade Effects of Mitochondria.,http://www.ncbi.nlm.nih.gov/pubmed/26515494
5070,25961376,Rational combination of MEK inhibitor and the STAT3 pathway modulator for the therapy in K-Ras mutated pancreatic and colon cancer cells.,http://www.ncbi.nlm.nih.gov/pubmed/25961376
5071,23625191,"An analysis of the treatment effect of panitumumab on overall survival from a phase 3, randomized, controlled, multicenter trial (20020408) in patients with chemotherapy refractory metastatic colorectal cancer.",http://www.ncbi.nlm.nih.gov/pubmed/23625191
5072,25964201,An Oral Formulation of YK-4-279: Preclinical Efficacy and Acquired Resistance Patterns in Ewing Sarcoma.,http://www.ncbi.nlm.nih.gov/pubmed/25964201
5073,26801760,Novel c-Met inhibitor suppresses the growth of c-Met-addicted gastric cancer cells.,http://www.ncbi.nlm.nih.gov/pubmed/26801760
5074,26721945,"Preclinical Evaluation of a Novel Orally Available SRC/Raf/VEGFR2 Inhibitor, SKLB646, in the Treatment of Triple-Negative Breast Cancer.",http://www.ncbi.nlm.nih.gov/pubmed/26721945
5075,26478441,Targeting transcription factor STAT3 for cancer prevention and therapy.,http://www.ncbi.nlm.nih.gov/pubmed/26478441
5076,20461084,STAT3 inhibitor WP1066 as a novel therapeutic agent for renal cell carcinoma.,http://www.ncbi.nlm.nih.gov/pubmed/20461084
5077,21613260,Missense mutations in PML-RARA are critical for the lack of responsiveness to arsenic trioxide treatment.,http://www.ncbi.nlm.nih.gov/pubmed/21613260
5078,23262510,On-target JAK2/STAT3 inhibition slows disease progression in orthotopic xenografts of human glioblastoma brain tumor stem cells.,http://www.ncbi.nlm.nih.gov/pubmed/23262510
5079,25636517,The STAT3 inhibitor WP1066 reverses the resistance of chronic lymphocytic leukemia cells to histone deacetylase inhibitors induced by interleukin-6.,http://www.ncbi.nlm.nih.gov/pubmed/25636517
5080,27016230,Copy number deletion of RAD50 as predictive marker of BRCAness and PARP inhibitor response in BRCA wild type ovarian cancer.,http://www.ncbi.nlm.nih.gov/pubmed/27016230
5081,26310543,"Seribantumab, an Anti-ERBB3 Antibody, Delays the Onset of Resistance and Restores Sensitivity to Letrozole in an Estrogen Receptor-Positive Breast Cancer Model.",http://www.ncbi.nlm.nih.gov/pubmed/26310543
5082,25010037,Potentiation of tumor responses to DNA damaging therapy by the selective ATR inhibitor VX-970.,http://www.ncbi.nlm.nih.gov/pubmed/25010037
5083,26832792,Inhibition of HSP90 by AUY922 Preferentially Kills Mutant KRAS Colon Cancer Cells by Activating Bim through ER Stress.,http://www.ncbi.nlm.nih.gov/pubmed/26832792
5084,26517239,The orally active and bioavailable ATR kinase inhibitor AZD6738 potentiates the anti-tumor effects of cisplatin to resolve ATM-deficient non-small cell lung cancer in vivo.,http://www.ncbi.nlm.nih.gov/pubmed/26517239
5085,26563132,ATR inhibition induces synthetic lethality and overcomes chemoresistance in TP53- or ATM-defective chronic lymphocytic leukemia cells.,http://www.ncbi.nlm.nih.gov/pubmed/26563132
5086,25585815,The ATM inhibitor KU55933 sensitizes radioresistant bladder cancer cells with DAB2IP gene defect.,http://www.ncbi.nlm.nih.gov/pubmed/25585815
5087,26116172,YU238259 Is a Novel Inhibitor of Homology-Dependent DNA Repair That Exhibits Synthetic Lethality and Radiosensitization in Repair-Deficient Tumors.,http://www.ncbi.nlm.nih.gov/pubmed/26116172
5088,26970174,The clinical outcome of pazopanib treatment in Japanese patients with relapsed soft tissue sarcoma: A Japanese Musculoskeletal Oncology Group (JMOG) study.,http://www.ncbi.nlm.nih.gov/pubmed/26970174
5089,26621868,"ML264, A Novel Small-Molecule Compound That Potently Inhibits Growth of Colorectal Cancer.",http://www.ncbi.nlm.nih.gov/pubmed/26621868
5090,25908781,"Pan-HER, an Antibody Mixture Simultaneously Targeting EGFR, HER2, and HER3, Effectively Overcomes Tumor Heterogeneity and Plasticity.",http://www.ncbi.nlm.nih.gov/pubmed/25908781
5091,26420857,Pan-HER Inhibitor Augments Radiation Response in Human Lung and Head and Neck Cancer Models.,http://www.ncbi.nlm.nih.gov/pubmed/26420857
5092,23830798,Retinoic acid receptor alpha amplifications and retinoic acid sensitivity in breast cancers.,http://www.ncbi.nlm.nih.gov/pubmed/23830798
5093,26671995,The New Antitumor Drug ABTL0812 Inhibits the Akt/mTORC1 Axis by Upregulating Tribbles-3 Pseudokinase.,http://www.ncbi.nlm.nih.gov/pubmed/26671995
5094,25915946,Molecular and Functional Characterization of Three Different Postzygotic Mutations in PIK3CA-Related Overgrowth Spectrum (PROS) Patients: Effects on PI3K/AKT/mTOR Signaling and Sensitivity to PIK3 Inhibitors.,http://www.ncbi.nlm.nih.gov/pubmed/25915946
5095,10049754,Mechanism of Ret activation by a mutation at aspartic acid 631 identified in sporadic pheochromocytoma.,http://www.ncbi.nlm.nih.gov/pubmed/10049754
5096,16276521,The glycine 90 to aspartate alteration in the Abeta subunit of PP2A (PPP2R1B) associates with breast cancer and causes a deficit in protein function.,http://www.ncbi.nlm.nih.gov/pubmed/16276521
5097,14767517,PPP2R1B gene alterations inhibit interaction of PP2A-Abeta and PP2A-C proteins in colorectal cancers.,http://www.ncbi.nlm.nih.gov/pubmed/14767517
5098,26880801,Small-Molecule Inhibition of GCNT3 Disrupts Mucin Biosynthesis and Malignant Cellular Behaviors in Pancreatic Cancer.,http://www.ncbi.nlm.nih.gov/pubmed/26880801
5099,24225776,Structural and molecular basis of ZNRF3/RNF43 transmembrane ubiquitin ligase inhibition by the Wnt agonist R-spondin.,http://www.ncbi.nlm.nih.gov/pubmed/24225776
5100,25688104,SU2C phase Ib study of paclitaxel and MK-2206 in advanced solid tumors and metastatic breast cancer.,http://www.ncbi.nlm.nih.gov/pubmed/25688104
5101,26668189,A Novel Inhibitor of Topoisomerase I Is Selectively Toxic for a Subset of Non-Small Cell Lung Cancer Cell Lines.,http://www.ncbi.nlm.nih.gov/pubmed/26668189
5102,26884555,Phase I Study of the Aurora A Kinase Inhibitor Alisertib in Combination With Irinotecan and Temozolomide for Patients With Relapsed or Refractory Neuroblastoma: A NANT (New Approaches to Neuroblastoma Therapy) Trial.,http://www.ncbi.nlm.nih.gov/pubmed/26884555
5103,26951227,Mutant Calreticulin Requires Both Its Mutant C-terminus and the Thrombopoietin Receptor for Oncogenic Transformation.,http://www.ncbi.nlm.nih.gov/pubmed/26951227
5104,25326232,"Analysis of 1,115 patients tested for MET amplification and therapy response in the MD Anderson Phase I Clinic.",http://www.ncbi.nlm.nih.gov/pubmed/25326232
5105,27004155,KDR Mutation as a Novel Predictive Biomarker of Exceptional Response to Regorafenib in Metastatic Colorectal Cancer.,http://www.ncbi.nlm.nih.gov/pubmed/27004155
5106,26826182,Functional Analyses of Mutations in Receptor Tyrosine Kinase Genes in Non-Small Cell Lung Cancer: Double-Edged Sword of DDR2.,http://www.ncbi.nlm.nih.gov/pubmed/26826182
5107,26716400,Sunitinib (SU11248) in patients with chemo naive extensive small cell lung cancer or who have a 'chemosensitive' relapse: A single-arm phase II study (EORTC-08061).,http://www.ncbi.nlm.nih.gov/pubmed/26716400
5108,27002107,Cetuximab continuation after first progression in metastatic colorectal cancer (CAPRI-GOIM): a randomized phase II trial of FOLFOX plus cetuximab versus FOLFOX.,http://www.ncbi.nlm.nih.gov/pubmed/27002107
5109,26760500,Metformin Treatment Does Not Inhibit Growth of Pancreatic Cancer Patient-Derived Xenografts.,http://www.ncbi.nlm.nih.gov/pubmed/26760500
5110,26883273,Identification of a Small Molecule That Overcomes HdmX-Mediated Suppression of p53.,http://www.ncbi.nlm.nih.gov/pubmed/26883273
5111,17850214,The selectivity of protein kinase inhibitors: a further update.,http://www.ncbi.nlm.nih.gov/pubmed/17850214
5112,21406405,MAP kinase-interacting kinase 1 regulates SMAD2-dependent TGF-β signaling pathway in human glioblastoma.,http://www.ncbi.nlm.nih.gov/pubmed/21406405
5113,26609108,Differential Regulation of ZEB1 and EMT by MAPK-Interacting Protein Kinases (MNK) and eIF4E in Pancreatic Cancer.,http://www.ncbi.nlm.nih.gov/pubmed/26609108
5114,21811581,The action mechanism of the Myc inhibitor termed Omomyc may give clues on how to target Myc for cancer therapy.,http://www.ncbi.nlm.nih.gov/pubmed/21811581
5115,25114221,Inhibitor of MYC identified in a Kröhnke pyridine library.,http://www.ncbi.nlm.nih.gov/pubmed/25114221
5116,27014780,Phase I dose escalation study of temsirolimus in combination with metformin in patients with advanced/refractory cancers.,http://www.ncbi.nlm.nih.gov/pubmed/27014780
5117,26666870,Evaluation of WO2014207069 A1: Multitarget Hedgehog pathway inhibitors and uses thereof.,http://www.ncbi.nlm.nih.gov/pubmed/26666870
5118,22735455,Protein L-isoaspartyl methyltransferase regulates p53 activity.,http://www.ncbi.nlm.nih.gov/pubmed/22735455
5119,26833127,STK11/LKB1 Deficiency Promotes Neutrophil Recruitment and Proinflammatory Cytokine Production to Suppress T-cell Activity in the Lung Tumor Microenvironment.,http://www.ncbi.nlm.nih.gov/pubmed/26833127
5120,27036973,Phase 2 Study of Bevacizumab and Temsirolimus After VEGFR TKI in Metastatic Renal Cell Carcinoma.,http://www.ncbi.nlm.nih.gov/pubmed/27036973
5121,25900182,Phase I study of the anti-IGF1R antibody cixutumumab with everolimus and octreotide in advanced well-differentiated neuroendocrine tumors.,http://www.ncbi.nlm.nih.gov/pubmed/25900182
5122,26832798,Dissecting Therapeutic Resistance to ERK Inhibition.,http://www.ncbi.nlm.nih.gov/pubmed/26832798
5123,25999370,DRUG DEVELOPMENT. Phthalimide conjugation as a strategy for in vivo target protein degradation.,http://www.ncbi.nlm.nih.gov/pubmed/25999370
5124,25043025,Targeting transcription regulation in cancer with a covalent CDK7 inhibitor.,http://www.ncbi.nlm.nih.gov/pubmed/25043025
5125,25416950,CDK7 inhibition suppresses super-enhancer-linked oncogenic transcription in MYCN-driven cancer.,http://www.ncbi.nlm.nih.gov/pubmed/25416950
5126,25490451,Targeting transcriptional addictions in small cell lung cancer with a covalent CDK7 inhibitor.,http://www.ncbi.nlm.nih.gov/pubmed/25490451
5127,26936398,Somatic Copy Number Amplification and Hyperactivating Somatic Mutations of EZH2 Correlate With DNA Methylation and Drive Epigenetic Silencing of Genes Involved in Tumor Suppression and Immune Responses in Melanoma.,http://www.ncbi.nlm.nih.gov/pubmed/26936398
5128,26369631,Sensitivity of KRAS-Mutant Colorectal Cancers to Combination Therapy That Cotargets MEK and CDK4/6.,http://www.ncbi.nlm.nih.gov/pubmed/26369631
5129,26314551,The distribution of BRAF gene fusions in solid tumors and response to targeted therapy.,http://www.ncbi.nlm.nih.gov/pubmed/26314551
5130,26939704,"Entrectinib, a Pan-TRK, ROS1, and ALK Inhibitor with Activity in Multiple Molecularly Defined Cancer Indications.",http://www.ncbi.nlm.nih.gov/pubmed/26939704
5131,26240273,Preclinical Efficacy and Safety Assessment of an Antibody-Drug Conjugate Targeting the c-RET Proto-Oncogene for Breast Carcinoma.,http://www.ncbi.nlm.nih.gov/pubmed/26240273
5132,26269605,CXCR4 Protein Epitope Mimetic Antagonist POL5551 Disrupts Metastasis and Enhances Chemotherapy Effect in Triple-Negative Breast Cancer.,http://www.ncbi.nlm.nih.gov/pubmed/26269605
5133,27040853,"ER2, a novel human anti-EGFR monoclonal antibody inhibit tumor activity in non-small cell lung cancer models.",http://www.ncbi.nlm.nih.gov/pubmed/27040853
5134,26918217,A Rare Finding of a BRAF Mutation in Renal Cell Carcinoma with Response to BRAF-Directed Targeted Therapy.,http://www.ncbi.nlm.nih.gov/pubmed/26918217
5135,26825170,EGF816 Exerts Anticancer Effects in Non-Small Cell Lung Cancer by Irreversibly and Selectively Targeting Primary and Acquired Activating Mutations in the EGF Receptor.,http://www.ncbi.nlm.nih.gov/pubmed/26825170
5136,24345920,BRAF fusions define a distinct molecular subset of melanomas with potential sensitivity to MEK inhibition.,http://www.ncbi.nlm.nih.gov/pubmed/24345920
5137,,Abstract 3942: Oncogenic BRAF fusion induces MAPK-pathway activation targeted by MEK inhibitor and phosphatidylinositol 3-kinase inhibitor combination treatment in mucosal melanoma,http://cancerres.aacrjournals.org/content/75/15_Supplement/3942
5138,11127820,MDM2-dependent ubiquitination of nuclear and cytoplasmic P53.,http://www.ncbi.nlm.nih.gov/pubmed/11127820
5139,16109776,Mutations in nucleophosmin (NPM1) in acute myeloid leukemia (AML): association with other gene abnormalities and previously established gene expression signatures and their favorable prognostic significance.,http://www.ncbi.nlm.nih.gov/pubmed/16109776
5140,26974125,Axin cancer mutants form nanoaggregates to rewire the Wnt signaling network.,http://www.ncbi.nlm.nih.gov/pubmed/26974125
5141,27042160,The BH3 mimetic drug ABT-737 induces apoptosis and acts synergistically with chemotherapeutic drugs in thyroid carcinoma cells.,http://www.ncbi.nlm.nih.gov/pubmed/27042160
5142,27022118,Intracranial Efficacy of Crizotinib Versus Chemotherapy in Patients With Advanced ALK-Positive Non-Small-Cell Lung Cancer: Results From PROFILE 1014.,http://www.ncbi.nlm.nih.gov/pubmed/27022118
5143,26698910,Resensitization to Crizotinib by the Lorlatinib ALK Resistance Mutation L1198F.,http://www.ncbi.nlm.nih.gov/pubmed/26698910
5144,25164765,Comparative sequencing analysis reveals high genomic concordance between matched primary and metastatic colorectal cancer lesions.,http://www.ncbi.nlm.nih.gov/pubmed/25164765
5145,15510160,Post-translational modification of p53 in tumorigenesis.,http://www.ncbi.nlm.nih.gov/pubmed/15510160
5146,23764045,The histone deacetylase inhibitor SAHA acts in synergism with fenretinide and doxorubicin to control growth of rhabdoid tumor cells.,http://www.ncbi.nlm.nih.gov/pubmed/23764045
5147,23190500,Inhibition of EZH2 suppresses self-renewal and induces radiation sensitivity in atypical rhabdoid teratoid tumor cells.,http://www.ncbi.nlm.nih.gov/pubmed/23190500
5148,21871868,Sensitivity of malignant rhabdoid tumor cell lines to PD 0332991 is inversely correlated with p16 expression.,http://www.ncbi.nlm.nih.gov/pubmed/21871868
5149,24247721,Prodigiosin rescues deficient p53 signaling and antitumor effects via upregulating p73 and disrupting its interaction with mutant p53.,http://www.ncbi.nlm.nih.gov/pubmed/24247721
5150,26759239,Small-Molecule Prodigiosin Restores p53 Tumor Suppressor Activity in Chemoresistant Colorectal Cancer Stem Cells via c-Jun-Mediated ΔNp73 Inhibition and p73 Activation.,http://www.ncbi.nlm.nih.gov/pubmed/26759239
5151,26791928,Impact of FOXL2 mutations on signaling in ovarian granulosa cell tumors.,http://www.ncbi.nlm.nih.gov/pubmed/26791928
5152,22810696,Comprehensive molecular characterization of human colon and rectal cancer.,http://www.ncbi.nlm.nih.gov/pubmed/22810696
5153,26423830,Whole-exome sequencing identifies novel MPL and JAK2 mutations in triple-negative myeloproliferative neoplasms.,http://www.ncbi.nlm.nih.gov/pubmed/26423830
5154,26437785,Oncogenic activation of MPL/thrombopoietin receptor by 17 mutations at W515: implications for myeloproliferative neoplasms.,http://www.ncbi.nlm.nih.gov/pubmed/26437785
5155,26615130,MEK1/2 Inhibitors: Molecular Activity and Resistance Mechanisms.,http://www.ncbi.nlm.nih.gov/pubmed/26615130
5156,24251790,Combination treatment for myeloproliferative neoplasms using JAK and pan-class I PI3K inhibitors.,http://www.ncbi.nlm.nih.gov/pubmed/24251790
5157,12370306,Identification of a novel mitogen-activated protein kinase kinase activation domain recognized by the inhibitor PD 184352.,http://www.ncbi.nlm.nih.gov/pubmed/12370306
5158,27052654,Trastuzumab emtansine (T-DM1) plus docetaxel with or without pertuzumab in patients with HER2-positive locally advanced or metastatic breast cancer: results from a phase Ib/IIa study.,http://www.ncbi.nlm.nih.gov/pubmed/27052654
5159,25802881,A positive genotype-phenotype correlation in a large cohort of patients with Pseudohypoparathyroidism Type Ia and Pseudo-pseudohypoparathyroidism and 33 newly identified mutations in the GNAS gene.,http://www.ncbi.nlm.nih.gov/pubmed/25802881
5160,22753075,Functional characterization of MLH1 missense variants identified in Lynch syndrome patients.,http://www.ncbi.nlm.nih.gov/pubmed/22753075
5161,20020535,A cell-free assay for the functional analysis of variants of the mismatch repair protein MLH1.,http://www.ncbi.nlm.nih.gov/pubmed/20020535
5162,26609494,EGFR mutation incidence in non-small-cell lung cancer of adenocarcinoma histology: a systematic review and global map by ethnicity (mutMapII).,http://www.ncbi.nlm.nih.gov/pubmed/26609494
5163,26023187,Porcupine inhibitor suppresses paracrine Wnt-driven growth of Rnf43;Znrf3-mutant neoplasia.,http://www.ncbi.nlm.nih.gov/pubmed/26023187
5164,25402820,Curaxin CBL0137 eradicates drug resistant cancer stem cells and potentiates efficacy of gemcitabine in preclinical models of pancreatic cancer.,http://www.ncbi.nlm.nih.gov/pubmed/25402820
5165,19461675,Adenovirus delivery of human CD40 ligand gene confers direct therapeutic effects on carcinomas.,http://www.ncbi.nlm.nih.gov/pubmed/19461675
5166,16083711,Functional significance and clinical phenotype of nontruncating mismatch repair variants of MLH1.,http://www.ncbi.nlm.nih.gov/pubmed/16083711
5167,10037723,The interaction of the human MutL homologues in hereditary nonpolyposis colon cancer.,http://www.ncbi.nlm.nih.gov/pubmed/10037723
5168,16982745,A human cell-based assay to evaluate the effects of alterations in the MLH1 mismatch repair gene.,http://www.ncbi.nlm.nih.gov/pubmed/16982745
5169,15256438,"Mismatch repair gene PMS2: disease-causing germline mutations are frequent in patients whose tumors stain negative for PMS2 protein, but paralogous genes obscure mutation detection and interpretation.",http://www.ncbi.nlm.nih.gov/pubmed/15256438
5170,26623725,Targeting the EWS-ETS transcriptional program by BET bromodomain inhibition in Ewing sarcoma.,http://www.ncbi.nlm.nih.gov/pubmed/26623725
5171,26603258,"First-in-Human Phase I Study of GSK2126458, an Oral Pan-Class I Phosphatidylinositol-3-Kinase Inhibitor, in Patients with Advanced Solid Tumor Malignancies.",http://www.ncbi.nlm.nih.gov/pubmed/26603258
5172,19609284,Mutations of ASXL1 gene in myeloproliferative neoplasms.,http://www.ncbi.nlm.nih.gov/pubmed/19609284
5173,18561205,A large fraction of unclassified variants of the mismatch repair genes MLH1 and MSH2 is associated with splicing defects.,http://www.ncbi.nlm.nih.gov/pubmed/18561205
5174,17510385,Functional analysis of human MLH1 variants using yeast and in vitro mismatch repair assays.,http://www.ncbi.nlm.nih.gov/pubmed/17510385
5175,17192056,"The use of microsatellite instability, immunohistochemistry and other variables in determining the clinical significance of MLH1 and MSH2 unclassified variants in Lynch syndrome.",http://www.ncbi.nlm.nih.gov/pubmed/17192056
5176,,"The novel, rationally-designed, ALK/SRC inhibitor TPX-0005 overcomes multiple acquired resistance mechanisms to current ALK inhibitors",http://www.abstractsonline.com/Plan/ViewAbstract.aspx?sKey=055d4461-9793-4f83-b663-f356d9ae0fdb&cKey=ff6f8d25-f06a-4ae4-9dbf-7e390ef45123&mKey={1D10D749-4B6A-4AB3-BCD4-F80FB1922267}
5177,26918358,Preclinical evaluation of biomarkers associated with antitumor activity of MELK inhibitor.,http://www.ncbi.nlm.nih.gov/pubmed/26918358
5178,27019001,A phase 2 clinical trial of everolimus plus bicalutamide for castration-resistant prostate cancer.,http://www.ncbi.nlm.nih.gov/pubmed/27019001
5179,26861457,Clinical Trial of Oral Nelfinavir before and during Radiation Therapy for Advanced Rectal Cancer.,http://www.ncbi.nlm.nih.gov/pubmed/26861457
5180,26941288,Cancer Differentiating Agent Hexamethylene Bisacetamide Inhibits BET Bromodomain Proteins.,http://www.ncbi.nlm.nih.gov/pubmed/26941288
5181,27020857,Early Adaptation and Acquired Resistance to CDK4/6 Inhibition in Estrogen Receptor-Positive Breast Cancer.,http://www.ncbi.nlm.nih.gov/pubmed/27020857
5182,27049722,"Brigatinib, an anaplastic lymphoma kinase inhibitor, abrogates activity and growth in ALK-positive neuroblastoma cells, Drosophila and mice.",http://www.ncbi.nlm.nih.gov/pubmed/27049722
5183,,"Effects of a CDK 4/6 inhibitor, G1T38, in androgen receptor sensitive and resistant models of castrate resistant prostate cancer",http://www.abstractsonline.com/Plan/ViewAbstract.aspx?mID=4017&sKey=12eab58f-9b3f-418d-ad0c-e55a553a95b9&cKey=90cf56d3-fe9d-4b4d-8477-6867a79402af&mKey=1d10d749-4b6a-4ab3-bcd4-f80fb1922267
5184,26859456,Exploitation of the Apoptosis-Primed State of MYCN-Amplified Neuroblastoma to Develop a Potent and Specific Targeted Therapy Combination.,http://www.ncbi.nlm.nih.gov/pubmed/26859456
5185,,"Phase I trial of the CDK 4/6 inhibitor, P1446A-05 (voruciclib) in combination with the BRAF inhibitor (BRAFi), vemurafenib in advanced, BRAF-mutant melanoma.",http://meetinglibrary.asco.org/content/153239-156
5186,,"ODM-207, a novel BET-bromodomain inhibitor as a therapeutic approach for the treatment of prostate and breast cancer",http://www.abstractsonline.com/Plan/ViewAbstract.aspx?mID=4017&sKey=177af784-a1f1-406c-9aa8-67b47302d29b&cKey=a3591182-1c63-4601-8452-da8fc4cf389d&mKey=1d10d749-4b6a-4ab3-bcd4-f80fb1922267
5187,,"PBA2, a dual BCR-ABL and GSK3?kinases inhibitor, represses a wide array of Imatinib resistant cell lines in chronic myeloid leukemia",http://www.abstractsonline.com/Plan/ViewAbstract.aspx?mID=4017&sKey=d0cbfd99-0744-49e4-a827-562c416014d8&cKey=72e71da1-be1f-4d1d-9554-e10537c87463&mKey=1d10d749-4b6a-4ab3-bcd4-f80fb1922267
5188,24140932,The novel VEGF receptor/MET-targeted kinase inhibitor TAS-115 has marked in vivo antitumor properties and a favorable tolerability profile.,http://www.ncbi.nlm.nih.gov/pubmed/24140932
5189,,"Novel in vivo pan-Hsp90 family protein inhibitor, Panvotinib-401, showed potent anticancer activities without HSF1 activation",http://www.abstractsonline.com/Plan/ViewAbstract.aspx?mID=4017&sKey=d0cbfd99-0744-49e4-a827-562c416014d8&cKey=5b87c7e4-79ec-456c-9ca0-037f038f5114&mKey=1d10d749-4b6a-4ab3-bcd4-f80fb1922267
5190,22784709,"Peptidomimetic Src/pretubulin inhibitor KX-01 alone and in combination with paclitaxel suppresses growth, metastasis in human ER/PR/HER2-negative tumor xenografts.",http://www.ncbi.nlm.nih.gov/pubmed/22784709
5191,23361621,"A phase I trial of KX2-391, a novel non-ATP competitive substrate-pocket- directed SRC inhibitor, in patients with advanced malignancies.",http://www.ncbi.nlm.nih.gov/pubmed/23361621
5192,23314737,"A phase 2 study of KX2-391, an oral inhibitor of Src kinase and tubulin polymerization, in men with bone-metastatic castration-resistant prostate cancer.",http://www.ncbi.nlm.nih.gov/pubmed/23314737
5193,24100628,Targeting SRC and tubulin in mucinous ovarian carcinoma.,http://www.ncbi.nlm.nih.gov/pubmed/24100628
5194,,"U3-1784, a human anti-FGFR4 antibody for the treatment of cancer",http://www.abstractsonline.com/Plan/ViewAbstract.aspx?mID=4017&sKey=800c7dcf-322a-4e97-830b-0887c43f4108&cKey=4b473f86-5e89-431f-b228-b5a1a902ce34&mKey=1d10d749-4b6a-4ab3-bcd4-f80fb1922267
5195,,"AP32788, a potent, selective inhibitor of EGFR and HER2 oncogenic mutants, including exon 20 insertions, in preclinical models",http://www.abstractsonline.com/Plan/ViewAbstract.aspx?mID=4017&sKey=407e597a-33c8-4936-87f4-08ee4b23e8b9&cKey=34ee7ebf-07c6-40ea-825f-28fb5018ec92&mKey=1d10d749-4b6a-4ab3-bcd4-f80fb1922267
5196,21609311,Topoisomerase I inhibitor SN-38 effectively attenuates growth of human non-small cell lung cancer cell lines in vitro and in vivo.,http://www.ncbi.nlm.nih.gov/pubmed/21609311
5197,26438158,PARP Inhibitors Sensitize Ewing Sarcoma Cells to Temozolomide-Induced Apoptosis via the Mitochondrial Pathway.,http://www.ncbi.nlm.nih.gov/pubmed/26438158
5198,,"First-in-human study of TAS-115, a novel oral MET/VEGFR inhibitor, in patients with advanced solid tumors",http://meeting.ascopubs.org/cgi/content/abstract/33/15_suppl/2532
5199,,"BAY 1436032: A highly selective, potent and orally available inhibitor of mutant forms of IDH1",http://www.abstractsonline.com/Plan/ViewAbstract.aspx?mID=4017&sKey=407e597a-33c8-4936-87f4-08ee4b23e8b9&cKey=7b015533-ade6-4611-8ab3-68f274bd3bac&mKey=1d10d749-4b6a-4ab3-bcd4-f80fb1922267
5200,25671299,Preclinical antitumor activity of ST7612AA1: a new oral thiol-based histone deacetylase (HDAC) inhibitor.,http://www.ncbi.nlm.nih.gov/pubmed/25671299
5201,20024066,Small-molecule modulators of the Sonic Hedgehog signaling pathway.,http://www.ncbi.nlm.nih.gov/pubmed/20024066
5202,26802156,"A randomized, double-blind phase II study evaluating cediranib versus cediranib and saracatinib in patients with relapsed metastatic clear-cell renal cancer (COSAK).",http://www.ncbi.nlm.nih.gov/pubmed/26802156
5203,27044931,Afatinib Activity in Platinum-Refractory Metastatic Urothelial Carcinoma in Patients With ERBB Alterations.,http://www.ncbi.nlm.nih.gov/pubmed/27044931
5204,27075627,Triple-negative breast cancers with amplification of JAK2 at the 9p24 locus demonstrate JAK2-specific dependence.,http://www.ncbi.nlm.nih.gov/pubmed/27075627
5205,,"NCCN Clinical Practice Guidelines in Oncology: Soft Tissue Sarcoma, Version 2.2016",http://www.nccn.org/professionals/physician_gls/f_guidelines.asp#sarcoma
5206,9462753,A novel ETV6-NTRK3 gene fusion in congenital fibrosarcoma.,http://www.ncbi.nlm.nih.gov/pubmed/9462753
5207,24517889,ChildSeq-RNA: A next-generation sequencing-based diagnostic assay to identify known fusion transcripts in childhood sarcomas.,http://www.ncbi.nlm.nih.gov/pubmed/24517889
5208,22240241,Molecular pathogenesis of granulosa cell tumors of the ovary.,http://www.ncbi.nlm.nih.gov/pubmed/22240241
5209,26961851,Hepatocellular adenoma classification: a comparative evaluation of immunohistochemistry and targeted mutational analysis.,http://www.ncbi.nlm.nih.gov/pubmed/26961851
5210,25434466,Hepatocellular adenoma management: call for shared guidelines and multidisciplinary approach.,http://www.ncbi.nlm.nih.gov/pubmed/25434466
5211,25193432,GEIS 2013 guidelines for gastrointestinal sarcomas (GIST).,http://www.ncbi.nlm.nih.gov/pubmed/25193432
5212,26276366,"The standard diagnosis, treatment, and follow-up of gastrointestinal stromal tumors based on guidelines.",http://www.ncbi.nlm.nih.gov/pubmed/26276366
5213,23384679,The novel TLR-9 agonist QbG10 shows clinical efficacy in persistent allergic asthma.,http://www.ncbi.nlm.nih.gov/pubmed/23384679
5214,22944768,IGHV gene features and MYD88 L265P mutation separate the three marginal zone lymphoma entities and Waldenström macroglobulinemia/lymphoplasmacytic lymphomas.,http://www.ncbi.nlm.nih.gov/pubmed/22944768
5215,,NCCN Guidelines Version 2.2016 Non-Hodgkin's Lymphomas,
5216,25495392,IDH2 mutation in gliomas including novel mutation.,http://www.ncbi.nlm.nih.gov/pubmed/25495392
5217,24886695,Succinate dehydrogenase deficient gastrointestinal stromal tumors (GISTs) - a review.,http://www.ncbi.nlm.nih.gov/pubmed/24886695
5218,27011036,Molecular Subtypes of KIT/PDGFRA Wild-Type Gastrointestinal Stromal Tumors: A Report From the National Institutes of Health Gastrointestinal Stromal Tumor Clinic.,http://www.ncbi.nlm.nih.gov/pubmed/27011036
5219,,"Archexin, a novel AKT-1–specific inhibitor for the treatment of metastatic renal cancer: Preliminary phase I data.",http://meetinglibrary.asco.org/content/158080-172
5220,18483311,Effective in vivo targeting of the mammalian target of rapamycin pathway in malignant peripheral nerve sheath tumors.,http://www.ncbi.nlm.nih.gov/pubmed/18483311
5221,,"Regorafenib for previously treated metastatic colorectal cancer (mCRC): A subgroup analysis of 364 patients in the USA treated in the international, open-label phase IIIb CONSIGN study.",http://meetinglibrary.asco.org/content/160044-173
5222,25048785,Targeting BCL2 for the treatment of lymphoid malignancies.,http://www.ncbi.nlm.nih.gov/pubmed/25048785
5223,26589495,ABT-199 (venetoclax) and BCL-2 inhibitors in clinical development.,http://www.ncbi.nlm.nih.gov/pubmed/26589495
5224,27014415,Venetoclax Shows Strong Activity in CLL.,http://www.ncbi.nlm.nih.gov/pubmed/27014415
5225,26406150,Cabozantinib versus Everolimus in Advanced Renal-Cell Carcinoma.,http://www.ncbi.nlm.nih.gov/pubmed/26406150
5226,26976114,Clinical Response of Carcinomas Harboring the BRD4-NUT Oncoprotein to the Targeted Bromodomain Inhibitor OTX015/MK-8628.,http://www.ncbi.nlm.nih.gov/pubmed/26976114
5227,26566875,Diverse and Targetable Kinase Alterations Drive Histiocytic Neoplasms.,http://www.ncbi.nlm.nih.gov/pubmed/26566875
5228,24652991,Somatic activating ARAF mutations in Langerhans cell histiocytosis.,http://www.ncbi.nlm.nih.gov/pubmed/24652991
5229,26851029,"A Phase II Study of BEZ235 in Patients with Everolimus-resistant, Advanced Pancreatic Neuroendocrine Tumours.",http://www.ncbi.nlm.nih.gov/pubmed/26851029
5230,26931343,Safety and tolerability of AZD5363 in Japanese patients with advanced solid tumors.,http://www.ncbi.nlm.nih.gov/pubmed/26931343
5231,,"eFT508, a Potent and Selective Mitogen-Activated Protein Kinase Interacting Kinase (MNK) 1 and 2 Inhibitor, Is Efficacious in Preclinical Models of Diffuse Large B-Cell Lymphoma (DLBCL)",http://www.bloodjournal.org/content/126/23/1554
5232,22605338,Anticancer peptidylarginine deiminase (PAD) inhibitors regulate the autophagy flux and the mammalian target of rapamycin complex 1 activity.,http://www.ncbi.nlm.nih.gov/pubmed/22605338
5233,25612620,ATF4 Gene Network Mediates Cellular Response to the Anticancer PAD Inhibitor YW3-56 in Triple-Negative Breast Cancer Cells.,http://www.ncbi.nlm.nih.gov/pubmed/25612620
5234,27063977,"Bromodomain inhibitor OTX015 in patients with acute leukaemia: a dose-escalation, phase 1 study.",http://www.ncbi.nlm.nih.gov/pubmed/27063977
5235,27043233,Hematologic malignancies: newer strategies to counter the BCL-2 protein.,http://www.ncbi.nlm.nih.gov/pubmed/27043233
5236,25848357,Clinical Response to Sorafenib in a Patient with Metastatic Colorectal Cancer and FLT3 Amplification.,http://www.ncbi.nlm.nih.gov/pubmed/25848357
5237,25394415,Decreased tumorigenesis in mice with a Kras point mutation at C118.,http://www.ncbi.nlm.nih.gov/pubmed/25394415
5238,27026198,Phase I Study of an AKT Inhibitor (MK-2206) Combined with Lapatinib in Adult Solid Tumors Followed by Dose Expansion in Advanced HER2+ Breast Cancer.,http://www.ncbi.nlm.nih.gov/pubmed/27026198
5239,23817809,A population-based study of low-grade gliomas and mutated isocitrate dehydrogenase 1 (IDH1).,http://www.ncbi.nlm.nih.gov/pubmed/23817809
5240,26220714,Prognostic role of IDH mutations in gliomas: a meta-analysis of 55 observational studies.,http://www.ncbi.nlm.nih.gov/pubmed/26220714
5241,23894344,IDH1/IDH2 mutations define the prognosis and molecular profiles of patients with gliomas: a meta-analysis.,http://www.ncbi.nlm.nih.gov/pubmed/23894344
5242,23904262,IDH1 mutation is associated with improved overall survival in patients with glioblastoma: a meta-analysis.,http://www.ncbi.nlm.nih.gov/pubmed/23904262
5243,26945349,Isocitrate Dehydrogenase (IDH)1/2 Mutations as Prognostic Markers in Patients With Glioblastomas.,http://www.ncbi.nlm.nih.gov/pubmed/26945349
5244,20560678,Prognostic value of IDH1 mutations identified with PCR-RFLP assay in glioblastoma patients.,http://www.ncbi.nlm.nih.gov/pubmed/20560678
5245,26429956,Dose-Finding Quantitative 18F-FDG PET Imaging Study with the Oral Pan-AKT Inhibitor GSK2141795 in Patients with Gynecologic Malignancies.,http://www.ncbi.nlm.nih.gov/pubmed/26429956
5246,23041832,Diagnostic implications of IDH1-R132H and OLIG2 expression patterns in rare and challenging glioblastoma variants.,http://www.ncbi.nlm.nih.gov/pubmed/23041832
5247,19755387,IDH1 mutations as molecular signature and predictive factor of secondary glioblastomas.,http://www.ncbi.nlm.nih.gov/pubmed/19755387
5248,19915484,"Diagnostic use of IDH1/2 mutation analysis in routine clinical testing of formalin-fixed, paraffin-embedded glioma tissues.",http://www.ncbi.nlm.nih.gov/pubmed/19915484
5249,26582061,Comparison of Prediction Models for Lynch Syndrome Among Individuals With Colorectal Cancer.,http://www.ncbi.nlm.nih.gov/pubmed/26582061
5250,19125127,EGAPP supplementary evidence review: DNA testing strategies aimed at reducing morbidity and mortality from Lynch syndrome.,http://www.ncbi.nlm.nih.gov/pubmed/19125127
5251,26578684,KDR Amplification Is Associated with VEGF-Induced Activation of the mTOR and Invasion Pathways but does not Predict Clinical Benefit to the VEGFR TKI Vandetanib.,http://www.ncbi.nlm.nih.gov/pubmed/26578684
5252,18497962,Mutations of epidermal growth factor receptor in colon cancer indicate susceptibility or resistance to gefitinib.,http://www.ncbi.nlm.nih.gov/pubmed/18497962
5253,24220272,Landscape of genetic lesions in 944 patients with myelodysplastic syndromes.,http://www.ncbi.nlm.nih.gov/pubmed/24220272
5254,21714648,Clinical effect of point mutations in myelodysplastic syndromes.,http://www.ncbi.nlm.nih.gov/pubmed/21714648
5255,26561558,InsR/IGF1R Pathway Mediates Resistance to EGFR Inhibitors in Glioblastoma.,http://www.ncbi.nlm.nih.gov/pubmed/26561558
5256,27049457,"Safety, tolerability, and preliminary activity of CUDC-907, a first-in-class, oral, dual inhibitor of HDAC and PI3K, in patients with relapsed or refractory lymphoma or multiple myeloma: an open-label, dose-escalation, phase 1 trial.",http://www.ncbi.nlm.nih.gov/pubmed/27049457
5257,26620496,"A phase I study of MK-5108, an oral aurora a kinase inhibitor, administered both as monotherapy and in combination with docetaxel, in patients with advanced or refractory solid tumors.",http://www.ncbi.nlm.nih.gov/pubmed/26620496
5258,27049350,"Simultaneous blockade of VEGF and Dll4 by HD105, a bispecific antibody, inhibits tumor progression and angiogenesis.",http://www.ncbi.nlm.nih.gov/pubmed/27049350
5259,26546619,mTOR Inhibitors Suppress Homologous Recombination Repair and Synergize with PARP Inhibitors via Regulating SUV39H1 in BRCA-Proficient Triple-Negative Breast Cancer.,http://www.ncbi.nlm.nih.gov/pubmed/26546619
5260,26175413,"CHZ868, a Type II JAK2 Inhibitor, Reverses Type I JAK Inhibitor Persistence and Demonstrates Efficacy in Myeloproliferative Neoplasms.",http://www.ncbi.nlm.nih.gov/pubmed/26175413
5261,21263000,Noonan syndrome gain-of-function mutations in NRAS cause zebrafish gastrulation defects.,http://www.ncbi.nlm.nih.gov/pubmed/21263000
5262,16761019,FLT3 is fused to ETV6 in a myeloproliferative disorder with hypereosinophilia and a t(12;13)(p13;q12) translocation.,http://www.ncbi.nlm.nih.gov/pubmed/16761019
5263,12203785,"A novel gene, MDS2, is fused to ETV6/TEL in a t(1;12)(p36.1;p13) in a patient with myelodysplastic syndrome.",http://www.ncbi.nlm.nih.gov/pubmed/12203785
5264,12661008,A novel cryptic translocation t(12;17)(p13;p12-p13) in a secondary acute myeloid leukemia results in a fusion of the ETV6 gene and the antisense strand of the PER1 gene.,http://www.ncbi.nlm.nih.gov/pubmed/12661008
5265,22373549,Detection of ETV6 gene rearrangements in adult acute lymphoblastic leukemia.,http://www.ncbi.nlm.nih.gov/pubmed/22373549
5266,18281529,ETV6-NCOA2: a novel fusion gene in acute leukemia associated with coexpression of T-lymphoid and myeloid markers and frequent NOTCH1 mutations.,http://www.ncbi.nlm.nih.gov/pubmed/18281529
5267,11672531,E2F repression by C/EBPalpha is required for adipogenesis and granulopoiesis in vivo.,http://www.ncbi.nlm.nih.gov/pubmed/11672531
5268,26828267,"AT13148, a first-in-class multi-AGC kinase inhibitor, potently inhibits gastric cancer cells both in vitro and in vivo.",http://www.ncbi.nlm.nih.gov/pubmed/26828267
5269,24619759,CSF-1R expression in tumor-associated macrophages is associated with worse prognosis in classical Hodgkin lymphoma.,http://www.ncbi.nlm.nih.gov/pubmed/24619759
5270,26066800,CSF1R Protein Expression in Reactive Lymphoid Tissues and Lymphoma: Its Relevance in Classical Hodgkin Lymphoma.,http://www.ncbi.nlm.nih.gov/pubmed/26066800
5271,22955918,Gene expression profiling of microdissected Hodgkin Reed-Sternberg cells correlates with treatment outcome in classical Hodgkin lymphoma.,http://www.ncbi.nlm.nih.gov/pubmed/22955918
5272,25964101,Pharmacologically Increasing Mdm2 Inhibits DNA Repair and Cooperates with Genotoxic Agents to Kill p53-Inactivated Ovarian Cancer Cells.,http://www.ncbi.nlm.nih.gov/pubmed/25964101
5273,24291104,Inhibition mechanism exploration of investigational drug TAK-441 as inhibitor against Vismodegib-resistant Smoothened mutant.,http://www.ncbi.nlm.nih.gov/pubmed/24291104
5274,25939769,Inhibition of colony stimulating factor-1 receptor improves antitumor efficacy of BRAF inhibition.,http://www.ncbi.nlm.nih.gov/pubmed/25939769
5275,11242107,"Dominant-negative mutations of CEBPA, encoding CCAAT/enhancer binding protein-alpha (C/EBPalpha), in acute myeloid leukemia.",http://www.ncbi.nlm.nih.gov/pubmed/11242107
5276,22616558,Potential application of IDH1 and IDH2 mutations as prognostic indicators in non-promyelocytic acute myeloid leukemia: a meta-analysis.,http://www.ncbi.nlm.nih.gov/pubmed/22616558
5277,23226625,Prognostic significance of IDH1 mutations in acute myeloid leukemia: a meta-analysis.,http://www.ncbi.nlm.nih.gov/pubmed/23226625
5278,26849014,Cytogenetic and molecular abnormalities in chronic myelomonocytic leukemia.,http://www.ncbi.nlm.nih.gov/pubmed/26849014
5279,23180629,RUNX family: Regulation and diversification of roles through interacting proteins.,http://www.ncbi.nlm.nih.gov/pubmed/23180629
5280,26208524,"BGB-283, a Novel RAF Kinase and EGFR Inhibitor, Displays Potent Antitumor Activity in BRAF-Mutated Colorectal Cancers.",http://www.ncbi.nlm.nih.gov/pubmed/26208524
5281,,"BAY 1143572: A first-in-class, highly selective, potent and orally available inhibitor of PTEFb/CDK9 currently in Phase I, inhibits MYC and shows convincing anti-tumor activity in multiple xenograft models by the induction of apoptosis",http://cancerres.aacrjournals.org/content/75/15_Supplement/DDT02-02.short
5282,22869879,Validation of a prognostic model and the impact of mutations in patients with lower-risk myelodysplastic syndromes.,http://www.ncbi.nlm.nih.gov/pubmed/22869879
5283,25043604,"Functional characterization of CFI-400945, a Polo-like kinase 4 inhibitor, as a potential anticancer agent.",http://www.ncbi.nlm.nih.gov/pubmed/25043604
5284,25266042,Acute megakaryoblastic leukemia with acquired trisomy 21 and GATA1 mutations in phenotypically normal children.,http://www.ncbi.nlm.nih.gov/pubmed/25266042
5285,14636651,Mutations in GATA1 in both transient myeloproliferative disorder and acute megakaryoblastic leukemia of Down syndrome.,http://www.ncbi.nlm.nih.gov/pubmed/14636651
5286,12586620,GATA1 mutations in transient leukemia and acute megakaryoblastic leukemia of Down syndrome.,http://www.ncbi.nlm.nih.gov/pubmed/12586620
5287,22180162,"Acute myeloid leukemia: 2012 update on diagnosis, risk stratification, and management.",http://www.ncbi.nlm.nih.gov/pubmed/22180162
5288,9746770,"The importance of diagnostic cytogenetics on outcome in AML: analysis of 1,612 patients entered into the MRC AML 10 trial. The Medical Research Council Adult and Children's Leukaemia Working Parties.",http://www.ncbi.nlm.nih.gov/pubmed/9746770
5289,25111512,Identification of molecular and cytogenetic risk factors for unfavorable core-binding factor-positive adult AML with post-remission treatment outcome analysis including transplantation.,http://www.ncbi.nlm.nih.gov/pubmed/25111512
5290,16384925,Prognostic impact of c-KIT mutations in core binding factor leukemias: an Italian retrospective study.,http://www.ncbi.nlm.nih.gov/pubmed/16384925
5291,,"KTN0158, a humanized anti-KIT monoclonal antibody, demonstrates antitumor activity in dogs with mast cell tumors",http://mct.aacrjournals.org/content/14/12_Supplement_2/C167.short?rss=1
5292,7969167,"Distinct residues of human p53 implicated in binding to DNA, simian virus 40 large T antigen, 53BP1, and 53BP2.",http://www.ncbi.nlm.nih.gov/pubmed/7969167
5293,7651437,Discrimination of DNA binding sites by mutant p53 proteins.,http://www.ncbi.nlm.nih.gov/pubmed/7651437
5294,15684376,"GATA1 function, a paradigm for transcription factors in hematopoiesis.",http://www.ncbi.nlm.nih.gov/pubmed/15684376
5295,26655846,A Phase I Study of the Anti-Activin Receptor-Like Kinase 1 (ALK-1) Monoclonal Antibody PF-03446962 in Patients with Advanced Solid Tumors.,http://www.ncbi.nlm.nih.gov/pubmed/26655846
5296,26603261,The Oncolytic Adenovirus VCN-01 as Therapeutic Approach Against Pediatric Osteosarcoma.,http://www.ncbi.nlm.nih.gov/pubmed/26603261
5297,24732596,Impaired hematopoietic differentiation of RUNX1-mutated induced pluripotent stem cells derived from FPD/AML patients.,http://www.ncbi.nlm.nih.gov/pubmed/24732596
5298,26476589,A Phase II Study of AT-101 to Overcome Bcl-2--Mediated Resistance to Androgen Deprivation Therapy in Patients With Newly Diagnosed Castration-Sensitive Metastatic Prostate Cancer.,http://www.ncbi.nlm.nih.gov/pubmed/26476589
5299,21937134,Novel MYH11 and ACTA2 mutations reveal a role for enhanced TGFβ signaling in FTAAD.,http://www.ncbi.nlm.nih.gov/pubmed/21937134
5300,14736823,Comprehensive analysis of CBFbeta-MYH11 fusion transcripts in acute myeloid leukemia by RT-PCR analysis.,http://www.ncbi.nlm.nih.gov/pubmed/14736823
5301,23174939,SDHA mutations in adult and pediatric wild-type gastrointestinal stromal tumors.,http://www.ncbi.nlm.nih.gov/pubmed/23174939
5302,20429931,Activity of the acyl-CoA synthetase ACSL6 isoforms: role of the fatty acid Gate-domains.,http://www.ncbi.nlm.nih.gov/pubmed/20429931
5303,10502316,Fusion of TEL/ETV6 to a novel ACS2 in myelodysplastic syndrome and acute myelogenous leukemia with t(5;12)(q31;p13).,http://www.ncbi.nlm.nih.gov/pubmed/10502316
5304,8555498,"LAF-4 encodes a lymphoid nuclear protein with transactivation potential that is homologous to AF-4, the gene fused to MLL in t(4;11) leukemias.",http://www.ncbi.nlm.nih.gov/pubmed/8555498
5305,12203795,"LAF4, an AF4-related gene, is fused to MLL in infant acute lymphoblastic leukemia.",http://www.ncbi.nlm.nih.gov/pubmed/12203795
5306,16461359,"A novel GTPase, CRAG, mediates promyelocytic leukemia protein-associated nuclear body formation and degradation of expanded polyglutamine protein.",http://www.ncbi.nlm.nih.gov/pubmed/16461359
5307,25562590,A role for AT1 receptor-associated proteins in blood pressure regulation.,http://www.ncbi.nlm.nih.gov/pubmed/25562590
5308,20613748,RAF translocations expand cancer targets.,http://www.ncbi.nlm.nih.gov/pubmed/20613748
5309,24518248,IRBIT: a regulator of ion channels and ion transporters.,http://www.ncbi.nlm.nih.gov/pubmed/24518248
5310,23222956,Recurrent SETBP1 mutations in atypical chronic myeloid leukemia.,http://www.ncbi.nlm.nih.gov/pubmed/23222956
5311,25842083,EGFR-targeting therapy as an evolving concept: learning from nimotuzumab clinical development.,http://www.ncbi.nlm.nih.gov/pubmed/25842083
5312,26667485,A Phase Ib/II Study of Afatinib in Combination with Nimotuzumab in Non-Small Cell Lung Cancer Patients with Acquired Resistance to Gefitinib or Erlotinib.,http://www.ncbi.nlm.nih.gov/pubmed/26667485
5313,26719536,Non-Small Cell Lung Cancer Cells Acquire Resistance to the ALK Inhibitor Alectinib by Activating Alternative Receptor Tyrosine Kinases.,http://www.ncbi.nlm.nih.gov/pubmed/26719536
5314,26577700,Maximizing the Efficacy of MAPK-Targeted Treatment in PTENLOF/BRAFMUT Melanoma through PI3K and IGF1R Inhibition.,http://www.ncbi.nlm.nih.gov/pubmed/26577700
5315,15050915,"In vivo antitumor activity of NVP-AEW541-A novel, potent, and selective inhibitor of the IGF-IR kinase.",http://www.ncbi.nlm.nih.gov/pubmed/15050915
5316,26748709,Cancer-Specific Synthetic Lethality between ATR and CHK1 Kinase Activities.,http://www.ncbi.nlm.nih.gov/pubmed/26748709
5317,26597303,Epithelial-Mesenchymal Transition Predicts Polo-Like Kinase 1 Inhibitor-Mediated Apoptosis in Non-Small Cell Lung Cancer.,http://www.ncbi.nlm.nih.gov/pubmed/26597303
5318,26396249,HDAC Inhibition for the Treatment of Epithelioid Sarcoma: Novel Cross Talk Between Epigenetic Components.,http://www.ncbi.nlm.nih.gov/pubmed/26396249
5319,26779812,Blocking c-Met-mediated PARP1 phosphorylation enhances anti-tumor effects of PARP inhibitors.,http://www.ncbi.nlm.nih.gov/pubmed/26779812
5320,26719535,Germline BAP1 Mutational Landscape of Asbestos-Exposed Malignant Mesothelioma Patients with Family History of Cancer.,http://www.ncbi.nlm.nih.gov/pubmed/26719535
5321,27083334,"Afatinib versus gefitinib as first-line treatment of patients with EGFR mutation-positive non-small-cell lung cancer (LUX-Lung 7): a phase 2B, open-label, randomised controlled trial.",http://www.ncbi.nlm.nih.gov/pubmed/27083334
5322,10895816,Molecular detection of the ETV6-NTRK3 gene fusion differentiates congenital fibrosarcoma from other childhood spindle cell tumors.,http://www.ncbi.nlm.nih.gov/pubmed/10895816
5323,21843073,Unusual presentation of congenital infantile fibrosarcoma in seven infants with molecular-genetic analysis.,http://www.ncbi.nlm.nih.gov/pubmed/21843073
5324,25510282,Splice factor mutations and alternative splicing as drivers of hematopoietic malignancy.,http://www.ncbi.nlm.nih.gov/pubmed/25510282
5325,26842708,Cancer-associated SF3B1 mutations affect alternative splicing by promoting alternative branchpoint usage.,http://www.ncbi.nlm.nih.gov/pubmed/26842708
5326,21877899,Update on cytogenetic and molecular changes in myelodysplastic syndromes.,http://www.ncbi.nlm.nih.gov/pubmed/21877899
5327,26769228,Myelodysplastic syndromes: Contemporary review and how we treat.,http://www.ncbi.nlm.nih.gov/pubmed/26769228
5328,26601784,The multifaceted functions of C/EBPα in normal and malignant haematopoiesis.,http://www.ncbi.nlm.nih.gov/pubmed/26601784
5329,22096241,SF3B1 mutations are prevalent in myelodysplastic syndromes with ring sideroblasts but do not hold independent prognostic value.,http://www.ncbi.nlm.nih.gov/pubmed/22096241
5330,21998214,Clinical significance of SF3B1 mutations in myelodysplastic syndromes and myelodysplastic/myeloproliferative neoplasms.,http://www.ncbi.nlm.nih.gov/pubmed/21998214
5331,26711002,Determination of ETV6-RUNX1 genomic breakpoint by next-generation sequencing.,http://www.ncbi.nlm.nih.gov/pubmed/26711002
5332,15704129,ETV6/RUNX1 fusion at diagnosis and relapse: some prognostic indications.,http://www.ncbi.nlm.nih.gov/pubmed/15704129
5333,8609706,TEL/AML1 fusion resulting from a cryptic t(12;21) is the most common genetic lesion in pediatric ALL and defines a subgroup of patients with an excellent prognosis.,http://www.ncbi.nlm.nih.gov/pubmed/8609706
5334,10086740,TEL-AML1 fusion transcript designates a favorable outcome with an intensified protocol in childhood acute lymphoblastic leukemia.,http://www.ncbi.nlm.nih.gov/pubmed/10086740
5335,11432885,Relapse of TEL-AML1--positive acute lymphoblastic leukemia in childhood: a matched-pair analysis.,http://www.ncbi.nlm.nih.gov/pubmed/11432885
5336,19171880,"Double CEBPA mutations, but not single CEBPA mutations, define a subgroup of acute myeloid leukemia with a distinctive gene expression profile that is uniquely associated with a favorable outcome.",http://www.ncbi.nlm.nih.gov/pubmed/19171880
5337,20038735,Acute myeloid leukemia with biallelic CEBPA gene mutations and normal karyotype represents a distinct genetic entity associated with a favorable clinical outcome.,http://www.ncbi.nlm.nih.gov/pubmed/20038735
5338,22915647,A novel hierarchical prognostic model of AML solely based on molecular mutations.,http://www.ncbi.nlm.nih.gov/pubmed/22915647
5339,24856830,Cohesin gene mutations in tumorigenesis: from discovery to clinical significance.,http://www.ncbi.nlm.nih.gov/pubmed/24856830
5340,23776448,Imbalance of SMC1 and SMC3 cohesins causes specific and distinct effects.,http://www.ncbi.nlm.nih.gov/pubmed/23776448
5341,24335498,Mutations in the cohesin complex in acute myeloid leukemia: clinical and prognostic implications.,http://www.ncbi.nlm.nih.gov/pubmed/24335498
5342,23955599,Recurrent mutations in multiple components of the cohesin complex in myeloid neoplasms.,http://www.ncbi.nlm.nih.gov/pubmed/23955599
5343,23690417,Prognostic score including gene mutations in chronic myelomonocytic leukemia.,http://www.ncbi.nlm.nih.gov/pubmed/23690417
5344,19901108,Mutations of e3 ubiquitin ligase cbl family members constitute a novel common pathogenic lesion in myeloid malignancies.,http://www.ncbi.nlm.nih.gov/pubmed/19901108
5345,22490330,Mutant DNMT3A: a marker of poor prognosis in acute myeloid leukemia.,http://www.ncbi.nlm.nih.gov/pubmed/22490330
5346,21881046,Gene mutation patterns and their prognostic impact in a cohort of 1185 patients with acute myeloid leukemia.,http://www.ncbi.nlm.nih.gov/pubmed/21881046
5347,21670448,Incidence and prognostic influence of DNMT3A mutations in acute myeloid leukemia.,http://www.ncbi.nlm.nih.gov/pubmed/21670448
5348,16586096,"Multidrug resistance-associated proteins 3, 4, and 5.",http://www.ncbi.nlm.nih.gov/pubmed/16586096
5349,25572969,Silencing of the ABCC4 gene by RNA interference reverses multidrug resistance in human gastric cancer.,http://www.ncbi.nlm.nih.gov/pubmed/25572969
5350,18353444,Multidrug resistance protein 4 (MRP4/ABCC4): a versatile efflux transporter for drugs and signalling molecules.,http://www.ncbi.nlm.nih.gov/pubmed/18353444
5351,26499190,ATP-binding cassette sub-family C member 4 (ABCC4) is overexpressed in human NK/T-cell lymphoma and regulates chemotherapy sensitivity: Potential as a functional therapeutic target.,http://www.ncbi.nlm.nih.gov/pubmed/26499190
5352,23521373,CEBPA double-mutated acute myeloid leukaemia harbours concomitant molecular mutations in 76·8% of cases with TET2 and GATA2 alterations impacting prognosis.,http://www.ncbi.nlm.nih.gov/pubmed/23521373
5353,25241285,GATA2 mutations in patients with acute myeloid leukemia-paired samples analyses show that the mutation is unstable during disease evolution.,http://www.ncbi.nlm.nih.gov/pubmed/25241285
5354,22425584,"ETV1, 4 and 5: an oncogenic subfamily of ETS transcription factors.",http://www.ncbi.nlm.nih.gov/pubmed/22425584
5355,23634237,Emergence of ETS transcription factors as diagnostic tools and therapeutic targets in prostate cancer.,http://www.ncbi.nlm.nih.gov/pubmed/23634237
5356,23814484,Novel 5' fusion partners of ETV1 and ETV4 in prostate cancer.,http://www.ncbi.nlm.nih.gov/pubmed/23814484
5357,26676635,"The prevalence and clinical profiles of FLT3-ITD, FLT3-TKD, NPM1, C-KIT, DNMT3A, and CEBPA mutations in a cohort of patients with de novo acute myeloid leukemia from southwest China.",http://www.ncbi.nlm.nih.gov/pubmed/26676635
5358,26586702,Bioinformatics Analysis to Determine Prognostic Mutations of 72 de novo Acute Myeloid Leukemia Cases from the Cancer Genome Atlas (TCGA) with 23 Most Common Mutations and no Abnormal Cytogenetics.,http://www.ncbi.nlm.nih.gov/pubmed/26586702
5359,26239249,Molecular Genetic Markers in Acute Myeloid Leukemia.,http://www.ncbi.nlm.nih.gov/pubmed/26239249
5360,25335741,The impact of IKZF1 deletion on the prognosis of acute lymphoblastic leukemia: an updated meta-analysis.,http://www.ncbi.nlm.nih.gov/pubmed/25335741
5361,26194343,Prognostic significance of copy number alterations in adolescent and adult patients with precursor B acute lymphoblastic leukemia enrolled in PETHEMA protocols.,http://www.ncbi.nlm.nih.gov/pubmed/26194343
5362,27067989,Prognostic impact of IKZF1 deletion in adults with common B-cell acute lymphoblastic leukemia.,http://www.ncbi.nlm.nih.gov/pubmed/27067989
5363,22689681,RUNX1 mutations in cytogenetically normal acute myeloid leukemia are associated with a poor prognosis and up-regulation of lymphoid genes.,http://www.ncbi.nlm.nih.gov/pubmed/22689681
5364,22753902,RUNX1 mutations are associated with poor outcome in younger and older patients with cytogenetically normal acute myeloid leukemia and with distinct gene and MicroRNA expression signatures.,http://www.ncbi.nlm.nih.gov/pubmed/22753902
5365,25652455,"Integrated genomic profiling, therapy response, and survival in adult acute myelogenous leukemia.",http://www.ncbi.nlm.nih.gov/pubmed/25652455
5366,26861460,Reduced Expression of SMAD4 Is Associated with Poor Survival in Colon Cancer.,http://www.ncbi.nlm.nih.gov/pubmed/26861460
5367,25681512,Smad4 inactivation predicts for worse prognosis and response to fluorouracil-based treatment in colorectal cancer.,http://www.ncbi.nlm.nih.gov/pubmed/25681512
5368,19478385,Presence of a high amount of stroma and downregulation of SMAD4 predict for worse survival for stage I-II colon cancer patients.,http://www.ncbi.nlm.nih.gov/pubmed/19478385
5369,25760429,SMAD4 expression predicts local spread and treatment failure in resected pancreatic cancer.,http://www.ncbi.nlm.nih.gov/pubmed/25760429
5370,22504380,SMAD4 genetic alterations predict a worse prognosis in patients with pancreatic ductal adenocarcinoma.,http://www.ncbi.nlm.nih.gov/pubmed/22504380
5371,19584151,SMAD4 gene mutations are associated with poor prognosis in pancreatic cancer.,http://www.ncbi.nlm.nih.gov/pubmed/19584151
5372,20013787,The clinical relevance of Wilms Tumour 1 (WT1) gene mutations in acute leukaemia.,http://www.ncbi.nlm.nih.gov/pubmed/20013787
5373,20368469,WT1 mutation in 470 adult patients with acute myeloid leukemia: stability during disease evolution and implication of its incorporation into a survival scoring system.,http://www.ncbi.nlm.nih.gov/pubmed/20368469
5374,20442368,Mutations of the Wilms tumor 1 gene (WT1) in older patients with primary cytogenetically normal acute myeloid leukemia: a Cancer and Leukemia Group B study.,http://www.ncbi.nlm.nih.gov/pubmed/20442368
5375,25110071,"WT1 mutations are secondary events in AML, show varying frequencies and impact on prognosis between genetic subgroups.",http://www.ncbi.nlm.nih.gov/pubmed/25110071
5376,24899685,A novel small molecule aurora kinase inhibitor attenuates breast tumor-initiating cells and overcomes drug resistance.,http://www.ncbi.nlm.nih.gov/pubmed/24899685
5377,24507812,Somatic mutations and epigenetic abnormalities in myelodysplastic syndromes.,http://www.ncbi.nlm.nih.gov/pubmed/24507812
5378,23099237,"TET2, ASXL1 and EZH2 mutations in Chinese with myelodysplastic syndromes.",http://www.ncbi.nlm.nih.gov/pubmed/23099237
5379,19666869,TET2 mutation is an independent favorable prognostic factor in myelodysplastic syndromes (MDSs).,http://www.ncbi.nlm.nih.gov/pubmed/19666869
5380,25901286,"Survival with AGS-003, an autologous dendritic cell-based immunotherapy, in combination with sunitinib in unfavorable risk patients with advanced renal cell carcinoma (RCC): Phase 2 study results.",http://www.ncbi.nlm.nih.gov/pubmed/25901286
5381,26296954,"Safety and tolerability of guadecitabine (SGI-110) in patients with myelodysplastic syndrome and acute myeloid leukaemia: a multicentre, randomised, dose-escalation phase 1 study.",http://www.ncbi.nlm.nih.gov/pubmed/26296954
5382,23828516,"NGR-TNF, a novel vascular-targeting agent, does not induce cytokine recruitment of proangiogenic bone marrow-derived cells.",http://www.ncbi.nlm.nih.gov/pubmed/23828516
5383,25799509,DNA methyltransferase inhibitor zebularine induces human cholangiocarcinoma cell death through alteration of DNA methylation status.,http://www.ncbi.nlm.nih.gov/pubmed/25799509
5384,26637369,The DNA Repair Inhibitor DT01 as a Novel Therapeutic Strategy for Chemosensitization of Colorectal Liver Metastasis.,http://www.ncbi.nlm.nih.gov/pubmed/26637369
5385,26126987,Fragment-Based Discovery of a Dual pan-RET/VEGFR2 Kinase Inhibitor Optimized for Single-Agent Polypharmacology.,http://www.ncbi.nlm.nih.gov/pubmed/26126987
5386,26294745,A Novel Inhibitor of AKT1-PDPK1 Interaction Efficiently Suppresses the Activity of AKT Pathway and Restricts Tumor Growth In Vivo.,http://www.ncbi.nlm.nih.gov/pubmed/26294745
5388,15034873,"Identification of a novel gene, FGFR1OP2, fused to FGFR1 in 8p11 myeloproliferative syndrome.",http://www.ncbi.nlm.nih.gov/pubmed/15034873
5389,15927964,Functional analysis of Slac2-c/MyRIP as a linker protein between melanosomes and myosin VIIa.,http://www.ncbi.nlm.nih.gov/pubmed/15927964
5390,,NCCN Guidelines Version 1.2016 Acute Lymphoblastic Leukemia,
5391,24763514,FIP1L1 presence in FIP1L1-RARA or FIP1L1-PDGFRA differentially contributes to the pathogenesis of distinct types of leukemia.,http://www.ncbi.nlm.nih.gov/pubmed/24763514
5392,25486562,ISWI chromatin remodeling complexes in the DNA damage response.,http://www.ncbi.nlm.nih.gov/pubmed/25486562
5393,,NCCN Guidelines Version 1.2016 Myelodysplastic Syndromes (MDS),
5394,21261476,SMARCA5 methylation and expression in gastric cancer.,http://www.ncbi.nlm.nih.gov/pubmed/21261476
5395,25377162,Overexpression of SMARCA5 correlates with cell proliferation and migration in breast cancer.,http://www.ncbi.nlm.nih.gov/pubmed/25377162
5396,25888189,Functional characterization of BC039389-GATM and KLK4-KRSP1 chimeric read-through transcripts which are up-regulated in renal cell cancer.,http://www.ncbi.nlm.nih.gov/pubmed/25888189
5397,25712528,SUMO modification regulates the protein stability of NDRG1.,http://www.ncbi.nlm.nih.gov/pubmed/25712528
5398,25405367,Role of the staphylococcal nuclease and tudor domain containing 1 in oncogenesis (review).,http://www.ncbi.nlm.nih.gov/pubmed/25405367
5399,24918049,Staphylococcal nuclease domain containing-1 (SND1) promotes migration and invasion via angiotensin II type 1 receptor (AT1R) and TGFβ signaling.,http://www.ncbi.nlm.nih.gov/pubmed/24918049
5400,19435788,Staphylococcal nuclease domain-containing protein 1 as a potential tissue marker for prostate cancer.,http://www.ncbi.nlm.nih.gov/pubmed/19435788
5401,17909068,"SND1, a component of RNA-induced silencing complex, is up-regulated in human colon cancers and implicated in early stage colon carcinogenesis.",http://www.ncbi.nlm.nih.gov/pubmed/17909068
5402,23807602,Growth hormone and cancer: an update on progress.,http://www.ncbi.nlm.nih.gov/pubmed/23807602
5403,23691483,GNAI1 Suppresses Tumor Cell Migration and Invasion and is Post-Transcriptionally Regulated by Mir-320a/c/d in Hepatocellular Carcinoma.,http://www.ncbi.nlm.nih.gov/pubmed/23691483
5404,15928679,NFAT proteins: key regulators of T-cell development and function.,http://www.ncbi.nlm.nih.gov/pubmed/15928679
5405,22950383,NFAT gene family in inflammation and cancer.,http://www.ncbi.nlm.nih.gov/pubmed/22950383
5406,21495113,"Sox6, jack of all trades: a versatile regulatory protein in vertebrate development.",http://www.ncbi.nlm.nih.gov/pubmed/21495113
5407,23731550,Decreased expression of SOX6 confers a poor prognosis in hepatocellular carcinoma.,http://www.ncbi.nlm.nih.gov/pubmed/23731550
5408,9218780,Crystal structure and mechanism of human L-arginine:glycine amidinotransferase: a mitochondrial enzyme involved in creatine biosynthesis.,http://www.ncbi.nlm.nih.gov/pubmed/9218780
5409,15696967,"Expression of a transcriptional factor, SOX6, in human gliomas.",http://www.ncbi.nlm.nih.gov/pubmed/15696967
5410,21084391,Characterization of tumor-suppressive function of SOX6 in human esophageal squamous cell carcinoma.,http://www.ncbi.nlm.nih.gov/pubmed/21084391
5411,17308965,Recent advances in growth hormone signaling.,http://www.ncbi.nlm.nih.gov/pubmed/17308965
5412,14749727,Human Fip1 is a subunit of CPSF that binds to U-rich RNA elements and stimulates poly(A) polymerase.,http://www.ncbi.nlm.nih.gov/pubmed/14749727
5413,20810260,The role of Sp1 and Sp3 in normal and cancer cell biology.,http://www.ncbi.nlm.nih.gov/pubmed/20810260
5414,26967243,"Specificity protein (Sp) transcription factors Sp1, Sp3 and Sp4 are non-oncogene addiction genes in cancer cells.",http://www.ncbi.nlm.nih.gov/pubmed/26967243
5415,26352013,Sp1 cooperates with Sp3 to upregulate MALAT1 expression in human hepatocellular carcinoma.,http://www.ncbi.nlm.nih.gov/pubmed/26352013
5416,22815231,Inhibition of rhabdomyosarcoma cell and tumor growth by targeting specificity protein (Sp) transcription factors.,http://www.ncbi.nlm.nih.gov/pubmed/22815231
5417,22841931,p62/SQSTM1/A170: physiology and pathology.,http://www.ncbi.nlm.nih.gov/pubmed/22841931
5418,22424619,p62: a versatile multitasker takes on cancer.,http://www.ncbi.nlm.nih.gov/pubmed/22424619
5419,26426686,IMP2/p62 induces genomic instability and an aggressive hepatocellular carcinoma phenotype.,http://www.ncbi.nlm.nih.gov/pubmed/26426686
5420,,"The Mdm2 inhibitor, NVP-CGM097, in combination with the BRAF inhibitor NVP-LGX818 elicits synergistic antitumor effects in melanoma",http://cancerres.aacrjournals.org/content/74/19_Supplement/5466.short
5421,14555511,Polymorphisms in BRCA1 and BRCA2 and risk of epithelial ovarian cancer.,http://www.ncbi.nlm.nih.gov/pubmed/14555511
5422,23674270,BRCA1 polymorphisms and breast cancer epidemiology in the Western New York exposures and breast cancer (WEB) study.,http://www.ncbi.nlm.nih.gov/pubmed/23674270
5423,26826115,"EC-70124, a Novel Glycosylated Indolocarbazole Multikinase Inhibitor, Reverts Tumorigenic and Stem Cell Properties in Prostate Cancer by Inhibiting STAT3 and NF-κB.",http://www.ncbi.nlm.nih.gov/pubmed/26826115
5424,26873728,Applying Small Molecule Signal Transducer and Activator of Transcription-3 (STAT3) Protein Inhibitors as Pancreatic Cancer Therapeutics.,http://www.ncbi.nlm.nih.gov/pubmed/26873728
5425,25823662,MLH1 V384D polymorphism associates with poor response to EGFR tyrosine kinase inhibitors in patients with EGFR L858R-positive lung adenocarcinoma.,http://www.ncbi.nlm.nih.gov/pubmed/25823662
5426,,,http://cancerres.aacrjournals.org/content/76/4_Supplement/P1-08-08
5427,26010985,Natural Product Inspired N-Terminal Hsp90 Inhibitors: From Bench to Bedside?,http://www.ncbi.nlm.nih.gov/pubmed/26010985
5428,21901340,Gene mutations in the Ras pathway and the prognostic implication in Korean patients with juvenile myelomonocytic leukemia.,http://www.ncbi.nlm.nih.gov/pubmed/21901340
5429,12538640,The coiled-coil membrane protein golgin-84 is a novel rab effector required for Golgi ribbon formation.,http://www.ncbi.nlm.nih.gov/pubmed/12538640
5430,10741739,"Pattern of radiation-induced RET and NTRK1 rearrangements in 191 post-chernobyl papillary thyroid carcinomas: biological, phenotypic, and clinical implications.",http://www.ncbi.nlm.nih.gov/pubmed/10741739
5431,25616555,Scaffolding protein GOPC regulates tight junction structure.,http://www.ncbi.nlm.nih.gov/pubmed/25616555
5432,23052255,Identification of KIF5B-RET and GOPC-ROS1 fusions in lung adenocarcinomas through a comprehensive mRNA-based screen for tyrosine kinase fusions.,http://www.ncbi.nlm.nih.gov/pubmed/23052255
5433,23108406,A tumor suppressor role for srGAP3 in mammary epithelial cells.,http://www.ncbi.nlm.nih.gov/pubmed/23108406
5434,23127797,The cellular function of srGAP3 and its role in neuronal morphogenesis.,http://www.ncbi.nlm.nih.gov/pubmed/23127797
5435,21283756,STK35L1 associates with nuclear actin and regulates cell cycle and migration of endothelial cells.,http://www.ncbi.nlm.nih.gov/pubmed/21283756
5436,19756140,Identifying and characterizing a novel protein kinase STK35L1 and deciphering its orthologs and close-homologs in vertebrates.,http://www.ncbi.nlm.nih.gov/pubmed/19756140
5437,17976384,Signal-induced functions of the transcription factor TFII-I.,http://www.ncbi.nlm.nih.gov/pubmed/17976384
5438,25284716,GTF2I-RARA is a novel fusion transcript in a t(7;17) variant of acute promyelocytic leukaemia with clinical resistance to retinoic acid.,http://www.ncbi.nlm.nih.gov/pubmed/25284716
5439,24974848,A specific missense mutation in GTF2I occurs at high frequency in thymic epithelial tumors.,http://www.ncbi.nlm.nih.gov/pubmed/24974848
5440,24333164,"STRIPAK complexes: structure, biological function, and involvement in human diseases.",http://www.ncbi.nlm.nih.gov/pubmed/24333164
5441,17956236,"The role of 2-hydroxyacyl-CoA lyase, a thiamin pyrophosphate-dependent enzyme, in the peroxisomal metabolism of 3-methyl-branched fatty acids and 2-hydroxy straight-chain fatty acids.",http://www.ncbi.nlm.nih.gov/pubmed/17956236
5442,10748158,"Zinedin, SG2NA, and striatin are calmodulin-binding, WD repeat proteins principally expressed in the brain.",http://www.ncbi.nlm.nih.gov/pubmed/10748158
5443,26933125,Oncogenic ALK Fusion in Rare and Aggressive Subtype of Colorectal Adenocarcinoma as a Potential Therapeutic Target.,http://www.ncbi.nlm.nih.gov/pubmed/26933125
5444,26936505,ATRX loss promotes tumor growth and impairs nonhomologous end joining DNA repair in glioma.,http://www.ncbi.nlm.nih.gov/pubmed/26936505
5445,17714910,Identification of six putative human transporters with structural similarity to the drug transporter SLC22 family.,http://www.ncbi.nlm.nih.gov/pubmed/17714910
5446,26853339,Gemcitabine Plus Radiation Therapy for High-Grade Glioma: Long-Term Results of a Phase 1 Dose-Escalation Study.,http://www.ncbi.nlm.nih.gov/pubmed/26853339
5447,23443540,Synapsin II desynchronizes neurotransmitter release at inhibitory synapses by interacting with presynaptic calcium channels.,http://www.ncbi.nlm.nih.gov/pubmed/23443540
5448,20438797,The synapsins: key actors of synapse function and plasticity.,http://www.ncbi.nlm.nih.gov/pubmed/20438797
5449,26098867,Consistent in-frame internal tandem duplications of BCOR characterize clear cell sarcoma of the kidney.,http://www.ncbi.nlm.nih.gov/pubmed/26098867
5450,26516930,Whole transcriptome sequencing identifies BCOR internal tandem duplication as a common feature of clear cell sarcoma of the kidney.,http://www.ncbi.nlm.nih.gov/pubmed/26516930
5451,26573325,Recurrent internal tandem duplications of BCOR in clear cell sarcoma of the kidney.,http://www.ncbi.nlm.nih.gov/pubmed/26573325
5452,26150234,Kidney cancer: BCOR mutations that might help in diagnosis of CCSK.,http://www.ncbi.nlm.nih.gov/pubmed/26150234
5453,27151974,Spliceosomal gene mutations in myelodysplasia: molecular links to clonal abnormalities of hematopoiesis.,http://www.ncbi.nlm.nih.gov/pubmed/27151974
5454,17379597,"A novel corepressor, BCoR-L1, represses transcription through an interaction with CtBP.",http://www.ncbi.nlm.nih.gov/pubmed/17379597
5455,22210327,The corepressors BCOR and BCORL1: two novel players in acute myeloid leukemia.,http://www.ncbi.nlm.nih.gov/pubmed/22210327
5456,26879601,BCORL1 is an independent prognostic marker and contributes to cell migration and invasion in human hepatocellular carcinoma.,http://www.ncbi.nlm.nih.gov/pubmed/26879601
5457,17904127,SVH-B interacts directly with p53 and suppresses the transcriptional activity of p53.,http://www.ncbi.nlm.nih.gov/pubmed/17904127
5458,24849811,Hypoxia-inducible aryl hydrocarbon receptor nuclear translocator (ARNT) (HIF-1β): is it a rare exception?,http://www.ncbi.nlm.nih.gov/pubmed/24849811
5459,24469860,Deregulation of AhR function by the human acute leukemia TEL-ARNT fusion protein.,http://www.ncbi.nlm.nih.gov/pubmed/24469860
5460,11948179,The kinetic mechanism of the human bifunctional enzyme ATIC (5-amino-4-imidazolecarboxamide ribonucleotide transformylase/inosine 5'-monophosphate cyclohydrolase). A surprising lack of substrate channeling.,http://www.ncbi.nlm.nih.gov/pubmed/11948179
5461,10702393,"ATIC-ALK: A novel variant ALK gene fusion in anaplastic large cell lymphoma resulting from the recurrent cryptic chromosomal inversion, inv(2)(p23q35).",http://www.ncbi.nlm.nih.gov/pubmed/10702393
5462,23693078,Insulin receptor tyrosine kinase substrate activates EGFR/ERK signalling pathway and promotes cell proliferation of hepatocellular carcinoma.,http://www.ncbi.nlm.nih.gov/pubmed/23693078
5463,18215522,IRSp53: crossing the road of membrane and actin dynamics in the formation of membrane protrusions.,http://www.ncbi.nlm.nih.gov/pubmed/18215522
5464,21922595,Two mutations in human BICC1 resulting in Wnt pathway hyperactivity associated with cystic renal dysplasia.,http://www.ncbi.nlm.nih.gov/pubmed/21922595
5465,24180494,A phase 2 trial of ponatinib in Philadelphia chromosome-positive leukemias.,http://www.ncbi.nlm.nih.gov/pubmed/24180494
5466,,Discovery and preclinical development of a highly potent NaPi2b-targeted antibody-drug conjugate (ADC) with significant activity in patient-derived non-small cell lung cancer (NSCLC) xenograft models,http://www.abstractsonline.com/Plan/ViewAbstract.aspx?mID=4017&sKey=43ef76fe-c845-4b4b-8531-601f2b1c2c32&cKey=132d0ba9-cd0a-4831-b61a-3bba3ae06518&mKey=1d10d749-4b6a-4ab3-bcd4-f80fb1922267
5467,26508027,"Genetic landscape of recurrent ASXL1, U2AF1, SF3B1, SRSF2, and EZH2 mutations in 304 Chinese patients with myelodysplastic syndromes.",http://www.ncbi.nlm.nih.gov/pubmed/26508027
5468,26161385,Leukemogenic rearrangements at the mixed lineage leukemia gene (MLL)-multiple rather than a single mechanism.,http://www.ncbi.nlm.nih.gov/pubmed/26161385
5469,17957188,"MLL translocations, histone modifications and leukaemia stem-cell development.",http://www.ncbi.nlm.nih.gov/pubmed/17957188
5470,21852505,Mutational inactivation of STAG2 causes aneuploidy in human cancer.,http://www.ncbi.nlm.nih.gov/pubmed/21852505
5471,24356817,Glioblastoma cells containing mutations in the cohesin component STAG2 are sensitive to PARP inhibition.,http://www.ncbi.nlm.nih.gov/pubmed/24356817
5472,22271902,Germ-line GATA2 p.THR354MET mutation in familial myelodysplastic syndrome with acquired monosomy 7 and ASXL1 mutation demonstrating rapid onset and poor survival.,http://www.ncbi.nlm.nih.gov/pubmed/22271902
5473,22147895,Loss-of-function germline GATA2 mutations in patients with MDS/AML or MonoMAC syndrome and primary lymphedema reveal a key role for GATA2 in the lymphatic vasculature.,http://www.ncbi.nlm.nih.gov/pubmed/22147895
5474,22533337,Marked genetic heterogeneity in familial myelodysplasia/acute myeloid leukaemia.,http://www.ncbi.nlm.nih.gov/pubmed/22533337
5475,26099018,The TET2 interactors and their links to hematological malignancies.,http://www.ncbi.nlm.nih.gov/pubmed/26099018
5476,25510268,TET proteins and 5-methylcytosine oxidation in hematological cancers.,http://www.ncbi.nlm.nih.gov/pubmed/25510268
5477,24487413,Comprehensive analysis of genetic alterations and their prognostic impacts in adult acute myeloid leukemia patients.,http://www.ncbi.nlm.nih.gov/pubmed/24487413
5478,22417203,Prognostic relevance of integrated genetic profiling in acute myeloid leukemia.,http://www.ncbi.nlm.nih.gov/pubmed/22417203
5479,,Mutations in SF3B1 lead to aberrant splicing through cryptic 3? splice site selection and impair hematopoietic cell differentiation,http://cancerres.aacrjournals.org/content/75/15_Supplement/2040
5480,26565915,Cancer-Associated SF3B1 Hotspot Mutations Induce Cryptic 3' Splice Site Selection through Use of a Different Branch Point.,http://www.ncbi.nlm.nih.gov/pubmed/26565915
5481,24524305,Prognostic significance of Tet methylcytosine dioxygenase 2 (TET2) gene mutations in adult patients with acute myeloid leukemia: a meta-analysis.,http://www.ncbi.nlm.nih.gov/pubmed/24524305
5482,25412851,"Next-generation sequencing of acute myeloid leukemia identifies the significance of TP53, U2AF1, ASXL1, and TET2 mutations.",http://www.ncbi.nlm.nih.gov/pubmed/25412851
5483,24994606,Clinical and biological impact of TET2 mutations and expression in younger adult AML patients treated within the EORTC/GIMEMA AML-12 clinical trial.,http://www.ncbi.nlm.nih.gov/pubmed/24994606
5484,11986236,The AF10 leucine zipper is required for leukemic transformation of myeloid progenitors by MLL-AF10.,http://www.ncbi.nlm.nih.gov/pubmed/11986236
5485,23138183,Abrogation of MLL-AF10 and CALM-AF10-mediated transformation through genetic inactivation or pharmacological inhibition of the H3K79 methyltransferase Dot1l.,http://www.ncbi.nlm.nih.gov/pubmed/23138183
5486,11964322,High frequency of point mutations clustered within the adenosine triphosphate-binding region of BCR/ABL in patients with chronic myeloid leukemia or Ph-positive acute lymphoblastic leukemia who develop imatinib (STI571) resistance.,http://www.ncbi.nlm.nih.gov/pubmed/11964322
5487,19201023,"Structural modeling of V299L and E459K Bcr-Abl mutation, and sequential therapy of tyrosine kinase inhibitors for the compound mutations.",http://www.ncbi.nlm.nih.gov/pubmed/19201023
5488,18094714,The role of CALM-AF10 gene fusion in acute leukemia.,http://www.ncbi.nlm.nih.gov/pubmed/18094714
5489,23284727,AF10 plays a key role in the survival of uncommitted hematopoietic cells.,http://www.ncbi.nlm.nih.gov/pubmed/23284727
5490,23673860,New MLLT10 gene recombinations in pediatric T-acute lymphoblastic leukemia.,http://www.ncbi.nlm.nih.gov/pubmed/23673860
5491,23852159,Identification of GSX2 and AF10 as NUP98 partner genes in myeloid malignancies.,http://www.ncbi.nlm.nih.gov/pubmed/23852159
5492,26432786,Cabozantinib (XL184) Inhibits Growth and Invasion of Preclinical TNBC Models.,http://www.ncbi.nlm.nih.gov/pubmed/26432786
5493,17643111,Spliceostatin A targets SF3b and inhibits both splicing and nuclear retention of pre-mRNA.,http://www.ncbi.nlm.nih.gov/pubmed/17643111
5494,25424858,SF3B1 mutations constitute a novel therapeutic target in breast cancer.,http://www.ncbi.nlm.nih.gov/pubmed/25424858
5495,,Sf3b1 K700E Mutation Impairs Pre-mRNA Splicing and Definitive Hematopoiesis in a Conditional Knock-in Mouse Model,http://www.bloodjournal.org/content/126/23/140?sso-checked=true
5496,26873726,Preclinical Evaluation of UAB30 in Pediatric Renal and Hepatic Malignancies.,http://www.ncbi.nlm.nih.gov/pubmed/26873726
5497,,Cancer-Associated Mutations in SF3B1 Exhibit Neomorphic Splicing Activity and Block Erythroid Differentiation,https://ash.confex.com/ash/2014/webprogram/Paper72943.html
5498,26819331,"7-(2-Thienyl)-7-Deazaadenosine (AB61), a New Potent Nucleoside Cytostatic with a Complex Mode of Action.",http://www.ncbi.nlm.nih.gov/pubmed/26819331
5499,20725108,"NFAT, immunity and cancer: a transcription factor comes of age.",http://www.ncbi.nlm.nih.gov/pubmed/20725108
5500,12975316,"Transcriptional regulation by calcium, calcineurin, and NFAT.",http://www.ncbi.nlm.nih.gov/pubmed/12975316
5501,22383527,"Characterization of EHop-016, novel small molecule inhibitor of Rac GTPase.",http://www.ncbi.nlm.nih.gov/pubmed/22383527
5502,26023736,Thymoquinone inhibits cancer metastasis by downregulating TWIST1 expression to reduce epithelial to mesenchymal transition.,http://www.ncbi.nlm.nih.gov/pubmed/26023736
5503,25847385,Mechanistic perspectives on cancer chemoprevention/chemotherapeutic effects of thymoquinone.,http://www.ncbi.nlm.nih.gov/pubmed/25847385
5504,26769123,"Choline Kinase Alpha (CHKα) as a Therapeutic Target in Pancreatic Ductal Adenocarcinoma: Expression, Predictive Value, and Sensitivity to Inhibitors.",http://www.ncbi.nlm.nih.gov/pubmed/26769123
5505,16512921,"The protein kinase DYRK1A phosphorylates the splicing factor SF3b1/SAP155 at Thr434, a novel in vivo phosphorylation site.",http://www.ncbi.nlm.nih.gov/pubmed/16512921
5506,27109549,Phase II evaluation of sunitinib in the treatment of recurrent or refractory high-grade glioma or ependymoma in children: a children's Oncology Group Study ACNS1021.,http://www.ncbi.nlm.nih.gov/pubmed/27109549
5507,27160228,Antitumor Response of VEGFR2- and VEGFR3-Amplified Angiosarcoma to Pazopanib.,http://www.ncbi.nlm.nih.gov/pubmed/27160228
5508,27131622,Early BCR-ABL1 Reduction Is Predictive of Better Event-free Survival in Patients With Newly Diagnosed Chronic Myeloid Leukemia Treated With Any Tyrosine Kinase Inhibitor.,http://www.ncbi.nlm.nih.gov/pubmed/27131622
5509,26603839,Compound mutations in BCR-ABL1 are not major drivers of primary or secondary resistance to ponatinib in CP-CML patients.,http://www.ncbi.nlm.nih.gov/pubmed/26603839
5510,19798095,Choosing the best treatment strategy for chronic myeloid leukemia patients resistant to imatinib: weighing the efficacy and safety of individual drugs with BCR-ABL mutations and patient history.,http://www.ncbi.nlm.nih.gov/pubmed/19798095
5511,24456693,"BCR-ABL kinase domain mutations, including 2 novel mutations in imatinib resistant Malaysian chronic myeloid leukemia patients-Frequency and clinical outcome.",http://www.ncbi.nlm.nih.gov/pubmed/24456693
5512,27083054,Nuclear factor one B (NFIB) encodes a subtype-specific tumour suppressor in glioblastoma.,http://www.ncbi.nlm.nih.gov/pubmed/27083054
5513,26846820,Effective Concentration of a Multikinase Inhibitor within Bone Marrow Correlates with In Vitro Cell Killing in Therapy-Resistant Chronic Myeloid Leukemia.,http://www.ncbi.nlm.nih.gov/pubmed/26846820
5514,26921392,Addition of DHA Synergistically Enhances the Efficacy of Regorafenib for Kidney Cancer Therapy.,http://www.ncbi.nlm.nih.gov/pubmed/26921392
5515,26823493,"Posaconazole, a Second-Generation Triazole Antifungal Drug, Inhibits the Hedgehog Signaling Pathway and Progression of Basal Cell Carcinoma.",http://www.ncbi.nlm.nih.gov/pubmed/26823493
5516,12417296,PSF and p54(nrb)/NonO--multi-functional nuclear proteins.,http://www.ncbi.nlm.nih.gov/pubmed/12417296
5517,26148231,p54(nrb)/NONO regulates lipid metabolism and breast cancer growth through SREBP-1A.,http://www.ncbi.nlm.nih.gov/pubmed/26148231
5518,25575134,Notch signaling activation in pediatric low-grade astrocytoma.,http://www.ncbi.nlm.nih.gov/pubmed/25575134
5519,26826116,Preclinical Characterization of G1T28: A Novel CDK4/6 Inhibitor for Reduction of Chemotherapy-Induced Myelosuppression.,http://www.ncbi.nlm.nih.gov/pubmed/26826116
5520,25759019,Genomic analysis of smoothened inhibitor resistance in basal cell carcinoma.,http://www.ncbi.nlm.nih.gov/pubmed/25759019
5521,27037412,"RG7386, a Novel Tetravalent FAP-DR5 Antibody, Effectively Triggers FAP-Dependent, Avidity-Driven DR5 Hyperclustering and Tumor Cell Apoptosis.",http://www.ncbi.nlm.nih.gov/pubmed/27037412
5522,25637314,The Selective PI3K Inhibitor XL147 (SAR245408) Inhibits Tumor Growth and Survival and Potentiates the Activity of Chemotherapeutic Agents in Preclinical Tumor Models.,http://www.ncbi.nlm.nih.gov/pubmed/25637314
5523,20631354,NR4A orphan nuclear receptors: transcriptional regulators of gene expression in metabolism and vascular biology.,http://www.ncbi.nlm.nih.gov/pubmed/20631354
5524,22566377,Molecular pathways: the role of NR4A orphan nuclear receptors in cancer.,http://www.ncbi.nlm.nih.gov/pubmed/22566377
5525,20215348,The RNA-binding protein bicaudal C regulates polycystin 2 in the kidney by antagonizing miR-17 activity.,http://www.ncbi.nlm.nih.gov/pubmed/20215348
5526,26043775,Identification of key genes and pathways in renal cell carcinoma through expression profiling data.,http://www.ncbi.nlm.nih.gov/pubmed/26043775
5527,,"Safety, pharmacokinetic, and antitumor activity of anlotinib, an oral multi-target tyrosine kinase inhibitor, in patients with advanced refractory solid tumors.",http://meetinglibrary.asco.org/content/149230-156
5528,20160729,"NUB1, an interferon-inducible protein, mediates anti-proliferative actions and apoptosis in renal cell carcinoma cells through cell-cycle regulation.",http://www.ncbi.nlm.nih.gov/pubmed/20160729
5529,17287906,Smoothened gene mutations found in digestive cancer have no aberrant Hedgehog signaling activity.,http://www.ncbi.nlm.nih.gov/pubmed/17287906
5530,,Ph1b study of the PI3K inhibitor taselisib (GDC-0032) in combination with letrozole in patients with hormone receptor-positive advanced breast cancer,http://cancerres.aacrjournals.org/content/75/9_Supplement/PD5-2.short
5531,24903481,MYD88 (L265P) mutation is an independent prognostic factor for outcome in patients with diffuse large B-cell lymphoma.,http://www.ncbi.nlm.nih.gov/pubmed/24903481
5532,25055137,"High frequency and clinical prognostic value of MYD88 L265P mutation in primary cutaneous diffuse large B-cell lymphoma, leg-type.",http://www.ncbi.nlm.nih.gov/pubmed/25055137
5533,26792260,"MYD88 L265P Mutations, But No Other Variants, Identify a Subpopulation of DLBCL Patients of Activated B-cell Origin, Extranodal Involvement, and Poor Outcome.",http://www.ncbi.nlm.nih.gov/pubmed/26792260
5534,26785607,Compound EGFR mutation is frequently detected with co-mutations of actionable genes and associated with poor clinical outcome in lung adenocarcinoma.,http://www.ncbi.nlm.nih.gov/pubmed/26785607
5535,27161723,"PO-36 - Thrombin Inhibition Preoperatively (TIP) in early breast cancer, the first clinical trial of NOACs as an anti-cancer agent: trial methodology.",http://www.ncbi.nlm.nih.gov/pubmed/27161723
5536,26712686,"Blocking HSP90 Addiction Inhibits Tumor Cell Proliferation, Metastasis Development, and Synergistically Acts with Zoledronic Acid to Delay Osteosarcoma Progression.",http://www.ncbi.nlm.nih.gov/pubmed/26712686
5537,26831717,"Mutations in TSC1, TSC2, and MTOR Are Associated with Response to Rapalogs in Patients with Metastatic Renal Cell Carcinoma.",http://www.ncbi.nlm.nih.gov/pubmed/26831717
5538,21193419,Philadelphia-positive acute lymphoblastic leukemia patients already harbor BCR-ABL kinase domain mutations at low levels at the time of diagnosis.,http://www.ncbi.nlm.nih.gov/pubmed/21193419
5539,26323360,"17-Demethoxy-reblastatin, an Hsp90 inhibitor, induces mitochondria-mediated apoptosis through downregulation of Mcl-1 in human hepatocellular carcinoma cells.",http://www.ncbi.nlm.nih.gov/pubmed/26323360
5540,,Optimizing kinase inhibitors to treat cancer,http://cancerres.aacrjournals.org/content/76/3_Supplement/IA32.short
5541,26482279,"Lenvatinib, everolimus, and the combination in patients with metastatic renal cell carcinoma: a randomised, phase 2, open-label, multicentre trial.",http://www.ncbi.nlm.nih.gov/pubmed/26482279
5542,26787835,Ovarian Cancers Harboring Inactivating Mutations in CDK12 Display a Distinct Genomic Instability Pattern Characterized by Large Tandem Duplications.,http://www.ncbi.nlm.nih.gov/pubmed/26787835
5543,23229552,PHF6 regulates cell cycle progression by suppressing ribosomal RNA synthesis.,http://www.ncbi.nlm.nih.gov/pubmed/23229552
5544,20228800,PHF6 mutations in T-cell acute lymphoblastic leukemia.,http://www.ncbi.nlm.nih.gov/pubmed/20228800
5545,25173427,Rationale for co-targeting IGF-1R and ALK in ALK fusion-positive lung cancer.,http://www.ncbi.nlm.nih.gov/pubmed/25173427
5546,26673800,A Novel Crizotinib-Resistant Solvent-Front Mutation Responsive to Cabozantinib Therapy in a Patient with ROS1-Rearranged Lung Cancer.,http://www.ncbi.nlm.nih.gov/pubmed/26673800
5547,25861989,TRAF Family Member-associated NF-κB Activator (TANK) Inhibits Genotoxic Nuclear Factor κB Activation by Facilitating Deubiquitinase USP10-dependent Deubiquitination of TRAF6 Ligase.,http://www.ncbi.nlm.nih.gov/pubmed/25861989
5548,23139637,TRAF family member-associated NF-κB activator (TANK) induced by RANKL negatively regulates osteoclasts survival and function.,http://www.ncbi.nlm.nih.gov/pubmed/23139637
5549,20484576,The scaffold protein TANK/I-TRAF inhibits NF-kappaB activation by recruiting polo-like kinase 1.,http://www.ncbi.nlm.nih.gov/pubmed/20484576
5550,26188006,"Missense mutations in TENM4, a regulator of axon guidance and central myelination, cause essential tremor.",http://www.ncbi.nlm.nih.gov/pubmed/26188006
5551,24648313,"Teneurin-4, a transmembrane protein, is a novel regulator that suppresses chondrogenic differentiation.",http://www.ncbi.nlm.nih.gov/pubmed/24648313
5552,24344332,Teneurin-4 promotes cellular protrusion formation and neurite outgrowth through focal adhesion kinase signaling.,http://www.ncbi.nlm.nih.gov/pubmed/24344332
5553,22841666,Teneurin protein family: an emerging role in human tumorigenesis and drug resistance.,http://www.ncbi.nlm.nih.gov/pubmed/22841666
5554,23991058,Breakpoint features of genomic rearrangements in neuroblastoma with unbalanced translocations and chromothripsis.,http://www.ncbi.nlm.nih.gov/pubmed/23991058
5555,24692687,Targeting tropomyosin-receptor kinase fused gene in cancer.,http://www.ncbi.nlm.nih.gov/pubmed/24692687
5556,16547966,"The TFG protein, involved in oncogenic rearrangements, interacts with TANK and NEMO, two proteins involved in the NF-kappaB pathway.",http://www.ncbi.nlm.nih.gov/pubmed/16547966
5557,27016228,"Tumor mutational analysis of GOG248, a phase II study of temsirolimus or temsirolimus and alternating megestrol acetate and tamoxifen for advanced endometrial cancer (EC): An NRG Oncology/Gynecologic Oncology Group study.",http://www.ncbi.nlm.nih.gov/pubmed/27016228
5558,26240174,Tropomyosin - master regulator of actin filament function in the cytoskeleton.,http://www.ncbi.nlm.nih.gov/pubmed/26240174
5559,23904035,Cytoskeletal tropomyosins: choreographers of actin filament functional diversity.,http://www.ncbi.nlm.nih.gov/pubmed/23904035
5560,26773439,ALK-rearranged renal cell carcinomas in children.,http://www.ncbi.nlm.nih.gov/pubmed/26773439
5561,26770062,"Detection of lung adenocarcinoma with ROS1 rearrangement by IHC, FISH, and RT-PCR and analysis of its clinicopathologic features.",http://www.ncbi.nlm.nih.gov/pubmed/26770062
5562,26644411,"A Phase I Study of the Safety, Pharmacokinetics, and Pharmacodynamics of Combination Therapy with Refametinib plus Sorafenib in Patients with Advanced Cancer.",http://www.ncbi.nlm.nih.gov/pubmed/26644411
5563,26976426,Phase II Randomized Preoperative Window-of-Opportunity Study of the PI3K Inhibitor Pictilisib Plus Anastrozole Compared With Anastrozole Alone in Patients With Estrogen Receptor-Positive Breast Cancer.,http://www.ncbi.nlm.nih.gov/pubmed/26976426
5564,23979156,Unshackling caspase-7 for cancer therapy.,http://www.ncbi.nlm.nih.gov/pubmed/23979156
5565,23549612,Regulation of tumor angiogenesis by the microtubule-binding protein CLIP-170.,http://www.ncbi.nlm.nih.gov/pubmed/23549612
5566,27108243,"Dual-targeted therapy with trastuzumab and lapatinib in treatment-refractory, KRAS codon 12/13 wild-type, HER2-positive metastatic colorectal cancer (HERACLES): a proof-of-concept, multicentre, open-label, phase 2 trial.",http://www.ncbi.nlm.nih.gov/pubmed/27108243
5567,10569618,Two mutations identified in the androgen receptor of the new human prostate cancer cell line MDA PCa 2a.,http://www.ncbi.nlm.nih.gov/pubmed/10569618
5568,26786929,Does Valproic Acid or Levetiracetam Improve Survival in Glioblastoma? A Pooled Analysis of Prospective Clinical Trials in Newly Diagnosed Glioblastoma.,http://www.ncbi.nlm.nih.gov/pubmed/26786929
5569,27068017,Phase II Study of Pazopanib and Paclitaxel in Patients With Refractory Urothelial Cancer.,http://www.ncbi.nlm.nih.gov/pubmed/27068017
5570,26733610,Ofatumumab and Lenalidomide for Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia: Correlation between Responses and Immune Characteristics.,http://www.ncbi.nlm.nih.gov/pubmed/26733610
5571,27013195,Enfortumab Vedotin Antibody-Drug Conjugate Targeting Nectin-4 Is a Highly Potent Therapeutic Agent in Multiple Preclinical Cancer Models.,http://www.ncbi.nlm.nih.gov/pubmed/27013195
5572,27066484,"Overcoming Hypoxia-Mediated Tumor Progression: Combinatorial Approaches Targeting pH Regulation, Angiogenesis and Immune Dysfunction.",http://www.ncbi.nlm.nih.gov/pubmed/27066484
5573,21415165,Targeting tumor hypoxia: suppression of breast tumor growth and metastasis by novel carbonic anhydrase IX inhibitors.,http://www.ncbi.nlm.nih.gov/pubmed/21415165
5574,27177928,Genotype-phenotype correlation of CTNNB1 mutations reveals different ß-catenin activity associated with liver tumor progression.,http://www.ncbi.nlm.nih.gov/pubmed/27177928
5575,26788199,Geldanamycin induces apoptosis in human gastric carcinomas by affecting multiple oncogenic kinases that have synergic effects with TNF-related apoptosis-inducing ligand.,http://www.ncbi.nlm.nih.gov/pubmed/26788199
5576,11927289,Hsp90 inhibitors as novel cancer chemotherapeutic agents.,http://www.ncbi.nlm.nih.gov/pubmed/11927289
5577,19850405,Geldanamycin and its anti-cancer activities.,http://www.ncbi.nlm.nih.gov/pubmed/19850405
5578,25888293,"Nectin-4 expression contributes to tumor proliferation, angiogenesis and patient prognosis in human pancreatic cancer.",http://www.ncbi.nlm.nih.gov/pubmed/25888293
5579,25348515,Low expression of the E3 ubiquitin ligase CBL confers chemoresistance in human pancreatic cancer and is targeted by epidermal growth factor receptor inhibition.,http://www.ncbi.nlm.nih.gov/pubmed/25348515
5580,25465125,The molecular basis and clinical significance of genetic mutations identified in myelodysplastic syndromes.,http://www.ncbi.nlm.nih.gov/pubmed/25465125
5581,22158538,Recurrent mutations in the U2AF1 splicing factor in myelodysplastic syndromes.,http://www.ncbi.nlm.nih.gov/pubmed/22158538
5582,22389253,"Frequency and prognostic impact of mutations in SRSF2, U2AF1, and ZRSR2 in patients with myelodysplastic syndromes.",http://www.ncbi.nlm.nih.gov/pubmed/22389253
5583,26177294,"Fasudil, a clinically safe ROCK inhibitor, decreases disease burden in a Cbl/Cbl-b deficiency-driven murine model of myeloproliferative disorders.",http://www.ncbi.nlm.nih.gov/pubmed/26177294
5584,21041408,The U2AF35-related protein Urp contacts the 3' splice site to promote U12-type intron splicing and the second step of U2-type intron splicing.,http://www.ncbi.nlm.nih.gov/pubmed/21041408
5585,25586593,Aberrant splicing of U12-type introns is the hallmark of ZRSR2 mutant myelodysplastic syndrome.,http://www.ncbi.nlm.nih.gov/pubmed/25586593
5586,21909114,Frequent pathway mutations of splicing machinery in myelodysplasia.,http://www.ncbi.nlm.nih.gov/pubmed/21909114
5587,26952546,"Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial.",http://www.ncbi.nlm.nih.gov/pubmed/26952546
5588,24351824,Cbl-b enhances sensitivity to 5-fluorouracil via EGFR- and mitochondria-mediated pathways in gastric cancer cells.,http://www.ncbi.nlm.nih.gov/pubmed/24351824
5589,10362357,cbl-3: a new mammalian cbl family protein.,http://www.ncbi.nlm.nih.gov/pubmed/10362357
5590,17671213,Clinical validity of the lung cancer biomarkers identified by bioinformatics analysis of public expression data.,http://www.ncbi.nlm.nih.gov/pubmed/17671213
5591,25883215,"Complementary genetic screens identify the E3 ubiquitin ligase CBLC, as a modifier of PARP inhibitor sensitivity.",http://www.ncbi.nlm.nih.gov/pubmed/25883215
5592,25795410,"Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomised, controlled, open-label, phase 3 trial.",http://www.ncbi.nlm.nih.gov/pubmed/25795410
5593,26028407,Nivolumab versus Docetaxel in Advanced Squamous-Cell Non-Small-Cell Lung Cancer.,http://www.ncbi.nlm.nih.gov/pubmed/26028407
5594,26486786,Clinical and molecular response to interferon-α therapy in essential thrombocythemia patients with CALR mutations.,http://www.ncbi.nlm.nih.gov/pubmed/26486786
5595,26697989,Myeloproliferative neoplasms: Current molecular biology and genetics.,http://www.ncbi.nlm.nih.gov/pubmed/26697989
5596,26449662,Differential clinical effects of different mutation subtypes in CALR-mutant myeloproliferative neoplasms.,http://www.ncbi.nlm.nih.gov/pubmed/26449662
5597,26071474,"The Prevalence of JAK2, MPL, and CALR Mutations in Chinese Patients With BCR-ABL1-Negative Myeloproliferative Neoplasms.",http://www.ncbi.nlm.nih.gov/pubmed/26071474
5598,25873496,"CALR, JAK2, and MPL mutation profiles in patients with four different subtypes of myeloproliferative neoplasms: primary myelofibrosis, essential thrombocythemia, polycythemia vera, and myeloproliferative neoplasm, unclassifiable.",http://www.ncbi.nlm.nih.gov/pubmed/25873496
5599,26406148,Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma.,http://www.ncbi.nlm.nih.gov/pubmed/26406148
5600,26768652,"Prognostic Effect of BRAF and KRAS Mutations in Patients With Stage III Colon Cancer Treated With Leucovorin, Fluorouracil, and Oxaliplatin With or Without Cetuximab: A Post Hoc Analysis of the PETACC-8 Trial.",http://www.ncbi.nlm.nih.gov/pubmed/26768652
5601,26880266,A Potent HER3 Monoclonal Antibody That Blocks Both Ligand-Dependent and -Independent Activities: Differential Impacts of PTEN Status on Tumor Response.,http://www.ncbi.nlm.nih.gov/pubmed/26880266
5602,26582713,"Identification of an ""Exceptional Responder"" Cell Line to MEK1 Inhibition: Clinical Implications for MEK-Targeted Therapy.",http://www.ncbi.nlm.nih.gov/pubmed/26582713
5603,22875611,The N676D and G697R mutations in the kinase domain of FLT3 confer resistance to the inhibitor AC220.,http://www.ncbi.nlm.nih.gov/pubmed/22875611
5604,26822154,The Dual MEK/FLT3 Inhibitor E6201 Exerts Cytotoxic Activity against Acute Myeloid Leukemia Cells Harboring Resistance-Conferring FLT3 Mutations.,http://www.ncbi.nlm.nih.gov/pubmed/26822154
5605,9920852,Fusion of ETV6 to the caudal-related homeobox gene CDX2 in acute myeloid leukemia with the t(12;13)(p13;q12).,http://www.ncbi.nlm.nih.gov/pubmed/9920852
5606,14718672,Ectopic expression of the homeobox gene Cdx2 is the transforming event in a mouse model of t(12;13)(p13;q12) acute myeloid leukemia.,http://www.ncbi.nlm.nih.gov/pubmed/14718672
5607,15611931,"Identification of a SRC-like tyrosine kinase gene, FRK, fused with ETV6 in a patient with acute myelogenous leukemia carrying a t(6;12)(q21;p13) translocation.",http://www.ncbi.nlm.nih.gov/pubmed/15611931
5608,16643428,Fusion of ETV6 with an intronic sequence of the BAZ2A gene in a paediatric pre-B acute lymphoblastic leukaemia with a cryptic chromosome 12 rearrangement.,http://www.ncbi.nlm.nih.gov/pubmed/16643428
5609,16061641,Cloning and characterization of the novel chimeric gene TEL/PTPRR in acute myelogenous leukemia with inv(12)(p13q13).,http://www.ncbi.nlm.nih.gov/pubmed/16061641
5610,22050763,PRDM16 (1p36) translocations define a distinct entity of myeloid malignancies with poor prognosis but may also occur in lymphoid malignancies.,http://www.ncbi.nlm.nih.gov/pubmed/22050763
5611,26391436,"Functional characterization, localization, and inhibitor sensitivity of the TPR-FGFR1 fusion in 8p11 myeloproliferative syndrome.",http://www.ncbi.nlm.nih.gov/pubmed/26391436
5612,21811608,Silencing nuclear pore protein Tpr elicits a senescent-like phenotype in cancer cells.,http://www.ncbi.nlm.nih.gov/pubmed/21811608
5613,22619110,"Identification of a novel partner gene, TPR, fused to FGFR1 in 8p11 myeloproliferative syndrome.",http://www.ncbi.nlm.nih.gov/pubmed/22619110
5614,19806165,Inhibition of cytokinesis by overexpression of NudCL that is localized to the centrosome and midbody.,http://www.ncbi.nlm.nih.gov/pubmed/19806165
5615,25743594,Inhibition of nucleoporin member Nup214 expression by miR-133b perturbs mitotic timing and leads to cell death.,http://www.ncbi.nlm.nih.gov/pubmed/25743594
5616,24073922,Forced expression of the DEK-NUP214 fusion protein promotes proliferation dependent on upregulation of mTOR.,http://www.ncbi.nlm.nih.gov/pubmed/24073922
5617,27196396,"OFD1, as a Ciliary Protein, Exhibits Neuroprotective Function in Photoreceptor Degeneration Models.",http://www.ncbi.nlm.nih.gov/pubmed/27196396
5618,22451673,"3'-Phosphoadenosine 5'-phosphosulfate (PAPS) synthases, naturally fragile enzymes specifically stabilized by nucleotide binding.",http://www.ncbi.nlm.nih.gov/pubmed/22451673
5619,15059611,HIP1: trafficking roles and regulation of tumorigenesis.,http://www.ncbi.nlm.nih.gov/pubmed/15059611
5620,24336083,PATZ1 interacts with p53 and regulates expression of p53-target genes enhancing apoptosis or cell survival based on the cellular context.,http://www.ncbi.nlm.nih.gov/pubmed/24336083
5621,18401526,"Zinc finger protein 278, a potential oncogene in human colorectal cancer.",http://www.ncbi.nlm.nih.gov/pubmed/18401526
5622,18241078,PATZ1 gene has a critical role in the spermatogenesis and testicular tumours.,http://www.ncbi.nlm.nih.gov/pubmed/18241078
5623,18594527,Heterogeneity and clinical significance of ETV1 translocations in human prostate cancer.,http://www.ncbi.nlm.nih.gov/pubmed/18594527
5624,15027122,D-PCa-2: a novel transcript highly overexpressed in human prostate and prostate cancer.,http://www.ncbi.nlm.nih.gov/pubmed/15027122
5625,26321680,HNRNPA2B1 Is a Mediator of m(6)A-Dependent Nuclear RNA Processing Events.,http://www.ncbi.nlm.nih.gov/pubmed/26321680
5626,19414390,Overexpression of hnRNPA2/B1 in bronchoscopic specimens: a potential early detection marker in lung cancer.,http://www.ncbi.nlm.nih.gov/pubmed/19414390
5627,26230842,High-Level HOOK3 Expression Is an Independent Predictor of Poor Prognosis Associated with Genomic Instability in Prostate Cancer.,http://www.ncbi.nlm.nih.gov/pubmed/26230842
5628,18799622,An FTS/Hook/p107(FHIP) complex interacts with and promotes endosomal clustering by the homotypic vacuolar protein sorting complex.,http://www.ncbi.nlm.nih.gov/pubmed/18799622
5629,15147274,Role of Herp in the endoplasmic reticulum stress response.,http://www.ncbi.nlm.nih.gov/pubmed/15147274
5630,26215567,A novel 3' splice site recognition by the two zinc fingers in the U2AF small subunit.,http://www.ncbi.nlm.nih.gov/pubmed/26215567
5631,16046538,"Inhibition of drug-resistant mutants of ABL, KIT, and EGF receptor kinases.",http://www.ncbi.nlm.nih.gov/pubmed/16046538
5632,11003668,Regulation of CDK7-carboxyl-terminal domain kinase activity by the tumor suppressor p16(INK4A) contributes to cell cycle regulation.,http://www.ncbi.nlm.nih.gov/pubmed/11003668
5633,24163379,The cyclin-dependent kinase inhibitor p16INK4a physically interacts with transcription factor Sp1 and cyclin-dependent kinase 4 to transactivate microRNA-141 and microRNA-146b-5p spontaneously and in response to ultraviolet light-induced DNA damage.,http://www.ncbi.nlm.nih.gov/pubmed/24163379
5634,24584070,A recurrent inactivating mutation in RHOA GTPase in angioimmunoblastic T cell lymphoma.,http://www.ncbi.nlm.nih.gov/pubmed/24584070
5635,19844164,Regulation of p53: TRIM24 enters the RING.,http://www.ncbi.nlm.nih.gov/pubmed/19844164
5636,24409330,Overexpression of TRIM24 is associated with the onset and progress of human hepatocellular carcinoma.,http://www.ncbi.nlm.nih.gov/pubmed/24409330
5637,21979307,TRIM proteins and cancer.,http://www.ncbi.nlm.nih.gov/pubmed/21979307
5638,25267526,U2AF1 mutations alter splice site recognition in hematological malignancies.,http://www.ncbi.nlm.nih.gov/pubmed/25267526
5639,25639486,Tumour suppressor TRIM33 targets nuclear β-catenin degradation.,http://www.ncbi.nlm.nih.gov/pubmed/25639486
5640,26282171,TIF1γ Suppresses Tumor Progression by Regulating Mitotic Checkpoints and Chromosomal Stability.,http://www.ncbi.nlm.nih.gov/pubmed/26282171
5641,22145905,A cohesin-RAD21 interactome.,http://www.ncbi.nlm.nih.gov/pubmed/22145905
5642,21255398,"Enhanced RAD21 cohesin expression confers poor prognosis and resistance to chemotherapy in high grade luminal, basal and HER2 breast cancers.",http://www.ncbi.nlm.nih.gov/pubmed/21255398
5643,24548858,RAD21 cohesin overexpression is a prognostic and predictive marker exacerbating poor prognosis in KRAS mutant colorectal carcinomas.,http://www.ncbi.nlm.nih.gov/pubmed/24548858
5644,23466368,Vinculin and metavinculin: oligomerization and interactions with F-actin.,http://www.ncbi.nlm.nih.gov/pubmed/23466368
5645,26195589,"Vinculin is required for cell polarization, migration, and extracellular matrix remodeling in 3D collagen.",http://www.ncbi.nlm.nih.gov/pubmed/26195589
5646,25413595,Epithelioid cell histiocytoma of the skin with clonal ALK gene rearrangement resulting in VCL-ALK and SQSTM1-ALK gene fusions.,http://www.ncbi.nlm.nih.gov/pubmed/25413595
5647,24081659,The CSF3R T618I mutation causes a lethal neutrophilic neoplasia in mice that is responsive to therapeutic JAK inhibition.,http://www.ncbi.nlm.nih.gov/pubmed/24081659
5648,24441292,An overview on CALR and CSF3R mutations and a proposal for revision of WHO diagnostic criteria for myeloproliferative neoplasms.,http://www.ncbi.nlm.nih.gov/pubmed/24441292
5649,15767545,Suppression of RAD21 gene expression decreases cell growth and enhances cytotoxicity of etoposide and bleomycin in human breast cancer cells.,http://www.ncbi.nlm.nih.gov/pubmed/15767545
5650,16611997,Essential dosage-dependent functions of the transcription factor yin yang 1 in late embryonic development and cell cycle progression.,http://www.ncbi.nlm.nih.gov/pubmed/16611997
5651,20081375,Yin yang 1 expression in human tumors.,http://www.ncbi.nlm.nih.gov/pubmed/20081375
5652,25787250,Neomorphic effects of recurrent somatic mutations in Yin Yang 1 in insulin-producing adenomas.,http://www.ncbi.nlm.nih.gov/pubmed/25787250
5653,16983801,JmjC-domain-containing proteins and histone demethylation.,http://www.ncbi.nlm.nih.gov/pubmed/16983801
5654,22143793,Increased expression of histone demethylase JHDM1D under nutrient starvation suppresses tumor growth via down-regulating angiogenesis.,http://www.ncbi.nlm.nih.gov/pubmed/22143793
5655,22693283,Novel mutations consolidate KCTD7 as a progressive myoclonus epilepsy gene.,http://www.ncbi.nlm.nih.gov/pubmed/22693283
5656,17030985,Shootin1: A protein involved in the organization of an asymmetric signal for neuronal polarization.,http://www.ncbi.nlm.nih.gov/pubmed/17030985
5657,24563076,New routes to targeted therapy of intrahepatic cholangiocarcinomas revealed by next-generation sequencing.,http://www.ncbi.nlm.nih.gov/pubmed/24563076
5658,26832791,Novel Mps1 Kinase Inhibitors with Potent Antitumor Activity.,http://www.ncbi.nlm.nih.gov/pubmed/26832791
5659,23868062,Pax8 has a critical role in epithelial cell survival and proliferation.,http://www.ncbi.nlm.nih.gov/pubmed/23868062
5660,23425942,"PAX8 is a novel marker for differentiating between various types of tumor, particularly ovarian epithelial carcinomas.",http://www.ncbi.nlm.nih.gov/pubmed/23425942
5661,26909611,The CDK4/6 inhibitor LY2835219 has potent activity in combination with mTOR inhibitor in head and neck squamous cell carcinoma.,http://www.ncbi.nlm.nih.gov/pubmed/26909611
5662,12743033,Conventional kinesin KIF5B mediates insulin-stimulated GLUT4 movements on microtubules.,http://www.ncbi.nlm.nih.gov/pubmed/12743033
5663,22125492,PBX1 genomic pioneer function drives ERα signaling underlying progression in breast cancer.,http://www.ncbi.nlm.nih.gov/pubmed/22125492
5664,1967983,A new homeobox gene contributes the DNA binding domain of the t(1;19) translocation protein in pre-B ALL.,http://www.ncbi.nlm.nih.gov/pubmed/1967983
5665,11144355,Axonal transport of amyloid precursor protein is mediated by direct binding to the kinesin light chain subunit of kinesin-I.,http://www.ncbi.nlm.nih.gov/pubmed/11144355
5666,26988987,Induction of Therapeutic Senescence in Vemurafenib-Resistant Melanoma by Extended Inhibition of CDK4/6.,http://www.ncbi.nlm.nih.gov/pubmed/26988987
5667,26847662,"Association Between BCR-ABL Tyrosine Kinase Inhibitors for Chronic Myeloid Leukemia and Cardiovascular Events, Major Molecular Response, and Overall Survival: A Systematic Review and Meta-analysis.",http://www.ncbi.nlm.nih.gov/pubmed/26847662
5668,19047294,Age-related risk profile and chemotherapy dose response in acute myeloid leukemia: a study by the German Acute Myeloid Leukemia Cooperative Group.,http://www.ncbi.nlm.nih.gov/pubmed/19047294
5669,24573385,The prognostic relevance of flt3 and npm1 mutations on older patients treated intensively or non-intensively: a study of 1312 patients in the UK NCRI AML16 trial.,http://www.ncbi.nlm.nih.gov/pubmed/24573385
5670,25713434,Prognostic significance of NPM1 mutations in the absence of FLT3-internal tandem duplication in older patients with acute myeloid leukemia: a SWOG and UK National Cancer Research Institute/Medical Research Council report.,http://www.ncbi.nlm.nih.gov/pubmed/25713434
5671,26603262,Cyclin E1 Inhibition can Overcome Sorafenib Resistance in Hepatocellular Carcinoma Cells Through Mcl-1 Suppression.,http://www.ncbi.nlm.nih.gov/pubmed/26603262
5672,23817177,RUNX1 meets MLL: epigenetic regulation of hematopoiesis by two leukemia genes.,http://www.ncbi.nlm.nih.gov/pubmed/23817177
5673,26438154,"BI 885578, a Novel IGF1R/INSR Tyrosine Kinase Inhibitor with Pharmacokinetic Properties That Dissociate Antitumor Efficacy and Perturbation of Glucose Homeostasis.",http://www.ncbi.nlm.nih.gov/pubmed/26438154
5674,26676759,Myc Induces miRNA-Mediated Apoptosis in Response to HDAC Inhibition in Hematologic Malignancies.,http://www.ncbi.nlm.nih.gov/pubmed/26676759
5675,26833125,An Integrated Analysis of Heterogeneous Drug Responses in Acute Myeloid Leukemia That Enables the Discovery of Predictive Biomarkers.,http://www.ncbi.nlm.nih.gov/pubmed/26833125
5676,21126581,The role of CDX2 in intestinal homeostasis and inflammation.,http://www.ncbi.nlm.nih.gov/pubmed/21126581
5677,23145505,Recessively inherited forms of osteogenesis imperfecta.,http://www.ncbi.nlm.nih.gov/pubmed/23145505
5678,22306263,CUX1 transcription factors: from biochemical activities and cell-based assays to mouse models and human diseases.,http://www.ncbi.nlm.nih.gov/pubmed/22306263
5679,25190083,"CUX1, a haploinsufficient tumour suppressor gene overexpressed in advanced cancers.",http://www.ncbi.nlm.nih.gov/pubmed/25190083
5680,25003536,Novel somatic KIT exon 8 mutation with dramatic response to imatinib in a patient with mucosal melanoma: a case report.,http://www.ncbi.nlm.nih.gov/pubmed/25003536
5681,,"A STUDY OF ABT-767 IN ADVANCED SOLID TUMORS WITH BRCA 1 AND BRCA 2 MUTATIONS AND HIGH GRADE SEROUS OVARIAN, FALLOPIAN TUBE, OR PRIMARY PERITONEAL CANCER",http://annonc.oxfordjournals.org/content/25/suppl_4/iv150.2.short
5682,20201941,The novel inhibitor of histone deacetylase resminostat (RAS2410) inhibits proliferation and induces apoptosis in multiple myeloma (MM) cells.,http://www.ncbi.nlm.nih.gov/pubmed/20201941
5683,24065624,"First-in-human, pharmacokinetic and pharmacodynamic phase I study of Resminostat, an oral histone deacetylase inhibitor, in patients with advanced solid tumors.",http://www.ncbi.nlm.nih.gov/pubmed/24065624
5684,26952006,Resminostat plus sorafenib as second-line therapy of advanced hepatocellular carcinoma - The SHELTER study.,http://www.ncbi.nlm.nih.gov/pubmed/26952006
5685,26773495,4SC-202 activates ASK1-dependent mitochondrial apoptosis pathway to inhibit hepatocellular carcinoma cells.,http://www.ncbi.nlm.nih.gov/pubmed/26773495
5686,,Overcoming the proliferation rate paradox: Clinical evaluation of a continuous dosing scheme of the novel oral Eg5 inhibitor 4SC-205.,http://meeting.ascopubs.org/cgi/content/abstract/33/15_suppl/2528
5687,26867820,Combined Epiregulin and Amphiregulin Expression Levels as a Predictive Biomarker for Panitumumab Therapy Benefit or Lack of Benefit in Patients With RAS Wild-Type Advanced Colorectal Cancer.,http://www.ncbi.nlm.nih.gov/pubmed/26867820
5688,,"A randomized phase Ib/II study evaluating the safety and efficacy of olaratumab (IMC-3G3), a human anti-platelet-derived growth factor ? (PDGFR?) monoclonal antibody, with or without doxorubicin (Dox), in advanced soft tissue sarcoma (STS).",http://meetinglibrary.asco.org/content/147332-156
5689,25605023,"HDAC1,2 inhibition impairs EZH2- and BBAP-mediated DNA repair to overcome chemoresistance in EZH2 gain-of-function mutant diffuse large B-cell lymphoma.",http://www.ncbi.nlm.nih.gov/pubmed/25605023
5690,,Identification of heregulin expression as a driver of a difficult-to-treat cancer phenotype and development of a prospective companion diagnostic for the heregulin-ErbB3 targeting drug seribantumab,http://files.shareholder.com/downloads/AMDA-IWDM2/2127694404x0x892308/7BACAE03-69E0-423A-A4D5-8A19EFED7AE1/MM-121_AACR_Precision_Medicine_Poster_11May2016_FINAL.pdf
5691,,First-in-human trial of ONC201 in patients with refractory solid tumors.,http://abstracts.asco.org/176/AbstView_176_166310.html
5692,,Phase Ib study of BGJ398 in combination with BYL719 in patients (pts) with select advanced solid tumors.,http://abstracts.asco.org/176/AbstView_176_164336.html
5693,,"A phase I dose escalation trial of PT2385, a first-in-class oral HIF-2a inhibitor, in patients with advanced clear cell renal cell carcinoma.",http://abstracts.asco.org/176/AbstView_176_171054.html
5694,,"Preliminary activity in the first in human study of the first-in-class fatty acid synthase (FASN) inhibitor, TVB-2640.",http://abstracts.asco.org/176/AbstView_176_166391.html
5695,26940138,"GZD856, a novel potent PDGFRα/β inhibitor, suppresses the growth and migration of lung cancer cells in vitro and in vivo.",http://www.ncbi.nlm.nih.gov/pubmed/26940138
5696,27185843,Randomized Phase II Study of Trabectedin and Doxorubicin Compared With Doxorubicin Alone as First-Line Treatment in Patients With Advanced Soft Tissue Sarcomas: A Spanish Group for Research on Sarcoma Study.,http://www.ncbi.nlm.nih.gov/pubmed/27185843
5697,23670235,Preclinical discovery of candidate genes to guide pharmacogenetics during phase I development: the example of the novel anticancer agent ABT-751.,http://www.ncbi.nlm.nih.gov/pubmed/23670235
5698,19398903,"ABT-751, a novel tubulin-binding agent, decreases tumor perfusion and disrupts tumor vasculature.",http://www.ncbi.nlm.nih.gov/pubmed/19398903
5699,26632033,Phase 1 Study of ABT-751 in Combination With CAPIRI (Capecitabine and Irinotecan) and Bevacizumab in Patients With Advanced Colorectal Cancer.,http://www.ncbi.nlm.nih.gov/pubmed/26632033
5700,26655844,SIRT1-Activating Compounds (STAC) Negatively Regulate Pancreatic Cancer Cell Growth and Viability Through a SIRT1 Lysosomal-Dependent Pathway.,http://www.ncbi.nlm.nih.gov/pubmed/26655844
5701,27099147,Palbociclib treatment of FLT3-ITD+ AML cells uncovers a kinase-dependent transcriptional regulation of FLT3 and PIM1 by CDK6.,http://www.ncbi.nlm.nih.gov/pubmed/27099147
5702,12403812,Assembly of centrosomal proteins and microtubule organization depends on PCM-1.,http://www.ncbi.nlm.nih.gov/pubmed/12403812
5703,23431203,Pattern discovery and cancer gene identification in integrated cancer genomic data.,http://www.ncbi.nlm.nih.gov/pubmed/23431203
5704,19451273,TIP47 functions in the biogenesis of lipid droplets.,http://www.ncbi.nlm.nih.gov/pubmed/19451273
5705,23555679,"Promyelocytic leukemia (PML) protein plays important roles in regulating cell adhesion, morphology, proliferation and migration.",http://www.ncbi.nlm.nih.gov/pubmed/23555679
5706,26733615,The Bromodomain Inhibitor JQ1 and the Histone Deacetylase Inhibitor Panobinostat Synergistically Reduce N-Myc Expression and Induce Anticancer Effects.,http://www.ncbi.nlm.nih.gov/pubmed/26733615
5707,26003532,Functions of Fibroblast Growth Factor Receptors in cancer defined by novel translocations and mutations.,http://www.ncbi.nlm.nih.gov/pubmed/26003532
5708,15629145,Tyrosine 769 of the keratinocyte growth factor receptor is required for receptor signaling but not endocytosis.,http://www.ncbi.nlm.nih.gov/pubmed/15629145
5709,26343583,Inhibition of RAF Isoforms and Active Dimers by LY3009120 Leads to Anti-tumor Activities in RAS or BRAF Mutant Cancers.,http://www.ncbi.nlm.nih.gov/pubmed/26343583
5710,20513808,Isocitrate dehydrogenase 1 and 2 mutations in cancer: alterations at a crossroads of cellular metabolism.,http://www.ncbi.nlm.nih.gov/pubmed/20513808
5711,23123965,Negative regulation of Shh levels by Kras and Fgfr2 during hair follicle development.,http://www.ncbi.nlm.nih.gov/pubmed/23123965
5712,22510884,"Distinct requirement for an intact dimer interface in wild-type, V600E and kinase-dead B-Raf signalling.",http://www.ncbi.nlm.nih.gov/pubmed/22510884
5713,20130576,RAF inhibitors prime wild-type RAF to activate the MAPK pathway and enhance growth.,http://www.ncbi.nlm.nih.gov/pubmed/20130576
5714,25450521,The role of eIF3 and its individual subunits in cancer.,http://www.ncbi.nlm.nih.gov/pubmed/25450521
5715,15218148,"Activation of transcription factor NF-kappaB requires ELKS, an IkappaB kinase regulatory subunit.",http://www.ncbi.nlm.nih.gov/pubmed/15218148
5716,21876675,An EMT-driven alternative splicing program occurs in human breast cancer and modulates cellular phenotype.,http://www.ncbi.nlm.nih.gov/pubmed/21876675
5717,26416732,The genomic landscape of response to EGFR blockade in colorectal cancer.,http://www.ncbi.nlm.nih.gov/pubmed/26416732
5718,26059438,Epidermal growth factor receptor mutation mediates cross-resistance to panitumumab and cetuximab in gastrointestinal cancer.,http://www.ncbi.nlm.nih.gov/pubmed/26059438
5719,26843189,MM-151 overcomes acquired resistance to cetuximab and panitumumab in colorectal cancers harboring EGFR extracellular domain mutations.,http://www.ncbi.nlm.nih.gov/pubmed/26843189
5720,26783290,A Phase I Study of the AKT Inhibitor MK-2206 in Combination with Hormonal Therapy in Postmenopausal Women with Estrogen Receptor-Positive Metastatic Breast Cancer.,http://www.ncbi.nlm.nih.gov/pubmed/26783290
5721,26341921,Afatinib plus Cetuximab Delays Resistance Compared to Single-Agent Erlotinib or Afatinib in Mouse Models of TKI-Naïve EGFR L858R-Induced Lung Adenocarcinoma.,http://www.ncbi.nlm.nih.gov/pubmed/26341921
5722,26988986,Proteasomal Inhibition by Ixazomib Induces CHK1 and MYC-Dependent Cell Death in T-cell and Hodgkin Lymphoma.,http://www.ncbi.nlm.nih.gov/pubmed/26988986
5723,26380059,Hereditary diffuse gastric cancer: What the clinician should know.,http://www.ncbi.nlm.nih.gov/pubmed/26380059
5724,27003961,Vedolizumab: A novel anti-integrin drug for treatment of inflammatory bowel disease.,http://www.ncbi.nlm.nih.gov/pubmed/27003961
5725,22377563,"A phase II trial (AGO 2.11) in platinum-resistant ovarian cancer: a randomized multicenter trial with sunitinib (SU11248) to evaluate dosage, schedule, tolerability, toxicity and effectiveness of a multitargeted receptor tyrosine kinase inhibitor monotherapy.",http://www.ncbi.nlm.nih.gov/pubmed/22377563
5726,26194424,Development and Integration of Antibody-Drug Conjugate in Non-Hodgkin Lymphoma.,http://www.ncbi.nlm.nih.gov/pubmed/26194424
5727,22263058,T790M and acquired resistance of EGFR TKI: a literature review of clinical reports.,http://www.ncbi.nlm.nih.gov/pubmed/22263058
5728,25044103,"Phase II study of the GI-4000 KRAS vaccine after curative therapy in patients with stage I-III lung adenocarcinoma harboring a KRAS G12C, G12D, or G12V mutation.",http://www.ncbi.nlm.nih.gov/pubmed/25044103
5729,25585100,"Pancreatic cancer, treatment options, and GI-4000.",http://www.ncbi.nlm.nih.gov/pubmed/25585100
5730,27048951,"A Novel Plant Sesquiterpene Lactone Derivative, DETD-35, Suppresses BRAFV600E Mutant Melanoma Growth and Overcomes Acquired Vemurafenib Resistance in Mice.",http://www.ncbi.nlm.nih.gov/pubmed/27048951
5731,26960983,"MK-4101, a Potent Inhibitor of the Hedgehog Pathway, Is Highly Active against Medulloblastoma and Basal Cell Carcinoma.",http://www.ncbi.nlm.nih.gov/pubmed/26960983
5732,24656771,The R882H DNMT3A mutation associated with AML dominantly inhibits wild-type DNMT3A by blocking its ability to form active tetramers.,http://www.ncbi.nlm.nih.gov/pubmed/24656771
5733,27048246,BRAFV600E Mutations in High-Grade Colorectal Neuroendocrine Tumors May Predict Responsiveness to BRAF-MEK Combination Therapy.,http://www.ncbi.nlm.nih.gov/pubmed/27048246
5734,21828050,Ubiquitin ligase activity of Cul3-KLHL7 protein is attenuated by autosomal dominant retinitis pigmentosa causative mutation.,http://www.ncbi.nlm.nih.gov/pubmed/21828050
5735,20701601,Detection of prognostically relevant genetic abnormalities in childhood B-cell precursor acute lymphoblastic leukaemia: recommendations from the Biology and Diagnosis Committee of the International Berlin-Frankfürt-Münster study group.,http://www.ncbi.nlm.nih.gov/pubmed/20701601
5736,24367103,AFF1 is a ubiquitous P-TEFb partner to enable Tat extraction of P-TEFb from 7SK snRNP and formation of SECs for HIV transactivation.,http://www.ncbi.nlm.nih.gov/pubmed/24367103
5737,8080983,"ENL, the gene fused with HRX in t(11;19) leukemias, encodes a nuclear protein with transcriptional activation potential in lymphoid and myeloid cells.",http://www.ncbi.nlm.nih.gov/pubmed/8080983
5738,19262598,New insights to the MLL recombinome of acute leukemias.,http://www.ncbi.nlm.nih.gov/pubmed/19262598
5739,19422821,The renal cell carcinoma-associated oncogenic fusion protein PRCCTFE3 provokes p21 WAF1/CIP1-mediated cell cycle delay.,http://www.ncbi.nlm.nih.gov/pubmed/19422821
5740,8986805,"Fusion of the transcription factor TFE3 gene to a novel gene, PRCC, in t(X;1)(p11;q21)-positive papillary renal cell carcinomas.",http://www.ncbi.nlm.nih.gov/pubmed/8986805
5741,18371451,MLLT3 regulates early human erythroid and megakaryocytic cell fate.,http://www.ncbi.nlm.nih.gov/pubmed/18371451
5742,10913441,Kinectin-kinesin binding domains and their effects on organelle motility.,http://www.ncbi.nlm.nih.gov/pubmed/10913441
5743,10850414,Translocation t(10;14)(q11.2:q22.1) fusing the kinetin to the RET gene creates a novel rearranged form (PTC8) of the RET proto-oncogene in radiation-induced childhood papillary thyroid carcinoma.,http://www.ncbi.nlm.nih.gov/pubmed/10850414
5744,25795305,Fusion genes with ALK as recurrent partner in ependymoma-like gliomas: a new brain tumor entity?,http://www.ncbi.nlm.nih.gov/pubmed/25795305
5745,23552869,"Protein tyrosine phosphatase kappa (PTPRK) is a negative regulator of adhesion and invasion of breast cancer cells, and associates with poor prognosis of breast cancer.",http://www.ncbi.nlm.nih.gov/pubmed/23552869
5746,25609089,Notch and TGF-β pathways cooperatively regulate receptor protein tyrosine phosphatase-κ (PTPRK) gene expression in human primary keratinocytes.,http://www.ncbi.nlm.nih.gov/pubmed/25609089
5747,25283634,Do lamin A and lamin C have unique roles?,http://www.ncbi.nlm.nih.gov/pubmed/25283634
5748,26563356,Evaluation of a Congenital Infantile Fibrosarcoma by Comprehensive Genomic Profiling Reveals an LMNA-NTRK1 Gene Fusion Responsive to Crizotinib.,http://www.ncbi.nlm.nih.gov/pubmed/26563356
5749,23207140,Sequential induction of type I and II interferons mediates a long-lasting gene induction in the liver in response to a novel toll-like receptor 9 agonist.,http://www.ncbi.nlm.nih.gov/pubmed/23207140
5750,18603554,The seventh pathogenic fusion gene FIP1L1-RARA was isolated from a t(4;17)-positive acute promyelocytic leukemia.,http://www.ncbi.nlm.nih.gov/pubmed/18603554
5751,22308453,Functional characterization of the guanine nucleotide exchange factor (GEF) motif of GIV protein reveals a threshold effect in signaling.,http://www.ncbi.nlm.nih.gov/pubmed/22308453
5752,,"IMGN853 (mirvetuximab soravtansine), a folate receptor alpha (FR?)-targeting antibody-drug conjugate (ADC): Single-agent activity in platinum-resistant epithelial ovarian cancer (EOC) patients (pts).",http://abstracts.asco.org/176/AbstView_176_169854.html
5753,,Brigatinib (BRG) in patients (pts) with crizotinib (CRZ)-refractory ALK+ non-small cell lung cancer (NSCLC): First report of efficacy and safety from a pivotal randomized phase (ph) 2 trial (ALTA).,http://abstracts.asco.org/176/AbstView_176_165056.html
5754,,Effect of controlled intratumoral viral delivery of Ad-RTS-hIL-12 + oral veledimex in subjects with recurrent or progressive glioma.,http://abstracts.asco.org/176/AbstView_176_168752.html
5755,,Galeterone in treatment-naïve patients with castration-resistant prostate cancer with C-terminal androgen receptor loss: Results from ARMOR2.,http://abstracts.asco.org/176/AbstView_176_170683.html
5756,20850016,Quantitative interaction proteomics and genome-wide profiling of epigenetic histone marks and their readers.,http://www.ncbi.nlm.nih.gov/pubmed/20850016
5757,21698156,"M402, a novel heparan sulfate mimetic, targets multiple pathways implicated in tumor progression and metastasis.",http://www.ncbi.nlm.nih.gov/pubmed/21698156
5758,,"Safety, pharmacokinetics, pharmacodynamics, and antitumor activity of necuparanib combined with nab-Paclitaxel and gemcitabine in patients with metastatic pancreatic cancer: Updated phase 1 results.",http://abstracts.asco.org/176/AbstView_176_167912.html
5759,10884424,Dysfunction of human Rad18 results in defective postreplication repair and hypersensitivity to multiple mutagens.,http://www.ncbi.nlm.nih.gov/pubmed/10884424
5760,25851173,Poly(ADP-ribose) polymerase-13 and RNA regulation in immunity and cancer.,http://www.ncbi.nlm.nih.gov/pubmed/25851173
5761,,Phase I trial of a first-in-class ATR inhibitor VX-970 as monotherapy (mono) or in combination (combo) with carboplatin (CP) incorporating pharmacodynamics (PD) studies.,http://abstracts.asco.org/176/AbstView_176_165738.html
5762,22531498,Poly(ADP-ribose) regulates post-transcriptional gene regulation in the cytoplasm.,http://www.ncbi.nlm.nih.gov/pubmed/22531498
5763,24113188,Down-modulation of nucleoporin RanBP2/Nup358 impaired chromosomal alignment and induced mitotic catastrophe.,http://www.ncbi.nlm.nih.gov/pubmed/24113188
5764,24613277,RANBP2-ALK fusion combined with monosomy 7 in acute myelomonocytic leukemia.,http://www.ncbi.nlm.nih.gov/pubmed/24613277
5765,,"Final results of a first-in-human study evaluating the safety, pharmacology and initial efficacy of MM-151, an oligoclonal anti-EGFR antibody in patients with refractory solid tumors.",http://abstracts.asco.org/176/AbstView_176_170118.html
5766,24470379,Identification of RANBP2-ALK fusion in ALK positive diffuse large B-cell lymphoma.,http://www.ncbi.nlm.nih.gov/pubmed/24470379
5767,12661011,Fusion of ALK to the Ran-binding protein 2 (RANBP2) gene in inflammatory myofibroblastic tumor.,http://www.ncbi.nlm.nih.gov/pubmed/12661011
5768,21855801,Interaction profiling identifies the human nuclear exosome targeting complex.,http://www.ncbi.nlm.nih.gov/pubmed/21855801
5769,25852104,RBM7 subunit of the NEXT complex binds U-rich sequences and targets 3'-end extended forms of snRNAs.,http://www.ncbi.nlm.nih.gov/pubmed/25852104
5770,27121553,Identification of ZCCHC8 as fusion partner of ROS1 in a case of congenital glioblastoma multiforme with a t(6;12)(q21;q24.3).,http://www.ncbi.nlm.nih.gov/pubmed/27121553
5771,,"Randomized phase 2 study of paclitaxel (PTX), trastuzumab (T) with or without MM-111 in HER2 expressing gastroesophageal cancers (GEC).",http://abstracts.asco.org/176/AbstView_176_166103.html
5772,,A phase I study of bevacizumab in combination with niraparib in patients with platinum-sensitive epithelial ovarian cancer: The ENGOT-OV24/AVANOVA1 trial.,http://abstracts.asco.org/176/AbstView_176_167216.html
5773,26722429,Silencing of ZNF139-siRNA induces apoptosis in human gastric cancer cell line BGC823.,http://www.ncbi.nlm.nih.gov/pubmed/26722429
5774,25561801,Zinc finger protein 139 expression in gastric cancer and its clinical significance.,http://www.ncbi.nlm.nih.gov/pubmed/25561801
5775,26013381,Activating MET kinase rearrangements in melanoma and Spitz tumours.,http://www.ncbi.nlm.nih.gov/pubmed/26013381
5776,,"Open-label phase Ib study of entinostat (E), and lapatinib (L) alone, and in combination with trastuzumab (T) in patients (pts) with HER2+ metastatic (mHER2+) breast cancer after progression on trastuzumab.",http://abstracts.asco.org/176/AbstView_176_170293.html
5777,,"A phase 2 study on efficacy, safety and intratumoral pharmacokinetics of oral selinexor (KPT-330) in patients with recurrent glioblastoma (GBM).",http://abstracts.asco.org/176/AbstView_176_170208.html
5778,10585779,"Isolation, characterization, and mapping of a zinc finger gene, ZFP95, containing both a SCAN box and an alternatively spliced KRAB A domain.",http://www.ncbi.nlm.nih.gov/pubmed/10585779
5779,,"Phase I trial of the combination of selinexor (SEL), liposomal doxorubicin (DOX) and dexamethasone (Dex) for relapsed and refractory multiple myeloma (RRMM).",http://abstracts.asco.org/176/AbstView_176_168723.html
5780,25731184,"Characterization of ABT-806, a Humanized Tumor-Specific Anti-EGFR Monoclonal Antibody.",http://www.ncbi.nlm.nih.gov/pubmed/25731184
5781,25895099,A phase 1 study of ABT-806 in subjects with advanced solid tumors.,http://www.ncbi.nlm.nih.gov/pubmed/25895099
5782,,Hybrid capture-based next-generation sequencing (HC NGS) in melanoma to identify markers of response to anti-PD-1/PD-L1.,http://abstracts.asco.org/176/AbstView_176_163406.html
5783,18806873,ZNF198 stabilizes the LSD1-CoREST-HDAC1 complex on chromatin through its MYM-type zinc fingers.,http://www.ncbi.nlm.nih.gov/pubmed/18806873
5784,26283374,Screen for multi-SUMO-binding proteins reveals a multi-SIM-binding mechanism for recruitment of the transcriptional regulator ZMYM2 to chromatin.,http://www.ncbi.nlm.nih.gov/pubmed/26283374
5785,27245147,"FGFR inhibitors: Effects on cancer cells, tumor microenvironment and whole-body homeostasis (Review).",http://www.ncbi.nlm.nih.gov/pubmed/27245147
5786,22875613,Ponatinib as targeted therapy for FGFR1 fusions associated with the 8p11 myeloproliferative syndrome.,http://www.ncbi.nlm.nih.gov/pubmed/22875613
5787,25858497,"A randomized, placebo-controlled phase III trial of masitinib plus gemcitabine in the treatment of advanced pancreatic cancer.",http://www.ncbi.nlm.nih.gov/pubmed/25858497
5788,20226962,8p11 myeloproliferative syndrome: a review.,http://www.ncbi.nlm.nih.gov/pubmed/20226962
5789,,"Clinical safety and activity from a phase I study of LOXO-101, a selective TRKA/B/C inhibitor, in solid-tumor patients with NTRK gene fusions",http://www.abstractsonline.com/Plan/ViewAbstract.aspx?mID=4017&sKey=dc4584a4-d39b-485a-9579-be210c4876e9&cKey=42a9d641-458f-4de1-a852-2f8a6fd52de3&mKey=1d10d749-4b6a-4ab3-bcd4-f80fb1922267
5790,,"Entrectinib, an oral pan-Trk, ROS1, and ALK inhibitor in TKI-naïve patients with advanced solid tumors harboring gene rearrangements: Updated phase I results",http://www.abstractsonline.com/Plan/ViewAbstract.aspx?mID=4017&sKey=dc4584a4-d39b-485a-9579-be210c4876e9&cKey=4abd89d1-63f0-4e65-b91c-486888d54e7a&mKey=1d10d749-4b6a-4ab3-bcd4-f80fb1922267
5791,18781147,Fusion in the ETS gene family and prostate cancer.,http://www.ncbi.nlm.nih.gov/pubmed/18781147
5792,21520040,ETV5 transcription factor is overexpressed in ovarian cancer and regulates cell adhesion in ovarian cancer cells.,http://www.ncbi.nlm.nih.gov/pubmed/21520040
5793,24924175,Role of ezrin in osteosarcoma metastasis.,http://www.ncbi.nlm.nih.gov/pubmed/24924175
5794,24421310,ERM proteins in cancer progression.,http://www.ncbi.nlm.nih.gov/pubmed/24421310
5795,25040262,Chromosome band 7q34 deletions resulting in KIAA1549-BRAF and FAM131B-BRAF fusions in pediatric low-grade Gliomas.,http://www.ncbi.nlm.nih.gov/pubmed/25040262
5796,22237106,The genetic basis of early T-cell precursor acute lymphoblastic leukaemia.,http://www.ncbi.nlm.nih.gov/pubmed/22237106
5797,21492125,Direct activation of STAT5 by ETV6-LYN fusion protein promotes induction of myeloproliferative neoplasm with myelofibrosis.,http://www.ncbi.nlm.nih.gov/pubmed/21492125
5798,25298122,Identification and characterization of OSTL (RNF217) encoding a RING-IBR-RING protein adjacent to a translocation breakpoint involving ETV6 in childhood ALL.,http://www.ncbi.nlm.nih.gov/pubmed/25298122
5799,25204415,The landscape of kinase fusions in cancer.,http://www.ncbi.nlm.nih.gov/pubmed/25204415
5800,25536104,Mutation profiling in cholangiocarcinoma: prognostic and therapeutic implications.,http://www.ncbi.nlm.nih.gov/pubmed/25536104
5801,10669742,"CIZ, a zinc finger protein that interacts with p130(cas) and activates the expression of matrix metalloproteinases.",http://www.ncbi.nlm.nih.gov/pubmed/10669742
5802,25943178,A novel recurrent EP300-ZNF384 gene fusion in B-cell precursor acute lymphoblastic leukemia.,http://www.ncbi.nlm.nih.gov/pubmed/25943178
5803,,"Safety and efficacy of single-agent rovalpituzumab tesirine (SC16LD6.5), a delta-like protein 3 (DLL3)-targeted antibody-drug conjugate (ADC) in recurrent or refractory small cell lung cancer (SCLC).",http://abstracts.asco.org/176/AbstView_176_162941.html
5804,16751810,Functional analyses and molecular modeling of two c-Kit mutations responsible for imatinib secondary resistance in GIST patients.,http://www.ncbi.nlm.nih.gov/pubmed/16751810
5805,,Atezolizumab (atezo) as first-line (1L) therapy in cisplatin-ineligible locally advanced/metastatic urothelial carcinoma (mUC): Primary analysis of IMvigor210 cohort 1.,http://meetinglibrary.asco.org/content/170759-176
5806,,"RUCAPANC: An open-label, phase 2 trial of the PARP inhibitor rucaparib in patients (pts) with pancreatic cancer (PC) and a known deleterious germline or somatic BRCA mutation.",http://meetinglibrary.asco.org/content/166810-176
5807,11978792,"Characterization of the human gene encoding the scavenger receptor expressed by endothelial cell and its regulation by a novel transcription factor, endothelial zinc finger protein-2.",http://www.ncbi.nlm.nih.gov/pubmed/11978792
5808,20815032,"EWSR1-POU5F1 fusion in soft tissue myoepithelial tumors. A molecular analysis of sixty-six cases, including soft tissue, bone, and visceral lesions, showing common involvement of the EWSR1 gene.",http://www.ncbi.nlm.nih.gov/pubmed/20815032
5809,20972453,The low frequency of clinical resistance to PDGFR inhibitors in myeloid neoplasms with abnormalities of PDGFRA might be related to the limited repertoire of possible PDGFRA kinase domain mutations in vitro.,http://www.ncbi.nlm.nih.gov/pubmed/20972453
5810,24060861,Mechanistic insight into ALK receptor tyrosine kinase in human cancer biology.,http://www.ncbi.nlm.nih.gov/pubmed/24060861
5811,25071110,Emergence of new ALK mutations at relapse of neuroblastoma.,http://www.ncbi.nlm.nih.gov/pubmed/25071110
5812,24419427,Stabilization of disease after targeted therapy in a thymic carcinoma with KIT mutation detected by clinical next-generation sequencing.,http://www.ncbi.nlm.nih.gov/pubmed/24419427
5813,21969494,Impressive response with imatinib in a heavily pretreated patient with metastatic c-KIT mutated thymic carcinoma.,http://www.ncbi.nlm.nih.gov/pubmed/21969494
5814,15201427,Thymic carcinoma with overexpression of mutated KIT and the response to imatinib.,http://www.ncbi.nlm.nih.gov/pubmed/15201427
5815,20970876,Promising efficacy of sorafenib in a relapsed thymic carcinoma with C-KIT exon 11 deletion mutation.,http://www.ncbi.nlm.nih.gov/pubmed/20970876
5816,11526490,STI571 inactivation of the gastrointestinal stromal tumor c-KIT oncoprotein: biological and clinical implications.,http://www.ncbi.nlm.nih.gov/pubmed/11526490
5817,19461405,Long lasting response to the multikinase inhibitor bay 43-9006 (Sorafenib) in a heavily pretreated metastatic thymic carcinoma.,http://www.ncbi.nlm.nih.gov/pubmed/19461405
5818,22357254,Activating c-KIT mutations in a subset of thymic carcinoma and response to different c-KIT inhibitors.,http://www.ncbi.nlm.nih.gov/pubmed/22357254
5819,23900716,Claudin 18.2 is a target for IMAB362 antibody in pancreatic neoplasms.,http://www.ncbi.nlm.nih.gov/pubmed/23900716
5820,16015387,Mutations in KIT and RAS are frequent events in pediatric core-binding factor acute myeloid leukemia.,http://www.ncbi.nlm.nih.gov/pubmed/16015387
5821,23082000,Translating the therapeutic potential of AZD4547 in FGFR1-amplified non-small cell lung cancer through the use of patient-derived tumor xenograft models.,http://www.ncbi.nlm.nih.gov/pubmed/23082000
5822,25274033,Androgen receptor is the key transcriptional mediator of the tumor suppressor SPOP in prostate cancer.,http://www.ncbi.nlm.nih.gov/pubmed/25274033
5823,26316776,Inactivity of imatinib in gastrointestinal stromal tumors (GISTs) harboring a KIT activation-loop domain mutation (exon 17 mutation pN822K).,http://www.ncbi.nlm.nih.gov/pubmed/26316776
5824,26813233,Functional analysis of androgen receptor mutations that confer anti-androgen resistance identified in circulating cell-free DNA from prostate cancer patients.,http://www.ncbi.nlm.nih.gov/pubmed/26813233
5825,9724771,"The APC variants I1307K and E1317Q are associated with colorectal tumors, but not always with a family history.",http://www.ncbi.nlm.nih.gov/pubmed/9724771
5826,27196760,TRX-E-002-1 Induces c-Jun-Dependent Apoptosis in Ovarian Cancer Stem Cells and Prevents Recurrence In Vivo.,http://www.ncbi.nlm.nih.gov/pubmed/27196760
5827,9690513,Akt activation by growth factors is a multiple-step process: the role of the PH domain.,http://www.ncbi.nlm.nih.gov/pubmed/9690513
5828,24211109,Mutation in the first Ig-like domain of Kit leads to JAK2 activation and myeloproliferation in mice.,http://www.ncbi.nlm.nih.gov/pubmed/24211109
5829,16143141,Novel germline mutation of KIT associated with familial gastrointestinal stromal tumors and mastocytosis.,http://www.ncbi.nlm.nih.gov/pubmed/16143141
5830,,Heritage: A phase III safety and efficacy trial of the proposed trastuzumab biosimilar Myl-1401O versus Herceptin.,http://meetinglibrary.asco.org/content/162159-176
5831,24637997,Bevacizumab combined with chemotherapy for platinum-resistant recurrent ovarian cancer: The AURELIA open-label randomized phase III trial.,http://www.ncbi.nlm.nih.gov/pubmed/24637997
5832,,Alectinib (ALC) versus crizotinib (CRZ) in ALK-inhibitor naive ALK-positive non-small cell lung cancer (ALK+ NSCLC): Primary results from the J-ALEX study.,http://meetinglibrary.asco.org/content/167434-176
5833,25994018,Intra-tumor genetic heterogeneity and alternative driver genetic alterations in breast cancers with heterogeneous HER2 gene amplification.,http://www.ncbi.nlm.nih.gov/pubmed/25994018
5834,,Safety and efficacy of lorlatinib (PF-06463922) from the dose-escalation component of a study in patients with advanced ALK+ or ROS1+ non-small cell lung cancer (NSCLC).,http://abstracts.asco.org/176/AbstView_176_161846.html
5835,,Results of NEMO: A phase III trial of binimetinib (BINI) vs dacarbazine (DTIC) in NRAS-mutant cutaneous melanoma.,http://meetinglibrary.asco.org/content/166136-176
5836,22454414,"Randomized, double-blind, placebo-controlled phase III trial comparing docetaxel and prednisone with or without bevacizumab in men with metastatic castration-resistant prostate cancer: CALGB 90401.",http://www.ncbi.nlm.nih.gov/pubmed/22454414
5837,,Efficacy and safety of crizotinib in patients (pts) with advanced MET exon 14-altered non-small cell lung cancer (NSCLC).,http://abstracts.asco.org/176/AbstView_176_167889.html
5838,19307500,Phase III trial of bevacizumab in combination with gemcitabine and erlotinib in patients with metastatic pancreatic cancer.,http://www.ncbi.nlm.nih.gov/pubmed/19307500
5839,16439621,Germline mutations in genes within the MAPK pathway cause cardio-facio-cutaneous syndrome.,http://www.ncbi.nlm.nih.gov/pubmed/16439621
5840,24265153,The genetic landscape of clinical resistance to RAF inhibition in metastatic melanoma.,http://www.ncbi.nlm.nih.gov/pubmed/24265153
5841,21948233,ALK mutations conferring differential resistance to structurally diverse ALK inhibitors.,http://www.ncbi.nlm.nih.gov/pubmed/21948233
5842,16818505,Functional analysis and molecular modeling show a preserved wild-type activity of p53(C238Y).,http://www.ncbi.nlm.nih.gov/pubmed/16818505
5843,26065894,Mitogen-Inducible Gene-6 Mediates Feedback Inhibition from Mutated BRAF towards the Epidermal Growth Factor Receptor and Thereby Limits Malignant Transformation.,http://www.ncbi.nlm.nih.gov/pubmed/26065894
5844,16474404,Germline KRAS and BRAF mutations in cardio-facio-cutaneous syndrome.,http://www.ncbi.nlm.nih.gov/pubmed/16474404
5845,24006493,"Mzt1/Tam4, a fission yeast MOZART1 homologue, is an essential component of the γ-tubulin complex and directly interacts with GCP3(Alp6).",http://www.ncbi.nlm.nih.gov/pubmed/24006493
5846,16257966,M-RIP targets myosin phosphatase to stress fibers to regulate myosin light chain phosphorylation in vascular smooth muscle cells.,http://www.ncbi.nlm.nih.gov/pubmed/16257966
5847,26729571,Review: Aberrant EVI1 expression in acute myeloid leukaemia.,http://www.ncbi.nlm.nih.gov/pubmed/26729571
5848,11980658,Expression of mitotic spindle checkpoint protein hsMAD1 correlates with cellular proliferation and is activated by a gain-of-function p53 mutant.,http://www.ncbi.nlm.nih.gov/pubmed/11980658
5849,11423979,"Mutations in the mitotic check point gene, MAD1L1, in human cancers.",http://www.ncbi.nlm.nih.gov/pubmed/11423979
5850,25183430,The LRIG family: enigmatic regulators of growth factor receptor signaling.,http://www.ncbi.nlm.nih.gov/pubmed/25183430
5851,25180912,LRIG and cancer prognosis.,http://www.ncbi.nlm.nih.gov/pubmed/25180912
5852,20060942,The Paf1 complex: platform or player in RNA polymerase II transcription?,http://www.ncbi.nlm.nih.gov/pubmed/20060942
5853,17599057,Human RNA polymerase II-associated factor complex: dysregulation in cancer.,http://www.ncbi.nlm.nih.gov/pubmed/17599057
5854,23325410,Physiology of SLC12 transporters: lessons from inherited human genetic mutations and genetically engineered mouse knockouts.,http://www.ncbi.nlm.nih.gov/pubmed/23325410
5855,23833300,"Clinical, pathologic, and biologic features associated with BRAF mutations in non-small cell lung cancer.",http://www.ncbi.nlm.nih.gov/pubmed/23833300
5856,19376813,Kinase-activating and kinase-impaired cardio-facio-cutaneous syndrome alleles have activity during zebrafish development and are sensitive to small molecule inhibitors.,http://www.ncbi.nlm.nih.gov/pubmed/19376813
5857,19111562,A missense mutation in the APC tumor suppressor gene disrupts an ASF/SF2 splicing enhancer motif and causes pathogenic skipping of exon 14.,http://www.ncbi.nlm.nih.gov/pubmed/19111562
5858,23680146,RAF inhibitors activate the MAPK pathway by relieving inhibitory autophosphorylation.,http://www.ncbi.nlm.nih.gov/pubmed/23680146
5859,20538618,Gatekeeper mutations mediate resistance to BRAF-targeted therapies.,http://www.ncbi.nlm.nih.gov/pubmed/20538618
5860,26324360,Extreme Outlier Analysis Identifies Occult Mitogen-Activated Protein Kinase Pathway Mutations in Patients With Low-Grade Serous Ovarian Cancer.,http://www.ncbi.nlm.nih.gov/pubmed/26324360
5861,21303910,Subunit organization of the human INO80 chromatin remodeling complex: an evolutionarily conserved core complex catalyzes ATP-dependent nucleosome remodeling.,http://www.ncbi.nlm.nih.gov/pubmed/21303910
5862,,,http://www.ncbi.nlm.nih.gov/gene
5863,26271483,Cytotoxicity of the CD37 antibody BI 836826 against chronic lymphocytic leukaemia cells in combination with chemotherapeutic agents or PI3K inhibitors.,http://www.ncbi.nlm.nih.gov/pubmed/26271483
5864,16633365,Ubiquitin ligases: cell-cycle control and cancer.,http://www.ncbi.nlm.nih.gov/pubmed/16633365
5865,23592700,Cullin1 is a novel marker of poor prognosis and a potential therapeutic target in human breast cancer.,http://www.ncbi.nlm.nih.gov/pubmed/23592700
5866,17145850,Demonstration of a genetic therapeutic index for tumors expressing oncogenic BRAF by the kinase inhibitor SB-590885.,http://www.ncbi.nlm.nih.gov/pubmed/17145850
5867,21928350,"Functional characterization of a novel FGFR2 mutation, E731K, in craniosynostosis.",http://www.ncbi.nlm.nih.gov/pubmed/21928350
5868,22960131,Amino acid residue E543 in JAK2 C618R is a potential therapeutic target for myeloproliferative disorders caused by JAK2 C618R mutation.,http://www.ncbi.nlm.nih.gov/pubmed/22960131
5869,17267906,JAK2 exon 12 mutations in polycythemia vera and idiopathic erythrocytosis.,http://www.ncbi.nlm.nih.gov/pubmed/17267906
5870,20182460,JAK2 mutation and disease phenotype: a double L611V/V617F in cis mutation of JAK2 is associated with isolated erythrocytosis and increased activation of AKT and ERK1/2 rather than STAT5.,http://www.ncbi.nlm.nih.gov/pubmed/20182460
5871,18805579,Mutations of JAK2 in acute lymphoblastic leukaemias associated with Down's syndrome.,http://www.ncbi.nlm.nih.gov/pubmed/18805579
5872,19543316,"SOCS-mediated downregulation of mutant Jak2 (V617F, T875N and K539L) counteracts cytokine-independent signaling.",http://www.ncbi.nlm.nih.gov/pubmed/19543316
5873,25515960,The role of the Janus-faced transcription factor PAX5-JAK2 in acute lymphoblastic leukemia.,http://www.ncbi.nlm.nih.gov/pubmed/25515960
5874,16001431,A BCR-JAK2 fusion gene as the result of a t(9;22)(p24;q11.2) translocation in a patient with a clinically typical chronic myeloid leukemia.,http://www.ncbi.nlm.nih.gov/pubmed/16001431
5875,,First-in-human trial of novel oral PARP inhibitor BMN 673 in patients with solid tumors,http://meetinglibrary.asco.org/content/111725-132
5876,25589624,"Randomized Trial of Oral Cyclophosphamide and Veliparib in High-Grade Serous Ovarian, Primary Peritoneal, or Fallopian Tube Cancers, or BRCA-Mutant Ovarian Cancer.",http://www.ncbi.nlm.nih.gov/pubmed/25589624
5877,25324140,A phase I dose escalation and expansion study of the anticancer stem cell agent demcizumab (anti-DLL4) in patients with previously treated solid tumors.,http://www.ncbi.nlm.nih.gov/pubmed/25324140
5878,,Phase I trial of the PARP inhibitor veliparib (V) in combination with carboplatin (C) in metastatic breast cancer (MBC).,http://meetinglibrary.asco.org/content/132155-144
5879,,"First-in-human study of LY3039478, a Notch signaling inhibitor in advanced or metastatic cancer",http://meetinglibrary.asco.org/content/144588-156
5880,,Preliminary activity of veliparib (V) in BRCA2-mutated metastatic castration-resistant prostate cancer (mCRPC).,http://meetinglibrary.asco.org/content/141499-159
5881,,Abstract C164: Dual targeting of the DLL4 and VEGF pathways with a bispecific monoclonal antibody inhibits tumor growth and reduces cancer stem cell frequency,http://mct.aacrjournals.org/content/14/12_Supplement_2/C164.short
5882,,A phase 1B/ phase 2A study of TRC105 (Endoglin Antibody) in combination with pazopanib (P) in patients (pts) with advanced soft tissue sarcoma (STS).,http://meetinglibrary.asco.org/content/168705-176
5883,16829519,PCAF modulates PTEN activity.,http://www.ncbi.nlm.nih.gov/pubmed/16829519
5884,9927204,Mutant p53 gain of function: differential effects of different p53 mutants on resistance of cultured cells to chemotherapy.,http://www.ncbi.nlm.nih.gov/pubmed/9927204
5885,24065105,The consequence of oncomorphic TP53 mutations in ovarian cancer.,http://www.ncbi.nlm.nih.gov/pubmed/24065105
5886,27066457,Oncogenic Intra-p53 Family Member Interactions in Human Cancers.,http://www.ncbi.nlm.nih.gov/pubmed/27066457
5887,14675182,A novel loss-of-function mutation (N48K) in the PTEN gene in a Spanish patient with Cowden disease.,http://www.ncbi.nlm.nih.gov/pubmed/14675182
5888,19329485,Evidence of ultraviolet type mutations in xeroderma pigmentosum melanomas.,http://www.ncbi.nlm.nih.gov/pubmed/19329485
5889,15342384,Mek1 alters epidermal growth and differentiation.,http://www.ncbi.nlm.nih.gov/pubmed/15342384
5890,23840064,PTEN loss defines a PI3K/AKT pathway-dependent germinal center subtype of diffuse large B-cell lymphoma.,http://www.ncbi.nlm.nih.gov/pubmed/23840064
5891,19106100,MCAF1/AM is involved in Sp1-mediated maintenance of cancer-associated telomerase activity.,http://www.ncbi.nlm.nih.gov/pubmed/19106100
5892,15805263,The t(8;9)(p22;p24) is a recurrent abnormality in chronic and acute leukemia that fuses PCM1 to JAK2.,http://www.ncbi.nlm.nih.gov/pubmed/15805263
5893,25951811,Identification of SPAG9 as a novel JAK2 fusion partner gene in pediatric acute lymphoblastic leukemia with t(9;17)(p24;q21).,http://www.ncbi.nlm.nih.gov/pubmed/25951811
5894,25310386,"SPAG9 expression is increased in human prostate cancer and promotes cell motility, invasion and angiogenesis in vitro.",http://www.ncbi.nlm.nih.gov/pubmed/25310386
5895,24801907,Overexpression of SPAG9 correlates with poor prognosis and tumor progression in hepatocellular carcinoma.,http://www.ncbi.nlm.nih.gov/pubmed/24801907
5896,18922895,"Sperm-associated antigen 9 is associated with tumor growth, migration, and invasion in renal cell carcinoma.",http://www.ncbi.nlm.nih.gov/pubmed/18922895
5897,18618714,Novel SSBP2-JAK2 fusion gene resulting from a t(5;9)(q14.1;p24.1) in pre-B acute lymphocytic leukemia.,http://www.ncbi.nlm.nih.gov/pubmed/18618714
5898,19683501,SOSS complexes participate in the maintenance of genomic stability.,http://www.ncbi.nlm.nih.gov/pubmed/19683501
5899,22472174,SSBP2 variants are associated with survival in glioblastoma patients.,http://www.ncbi.nlm.nih.gov/pubmed/22472174
5900,1894650,p21 with a phenylalanine 28----leucine mutation reacts normally with the GTPase activating protein GAP but nevertheless has transforming properties.,http://www.ncbi.nlm.nih.gov/pubmed/1894650
5901,26811601,Targeted therapies in gastric cancer and future perspectives.,http://www.ncbi.nlm.nih.gov/pubmed/26811601
5902,17218261,Ubiquitination regulates PTEN nuclear import and tumor suppression.,http://www.ncbi.nlm.nih.gov/pubmed/17218261
5903,21844183,Downregulation of RBMS3 is associated with poor prognosis in esophageal squamous cell carcinoma.,http://www.ncbi.nlm.nih.gov/pubmed/21844183
5904,25588924,RBMS3 is a tumor suppressor gene that acts as a favorable prognostic marker in lung squamous cell carcinoma.,http://www.ncbi.nlm.nih.gov/pubmed/25588924
5905,25263454,A new class of cancer-associated PTEN mutations defined by membrane translocation defects.,http://www.ncbi.nlm.nih.gov/pubmed/25263454
5906,16549277,"h-Goliath, paralog of GRAIL, is a new E3 ligase protein, expressed in human leukocytes.",http://www.ncbi.nlm.nih.gov/pubmed/16549277
5907,25228972,RING finger proteins are involved in the progression of barrett esophagus to esophageal adenocarcinoma: a preliminary study.,http://www.ncbi.nlm.nih.gov/pubmed/25228972
5908,11877430,Interaction between tyrosine kinase Etk and a RUN domain- and FYVE domain-containing protein RUFY1. A possible role of ETK in regulation of vesicle trafficking.,http://www.ncbi.nlm.nih.gov/pubmed/11877430
5909,25384085,Anchored multiplex PCR for targeted next-generation sequencing.,http://www.ncbi.nlm.nih.gov/pubmed/25384085
5910,27012813,DiSCoVERing Innovative Therapies for Rare Tumors: Combining Genetically Accurate Disease Models with In Silico Analysis to Identify Novel Therapeutic Targets.,http://www.ncbi.nlm.nih.gov/pubmed/27012813
5911,11245466,"Identification and characterization of prostein, a novel prostate-specific protein.",http://www.ncbi.nlm.nih.gov/pubmed/11245466
5912,23506898,The SLC45 gene family of putative sugar transporters.,http://www.ncbi.nlm.nih.gov/pubmed/23506898
5913,12761502,FEV acts as a transcriptional repressor through its DNA-binding ETS domain and alanine-rich domain.,http://www.ncbi.nlm.nih.gov/pubmed/12761502
5914,24898918,"Ewing sarcoma of the small bowel: a study of seven cases, including one with the uncommonly reported EWSR1-FEV translocation.",http://www.ncbi.nlm.nih.gov/pubmed/24898918
5915,23059812,Diverging gain-of-function mechanisms of two novel KRAS mutations associated with Noonan and cardio-facio-cutaneous syndromes.,http://www.ncbi.nlm.nih.gov/pubmed/23059812
5916,21375404,A novel polymorphism in codon 25 of the KRAS gene associated with gallbladder carcinoma patients of the eastern part of India.,http://www.ncbi.nlm.nih.gov/pubmed/21375404
5917,11333268,Structure-based mutagenesis reveals distinct functions for Ras switch 1 and switch 2 in Sos-catalyzed guanine nucleotide exchange.,http://www.ncbi.nlm.nih.gov/pubmed/11333268
5918,26080442,Ras-GTP dimers activate the Mitogen-Activated Protein Kinase (MAPK) pathway.,http://www.ncbi.nlm.nih.gov/pubmed/26080442
5919,26841430,Allele-specific inhibitors inactivate mutant KRAS G12C by a trapping mechanism.,http://www.ncbi.nlm.nih.gov/pubmed/26841430
5920,22387997,A new subtype of bone sarcoma defined by BCOR-CCNB3 gene fusion.,http://www.ncbi.nlm.nih.gov/pubmed/22387997
5921,24586690,"Runx1t1 (Runt-related transcription factor 1; translocated to, 1) epigenetically regulates the proliferation and nitric oxide production of microglia.",http://www.ncbi.nlm.nih.gov/pubmed/24586690
5922,21499216,RUNX1T1: a novel predictor of liver metastasis in primary pancreatic endocrine neoplasms.,http://www.ncbi.nlm.nih.gov/pubmed/21499216
5923,23844358,Expression of syndecan-4 and correlation with metastatic potential in testicular germ cell tumours.,http://www.ncbi.nlm.nih.gov/pubmed/23844358
5924,25361632,Association of heparan sulfate proteoglycans SDC1 and SDC4 polymorphisms with breast cancer in an Australian Caucasian population.,http://www.ncbi.nlm.nih.gov/pubmed/25361632
5925,22919003,Identifying and targeting ROS1 gene fusions in non-small cell lung cancer.,http://www.ncbi.nlm.nih.gov/pubmed/22919003
5926,25715771,SEC31A-ALK Fusion Gene in Lung Adenocarcinoma.,http://www.ncbi.nlm.nih.gov/pubmed/25715771
5927,21325169,"JAK2 rearrangements, including the novel SEC31A-JAK2 fusion, are recurrent in classical Hodgkin lymphoma.",http://www.ncbi.nlm.nih.gov/pubmed/21325169
5928,20813759,The splicing-factor related protein SFPQ/PSF interacts with RAD51D and is necessary for homology-directed repair and sister chromatid cohesion.,http://www.ncbi.nlm.nih.gov/pubmed/20813759
5929,26274027,"PSF/SFPQ is a very common gene fusion partner in TFE3 rearrangement-associated perivascular epithelioid cell tumors (PEComas) and melanotic Xp11 translocation renal cancers: clinicopathologic, immunohistochemical, and molecular characteristics suggesting classification as a distinct entity.",http://www.ncbi.nlm.nih.gov/pubmed/26274027
5930,21733850,K-Cl cotransporter gene expression during human and murine erythroid differentiation.,http://www.ncbi.nlm.nih.gov/pubmed/21733850
5931,26454676,DNA copy amplification and overexpression of SLC12A7 in adrenocortical carcinoma.,http://www.ncbi.nlm.nih.gov/pubmed/26454676
5932,15118077,Regulation of the MiTF/TFE bHLH-LZ transcription factors through restricted spatial expression and alternative splicing of functional domains.,http://www.ncbi.nlm.nih.gov/pubmed/15118077
5933,26975036,TFE3-Fusion Variant Analysis Defines Specific Clinicopathologic Associations Among Xp11 Translocation Cancers.,http://www.ncbi.nlm.nih.gov/pubmed/26975036
5934,24455396,Renal Cell Carcinoma Associated with Xp11.2 Translocation/TFE3 Gene Fusion: A Rare Case Report with Review of the Literature.,http://www.ncbi.nlm.nih.gov/pubmed/24455396
5935,26831715,Phase I Dose-Escalation Study of Linsitinib (OSI-906) and Erlotinib in Patients with Advanced Solid Tumors.,http://www.ncbi.nlm.nih.gov/pubmed/26831715
5936,26801247,Phase I Study of Veliparib (ABT-888) Combined with Cisplatin and Vinorelbine in Advanced Triple-Negative Breast Cancer and/or BRCA Mutation-Associated Breast Cancer.,http://www.ncbi.nlm.nih.gov/pubmed/26801247
5937,10079173,Analysis of the RNA recognition motifs of human neuronal ELAV-like proteins in binding to a cytokine mRNA.,http://www.ncbi.nlm.nih.gov/pubmed/10079173
5938,17534028,Neuron-specific Hu proteins sub-cellular localization in primary sensory neurons.,http://www.ncbi.nlm.nih.gov/pubmed/17534028
5939,25173936,Lyn tyrosine kinase promotes silencing of ATM-dependent checkpoint signaling during recovery from DNA double-strand breaks.,http://www.ncbi.nlm.nih.gov/pubmed/25173936
5940,27154914,UM-164: A Potent c-Src/p38 Kinase Inhibitor with In Vivo Activity against Triple-Negative Breast Cancer.,http://www.ncbi.nlm.nih.gov/pubmed/27154914
5941,19620960,Gain-of-function of mutated C-CBL tumour suppressor in myeloid neoplasms.,http://www.ncbi.nlm.nih.gov/pubmed/19620960
5942,7936666,Constitutively active mutants of MAP kinase kinase (MEK1) induce growth factor-relaxation and oncogenicity when expressed in fibroblasts.,http://www.ncbi.nlm.nih.gov/pubmed/7936666
5943,17173546,"BIRB 796 enhances cytotoxicity triggered by bortezomib, heat shock protein (Hsp) 90 inhibitor, and dexamethasone via inhibition of p38 mitogen-activated protein kinase/Hsp27 pathway in multiple myeloma cell lines and inhibits paracrine tumour growth.",http://www.ncbi.nlm.nih.gov/pubmed/17173546
5944,20501843,Cbl and human myeloid neoplasms: the Cbl oncogene comes of age.,http://www.ncbi.nlm.nih.gov/pubmed/20501843
5945,27126991,TAS-102 for Treatment of Advanced Colorectal Cancers That Are No Longer Responding to Other Therapies.,http://www.ncbi.nlm.nih.gov/pubmed/27126991
5946,27077907,Association of BIM Deletion Polymorphism With Intrinsic Resistance to EGFR Tyrosine Kinase Inhibitors in Patients With Lung Adenocarcinoma.,http://www.ncbi.nlm.nih.gov/pubmed/27077907
5947,27228302,Does Notch play a tumor suppressor role across diverse squamous cell carcinomas?,http://www.ncbi.nlm.nih.gov/pubmed/27228302
5948,,"Crenolanib besylate, a type I pan-FLT3 inhibitor, to demonstrate clinical activity in multiply relapsed FLT3-ITD and D835 AML.",http://meetinglibrary.asco.org/content/170782-176
5949,,"Phase II study of everolimus, letrozole, and metformin in women with advanced/recurrent endometrial cancer.",http://meetinglibrary.asco.org/content/167204-176
5950,19015641,Disruption of the EGFR E884-R958 ion pair conserved in the human kinome differentially alters signaling and inhibitor sensitivity.,http://www.ncbi.nlm.nih.gov/pubmed/19015641
5951,,Effect of bortezomib on complete remission (CR) rate when added to bendamustine-rituximab (BR) in previously untreated high-risk (HR) follicular lymphoma (FL): A randomized phase II trial of the ECOG-ACRIN Cancer Research Group (E2408).,http://abstracts.asco.org/176/AbstView_176_163059.html
5952,21422421,Good response to gefitinib in a lung adenocarcinoma harboring a heterozygous complex mutation of L833V and H835L in epidermal growth factor receptor gene.,http://www.ncbi.nlm.nih.gov/pubmed/21422421
5953,11571647,Differential requirement of the last C-terminal tail of Met receptor for cell transformation and invasiveness.,http://www.ncbi.nlm.nih.gov/pubmed/11571647
5954,21575252,Germ-line mutations in epidermal growth factor receptor (EGFR) are rare but may contribute to oncogenesis: a novel germ-line mutation in EGFR detected in a patient with lung adenocarcinoma.,http://www.ncbi.nlm.nih.gov/pubmed/21575252
5955,27001765,Novel Small-Molecule CX3CR1 Antagonist Impairs Metastatic Seeding and Colonization of Breast Cancer Cells.,http://www.ncbi.nlm.nih.gov/pubmed/27001765
5956,27020862,AZD9496: An Oral Estrogen Receptor Inhibitor That Blocks the Growth of ER-Positive and ESR1-Mutant Breast Tumors in Preclinical Models.,http://www.ncbi.nlm.nih.gov/pubmed/27020862
5957,27196749,"Preclinical Evaluation of AMG 337, a Highly Selective Small Molecule MET Inhibitor, in Hepatocellular Carcinoma.",http://www.ncbi.nlm.nih.gov/pubmed/27196749
5958,26909613,Effective use of PI3K inhibitor BKM120 and PARP inhibitor Olaparib to treat PIK3CA mutant ovarian cancer.,http://www.ncbi.nlm.nih.gov/pubmed/26909613
5959,26861247,"Bortezomib Inhibits Giant Cell Tumor of Bone through Induction of Cell Apoptosis and Inhibition of Osteoclast Recruitment, Giant Cell Formation, and Bone Resorption.",http://www.ncbi.nlm.nih.gov/pubmed/26861247
5960,26846818,"ABT-414, an Antibody-Drug Conjugate Targeting a Tumor-Selective EGFR Epitope.",http://www.ncbi.nlm.nih.gov/pubmed/26846818
5961,,A first-in-human phase 1 study to evaluate the brain-penetrant PI3K/mTOR inhibitor GDC-0084 in patients with progressive or recurrent high-grade glioma.,http://meeting.ascopubs.org/cgi/content/abstract/34/15_suppl/2012
5962,26986192,"ATR-101, a Selective and Potent Inhibitor of Acyl-CoA Acyltransferase 1, Induces Apoptosis in H295R Adrenocortical Cells and in the Adrenal Cortex of Dogs.",http://www.ncbi.nlm.nih.gov/pubmed/26986192
5963,23108626,The androgen receptor: a biologically relevant vaccine target for the treatment of prostate cancer.,http://www.ncbi.nlm.nih.gov/pubmed/23108626
5964,26297272,"Pre-clinical Specificity and Safety of UC-961, a First-In-Class Monoclonal Antibody Targeting ROR1.",http://www.ncbi.nlm.nih.gov/pubmed/26297272
5965,26680512,Cancer associated missense mutations in BAP1 catalytic domain induce amyloidogenic aggregation: A new insight in enzymatic inactivation.,http://www.ncbi.nlm.nih.gov/pubmed/26680512
5966,25830670,BAP1 missense mutation c.2054 A>T (p.E685V) completely disrupts normal splicing through creation of a novel 5' splice site in a human mesothelioma cell line.,http://www.ncbi.nlm.nih.gov/pubmed/25830670
5967,26015513,Anti-EFNA4 Calicheamicin Conjugates Effectively Target Triple-Negative Breast and Ovarian Tumor-Initiating Cells to Result in Sustained Tumor Regressions.,http://www.ncbi.nlm.nih.gov/pubmed/26015513
5968,,TAS3681: New class of androgen receptor antagonist with androgen receptor downregulating activity.,http://meetinglibrary.asco.org/content/140838-159
5969,26701849,Recurrent AKT mutations in human cancers: functional consequences and effects on drug sensitivity.,http://www.ncbi.nlm.nih.gov/pubmed/26701849
5970,25395580,"INPP5E interacts with AURKA, linking phosphoinositide signaling to primary cilium stability.",http://www.ncbi.nlm.nih.gov/pubmed/25395580
5971,20815813,Regulation of the tumour suppressor Fbw7α by PKC-dependent phosphorylation and cancer-associated mutations.,http://www.ncbi.nlm.nih.gov/pubmed/20815813
5972,20516115,Comprehensive analysis of missense variations in the BRCT domain of BRCA1 by structural and functional assays.,http://www.ncbi.nlm.nih.gov/pubmed/20516115
5973,26537258,Plasma AR and abiraterone-resistant prostate cancer.,http://www.ncbi.nlm.nih.gov/pubmed/26537258
5974,26545934,"Antitumor effect of afatinib, as a human epidermal growth factor receptor 2-targeted therapy, in lung cancers harboring HER2 oncogene alterations.",http://www.ncbi.nlm.nih.gov/pubmed/26545934
5975,10725406,BRCA1 interaction with RNA polymerase II reveals a role for hRPB2 and hRPB10alpha in activated transcription.,http://www.ncbi.nlm.nih.gov/pubmed/10725406
5976,18223690,Isolation of a distinct class of gain-of-function SHP-2 mutants with oncogenic RAS-like transforming activity from solid tumors.,http://www.ncbi.nlm.nih.gov/pubmed/18223690
5977,16166557,Noonan syndrome mutation Q79R in Shp2 increases proliferation of valve primordia mesenchymal cells via extracellular signal-regulated kinase 1/2 signaling.,http://www.ncbi.nlm.nih.gov/pubmed/16166557
5978,24452393,"First-in-human, phase I dose-escalation study of single and multiple doses of a first-in-class enhancer of fluoropyrimidines, a dUTPase inhibitor (TAS-114) in healthy male volunteers.",http://www.ncbi.nlm.nih.gov/pubmed/24452393
5979,27115568,"Mipsagargin, a novel thapsigargin-based PSMA-activated prodrug: results of a first-in-man phase I clinical trial in patients with refractory, advanced or metastatic solid tumours.",http://www.ncbi.nlm.nih.gov/pubmed/27115568
5980,27055731,"Targeting tumour-associated macrophages with CCR2 inhibition in combination with FOLFIRINOX in patients with borderline resectable and locally advanced pancreatic cancer: a single-centre, open-label, dose-finding, non-randomised, phase 1b trial.",http://www.ncbi.nlm.nih.gov/pubmed/27055731
5981,25223583,"Phase II, multicenter, randomized trial of CPX-351 (cytarabine:daunorubicin) liposome injection versus intensive salvage therapy in adults with first relapse AML.",http://www.ncbi.nlm.nih.gov/pubmed/25223583
5982,26000489,Integrative clinical genomics of advanced prostate cancer.,http://www.ncbi.nlm.nih.gov/pubmed/26000489
5983,18413839,EXEL-7647 inhibits mutant forms of ErbB2 associated with lapatinib resistance and neoplastic transformation.,http://www.ncbi.nlm.nih.gov/pubmed/18413839
5984,,"Phase 1 Study of Tazemetostat (EPZ-6438), an Inhibitor of Enhancer of Zeste-Homolog 2 (EZH2): Preliminary Safety and Activity in Relapsed or Refractory Non-Hodgkin Lymphoma (NHL) Patients",https://ash.confex.com/ash/2015/webprogram/Paper78128.html
5985,,Predictive value of KRAS mutation status in metastatic colorectal cancer (mCRC) patients treated with capecitabine and bevacizumab (CAP-B) maintenance treatment vs observation in the phase III CAIRO3 study.,http://meetinglibrary.asco.org/content/162510-176
5986,,Efficacy of panitumumab vs cetuximab in patients with wild-type KRAS exon 2 metastatic colorectal cancer treated with prior bevacizumab: Results from ASPECCT.,http://meetinglibrary.asco.org/content/165575-176
5987,,Phase 2 results: Encorafenib (ENCO) and cetuximab (CETUX) with or without alpelisib (ALP) in patients with advanced BRAF-mutant colorectal cancer (BRAFm CRC).,http://meetinglibrary.asco.org/content/166237-176
5988,,Phase Ib study of cabozantinib plus panitumumab in KRAS wild-type (WT) metastatic colorectal cancer (mCRC).,http://meetinglibrary.asco.org/content/166423-176
5989,25435280,HER family kinase domain mutations promote tumor progression and can predict response to treatment in human breast cancer.,http://www.ncbi.nlm.nih.gov/pubmed/25435280
5990,,Onset of neutropenia as an indicator of treatment response in the randomized phase II of TAS-102 vs placebo in Japanese patients with metastatic colorectal cancer (Study J003-10040030).,http://meetinglibrary.asco.org/content/168687-176
5991,,"Phase 2 trial results of DN24-02, a HER2-targeted autologous cellular immunotherapy in HER2+ urothelial cancer patients (pts).",http://meetinglibrary.asco.org/content/162594-176
5993,,A phase II study of cabozantinib in patients (pts) with relapsed or refractory metastatic urothelial carcinoma (mUC).,http://meetinglibrary.asco.org/content/169119-176
5994,,"Efficacy of BGJ398, a fibroblast growth factor receptor (FGFR) 1-3 inhibitor, in patients (pts) with previously treated advanced/metastatic urothelial carcinoma (mUC) with FGFR3 alterations.",http://meetinglibrary.asco.org/content/164341-176
5995,22393464,ErbB2 Is Necessary for ErbB4 Ligands to Stimulate Oncogenic Activities in Models of Human Breast Cancer.,http://www.ncbi.nlm.nih.gov/pubmed/22393464
5996,,FIESTA: a Phase Ib and pharmacokinetic trial of AZD4547 in combination with gemcitabine and cisplatin.,http://meetinglibrary.asco.org/content/164872-176
5997,,Phase 2 trial of dovitinib in Bacillus Calmette-Guerin (BCG) refractory urothelial carcinoma (UC) with tumor FGFR3 mutations or over-expression: Hoosier Cancer Research Network GU12-157.,http://meetinglibrary.asco.org/content/167294-176
5998,,"Phase II study of everolimus (EV) and bevacizumab (BEV) in recurrent ovarian, peritoneal, and fallopian tube cancer.",http://meetinglibrary.asco.org/content/167086-176
5999,,A phase Ib study of AZD1775 and olaparib combination in patients with refractory solid tumors.,http://meetinglibrary.asco.org/content/168788-176
6000,,A phase II open-label single-arm study of vandetanib in patients with advanced RET-rearranged non-small cell lung cancer (NSCLC): Luret study.,http://meetinglibrary.asco.org/content/163941-176
6001,23843458,Carboxyl group footprinting mass spectrometry and molecular dynamics identify key interactions in the HER2-HER3 receptor tyrosine kinase interface.,http://www.ncbi.nlm.nih.gov/pubmed/23843458
6002,,A phase II study of vandetanib in patients with non-small cell lung cancer harboring RET rearrangement.,http://meetinglibrary.asco.org/content/166941-176
6003,,Phase II study of crizotinib in east Asian patients (pts) with ROS1-positive advanced non-small cell lung cancer (NSCLC).,http://meetinglibrary.asco.org/content/168126-176
6004,,"Updated results of a phase 1 study of EGF816, a third-generation, mutant-selective EGFR tyrosine kinase inhibitor (TKI), in advanced non-small cell lung cancer (NSCLC) harboring T790M.",http://meetinglibrary.asco.org/content/162578-176
6005,,Antitumor activity of ASP8273 300 mg in subjects with EGFR mutation-positive non-small cell lung cancer: Interim results from an ongoing phase 1 study.,http://meetinglibrary.asco.org/content/162561-176
6006,,Role of TP53 mutations in predicting response to TKI treatment in EGFR-mutated NSCLC patients.,http://meetinglibrary.asco.org/content/165599-176
6007,27196756,The Effect of F877L and T878A Mutations on Androgen Receptor Response to Enzalutamide.,http://www.ncbi.nlm.nih.gov/pubmed/27196756
6008,9092797,Dehydroepiandrosterone activates mutant androgen receptors expressed in the androgen-dependent human prostate cancer xenograft CWR22 and LNCaP cells.,http://www.ncbi.nlm.nih.gov/pubmed/9092797
6009,16116421,The BRIP1 helicase functions independently of BRCA1 in the Fanconi anemia pathway for DNA crosslink repair.,http://www.ncbi.nlm.nih.gov/pubmed/16116421
6010,18345034,Expression of the BRCA1-interacting protein Brip1/BACH1/FANCJ is driven by E2F and correlates with human breast cancer malignancy.,http://www.ncbi.nlm.nih.gov/pubmed/18345034
6011,12569564,BACH1 517C-->T transition impairs protein translocation to nucleus: a role in breast cancer susceptibility?,http://www.ncbi.nlm.nih.gov/pubmed/12569564
6012,17033622,Truncating mutations in the Fanconi anemia J gene BRIP1 are low-penetrance breast cancer susceptibility alleles.,http://www.ncbi.nlm.nih.gov/pubmed/17033622
6013,20623551,Constitutive activation of Bruton's tyrosine kinase induces the formation of autoreactive IgM plasma cells.,http://www.ncbi.nlm.nih.gov/pubmed/20623551
6014,23918663,CDK6 associates with the centrosome during mitosis and is mutated in a large Pakistani family with primary microcephaly.,http://www.ncbi.nlm.nih.gov/pubmed/23918663
6015,18397877,Bladder tumour-derived somatic TSC1 missense mutations cause loss of function via distinct mechanisms.,http://www.ncbi.nlm.nih.gov/pubmed/18397877
6016,22711529,Counteracting effects operating on Src homology 2 domain-containing protein-tyrosine phosphatase 2 (SHP2) function drive selection of the recurrent Y62D and Y63C substitutions in Noonan syndrome.,http://www.ncbi.nlm.nih.gov/pubmed/22711529
6017,15987685,Diverse biochemical properties of Shp2 mutants. Implications for disease phenotypes.,http://www.ncbi.nlm.nih.gov/pubmed/15987685
6018,14504054,Microsatellite instability and mutation analysis among southern Italian patients with colorectal carcinoma: detection of different alterations accounting for MLH1 and MSH2 inactivation in familial cases.,http://www.ncbi.nlm.nih.gov/pubmed/14504054
6019,20533529,Identification of Lynch syndrome mutations in the MLH1-PMS2 interface that disturb dimerization and mismatch repair.,http://www.ncbi.nlm.nih.gov/pubmed/20533529
6020,23842040,Functional analysis of BRCA1 missense variants of uncertain significance in Japanese breast cancer families.,http://www.ncbi.nlm.nih.gov/pubmed/23842040
6021,22646717,Effects on human transcriptome of mutated BRCA1 BRCT domain: a microarray study.,http://www.ncbi.nlm.nih.gov/pubmed/22646717
6022,23867111,A high-throughput functional complementation assay for classification of BRCA1 missense variants.,http://www.ncbi.nlm.nih.gov/pubmed/23867111
6023,12496477,Mutations in the BRCT domain confer temperature sensitivity to BRCA1 in transcription activation.,http://www.ncbi.nlm.nih.gov/pubmed/12496477
6024,21165163,EGFR-mutated lung cancer: a paradigm of molecular oncology.,http://www.ncbi.nlm.nih.gov/pubmed/21165163
6025,21725363,Functional differences among BRCA1 missense mutations in the control of centrosome duplication.,http://www.ncbi.nlm.nih.gov/pubmed/21725363
6026,25057940,"V843I, a lung cancer predisposing EGFR mutation, is responsible for resistance to EGFR tyrosine kinase inhibitors.",http://www.ncbi.nlm.nih.gov/pubmed/25057940
6027,16152581,Epidermal growth factor receptor mutations in needle biopsy/aspiration samples predict response to gefitinib therapy and survival of patients with advanced nonsmall cell lung cancer.,http://www.ncbi.nlm.nih.gov/pubmed/16152581
6028,16403807,Genetic analysis of BRCA1 ubiquitin ligase activity and its relationship to breast cancer susceptibility.,http://www.ncbi.nlm.nih.gov/pubmed/16403807
6029,16720839,Evidence for subcomplexes in the Fanconi anemia pathway.,http://www.ncbi.nlm.nih.gov/pubmed/16720839
6030,19543972,Characterization of BRCA1 ring finger variants of uncertain significance.,http://www.ncbi.nlm.nih.gov/pubmed/19543972
6031,10635334,Genetic analysis of BRCA1 function in a defined tumor cell line.,http://www.ncbi.nlm.nih.gov/pubmed/10635334
6032,12955722,Spectrum of FANCA mutations in Italian Fanconi anemia patients: identification of six novel alleles and phenotypic characterization of the S858R variant.,http://www.ncbi.nlm.nih.gov/pubmed/12955722
6033,11161829,"Functional analysis of the putative peroxidase domain of FANCA, the Fanconi anemia complementation group A protein.",http://www.ncbi.nlm.nih.gov/pubmed/11161829
6034,25452114,Increased MAPK reactivation in early resistance to dabrafenib/trametinib combination therapy of BRAF-mutant metastatic melanoma.,http://www.ncbi.nlm.nih.gov/pubmed/25452114
6035,21922593,Assessment of human Nter and Cter BRCA1 mutations using growth and localization assays in yeast.,http://www.ncbi.nlm.nih.gov/pubmed/21922593
6036,24265154,MAP kinase pathway alterations in BRAF-mutant melanoma patients with acquired resistance to combined RAF/MEK inhibition.,http://www.ncbi.nlm.nih.gov/pubmed/24265154
6037,15004537,Functional characterization of BRCA1 sequence variants using a yeast small colony phenotype assay.,http://www.ncbi.nlm.nih.gov/pubmed/15004537
6038,11016938,A functional comparison of BRCA1 C-terminal domains in transcription activation and chromatin remodeling.,http://www.ncbi.nlm.nih.gov/pubmed/11016938
6039,10811118,Functional assay for BRCA1: mutagenesis of the COOH-terminal region reveals critical residues for transcription activation.,http://www.ncbi.nlm.nih.gov/pubmed/10811118
6040,26381082,MSH2 role in BRCA1-driven tumorigenesis: A preliminary study in yeast and in human tumors from BRCA1-VUS carriers.,http://www.ncbi.nlm.nih.gov/pubmed/26381082
6041,17981815,Germline mutations of MEK in cardio-facio-cutaneous syndrome are sensitive to MEK and RAF inhibition: implications for therapeutic options.,http://www.ncbi.nlm.nih.gov/pubmed/17981815
6042,24055054,Concurrent MEK2 mutation and BRAF amplification confer resistance to BRAF and MEK inhibitors in melanoma.,http://www.ncbi.nlm.nih.gov/pubmed/24055054
6043,27197169,The Small Molecule IMR-1 Inhibits the Notch Transcriptional Activation Complex to Suppress Tumorigenesis.,http://www.ncbi.nlm.nih.gov/pubmed/27197169
6044,25409143,An ERK/Cdk5 axis controls the diabetogenic actions of PPARγ.,http://www.ncbi.nlm.nih.gov/pubmed/25409143
6045,20358587,Molecular and functional analysis of a novel MEK2 mutation in cardio-facio-cutaneous syndrome: transmission through four generations.,http://www.ncbi.nlm.nih.gov/pubmed/20358587
6046,26781311,Targeting hedgehog signaling pathway in pediatric tumors: in vitro evaluation of SMO and GLI inhibitors.,http://www.ncbi.nlm.nih.gov/pubmed/26781311
6047,27292104,Inotuzumab Ozogamicin versus Standard Therapy for Acute Lymphoblastic Leukemia.,http://www.ncbi.nlm.nih.gov/pubmed/27292104
6048,26965451,Novel MET/TIE2/VEGFR2 inhibitor altiratinib inhibits tumor growth and invasiveness in bevacizumab-resistant glioblastoma mouse models.,http://www.ncbi.nlm.nih.gov/pubmed/26965451
6049,27312177,Oncogenic Deregulation of EZH2 as an Opportunity for Targeted Therapy in Lung Cancer.,http://www.ncbi.nlm.nih.gov/pubmed/27312177
6050,27196784,Quantitative Phosphoproteomics Reveals Wee1 Kinase as a Therapeutic Target in a Model of Proneural Glioblastoma.,http://www.ncbi.nlm.nih.gov/pubmed/27196784
6051,,"Efficacy results of a phase 1b study of ont-380, a CNS-penetrant TKI, in combination with T-DM1 in HER2+ metastatic breast cancer (MBC), including patients (pts) with brain metastases.",http://meetinglibrary.asco.org/content/170543-176
6052,,"Phase II trial of neratinib for HER2 mutated, non-amplified metastatic breast cancer (HER2mut MBC).",http://meetinglibrary.asco.org/content/164601-176
6053,,A phase I study of MEK162 and FOLFOX in chemotherapy-resistant metastatic colorectal cancer.,http://meetinglibrary.asco.org/content/162654-176
6054,,"Phase 1 trial of MM-151, a novel oligoclonal anti-EGFR antibody combination in patients with refractory solid tumors.",http://meetinglibrary.asco.org/content/132144-144
6055,9660926,Tumor suppressor p16INK4A: determination of solution structure and analyses of its interaction with cyclin-dependent kinase 4.,http://www.ncbi.nlm.nih.gov/pubmed/9660926
6057,,"BI 1482694 (HM61713), an EGFR mutant-specific inhibitor, in T790M+ NSCLC: Efficacy and safety at the RP2D.",http://meetinglibrary.asco.org/content/164852-176
6058,,Plasma genotyping of patients enrolled on the expansion phase I/II trial of X-396 in patients (pts) with ALK+ non-small cell lung cancer (NSCLC).,http://meetinglibrary.asco.org/content/169016-176
6059,,Activity and safety of brigatinib (BRG) in patients (pts) with ALK+ non–small cell lung cancer (NSCLC): Phase (ph) 1/2 trial results.,http://meetinglibrary.asco.org/content/164989-176
6060,,Phase 3 study of first-line crizotinib vs pemetrexed?cisplatin/carboplatin (PCC) in East Asian patients (pts) with ALK+ advanced non-squamous non-small cell lung cancer (NSCLC).,http://meetinglibrary.asco.org/content/165546-176
6061,8264648,Functional significance of lysine 1423 of neurofibromin and characterization of a second site suppressor which rescues mutations at this residue and suppresses RAS2Val-19-activated phenotypes.,http://www.ncbi.nlm.nih.gov/pubmed/8264648
6062,9219873,Mutations in the GAP-related domain impair the ability of neurofibromin to associate with microtubules.,http://www.ncbi.nlm.nih.gov/pubmed/9219873
6063,,Addition of HSP90 inhibitor onalespib to crizotinib prior to progression in patients with ALK-pos NSCLC: Results of a randomized phase 2 study.,http://meetinglibrary.asco.org/content/171030-176
6064,,Phase (Ph) I study of the safety and efficacy of the cMET inhibitor capmatinib (INC280) in patients (pts) with advanced cMET+ non-small cell lung cancer (NSCLC).,http://meetinglibrary.asco.org/content/165406-176
6065,,Significant systemic and CNS activity of RET inhibitor vandetanib combined with mTOR inhibitor everolimus in patients with advanced NSCLC with RET fusion.,http://meetinglibrary.asco.org/content/170878-176
6066,24248379,"RVX-208, an inhibitor of BET transcriptional regulators with selectivity for the second bromodomain.",http://www.ncbi.nlm.nih.gov/pubmed/24248379
6067,11080503,Neurofibromin GTPase-activating protein-related domains restore normal growth in Nf1-/- cells.,http://www.ncbi.nlm.nih.gov/pubmed/11080503
6068,9668168,Selective disactivation of neurofibromin GAP activity in neurofibromatosis type 1.,http://www.ncbi.nlm.nih.gov/pubmed/9668168
6069,26243863,HER2 activating mutations are targets for colorectal cancer treatment.,http://www.ncbi.nlm.nih.gov/pubmed/26243863
6070,11258625,Exon 10b of the NF1 gene represents a mutational hotspot and harbors a recurrent missense mutation Y489C associated with aberrant splicing.,http://www.ncbi.nlm.nih.gov/pubmed/11258625
6071,10607834,Mutations affecting mRNA splicing are the most common molecular defects in patients with neurofibromatosis type 1.,http://www.ncbi.nlm.nih.gov/pubmed/10607834
6072,17624602,"BRCA1, BRCA2, TP53, and CDKN2A germline mutations in patients with breast cancer and cutaneous melanoma.",http://www.ncbi.nlm.nih.gov/pubmed/17624602
6073,14508519,Germline splicing mutations of CDKN2A predispose to melanoma.,http://www.ncbi.nlm.nih.gov/pubmed/14508519
6074,10887137,ZNF198-FGFR1 transforming activity depends on a novel proline-rich ZNF198 oligomerization domain.,http://www.ncbi.nlm.nih.gov/pubmed/10887137
6075,9484786,"t(6;8), t(8;9) and t(8;13) translocations associated with stem cell myeloproliferative disorders have close or identical breakpoints in chromosome region 8p11-12.",http://www.ncbi.nlm.nih.gov/pubmed/9484786
6076,11689702,8p12 stem cell myeloproliferative disorder: the FOP-fibroblast growth factor receptor 1 fusion protein of the t(6;8) translocation induces cell survival mediated by mitogen-activated protein kinase and phosphatidylinositol 3-kinase/Akt/mTOR pathways.,http://www.ncbi.nlm.nih.gov/pubmed/11689702
6077,16314388,"A complex of two centrosomal proteins, CAP350 and FOP, cooperates with EB1 in microtubule anchoring.",http://www.ncbi.nlm.nih.gov/pubmed/16314388
6078,26905588,"Polymorphisms of the centrosomal gene (FGFR1OP) and lung cancer risk: a meta-analysis of 14,463 cases and 44,188 controls.",http://www.ncbi.nlm.nih.gov/pubmed/26905588
6080,10688839,FGFR1 is fused to the centrosome-associated protein CEP110 in the 8p12 stem cell myeloproliferative disorder with t(8;9)(p12;q33).,http://www.ncbi.nlm.nih.gov/pubmed/10688839
6081,11956314,CEP110 and ninein are located in a specific domain of the centrosome associated with centrosome maturation.,http://www.ncbi.nlm.nih.gov/pubmed/11956314
6082,21330321,The kinase inhibitor TKI258 is active against the novel CUX1-FGFR1 fusion detected in a patient with T-lymphoblastic leukemia/lymphoma and t(7;8)(q22;p11).,http://www.ncbi.nlm.nih.gov/pubmed/21330321
6083,22681620,ERLIN2 promotes breast cancer cell survival by modulating endoplasmic reticulum stress pathways.,http://www.ncbi.nlm.nih.gov/pubmed/22681620
6084,22690709,Endoplasmic reticulum factor ERLIN2 regulates cytosolic lipid content in cancer cells.,http://www.ncbi.nlm.nih.gov/pubmed/22690709
6085,16982735,Rare germ line CHEK2 variants identified in breast cancer families encode proteins that show impaired activation.,http://www.ncbi.nlm.nih.gov/pubmed/16982735
6086,16835864,Characterization of CHEK2 mutations in prostate cancer.,http://www.ncbi.nlm.nih.gov/pubmed/16835864
6087,26871722,"Intact Cohesion, Anaphase, and Chromosome Segregation in Human Cells Harboring Tumor-Derived Mutations in STAG2.",http://www.ncbi.nlm.nih.gov/pubmed/26871722
6088,25428262,Disruption of SF3B1 results in deregulated expression and splicing of key genes and pathways in myelodysplastic syndrome hematopoietic stem and progenitor cells.,http://www.ncbi.nlm.nih.gov/pubmed/25428262
6089,15689452,Classification of BRCA1 missense variants of unknown clinical significance.,http://www.ncbi.nlm.nih.gov/pubmed/15689452
6090,17114005,Stattic: a small-molecule inhibitor of STAT3 activation and dimerization.,http://www.ncbi.nlm.nih.gov/pubmed/17114005
6091,23382914,Stat3 inhibitor Stattic exhibits potent antitumor activity and induces chemo- and radio-sensitivity in nasopharyngeal carcinoma.,http://www.ncbi.nlm.nih.gov/pubmed/23382914
6092,26675719,Germline variant FGFR4  p.G388R exposes a membrane-proximal STAT3 binding site.,http://www.ncbi.nlm.nih.gov/pubmed/26675719
6093,24625004,FGFR4 polymorphic variants modulate phenotypic features of Cushing disease.,http://www.ncbi.nlm.nih.gov/pubmed/24625004
6094,24590057,"HO-3867, a safe STAT3 inhibitor, is selectively cytotoxic to ovarian cancer.",http://www.ncbi.nlm.nih.gov/pubmed/24590057
6095,16808060,Cetuximab approved by FDA for treatment of head and neck squamous cell cancer.,http://www.ncbi.nlm.nih.gov/pubmed/16808060
6096,17020472,The P1812A and P25T BRCA1 and the 5164del4 BRCA2 mutations: occurrence in high-risk non-Ashkenazi Jews.,http://www.ncbi.nlm.nih.gov/pubmed/17020472
6097,15133503,Structural basis of phosphopeptide recognition by the BRCT domain of BRCA1.,http://www.ncbi.nlm.nih.gov/pubmed/15133503
6098,21901007,BRCA1 tumour suppression occurs via heterochromatin-mediated silencing.,http://www.ncbi.nlm.nih.gov/pubmed/21901007
6099,23576486,Approval summary: Cetuximab in combination with cisplatin or carboplatin and 5-fluorouracil for the first-line treatment of patients with recurrent locoregional or metastatic squamous cell head and neck cancer.,http://www.ncbi.nlm.nih.gov/pubmed/23576486
6100,20737206,A recombination-based method to characterize human BRCA1 missense variants.,http://www.ncbi.nlm.nih.gov/pubmed/20737206
6101,19493677,Characterisation of gene expression profiles of yeast cells expressing BRCA1 missense variants.,http://www.ncbi.nlm.nih.gov/pubmed/19493677
6102,18992264,"Analysis of a set of missense, frameshift, and in-frame deletion variants of BRCA1.",http://www.ncbi.nlm.nih.gov/pubmed/18992264
6103,25617146,Giant cell tumour of bone: new treatments in development.,http://www.ncbi.nlm.nih.gov/pubmed/25617146
6105,,A phase Ib/II study of cancer stemness inhibitor napabucasin (BB608) combined with weekly paclitaxel in platinum-resistant ovarian cancer.,http://meeting.ascopubs.org/cgi/content/abstract/34/15_suppl/5578
6106,27103434,The inhibition of Akt-Pdpk1 interaction efficiently suppresses the growth of murine primary liver tumor cells.,http://www.ncbi.nlm.nih.gov/pubmed/27103434
6107,,A phase 1b study of the anticancer stem cell agent demcizumab (DEM) and gemcitabine (GEM) with or without paclitaxel protein bound particles (nab-paclitaxel) in patients with pancreatic cancer.,http://hwmaint.meeting.ascopubs.org/cgi/content/abstract/32/3_suppl/279
6108,,"Abstract 22: Cyclin E amplification, a novel mechanism of resistance to trastuzumab in HER2 amplified breast cancer",http://cancerres.aacrjournals.org/content/70/8_Supplement/22
6109,,Anti-DLL4 (demcizumab) inhibits tumor growth and reduces cancer stem cell frequency in patient-derived ovarian cancer xenografts.,http://cancerres.aacrjournals.org/content/73/8_Supplement/3725.short
6110,,"A phase 1b study of the anticancer stem cell agent demcizumab (DEM), pemetrexed (PEM), and carboplatin (CARBO) in pts with first-line nonsquamous NSCLC.",http://meeting.ascopubs.org/cgi/content/abstract/32/15_suppl/2544
6111,,Anti-Notch1 antibody (OMP-52M51) impedes tumor growth and cancer stem cell frequency (CSC) in a chemo-refractory breast cancer xenograft model with an activating Notch1 mutation and screening for activated Notch1 across multiple solid tumor types.,http://cancerres.aacrjournals.org/content/73/8_Supplement/3728.short
6112,,"Safety and preliminary efficacy results of a first-in-human phase I study of the novel cancer stem cell (CSC) targeting antibody brontictuzumab (OMP-52M51, anti-Notch1) administered intravenously to patients with certain advanced solid tumors",http://mct.aacrjournals.org/content/14/12_Supplement_2/C42.short
6113,22772063,"Phase II study of MLN8237 (alisertib), an investigational Aurora A kinase inhibitor, in patients with platinum-resistant or -refractory epithelial ovarian, fallopian tube, or primary peritoneal carcinoma.",http://www.ncbi.nlm.nih.gov/pubmed/22772063
6114,,The BET inhibitor INCB054329 is synergistic with JAK1 inhibition in models of multiple myeloma,http://cancerres.aacrjournals.org/content/75/15_Supplement/692.short
6115,,The BET inhibitor INCB054329 is efficacious as a single agent or in combination with targeted agents in colorectal cancer models,http://cancerres.aacrjournals.org/content/75/15_Supplement/3525.short
6117,,,http://www.ncbi.nlm.nih.gov/clinvar
6118,21618645,A recurrent CHEK2 p.H371Y mutation is associated with breast cancer risk in Chinese women.,http://www.ncbi.nlm.nih.gov/pubmed/21618645
6119,26231785,AFM13: a first-in-class tetravalent bispecific anti-CD30/CD16A antibody for NK cell-mediated immunotherapy.,http://www.ncbi.nlm.nih.gov/pubmed/26231785
6120,21730163,The p53 inhibitors MDM2/MDMX complex is required for control of p53 activity in vivo.,http://www.ncbi.nlm.nih.gov/pubmed/21730163
6121,10608892,Stabilization of the MDM2 oncoprotein by interaction with the structurally related MDMX protein.,http://www.ncbi.nlm.nih.gov/pubmed/10608892
6122,15199139,Amplification of Mdmx (or Mdm4) directly contributes to tumor formation by inhibiting p53 tumor suppressor activity.,http://www.ncbi.nlm.nih.gov/pubmed/15199139
6123,15788536,Phosphorylation of Hdmx mediates its Hdm2- and ATM-dependent degradation in response to DNA damage.,http://www.ncbi.nlm.nih.gov/pubmed/15788536
6124,23161852,Analysis of BRCA1 variants in double-strand break repair by homologous recombination and single-strand annealing.,http://www.ncbi.nlm.nih.gov/pubmed/23161852
6125,23613828,Functional and structural analysis of C-terminal BRCA1 missense variants.,http://www.ncbi.nlm.nih.gov/pubmed/23613828
6126,19664991,DLL4 blockade inhibits tumor growth and reduces tumor-initiating cell frequency.,http://www.ncbi.nlm.nih.gov/pubmed/19664991
6127,22753465,Wnt pathway inhibition via the targeting of Frizzled receptors results in decreased growth and tumorigenicity of human tumors.,http://www.ncbi.nlm.nih.gov/pubmed/22753465
6128,,"Phase 1b study of WNT inhibitor vantictumab (VAN, human monoclonal antibody) with Paclitaxel (P) in patients (pts) with 1st- to 3rd-line metastatic HER2-negative breast cancer (BC).",http://meetinglibrary.asco.org/content/166396-176
6129,25172549,Targeting the Wnt pathway in human cancers: therapeutic targeting with a focus on OMP-54F28.,http://www.ncbi.nlm.nih.gov/pubmed/25172549
6130,,"Abstract A165: Result of a phase 1 (dose-escalation stage), first-in-human study of ASP5878, an oral FGFR inhibitor, in patients with advanced solid tumors",http://mct.aacrjournals.org/content/14/12_Supplement_2/A165.short
6131,,"Phase 1b of WNT inhibitor ipafricept (IPA, decoy receptor for WNT ligands) with carboplatin (C) and paclitaxel (P) in recurrent platinum-sensitive ovarian cancer (OC).",http://meetinglibrary.asco.org/content/165914-176
6132,22807134,Assessment of the potential pathogenicity of missense mutations identified in the GTPase-activating protein (GAP)-related domain of the neurofibromatosis type-1 (NF1) gene.,http://www.ncbi.nlm.nih.gov/pubmed/22807134
6133,22108604,Exploring the somatic NF1 mutational spectrum associated with NF1 cutaneous neurofibromas.,http://www.ncbi.nlm.nih.gov/pubmed/22108604
6134,24971884,Impact of ERBB2 mutations on in vitro sensitivity of bladder cancer to lapatinib.,http://www.ncbi.nlm.nih.gov/pubmed/24971884
6135,9003501,Mutational and functional analysis of the neurofibromatosis type 1 (NF1) gene.,http://www.ncbi.nlm.nih.gov/pubmed/9003501
6136,,Abstract 771: Preclinical characterization of the selective FGFR inhibitor INCB054828,http://cancerres.aacrjournals.org/content/75/15_Supplement/771.short
6137,10712197,Minor lesion mutational spectrum of the entire NF1 gene does not explain its high mutability but points to a functional domain upstream of the GAP-related domain.,http://www.ncbi.nlm.nih.gov/pubmed/10712197
6138,17638894,Breast cancer expressing the activated HER2/neu is sensitive to gefitinib in vitro and in vivo and acquires resistance through a novel point mutation in the HER2/neu.,http://www.ncbi.nlm.nih.gov/pubmed/17638894
6139,21123452,Small molecule inhibition of GDC-0449 refractory smoothened mutants and downstream mechanisms of drug resistance.,http://www.ncbi.nlm.nih.gov/pubmed/21123452
6140,25699170,Primary Synovial Sarcoma (SS) of the digestive system: a molecular and clinicopathological study of fifteen cases.,http://www.ncbi.nlm.nih.gov/pubmed/25699170
6141,12552571,Functional analysis of LKB1/STK11 mutants and two aberrant isoforms found in Peutz-Jeghers Syndrome patients.,http://www.ncbi.nlm.nih.gov/pubmed/12552571
6142,14668798,Stability of the Peutz-Jeghers syndrome kinase LKB1 requires its binding to the molecular chaperones Hsp90/Cdc37.,http://www.ncbi.nlm.nih.gov/pubmed/14668798
6143,25733895,Recurrent BCAM-AKT2 fusion gene leads to a constitutively activated AKT2 fusion kinase in high-grade serous ovarian carcinoma.,http://www.ncbi.nlm.nih.gov/pubmed/25733895
6144,,Clinically efficacy of the BET bromodomain inhibitor TEN-010 in an open-label substudy with patients with documented NUT-midline carcinoma (NMC),http://mct.aacrjournals.org/content/14/12_Supplement_2/A49
6145,23935373,Critical analysis of the potential for targeting STAT3 in human malignancy.,http://www.ncbi.nlm.nih.gov/pubmed/23935373
6146,25238247,Modulation of ErbB2 blockade in ErbB2-positive cancers: the role of ErbB2 Mutations and PHLDA1.,http://www.ncbi.nlm.nih.gov/pubmed/25238247
6147,23970477,Novel oncogenic PDGFRA mutations in pediatric high-grade gliomas.,http://www.ncbi.nlm.nih.gov/pubmed/23970477
6148,24036115,The lutheran/basal cell adhesion molecule promotes tumor cell migration by modulating integrin-mediated cell attachment to laminin-511 protein.,http://www.ncbi.nlm.nih.gov/pubmed/24036115
6149,24223164,"The FBI1/Akirin2 target gene, BCAM, acts as a suppressive oncogene.",http://www.ncbi.nlm.nih.gov/pubmed/24223164
6150,12569364,A human brain tumor-derived PDGFR-alpha deletion mutant is transforming.,http://www.ncbi.nlm.nih.gov/pubmed/12569364
6151,17087943,Intestinal neurofibromatosis is a subtype of familial GIST and results from a dominant activating mutation in PDGFRA.,http://www.ncbi.nlm.nih.gov/pubmed/17087943
6152,19818716,KEAP1 E3 ligase-mediated downregulation of NF-kappaB signaling by targeting IKKbeta.,http://www.ncbi.nlm.nih.gov/pubmed/19818716
6153,17822677,A mutation of Keap1 found in breast cancer impairs its ability to repress Nrf2 activity.,http://www.ncbi.nlm.nih.gov/pubmed/17822677
6154,21177379,Select heterozygous Keap1 mutations have a dominant-negative effect on wild-type Keap1 in vivo.,http://www.ncbi.nlm.nih.gov/pubmed/21177379
6155,18316592,Loss of Keap1 function activates Nrf2 and provides advantages for lung cancer cell growth.,http://www.ncbi.nlm.nih.gov/pubmed/18316592
6156,25582950,Molecular effects of cancer-associated somatic mutations on the structural and target recognition properties of Keap1.,http://www.ncbi.nlm.nih.gov/pubmed/25582950
6157,20807888,BCOR as a novel fusion partner of retinoic acid receptor alpha in a t(X;17)(p11;q12) variant of acute promyelocytic leukemia.,http://www.ncbi.nlm.nih.gov/pubmed/20807888
6158,15159406,Directed evolution of human estrogen receptor variants with significantly enhanced androgen specificity and affinity.,http://www.ncbi.nlm.nih.gov/pubmed/15159406
6159,9234721,Probing the structure and function of the estrogen receptor ligand binding domain by analysis of mutants with altered transactivation characteristics.,http://www.ncbi.nlm.nih.gov/pubmed/9234721
6160,25873174,Convergent mutations and kinase fusions lead to oncogenic STAT3 activation in anaplastic large cell lymphoma.,http://www.ncbi.nlm.nih.gov/pubmed/25873174
6161,16474838,"The mutation in the ATP-binding region of JAK1, identified in human uterine leiomyosarcomas, results in defective interferon-gamma inducibility of TAP1 and LMP2.",http://www.ncbi.nlm.nih.gov/pubmed/16474838
6162,21551237,PTPN2 negatively regulates oncogenic JAK1 in T-cell acute lymphoblastic leukemia.,http://www.ncbi.nlm.nih.gov/pubmed/21551237
6163,27111231,"Hyperactivation of JAK1 tyrosine kinase induces stepwise, progressive pruritic dermatitis.",http://www.ncbi.nlm.nih.gov/pubmed/27111231
6164,23788652,Whole-genome sequencing identifies recurrent mutations in hepatocellular carcinoma.,http://www.ncbi.nlm.nih.gov/pubmed/23788652
6165,20868368,"Transforming JAK1 mutations exhibit differential signalling, FERM domain requirements and growth responses to interferon-γ.",http://www.ncbi.nlm.nih.gov/pubmed/20868368
6166,18383312,Accurate classification of MLH1/MSH2 missense variants with multivariate analysis of protein polymorphisms-mismatch repair (MAPP-MMR).,http://www.ncbi.nlm.nih.gov/pubmed/18383312
6167,23435383,Structure of the MutLα C-terminal domain reveals how Mlh1 contributes to Pms1 endonuclease site.,http://www.ncbi.nlm.nih.gov/pubmed/23435383
6168,26834953,Targeting the leukemia-stroma interaction in acute myeloid leukemia: rationale and latest evidence.,http://www.ncbi.nlm.nih.gov/pubmed/26834953
6169,,Adhesion Of Acute Myeloid Leukemia Blasts To E-Selectin In The Vascular Niche Enhances Their Survival By Mechanisms Such As Wnt Activation,http://www.bloodjournal.org/content/122/21/61.short?sso-checked=true
6170,,A small molecule glycomimetic antagonist of E-selectin (GMI-1271) prevents pancreatic tumor metastasis and offers a novel treatment for improved efficacy of chemotherapy,http://cancerres.aacrjournals.org/content/74/19_Supplement/4503.short
6171,,Exploration of a potent E-Selectin antagonist (GMI-1271) as a potential novel therapeutic for treating breast cancer metastasis to the bone and lung,http://cancerres.aacrjournals.org/content/74/19_Supplement/4039.short
6172,23319569,Integrin alpha4 blockade sensitizes drug resistant pre-B acute lymphoblastic leukemia to chemotherapy.,http://www.ncbi.nlm.nih.gov/pubmed/23319569
6173,26769750,Not all NOTCH Is Created Equal: The Oncogenic Role of NOTCH2 in Bladder Cancer and Its Implications for Targeted Therapy.,http://www.ncbi.nlm.nih.gov/pubmed/26769750
6174,23403630,Expression defect size among unclassified MLH1 variants determines pathogenicity in Lynch syndrome diagnosis.,http://www.ncbi.nlm.nih.gov/pubmed/23403630
6175,12208847,Cancer predisposition and hematopoietic failure in Rad50(S/S) mice.,http://www.ncbi.nlm.nih.gov/pubmed/12208847
6176,16857186,Rad50S alleles of the Mre11 complex: questions answered and questions raised.,http://www.ncbi.nlm.nih.gov/pubmed/16857186
6177,27174596,Heterogeneity and clinical significance of ESR1 mutations in ER-positive metastatic breast cancer patients receiving fulvestrant.,http://www.ncbi.nlm.nih.gov/pubmed/27174596
6178,16724012,"Assessing the pathogenicity of MLH1 missense mutations in patients with suspected hereditary nonpolyposis colorectal cancer: correlation with clinical, genetic and functional features.",http://www.ncbi.nlm.nih.gov/pubmed/16724012
6179,16474176,RAD50 and NBS1 are breast cancer susceptibility genes associated with genomic instability.,http://www.ncbi.nlm.nih.gov/pubmed/16474176
6180,26034219,Safety and Pharmacokinetics/Pharmacodynamics of the First-in-Class Dual Action HER3/EGFR Antibody MEHD7945A in Locally Advanced or Metastatic Epithelial Tumors.,http://www.ncbi.nlm.nih.gov/pubmed/26034219
6181,25891173,Pembrolizumab versus Ipilimumab in Advanced Melanoma.,http://www.ncbi.nlm.nih.gov/pubmed/25891173
6182,17452677,Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group.,http://www.ncbi.nlm.nih.gov/pubmed/17452677
6183,18451237,"Phase II, open-label study evaluating the activity of imatinib in treating life-threatening malignancies known to be associated with imatinib-sensitive tyrosine kinases.",http://www.ncbi.nlm.nih.gov/pubmed/18451237
6184,,Updated Results of a Phase II Randomized Study (ROMULUS) of Polatuzumab Vedotin or Pinatuzumab Vedotin Plus Rituximab in Patients with Relapsed/Refractory Non-Hodgkin Lymphoma,http://www.bloodjournal.org/content/124/21/4457.abstract?sso-checked=true
6185,22736432,Comprehensive functional assessment of MLH1 variants of unknown significance.,http://www.ncbi.nlm.nih.gov/pubmed/22736432
6186,21383154,Missense mutations in the NF2 gene result in the quantitative loss of merlin protein and minimally affect protein intrinsic function.,http://www.ncbi.nlm.nih.gov/pubmed/21383154
6187,22799452,Identification of 3 novel VHL germ-line mutations in Danish VHL patients.,http://www.ncbi.nlm.nih.gov/pubmed/22799452
6188,11448944,Functional analysis of neurofibromatosis 2 (NF2) missense mutations.,http://www.ncbi.nlm.nih.gov/pubmed/11448944
6189,16261165,Renal cell carcinoma risk in type 2 von Hippel-Lindau disease correlates with defects in pVHL stability and HIF-1alpha interactions.,http://www.ncbi.nlm.nih.gov/pubmed/16261165
6190,19030229,VHL type 2B mutations retain VBC complex form and function.,http://www.ncbi.nlm.nih.gov/pubmed/19030229
6191,10535940,Identification of the von Hippel-lindau tumor-suppressor protein as part of an active E3 ubiquitin ligase complex.,http://www.ncbi.nlm.nih.gov/pubmed/10535940
6192,22105711,Effects of point mutations in pVHL on the binding of HIF-1α.,http://www.ncbi.nlm.nih.gov/pubmed/22105711
6193,16339315,The oncogenic properties of mutant p110alpha and p110beta phosphatidylinositol 3-kinases in human mammary epithelial cells.,http://www.ncbi.nlm.nih.gov/pubmed/16339315
6194,27259270,BET bromodomain inhibitors suppress EWS-FLI1-dependent transcription and the IGF1 autocrine mechanism in Ewing sarcoma.,http://www.ncbi.nlm.nih.gov/pubmed/27259270
6195,18704194,"Ablation of PI3K blocks BCR-ABL leukemogenesis in mice, and a dual PI3K/mTOR inhibitor prevents expansion of human BCR-ABL+ leukemia cells.",http://www.ncbi.nlm.nih.gov/pubmed/18704194
6196,11673408,Fanconi anemia and DNA repair.,http://www.ncbi.nlm.nih.gov/pubmed/11673408
6197,12509764,The Fanconi anaemia/BRCA pathway.,http://www.ncbi.nlm.nih.gov/pubmed/12509764
6198,25455269,Fanconi anemia and the development of leukemia.,http://www.ncbi.nlm.nih.gov/pubmed/25455269
6199,18830229,Missense mutations to the TSC1 gene cause tuberous sclerosis complex.,http://www.ncbi.nlm.nih.gov/pubmed/18830229
6200,27330107,Plk1 Inhibitors in Cancer Therapy: From Laboratory to Clinics.,http://www.ncbi.nlm.nih.gov/pubmed/27330107
6201,21892207,"c-Abl and Arg are activated in human primary melanomas, promote melanoma cell invasion via distinct pathways, and drive metastatic progression.",http://www.ncbi.nlm.nih.gov/pubmed/21892207
6202,25900027,The impact of FGFR1 and FRS2α expression on sorafenib treatment in metastatic renal cell carcinoma.,http://www.ncbi.nlm.nih.gov/pubmed/25900027
6203,26222319,"Discovery of 2-[1-(4,4-Difluorocyclohexyl)piperidin-4-yl]-6-fluoro-3-oxo-2,3-dihydro-1H-isoindole-4-carboxamide (NMS-P118): A Potent, Orally Available, and Highly Selective PARP-1 Inhibitor for Cancer Therapy.",http://www.ncbi.nlm.nih.gov/pubmed/26222319
6204,26896565,DNA repair targeted therapy: The past or future of cancer treatment?,http://www.ncbi.nlm.nih.gov/pubmed/26896565
6205,24905007,The genetic and biochemical basis of FANCD2 monoubiquitination.,http://www.ncbi.nlm.nih.gov/pubmed/24905007
6206,26658157,Fancb deficiency impairs hematopoietic stem cell function.,http://www.ncbi.nlm.nih.gov/pubmed/26658157
6207,26555154,AXL Inhibitors in Cancer: A Medicinal Chemistry Perspective.,http://www.ncbi.nlm.nih.gov/pubmed/26555154
6208,15502827,X-linked inheritance of Fanconi anemia complementation group B.,http://www.ncbi.nlm.nih.gov/pubmed/15502827
6209,23613520,"Massively parallel sequencing, aCGH, and RNA-Seq technologies provide a comprehensive molecular diagnosis of Fanconi anemia.",http://www.ncbi.nlm.nih.gov/pubmed/23613520
6210,26287259,Inhibition of Topoisomerase (DNA) I (TOP1): DNA Damage Repair and Anticancer Therapy.,http://www.ncbi.nlm.nih.gov/pubmed/26287259
6211,25615400,TOP1 gene copy numbers are increased in cancers of the bile duct and pancreas.,http://www.ncbi.nlm.nih.gov/pubmed/25615400
6212,25855483,Topoisomerase-1 gene copy aberrations are frequent in patients with breast cancer.,http://www.ncbi.nlm.nih.gov/pubmed/25855483
6213,22675617,Towards a molecular understanding of the fanconi anemia core complex.,http://www.ncbi.nlm.nih.gov/pubmed/22675617
6214,27145721,The Fanconi anaemia pathway: new players and new functions.,http://www.ncbi.nlm.nih.gov/pubmed/27145721
6215,27029323,Characterization of DNA topoisomerase I in three SN-38 resistant human colon cancer cell lines reveals a new pair of resistance-associated mutations.,http://www.ncbi.nlm.nih.gov/pubmed/27029323
6216,27165003,The Fanconi anemia DNA damage repair pathway in the spotlight for germline predisposition to colorectal cancer.,http://www.ncbi.nlm.nih.gov/pubmed/27165003
6217,15695377,Germ line Fanconi anemia complementation group C mutations and pancreatic cancer.,http://www.ncbi.nlm.nih.gov/pubmed/15695377
6218,24517248,Synthesis and biological evaluation of new carbohydrate-substituted indenoisoquinoline topoisomerase I inhibitors and improved syntheses of the experimental anticancer agents indotecan (LMP400) and indimitecan (LMP776).,http://www.ncbi.nlm.nih.gov/pubmed/24517248
6219,25609062,Acquisition of Relative Interstrand Crosslinker Resistance and PARP Inhibitor Sensitivity in Fanconi Anemia Head and Neck Cancers.,http://www.ncbi.nlm.nih.gov/pubmed/25609062
6220,17431503,Fanconi anemia pathway-deficient tumor cells are hypersensitive to inhibition of ataxia telangiectasia mutated.,http://www.ncbi.nlm.nih.gov/pubmed/17431503
6221,18835266,The proto-oncoprotein SYT (SS18) controls ATP release and regulates cyst formation by polarized MDCK cells.,http://www.ncbi.nlm.nih.gov/pubmed/18835266
6222,25438927,Synovial sarcoma: defining features and diagnostic evolution.,http://www.ncbi.nlm.nih.gov/pubmed/25438927
6223,26905812,The fusion protein SS18-SSX1 employs core Wnt pathway transcription factors to induce a partial Wnt signature in synovial sarcoma.,http://www.ncbi.nlm.nih.gov/pubmed/26905812
6224,26217552,Prognostic value of SS18-SSX fusion type in synovial sarcoma; systematic review and meta-analysis.,http://www.ncbi.nlm.nih.gov/pubmed/26217552
6225,24025411,Advances in the understanding of the Fanconi anemia tumor suppressor pathway.,http://www.ncbi.nlm.nih.gov/pubmed/24025411
6226,24166495,SS18-SSX fusion protein-induced Wnt/β-catenin signaling is a therapeutic target in synovial sarcoma.,http://www.ncbi.nlm.nih.gov/pubmed/24166495
6227,21309039,Functional assessment of variants in the TSC1 and TSC2 genes identified in individuals with Tuberous Sclerosis Complex.,http://www.ncbi.nlm.nih.gov/pubmed/21309039
6228,17308347,Insights into Fanconi Anaemia from the structure of human FANCE.,http://www.ncbi.nlm.nih.gov/pubmed/17308347
6229,25237197,Stress and DNA repair biology of the Fanconi anemia pathway.,http://www.ncbi.nlm.nih.gov/pubmed/25237197
6230,,Phase I study of RAF dimer inhibitor BGB-283 in patients with B-RAF or K-RAS/N-RAS mutated solid tumors,http://www.abstractsonline.com/Plan/ViewAbstract.aspx?mID=4017&sKey=dc4584a4-d39b-485a-9579-be210c4876e9&cKey=46a0776a-1444-49d6-b533-4f68e298c39d&mKey=1d10d749-4b6a-4ab3-bcd4-f80fb1922267
6231,23550303,BAP1 and cancer.,http://www.ncbi.nlm.nih.gov/pubmed/23550303
6232,,Safety and efficacy of cobimetinib (cobi) and atezolizumab (atezo) in a Phase 1b study of metastatic colorectal cancer (mCRC),http://annonc.oxfordjournals.org/content/27/suppl_2/ii140.1.full
6233,15743666,Poly(ADP-ribose) polymerases: managing genome stability.,http://www.ncbi.nlm.nih.gov/pubmed/15743666
6234,25483710,"BRCA1, PARP1 and γH2AX in acute myeloid leukemia: Role as biomarkers of response to the PARP inhibitor olaparib.",http://www.ncbi.nlm.nih.gov/pubmed/25483710
6235,25528020,Biological and clinical significance of PARP1 protein expression in breast cancer.,http://www.ncbi.nlm.nih.gov/pubmed/25528020
6236,16809031,Overexpression of poly(ADP-ribose) polymerase-1 (PARP-1) in the early stage of colorectal carcinogenesis.,http://www.ncbi.nlm.nih.gov/pubmed/16809031
6237,25111073,Mutational landscape of candidate genes in familial prostate cancer.,http://www.ncbi.nlm.nih.gov/pubmed/25111073
6238,21915857,Fancf-deficient mice are prone to develop ovarian tumours.,http://www.ncbi.nlm.nih.gov/pubmed/21915857
6239,27197561,Expression of an Oncogenic BARD1 Splice Variant Impairs Homologous Recombination and Predicts Response to PARP-1 Inhibitor Therapy in Colon Cancer.,http://www.ncbi.nlm.nih.gov/pubmed/27197561
6240,21118969,Genomic instability in mice is greater in Fanconi anemia caused by deficiency of Fancd2 than Fancg.,http://www.ncbi.nlm.nih.gov/pubmed/21118969
6241,26822949,Hereditary truncating mutations of DNA repair and other genes in BRCA1/BRCA2/PALB2-negatively tested breast cancer patients.,http://www.ncbi.nlm.nih.gov/pubmed/26822949
6242,25288723,Exome sequencing identifies FANCM as a susceptibility gene for triple-negative breast cancer.,http://www.ncbi.nlm.nih.gov/pubmed/25288723
6243,26593718,The Fanconi Anemia Pathway Maintains Genome Stability by Coordinating Replication and Transcription.,http://www.ncbi.nlm.nih.gov/pubmed/26593718
6244,27320729,"POLD1: Central mediator of DNA replication and repair, and implication in cancer and other pathologies.",http://www.ncbi.nlm.nih.gov/pubmed/27320729
6245,18927431,A peptomimetic inhibitor of BCL6 with potent antilymphoma effects in vitro and in vivo.,http://www.ncbi.nlm.nih.gov/pubmed/18927431
6246,21079801,"POLD2 and KSP37 (FGFBP2) correlate strongly with histology, stage and outcome in ovarian carcinomas.",http://www.ncbi.nlm.nih.gov/pubmed/21079801
6247,25875127,Tensor GSVD of patient- and platform-matched tumor and normal DNA copy-number profiles uncovers chromosome arm-wide patterns of tumor-exclusive platform-consistent alterations encoding for cell transformation and predicting ovarian cancer survival.,http://www.ncbi.nlm.nih.gov/pubmed/25875127
6248,20498019,BCL6 is critical for the development of a diverse primary B cell repertoire.,http://www.ncbi.nlm.nih.gov/pubmed/20498019
6249,24917186,B-cell lymphoma 6 protein stimulates oncogenicity of human breast cancer cells.,http://www.ncbi.nlm.nih.gov/pubmed/24917186
6250,19706770,Identification of novel gene amplifications in breast cancer and coexistence of gene amplification with an activating mutation of PIK3CA.,http://www.ncbi.nlm.nih.gov/pubmed/19706770
6251,17384679,Frequent alteration of DNA damage signalling and repair pathways in human colorectal cancers with microsatellite instability.,http://www.ncbi.nlm.nih.gov/pubmed/17384679
6252,25529843,Frequency and phenotypic spectrum of germline mutations in POLE and seven other polymerase genes in 266 patients with colorectal adenomas and carcinomas.,http://www.ncbi.nlm.nih.gov/pubmed/25529843
6253,20861182,Regulation of DNA polymerase POLD4 influences genomic instability in lung cancer.,http://www.ncbi.nlm.nih.gov/pubmed/20861182
6254,26822575,A panoply of errors: polymerase proofreading domain mutations in cancer.,http://www.ncbi.nlm.nih.gov/pubmed/26822575
6255,27256874,Phase I Study of Lenalidomide and Sorafenib in Patients With Advanced Hepatocellular Carcinoma.,http://www.ncbi.nlm.nih.gov/pubmed/27256874
6256,27315356,"Efficacy and safety of dovitinib in pretreated patients with advanced squamous non-small cell lung cancer with FGFR1 amplification: A single-arm, phase 2 study.",http://www.ncbi.nlm.nih.gov/pubmed/27315356
6257,27196781,PIM Kinase Inhibitors Kill Hypoxic Tumor Cells by Reducing Nrf2 Signaling and Increasing Reactive Oxygen Species.,http://www.ncbi.nlm.nih.gov/pubmed/27196781
6258,25228659,Exonuclease mutations in DNA polymerase epsilon reveal replication strand specific mutation patterns and human origins of replication.,http://www.ncbi.nlm.nih.gov/pubmed/25228659
6260,27159395,Immune activation and response to pembrolizumab in POLE-mutant endometrial cancer.,http://www.ncbi.nlm.nih.gov/pubmed/27159395
6261,27196752,"The Discovery and Characterization of K-756, a Novel Wnt/β-Catenin Pathway Inhibitor Targeting Tankyrase.",http://www.ncbi.nlm.nih.gov/pubmed/27196752
6262,23079656,Therapeutic targeting of the cyclin D3:CDK4/6 complex in T cell leukemia.,http://www.ncbi.nlm.nih.gov/pubmed/23079656
6263,16402392,Update on the molecular biology of mantle cell lymphoma.,http://www.ncbi.nlm.nih.gov/pubmed/16402392
6264,16322284,Identification of CCND3 and BYSL as candidate targets for the 6p21 amplification in diffuse large B-cell lymphoma.,http://www.ncbi.nlm.nih.gov/pubmed/16322284
6265,24151134,Involvement and targeted intervention of dysregulated Hedgehog signaling in osteosarcoma.,http://www.ncbi.nlm.nih.gov/pubmed/24151134
6266,25637283,Activation of protein phosphatase 2A tumor suppressor as potential treatment of pancreatic cancer.,http://www.ncbi.nlm.nih.gov/pubmed/25637283
6267,23341130,A novel small molecule RAD51 inactivator overcomes imatinib-resistance in chronic myeloid leukaemia.,http://www.ncbi.nlm.nih.gov/pubmed/23341130
6268,20054396,Chronic active B-cell-receptor signalling in diffuse large B-cell lymphoma.,http://www.ncbi.nlm.nih.gov/pubmed/20054396
6269,27196762,Suppression of SRC Signaling Is Effective in Reducing Synergy between Glioblastoma and Stromal Cells.,http://www.ncbi.nlm.nih.gov/pubmed/27196762
6270,27300349,The clinicopathological significance of miR-149 and PARP-2 in hepatocellular carcinoma and their roles in chemo/radiotherapy.,http://www.ncbi.nlm.nih.gov/pubmed/27300349
6271,27216187,Mitochondria-Targeted Analogues of Metformin Exhibit Enhanced Antiproliferative and Radiosensitizing Effects in Pancreatic Cancer Cells.,http://www.ncbi.nlm.nih.gov/pubmed/27216187
6272,8668164,A dominant inhibitory mutant of the type II transforming growth factor beta receptor in the malignant progression of a cutaneous T-cell lymphoma.,http://www.ncbi.nlm.nih.gov/pubmed/8668164
6273,27147599,Systematic Functional Interrogation of Rare Cancer Variants Identifies Oncogenic Alleles.,http://www.ncbi.nlm.nih.gov/pubmed/27147599
6274,26403419,A mutation in the POT1 gene is responsible for cardiac angiosarcoma in TP53-negative Li-Fraumeni-like families.,http://www.ncbi.nlm.nih.gov/pubmed/26403419
6275,24686849,POT1 loss-of-function variants predispose to familial melanoma.,http://www.ncbi.nlm.nih.gov/pubmed/24686849
6276,24686846,Rare missense variants in POT1 predispose to familial cutaneous malignant melanoma.,http://www.ncbi.nlm.nih.gov/pubmed/24686846
6277,23502782,POT1 mutations cause telomere dysfunction in chronic lymphocytic leukemia.,http://www.ncbi.nlm.nih.gov/pubmed/23502782
6278,26493492,Saracatinib as a metastasis inhibitor in metastatic castration-resistant prostate cancer: A University of Chicago Phase 2 Consortium and DOD/PCF Prostate Cancer Clinical Trials Consortium Study.,http://www.ncbi.nlm.nih.gov/pubmed/26493492
6279,18991062,Coordinated molecular control of otic capsule differentiation: functional role of Wnt5a signaling and opposition by sfrp3 activity.,http://www.ncbi.nlm.nih.gov/pubmed/18991062
6280,20151426,Fyn: a novel molecular target in cancer.,http://www.ncbi.nlm.nih.gov/pubmed/20151426
6281,26305432,Fyn is an important molecule in cancer pathogenesis and drug resistance.,http://www.ncbi.nlm.nih.gov/pubmed/26305432
6282,7862150,Disruption of transforming growth factor beta signaling by a mutation that prevents transphosphorylation within the receptor complex.,http://www.ncbi.nlm.nih.gov/pubmed/7862150
6283,25851935,GNAS Spectrum of Disorders.,http://www.ncbi.nlm.nih.gov/pubmed/25851935
6284,15483652,Distinct effects of single amino-acid changes to tuberin on the function of the tuberin-hamartin complex.,http://www.ncbi.nlm.nih.gov/pubmed/15483652
6285,,A phase 1 study of AZD6244 in children with recurrent or refractory low-grade gliomas: A Pediatric Brain Tumor Consortium report.,http://meetinglibrary.asco.org/content/134121-144
6286,9742112,Functional activity of the fanconi anemia protein FAA requires FAC binding and nuclear localization.,http://www.ncbi.nlm.nih.gov/pubmed/9742112
6287,25766326,Endometrial cancer-associated mutants of SPOP are defective in regulating estrogen receptor-α protein turnover.,http://www.ncbi.nlm.nih.gov/pubmed/25766326
6288,26344095,SPOP Promotes Ubiquitination and Degradation of the ERG Oncoprotein to Suppress Prostate Cancer Progression.,http://www.ncbi.nlm.nih.gov/pubmed/26344095
6289,22610119,"Exome sequencing identifies recurrent SPOP, FOXA1 and MED12 mutations in prostate cancer.",http://www.ncbi.nlm.nih.gov/pubmed/22610119
6290,26374986,SPOP mutation leads to genomic instability in prostate cancer.,http://www.ncbi.nlm.nih.gov/pubmed/26374986
6291,25278611,Prostate cancer. Ubiquitylome analysis identifies dysregulation of effector substrates in SPOP-mutant prostate cancer.,http://www.ncbi.nlm.nih.gov/pubmed/25278611
6292,27238081,TRIM24 Is an Oncogenic Transcriptional Activator in Prostate Cancer.,http://www.ncbi.nlm.nih.gov/pubmed/27238081
6293,19290918,"T-cell receptor proximal signaling via the Src-family kinases, Lck and Fyn, influences T-cell activation, differentiation, and tolerance.",http://www.ncbi.nlm.nih.gov/pubmed/19290918
6294,23505068,LCK is an important mediator of B-cell receptor signaling in chronic lymphocytic leukemia cells.,http://www.ncbi.nlm.nih.gov/pubmed/23505068
6295,11865071,Diverse effects of mutations in exon II of the von Hippel-Lindau (VHL) tumor suppressor gene on the interaction of pVHL with the cytosolic chaperonin and pVHL-dependent ubiquitin ligase activity.,http://www.ncbi.nlm.nih.gov/pubmed/11865071
6296,15175350,"A Bcr/Abl-independent, Lyn-dependent form of imatinib mesylate (STI-571) resistance is associated with altered expression of Bcl-2.",http://www.ncbi.nlm.nih.gov/pubmed/15175350
6297,11672542,Gain- and loss-of-function Lyn mutant mice define a critical inhibitory role for Lyn in the myeloid lineage.,http://www.ncbi.nlm.nih.gov/pubmed/11672542
6298,26503325,E2-EPF UCP regulates stability and functions of missense mutant pVHL via ubiquitin mediated proteolysis.,http://www.ncbi.nlm.nih.gov/pubmed/26503325
6299,27283171,The Relevance of Hereditary Cancer Risks to Precision Oncology: What Should Providers Consider When Conducting Tumor Genomic Profiling?,http://www.ncbi.nlm.nih.gov/pubmed/27283171
6300,26912052,Axitinib and sorafenib are potent in tyrosine kinase inhibitor resistant chronic myeloid leukemia cells.,http://www.ncbi.nlm.nih.gov/pubmed/26912052
6301,22034009,Fibroblast growth factor receptor 4 gene (FGFR4) 388Arg allele predicts prolonged survival and platinum sensitivity in advanced ovarian cancer.,http://www.ncbi.nlm.nih.gov/pubmed/22034009
6302,20147743,FGFR4 Arg388 genotype is associated with pathological complete response to neoadjuvant chemotherapy for primary breast cancer.,http://www.ncbi.nlm.nih.gov/pubmed/20147743
6303,,Phase II study of anlotinib for treatment of advanced soft tissues sarcomas.,http://meetinglibrary.asco.org/content/167465-176
6304,27197306,Inhibition of PI3K/BMX Cell Survival Pathway Sensitizes to BH3 Mimetics in SCLC.,http://www.ncbi.nlm.nih.gov/pubmed/27197306
6305,27213589,Phase I study of pemetrexed with sorafenib in advanced solid tumors.,http://www.ncbi.nlm.nih.gov/pubmed/27213589
6306,20004243,A single-point mutation in FGFR2 affects cell cycle and Tgfbeta signalling in osteoblasts.,http://www.ncbi.nlm.nih.gov/pubmed/20004243
6307,16844695,"Intracellular retention, degradation, and signaling of glycosylation-deficient FGFR2 and craniosynostosis syndrome-associated FGFR2C278F.",http://www.ncbi.nlm.nih.gov/pubmed/16844695
6308,27203384,The novel VEGF receptor 2 inhibitor YLL545 inhibits angiogenesis and growth in breast cancer.,http://www.ncbi.nlm.nih.gov/pubmed/27203384
6309,27196775,A Novel Glycogen Synthase Kinase-3 Inhibitor Optimized for Acute Myeloid Leukemia Differentiation Activity.,http://www.ncbi.nlm.nih.gov/pubmed/27196775
6310,26758680,Somatically mutated ABL1 is an actionable and essential NSCLC survival gene.,http://www.ncbi.nlm.nih.gov/pubmed/26758680
6311,24908667,Bent bone dysplasia syndrome reveals nucleolar activity for FGFR2 in ribosomal DNA transcription.,http://www.ncbi.nlm.nih.gov/pubmed/24908667
6312,26152787,A NOTCH1 gene copy number gain is a prognostic indicator of worse survival and a predictive biomarker to a Notch1 targeting antibody in colorectal cancer.,http://www.ncbi.nlm.nih.gov/pubmed/26152787
6313,27157619,Characterization of activating mutations of NOTCH3 in T-cell acute lymphoblastic leukemia and anti-leukemic activity of NOTCH3 inhibitory antibodies.,http://www.ncbi.nlm.nih.gov/pubmed/27157619
6314,9539778,Activating mutations in the extracellular domain of the fibroblast growth factor receptor 2 function by disruption of the disulfide bond in the third immunoglobulin-like domain.,http://www.ncbi.nlm.nih.gov/pubmed/9539778
6315,26000263,Immunotherapy for bladder cancer.,http://www.ncbi.nlm.nih.gov/pubmed/26000263
6316,26992226,Landscape of activating cancer mutations in FGFR kinases and their differential responses to inhibitors in clinical use.,http://www.ncbi.nlm.nih.gov/pubmed/26992226
6317,26074087,The ERCC1 and ERCC4 (XPF) genes and gene products.,http://www.ncbi.nlm.nih.gov/pubmed/26074087
6318,26179868,The prognostic and predictive value of excision repair cross-complementation group 1 (ERCC1) protein in 1288 patients with head and neck squamous cell carcinoma treated with platinum-based therapy: a meta-analysis.,http://www.ncbi.nlm.nih.gov/pubmed/26179868
6319,26804248,Cisplatin resistance and opportunities for precision medicine.,http://www.ncbi.nlm.nih.gov/pubmed/26804248
6320,26870207,"Analysis of ERCC1, BRCA1, RRM1 and TUBB3 as predictors of prognosis in patients with non-small cell lung cancer who received cisplatin-based adjuvant chemotherapy: A prospective study.",http://www.ncbi.nlm.nih.gov/pubmed/26870207
6321,26073592,Novel EPHB4 Receptor Tyrosine Kinase Mutations and Kinomic Pathway Analysis in Lung Cancer.,http://www.ncbi.nlm.nih.gov/pubmed/26073592
6322,27231123,Isocitrate Dehydrogenase Mutations Confer Dasatinib Hypersensitivity and SRC Dependence in Intrahepatic Cholangiocarcinoma.,http://www.ncbi.nlm.nih.gov/pubmed/27231123
6323,23613359,Roles of Chk1 in cell biology and cancer therapy.,http://www.ncbi.nlm.nih.gov/pubmed/23613359
6324,12781359,Chk1 and Chk2 kinases in checkpoint control and cancer.,http://www.ncbi.nlm.nih.gov/pubmed/12781359
6325,27338794,A combinatorial strategy for treating KRAS-mutant lung cancer.,http://www.ncbi.nlm.nih.gov/pubmed/27338794
6326,26884591,What hides behind the MASC: clinical response and acquired resistance to entrectinib after ETV6-NTRK3 identification in a mammary analogue secretory carcinoma (MASC).,http://www.ncbi.nlm.nih.gov/pubmed/26884591
6327,27133164,Fanconi Anemia Proteins Function in Mitophagy and Immunity.,http://www.ncbi.nlm.nih.gov/pubmed/27133164
6328,27093299,Infantile Fibrosarcoma With NTRK3-ETV6 Fusion Successfully Treated With the Tropomyosin-Related Kinase Inhibitor LOXO-101.,http://www.ncbi.nlm.nih.gov/pubmed/27093299
6329,,Abstract 790: Altiratinib is a potent inhibitor of TRK kinases and is efficacious in TRK-fusion driven cancer models,http://cancerres.aacrjournals.org/content/75/15_Supplement/790.short
6330,,"A phase I pharmacokinetic and pharmacodynamic study of AMG 479, a fully human monoclonal antibody against insulin-like growth factor type 1 receptor (IGF-1R), in advanced solid tumors",http://hwmaint.meeting.ascopubs.org/cgi/content/abstract/25/18_suppl/3002
6331,22578774,ETV6 fusion genes in hematological malignancies: a review.,http://www.ncbi.nlm.nih.gov/pubmed/22578774
6332,26603525,Targeting p300 Addiction in CBP-Deficient Cancers Causes Synthetic Lethality by Apoptotic Cell Death due to Abrogation of MYC Expression.,http://www.ncbi.nlm.nih.gov/pubmed/26603525
6333,8661101,"A novel human CCAAT/enhancer binding protein gene, C/EBPepsilon, is expressed in cells of lymphoid and myeloid lineages and is localized on chromosome 14q11.2 close to the T-cell receptor alpha/delta locus.",http://www.ncbi.nlm.nih.gov/pubmed/8661101
6334,19027493,Translocation (14;14)(q11;q32) with simultaneous involvement of the IGH and CEBPE genes in B-lineage acute lymphoblastic leukemia.,http://www.ncbi.nlm.nih.gov/pubmed/19027493
6335,27019113,Recurrent DUX4 fusions in B cell acute lymphoblastic leukemia of adolescents and young adults.,http://www.ncbi.nlm.nih.gov/pubmed/27019113
6336,19164581,The coactivator CRTC1 promotes cell proliferation and transformation via AP-1.,http://www.ncbi.nlm.nih.gov/pubmed/19164581
6337,23018873,Genomic profiles and CRTC1-MAML2 fusion distinguish different subtypes of mucoepidermoid carcinoma.,http://www.ncbi.nlm.nih.gov/pubmed/23018873
6338,18451181,Functional assays for classification of BRCA2 variants of uncertain significance.,http://www.ncbi.nlm.nih.gov/pubmed/18451181
6339,27272783,Novel Tumor-specific Mutations in Receptor Tyrosine Kinase Subdomain IX Significantly Reduce Extracellular Signal-regulated Kinase Activity.,http://www.ncbi.nlm.nih.gov/pubmed/27272783
6340,26116361,AKT Antagonist AZD5363 Influences Estrogen Receptor Function in Endocrine-Resistant Breast Cancer and Synergizes with Fulvestrant (ICI182780) In Vivo.,http://www.ncbi.nlm.nih.gov/pubmed/26116361
6341,27214401,An inhibitor of KDM5 demethylases reduces survival of drug-tolerant cancer cells.,http://www.ncbi.nlm.nih.gov/pubmed/27214401
6342,26415585,Genomic analyses reveal recurrent mutations in epigenetic modifiers and the JAK-STAT pathway in Sézary syndrome.,http://www.ncbi.nlm.nih.gov/pubmed/26415585
6343,26446793,Distinct Acute Lymphoblastic Leukemia (ALL)-associated Janus Kinase 3 (JAK3) Mutants Exhibit Different Cytokine-Receptor Requirements and JAK Inhibitor Specificities.,http://www.ncbi.nlm.nih.gov/pubmed/26446793
6344,11741532,Unexpected effects of FERM domain mutations on catalytic activity of Jak3: structural implication for Janus kinases.,http://www.ncbi.nlm.nih.gov/pubmed/11741532
6345,26964772,Pulse Afatinib for ERBB2 Exon 20 Insertion-Mutated Lung Adenocarcinomas.,http://www.ncbi.nlm.nih.gov/pubmed/26964772
6346,23328489,Effect of the expression of BRCA2 on spontaneous homologous recombination and DNA damage-induced nuclear foci in Saccharomyces cerevisiae.,http://www.ncbi.nlm.nih.gov/pubmed/23328489
6347,21719596,A comprehensive functional characterization of BRCA2 variants associated with Fanconi anemia using mouse ES cell-based assay.,http://www.ncbi.nlm.nih.gov/pubmed/21719596
6348,22962691,Multiple sequence variants of BRCA2 exon 7 alter splicing regulation.,http://www.ncbi.nlm.nih.gov/pubmed/22962691
6349,18607349,Mouse embryonic stem cell-based functional assay to evaluate mutations in BRCA2.,http://www.ncbi.nlm.nih.gov/pubmed/18607349
6350,24835992,BRCA2 coordinates the activities of cell-cycle kinases to promote genome stability.,http://www.ncbi.nlm.nih.gov/pubmed/24835992
6351,26936915,Targeting MDM2 for Treatment of Adenoid Cystic Carcinoma.,http://www.ncbi.nlm.nih.gov/pubmed/26936915
6352,27216193,A Novel Bispecific Antibody Targeting EGFR and cMet Is Effective against EGFR Inhibitor-Resistant Lung Tumors.,http://www.ncbi.nlm.nih.gov/pubmed/27216193
6353,,Abstract 5070: Inhibition of collagen receptor discoidin domain receptor-1 (DDR1) reduces colon cancer cell migration and metastasis,http://cancerres.aacrjournals.org/content/75/15_Supplement/5070.short
6354,19098422,Using kinomics to delineate signaling pathways: control of CRTC2/TORC2 by the AMPK family.,http://www.ncbi.nlm.nih.gov/pubmed/19098422
6355,24484648,Identification and validation of PROM1 and CRTC2 mutations in lung cancer patients.,http://www.ncbi.nlm.nih.gov/pubmed/24484648
6356,27217383,"Efficacy and Safety of Abemaciclib, an Inhibitor of CDK4 and CDK6, for Patients with Breast Cancer, Non-Small Cell Lung Cancer, and Other Solid Tumors.",http://www.ncbi.nlm.nih.gov/pubmed/27217383
6357,8302604,Site-specific modulation of c-Myc cotransformation by residues phosphorylated in vivo.,http://www.ncbi.nlm.nih.gov/pubmed/8302604
6358,21266350,Phosphorylation regulates c-Myc's oncogenic activity in the mammary gland.,http://www.ncbi.nlm.nih.gov/pubmed/21266350
6359,10825194,The c-Myc transactivation domain is a direct modulator of apoptotic versus proliferative signals.,http://www.ncbi.nlm.nih.gov/pubmed/10825194
6360,15800673,The t(8;17)(p11;q23) in the 8p11 myeloproliferative syndrome fuses MYO18A to FGFR1.,http://www.ncbi.nlm.nih.gov/pubmed/15800673
6361,12661006,Fusion of FIG to the receptor tyrosine kinase ROS in a glioblastoma with an interstitial del(6)(q21q21).,http://www.ncbi.nlm.nih.gov/pubmed/12661006
6362,25708834,Anti-CD22 and anti-CD79B antibody drug conjugates are active in different molecular diffuse large B-cell lymphoma subtypes.,http://www.ncbi.nlm.nih.gov/pubmed/25708834
6363,26270481,Development and Characterization of Bladder Cancer Patient-Derived Xenografts for Molecularly Guided Targeted Therapy.,http://www.ncbi.nlm.nih.gov/pubmed/26270481
6364,26432419,Transforming somatic mutations of mammalian target of rapamycin kinase in human cancer.,http://www.ncbi.nlm.nih.gov/pubmed/26432419
6365,27433843,Mutations Associated with Acquired Resistance to PD-1 Blockade in Melanoma.,http://www.ncbi.nlm.nih.gov/pubmed/27433843
6366,27322743,RANK ligand as a potential target for breast cancer prevention in BRCA1-mutation carriers.,http://www.ncbi.nlm.nih.gov/pubmed/27322743
6367,27279227,Overcoming mTOR resistance mutations with a new-generation mTOR inhibitor.,http://www.ncbi.nlm.nih.gov/pubmed/27279227
6368,22832581,"Subgroup-specific structural variation across 1,000 medulloblastoma genomes.",http://www.ncbi.nlm.nih.gov/pubmed/22832581
6369,23041776,"A translocation t(2;8)(q12;p11) fuses FGFR1 to a novel partner gene, RANBP2/NUP358, in a myeloproliferative/myelodysplastic neoplasm.",http://www.ncbi.nlm.nih.gov/pubmed/23041776
6370,19016745,Role of the RUNX1-EVI1 fusion gene in leukemogenesis.,http://www.ncbi.nlm.nih.gov/pubmed/19016745
6371,26916619,RUNX1 prevents oestrogen-mediated AXIN1 suppression and β-catenin activation in ER-positive breast cancer.,http://www.ncbi.nlm.nih.gov/pubmed/26916619
6372,23848403,"RUNX1, but not its familial platelet disorder mutants, synergistically activates PF4 gene expression in combination with ETS family proteins.",http://www.ncbi.nlm.nih.gov/pubmed/23848403
6373,23979164,Transcription factor RUNX1 promotes survival of acute myeloid leukemia cells.,http://www.ncbi.nlm.nih.gov/pubmed/23979164
6374,19369959,"LRRFIP1, a new FGFR1 partner gene associated with 8p11 myeloproliferative syndrome.",http://www.ncbi.nlm.nih.gov/pubmed/19369959
6375,22722202,Sequence analysis of mutations and translocations across breast cancer subtypes.,http://www.ncbi.nlm.nih.gov/pubmed/22722202
6376,11550283,Identification of four new translocations involving FGFR1 in myeloid disorders.,http://www.ncbi.nlm.nih.gov/pubmed/11550283
6377,19179552,Two mutations of BRCA2 gene at exon and splicing site in a woman who underwent oncogenetic counseling.,http://www.ncbi.nlm.nih.gov/pubmed/19179552
6378,22771033,BRCA2 localization to the midbody by filamin A regulates cep55 signaling and completion of cytokinesis.,http://www.ncbi.nlm.nih.gov/pubmed/22771033
6379,24894717,Germline mutations in BAP1 impair its function in DNA double-strand break repair.,http://www.ncbi.nlm.nih.gov/pubmed/24894717
6380,25501022,A novel fusion of SQSTM1 and FGFR1 in a patient with acute myelomonocytic leukemia with t(5;8)(q35;p11) translocation.,http://www.ncbi.nlm.nih.gov/pubmed/25501022
6382,24875859,Inflammatory myofibroblastic tumors harbor multiple potentially actionable kinase fusions.,http://www.ncbi.nlm.nih.gov/pubmed/24875859
6383,27196761,Targeting IκB Kinase β/NF-κB Signaling in Human Prostate Cancer by a Novel IκB Kinase β Inhibitor CmpdA.,http://www.ncbi.nlm.nih.gov/pubmed/27196761
6384,27354483,Differential Crizotinib Response Duration Among ALK Fusion Variants in ALK-Positive Non-Small-Cell Lung Cancer.,http://www.ncbi.nlm.nih.gov/pubmed/27354483
6385,10777217,Tumor-derived mutations within the DNA-binding domain of p53 that phenotypically resemble the deletion of the proline-rich domain.,http://www.ncbi.nlm.nih.gov/pubmed/10777217
6386,16951253,Crystal structure of SV40 large T-antigen bound to p53: interplay between a viral oncoprotein and a cellular tumor suppressor.,http://www.ncbi.nlm.nih.gov/pubmed/16951253
6387,27400939,Improved Outcomes With Retinoic Acid and Arsenic Trioxide Compared With Retinoic Acid and Chemotherapy in Non-High-Risk Acute Promyelocytic Leukemia: Final Results of the Randomized Italian-German APL0406 Trial.,http://www.ncbi.nlm.nih.gov/pubmed/27400939
6388,15609342,8p11 myeloproliferative syndrome with a novel t(7;8) translocation leading to fusion of the FGFR1 and TIF1 genes.,http://www.ncbi.nlm.nih.gov/pubmed/15609342
6389,26786262,Phase II Study of Olaparib (AZD-2281) After Standard Systemic Therapies for Disseminated Colorectal Cancer.,http://www.ncbi.nlm.nih.gov/pubmed/26786262
6390,10587522,"Synthetic peptides define critical contacts between elongin C, elongin B, and the von Hippel-Lindau protein.",http://www.ncbi.nlm.nih.gov/pubmed/10587522
6391,20855504,Quantitative image analysis identifies pVHL as a key regulator of microtubule dynamic instability.,http://www.ncbi.nlm.nih.gov/pubmed/20855504
6392,25612511,Expression of ROS1 predicts ROS1 gene rearrangement in inflammatory myofibroblastic tumors.,http://www.ncbi.nlm.nih.gov/pubmed/25612511
6393,23580382,Fusion of the ZC3H7B and BCOR genes in endometrial stromal sarcomas carrying an X;22-translocation.,http://www.ncbi.nlm.nih.gov/pubmed/23580382
6394,27362227,Allosteric inhibition of SHP2 phosphatase inhibits cancers driven by receptor tyrosine kinases.,http://www.ncbi.nlm.nih.gov/pubmed/27362227
6395,18007576,Fusion of ZMIZ1 to ABL1 in a B-cell acute lymphoblastic leukaemia with a t(9;10)(q34;q22.3) translocation.,http://www.ncbi.nlm.nih.gov/pubmed/18007576
6396,27418649,Mutational correlates of response to hypomethylating agent therapy in acute myeloid leukemia.,http://www.ncbi.nlm.nih.gov/pubmed/27418649
6397,26936919,KIT Exon 11 Codons 557-558 Deletion Mutation Promotes Liver Metastasis Through the CXCL12/CXCR4 Axis in Gastrointestinal Stromal Tumors.,http://www.ncbi.nlm.nih.gov/pubmed/26936919
6398,26842236,"Phase I Safety, Pharmacokinetic, and Pharmacodynamic Study of the Poly(ADP-ribose) Polymerase (PARP) Inhibitor Veliparib (ABT-888) in Combination with Irinotecan in Patients with Advanced Solid Tumors.",http://www.ncbi.nlm.nih.gov/pubmed/26842236
6399,26864210,"A Phase I Clinical, Pharmacokinetic, and Pharmacodynamic Study of Weekly or Every Three Week Ixabepilone and Daily Sunitinib in Patients with Advanced Solid Tumors.",http://www.ncbi.nlm.nih.gov/pubmed/26864210
6400,27279544,"Cabozantinib versus everolimus in advanced renal cell carcinoma (METEOR): final results from a randomised, open-label, phase 3 trial.",http://www.ncbi.nlm.nih.gov/pubmed/27279544
6401,27299749,"A Phase I study of safety and pharmacokinetics of fruquintinib, a novel selective inhibitor of vascular endothelial growth factor receptor-1, -2, and -3 tyrosine kinases in Chinese patients with advanced solid tumors.",http://www.ncbi.nlm.nih.gov/pubmed/27299749
6402,27100354,Phase I trial of dovitinib (TKI258) in recurrent glioblastoma.,http://www.ncbi.nlm.nih.gov/pubmed/27100354
6403,26279064,Optimized Plk1 PBD Inhibitors Based on Poloxin Induce Mitotic Arrest and Apoptosis in Tumor Cells.,http://www.ncbi.nlm.nih.gov/pubmed/26279064
6404,27102076,EGFR Fusions as Novel Therapeutic Targets in Lung Cancer.,http://www.ncbi.nlm.nih.gov/pubmed/27102076
6405,19496623,Mechanism of strand-specific smooth muscle alpha-actin enhancer interaction by purine-rich element binding protein B (Purbeta).,http://www.ncbi.nlm.nih.gov/pubmed/19496623
6406,11417483,"Deletions of PURA, at 5q31, and PURB, at 7p13, in myelodysplastic syndrome and progression to acute myelogenous leukemia.",http://www.ncbi.nlm.nih.gov/pubmed/11417483
6407,21741379,A new assay for functional screening of BRCA2 linker region mutations identifies variants that alter chemoresistance to cisplatin.,http://www.ncbi.nlm.nih.gov/pubmed/21741379
6408,17107900,Ten years and counting: so what do we know about t(4;14)(p16;q32) multiple myeloma.,http://www.ncbi.nlm.nih.gov/pubmed/17107900
6409,22980976,Genomic landscape of non-small cell lung cancer in smokers and never-smokers.,http://www.ncbi.nlm.nih.gov/pubmed/22980976
6410,27080216,"Dabrafenib in patients with BRAF(V600E)-positive advanced non-small-cell lung cancer: a single-arm, multicentre, open-label, phase 2 trial.",http://www.ncbi.nlm.nih.gov/pubmed/27080216
6411,27082517,Integrating Genomics Into Clinical Pediatric Oncology Using the Molecular Tumor Board at the Memorial Sloan Kettering Cancer Center.,http://www.ncbi.nlm.nih.gov/pubmed/27082517
6412,24550739,"Integrated genomic characterization reveals novel, therapeutically relevant drug targets in FGFR and EGFR pathways in sporadic intrahepatic cholangiocarcinoma.",http://www.ncbi.nlm.nih.gov/pubmed/24550739
6413,24563622,Personalized ovarian cancer disease surveillance and detection of candidate therapeutic drug target in circulating tumor DNA.,http://www.ncbi.nlm.nih.gov/pubmed/24563622
6414,27124835,Progression-Free Survival Among Patients With Well-Differentiated or Dedifferentiated Liposarcoma Treated With CDK4 Inhibitor Palbociclib: A Phase 2 Clinical Trial.,http://www.ncbi.nlm.nih.gov/pubmed/27124835
6415,27080472,A phase II study of axitinib in advanced neuroendocrine tumors.,http://www.ncbi.nlm.nih.gov/pubmed/27080472
6416,24727320,Druggable oncogene fusions in invasive mucinous lung adenocarcinoma.,http://www.ncbi.nlm.nih.gov/pubmed/24727320
6417,27025186,"Cediranib in patients with relapsed platinum-sensitive ovarian cancer (ICON6): a randomised, double-blind, placebo-controlled phase 3 trial.",http://www.ncbi.nlm.nih.gov/pubmed/27025186
6418,26929887,Long-term Remission Over Six Years for a Patient with Recurrent Glioblastoma Treated with Cediranib/Lomustine.,http://www.ncbi.nlm.nih.gov/pubmed/26929887
6419,27434671,Small-molecule inhibitors identify the RAD52-ssDNA interaction as critical for recovery from replication stress and for survival of BRCA2 deficient cells.,http://www.ncbi.nlm.nih.gov/pubmed/27434671
6420,26884585,"Randomized, Double-Blind, Placebo-Controlled Phase III Trial of Apatinib in Patients With Chemotherapy-Refractory Advanced or Metastatic Adenocarcinoma of the Stomach or Gastroesophageal Junction.",http://www.ncbi.nlm.nih.gov/pubmed/26884585
6421,26077237,"BEST: A Randomized Phase II Study of Vascular Endothelial Growth Factor, RAF Kinase, and Mammalian Target of Rapamycin Combination Targeted Therapy With Bevacizumab, Sorafenib, and Temsirolimus in Advanced Renal Cell Carcinoma--A Trial of the ECOG-ACRIN Cancer Research Group (E2804).",http://www.ncbi.nlm.nih.gov/pubmed/26077237
6422,27085251,Randomized phase II placebo controlled study of codrituzumab in previously treated patients with advanced hepatocellular carcinoma.,http://www.ncbi.nlm.nih.gov/pubmed/27085251
6423,11243405,Fusion of MOZ and p300 histone acetyltransferases in acute monocytic leukemia with a t(8;22)(p11;q13) chromosome translocation.,http://www.ncbi.nlm.nih.gov/pubmed/11243405
6424,20980053,Novel variant form of t(11;22)(q23;q13)/MLL-EP300 fusion transcript in the evolution of an acute myeloid leukemia with myelodysplasia-related changes.,http://www.ncbi.nlm.nih.gov/pubmed/20980053
6425,24996197,Brivanib as adjuvant therapy to transarterial chemoembolization in patients with hepatocellular carcinoma: A randomized phase III trial.,http://www.ncbi.nlm.nih.gov/pubmed/24996197
6426,25099679,Recurrent ESR1-CCDC170 rearrangements in an aggressive subset of oestrogen receptor-positive breast cancers.,http://www.ncbi.nlm.nih.gov/pubmed/25099679
6427,23980084,"Brivanib versus sorafenib as first-line therapy in patients with unresectable, advanced hepatocellular carcinoma: results from the randomized phase III BRISK-FL study.",http://www.ncbi.nlm.nih.gov/pubmed/23980084
6428,21666686,FOXO1-FGFR1 fusion and amplification in a solid variant of alveolar rhabdomyosarcoma.,http://www.ncbi.nlm.nih.gov/pubmed/21666686
6429,27116183,"Canadian Cancer Trials Group IND197: a phase II study of foretinib in patients with estrogen receptor, progesterone receptor, and human epidermal growth factor receptor 2-negative recurrent or metastatic breast cancer.",http://www.ncbi.nlm.nih.gov/pubmed/27116183
6430,,Phase I study of anti-VEGF receptor-3 (VEGFR-3) monoclonal antibody (mab) LY3022856/IMC-3C5 (3C5),http://hwmaint.meeting.ascopubs.org/cgi/content/abstract/33/15_suppl/3530
6431,27451907,PDK1-SGK1 Signaling Sustains AKT-Independent mTORC1 Activation and Confers Resistance to PI3Kα Inhibition.,http://www.ncbi.nlm.nih.gov/pubmed/27451907
6432,17848578,Structural requirements for the BARD1 tumor suppressor in chromosomal stability and homology-directed DNA repair.,http://www.ncbi.nlm.nih.gov/pubmed/17848578
6433,24850843,FGFR1/3 tyrosine kinase fusions define a unique molecular subtype of non-small cell lung cancer.,http://www.ncbi.nlm.nih.gov/pubmed/24850843
6434,27179038,High-Level Clonal FGFR Amplification and Response to FGFR Inhibition in a Translational Clinical Trial.,http://www.ncbi.nlm.nih.gov/pubmed/27179038
6435,23403628,"First-in-human phase I trial of two schedules of OSI-930, a novel multikinase inhibitor, incorporating translational proof-of-mechanism studies.",http://www.ncbi.nlm.nih.gov/pubmed/23403628
6436,27251290,Overcoming EGFR(T790M) and EGFR(C797S) resistance with mutant-selective allosteric inhibitors.,http://www.ncbi.nlm.nih.gov/pubmed/27251290
6437,27325864,Regorafenib for the Treatment of Advanced Gastric Cancer (INTEGRATE): A Multinational Placebo-Controlled Phase II Trial.,http://www.ncbi.nlm.nih.gov/pubmed/27325864
6438,27232884,Multi-Center Randomized Phase II Study Comparing Cediranib plus Gefitinib with Cediranib plus Placebo in Subjects with Recurrent/Progressive Glioblastoma.,http://www.ncbi.nlm.nih.gov/pubmed/27232884
6439,25370473,Preexisting MEK1P124 mutations diminish response to BRAF inhibitors in metastatic melanoma patients.,http://www.ncbi.nlm.nih.gov/pubmed/25370473
6440,27197184,"M-COPA, a Golgi Disruptor, Inhibits Cell Surface Expression of MET Protein and Exhibits Antitumor Activity against MET-Addicted Gastric Cancers.",http://www.ncbi.nlm.nih.gov/pubmed/27197184
6441,27466265,Local Tumor Treatment in Combination with Systemic Ipilimumab Immunotherapy Prolongs Overall Survival in Patients with Advanced Malignant Melanoma.,http://www.ncbi.nlm.nih.gov/pubmed/27466265
6442,27196768,EGFR-Mediated Reactivation of MAPK Signaling Induces Acquired Resistance to GSK2118436 in BRAF V600E-Mutant NSCLC Cell Lines.,http://www.ncbi.nlm.nih.gov/pubmed/27196768
6443,26095784,"Ramucirumab versus placebo as second-line treatment in patients with advanced hepatocellular carcinoma following first-line therapy with sorafenib (REACH): a randomised, double-blind, multicentre, phase 3 trial.",http://www.ncbi.nlm.nih.gov/pubmed/26095784
6444,26087190,MYC amplifications in myeloma cell lines: correlation with MYC-inhibitor efficacy.,http://www.ncbi.nlm.nih.gov/pubmed/26087190
6445,27312529,Molecular Landscape of Acquired Resistance to Targeted Therapy Combinations in BRAF-Mutant Colorectal Cancer.,http://www.ncbi.nlm.nih.gov/pubmed/27312529
6446,24859015,Targeting of the MYCN protein with small molecule c-MYC inhibitors.,http://www.ncbi.nlm.nih.gov/pubmed/24859015
6447,25253726,Tumor cell-specific inhibition of MYC function using small molecule inhibitors of the HUWE1 ubiquitin ligase.,http://www.ncbi.nlm.nih.gov/pubmed/25253726
6448,27256376,"SYD985, a Novel Duocarmycin-Based HER2-Targeting Antibody-Drug Conjugate, Shows Antitumor Activity in Uterine Serous Carcinoma with HER2/Neu Expression.",http://www.ncbi.nlm.nih.gov/pubmed/27256376
6449,23548269,ATR inhibition broadly sensitizes ovarian cancer cells to chemotherapy independent of BRCA status.,http://www.ncbi.nlm.nih.gov/pubmed/23548269
6450,17237275,Cell cycle phenotype-based optimization of G2-abrogating peptides yields CBP501 with a unique mechanism of action at the G2 checkpoint.,http://www.ncbi.nlm.nih.gov/pubmed/17237275
6451,23598172,Axitinib versus sorafenib as second-line treatment for advanced renal cell carcinoma: overall survival analysis and updated results from a randomised phase 3 trial.,http://www.ncbi.nlm.nih.gov/pubmed/23598172
6452,27236772,Overall Survival Analysis From a Randomized Phase II Study of Axitinib With or Without Dose Titration in First-Line Metastatic Renal Cell Carcinoma.,http://www.ncbi.nlm.nih.gov/pubmed/27236772
6453,26927662,A Phase III Clinical Trial of the Epidermal Growth Factor Vaccine CIMAvax-EGF as Switch Maintenance Therapy in Advanced Non-Small Cell Lung Cancer Patients.,http://www.ncbi.nlm.nih.gov/pubmed/26927662
6454,26743856,"Monotherapy Administration of Sorafenib in Patients With Non-Small Cell Lung Cancer (MISSION) Trial: A Phase III, Multicenter, Placebo-Controlled Trial of Sorafenib in Patients with Relapsed or Refractory Predominantly Nonsquamous Non-Small-Cell Lung Cancer after 2 or 3 Previous Treatment Regimens.",http://www.ncbi.nlm.nih.gov/pubmed/26743856
6455,,Preliminary results from KEYNOTE-055: Pembrolizumab after platinum and cetuximab failure in head and neck squamous cell carcinoma (HNSCC).,http://meetinglibrary.asco.org/content/166094-176
6456,27026676,FDA Approval Summary: Pembrolizumab for the Treatment of Patients With Metastatic Non-Small Cell Lung Cancer Whose Tumors Express Programmed Death-Ligand 1.,http://www.ncbi.nlm.nih.gov/pubmed/27026676
6457,27421652,Everolimus downregulates estrogen receptor and induces autophagy in aromatase inhibitor-resistant breast cancer cells.,http://www.ncbi.nlm.nih.gov/pubmed/27421652
6458,21705440,Identification of the MEK1(F129L) activating mutation as a potential mechanism of acquired resistance to MEK inhibition in human cancers carrying the B-RafV600E mutation.,http://www.ncbi.nlm.nih.gov/pubmed/21705440
6459,19244124,Characterization of a novel mitogen-activated protein kinase kinase 1/2 inhibitor with a unique mechanism of action for cancer therapy.,http://www.ncbi.nlm.nih.gov/pubmed/19244124
6460,7838524,Efficient cell transformation by the Tpr-Met oncoprotein is dependent upon tyrosine 489 in the carboxy-terminus.,http://www.ncbi.nlm.nih.gov/pubmed/7838524
6461,26858309,A Multi-Institution Phase I Trial of Ruxolitinib in Patients with Chronic Myelomonocytic Leukemia (CMML).,http://www.ncbi.nlm.nih.gov/pubmed/26858309
6462,27382098,CALGB 80403 (Alliance)/E1206: A Randomized Phase II Study of Three Chemotherapy Regimens Plus Cetuximab in Metastatic Esophageal and Gastroesophageal Junction Cancers.,http://www.ncbi.nlm.nih.gov/pubmed/27382098
6463,27412268,"Weekly paclitaxel, capecitabine, and bevacizumab with maintenance capecitabine and bevacizumab as first-line therapy for triple-negative, metastatic, or locally advanced breast cancer: Results from the GINECO A-TaXel phase 2 study.",http://www.ncbi.nlm.nih.gov/pubmed/27412268
6464,27480147,The BATTLE-2 Study: A Biomarker-Integrated Targeted Therapy Study in Previously Treated Patients With Advanced Non-Small-Cell Lung Cancer.,http://www.ncbi.nlm.nih.gov/pubmed/27480147
6465,21505078,Functional significance of mutations in the Snf2 domain of ATRX.,http://www.ncbi.nlm.nih.gov/pubmed/21505078
6466,26920887,"Relationship between Tumor Biomarkers and Efficacy in EMILIA, a Phase III Study of Trastuzumab Emtansine in HER2-Positive Metastatic Breast Cancer.",http://www.ncbi.nlm.nih.gov/pubmed/26920887
6467,25398829,Inhibition of PI3Kβ signaling with AZD8186 inhibits growth of PTEN-deficient breast and prostate tumors alone and in combination with docetaxel.,http://www.ncbi.nlm.nih.gov/pubmed/25398829
6468,,"MRX34, a liposomal miR-34 mimic, in patients with advanced solid tumors: Final dose-escalation results from a first-in-human phase I trial of microRNA therapy.",http://meetinglibrary.asco.org/content/166294-176
6469,,A first in human phase I study of receptor tyrosine kinase (RTK) inhibitor MGCD516 in patients with advanced solid tumors.,http://meetinglibrary.asco.org/content/165199-176
6470,27231576,"A long-term surviving patient with recurrent low-grade serous ovarian carcinoma treated with the MEK1/2 inhibitor, selumetinib.",http://www.ncbi.nlm.nih.gov/pubmed/27231576
6471,,"A phase 1 study of the PI3K/mTOR inhibitor PQR309 evaluating safety, pharmacokinetics (PK) and pharmacodynamics (PD) in patients (pts) with advanced solid tumors.",http://meetinglibrary.asco.org/content/170190-176
6472,,"First-in-human, phase I, dose-escalation study of selective PI3K? isoform inhibitor MLN1117 in patients (pts) with advanced solid malignancies",http://meeting.ascopubs.org/cgi/content/abstract/33/15_suppl/2501
6473,25232318,"Durable Response to Crizotinib in a MET-Amplified, KRAS-Mutated Carcinoma of Unknown Primary.",http://www.ncbi.nlm.nih.gov/pubmed/25232318
6474,27245685,Development and clinical application of an integrative genomic approach to personalized cancer therapy.,http://www.ncbi.nlm.nih.gov/pubmed/27245685
6475,,"Phase I, first-in-human trial of an oral VEGFR tyrosine kinase inhibitor (TKI) x-82 in patients (pts) with advanced solid tumors.",http://meetinglibrary.asco.org/content/98269-114
6476,,First-in-human phase I study of a selective VEGFR/FGFR dual inhibitor sulfatinib in patients with advanced solid tumors.,http://meetinglibrary.asco.org/content/97464-114
6477,,"A phase 1 dose escalation study of RXDX-105, an oral RET and BRAF inhibitor, in patients with advanced solid tumors.",http://meetinglibrary.asco.org/content/165045-176
6478,25363205,Dual antiangiogenic inhibition: a phase I dose escalation and expansion trial targeting VEGF-A and VEGFR in patients with advanced solid tumors.,http://www.ncbi.nlm.nih.gov/pubmed/25363205
6479,21445056,Gain of function of mutant p53 by coaggregation with multiple tumor suppressors.,http://www.ncbi.nlm.nih.gov/pubmed/21445056
6480,,"Abstract P3-14-10: Phase Ia/Ib study of taselisib (GDC-0032), a potent and selective phosphoinositide 3-kinase inhibitor, in Japanese patients with advanced solid tumors or hormone receptor-positive locally advanced or metastatic breast cancer (JO29196 st",http://cancerres.aacrjournals.org/content/76/4_Supplement/P3-14-10
6481,27149458,Recurrent Olfactory Neuroblastoma Treated With Cetuximab and Sunitinib: A Case Report.,http://www.ncbi.nlm.nih.gov/pubmed/27149458
6482,15905307,"Clinical evaluation of ZD6474, an orally active inhibitor of VEGF and EGF receptor signaling, in patients with solid, malignant tumors.",http://www.ncbi.nlm.nih.gov/pubmed/15905307
6483,18205209,The t(1;9)(p34;q34) and t(8;12)(p11;q15) fuse pre-mRNA processing proteins SFPQ (PSF) and CPSF6 to ABL and FGFR1.,http://www.ncbi.nlm.nih.gov/pubmed/18205209
6484,24752867,Dual inhibition of the vascular endothelial growth factor pathway: a phase 1 trial evaluating bevacizumab and AZD2171 (cediranib) in patients with advanced solid tumors.,http://www.ncbi.nlm.nih.gov/pubmed/24752867
6485,,A novel MET-EGFR bispecific antibody LY3164530 shows advantage over combining MET and EGFR antibodies in tumor inhibition and overcome resistance,http://cancerres.aacrjournals.org/content/76/14_Supplement/873
6486,27411843,Discovery and in Vivo Evaluation of the Potent and Selective PI3Kδ Inhibitors 2-((1S)-1-((6-Amino-5-cyano-4-pyrimidinyl)amino)ethyl)-6-fluoro-N-methyl-3-(2-pyridinyl)-4-quinolinecarboxamide (AM-0687) and 2-((1S)-1-((6-Amino-5-cyano-4-pyrimidinyl)amino)ethyl)-5-fluoro-N-methyl-3-(2-pyridinyl)-4-quinolinecarboxamide (AM-1430).,http://www.ncbi.nlm.nih.gov/pubmed/27411843
6487,27302160,Inhibiting DX2-p14/ARF Interaction Exerts Antitumor Effects in Lung Cancer and Delays Tumor Progression.,http://www.ncbi.nlm.nih.gov/pubmed/27302160
6488,,High Frequency of C-Terminal Frame-Shift Mutations of RUNX1 Gene in De Novo AML with Partial Tandem Duplication of MLL,http://www.bloodjournal.org/content/114/22/3468?sso-checked=true
6489,26920889,A Phase I Study of Quizartinib Combined with Chemotherapy in Relapsed Childhood Leukemia: A Therapeutic Advances in Childhood Leukemia & Lymphoma (TACL) Study.,http://www.ncbi.nlm.nih.gov/pubmed/26920889
6491,27196754,Concomitant Inhibition of PI3Kβ and BRAF or MEK in PTEN-Deficient/BRAF-Mutant Melanoma Treatment: Preclinical Assessment of SAR260301 Oral PI3Kβ-Selective Inhibitor.,http://www.ncbi.nlm.nih.gov/pubmed/27196754
6492,27287719,Pexmetinib: A Novel Dual Inhibitor of Tie2 and p38 MAPK with Efficacy in Preclinical Models of Myelodysplastic Syndromes and Acute Myeloid Leukemia.,http://www.ncbi.nlm.nih.gov/pubmed/27287719
6493,27196767,Cetuximab Resistance in Squamous Carcinomas of the Upper Aerodigestive Tract Is Driven by Receptor Tyrosine Kinase Plasticity: Potential for mAb Mixtures.,http://www.ncbi.nlm.nih.gov/pubmed/27196767
6494,25673643,FGFR-Mediated Reactivation of MAPK Signaling Attenuates Antitumor Effects of Imatinib in Gastrointestinal Stromal Tumors.,http://www.ncbi.nlm.nih.gov/pubmed/25673643
6495,27466356,TP53 Alterations Correlate with Response to VEGF/VEGFR Inhibitors: Implications for Targeted Therapeutics.,http://www.ncbi.nlm.nih.gov/pubmed/27466356
6496,26841902,"A phase II study of cediranib, an oral VEGF inhibitor, in previously untreated patients with metastatic or recurrent malignant melanoma.",http://www.ncbi.nlm.nih.gov/pubmed/26841902
6497,27500726,Loss of cohesin complex components STAG2 or STAG3 confers resistance to BRAF inhibition in melanoma.,http://www.ncbi.nlm.nih.gov/pubmed/27500726
6498,16043829,TRIBUTE: a phase III trial of erlotinib hydrochloride (OSI-774) combined with carboplatin and paclitaxel chemotherapy in advanced non-small-cell lung cancer.,http://www.ncbi.nlm.nih.gov/pubmed/16043829
6499,27468240,Clinical efficacy of first-generation EGFR-TKIs in patients with advanced non-small-cell lung cancer harboring EGFR exon 20 mutations.,http://www.ncbi.nlm.nih.gov/pubmed/27468240
6500,27216191,LIM Kinase Inhibitor Pyr1 Reduces the Growth and Metastatic Load of Breast Cancers.,http://www.ncbi.nlm.nih.gov/pubmed/27216191
6501,27509865,HER2-targeted antibody drug conjugates for ovarian cancer therapy.,http://www.ncbi.nlm.nih.gov/pubmed/27509865
6502,27297869,Upregulation of AKT3 Confers Resistance to the AKT Inhibitor MK2206 in Breast Cancer.,http://www.ncbi.nlm.nih.gov/pubmed/27297869
6503,27216155,"A Novel EGFR Extracellular Domain Mutant, EGFRΔ768, Possesses Distinct Biological and Biochemical Properties in Neuroblastoma.",http://www.ncbi.nlm.nih.gov/pubmed/27216155
6504,26360609,Acquisition of a single EZH2 D1 domain mutation confers acquired resistance to EZH2-targeted inhibitors.,http://www.ncbi.nlm.nih.gov/pubmed/26360609
6505,27197158,Rictor/mTORC2 Drives Progression and Therapeutic Resistance of HER2-Amplified Breast Cancers.,http://www.ncbi.nlm.nih.gov/pubmed/27197158
6506,25873592,The Novel ATP-Competitive MEK/Aurora Kinase Inhibitor BI-847325 Overcomes Acquired BRAF Inhibitor Resistance through Suppression of Mcl-1 and MEK Expression.,http://www.ncbi.nlm.nih.gov/pubmed/25873592
6507,26936917,FGFR1 Is a Potential Prognostic Biomarker and Therapeutic Target in Head and Neck Squamous Cell Carcinoma.,http://www.ncbi.nlm.nih.gov/pubmed/26936917
6508,27222538,The Mitogen-Activated Protein Kinase Pathway Facilitates Resistance to the Src Inhibitor Dasatinib in Thyroid Cancer.,http://www.ncbi.nlm.nih.gov/pubmed/27222538
6509,25700705,Trifluridine Induces p53-Dependent Sustained G2 Phase Arrest with Its Massive Misincorporation into DNA and Few DNA Strand Breaks.,http://www.ncbi.nlm.nih.gov/pubmed/25700705
6510,26090615,"YM155, a survivin suppressant, triggers PARP-dependent cell death (parthanatos) and inhibits esophageal squamous-cell carcinoma xenografts in mice.",http://www.ncbi.nlm.nih.gov/pubmed/26090615
6511,25944801,Inhibition of Survivin with YM155 Induces Durable Tumor Response in Anaplastic Thyroid Cancer.,http://www.ncbi.nlm.nih.gov/pubmed/25944801
6512,24714131,Anetumab ravtansine: a novel mesothelin-targeting antibody-drug conjugate cures tumors with heterogeneous target expression favored by bystander effect.,http://www.ncbi.nlm.nih.gov/pubmed/24714131
6513,15475387,Human MutL homolog (MLH1) function in DNA mismatch repair: a prospective screen for missense mutations in the ATPase domain.,http://www.ncbi.nlm.nih.gov/pubmed/15475387
6514,16043828,Mutations in the epidermal growth factor receptor and in KRAS are predictive and prognostic indicators in patients with non-small-cell lung cancer treated with chemotherapy alone and in combination with erlotinib.,http://www.ncbi.nlm.nih.gov/pubmed/16043828
6515,18626007,Role of KRAS and EGFR as biomarkers of response to erlotinib in National Cancer Institute of Canada Clinical Trials Group Study BR.21.,http://www.ncbi.nlm.nih.gov/pubmed/18626007
6516,19276360,Antitumor efficacy of the novel RAF inhibitor GDC-0879 is predicted by BRAFV600E mutational status and sustained extracellular signal-regulated kinase/mitogen-activated protein kinase pathway suppression.,http://www.ncbi.nlm.nih.gov/pubmed/19276360
6517,19281821,PAC-1 activates procaspase-3 in vitro through relief of zinc-mediated inhibition.,http://www.ncbi.nlm.nih.gov/pubmed/19281821
6518,27297867,The Combination of Vemurafenib and Procaspase-3 Activation Is Synergistic in Mutant BRAF Melanomas.,http://www.ncbi.nlm.nih.gov/pubmed/27297867
6519,27207775,Afatinib against Esophageal or Head-and-Neck Squamous Cell Carcinoma: Significance of Activating Oncogenic HER4 Mutations in HNSCC.,http://www.ncbi.nlm.nih.gov/pubmed/27207775
6520,16219544,Congenital amegakaryocytic thrombocytopenia in three siblings: molecular analysis of atypical clinical presentation.,http://www.ncbi.nlm.nih.gov/pubmed/16219544
6521,26466569,RAF inhibitors that evade paradoxical MAPK pathway activation.,http://www.ncbi.nlm.nih.gov/pubmed/26466569
6522,27523909,An Integrated Model of RAF Inhibitor Action Predicts Inhibitor Activity against Oncogenic BRAF Signaling.,http://www.ncbi.nlm.nih.gov/pubmed/27523909
6523,25790901,Successful treatment of acute promyelocytic leukemia with a t(X;17)(p11.4;q21) and BCOR-RARA fusion gene.,http://www.ncbi.nlm.nih.gov/pubmed/25790901
6524,27196765,PAXIP1 Potentiates the Combination of WEE1 Inhibitor AZD1775 and Platinum Agents in Lung Cancer.,http://www.ncbi.nlm.nih.gov/pubmed/27196765
6525,26920892,Low-Dose Histone Deacetylase Inhibitor Treatment Leads to Tumor Growth Arrest and Multi-Lineage Differentiation of Malignant Rhabdoid Tumors.,http://www.ncbi.nlm.nih.gov/pubmed/26920892
6526,26703895,Ph-like ALL-related novel fusion kinase ATF7IP-PDGFRB exhibits high sensitivity to tyrosine kinase inhibitors in murine cells.,http://www.ncbi.nlm.nih.gov/pubmed/26703895
6527,12200364,X-linked thrombocytopenia with thalassemia from a mutation in the amino finger of GATA-1 affecting DNA binding rather than FOG-1 interaction.,http://www.ncbi.nlm.nih.gov/pubmed/12200364
6528,26013318,Inhibition of PI3K Pathway Reduces Invasiveness and Epithelial-to-Mesenchymal Transition in Squamous Lung Cancer Cell Lines Harboring PIK3CA Gene Alterations.,http://www.ncbi.nlm.nih.gov/pubmed/26013318
6529,,A phase II study of everolimus for advanced melanoma patients with mTOR mutations.,http://meetinglibrary.asco.org/content/149762-156
6530,24520093,Combination immunotherapy after ASCT for multiple myeloma using MAGE-A3/Poly-ICLC immunizations followed by adoptive transfer of vaccine-primed and costimulated autologous T cells.,http://www.ncbi.nlm.nih.gov/pubmed/24520093
6531,27406088,"A phase I trial of the aurora kinase inhibitor, ENMD-2076, in patients with relapsed or refractory acute myeloid leukemia or chronic myelomonocytic leukemia.",http://www.ncbi.nlm.nih.gov/pubmed/27406088
6532,26817645,Preclinical Study of a Combination of Erlotinib and Bevacizumab in Early Stages of Unselected Non-Small Cell Lung Cancer Patient-Derived Xenografts.,http://www.ncbi.nlm.nih.gov/pubmed/26817645
6533,27540718,Anti-myeloma activity of MELK inhibitor OTS167: effects on drug-resistant myeloma cells and putative myeloma stem cell replenishment of malignant plasma cells.,http://www.ncbi.nlm.nih.gov/pubmed/27540718
6534,27556948,Small molecule stabilization of the KSR inactive state antagonizes oncogenic Ras signalling.,http://www.ncbi.nlm.nih.gov/pubmed/27556948
6535,27494825,Crizotinib treatment for refractory pediatric acute myeloid leukemia with RAN-binding protein 2-anaplastic lymphoma kinase fusion gene.,http://www.ncbi.nlm.nih.gov/pubmed/27494825
6536,27520294,Efficacy and Biological Correlates of Response in a Phase II Study of Venetoclax Monotherapy in Patients with Acute Myelogenous Leukemia.,http://www.ncbi.nlm.nih.gov/pubmed/27520294
6537,27535980,Targeting Fibroblast Growth Factor Receptor 1 for Treatment of Soft-Tissue Sarcoma.,http://www.ncbi.nlm.nih.gov/pubmed/27535980
6538,27563888,"Oridonin, a Promising ent-Kaurane Diterpenoid Lead Compound.",http://www.ncbi.nlm.nih.gov/pubmed/27563888
6539,22965953,Targeting p53 in vivo: a first-in-human study with p53-targeting compound APR-246 in refractory hematologic malignancies and prostate cancer.,http://www.ncbi.nlm.nih.gov/pubmed/22965953
6540,25939761,"Preclinical Test of Dacomitinib, an Irreversible EGFR Inhibitor, Confirms Its Effectiveness for Glioblastoma.",http://www.ncbi.nlm.nih.gov/pubmed/25939761
6541,27532364,Prevalence of ESR1 Mutations in Cell-Free DNA and Outcomes in Metastatic Breast Cancer: A Secondary Analysis of the BOLERO-2 Clinical Trial.,http://www.ncbi.nlm.nih.gov/pubmed/27532364
6542,27235164,Combination of Eribulin and Aurora A Inhibitor MLN8237 Prevents Metastatic Colonization and Induces Cytotoxic Autophagy in Breast Cancer.,http://www.ncbi.nlm.nih.gov/pubmed/27235164
6543,27364904,Synthetic Lethal Targeting of ARID1A-Mutant Ovarian Clear Cell Tumors with Dasatinib.,http://www.ncbi.nlm.nih.gov/pubmed/27364904
6544,27256375,In Silico Analysis Guides Selection of BET Inhibitors for Triple-Negative Breast Cancer Treatment.,http://www.ncbi.nlm.nih.gov/pubmed/27256375
6545,23056499,AZD1480 blocks growth and tumorigenesis of RET- activated thyroid cancer cell lines.,http://www.ncbi.nlm.nih.gov/pubmed/23056499
6546,25299775,The bromodomain and extra-terminal inhibitor CPI203 enhances the antiproliferative effects of rapamycin on human neuroendocrine tumors.,http://www.ncbi.nlm.nih.gov/pubmed/25299775
6547,26130651,"RAS/MAPK Activation Drives Resistance to Smo Inhibition, Metastasis, and Tumor Evolution in Shh Pathway-Dependent Tumors.",http://www.ncbi.nlm.nih.gov/pubmed/26130651
6548,11056542,Mutations in the Plk gene lead to instability of Plk protein in human tumour cell lines.,http://www.ncbi.nlm.nih.gov/pubmed/11056542
6549,27169995,Regulation of GLI Underlies a Role for BET Bromodomains in Pancreatic Cancer Growth and the Tumor Microenvironment.,http://www.ncbi.nlm.nih.gov/pubmed/27169995
6550,23879168,Alterations of axis inhibition protein 1 (AXIN1) in hepatitis B virus-related hepatocellular carcinoma and overexpression of AXIN1 induces apoptosis in hepatocellular cancer cells.,http://www.ncbi.nlm.nih.gov/pubmed/23879168
6551,24265152,A novel AKT1 mutant amplifies an adaptive melanoma response to BRAF inhibition.,http://www.ncbi.nlm.nih.gov/pubmed/24265152
6552,27528027,Stromal remodeling by the BET bromodomain inhibitor JQ1 suppresses the progression of human pancreatic cancer.,http://www.ncbi.nlm.nih.gov/pubmed/27528027
6553,27432794,The WASF3-NCKAP1-CYFIP1 Complex Is Essential for Breast Cancer Metastasis.,http://www.ncbi.nlm.nih.gov/pubmed/27432794
6554,23667612,The natural human IgM antibody PAT-SM6 induces apoptosis in primary human multiple myeloma cells by targeting heat shock protein GRP78.,http://www.ncbi.nlm.nih.gov/pubmed/23667612
6555,27029491,A GRP78-Directed Monoclonal Antibody Recaptures Response in Refractory Multiple Myeloma with Extramedullary Involvement.,http://www.ncbi.nlm.nih.gov/pubmed/27029491
6556,,"GSK525762, a selective bromodomain (BRD) and extra terminal protein (BET) inhibitor: results from part 1 of a phase I/II open-label single-agent study in patients with NUT midline carcinoma (NMC) and other cancers",http://cancerres.aacrjournals.org/content/76/14_Supplement/CT014.short
6557,14536078,Multisite phosphorylation by Cdk2 and GSK3 controls cyclin E degradation.,http://www.ncbi.nlm.nih.gov/pubmed/14536078
6558,17434132,Structure of a Fbw7-Skp1-cyclin E complex: multisite-phosphorylated substrate recognition by SCF ubiquitin ligases.,http://www.ncbi.nlm.nih.gov/pubmed/17434132
6559,27458141,A Phase I Trial to Evaluate Antibody-Dependent Cellular Cytotoxicity of Cetuximab and Lenalidomide in Advanced Colorectal and Head and Neck Cancer.,http://www.ncbi.nlm.nih.gov/pubmed/27458141
6560,27325282,MET-Driven Resistance to Dual EGFR and BRAF Blockade May Be Overcome by Switching from EGFR to MET Inhibition in BRAF-Mutated Colorectal Cancer.,http://www.ncbi.nlm.nih.gov/pubmed/27325282
6561,27325685,A Phase II Biomarker-Embedded Study of Lapatinib plus Capecitabine as First-line Therapy in Patients with Advanced or Metastatic Gastric Cancer.,http://www.ncbi.nlm.nih.gov/pubmed/27325685
6562,27012811,Polyamine Antagonist Therapies Inhibit Neuroblastoma Initiation and Progression.,http://www.ncbi.nlm.nih.gov/pubmed/27012811
6563,27422810,Targeting the HER Family with Pan-HER Effectively Overcomes Resistance to Cetuximab.,http://www.ncbi.nlm.nih.gov/pubmed/27422810
6564,27406985,"MOR209/ES414, a Novel Bispecific Antibody Targeting PSMA for the Treatment of Metastatic Castration-Resistant Prostate Cancer.",http://www.ncbi.nlm.nih.gov/pubmed/27406985
6565,20725099,Development of a live and highly attenuated Listeria monocytogenes-based vaccine for the treatment of Her2/neu-overexpressing cancers in human.,http://www.ncbi.nlm.nih.gov/pubmed/20725099
6566,26784138,"Midostaurin, bortezomib and MEC in relapsed/refractory acute myeloid leukemia.",http://www.ncbi.nlm.nih.gov/pubmed/26784138
6567,27406984,BET Inhibition Induces Apoptosis in Aggressive B-Cell Lymphoma via Epigenetic Regulation of BCL-2 Family Members.,http://www.ncbi.nlm.nih.gov/pubmed/27406984
6568,27432917,Multicenter Phase II Study of Whole-Body and Intracranial Activity With Ceritinib in Patients With ALK-Rearranged Non-Small-Cell Lung Cancer Previously Treated With Chemotherapy and Crizotinib: Results From ASCEND-2.,http://www.ncbi.nlm.nih.gov/pubmed/27432917
6569,27012814,Chaperonin Containing TCP-1 Protein Level in Breast Cancer Cells Predicts Therapeutic Application of a Cytotoxic Peptide.,http://www.ncbi.nlm.nih.gov/pubmed/27012814
6570,27390344,Dual and Specific Inhibition of NAMPT and PAK4 By KPT-9274 Decreases Kidney Cancer Growth.,http://www.ncbi.nlm.nih.gov/pubmed/27390344
6571,27325686,ST-11: A New Brain-Penetrant Microtubule-Destabilizing Agent with Therapeutic Potential for Glioblastoma Multiforme.,http://www.ncbi.nlm.nih.gov/pubmed/27325686
6572,19641190,"Deregulated expression of cytokine receptor gene, CRLF2, is involved in lymphoid transformation in B-cell precursor acute lymphoblastic leukemia.",http://www.ncbi.nlm.nih.gov/pubmed/19641190
6573,21289267,The Akt-specific inhibitor MK2206 selectively inhibits thyroid cancer cells harboring mutations that can activate the PI3K/Akt pathway.,http://www.ncbi.nlm.nih.gov/pubmed/21289267
6574,,In vivo monitoring of JAK/STAT and PI3K/mTOR signal transduction inhibition in pediatric CRLF2-rearranged acute lymphoblastic leukemia (ALL),http://meetinglibrary.asco.org/content/98540-114
6575,23541343,"Complete haplotype sequence of the human immunoglobulin heavy-chain variable, diversity, and joining genes and characterization of allelic and copy-number variation.",http://www.ncbi.nlm.nih.gov/pubmed/23541343
6576,10361104,"Ig heavy chain gene rearrangements in T-cell acute lymphoblastic leukemia exhibit predominant DH6-19 and DH7-27 gene usage, can result in complete V-D-J rearrangements, and are rare in T-cell receptor alpha beta lineage.",http://www.ncbi.nlm.nih.gov/pubmed/10361104
6577,18000389,Molecular cytogenetics of IGH rearrangements in non-Hodgkin B-cell lymphoma.,http://www.ncbi.nlm.nih.gov/pubmed/18000389
6578,25573956,Inhibition of p70S6K1 Activation by Pdcd4 Overcomes the Resistance to an IGF-1R/IR Inhibitor in Colon Carcinoma Cells.,http://www.ncbi.nlm.nih.gov/pubmed/25573956
6579,26771549,The p70S6K Specific Inhibitor PF-4708671 Impedes Non-Small Cell Lung Cancer Growth.,http://www.ncbi.nlm.nih.gov/pubmed/26771549
6580,27406983,"A Histone Deacetylase Inhibitor, OBP-801, and Celecoxib Synergistically Inhibit the Cell Growth with Apoptosis via a DR5-Dependent Pathway in Bladder Cancer Cells.",http://www.ncbi.nlm.nih.gov/pubmed/27406983
6581,27403962,"Effect of BET Missense Mutations on Bromodomain Function, Inhibitor Binding and Stability.",http://www.ncbi.nlm.nih.gov/pubmed/27403962
6582,27256378,Bruton's Tyrosine Kinase Inhibitors Prevent Therapeutic Escape in Breast Cancer Cells.,http://www.ncbi.nlm.nih.gov/pubmed/27256378
6583,27103402,Binding of Released Bim to Mcl-1 is a Mechanism of Intrinsic Resistance to ABT-199 which can be Overcome by Combination with Daunorubicin or Cytarabine in AML Cells.,http://www.ncbi.nlm.nih.gov/pubmed/27103402
6584,25952648,Paracrine Effect of NRG1 and HGF Drives Resistance to MEK Inhibitors in Metastatic Uveal Melanoma.,http://www.ncbi.nlm.nih.gov/pubmed/25952648
6585,25977343,MEK Inhibitor PD-0325901 Overcomes Resistance to PI3K/mTOR Inhibitor PF-5212384 and Potentiates Antitumor Effects in Human Head and Neck Squamous Cell Carcinoma.,http://www.ncbi.nlm.nih.gov/pubmed/25977343
6586,27595393,On-target efficacy of a HIF-2α antagonist in preclinical kidney cancer models.,http://www.ncbi.nlm.nih.gov/pubmed/27595393
6587,25589493,The Preclinical Profile of the Duocarmycin-Based HER2-Targeting ADC SYD985 Predicts for Clinical Benefit in Low HER2-Expressing Breast Cancers.,http://www.ncbi.nlm.nih.gov/pubmed/25589493
6588,26162687,Small Molecule Inhibition of MDM2-p53 Interaction Augments Radiation Response in Human Tumors.,http://www.ncbi.nlm.nih.gov/pubmed/26162687
6589,26141945,Heat Shock Protein 90 Is a Potential Therapeutic Target in Cholangiocarcinoma.,http://www.ncbi.nlm.nih.gov/pubmed/26141945
6590,22929806,CCT244747 is a novel potent and selective CHK1 inhibitor with oral efficacy alone and in combination with genotoxic anticancer drugs.,http://www.ncbi.nlm.nih.gov/pubmed/22929806
6591,27422809,CHK1 Inhibition Radiosensitizes Head and Neck Cancers to Paclitaxel-Based Chemoradiotherapy.,http://www.ncbi.nlm.nih.gov/pubmed/27422809
6592,12437373,Structural analysis of the inhibition of Cdk4 and Cdk6 by p16(INK4a) through molecular dynamics simulations.,http://www.ncbi.nlm.nih.gov/pubmed/12437373
6593,26141946,"Antitumor Effects of MEHD7945A, a Dual-Specific Antibody against EGFR and HER3, in Combination with Radiation in Lung and Head and Neck Cancers.",http://www.ncbi.nlm.nih.gov/pubmed/26141946
6594,22223529,"Results of a phase 1 study of AME-133v (LY2469298), an Fc-engineered humanized monoclonal anti-CD20 antibody, in FcγRIIIa-genotyped patients with previously treated follicular lymphoma.",http://www.ncbi.nlm.nih.gov/pubmed/22223529
6595,23547558,"Phase I study of OM-174, a lipid A analogue, with assessment of immunological response, in patients with refractory solid tumors.",http://www.ncbi.nlm.nih.gov/pubmed/23547558
6596,25146490,"Otlertuzumab (TRU-016), an anti-CD37 monospecific ADAPTIR(™) therapeutic protein, for relapsed or refractory NHL patients.",http://www.ncbi.nlm.nih.gov/pubmed/25146490
6597,24381226,"A phase 1 study evaluating the safety and tolerability of otlertuzumab, an anti-CD37 mono-specific ADAPTIR therapeutic protein in chronic lymphocytic leukemia.",http://www.ncbi.nlm.nih.gov/pubmed/24381226
6598,23449360,"A first-in-class, first-in-human, phase I trial of p28, a non-HDM2-mediated peptide inhibitor of p53 ubiquitination in patients with advanced solid tumours.",http://www.ncbi.nlm.nih.gov/pubmed/23449360
6599,22711542,"A phase IB trial of 24-hour intravenous PX-12, a thioredoxin-1 inhibitor, in patients with advanced gastrointestinal cancers.",http://www.ncbi.nlm.nih.gov/pubmed/22711542
6600,25483731,"Thioredoxin-1 inhibitor, 1-methylpropyl 2-imidazolyl disulfide, inhibits the growth, migration and invasion of colorectal cancer cell lines.",http://www.ncbi.nlm.nih.gov/pubmed/25483731
6601,23090290,Clinical safety and pharmacological profile of the HLA-DR antibody 1D09C3 in patients with B cell chronic lymphocytic leukemia and lymphoma: results from a phase I study.,http://www.ncbi.nlm.nih.gov/pubmed/23090290
6602,27502708,Phase II study of MLN8237 (Alisertib) in advanced/metastatic sarcoma.,http://www.ncbi.nlm.nih.gov/pubmed/27502708
6603,22020316,"Phase I rapid dose-escalation study of AGS-1C4D4, a human anti-PSCA (prostate stem cell antigen) monoclonal antibody, in patients with castration-resistant prostate cancer: a PCCTC trial.",http://www.ncbi.nlm.nih.gov/pubmed/22020316
6604,22553195,A phase I/IIA study of AGS-PSCA for castration-resistant prostate cancer.,http://www.ncbi.nlm.nih.gov/pubmed/22553195
6605,27265742,"Docetaxel Combined With Bavituximab in Previously Treated, Advanced Nonsquamous Non-Small-Cell Lung Cancer.",http://www.ncbi.nlm.nih.gov/pubmed/27265742
6606,21447719,"A phase 1 study of AS1409, a novel antibody-cytokine fusion protein, in patients with malignant melanoma or renal cell carcinoma.",http://www.ncbi.nlm.nih.gov/pubmed/21447719
6607,24132920,"A dose-escalation study of SAR3419, an anti-CD19 antibody maytansinoid conjugate, administered by intravenous infusion once weekly in patients with relapsed/refractory B-cell non-Hodgkin lymphoma.",http://www.ncbi.nlm.nih.gov/pubmed/24132920
6608,24023523,Targeting CD19 in B-cell lymphoma: emerging role of SAR3419.,http://www.ncbi.nlm.nih.gov/pubmed/24023523
6609,22918078,A phase I dose-escalation study of the immunocytokine EMD 521873 (Selectikine) in patients with advanced solid tumours.,http://www.ncbi.nlm.nih.gov/pubmed/22918078
6610,26908627,The Bromodomain BET Inhibitor JQ1 Suppresses Tumor Angiogenesis in Models of Childhood Sarcoma.,http://www.ncbi.nlm.nih.gov/pubmed/26908627
6611,20605934,Phase I trial of SU14813 in patients with advanced solid malignancies.,http://www.ncbi.nlm.nih.gov/pubmed/20605934
6612,16891463,SU14813: a novel multiple receptor tyrosine kinase inhibitor with potent antiangiogenic and antitumor activity.,http://www.ncbi.nlm.nih.gov/pubmed/16891463
6613,22333707,"A phase I, dose-escalation study of TB-403, a monoclonal antibody directed against PlGF, in patients with advanced solid tumours.",http://www.ncbi.nlm.nih.gov/pubmed/22333707
6614,26631615,Targeting MYCN-Driven Transcription By BET-Bromodomain Inhibition.,http://www.ncbi.nlm.nih.gov/pubmed/26631615
6615,23647373,A phase I first-in-human study with tefinostat - a monocyte/macrophage targeted histone deacetylase inhibitor - in patients with advanced haematological malignancies.,http://www.ncbi.nlm.nih.gov/pubmed/23647373
6616,11196150,Characterization of the antitumor effects of the selective farnesyl protein transferase inhibitor R115777 in vivo and in vitro.,http://www.ncbi.nlm.nih.gov/pubmed/11196150
6617,12039935,Phase I clinical and pharmacologic study of chronic oral administration of the farnesyl protein transferase inhibitor R115777 in advanced cancer.,http://www.ncbi.nlm.nih.gov/pubmed/12039935
6618,17620430,"ZD4054, a specific antagonist of the endothelin A receptor, inhibits tumor growth and enhances paclitaxel activity in human ovarian carcinoma in vitro and in vivo.",http://www.ncbi.nlm.nih.gov/pubmed/17620430
6619,18616419,ZD4054: a specific endothelin A receptor antagonist with promising activity in metastatic castration-resistant prostate cancer.,http://www.ncbi.nlm.nih.gov/pubmed/18616419
6620,23381694,"Phase III, randomized, placebo-controlled study of once-daily oral zibotentan (ZD4054) in patients with non-metastatic castration-resistant prostate cancer.",http://www.ncbi.nlm.nih.gov/pubmed/23381694
6621,27605552,Combined targeting of BCL-2 and BCR-ABL tyrosine kinase eradicates chronic myeloid leukemia stem cells.,http://www.ncbi.nlm.nih.gov/pubmed/27605552
6622,25193511,"MEDI-573, alone or in combination with mammalian target of rapamycin inhibitors, targets the insulin-like growth factor pathway in sarcomas.",http://www.ncbi.nlm.nih.gov/pubmed/25193511
6623,25589492,Synergistic Blockade of EGFR and HER2 by New-Generation EGFR Tyrosine Kinase Inhibitor Enhances Radiation Effect in Bladder Cancer Cells.,http://www.ncbi.nlm.nih.gov/pubmed/25589492
6624,27196766,Sensitizing Triple-Negative Breast Cancer to PI3K Inhibition by Cotargeting IGF1R.,http://www.ncbi.nlm.nih.gov/pubmed/27196766
6625,27401612,Novel Bispecific Domain Antibody to LRP6 Inhibits Wnt and R-spondin Ligand-Induced Wnt Signaling and Tumor Growth.,http://www.ncbi.nlm.nih.gov/pubmed/27401612
6626,26208525,Antitumor Activity and Acquired Resistance Mechanism of Dovitinib (TKI258) in RET-Rearranged Lung Adenocarcinoma.,http://www.ncbi.nlm.nih.gov/pubmed/26208525
6627,25589496,Mechanism of Oncogenic Signal Activation by the Novel Fusion Kinase FGFR3-BAIAP2L1.,http://www.ncbi.nlm.nih.gov/pubmed/25589496
6628,26141948,LY2606368 Causes Replication Catastrophe and Antitumor Effects through CHK1-Dependent Mechanisms.,http://www.ncbi.nlm.nih.gov/pubmed/26141948
6629,26815195,Identification of a Benzoisoxazoloazepine Inhibitor (CPI-0610) of the Bromodomain and Extra-Terminal (BET) Family as a Candidate for Human Clinical Trials.,http://www.ncbi.nlm.nih.gov/pubmed/26815195
6630,,BET Inhibitor CPI-0610 Is Well Tolerated and Induces Responses in Diffuse Large B-Cell Lymphoma and Follicular Lymphoma: Preliminary Analysis of an Ongoing Phase 1 Study,http://www.bloodjournal.org/content/126/23/1491
6631,26733612,"Strategically Timing Inhibition of Phosphatidylinositol 3-Kinase to Maximize Therapeutic Index in Estrogen Receptor Alpha-Positive, PIK3CA-Mutant Breast Cancer.",http://www.ncbi.nlm.nih.gov/pubmed/26733612
6632,23243058,Antitumor activity and pharmacodynamic biomarkers of a novel and orally available small-molecule antagonist of inhibitor of apoptosis proteins.,http://www.ncbi.nlm.nih.gov/pubmed/23243058
6633,27608596,"T-3256336, a novel and orally available small molecule IAP antagonist, induced tumor cell death via induction of systemic TNF alpha production.",http://www.ncbi.nlm.nih.gov/pubmed/27608596
6634,12215251,Characterization of common BRCA1 and BRCA2 variants.,http://www.ncbi.nlm.nih.gov/pubmed/12215251
6635,27342398,Idelalisib Impacts Cell Growth through Inhibiting Translation-Regulatory Mechanisms in Mantle Cell Lymphoma.,http://www.ncbi.nlm.nih.gov/pubmed/27342398
6636,26554404,The ALK/ROS1 Inhibitor PF-06463922 Overcomes Primary Resistance to Crizotinib in ALK-Driven Neuroblastoma.,http://www.ncbi.nlm.nih.gov/pubmed/26554404
6637,26115193,"Disrupting NOTCH Slows Diffuse Intrinsic Pontine Glioma Growth, Enhances Radiation Sensitivity, and Shows Combinatorial Efficacy With Bromodomain Inhibition.",http://www.ncbi.nlm.nih.gov/pubmed/26115193
6638,24278334,rs929387 of GLI3 is involved in tooth agenesis in Chinese Han population.,http://www.ncbi.nlm.nih.gov/pubmed/24278334
6639,25813020,HDAC Inhibition Overcomes Acute Resistance to MEK Inhibition in BRAF-Mutant Colorectal Cancer by Downregulation of c-FLIPL.,http://www.ncbi.nlm.nih.gov/pubmed/25813020
6640,,"PRN1371, an irreversible, covalent inhibitor of FGFR1, 2, 3 and 4 is highly efficacious in preclinical tumor models",http://cancerres.aacrjournals.org/content/76/14_Supplement/1249
6641,22615798,Targeting FGFR4 inhibits hepatocellular carcinoma in preclinical mouse models.,http://www.ncbi.nlm.nih.gov/pubmed/22615798
6642,25425971,"E7080 (lenvatinib), a multi-targeted tyrosine kinase inhibitor, demonstrates antitumor activities against colorectal cancer xenografts.",http://www.ncbi.nlm.nih.gov/pubmed/25425971
6643,,Prevalent aberrations of CDK4 pathway in acral melanoma and implications for targeted therapy,http://meetinglibrary.asco.org/content/167622-176
6644,,A dose-escalation phase I study of a first-in-class cancer stemness inhibitor in patients with advanced malignancies,http://meeting.ascopubs.org/cgi/content/abstract/31/15_suppl/2542
6645,,A phase 2 study of ponatinib in patients (pts) with advanced gastrointestinal stromal tumors (GIST) after failure of tyrosine kinase inhibitor (TKI) therapy: Initial report.,http://hwmaint.meeting.ascopubs.org/cgi/content/abstract/32/15_suppl/10506
6647,27638859,ATM Expression Predicts Veliparib and Irinotecan Sensitivity in Gastric Cancer by Mediating P53-Independent Regulation of Cell Cycle and Apoptosis.,http://www.ncbi.nlm.nih.gov/pubmed/27638859
6648,21300883,Nonhomologous end joining drives poly(ADP-ribose) polymerase (PARP) inhibitor lethality in homologous recombination-deficient cells.,http://www.ncbi.nlm.nih.gov/pubmed/21300883
6649,11919202,Molecular enzymology of the catalytic domains of the Dnmt3a and Dnmt3b DNA methyltransferases.,http://www.ncbi.nlm.nih.gov/pubmed/11919202
6650,12601140,Structural basis of ICF-causing mutations in the methyltransferase domain of DNMT3B.,http://www.ncbi.nlm.nih.gov/pubmed/12601140
6651,27076631,"A Phase I, First-in-Human Study of AMG 780, an Angiopoietin-1 and -2 Inhibitor, in Patients with Advanced Solid Tumors.",http://www.ncbi.nlm.nih.gov/pubmed/27076631
6652,27225694,EGFR Mutations and ALK Rearrangements Are Associated with Low Response Rates to PD-1 Pathway Blockade in Non-Small Cell Lung Cancer: A Retrospective Analysis.,http://www.ncbi.nlm.nih.gov/pubmed/27225694
6653,26183887,Estrogen receptor mutations and functional consequences for breast cancer.,http://www.ncbi.nlm.nih.gov/pubmed/26183887
6654,27372070,Recurrent and pathological gene fusions in breast cancer: current advances in genomic discovery and clinical implications.,http://www.ncbi.nlm.nih.gov/pubmed/27372070
6655,27140927,Dual Block with Lapatinib and Trastuzumab Versus Single-Agent Trastuzumab Combined with Chemotherapy as Neoadjuvant Treatment of HER2-Positive Breast Cancer: A Meta-analysis of Randomized Trials.,http://www.ncbi.nlm.nih.gov/pubmed/27140927
6656,27509035,A propensity score matching analysis of dasatinib and nilotinib as a frontline therapy for patients with chronic myeloid leukemia in chronic phase.,http://www.ncbi.nlm.nih.gov/pubmed/27509035
6657,27117181,Phase I Clinical Trial of Marizomib (NPI-0052) in Patients with Advanced Malignancies Including Multiple Myeloma: Study NPI-0052-102 Final Results.,http://www.ncbi.nlm.nih.gov/pubmed/27117181
6658,27076626,"A Phase I Dose-Escalation Study Evaluating the Safety Tolerability and Pharmacokinetics of CUDC-427, a Potent, Oral, Monovalent IAP Antagonist, in Patients with Refractory Solid Tumors.",http://www.ncbi.nlm.nih.gov/pubmed/27076626
6659,27626654,BET Bromodomain Inhibition Promotes Anti-tumor Immunity by Suppressing PD-L1 Expression.,http://www.ncbi.nlm.nih.gov/pubmed/27626654
6660,26977878,Overcoming Therapeutic Resistance in HER2-Positive Breast Cancers with CDK4/6 Inhibitors.,http://www.ncbi.nlm.nih.gov/pubmed/26977878
6661,,"Preclinical evaluation of JTX-2011, an anti-ICOS agonist antibody",http://cancerres.aacrjournals.org/content/76/14_Supplement/573
6662,,Immuno-oncology agent CB-1158 is a potent and selective arginase inhibitor and causes an immune-mediated anti-tumor response,http://cancerres.aacrjournals.org/content/76/14_Supplement/552
6663,27601542,Phase II Trial and Correlative Genomic Analysis of Everolimus Plus Bevacizumab in Advanced Non-Clear Cell Renal Cell Carcinoma.,http://www.ncbi.nlm.nih.gov/pubmed/27601542
6664,27496709,Accumulation of MDSC and Th17 Cells in Patients with Metastatic Colorectal Cancer Predicts the Efficacy of a FOLFOX-Bevacizumab Drug Treatment Regimen.,http://www.ncbi.nlm.nih.gov/pubmed/27496709
6665,11719521,Novel pathogenic mechanisms of congenital insensitivity to pain with anhidrosis genetic disorder unveiled by functional analysis of neurotrophic tyrosine receptor kinase type 1/nerve growth factor receptor mutations.,http://www.ncbi.nlm.nih.gov/pubmed/11719521
6666,20173781,Targeting the FANCJ-BRCA1 interaction promotes a switch from recombination to poleta-dependent bypass.,http://www.ncbi.nlm.nih.gov/pubmed/20173781
6667,26676756,Modulation of EZH2 Expression by MEK-ERK or PI3K-AKT Signaling in Lung Cancer Is Dictated by Different KRAS Oncogene Mutations.,http://www.ncbi.nlm.nih.gov/pubmed/26676756
6668,26855591,New developments in the management of chronic lymphocytic leukemia: role of ofatumumab.,http://www.ncbi.nlm.nih.gov/pubmed/26855591
6669,25882396,"Chlorambucil plus ofatumumab versus chlorambucil alone in previously untreated patients with chronic lymphocytic leukaemia (COMPLEMENT 1): a randomised, multicentre, open-label phase 3 trial.",http://www.ncbi.nlm.nih.gov/pubmed/25882396
6670,20194866,Ofatumumab as single-agent CD20 immunotherapy in fludarabine-refractory chronic lymphocytic leukemia.,http://www.ncbi.nlm.nih.gov/pubmed/20194866
6671,26377300,"Ofatumumab maintenance versus observation in relapsed chronic lymphocytic leukaemia (PROLONG): an open-label, multicentre, randomised phase 3 study.",http://www.ncbi.nlm.nih.gov/pubmed/26377300
6672,23566679,B-cell targeted therapeutics in clinical development.,http://www.ncbi.nlm.nih.gov/pubmed/23566679
6673,27262172,A Novel Chemotherapeutic Agent to Treat Tumors with DNA Mismatch Repair Deficiencies.,http://www.ncbi.nlm.nih.gov/pubmed/27262172
6674,27595394,Targeting renal cell carcinoma with a HIF-2 antagonist.,http://www.ncbi.nlm.nih.gov/pubmed/27595394
6675,27633584,In vitro and in vivo activities of an antitumor peptide HM-3: A special dose-efficacy relationship on an HCT‑116 xenograft model in nude mice.,http://www.ncbi.nlm.nih.gov/pubmed/27633584
6676,26522332,Germline genetic variation in ETV6 and risk of childhood acute lymphoblastic leukaemia: a systematic genetic study.,http://www.ncbi.nlm.nih.gov/pubmed/26522332
6677,26102509,Germline ETV6 Mutations Confer Susceptibility to Acute Lymphoblastic Leukemia and Thrombocytopenia.,http://www.ncbi.nlm.nih.gov/pubmed/26102509
6678,24349361,"Association between the STK15 F31I polymorphism and cancer susceptibility: a meta-analysis involving 43,626 subjects.",http://www.ncbi.nlm.nih.gov/pubmed/24349361
6679,25154511,Association between the STK15 polymorphisms and risk of cancer: a meta-analysis.,http://www.ncbi.nlm.nih.gov/pubmed/25154511
6680,23803310,Two nonsynonymous polymorphisms (F31I and V57I) of the STK15 gene and breast cancer risk: a meta-analysis based on 5966 cases and 7609 controls.,http://www.ncbi.nlm.nih.gov/pubmed/23803310
6681,27450453,JNK Pathway Activation Modulates Acquired Resistance to EGFR/HER2-Targeted Therapies.,http://www.ncbi.nlm.nih.gov/pubmed/27450453
6682,26384399,MEK Inhibitor Selumetinib (AZD6244; ARRY-142886) Prevents Lung Metastasis in a Triple-Negative Breast Cancer Xenograft Model.,http://www.ncbi.nlm.nih.gov/pubmed/26384399
6683,27488531,An In Vivo Reporter to Quantitatively and Temporally Analyze the Effects of CDK4/6 Inhibitor-Based Therapies in Melanoma.,http://www.ncbi.nlm.nih.gov/pubmed/27488531
6684,26406377,CDK7-dependent transcriptional addiction in triple-negative breast cancer.,http://www.ncbi.nlm.nih.gov/pubmed/26406377
6685,26289068,Cabozantinib Inhibits Abiraterone's Upregulation of IGFIR Phosphorylation and Enhances Its Anti-Prostate Cancer Activity.,http://www.ncbi.nlm.nih.gov/pubmed/26289068
6686,27104980,A Small Molecule RAS-Mimetic Disrupts RAS Association with Effector Proteins to Block Signaling.,http://www.ncbi.nlm.nih.gov/pubmed/27104980
6687,17065430,Allele-specific polymerase chain reaction for the imatinib-resistant KIT D816V and D816F mutations in mastocytosis and acute myelogenous leukemia.,http://www.ncbi.nlm.nih.gov/pubmed/17065430
6688,26983878,"Dual Targeting of Bromodomain and Extraterminal Domain Proteins, and WNT or MAPK Signaling, Inhibits c-MYC Expression and Proliferation of Colorectal Cancer Cells.",http://www.ncbi.nlm.nih.gov/pubmed/26983878
6689,26272063,MEK plus PI3K/mTORC1/2 Therapeutic Efficacy Is Impacted by TP53 Mutation in Preclinical Models of Colorectal Cancer.,http://www.ncbi.nlm.nih.gov/pubmed/26272063
6690,26687836,Long-term outcome of molecular subgroups of GIST patients treated with standard-dose imatinib in the BFR14 trial of the French Sarcoma Group.,http://www.ncbi.nlm.nih.gov/pubmed/26687836
6691,27371698,Long-term follow-up results of the multicenter phase II trial of regorafenib in patients with metastatic and/or unresectable GI stromal tumor after failure of standard tyrosine kinase inhibitor therapy.,http://www.ncbi.nlm.nih.gov/pubmed/27371698
6692,27199435,The tumor microenvironment underlies acquired resistance to CSF-1R inhibition in gliomas.,http://www.ncbi.nlm.nih.gov/pubmed/27199435
6693,26058079,Kinase and BET Inhibitors Together Clamp Inhibition of PI3K Signaling and Overcome Resistance to Therapy.,http://www.ncbi.nlm.nih.gov/pubmed/26058079
6694,,"Abstract 2690: DCC-2618 is a potent inhibitor of wild-type and mutant KIT, including refractory Exon 17 D816 KIT mutations, and exhibits efficacy in refractory GIST and AML xenograft models",http://cancerres.aacrjournals.org/content/75/15_Supplement/2690
6695,,Ponatinib efficacy and safety in patients (pts) with advanced gastrointestinal stromal tumors (GIST) after tyrosine kinase inhibitor (TKI) failure: Results from a phase 2 study.,http://meetinglibrary.asco.org/content/148063-156
6696,19671763,"Activity of dasatinib against L576P KIT mutant melanoma: molecular, cellular, and clinical correlates.",http://www.ncbi.nlm.nih.gov/pubmed/19671763
6697,22270258,Sorafenib in patients with metastatic gastrointestinal stromal tumors who failed two or more prior tyrosine kinase inhibitors: a phase II study of Korean gastrointestinal stromal tumors study group.,http://www.ncbi.nlm.nih.gov/pubmed/22270258
6698,,A phase II study of dasatinib for patients with imatinib-resistant gastrointestinal stromal tumor (GIST).,http://meetinglibrary.asco.org/content/79120-102
6699,,Phase III trial of nilotinib versus imatinib as first-line targeted therapy of advanced gastrointestinal stromal tumors (GIST),http://meeting.ascopubs.org/cgi/content/abstract/31/15_suppl/10501
6700,20372153,Clinical responses observed with imatinib or sorafenib in melanoma patients expressing mutations in KIT.,http://www.ncbi.nlm.nih.gov/pubmed/20372153
6701,19139124,Sorafenib induces growth suppression in mouse models of gastrointestinal stromal tumor.,http://www.ncbi.nlm.nih.gov/pubmed/19139124
6702,20028770,Targeting the cyclin E-Cdk-2 complex represses lung cancer growth by triggering anaphase catastrophe.,http://www.ncbi.nlm.nih.gov/pubmed/20028770
6703,,"Abstract C188: A phase 1 study of RXDX-105, an oral RET, BRAF and EGFR tyrosine kinase inhibitor, in patients with advanced or metastatic cancers",http://mct.aacrjournals.org/content/14/12_Supplement_2/C188
6704,19597027,Efficacy and safety of axitinib in patients with advanced non-small-cell lung cancer: results from a phase II study.,http://www.ncbi.nlm.nih.gov/pubmed/19597027
6705,27666947,Discovery of Dual Inhibitors of MDM2 and XIAP for Cancer Treatment.,http://www.ncbi.nlm.nih.gov/pubmed/27666947
6706,27432227,Molecular Mechanisms of Resistance to First- and Second-Generation ALK Inhibitors in ALK-Rearranged Lung Cancer.,http://www.ncbi.nlm.nih.gov/pubmed/27432227
6707,27454287,BRCA1185delAG tumors may acquire therapy resistance through expression of RING-less BRCA1.,http://www.ncbi.nlm.nih.gov/pubmed/27454287
6708,26351322,Combined Pan-RAF and MEK Inhibition Overcomes Multiple Resistance Mechanisms to Selective RAF Inhibitors.,http://www.ncbi.nlm.nih.gov/pubmed/26351322
6709,27485451,Recurrent PPP2R1A Mutations in Uterine Cancer Act through a Dominant-Negative Mechanism to Promote Malignant Cell Growth.,http://www.ncbi.nlm.nih.gov/pubmed/27485451
6710,27530328,Cytotoxic Properties of a DEPTOR-mTOR Inhibitor in Multiple Myeloma Cells.,http://www.ncbi.nlm.nih.gov/pubmed/27530328
6711,27512117,"BPR1J373, an Oral Multiple Tyrosine Kinase Inhibitor, Targets c-KIT for the Treatment of c-KIT-Driven Myeloid Leukemia.",http://www.ncbi.nlm.nih.gov/pubmed/27512117
6712,25971938,Activation of MET via diverse exon 14 splicing alterations occurs in multiple tumor types and confers clinical sensitivity to MET inhibitors.,http://www.ncbi.nlm.nih.gov/pubmed/25971938
6713,27550450,Antitumor Properties of an IgG2-Enhanced Next-Generation MET Monoclonal Antibody That Degrades Wild-Type and Mutant MET Receptors.,http://www.ncbi.nlm.nih.gov/pubmed/27550450
6714,27697975,Response to Targeted Therapy in BRAF Mutant Anaplastic Thyroid Cancer.,http://www.ncbi.nlm.nih.gov/pubmed/27697975
6715,25547503,"SEARCH: a phase III, randomized, double-blind, placebo-controlled trial of sorafenib plus erlotinib in patients with advanced hepatocellular carcinoma.",http://www.ncbi.nlm.nih.gov/pubmed/25547503
6716,27681866,"A phase Ib study of selumetinib (AZD6244, ARRY-142886) in combination with sorafenib in advanced hepatocellular carcinoma (HCC).",http://www.ncbi.nlm.nih.gov/pubmed/27681866
6717,27496134,Preclinical Modeling of KIF5B-RET Fusion Lung Adenocarcinoma.,http://www.ncbi.nlm.nih.gov/pubmed/27496134
6719,27154916,Molecular and Clinical Effects of Notch Inhibition in Glioma Patients: A Phase 0/I Trial.,http://www.ncbi.nlm.nih.gov/pubmed/27154916
6720,27697991,Dual Characteristics of Novel HER2 Kinase Domain Mutations in Response to HER2-Targeted Therapies in Human Breast Cancer.,http://www.ncbi.nlm.nih.gov/pubmed/27697991
6722,27466357,Inhibition of Breast Cancer Metastasis by Presurgical Treatment with an Oral Matrix Metalloproteinase Inhibitor: A Preclinical Proof-of-Principle Study.,http://www.ncbi.nlm.nih.gov/pubmed/27466357
6723,,Phase III study of intraperitoneal paclitaxel plus s-1/paclitaxel compared with s-1/cisplatin in gastric cancer patients with peritoneal metastasis: PHOENIX-GC trial.,http://meetinglibrary.asco.org/content/166629-176
6724,27556922,An integrative genomics approach for identifying novel functional consequences of PBRM1 truncated mutations in clear cell renal cell carcinoma (ccRCC).,http://www.ncbi.nlm.nih.gov/pubmed/27556922
6725,,"A randomized, open-label, multicenter, adaptive phase 2/3 study of trastuzumab emtansine (T-DM1) versus a taxane (TAX) in patients (pts) with previously treated HER2-positive locally advanced or metastatic gastric/gastroesophageal junction adenocarcinoma",http://meetinglibrary.asco.org/content/159174-173
6726,23594787,"Epirubicin, oxaliplatin, and capecitabine with or without panitumumab for patients with previously untreated advanced oesophagogastric cancer (REAL3): a randomised, open-label phase 3 trial.",http://www.ncbi.nlm.nih.gov/pubmed/23594787
6727,23594786,"Capecitabine and cisplatin with or without cetuximab for patients with previously untreated advanced gastric cancer (EXPAND): a randomised, open-label phase 3 trial.",http://www.ncbi.nlm.nih.gov/pubmed/23594786
6728,24043745,"Everolimus for previously treated advanced gastric cancer: results of the randomized, double-blind, phase III GRANITE-1 study.",http://www.ncbi.nlm.nih.gov/pubmed/24043745
6729,,"Phase III, randomized, double-blind, multicenter, placebo (P)-controlled trial of rilotumumab (R) plus epirubicin, cisplatin and capecitabine (ECX) as first-line therapy in patients (pts) with advanced MET-positive (pos) gastric or gastroesophageal juncti",http://meetinglibrary.asco.org/content/147255-156
6730,,METGastric: A phase III study of onartuzumab plus mFOLFOX6 in patients with metastatic HER2-negative (HER2-) and MET-positive (MET+) adenocarcinoma of the stomach or gastroesophageal junction (GEC).,http://meetinglibrary.asco.org/content/147779-156
6731,21844504,"Bevacizumab in combination with chemotherapy as first-line therapy in advanced gastric cancer: a randomized, double-blind, placebo-controlled phase III study.",http://www.ncbi.nlm.nih.gov/pubmed/21844504
6732,26552009,SWI/SNF-mutant cancers depend on catalytic and non-catalytic activity of EZH2.,http://www.ncbi.nlm.nih.gov/pubmed/26552009
6733,25185971,Randomized phase II trial of nimotuzumab plus irinotecan versus irinotecan alone as second-line therapy for patients with advanced gastric cancer.,http://www.ncbi.nlm.nih.gov/pubmed/25185971
6734,,"INTEGRATE: A randomized, phase II, double-blind, placebo-controlled study of regorafenib in refractory advanced oesophagogastric cancer (AOGC): A study by the Australasian Gastrointestinal Trials Group (AGITG)—Final overall and subgroup results.",http://meetinglibrary.asco.org/content/147938-156
6735,26282658,"Randomized, Double-Blind Phase II Trial With Prospective Classification by ATM Protein Level to Evaluate the Efficacy and Tolerability of Olaparib Plus Paclitaxel in Patients With Recurrent or Metastatic Gastric Cancer.",http://www.ncbi.nlm.nih.gov/pubmed/26282658
6736,,"FAST: An international, multicenter, randomized, phase II trial of epirubicin, oxaliplatin, and capecitabine (EOX) with or without IMAB362, a first-in-class anti-CLDN18.2 antibody, as first-line therapy in patients with advanced CLDN18.2+ gastric and gast",http://meetinglibrary.asco.org/content/164788-176
6737,27143690,Phase II Study of Radiotherapy and Temsirolimus versus Radiochemotherapy with Temozolomide in Patients with Newly Diagnosed Glioblastoma without MGMT Promoter Hypermethylation (EORTC 26082).,http://www.ncbi.nlm.nih.gov/pubmed/27143690
6738,,"A randomized, open-label, two-arm phase II trial comparing the efficacy of sequential ipilimumab (ipi) versus best supportive care (BSC) following first-line (1L) chemotherapy in patients with unresectable, locally advanced/metastatic (A/M) gastric or gas",http://meetinglibrary.asco.org/content/166431-176
6739,,Phase Ib/II study of cancer stem cell (CSC) inhibitor BBI608 combined with paclitaxel in advanced gastric and gastroesophageal junction (GEJ) adenocarcinoma.,http://meetinglibrary.asco.org/content/153561-156
6740,19244112,The critical role of the class III histone deacetylase SIRT1 in cancer.,http://www.ncbi.nlm.nih.gov/pubmed/19244112
6741,24020000,The Roles of SIRT1 in Cancer.,http://www.ncbi.nlm.nih.gov/pubmed/24020000
6742,26481524,Targeting aberrant cancer metabolism - The role of sirtuins.,http://www.ncbi.nlm.nih.gov/pubmed/26481524
6743,27157491,"Pembrolizumab for patients with PD-L1-positive advanced gastric cancer (KEYNOTE-012): a multicentre, open-label, phase 1b trial.",http://www.ncbi.nlm.nih.gov/pubmed/27157491
6744,,"A phase I dose expansion trial of avelumab (MSB0010718C), an anti-PD-L1 antibody, in Japanese patients with advanced gastric cancer.",http://meetinglibrary.asco.org/content/147815-156
6745,,"CheckMate-032: Phase I/II, open-label study of safety and activity of nivolumab (nivo) alone or with ipilimumab (ipi) in advanced and metastatic (A/M) gastric cancer (GC).",http://meetinglibrary.asco.org/content/165665-176
6746,,Abstract 4707: Investigating the role of EZH2 as a therapeutic target in clear cell renal cell carcinoma (ccRCC),http://cancerres.aacrjournals.org/content/76/14_Supplement/4707
6747,27486225,A Novel Small Molecule Activator of Nuclear Receptor SHP Inhibits HCC Cell Migration via Suppressing Ccl2.,http://www.ncbi.nlm.nih.gov/pubmed/27486225
6748,27154357,"A Randomized, Open-Label Phase 2 Study of the CXCR4 Inhibitor LY2510924 in Combination with Sunitinib Versus Sunitinib Alone in Patients with Metastatic Renal Cell Carcinoma (RCC).",http://www.ncbi.nlm.nih.gov/pubmed/27154357
6749,27681596,Small Molecule Inhibition of the Ubiquitin-specific Protease USP2 Accelerates cyclin D1 Degradation and Leads to Cell Cycle Arrest in Colorectal Cancer and Mantle Cell Lymphoma Models.,http://www.ncbi.nlm.nih.gov/pubmed/27681596
6750,27679486,Identification of Small Molecule Inhibitors of Human Cytochrome c Oxidase That Target Chemoresistant Glioma Cells.,http://www.ncbi.nlm.nih.gov/pubmed/27679486
6751,27496137,"Pharmacological Profile of BI 847325, an Orally Bioavailable, ATP-Competitive Inhibitor of MEK and Aurora Kinases.",http://www.ncbi.nlm.nih.gov/pubmed/27496137
6752,27496133,"Barasertib (AZD1152), a Small Molecule Aurora B Inhibitor, Inhibits the Growth of SCLC Cell Lines In Vitro and In Vivo.",http://www.ncbi.nlm.nih.gov/pubmed/27496133
6753,27154915,Phase I Study of Inotuzumab Ozogamicin Combined with R-CVP for Relapsed/Refractory CD22+ B-cell Non-Hodgkin Lymphoma.,http://www.ncbi.nlm.nih.gov/pubmed/27154915
6754,25579209,Identifying drug-target selectivity of small-molecule CRM1/XPO1 inhibitors by CRISPR/Cas9 genome editing.,http://www.ncbi.nlm.nih.gov/pubmed/25579209
6755,23373539,KPT-330 inhibitor of CRM1 (XPO1)-mediated nuclear export has selective anti-leukaemic activity in preclinical models of T-cell acute lymphoblastic leukaemia and acute myeloid leukaemia.,http://www.ncbi.nlm.nih.gov/pubmed/23373539
6756,27252416,Heterogeneous Mechanisms of Primary and Acquired Resistance to Third-Generation EGFR Inhibitors.,http://www.ncbi.nlm.nih.gov/pubmed/27252416
6757,27699769,"BAY 1125976, a selective allosteric AKT1/2 inhibitor, exhibits high efficacy on AKT signaling-dependent tumor growth in mouse models.",http://www.ncbi.nlm.nih.gov/pubmed/27699769
6758,27680702,XPO1-dependent nuclear export is a druggable vulnerability in KRAS-mutant lung cancer.,http://www.ncbi.nlm.nih.gov/pubmed/27680702
6759,27482887,Rationally designed BCL6 inhibitors target activated B cell diffuse large B cell lymphoma.,http://www.ncbi.nlm.nih.gov/pubmed/27482887
6760,27106068,Preclinical Evaluation of Fatty Acid Synthase and EGFR Inhibition in Triple-Negative Breast Cancer.,http://www.ncbi.nlm.nih.gov/pubmed/27106068
6761,27482884,Mechanistically distinct cancer-associated mTOR activation clusters predict sensitivity to rapamycin.,http://www.ncbi.nlm.nih.gov/pubmed/27482884
6762,22103913,Characterization of a novel PTEN mutation in MDA-MB-453 breast carcinoma cell line.,http://www.ncbi.nlm.nih.gov/pubmed/22103913
6763,27454289,RING domain-deficient BRCA1 promotes PARP inhibitor and platinum resistance.,http://www.ncbi.nlm.nih.gov/pubmed/27454289
6764,25995436,"23814, an Inhibitory Antibody of Ligand-Mediated Notch1 Activation, Modulates Angiogenesis and Inhibits Tumor Growth without Gastrointestinal Toxicity.",http://www.ncbi.nlm.nih.gov/pubmed/25995436
6765,27439479,"Debio 0617B Inhibits Growth of STAT3-Driven Solid Tumors through Combined Inhibition of JAK, SRC, and Class III/V Receptor Tyrosine Kinases.",http://www.ncbi.nlm.nih.gov/pubmed/27439479
6766,27647909,Whole-exome sequencing identifies multiple loss-of-function mutations of NF-κB pathway regulators in nasopharyngeal carcinoma.,http://www.ncbi.nlm.nih.gov/pubmed/27647909
6767,18794084,"Activity of dasatinib, a dual SRC/ABL kinase inhibitor, and IPI-504, a heat shock protein 90 inhibitor, against gastrointestinal stromal tumor-associated PDGFRAD842V mutation.",http://www.ncbi.nlm.nih.gov/pubmed/18794084
6768,,Phase 1 Clinical Results of the ZUMA-1 (KTE-C19-101) Study: A Phase 1-2 Multi-Center Study Evaluating the Safety and Efficacy of Anti-CD19 CAR T Cells (KTE-C19) in Subjects with Refractory Aggressive Non-Hodgkin Lymphoma (NHL),http://www.bloodjournal.org/content/126/23/3991
6769,26294741,Antitumor Effects and Mechanisms of AZD4547 on FGFR2-Deregulated Endometrial Cancer Cells.,http://www.ncbi.nlm.nih.gov/pubmed/26294741
6770,26144316,The Utilization of Extracellular Proteins as Nutrients Is Suppressed by mTORC1.,http://www.ncbi.nlm.nih.gov/pubmed/26144316
6771,27407089,"FDA Approval of Palbociclib in Combination with Fulvestrant for the Treatment of Hormone Receptor-Positive, HER2-Negative Metastatic Breast Cancer.",http://www.ncbi.nlm.nih.gov/pubmed/27407089
6772,,Phase III trial of sunitinib (SU) vs placebo (PBO) as adjuvant treatment for high-risk renal cell carcinoma (RCC) after nephrectomy (S-TRAC),http://www.esmo.org/Conferences/ESMO-2016-Congress/Press-Media/Longer-Disease-free-Survival-in-Phase-III-Trial-of-Sunitinib-as-Adjuvant-Treatment-for-Kidney-Cancer
6773,,CABOzantinib versus SUNitinib (CABOSUN) as initial targeted therapy for patients with metastatic renal cell carcinoma (mRCC) of poor and intermediate risk groups: Results from ALLIANCE A031203 trial,http://www.esmo.org/Conferences/ESMO-2016-Congress/Press-Media/Cabozantinib-Improves-Progression-free-Survival-in-Metastatic-Renal-Cell-Carcinoma
6774,27401244,BATON-CRC: A Phase II Randomized Trial Comparing Tivozanib Plus mFOLFOX6 with Bevacizumab Plus mFOLFOX6 in Stage IV Metastatic Colorectal Cancer.,http://www.ncbi.nlm.nih.gov/pubmed/27401244
6775,27556950,HER2 expression identifies dynamic functional states within circulating breast cancer cells.,http://www.ncbi.nlm.nih.gov/pubmed/27556950
6776,27267850,A Novel HSP90 Inhibitor-Drug Conjugate to SN38 Is Highly Effective in Small Cell Lung Cancer.,http://www.ncbi.nlm.nih.gov/pubmed/27267850
6778,27002934,Phase 2 multicentre trial investigating intermittent and continuous dosing schedules of the poly(ADP-ribose) polymerase inhibitor rucaparib in germline BRCA mutation carriers with advanced ovarian and breast cancer.,http://www.ncbi.nlm.nih.gov/pubmed/27002934
6779,,A phase I dose-escalation and PK study of continuous oral rucaparib in patients with advanced solid tumors.,http://meetinglibrary.asco.org/content/115538-132
6780,27026201,"DS-8201a, A Novel HER2-Targeting ADC with a Novel DNA Topoisomerase I Inhibitor, Demonstrates a Promising Antitumor Efficacy with Differentiation from T-DM1.",http://www.ncbi.nlm.nih.gov/pubmed/27026201
6781,26527528,The K167I variant of DNA polymerase β that is found in Esophageal Carcinoma patients impairs polymerase activity and BER.,http://www.ncbi.nlm.nih.gov/pubmed/26527528
6782,27604488,Systematic Functional Characterization of Resistance to PI3K Inhibition in Breast Cancer.,http://www.ncbi.nlm.nih.gov/pubmed/27604488
6783,27178743,Phase I Study of the Investigational Anti-Guanylyl Cyclase Antibody-Drug Conjugate TAK-264 (MLN0264) in Adult Patients with Advanced Gastrointestinal Malignancies.,http://www.ncbi.nlm.nih.gov/pubmed/27178743
6784,26645562,A Small-Molecule Antagonist of the β-Catenin/TCF4 Interaction Blocks the Self-Renewal of Cancer Stem Cells and Suppresses Tumorigenesis.,http://www.ncbi.nlm.nih.gov/pubmed/26645562
6785,26118643,Small Molecule Inhibition of the Autophagy Kinase ULK1 and Identification of ULK1 Substrates.,http://www.ncbi.nlm.nih.gov/pubmed/26118643
6786,27254750,Safety and Efficacy of Pazopanib Therapy Prior to Planned Nephrectomy in Metastatic Clear Cell Renal Cancer.,http://www.ncbi.nlm.nih.gov/pubmed/27254750
6787,,Dose escalating study of crenolanib besylate in advanced GIST patients with PDGFRA D842V activating mutations.,http://meetinglibrary.asco.org/content/170566-176
6788,25905001,"Regorafenib treatment for advanced, refractory gastrointestinal stromal tumor: a report of the UK managed access program.",http://www.ncbi.nlm.nih.gov/pubmed/25905001
6789,24407160,"Identification of Ponatinib as a potent inhibitor of growth, migration, and activation of neoplastic eosinophils carrying FIP1L1-PDGFRA.",http://www.ncbi.nlm.nih.gov/pubmed/24407160
6790,27592805,"Avelumab in patients with chemotherapy-refractory metastatic Merkel cell carcinoma: a multicentre, single-group, open-label, phase 2 trial.",http://www.ncbi.nlm.nih.gov/pubmed/27592805
6791,27196759,MSK1-Mediated β-Catenin Phosphorylation Confers Resistance to PI3K/mTOR Inhibitors in Glioblastoma.,http://www.ncbi.nlm.nih.gov/pubmed/27196759
6792,27439478,"Characterization of LY3023414, a Novel PI3K/mTOR Dual Inhibitor Eliciting Transient Target Modulation to Impede Tumor Growth.",http://www.ncbi.nlm.nih.gov/pubmed/27439478
6793,27550455,The PARP Inhibitor AZD2461 Provides Insights into the Role of PARP3 Inhibition for Both Synthetic Lethality and Tolerability with Chemotherapy in Preclinical Models.,http://www.ncbi.nlm.nih.gov/pubmed/27550455
6794,19744331,Structural effects of clinically observed mutations in JAK2 exons 13-15: comparison with V617F and exon 12 mutations.,http://www.ncbi.nlm.nih.gov/pubmed/19744331
6795,16843266,Activating alleles of JAK3 in acute megakaryoblastic leukemia.,http://www.ncbi.nlm.nih.gov/pubmed/16843266
6796,24910428,Modularized functions of the Fanconi anemia core complex.,http://www.ncbi.nlm.nih.gov/pubmed/24910428
6797,26507869,Promoter Hypermethylation of FANCF and Susceptibility and Prognosis of Epithelial Ovarian Cancer.,http://www.ncbi.nlm.nih.gov/pubmed/26507869
6798,16675878,The Fanconi anemia pathway of genomic maintenance.,http://www.ncbi.nlm.nih.gov/pubmed/16675878
6799,21146537,Active mutants of the TCR-mediated p38α alternative activation site show changes in the phosphorylation lip and DEF site formation.,http://www.ncbi.nlm.nih.gov/pubmed/21146537
6800,27742744,A novel L-fucose-binding lectin from Fenneropenaeus indicus induced cytotoxicity in breast cancer cells.,http://www.ncbi.nlm.nih.gov/pubmed/27742744
6801,15284239,Active mutants of the human p38alpha mitogen-activated protein kinase.,http://www.ncbi.nlm.nih.gov/pubmed/15284239
6802,27717303,"Ribociclib as First-Line Therapy for HR-Positive, Advanced Breast Cancer.",http://www.ncbi.nlm.nih.gov/pubmed/27717303
6803,24578542,"Genetic polymorphism of NFKB1 and NFKBIA genes and liver cancer risk: a nested case-control study in Shanghai, China.",http://www.ncbi.nlm.nih.gov/pubmed/24578542
6804,19507254,"Mutations of NFKBIA, encoding IkappaB alpha, are a recurrent finding in classical Hodgkin lymphoma but are not a unifying feature of non-EBV-associated cases.",http://www.ncbi.nlm.nih.gov/pubmed/19507254
6805,21774728,NFKBIA deletion in glioblastomas.,http://www.ncbi.nlm.nih.gov/pubmed/21774728
6806,27742657,Chromoplectic TPM3-ALK rearrangement in a patient with inflammatory myofibroblastic tumor who responded to ceritinib after progression on crizotinib.,http://www.ncbi.nlm.nih.gov/pubmed/27742657
6807,27705267,"Daratumumab, Lenalidomide, and Dexamethasone for Multiple Myeloma.",http://www.ncbi.nlm.nih.gov/pubmed/27705267
6808,26206868,Nintedanib Is a Highly Effective Therapeutic for Neuroendocrine Carcinoma of the Pancreas (PNET) in the Rip1Tag2 Transgenic Mouse Model.,http://www.ncbi.nlm.nih.gov/pubmed/26206868
6809,22729463,"Traditional and targeted exome sequencing reveals common, rare and novel functional deleterious variants in RET-signaling complex in a cohort of living US patients with urinary tract malformations.",http://www.ncbi.nlm.nih.gov/pubmed/22729463
6810,21804922,The neuroblastoma ALK(I1250T) mutation is a kinase-dead RTK in vitro and in vivo.,http://www.ncbi.nlm.nih.gov/pubmed/21804922
6811,,"Preclinical characterization of MG516, a novel inhibitor of receptor tyrosine kinases involved in resistance to targeted therapies.",http://cancerres.aacrjournals.org/content/73/8_Supplement/930
6812,26377941,The Stress Kinase p38α as a Target for Cancer Therapy.,http://www.ncbi.nlm.nih.gov/pubmed/26377941
6813,25552927,Epithelial cell polarity determinant CRB3 in cancer development.,http://www.ncbi.nlm.nih.gov/pubmed/25552927
6814,26932476,Nudt3 is an mRNA decapping enzyme that modulates cell migration.,http://www.ncbi.nlm.nih.gov/pubmed/26932476
6815,11550278,Identification of target genes within an amplicon at 14q12-q13 in esophageal squamous cell carcinoma.,http://www.ncbi.nlm.nih.gov/pubmed/11550278
6816,15356269,Differential regulation of the TRAIL death receptors DR4 and DR5 by the signal recognition particle.,http://www.ncbi.nlm.nih.gov/pubmed/15356269
6817,27272503,The Putative SLC Transporters Mfsd5 and Mfsd11 Are Abundantly Expressed in the Mouse Brain and Have a Potential Role in Energy Homeostasis.,http://www.ncbi.nlm.nih.gov/pubmed/27272503
6818,19665072,A NUP98-positive acute myeloid leukemia with a t(11;12)(p15;q13) without HOXC cluster gene involvement.,http://www.ncbi.nlm.nih.gov/pubmed/19665072
6819,16188880,"The lysosome-associated apoptosis-inducing protein containing the pleckstrin homology (PH) and FYVE domains (LAPF), representative of a novel family of PH and FYVE domain-containing proteins, induces caspase-independent apoptosis via the lysosomal-mitochondrial pathway.",http://www.ncbi.nlm.nih.gov/pubmed/16188880
6820,20510020,"SAMD4B, a novel SAM-containing protein, inhibits AP-1-, p53- and p21-mediated transcriptional activity.",http://www.ncbi.nlm.nih.gov/pubmed/20510020
6821,27692986,USP38 Inhibits Type I Interferon Signaling by Editing TBK1 Ubiquitination through NLRP4 Signalosome.,http://www.ncbi.nlm.nih.gov/pubmed/27692986
6822,22961600,Subdivision of molecularly-classified groups by new gene signatures in breast cancer patients.,http://www.ncbi.nlm.nih.gov/pubmed/22961600
6823,,"Abstract 3259: LY3127804, a novel anti-Angiopoietin-2 antibody in combination with an anti-VEGFR2 antibody potently inhibits angiogenesis, tumor growth and metastasis",http://cancerres.aacrjournals.org/content/76/14_Supplement/3259
6824,17721994,Genetic and functional analysis of CHEK2 (CHK2) variants in multiethnic cohorts.,http://www.ncbi.nlm.nih.gov/pubmed/17721994
6825,22114986,CHEK2 contribution to hereditary breast cancer in non-BRCA families.,http://www.ncbi.nlm.nih.gov/pubmed/22114986
6826,27435396,"Preclinical Comparison of Osimertinib with Other EGFR-TKIs in EGFR-Mutant NSCLC Brain Metastases Models, and Early Evidence of Clinical Brain Metastases Activity.",http://www.ncbi.nlm.nih.gov/pubmed/27435396
6827,27748765,Genomic modelling of the ESR1 Y537S mutation for evaluating function and new therapeutic approaches for metastatic breast cancer.,http://www.ncbi.nlm.nih.gov/pubmed/27748765
6828,19649315,EPHA2 is associated with age-related cortical cataract in mice and humans.,http://www.ncbi.nlm.nih.gov/pubmed/19649315
6829,18682749,Germline EPHB2 receptor variants in familial colorectal cancer.,http://www.ncbi.nlm.nih.gov/pubmed/18682749
6830,19962662,Proliferation and tumor suppression: not mutually exclusive for Eph receptors.,http://www.ncbi.nlm.nih.gov/pubmed/19962662
6831,26289070,Preclinical Efficacy of Ron Kinase Inhibitors Alone and in Combination with PI3K Inhibitors for Treatment of sfRon-Expressing Breast Cancer Patient-Derived Xenografts.,http://www.ncbi.nlm.nih.gov/pubmed/26289070
6832,23773865,"Novel 6-aminofuro[3,2-c]pyridines as potent, orally efficacious inhibitors of cMET and RON kinases.",http://www.ncbi.nlm.nih.gov/pubmed/23773865
6833,10851026,Signaling by fibroblast growth factors (FGF) and fibroblast growth factor receptor 2 (FGFR2)-activating mutations blocks mineralization and induces apoptosis in osteoblasts.,http://www.ncbi.nlm.nih.gov/pubmed/10851026
6834,15316116,A gain-of-function mutation of Fgfr2c demonstrates the roles of this receptor variant in osteogenesis.,http://www.ncbi.nlm.nih.gov/pubmed/15316116
6835,22773955,The CRM1 nuclear export protein in normal development and disease.,http://www.ncbi.nlm.nih.gov/pubmed/22773955
6836,22209898,Nuclear export of proteins and drug resistance in cancer.,http://www.ncbi.nlm.nih.gov/pubmed/22209898
6837,12447696,Gain of function mutations of RTK conserved residues display differential effects on NTRK1 kinase activity.,http://www.ncbi.nlm.nih.gov/pubmed/12447696
6838,26250460,CP-31398 inhibits the growth of p53-mutated liver cancer cells in vitro and in vivo.,http://www.ncbi.nlm.nih.gov/pubmed/26250460
6839,11313867,A novel mutation within the extracellular domain of TrkA causes constitutive receptor activation.,http://www.ncbi.nlm.nih.gov/pubmed/11313867
6840,22419737,Response to DNA damage of CHEK2 missense mutations in familial breast cancer.,http://www.ncbi.nlm.nih.gov/pubmed/22419737
6841,10807789,Further demonstration of the diversity of chromosomal changes involving 2p23 in ALK-positive lymphoma: 2 cases expressing ALK kinase fused to CLTCL (clathrin chain polypeptide-like).,http://www.ncbi.nlm.nih.gov/pubmed/10807789
6842,8733129,Characterization of a second human clathrin heavy chain polypeptide gene (CLH-22) from chromosome 22q11.,http://www.ncbi.nlm.nih.gov/pubmed/8733129
6843,19509056,Functional equivalence of the clathrin heavy chains CHC17 and CHC22 in endocytosis and mitosis.,http://www.ncbi.nlm.nih.gov/pubmed/19509056
6844,26622902,Sequencing study on familial lung squamous cancer.,http://www.ncbi.nlm.nih.gov/pubmed/26622902
6845,22496928,Down-regulation of ANAPC13 and CLTCL1: Early Events in the Progression of Preinvasive Ductal Carcinoma of the Breast.,http://www.ncbi.nlm.nih.gov/pubmed/22496928
6846,26934577,Exome sequencing of oral squamous cell carcinoma in users of Arabian snuff reveals novel candidates for driver genes.,http://www.ncbi.nlm.nih.gov/pubmed/26934577
6847,9826708,Uncoupling signal transducers from oncogenic MET mutants abrogates cell transformation and inhibits invasive growth.,http://www.ncbi.nlm.nih.gov/pubmed/9826708
6848,27422710,Phosphoproteomics Reveals MAPK Inhibitors Enhance MET- and EGFR-Driven AKT Signaling in KRAS-Mutant Lung Cancer.,http://www.ncbi.nlm.nih.gov/pubmed/27422710
6849,27507852,"FTY720 (Fingolimod) Inhibits HIF1 and HIF2 Signaling, Promotes Vascular Remodeling, and Chemosensitizes in Renal Cell Carcinoma Animal Model.",http://www.ncbi.nlm.nih.gov/pubmed/27507852
6850,27717299,"Niraparib Maintenance Therapy in Platinum-Sensitive, Recurrent Ovarian Cancer.",http://www.ncbi.nlm.nih.gov/pubmed/27717299
6851,27760111,The MCL1 inhibitor S63845 is tolerable and effective in diverse cancer models.,http://www.ncbi.nlm.nih.gov/pubmed/27760111
6852,27756834,Ibrutinib for relapsed/refractory chronic lymphocytic leukemia: a UK and Ireland analysis of outcomes in 315 patients.,http://www.ncbi.nlm.nih.gov/pubmed/27756834
6853,24881631,Ibrutinib versus ofatumumab in previously treated chronic lymphoid leukemia.,http://www.ncbi.nlm.nih.gov/pubmed/24881631
6854,26358751,"AZD2014, an Inhibitor of mTORC1 and mTORC2, Is Highly Effective in ER+ Breast Cancer When Administered Using Intermittent or Continuous Schedules.",http://www.ncbi.nlm.nih.gov/pubmed/26358751
6855,27291997,Olaratumab and doxorubicin versus doxorubicin alone for treatment of soft-tissue sarcoma: an open-label phase 1b and randomised phase 2 trial.,http://www.ncbi.nlm.nih.gov/pubmed/27291997
6856,26970723,"Atezolizumab versus docetaxel for patients with previously treated non-small-cell lung cancer (POPLAR): a multicentre, open-label, phase 2 randomised controlled trial.",http://www.ncbi.nlm.nih.gov/pubmed/26970723
6857,27587383,Erlotinib synergizes with the poly(ADP-ribose) glycohydrolase inhibitor ethacridine in acute myeloid leukemia cells.,http://www.ncbi.nlm.nih.gov/pubmed/27587383
6858,15649950,Functional and genomic approaches reveal an ancient CHEK2 allele associated with breast cancer in the Ashkenazi Jewish population.,http://www.ncbi.nlm.nih.gov/pubmed/15649950
6859,27548314,Recurrent somatic mutations in POLR2A define a distinct subset of meningiomas.,http://www.ncbi.nlm.nih.gov/pubmed/27548314
6860,25098841,The role of vertebrate nonmuscle Myosin II in development and human disease.,http://www.ncbi.nlm.nih.gov/pubmed/25098841
6861,24436421,Direct in vivo RNAi screen unveils myosin IIa as a tumor suppressor of squamous cell carcinomas.,http://www.ncbi.nlm.nih.gov/pubmed/24436421
6862,21951916,Nonmuscle myosin IIA is associated with poor prognosis of esophageal squamous cancer.,http://www.ncbi.nlm.nih.gov/pubmed/21951916
6863,25826333,Prognostic significance of MYH9 expression in resected non-small cell lung cancer.,http://www.ncbi.nlm.nih.gov/pubmed/25826333
6864,12800156,Non-muscle myosin heavy chain (MYH9): a new partner fused to ALK in anaplastic large cell lymphoma.,http://www.ncbi.nlm.nih.gov/pubmed/12800156
6865,20473317,Mammal-restricted elements predispose human RET to folding impairment by HSCR mutations.,http://www.ncbi.nlm.nih.gov/pubmed/20473317
6866,26542378,A phase 1 clinical trial of the selective BTK inhibitor ONO/GS-4059 in relapsed and refractory mature B-cell malignancies.,http://www.ncbi.nlm.nih.gov/pubmed/26542378
6867,14996833,Autoinhibition of the platelet-derived growth factor beta-receptor tyrosine kinase by its C-terminal tail.,http://www.ncbi.nlm.nih.gov/pubmed/14996833
6868,18811945,The Serine/threonine kinase Stk33 exhibits autophosphorylation and phosphorylates the intermediate filament protein Vimentin.,http://www.ncbi.nlm.nih.gov/pubmed/18811945
6869,25398772,STK33 promotes hepatocellular carcinoma through binding to c-Myc.,http://www.ncbi.nlm.nih.gov/pubmed/25398772
6870,25603720,STK33 overexpression in hypopharyngeal squamous cell carcinoma: possible role in tumorigenesis.,http://www.ncbi.nlm.nih.gov/pubmed/25603720
6871,25662617,STK33 plays an important positive role in the development of human large cell lung cancers with variable metastatic potential.,http://www.ncbi.nlm.nih.gov/pubmed/25662617
6872,2424022,Activation of the transforming potential of p60c-src by a single amino acid change.,http://www.ncbi.nlm.nih.gov/pubmed/2424022
6873,20140017,Activating ROCK1 somatic mutations in human cancer.,http://www.ncbi.nlm.nih.gov/pubmed/20140017
6874,26475335,SAR405838: A Novel and Potent Inhibitor of the MDM2:p53 Axis for the Treatment of Dedifferentiated Liposarcoma.,http://www.ncbi.nlm.nih.gov/pubmed/26475335
6875,26725045,Novel Insights into the Roles of Rho Kinase in Cancer.,http://www.ncbi.nlm.nih.gov/pubmed/26725045
6876,24553779,"The actin-myosin regulatory MRCK kinases: regulation, biological functions and associations with human cancer.",http://www.ncbi.nlm.nih.gov/pubmed/24553779
6877,9012462,The different RET-activating capability of mutations of cysteine 620 or cysteine 634 correlates with the multiple endocrine neoplasia type 2 disease phenotype.,http://www.ncbi.nlm.nih.gov/pubmed/9012462
6878,27196782,"In Vitro and In Vivo Activity of AMG 337, a Potent and Selective MET Kinase Inhibitor, in MET-Dependent Cancer Models.",http://www.ncbi.nlm.nih.gov/pubmed/27196782
6879,10918602,A novel type of mutation in the cysteine rich domain of the RET receptor causes ligand independent activation.,http://www.ncbi.nlm.nih.gov/pubmed/10918602
6880,27255157,Dabrafenib in an elderly patient with metastatic melanoma and BRAF V600R mutation: a case report.,http://www.ncbi.nlm.nih.gov/pubmed/27255157
6881,18248647,The Y606C RET mutation causes a receptor gain of function.,http://www.ncbi.nlm.nih.gov/pubmed/18248647
6882,15364927,Negative regulation of p53 functions by Daxx and the involvement of MDM2.,http://www.ncbi.nlm.nih.gov/pubmed/15364927
6883,17496201,Dasatinib induces rapid hematologic and cytogenetic responses in adult patients with Philadelphia chromosome positive acute lymphoblastic leukemia with resistance or intolerance to imatinib: interim results of a phase 2 study.,http://www.ncbi.nlm.nih.gov/pubmed/17496201
6884,27053219,Evaluation of FGFR3 as a Therapeutic Target in Head and Neck Squamous Cell Carcinoma.,http://www.ncbi.nlm.nih.gov/pubmed/27053219
6885,27050099,N-Myc Drives Neuroendocrine Prostate Cancer Initiated from Human Prostate Epithelial Cells.,http://www.ncbi.nlm.nih.gov/pubmed/27050099
6886,26351319,Poly-ADP-Ribose Polymerase as a Therapeutic Target in Pediatric Diffuse Intrinsic Pontine Glioma and Pediatric High-Grade Astrocytoma.,http://www.ncbi.nlm.nih.gov/pubmed/26351319
6887,27582059,Targeting BCL-2 and ABL/LYN in Philadelphia chromosome-positive acute lymphoblastic leukemia.,http://www.ncbi.nlm.nih.gov/pubmed/27582059
6888,27196780,Dual mTORC1/2 Inhibition as a Novel Strategy for the Resensitization and Treatment of Platinum-Resistant Ovarian Cancer.,http://www.ncbi.nlm.nih.gov/pubmed/27196780
6889,26351320,Targeting FGFR Pathway in Human Hepatocellular Carcinoma: Expressing pFGFR and pMET for Antitumor Activity.,http://www.ncbi.nlm.nih.gov/pubmed/26351320
6890,26036643,Combined EGFR/MEK Inhibition Prevents the Emergence of Resistance in EGFR-Mutant Lung Cancer.,http://www.ncbi.nlm.nih.gov/pubmed/26036643
6891,26333383,Dual HER2/PIK3CA Targeting Overcomes Single-Agent Acquired Resistance in HER2-Amplified Uterine Serous Carcinoma Cell Lines In Vitro and In Vivo.,http://www.ncbi.nlm.nih.gov/pubmed/26333383
6892,21799892,Identification of RNF213 as a susceptibility gene for moyamoya disease and its possible role in vascular development.,http://www.ncbi.nlm.nih.gov/pubmed/21799892
6893,26735018,An ID2-dependent mechanism for VHL inactivation in cancer.,http://www.ncbi.nlm.nih.gov/pubmed/26735018
6894,26682573,Activation of EGFR Bypass Signaling by TGFα Overexpression Induces Acquired Resistance to Alectinib in ALK-Translocated Lung Cancer Cells.,http://www.ncbi.nlm.nih.gov/pubmed/26682573
6895,27706135,The epichaperome is an integrated chaperome network that facilitates tumour survival.,http://www.ncbi.nlm.nih.gov/pubmed/27706135
6896,26487278,Preclinical Evidence That Trametinib Enhances the Response to Antiangiogenic Tyrosine Kinase Inhibitors in Renal Cell Carcinoma.,http://www.ncbi.nlm.nih.gov/pubmed/26487278
6897,26202948,"Notch Pathway Inhibition Using PF-03084014, a γ-Secretase Inhibitor (GSI), Enhances the Antitumor Effect of Docetaxel in Prostate Cancer.",http://www.ncbi.nlm.nih.gov/pubmed/26202948
6898,26917818,Dinutuximab: An Anti-GD2 Monoclonal Antibody for High-Risk Neuroblastoma.,http://www.ncbi.nlm.nih.gov/pubmed/26917818
6899,27102283,Expression analysis of 0-series gangliosides in human cancer cell lines with monoclonal antibodies generated using knockout mice of ganglioside synthase genes.,http://www.ncbi.nlm.nih.gov/pubmed/27102283
6900,27775715,Design and characterization of bivalent BET inhibitors.,http://www.ncbi.nlm.nih.gov/pubmed/27775715
6901,22106379,"The Nek8 protein kinase, mutated in the human cystic kidney disease nephronophthisis, is both activated and degraded during ciliogenesis.",http://www.ncbi.nlm.nih.gov/pubmed/22106379
6902,15019993,"Nek8, a NIMA family kinase member, is overexpressed in primary human breast tumors.",http://www.ncbi.nlm.nih.gov/pubmed/15019993
6903,25451921,The tumor suppressor pVHL down-regulates never-in-mitosis A-related kinase 8 via hypoxia-inducible factors to maintain cilia in human renal cancer cells.,http://www.ncbi.nlm.nih.gov/pubmed/25451921
6904,7713939,Characterization of a protein kinase C-delta (PKC-delta) ATP binding mutant. An inactive enzyme that competitively inhibits wild type PKC-delta enzymatic activity.,http://www.ncbi.nlm.nih.gov/pubmed/7713939
6905,10951578,The contribution of the RING finger domain of MDM2 to cell cycle progression.,http://www.ncbi.nlm.nih.gov/pubmed/10951578
6906,27798265,Selective targeting of mutant adenomatous polyposis coli (APC) in colorectal cancer.,http://www.ncbi.nlm.nih.gov/pubmed/27798265
6907,27797971,"An Open-Label, Dose-Escalation Phase I Study of Anti-TYRP1 Monoclonal Antibody IMC-20D7S for Patients with Relapsed or Refractory Melanoma.",http://www.ncbi.nlm.nih.gov/pubmed/27797971
6908,27634756,RK-33 Radiosensitizes Prostate Cancer Cells by Blocking the RNA Helicase DDX3.,http://www.ncbi.nlm.nih.gov/pubmed/27634756
6909,21324755,Tyrosinase related protein 1 (TYRP1/gp75) in human cutaneous melanoma.,http://www.ncbi.nlm.nih.gov/pubmed/21324755
6910,22045183,TYRP1 mRNA expression in melanoma metastases correlates with clinical outcome.,http://www.ncbi.nlm.nih.gov/pubmed/22045183
6911,27543601,Preclinical Efficacy of the Auristatin-Based Antibody-Drug Conjugate BAY 1187982 for the Treatment of FGFR2-Positive Solid Tumors.,http://www.ncbi.nlm.nih.gov/pubmed/27543601
6912,27749844,Prospective functional classification of all possible missense variants in PPARG.,http://www.ncbi.nlm.nih.gov/pubmed/27749844
6913,26541825,"DDX3, a potential target for cancer treatment.",http://www.ncbi.nlm.nih.gov/pubmed/26541825
6914,27180681,Cancer-associated DDX3X mutations drive stress granule assembly and impair global translation.,http://www.ncbi.nlm.nih.gov/pubmed/27180681
6915,27333990,"Aphanin, a triterpenoid from Amoora rohituka inhibits K-Ras mutant activity and STAT3 in pancreatic carcinoma cells.",http://www.ncbi.nlm.nih.gov/pubmed/27333990
6916,26437366,Loss of BAP1 function leads to EZH2-dependent transformation.,http://www.ncbi.nlm.nih.gov/pubmed/26437366
6917,22031859,"IPH2101, a novel anti-inhibitory KIR antibody, and lenalidomide combine to enhance the natural killer cell versus multiple myeloma effect.",http://www.ncbi.nlm.nih.gov/pubmed/22031859
6918,18574028,Two opposite signaling outputs are driven by the KIR2DL1 receptor in human CD4+ T cells.,http://www.ncbi.nlm.nih.gov/pubmed/18574028
6919,24592397,Killer immunoglobulin-like receptors and tumor immunity.,http://www.ncbi.nlm.nih.gov/pubmed/24592397
6920,27307594,Checkpoint Inhibition of KIR2D with the Monoclonal Antibody IPH2101 Induces Contraction and Hyporesponsiveness of NK Cells in Patients with Myeloma.,http://www.ncbi.nlm.nih.gov/pubmed/27307594
6921,27217440,BRAF Status in Personalizing Treatment Approaches for Pediatric Gliomas.,http://www.ncbi.nlm.nih.gov/pubmed/27217440
6922,27646843,"Ricolinostat plus lenalidomide, and dexamethasone in relapsed or refractory multiple myeloma: a multicentre phase 1b trial.",http://www.ncbi.nlm.nih.gov/pubmed/27646843
6923,27540016,The Novel Tubulin-Binding Checkpoint Activator BAL101553 Inhibits EB1-Dependent Migration and Invasion and Promotes Differentiation of Glioblastoma Stem-like Cells.,http://www.ncbi.nlm.nih.gov/pubmed/27540016
6924,27573423,"AC0010, an Irreversible EGFR Inhibitor Selectively Targeting Mutated EGFR and Overcoming T790M-Induced Resistance in Animal Models and Lung Cancer Patients.",http://www.ncbi.nlm.nih.gov/pubmed/27573423
6925,27550940,Identification of Pharmacodynamic Transcript Biomarkers in Response to FGFR Inhibition by AZD4547.,http://www.ncbi.nlm.nih.gov/pubmed/27550940
6926,27530131,Reactive Oxygen Species Mediates the Synergistic Activity of Fenretinide Combined with the Microtubule Inhibitor ABT-751 against Multidrug-Resistant Recurrent Neuroblastoma Xenografts.,http://www.ncbi.nlm.nih.gov/pubmed/27530131
6927,27573426,AZD5153: A Novel Bivalent BET Bromodomain Inhibitor Highly Active against Hematologic Malignancies.,http://www.ncbi.nlm.nih.gov/pubmed/27573426
6928,27535969,"E7090, a Novel Selective Inhibitor of Fibroblast Growth Factor Receptors, Displays Potent Antitumor Activity and Prolongs Survival in Preclinical Models.",http://www.ncbi.nlm.nih.gov/pubmed/27535969
6929,7506125,MDA-MB-134 breast carcinoma cells overexpress fibroblast growth factor (FGF) receptors and are growth-inhibited by FGF ligands.,http://www.ncbi.nlm.nih.gov/pubmed/7506125
6930,19901323,"Multiple myeloma phosphotyrosine proteomic profile associated with FGFR3 expression, ligand activation, and drug inhibition.",http://www.ncbi.nlm.nih.gov/pubmed/19901323
6931,27550941,Dinaciclib Induces Anaphase Catastrophe in Lung Cancer Cells via Inhibition of Cyclin-Dependent Kinases 1 and 2.,http://www.ncbi.nlm.nih.gov/pubmed/27550941
6932,27582525,"RN927C, a Site-Specific Trop-2 Antibody-Drug Conjugate (ADC) with Enhanced Stability, Is Highly Efficacious in Preclinical Solid Tumor Models.",http://www.ncbi.nlm.nih.gov/pubmed/27582525
6933,10980545,NF1 gene analysis focused on CpG-rich exons in a cohort of 93 patients with neurofibromatosis type 1.,http://www.ncbi.nlm.nih.gov/pubmed/10980545
6934,15060124,Automated comparative sequence analysis identifies mutations in 89% of NF1 patients and confirms a mutation cluster in exons 11-17 distinct from the GAP related domain.,http://www.ncbi.nlm.nih.gov/pubmed/15060124
6935,27550944,"The Discovery and Preclinical Development of ASG-5ME, an Antibody-Drug Conjugate Targeting SLC44A4-Positive Epithelial Tumors Including Pancreatic and Prostate Cancer.",http://www.ncbi.nlm.nih.gov/pubmed/27550944
6936,16574953,Variants in the ATM-BRCA2-CHEK2 axis predispose to chronic lymphocytic leukemia.,http://www.ncbi.nlm.nih.gov/pubmed/16574953
6937,25625042,ATM gene mutations in sporadic breast cancer patients from Brazil.,http://www.ncbi.nlm.nih.gov/pubmed/25625042
6938,20179705,RAF inhibitors transactivate RAF dimers and ERK signalling in cells with wild-type BRAF.,http://www.ncbi.nlm.nih.gov/pubmed/20179705
6939,23624108,"Association between variants of PRDM1 and NDP52 and Crohn's disease, based on exome sequencing and functional studies.",http://www.ncbi.nlm.nih.gov/pubmed/23624108
6940,22280327,Phase I clinical trial of Exherin (ADH-1) in patients with advanced solid tumors.,http://www.ncbi.nlm.nih.gov/pubmed/22280327
6941,15349821,"N-cadherin in the spotlight of cell-cell adhesion, differentiation, embryogenesis, invasion and signalling.",http://www.ncbi.nlm.nih.gov/pubmed/15349821
6942,24442140,Beyond E-cadherin: roles of other cadherin superfamily members in cancer.,http://www.ncbi.nlm.nih.gov/pubmed/24442140
6943,21720365,Integrated genomic analyses of ovarian carcinoma.,http://www.ncbi.nlm.nih.gov/pubmed/21720365
6944,8840966,A p18 mutant defective in CDK6 binding in human breast cancer cells.,http://www.ncbi.nlm.nih.gov/pubmed/8840966
6945,11485924,"Alterations of the tumor suppressor genes CDKN2A (p16(INK4a)), p14(ARF), CDKN2B (p15(INK4b)), and CDKN2C (p18(INK4c)) in atypical and anaplastic meningiomas.",http://www.ncbi.nlm.nih.gov/pubmed/11485924
6946,27288520,Spectrum and prognostic relevance of driver gene mutations in acute myeloid leukemia.,http://www.ncbi.nlm.nih.gov/pubmed/27288520
6947,24236184,Molecular typing of lung adenocarcinoma on cytological samples using a multigene next generation sequencing panel.,http://www.ncbi.nlm.nih.gov/pubmed/24236184
6948,18772396,An integrated genomic analysis of human glioblastoma multiforme.,http://www.ncbi.nlm.nih.gov/pubmed/18772396
6949,10225439,Mutations of the p53 gene in oral squamous-cell carcinomas from Sudanese dippers of nitrosamine-rich toombak and non-snuff-dippers from the Sudan and Scandinavia.,http://www.ncbi.nlm.nih.gov/pubmed/10225439
6950,17000668,EWS-CREB1: a recurrent variant fusion in clear cell sarcoma--association with gastrointestinal location and absence of melanocytic differentiation.,http://www.ncbi.nlm.nih.gov/pubmed/17000668
6951,24441665,Recurrent EWSR1-CREB3L1 gene fusions in sclerosing epithelioid fibrosarcoma.,http://www.ncbi.nlm.nih.gov/pubmed/24441665
6952,23588368,EWSR1-CREB3L1 gene fusion: a novel alternative molecular aberration of low-grade fibromyxoid sarcoma.,http://www.ncbi.nlm.nih.gov/pubmed/23588368
6953,22766791,"Expression of ERG, an Ets family transcription factor, identifies ERG-rearranged Ewing sarcoma.",http://www.ncbi.nlm.nih.gov/pubmed/22766791
6954,24993903,Malignant round cell tumor of bone with EWSR1-NFATC2 gene fusion.,http://www.ncbi.nlm.nih.gov/pubmed/24993903
6955,22622578,Melanoma genome sequencing reveals frequent PREX2 mutations.,http://www.ncbi.nlm.nih.gov/pubmed/22622578
6956,18948947,Somatic mutations affect key pathways in lung adenocarcinoma.,http://www.ncbi.nlm.nih.gov/pubmed/18948947
6957,18559588,Somatic mutations of JAK1 and JAK3 in acute leukemias and solid cancers.,http://www.ncbi.nlm.nih.gov/pubmed/18559588
6958,24816253,Whole-genome sequencing and comprehensive molecular profiling identify new driver mutations in gastric cancer.,http://www.ncbi.nlm.nih.gov/pubmed/24816253
6959,22941189,Comprehensive genomic analysis identifies SOX2 as a frequently amplified gene in small-cell lung cancer.,http://www.ncbi.nlm.nih.gov/pubmed/22941189
6960,22156295,Whole-exome sequencing of human pancreatic cancers and characterization of genomic instability caused by MLH1 haploinsufficiency and complete deficiency.,http://www.ncbi.nlm.nih.gov/pubmed/22156295
6961,24185509,"Exome sequencing identifies frequent inactivating mutations in BAP1, ARID1A and PBRM1 in intrahepatic cholangiocarcinomas.",http://www.ncbi.nlm.nih.gov/pubmed/24185509
6962,24755471,Colorectal cancer cell lines are representative models of the main molecular subtypes of primary cancer.,http://www.ncbi.nlm.nih.gov/pubmed/24755471
6963,25589618,Genomic analysis of metastatic cutaneous squamous cell carcinoma.,http://www.ncbi.nlm.nih.gov/pubmed/25589618
6964,23856246,The exomes of the NCI-60 panel: a genomic resource for cancer biology and systems pharmacology.,http://www.ncbi.nlm.nih.gov/pubmed/23856246
6965,,"Clinical activity of the poly(ADP-ribose) polymerase (PARP) inhibitor rucaparib in patients (pts) with high-grade ovarian carcinoma (HGOC) and a BRCA mutation (BRCAmut): Analysis of pooled data from Study 10 (parts 1, 2a, and 3) and ARIEL2 (parts 1 and 2)",http://clovisoncology.com/files/Rucaparib_RKristeleit_ESMO2016.pdf
6966,16863688,"TBC1D3, a hominoid oncoprotein, is encoded by a cluster of paralogues located on chromosome 17q12.",http://www.ncbi.nlm.nih.gov/pubmed/16863688
6967,15054085,The enigmatic protein kinase Cdelta: complex roles in cell proliferation and survival.,http://www.ncbi.nlm.nih.gov/pubmed/15054085
6968,27687302,Pathway level alterations rather than mutations in single genes predict response to HER2-targeted therapies in the neo-ALTTO trial.,http://www.ncbi.nlm.nih.gov/pubmed/27687302
6969,26811494,Genetic alterations and their clinical implications in gastric cancer peritoneal carcinomatosis revealed by whole-exome sequencing of malignant ascites.,http://www.ncbi.nlm.nih.gov/pubmed/26811494
6970,26015399,K-Ras stabilization by estrogen via PKCδ is involved in endometrial tumorigenesis.,http://www.ncbi.nlm.nih.gov/pubmed/26015399
6971,23474764,Protein kinase Cδ is required for ErbB2-driven mammary gland tumorigenesis and negatively correlates with prognosis in human breast cancer.,http://www.ncbi.nlm.nih.gov/pubmed/23474764
6972,12417016,Protein kinase C gamma (PKC gamma): function of neuron specific isotype.,http://www.ncbi.nlm.nih.gov/pubmed/12417016
6973,15028022,Characterization of expression of protein kinase C isozymes in human B-cell lymphoma: Relationship between its expression and prognosis.,http://www.ncbi.nlm.nih.gov/pubmed/15028022
6974,25252845,Single-nucleotide polymorphisms of the PRKCG gene and osteosarcoma susceptibility.,http://www.ncbi.nlm.nih.gov/pubmed/25252845
6975,27550943,A Novel Polyphenol Conjugate Sensitizes Cisplatin-Resistant Head and Neck Cancer Cells to Cisplatin via Nrf2 Inhibition.,http://www.ncbi.nlm.nih.gov/pubmed/27550943
6976,10783308,Effect of a tyrosine 155 to phenylalanine mutation of protein kinase cdelta on the proliferative and tumorigenic properties of NIH 3T3 fibroblasts.,http://www.ncbi.nlm.nih.gov/pubmed/10783308
6977,18059334,Tyrosine phosphorylation regulates nuclear translocation of PKCdelta.,http://www.ncbi.nlm.nih.gov/pubmed/18059334
6978,16828200,R659S mutation of gammaPKC is susceptible to cell death: implication of this mutation/polymorphism in the pathogenesis of retinitis pigmentosa.,http://www.ncbi.nlm.nih.gov/pubmed/16828200
6979,25810375,CDK4 Amplification Reduces Sensitivity to CDK4/6 Inhibition in Fusion-Positive Rhabdomyosarcoma.,http://www.ncbi.nlm.nih.gov/pubmed/25810375
6980,27622333,"Physiologic Expression of Sf3b1(K700E) Causes Impaired Erythropoiesis, Aberrant Splicing, and Sensitivity to Therapeutic Spliceosome Modulation.",http://www.ncbi.nlm.nih.gov/pubmed/27622333
6981,19934279,"SGX523 is an exquisitely selective, ATP-competitive inhibitor of the MET receptor tyrosine kinase with antitumor activity in vivo.",http://www.ncbi.nlm.nih.gov/pubmed/19934279
6982,26483207,c-Myc alterations confer therapeutic response and acquired resistance to c-Met inhibitors in MET-addicted cancers.,http://www.ncbi.nlm.nih.gov/pubmed/26483207
6983,12522551,Neurofibromatosis type 1 gene as a mutational target in a mismatch repair-deficient cell type.,http://www.ncbi.nlm.nih.gov/pubmed/12522551
6984,19332150,"SERPINB3, apoptosis and autoimmunity.",http://www.ncbi.nlm.nih.gov/pubmed/19332150
6985,25984243,"SERPINB3 (serpin peptidase inhibitor, clade B (ovalbumin), member 3).",http://www.ncbi.nlm.nih.gov/pubmed/25984243
6986,27668655,Recurrent SERPINB3 and SERPINB4 mutations in patients who respond to anti-CTLA4 immunotherapy.,http://www.ncbi.nlm.nih.gov/pubmed/27668655
6987,27655433,A Recurrent ERCC3 Truncating Mutation Confers Moderate Risk for Breast Cancer.,http://www.ncbi.nlm.nih.gov/pubmed/27655433
6988,25315765,Metastatic tumor evolution and organoid modeling implicate TGFBR2 as a cancer driver in diffuse gastric cancer.,http://www.ncbi.nlm.nih.gov/pubmed/25315765
6989,23103869,Pancreatic cancer genomes reveal aberrations in axon guidance pathway genes.,http://www.ncbi.nlm.nih.gov/pubmed/23103869
6990,26645726,Thoracic Myoepithelial Tumors: A Pathologic and Molecular Study of 8 Cases With Review of the Literature.,http://www.ncbi.nlm.nih.gov/pubmed/26645726
6991,22825745,Alterations of MEN1 and E-cadherin/β-catenin complex in sporadic pulmonary carcinoids.,http://www.ncbi.nlm.nih.gov/pubmed/22825745
6992,25589003,Sporadic hemangioblastomas are characterized by cryptic VHL inactivation.,http://www.ncbi.nlm.nih.gov/pubmed/25589003
6993,26124202,Wee-1 Kinase Inhibition Sensitizes High-Risk HPV+ HNSCC to Apoptosis Accompanied by Downregulation of MCl-1 and XIAP Antiapoptotic Proteins.,http://www.ncbi.nlm.nih.gov/pubmed/26124202
6994,27669459,Sustained ERK inhibition maximizes responses of BrafV600E thyroid cancers to radioiodine.,http://www.ncbi.nlm.nih.gov/pubmed/27669459
6995,26168399,Comprehensive genomic profiles of small cell lung cancer.,http://www.ncbi.nlm.nih.gov/pubmed/26168399
6996,16959974,The consensus coding sequences of human breast and colorectal cancers.,http://www.ncbi.nlm.nih.gov/pubmed/16959974
6997,22037554,Exome sequencing identifies frequent mutation of ARID1A in molecular subtypes of gastric cancer.,http://www.ncbi.nlm.nih.gov/pubmed/22037554
6998,24121792,Whole-genome and whole-exome sequencing of bladder cancer identifies frequent alterations in genes involved in sister chromatid cohesion and segregation.,http://www.ncbi.nlm.nih.gov/pubmed/24121792
6999,21798893,The mutational landscape of head and neck squamous cell carcinoma.,http://www.ncbi.nlm.nih.gov/pubmed/21798893
7000,26494859,Potentiation of Carboplatin-Mediated DNA Damage by the Mdm2 Modulator Nutlin-3a in a Humanized Orthotopic Breast-to-Lung Metastatic Model.,http://www.ncbi.nlm.nih.gov/pubmed/26494859
7001,27637160,SERPINB3 and B4: From biochemistry to biology.,http://www.ncbi.nlm.nih.gov/pubmed/27637160
7002,27727447,A phase 2 study of the sphingosine-1-phosphate antibody sonepcizumab in patients with metastatic renal cell carcinoma.,http://www.ncbi.nlm.nih.gov/pubmed/27727447
7003,27535971,Bazedoxifene as a Novel GP130 Inhibitor for Pancreatic Cancer Therapy.,http://www.ncbi.nlm.nih.gov/pubmed/27535971
7004,25957691,Prospective derivation of a living organoid biobank of colorectal cancer patients.,http://www.ncbi.nlm.nih.gov/pubmed/25957691
7005,9079651,Blockade of transforming growth factor-beta signaling does not abrogate antiestrogen-induced growth inhibition of human breast carcinoma cells.,http://www.ncbi.nlm.nih.gov/pubmed/9079651
7006,25303977,Mutational landscape of aggressive cutaneous squamous cell carcinoma.,http://www.ncbi.nlm.nih.gov/pubmed/25303977
7007,26206338,Assessment of the In Vivo Activity of PI3K and MEK Inhibitors in Genetically Defined Models of Colorectal Cancer.,http://www.ncbi.nlm.nih.gov/pubmed/26206338
7008,21098638,Quantitative analysis of TGFBR2 mutations in Marfan-syndrome-related disorders suggests a correlation between phenotypic severity and Smad signaling activity.,http://www.ncbi.nlm.nih.gov/pubmed/21098638
7009,18781618,"Identification of 23 TGFBR2 and 6 TGFBR1 gene mutations and genotype-phenotype investigations in 457 patients with Marfan syndrome type I and II, Loeys-Dietz syndrome and related disorders.",http://www.ncbi.nlm.nih.gov/pubmed/18781618
7010,25561229,Gene mutation analysis in EGFR wild type NSCLC responsive to erlotinib: are there features to guide patient selection?,http://www.ncbi.nlm.nih.gov/pubmed/25561229
7011,25480502,Targeted next-generation sequencing in chronic lymphocytic leukemia: a high-throughput yet tailored approach will facilitate implementation in a clinical setting.,http://www.ncbi.nlm.nih.gov/pubmed/25480502
7012,22102435,Low-grade serous carcinomas of the ovary contain very few point mutations.,http://www.ncbi.nlm.nih.gov/pubmed/22102435
7013,27443518,Characterization of FN1-FGFR1 and novel FN1-FGF1 fusion genes in a large series of phosphaturic mesenchymal tumors.,http://www.ncbi.nlm.nih.gov/pubmed/27443518
7014,9315851,Random mutagenesis of the poly(ADP-ribose) polymerase catalytic domain reveals amino acids involved in polymer branching.,http://www.ncbi.nlm.nih.gov/pubmed/9315851
7015,26674132,Mismatch repair deficiency associated with complete remission to combination programmed cell death ligand immune therapy in a patient with sporadic urothelial carcinoma: immunotheranostic considerations.,http://www.ncbi.nlm.nih.gov/pubmed/26674132
7016,21156417,A new mutation in the hMSH2 gene in a Spanish Lynch syndrome family.,http://www.ncbi.nlm.nih.gov/pubmed/21156417
7017,25126449,The determinants of head and neck cancer: Unmasking the PI3K pathway mutations.,http://www.ncbi.nlm.nih.gov/pubmed/25126449
7018,22138691,Frequent mutations of genes encoding ubiquitin-mediated proteolysis pathway components in clear cell renal cell carcinoma.,http://www.ncbi.nlm.nih.gov/pubmed/22138691
7019,27512118,Trabectedin Is Active against Malignant Pleural Mesothelioma Cell and Xenograft Models and Synergizes with Chemotherapy and Bcl-2 Inhibition In Vitro.,http://www.ncbi.nlm.nih.gov/pubmed/27512118
7020,27718784,Nivolumab for Recurrent Squamous-Cell Carcinoma of the Head and Neck.,http://www.ncbi.nlm.nih.gov/pubmed/27718784
7021,23525077,Exome and whole-genome sequencing of esophageal adenocarcinoma identifies recurrent driver events and mutational complexity.,http://www.ncbi.nlm.nih.gov/pubmed/23525077
7022,25822088,Exome sequencing of hepatocellular carcinomas identifies new mutational signatures and potential therapeutic targets.,http://www.ncbi.nlm.nih.gov/pubmed/25822088
7023,22722201,The landscape of cancer genes and mutational processes in breast cancer.,http://www.ncbi.nlm.nih.gov/pubmed/22722201
7024,25855536,Whole-exome sequencing of pancreatic cancer defines genetic diversity and therapeutic targets.,http://www.ncbi.nlm.nih.gov/pubmed/25855536
7025,27135926,Landscape of somatic mutations in 560 breast cancer whole-genome sequences.,http://www.ncbi.nlm.nih.gov/pubmed/27135926
7026,15926618,Spectrum of germ-line MLH1 and MSH2 mutations in Austrian patients with hereditary nonpolyposis colorectal cancer.,http://www.ncbi.nlm.nih.gov/pubmed/15926618
7027,15655560,hMSH2 is the most commonly mutated MMR gene in a cohort of Greek HNPCC patients.,http://www.ncbi.nlm.nih.gov/pubmed/15655560
7028,26390038,Pre-Clinical Development of a Humanized Anti-CD47 Antibody with Anti-Cancer Therapeutic Potential.,http://www.ncbi.nlm.nih.gov/pubmed/26390038
7029,,"A first-in-human, first-in-class phase I trial of the anti-CD47 antibody Hu5F9-G4 in patients with advanced cancers.",http://meetinglibrary.asco.org/content/162472-176
7030,25042771,The mutational burdens and evolutionary ages of early gastric cancers are comparable to those of advanced gastric cancers.,http://www.ncbi.nlm.nih.gov/pubmed/25042771
7031,27528706,Development of a RSK Inhibitor as a Novel Therapy for Triple-Negative Breast Cancer.,http://www.ncbi.nlm.nih.gov/pubmed/27528706
7032,15705904,Identification of the first specific inhibitor of p90 ribosomal S6 kinase (RSK) reveals an unexpected role for RSK in cancer cell proliferation.,http://www.ncbi.nlm.nih.gov/pubmed/15705904
7033,8384311,Mos stimulates MAP kinase in Xenopus oocytes and activates a MAP kinase kinase in vitro.,http://www.ncbi.nlm.nih.gov/pubmed/8384311
7034,27469115,SMAC Mimetic Birinapant plus Radiation Eradicates Human Head and Neck Cancers with Genomic Amplifications of Cell Death Genes FADD and BIRC2.,http://www.ncbi.nlm.nih.gov/pubmed/27469115
7035,8972231,Synergy between the Mos/mitogen-activated protein kinase pathway and loss of p53 function in transformation and chromosome instability.,http://www.ncbi.nlm.nih.gov/pubmed/8972231
7036,7588633,The Mos/MAP kinase pathway stabilizes c-Fos by phosphorylation and augments its transforming activity in NIH 3T3 cells.,http://www.ncbi.nlm.nih.gov/pubmed/7588633
7037,24215318,"The interaction between signal regulatory protein alpha (SIRPα) and CD47: structure, function, and therapeutic target.",http://www.ncbi.nlm.nih.gov/pubmed/24215318
7038,24627525,The CD47-SIRPα signalling system: its physiological roles and therapeutic application.,http://www.ncbi.nlm.nih.gov/pubmed/24627525
7039,27496136,"Single Agent and Synergistic Activity of the ""First-in-Class"" Dual PI3K/BRD4 Inhibitor SF1126 with Sorafenib in Hepatocellular Carcinoma.",http://www.ncbi.nlm.nih.gov/pubmed/27496136
7040,23355037,"An integrin-targeted, pan-isoform, phosphoinositide-3 kinase inhibitor, SF1126, has activity against multiple myeloma in vivo.",http://www.ncbi.nlm.nih.gov/pubmed/23355037
7041,27308622,Characterization of cancer-associated missense mutations in MDM2.,http://www.ncbi.nlm.nih.gov/pubmed/27308622
7042,27694802,Oligosaccharyltransferase inhibition induces senescence in RTK-driven tumor cells.,http://www.ncbi.nlm.nih.gov/pubmed/27694802
7043,27836716,"Activity and safety of brigatinib in ALK-rearranged non-small-cell lung cancer and other malignancies: a single-arm, open-label, phase 1/2 trial.",http://www.ncbi.nlm.nih.gov/pubmed/27836716
7044,27780853,The Potent ALK Inhibitor Brigatinib (AP26113) Overcomes Mechanisms of Resistance to First- and Second-Generation ALK Inhibitors in Preclinical Models.,http://www.ncbi.nlm.nih.gov/pubmed/27780853
7045,27393507,High MET amplification level as a resistance mechanism to osimertinib (AZD9291) in a patient that symptomatically responded to crizotinib treatment post-osimertinib progression.,http://www.ncbi.nlm.nih.gov/pubmed/27393507
7046,27178741,PAK1 Is a Novel Therapeutic Target in Tyrosine Kinase Inhibitor-Resistant Lung Adenocarcinoma Activated by the PI3K/AKT Signaling Regardless of EGFR Mutation.,http://www.ncbi.nlm.nih.gov/pubmed/27178741
7047,27283993,Circulating tumour DNA profiling reveals heterogeneity of EGFR inhibitor resistance mechanisms in lung cancer patients.,http://www.ncbi.nlm.nih.gov/pubmed/27283993
7048,25914548,A case of EGFR mutant lung adenocarcinoma that acquired resistance to EGFR-tyrosine kinase inhibitors with MET amplification and epithelial-to-mesenchymal transition.,http://www.ncbi.nlm.nih.gov/pubmed/25914548
7049,26187428,Emergence of RET rearrangement co-existing with activated EGFR mutation in EGFR-mutated NSCLC patients who had progressed on first- or second-generation EGFR TKI.,http://www.ncbi.nlm.nih.gov/pubmed/26187428
7050,22190405,Germline mutations in the oncogene EZH2 cause Weaver syndrome and increased human height.,http://www.ncbi.nlm.nih.gov/pubmed/22190405
7051,23613835,EZH2 mutations are related to low blast percentage in bone marrow and -7/del(7q) in de novo acute myeloid leukemia.,http://www.ncbi.nlm.nih.gov/pubmed/23613835
7052,27276561,Genomic Classification and Prognosis in Acute Myeloid Leukemia.,http://www.ncbi.nlm.nih.gov/pubmed/27276561
7053,20724984,Novel homo- and hemizygous mutations in EZH2 in myeloid malignancies.,http://www.ncbi.nlm.nih.gov/pubmed/20724984
7054,23392356,The secondary FLT3-ITD F691L mutation induces resistance to AC220 in FLT3-ITD+ AML but retains in vitro sensitivity to PKC412 and Sunitinib.,http://www.ncbi.nlm.nih.gov/pubmed/23392356
7055,27565908,De novo ALK kinase domain mutations are uncommon in kinase inhibitor-naïve ALK rearranged lung cancers.,http://www.ncbi.nlm.nih.gov/pubmed/27565908
7056,20520641,Identification of a secondary FLT3/A848P mutation in a patient with FLT3-ITD-positive blast phase CMML and response to sunitinib and sorafenib.,http://www.ncbi.nlm.nih.gov/pubmed/20520641
7057,26472108,Transient rRNA synthesis inhibition with CX-5461 is sufficient to elicit growth arrest and cell death in acute lymphoblastic leukemia cells.,http://www.ncbi.nlm.nih.gov/pubmed/26472108
7058,26437031,Integrated molecular analysis of adult T cell leukemia/lymphoma.,http://www.ncbi.nlm.nih.gov/pubmed/26437031
7059,26530882,Targeted DNA Sequencing Detects Mutations Related to Susceptibility among Familial Non-medullary Thyroid Cancer.,http://www.ncbi.nlm.nih.gov/pubmed/26530882
7060,26320869,Mutations in the Kinase Domain of the HER2/ERBB2 Gene Identified in a Wide Variety of Human Cancers.,http://www.ncbi.nlm.nih.gov/pubmed/26320869
7061,23741632,An In Silico Evaluation of Deleterious Nonsynonymous Single Nucleotide Polymorphisms in the ErbB3 Oncogene.,http://www.ncbi.nlm.nih.gov/pubmed/23741632
7062,27601554,"Phase I Study Evaluating WEE1 Inhibitor AZD1775 As Monotherapy and in Combination With Gemcitabine, Cisplatin, or Carboplatin in Patients With Advanced Solid Tumors.",http://www.ncbi.nlm.nih.gov/pubmed/27601554
7063,26884599,ATF4 induction through an atypical integrated stress response to ONC201 triggers p53-independent apoptosis in hematological malignancies.,http://www.ncbi.nlm.nih.gov/pubmed/26884599
7064,26011570,"The repertoire of somatic genetic alterations of acinic cell carcinomas of the breast: an exploratory, hypothesis-generating study.",http://www.ncbi.nlm.nih.gov/pubmed/26011570
7065,27172896,"Loss of ARID1A Activates ANXA1, which Serves as a Predictive Biomarker for Trastuzumab Resistance.",http://www.ncbi.nlm.nih.gov/pubmed/27172896
7066,26586721,"GC1118, an Anti-EGFR Antibody with a Distinct Binding Epitope and Superior Inhibitory Activity against High-Affinity EGFR Ligands.",http://www.ncbi.nlm.nih.gov/pubmed/26586721
7067,22225590,Impact of complex NOTCH1 mutations on survival in paediatric T-cell leukaemia.,http://www.ncbi.nlm.nih.gov/pubmed/22225590
7068,19794083,Prognostic implications of NOTCH1 and FBXW7 mutations in adult acute T-lymphoblastic leukemia.,http://www.ncbi.nlm.nih.gov/pubmed/19794083
7069,24686850,Genomic and molecular characterization of esophageal squamous cell carcinoma.,http://www.ncbi.nlm.nih.gov/pubmed/24686850
7070,27486174,The Dual Inhibition of RNA Pol I Transcription and PIM Kinase as a New Therapeutic Approach to Treat Advanced Prostate Cancer.,http://www.ncbi.nlm.nih.gov/pubmed/27486174
7071,26888827,The First-in-class Anti-EGFR Antibody Mixture Sym004 Overcomes Cetuximab Resistance Mediated by EGFR Extracellular Domain Mutations in Colorectal Cancer.,http://www.ncbi.nlm.nih.gov/pubmed/26888827
7072,26482041,Preclinical Efficacy of the MDM2 Inhibitor RG7112 in MDM2-Amplified and TP53 Wild-type Glioblastomas.,http://www.ncbi.nlm.nih.gov/pubmed/26482041
7073,26286987,Phylogenetic analyses of melanoma reveal complex patterns of metastatic dissemination.,http://www.ncbi.nlm.nih.gov/pubmed/26286987
7074,25749049,Multiple mechanisms of MYCN dysregulation in Wilms tumour.,http://www.ncbi.nlm.nih.gov/pubmed/25749049
7075,22158988,Whole-exome sequencing of neoplastic cysts of the pancreas reveals recurrent mutations in components of ubiquitin-dependent pathways.,http://www.ncbi.nlm.nih.gov/pubmed/22158988
7076,24997986,Whole-exome and targeted gene sequencing of gallbladder carcinoma identifies recurrent mutations in the ErbB pathway.,http://www.ncbi.nlm.nih.gov/pubmed/24997986
7077,,"Preclinical activity of MDM2 antagonist RO6839921, a pegylated prodrug for intravenous administration",http://mct.aacrjournals.org/content/14/12_Supplement_2/A156.short
7078,,Selumetinib in combination with docetaxel as second-line treatment for patients with KRAS-mutant advanced NSCLC: Results from the phase III SELECT-1 trial,http://annonc.oxfordjournals.org/content/27/suppl_6/LBA47_PR.full
7079,24156336,Potential role of Anxa1 in cancer.,http://www.ncbi.nlm.nih.gov/pubmed/24156336
7080,17215481,Annexin 1: the new face of an old molecule.,http://www.ncbi.nlm.nih.gov/pubmed/17215481
7081,21364689,Targeted therapy in GIST: in silico modeling for prediction of resistance.,http://www.ncbi.nlm.nih.gov/pubmed/21364689
7082,18488160,Molecular analysis of secondary kinase mutations in imatinib-resistant gastrointestinal stromal tumors.,http://www.ncbi.nlm.nih.gov/pubmed/18488160
7083,21653699,Cellular inhibitor of apoptosis protein-1 (cIAP1) can regulate E2F1 transcription factor-mediated control of cyclin transcription.,http://www.ncbi.nlm.nih.gov/pubmed/21653699
7084,26094954,Oncogenic activity of BIRC2 and BIRC3 mutants independent of nuclear factor-κB-activating potential.,http://www.ncbi.nlm.nih.gov/pubmed/26094954
7085,22733500,BIRC2 amplification in squamous cell carcinomas of the uterine cervix.,http://www.ncbi.nlm.nih.gov/pubmed/22733500
7086,20576468,FADD: a regulator of life and death.,http://www.ncbi.nlm.nih.gov/pubmed/20576468
7087,15520222,Absence or low expression of fas-associated protein with death domain in acute myeloid leukemia cells predicts resistance to chemotherapy and poor outcome.,http://www.ncbi.nlm.nih.gov/pubmed/15520222
7088,27626067,Testing ERBB2 p.L755S kinase domain mutation as a druggable target in a patient with advanced colorectal cancer.,http://www.ncbi.nlm.nih.gov/pubmed/27626067
7089,24379411,Molecular identification and functional characterization of the human colonic thiamine pyrophosphate transporter.,http://www.ncbi.nlm.nih.gov/pubmed/24379411
7090,21551320,Expression of Trop2 cell surface glycoprotein in normal and tumor tissues: potential implications as a cancer therapeutic target.,http://www.ncbi.nlm.nih.gov/pubmed/21551320
7091,26059528,Clinical investigation of TROP-2 as an independent biomarker and potential therapeutic target in colon cancer.,http://www.ncbi.nlm.nih.gov/pubmed/26059528
7092,26773504,TROP2 overexpression promotes proliferation and invasion of lung adenocarcinoma cells.,http://www.ncbi.nlm.nih.gov/pubmed/26773504
7093,24492008,End-binding protein 1 (EB1) up-regulation is an early event in colorectal carcinogenesis.,http://www.ncbi.nlm.nih.gov/pubmed/24492008
7094,26342024,MAPRE1 as a plasma biomarker for early-stage colorectal cancer and adenomas.,http://www.ncbi.nlm.nih.gov/pubmed/26342024
7095,27449595,Overcoming ABC transporter-mediated multidrug resistance: Molecular mechanisms and novel therapeutic drug strategies.,http://www.ncbi.nlm.nih.gov/pubmed/27449595
7096,27180306,ABC transporters as mediators of drug resistance and contributors to cancer cell biology.,http://www.ncbi.nlm.nih.gov/pubmed/27180306
7097,27697767,Lurbinectedin Inactivates the Ewing Sarcoma Oncoprotein EWS-FLI1 by Redistributing It within the Nucleus.,http://www.ncbi.nlm.nih.gov/pubmed/27697767
7098,26981247,Phase I study with ONCOS-102 for the treatment of solid tumors - an evaluation of clinical response and exploratory analyses of immune markers.,http://www.ncbi.nlm.nih.gov/pubmed/26981247
7099,14500346,BRAF mutations in colon cancer are not likely attributable to defective DNA mismatch repair.,http://www.ncbi.nlm.nih.gov/pubmed/14500346
7100,15935100,Preponderance of the oncogenic V599E and V599K mutations in B-raf kinase domain is enhanced in melanoma cutaneous/subcutaneous metastases.,http://www.ncbi.nlm.nih.gov/pubmed/15935100
7101,15331929,B-raf exon 15 mutations are common in primary melanoma resection specimens but not associated with clinical outcome.,http://www.ncbi.nlm.nih.gov/pubmed/15331929
7102,17360030,"Inverse correlation between RASSF1A hypermethylation, KRAS and BRAF mutations in cervical adenocarcinoma.",http://www.ncbi.nlm.nih.gov/pubmed/17360030
7103,21825258,Clinical features and outcome of patients with non-small-cell lung cancer harboring BRAF mutations.,http://www.ncbi.nlm.nih.gov/pubmed/21825258
7104,15837970,"Phase I trial of 177lutetium-labeled J591, a monoclonal antibody to prostate-specific membrane antigen, in patients with androgen-independent prostate cancer.",http://www.ncbi.nlm.nih.gov/pubmed/15837970
7105,19152441,High prevalence of BRAF mutation in a Brazilian cohort of patients with sporadic papillary thyroid carcinomas: correlation with more aggressive phenotype and decreased expression of iodide-metabolizing genes.,http://www.ncbi.nlm.nih.gov/pubmed/19152441
7106,23658559,Comparison of responses of human melanoma cell lines to MEK and BRAF inhibitors.,http://www.ncbi.nlm.nih.gov/pubmed/23658559
7107,15917418,BRAF and NRAS mutations are uncommon in melanomas arising in diverse internal organs.,http://www.ncbi.nlm.nih.gov/pubmed/15917418
7108,26186911,A phase II evaluation of cediranib in the treatment of recurrent or persistent endometrial cancer: An NRG Oncology/Gynecologic Oncology Group study.,http://www.ncbi.nlm.nih.gov/pubmed/26186911
7109,22842228,Exome sequencing identifies recurrent somatic RAC1 mutations in melanoma.,http://www.ncbi.nlm.nih.gov/pubmed/22842228
7110,16404419,BRAF mutations and phosphorylation status of mitogen-activated protein kinases in the development of flat and depressed-type colorectal neoplasias.,http://www.ncbi.nlm.nih.gov/pubmed/16404419
7111,15578519,BRAF mutations distinguish anorectal from cutaneous melanoma at the molecular level.,http://www.ncbi.nlm.nih.gov/pubmed/15578519
7112,16773193,The oncogenic B-raf V599E mutation occurs more frequently in melanomas at sun-protected body sites.,http://www.ncbi.nlm.nih.gov/pubmed/16773193
7113,15513360,Mutational activation of the RAS-RAF-MAPK and the Wnt pathway in small intestinal adenocarcinomas.,http://www.ncbi.nlm.nih.gov/pubmed/15513360
7114,16179870,Preponderance of the oncogenic V599E and V599K mutations in the B-raf kinase domain is enhanced in melanoma lymph node metastases.,http://www.ncbi.nlm.nih.gov/pubmed/16179870
7115,16827904,Clinical response to therapy targeted at vascular endothelial growth factor in metastatic renal cell carcinoma: impact of patient characteristics and Von Hippel-Lindau gene status.,http://www.ncbi.nlm.nih.gov/pubmed/16827904
7116,9816319,Prostate-specific membrane antigen: a novel folate hydrolase in human prostatic carcinoma cells.,http://www.ncbi.nlm.nih.gov/pubmed/9816319
7117,8570628,Prostate-specific membrane antigen is a hydrolase with substrate and pharmacologic characteristics of a neuropeptidase.,http://www.ncbi.nlm.nih.gov/pubmed/8570628
7118,16985927,Overview of prostate-specific membrane antigen.,http://www.ncbi.nlm.nih.gov/pubmed/16985927
7119,27026200,Carfilzomib Triggers Cell Death in Chronic Lymphocytic Leukemia by Inducing Proapoptotic and Endoplasmic Reticulum Stress Responses.,http://www.ncbi.nlm.nih.gov/pubmed/27026200
7120,26957312,Metformin sensitizes sorafenib to inhibit postoperative recurrence and metastasis of hepatocellular carcinoma in orthotopic mouse models.,http://www.ncbi.nlm.nih.gov/pubmed/26957312
7121,26359452,Kinome RNAi Screens Reveal Synergistic Targeting of MTOR and FGFR1 Pathways for Treatment of Lung Cancer and HNSCC.,http://www.ncbi.nlm.nih.gov/pubmed/26359452
7122,27672108,"First-in-human phase I study of copanlisib (BAY 80-6946), an intravenous pan-class I phosphatidylinositol 3-kinase inhibitor, in patients with advanced solid tumors and non-Hodgkin's lymphomas.",http://www.ncbi.nlm.nih.gov/pubmed/27672108
7123,,"EFFICACY OF A NOVEL ANTIBODY-DRUG CONJUGATE (ADC), ABT-414, AS MONOTHERAPY IN EPIDERMAL GROWTH FACTOR RECEPTOR (EGFR) AMPLIFIED (EGFRamp), RECURRENT GLIOBLASTOMA (rGBM)",http://neuro-oncology.oxfordjournals.org/content/18/suppl_6/vi2.3.abstract?sid=ef6007c0-0537-40d1-920d-fceb55d555f5
7124,,RESULTS OF THE PHASE IB KEYNOTE-028 MULTI-COHORT TRIAL OF PEMBROLIZUMAB MONOTHERAPY IN PATIENTS WITH RECURRENT PD-L1-POSITIVE GLIOBLASTOMA MULTIFORME (GBM),http://neuro-oncology.oxfordjournals.org/content/18/suppl_6/vi25.4.abstract?sid=af283a96-f950-4f1d-a7cb-611b9ddd3325
7125,,"PHASE 2 STUDY TO EVALUATE THE CLINICAL EFFICACY AND SAFETY OF MEDI4736 (DURVALUMAB [DUR]) IN PATIENTS WITH GLIOBLASTOMA (GBM): RESULTS FOR COHORT B (DUR MONOTHERAPY), BEVACIZUMAB (BEV) NAÏVE PATIENTS WITH RECURRENT GBM",http://neuro-oncology.oxfordjournals.org/content/18/suppl_6/vi18.1.abstract?sid=fff79e74-73b2-44b6-a1ee-800e65801125
7126,,"AG120, A FIRST-IN-CLASS MUTANT IDH1 INHIBITOR IN PATIENTS WITH RECURRENT OR PROGRESSIVE IDH1 MUTANT GLIOMA: RESULTS FROM THE PHASE 1 GLIOMA EXPANSION COHORTS",http://neuro-oncology.oxfordjournals.org/content/18/suppl_6/vi12.1.abstract?sid=36b4e22f-cb42-46ee-b8dd-4ea89b6a04fe
7127,27404348,Metformin Elicits Antitumor Effects and Downregulates the Histone Methyltransferase Multiple Myeloma SET Domain (MMSET) in Prostate Cancer Cells.,http://www.ncbi.nlm.nih.gov/pubmed/27404348
7128,26725216,Long-Term ERK Inhibition in KRAS-Mutant Pancreatic Cancer Is Associated with MYC Degradation and Senescence-like Growth Suppression.,http://www.ncbi.nlm.nih.gov/pubmed/26725216
7129,19393077,Association between the NBS1 E185Q polymorphism and cancer risk: a meta-analysis.,http://www.ncbi.nlm.nih.gov/pubmed/19393077
7130,22877736,Comparative genomic analysis of esophageal adenocarcinoma and squamous cell carcinoma.,http://www.ncbi.nlm.nih.gov/pubmed/22877736
7131,26109429,Genome-wide mutation profiles of colorectal tumors and associated liver metastases at the exome and transcriptome levels.,http://www.ncbi.nlm.nih.gov/pubmed/26109429
7132,23619168,Integrative genomic characterization of oral squamous cell carcinoma identifies frequent somatic drivers.,http://www.ncbi.nlm.nih.gov/pubmed/23619168
7133,17991446,"Mechanisms of BSO (L-buthionine-S,R-sulfoximine)-induced cytotoxic effects in neuroblastoma.",http://www.ncbi.nlm.nih.gov/pubmed/17991446
7134,27197195,mTORC1-Driven Tumor Cells Are Highly Sensitive to Therapeutic Targeting by Antagonists of Oxidative Stress.,http://www.ncbi.nlm.nih.gov/pubmed/27197195
7135,26232337,Characterization of patient-derived tumor xenograft models of endometrial cancer for preclinical evaluation of targeted therapies.,http://www.ncbi.nlm.nih.gov/pubmed/26232337
7136,14722917,Characterization of the somatic mutational spectrum of the neurofibromatosis type 1 (NF1) gene in neurofibromatosis patients with benign and malignant tumors.,http://www.ncbi.nlm.nih.gov/pubmed/14722917
7137,27577794,Integrin-α10 Dependency Identifies RAC and RICTOR as Therapeutic Targets in High-Grade Myxofibrosarcoma.,http://www.ncbi.nlm.nih.gov/pubmed/27577794
7138,19142971,Germline and somatic NF1 mutations in sporadic and NF1-associated malignant peripheral nerve sheath tumours.,http://www.ncbi.nlm.nih.gov/pubmed/19142971
7139,26343386,Exome sequencing of desmoplastic melanoma identifies recurrent NFKBIE promoter mutations and diverse activating mutations in the MAPK pathway.,http://www.ncbi.nlm.nih.gov/pubmed/26343386
7140,26637667,Control of PD-L1 Expression by Oncogenic Activation of the AKT-mTOR Pathway in Non-Small Cell Lung Cancer.,http://www.ncbi.nlm.nih.gov/pubmed/26637667
7141,26343582,BRAF Mutants Evade ERK-Dependent Feedback by Different Mechanisms that Determine Their Sensitivity to Pharmacologic Inhibition.,http://www.ncbi.nlm.nih.gov/pubmed/26343582
7142,23297126,Hierarchy in somatic mutations arising during genomic evolution and progression of follicular lymphoma.,http://www.ncbi.nlm.nih.gov/pubmed/23297126
7143,24388756,Genetics of follicular lymphoma transformation.,http://www.ncbi.nlm.nih.gov/pubmed/24388756
7144,26619011,Identifying recurrent mutations in cancer reveals widespread lineage diversity and mutational specificity.,http://www.ncbi.nlm.nih.gov/pubmed/26619011
7145,26927665,Clinical and Biologic Significance of MYC Genetic Mutations in De Novo Diffuse Large B-cell Lymphoma.,http://www.ncbi.nlm.nih.gov/pubmed/26927665
7146,20634801,8q24 allelic imbalance and MYC gene copy number in primary prostate cancer.,http://www.ncbi.nlm.nih.gov/pubmed/20634801
7147,26806338,Genomic Sequencing Identifies ELF3 as a Driver of Ampullary Carcinoma.,http://www.ncbi.nlm.nih.gov/pubmed/26806338
7148,22071139,Older patients with normal karyotype acute myeloid leukemia have a higher rate of genomic changes compared to young patients as determined by SNP array analysis.,http://www.ncbi.nlm.nih.gov/pubmed/22071139
7149,20678218,"Combined mutations of ASXL1, CBL, FLT3, IDH1, IDH2, JAK2, KRAS, NPM1, NRAS, RUNX1, TET2 and WT1 genes in myelodysplastic syndromes and acute myeloid leukemias.",http://www.ncbi.nlm.nih.gov/pubmed/20678218
7150,23010802,Activating CBL mutations are associated with a distinct MDS/MPN phenotype.,http://www.ncbi.nlm.nih.gov/pubmed/23010802
7151,26214590,Exome sequencing identifies recurrent mutations in NF1 and RASopathy genes in sun-exposed melanomas.,http://www.ncbi.nlm.nih.gov/pubmed/26214590
7152,26956871,Recurrent neomorphic mutations of MTOR in central nervous system and testicular germ cell tumors may be targeted for therapy.,http://www.ncbi.nlm.nih.gov/pubmed/26956871
7153,16612978,NF2 mutations in secretory and other rare variants of meningiomas.,http://www.ncbi.nlm.nih.gov/pubmed/16612978
7154,26554828,Gender-Specific Molecular and Clinical Features Underlie Malignant Pleural Mesothelioma.,http://www.ncbi.nlm.nih.gov/pubmed/26554828
7155,7669741,Predominant occurrence of somatic mutations of the NF2 gene in meningiomas and schwannomas.,http://www.ncbi.nlm.nih.gov/pubmed/7669741
7156,8379998,Alteration in a new gene encoding a putative membrane-organizing protein causes neuro-fibromatosis type 2.,http://www.ncbi.nlm.nih.gov/pubmed/8379998
7157,15609345,Genetic and epigenetic alteration of the NF2 gene in sporadic meningiomas.,http://www.ncbi.nlm.nih.gov/pubmed/15609345
7158,23975423,Overexpression and promoter mutation of the TERT gene in malignant pleural mesothelioma.,http://www.ncbi.nlm.nih.gov/pubmed/23975423
7159,17222329,Comprehensive genetic and epigenetic analysis of sporadic meningioma for macro-mutations on 22q and micro-mutations within the NF2 locus.,http://www.ncbi.nlm.nih.gov/pubmed/17222329
7160,24292195,Mutational landscape of gingivo-buccal oral squamous cell carcinoma reveals new recurrently-mutated genes and molecular subgroups.,http://www.ncbi.nlm.nih.gov/pubmed/24292195
7161,26873401,Genomic Landscape of Esophageal Squamous Cell Carcinoma in a Japanese Population.,http://www.ncbi.nlm.nih.gov/pubmed/26873401
7162,20421815,NFE2L2 gene mutation in male Japanese squamous cell carcinoma of the lung.,http://www.ncbi.nlm.nih.gov/pubmed/20421815
7163,19593635,Distinct gene mutation profiles among luminal-type and basal-type breast cancer cell lines.,http://www.ncbi.nlm.nih.gov/pubmed/19593635
7164,24436120,Differential mechanisms of CDKN2A (p16) alteration in oral tongue squamous cell carcinomas and correlation with patient outcome.,http://www.ncbi.nlm.nih.gov/pubmed/24436120
7165,23851445,Mutual exclusivity analysis of genetic and epigenetic drivers in melanoma identifies a link between p14 ARF and RARβ signaling.,http://www.ncbi.nlm.nih.gov/pubmed/23851445
7166,22941188,Integrative genome analyses identify key somatic driver mutations of small-cell lung cancer.,http://www.ncbi.nlm.nih.gov/pubmed/22941188
7167,,In-Frame Exon 9 CALR Deletions Co-Occur with Other Alterations in the JAK-STAT Pathway in Myeloproliferative Neoplasms,http://www.bloodjournal.org/content/124/21/4588?sso-checked=true
7168,22722829,Novel mutations target distinct subgroups of medulloblastoma.,http://www.ncbi.nlm.nih.gov/pubmed/22722829
7169,19967722,Oncogenic NRF2 mutations in squamous cell carcinomas of oesophagus and skin.,http://www.ncbi.nlm.nih.gov/pubmed/19967722
7170,21964605,Mutation of the Nrf2 gene in non-small cell lung cancer.,http://www.ncbi.nlm.nih.gov/pubmed/21964605
7171,24736102,Mutation spectrum of hepatocellular carcinoma from eastern-European patients betrays the impact of a complex exposome.,http://www.ncbi.nlm.nih.gov/pubmed/24736102
7172,22561517,Integrated analysis of somatic mutations and focal copy-number changes identifies key genes and pathways in hepatocellular carcinoma.,http://www.ncbi.nlm.nih.gov/pubmed/22561517
7173,25021421,Integration of tumour and viral genomic characterizations in HBV-related hepatocellular carcinomas.,http://www.ncbi.nlm.nih.gov/pubmed/25021421
7174,25783764,"Nrf2, but not β-catenin, mutation represents an early event in rat hepatocarcinogenesis.",http://www.ncbi.nlm.nih.gov/pubmed/25783764
7175,21897267,Association of keap1 and nrf2 genetic mutations and polymorphisms with endometrioid endometrial adenocarcinoma survival.,http://www.ncbi.nlm.nih.gov/pubmed/21897267
7176,24983367,Validation and utilisation of high-coverage next-generation sequencing to deliver the pharmacological audit trail.,http://www.ncbi.nlm.nih.gov/pubmed/24983367
7177,21984974,Temporal dissection of tumorigenesis in primary cancers.,http://www.ncbi.nlm.nih.gov/pubmed/21984974
7178,16140923,Somatic mutations of the protein kinase gene family in human lung cancer.,http://www.ncbi.nlm.nih.gov/pubmed/16140923
7179,22586465,Proteome-wide analysis of single-nucleotide variations in the N-glycosylation sequon of human genes.,http://www.ncbi.nlm.nih.gov/pubmed/22586465
7180,24469795,Whole-genome sequencing identifies genomic heterogeneity at a nucleotide and chromosomal level in bladder cancer.,http://www.ncbi.nlm.nih.gov/pubmed/24469795
7181,22696596,Exome sequencing identifies MXRA5 as a novel cancer gene frequently mutated in non-small cell lung carcinoma from Chinese patients.,http://www.ncbi.nlm.nih.gov/pubmed/22696596
7182,,BGB-3111 is a novel and highly selective Bruton's tyrosine kinase (BTK) inhibitor,http://cancerres.aacrjournals.org/content/75/15_Supplement/2597
7183,26460303,Phase II Pilot Study of Vemurafenib in Patients With Metastatic BRAF-Mutated Colorectal Cancer.,http://www.ncbi.nlm.nih.gov/pubmed/26460303
7184,26482043,"MAPK Activation Predicts Poor Outcome and the MEK Inhibitor, Selumetinib, Reverses Antiestrogen Resistance in ER-Positive High-Grade Serous Ovarian Cancer.",http://www.ncbi.nlm.nih.gov/pubmed/26482043
7185,24824310,U.S. Food and drug administration approval: obinutuzumab in combination with chlorambucil for the treatment of previously untreated chronic lymphocytic leukemia.,http://www.ncbi.nlm.nih.gov/pubmed/24824310
7186,25972157,"Hypermorphic mutation of phospholipase C, γ2 acquired in ibrutinib-resistant CLL confers BTK independency upon B-cell receptor activation.",http://www.ncbi.nlm.nih.gov/pubmed/25972157
7187,27158668,The MERTK/FLT3 inhibitor MRX-2843 overcomes resistance-conferring FLT3 mutations in acute myeloid leukemia.,http://www.ncbi.nlm.nih.gov/pubmed/27158668
7188,15896463,A novel missense germline mutation in exon 2 of the hMSH2 gene in a HNPCC family from Southern Italy.,http://www.ncbi.nlm.nih.gov/pubmed/15896463
7189,16203774,High frequency of hereditary colorectal cancer in Newfoundland likely involves novel susceptibility genes.,http://www.ncbi.nlm.nih.gov/pubmed/16203774
7190,27333051,Inactivation of the CRL4-CDT2-SET8/p21 ubiquitylation and degradation axis underlies the therapeutic efficacy of pevonedistat in melanoma.,http://www.ncbi.nlm.nih.gov/pubmed/27333051
7191,22493262,Aristolochic acid-associated urothelial cancer in Taiwan.,http://www.ncbi.nlm.nih.gov/pubmed/22493262
7192,22986143,Loss of function germline mutations in RAD51D in women with ovarian carcinoma.,http://www.ncbi.nlm.nih.gov/pubmed/22986143
7193,26010367,Comprehensive assessment of genetic sequence variants in the antioxidant 'master regulator' NRF2 in idiopathic Parkinson's disease.,http://www.ncbi.nlm.nih.gov/pubmed/26010367
7194,27828943,Overcoming resistance to checkpoint blockade therapy by targeting PI3Kγ in myeloid cells.,http://www.ncbi.nlm.nih.gov/pubmed/27828943
7195,26719576,"A Cyclin-Dependent Kinase Inhibitor, Dinaciclib, Impairs Homologous Recombination and Sensitizes Multiple Myeloma Cells to PARP Inhibition.",http://www.ncbi.nlm.nih.gov/pubmed/26719576
7196,27196758,Src as a Therapeutic Target in Biliary Tract Cancer.,http://www.ncbi.nlm.nih.gov/pubmed/27196758
7197,26544513,Mutant HRAS as novel target for MEK and mTOR inhibitors.,http://www.ncbi.nlm.nih.gov/pubmed/26544513
7198,26358474,Impact of p53 Status on Radiosensitization of Tumor Cells by MET Inhibition-Associated Checkpoint Abrogation.,http://www.ncbi.nlm.nih.gov/pubmed/26358474
7199,,"PHASE 2 TRIAL OF SL-701, A NOVEL IMMUNOTHERAPY COMPRISED OF SYNTHETIC SHORT PEPTIDES AGAINST GBM TARGETS IL-13R?2, EphA2, AND SURVIVIN, IN ADULTS WITH SECOND-LINE RECURRENT GBM: INTERIM RESULTS",http://neuro-oncology.oxfordjournals.org/content/18/suppl_6/vi20.1.abstract?sid=70edd8a6-f8e7-47d1-927b-032ac6c0b974
7200,,"A PHASE 1A/1B, MULTI-CENTER, OPEN-LABEL DOSE FINDING STUDY TO ASSESS THE SAFETY, TOLERABILITY AND EFFICACY OF THE PLEIOTROPIC PATHWAY MODIFIER CC-122 ADMINISTERED ORALLY TO PATIENTS WITH GLIOBLASTOMA MULTIFORME (GBM) AND OTHER BRAIN TUMORS",http://neuro-oncology.oxfordjournals.org/content/18/suppl_6/vi24.1.abstract?sid=d99b8d46-acae-4427-baa2-93c7065a25a7
7201,,A PROSPECTIVE PHASE II STUDY OF EVEROLIMUS FOR RECURRENT ADULT LOW GRADE GLIOMAS,http://neuro-oncology.oxfordjournals.org/content/18/suppl_6/vi8.4.abstract?sid=d8ee130e-a72b-4041-8e4b-de5e91956109
7202,,"MARIZOMIB (MRZ) WITH BEVACIZUMAB (BEV) IN WHO GRADE IV MALIGNANT GLIOMA (G4 MG): FULL ENROLLMENT RESULTS FROM THE PHASE 1, MULTICENTER, OPEN-LABEL STUDY",http://neuro-oncology.oxfordjournals.org/content/18/suppl_6/vi13.1.abstract?sid=ad844053-14c2-462b-b5b1-989be93a747b
7203,,INITIAL RESULTS OF PLX108-08: AN OPEN LABEL PHASE 1B/2 STUDY OF ORALLY ADMINISTERED PEXIDARTINIB (PLX3397) IN COMBINATION WITH RADIATION THERAPY AND TEMOZOLOMIDE IN PATIENTS WITH NEWLY DIAGNOSED GLIOBLASTOMA,http://neuro-oncology.oxfordjournals.org/content/18/suppl_6/vi6.1.abstract?sid=4bb3de14-d380-4d46-a482-fff2514faa51
7204,,COMPLEMENTARY CLINICAL AND ANCILLARY DATA FROM 123 PATIENTS WITH RECURRENT HIGH GRADE GLIOMA FROM THREE PHASE 1 TRIALS OF TOCA 511 AND TOCA FC: UPDATE AND JUSTIFICATION FOR A PHASE 2/3 TRIAL,http://neuro-oncology.oxfordjournals.org/content/18/suppl_6/vi18.2.abstract?sid=a0cb3fc1-c011-4ac9-814c-2056450bbaa4
7205,25056374,Integrative and comparative genomic analysis of HPV-positive and HPV-negative head and neck squamous cell carcinomas.,http://www.ncbi.nlm.nih.gov/pubmed/25056374
7206,23263491,Exome sequencing identifies mutation in CNOT3 and ribosomal genes RPL5 and RPL10 in T-cell acute lymphoblastic leukemia.,http://www.ncbi.nlm.nih.gov/pubmed/23263491
7207,24145436,Landscape of somatic mutations and clonal evolution in mantle cell lymphoma.,http://www.ncbi.nlm.nih.gov/pubmed/24145436
7208,15908952,A screen of the complete protein kinase gene family identifies diverse patterns of somatic mutations in human breast cancer.,http://www.ncbi.nlm.nih.gov/pubmed/15908952
7209,16764984,Mutations in fibroblast growth factor receptor 1 cause Kallmann syndrome with a wide spectrum of reproductive phenotypes.,http://www.ncbi.nlm.nih.gov/pubmed/16764984
7210,26645239,Mutational analysis of pulmonary tumours with neuroendocrine features using targeted massive parallel sequencing: a comparison of a neglected tumour group.,http://www.ncbi.nlm.nih.gov/pubmed/26645239
7211,8696350,Fibroblast growth factor receptor 2 mutations in Beare-Stevenson cutis gyrata syndrome.,http://www.ncbi.nlm.nih.gov/pubmed/8696350
7212,11781872,Genomic screening of fibroblast growth-factor receptor 2 reveals a wide spectrum of mutations in patients with syndromic craniosynostosis.,http://www.ncbi.nlm.nih.gov/pubmed/11781872
7213,24360661,FGFR3 overexpression is prognostic of adverse outcome for muscle-invasive bladder carcinoma treated with adjuvant chemotherapy.,http://www.ncbi.nlm.nih.gov/pubmed/24360661
7214,19327639,Identification of novel fibroblast growth factor receptor 3 gene mutations in actinic cheilitis and squamous cell carcinoma of the lip.,http://www.ncbi.nlm.nih.gov/pubmed/19327639
7215,19377444,FGFR3 mutations in prostate cancer: association with low-grade tumors.,http://www.ncbi.nlm.nih.gov/pubmed/19377444
7216,26517354,Mutational profiling of colorectal cancers with microsatellite instability.,http://www.ncbi.nlm.nih.gov/pubmed/26517354
7217,24490605,"Enobosarm (GTx-024, S-22): a potential treatment for cachexia.",http://www.ncbi.nlm.nih.gov/pubmed/24490605
7218,26112004,Phase I/II Study of Weekly Oraxol for the Second-Line Treatment of Patients With Metastatic or Recurrent Gastric Cancer.,http://www.ncbi.nlm.nih.gov/pubmed/26112004
7219,,"Initial results from a phase 1a/b study of OMP-131R10, a first-in-class anti-RSPO3 antibody, in advanced solid tumors and previously treated metastatic colorectal cancer (CRC)",http://www.ecco-org.eu/Events/ENA2016/Searchable-Programme#anchorScpr
7220,27323706,Ectrodactyly and Lethal Pulmonary Acinar Dysplasia Associated with Homozygous FGFR2 Mutations Identified by Exome Sequencing.,http://www.ncbi.nlm.nih.gov/pubmed/27323706
7221,,Abstract C103: The combination of PI3k-delta-selective inhibition and immunomodulation shows efficacy in solid tumor models,http://mct.aacrjournals.org/content/14/12_Supplement_2/C103.short
7222,22025615,"The antifungal drug itraconazole inhibits vascular endothelial growth factor receptor 2 (VEGFR2) glycosylation, trafficking, and signaling in endothelial cells.",http://www.ncbi.nlm.nih.gov/pubmed/22025615
7223,19383971,The histone deacetylase inhibitors LAQ824 and LBH589 do not require death receptor signaling or a functional apoptosome to mediate tumor cell death or therapeutic efficacy.,http://www.ncbi.nlm.nih.gov/pubmed/19383971
7224,27813535,"Coinhibition of the deubiquitinating enzymes, USP14 and UCHL5, with VLX1570 is lethal to ibrutinib- or bortezomib-resistant Waldenstrom macroglobulinemia tumor cells.",http://www.ncbi.nlm.nih.gov/pubmed/27813535
7225,27443263,Systematic chemical and molecular profiling of MLL-rearranged infant acute lymphoblastic leukemia reveals efficacy of romidepsin.,http://www.ncbi.nlm.nih.gov/pubmed/27443263
7226,27542767,A Phase I Study of the Cyclin-Dependent Kinase 4/6 Inhibitor Ribociclib (LEE011) in Patients with Advanced Solid Tumors and Lymphomas.,http://www.ncbi.nlm.nih.gov/pubmed/27542767
7227,27671675,FGF2 from Marrow Microenvironment Promotes Resistance to FLT3 Inhibitors in Acute Myeloid Leukemia.,http://www.ncbi.nlm.nih.gov/pubmed/27671675
7228,27161972,Evaluating Cancer of the Central Nervous System Through Next-Generation Sequencing of Cerebrospinal Fluid.,http://www.ncbi.nlm.nih.gov/pubmed/27161972
7229,16249792,Preclinical pharmacokinetics and metabolism of a novel prototype DNA-PK inhibitor NU7026.,http://www.ncbi.nlm.nih.gov/pubmed/16249792
7230,26716839,DNA-Dependent Protein Kinase As Molecular Target for Radiosensitization of Neuroblastoma Cells.,http://www.ncbi.nlm.nih.gov/pubmed/26716839
7231,25233892,Genomic analyses of gynaecologic carcinosarcomas reveal frequent mutations in chromatin remodelling genes.,http://www.ncbi.nlm.nih.gov/pubmed/25233892
7232,23528559,DNA polymerase ε and δ exonuclease domain mutations in endometrial cancer.,http://www.ncbi.nlm.nih.gov/pubmed/23528559
7233,19305151,PIK3CA mutations in human solid tumors: role in sensitivity to various therapeutic approaches.,http://www.ncbi.nlm.nih.gov/pubmed/19305151
7234,16707462,Preclinical evaluation of a potent novel DNA-dependent protein kinase inhibitor NU7441.,http://www.ncbi.nlm.nih.gov/pubmed/16707462
7235,27341700,Nontoxic concentration of DNA-PK inhibitor NU7441 radio-sensitizes lung tumor cells with little effect on double strand break repair.,http://www.ncbi.nlm.nih.gov/pubmed/27341700
7236,19900191,L-type amino acid transporter 1 inhibitors inhibit tumor cell growth.,http://www.ncbi.nlm.nih.gov/pubmed/19900191
7237,24492461,"JPH203, an L-type amino acid transporter 1-selective compound, induces apoptosis of YD-38 human oral cancer cells.",http://www.ncbi.nlm.nih.gov/pubmed/24492461
7238,27262901,Metformin enhances anti-tumor effect of L-type amino acid transporter 1 (LAT1) inhibitor.,http://www.ncbi.nlm.nih.gov/pubmed/27262901
7239,19420352,"Genetic characterization of TET1, TET2, and TET3 alterations in myeloid malignancies.",http://www.ncbi.nlm.nih.gov/pubmed/19420352
7240,,,http://mct.aacrjournals.org/content/14/12_Supplement_2/A174
7241,,,http://cancerres.aacrjournals.org/content/74/19_Supplement/5466
7242,25512523,Complementary genomic approaches highlight the PI3K/mTOR pathway as a common vulnerability in osteosarcoma.,http://www.ncbi.nlm.nih.gov/pubmed/25512523
7243,,"ABBV-075, a novel BET family inhibitor, disrupts critical transcription programs that drive prostate cancer growth to induce potent anti-tumor activity in vitro and in vivo",http://cancerres.aacrjournals.org/content/76/14_Supplement/4694
7244,24982411,Impact of itraconazole on the survival of heavily pre-treated patients with triple-negative breast cancer.,http://www.ncbi.nlm.nih.gov/pubmed/24982411
7245,27615706,Widely metastatic atypical pituitary adenoma with mTOR pathway STK11(F298L) mutation treated with everolimus therapy.,http://www.ncbi.nlm.nih.gov/pubmed/27615706
7246,27287072,"Phase 1 Study of Tabalumab, a Human Anti-B-Cell Activating Factor Antibody, and Bortezomib in Patients with Relapsed/Refractory Multiple Myeloma.",http://www.ncbi.nlm.nih.gov/pubmed/27287072
7247,27694386,Acquired METD1228V Mutation and Resistance to MET Inhibition in Lung Cancer.,http://www.ncbi.nlm.nih.gov/pubmed/27694386
7248,23797736,Integrated molecular analysis of clear-cell renal cell carcinoma.,http://www.ncbi.nlm.nih.gov/pubmed/23797736
7249,26798595,"MET exon 14 deletion (METex14): finally, a frequent-enough actionable oncogenic driver mutation in non-small cell lung cancer to lead MET inhibitors out of ""40 years of wilderness"" and into a clear path of regulatory approval.",http://www.ncbi.nlm.nih.gov/pubmed/26798595
7250,24421395,Residual complexes containing SMARCA2 (BRM) underlie the oncogenic drive of SMARCA4 (BRG1) mutation.,http://www.ncbi.nlm.nih.gov/pubmed/24421395
7251,24140581,The genetic landscape of anaplastic astrocytoma.,http://www.ncbi.nlm.nih.gov/pubmed/24140581
7252,24705251,The genomic landscape of diffuse intrinsic pontine glioma and pediatric non-brainstem high-grade glioma.,http://www.ncbi.nlm.nih.gov/pubmed/24705251
7253,21921040,EZH2 mutational status predicts poor survival in myelofibrosis.,http://www.ncbi.nlm.nih.gov/pubmed/21921040
7254,26608593,Whole exome sequencing of relapsed/refractory patients expands the repertoire of somatic mutations in diffuse large B-cell lymphoma.,http://www.ncbi.nlm.nih.gov/pubmed/26608593
7255,24970810,Mutational analysis of primary central nervous system lymphoma.,http://www.ncbi.nlm.nih.gov/pubmed/24970810
7256,21796119,Frequent mutation of histone-modifying genes in non-Hodgkin lymphoma.,http://www.ncbi.nlm.nih.gov/pubmed/21796119
7257,24293293,Whole-exome sequencing of pancreatic neoplasms with acinar differentiation.,http://www.ncbi.nlm.nih.gov/pubmed/24293293
7258,26647218,Genetic Landscapes of Relapsed and Refractory Diffuse Large B-Cell Lymphomas.,http://www.ncbi.nlm.nih.gov/pubmed/26647218
7259,23292937,Genetic heterogeneity of diffuse large B-cell lymphoma.,http://www.ncbi.nlm.nih.gov/pubmed/23292937
7260,15808862,Crystal structures of proto-oncogene kinase Pim1: a target of aberrant somatic hypermutations in diffuse large cell lymphoma.,http://www.ncbi.nlm.nih.gov/pubmed/15808862
7261,27556513,Control of translational activation by PIM kinase in activated B-cell diffuse large B-cell lymphoma confers sensitivity to inhibition by PIM447.,http://www.ncbi.nlm.nih.gov/pubmed/27556513
7262,24127483,Genetic lesions associated with chronic lymphocytic leukemia transformation to Richter syndrome.,http://www.ncbi.nlm.nih.gov/pubmed/24127483
7263,26285778,"Altiratinib Inhibits Tumor Growth, Invasion, Angiogenesis, and Microenvironment-Mediated Drug Resistance via Balanced Inhibition of MET, TIE2, and VEGFR2.",http://www.ncbi.nlm.nih.gov/pubmed/26285778
7264,,"Abstract 3609: MGCD265, an orally active Met/VEGFR multitargeted kinase inhibitor in Phase II clinical development, potently inhibits clinically relevant Met mutants",http://cancerres.aacrjournals.org/content/70/8_Supplement/3609.short
7265,27638856,"CT-707, a Novel FAK Inhibitor, Synergizes with Cabozantinib to Suppress Hepatocellular Carcinoma by Blocking Cabozantinib-Induced FAK Activation.",http://www.ncbi.nlm.nih.gov/pubmed/27638856
7266,27765850,Reactivation of p53 by MDM2 Inhibitor MI-77301 for the Treatment of Endocrine-Resistant Breast Cancer.,http://www.ncbi.nlm.nih.gov/pubmed/27765850
7267,27167172,Multiparameter Lead Optimization to Give an Oral Checkpoint Kinase 1 (CHK1) Inhibitor Clinical Candidate: (R)-5-((4-((Morpholin-2-ylmethyl)amino)-5-(trifluoromethyl)pyridin-2-yl)amino)pyrazine-2-carbonitrile (CCT245737).,http://www.ncbi.nlm.nih.gov/pubmed/27167172
7268,26807226,Enhanced antitumor effect of combining chemotherapy with Epstein-Barr virus (EBV)-specific cytotoxic T lymphocytes in mice with EBV-related non-Hodgkin's lymphoma.,http://www.ncbi.nlm.nih.gov/pubmed/26807226
7269,26428384,Adoptive T-Cell Immunotherapy.,http://www.ncbi.nlm.nih.gov/pubmed/26428384
7270,27804235,"A phase IIa study of afuresertib, an oral pan-AKT inhibitor, in patients with Langerhans cell histiocytosis.",http://www.ncbi.nlm.nih.gov/pubmed/27804235
7271,27612490,Acquired Resistance Mechanisms to Combination Met-TKI/EGFR-TKI Exposure in Met-Amplified EGFR-TKI-Resistant Lung Adenocarcinoma Harboring an Activating EGFR Mutation.,http://www.ncbi.nlm.nih.gov/pubmed/27612490
7272,26261251,"Contribution of Germline Mutations in the RAD51B, RAD51C, and RAD51D Genes to Ovarian Cancer in the Population.",http://www.ncbi.nlm.nih.gov/pubmed/26261251
7273,18655123,Mutational analysis of SHH and GLI3 in anorectal malformations.,http://www.ncbi.nlm.nih.gov/pubmed/18655123
7274,27881154,Targeted next generation sequencing identifies novel NOTCH3 gene mutations in CADASIL diagnostics patients.,http://www.ncbi.nlm.nih.gov/pubmed/27881154
7275,23889897,Colony stimulation factor 1 receptor (CSF1R) is not a common cause of multiple sclerosis.,http://www.ncbi.nlm.nih.gov/pubmed/23889897
7276,21225506,"EGFR, PIK3CA and PTEN gene status and their protein product expression in neuroblastic tumours.",http://www.ncbi.nlm.nih.gov/pubmed/21225506
7277,16822308,Mutations in PIK3CA are infrequent in neuroblastoma.,http://www.ncbi.nlm.nih.gov/pubmed/16822308
7278,,Brentuximab Vedotin Demonstrates Significantly Superior Clinical Outcomes in Patients with CD30-Expressing Cutaneous T Cell Lymphoma Versus Physician's Choice (Methotrexate or Bexarotene): The Phase 3 Alcanza Study,https://ash.confex.com/ash/2016/webprogram/Paper91517.html
7279,,"First-line Ceritinib Versus Chemotherapy in Patients With ALK-rearranged (ALK+) NSCLC: A Randomized, Phase 3 Study (ASCEND-4)",http://library.iaslc.org/virtual-library-search?product_id=6&author=&category=&date=&session_type=&session=&presentation=PL03.07&keyword=
7280,27369047,Enhancing PD-1 Blockade in Solid Tumors.,http://www.ncbi.nlm.nih.gov/pubmed/27369047
7281,25971939,Response to MET inhibitors in patients with stage IV lung adenocarcinomas harboring MET mutations causing exon 14 skipping.,http://www.ncbi.nlm.nih.gov/pubmed/25971939
7282,27928026,"AZD3759, a BBB-penetrating EGFR inhibitor for the treatment of EGFR mutant NSCLC with CNS metastases.",http://www.ncbi.nlm.nih.gov/pubmed/27928026
7283,27923043,Clonal Evolutionary Analysis during HER2 Blockade in HER2-Positive Inflammatory Breast Cancer: A Phase II Open-Label Clinical Trial of Afatinib +/- Vinorelbine.,http://www.ncbi.nlm.nih.gov/pubmed/27923043
7284,27765849,Mutant BRAF Upregulates MCL-1 to Confer Apoptosis Resistance that Is Reversed by MCL-1 Antagonism and Cobimetinib in Colorectal Cancer.,http://www.ncbi.nlm.nih.gov/pubmed/27765849
7285,27354472,Hsp90 Inhibitor Ganetespib Sensitizes Non-Small Cell Lung Cancer to Radiation but Has Variable Effects with Chemoradiation.,http://www.ncbi.nlm.nih.gov/pubmed/27354472
7286,24972766,The activating STAT5B N642H mutation is a common abnormality in pediatric T-cell acute lymphoblastic leukemia and confers a higher risk of relapse.,http://www.ncbi.nlm.nih.gov/pubmed/24972766
7287,26757360,Targeting c-MET by LY2801653 for treatment of cholangiocarcinoma.,http://www.ncbi.nlm.nih.gov/pubmed/26757360
7288,26308596,Targeting CD38 with Daratumumab Monotherapy in Multiple Myeloma.,http://www.ncbi.nlm.nih.gov/pubmed/26308596
7289,21165770,PALB2 mutations in German and Russian patients with bilateral breast cancer.,http://www.ncbi.nlm.nih.gov/pubmed/21165770
7290,25636233,Association of PALB2 sequence variants with the risk of familial and early-onset breast cancer in a South-American population.,http://www.ncbi.nlm.nih.gov/pubmed/25636233
7291,20927582,Mutations in BRCA2 and PALB2 in male breast cancer cases from the United States.,http://www.ncbi.nlm.nih.gov/pubmed/20927582
7292,25833210,Two PALB2 germline mutations found in both BRCA1+ and BRCAx familial breast cancer.,http://www.ncbi.nlm.nih.gov/pubmed/25833210
7293,27557302,"Daratumumab, Bortezomib, and Dexamethasone for Multiple Myeloma.",http://www.ncbi.nlm.nih.gov/pubmed/27557302
7294,19592507,Chimeric transcript discovery by paired-end transcriptome sequencing.,http://www.ncbi.nlm.nih.gov/pubmed/19592507
7295,16303180,ELF4 is fused to ERG in a case of acute myeloid leukemia with a t(X;21)(q25-26;q22).,http://www.ncbi.nlm.nih.gov/pubmed/16303180
7296,16496320,Genotype-phenotype correlation in hepatocellular adenoma: new classification and relationship with HCC.,http://www.ncbi.nlm.nih.gov/pubmed/16496320
7297,17187432,Transcriptome classification of HCC is related to gene alterations and to new therapeutic targets.,http://www.ncbi.nlm.nih.gov/pubmed/17187432
7298,27078022,Neratinib Plus Paclitaxel vs Trastuzumab Plus Paclitaxel in Previously Untreated Metastatic ERBB2-Positive Breast Cancer: The NEfERT-T Randomized Clinical Trial.,http://www.ncbi.nlm.nih.gov/pubmed/27078022
7299,20855820,Phase II study of dasatinib in patients with advanced non-small-cell lung cancer.,http://www.ncbi.nlm.nih.gov/pubmed/20855820
7300,27777285,Cabozantinib Is Active against Human Gastrointestinal Stromal Tumor Xenografts Carrying Different KIT Mutations.,http://www.ncbi.nlm.nih.gov/pubmed/27777285
7301,26351208,Combined Use of Metformin and Everolimus Is Synergistic in the Treatment of Breast Cancer Cells.,http://www.ncbi.nlm.nih.gov/pubmed/26351208
7302,12297840,P53 gene and Wnt signaling in benign neoplasms: beta-catenin mutations in hepatic adenoma but not in focal nodular hyperplasia.,http://www.ncbi.nlm.nih.gov/pubmed/12297840
7303,16356174,"Mutations in APC, CTNNB1 and K-ras genes and expression of hMLH1 in sporadic colorectal carcinomas from the Netherlands Cohort Study.",http://www.ncbi.nlm.nih.gov/pubmed/16356174
7304,22744289,Role of tumor-associated macrophages and angiogenesis in desmoid-type fibromatosis.,http://www.ncbi.nlm.nih.gov/pubmed/22744289
7305,27389594,Genetic Landscape of Sporadic Unilateral Adrenocortical Adenomas Without PRKACA p.Leu206Arg Mutation.,http://www.ncbi.nlm.nih.gov/pubmed/27389594
7306,22470196,Stratification of Wilms tumor by genetic and epigenetic analysis.,http://www.ncbi.nlm.nih.gov/pubmed/22470196
7307,11329142,Frequent nuclear beta-catenin accumulation and associated mutations in endometrioid-type endometrial and ovarian carcinomas with squamous differentiation.,http://www.ncbi.nlm.nih.gov/pubmed/11329142
7308,25012536,β-catenin (CTNNB1) mutations are not associated with prognosis in advanced hepatocellular carcinoma.,http://www.ncbi.nlm.nih.gov/pubmed/25012536
7309,18715618,Correlation between beta-catenin widespread nuclear expression and matrix metalloproteinase-7 overexpression in sporadic desmoid tumors.,http://www.ncbi.nlm.nih.gov/pubmed/18715618
7310,20923573,Genetic and epigenetic characteristics of human multiple hepatocellular carcinoma.,http://www.ncbi.nlm.nih.gov/pubmed/20923573
7311,20696052,Mutations in the WTX-gene are found in some high-grade microsatellite instable (MSI-H) colorectal cancers.,http://www.ncbi.nlm.nih.gov/pubmed/20696052
7312,11282485,Frequent beta-catenin aberration in human hepatocellular carcinoma.,http://www.ncbi.nlm.nih.gov/pubmed/11282485
7313,18467159,Chromosome instability in human hepatocellular carcinoma depends on p53 status and aflatoxin exposure.,http://www.ncbi.nlm.nih.gov/pubmed/18467159
7314,21067377,DNMT3A mutations in acute myeloid leukemia.,http://www.ncbi.nlm.nih.gov/pubmed/21067377
7315,27959700,Osimertinib or Platinum-Pemetrexed in EGFR T790M-Positive Lung Cancer.,http://www.ncbi.nlm.nih.gov/pubmed/27959700
7316,26637365,"Specific Antileukemic Activity of PD0332991, a CDK4/6 Inhibitor, against Philadelphia Chromosome-Positive Lymphoid Leukemia.",http://www.ncbi.nlm.nih.gov/pubmed/26637365
7317,26772202,RON Nuclear Translocation under Hypoxia Potentiates Chemoresistance to DNA Double-Strand Break-Inducing Anticancer Drugs.,http://www.ncbi.nlm.nih.gov/pubmed/26772202
7318,27486019,Rare Variation in TET2 Is Associated with Clinically Relevant Prostate Carcinoma in African Americans.,http://www.ncbi.nlm.nih.gov/pubmed/27486019
7319,19410716,Cetuximab plus chemotherapy in patients with advanced non-small-cell lung cancer (FLEX): an open-label randomised phase III trial.,http://www.ncbi.nlm.nih.gov/pubmed/19410716
7320,,"105 BIIB024, a potent pan-Raf kinase inhibitor for melanoma and solid tumors",http://www.ejcancersupplements.com/article/S1359-6349%2810%2971810-3/abstract
7321,24035431,Lung adenocarcinoma with BRAF G469L mutation refractory to vemurafenib.,http://www.ncbi.nlm.nih.gov/pubmed/24035431
7322,27577079,Non-V600 BRAF mutations recurrently found in lung cancer predict sensitivity to the combination of Trametinib and Dabrafenib.,http://www.ncbi.nlm.nih.gov/pubmed/27577079
7323,27388325,Efficacy of sorafenib in BRAF-mutated non-small-cell lung cancer (NSCLC) and no response in synchronous BRAF wild type-hepatocellular carcinoma: a case report.,http://www.ncbi.nlm.nih.gov/pubmed/27388325
7324,25706985,Trametinib with or without vemurafenib in BRAF mutated non-small cell lung cancer.,http://www.ncbi.nlm.nih.gov/pubmed/25706985
7325,24923295,Isolated trisomy 13 defines a homogeneous AML subgroup with high frequency of mutations in spliceosome genes and poor prognosis.,http://www.ncbi.nlm.nih.gov/pubmed/24923295
7326,22722750,Mutations in the DNMT3A exon 23 independently predict poor outcome in older patients with acute myeloid leukemia: a SWOG report.,http://www.ncbi.nlm.nih.gov/pubmed/22722750
7327,25886620,Next generation sequencing of exceptional responders with BRAF-mutant melanoma: implications for sensitivity and resistance.,http://www.ncbi.nlm.nih.gov/pubmed/25886620
7328,22749068,Decreased DNA methylation in acute myeloid leukemia patients with DNMT3A mutations and prognostic implications of DNA methylation.,http://www.ncbi.nlm.nih.gov/pubmed/22749068
7329,22817890,The origin and evolution of mutations in acute myeloid leukemia.,http://www.ncbi.nlm.nih.gov/pubmed/22817890
7330,22642896,Detection of high-frequency and novel DNMT3A mutations in acute myeloid leukemia by high-resolution melting curve analysis.,http://www.ncbi.nlm.nih.gov/pubmed/22642896
7331,27869830,Inactivation of Capicua drives cancer metastasis.,http://www.ncbi.nlm.nih.gov/pubmed/27869830
7332,21519343,"DNMT3A mutational analysis in primary myelofibrosis, chronic myelomonocytic leukemia and advanced phases of myeloproliferative neoplasms.",http://www.ncbi.nlm.nih.gov/pubmed/21519343
7333,23135354,"Mutations of the epigenetics-modifying gene (DNMT3a, TET2, IDH1/2) at diagnosis may induce FLT3-ITD at relapse in de novo acute myeloid leukemia.",http://www.ncbi.nlm.nih.gov/pubmed/23135354
7334,21993668,"Frequency, onset and clinical impact of somatic DNMT3A mutations in therapy-related and secondary acute myeloid leukemia.",http://www.ncbi.nlm.nih.gov/pubmed/21993668
7335,21967546,Prognostic impact of DNMT3A mutations in patients with intermediate cytogenetic risk profile acute myeloid leukemia.,http://www.ncbi.nlm.nih.gov/pubmed/21967546
7336,24931631,The spectrum of somatic mutations in high-risk acute myeloid leukaemia with -7/del(7q).,http://www.ncbi.nlm.nih.gov/pubmed/24931631
7337,20601954,Somatic mutations of the histone methyltransferase gene EZH2 in myelodysplastic syndromes.,http://www.ncbi.nlm.nih.gov/pubmed/20601954
7338,22237151,Genetic inactivation of the polycomb repressive complex 2 in T cell acute lymphoblastic leukemia.,http://www.ncbi.nlm.nih.gov/pubmed/22237151
7339,24478400,Clonal evolution and clinical correlates of somatic mutations in myeloproliferative neoplasms.,http://www.ncbi.nlm.nih.gov/pubmed/24478400
7340,26812882,Genomic loss of EZH2 leads to epigenetic modifications and overexpression of the HOX gene clusters in myelodysplastic syndrome.,http://www.ncbi.nlm.nih.gov/pubmed/26812882
7341,22390313,Cytogenetic and molecular predictors of response in patients with myeloid malignancies without del[5q] treated with lenalidomide.,http://www.ncbi.nlm.nih.gov/pubmed/22390313
7342,16371029,Novel observation of three FLT3 codons mutated in tandem in an elderly acute myeloid leukaemia patient.,http://www.ncbi.nlm.nih.gov/pubmed/16371029
7343,16912228,Clinical implications of FLT3 mutations in pediatric AML.,http://www.ncbi.nlm.nih.gov/pubmed/16912228
7344,15390271,Activating FLT3 mutations are rare in children with juvenile myelomonocytic leukemia.,http://www.ncbi.nlm.nih.gov/pubmed/15390271
7345,15625552,A novel FLT3 activation loop mutation N841K in acute myeloblastic leukemia.,http://www.ncbi.nlm.nih.gov/pubmed/15625552
7346,26689913,Patterns and functional implications of rare germline variants across 12 cancer types.,http://www.ncbi.nlm.nih.gov/pubmed/26689913
7347,26999641,Aberrant activation of the PI3K/mTOR pathway promotes resistance to sorafenib in AML.,http://www.ncbi.nlm.nih.gov/pubmed/26999641
7348,27626065,A novel TP53-KPNA3 translocation defines a de novo treatment-resistant clone in osteosarcoma.,http://www.ncbi.nlm.nih.gov/pubmed/27626065
7349,21798897,Exome sequencing of head and neck squamous cell carcinoma reveals inactivating mutations in NOTCH1.,http://www.ncbi.nlm.nih.gov/pubmed/21798897
7350,24345752,A targeted mutational landscape of angioimmunoblastic T-cell lymphoma.,http://www.ncbi.nlm.nih.gov/pubmed/24345752
7351,25257301,Clinical multiplexed exome sequencing distinguishes adult oligodendroglial neoplasms from astrocytic and mixed lineage gliomas.,http://www.ncbi.nlm.nih.gov/pubmed/25257301
7352,27203738,Targeted next generation sequencing of endoscopic ultrasound acquired cytology from ampullary and pancreatic adenocarcinoma has the potential to aid patient stratification for optimal therapy selection.,http://www.ncbi.nlm.nih.gov/pubmed/27203738
7353,27590631,Synthetic Lethality in PTEN-Mutant Prostate Cancer Is Induced by Combinatorial PI3K/Akt and BCL-XL Inhibition.,http://www.ncbi.nlm.nih.gov/pubmed/27590631
7354,27908594,"Rucaparib in relapsed, platinum-sensitive high-grade ovarian carcinoma (ARIEL2 Part 1): an international, multicentre, open-label, phase 2 trial.",http://www.ncbi.nlm.nih.gov/pubmed/27908594
7355,27334835,"Profiling of 149 Salivary Duct Carcinomas, Carcinoma Ex Pleomorphic Adenomas, and Adenocarcinomas, Not Otherwise Specified Reveals Actionable Genomic Alterations.",http://www.ncbi.nlm.nih.gov/pubmed/27334835
7356,27531525,Long-term bosutinib for chronic phase chronic myeloid leukemia after failure of imatinib plus dasatinib and/or nilotinib.,http://www.ncbi.nlm.nih.gov/pubmed/27531525
7357,27401242,Crizotinib-Resistant ROS1 Mutations Reveal a Predictive Kinase Inhibitor Sensitivity Model for ROS1- and ALK-Rearranged Lung Cancers.,http://www.ncbi.nlm.nih.gov/pubmed/27401242
7358,27959684,T-Cell Transfer Therapy Targeting Mutant KRAS in Cancer.,http://www.ncbi.nlm.nih.gov/pubmed/27959684
7359,24553136,The E3 ligase Cbl-b and TAM receptors regulate cancer metastasis via natural killer cells.,http://www.ncbi.nlm.nih.gov/pubmed/24553136
7360,24014597,TIG1 promotes the development and progression of inflammatory breast cancer through activation of Axl kinase.,http://www.ncbi.nlm.nih.gov/pubmed/24014597
7361,23091115,An epithelial-mesenchymal transition gene signature predicts resistance to EGFR and PI3K inhibitors and identifies Axl as a therapeutic target for overcoming EGFR inhibitor resistance.,http://www.ncbi.nlm.nih.gov/pubmed/23091115
7362,25740784,Somatic POLE mutations cause an ultramutated giant cell high-grade glioma subtype with better prognosis.,http://www.ncbi.nlm.nih.gov/pubmed/25740784
7363,24229379,PIK3R1 underexpression is an independent prognostic marker in breast cancer.,http://www.ncbi.nlm.nih.gov/pubmed/24229379
7364,23143597,The genetic landscape of mutations in Burkitt lymphoma.,http://www.ncbi.nlm.nih.gov/pubmed/23143597
7365,24285547,H3F3A K27M mutations in thalamic gliomas from young adult patients.,http://www.ncbi.nlm.nih.gov/pubmed/24285547
7366,24173966,"NPS-1034, a novel MET inhibitor, inhibits the activated MET receptor and its constitutively active mutants.",http://www.ncbi.nlm.nih.gov/pubmed/24173966
7367,24165158,MET and AXL inhibitor NPS-1034 exerts efficacy against lung cancer cells resistant to EGFR kinase inhibitors because of MET or AXL activation.,http://www.ncbi.nlm.nih.gov/pubmed/24165158
7368,23542356,Acquired resistance to EGFR inhibitors is associated with a manifestation of stem cell-like properties in cancer cells.,http://www.ncbi.nlm.nih.gov/pubmed/23542356
7369,27924459,Patient-Reported Outcomes and Quality of Life with Sunitinib Versus Placebo for Pancreatic Neuroendocrine Tumors: Results From an International Phase III Trial.,http://www.ncbi.nlm.nih.gov/pubmed/27924459
7370,25806189,MET inhibitors in combination with other therapies in non-small cell lung cancer.,http://www.ncbi.nlm.nih.gov/pubmed/25806189
7371,23485734,R132C IDH1 mutations are found in spindle cell hemangiomas and not in other vascular tumors or malformations.,http://www.ncbi.nlm.nih.gov/pubmed/23485734
7372,20567020,IDH1 and IDH2 mutations are frequent genetic alterations in acute myeloid leukemia and confer adverse prognosis in cytogenetically normal acute myeloid leukemia with NPM1 mutation without FLT3 internal tandem duplication.,http://www.ncbi.nlm.nih.gov/pubmed/20567020
7373,21647152,Prevalence and prognostic value of IDH1 and IDH2 mutations in childhood AML: a study of the AML-BFM and DCOG study groups.,http://www.ncbi.nlm.nih.gov/pubmed/21647152
7374,24532263,Analysis of KIAA1549-BRAF fusion gene expression and IDH1/IDH2 mutations in low grade pediatric astrocytomas.,http://www.ncbi.nlm.nih.gov/pubmed/24532263
7375,24403254,Isocitrate dehydrogenase 2 mutation is a frequent event in osteosarcoma detected by a multi-specific monoclonal antibody MsMab-1.,http://www.ncbi.nlm.nih.gov/pubmed/24403254
7376,22520341,Adverse impact of IDH1 and IDH2 mutations in primary AML: experience of the Spanish CETLAM group.,http://www.ncbi.nlm.nih.gov/pubmed/22520341
7377,24760710,Isocitrate dehydrogenase 1 (IDH1) mutation in breast adenocarcinoma is associated with elevated levels of serum and urine 2-hydroxyglutarate.,http://www.ncbi.nlm.nih.gov/pubmed/24760710
7378,19634059,Somatic mutation of PIK3R1 gene is rare in common human cancers.,http://www.ncbi.nlm.nih.gov/pubmed/19634059
7379,18772890,Comprehensive genomic characterization defines human glioblastoma genes and core pathways.,http://www.ncbi.nlm.nih.gov/pubmed/18772890
7380,20668451,Diverse somatic mutation patterns and pathway alterations in human cancers.,http://www.ncbi.nlm.nih.gov/pubmed/20668451
7381,21533174,A systematic study of gene mutations in urothelial carcinoma; inactivating mutations in TSC2 and PIK3R1.,http://www.ncbi.nlm.nih.gov/pubmed/21533174
7382,25450694,Inhibition of Axl improves the targeted therapy against ALK-mutated neuroblastoma.,http://www.ncbi.nlm.nih.gov/pubmed/25450694
7383,19671800,Novel mechanism of lapatinib resistance in HER2-positive breast tumor cells: activation of AXL.,http://www.ncbi.nlm.nih.gov/pubmed/19671800
7384,17325667,A novel tyrosine kinase switch is a mechanism of imatinib resistance in gastrointestinal stromal tumors.,http://www.ncbi.nlm.nih.gov/pubmed/17325667
7385,24695838,Multigene profiling to identify alternative treatment options for glioblastoma: a pilot study.,http://www.ncbi.nlm.nih.gov/pubmed/24695838
7386,26681737,T cell neoepitope discovery in colorectal cancer by high throughput profiling of somatic mutations in expressed genes.,http://www.ncbi.nlm.nih.gov/pubmed/26681737
7387,27738081,Analysis of genes involved in the PI3K/Akt pathway in radiation- and MNU-induced rat mammary carcinomas.,http://www.ncbi.nlm.nih.gov/pubmed/27738081
7388,23066039,PIK3CA mutation H1047R is associated with response to PI3K/AKT/mTOR signaling pathway inhibitors in early-phase clinical trials.,http://www.ncbi.nlm.nih.gov/pubmed/23066039
7389,18852163,Frequent mutations and amplifications of the PIK3CA gene in pituitary tumors.,http://www.ncbi.nlm.nih.gov/pubmed/18852163
7390,16764926,"Rare mutations of the PIK3CA gene in malignancies of the hematopoietic system as well as endometrium, ovary, prostate and osteosarcomas, and discovery of a PIK3CA pseudogene.",http://www.ncbi.nlm.nih.gov/pubmed/16764926
7391,25680416,Driver gene mutations of non-small-cell lung cancer are rare in primary carcinoids of the lung: NGS study by ion Torrent.,http://www.ncbi.nlm.nih.gov/pubmed/25680416
7392,22949056,Phosphatidylinositol-3-kinase α catalytic subunit gene somatic mutations in bronchopulmonary neuroendocrine tumours.,http://www.ncbi.nlm.nih.gov/pubmed/22949056
7393,21497288,"Nested high-resolution melting curve analysis a highly sensitive, reliable, and simple method for detection of JAK2 exon 12 mutations--clinical relevance in the monitoring of polycythemia.",http://www.ncbi.nlm.nih.gov/pubmed/21497288
7394,22762550,Lack of JAK2 activating non-synonymous mutations in diffuse large B-cell tumors: JAK2 deregulation still unexplained.,http://www.ncbi.nlm.nih.gov/pubmed/22762550
7395,21452873,A triad interaction in the fingers subdomain of DNA polymerase beta controls polymerase activity.,http://www.ncbi.nlm.nih.gov/pubmed/21452873
7396,18452195,Surgical intervention following imatinib treatment in patients with advanced gastrointestinal stromal tumors (GISTs).,http://www.ncbi.nlm.nih.gov/pubmed/18452195
7397,10485475,Effect of c-kit mutation on prognosis of gastrointestinal stromal tumors.,http://www.ncbi.nlm.nih.gov/pubmed/10485475
7398,17710669,Multiple novel alterations in Kit tyrosine kinase in patients with gastrointestinally pronounced systemic mast cell activation disorder.,http://www.ncbi.nlm.nih.gov/pubmed/17710669
7399,20861712,Molecular and clinicopathologic characterization of gastrointestinal stromal tumors (GISTs) of small size.,http://www.ncbi.nlm.nih.gov/pubmed/20861712
7400,16770100,[A case of recurrent GIST successfully treated with low-dose imatinib mesilate].,http://www.ncbi.nlm.nih.gov/pubmed/16770100
7401,11376557,Mutations in c-kit gene exons 9 and 13 in gastrointestinal stromal tumors among Japanese.,http://www.ncbi.nlm.nih.gov/pubmed/11376557
7402,23014346,BRAF mutations and KIT aberrations and their clinicopathological correlation in 202 Korean melanomas.,http://www.ncbi.nlm.nih.gov/pubmed/23014346
7403,21387320,Mutational status of KIT and PDGFRA and expression of PDGFRA are not associated with prognosis after curative resection of primary gastrointestinal stromal tumors (GISTs).,http://www.ncbi.nlm.nih.gov/pubmed/21387320
7404,21326036,The activated targets of mTOR signaling pathway are characteristic for PDGFRA mutant and wild-type rather than KIT mutant GISTs.,http://www.ncbi.nlm.nih.gov/pubmed/21326036
7405,24522528,Identification of pre-leukaemic haematopoietic stem cells in acute leukaemia.,http://www.ncbi.nlm.nih.gov/pubmed/24522528
7406,26744134,Targeted next generation sequencing reveals unique mutation profile of primary melanocytic tumors of the central nervous system.,http://www.ncbi.nlm.nih.gov/pubmed/26744134
7407,17566038,Double resistance to imatinib and AMG 706 caused by multiple acquired KIT exon 17 mutations in a gastrointestinal stromal tumour.,http://www.ncbi.nlm.nih.gov/pubmed/17566038
7408,26971368,Highly Concordant Key Genetic Alterations in Primary Tumors and Matched Distant Metastases in Differentiated Thyroid Cancer.,http://www.ncbi.nlm.nih.gov/pubmed/26971368
7409,12759497,Mutations in exon 11 of the c-kit gene in a myogenic tumor and a neurogenic tumor as well as in gastrointestinal stromal tumors. Utility of c-kit mutation as a prognostic biomarker for gastrointestinal mesenchymal tumor.,http://www.ncbi.nlm.nih.gov/pubmed/12759497
7410,26424760,Phase II Trial of Nilotinib in Patients With Metastatic Malignant Melanoma Harboring KIT Gene Aberration: A Multicenter Trial of Korean Cancer Study Group (UN10-06).,http://www.ncbi.nlm.nih.gov/pubmed/26424760
7411,21325067,Large-scale analysis of KIT aberrations in Chinese patients with melanoma.,http://www.ncbi.nlm.nih.gov/pubmed/21325067
7412,15217946,Expression and mutational status of c-kit in small-cell lung cancer: prognostic relevance.,http://www.ncbi.nlm.nih.gov/pubmed/15217946
7413,11719439,KIT activation is a ubiquitous feature of gastrointestinal stromal tumors.,http://www.ncbi.nlm.nih.gov/pubmed/11719439
7414,21680547,KIT pathway alterations in mucosal melanomas of the vulva and other sites.,http://www.ncbi.nlm.nih.gov/pubmed/21680547
7415,21836495,KIT-negative gastrointestinal stromal tumor of the abdominal soft tissue: a clinicopathologic and genetic study of 10 cases.,http://www.ncbi.nlm.nih.gov/pubmed/21836495
7416,16551858,Polyclonal evolution of multiple secondary KIT mutations in gastrointestinal stromal tumors under treatment with imatinib mesylate.,http://www.ncbi.nlm.nih.gov/pubmed/16551858
7417,11786393,The complexity of KIT gene mutations and chromosome rearrangements and their clinical correlation in gastrointestinal stromal (pacemaker cell) tumors.,http://www.ncbi.nlm.nih.gov/pubmed/11786393
7418,19617878,Identification of c-kit gene mutations in primary adenoid cystic carcinoma of the salivary gland.,http://www.ncbi.nlm.nih.gov/pubmed/19617878
7419,23106360,Spectrum of mutations in gastrointestinal stromal tumor patients - a population-based study from Slovakia.,http://www.ncbi.nlm.nih.gov/pubmed/23106360
7420,14694524,Absence of c-kit gene mutations in gastrointestinal stromal tumours from neurofibromatosis type 1 patients.,http://www.ncbi.nlm.nih.gov/pubmed/14694524
7421,27845314,[Efficacy of cortexin in acute and recovery periodes of hemispheric ischemic stroke].,http://www.ncbi.nlm.nih.gov/pubmed/27845314
7422,19996202,Analysis of VHL Gene Alterations and their Relationship to Clinical Parameters in Sporadic Conventional Renal Cell Carcinoma.,http://www.ncbi.nlm.nih.gov/pubmed/19996202
7423,24504440,"Multilayer-omics analysis of renal cell carcinoma, including the whole exome, methylome and transcriptome.",http://www.ncbi.nlm.nih.gov/pubmed/24504440
7424,9458097,Loss of heterozygosity and somatic mutations of the VHL tumor suppressor gene in sporadic cerebellar hemangioblastomas.,http://www.ncbi.nlm.nih.gov/pubmed/9458097
7425,23558940,VHL gene alterations in Italian patients with isolated renal cell carcinomas.,http://www.ncbi.nlm.nih.gov/pubmed/23558940
7426,24446253,VHL and HIF-1α: gene variations and prognosis in early-stage clear cell renal cell carcinoma.,http://www.ncbi.nlm.nih.gov/pubmed/24446253
7427,10766184,VHL alterations in human clear cell renal cell carcinoma: association with advanced tumor stage and a novel hot spot mutation.,http://www.ncbi.nlm.nih.gov/pubmed/10766184
7428,24335534,Molecular dissection of the VHL gene in solitary capillary hemangioblastoma of the central nervous system.,http://www.ncbi.nlm.nih.gov/pubmed/24335534
7429,25691774,pVHL/HIF-regulated CD70 expression is associated with infiltration of CD27+ lymphocytes and increased serum levels of soluble CD27 in clear cell renal cell carcinoma.,http://www.ncbi.nlm.nih.gov/pubmed/25691774
7430,23606570,Combined mutation of Vhl and Trp53 causes renal cysts and tumours in mice.,http://www.ncbi.nlm.nih.gov/pubmed/23606570
7431,25583177,Molecular subtypes of clear cell renal cell carcinoma are associated with sunitinib response in the metastatic setting.,http://www.ncbi.nlm.nih.gov/pubmed/25583177
7432,24727139,Unique molecular alteration patterns in von Hippel-Lindau (VHL) gene in a cohort of sporadic renal cell carcinoma patients from Pakistan.,http://www.ncbi.nlm.nih.gov/pubmed/24727139
7433,20054297,Systematic sequencing of renal carcinoma reveals inactivation of histone modifying genes.,http://www.ncbi.nlm.nih.gov/pubmed/20054297
7434,23036577,Clinical and pathologic impact of select chromatin-modulating tumor suppressors in clear cell renal cell carcinoma.,http://www.ncbi.nlm.nih.gov/pubmed/23036577
7435,24166983,"Clinical and pathological impact of VHL, PBRM1, BAP1, SETD2, KDM6A, and JARID1c in clear cell renal cell carcinoma.",http://www.ncbi.nlm.nih.gov/pubmed/24166983
7436,11536052,VHL gene alterations in renal cell carcinoma patients: novel hotspot or founder mutations and linkage disequilibrium.,http://www.ncbi.nlm.nih.gov/pubmed/11536052
7437,21602815,Clear-cell papillary renal cell carcinoma: molecular and immunohistochemical analysis with emphasis on the von Hippel-Lindau gene and hypoxia-inducible factor pathway-related proteins.,http://www.ncbi.nlm.nih.gov/pubmed/21602815
7438,26111976,Intratumoral morphologic and molecular heterogeneity of rhabdoid renal cell carcinoma: challenges for personalized therapy.,http://www.ncbi.nlm.nih.gov/pubmed/26111976
7439,7881415,Somatic mutations of the von Hippel-Lindau disease tumour suppressor gene in non-familial clear cell renal carcinoma.,http://www.ncbi.nlm.nih.gov/pubmed/7881415
7440,15932632,Prevalence of von Hippel-Lindau gene mutations in sporadic renal cell carcinoma: results from The Netherlands cohort study.,http://www.ncbi.nlm.nih.gov/pubmed/15932632
7441,24471421,Loss of BRM expression is a frequently observed event in poorly differentiated clear cell renal cell carcinoma.,http://www.ncbi.nlm.nih.gov/pubmed/24471421
7442,22832583,Dissecting the genomic complexity underlying medulloblastoma.,http://www.ncbi.nlm.nih.gov/pubmed/22832583
7443,25790293,Rise and fall of subclones from diagnosis to relapse in pediatric B-acute lymphoblastic leukaemia.,http://www.ncbi.nlm.nih.gov/pubmed/25790293
7444,10448035,Human Rad51 amino acid residues required for Rad52 binding.,http://www.ncbi.nlm.nih.gov/pubmed/10448035
7445,27153211,RAD51 variant proteins from human lung and kidney tumors exhibit DNA strand exchange defects.,http://www.ncbi.nlm.nih.gov/pubmed/27153211
7446,11085541,"BRG1, a component of the SWI-SNF complex, is mutated in multiple human tumor cell lines.",http://www.ncbi.nlm.nih.gov/pubmed/11085541
7447,24816255,Recurrent gain-of-function mutations of RHOA in diffuse-type gastric carcinoma.,http://www.ncbi.nlm.nih.gov/pubmed/24816255
7448,15121768,Genotype-phenotype correlations in Peutz-Jeghers syndrome.,http://www.ncbi.nlm.nih.gov/pubmed/15121768
7449,26087898,Exome-level comparison of primary well-differentiated neuroendocrine tumors and their cell lines.,http://www.ncbi.nlm.nih.gov/pubmed/26087898
7450,21532627,Frequent homozygous deletion of the LKB1/STK11 gene in non-small cell lung cancer.,http://www.ncbi.nlm.nih.gov/pubmed/21532627
7451,17711506,LKB1 gene mutations in Japanese lung cancer patients.,http://www.ncbi.nlm.nih.gov/pubmed/17711506
7452,24587179,Comparative genomic and transcriptomic analyses of LNCaP and C4-2B prostate cancer cell lines.,http://www.ncbi.nlm.nih.gov/pubmed/24587179
7453,15656799,"Somatic mutations in the PTCH, SMOH, SUFUH and TP53 genes in sporadic basal cell carcinomas.",http://www.ncbi.nlm.nih.gov/pubmed/15656799
7454,27081527,A deleterious RNF43 germline mutation in a severely affected serrated polyposis kindred.,http://www.ncbi.nlm.nih.gov/pubmed/27081527
7455,24747642,Integrated genomic characterization of adrenocortical carcinoma.,http://www.ncbi.nlm.nih.gov/pubmed/24747642
7456,20826764,Frequent mutations of chromatin remodeling gene ARID1A in ovarian clear cell carcinoma.,http://www.ncbi.nlm.nih.gov/pubmed/20826764
7457,23088494,Alterations of the SWI/SNF chromatin remodelling subunit-BRG1 and BRM in hepatocellular carcinoma.,http://www.ncbi.nlm.nih.gov/pubmed/23088494
7458,25401301,Spectrum of diverse genomic alterations define non-clear cell renal carcinoma subtypes.,http://www.ncbi.nlm.nih.gov/pubmed/25401301
7459,22820256,Medulloblastoma exome sequencing uncovers subtype-specific somatic mutations.,http://www.ncbi.nlm.nih.gov/pubmed/22820256
7460,21625565,deFuse: an algorithm for gene fusion discovery in tumor RNA-Seq data.,http://www.ncbi.nlm.nih.gov/pubmed/21625565
7461,24681847,The immunocytokine NHS-IL12 as a potential cancer therapeutic.,http://www.ncbi.nlm.nih.gov/pubmed/24681847
7462,27267856,An FGFR3 Autocrine Loop Sustains Acquired Resistance to Trastuzumab in Gastric Cancer Patients.,http://www.ncbi.nlm.nih.gov/pubmed/27267856
7463,27158387,Treatment with retinoid X receptor agonist IRX4204 ameliorates experimental autoimmune encephalomyelitis.,http://www.ncbi.nlm.nih.gov/pubmed/27158387
7464,25795722,"Resimmune, an anti-CD3ε recombinant immunotoxin, induces durable remissions in patients with cutaneous T-cell lymphoma.",http://www.ncbi.nlm.nih.gov/pubmed/25795722
7465,27696380,"Phase 2 study of dasatinib in patients with alveolar soft part sarcoma, chondrosarcoma, chordoma, epithelioid sarcoma, or solitary fibrous tumor.",http://www.ncbi.nlm.nih.gov/pubmed/27696380
7466,27758886,Targeting BRK-Positive Breast Cancers with Small-Molecule Kinase Inhibitors.,http://www.ncbi.nlm.nih.gov/pubmed/27758886
7467,15471878,The nuclear tyrosine kinase BRK/Sik phosphorylates and inhibits the RNA-binding activities of the Sam68-like mammalian proteins SLM-1 and SLM-2.,http://www.ncbi.nlm.nih.gov/pubmed/15471878
7468,26489445,Comprehensive analyses using next-generation sequencing and immunohistochemistry enable precise treatment in advanced gastric cancer.,http://www.ncbi.nlm.nih.gov/pubmed/26489445
7469,27499911,The molecular landscape of extraskeletal osteosarcoma: A clinicopathological and molecular biomarker study.,http://www.ncbi.nlm.nih.gov/pubmed/27499911
7470,23791828,Comprehensive genomic profiling of epithelial ovarian cancer by next generation sequencing-based diagnostic assay reveals new routes to targeted therapies.,http://www.ncbi.nlm.nih.gov/pubmed/23791828
7471,21163964,The genetic landscape of the childhood cancer medulloblastoma.,http://www.ncbi.nlm.nih.gov/pubmed/21163964
7472,24944587,Genome-wide mutational landscape of mucinous carcinomatosis peritonei of appendiceal origin.,http://www.ncbi.nlm.nih.gov/pubmed/24944587
7473,27231908,EIYMNVPV Motif is Essential for A1CF Nucleus Localization and A1CF (-8aa) Promotes Proliferation of MDA-MB-231 Cells via Up-Regulation of IL-6.,http://www.ncbi.nlm.nih.gov/pubmed/27231908
7474,27486175,Phase II Study of Alemtuzumab (CAMPATH-1) in Patients with HTLV-1-Associated Adult T-cell Leukemia/lymphoma.,http://www.ncbi.nlm.nih.gov/pubmed/27486175
7475,27784746,"CRLX101, a Nanoparticle-Drug Conjugate Containing Camptothecin, Improves Rectal Cancer Chemoradiotherapy by Inhibiting DNA Repair and HIF1α.",http://www.ncbi.nlm.nih.gov/pubmed/27784746
7476,17942920,"Discovery and pharmacologic characterization of CP-724,714, a selective ErbB2 tyrosine kinase inhibitor.",http://www.ncbi.nlm.nih.gov/pubmed/17942920
7477,23143595,"Recurrent mutation of the ID3 gene in Burkitt lymphoma identified by integrated genome, exome and transcriptome sequencing.",http://www.ncbi.nlm.nih.gov/pubmed/23143595
7478,23890154,Melanomas of unknown primary have a mutation profile consistent with cutaneous sun-exposed melanoma.,http://www.ncbi.nlm.nih.gov/pubmed/23890154
7479,27267632,Polyplex-mediated inhibition of chemokine receptor CXCR4 and chromatin-remodeling enzyme NCOA3 impedes pancreatic cancer progression and metastasis.,http://www.ncbi.nlm.nih.gov/pubmed/27267632
7480,27635088,Administration of Non-Torsadogenic human Ether-à-go-go-Related Gene Inhibitors Is Associated with Better Survival for High hERG-Expressing Glioblastoma Patients.,http://www.ncbi.nlm.nih.gov/pubmed/27635088
7481,18497958,Pharmacological separation of hEAG and hERG K+ channel function in the human mammary carcinoma cell line MCF-7.,http://www.ncbi.nlm.nih.gov/pubmed/18497958
7482,28011764,Inhibition of radiation-induced glioblastoma invasion by genetic and pharmacological targeting of MDA-9/Syntenin.,http://www.ncbi.nlm.nih.gov/pubmed/28011764
7483,27370604,Combination of Imatinib Mesylate and AKT Inhibitor Provides Synergistic Effects in Preclinical Study of Gastrointestinal Stromal Tumor.,http://www.ncbi.nlm.nih.gov/pubmed/27370604
7484,27126994,"A Phase Ib Study of Alpelisib (BYL719), a PI3Kα-Specific Inhibitor, with Letrozole in ER+/HER2- Metastatic Breast Cancer.",http://www.ncbi.nlm.nih.gov/pubmed/27126994
7485,27707886,Exploitation of Castration-Resistant Prostate Cancer Transcription Factor Dependencies by the Novel BET Inhibitor ABBV-075.,http://www.ncbi.nlm.nih.gov/pubmed/27707886
7486,27818134,Transcriptomic Characterization of SF3B1 Mutation Reveals Its Pleiotropic Effects in Chronic Lymphocytic Leukemia.,http://www.ncbi.nlm.nih.gov/pubmed/27818134
7487,27872130,A First-in-Human Phase I Study of the ATP-Competitive AKT Inhibitor Ipatasertib Demonstrates Robust and Safe Targeting of AKT in Patients with Solid Tumors.,http://www.ncbi.nlm.nih.gov/pubmed/27872130
7488,28040715,"Prolonged Response to HER2-Directed Therapy in a Patient With HER2-Amplified, Rapidly Progressive Metastatic Colorectal Cancer.",http://www.ncbi.nlm.nih.gov/pubmed/28040715
7489,27370605,Identification of Existing Drugs That Effectively Target NTRK1 and ROS1 Rearrangements in Lung Cancer.,http://www.ncbi.nlm.nih.gov/pubmed/27370605
7490,24211491,Colorectal carcinomas with CpG island methylator phenotype 1 frequently contain mutations in chromatin regulators.,http://www.ncbi.nlm.nih.gov/pubmed/24211491
7491,17047397,"Mutational analysis of AKT1, AKT2 and AKT3 genes in common human carcinomas.",http://www.ncbi.nlm.nih.gov/pubmed/17047397
7492,19738612,Somatic mutations are present in all members of the AKT family in endometrial carcinoma.,http://www.ncbi.nlm.nih.gov/pubmed/19738612
7493,16094359,Colorectal cancer: mutations in a signalling pathway.,http://www.ncbi.nlm.nih.gov/pubmed/16094359
7494,18923524,Oncogenic mutations of ALK kinase in neuroblastoma.,http://www.ncbi.nlm.nih.gov/pubmed/18923524
7495,27941795,Smarca4 ATPase mutations disrupt direct eviction of PRC1 from chromatin.,http://www.ncbi.nlm.nih.gov/pubmed/27941795
7496,21807601,Analysis of molecular aberrations of Wnt pathway gladiators in colorectal cancer in the Kashmiri population.,http://www.ncbi.nlm.nih.gov/pubmed/21807601
7497,24793135,A recurrent neomorphic mutation in MYOD1 defines a clinically aggressive subset of embryonal rhabdomyosarcoma associated with PI3K-AKT pathway mutations.,http://www.ncbi.nlm.nih.gov/pubmed/24793135
7498,16631465,ATM alterations in childhood non-Hodgkin lymphoma.,http://www.ncbi.nlm.nih.gov/pubmed/16631465
7499,23131393,Diagnostic value of immunohistochemistry for the detection of the BRAFV600E mutation in primary lung adenocarcinoma Caucasian patients.,http://www.ncbi.nlm.nih.gov/pubmed/23131393
7500,19474002,Concomitant mutations and splice variants in KRAS and BRAF demonstrate complex perturbation of the Ras/Raf signalling pathway in advanced colorectal cancer.,http://www.ncbi.nlm.nih.gov/pubmed/19474002
7501,25416589,Identification by array comparative genomic hybridization of a new amplicon on chromosome 17q highly recurrent in BRCA1 mutated triple negative breast cancer.,http://www.ncbi.nlm.nih.gov/pubmed/25416589
7502,17161371,"""Similarity trap"" in protein-protein interactions could be carcinogenic: simulations of p53 core domain complexed with 53BP1 and BRCA1 BRCT domains.",http://www.ncbi.nlm.nih.gov/pubmed/17161371
7503,21473589,Impact of BRCA1 BRCT domain missense substitutions on phosphopeptide recognition.,http://www.ncbi.nlm.nih.gov/pubmed/21473589
7504,11573085,Structure of a BRCA1-BARD1 heterodimeric RING-RING complex.,http://www.ncbi.nlm.nih.gov/pubmed/11573085
7505,15172985,Structure-based assessment of missense mutations in human BRCA1: implications for breast and ovarian cancer predisposition.,http://www.ncbi.nlm.nih.gov/pubmed/15172985
7506,18779604,Performance of BRCA1/2 mutation prediction models in Asian Americans.,http://www.ncbi.nlm.nih.gov/pubmed/18779604
7507,17719744,Identification and in silico analysis of functional SNPs of the BRCA1 gene.,http://www.ncbi.nlm.nih.gov/pubmed/17719744
7508,19584272,Modification of ovarian cancer risk by BRCA1/2-interacting genes in a multicenter cohort of BRCA1/2 mutation carriers.,http://www.ncbi.nlm.nih.gov/pubmed/19584272
7509,26975901,"The influence of clinical and genetic factors on patient outcome in small cell carcinoma of the ovary, hypercalcemic type.",http://www.ncbi.nlm.nih.gov/pubmed/26975901
7510,26343384,SMARCA4 inactivation defines a group of undifferentiated thoracic malignancies transcriptionally related to BAF-deficient sarcomas.,http://www.ncbi.nlm.nih.gov/pubmed/26343384
7511,24658002,"Germline and somatic SMARCA4 mutations characterize small cell carcinoma of the ovary, hypercalcemic type.",http://www.ncbi.nlm.nih.gov/pubmed/24658002
7512,,"Abstract CT027: A phase I, open-label study of GSK3174998 administered alone and in combination with pembrolizumab in patients (pts) with selected advanced solid tumors (ENGAGE-1)",http://cancerres.aacrjournals.org/content/76/14_Supplement/CT027
7513,27825636,"Cabozantinib in patients with advanced RET-rearranged non-small-cell lung cancer: an open-label, single-centre, phase 2, single-arm trial.",http://www.ncbi.nlm.nih.gov/pubmed/27825636
7514,23737213,Novel YAP1-TFE3 fusion defines a distinct subset of epithelioid hemangioendothelioma.,http://www.ncbi.nlm.nih.gov/pubmed/23737213
7515,17305420,Functional impact of missense variants in BRCA1 predicted by supervised learning.,http://www.ncbi.nlm.nih.gov/pubmed/17305420
7516,27870574,"Evaluation of BGJ398, a Fibroblast Growth Factor Receptor 1-3 Kinase Inhibitor, in Patients With Advanced Solid Tumors Harboring Genetic Alterations in Fibroblast Growth Factor Receptors: Results of a Global Phase I, Dose-Escalation and Dose-Expansion Study.",http://www.ncbi.nlm.nih.gov/pubmed/27870574
7517,27760835,N-Arachidonoyl Dopamine Inhibits NRAS Neoplastic Transformation by Suppressing Its Plasma Membrane Translocation.,http://www.ncbi.nlm.nih.gov/pubmed/27760835
7518,27837031,Pharmacological Inhibition of Myocardin-related Transcription Factor Pathway Blocks Lung Metastases of RhoC-Overexpressing Melanoma.,http://www.ncbi.nlm.nih.gov/pubmed/27837031
7519,27825638,"Erlotinib, cabozantinib, or erlotinib plus cabozantinib as second-line or third-line treatment of patients with EGFR wild-type advanced non-small-cell lung cancer (ECOG-ACRIN 1512): a randomised, controlled, open-label, multicentre, phase 2 trial.",http://www.ncbi.nlm.nih.gov/pubmed/27825638
7520,27073162,Perifosine and ABT-737 synergistically inhibit lung cancer cells in vitro and in vivo.,http://www.ncbi.nlm.nih.gov/pubmed/27073162
7521,26812616,Early-Stage Induction of SWI/SNF Mutations during Esophageal Squamous Cell Carcinogenesis.,http://www.ncbi.nlm.nih.gov/pubmed/26812616
7522,27671334,AXL Inhibition Suppresses the DNA Damage Response and Sensitizes Cells to PARP Inhibition in Multiple Cancers.,http://www.ncbi.nlm.nih.gov/pubmed/27671334
7523,28062703,"TAS-116, a Novel Hsp90 Inhibitor, Selectively Enhances Radiosensitivity of Human Cancer Cells to X-rays and Carbon Ion Radiation.",http://www.ncbi.nlm.nih.gov/pubmed/28062703
7524,27980105,The mTORC1/2 Inhibitor AZD8055 Strengthens the Efficiency of the MEK Inhibitor Trametinib to Reduce the Mcl-1/[Bim and Puma] ratio and to Sensitize Ovarian Carcinoma Cells to ABT-737.,http://www.ncbi.nlm.nih.gov/pubmed/27980105
7525,21045145,Inhibition of glutaminase preferentially slows growth of glioma cells with mutant IDH1.,http://www.ncbi.nlm.nih.gov/pubmed/21045145
7526,25915584,Targeted inhibition of tumor-specific glutaminase diminishes cell-autonomous tumorigenesis.,http://www.ncbi.nlm.nih.gov/pubmed/25915584
7527,28031424,The DART Study: Results from the Dose-Escalation and Expansion Cohorts Evaluating the Combination of Dalantercept plus Axitinib in Advanced Renal Cell Carcinoma.,http://www.ncbi.nlm.nih.gov/pubmed/28031424
7528,9172002,Chromosome 1 rearrangements involving the genes TPR and NTRK1 produce structurally different thyroid-specific TRK oncogenes.,http://www.ncbi.nlm.nih.gov/pubmed/9172002
7529,27259011,Recurrent NTRK1 Gene Fusions Define a Novel Subset of Locally Aggressive Lipofibromatosis-like Neural Tumors.,http://www.ncbi.nlm.nih.gov/pubmed/27259011
7530,19184099,RABGAP1L gene rearrangement resulting from a der(Y)t(Y;1)(q12;q25) in acute myeloid leukemia arising in a child with Klinefelter syndrome.,http://www.ncbi.nlm.nih.gov/pubmed/19184099
7531,20840587,Proteoglycans in health and disease: novel roles for proteoglycans in malignancy and their pharmacological targeting.,http://www.ncbi.nlm.nih.gov/pubmed/20840587
7532,16061654,Novel tumor-specific isoforms of BEHAB/brevican identified in human malignant gliomas.,http://www.ncbi.nlm.nih.gov/pubmed/16061654
7533,24647444,NTRK1 fusion in glioblastoma multiforme.,http://www.ncbi.nlm.nih.gov/pubmed/24647444
7534,22306302,Neurofascin: a switch between neuronal plasticity and stability.,http://www.ncbi.nlm.nih.gov/pubmed/22306302
7535,26189108,Next-generation-sequencing of recurrent childhood high hyperdiploid acute lymphoblastic leukemia reveals mutations typically associated with high risk patients.,http://www.ncbi.nlm.nih.gov/pubmed/26189108
7536,24943349,Whole genome sequencing reveals potential targets for therapy in patients with refractory KRAS mutated metastatic colorectal cancer.,http://www.ncbi.nlm.nih.gov/pubmed/24943349
7537,25732823,DBC1 functions as a tumor suppressor by regulating p53 stability.,http://www.ncbi.nlm.nih.gov/pubmed/25732823
7538,27725203,CCAR2 Is Required for Proliferation and Tumor Maintenance in Human Squamous Cell Carcinoma.,http://www.ncbi.nlm.nih.gov/pubmed/27725203
7539,27809307,A novel crosstalk between CCAR2 and AKT pathway in the regulation of cancer cell proliferation.,http://www.ncbi.nlm.nih.gov/pubmed/27809307
7540,28065413,Therapeutic Targeting of MLL Degradation Pathways in MLL-Rearranged Leukemia.,http://www.ncbi.nlm.nih.gov/pubmed/28065413
7541,14726021,Repair of DNA double strand breaks by non-homologous end joining.,http://www.ncbi.nlm.nih.gov/pubmed/14726021
7542,24680878,DNA-PK: a dynamic enzyme in a versatile DSB repair pathway.,http://www.ncbi.nlm.nih.gov/pubmed/24680878
7543,26992638,"Identification of PRKDC (Protein Kinase, DNA-Activated, Catalytic Polypeptide) as an essential gene for colorectal cancer (CRCs) cells.",http://www.ncbi.nlm.nih.gov/pubmed/26992638
7544,27856181,"Down-regulation of protein kinase, DNA-activated, catalytic polypeptide attenuates tumor progression and is an independent prognostic predictor of survival in prostate cancer.",http://www.ncbi.nlm.nih.gov/pubmed/27856181
7545,25787093,"Prevalence of Germline BAP1, CDKN2A, and CDK4 Mutations in an Australian Population-Based Sample of Cutaneous Melanoma Cases.",http://www.ncbi.nlm.nih.gov/pubmed/25787093
7546,8895759,"Loss of the p16INK4a and p15INK4b genes, as well as neighboring 9p21 markers, in sporadic melanoma.",http://www.ncbi.nlm.nih.gov/pubmed/8895759
7547,21462282,Classifying variants of CDKN2A using computational and laboratory studies.,http://www.ncbi.nlm.nih.gov/pubmed/21462282
7548,25468431,A clinical grade sequencing-based assay for CEBPA mutation testing: report of a large series of myeloid neoplasms.,http://www.ncbi.nlm.nih.gov/pubmed/25468431
7549,12738854,Mutational analysis of the tyrosine kinome in colorectal cancers.,http://www.ncbi.nlm.nih.gov/pubmed/12738854
7550,24750136,A comparative analysis of MAPK pathway hallmark alterations in pilocytic astrocytomas: age-related and mutually exclusive. [corrected].,http://www.ncbi.nlm.nih.gov/pubmed/24750136
7551,15625620,Mutations that cause osteoglophonic dysplasia define novel roles for FGFR1 in bone elongation.,http://www.ncbi.nlm.nih.gov/pubmed/15625620
7552,23348274,FGFR1 and FGFR2 mutations in Pfeiffer syndrome.,http://www.ncbi.nlm.nih.gov/pubmed/23348274
7553,16186508,Sequence survey of receptor tyrosine kinases reveals mutations in glioblastomas.,http://www.ncbi.nlm.nih.gov/pubmed/16186508
7554,25186949,The genomic landscape of pediatric Ewing sarcoma.,http://www.ncbi.nlm.nih.gov/pubmed/25186949
7555,23887298,Advanced urothelial carcinoma: next-generation sequencing reveals diverse genomic alterations and targets of therapy.,http://www.ncbi.nlm.nih.gov/pubmed/23887298
7556,17360555,Impaired FGF signaling contributes to cleft lip and palate.,http://www.ncbi.nlm.nih.gov/pubmed/17360555
7557,28077676,A PTK7-targeted antibody-drug conjugate reduces tumor-initiating cells and induces sustained tumor regressions.,http://www.ncbi.nlm.nih.gov/pubmed/28077676
7558,20106510,FGFR2 mutations are rare across histologic subtypes of ovarian cancer.,http://www.ncbi.nlm.nih.gov/pubmed/20106510
7559,16418739,Mutation screening in patients with syndromic craniosynostoses indicates that a limited number of recurrent FGFR2 mutations accounts for severe forms of Pfeiffer syndrome.,http://www.ncbi.nlm.nih.gov/pubmed/16418739
7560,22383975,"FGFR2 point mutations in 466 endometrioid endometrial tumors: relationship with MSI, KRAS, PIK3CA, CTNNB1 mutations and clinicopathological features.",http://www.ncbi.nlm.nih.gov/pubmed/22383975
7561,27425854,Genomic characterization of recurrent high-grade astroblastoma.,http://www.ncbi.nlm.nih.gov/pubmed/27425854
7562,19066959,Q289P mutation in the FGFR2 gene: first report in a patient with type 1 Pfeiffer syndrome.,http://www.ncbi.nlm.nih.gov/pubmed/19066959
7563,11325814,Mutations in fibroblast growth factor receptor 2 and fibroblast growth factor receptor 3 genes associated with human gastric and colorectal cancers.,http://www.ncbi.nlm.nih.gov/pubmed/11325814
7564,12544231,FGFR2 mutations among Thai children with Crouzon and Apert syndromes.,http://www.ncbi.nlm.nih.gov/pubmed/12544231
7565,8528214,Novel FGFR2 mutations in Crouzon and Jackson-Weiss syndromes show allelic heterogeneity and phenotypic variability.,http://www.ncbi.nlm.nih.gov/pubmed/8528214
7566,25759925,The C342R mutation in FGFR2 causes Crouzon syndrome with elbow deformity.,http://www.ncbi.nlm.nih.gov/pubmed/25759925
7567,10712195,Paternal origin of FGFR2 mutations in sporadic cases of Crouzon syndrome and Pfeiffer syndrome.,http://www.ncbi.nlm.nih.gov/pubmed/10712195
7568,25035393,Kinase domain activation of FGFR2 yields high-grade lung adenocarcinoma sensitive to a Pan-FGFR inhibitor in a mouse model of NSCLC.,http://www.ncbi.nlm.nih.gov/pubmed/25035393
7569,24578066,Quantification of facial skeletal shape variation in fibroblast growth factor receptor-related craniosynostosis syndromes.,http://www.ncbi.nlm.nih.gov/pubmed/24578066
7570,25669975,Comprehensive analysis of targetable oncogenic mutations in chinese cervical cancers.,http://www.ncbi.nlm.nih.gov/pubmed/25669975
7571,12357470,"FGFs, their receptors, and human limb malformations: clinical and molecular correlations.",http://www.ncbi.nlm.nih.gov/pubmed/12357470
7572,23550210,Integrative analysis of complex cancer genomics and clinical profiles using the cBioPortal.,http://www.ncbi.nlm.nih.gov/pubmed/23550210
7573,26920151,Germline and somatic FGFR1 abnormalities in dysembryoplastic neuroepithelial tumors.,http://www.ncbi.nlm.nih.gov/pubmed/26920151
7574,27034505,An African-specific polymorphism in the TP53 gene impairs p53 tumor suppressor function in a mouse model.,http://www.ncbi.nlm.nih.gov/pubmed/27034505
7575,28068178,Cetuximab Plus Chemoradiotherapy in Immunocompetent Patients With Anal Carcinoma: A Phase II Eastern Cooperative Oncology Group-American College of Radiology Imaging Network Cancer Research Group Trial (E3205).,http://www.ncbi.nlm.nih.gov/pubmed/28068178
7576,27896051,Screening of mutations affecting protein stability and dynamics of FGFR1-A simulation analysis.,http://www.ncbi.nlm.nih.gov/pubmed/27896051
7577,8942979,Evidence for a transcriptional activation function of BRCA1 C-terminal region.,http://www.ncbi.nlm.nih.gov/pubmed/8942979
7578,12497638,BRCA1 germline mutations in Indian familial breast cancer.,http://www.ncbi.nlm.nih.gov/pubmed/12497638
7579,7874170,Jackson-Weiss and Crouzon syndromes are allelic with mutations in fibroblast growth factor receptor 2.,http://www.ncbi.nlm.nih.gov/pubmed/7874170
7580,11556600,A case of Pfeiffer syndrome type 1 with an A344P mutation in the FGFR2 gene.,http://www.ncbi.nlm.nih.gov/pubmed/11556600
7581,22520759,Small-molecule inhibitors of the c-Fes protein-tyrosine kinase.,http://www.ncbi.nlm.nih.gov/pubmed/22520759
7582,11509660,A point mutation in the N-terminal coiled-coil domain releases c-Fes tyrosine kinase activity and survival signaling in myeloid leukemia cells.,http://www.ncbi.nlm.nih.gov/pubmed/11509660
7583,27542411,The Phospholipase Cγ2 Mutants R665W and L845F Identified in Ibrutinib-resistant Chronic Lymphocytic Leukemia Patients Are Hypersensitive to the Rho GTPase Rac2 Protein.,http://www.ncbi.nlm.nih.gov/pubmed/27542411
7584,17932039,"Specificity and mechanism of action of EHT 1864, a novel small molecule inhibitor of Rac family small GTPases.",http://www.ncbi.nlm.nih.gov/pubmed/17932039
7585,27837028,"ASP5878, a Novel Inhibitor of FGFR1, 2, 3, and 4, Inhibits the Growth of FGF19-Expressing Hepatocellular Carcinoma.",http://www.ncbi.nlm.nih.gov/pubmed/27837028
7586,27458550,"Chronic eosinophilic leukemia, NOS with t(5;12)(q31;p13)/ETV6-ACSL6 gene fusion: a novel variant of myeloid proliferative neoplasm with eosinophilia.",http://www.ncbi.nlm.nih.gov/pubmed/27458550
7587,18310541,ETV6/GOT1 fusion in a case of t(10;12)(q24;p13)-positive myelodysplastic syndrome.,http://www.ncbi.nlm.nih.gov/pubmed/18310541
7588,26585234,"Specific TP53 Mutants Overrepresented in Ovarian Cancer Impact CNV, TP53 Activity, Responses to Nutlin-3a, and Cell Survival.",http://www.ncbi.nlm.nih.gov/pubmed/26585234
7589,24006744,"Breaking the chain. Hospitals set supply cost-cutting targets, push physicians to change behavior.",http://www.ncbi.nlm.nih.gov/pubmed/24006744
7590,,The Bruton's Tyrosine Kinase (BTK) Inhibitor ARQ 531 Effectively Inhibits Wild Type and C481S Mutant BTK and Is Superior to Ibrutinib in a Mouse Model of Chronic Lymphocytic Leukemia,http://www.bloodjournal.org/content/128/22/3232?sso-checked=true
7591,26061751,"Comprehensive, Integrative Genomic Analysis of Diffuse Lower-Grade Gliomas.",http://www.ncbi.nlm.nih.gov/pubmed/26061751
7592,25322323,ALK inhibitors in non-small cell lung cancer: crizotinib and beyond.,http://www.ncbi.nlm.nih.gov/pubmed/25322323
7593,17488663,Translocations and mutations involving the nucleophosmin (NPM1) gene in lymphomas and leukemias.,http://www.ncbi.nlm.nih.gov/pubmed/17488663
7594,26786851,Novel ALK inhibitor AZD3463 inhibits neuroblastoma growth by overcoming crizotinib resistance and inducing apoptosis.,http://www.ncbi.nlm.nih.gov/pubmed/26786851
7595,27345636,"Obinutuzumab plus bendamustine versus bendamustine monotherapy in patients with rituximab-refractory indolent non-Hodgkin lymphoma (GADOLIN): a randomised, controlled, open-label, multicentre, phase 3 trial.",http://www.ncbi.nlm.nih.gov/pubmed/27345636
7596,28034904,RAD51 Mediates Resistance of Cancer Stem Cells to PARP Inhibition in Triple-Negative Breast Cancer.,http://www.ncbi.nlm.nih.gov/pubmed/28034904
7597,,"Preliminary safety and activity in a first-in-human phase 1 study of BLU-285, a potent, highly-selective inhibitor of KIT and PDGFRa activation loop mutants in advanced gastrointestinal stromal tumor (GIST)",http://www.ecco-org.eu/Events/ENA2016/Searchable-Programme#anchorScpr
7598,,"DCC-2618, a pan KIT and PDGFR switch control inhibitor, achieves proof-of-concept in a first-in-human study",http://www.ecco-org.eu/Events/ENA2016/Searchable-Programme#anchorScpr
7599,27389056,Exome sequencing identifies highly recurrent somatic GATA2 and CEBPA mutations in acute erythroid leukemia.,http://www.ncbi.nlm.nih.gov/pubmed/27389056
7600,27820802,Inhibition of RAS function through targeting an allosteric regulatory site.,http://www.ncbi.nlm.nih.gov/pubmed/27820802
7601,27287717,IKBKE Is a Substrate of EGFR and a Therapeutic Target in Non-Small Cell Lung Cancer with Activating Mutations of EGFR.,http://www.ncbi.nlm.nih.gov/pubmed/27287717
7602,16337122,SAR and inhibitor complex structure determination of a novel class of potent and specific Aurora kinase inhibitors.,http://www.ncbi.nlm.nih.gov/pubmed/16337122
7603,26842935,Aurora kinase targeting in lung cancer reduces KRAS-induced transformation.,http://www.ncbi.nlm.nih.gov/pubmed/26842935
7604,27440267,"The Novel Pan-PIM Kinase Inhibitor, PIM447, Displays Dual Antimyeloma and Bone-Protective Effects, and Potently Synergizes with Current Standards of Care.",http://www.ncbi.nlm.nih.gov/pubmed/27440267
7605,12034820,Redox state of tumor suppressor p53 regulates its sequence-specific DNA binding in DNA-damaged cells by cysteine 277.,http://www.ncbi.nlm.nih.gov/pubmed/12034820
7606,19850740,"Monoallelic and biallelic inactivation of TP53 gene in chronic lymphocytic leukemia: selection, impact on survival, and response to DNA damage.",http://www.ncbi.nlm.nih.gov/pubmed/19850740
7607,27821489,A Transcriptional Signature Identifies LKB1 Functional Status as a Novel Determinant of MEK Sensitivity in Lung Adenocarcinoma.,http://www.ncbi.nlm.nih.gov/pubmed/27821489
7608,18594528,Mutations in the LKB1 tumour suppressor are frequently detected in tumours from Caucasian but not Asian lung cancer patients.,http://www.ncbi.nlm.nih.gov/pubmed/18594528
7609,20832360,Brk/PTK6 signaling in normal and cancer cell models.,http://www.ncbi.nlm.nih.gov/pubmed/20832360
7610,25999240,Tracing the footprints of the breast cancer oncogene BRK - Past till present.,http://www.ncbi.nlm.nih.gov/pubmed/25999240
7611,23459091,hERG channel function: beyond long QT.,http://www.ncbi.nlm.nih.gov/pubmed/23459091
7612,21850047,Novel roles for hERG K(+) channels in cell proliferation and apoptosis.,http://www.ncbi.nlm.nih.gov/pubmed/21850047
7613,21190577,Eag and HERG potassium channels as novel therapeutic targets in cancer.,http://www.ncbi.nlm.nih.gov/pubmed/21190577
7614,8816445,"RREB-1, a novel zinc finger protein, is involved in the differentiation response to Ras in human medullary thyroid carcinomas.",http://www.ncbi.nlm.nih.gov/pubmed/8816445
7615,24418439,Drosophila Hindsight and mammalian RREB-1 are evolutionarily conserved DNA-binding transcriptional attenuators.,http://www.ncbi.nlm.nih.gov/pubmed/24418439
7616,21703425,RREB1 transcription factor splice variants in urologic cancer.,http://www.ncbi.nlm.nih.gov/pubmed/21703425
7617,22751122,RREB1 repressed miR-143/145 modulates KRAS signaling through downregulation of multiple targets.,http://www.ncbi.nlm.nih.gov/pubmed/22751122
7618,27438854,"Ptk7 and Mcc, Unfancied Components in Non-Canonical Wnt Signaling and Cancer.",http://www.ncbi.nlm.nih.gov/pubmed/27438854
7619,27499181,PTK7 overexpression in colorectal tumors: Clinicopathological correlation and prognosis relevance.,http://www.ncbi.nlm.nih.gov/pubmed/27499181
7620,25550828,PTK7 protein is decreased in epithelial ovarian carcinomas with poor prognosis.,http://www.ncbi.nlm.nih.gov/pubmed/25550828
7621,27179933,Strong synergy with APR-246 and DNA-damaging drugs in primary cancer cells from patients with TP53 mutant High-Grade Serous ovarian cancer.,http://www.ncbi.nlm.nih.gov/pubmed/27179933
7622,17764544,High resolution melting for mutation scanning of TP53 exons 5-8.,http://www.ncbi.nlm.nih.gov/pubmed/17764544
7623,20195489,Activation of p73 and induction of Noxa by DNA damage requires NF-kappa B.,http://www.ncbi.nlm.nih.gov/pubmed/20195489
7624,24406744,Crystal structure of the F27G AIM2 PYD mutant and similarities of its self-association to DED/DED interactions.,http://www.ncbi.nlm.nih.gov/pubmed/24406744
7625,24728327,"Germline variation in cancer-susceptibility genes in a healthy, ancestrally diverse cohort: implications for individual genome sequencing.",http://www.ncbi.nlm.nih.gov/pubmed/24728327
7626,10570911,Mutational analysis of TSC1 and TSC2 genes in Japanese patients with tuberous sclerosis complex.,http://www.ncbi.nlm.nih.gov/pubmed/10570911
7627,18422784,Functional analysis of single amino-acid mutations in the thrombopoietin-receptor Mpl underlying congenital amegakaryocytic thrombocytopenia.,http://www.ncbi.nlm.nih.gov/pubmed/18422784
7628,24722014,Use of long term molecular dynamics simulation in predicting cancer associated SNPs.,http://www.ncbi.nlm.nih.gov/pubmed/24722014
7629,18406877,A novel missense MSH2 gene mutation in a patient of a Korean family with hereditary nonpolyposis colorectal cancer.,http://www.ncbi.nlm.nih.gov/pubmed/18406877
7630,15996210,Clinical and molecular characteristics of hereditary non-polyposis colorectal cancer families in Southeast Asia.,http://www.ncbi.nlm.nih.gov/pubmed/15996210
7631,23960188,DNA repair genes are selectively mutated in diffuse large B cell lymphomas.,http://www.ncbi.nlm.nih.gov/pubmed/23960188
7632,12807981,Recurrent mutations in the NF1 gene are common among neurofibromatosis type 1 patients.,http://www.ncbi.nlm.nih.gov/pubmed/12807981
7633,10726756,Analysis of the NF1 gene by temperature gradient gel electrophoresis reveals a high incidence of mutations in exon 4b.,http://www.ncbi.nlm.nih.gov/pubmed/10726756
7634,15863657,Pitfalls of automated comparative sequence analysis as a single platform for routine clinical testing for NF1.,http://www.ncbi.nlm.nih.gov/pubmed/15863657
7635,9990505,Role of Bcl-2 family proteins in apoptosis: apoptosomes or mitochondria?,http://www.ncbi.nlm.nih.gov/pubmed/9990505
7636,9242549,BCL2 overexpression associated with chromosomal amplification in diffuse large B-cell lymphoma.,http://www.ncbi.nlm.nih.gov/pubmed/9242549
7637,25452615,BCL2 mutations are associated with increased risk of transformation and shortened survival in follicular lymphoma.,http://www.ncbi.nlm.nih.gov/pubmed/25452615
7638,26790966,Analysis of BRIP1 Variants among Korean Patients with BRCA1/2 Mutation-Negative High-Risk Breast Cancer.,http://www.ncbi.nlm.nih.gov/pubmed/26790966
7639,25933833,"Phase 1 dose escalation trial of ilorasertib, a dual Aurora/VEGF receptor kinase inhibitor, in patients with hematologic malignancies.",http://www.ncbi.nlm.nih.gov/pubmed/25933833
7640,,"Potent in vivo activity of the Aurora kinase inhibitor ABT-348 in a broad spectrum of histological types: Evaluation of efficacy, dosing/scheduling, and PK/PD",http://mct.aacrjournals.org/content/10/11_Supplement/B231.short
7641,26807250,"A phase I multicenter study of antroquinonol in patients with metastatic non-small-cell lung cancer who have received at least two prior systemic treatment regimens, including one platinum-based chemotherapy regimen.",http://www.ncbi.nlm.nih.gov/pubmed/26807250
7642,26098748,Safety and Efficacy of Buparlisib (BKM120) in Patients with PI3K Pathway-Activated Non-Small Cell Lung Cancer: Results from the Phase II BASALT-1 Study.,http://www.ncbi.nlm.nih.gov/pubmed/26098748
7643,27186432,M2698 is a potent dual-inhibitor of p70S6K and Akt that affects tumor growth in mouse models of cancer and crosses the blood-brain barrier.,http://www.ncbi.nlm.nih.gov/pubmed/27186432
7644,18235126,"Multicenter, phase II trial of sunitinib in previously treated, advanced non-small-cell lung cancer.",http://www.ncbi.nlm.nih.gov/pubmed/18235126
7645,,"A FIRST IN HUMAN, DOSE ESCALATION TRIAL OF MSC2363318A - A DUAL P70S6K/AKT INHIBITOR, FOR PATIENTS WITH ADVANCED MALIGNANCIES",http://oup.silverchair-cdn.com/oup/backfile/Content_public/Journal/annonc/26/suppl_2/10.1093_annonc_mdv094.1/3/mdv094.1.pdf?Expires=1485612028&Signature=JoQKC8sVU14rOLnGDs5B85m-vEzduY5hMhBWvxZjYnC8qeS
7646,,"Phase I study of regorafenib (BAY 73-4506), an inhibitor of oncogenic and angiogenic kinases, administered continuously in patients (pts) with advanced refractory non-small cell lung cancer (NSCLC).",http://meetinglibrary.asco.org/content/53410-74
7647,26474387,TIC10/ONC201 synergizes with Bcl-2/Bcl-xL inhibition in glioblastoma by suppression of Mcl-1 and its binding partners in vitro and in vivo.,http://www.ncbi.nlm.nih.gov/pubmed/26474387
7648,,A first-in-man phase 1a study of the bispecific anti-DLL4/anti-VEGF antibody OMP-305B83 in patients with previously treated solid tumors,http://www.ejcancer.com/article/S0959-8049(16)32686-7/abstract
7649,22965962,"Aflibercept and Docetaxel versus Docetaxel alone after platinum failure in patients with advanced or metastatic non-small-cell lung cancer: a randomized, controlled phase III trial.",http://www.ncbi.nlm.nih.gov/pubmed/22965962
7650,20516450,Phase II proof-of-concept study of pazopanib monotherapy in treatment-naive patients with stage I/II resectable non-small-cell lung cancer.,http://www.ncbi.nlm.nih.gov/pubmed/20516450
7651,22576795,Antiproliferative action of metformin in human lung cancer cell lines.,http://www.ncbi.nlm.nih.gov/pubmed/22576795
7652,26847819,Metformin inhibits growth of human non-small cell lung cancer cells via liver kinase B-1-independent activation of adenosine monophosphate-activated protein kinase.,http://www.ncbi.nlm.nih.gov/pubmed/26847819
7653,26530254,A novel aspirin prodrug inhibits NFκB activity and breast cancer stem cell properties.,http://www.ncbi.nlm.nih.gov/pubmed/26530254
7654,28017406,"Bortezomib with lenalidomide and dexamethasone versus lenalidomide and dexamethasone alone in patients with newly diagnosed myeloma without intent for immediate autologous stem-cell transplant (SWOG S0777): a randomised, open-label, phase 3 trial.",http://www.ncbi.nlm.nih.gov/pubmed/28017406
7655,12754375,Gastrointestinal stromal tumors in a mouse model by targeted mutation of the Kit receptor tyrosine kinase.,http://www.ncbi.nlm.nih.gov/pubmed/12754375
7656,27470968,PD-1/PD-L1 Blockade Enhances T-cell Activity and Antitumor Efficacy of Imatinib in Gastrointestinal Stromal Tumors.,http://www.ncbi.nlm.nih.gov/pubmed/27470968
7657,11069286,Mice with a targeted mutation in the thyroid hormone beta receptor gene exhibit impaired growth and resistance to thyroid hormone.,http://www.ncbi.nlm.nih.gov/pubmed/11069286
7658,1661299,"Characterization of seven novel mutations of the c-erbA beta gene in unrelated kindreds with generalized thyroid hormone resistance. Evidence for two ""hot spot"" regions of the ligand binding domain.",http://www.ncbi.nlm.nih.gov/pubmed/1661299
7659,27440272,Bromodomain and Extraterminal Protein Inhibitor JQ1 Suppresses Thyroid Tumor Growth in a Mouse Model.,http://www.ncbi.nlm.nih.gov/pubmed/27440272
7660,28053023,"Ricolinostat, the First Selective Histone Deacetylase 6 Inhibitor, in Combination with Bortezomib and Dexamethasone for Relapsed or Refractory Multiple Myeloma.",http://www.ncbi.nlm.nih.gov/pubmed/28053023
7661,27307592,Sorafenib and Quinacrine Target Anti-Apoptotic Protein MCL1: A Poor Prognostic Marker in Anaplastic Thyroid Cancer (ATC).,http://www.ncbi.nlm.nih.gov/pubmed/27307592
7662,20838624,Mutational profiling of kinases in human tumours of pancreatic origin identifies candidate cancer genes in ductal and ampulla of vater carcinomas.,http://www.ncbi.nlm.nih.gov/pubmed/20838624
7663,22960745,Comprehensive genomic characterization of squamous cell lung cancers.,http://www.ncbi.nlm.nih.gov/pubmed/22960745
7664,23000897,Comprehensive molecular portraits of human breast tumours.,http://www.ncbi.nlm.nih.gov/pubmed/23000897
7665,27939638,"Proteome-Scale Investigation of Protein Allosteric Regulation Perturbed by Somatic Mutations in 7,000 Cancer Genomes.",http://www.ncbi.nlm.nih.gov/pubmed/27939638
7666,14684699,Mutation screening of Mre11 complex genes: indication of RAD50 involvement in breast and ovarian cancer susceptibility.,http://www.ncbi.nlm.nih.gov/pubmed/14684699
7667,1638557,A phase I study of neuroblastoma with the anti-ganglioside GD2 antibody 14.G2a.,http://www.ncbi.nlm.nih.gov/pubmed/1638557
7668,16385572,Evaluation of RAD50 in familial breast cancer predisposition.,http://www.ncbi.nlm.nih.gov/pubmed/16385572
7669,20122277,A novel germline PALB2 deletion in Polish breast and ovarian cancer patients.,http://www.ncbi.nlm.nih.gov/pubmed/20122277
7670,21618343,Germline mutations in the PALB2 gene are population specific and occur with low frequencies in familial breast cancer.,http://www.ncbi.nlm.nih.gov/pubmed/21618343
7671,17200668,"PALB2, which encodes a BRCA2-interacting protein, is a breast cancer susceptibility gene.",http://www.ncbi.nlm.nih.gov/pubmed/17200668
7672,26283626,Prevalence of PALB2 mutations in Australian familial breast cancer cases and controls.,http://www.ncbi.nlm.nih.gov/pubmed/26283626
7673,25356972,"BRCA1, BRCA2, PALB2, and CDKN2A mutations in familial pancreatic cancer: a PACGENE study.",http://www.ncbi.nlm.nih.gov/pubmed/25356972
7674,27584578,Arginine Deprivation With Pegylated Arginine Deiminase in Patients With Argininosuccinate Synthetase 1-Deficient Malignant Pleural Mesothelioma: A Randomized Clinical Trial.,http://www.ncbi.nlm.nih.gov/pubmed/27584578
7675,27250763,Evaluation of the Therapeutic Potential of the Novel Isotype Specific HDAC Inhibitor 4SC-202 in Urothelial Carcinoma Cell Lines.,http://www.ncbi.nlm.nih.gov/pubmed/27250763
7676,28089889,MYC Drives Progression of Small Cell Lung Cancer to a Variant Neuroendocrine Subtype with Vulnerability to Aurora Kinase Inhibition.,http://www.ncbi.nlm.nih.gov/pubmed/28089889
7677,27626698,Identification of a structurally novel BTK mutation that drives ibrutinib resistance in CLL.,http://www.ncbi.nlm.nih.gov/pubmed/27626698
7678,27282255,"Substitution scanning identifies a novel, catalytically active ibrutinib-resistant BTK cysteine 481 to threonine (C481T) variant.",http://www.ncbi.nlm.nih.gov/pubmed/27282255
7679,27225693,Therapeutic Benefit of Selective Inhibition of p110α PI3-Kinase in Pancreatic Neuroendocrine Tumors.,http://www.ncbi.nlm.nih.gov/pubmed/27225693
7680,26081429,Targeting PBK/TOPK decreases growth and survival of glioma initiating cells in vitro and attenuates tumor growth in vivo.,http://www.ncbi.nlm.nih.gov/pubmed/26081429
7681,25881543,"TOPK is highly expressed in circulating tumor cells, enabling metastasis of prostate cancer.",http://www.ncbi.nlm.nih.gov/pubmed/25881543
7682,25575812,Identification of the oncogenic kinase TOPK/PBK as a master mitotic regulator of C2H2 zinc finger proteins.,http://www.ncbi.nlm.nih.gov/pubmed/25575812
7683,27334838,T-LAK Cell-Originated Protein Kinase (TOPK) as a Prognostic Factor and a Potential Therapeutic Target in Ovarian Cancer.,http://www.ncbi.nlm.nih.gov/pubmed/27334838
7684,23935836,Analysis of PALB2 gene in BRCA1/BRCA2 negative Spanish hereditary breast/ovarian cancer families with pancreatic cancer cases.,http://www.ncbi.nlm.nih.gov/pubmed/23935836
7685,24891362,VEGFA genomic amplification tailors treatment of HCCs with sorafenib.,http://www.ncbi.nlm.nih.gov/pubmed/24891362
7686,24687604,Human and mouse VEGFA-amplified hepatocellular carcinomas are highly sensitive to sorafenib treatment.,http://www.ncbi.nlm.nih.gov/pubmed/24687604
7687,,"Preliminary Results of a Phase II Study about the Efficacy and Safety
of Pyrotinib in Patients with HER2 Mutant Advanced NSCLC",http://www.jto.org/article/S1556-0864(16)31640-9/pdf
7688,,Preliminary Results of a Phase II Study about the Efficacy and Safety of Pyrotinib in Patients with HER2 Mutant Advanced NSCLC,http://www.jto.org/action/doSearch?seriesISSNFltraddfilter=1556-0864&issueType=normal&issue=1&volume=12&searchType=singleIssue&journalCode=jtho&searchText=Pyrotinib&occurrences=all
7689,,"Abstract P4-14-18: Phase I study of single-agent pyrotinib, a novel irreversible pan-ErbB receptor tyrosine kinase inhibitor, in patients with ErbB2+ metastatic breast cancer",http://cancerres.aacrjournals.org/content/76/4_Supplement/P4-14-18
7690,26254023,"Phase I trial of afatinib plus vinorelbine in Japanese patients with advanced solid tumors, including breast cancer.",http://www.ncbi.nlm.nih.gov/pubmed/26254023
7691,20592359,Multiplicity of EGFR and KRAS mutations in non-small cell lung cancer (NSCLC) patients treated with tyrosine kinase inhibitors.,http://www.ncbi.nlm.nih.gov/pubmed/20592359
7692,28031051,The status of Her2 amplification and Kras mutations in mucinous ovarian carcinoma.,http://www.ncbi.nlm.nih.gov/pubmed/28031051
7693,25886136,"A retrospective observational study of clinicopathological features of KRAS, NRAS, BRAF and PIK3CA mutations in Japanese patients with metastatic colorectal cancer.",http://www.ncbi.nlm.nih.gov/pubmed/25886136
7694,24811063,"Evidence for different expression profiles for c-Met, EGFR, PTEN and the mTOR pathway in low and high grade endometrial carcinomas in a cohort of consecutive women. Occurrence of PIK3CA and K-Ras mutations and microsatellite instability.",http://www.ncbi.nlm.nih.gov/pubmed/24811063
7695,22931052,"Prevalence of KRAS, BRAF, and PIK3CA somatic mutations in patients with colorectal carcinoma may vary in the same population: clues from Sardinia.",http://www.ncbi.nlm.nih.gov/pubmed/22931052
7696,23125007,"Survey of KRAS, BRAF and PIK3CA mutational status in 209 consecutive Italian colorectal cancer patients.",http://www.ncbi.nlm.nih.gov/pubmed/23125007
7697,23468066,Increased detection rates of EGFR and KRAS mutations in NSCLC specimens with low tumour cell content by 454 deep sequencing.,http://www.ncbi.nlm.nih.gov/pubmed/23468066
7698,21680795,Key pathways are frequently mutated in high-risk childhood acute lymphoblastic leukemia: a report from the Children's Oncology Group.,http://www.ncbi.nlm.nih.gov/pubmed/21680795
7699,24594115,KRAS insertions in colorectal cancer: what do we know about unusual KRAS mutations?,http://www.ncbi.nlm.nih.gov/pubmed/24594115
7700,21704278,"KRAS, NRAS, PIK3CA exon 20, and BRAF genotypes in synchronous and metachronous primary colorectal cancers diagnostic and therapeutic implications.",http://www.ncbi.nlm.nih.gov/pubmed/21704278
7701,24030381,Clinical and biological implications of driver mutations in myelodysplastic syndromes.,http://www.ncbi.nlm.nih.gov/pubmed/24030381
7702,24200637,Low frequency KRAS mutations in colorectal cancer patients and the presence of multiple mutations in oncogenic drivers in non-small cell lung cancer patients.,http://www.ncbi.nlm.nih.gov/pubmed/24200637
7703,23765226,Novel recurrent mutations in the RAS-like GTP-binding gene RIT1 in myeloid malignancies.,http://www.ncbi.nlm.nih.gov/pubmed/23765226
7704,23685749,The mutational landscape of adenoid cystic carcinoma.,http://www.ncbi.nlm.nih.gov/pubmed/23685749
7705,9150739,Characterization and significance of nine novel mutations in exon 16 of the neurofibromatosis type 1 (NF1) gene.,http://www.ncbi.nlm.nih.gov/pubmed/9150739
7706,24789688,Fifty-four novel mutations in the NF1 gene and integrated analyses of the mutations that modulate splicing.,http://www.ncbi.nlm.nih.gov/pubmed/24789688
7707,18757431,CREB3L2-PPARgamma fusion mutation identifies a thyroid signaling pathway regulated by intramembrane proteolysis.,http://www.ncbi.nlm.nih.gov/pubmed/18757431
7708,27835869,"OTX015 (MK-8628), a novel BET inhibitor, exhibits antitumor activity in non-small cell and small cell lung cancer models harboring different oncogenic mutations.",http://www.ncbi.nlm.nih.gov/pubmed/27835869
7709,26130666,Efficacy of Imatinib in Patients with Platelet-Derived Growth Factor Receptor Alpha-Mutated Gastrointestinal Stromal Tumors.,http://www.ncbi.nlm.nih.gov/pubmed/26130666
7710,25239601,Integrated genomic study of quadruple-WT GIST (KIT/PDGFRA/SDH/RAS pathway wild-type GIST).,http://www.ncbi.nlm.nih.gov/pubmed/25239601
7711,24638008,In vivo imatinib sensitivity in a patient with GI stromal tumor bearing a PDGFRA deletion DIM842-844.,http://www.ncbi.nlm.nih.gov/pubmed/24638008
7712,18657298,A gastrointestinal stromal tumor of the stomach morphologically resembling a neurofibroma: demonstration of a novel platelet-derived growth factor receptor alpha exon 18 mutation.,http://www.ncbi.nlm.nih.gov/pubmed/18657298
7713,15644419,A functional single-nucleotide polymorphism of the G-CSF receptor gene predisposes individuals to high-risk myelodysplastic syndrome.,http://www.ncbi.nlm.nih.gov/pubmed/15644419
7714,20071345,Dysregulation of the PDGFRA gene causes inflow tract anomalies including TAPVR: integrating evidence from human genetics and model organisms.,http://www.ncbi.nlm.nih.gov/pubmed/20071345
7715,19755855,Amplification of chromosomal segment 4q12 in non-small cell lung cancer.,http://www.ncbi.nlm.nih.gov/pubmed/19755855
7716,26396737,Response to sunitinib of a gastrointestinal stromal tumor with a rare exon 12 PDGFRA mutation.,http://www.ncbi.nlm.nih.gov/pubmed/26396737
7717,24171924,Characterization of WZ4003 and HTH-01-015 as selective inhibitors of the LKB1-tumour-suppressor-activated NUAK kinases.,http://www.ncbi.nlm.nih.gov/pubmed/24171924
7718,28126333,"First-line ceritinib versus platinum-based chemotherapy in advanced ALK-rearranged non-small-cell lung cancer (ASCEND-4): a randomised, open-label, phase 3 study.",http://www.ncbi.nlm.nih.gov/pubmed/28126333
7719,28135143,"Italian, Multicenter, Phase III, Randomized Study of Cisplatin Plus Etoposide With or Without Bevacizumab as First-Line Treatment in Extensive-Disease Small-Cell Lung Cancer: The GOIRC-AIFA FARM6PMFJM Trial.",http://www.ncbi.nlm.nih.gov/pubmed/28135143
7720,28115009,3D clusters of somatic mutations in cancer reveal numerous rare mutations as functional targets.,http://www.ncbi.nlm.nih.gov/pubmed/28115009
7721,,"Expression of COX-2 and 15-PGDH in adenomas removed during pretreatment colonoscopy to predict chemopreventive efficacy of the selective COX-2 inhibitor, celecoxib.",http://meetinglibrary.asco.org/content/175867-195
7723,,"Efficacy and tolerability of veliparib (V, ABT-888) in combination with carboplatin (C) and paclitaxel (P) vs placebo (Plc)+C/P in patients (pts) with BRCA1 or BRCA2 mutations and metastatic breast cancer- A randomized, phase 2 study",https://www.sabcs.org/Past-Meetings
7724,,Randomized trial of irinotecan and cetuximab with or without vemurafenib in BRAF-mutant metastatic colorectal cancer (SWOG 1406).,http://abstracts.asco.org/195/AbstView_195_176737.html
7725,,"Outcomes with sorafenib (SOR) followed by regorafenib (REG) or placebo (PBO) for hepatocellular carcinoma (HCC): Results of the international, randomized phase 3 RESORCE trial.",http://meetinglibrary.asco.org/content/176536-195
7726,,"BELLE-3: A phase III study of buparlisib + fulvestrant in postmenopausal women with HR+, HER2–, aromatase inhibitor-treated, locally advanced or metastatic breast cancer, who progressed on or after mTOR inhibitor-based treatment",https://www.sabcs.org/Past-Meetings
7727,,Combination of the BET Inhibitor GS-5829 and a BCL2 Inhibitor Resulted in Broader Activity in DLBCL and MCL Cell Lines,http://www.bloodjournal.org/content/128/22/5104?sso-checked=true
7728,,CHARTA: FOLFOX+bevacizumab +/- irinotecan in advanced colorectal cancer (CRC)—Final results of the randomized phase II trial of the AIO (KRK 0209).,http://meetinglibrary.asco.org/content/176957-195
7729,,"Abstract CT024: First-in-human phase 1 dose-escalation study of DS-6051b, an oral ROS1 and NTRK inhibitor, in subjects with advanced solid tumors",http://cancerres.aacrjournals.org/content/76/14_Supplement/CT024.short
7730,,A BCMA-specific CAR T cell produced with clinically scalable lentiviral and T cell manufacturing processes has potent anti-multiple myeloma activity,https://jitc.biomedcentral.com/articles/10.1186/2051-1426-3-S2-P124
7731,,"Clinical remissions and limited toxicity in a first-in-human multicenter study of bb2121, a novel anti-BCMA CAR T cell therapy for relapsed/refractory multiple myeloma",http://www.ecco-org.eu/Events/ENA2016/Searchable-Programme#anchorScpr
7732,11159536,Constitutive kinase activation of the TEL-Syk fusion gene in myelodysplastic syndrome with t(9;12)(q22;p12).,http://www.ncbi.nlm.nih.gov/pubmed/11159536
7733,,"HMPL-523, a Novel SYK Inhibitor Showed Anti-Tumor Activities In Vitro and In Vivo",http://www.bloodjournal.org/content/128/22/3970?sso-checked=true
7734,,"Phase 1 study of CB-839, a small molecule inhibitor of glutaminase, in combination with everolimus in patients (pts) with clear cell and papillary renal cell cancer (RCC)",http://www.ecco-org.eu/Events/ENA2016/Searchable-Programme#anchorScpr
7735,,Abstract LB-318: SMARCA4-inactivating mutations increase sensitivity to Aurora kinase A-targeted therapies in non-small cell lung cancers (NSCLCs),http://cancerres.aacrjournals.org/content/76/14_Supplement/LB-318.short
7736,27493709,Elotuzumab: the first approved monoclonal antibody for multiple myeloma treatment.,http://www.ncbi.nlm.nih.gov/pubmed/27493709
7737,,Abstract C186: SNS-062 is a potent noncovalent BTK inhibitor with comparable activity against wild type BTK and BTK with an acquired resistance mutation,http://mct.aacrjournals.org/content/14/12_Supplement_2/C186
7738,24027009,Inactivation of DNA mismatch repair by variants of uncertain significance in the PMS2 gene.,http://www.ncbi.nlm.nih.gov/pubmed/24027009
7739,25338684,Feasibility of low-throughput next generation sequencing for germline DNA screening.,http://www.ncbi.nlm.nih.gov/pubmed/25338684
7740,10480359,"Prevalence of germline mutations of hMLH1, hMSH2, hPMS1, hPMS2, and hMSH6 genes in 75 French kindreds with nonpolyposis colorectal cancer.",http://www.ncbi.nlm.nih.gov/pubmed/10480359
7741,16619239,Long-range PCR facilitates the identification of PMS2-specific mutations.,http://www.ncbi.nlm.nih.gov/pubmed/16619239
7742,21239990,Integrated analysis of unclassified variants in mismatch repair genes.,http://www.ncbi.nlm.nih.gov/pubmed/21239990
7743,11707818,DAB(389)IL-2 (ONTAK): a novel fusion toxin therapy for lymphoma.,http://www.ncbi.nlm.nih.gov/pubmed/11707818
7744,27737881,Biphasic Rapamycin Effects in Lymphoma and Carcinoma Treatment.,http://www.ncbi.nlm.nih.gov/pubmed/27737881
7745,26437033,Genomic landscapes of breast fibroepithelial tumors.,http://www.ncbi.nlm.nih.gov/pubmed/26437033
7746,11244497,Disruption of protein phosphatase 2A subunit interaction in human cancers with mutations in the A alpha subunit gene.,http://www.ncbi.nlm.nih.gov/pubmed/11244497
7747,21791616,Human cancer-associated mutations in the Aα subunit of protein phosphatase 2A increase lung cancer incidence in Aα knock-in and knockout mice.,http://www.ncbi.nlm.nih.gov/pubmed/21791616
7748,22653804,Use of mutation profiles to refine the classification of endometrial carcinomas.,http://www.ncbi.nlm.nih.gov/pubmed/22653804
7749,22495314,The clonal and mutational evolution spectrum of primary triple-negative breast cancers.,http://www.ncbi.nlm.nih.gov/pubmed/22495314
7750,26977882,HDAC and PI3K Antagonists Cooperate to Inhibit Growth of MYC-Driven Medulloblastoma.,http://www.ncbi.nlm.nih.gov/pubmed/26977882
7752,,"Biological effects of abemaciclib in a phase 2 neoadjuvantstudy for postmenopausal patients with HR+, HER2- breast cancer",https://www.sabcs.org/Past-Meetings
7753,27630125,Epigenetic Reprogramming Sensitizes CML Stem Cells to Combined EZH2 and Tyrosine Kinase Inhibition.,http://www.ncbi.nlm.nih.gov/pubmed/27630125
7754,27903753,A Novel LSD1 Inhibitor T-3775440 Disrupts GFI1B-Containing Complex Leading to Transdifferentiation and Impaired Growth of AML Cells.,http://www.ncbi.nlm.nih.gov/pubmed/27903753
7755,21381030,Subtype-specific mutation of PPP2R1A in endometrial and ovarian carcinomas.,http://www.ncbi.nlm.nih.gov/pubmed/21381030
7756,27903500,Primary Resistance to PD-1 Blockade Mediated by JAK1/2 Mutations.,http://www.ncbi.nlm.nih.gov/pubmed/27903500
7757,27980106,"Imatinib Spares cKit-Expressing Prostate Neuroendocrine Tumors, whereas Kills Seminal Vesicle Epithelial-Stromal Tumors by Targeting PDGFR-β.",http://www.ncbi.nlm.nih.gov/pubmed/27980106
7758,27980108,Dual HDAC and PI3K Inhibitor CUDC-907 Downregulates MYC and Suppresses Growth of MYC-dependent Cancers.,http://www.ncbi.nlm.nih.gov/pubmed/27980108
7759,,"REDX08608, a Novel, Potent and Selective, Reversible BTK Inhibitor with Efficacy and Equivalent Potency Against Wild-Type and Mutant C481S BTK",http://www.bloodjournal.org/content/128/22/4399?sso-checked=true
7760,27913578,"Characterization of EGFR T790M, L792F, and C797S Mutations as Mechanisms of Acquired Resistance to Afatinib in Lung Cancer.",http://www.ncbi.nlm.nih.gov/pubmed/27913578
7761,27667683,Loss of IFN-γ Pathway Genes in Tumor Cells as a Mechanism of Resistance to Anti-CTLA-4 Therapy.,http://www.ncbi.nlm.nih.gov/pubmed/27667683
7762,16905680,"Evaluation of BRCA1 and BRCA2 mutation prevalence, risk prediction models and a multistep testing approach in French-Canadian families with high risk of breast and ovarian cancer.",http://www.ncbi.nlm.nih.gov/pubmed/16905680
7763,11438209,Novel mutation in the PML/RARalpha chimeric gene exhibits dramatically decreased ligand-binding activity and confers acquired resistance to retinoic acid in acute promyelocytic leukemia.,http://www.ncbi.nlm.nih.gov/pubmed/11438209
7764,26294332,Evaluating frequency of PML-RARA mutations and conferring resistance to arsenic trioxide-based therapy in relapsed acute promyelocytic leukemia patients.,http://www.ncbi.nlm.nih.gov/pubmed/26294332
7765,25038752,Exome sequencing identifies highly recurrent MED12 somatic mutations in breast fibroadenoma.,http://www.ncbi.nlm.nih.gov/pubmed/25038752
7766,26537301,Varying responses of PML-RARA with different genetic mutations to arsenic trioxide.,http://www.ncbi.nlm.nih.gov/pubmed/26537301
7767,19336415,"Human DNA polymerase beta polymorphism, Arg137Gln, impairs its polymerase activity and interaction with PCNA and the cellular base excision repair capacity.",http://www.ncbi.nlm.nih.gov/pubmed/19336415
7768,20684013,Inheritance and variable expression in Rubinstein-Taybi syndrome.,http://www.ncbi.nlm.nih.gov/pubmed/20684013
7769,18302728,Functional characterisation of the TSC1-TSC2 complex to assess multiple TSC2 variants identified in single families affected by tuberous sclerosis complex.,http://www.ncbi.nlm.nih.gov/pubmed/18302728
7770,25422467,Mitochondrial serine protease HTRA2 p.G399S in a kindred with essential tremor and Parkinson disease.,http://www.ncbi.nlm.nih.gov/pubmed/25422467
7771,19127258,A recurrent truncating germline mutation in the BRIP1/FANCJ gene and susceptibility to prostate cancer.,http://www.ncbi.nlm.nih.gov/pubmed/19127258
7772,9808520,p53 and p16/CDKN2 gene mutations in esophageal tumors from a high-incidence area in South Africa.,http://www.ncbi.nlm.nih.gov/pubmed/9808520
7773,8589032,Alterations of CDKN2 (p16) in non-small cell lung cancer.,http://www.ncbi.nlm.nih.gov/pubmed/8589032
7774,25530832,Kinome sequencing reveals RET G691S polymorphism in human neuroendocrine lung cancer cell lines.,http://www.ncbi.nlm.nih.gov/pubmed/25530832
7775,16354195,Recurrent patterns of dual RB and p53 pathway inactivation in melanoma.,http://www.ncbi.nlm.nih.gov/pubmed/16354195
7776,26164066,Spectrum of gene mutations detected by next generation exome sequencing in brain metastases of lung adenocarcinoma.,http://www.ncbi.nlm.nih.gov/pubmed/26164066
7777,8747595,Infrequent somatic mutations of the p16 and p15 genes in human bladder cancer: p16 mutations occur only in low-grade and superficial bladder cancers.,http://www.ncbi.nlm.nih.gov/pubmed/8747595
7778,9495360,p16/MTS1 inactivation in ovarian carcinomas: high frequency of reduced protein expression associated with hyper-methylation or mutation in endometrioid and mucinous tumors.,http://www.ncbi.nlm.nih.gov/pubmed/9495360
7779,10369293,Establishment and characterization of human laryngeal squamous cell carcinoma cell lines.,http://www.ncbi.nlm.nih.gov/pubmed/10369293
7780,27657674,Ramucirumab as Second-Line Treatment in Patients With Advanced Hepatocellular Carcinoma: Analysis of REACH Trial Results by Child-Pugh Score.,http://www.ncbi.nlm.nih.gov/pubmed/27657674
7781,28053022,"Phase I Study of ONT-380, a HER2 Inhibitor, in Patients with HER2(+)-Advanced Solid Tumors, with an Expansion Cohort in HER2(+) Metastatic Breast Cancer (MBC).",http://www.ncbi.nlm.nih.gov/pubmed/28053022
7782,27659046,High-Order Drug Combinations Are Required to Effectively Kill Colorectal Cancer Cells.,http://www.ncbi.nlm.nih.gov/pubmed/27659046
7783,28108625,Combined Parthenolide and Balsalazide Have Enhanced Antitumor Efficacy Through Blockade of NF-κB Activation.,http://www.ncbi.nlm.nih.gov/pubmed/28108625
7784,8637233,Alterations of CDKN2 gene structure in childhood acute lymphoblastic leukemia: mutations of CDKN2 are observed preferentially in T lineage.,http://www.ncbi.nlm.nih.gov/pubmed/8637233
7785,11255261,Somatic INK4a-ARF locus mutations: a significant mechanism of gene inactivation in squamous cell carcinomas of the head and neck.,http://www.ncbi.nlm.nih.gov/pubmed/11255261
7786,27415609,Overview of major molecular alterations during progression from Barrett's esophagus to esophageal adenocarcinoma.,http://www.ncbi.nlm.nih.gov/pubmed/27415609
7787,9462707,Mutations in the CDKN2A (p16INK4a) gene in microdissected sporadic primary melanomas.,http://www.ncbi.nlm.nih.gov/pubmed/9462707
7788,12117769,Alterations of the p16(INK4) locus in human malignant mesothelial tumors.,http://www.ncbi.nlm.nih.gov/pubmed/12117769
7789,22817889,A landscape of driver mutations in melanoma.,http://www.ncbi.nlm.nih.gov/pubmed/22817889
7790,12870051,Analysis of p16 gene mutations and deletions in childhood acute lymphoblastic leukemias.,http://www.ncbi.nlm.nih.gov/pubmed/12870051
7791,27311873,"Circumscribed sebaceous neoplasms: a morphological, immunohistochemical and molecular analysis.",http://www.ncbi.nlm.nih.gov/pubmed/27311873
7792,14556920,Frequent methylation of p16INK4A and p14ARF genes implicated in the evolution of chronic myeloid leukaemia from its chronic to accelerated phase.,http://www.ncbi.nlm.nih.gov/pubmed/14556920
7793,9414654,p16INK4 gene mutations are relatively frequent in ampullary carcinomas.,http://www.ncbi.nlm.nih.gov/pubmed/9414654
7794,8640773,Deletion and mutation analyses of the P16/MTS-1 tumor suppressor gene in human ductal pancreatic cancer reveals a higher frequency of abnormalities in tumor-derived cell lines than in primary ductal adenocarcinomas.,http://www.ncbi.nlm.nih.gov/pubmed/8640773
7795,21603970,"Parthenolide, a sesquiterpene lactone, expresses multiple anti-cancer and anti-inflammatory activities.",http://www.ncbi.nlm.nih.gov/pubmed/21603970
7796,12614625,Design and characterization of a hyperstable p16INK4a that restores Cdk4 binding activity when combined with oncogenic mutations.,http://www.ncbi.nlm.nih.gov/pubmed/12614625
7797,28148839,2-Hydroxyglutarate produced by neomorphic IDH mutations suppresses homologous recombination and induces PARP inhibitor sensitivity.,http://www.ncbi.nlm.nih.gov/pubmed/28148839
7798,10666372,APC mutations in sporadic medulloblastomas.,http://www.ncbi.nlm.nih.gov/pubmed/10666372
7799,18369740,Somatic APC inactivation mechanisms in sporadic colorectal cancer cases in Hungary.,http://www.ncbi.nlm.nih.gov/pubmed/18369740
7800,10440612,Germline and somatic mutations in exon 15 of the APC gene and K-ras mutations in duodenal adenomas in patients with familial adenomatous polyposis.,http://www.ncbi.nlm.nih.gov/pubmed/10440612
7801,8242071,Somatic mutations of the APC gene in precancerous lesion of the stomach.,http://www.ncbi.nlm.nih.gov/pubmed/8242071
7802,18844223,Somatic mutations of adenomatous polyposis coli gene and nuclear b-catenin accumulation have prognostic significance in invasive urothelial carcinomas: evidence for Wnt pathway implication.,http://www.ncbi.nlm.nih.gov/pubmed/18844223
7803,20569184,Identification of novel SNPs by next-generation sequencing of the genomic region containing the APC gene in colorectal cancer patients in China.,http://www.ncbi.nlm.nih.gov/pubmed/20569184
7804,25545608,"Target-enriched next-generation sequencing reveals differences between primary and secondary ovarian tumors in formalin-fixed, paraffin-embedded tissue.",http://www.ncbi.nlm.nih.gov/pubmed/25545608
7805,17257127,Phenotypes of invasion in sporadic colorectal carcinomas related to aberrations of the adenomatous polyposis coli (APC ) gene.,http://www.ncbi.nlm.nih.gov/pubmed/17257127
7806,8221638,Coexistence of somatic and germ-line mutations of APC gene in desmoid tumors from patients with familial adenomatous polyposis.,http://www.ncbi.nlm.nih.gov/pubmed/8221638
7807,18632876,Adenomatous polyposis coli alteration in digestive endocrine tumours: correlation with nuclear translocation of beta-catenin and chromosomal instability.,http://www.ncbi.nlm.nih.gov/pubmed/18632876
7808,8055154,Lack of mutations of the adenomatous polyposis coli gene in oesophageal and gastric carcinomas.,http://www.ncbi.nlm.nih.gov/pubmed/8055154
7809,22864938,"Dietary, lifestyle and clinicopathological factors associated with APC mutations and promoter methylation in colorectal cancers from the EPIC-Norfolk study.",http://www.ncbi.nlm.nih.gov/pubmed/22864938
7810,14578138,The APC E1317Q variant in adenomatous polyps and colorectal cancers.,http://www.ncbi.nlm.nih.gov/pubmed/14578138
7811,22848674,Comprehensive mutation analysis in colorectal flat adenomas.,http://www.ncbi.nlm.nih.gov/pubmed/22848674
7812,9419979,Drastic genetic instability of tumors and normal tissues in Turcot syndrome.,http://www.ncbi.nlm.nih.gov/pubmed/9419979
7813,15122587,Definition of candidate low risk APC alleles in a Swedish population.,http://www.ncbi.nlm.nih.gov/pubmed/15122587
7814,16906516,Phenotype-genotype correlation: challenge of intestinal-type adenocarcinoma of the nasal cavity and paranasal sinuses.,http://www.ncbi.nlm.nih.gov/pubmed/16906516
7815,17558858,Analysis of APC/beta-catenin genes mutations and Wnt signalling pathway in desmoid-type fibromatosis.,http://www.ncbi.nlm.nih.gov/pubmed/17558858
7816,1338691,Somatic mutation of the APC gene in gastric cancer: frequent mutations in very well differentiated adenocarcinoma and signet-ring cell carcinoma.,http://www.ncbi.nlm.nih.gov/pubmed/1338691
7817,8118796,Mutations of the APC gene occur during early stages of gastric adenoma development.,http://www.ncbi.nlm.nih.gov/pubmed/8118796
7818,22377896,Sequencing histone-modifying enzymes identifies UTX mutations in acute lymphoblastic leukemia.,http://www.ncbi.nlm.nih.gov/pubmed/22377896
7819,24347639,Tumor suppressor and deubiquitinase BAP1 promotes DNA double-strand break repair.,http://www.ncbi.nlm.nih.gov/pubmed/24347639
7820,26324075,Trametinib with and without pazopanib has potent preclinical activity in thyroid cancer.,http://www.ncbi.nlm.nih.gov/pubmed/26324075
7821,,Abstract 4822: Combination efficacy of the selective HDAC inhibitor ACY-241 and paclitaxel in solid tumor models,http://cancerres.aacrjournals.org/content/76/14_Supplement/4822.short
7822,,Safety and efficacy results from a phase 1 dose-escalation trial of the parp inhibitor talazoparib (bmn-673) in combination with either temozolomide or irinotecan in patients with advanced malignancies,http://www.ejcancer.com/article/S0959-8049(16)30182-4/abstract
7823,26249178,A Molecular Portrait of High-Grade Ductal Carcinoma In Situ.,http://www.ncbi.nlm.nih.gov/pubmed/26249178
7824,25148578,Beyond BRAF(V600): clinical mutation panel testing by next-generation sequencing in advanced melanoma.,http://www.ncbi.nlm.nih.gov/pubmed/25148578
7825,19276253,CBL exon 8/9 mutants activate the FLT3 pathway and cluster in core binding factor/11q deletion acute myeloid leukemia/myelodysplastic syndrome subtypes.,http://www.ncbi.nlm.nih.gov/pubmed/19276253
7826,25970771,Loss of the deubiquitylase BAP1 alters class I histone deacetylase expression and sensitivity of mesothelioma cells to HDAC inhibitors.,http://www.ncbi.nlm.nih.gov/pubmed/25970771
7827,18579665,"A phase I and pharmacokinetic study of the oral histone deacetylase inhibitor, MS-275, in patients with refractory solid tumors and lymphomas.",http://www.ncbi.nlm.nih.gov/pubmed/18579665
7828,,"Abstract 1219: Sym015, a novel antibody mixture targeting non-overlapping epitopes of MET, effectively inhibits growth of MET dependent tumors and overcomes resistance to a single monoclonal antibody",http://cancerres.aacrjournals.org/content/76/14_Supplement/1219
7829,25256830,The c-Met Inhibitor MSC2156119J Effectively Inhibits Tumor Growth in Liver Cancer Models.,http://www.ncbi.nlm.nih.gov/pubmed/25256830
7830,,"A phase I, first-in-human study of argx-111, a monoclonal antibody targeting c-met in patients with solid tumors",http://ascopubs.org/doi/abs/10.1200/jco.2015.33.15_suppl.2580
7831,,"First-in-human dose escalation study of LY2875358 (LY), a bivalent MET antibody, as monotherapy and in combination with erlotinib (E) in patients with advanced cancer.",http://meetinglibrary.asco.org/content/115545-132
7832,24901237,Phase I ficlatuzumab monotherapy or with erlotinib for refractory advanced solid tumours and multiple myeloma.,http://www.ncbi.nlm.nih.gov/pubmed/24901237
7833,27573171,"ABBV-399, a c-Met Antibody-Drug Conjugate that Targets Both MET-Amplified and c-Met-Overexpressing Tumors, Irrespective of MET Pathway Dependence.",http://www.ncbi.nlm.nih.gov/pubmed/27573171
7834,,"Phase 1, open-label, dose-escalation and expansion study of ABBV-399, an antibody drug conjugate (ADC) targeting c-Met, in patients (pts) with advanced solid tumors.",http://meetinglibrary.asco.org/content/164513-176
7835,,"A phase I dose-escalation study of INCB028060, an inhibitor of c-MET receptor tyrosine kinase, in patients with advanced solid tumors.",http://meetinglibrary.asco.org/content/82236-102
7836,,Discovery of NVP-HDM201 - First disclosure of a Next-Generation Mdm2 inhibitor with superior characteristics,http://cancerres.aacrjournals.org/content/76/14_Supplement/4855
7837,,A phase 1 study of the MDM2 inhibitor DS-3032b in patients (pts) with advanced solid tumors and lymphomas.,http://meetinglibrary.asco.org/content/166204-176
7838,27359055,Mutation profiling of 19 candidate genes in acute myeloid leukemia suggests significance of DNMT3A mutations.,http://www.ncbi.nlm.nih.gov/pubmed/27359055
7839,12325025,PTPN11 mutations in Noonan syndrome type I: detection of recurrent mutations in exons 3 and 13.,http://www.ncbi.nlm.nih.gov/pubmed/12325025
7840,20169295,Platelet-derived growth factor receptor alpha gene mutations in vitiligo vulgaris.,http://www.ncbi.nlm.nih.gov/pubmed/20169295
7841,22855146,Tyrosine-kinase mutations in c-KIT and PDGFR-alpha genes of imatinib naïve adult patients with gastrointestinal stromal tumours (GISTs) of the stomach and small intestine: relation to tumour-biological risk-profile and long-term outcome.,http://www.ncbi.nlm.nih.gov/pubmed/22855146
7842,19585585,High density DNA array analysis reveals distinct genomic profiles in a subset of gastrointestinal stromal tumors.,http://www.ncbi.nlm.nih.gov/pubmed/19585585
7843,18547963,PDGFRalpha gene mutation and protein expression in gastrointestinal stromal tumors.,http://www.ncbi.nlm.nih.gov/pubmed/18547963
7844,27449473,Rapid Molecular Profiling of Myeloproliferative Neoplasms Using Targeted Exon Resequencing of 86 Genes Involved in JAK-STAT Signaling and Epigenetic Regulation.,http://www.ncbi.nlm.nih.gov/pubmed/27449473
7845,16461462,Mutation and genomic deletion status of ataxia telangiectasia mutated (ATM) and p53 confer specific gene expression profiles in mantle cell lymphoma.,http://www.ncbi.nlm.nih.gov/pubmed/16461462
7846,23415222,Evolution and impact of subclonal mutations in chronic lymphocytic leukemia.,http://www.ncbi.nlm.nih.gov/pubmed/23415222
7847,22952040,Incidence and clinical implications of ATM aberrations in chronic lymphocytic leukemia.,http://www.ncbi.nlm.nih.gov/pubmed/22952040
7848,24069199,Identification and characterization of cancer mutations in Japanese lung adenocarcinoma without sequencing of normal tissue counterparts.,http://www.ncbi.nlm.nih.gov/pubmed/24069199
7849,24147083,"Complex patterns of chromosome 11 aberrations in myeloid malignancies target CBL, MLL, DDB1 and LMO2.",http://www.ncbi.nlm.nih.gov/pubmed/24147083
7850,27540300,Modulation of expression of the nuclear receptor NR0B2 (small heterodimer partner 1) and its impact on proliferation of renal carcinoma cells.,http://www.ncbi.nlm.nih.gov/pubmed/27540300
7851,26504773,New Insights into Orphan Nuclear Receptor SHP in Liver Cancer.,http://www.ncbi.nlm.nih.gov/pubmed/26504773
7852,17085480,DTL/CDT2 is essential for both CDT1 regulation and the early G2/M checkpoint.,http://www.ncbi.nlm.nih.gov/pubmed/17085480
7853,26472028,Overexpression of denticleless E3 ubiquitin protein ligase homolog (DTL) is related to poor outcome in gastric carcinoma.,http://www.ncbi.nlm.nih.gov/pubmed/26472028
7854,16216232,Functions and regulations of fibroblast growth factor signaling during embryonic development.,http://www.ncbi.nlm.nih.gov/pubmed/16216232
7855,27007053,Molecular and clinical significance of fibroblast growth factor 2 (FGF2 /bFGF) in malignancies of solid and hematological cancers for personalized therapies.,http://www.ncbi.nlm.nih.gov/pubmed/27007053
7856,16204312,Phospholipase C-gamma2 is essential for NK cell cytotoxicity and innate immunity to malignant and virally infected cells.,http://www.ncbi.nlm.nih.gov/pubmed/16204312
7857,25456276,Dysfunction of phospholipase Cγ in immune disorders and cancer.,http://www.ncbi.nlm.nih.gov/pubmed/25456276
7858,16982695,Prostaglandin E2 induces fibroblast growth factor 9 via EP3-dependent protein kinase Cdelta and Elk-1 signaling.,http://www.ncbi.nlm.nih.gov/pubmed/16982695
7859,24453997,Targeting arginine-dependent cancers with arginine-degrading enzymes: opportunities and challenges.,http://www.ncbi.nlm.nih.gov/pubmed/24453997
7860,26560030,Diversion of aspartate in ASS1-deficient tumours fosters de novo pyrimidine synthesis.,http://www.ncbi.nlm.nih.gov/pubmed/26560030
7861,27452468,Inhibition of the Polyamine Synthesis Pathway Is Synthetically Lethal with Loss of Argininosuccinate Synthase 1.,http://www.ncbi.nlm.nih.gov/pubmed/27452468
7862,20051527,Molecular aspects of thyroid hormone actions.,http://www.ncbi.nlm.nih.gov/pubmed/20051527
7863,11427693,Physiological and molecular basis of thyroid hormone action.,http://www.ncbi.nlm.nih.gov/pubmed/11427693
7864,22507269,Thyroid hormone receptors and cancer.,http://www.ncbi.nlm.nih.gov/pubmed/22507269
7865,12406085,Identification of an ETV6-ABL2 fusion transcript in combination with an ETV6 point mutation in a T-cell acute lymphoblastic leukaemia cell line.,http://www.ncbi.nlm.nih.gov/pubmed/12406085
7866,15923161,Association of mismatch repair deficiency with PTEN frameshift mutations in endometrial cancers and the precursors in a Japanese population.,http://www.ncbi.nlm.nih.gov/pubmed/15923161
7867,18757403,Inhibition of activated fibroblast growth factor receptor 2 in endometrial cancer cells induces cell death despite PTEN abrogation.,http://www.ncbi.nlm.nih.gov/pubmed/18757403
7868,11395387,"Frequent loss of PTEN expression is linked to elevated phosphorylated Akt levels, but not associated with p27 and cyclin D1 expression, in primary epithelial ovarian carcinomas.",http://www.ncbi.nlm.nih.gov/pubmed/11395387
7869,26675346,Whole-exome sequencing in relapsing chronic lymphocytic leukemia: clinical impact of recurrent RPS15 mutations.,http://www.ncbi.nlm.nih.gov/pubmed/26675346
7870,11756177,ATM gene inactivation in mantle cell lymphoma mainly occurs by truncating mutations and missense mutations involving the phosphatidylinositol-3 kinase domain and is associated with increasing numbers of chromosomal imbalances.,http://www.ncbi.nlm.nih.gov/pubmed/11756177
7871,10397742,Somatic ATM mutations indicate a pathogenic role of ATM in B-cell chronic lymphocytic leukemia.,http://www.ncbi.nlm.nih.gov/pubmed/10397742
7872,23407552,The E3 ubiquitin ligase UBR5 is recurrently mutated in mantle cell lymphoma.,http://www.ncbi.nlm.nih.gov/pubmed/23407552
7873,12673804,ATM gene alterations in childhood acute lymphoblastic leukemias.,http://www.ncbi.nlm.nih.gov/pubmed/12673804
7874,26487540,BRAF alteration status and the histone H3F3A gene K27M mutation segregate spinal cord astrocytoma histology.,http://www.ncbi.nlm.nih.gov/pubmed/26487540
7875,25115387,Targeted ultra-deep sequencing reveals recurrent and mutually exclusive mutations of cancer genes in blastic plasmacytoid dendritic cell neoplasm.,http://www.ncbi.nlm.nih.gov/pubmed/25115387
7876,24682267,The genomic landscape of mantle cell lymphoma is related to the epigenetically determined chromatin state of normal B cells.,http://www.ncbi.nlm.nih.gov/pubmed/24682267
7877,22634756,Whole-genome sequencing of liver cancers identifies etiological influences on mutation patterns and recurrent mutations in chromatin regulators.,http://www.ncbi.nlm.nih.gov/pubmed/22634756
7878,25846456,Profiling of actionable gene alterations in ovarian cancer by targeted deep sequencing.,http://www.ncbi.nlm.nih.gov/pubmed/25846456
7879,27693639,Integrative genomic and functional analysis of human oral squamous cell carcinoma cell lines reveals synergistic effects of FAT1 and CASP8 inactivation.,http://www.ncbi.nlm.nih.gov/pubmed/27693639
7880,23104009,Exome sequencing of serous endometrial tumors identifies recurrent somatic mutations in chromatin-remodeling and ubiquitin ligase complex genes.,http://www.ncbi.nlm.nih.gov/pubmed/23104009
7881,21447618,Pancreatic endocrine tumours: mutational and immunohistochemical survey of protein kinases reveals alterations in targetable kinases in cancer cell lines and rare primaries.,http://www.ncbi.nlm.nih.gov/pubmed/21447618
7882,24628946,Targeted next generation sequencing identifies clinically actionable mutations in patients with melanoma.,http://www.ncbi.nlm.nih.gov/pubmed/24628946
7883,20799949,The association between ATM D1853N polymorphism and breast cancer susceptibility: a meta-analysis.,http://www.ncbi.nlm.nih.gov/pubmed/20799949
7884,15280931,ATM polymorphisms as risk factors for prostate cancer development.,http://www.ncbi.nlm.nih.gov/pubmed/15280931
7885,16832357,ATM mutations that cause ataxia-telangiectasia are breast cancer susceptibility alleles.,http://www.ncbi.nlm.nih.gov/pubmed/16832357
7886,12697903,Oligonucleotide microarrays demonstrate the highest frequency of ATM mutations in the mantle cell subtype of lymphoma.,http://www.ncbi.nlm.nih.gov/pubmed/12697903
7887,27206246,Comparison of intramedullary myeloma and corresponding extramedullary soft tissue plasmacytomas using genetic mutational panel analyses.,http://www.ncbi.nlm.nih.gov/pubmed/27206246
7888,27856600,TTI-621 (SIRPαFc): A CD47-Blocking Innate Immune Checkpoint Inhibitor with Broad Antitumor Activity and Minimal Erythrocyte Binding.,http://www.ncbi.nlm.nih.gov/pubmed/27856600
7889,16652348,The ATM missense mutation p.Ser49Cys (c.146C>G) and the risk of breast cancer.,http://www.ncbi.nlm.nih.gov/pubmed/16652348
7890,28199309,Phosphatidylinositol 3-kinase δ blockade increases genomic instability in B cells.,http://www.ncbi.nlm.nih.gov/pubmed/28199309
7891,,A Phase I Study of IDH305 in Patients with Advanced Malignancies Including Relapsed/Refractory AML and MDS That Harbor IDH1R132 Mutations,http://www.bloodjournal.org/content/128/22/1073?sso-checked=true
7892,20385364,A small-molecule inhibitor of BCL6 kills DLBCL cells in vitro and in vivo.,http://www.ncbi.nlm.nih.gov/pubmed/20385364
7893,27683182,A Phase II Trial of Abiraterone Combined with Dutasteride for Men with Metastatic Castration-Resistant Prostate Cancer.,http://www.ncbi.nlm.nih.gov/pubmed/27683182
7894,12944904,BCL-6 is expressed in breast cancer and prevents mammary epithelial differentiation.,http://www.ncbi.nlm.nih.gov/pubmed/12944904
7895,27551000,"A Phase I Study of Topotecan, Carboplatin and the PARP Inhibitor Veliparib in Acute Leukemias, Aggressive Myeloproliferative Neoplasms, and Chronic Myelomonocytic Leukemia.",http://www.ncbi.nlm.nih.gov/pubmed/27551000
7896,21764904,"Potent, selective inhibitors of fibroblast growth factor receptor define fibroblast growth factor dependence in preclinical cancer models.",http://www.ncbi.nlm.nih.gov/pubmed/21764904
7897,24334454,Alveolar rhabdomyosarcoma-associated PAX3-FOXO1 promotes tumorigenesis via Hippo pathway suppression.,http://www.ncbi.nlm.nih.gov/pubmed/24334454
7898,19221588,"Integrated functions of Pax3 and Pax7 in the regulation of proliferation, cell size and myogenic differentiation.",http://www.ncbi.nlm.nih.gov/pubmed/19221588
7899,27401245,c-Myc Alteration Determines the Therapeutic Response to FGFR Inhibitors.,http://www.ncbi.nlm.nih.gov/pubmed/27401245
7900,26434631,Molecular characteristics of colorectal neuroendocrine carcinoma; similarities with adenocarcinoma rather than neuroendocrine tumor.,http://www.ncbi.nlm.nih.gov/pubmed/26434631
7901,20068183,Oncogenic BRAF mutation with CDKN2A inactivation is characteristic of a subset of pediatric malignant astrocytomas.,http://www.ncbi.nlm.nih.gov/pubmed/20068183
7902,22991414,Clinical significance of the genetic landscape of pancreatic cancer and implications for identification of potential long-term survivors.,http://www.ncbi.nlm.nih.gov/pubmed/22991414
7903,19373669,"Presence of a new BCR-ABL kinase domain mutation, C330G in an imatinib naive patient with chronic myeloid leukemia: very low prevalence of BCR-ABL kinase domain mutations in patients with chronic myeloid leukemia from eastern India.",http://www.ncbi.nlm.nih.gov/pubmed/19373669
7904,20512393,Rapid and sensitive allele-specific (AS)-RT-PCR assay for detection of T315I mutation in chronic myeloid leukemia patients treated with tyrosine-kinase inhibitors.,http://www.ncbi.nlm.nih.gov/pubmed/20512393
7905,21442193,Imatinib resistance and blast transformation of chronic myeloid leukemia associated with a novel tri-nucleotide insertion mutation of BCR-ABL kinase domain at position K294.,http://www.ncbi.nlm.nih.gov/pubmed/21442193
7906,18715783,Unravelling the tumor-suppressive functions of FOXO proteins.,http://www.ncbi.nlm.nih.gov/pubmed/18715783
7907,25099012,Diindolylmethane analogs bind NR4A1 and are NR4A1 antagonists in colon cancer cells.,http://www.ncbi.nlm.nih.gov/pubmed/25099012
7908,27864345,PAX3-FOXO1A Expression in Rhabdomyosarcoma Is Driven by the Targetable Nuclear Receptor NR4A1.,http://www.ncbi.nlm.nih.gov/pubmed/27864345
7909,28062704,Radiosensitization by the ATR Inhibitor AZD6738 through Generation of Acentric Micronuclei.,http://www.ncbi.nlm.nih.gov/pubmed/28062704
7910,18824701,Clinically applicable models to characterize BRCA1 and BRCA2 variants of uncertain significance.,http://www.ncbi.nlm.nih.gov/pubmed/18824701
7911,21218378,Detection of BRCA1 and BRCA2 mutations in a selected Hawaii population.,http://www.ncbi.nlm.nih.gov/pubmed/21218378
7912,11802209,Comprehensive analysis of 989 patients with breast or ovarian cancer provides BRCA1 and BRCA2 mutation profiles and frequencies for the German population.,http://www.ncbi.nlm.nih.gov/pubmed/11802209
7913,16489001,Genetic and histopathologic evaluation of BRCA1 and BRCA2 DNA sequence variants of unknown clinical significance.,http://www.ncbi.nlm.nih.gov/pubmed/16489001
7914,21990165,Classification of missense substitutions in the BRCA genes: a database dedicated to Ex-UVs.,http://www.ncbi.nlm.nih.gov/pubmed/21990165
7915,17924331,"A systematic genetic assessment of 1,433 sequence variants of unknown clinical significance in the BRCA1 and BRCA2 breast cancer-predisposition genes.",http://www.ncbi.nlm.nih.gov/pubmed/17924331
7916,16284991,BRCA1 and BRCA2 mutations account for a large proportion of ovarian carcinoma cases.,http://www.ncbi.nlm.nih.gov/pubmed/16284991
7917,20694749,Comprehensive BRCA1 and BRCA2 mutation analyses and review of French Canadian families with at least three cases of breast cancer.,http://www.ncbi.nlm.nih.gov/pubmed/20694749
7918,18431501,BRCA1 and BRCA2 germline mutations in Malaysian women with early-onset breast cancer without a family history.,http://www.ncbi.nlm.nih.gov/pubmed/18431501
7919,25802882,Detection of BRCA1 and BRCA2 germline mutations in Japanese population using next-generation sequencing.,http://www.ncbi.nlm.nih.gov/pubmed/25802882
7920,27550999,Therapeutic Inhibition of the MDM2-p53 Interaction Prevents Recurrence of Adenoid Cystic Carcinomas.,http://www.ncbi.nlm.nih.gov/pubmed/27550999
7921,28151717,Synergistic Drug Combinations with a CDK4/6 Inhibitor in T-cell Acute Lymphoblastic Leukemia.,http://www.ncbi.nlm.nih.gov/pubmed/28151717
7922,28011623,Sunitinib Treatment Enhances Metastasis of Innately Drug-Resistant Breast Tumors.,http://www.ncbi.nlm.nih.gov/pubmed/28011623
7923,9013443,Aquaporin-1 water channel expression in human kidney.,http://www.ncbi.nlm.nih.gov/pubmed/9013443
7924,15809704,"Heterogeneous expression of the aquaporin 1 (AQP1) water channel in tumors of the prostate, breast, ovary, colon and lung: a study using high density multiple human tumor tissue microarrays.",http://www.ncbi.nlm.nih.gov/pubmed/15809704
7925,24682512,p53 protein expression independently predicts outcome in patients with lower-risk myelodysplastic syndromes with del(5q).,http://www.ncbi.nlm.nih.gov/pubmed/24682512
7926,27095739,Targeted next-generation sequencing detects a high frequency of potentially actionable mutations in metastatic breast cancers.,http://www.ncbi.nlm.nih.gov/pubmed/27095739
7927,25556971,Next-generation sequencing of the BRCA1 and BRCA2 genes for the genetic diagnostics of hereditary breast and/or ovarian cancer.,http://www.ncbi.nlm.nih.gov/pubmed/25556971
7928,22550420,Low Prevalence of TP53 Mutations and MDM2 Amplifications in Pediatric Rhabdomyosarcoma.,http://www.ncbi.nlm.nih.gov/pubmed/22550420
7929,27859003,"Targeted next generation sequencing of breast implant-associated anaplastic large cell lymphoma reveals mutations in JAK/STAT signalling pathway genes, TP53 and DNMT3A.",http://www.ncbi.nlm.nih.gov/pubmed/27859003
7930,22669068,p53 expression and mutation analysis of odontogenic cysts with and without dysplasia.,http://www.ncbi.nlm.nih.gov/pubmed/22669068
7931,19930417,Beyond BRCA1 and BRCA2 wild-type breast and/or ovarian cancer families: germline mutations in TP53 and PTEN.,http://www.ncbi.nlm.nih.gov/pubmed/19930417
7932,27903752,HEXIM1 as a Robust Pharmacodynamic Marker for Monitoring Target Engagement of BET Family Bromodomain Inhibitors in Tumors and Surrogate Tissues.,http://www.ncbi.nlm.nih.gov/pubmed/27903752
7933,20104584,Characterization of BRCA1 and BRCA2 deleterious mutations and variants of unknown clinical significance in unilateral and bilateral breast cancer: the WECARE study.,http://www.ncbi.nlm.nih.gov/pubmed/20104584
7934,25534115,ASPP2 enhances oxaliplatin (L-OHP)-induced colorectal cancer cell apoptosis in a p53-independent manner by inhibiting cell autophagy.,http://www.ncbi.nlm.nih.gov/pubmed/25534115
7935,25236910,AXIN1 and AXIN2 variants in gastrointestinal cancers.,http://www.ncbi.nlm.nih.gov/pubmed/25236910
7936,20404912,"Inhibition of the proprotein convertases represses the invasiveness of human primary melanoma cells with altered p53, CDKN2A and N-Ras genes.",http://www.ncbi.nlm.nih.gov/pubmed/20404912
7937,18818522,Mutant p53 protein localized in the cytoplasm inhibits autophagy.,http://www.ncbi.nlm.nih.gov/pubmed/18818522
7938,16258521,GISTs with PDGFRA exon 14 mutations represent subset of clinically favorable gastric tumors with epithelioid morphology.,http://www.ncbi.nlm.nih.gov/pubmed/16258521
7939,18186519,Rapid identification of somatic mutations in colorectal and breast cancer tissues using mismatch repair detection (MRD).,http://www.ncbi.nlm.nih.gov/pubmed/18186519
7940,26700204,Recurrent Mutations of Chromatin-Remodeling Genes and Kinase Receptors in Pheochromocytomas and Paragangliomas.,http://www.ncbi.nlm.nih.gov/pubmed/26700204
7941,27438523,"Tubular, lactating, and ductal adenomas are devoid of MED12 Exon2 mutations, and ductal adenomas show recurrent mutations in GNAS and the PI3K-AKT pathway.",http://www.ncbi.nlm.nih.gov/pubmed/27438523
7942,18925961,Genome profiling of chronic myelomonocytic leukemia: frequent alterations of RAS and RUNX1 genes.,http://www.ncbi.nlm.nih.gov/pubmed/18925961
7943,20371674,Genetic and expression analysis of HER-2 and EGFR genes in salivary duct carcinoma: empirical and therapeutic significance.,http://www.ncbi.nlm.nih.gov/pubmed/20371674
7944,17457043,High copy amplification of the Aurora-A gene is associated with chromosomal instability phenotype in human colorectal cancers.,http://www.ncbi.nlm.nih.gov/pubmed/17457043
7945,18258923,Epidermal growth factor receptor (EGFR) high gene copy number and activating mutations in lung adenocarcinomas are not consistently accompanied by positivity for EGFR protein by standard immunohistochemistry.,http://www.ncbi.nlm.nih.gov/pubmed/18258923
7946,24891042,A comparison of epidermal growth factor receptor mutation testing methods in different tissue types in non-small cell lung cancer.,http://www.ncbi.nlm.nih.gov/pubmed/24891042
7947,16357143,CDC4 mutations occur in a subset of colorectal cancers but are not predicted to cause loss of function and are not associated with chromosomal instability.,http://www.ncbi.nlm.nih.gov/pubmed/16357143
7948,22923510,Identification of molecular pathway aberrations in uterine serous carcinoma by genome-wide analyses.,http://www.ncbi.nlm.nih.gov/pubmed/22923510
7949,25304185,Possible differential EGFR-TKI efficacy among exon 19 deletional locations in EGFR-mutant non-small cell lung cancer.,http://www.ncbi.nlm.nih.gov/pubmed/25304185
7950,27879972,Responses of metastatic basal cell and cutaneous squamous cell carcinomas to anti-PD1 monoclonal antibody REGN2810.,http://www.ncbi.nlm.nih.gov/pubmed/27879972
7951,19109228,NOTCH1/FBXW7 mutation identifies a large subgroup with favorable outcome in adult T-cell acute lymphoblastic leukemia (T-ALL): a Group for Research on Adult Acute Lymphoblastic Leukemia (GRAALL) study.,http://www.ncbi.nlm.nih.gov/pubmed/19109228
7952,28086948,Is there still a role for cytotoxic chemotherapy after targeted therapy and immunotherapy in metastatic melanoma? A case report and literature review.,http://www.ncbi.nlm.nih.gov/pubmed/28086948
7953,26066407,Next-generation sequencing for molecular diagnosis of lung adenocarcinoma specimens obtained by fine needle aspiration cytology.,http://www.ncbi.nlm.nih.gov/pubmed/26066407
7954,24040454,Screening for EGFR and KRAS mutations in non-small cell lung carcinomas using DNA extraction by hydrothermal pressure coupled with PCR-based direct sequencing.,http://www.ncbi.nlm.nih.gov/pubmed/24040454
7955,25623536,Inter- and intra-tumor profiling of multi-regional colon cancer and metastasis.,http://www.ncbi.nlm.nih.gov/pubmed/25623536
7956,26155992,Genetic profiles of cervical tumors by high-throughput sequencing for personalized medical care.,http://www.ncbi.nlm.nih.gov/pubmed/26155992
7957,25343854,High-throughput profiling identifies clinically actionable mutations in salivary duct carcinoma.,http://www.ncbi.nlm.nih.gov/pubmed/25343854
7958,18701186,Pilot study of gefitinib and fulvestrant in the treatment of post-menopausal women with advanced non-small cell lung cancer.,http://www.ncbi.nlm.nih.gov/pubmed/18701186
7959,28223509,High-throughput screening of rare metabolically active tumor cells in pleural effusion and peripheral blood of lung cancer patients.,http://www.ncbi.nlm.nih.gov/pubmed/28223509
7960,25617745,A pathway-centric survey of somatic mutations in Chinese patients with colorectal carcinomas.,http://www.ncbi.nlm.nih.gov/pubmed/25617745
7961,27101000,Validation and Application of a Custom-Designed Targeted Next-Generation Sequencing Panel for the Diagnostic Mutational Profiling of Solid Tumors.,http://www.ncbi.nlm.nih.gov/pubmed/27101000
7962,19245433,FBXW7 and NOTCH1 mutations in childhood T cell acute lymphoblastic leukaemia and T cell non-Hodgkin lymphoma.,http://www.ncbi.nlm.nih.gov/pubmed/19245433
7963,26146591,Proteomic analysis of HEK293 cells expressing non small cell lung carcinoma associated epidermal growth factor receptor variants reveals induction of heat shock response.,http://www.ncbi.nlm.nih.gov/pubmed/26146591
7964,25450649,FBXW7 mutation analysis and its correlation with clinicopathological features and prognosis in colorectal cancer patients.,http://www.ncbi.nlm.nih.gov/pubmed/25450649
7965,16824748,Mutational analysis of the hCDC4 gene in gastric carcinomas.,http://www.ncbi.nlm.nih.gov/pubmed/16824748
7966,21282377,"FBXW7 influences murine intestinal homeostasis and cancer, targeting Notch, Jun, and DEK for degradation.",http://www.ncbi.nlm.nih.gov/pubmed/21282377
7967,25552401,Phase I/II study of gefitinib (Iressa(®)) and vorinostat (IVORI) in previously treated patients with advanced non-small cell lung cancer.,http://www.ncbi.nlm.nih.gov/pubmed/25552401
7968,16870303,Complex mutation patterns of epidermal growth factor receptor gene associated with variable responses to gefitinib treatment in patients with non-small cell lung cancer.,http://www.ncbi.nlm.nih.gov/pubmed/16870303
7969,19060236,Good response to gefitinib in lung adenocarcinoma of complex epidermal growth factor receptor (EGFR) mutations with the classical mutation pattern.,http://www.ncbi.nlm.nih.gov/pubmed/19060236
7970,26773740,Examining Treatment Outcomes with Erlotinib in Patients with Advanced Non-Small Cell Lung Cancer Whose Tumors Harbor Uncommon EGFR Mutations.,http://www.ncbi.nlm.nih.gov/pubmed/26773740
7971,25809292,Morphological and molecular characteristics of HER2 amplified urothelial bladder cancer.,http://www.ncbi.nlm.nih.gov/pubmed/25809292
7972,21087480,Targeting EGFR/HER2 pathways enhances the antiproliferative effect of gemcitabine in biliary tract and gallbladder carcinomas.,http://www.ncbi.nlm.nih.gov/pubmed/21087480
7973,26462025,Phase II clinical and exploratory biomarker study of dacomitinib in recurrent and/or metastatic esophageal squamous cell carcinoma.,http://www.ncbi.nlm.nih.gov/pubmed/26462025
7974,26101090,Mechanistic Insights into R776H Mediated Activation of Epidermal Growth Factor Receptor Kinase.,http://www.ncbi.nlm.nih.gov/pubmed/26101090
7975,22761469,"Prevalence, clinicopathologic associations, and molecular spectrum of ERBB2 (HER2) tyrosine kinase mutations in lung adenocarcinomas.",http://www.ncbi.nlm.nih.gov/pubmed/22761469
7976,17409929,PTEN and PIK3CA expression is associated with prolonged survival after gefitinib treatment in EGFR-mutated lung cancer patients.,http://www.ncbi.nlm.nih.gov/pubmed/17409929
7977,15604253,Mutations of the epidermal growth factor receptor gene in lung cancer: biological and clinical implications.,http://www.ncbi.nlm.nih.gov/pubmed/15604253
7978,16638863,"Optimization of patient selection for gefitinib in non-small cell lung cancer by combined analysis of epidermal growth factor receptor mutation, K-ras mutation, and Akt phosphorylation.",http://www.ncbi.nlm.nih.gov/pubmed/16638863
7979,16397024,"Somatic mutations of ERBB2 kinase domain in gastric, colorectal, and breast carcinomas.",http://www.ncbi.nlm.nih.gov/pubmed/16397024
7980,21347793,Identification of the coexisting HER2 gene amplification and novel mutations in the HER2 protein-overexpressed mucinous epithelial ovarian cancer.,http://www.ncbi.nlm.nih.gov/pubmed/21347793
7981,23700467,Targeted sequencing of cancer-related genes in colorectal cancer using next-generation sequencing.,http://www.ncbi.nlm.nih.gov/pubmed/23700467
7982,24797764,ERBB2 gene as a potential therapeutic target in small bowel adenocarcinoma.,http://www.ncbi.nlm.nih.gov/pubmed/24797764
7983,16189274,Functional analysis of HGF/MET signaling and aberrant HGF-activator expression in diffuse large B-cell lymphoma.,http://www.ncbi.nlm.nih.gov/pubmed/16189274
7984,25453846,Gene mutations in small-cell lung cancer (SCLC): results of a panel of 6 genes in a cohort of Italian patients.,http://www.ncbi.nlm.nih.gov/pubmed/25453846
7985,23242437,Compound EGFR mutations and response to EGFR tyrosine kinase inhibitors.,http://www.ncbi.nlm.nih.gov/pubmed/23242437
7986,18036700,ERCC1 expression by immunohistochemistry and EGFR mutations in resected non-small cell lung cancer.,http://www.ncbi.nlm.nih.gov/pubmed/18036700
7987,22776705,An evaluation study of EGFR mutation tests utilized for non-small-cell lung cancer in the diagnostic setting.,http://www.ncbi.nlm.nih.gov/pubmed/22776705
7988,26725423,Hotspot mutations in polyomavirus positive and negative Merkel cell carcinomas.,http://www.ncbi.nlm.nih.gov/pubmed/26725423
7989,19648884,EGFR-dependent and independent activation of Akt/mTOR cascade in bone and soft tissue tumors.,http://www.ncbi.nlm.nih.gov/pubmed/19648884
7990,16533793,Distinct epidermal growth factor receptor and KRAS mutation patterns in non-small cell lung cancer patients with different tobacco exposure and clinicopathologic features.,http://www.ncbi.nlm.nih.gov/pubmed/16533793
7991,22649101,Essential role of TAK1 in regulating mantle cell lymphoma survival.,http://www.ncbi.nlm.nih.gov/pubmed/22649101
7992,27655129,MEK and TAK1 Regulate Apoptosis in Colon Cancer Cells with KRAS-Dependent Activation of Proinflammatory Signaling.,http://www.ncbi.nlm.nih.gov/pubmed/27655129
7993,27178821,"PDGFRA and KIT Mutation Status and Its Association With Clinicopathological Properties, Including DOG1.",http://www.ncbi.nlm.nih.gov/pubmed/27178821
7994,11454518,Molecular analysis of CDKN1C and TP53 in sporadic adrenal tumors.,http://www.ncbi.nlm.nih.gov/pubmed/11454518
7995,15523690,DHPLC is superior to SSCP in screening p53 mutations in esophageal cancer tissues.,http://www.ncbi.nlm.nih.gov/pubmed/15523690
7996,25157968,Prospective enterprise-level molecular genotyping of a cohort of cancer patients.,http://www.ncbi.nlm.nih.gov/pubmed/25157968
7997,26279503,First in human nanotechnology doxorubicin delivery system to target epidermal growth factor receptors in recurrent glioblastoma.,http://www.ncbi.nlm.nih.gov/pubmed/26279503
7998,17325666,Xeroderma pigmentosum group C gene expression is predominantly regulated by promoter hypermethylation and contributes to p53 mutation in lung cancers.,http://www.ncbi.nlm.nih.gov/pubmed/17325666
7999,26271412,Comparison of TP53 mutations screening by functional assay of separated allele in yeast and next-generation sequencing in myelodysplastic syndromes.,http://www.ncbi.nlm.nih.gov/pubmed/26271412
8000,24766216,Induction of p53-mediated transcription and apoptosis by exportin-1 (XPO1) inhibition in mantle cell lymphoma.,http://www.ncbi.nlm.nih.gov/pubmed/24766216
8001,20385133,p53 inhibits tumor cell invasion via the degradation of snail protein in hepatocellular carcinoma.,http://www.ncbi.nlm.nih.gov/pubmed/20385133
8002,27974663,PIK3CA mutations enable targeting of a breast tumor dependency through mTOR-mediated MCL-1 translation.,http://www.ncbi.nlm.nih.gov/pubmed/27974663
8003,15170669,Genetic evolution in colon cancer KM12 cells and metastatic derivates.,http://www.ncbi.nlm.nih.gov/pubmed/15170669
8004,26876197,Heterozygous p53(V172F) mutation in cisplatin-resistant human tumor cells promotes MDM4 recruitment and decreases stability and transactivity of p53.,http://www.ncbi.nlm.nih.gov/pubmed/26876197
8005,,R399H Mutated ETS Domain Leads to a Functional ETV6 Double-Knock-Out in Acute Leukemia and Completely Alters the Physiological Function of ETV6,http://www.bloodjournal.org/content/104/11/2055?sso-checked=true
8006,22722193,Whole-genome analysis informs breast cancer response to aromatase inhibition.,http://www.ncbi.nlm.nih.gov/pubmed/22722193
8007,18709663,Expression and mutational analysis of MET in human solid cancers.,http://www.ncbi.nlm.nih.gov/pubmed/18709663
8008,26887047,Retrospective study testing next generation sequencing of selected cancer-associated genes in resected prostate cancer.,http://www.ncbi.nlm.nih.gov/pubmed/26887047
8009,18193083,Clinicopathological analysis of colorectal cancers with PIK3CA mutations in Middle Eastern population.,http://www.ncbi.nlm.nih.gov/pubmed/18193083
8010,22498935,"Molecular characterization of endometrial cancer: a correlative study assessing microsatellite instability, MLH1 hypermethylation, DNA mismatch repair protein expression, and PTEN, PIK3CA, KRAS, and BRAF mutation analysis.",http://www.ncbi.nlm.nih.gov/pubmed/22498935
8011,23665199,Frequent genetic alterations in EGFR- and HER2-driven pathways in breast cancer brain metastases.,http://www.ncbi.nlm.nih.gov/pubmed/23665199
8012,18022911,PIK3CA cancer mutations display gender and tissue specificity patterns.,http://www.ncbi.nlm.nih.gov/pubmed/18022911
8013,22357840,Prognostic role of PIK3CA mutation in colorectal cancer: cohort study and literature review.,http://www.ncbi.nlm.nih.gov/pubmed/22357840
8014,22753589,"Specific mutations in KRAS codons 12 and 13, and patient prognosis in 1075 BRAF wild-type colorectal cancers.",http://www.ncbi.nlm.nih.gov/pubmed/22753589
8015,25150293,Recurrent RAS and PIK3CA mutations in Erdheim-Chester disease.,http://www.ncbi.nlm.nih.gov/pubmed/25150293
8016,21239505,KRAS mutation is associated with lung metastasis in patients with curatively resected colorectal cancer.,http://www.ncbi.nlm.nih.gov/pubmed/21239505
8017,23603658,Structure-guided design of a selective BCL-X(L) inhibitor.,http://www.ncbi.nlm.nih.gov/pubmed/23603658
8018,21697284,A drug resistance screen using a selective MET inhibitor reveals a spectrum of mutations that partially overlap with activating mutations found in cancer patients.,http://www.ncbi.nlm.nih.gov/pubmed/21697284
8019,28062706,Combinatorial Drug Screening Identifies Ewing Sarcoma-specific Sensitivities.,http://www.ncbi.nlm.nih.gov/pubmed/28062706
8020,27793840,Targeting of PYK2 Synergizes with EGFR Antagonists in Basal-like TNBC and Circumvents HER3-Associated Resistance via the NEDD4-NDRG1 Axis.,http://www.ncbi.nlm.nih.gov/pubmed/27793840
8021,23107319,A comprehensive immunohistochemical and molecular approach to the PI3K/AKT/mTOR (phosphoinositide 3-kinase/v-akt murine thymoma viral oncogene/mammalian target of rapamycin) pathway in bladder urothelial carcinoma.,http://www.ncbi.nlm.nih.gov/pubmed/23107319
8022,26796526,Frequency and clinicopathologic profile of PIK3CA mutant GISTs: molecular genetic study of 529 cases.,http://www.ncbi.nlm.nih.gov/pubmed/26796526
8023,25850943,Uncovering the genomic heterogeneity of multifocal breast cancer.,http://www.ncbi.nlm.nih.gov/pubmed/25850943
8024,27302833,Frequent PIK3CA Mutations in Colorectal and Endometrial Tumors With 2 or More Somatic Mutations in Mismatch Repair Genes.,http://www.ncbi.nlm.nih.gov/pubmed/27302833
8025,23219661,"High-throughput interrogation of PIK3CA, PTEN, KRAS, FBXW7 and TP53 mutations in primary endometrial carcinoma.",http://www.ncbi.nlm.nih.gov/pubmed/23219661
8026,22330809,"PIK3CA mutation impact on survival in breast cancer patients and in ERα, PR and ERBB2-based subgroups.",http://www.ncbi.nlm.nih.gov/pubmed/22330809
8027,23718828,Targeted next-generation sequencing of head and neck squamous cell carcinoma identifies novel genetic alterations in HPV+ and HPV- tumors.,http://www.ncbi.nlm.nih.gov/pubmed/23718828
8028,25624430,Phase II study of everolimus and letrozole in patients with recurrent endometrial carcinoma.,http://www.ncbi.nlm.nih.gov/pubmed/25624430
8029,26850916,Targeted and exome sequencing identified somatic mutations in hepatocellular carcinoma.,http://www.ncbi.nlm.nih.gov/pubmed/26850916
8030,17317825,Genetic alterations and their relationship in the phosphatidylinositol 3-kinase/Akt pathway in thyroid cancer.,http://www.ncbi.nlm.nih.gov/pubmed/17317825
8031,26214578,Combined transcriptome studies identify AFF3 as a mediator of the oncogenic effects of β-catenin in adrenocortical carcinoma.,http://www.ncbi.nlm.nih.gov/pubmed/26214578
8032,,"IL-17 neutralization by subcutaneous CJM112, a fully human anti IL-17A monoclonal antibody for the treatment of relapsing-remitting multiple sclerosis: study design of a phase 2 trial",http://onlinelibrary.ectrims-congress.eu/ectrims/2015/31st/115615/heinz.weindl.il-17.neutralization.by.subcutaneous.cjm112.a.fully.human.anti.html
8033,23633456,PIK3CA and PTEN gene and exon mutation-specific clinicopathologic and molecular associations in colorectal cancer.,http://www.ncbi.nlm.nih.gov/pubmed/23633456
8034,24336570,Mutational analysis reveals the origin and therapy-driven evolution of recurrent glioma.,http://www.ncbi.nlm.nih.gov/pubmed/24336570
8035,22807394,Molecular alterations in endometrial archived liquid-based cytology.,http://www.ncbi.nlm.nih.gov/pubmed/22807394
8036,11916965,Reversible inactivation of the tumor suppressor PTEN by H2O2.,http://www.ncbi.nlm.nih.gov/pubmed/11916965
8037,19471547,Pharmacogenomic profiling of the PI3K/PTEN pathway in sporadic breast cancer.,http://www.ncbi.nlm.nih.gov/pubmed/19471547
8038,15987703,LKB1 interacts with and phosphorylates PTEN: a functional link between two proteins involved in cancer predisposing syndromes.,http://www.ncbi.nlm.nih.gov/pubmed/15987703
8039,12695913,Mutation analysis of the putative tumor suppressor gene PTEN/MMAC1 in advanced gastric carcinomas.,http://www.ncbi.nlm.nih.gov/pubmed/12695913
8040,28069799,IKBKE Is Required during KRAS-Induced Pancreatic Tumorigenesis.,http://www.ncbi.nlm.nih.gov/pubmed/28069799
8041,10096247,Mutational analysis of the PTEN gene in gliomas: molecular and pathological correlations.,http://www.ncbi.nlm.nih.gov/pubmed/10096247
8042,24425785,Genomic analysis of head and neck squamous cell carcinoma cell lines and human tumors: a rational approach to preclinical model selection.,http://www.ncbi.nlm.nih.gov/pubmed/24425785
8043,21266357,Multiple mutations and bypass mechanisms can contribute to development of acquired resistance to MET inhibitors.,http://www.ncbi.nlm.nih.gov/pubmed/21266357
8044,28027320,Genomic Analysis of Uterine Lavage Fluid Detects Early Endometrial Cancers and Reveals a Prevalent Landscape of Driver Mutations in Women without Histopathologic Evidence of Cancer: A Prospective Cross-Sectional Study.,http://www.ncbi.nlm.nih.gov/pubmed/28027320
8045,15069681,Molecular alterations associated with cyclin D1 overexpression in endometrial cancer.,http://www.ncbi.nlm.nih.gov/pubmed/15069681
8046,20300775,PTEN mutation spectrum in breast cancers and breast hyperplasia.,http://www.ncbi.nlm.nih.gov/pubmed/20300775
8047,10955808,Somatic mutation of PTEN in vulvar cancer.,http://www.ncbi.nlm.nih.gov/pubmed/10955808
8048,11123721,Molecular genetics of radiographically defined de novo glioblastoma multiforme.,http://www.ncbi.nlm.nih.gov/pubmed/11123721
8049,25003235,PTEN mutations and activation of the PI3K/Akt/mTOR signaling pathway in papillary tumors of the pineal region.,http://www.ncbi.nlm.nih.gov/pubmed/25003235
8050,27148581,A common founding clone with TP53 and PTEN mutations gives rise to a concurrent germ cell tumor and acute megakaryoblastic leukemia.,http://www.ncbi.nlm.nih.gov/pubmed/27148581
8051,27307593,PI3K Pathway Inhibition Achieves Potent Antitumor Activity in Melanoma Brain Metastases In Vitro and In Vivo.,http://www.ncbi.nlm.nih.gov/pubmed/27307593
8052,10092130,Analysis of PTEN mutations and deletions in B-cell non-Hodgkin's lymphomas.,http://www.ncbi.nlm.nih.gov/pubmed/10092130
8053,10653004,Loss of heterozygosity on chromosome 10 is more extensive in primary (de novo) than in secondary glioblastomas.,http://www.ncbi.nlm.nih.gov/pubmed/10653004
8054,18953432,p16INK4a expression and absence of activated B-RAF are independent predictors of chemosensitivity in melanoma tumors.,http://www.ncbi.nlm.nih.gov/pubmed/18953432
8055,27829222,PTEN dephosphorylates AKT to prevent the expression of GLUT1 on plasmamembrane and to limit glucose consumption in cancer cells.,http://www.ncbi.nlm.nih.gov/pubmed/27829222
8056,21103049,DNA sequence profiles of the colorectal cancer critical gene set KRAS-BRAF-PIK3CA-PTEN-TP53 related to age at disease onset.,http://www.ncbi.nlm.nih.gov/pubmed/21103049
8057,10851265,Expression of PTEN and PTEN pseudogene in endometrial carcinoma.,http://www.ncbi.nlm.nih.gov/pubmed/10851265
8058,21667306,Low frequency of PIK3CA gene mutations in hepatocellular carcinoma in Chinese population.,http://www.ncbi.nlm.nih.gov/pubmed/21667306
8059,25426553,Targeted PI3K/AKT/mTOR therapy for metastatic carcinomas of the cervix: A phase I clinical experience.,http://www.ncbi.nlm.nih.gov/pubmed/25426553
8060,26276776,Distinct β-catenin and PIK3CA mutation profiles in endometriosis-associated ovarian endometrioid and clear cell carcinomas.,http://www.ncbi.nlm.nih.gov/pubmed/26276776
8061,16376301,Correlation of PIK3Ca mutations with gene expression and drug sensitivity in NCI-60 cell lines.,http://www.ncbi.nlm.nih.gov/pubmed/16376301
8062,19349352,Frequent activating mutations of PIK3CA in ovarian clear cell carcinoma.,http://www.ncbi.nlm.nih.gov/pubmed/19349352
8063,23977390,Prevalence of PALB2 mutations in breast cancer patients in multi-ethnic Asian population in Malaysia and Singapore.,http://www.ncbi.nlm.nih.gov/pubmed/23977390
8064,16278407,Molecular study of malignant gliomas treated with epidermal growth factor receptor inhibitors: tissue analysis from North American Brain Tumor Consortium Trials 01-03 and 00-01.,http://www.ncbi.nlm.nih.gov/pubmed/16278407
8065,27852700,Genomic Evolution after Chemoradiotherapy in Anal Squamous Cell Carcinoma.,http://www.ncbi.nlm.nih.gov/pubmed/27852700
8066,27343442,Acquired Resistance to Crizotinib in NSCLC with MET Exon 14 Skipping.,http://www.ncbi.nlm.nih.gov/pubmed/27343442
8067,10560660,Mutational profile of the PTEN gene in primary human astrocytic tumors and cultivated xenografts.,http://www.ncbi.nlm.nih.gov/pubmed/10560660
8068,11438483,PTEN is a target of chromosome 10q loss in anaplastic oligodendrogliomas and PTEN alterations are associated with poor prognosis.,http://www.ncbi.nlm.nih.gov/pubmed/11438483
8069,18379359,Evidence for disease control with erlotinib after gefitinib failure in typical gefitinib-sensitive Asian patients with non-small cell lung cancer.,http://www.ncbi.nlm.nih.gov/pubmed/18379359
8070,11801303,Detection of new PTEN/MMAC1 mutations in head and neck squamous cell carcinomas with loss of chromosome 10.,http://www.ncbi.nlm.nih.gov/pubmed/11801303
8071,25769001,Mutational dichotomy in desmoplastic malignant melanoma corroborated by multigene panel analysis.,http://www.ncbi.nlm.nih.gov/pubmed/25769001
8072,14724591,PTEN mutations are common in sporadic microsatellite stable colorectal cancer.,http://www.ncbi.nlm.nih.gov/pubmed/14724591
8073,11108659,Inactivation of MMAC1 in bladder transitional-cell carcinoma cell lines and specimens.,http://www.ncbi.nlm.nih.gov/pubmed/11108659
8074,26362251,A systematic screening to identify de novo mutations causing sporadic early-onset Parkinson's disease.,http://www.ncbi.nlm.nih.gov/pubmed/26362251
8075,23361946,Macrocephaly as a clinical indicator of genetic subtypes in autism.,http://www.ncbi.nlm.nih.gov/pubmed/23361946
8076,20544847,Somatic alterations in the melanoma genome: a high-resolution array-based comparative genomic hybridization study.,http://www.ncbi.nlm.nih.gov/pubmed/20544847
8077,25910966,A wide spectrum of EGFR mutations in glioblastoma is detected by a single clinical oncology targeted next-generation sequencing panel.,http://www.ncbi.nlm.nih.gov/pubmed/25910966
8078,15195137,BRAF alterations are associated with complex mutational profiles in malignant melanoma.,http://www.ncbi.nlm.nih.gov/pubmed/15195137
8079,24132290,Mutational landscape and significance across 12 major cancer types.,http://www.ncbi.nlm.nih.gov/pubmed/24132290
8080,25529460,Assessment of EGFR and KRAS mutation status from FNAs and core-needle biopsies of non-small cell lung cancer.,http://www.ncbi.nlm.nih.gov/pubmed/25529460
8081,20512074,Epidermal growth factor receptor mutation and p53 overexpression during the multistage progression of small adenocarcinoma of the lung.,http://www.ncbi.nlm.nih.gov/pubmed/20512074
8082,22026926,The human epidermal growth factor receptor (EGFR) gene in European patients with advanced colorectal cancer harbors infrequent mutations in its tyrosine kinase domain.,http://www.ncbi.nlm.nih.gov/pubmed/22026926
8083,27121209,Targeted sequencing identifies genetic alterations that confer primary resistance to EGFR tyrosine kinase inhibitor (Korean Lung Cancer Consortium).,http://www.ncbi.nlm.nih.gov/pubmed/27121209
8084,9393744,PTEN/MMAC1 mutations and EGFR amplification in glioblastomas.,http://www.ncbi.nlm.nih.gov/pubmed/9393744
8085,27322546,Functional characterization of somatic mutations in cancer using network-based inference of protein activity.,http://www.ncbi.nlm.nih.gov/pubmed/27322546
8086,27875527,Non-classic EGFR mutations in a cohort of Dutch EGFR-mutated NSCLC patients and outcomes following EGFR-TKI treatment.,http://www.ncbi.nlm.nih.gov/pubmed/27875527
8087,17192902,The impact of epidermal growth factor receptor gene status on gefitinib-treated Japanese patients with non-small-cell lung cancer.,http://www.ncbi.nlm.nih.gov/pubmed/17192902
8088,21057220,Prognostic effect of epidermal growth factor receptor gene mutations and the aberrant phosphorylation of Akt and ERK in ovarian cancer.,http://www.ncbi.nlm.nih.gov/pubmed/21057220
8089,16467085,A rapid and sensitive enzymatic method for epidermal growth factor receptor mutation screening.,http://www.ncbi.nlm.nih.gov/pubmed/16467085
8090,17626639,Correlations of EGFR mutations and increases in EGFR and HER2 copy number to gefitinib response in a retrospective analysis of lung cancer patients.,http://www.ncbi.nlm.nih.gov/pubmed/17626639
8091,22528563,EGFR and KRAS mutations in lung carcinomas in the Dutch population: increased EGFR mutation frequency in malignant pleural effusion of lung adenocarcinoma.,http://www.ncbi.nlm.nih.gov/pubmed/22528563
8092,22389883,Novel mutations in CEBPA in Korean Patients with acute myeloid leukemia with a normal karyotype.,http://www.ncbi.nlm.nih.gov/pubmed/22389883
8093,22649106,GATA2 zinc finger 1 mutations associated with biallelic CEBPA mutations define a unique genetic entity of acute myeloid leukemia.,http://www.ncbi.nlm.nih.gov/pubmed/22649106
8094,15645492,Acute myeloid leukemia with deletion 9q within a noncomplex karyotype is associated with CEBPA loss-of-function mutations.,http://www.ncbi.nlm.nih.gov/pubmed/15645492
8095,17224267,EGFR mutations and human papillomavirus in squamous cell carcinoma of tongue and tonsil.,http://www.ncbi.nlm.nih.gov/pubmed/17224267
8096,26901614,Programmed cell death-ligand 1 expression is associated with a favourable immune microenvironment and better overall survival in stage I pulmonary squamous cell carcinoma.,http://www.ncbi.nlm.nih.gov/pubmed/26901614
8097,18729193,CCAAT/enhancer binding protein-alpha polymorphisms occur more frequently than mutations in acute myeloid leukemia and exist across all cytogenetic risk groups and leukemia subtypes.,http://www.ncbi.nlm.nih.gov/pubmed/18729193
8098,14726504,CEBPA mutations in younger adults with acute myeloid leukemia and normal cytogenetics: prognostic relevance and analysis of cooperating mutations.,http://www.ncbi.nlm.nih.gov/pubmed/14726504
8099,19238633,Comparison of EGFR and K-RAS gene status between primary tumours and corresponding metastases in NSCLC.,http://www.ncbi.nlm.nih.gov/pubmed/19238633
8100,23139256,Aberrations in the epidermal growth factor receptor gene in 958 patients with diverse advanced tumors: implications for therapy.,http://www.ncbi.nlm.nih.gov/pubmed/23139256
8101,16857803,Epidermal growth factor receptor kinase domain mutations in esophageal and pancreatic adenocarcinomas.,http://www.ncbi.nlm.nih.gov/pubmed/16857803
8102,15863375,Gene copy number for epidermal growth factor receptor (EGFR) and clinical response to antiEGFR treatment in colorectal cancer: a cohort study.,http://www.ncbi.nlm.nih.gov/pubmed/15863375
8103,19190079,"Mutational analysis of the BRAF, RAS and EGFR genes in human adrenocortical carcinomas.",http://www.ncbi.nlm.nih.gov/pubmed/19190079
8104,21030498,Development of central nervous system metastases in patients with advanced non-small cell lung cancer and somatic EGFR mutations treated with gefitinib or erlotinib.,http://www.ncbi.nlm.nih.gov/pubmed/21030498
8105,23800712,Revisiting clinical trials using EGFR inhibitor-based regimens in patients with advanced non-small cell lung cancer: a retrospective analysis of an MD Anderson Cancer Center phase I population.,http://www.ncbi.nlm.nih.gov/pubmed/23800712
8106,18176089,Prognostic factors for gefitinib-treated postoperative recurrence in non-small cell lung cancer.,http://www.ncbi.nlm.nih.gov/pubmed/18176089
8107,23584298,Clinical and biomarker outcomes of the phase II vandetanib study from the BATTLE trial.,http://www.ncbi.nlm.nih.gov/pubmed/23584298
8108,15753462,Phase I/II trial evaluating the anti-vascular endothelial growth factor monoclonal antibody bevacizumab in combination with the HER-1/epidermal growth factor receptor tyrosine kinase inhibitor erlotinib for patients with recurrent non-small-cell lung cancer.,http://www.ncbi.nlm.nih.gov/pubmed/15753462
8109,19536777,Second-line treatments after first-line gefitinib therapy in advanced nonsmall cell lung cancer.,http://www.ncbi.nlm.nih.gov/pubmed/19536777
8110,11830484,Mutations in the gene encoding the transcription factor CCAAT/enhancer binding protein alpha in myelodysplastic syndromes and acute myeloid leukemias.,http://www.ncbi.nlm.nih.gov/pubmed/11830484
8111,26796102,Clinical evaluation of panel testing by next-generation sequencing (NGS) for gene mutations in myeloid neoplasms.,http://www.ncbi.nlm.nih.gov/pubmed/26796102
8112,25130612,Efficacy analysis of tyrosine kinase inhibitors on rare non-small cell lung cancer patients harboring complex EGFR mutations.,http://www.ncbi.nlm.nih.gov/pubmed/25130612
8113,15329413,"EGF receptor gene mutations are common in lung cancers from ""never smokers"" and are associated with sensitivity of tumors to gefitinib and erlotinib.",http://www.ncbi.nlm.nih.gov/pubmed/15329413
8114,18509184,Specific EGFR mutations predict treatment outcome of stage IIIB/IV patients with chemotherapy-naive non-small-cell lung cancer receiving first-line gefitinib monotherapy.,http://www.ncbi.nlm.nih.gov/pubmed/18509184
8115,27899382,A Metastatic Mouse Model Identifies Genes That Regulate Neuroblastoma Metastasis.,http://www.ncbi.nlm.nih.gov/pubmed/27899382
8116,28131785,"Nivolumab in metastatic urothelial carcinoma after platinum therapy (CheckMate 275): a multicentre, single-arm, phase 2 trial.",http://www.ncbi.nlm.nih.gov/pubmed/28131785
8117,22588880,Functional characterization of an isoform-selective inhibitor of PI3K-p110β as a potential anticancer agent.,http://www.ncbi.nlm.nih.gov/pubmed/22588880
8118,17873882,Mutational loss of PTEN induces resistance to NOTCH1 inhibition in T-cell leukemia.,http://www.ncbi.nlm.nih.gov/pubmed/17873882
8119,19737859,"Mutational analysis of FANCL, FANCM and the recently identified FANCI suggests that among the 13 known Fanconi Anemia genes, only FANCD1/BRCA2 plays a major role in high-risk breast cancer predisposition.",http://www.ncbi.nlm.nih.gov/pubmed/19737859
8120,25032700,NCI-60 whole exome sequencing and pharmacological CellMiner analyses.,http://www.ncbi.nlm.nih.gov/pubmed/25032700
8121,16914028,ATM variants and cancer risk in breast cancer patients from Southern Finland.,http://www.ncbi.nlm.nih.gov/pubmed/16914028
8122,17350623,PKCzetaII is a target for degradation through the tumour suppressor protein pVHL.,http://www.ncbi.nlm.nih.gov/pubmed/17350623
8123,21204214,IGF1R variants associated with isolated single suture craniosynostosis.,http://www.ncbi.nlm.nih.gov/pubmed/21204214
8124,27478040,High-throughput Phenotyping of Lung Cancer Somatic Mutations.,http://www.ncbi.nlm.nih.gov/pubmed/27478040
8125,24744697,Subcellular targeting and dynamic regulation of PTEN: implications for neuronal cells and neurological disorders.,http://www.ncbi.nlm.nih.gov/pubmed/24744697
8126,19644652,Different molecular patterns in glioblastoma multiforme subtypes upon recurrence.,http://www.ncbi.nlm.nih.gov/pubmed/19644652
8127,9619835,PTEN mutations in gliomas and glioneuronal tumors.,http://www.ncbi.nlm.nih.gov/pubmed/9619835
8128,11476841,Association of germline mutation in the PTEN tumour suppressor gene and Proteus and Proteus-like syndromes.,http://www.ncbi.nlm.nih.gov/pubmed/11476841
8129,27494611,Comprehensive Analysis of the Transcriptional and Mutational Landscape of Follicular and Papillary Thyroid Cancers.,http://www.ncbi.nlm.nih.gov/pubmed/27494611
8130,24138990,Frequent concerted genetic mechanisms disrupt multiple components of the NRF2 inhibitor KEAP1/CUL3/RBX1 E3-ubiquitin ligase complex in thyroid cancer.,http://www.ncbi.nlm.nih.gov/pubmed/24138990
8131,27263465,The Dual Roles of NRF2 in Cancer.,http://www.ncbi.nlm.nih.gov/pubmed/27263465
8132,24630729,Genetic and clonal dissection of murine small cell lung carcinoma progression by genome sequencing.,http://www.ncbi.nlm.nih.gov/pubmed/24630729
8133,11555573,"PTEN mutation located only outside exons 5, 6, and 7 is an independent predictor of favorable survival in endometrial carcinomas.",http://www.ncbi.nlm.nih.gov/pubmed/11555573
8134,16344319,High frequency of submicroscopic hemizygous deletion is a major mechanism of loss of expression of PTEN in uveal melanoma.,http://www.ncbi.nlm.nih.gov/pubmed/16344319
8135,25016225,Paediatric hepatocellular carcinoma due to somatic CTNNB1 and NFE2L2 mutations in the setting of inherited bi-allelic ABCB11 mutations.,http://www.ncbi.nlm.nih.gov/pubmed/25016225
8136,25406187,Notch1 mutations are drivers of oral tumorigenesis.,http://www.ncbi.nlm.nih.gov/pubmed/25406187
8137,16778113,PIK3CA mutations in intraductal papillary mucinous neoplasm/carcinoma of the pancreas.,http://www.ncbi.nlm.nih.gov/pubmed/16778113
8138,18343945,"PIK3CA, KRAS, and BRAF mutations in intraductal papillary mucinous neoplasm/carcinoma (IPMN/C) of the pancreas.",http://www.ncbi.nlm.nih.gov/pubmed/18343945
8139,25073438,"Molecular spectrum of KRAS, BRAF, and PIK3CA gene mutation: determination of frequency, distribution pattern in Indian colorectal carcinoma.",http://www.ncbi.nlm.nih.gov/pubmed/25073438
8140,28157218,"Expanded safety analysis of pevonedistat, a first-in-class NEDD8-activating enzyme inhibitor, in patients with acute myeloid leukemia and myelodysplastic syndromes.",http://www.ncbi.nlm.nih.gov/pubmed/28157218
8141,28167203,ERBB2-Mutated Metastatic Non-Small Cell Lung Cancer: Response and Resistance to Targeted Therapies.,http://www.ncbi.nlm.nih.gov/pubmed/28167203
8142,28211885,The novel BMI-1 inhibitor PTC596 downregulates MCL-1 and induces p53-independent mitochondrial apoptosis in acute myeloid leukemia progenitor cells.,http://www.ncbi.nlm.nih.gov/pubmed/28211885
8143,19357396,High frequency of RUNX1 biallelic alteration in acute myeloid leukemia secondary to familial platelet disorder.,http://www.ncbi.nlm.nih.gov/pubmed/19357396
8144,26080840,Genome Analysis of Latin American Cervical Cancer: Frequent Activation of the PIK3CA Pathway.,http://www.ncbi.nlm.nih.gov/pubmed/26080840
8145,2700708,[Shear strength measurements for the clinical evaluation of bonded ceramic systems].,http://www.ncbi.nlm.nih.gov/pubmed/2700708
8146,28034880,Polyclonal Secondary FGFR2 Mutations Drive Acquired Resistance to FGFR Inhibition in Patients with FGFR2 Fusion-Positive Cholangiocarcinoma.,http://www.ncbi.nlm.nih.gov/pubmed/28034880
8147,23527154,The IKK inhibitor Bay 11-7082 induces cell death independent from inhibition of activation of NFκB transcription factors.,http://www.ncbi.nlm.nih.gov/pubmed/23527154
8148,27872098,Systematic Drug Screening Identifies Tractable Targeted Combination Therapies in Triple-Negative Breast Cancer.,http://www.ncbi.nlm.nih.gov/pubmed/27872098
8149,15870708,The Akt inhibitor KP372-1 suppresses Akt activity and cell proliferation and induces apoptosis in thyroid cancer cells.,http://www.ncbi.nlm.nih.gov/pubmed/15870708
8150,21454610,A novel mode of protein kinase inhibition exploiting hydrophobic motifs of autoinhibited kinases: discovery of ATP-independent inhibitors of fibroblast growth factor receptor.,http://www.ncbi.nlm.nih.gov/pubmed/21454610
8151,,"Abstract LB-92: RVX-2135 is a novel, orally bioavailable epigenetic BET inhibitor that synergizes with cytarabine and idarubicin to inhibit proliferation of acute myeloid leukemia cells.",http://cancerres.aacrjournals.org/content/73/8_Supplement/LB-92
8152,26804177,"BET bromodomain inhibitors synergize with ATR inhibitors to induce DNA damage, apoptosis, senescence-associated secretory pathway and ER stress in Myc-induced lymphoma cells.",http://www.ncbi.nlm.nih.gov/pubmed/26804177
8153,25078343,"Molecular alterations of PIK3CA in uterine carcinosarcoma, clear cell, and serous tumors.",http://www.ncbi.nlm.nih.gov/pubmed/25078343
8154,24440717,Assessing PIK3CA and PTEN in early-phase trials with PI3K/AKT/mTOR inhibitors.,http://www.ncbi.nlm.nih.gov/pubmed/24440717
8155,18084252,PIK3CA mutations in the kinase domain (exon 20) of uterine endometrial adenocarcinomas are associated with adverse prognostic parameters.,http://www.ncbi.nlm.nih.gov/pubmed/18084252
8156,15289301,"Mutations of PIK3CA in anaplastic oligodendrogliomas, high-grade astrocytomas, and medulloblastomas.",http://www.ncbi.nlm.nih.gov/pubmed/15289301
8157,24277457,Common and complex Notch1 mutations in Chinese oral squamous cell carcinoma.,http://www.ncbi.nlm.nih.gov/pubmed/24277457
8158,27035284,Somatic Mutations and Genetic Variants of NOTCH1 in Head and Neck Squamous Cell Carcinoma Occurrence and Development.,http://www.ncbi.nlm.nih.gov/pubmed/27035284
8159,25349422,Development of covalent inhibitors that can overcome resistance to first-generation FGFR kinase inhibitors.,http://www.ncbi.nlm.nih.gov/pubmed/25349422
8160,27986707,Activating ESR1 Mutations Differentially Affect the Efficacy of ER Antagonists.,http://www.ncbi.nlm.nih.gov/pubmed/27986707
8161,26573800,Targeting a Plk1-Controlled Polarity Checkpoint in Therapy-Resistant Glioblastoma-Propagating Cells.,http://www.ncbi.nlm.nih.gov/pubmed/26573800
8162,28221861,Inhibiting Histone Deacetylase as a Means to Reverse Resistance to Angiogenesis Inhibitors: Phase I Study of Abexinostat Plus Pazopanib in Advanced Solid Tumor Malignancies.,http://www.ncbi.nlm.nih.gov/pubmed/28221861
8163,28222071,"Combination of the histone deacetylase inhibitor vorinostat with bevacizumab in patients with clear-cell renal cell carcinoma: a multicentre, single-arm phase I/II clinical trial.",http://www.ncbi.nlm.nih.gov/pubmed/28222071
8164,25839328,Genomic analyses reveal mutational signatures and frequently altered genes in esophageal squamous cell carcinoma.,http://www.ncbi.nlm.nih.gov/pubmed/25839328
8165,16424867,High incidence of Notch-1 mutations in adult patients with T-cell acute lymphoblastic leukemia.,http://www.ncbi.nlm.nih.gov/pubmed/16424867
8166,22547598,"Clinical impact of NOTCH1 and/or FBXW7 mutations, FLASH deletion, and TCR status in pediatric T-cell lymphoblastic lymphoma.",http://www.ncbi.nlm.nih.gov/pubmed/22547598
8167,27870570,"Activating NOTCH1 Mutations Define a Distinct Subgroup of Patients With Adenoid Cystic Carcinoma Who Have Poor Prognosis, Propensity to Bone and Liver Metastasis, and Potential Responsiveness to Notch1 Inhibitors.",http://www.ncbi.nlm.nih.gov/pubmed/27870570
8168,28215400,Somatic Mutations in TSC1 and TSC2 Cause Focal Cortical Dysplasia.,http://www.ncbi.nlm.nih.gov/pubmed/28215400
8169,28126962,"Safety and efficacy of abexinostat, a pan-histone deacetylase inhibitor, in non-Hodgkin lymphoma and chronic lymphocytic leukemia: results of a phase II study.",http://www.ncbi.nlm.nih.gov/pubmed/28126962
8170,17909066,Definition of functionally important mechanistic differences among selective estrogen receptor down-regulators.,http://www.ncbi.nlm.nih.gov/pubmed/17909066
8171,8142294,"RU 58,668, a new pure antiestrogen inducing a regression of human mammary carcinoma implanted in nude mice.",http://www.ncbi.nlm.nih.gov/pubmed/8142294
8172,27188390,"Combinatorial Study of a Novel Poly (ADP-ribose) Polymerase Inhibitor and an HDAC Inhibitor, SAHA, in Leukemic Cell Lines.",http://www.ncbi.nlm.nih.gov/pubmed/27188390
8173,28228601,Loss of tumor suppressor KDM6A amplifies PRC2-regulated transcriptional repression in bladder cancer and can be targeted through inhibition of EZH2.,http://www.ncbi.nlm.nih.gov/pubmed/28228601
8174,28169392,Afatinib versus gefitinib in patients with EGFR mutation-positive advanced non-small-cell lung cancer: overall survival data from the phase IIb LUX-Lung 7 trial.,http://www.ncbi.nlm.nih.gov/pubmed/28169392
8175,24382590,"Exome sequencing reveals frequent inactivating mutations in ARID1A, ARID1B, ARID2 and ARID4A in microsatellite unstable colorectal cancer.",http://www.ncbi.nlm.nih.gov/pubmed/24382590
8176,20942669,ARID1A mutations in endometriosis-associated ovarian carcinomas.,http://www.ncbi.nlm.nih.gov/pubmed/20942669
8177,22009941,Somatic mutations in the chromatin remodeling gene ARID1A occur in several tumor types.,http://www.ncbi.nlm.nih.gov/pubmed/22009941
8178,27284491,Mutation profiles of synchronous colorectal cancers from a patient with Lynch syndrome suggest distinct oncogenic pathways.,http://www.ncbi.nlm.nih.gov/pubmed/27284491
8179,27965306,Dendritic Cell Vaccination Enhances Immune Responses and Induces Regression of HER2(pos) DCIS Independent of Route: Results of Randomized Selection Design Trial.,http://www.ncbi.nlm.nih.gov/pubmed/27965306
8180,26285240,Cancer Signature Investigation: ERBB2 (HER2)-Activating Mutation and Amplification-Positive Breast Carcinoma Mimicking Lung Primary.,http://www.ncbi.nlm.nih.gov/pubmed/26285240
8181,23334667,Genomic sequencing of meningiomas identifies oncogenic SMO and AKT1 mutations.,http://www.ncbi.nlm.nih.gov/pubmed/23334667
8182,22426987,Patients with peritoneal mesothelioma lack epidermal growth factor receptor tyrosine kinase mutations that would make them sensitive to tyrosine kinase inhibitors.,http://www.ncbi.nlm.nih.gov/pubmed/22426987
8183,21070477,Unique p53 and epidermal growth factor receptor gene mutation status in 46 pulmonary lymphoepithelioma-like carcinomas.,http://www.ncbi.nlm.nih.gov/pubmed/21070477
8184,25862146,PD-L1 is highly expressed in lung lymphoepithelioma-like carcinoma: A potential rationale for immunotherapy.,http://www.ncbi.nlm.nih.gov/pubmed/25862146
8185,24670920,Frequent mutations in chromatin-remodelling genes in pulmonary carcinoids.,http://www.ncbi.nlm.nih.gov/pubmed/24670920
8186,26456833,Myeloid Dysregulation in a Human Induced Pluripotent Stem Cell Model of PTPN11-Associated Juvenile Myelomonocytic Leukemia.,http://www.ncbi.nlm.nih.gov/pubmed/26456833
8187,17053061,PTPN11 is the first identified proto-oncogene that encodes a tyrosine phosphatase.,http://www.ncbi.nlm.nih.gov/pubmed/17053061
8188,18701506,Mutation of genes affecting the RAS pathway is common in childhood acute lymphoblastic leukemia.,http://www.ncbi.nlm.nih.gov/pubmed/18701506
8189,26817465,Mutation Spectrum and Phenotypic Features in Noonan Syndrome with PTPN11 Mutations: Definition of Two Novel Mutations.,http://www.ncbi.nlm.nih.gov/pubmed/26817465
8190,16518851,Mutations of the PTPN11 and RAS genes in rhabdomyosarcoma and pediatric hematological malignancies.,http://www.ncbi.nlm.nih.gov/pubmed/16518851
8191,17575133,"Patterns of EGFR, HER2, TP53, and KRAS mutations of p14arf expression in non-small cell lung cancers in relation to smoking history.",http://www.ncbi.nlm.nih.gov/pubmed/17575133
8192,25521408,Two cases of non-small-cell lung cancer with rare complex mutation of EGFR exon 18 but different response to targeted therapy.,http://www.ncbi.nlm.nih.gov/pubmed/25521408
8193,26046796,"Erlotinib is effective in pancreatic cancer with epidermal growth factor receptor mutations: a randomized, open-label, prospective trial.",http://www.ncbi.nlm.nih.gov/pubmed/26046796
8194,16324836,Low incidence of mutations in EGFR kinase domain in Caucasian patients with head and neck squamous cell carcinoma.,http://www.ncbi.nlm.nih.gov/pubmed/16324836
8195,22885469,Lapatinib and potential prognostic value of EGFR mutations in a Gynecologic Oncology Group phase II trial of persistent or recurrent endometrial cancer.,http://www.ncbi.nlm.nih.gov/pubmed/22885469
8196,20881644,Somatic mutations in epidermal growth factor receptor signaling pathway genes in non-small cell lung cancers.,http://www.ncbi.nlm.nih.gov/pubmed/20881644
8197,23945384,Association of exon 19 and 21 EGFR mutation patterns with treatment outcome after first-line tyrosine kinase inhibitor in metastatic non-small-cell lung cancer.,http://www.ncbi.nlm.nih.gov/pubmed/23945384
8198,26980768,Enhanced Histone Deacetylase Activity in Malignant Melanoma Provokes RAD51 and FANCD2-Triggered Drug Resistance.,http://www.ncbi.nlm.nih.gov/pubmed/26980768
8199,18676761,Lung cancer with epidermal growth factor receptor exon 20 mutations is associated with poor gefitinib treatment response.,http://www.ncbi.nlm.nih.gov/pubmed/18676761
8200,26923333,Screening for major driver oncogene alterations in adenosquamous lung carcinoma using PCR coupled with next-generation and Sanger sequencing methods.,http://www.ncbi.nlm.nih.gov/pubmed/26923333
8201,21610522,Detection of epithelial growth factor receptor mutations in cerebrospinal fluid from patients with lung adenocarcinoma suspected of neoplastic meningitis.,http://www.ncbi.nlm.nih.gov/pubmed/21610522
8202,18000506,'Classical' but not 'other' mutations of EGFR kinase domain are associated with clinical outcome in gefitinib-treated patients with non-small cell lung cancer.,http://www.ncbi.nlm.nih.gov/pubmed/18000506
8203,25625926,Clinical trials of dendritic cell-based cancer vaccines in hematologic malignancies.,http://www.ncbi.nlm.nih.gov/pubmed/25625926
8204,,Clinical Trial Evaluating DC/AML Fusion Cell Vaccination In AML Patients,http://www.bloodjournal.org/content/122/21/3928?sso-checked=true
8205,11161377,INI1 mutations in meningiomas at a potential hotspot in exon 9.,http://www.ncbi.nlm.nih.gov/pubmed/11161377
8206,16014883,Erlotinib in lung cancer - molecular and clinical predictors of outcome.,http://www.ncbi.nlm.nih.gov/pubmed/16014883
8207,23244191,Epidermal growth factor receptor (EGFR) mutations and expression in squamous cell carcinoma of the esophagus in central Asia.,http://www.ncbi.nlm.nih.gov/pubmed/23244191
8208,27895798,Exploring the impact of EGFR T790M neighboring SNPs on ARMS-based T790M mutation assay.,http://www.ncbi.nlm.nih.gov/pubmed/27895798
8209,27131295,A Triple Rare E709K and L833V/H835L EGFR Mutation Responsive to an Irreversible Pan-HER Inhibitor: A Case Report of Lung Adenocarcinoma Treated with Afatinib.,http://www.ncbi.nlm.nih.gov/pubmed/27131295
8210,19258443,Ligand-dependent Notch signaling is involved in tumor initiation and tumor maintenance in pancreatic cancer.,http://www.ncbi.nlm.nih.gov/pubmed/19258443
8211,18322257,In vitro validation of gamma-secretase inhibitors alone or in combination with other anti-cancer drugs for the treatment of T-cell acute lymphoblastic leukemia.,http://www.ncbi.nlm.nih.gov/pubmed/18322257
8212,23295735,NOTCH1 mutations identify a genetic subgroup of chronic lymphocytic leukemia patients with high risk of transformation and poor outcome.,http://www.ncbi.nlm.nih.gov/pubmed/23295735
8213,25633867,"Cleaved NOTCH1 Expression Pattern in Head and Neck Squamous Cell Carcinoma Is Associated with NOTCH1 Mutation, HPV Status, and High-Risk Features.",http://www.ncbi.nlm.nih.gov/pubmed/25633867
8214,15866548,The breakpoint cluster region gene on chromosome 22q11 is associated with bipolar disorder.,http://www.ncbi.nlm.nih.gov/pubmed/15866548
8215,,,http://www.bloodjournal.org/content/126/23/4994
8216,26648538,Age-related mutations and chronic myelomonocytic leukemia.,http://www.ncbi.nlm.nih.gov/pubmed/26648538
8217,21670202,Analysis of the chronic lymphocytic leukemia coding genome: role of NOTCH1 mutational activation.,http://www.ncbi.nlm.nih.gov/pubmed/21670202
8218,19631984,T-cell lymphoblastic leukemia in early childhood presents NOTCH1 mutations and MLL rearrangements.,http://www.ncbi.nlm.nih.gov/pubmed/19631984
8219,27127180,Bone marrow fibrosis in myelodysplastic syndromes: a prospective evaluation including mutational analysis.,http://www.ncbi.nlm.nih.gov/pubmed/27127180
8220,26034076,Elevated level of serum carbohydrate antigen 19.9 as predictor of mortality in patients with advanced medullary thyroid cancer.,http://www.ncbi.nlm.nih.gov/pubmed/26034076
8221,28072762,Giving AXL the axe: targeting AXL in human malignancy.,http://www.ncbi.nlm.nih.gov/pubmed/28072762
8222,28251492,Key Roles of AXL and MER Receptor Tyrosine Kinases in Resistance to Multiple Anticancer Therapies.,http://www.ncbi.nlm.nih.gov/pubmed/28251492
8223,28233309,A histone deacetylase inhibitor enhances expression of genes inhibiting Wnt pathway and augments activity of DNA demethylation reagent against nonsmall-cell lung cancer.,http://www.ncbi.nlm.nih.gov/pubmed/28233309
8224,28134290,"A novel HDAC inhibitor, CG200745, inhibits pancreatic cancer cell growth and overcomes gemcitabine resistance.",http://www.ncbi.nlm.nih.gov/pubmed/28134290
8225,25781604,Epigenetic modulation with HDAC inhibitor CG200745 induces anti-proliferation in non-small cell lung cancer cells.,http://www.ncbi.nlm.nih.gov/pubmed/25781604
8226,26970307,Pre-clinical assessment of A-674563 as an anti-melanoma agent.,http://www.ncbi.nlm.nih.gov/pubmed/26970307
8227,,PTEN loss as a predictive biomarker for the Akt inhibitor ipatasertib combined with abiraterone acetate in patients with metastatic castration-resistant prostate cancer (mCRPC),https://academic.oup.com/annonc/article/27/suppl_6/718O/2799456/PTEN-loss-as-a-predictive-biomarker-for-the-Akt
8228,25852060,Effective Targeting of Estrogen Receptor-Negative Breast Cancers with the Protein Kinase D Inhibitor CRT0066101.,http://www.ncbi.nlm.nih.gov/pubmed/25852060
8229,18497959,CI-994 (N-acetyl-dinaline) in combination with conventional anti-cancer agents is effective against acute myeloid leukemia in vitro and in vivo.,http://www.ncbi.nlm.nih.gov/pubmed/18497959
8230,16391874,Histone deacetylase inhibitors: a novel target of anticancer therapy (review).,http://www.ncbi.nlm.nih.gov/pubmed/16391874
8231,15641487,Phase I study of oral CI-994 in combination with carboplatin and paclitaxel in the treatment of patients with advanced solid tumors.,http://www.ncbi.nlm.nih.gov/pubmed/15641487
8232,26140595,A Synergistic Interaction between Chk1- and MK2 Inhibitors in KRAS-Mutant Cancer.,http://www.ncbi.nlm.nih.gov/pubmed/26140595
8233,16641168,"Gemcitabine plus CI-994 offers no advantage over gemcitabine alone in the treatment of patients with advanced pancreatic cancer: results of a phase II randomized, double-blind, placebo-controlled, multicenter study.",http://www.ncbi.nlm.nih.gov/pubmed/16641168
8234,26469692,"Targeting AKT1-E17K and the PI3K/AKT Pathway with an Allosteric AKT Inhibitor, ARQ 092.",http://www.ncbi.nlm.nih.gov/pubmed/26469692
8235,10205261,Comprehensive mutation analysis of TSC1 and TSC2-and phenotypic correlations in 150 families with tuberous sclerosis.,http://www.ncbi.nlm.nih.gov/pubmed/10205261
8236,20053768,Selective inhibition of histone deacetylases sensitizes malignant cells to death receptor ligands.,http://www.ncbi.nlm.nih.gov/pubmed/20053768
8237,26947884,"Droxinostat, a Histone Deacetylase Inhibitor, Induces Apoptosis in Hepatocellular Carcinoma Cell Lines via Activation of the Mitochondrial Pathway and Downregulation of FLIP.",http://www.ncbi.nlm.nih.gov/pubmed/26947884
8238,17230517,Inhibitors of histone deacetylases as potential therapeutic tools for high-risk embryonal tumors of the nervous system of childhood.,http://www.ncbi.nlm.nih.gov/pubmed/17230517
8239,26848524,"Inhibiting receptor tyrosine kinase AXL with small molecule inhibitor BMS-777607 reduces glioblastoma growth, migration, and invasion in vitro and in vivo.",http://www.ncbi.nlm.nih.gov/pubmed/26848524
8240,,"A first-in-patient phase I study of BGB324, a selective Axl kinase inhibitor in patients with refractory/relapsed AML and high-risk MDS.",http://meetinglibrary.asco.org/content/170403-176
8241,25520806,"PCI-24781 (abexinostat), a novel histone deacetylase inhibitor, induces reactive oxygen species-dependent apoptosis and is synergistic with bortezomib in neuroblastoma.",http://www.ncbi.nlm.nih.gov/pubmed/25520806
8242,16731764,CRA-024781: a novel synthetic inhibitor of histone deacetylase enzymes with antitumor activity in vitro and in vivo.,http://www.ncbi.nlm.nih.gov/pubmed/16731764
8243,22262760,"Preclinical activity, pharmacodynamic, and pharmacokinetic properties of a selective HDAC6 inhibitor, ACY-1215, in combination with bortezomib in multiple myeloma.",http://www.ncbi.nlm.nih.gov/pubmed/22262760
8244,27926524,Selective HDAC inhibition by ACY-241 enhances the activity of paclitaxel in solid tumor models.,http://www.ncbi.nlm.nih.gov/pubmed/27926524
8245,28264055,"Enhancement of pomalidomide anti-tumor response with ACY-241, a selective HDAC6 inhibitor.",http://www.ncbi.nlm.nih.gov/pubmed/28264055
8246,16928830,"Activity of PXD101, a histone deacetylase inhibitor, in preclinical ovarian cancer studies.",http://www.ncbi.nlm.nih.gov/pubmed/16928830
8247,17935615,The histone deacetylase inhibitor belinostat (PXD101) suppresses bladder cancer cell growth in vitro and in vivo.,http://www.ncbi.nlm.nih.gov/pubmed/17935615
8248,12939461,Pharmacodynamic response and inhibition of growth of human tumor xenografts by the novel histone deacetylase inhibitor PXD101.,http://www.ncbi.nlm.nih.gov/pubmed/12939461
8249,22730114,Sirtuin activators and inhibitors.,http://www.ncbi.nlm.nih.gov/pubmed/22730114
8250,23339189,Antitumor effect of SIRT1 inhibition in human HCC tumor models in vitro and in vivo.,http://www.ncbi.nlm.nih.gov/pubmed/23339189
8251,23265383,The mitochondrial and autosomal mutation landscapes of prostate cancer.,http://www.ncbi.nlm.nih.gov/pubmed/23265383
8252,19948058,GLI1 genotypes do not predict basal cell carcinoma risk: a case control study.,http://www.ncbi.nlm.nih.gov/pubmed/19948058
8253,20016485,A comprehensive catalogue of somatic mutations from a human cancer genome.,http://www.ncbi.nlm.nih.gov/pubmed/20016485
8254,,Whole-Exome Sequencing in Korean Children with Acute Lymphoblastic Leukemia,http://www.bloodjournal.org/content/126/23/4994?sso-checked=true
8255,17383217,"MS-275, a potent orally available inhibitor of histone deacetylases--the development of an anticancer agent.",http://www.ncbi.nlm.nih.gov/pubmed/17383217
8256,19724929,"Efficacy of MS-275, a selective inhibitor of class I histone deacetylases, in human colon cancer models.",http://www.ncbi.nlm.nih.gov/pubmed/19724929
8257,22928010,"Anticancer activity of MPT0E028, a novel potent histone deacetylase inhibitor, in human colorectal cancer HCT116 cells in vitro and in vivo.",http://www.ncbi.nlm.nih.gov/pubmed/22928010
8258,19671764,The HDAC inhibitor panobinostat (LBH589) inhibits mesothelioma and lung cancer cells in vitro and in vivo with particular efficacy for small cell lung cancer.,http://www.ncbi.nlm.nih.gov/pubmed/19671764
8259,27802904,Panobinostat induces apoptosis via production of reactive oxygen species and synergizes with topoisomerase inhibitors in cervical cancer cells.,http://www.ncbi.nlm.nih.gov/pubmed/27802904
8260,18349321,"The novel histone deacetylase inhibitor, LBH589, induces expression of DNA damage response genes and apoptosis in Ph- acute lymphoblastic leukemia cells.",http://www.ncbi.nlm.nih.gov/pubmed/18349321
8261,20197387,"SB939, a novel potent and orally active histone deacetylase inhibitor with high tumor exposure and efficacy in mouse models of colorectal cancer.",http://www.ncbi.nlm.nih.gov/pubmed/20197387
8262,12208741,FK228 (depsipeptide) as a natural prodrug that inhibits class I histone deacetylases.,http://www.ncbi.nlm.nih.gov/pubmed/12208741
8263,21258344,Chemoproteomics profiling of HDAC inhibitors reveals selective targeting of HDAC complexes.,http://www.ncbi.nlm.nih.gov/pubmed/21258344
8264,12234611,"Effects of FK228, a novel histone deacetylase inhibitor, on human lymphoma U-937 cells in vitro and in vivo.",http://www.ncbi.nlm.nih.gov/pubmed/12234611
8265,25075128,"The novel AKT inhibitor afuresertib shows favorable safety, pharmacokinetics, and clinical activity in multiple myeloma.",http://www.ncbi.nlm.nih.gov/pubmed/25075128
8266,24015967,Discovery of epigenetic regulator I-BET762: lead optimization to afford a clinical candidate inhibitor of the BET bromodomains.,http://www.ncbi.nlm.nih.gov/pubmed/24015967
8267,22158273,Differential response of cancer cells to HDAC inhibitors trichostatin A and depsipeptide.,http://www.ncbi.nlm.nih.gov/pubmed/22158273
8268,16418332,"Perifosine, an oral bioactive novel alkylphospholipid, inhibits Akt and induces in vitro and in vivo cytotoxicity in human multiple myeloma cells.",http://www.ncbi.nlm.nih.gov/pubmed/16418332
8269,11742974,Valproic acid defines a novel class of HDAC inhibitors inducing differentiation of transformed cells.,http://www.ncbi.nlm.nih.gov/pubmed/11742974
8270,14978230,Valproic acid inhibits angiogenesis in vitro and in vivo.,http://www.ncbi.nlm.nih.gov/pubmed/14978230
8271,11731433,The histone deacetylase inhibitor suberoylanilide hydroxamic acid induces differentiation of human breast cancer cells.,http://www.ncbi.nlm.nih.gov/pubmed/11731433
8272,11016644,"Suberoylanilide hydroxamic acid, an inhibitor of histone deacetylase, suppresses the growth of prostate cancer cells in vitro and in vivo.",http://www.ncbi.nlm.nih.gov/pubmed/11016644
8273,9501205,A class of hybrid polar inducers of transformed cell differentiation inhibits histone deacetylases.,http://www.ncbi.nlm.nih.gov/pubmed/9501205
8274,18483379,Evaluation of the in vitro and in vivo antitumor activity of histone deacetylase inhibitors for the therapy of retinoblastoma.,http://www.ncbi.nlm.nih.gov/pubmed/18483379
8275,23498719,"Characterisation of retinoblastomas without RB1 mutations: genomic, gene expression, and clinical studies.",http://www.ncbi.nlm.nih.gov/pubmed/23498719
8276,21097718,Genetic and structural variation in the gastric cancer kinome revealed through targeted deep sequencing.,http://www.ncbi.nlm.nih.gov/pubmed/21097718
8277,26552419,"Combined Microsatellite Instability, MLH1 Methylation Analysis, and Immunohistochemistry for Lynch Syndrome Screening in Endometrial Cancers From GOG210: An NRG Oncology and Gynecologic Oncology Group Study.",http://www.ncbi.nlm.nih.gov/pubmed/26552419
8278,258555360,,http://www.ncbi.nlm.nih.gov/pubmed/258555360
8279,28166211,Divergent effects of intrinsically active MEK variants on developmental Ras signaling.,http://www.ncbi.nlm.nih.gov/pubmed/28166211
8280,25078279,Novel MSH6 mutations in treatment-naïve glioblastoma and anaplastic oligodendroglioma contribute to temozolomide resistance independently of MGMT promoter methylation.,http://www.ncbi.nlm.nih.gov/pubmed/25078279
8281,12732731,Prevalence of defective DNA mismatch repair and MSH6 mutation in an unselected series of endometrial cancers.,http://www.ncbi.nlm.nih.gov/pubmed/12732731
8282,22814321,MSH6 mutation in a family affected by Muir-Torre syndrome.,http://www.ncbi.nlm.nih.gov/pubmed/22814321
8283,16940983,MSH6 germline mutations in early-onset colorectal cancer patients without family history of the disease.,http://www.ncbi.nlm.nih.gov/pubmed/16940983
8284,16270383,Low prevalence of germline hMSH6 mutations in colorectal cancer families from Spain.,http://www.ncbi.nlm.nih.gov/pubmed/16270383
8285,24491297,"In vitro screening of embryos by whole-genome sequencing: now, in the future or never?",http://www.ncbi.nlm.nih.gov/pubmed/24491297
8286,16021471,DNA sequencing of CREBBP demonstrates mutations in 56% of patients with Rubinstein-Taybi syndrome (RSTS) and in another patient with incomplete RSTS.,http://www.ncbi.nlm.nih.gov/pubmed/16021471
8287,23770606,Frequent mutation of the major cartilage collagen gene COL2A1 in chondrosarcoma.,http://www.ncbi.nlm.nih.gov/pubmed/23770606
8288,2183888,The pattern of mutational involvement of RAS genes in human hematologic malignancies determined by DNA amplification and direct sequencing.,http://www.ncbi.nlm.nih.gov/pubmed/2183888
8289,22261812,Sunitinib therapy for melanoma patients with KIT mutations.,http://www.ncbi.nlm.nih.gov/pubmed/22261812
8290,19657110,Recurring mutations found by sequencing an acute myeloid leukemia genome.,http://www.ncbi.nlm.nih.gov/pubmed/19657110
8291,22177731,"Needle core biopsies provide ample material for genomic and proteomic studies of kidney cancer: observations on DNA, RNA, protein extractions and VHL mutation detection.",http://www.ncbi.nlm.nih.gov/pubmed/22177731
8292,17102087,Germline mutation of von Hippel-Lindau (VHL) gene 695 G>A (R161Q) in a patient with a peculiar phenotype with type 2C VHL syndrome.,http://www.ncbi.nlm.nih.gov/pubmed/17102087
8293,14767570,A variety of phenotype with R161Q germline mutation of the von Hippel-Lindau tumor suppressor gene in Japanese kindred.,http://www.ncbi.nlm.nih.gov/pubmed/14767570
8294,23842656,p.N78S and p.R161Q germline mutations of the VHL gene are present in von Hippel-Lindau syndrome in two pedigrees.,http://www.ncbi.nlm.nih.gov/pubmed/23842656
8295,15128949,Rational design and characterization of a Rac GTPase-specific small molecule inhibitor.,http://www.ncbi.nlm.nih.gov/pubmed/15128949
8296,20515940,"Blockade of Rac1 activity induces G1 cell cycle arrest or apoptosis in breast cancer cells through downregulation of cyclin D1, survivin, and X-linked inhibitor of apoptosis protein.",http://www.ncbi.nlm.nih.gov/pubmed/20515940
8297,26603260,Defects in the Fanconi Anemia Pathway in Head and Neck Cancer Cells Stimulate Tumor Cell Invasion through DNA-PK and Rac1 Signaling.,http://www.ncbi.nlm.nih.gov/pubmed/26603260
8298,28179366,Genome-wide chemical mutagenesis screens allow unbiased saturation of the cancer genome and identification of drug resistance mutations.,http://www.ncbi.nlm.nih.gov/pubmed/28179366
8299,28004478,"CS2164, a novel multi-target inhibitor against tumor angiogenesis, mitosis and chronic inflammation with anti-tumor potency.",http://www.ncbi.nlm.nih.gov/pubmed/28004478
8300,15906358,Efficient induction of T-cell responses to carcinoembryonic antigen by a heterologous prime-boost regimen using DNA and adenovirus vectors carrying a codon usage optimized cDNA.,http://www.ncbi.nlm.nih.gov/pubmed/15906358
8301,17053815,CD4+CD25+ regulatory T-cell-inactivation in combination with adenovirus vaccines enhances T-cell responses and protects mice from tumor challenge.,http://www.ncbi.nlm.nih.gov/pubmed/17053815
8302,22210878,Whole transcriptome sequencing reveals recurrent NOTCH1 mutations in mantle cell lymphoma.,http://www.ncbi.nlm.nih.gov/pubmed/22210878
8303,,"First-in-human study of LY3039478, an oral Notch signaling inhibitor in advanced or metastatic cancer",http://www.sciencedirect.com/science/article/pii/S0959804916326326?via%3Dihub
8304,26766589,Targeting Aberrant Epigenetic Networks Mediated by PRMT1 and KDM4C in Acute Myeloid Leukemia.,http://www.ncbi.nlm.nih.gov/pubmed/26766589
8305,,"Neoadjuvant sorafenib, gemcitabine, and cisplatin (SGC) for muscle-invasive urothelial bladder cancer (MIUBC): Final results and translational findings of an open-label, single-arm, phase II study.",http://meetinglibrary.asco.org/content/179076-197
8306,12620410,MLL-GAS7 transforms multipotent hematopoietic progenitors and induces mixed lineage leukemias in mice.,http://www.ncbi.nlm.nih.gov/pubmed/12620410
8307,,"The evaluation of INCB059872, an FAD-directed inhibitor of LSD1, in preclinical models of human small cell lung cancer",http://cancerres.aacrjournals.org/content/76/14_Supplement/4704
8308,,Combination of BET inhibitor INCB054329 and LSD1 inhibitor INCB059872 is synergistic for the treatment of AML in vitro and in vivo,http://cancerres.aacrjournals.org/content/76/14_Supplement/4702.short
8310,24446090,"The leucine twenty homeobox (LEUTX) gene, which lacks a histone acetyltransferase domain, is fused to KAT6A in therapy-related acute myeloid leukemia with t(8;19)(p11;q13).",http://www.ncbi.nlm.nih.gov/pubmed/24446090
8311,26832745,"NKTR-214, an Engineered Cytokine with Biased IL2 Receptor Binding, Increased Tumor Exposure, and Marked Efficacy in Mouse Tumor Models.",http://www.ncbi.nlm.nih.gov/pubmed/26832745
8312,,The combination of ACP-196 and ACP-319 leads to increased survival in the TCL1-192 CLL mouse model,http://cancerres.aacrjournals.org/content/76/14_Supplement/4797.short
8313,26224873,Tankyrase Inhibition Blocks Wnt/β-Catenin Pathway and Reverts Resistance to PI3K and AKT Inhibitors in the Treatment of Colorectal Cancer.,http://www.ncbi.nlm.nih.gov/pubmed/26224873
8314,27731748,Ofatumumab plus fludarabine and cyclophosphamide in relapsed chronic lymphocytic leukemia: results from the COMPLEMENT 2 trial.,http://www.ncbi.nlm.nih.gov/pubmed/27731748
8315,28275151,Antagonism of EGFR and Notch limits resistance to EGFR inhibitors and radiation by decreasing tumor-initiating cell frequency.,http://www.ncbi.nlm.nih.gov/pubmed/28275151
8316,28284557,"Binimetinib versus dacarbazine in patients with advanced NRAS-mutant melanoma (NEMO): a multicentre, open-label, randomised, phase 3 trial.",http://www.ncbi.nlm.nih.gov/pubmed/28284557
8317,27663586,AZ1366: An Inhibitor of Tankyrase and the Canonical Wnt Pathway that Limits the Persistence of Non-Small Cell Lung Cancer Cells Following EGFR Inhibition.,http://www.ncbi.nlm.nih.gov/pubmed/27663586
8318,27649555,"UNC2025, a MERTK Small-Molecule Inhibitor, Is Therapeutically Effective Alone and in Combination with Methotrexate in Leukemia Models.",http://www.ncbi.nlm.nih.gov/pubmed/27649555
8319,27490930,Inhibitor of apoptosis protein expression in glioblastomas and their in vitro and in vivo targeting by SMAC mimetic GDC-0152.,http://www.ncbi.nlm.nih.gov/pubmed/27490930
8320,15269348,Mpl Baltimore: a thrombopoietin receptor polymorphism associated with thrombocytosis.,http://www.ncbi.nlm.nih.gov/pubmed/15269348
8321,22675565,High accuracy mutation detection in leukemia on a selected panel of cancer genes.,http://www.ncbi.nlm.nih.gov/pubmed/22675565
8322,27733371,TLR Adaptor Protein MYD88 Mediates Sensitivity to HDAC Inhibitors via a Cytokine-Dependent Mechanism.,http://www.ncbi.nlm.nih.gov/pubmed/27733371
8323,23994117,Detection of MPL mutations by a novel allele-specific PCR-based strategy.,http://www.ncbi.nlm.nih.gov/pubmed/23994117
8324,25801912,Mutations and long-term outcome of 217 young patients with essential thrombocythemia or early primary myelofibrosis.,http://www.ncbi.nlm.nih.gov/pubmed/25801912
8325,20717765,Analysis of β-catenin alterations in colon tumors: a novel exon 3 mutation.,http://www.ncbi.nlm.nih.gov/pubmed/20717765
8326,24338713,The association between the ERCC1/2 polymorphisms and the clinical outcomes of the platinum-based chemotherapy in non-small cell lung cancer (NSCLC): a systematic review and meta-analysis.,http://www.ncbi.nlm.nih.gov/pubmed/24338713
8327,20627704,ERCC2 Lys751Gln polymorphism is associated with lung cancer among Caucasians.,http://www.ncbi.nlm.nih.gov/pubmed/20627704
8328,25642963,Homologous-recombination-deficient tumours are dependent on Polθ-mediated repair.,http://www.ncbi.nlm.nih.gov/pubmed/25642963
8329,14651845,EMSY links the BRCA2 pathway to sporadic breast and ovarian cancer.,http://www.ncbi.nlm.nih.gov/pubmed/14651845
8330,25483052,PP2A: more than a reset switch to activate pRB proteins during the cell cycle and in response to signaling cues.,http://www.ncbi.nlm.nih.gov/pubmed/25483052
8331,26893480,PR55α Subunit of Protein Phosphatase 2A Supports the Tumorigenic and Metastatic Potential of Pancreatic Cancer Cells by Sustaining Hyperactive Oncogenic Signaling.,http://www.ncbi.nlm.nih.gov/pubmed/26893480
8332,25879784,Altered PPP2R2A and Cyclin D1 expression defines a subgroup of aggressive luminal-like breast cancer.,http://www.ncbi.nlm.nih.gov/pubmed/25879784
8333,25537362,Identification of a Dutch founder mutation in MUSK causing fetal akinesia deformation sequence.,http://www.ncbi.nlm.nih.gov/pubmed/25537362
8334,25031321,"GPR107, a G-protein-coupled receptor essential for intoxication by Pseudomonas aeruginosa exotoxin A, localizes to the Golgi and is cleaved by furin.",http://www.ncbi.nlm.nih.gov/pubmed/25031321
8335,27258612,Transcriptome analysis of G protein-coupled receptors in distinct genetic subgroups of acute myeloid leukemia: identification of potential disease-specific targets.,http://www.ncbi.nlm.nih.gov/pubmed/27258612
8336,26753004,ALK inhibitors in non-small cell lung cancer: the latest evidence and developments.,http://www.ncbi.nlm.nih.gov/pubmed/26753004
8337,,"Phase (Ph) 1/2a study of TSR-011, a potent inhibitor of ALK and TRK, in advanced solid tumors including crizotinib-resistant ALK positive non-small cell lung cancer.",http://meetinglibrary.asco.org/content/148387-156
8338,,"TPX-0005, a novel ALK/ROS1/TRK inhibitor, effectively inhibited a broad spectrum of mutations including solvent front ALK G1202R, ROS1 G2032R and TRKA G595R mutants",http://www.ejcancer.com/article/S0959-8049%2816%2932675-2/abstract
8339,,"Phase 1 open label, dose escalation study of RXDX101, an oral pan-trk, ROS1, and ALK inhibitor, in patients with advanced solid tumors with relevant molecular alterations.",http://meetinglibrary.asco.org/content/131059-144
8340,27003761,"Discovery of Entrectinib: A New 3-Aminoindazole As a Potent Anaplastic Lymphoma Kinase (ALK), c-ros Oncogene 1 Kinase (ROS1), and Pan-Tropomyosin Receptor Kinases (Pan-TRKs) inhibitor.",http://www.ncbi.nlm.nih.gov/pubmed/27003761
8341,25466244,"P7170, a novel inhibitor of mTORC1/mTORC2 and Activin receptor-like Kinase 1 (ALK1) inhibits the growth of non small cell lung cancer.",http://www.ncbi.nlm.nih.gov/pubmed/25466244
8342,11520139,Cytoplasmic/nuclear expression without mutation of exon 3 of the beta-catenin gene is frequent in the development of the neoplasm of the uterine cervix.,http://www.ncbi.nlm.nih.gov/pubmed/11520139
8343,12824925,"Analysis of p53, K-ras, c-kit, and beta-catenin gene mutations in sinonasal NK/T cell lymphoma in northeast district of China.",http://www.ncbi.nlm.nih.gov/pubmed/12824925
8344,9515795,Mutational analysis of the APC/beta-catenin/Tcf pathway in colorectal cancer.,http://www.ncbi.nlm.nih.gov/pubmed/9515795
8345,18464243,Duplication of paternal IGF2 or loss of maternal IGF2 imprinting occurs in half of Wilms tumors with various structural WT1 abnormalities.,http://www.ncbi.nlm.nih.gov/pubmed/18464243
8346,17510384,Extensive methylation is associated with beta-catenin mutations in hepatocellular carcinoma: evidence for two distinct pathways of human hepatocarcinogenesis.,http://www.ncbi.nlm.nih.gov/pubmed/17510384
8347,25393105,Clonal architectures and driver mutations in metastatic melanomas.,http://www.ncbi.nlm.nih.gov/pubmed/25393105
8348,25859559,Clinical next generation sequencing of pediatric-type malignancies in adult patients identifies novel somatic aberrations.,http://www.ncbi.nlm.nih.gov/pubmed/25859559
8349,26822237,Diagnostic Yield of Clinical Tumor and Germline Whole-Exome Sequencing for Children With Solid Tumors.,http://www.ncbi.nlm.nih.gov/pubmed/26822237
8350,17011185,Mutational analysis of beta-catenin and the RAS-RAF signalling pathway in early flat-type colorectal tumours.,http://www.ncbi.nlm.nih.gov/pubmed/17011185
8351,27601661,Whole-exome sequencing identifies recurrent AKT1 mutations in sclerosing hemangioma of lung.,http://www.ncbi.nlm.nih.gov/pubmed/27601661
8352,23202128,Integrated genomic analyses identify ARID1A and ARID1B alterations in the childhood cancer neuroblastoma.,http://www.ncbi.nlm.nih.gov/pubmed/23202128
8353,22996659,Cis-element mutated in GATA2-dependent immunodeficiency governs hematopoiesis and vascular integrity.,http://www.ncbi.nlm.nih.gov/pubmed/22996659
8354,20657180,Multiple tumor-suppressor genes on chromosome 3p contribute to head and neck squamous cell carcinoma tumorigenesis.,http://www.ncbi.nlm.nih.gov/pubmed/20657180
8355,22473592,"Phase II study of everolimus in patients with locally advanced or metastatic transitional cell carcinoma of the urothelial tract: clinical activity, molecular response, and biomarkers.",http://www.ncbi.nlm.nih.gov/pubmed/22473592
8356,28193767,The Role of Nuclear Receptor-Binding SET Domain Family Histone Lysine Methyltransferases in Cancer.,http://www.ncbi.nlm.nih.gov/pubmed/28193767
8357,25188243,Histone methyltransferase MMSET/NSD2 alters EZH2 binding and reprograms the myeloma epigenome through global and focal changes in H3K36 and H3K27 methylation.,http://www.ncbi.nlm.nih.gov/pubmed/25188243
8358,27604143,NSD2 contributes to oncogenic RAS-driven transcription in lung cancer cells through long-range epigenetic activation.,http://www.ncbi.nlm.nih.gov/pubmed/27604143
8359,28321130,Effective combinatorial immunotherapy for castration-resistant prostate cancer.,http://www.ncbi.nlm.nih.gov/pubmed/28321130
8360,24874471,Identification of druggable cancer driver genes amplified across TCGA datasets.,http://www.ncbi.nlm.nih.gov/pubmed/24874471
8361,11193761,The role of CC10 in pulmonary carcinogenesis: from a marker to tumor suppression.,http://www.ncbi.nlm.nih.gov/pubmed/11193761
8362,20797633,"MMXD, a TFIIH-independent XPD-MMS19 protein complex involved in chromosome segregation.",http://www.ncbi.nlm.nih.gov/pubmed/20797633
8363,24609898,The function of EMSY in cancer development.,http://www.ncbi.nlm.nih.gov/pubmed/24609898
8364,27571029,Battling Btk Mutants With Noncovalent Inhibitors That Overcome Cys481 and Thr474 Mutations.,http://www.ncbi.nlm.nih.gov/pubmed/27571029
8365,20925459,"A novel conditionally replicating ""armed"" adenovirus selectively targeting gastrointestinal tumors with aberrant wnt signaling.",http://www.ncbi.nlm.nih.gov/pubmed/20925459
8366,,"ABL001, a Potent, Allosteric Inhibitor of BCR-ABL, Exhibits Safety and Promising Single- Agent Activity in a Phase I Study of Patients with CML with Failure of Prior TKI Therapy",http://www.bloodjournal.org/content/126/23/138
8367,26237138,"A Novel Covalent mTOR Inhibitor, DHM25, Shows in Vivo Antitumor Activity against Triple-Negative Breast Cancer Cells.",http://www.ncbi.nlm.nih.gov/pubmed/26237138
8368,,"A phase 1, first-time-in-human study of MEDI9197, a TLR7/8 agonist, administered intratumorally in subjects with a solid tumor cancer.",http://meetinglibrary.asco.org/content/162713-176
8369,20049837,Additional value of EGFR downstream signaling phosphoprotein expression to KRAS status for response to anti-EGFR antibodies in colorectal cancer.,http://www.ncbi.nlm.nih.gov/pubmed/20049837
8370,26832993,"Massively parallel sequencing of phyllodes tumours of the breast reveals actionable mutations, and TERT promoter hotspot mutations and TERT gene amplification as likely drivers of progression.",http://www.ncbi.nlm.nih.gov/pubmed/26832993
8371,17990317,Novel mutant-enriched sequencing identified high frequency of PIK3CA mutations in pharyngeal cancer.,http://www.ncbi.nlm.nih.gov/pubmed/17990317
8372,25054828,PIK3CA gene mutations and overexpression: implications for prognostic biomarker and therapeutic target in Chinese esophageal squamous cell carcinoma.,http://www.ncbi.nlm.nih.gov/pubmed/25054828
8373,24497998,Megalencephaly syndromes: exome pipeline strategies for detecting low-level mosaic mutations.,http://www.ncbi.nlm.nih.gov/pubmed/24497998
8374,24062397,Evaluation of PIK3CA mutation as a predictor of benefit from nonsteroidal anti-inflammatory drug therapy in colorectal cancer.,http://www.ncbi.nlm.nih.gov/pubmed/24062397
8375,23266353,PIK3CA mutational status and overall survival in patients with cervical cancer treated with radical chemoradiotherapy.,http://www.ncbi.nlm.nih.gov/pubmed/23266353
8376,17052259,PIK3CA mutation is an oncogenic aberration at advanced stages of oral squamous cell carcinoma.,http://www.ncbi.nlm.nih.gov/pubmed/17052259
8377,24982505,High prevalence of somatic MAP2K1 mutations in BRAF V600E-negative Langerhans cell histiocytosis.,http://www.ncbi.nlm.nih.gov/pubmed/24982505
8378,27511764,Development of a robust DNA quality and quantity assessment qPCR assay for targeted next-generation sequencing library preparation.,http://www.ncbi.nlm.nih.gov/pubmed/27511764
8379,27325104,Pediatric-type nodal follicular lymphoma: a biologically distinct lymphoma with frequent MAPK pathway mutations.,http://www.ncbi.nlm.nih.gov/pubmed/27325104
8380,,Activin receptor type IA in pancreatic cancer and its implications in tumor progression,http://cancerres.aacrjournals.org/content/76/24_Supplement/A43.short
8381,24886203,"Homozygous deletion of the activin A receptor, type IB gene is associated with an aggressive cancer phenotype in pancreatic cancer.",http://www.ncbi.nlm.nih.gov/pubmed/24886203
8382,28238438,ARID2 modulates DNA damage response in human hepatocellular carcinoma cells.,http://www.ncbi.nlm.nih.gov/pubmed/28238438
8383,25790038,Recurrent chromosomal gains and heterogeneous driver mutations characterise papillary renal cancer evolution.,http://www.ncbi.nlm.nih.gov/pubmed/25790038
8384,23047306,Recurrent inactivating mutations of ARID2 in non-small cell lung carcinoma.,http://www.ncbi.nlm.nih.gov/pubmed/23047306
8385,27737960,SWI/SNF regulates a transcriptional program that induces senescence to prevent liver cancer.,http://www.ncbi.nlm.nih.gov/pubmed/27737960
8386,28105368,Clinical and immunologic correlates of response to PD-1 blockade in a patient with metastatic renal medullary carcinoma.,http://www.ncbi.nlm.nih.gov/pubmed/28105368
8387,25500996,Promoter-dependent activity on androgen receptor N-terminal domain mutations in androgen insensitivity syndrome.,http://www.ncbi.nlm.nih.gov/pubmed/25500996
8388,28147341,Aurora kinases: novel therapy targets in cancers.,http://www.ncbi.nlm.nih.gov/pubmed/28147341
8389,27332895,Aurora-C Interactions with Survivin and INCENP Reveal Shared and Distinct Features Compared with Aurora-B Chromosome Passenger Protein Complex.,http://www.ncbi.nlm.nih.gov/pubmed/27332895
8390,,Vaccine Targeting HIF1a in Triple Negative Breast Cancer,http://www.ejcancer.com/article/S0959-8049(17)30164-8/abstract
8391,20039896,A novel de novo germ-line V292M mutation in the extracellular region of RET in a patient with phaeochromocytoma and medullary thyroid carcinoma: functional characterization.,http://www.ncbi.nlm.nih.gov/pubmed/20039896
8392,28276867,Pathogenesis and treatment of adult-type granulosa cell tumor of the ovary.,http://www.ncbi.nlm.nih.gov/pubmed/28276867
8393,27106102,Characterization of macrozoospermia-associated AURKC mutations in a mammalian meiotic system.,http://www.ncbi.nlm.nih.gov/pubmed/27106102
8394,23581231,Gene amplification and overexpression of Aurora-C in breast and prostate cancer cell lines.,http://www.ncbi.nlm.nih.gov/pubmed/23581231
8395,22388726,CREBBP HAT domain mutations prevail in relapse cases of high hyperdiploid childhood acute lymphoblastic leukemia.,http://www.ncbi.nlm.nih.gov/pubmed/22388726
8396,27900369,"Genomic profiling of multiple sequentially acquired tumor metastatic sites from an ""exceptional responder"" lung adenocarcinoma patient reveals extensive genomic heterogeneity and novel somatic variants driving treatment response.",http://www.ncbi.nlm.nih.gov/pubmed/27900369
8397,26577933,Emerging role of PLAG1 as a regulator of growth and reproduction.,http://www.ncbi.nlm.nih.gov/pubmed/26577933
8398,17332914,"PLAG1, the prototype of the PLAG gene family: versatility in tumour development (review).",http://www.ncbi.nlm.nih.gov/pubmed/17332914
8399,26934405,α-Smooth Muscle Actin and ACTA2 Gene Expressions in Vasculopathies.,http://www.ncbi.nlm.nih.gov/pubmed/26934405
8400,23995859,Alpha-smooth muscle actin (ACTA2) is required for metastatic potential of human lung adenocarcinoma.,http://www.ncbi.nlm.nih.gov/pubmed/23995859
8401,23605952,"Stage I of a phase 2 study assessing the efficacy, safety, and tolerability of barasertib (AZD1152) versus low-dose cytosine arabinoside in elderly patients with acute myeloid leukemia.",http://www.ncbi.nlm.nih.gov/pubmed/23605952
8402,27842521,Clinical outcomes of patients with gastrointestinal stromal tumor in phase I clinical trials.,http://www.ncbi.nlm.nih.gov/pubmed/27842521
8403,27751846,"Safety and efficacy of regorafenib in patients with advanced soft tissue sarcoma (REGOSARC): a randomised, double-blind, placebo-controlled, phase 2 trial.",http://www.ncbi.nlm.nih.gov/pubmed/27751846
8404,27932229,"Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomised, double-blind, placebo-controlled, phase 3 trial.",http://www.ncbi.nlm.nih.gov/pubmed/27932229
8405,27704266,Phase 2 study of lenvatinib in patients with advanced hepatocellular carcinoma.,http://www.ncbi.nlm.nih.gov/pubmed/27704266
8406,26813359,Phase Ib Study of PEGylated Recombinant Human Hyaluronidase and Gemcitabine in Patients with Advanced Pancreatic Cancer.,http://www.ncbi.nlm.nih.gov/pubmed/26813359
8407,25887498,A phase I study of danusertib (PHA-739358) in adult patients with accelerated or blastic phase chronic myeloid leukemia and Philadelphia chromosome-positive acute lymphoblastic leukemia resistant or intolerant to imatinib and/or other second generation c-ABL therapy.,http://www.ncbi.nlm.nih.gov/pubmed/25887498
8408,27525386,"Correlative analyses of RET and RAS mutations in a phase 3 trial of cabozantinib in patients with progressive, metastatic medullary thyroid cancer.",http://www.ncbi.nlm.nih.gov/pubmed/27525386
8409,28243117,AIM2 regulates viability and apoptosis in human colorectal cancer cells via the PI3K/Akt pathway.,http://www.ncbi.nlm.nih.gov/pubmed/28243117
8410,27167192,Loss of AIM2 expression promotes hepatocarcinoma progression through activation of mTOR-S6K1 pathway.,http://www.ncbi.nlm.nih.gov/pubmed/27167192
8411,28370201,"A phase 1 study of AMG 900, an orally administered pan-aurora kinase inhibitor, in adult patients with acute myeloid leukemia.",http://www.ncbi.nlm.nih.gov/pubmed/28370201
8412,25367255,"AMG 900, a potent inhibitor of aurora kinases causes pharmacodynamic changes in p-Histone H3 immunoreactivity in human tumor xenografts and proliferating mouse tissues.",http://www.ncbi.nlm.nih.gov/pubmed/25367255
8413,24476310,Inhibition of Aurora B by CCT137690 sensitizes colorectal cells to radiotherapy.,http://www.ncbi.nlm.nih.gov/pubmed/24476310
8414,,"Phase I, Dose-Escalation Study of 2 Dosing Regimens of AS703569, An Inhibitor of Aurora and Other Kinases, Administered Orally in Patients with Advanced Hematological Malignancies",http://www.bloodjournal.org/content/112/11/2963?sso-checked=true
8415,18026198,Enhancement of radiation response by inhibition of Aurora-A kinase using siRNA or a selective Aurora kinase inhibitor PHA680632 in p53-deficient cancer cells.,http://www.ncbi.nlm.nih.gov/pubmed/18026198
8416,27256407,Combined cisplatin and aurora inhibitor treatment increase neuroblastoma cell death but surviving cells overproduce BDNF.,http://www.ncbi.nlm.nih.gov/pubmed/27256407
8417,23099978,Effects of the Aurora kinases pan-inhibitor SNS-314 mesylate on anaplastic thyroid cancer derived cell lines.,http://www.ncbi.nlm.nih.gov/pubmed/23099978
8418,28077684,Targeting Aurora kinase A and JAK2 prevents GVHD while maintaining Treg and antitumor CTL function.,http://www.ncbi.nlm.nih.gov/pubmed/28077684
8419,6999067,Public health nutrition services: issues today and tomorrow.,http://www.ncbi.nlm.nih.gov/pubmed/6999067
8420,26999067,"An update on the pharmacokinetics and pharmacodynamics of alisertib, a selective Aurora kinase A inhibitor.",http://www.ncbi.nlm.nih.gov/pubmed/26999067
8421,21852114,"Phase I, open-label, multicentre, dose-escalation, pharmacokinetic and pharmacodynamic trial of the oral aurora kinase inhibitor PF-03814735 in advanced solid tumours.",http://www.ncbi.nlm.nih.gov/pubmed/21852114
8422,28292940,Optimizing Therapeutic Effect of Aurora B Inhibition in Acute Myeloid Leukemia with AZD2811 Nanoparticles.,http://www.ncbi.nlm.nih.gov/pubmed/28292940
8423,25078331,Next-generation sequencing of adrenocortical carcinoma reveals new routes to targeted therapies.,http://www.ncbi.nlm.nih.gov/pubmed/25078331
8424,26199132,"High proliferation index, as determined by immunohistochemical expression of Aurora kinase B and geminin, indicates poor prognosis in neuroblastomas.",http://www.ncbi.nlm.nih.gov/pubmed/26199132
8425,28103611,Phase II randomised discontinuation trial of the MET/VEGF receptor inhibitor cabozantinib in metastatic melanoma.,http://www.ncbi.nlm.nih.gov/pubmed/28103611
8426,28199818,Cabozantinib Versus Sunitinib As Initial Targeted Therapy for Patients With Metastatic Renal Cell Carcinoma of Poor or Intermediate Risk: The Alliance A031203 CABOSUN Trial.,http://www.ncbi.nlm.nih.gov/pubmed/28199818
8427,28352985,A phase Ib/II study of cabozantinib (XL184) with or without erlotinib in patients with non-small cell lung cancer.,http://www.ncbi.nlm.nih.gov/pubmed/28352985
8428,28192597,A phase 2 and biomarker study of cabozantinib in patients with advanced cholangiocarcinoma.,http://www.ncbi.nlm.nih.gov/pubmed/28192597
8429,28337527,Phase II study of the c-MET inhibitor tivantinib (ARQ 197) in patients with relapsed or relapsed/refractory multiple myeloma.,http://www.ncbi.nlm.nih.gov/pubmed/28337527
8430,27544060,Clinical Activity of Alectinib in Advanced RET-Rearranged Non-Small Cell Lung Cancer.,http://www.ncbi.nlm.nih.gov/pubmed/27544060
8431,27565911,Identification of I1171N resistance mutation in ALK-positive non-small-cell lung cancer tumor sample and circulating tumor DNA.,http://www.ncbi.nlm.nih.gov/pubmed/27565911
8432,27905678,"A phase I/II trial of AT9283, a selective inhibitor of aurora kinase in children with relapsed or refractory acute leukemia: challenges to run early phase clinical trials for children with leukemia.",http://www.ncbi.nlm.nih.gov/pubmed/27905678
8433,28034990,Phase I study of the aurora A kinase inhibitor alisertib with induction chemotherapy in patients with acute myeloid leukemia.,http://www.ncbi.nlm.nih.gov/pubmed/28034990
8434,28352668,Genomic profiling reveals mutational landscape in parathyroid carcinomas.,http://www.ncbi.nlm.nih.gov/pubmed/28352668
8435,15072829,APC mutations are infrequent but present in human lung cancer.,http://www.ncbi.nlm.nih.gov/pubmed/15072829
8436,27563066,The Lysosomal Trafficking Transmembrane Protein 106B Is Linked to Cell Death.,http://www.ncbi.nlm.nih.gov/pubmed/27563066
8437,28299358,"A novel, potentially targetable TMEM106B-BRAF fusion in pleomorphic xanthoastrocytoma.",http://www.ncbi.nlm.nih.gov/pubmed/28299358
8438,28069802,Genomic Profiling of a Large Set of Diverse Pediatric Cancers Identifies Known and Novel Mutations across Tumor Spectra.,http://www.ncbi.nlm.nih.gov/pubmed/28069802
8439,25851827,Identification of a novel TMEM106B-ROS1 fusion variant in lung adenocarcinoma by comprehensive genomic profiling.,http://www.ncbi.nlm.nih.gov/pubmed/25851827
8440,26399658,MEK1 and MEK2 inhibitors and cancer therapy: the long and winding road.,http://www.ncbi.nlm.nih.gov/pubmed/26399658
8441,26787234,Genome sequencing for nonsmall-cell lung cancer identifies a basis for nintedanib sensitivity.,http://www.ncbi.nlm.nih.gov/pubmed/26787234
8442,28259610,"Vandetanib plus gemcitabine versus placebo plus gemcitabine in locally advanced or metastatic pancreatic carcinoma (ViP): a prospective, randomised, double-blind, multicentre phase 2 trial.",http://www.ncbi.nlm.nih.gov/pubmed/28259610
8443,28161554,"Maintenance Sunitinib following Initial Platinum-Based Combination Chemotherapy in Advanced-Stage IIIB/IV Non-Small Cell Lung Cancer: A Randomized, Double-Blind, Placebo-Controlled Phase III Study-CALGB 30607 (Alliance).",http://www.ncbi.nlm.nih.gov/pubmed/28161554
8444,27712045,Systematic Analysis of Tyrosine Kinase Inhibitor Response to RET Gatekeeper Mutations in Thyroid Cancer.,http://www.ncbi.nlm.nih.gov/pubmed/27712045
8445,27751729,Genomic Biomarkers of a Randomized Trial Comparing First-line Everolimus and Sunitinib in Patients with Metastatic Renal Cell Carcinoma.,http://www.ncbi.nlm.nih.gov/pubmed/27751729
8446,19029224,Identification of tyrosine 806 as a molecular determinant of RET kinase sensitivity to ZD6474.,http://www.ncbi.nlm.nih.gov/pubmed/19029224
8447,27992451,Phase I/II Trial of Sorafenib in Combination with Vinorelbine as First-Line Chemotherapy for Metastatic Breast Cancer.,http://www.ncbi.nlm.nih.gov/pubmed/27992451
8448,26181658,Safety and Efficacy of Fedratinib in Patients With Primary or Secondary Myelofibrosis: A Randomized Clinical Trial.,http://www.ncbi.nlm.nih.gov/pubmed/26181658
8449,28285684,Dual occurrence of ALK G1202R solvent front mutation and small cell lung cancer transformation as resistance mechanisms to second generation ALK inhibitors without prior exposure to crizotinib. Pitfall of solely relying on liquid re-biopsy?,http://www.ncbi.nlm.nih.gov/pubmed/28285684
8450,27583688,"A randomized, double-blind, phase 2 trial of platinum therapy plus etoposide with or without concurrent vandetanib (ZD6474) in patients with previously untreated extensive-stage small cell lung cancer: Hoosier Cancer Research Network LUN06-113.",http://www.ncbi.nlm.nih.gov/pubmed/27583688
8451,27379749,Individualized multimodal treatment strategy for anaplastic thyroid carcinoma-Case report of long-term remission and review of literature.,http://www.ncbi.nlm.nih.gov/pubmed/27379749
8452,25351745,MAP2K1 (MEK1) Mutations Define a Distinct Subset of Lung Adenocarcinoma Associated with Smoking.,http://www.ncbi.nlm.nih.gov/pubmed/25351745
8453,27467210,Selumetinib in the treatment of non-small-cell lung cancer.,http://www.ncbi.nlm.nih.gov/pubmed/27467210
8454,26439693,"Antitumor activity of a potent MEK inhibitor, TAK-733, against colorectal cancer cell lines and patient derived xenografts.",http://www.ncbi.nlm.nih.gov/pubmed/26439693
8455,27956260,Allosteric MEK1/2 inhibitors including cobimetanib and trametinib in the treatment of cutaneous melanomas.,http://www.ncbi.nlm.nih.gov/pubmed/27956260
8456,27837257,Enhanced anti-tumour activity of the combination of the novel MEK inhibitor WX-554 and the novel PI3K inhibitor WX-037.,http://www.ncbi.nlm.nih.gov/pubmed/27837257
8457,28278718,A phase 2 trial of alisertib in patients with relapsed or refractory B-cellnon-Hodgkin lymphoma.,http://www.ncbi.nlm.nih.gov/pubmed/28278718
8458,22426462,Regulation of mTOR complex 2 signaling in neurofibromatosis 2-deficient target cell types.,http://www.ncbi.nlm.nih.gov/pubmed/22426462
8459,27993816,Final efficacy and updated safety results of the randomized phase III BEATRICE trial evaluating adjuvant bevacizumab-containing therapy in triple-negative early breast cancer.,http://www.ncbi.nlm.nih.gov/pubmed/27993816
8460,28049139,A randomized phase 2 study of MK-2206 versus everolimus in refractory renal cell carcinoma.,http://www.ncbi.nlm.nih.gov/pubmed/28049139
8461,28119295,"First-in-human phase 1 study of margetuximab (MGAH22), an Fc-modified chimeric monoclonal antibody, in patients with HER2-positive advanced solid tumors.",http://www.ncbi.nlm.nih.gov/pubmed/28119295
8462,25965831,Genetic/molecular alterations of meningiomas and the signaling pathways targeted.,http://www.ncbi.nlm.nih.gov/pubmed/25965831
8463,20368568,Phase II clinical trial of sorafenib in metastatic medullary thyroid cancer.,http://www.ncbi.nlm.nih.gov/pubmed/20368568
8464,,"Abstract A34: GDC-0980, a dual PI3K/mTOR inhibitor, selectively inhibits NF2 mutant malignant mesothelioma (MM) cells and inhibits TOR signaling without activating Akt or ERK",http://mct.aacrjournals.org/content/14/7_Supplement/A34
8465,28152546,"A phase 1 dose-escalation and expansion study of binimetinib (MEK162), a potent and selective oral MEK1/2 inhibitor.",http://www.ncbi.nlm.nih.gov/pubmed/28152546
8466,25630452,Exceptional Response on Addition of Everolimus to Taxane in Urothelial Carcinoma Bearing an NF2 Mutation.,http://www.ncbi.nlm.nih.gov/pubmed/25630452
8467,26837761,Pharmacological Inhibition of the Histone Lysine Demethylase KDM1A Suppresses the Growth of Multiple Acute Myeloid Leukemia Subtypes.,http://www.ncbi.nlm.nih.gov/pubmed/26837761
8468,26765577,"A 6-Base Pair in Frame Germline Deletion in Exon 7 Of RET Leads to Increased RET Phosphorylation, ERK Activation, and MEN2A.",http://www.ncbi.nlm.nih.gov/pubmed/26765577
8469,8626834,Mutations of the ret protooncogene in German multiple endocrine neoplasia families: relation between genotype and phenotype. German Medullary Thyroid Carcinoma Study Group.,http://www.ncbi.nlm.nih.gov/pubmed/8626834
8470,18062802,Familial prevalence and age of RET germline mutations: implications for screening.,http://www.ncbi.nlm.nih.gov/pubmed/18062802
8471,28167836,Autism-associated Dyrk1a truncation mutants impair neuronal dendritic and spine growth and interfere with postnatal cortical development.,http://www.ncbi.nlm.nih.gov/pubmed/28167836
8472,25223734,Genomic landscape of Ewing sarcoma defines an aggressive subtype with co-association of STAG2 and TP53 mutations.,http://www.ncbi.nlm.nih.gov/pubmed/25223734
8473,19109019,"Potent and selective adenosine A2A receptor antagonists: 1,2,4-Triazolo[1,5-c]pyrimidines.",http://www.ncbi.nlm.nih.gov/pubmed/19109019
8474,22676397,"Safety, tolerability and pharmacokinetics after single and multiple doses of preladenant (SCH420814) administered in healthy subjects.",http://www.ncbi.nlm.nih.gov/pubmed/22676397
8475,18631007,A new germline point mutation in Ret exon 8 (cys515ser) in a family with medullary thyroid carcinoma.,http://www.ncbi.nlm.nih.gov/pubmed/18631007
8476,16343103,Multiple endocrine neoplasia 2A due to a unique C609S RET mutation presents with pheochromocytoma and reduced penetrance of medullary thyroid carcinoma.,http://www.ncbi.nlm.nih.gov/pubmed/16343103
8477,9068588,"Rapid, nonradioactive screening for mutations in exons 10, 11, and 16 of the RET protooncogene associated with inherited medullary thyroid carcinoma.",http://www.ncbi.nlm.nih.gov/pubmed/9068588
8478,24699901,RET gene mutations (genotype and phenotype) of multiple endocrine neoplasia type 2 and familial medullary thyroid carcinoma.,http://www.ncbi.nlm.nih.gov/pubmed/24699901
8479,12734540,Cys611Ser mutation in RET proto-oncogene in a kindred with medullary thyroid carcinoma and Hirschsprung's disease.,http://www.ncbi.nlm.nih.gov/pubmed/12734540
8480,25242331,RET recognition of GDNF-GFRα1 ligand by a composite binding site promotes membrane-proximal self-association.,http://www.ncbi.nlm.nih.gov/pubmed/25242331
8481,21422198,Combined RET and Ki-67 assessment in sporadic medullary thyroid carcinoma: a useful tool for patient risk stratification.,http://www.ncbi.nlm.nih.gov/pubmed/21422198
8482,23744765,Thyroid cancer and co-occurring RET mutations in Hirschsprung disease.,http://www.ncbi.nlm.nih.gov/pubmed/23744765
8483,25163725,mTOR activation in medullary thyroid carcinoma with RAS mutation.,http://www.ncbi.nlm.nih.gov/pubmed/25163725
8484,9677065,Novel point mutation in exon 10 of the RET proto-oncogene in a family with medullary thyroid carcinoma.,http://www.ncbi.nlm.nih.gov/pubmed/9677065
8485,11331212,Presentation of a kindred with familial medullary thyroid carcinoma and Cys611Phe mutation of the RET proto-oncogene demonstrating low grade malignancy.,http://www.ncbi.nlm.nih.gov/pubmed/11331212
8486,9950371,High prevalence of the C634Y mutation in the RET proto-oncogene in MEN 2A families in Spain.,http://www.ncbi.nlm.nih.gov/pubmed/9950371
8487,27809725,Distribution of RET Mutations in Multiple Endocrine Neoplasia 2 in Denmark 1994-2014: A Nationwide Study.,http://www.ncbi.nlm.nih.gov/pubmed/27809725
8488,22199277,"Mutational screening of RET, HRAS, KRAS, NRAS, BRAF, AKT1, and CTNNB1 in medullary thyroid carcinoma.",http://www.ncbi.nlm.nih.gov/pubmed/22199277
8489,17384210,"RET proto-oncogene genotyping using unlabeled probes, the masking technique, and amplicon high-resolution melting analysis.",http://www.ncbi.nlm.nih.gov/pubmed/17384210
8490,14718397,Pyrosequencing technology as a method for the diagnosis of multiple endocrine neoplasia type 2.,http://www.ncbi.nlm.nih.gov/pubmed/14718397
8491,19401695,Correlation of RET somatic mutations with clinicopathological features in sporadic medullary thyroid carcinomas.,http://www.ncbi.nlm.nih.gov/pubmed/19401695
8492,,"Multiple endocrine neoplasia type 2A in a large family with a C620G mutation of the RET proto-oncogene: diagnostic, treatment, and ethical challenges",http://www.endocrine-abstracts.org/ea/0034/ea0034p189.htm
8493,9223675,Novel germline RET proto-oncogene mutations associated with medullary thyroid carcinoma (MTC): mutation analysis in Japanese patients with MTC.,http://www.ncbi.nlm.nih.gov/pubmed/9223675
8494,22584707,"RET haplotype, not linked to the C620R activating mutation, associated with Hirschsprung disease in a novel MEN2 family.",http://www.ncbi.nlm.nih.gov/pubmed/22584707
8495,8625130,Analysis of RET protooncogene point mutations distinguishes heritable from nonheritable medullary thyroid carcinomas.,http://www.ncbi.nlm.nih.gov/pubmed/8625130
8496,21690267,Functional characterization of the MTC-associated germline RET-K666E mutation: evidence of oncogenic potential enhanced by the G691S polymorphism.,http://www.ncbi.nlm.nih.gov/pubmed/21690267
8497,15240641,A novel point mutation of the RET protooncogene involving the second intracellular tyrosine kinase domain in a family with medullary thyroid carcinoma.,http://www.ncbi.nlm.nih.gov/pubmed/15240641
8498,17047083,RET is constitutively activated by novel tandem mutations that alter the active site resulting in multiple endocrine neoplasia type 2B.,http://www.ncbi.nlm.nih.gov/pubmed/17047083
8499,11788682,Atypical MEN type 2B associated with two germline RET mutations on the same allele not involving codon 918.,http://www.ncbi.nlm.nih.gov/pubmed/11788682
8500,19169500,Early diagnosis of multiple endocrine neoplasia type 2B: a challenge for physicians.,http://www.ncbi.nlm.nih.gov/pubmed/19169500
8501,19357306,A single amino acid change converts Aurora-A into Aurora-B-like kinase in terms of partner specificity and cellular function.,http://www.ncbi.nlm.nih.gov/pubmed/19357306
8502,26833684,The genomic landscape of cutaneous melanoma.,http://www.ncbi.nlm.nih.gov/pubmed/26833684
8503,,FANCA variants (A181V and V1287I) are overrepresented in breast tumors from women of African ancestry,http://cancerres.aacrjournals.org/content/67/9_Supplement/4255
8504,14695169,Evaluation of Fanconi Anemia genes in familial breast cancer predisposition.,http://www.ncbi.nlm.nih.gov/pubmed/14695169
8505,19012493,Common variants in immune and DNA repair genes and risk for human papillomavirus persistence and progression to cervical cancer.,http://www.ncbi.nlm.nih.gov/pubmed/19012493
8506,10094191,Heterogeneous spectrum of mutations in the Fanconi anaemia group A gene.,http://www.ncbi.nlm.nih.gov/pubmed/10094191
8507,26181256,Whole-Exome Sequencing of Metastatic Cancer and Biomarkers of Treatment Response.,http://www.ncbi.nlm.nih.gov/pubmed/26181256
8508,28263969,Activated MEK cooperates with Cdkn2a and Pten loss to promote the development and maintenance of melanoma.,http://www.ncbi.nlm.nih.gov/pubmed/28263969
8509,23284172,RAC1P29S is a spontaneously activating cancer-associated GTPase.,http://www.ncbi.nlm.nih.gov/pubmed/23284172
8510,26388441,Kinome-wide decoding of network-attacking mutations rewiring cancer signaling.,http://www.ncbi.nlm.nih.gov/pubmed/26388441
8511,24088985,Mutationally activated Rho GTPases in cancer.,http://www.ncbi.nlm.nih.gov/pubmed/24088985
8512,16204220,Interactions of UNC-34 Enabled with Rac GTPases and the NIK kinase MIG-15 in Caenorhabditis elegans axon pathfinding and neuronal migration.,http://www.ncbi.nlm.nih.gov/pubmed/16204220
8513,18680479,Phosphoregulation of human Mps1 kinase.,http://www.ncbi.nlm.nih.gov/pubmed/18680479
8514,18545697,Chromosomal instability by inefficient Mps1 auto-activation due to a weakened mitotic checkpoint and lagging chromosomes.,http://www.ncbi.nlm.nih.gov/pubmed/18545697
8515,25265012,Dynamic autophosphorylation of mps1 kinase is required for faithful mitotic progression.,http://www.ncbi.nlm.nih.gov/pubmed/25265012
8516,14744429,Rho and Rac take center stage.,http://www.ncbi.nlm.nih.gov/pubmed/14744429
8517,27991930,Rho GTPases: Anti- or pro-neoplastic targets?,http://www.ncbi.nlm.nih.gov/pubmed/27991930
8518,27633003,MPS1 kinase as a potential therapeutic target in medulloblastoma.,http://www.ncbi.nlm.nih.gov/pubmed/27633003
8519,17178827,"BBF2H7, a novel transmembrane bZIP transcription factor, is a new type of endoplasmic reticulum stress transducer.",http://www.ncbi.nlm.nih.gov/pubmed/17178827
8520,17117415,Characterization of the native CREB3L2 transcription factor and the FUS/CREB3L2 chimera.,http://www.ncbi.nlm.nih.gov/pubmed/17117415
8521,15139001,The chimeric FUS/CREB3l2 gene is specific for low-grade fibromyxoid sarcoma.,http://www.ncbi.nlm.nih.gov/pubmed/15139001
8522,27693888,"A phase I pharmacokinetic and pharmacodynamic study of the oral mitogen-activated protein kinase kinase (MEK) inhibitor, WX-554, in patients with advanced solid tumours.",http://www.ncbi.nlm.nih.gov/pubmed/27693888
8523,10373451,Cloning and characterization of a novel human phosphodiesterase that hydrolyzes both cAMP and cGMP (PDE10A).,http://www.ncbi.nlm.nih.gov/pubmed/10373451
8524,25159072,Emerging biology of PDE10A.,http://www.ncbi.nlm.nih.gov/pubmed/25159072
8525,24704829,Phosphodiesterase 10A: a novel target for selective inhibition of colon tumor cell growth and β-catenin-dependent TCF transcriptional activity.,http://www.ncbi.nlm.nih.gov/pubmed/24704829
8526,26713600,"β-catenin nuclear translocation in colorectal cancer cells is suppressed by PDE10A inhibition, cGMP elevation, and activation of PKG.",http://www.ncbi.nlm.nih.gov/pubmed/26713600
8527,27650277,"A phase I dose-escalation study of TAK-733, an investigational oral MEK inhibitor, in patients with advanced solid tumors.",http://www.ncbi.nlm.nih.gov/pubmed/27650277
8528,28377484,Phase Ib/II study of safety & efficacy of combination therapy with multikinase VEGF inhibitor Pazopanib and MEK inhibitor Trametinib in advanced soft tissue sarcoma.,http://www.ncbi.nlm.nih.gov/pubmed/28377484
8529,28178630,Combination of SL327 and Sunitinib Malate leads to an additive anti-cancer effect in doxorubicin resistant thyroid carcinoma cells.,http://www.ncbi.nlm.nih.gov/pubmed/28178630
8530,10969080,Regulation of cyclooxygenase-2 induction in the mouse uterus during decidualization. An event of early pregnancy.,http://www.ncbi.nlm.nih.gov/pubmed/10969080
8531,26666244,"A phase I study of selumetinib (AZD6244/ARRY-142866), a MEK1/2 inhibitor, in combination with cetuximab in refractory solid tumors and KRAS mutant colorectal cancer.",http://www.ncbi.nlm.nih.gov/pubmed/26666244
8532,28264648,A phase I dose-escalation study of selumetinib in combination with docetaxel or dacarbazine in patients with advanced solid tumors.,http://www.ncbi.nlm.nih.gov/pubmed/28264648
8533,28057017,"The brain-penetrating CXCR4 antagonist, PRX177561, increases the antitumor effects of bevacizumab and sunitinib in preclinical models of human glioblastoma.",http://www.ncbi.nlm.nih.gov/pubmed/28057017
8534,27978579,Effect of Selumetinib and MK-2206 vs Oxaliplatin and Fluorouracil in Patients With Metastatic Pancreatic Cancer After Prior Therapy: SWOG S1115 Study Randomized Clinical Trial.,http://www.ncbi.nlm.nih.gov/pubmed/27978579
8535,27043662,"The SMAC mimetic, LCL-161, reduces survival in aggressive MYC-driven lymphoma while promoting susceptibility to endotoxic shock.",http://www.ncbi.nlm.nih.gov/pubmed/27043662
8536,24401133,The G1057D polymorphism of insulin receptor substrate-2 associated with gestational diabetes mellitus.,http://www.ncbi.nlm.nih.gov/pubmed/24401133
8537,22653642,Novel nonsense and frameshift NTRK1 gene mutations in Chinese patients with congenital insensitivity to pain with anhidrosis.,http://www.ncbi.nlm.nih.gov/pubmed/22653642
8538,27030077,Treating cancer with selective CDK4/6 inhibitors.,http://www.ncbi.nlm.nih.gov/pubmed/27030077
8539,21910158,The CDKN2A/CDKN2B/CDK4/CCND1 pathway is pivotal in well-differentiated and dedifferentiated liposarcoma oncogenesis: an analysis of 104 tumors.,http://www.ncbi.nlm.nih.gov/pubmed/21910158
8540,25887776,Emerging EPO and EPO receptor regulators and signal transducers.,http://www.ncbi.nlm.nih.gov/pubmed/25887776
8541,14749703,Deletion and reduced expression of the Fanconi anemia FANCA gene in sporadic acute myeloid leukemia.,http://www.ncbi.nlm.nih.gov/pubmed/14749703
8542,23021409,Polymorphic variations in the FANCA gene in high-risk non-BRCA1/2 breast cancer individuals from the French Canadian population.,http://www.ncbi.nlm.nih.gov/pubmed/23021409
8543,21273304,"Origin, functional role, and clinical impact of Fanconi anemia FANCA mutations.",http://www.ncbi.nlm.nih.gov/pubmed/21273304
8544,19332049,The G1057D polymorphism of IRS-2 gene is not associated with type 2 diabetes and obese patients among ethnic groups in Tunisian population.,http://www.ncbi.nlm.nih.gov/pubmed/19332049
8545,25959789,Association of the G1057D polymorphism in insulin receptor substrate 2 gene with type 2 diabetes mellitus: a meta-analysis.,http://www.ncbi.nlm.nih.gov/pubmed/25959789
8546,28182322,Somatic cancer mutations in the MLL1 histone methyltransferase modulate its enzymatic activity and dependence on the WDR5/RBBP5/ASH2L complex.,http://www.ncbi.nlm.nih.gov/pubmed/28182322
8547,,First-In-Human Phase I Dose Escalation Study of a Humanized Anti-CD200 Antibody (Samalizumab) In Patients with Advanced Stage B Cell Chronic Lymphocytic Leukemia (B-CLL) or Multiple Myeloma (MM),http://www.bloodjournal.org/content/116/21/2465?sso-checked=true
8548,27013443,Decitabine enhances anti-CD33 monoclonal antibody BI 836858-mediated natural killer ADCC against AML blasts.,http://www.ncbi.nlm.nih.gov/pubmed/27013443
8549,26387629,Prevalence of BTK mutations in male Algerian patterns with agammaglobulinemia and severe B cell lymphopenia.,http://www.ncbi.nlm.nih.gov/pubmed/26387629
8550,10786688,HMSH6 alterations in patients with microsatellite instability-low colorectal cancer.,http://www.ncbi.nlm.nih.gov/pubmed/10786688
8551,19039656,Mutation of the BTK gene and clinical feature of X-linked agammaglobulinemia in mainland China.,http://www.ncbi.nlm.nih.gov/pubmed/19039656
8552,21765987,"Predominant RET Germline Mutations in Exons 10, 11, and 16 in Iranian Patients with Hereditary Medullary Thyroid Carcinoma.",http://www.ncbi.nlm.nih.gov/pubmed/21765987
8553,25694125,Skewed mutational spectrum of RET proto-oncogene Exon10 in Iranian patients with medullary thyroid carcinoma.,http://www.ncbi.nlm.nih.gov/pubmed/25694125
8554,16705552,Double germline mutations in the RET Proto-oncogene in MEN 2A and MEN 2B kindreds.,http://www.ncbi.nlm.nih.gov/pubmed/16705552
8555,27207748,Comprehensive Genomic Profiling of Clinically Advanced Medullary Thyroid Carcinoma.,http://www.ncbi.nlm.nih.gov/pubmed/27207748
8556,18063059,Pheochromocytoma penetrance varies by RET mutation in MEN 2A.,http://www.ncbi.nlm.nih.gov/pubmed/18063059
8557,27704398,The RET E616Q Variant is a Gain of Function Mutation Present in a Family with Features of Multiple Endocrine Neoplasia 2A.,http://www.ncbi.nlm.nih.gov/pubmed/27704398
8558,23532519,Screening of RB1 alterations in Brazilian patients with retinoblastoma and relatives with retinoma: phenotypic and genotypic associations.,http://www.ncbi.nlm.nih.gov/pubmed/23532519
8559,10486322,Temperature-sensitive RB mutations linked to incomplete penetrance of familial retinoblastoma in 12 families.,http://www.ncbi.nlm.nih.gov/pubmed/10486322
8560,22084214,Outcomes of integrating genetics in management of patients with retinoblastoma.,http://www.ncbi.nlm.nih.gov/pubmed/22084214
8561,10671068,Twelve novel RB1 gene mutations in patients with hereditary retinoblastoma. Mutations in brief no. 206. Online.,http://www.ncbi.nlm.nih.gov/pubmed/10671068
8562,22250089,Human MSH6 deficiency is associated with impaired antibody maturation.,http://www.ncbi.nlm.nih.gov/pubmed/22250089
8563,10675480,Missense mutation of the hMSH6 and p53 genes in sporadic urothelial transitional cell carcinoma.,http://www.ncbi.nlm.nih.gov/pubmed/10675480
8564,21408192,"High-content, high-throughput analysis of cell cycle perturbations induced by the HSP90 inhibitor XL888.",http://www.ncbi.nlm.nih.gov/pubmed/21408192
8565,28343545,Compound Uncommon EGFR Mutations in a Patient with Advanced NSCLC and Durable Response to Sequential EGFR Targeted Therapies.,http://www.ncbi.nlm.nih.gov/pubmed/28343545
8566,28183697,"Safety and Antitumor Activity of the Multitargeted Pan-TRK, ROS1, and ALK Inhibitor Entrectinib: Combined Results from Two Phase I Trials (ALKA-372-001 and STARTRK-1).",http://www.ncbi.nlm.nih.gov/pubmed/28183697
8567,28363995,Response Heterogeneity of EGFR and HER2 Exon 20 Insertions to Covalent EGFR and HER2 Inhibitors.,http://www.ncbi.nlm.nih.gov/pubmed/28363995
8568,21220471,"Phase I dose-escalation study of the pan-HER inhibitor, PF299804, in patients with advanced malignant solid tumors.",http://www.ncbi.nlm.nih.gov/pubmed/21220471
8569,27915408,A Phase I study of intravenous PI3K inhibitor copanlisib in Japanese patients with advanced or refractory solid tumors.,http://www.ncbi.nlm.nih.gov/pubmed/27915408
8570,28355112,Final Results of the IELSG-19 Randomized Trial of Mucosa-Associated Lymphoid Tissue Lymphoma: Improved Event-Free and Progression-Free Survival With Rituximab Plus Chlorambucil Versus Either Chlorambucil or Rituximab Monotherapy.,http://www.ncbi.nlm.nih.gov/pubmed/28355112
8571,22413011,Cadherin-23 mediates heterotypic cell-cell adhesion between breast cancer epithelial cells and fibroblasts.,http://www.ncbi.nlm.nih.gov/pubmed/22413011
8572,28268172,Evolution and diversity of cadherins and catenins.,http://www.ncbi.nlm.nih.gov/pubmed/28268172
8573,20498078,Structure of the N terminus of cadherin 23 reveals a new adhesion mechanism for a subset of cadherin superfamily members.,http://www.ncbi.nlm.nih.gov/pubmed/20498078
8574,25899785,Targeting HER2 aberrations as actionable drivers in lung cancers: phase II trial of the pan-HER tyrosine kinase inhibitor dacomitinib in patients with HER2-mutant or amplified tumors.,http://www.ncbi.nlm.nih.gov/pubmed/25899785
8575,27975152,Phase I/II Study of Refametinib (BAY 86-9766) in Combination with Gemcitabine in Advanced Pancreatic cancer.,http://www.ncbi.nlm.nih.gov/pubmed/27975152
8576,12060124,A novel inherited mutation of the transcription factor RUNX1 causes thrombocytopenia and may predispose to acute myeloid leukaemia.,http://www.ncbi.nlm.nih.gov/pubmed/12060124
8577,23831921,Targeted re-sequencing analysis of 25 genes commonly mutated in myeloid disorders in del(5q) myelodysplastic syndromes.,http://www.ncbi.nlm.nih.gov/pubmed/23831921
8578,8157004,Correction of xeroderma pigmentosum repair defect by basal transcription factor BTF2 (TFIIH).,http://www.ncbi.nlm.nih.gov/pubmed/8157004
8579,27384421,Screening of Conditionally Reprogrammed Patient-Derived Carcinoma Cells Identifies ERCC3-MYC Interactions as a Target in Pancreatic Cancer.,http://www.ncbi.nlm.nih.gov/pubmed/27384421
8580,25072962,Histone deacetylase 2 controls p53 and is a critical factor in tumorigenesis.,http://www.ncbi.nlm.nih.gov/pubmed/25072962
8581,22733740,p85β phosphoinositide 3-kinase subunit regulates tumor progression.,http://www.ncbi.nlm.nih.gov/pubmed/22733740
8582,21249429,Endothelial-specific intron-derived miR-126 is down-regulated in human breast cancer and targets both VEGFA and PIK3R2.,http://www.ncbi.nlm.nih.gov/pubmed/21249429
8583,27698796,Mechanism analysis of colorectal cancer according to the microRNA expression profile.,http://www.ncbi.nlm.nih.gov/pubmed/27698796
8584,27578985,MiR-126 regulates proliferation and invasion in the bladder cancer BLS cell line by targeting the PIK3R2-mediated PI3K/Akt signaling pathway.,http://www.ncbi.nlm.nih.gov/pubmed/27578985
8585,21673068,ERK1/2 and p38α/β signaling in tumor cell quiescence: opportunities to control dormant residual disease.,http://www.ncbi.nlm.nih.gov/pubmed/21673068
8586,25066918,MAPK11 in breast cancer cells enhances osteoclastogenesis and bone resorption.,http://www.ncbi.nlm.nih.gov/pubmed/25066918
8587,21771581,SDH mutations in cancer.,http://www.ncbi.nlm.nih.gov/pubmed/21771581
8588,24781757,SDHA mutations causing a multisystem mitochondrial disease: novel mutations and genetic overlap with hereditary tumors.,http://www.ncbi.nlm.nih.gov/pubmed/24781757
8589,20484225,SDHA is a tumor suppressor gene causing paraganglioma.,http://www.ncbi.nlm.nih.gov/pubmed/20484225
8590,23730622,Succinate dehydrogenase deficiency in pediatric and adult gastrointestinal stromal tumors.,http://www.ncbi.nlm.nih.gov/pubmed/23730622
8591,23457139,Genetic aspects of pheochromocytoma.,http://www.ncbi.nlm.nih.gov/pubmed/23457139
8592,19454582,The succinate dehydrogenase genetic testing in a large prospective series of patients with paragangliomas.,http://www.ncbi.nlm.nih.gov/pubmed/19454582
8593,17557926,Genetic screening for pheochromocytoma: should SDHC gene analysis be included?,http://www.ncbi.nlm.nih.gov/pubmed/17557926
8594,16317055,Clinical presentation and penetrance of pheochromocytoma/paraganglioma syndromes.,http://www.ncbi.nlm.nih.gov/pubmed/16317055
8595,15328326,Distinct clinical features of paraganglioma syndromes associated with SDHB and SDHD gene mutations.,http://www.ncbi.nlm.nih.gov/pubmed/15328326
8596,16269091,"RB1 gene mutation up-date, a meta-analysis based on 932 reported mutations available in a searchable database.",http://www.ncbi.nlm.nih.gov/pubmed/16269091
8597,9194486,Analysis of the Rb gene and cyclin-dependent kinase 4 inhibitor genes (p16INK4 and p15INK4B) in human ovarian carcinoma cell lines.,http://www.ncbi.nlm.nih.gov/pubmed/9194486
8598,19372580,Genetic alterations and oncogenic pathways associated with breast cancer subtypes.,http://www.ncbi.nlm.nih.gov/pubmed/19372580
8600,27350795,A novel BCR-ABL1 fusion gene identified by next-generation sequencing in chronic myeloid leukemia.,http://www.ncbi.nlm.nih.gov/pubmed/27350795
8601,26870252,"Genetic heterogeneity of RPMI-8402, a T-acute lymphoblastic leukemia cell line.",http://www.ncbi.nlm.nih.gov/pubmed/26870252
8602,26718898,"Analysis of somatic mutations in BRAF, CDKN2A/p16 and PI3KCA in patients with medullary thyroid carcinoma.",http://www.ncbi.nlm.nih.gov/pubmed/26718898
8603,19628422,Detection of two novel mutations and relatively high incidence of H-RAS mutations in Vietnamese oral cancer.,http://www.ncbi.nlm.nih.gov/pubmed/19628422
8604,25360634,Cutaneous epithelial tumors induced by vemurafenib involve the MAPK and Pi3KCA pathways but not HPV nor HPyV viral infection.,http://www.ncbi.nlm.nih.gov/pubmed/25360634
8605,26274561,Specific cancer-associated mutations in the switch III region of Ras increase tumorigenicity by nanocluster augmentation.,http://www.ncbi.nlm.nih.gov/pubmed/26274561
8606,28229982,Circulating-free DNA Mutation Associated with Response of Targeted Therapy in Human Epidermal Growth Factor Receptor 2-positive Metastatic Breast Cancer.,http://www.ncbi.nlm.nih.gov/pubmed/28229982
8607,22185227,Detection of low prevalence somatic mutations in solid tumors with ultra-deep targeted sequencing.,http://www.ncbi.nlm.nih.gov/pubmed/22185227
8608,14616967,"Alterations of RAS signalling in Chinese multiple myeloma patients: absent BRAF and rare RAS mutations, but frequent inactivation of RASSF1A by transcriptional silencing or expression of a non-functional variant transcript.",http://www.ncbi.nlm.nih.gov/pubmed/14616967
8609,24076604,Global chromatin profiling reveals NSD2 mutations in pediatric acute lymphoblastic leukemia.,http://www.ncbi.nlm.nih.gov/pubmed/24076604
8610,22099308,NSD2 links dimethylation of histone H3 at lysine 36 to oncogenic programming.,http://www.ncbi.nlm.nih.gov/pubmed/22099308
8611,24845513,The rare intracellular RET mutation p.S891A in a Chinese Han family with familial medullary thyroid carcinoma.,http://www.ncbi.nlm.nih.gov/pubmed/24845513
8612,21984973,Multiple gene dysfunctions lead to high cancer-susceptibility: evidences from a whole-exome sequencing study.,http://www.ncbi.nlm.nih.gov/pubmed/21984973
8613,28330462,Prospective phase II trial of everolimus in PIK3CA amplification/mutation and/or PTEN loss patients with advanced solid tumors refractory to standard therapy.,http://www.ncbi.nlm.nih.gov/pubmed/28330462
8614,,High Frequency of C-Terminal Frame-Shift Mutations of RUNX1 Gene in De Novo AML with Partial Tandem Duplication of MLL.,http://www.bloodjournal.org/content/114/22/3468?sso-checked=true
8615,27601506,A Retrospective Analysis of Precision Medicine Outcomes in Patients With Advanced Cancer Reveals Improved Progression-Free Survival Without Increased Health Care Costs.,http://www.ncbi.nlm.nih.gov/pubmed/27601506
8616,23705826,Cell cycle-dependent activity of the novel dual PI3K-MTORC1/2 inhibitor NVP-BGT226 in acute leukemia.,http://www.ncbi.nlm.nih.gov/pubmed/23705826
8617,27649553,Inhibition of the Nuclear Export Receptor XPO1 as a Therapeutic Target for Platinum-Resistant Ovarian Cancer.,http://www.ncbi.nlm.nih.gov/pubmed/27649553
8618,28179481,APC Mutations as a Potential Biomarker for Sensitivity to Tankyrase Inhibitors in Colorectal Cancer.,http://www.ncbi.nlm.nih.gov/pubmed/28179481
8619,16798748,Adenomatous polyposis coli (APC) differentially regulates beta-catenin phosphorylation and ubiquitination in colon cancer cells.,http://www.ncbi.nlm.nih.gov/pubmed/16798748
8620,25725622,Identification and characterization of two novel germline RET variants associated with medullary thyroid carcinoma.,http://www.ncbi.nlm.nih.gov/pubmed/25725622
8621,21834681,The RET p.G533C mutation confers predisposition to multiple endocrine neoplasia type 2A in a Brazilian kindred and is able to induce a malignant phenotype in vitro and in vivo.,http://www.ncbi.nlm.nih.gov/pubmed/21834681
8622,8807338,"Diagnosis of multiple endocrine neoplasia [MEN] 2A, 2B and familial medullary thyroid cancer [FMTC] by multiplex PCR and heteroduplex analyses of RET proto-oncogene mutations.",http://www.ncbi.nlm.nih.gov/pubmed/8807338
8623,26070072,Significant Differences in the Development of Acquired Resistance to the MDM2 Inhibitor SAR405838 between In Vitro and In Vivo Drug Treatment.,http://www.ncbi.nlm.nih.gov/pubmed/26070072
8624,8916968,p21/WAF1 cyclin-kinase inhibitor expression in non-Hodgkin's lymphomas: a potential marker of p53 tumor-suppressor gene function.,http://www.ncbi.nlm.nih.gov/pubmed/8916968
8625,12637159,ING1 and p53 tumor suppressor gene alterations in adenocarcinomas of the esophagogastric junction.,http://www.ncbi.nlm.nih.gov/pubmed/12637159
8626,27270435,Amplification of R-spondin1 signaling induces granulosa cell fate defects and cancers in mouse adult ovary.,http://www.ncbi.nlm.nih.gov/pubmed/27270435
8627,22439850,The R-spondin protein family.,http://www.ncbi.nlm.nih.gov/pubmed/22439850
8628,24894155,The expression pattern of 19 genes predicts the histology of endometrial carcinoma.,http://www.ncbi.nlm.nih.gov/pubmed/24894155
8629,19385064,Loss-of-function point mutations and two-furin domain derivatives provide insights about R-spondin2 structure and function.,http://www.ncbi.nlm.nih.gov/pubmed/19385064
8630,22158541,Exome sequencing identifies recurrent mutations of the splicing factor SF3B1 gene in chronic lymphocytic leukemia.,http://www.ncbi.nlm.nih.gov/pubmed/22158541
8631,28268064,"Combination of dabrafenib plus trametinib for BRAF and MEK inhibitor pretreated patients with advanced BRAF(V600)-mutant melanoma: an open-label, single arm, dual-centre, phase 2 clinical trial.",http://www.ncbi.nlm.nih.gov/pubmed/28268064
8632,28011619,The Natural Diterpenoid Isoforretin A Inhibits Thioredoxin-1 and Triggers Potent ROS-Mediated Antitumor Effects.,http://www.ncbi.nlm.nih.gov/pubmed/28011619
8633,28329763,The allosteric inhibitor ABL001 enables dual targeting of BCR-ABL1.,http://www.ncbi.nlm.nih.gov/pubmed/28329763
8634,21453190,"Thioredoxin 1-mediated post-translational modifications: reduction, transnitrosylation, denitrosylation, and related proteomics methodologies.",http://www.ncbi.nlm.nih.gov/pubmed/21453190
8635,21816872,LKB1 mutations frequently detected in mucinous bronchioloalveolar carcinoma.,http://www.ncbi.nlm.nih.gov/pubmed/21816872
8636,27081308,Unraveling the Deleterious Effects of Cancer-Driven STK11 Mutants Through Conformational Sampling Approach.,http://www.ncbi.nlm.nih.gov/pubmed/27081308
8637,11389158,Peutz-Jeghers families unlinked to STK11/LKB1 gene mutations are highly predisposed to primitive biliary adenocarcinoma.,http://www.ncbi.nlm.nih.gov/pubmed/11389158
8638,25234657,Tongue carcinoma infrequently harbor common actionable genetic alterations.,http://www.ncbi.nlm.nih.gov/pubmed/25234657
8639,24292813,Characterizing the heterogeneity of triple-negative breast cancers using microdissected normal ductal epithelium and RNA-sequencing.,http://www.ncbi.nlm.nih.gov/pubmed/24292813
8640,25849130,Studying clonal dynamics in response to cancer therapy using high-complexity barcoding.,http://www.ncbi.nlm.nih.gov/pubmed/25849130
8641,19573802,Gardner's syndrome (familial adenomatous polyposis): a cilia-related disorder.,http://www.ncbi.nlm.nih.gov/pubmed/19573802
8642,,"Expanded Phase 1 Study of ABL001, a Potent, Allosteric Inhibitor of BCR-ABL, Reveals Significant and Durable Responses in Patients with CML-Chronic Phase with Failure of Prior TKI Therapy",https://ash.confex.com/ash/2016/webprogram/Paper92633.html
8643,22148048,"Birt-hogg-dubé syndrome, a rare case in Korea confirmed by genetic analysis.",http://www.ncbi.nlm.nih.gov/pubmed/22148048
8644,25846551,Profiling cancer gene mutations in longitudinal epithelial ovarian cancer biopsies by targeted next-generation sequencing: a retrospective study.,http://www.ncbi.nlm.nih.gov/pubmed/25846551
8645,24058806,The tumor suppressor function of STAT1 in breast cancer.,http://www.ncbi.nlm.nih.gov/pubmed/24058806
8646,14964307,The STATs of cancer--new molecular targets come of age.,http://www.ncbi.nlm.nih.gov/pubmed/14964307
8647,12374673,Prognostic significance of signal transducer and activator of transcription 1 activation in breast cancer.,http://www.ncbi.nlm.nih.gov/pubmed/12374673
8648,24725474,High STAT1 mRNA levels but not its tyrosine phosphorylation are associated with macrophage infiltration and bad prognosis in breast cancer.,http://www.ncbi.nlm.nih.gov/pubmed/24725474
8649,24416652,STAT2 phosphorylation and signaling.,http://www.ncbi.nlm.nih.gov/pubmed/24416652
8650,22280068,The role of signal transducer and activator of transcription-2 in the interferon response.,http://www.ncbi.nlm.nih.gov/pubmed/22280068
8651,25798064,Signal transducer and activator of transcription 4 in liver diseases.,http://www.ncbi.nlm.nih.gov/pubmed/25798064
8652,28114283,An integrated analysis identifies STAT4 as a key regulator of ovarian cancer metastasis.,http://www.ncbi.nlm.nih.gov/pubmed/28114283
8653,24470978,STATs get their move on.,http://www.ncbi.nlm.nih.gov/pubmed/24470978
8654,28385737,Lack of STAT6 Attenuates Inflammation and Drives Protection against Early Steps of Colitis-Associated Colon Cancer.,http://www.ncbi.nlm.nih.gov/pubmed/28385737
8655,19935797,Absence of truncating BRIP1 mutations in chromosome 17q-linked hereditary prostate cancer families.,http://www.ncbi.nlm.nih.gov/pubmed/19935797
8656,21990299,"Association of BRCA1 and BRCA2 mutations with survival, chemotherapy sensitivity, and gene mutator phenotype in patients with ovarian cancer.",http://www.ncbi.nlm.nih.gov/pubmed/21990299
8657,14576433,The BRCT domain is a phospho-protein binding domain.,http://www.ncbi.nlm.nih.gov/pubmed/14576433
8658,24755198,A meta-analysis of somatic mutations from next generation sequencing of 241 melanomas: a road map for the study of genes with potential clinical relevance.,http://www.ncbi.nlm.nih.gov/pubmed/24755198
8659,25653542,Oncogenic mutation profiling in new lung cancer and mesothelioma cell lines.,http://www.ncbi.nlm.nih.gov/pubmed/25653542
8660,28344857,Metastatic BRAF K601E-mutated melanoma reaches complete response to MEK inhibitor trametinib administered for over 36 months.,http://www.ncbi.nlm.nih.gov/pubmed/28344857
8661,27803064,"Randomized, Placebo-Controlled, Phase II Study of Veliparib in Combination with Carboplatin and Paclitaxel for Advanced/Metastatic Non-Small Cell Lung Cancer.",http://www.ncbi.nlm.nih.gov/pubmed/27803064
8662,27265506,ARF6 Is an Actionable Node that Orchestrates Oncogenic GNAQ Signaling in Uveal Melanoma.,http://www.ncbi.nlm.nih.gov/pubmed/27265506
8663,22653968,Protein kinase C inhibitor AEB071 targets ocular melanoma harboring GNAQ mutations via effects on the PKC/Erk1/2 and PKC/NF-κB pathways.,http://www.ncbi.nlm.nih.gov/pubmed/22653968
8664,28138034,"AZD6738, A Novel Oral Inhibitor of ATR, Induces Synthetic Lethality with ATM Deficiency in Gastric Cancer Cells.",http://www.ncbi.nlm.nih.gov/pubmed/28138034
8665,25777788,Characterization of all possible single-nucleotide change caused amino acid substitutions in the kinase domain of Bruton tyrosine kinase.,http://www.ncbi.nlm.nih.gov/pubmed/25777788
8666,26091878,De novo mutations from sporadic schizophrenia cases highlight important signaling genes in an independent sample.,http://www.ncbi.nlm.nih.gov/pubmed/26091878
8667,15466623,Bruton's tyrosine kinase is essential for human B cell tolerance.,http://www.ncbi.nlm.nih.gov/pubmed/15466623
8668,9260159,Molecular and structural characterization of five novel mutations in the Bruton's tyrosine kinase gene from patients with X-linked agammaglobulinemia.,http://www.ncbi.nlm.nih.gov/pubmed/9260159
8669,26582655,Circulating tumor DNA identified by targeted sequencing in advanced-stage non-small cell lung cancer patients.,http://www.ncbi.nlm.nih.gov/pubmed/26582655
8670,9803264,A mutation screen of the TSC1 gene reveals 26 protein truncating mutations and 1 splice site mutation in a panel of 79 tuberous sclerosis patients.,http://www.ncbi.nlm.nih.gov/pubmed/9803264
8671,9328481,Molecular genetic and phenotypic analysis reveals differences between TSC1 and TSC2 associated familial and sporadic tuberous sclerosis.,http://www.ncbi.nlm.nih.gov/pubmed/9328481
8672,22515704,Antitumor effects of the investigational selective MEK inhibitor TAK733 against cutaneous and uveal melanoma cell lines.,http://www.ncbi.nlm.nih.gov/pubmed/22515704
8673,,Blocking Colony Stimulating Factor 1 Receptor (CSF-1R) and Tropomyosin Receptor Kinase (Trk) improves antitumor efficacy of immunotherapy,http://cancerimmunolres.aacrjournals.org/content/5/3_Supplement/PR01
8674,17671157,"Enzastaurin, a protein kinase Cbeta- selective inhibitor, and its potential application as an anticancer agent in lung cancer.",http://www.ncbi.nlm.nih.gov/pubmed/17671157
8675,27308390,YAP inhibition blocks uveal melanogenesis driven by GNAQ or GNA11 mutations.,http://www.ncbi.nlm.nih.gov/pubmed/27308390
8676,27683183,"RET Aberrations in Diverse Cancers: Next-Generation Sequencing of 4,871 Patients.",http://www.ncbi.nlm.nih.gov/pubmed/27683183
8677,22550165,"Identification of unique MEK-dependent genes in GNAQ mutant uveal melanoma involved in cell growth, tumor cell invasion, and MEK resistance.",http://www.ncbi.nlm.nih.gov/pubmed/22550165
8678,24938562,Effect of selumetinib vs chemotherapy on progression-free survival in uveal melanoma: a randomized clinical trial.,http://www.ncbi.nlm.nih.gov/pubmed/24938562
8679,25113308,Biology of advanced uveal melanoma and next steps for clinical therapeutics.,http://www.ncbi.nlm.nih.gov/pubmed/25113308
8680,27166257,Minimal contribution of ERK1/2-MAPK signalling towards the maintenance of oncogenic GNAQQ209P-driven uveal melanomas in zebrafish.,http://www.ncbi.nlm.nih.gov/pubmed/27166257
8681,27803065,"A First-in-Human Phase I Study of a Bivalent MET Antibody, Emibetuzumab (LY2875358), as Monotherapy and in Combination with Erlotinib in Advanced Cancer.",http://www.ncbi.nlm.nih.gov/pubmed/27803065
8682,28289658,"Expressions and Clinical Significances of Angiopoietin-1, Angiopoietin-2, and Tie-2 Receptor in Patients With Colorectal Cancer.",http://www.ncbi.nlm.nih.gov/pubmed/28289658
8683,28062977,Angiopoietin pathway gene expression associated with poor breast cancer survival.,http://www.ncbi.nlm.nih.gov/pubmed/28062977
8684,21723852,The adaptor Lnk (SH2B3): an emerging regulator in vascular cells and a link between immune and inflammatory signaling.,http://www.ncbi.nlm.nih.gov/pubmed/21723852
8685,23908464,Genetic loss of SH2B3 in acute lymphoblastic leukemia.,http://www.ncbi.nlm.nih.gov/pubmed/23908464
8686,26522763,Mutational analysis of SH2B3 in Korean patients with BCR-ABL1 negative myeloproliferative neoplasm.,http://www.ncbi.nlm.nih.gov/pubmed/26522763
8687,24704825,LNK (SH2B3): paradoxical effects in ovarian cancer.,http://www.ncbi.nlm.nih.gov/pubmed/24704825
8688,24190998,Molecular determinants of PI3Kγ-mediated activation downstream of G-protein-coupled receptors (GPCRs).,http://www.ncbi.nlm.nih.gov/pubmed/24190998
8689,22912864,Novel somatic mutations to PI3K pathway genes in metastatic melanoma.,http://www.ncbi.nlm.nih.gov/pubmed/22912864
8690,25116689,Localization of MLH3 at the centrosomes.,http://www.ncbi.nlm.nih.gov/pubmed/25116689
8691,24759751,Mismatch repair gene MLH3 Pro844Leu and Thr942Ile polymorphisms and the susceptibility to cervical carcinoma and HPV infection: a case-control study in a Chinese population.,http://www.ncbi.nlm.nih.gov/pubmed/24759751
8692,8128956,Mutation analysis of the Fanconi anemia gene FACC.,http://www.ncbi.nlm.nih.gov/pubmed/8128956
8693,15277238,Functional defects in the fanconi anemia pathway in pancreatic cancer cells.,http://www.ncbi.nlm.nih.gov/pubmed/15277238
8694,27823983,Genomic profiling is predictive of response to cisplatin treatment but not to PI3K inhibition in bladder cancer patient-derived xenografts.,http://www.ncbi.nlm.nih.gov/pubmed/27823983
8695,28273450,ATR Mutations Promote the Growth of Melanoma Tumors by Modulating the Immune Microenvironment.,http://www.ncbi.nlm.nih.gov/pubmed/28273450
8696,26192917,Exome sequencing identifies somatic mutations of DDX3X in natural killer/T-cell lymphoma.,http://www.ncbi.nlm.nih.gov/pubmed/26192917
8697,22733540,Combination small molecule MEK and PI3K inhibition enhances uveal melanoma cell death in a mutant GNAQ- and GNA11-dependent manner.,http://www.ncbi.nlm.nih.gov/pubmed/22733540
8698,27638506,Brain Distribution and Efficacy of the Brain Penetrant PI3K Inhibitor GDC-0084 in Orthotopic Mouse Models of Human Glioblastoma.,http://www.ncbi.nlm.nih.gov/pubmed/27638506
8699,19584227,"Biological properties of potent inhibitors of class I phosphatidylinositide 3-kinases: from PI-103 through PI-540, PI-620 to the oral agent GDC-0941.",http://www.ncbi.nlm.nih.gov/pubmed/19584227
8700,10700188,Mutations truncating the EP300 acetylase in human cancers.,http://www.ncbi.nlm.nih.gov/pubmed/10700188
8701,11807987,Somatic mutation of vascular endothelial growth factor receptors in juvenile hemangioma.,http://www.ncbi.nlm.nih.gov/pubmed/11807987
8702,19078957,Frequent somatic mutations of GNAQ in uveal melanoma and blue naevi.,http://www.ncbi.nlm.nih.gov/pubmed/19078957
8703,12149228,ATM mutations are associated with inactivation of the ARF-TP53 tumor suppressor pathway in diffuse large B-cell lymphoma.,http://www.ncbi.nlm.nih.gov/pubmed/12149228
8704,23091097,Biallelic ATM inactivation significantly reduces survival in patients treated on the United Kingdom Leukemia Research Fund Chronic Lymphocytic Leukemia 4 trial.,http://www.ncbi.nlm.nih.gov/pubmed/23091097
8705,8844212,Novel mutations and polymorphisms in the Fanconi anemia group C gene.,http://www.ncbi.nlm.nih.gov/pubmed/8844212
8706,,Regulated Expression of a FANCL Splicing Variant as a Potential Modifier of DNA Repair Activity,https://www.omicsonline.org/regulated-expression-of-a-fancl-splicing-variant-as-a-potential-modifier-of-dna-repair-activity-2157-7412.1000143.php?aid=15560
8707,28139405,"Idelalisib or placebo in combination with bendamustine and rituximab in patients with relapsed or refractory chronic lymphocytic leukaemia: interim results from a phase 3, randomised, double-blind, placebo-controlled trial.",http://www.ncbi.nlm.nih.gov/pubmed/28139405
8708,28355115,"Complete Hematologic and Molecular Response in Adult Patients With Relapsed/Refractory Philadelphia Chromosome-Positive B-Precursor Acute Lymphoblastic Leukemia Following Treatment With Blinatumomab: Results From a Phase II, Single-Arm, Multicenter Study.",http://www.ncbi.nlm.nih.gov/pubmed/28355115
8709,27893038,Targeting the PI3K/AKT/mTOR Pathway for the Treatment of Mesenchymal Triple-Negative Breast Cancer: Evidence From a Phase 1 Trial of mTOR Inhibition in Combination With Liposomal Doxorubicin and Bevacizumab.,http://www.ncbi.nlm.nih.gov/pubmed/27893038
8710,27918762,Alternating Treatment With Pazopanib and Everolimus vs Continuous Pazopanib to Delay Disease Progression in Patients With Metastatic Clear Cell Renal Cell Cancer: The ROPETAR Randomized Clinical Trial.,http://www.ncbi.nlm.nih.gov/pubmed/27918762
8711,27612558,"Glutamate release inhibitor, Riluzole, inhibited proliferation of human hepatocellular carcinoma cells by elevated ROS production.",http://www.ncbi.nlm.nih.gov/pubmed/27612558
8712,17412408,"Identification of the FANCI protein, a monoubiquitinated FANCD2 paralog required for DNA repair.",http://www.ncbi.nlm.nih.gov/pubmed/17412408
8713,26296701,Exome sequencing reveals frequent deleterious germline variants in cancer susceptibility genes in women with invasive breast cancer undergoing neoadjuvant chemotherapy.,http://www.ncbi.nlm.nih.gov/pubmed/26296701
8714,26824983,Multiple gene sequencing for risk assessment in patients with early-onset or familial breast cancer.,http://www.ncbi.nlm.nih.gov/pubmed/26824983
8715,17525340,Abraxas and RAP80 form a BRCA1 protein complex required for the DNA damage response.,http://www.ncbi.nlm.nih.gov/pubmed/17525340
8716,22357538,Breast cancer-associated Abraxas mutation disrupts nuclear localization and DNA damage response functions.,http://www.ncbi.nlm.nih.gov/pubmed/22357538
8717,27270457,ABRAXAS (FAM175A) and Breast Cancer Susceptibility: No Evidence of Association in the Breast Cancer Family Registry.,http://www.ncbi.nlm.nih.gov/pubmed/27270457
8718,22187458,B-cell adaptor for PI3K (BCAP) negatively regulates Toll-like receptor signaling through activation of PI3K.,http://www.ncbi.nlm.nih.gov/pubmed/22187458
8719,22187460,Role for B-cell adapter for PI3K (BCAP) as a signaling adapter linking Toll-like receptors (TLRs) to serine/threonine kinases PI3K/Akt.,http://www.ncbi.nlm.nih.gov/pubmed/22187460
8720,25261097,Novel gene targets detected by genomic profiling in a consecutive series of 126 adults with acute lymphoblastic leukemia.,http://www.ncbi.nlm.nih.gov/pubmed/25261097
8721,25502460,Chromosomal Instability and Phosphoinositide Pathway Gene Signatures in Glioblastoma Multiforme.,http://www.ncbi.nlm.nih.gov/pubmed/25502460
8722,28327556,Control of structure-specific endonucleases to maintain genome stability.,http://www.ncbi.nlm.nih.gov/pubmed/28327556
8723,20512659,Mutation and association analysis of GEN1 in breast cancer susceptibility.,http://www.ncbi.nlm.nih.gov/pubmed/20512659
8724,15929099,Survival role of protein kinase C (PKC) in chronic lymphocytic leukemia and determination of isoform expression pattern and genes altered by PKC inhibition.,http://www.ncbi.nlm.nih.gov/pubmed/15929099
8725,19145271,Bacillus calmette-guérin failures and beyond: contemporary management of non-muscle-invasive bladder cancer.,http://www.ncbi.nlm.nih.gov/pubmed/19145271
8726,20554745,Topical application of valrubicin has a beneficial effect on developing skin tumors.,http://www.ncbi.nlm.nih.gov/pubmed/20554745
8727,27824120,Aurora A Kinase Inhibitor AKI603 Induces Cellular Senescence in Chronic Myeloid Leukemia Cells Harboring T315I Mutation.,http://www.ncbi.nlm.nih.gov/pubmed/27824120
8728,10687972,Efficacy and safety of valrubicin for the treatment of Bacillus Calmette-Guerin refractory carcinoma in situ of the bladder. The Valrubicin Study Group.,http://www.ncbi.nlm.nih.gov/pubmed/10687972
8729,28404754,Therapeutic Response of Metastatic Colorectal Cancer Harboring a KRAS Missense Mutation After Combination Chemotherapy With the EGFR Inhibitor Panitumumab.,http://www.ncbi.nlm.nih.gov/pubmed/28404754
8730,26928769,High-throughput identification of genotype-specific cancer vulnerabilities in mixtures of barcoded tumor cell lines.,http://www.ncbi.nlm.nih.gov/pubmed/26928769
8731,10209967,"Novel and classical protein kinase C isoforms have different functions in proliferation, survival and differentiation of neuroblastoma cells.",http://www.ncbi.nlm.nih.gov/pubmed/10209967
8732,8882868,"Sequence variations in the Fanconi anaemia gene, FAC: pathogenicity of 1806insA and R548X and recognition of D195V as a polymorphic variant.",http://www.ncbi.nlm.nih.gov/pubmed/8882868
8733,23285130,Genotyping of fanconi anemia patients by whole exome sequencing: advantages and challenges.,http://www.ncbi.nlm.nih.gov/pubmed/23285130
8734,28158234,Yes1 signaling mediates the resistance to Trastuzumab/Lap atinib in breast cancer.,http://www.ncbi.nlm.nih.gov/pubmed/28158234
8735,28416483,SFK/FAK Signaling Attenuates Osimertinib Efficacy in Both Drug-Sensitive and Drug-Resistant Models of EGFR-Mutant Lung Cancer.,http://www.ncbi.nlm.nih.gov/pubmed/28416483
8736,17704648,Src kinase inhibitors induce apoptosis and mediate cell cycle arrest in lymphoma cells.,http://www.ncbi.nlm.nih.gov/pubmed/17704648
8737,28418910,Erythropoietin drives breast cancer progression by activation of its receptor EPOR.,http://www.ncbi.nlm.nih.gov/pubmed/28418910
8738,16222314,Cisplatin-incorporating polymeric micelles (NC-6004) can reduce nephrotoxicity and neurotoxicity of cisplatin in rats.,http://www.ncbi.nlm.nih.gov/pubmed/16222314
8739,18406004,Poly (amino acid) micelle nanocarriers in preclinical and clinical studies.,http://www.ncbi.nlm.nih.gov/pubmed/18406004
8740,27713168,The Aurora kinase A inhibitor TC-A2317 disrupts mitotic progression and inhibits cancer cell proliferation.,http://www.ncbi.nlm.nih.gov/pubmed/27713168
8741,22293494,The induction of polyploidy or apoptosis by the Aurora A kinase inhibitor MK8745 is p53-dependent.,http://www.ncbi.nlm.nih.gov/pubmed/22293494
8742,27678457,The MAPK Pathway Regulates Intrinsic Resistance to BET Inhibitors in Colorectal Cancer.,http://www.ncbi.nlm.nih.gov/pubmed/27678457
8743,27887633,"Antitumor activity of TY-011 against gastric cancer by inhibiting Aurora A, Aurora B and VEGFR2 kinases.",http://www.ncbi.nlm.nih.gov/pubmed/27887633
8744,17341484,"Counting potentially functional variants in BRCA1, BRCA2 and ATM predicts breast cancer susceptibility.",http://www.ncbi.nlm.nih.gov/pubmed/17341484
8745,14722926,Novel germline mutations in the BRCA1 and BRCA2 genes in Indian breast and breast-ovarian cancer families.,http://www.ncbi.nlm.nih.gov/pubmed/14722926
8746,22015057,"Single nucleotide polymorphism associations with response and toxic effects in patients with advanced renal-cell carcinoma treated with first-line sunitinib: a multicentre, observational, prospective study.",http://www.ncbi.nlm.nih.gov/pubmed/22015057
8747,28408243,"Erlotinib and bevacizumab in patients with advanced non-small-cell lung cancer and activating EGFR mutations (BELIEF): an international, multicentre, single-arm, phase 2 trial.",http://www.ncbi.nlm.nih.gov/pubmed/28408243
8748,28100566,Loss of AXIN1 drives acquired resistance to WNT pathway blockade in colorectal cancer cells carrying RSPO3 fusions.,http://www.ncbi.nlm.nih.gov/pubmed/28100566
8749,27507190,Dual inhibition of protein kinase C and p53-MDM2 or PKC and mTORC1 are novel efficient therapeutic approaches for uveal melanoma.,http://www.ncbi.nlm.nih.gov/pubmed/27507190
8750,10998351,Specificity and mechanism of action of some commonly used protein kinase inhibitors.,http://www.ncbi.nlm.nih.gov/pubmed/10998351
8751,8529658,Different susceptibility of protein kinases to staurosporine inhibition. Kinetic studies and molecular bases for the resistance of protein kinase CK2.,http://www.ncbi.nlm.nih.gov/pubmed/8529658
8752,8913270,"Staurosporine inhibits the proliferation, alters the cell cycle distribution and induces apoptosis in HT-29 human colon adenocarcinoma cells.",http://www.ncbi.nlm.nih.gov/pubmed/8913270
8753,26775591,A novel acquired ALK F1245C mutation confers resistance to crizotinib in ALK-positive NSCLC but is sensitive to ceritinib.,http://www.ncbi.nlm.nih.gov/pubmed/26775591
8754,27148356,Gnaq and Gna11 in the Endothelin Signaling Pathway and Melanoma.,http://www.ncbi.nlm.nih.gov/pubmed/27148356
8755,27267837,BEZ235 (PIK3/mTOR inhibitor) Overcomes Pazopanib Resistance in Patient-Derived Refractory Soft Tissue Sarcoma Cells.,http://www.ncbi.nlm.nih.gov/pubmed/27267837
8756,26994139,Allosteric Modulation of the Calcium-sensing Receptor Rectifies Signaling Abnormalities Associated with G-protein α-11 Mutations Causing Hypercalcemic and Hypocalcemic Disorders.,http://www.ncbi.nlm.nih.gov/pubmed/26994139
8757,27521448,Impact of Blood-Brain Barrier Integrity on Tumor Growth and Therapy Response in Brain Metastases.,http://www.ncbi.nlm.nih.gov/pubmed/27521448
8758,28187451,GSK1059615 kills head and neck squamous cell carcinoma cells possibly via activating mitochondrial programmed necrosis pathway.,http://www.ncbi.nlm.nih.gov/pubmed/28187451
8759,27647839,Disorders of the calcium-sensing receptor and partner proteins: insights into the molecular basis of calcium homeostasis.,http://www.ncbi.nlm.nih.gov/pubmed/27647839
8760,16928994,Aneurysm syndromes caused by mutations in the TGF-beta receptor.,http://www.ncbi.nlm.nih.gov/pubmed/16928994
8761,,"Abstract 4514: PQR309: A potent, brain-penetrant, dual pan-PI3K/mTOR inhibitor with excellent oral bioavailability and tolerability",http://cancerres.aacrjournals.org/content/75/15_Supplement/4514.short
8762,21083380,Mutations in GNA11 in uveal melanoma.,http://www.ncbi.nlm.nih.gov/pubmed/21083380
8763,12001124,Multiple primary melanoma revisited.,http://www.ncbi.nlm.nih.gov/pubmed/12001124
8764,28408749,High prevalence of TP53 mutations is associated with poor survival and an EMT signature in gliosarcoma patients.,http://www.ncbi.nlm.nih.gov/pubmed/28408749
8765,20509860,Genetic inactivation of the Fanconi anemia gene FANCC identified in the hepatocellular carcinoma cell line HuH-7 confers sensitivity towards DNA-interstrand crosslinking agents.,http://www.ncbi.nlm.nih.gov/pubmed/20509860
8766,20361013,Autosomal recessive congenital cataract linked to EPHA2 in a consanguineous Pakistani family.,http://www.ncbi.nlm.nih.gov/pubmed/20361013
8767,23793026,Exome sequencing identifies recurrent somatic mutations in EIF1AX and SF3B1 in uveal melanoma with disomy 3.,http://www.ncbi.nlm.nih.gov/pubmed/23793026
8768,24634413,Characterization of the activity of the PI3K/mTOR inhibitor XL765 (SAR245409) in tumor models with diverse genetic alterations affecting the PI3K pathway.,http://www.ncbi.nlm.nih.gov/pubmed/24634413
8769,26778290,Mosaic Activating Mutations in GNA11 and GNAQ Are Associated with Phakomatosis Pigmentovascularis and Extensive Dermal Melanocytosis.,http://www.ncbi.nlm.nih.gov/pubmed/26778290
8770,24756792,Regorafenib.,http://www.ncbi.nlm.nih.gov/pubmed/24756792
8771,24504448,Whole-genome sequencing reveals complex mechanisms of intrinsic resistance to BRAF inhibition.,http://www.ncbi.nlm.nih.gov/pubmed/24504448
8772,23904987,GNAQ and BRAF mutations show differential activation of the mTOR pathway in human transformed cells.,http://www.ncbi.nlm.nih.gov/pubmed/23904987
8773,23656586,Sturge-Weber syndrome and port-wine stains caused by somatic mutation in GNAQ.,http://www.ncbi.nlm.nih.gov/pubmed/23656586
8774,21239882,PRIMA-1Met/APR-246 induces wild-type p53-dependent suppression of malignant melanoma tumor growth in 3D culture and in vivo.,http://www.ncbi.nlm.nih.gov/pubmed/21239882
8775,18172313,"A vascular targeted pan phosphoinositide 3-kinase inhibitor prodrug, SF1126, with antitumor and antiangiogenic activity.",http://www.ncbi.nlm.nih.gov/pubmed/18172313
8776,17875924,Mutant p53 attenuates the SMAD-dependent transforming growth factor beta1 (TGF-beta1) signaling pathway by repressing the expression of TGF-beta receptor type II.,http://www.ncbi.nlm.nih.gov/pubmed/17875924
8777,,"The Multi-Kinase Inhibitor Midostaurin (M) Prolongs Survival Compared with Placebo (P) in Combination with Daunorubicin (D)/Cytarabine (C) Induction (ind), High-Dose C Consolidation (consol), and As Maintenance (maint) Therapy in Newly Diagnosed Acute Mye",http://www.bloodjournal.org/content/126/23/6
8778,25943534,"Identification and Characterization of MEDI4736, an Antagonistic Anti-PD-L1 Monoclonal Antibody.",http://www.ncbi.nlm.nih.gov/pubmed/25943534
8779,28214651,A review on the evolution of PD-1/PD-L1 immunotherapy for bladder cancer: The future is now.,http://www.ncbi.nlm.nih.gov/pubmed/28214651
8780,,Updated efficacy and tolerability of durvalumab in locally advanced or metastatic urothelial carcinoma.,http://meetinglibrary.asco.org/content/178823-197
8781,28339086,Identification of novel mutations in endometrial cancer patients by whole-exome sequencing.,http://www.ncbi.nlm.nih.gov/pubmed/28339086
8782,20498645,Pharmacological reactivation of mutant p53: from protein structure to the cancer patient.,http://www.ncbi.nlm.nih.gov/pubmed/20498645
8783,25809858,Phase I and pharmacokinetics/pharmacodynamics study of the MEK inhibitor RO4987655 in Japanese patients with advanced solid tumors.,http://www.ncbi.nlm.nih.gov/pubmed/25809858
8784,23860959,"Phase I and pharmacokinetic/pharmacodynamic study of RO5126766, a first-in-class dual Raf/MEK inhibitor, in Japanese patients with advanced solid tumors.",http://www.ncbi.nlm.nih.gov/pubmed/23860959
8785,28240971,Phase I Trial of the Human Double Minute 2 Inhibitor MK-8242 in Patients With Advanced Solid Tumors.,http://www.ncbi.nlm.nih.gov/pubmed/28240971
8786,27544076,A phase I trial of the human double minute 2 inhibitor (MK-8242) in patients with refractory/recurrent acute myelogenous leukemia (AML).,http://www.ncbi.nlm.nih.gov/pubmed/27544076
8787,21831953,A phase I first-in-human pharmacokinetic and pharmacodynamic study of serdemetan in patients with advanced solid tumors.,http://www.ncbi.nlm.nih.gov/pubmed/21831953
8788,27999193,The novel anticancer agent JNJ-26854165 is active in chronic myeloid leukemic cells with unmutated BCR/ABL and T315I mutant BCR/ABL through promoting proteosomal degradation of BCR/ABL proteins.,http://www.ncbi.nlm.nih.gov/pubmed/27999193
8789,18767981,PTEN and the PI3-kinase pathway in cancer.,http://www.ncbi.nlm.nih.gov/pubmed/18767981
8790,,Kevetrin induces p53-dependent and independent cell cycle arrest and apoptosis in ovarian cancer cell lines representing heterogeneous histologies,http://www.abstractsonline.com/pp8/#!/4292/presentation/3876
8791,28193778,"AG-221, a First-in-Class Therapy Targeting Acute Myeloid Leukemia Harboring Oncogenic IDH2 Mutations.",http://www.ncbi.nlm.nih.gov/pubmed/28193778
8792,28209615,Targeted Degradation of BET Proteins in Triple-Negative Breast Cancer.,http://www.ncbi.nlm.nih.gov/pubmed/28209615
8793,28453702,"A phase 2, randomized, double-blind, placebo- controlled study of chemo-immunotherapy combination using motolimod with pegylated liposomal doxorubicin in recurrent or persistent ovarian cancer: a Gynecologic Oncology Group partners study.",http://www.ncbi.nlm.nih.gov/pubmed/28453702
8794,19412175,Common variations in BARD1 influence susceptibility to high-risk neuroblastoma.,http://www.ncbi.nlm.nih.gov/pubmed/19412175
8795,26350354,Functional Analysis of BARD1 Missense Variants in Homology-Directed Repair of DNA Double Strand Breaks.,http://www.ncbi.nlm.nih.gov/pubmed/26350354
8796,18480049,Crystal structure of the BARD1 ankyrin repeat domain and its functional consequences.,http://www.ncbi.nlm.nih.gov/pubmed/18480049
8797,,The novel BTK and PI3K-delta inhibitors acalabrutinib (ACP-196) and ACP-319 show activity in pre-clinical B-cell lymphoma models,http://www.ejcancer.com/article/S0959-8049(16)32699-5/abstract
8798,26390965,EphB4 inhibitor overcome the acquired resistance to cisplatin in melanomas xenograft model.,http://www.ncbi.nlm.nih.gov/pubmed/26390965
8799,11292664,"VEGFR3 gene structure, regulatory region, and sequence polymorphisms.",http://www.ncbi.nlm.nih.gov/pubmed/11292664
8800,12960217,Identification of eight novel VEGFR-3 mutations in families with primary congenital lymphoedema.,http://www.ncbi.nlm.nih.gov/pubmed/12960217
8801,25355294,The mutational landscape in pediatric acute lymphoblastic leukemia deciphered by whole genome sequencing.,http://www.ncbi.nlm.nih.gov/pubmed/25355294
8802,26365907,"A pilot study of JI-101, an inhibitor of VEGFR-2, PDGFR-β, and EphB4 receptors, in combination with everolimus and as a single agent in an ovarian cancer expansion cohort.",http://www.ncbi.nlm.nih.gov/pubmed/26365907
8803,26254278,"Impact of VEGF, VEGFR, PDGFR, HIF and ERCC1 gene polymorphisms on thymic malignancies outcome after thymectomy.",http://www.ncbi.nlm.nih.gov/pubmed/26254278
8804,26681674,Minimally invasive genomic and transcriptomic profiling of visceral cancers by next-generation sequencing of circulating exosomes.,http://www.ncbi.nlm.nih.gov/pubmed/26681674
8805,25278451,"A phase I, dose-escalation study of the multitargeted receptor tyrosine kinase inhibitor, golvatinib, in patients with advanced solid tumors.",http://www.ncbi.nlm.nih.gov/pubmed/25278451
8806,22762016,Signal transduction by vascular endothelial growth factor receptors.,http://www.ncbi.nlm.nih.gov/pubmed/22762016
8807,27927766,Phase 1 dose-finding study of rebastinib (DCC-2036) in patients with relapsed chronic myeloid leukemia and acute myeloid leukemia.,http://www.ncbi.nlm.nih.gov/pubmed/27927766
8808,28327905,"Phase II study of idelalisib, a selective inhibitor of PI3Kδ, for relapsed/refractory classical Hodgkin lymphoma.",http://www.ncbi.nlm.nih.gov/pubmed/28327905
8809,22789825,Dual inhibition of Met kinase and angiogenesis to overcome HGF-induced EGFR-TKI resistance in EGFR mutant lung cancer.,http://www.ncbi.nlm.nih.gov/pubmed/22789825
8810,27876675,A Phase 1/1b Study Evaluating Trametinib Plus Docetaxel or Pemetrexed in Patients With Advanced Non-Small Cell Lung Cancer.,http://www.ncbi.nlm.nih.gov/pubmed/27876675
8811,28119489,PI3K Inhibitors Synergize with FGFR Inhibitors to Enhance Antitumor Responses in FGFR2(mutant) Endometrial Cancers.,http://www.ncbi.nlm.nih.gov/pubmed/28119489
8812,27140928,Targeting Androgen Receptor Activation Function-1 with EPI to Overcome Resistance Mechanisms in Castration-Resistant Prostate Cancer.,http://www.ncbi.nlm.nih.gov/pubmed/27140928
8813,27628492,Targeting the N-Terminal Domain of the Androgen Receptor: A New Approach for the Treatment of Advanced Prostate Cancer.,http://www.ncbi.nlm.nih.gov/pubmed/27628492
8814,27596331,Pathogenic Cysteine Removal Mutations in FGFR Extracellular Domains Stabilize Receptor Dimers and Perturb the TM Dimer Structure.,http://www.ncbi.nlm.nih.gov/pubmed/27596331
8815,17344920,Expression and mutation status of candidate kinases in multiple myeloma.,http://www.ncbi.nlm.nih.gov/pubmed/17344920
8816,28398638,"A functional screening of the kinome identifies the Polo-like kinase 4 as a potential therapeutic target for malignant rhabdoid tumors, and possibly, other embryonal tumors of the brain.",http://www.ncbi.nlm.nih.gov/pubmed/28398638
8817,22772060,"MK-0457, an Aurora kinase and BCR-ABL inhibitor, is active in patients with BCR-ABL T315I leukemia.",http://www.ncbi.nlm.nih.gov/pubmed/22772060
8818,27082306,The p38 MAPK inhibitor BIRB796 enhances the antitumor effects of VX680 in cervical cancer.,http://www.ncbi.nlm.nih.gov/pubmed/27082306
8819,27517489,Suppression of c-Myc and RRM2 expression in pancreatic cancer cells by the sphingosine kinase-2 inhibitor ABC294640.,http://www.ncbi.nlm.nih.gov/pubmed/27517489
8820,21233403,"Specifically targeting angiopoietin-2 inhibits angiogenesis, Tie2-expressing monocyte infiltration, and tumor growth.",http://www.ncbi.nlm.nih.gov/pubmed/21233403
8821,21149738,Chemical generation of bispecific antibodies.,http://www.ncbi.nlm.nih.gov/pubmed/21149738
8822,27651308,"Efficacy of Cotargeting Angiopoietin-2 and the VEGF Pathway in the Adjuvant Postsurgical Setting for Early Breast, Colorectal, and Renal Cancers.",http://www.ncbi.nlm.nih.gov/pubmed/27651308
8823,28102363,SMARCA4-inactivating mutations increase sensitivity to Aurora kinase A inhibitor VX-680 in non-small cell lung cancers.,http://www.ncbi.nlm.nih.gov/pubmed/28102363
8824,28440955,"Phase 1 dose-escalation study of mirvetuximab soravtansine (IMGN853), a folate receptor α-targeting antibody-drug conjugate, in patients with solid tumors.",http://www.ncbi.nlm.nih.gov/pubmed/28440955
8825,,Activity of sorafenib in radiation-associated breast angiosarcomas harboring MYC and FLT4 amplifications.,http://meetinglibrary.asco.org/content/92128-114
8826,9452043,Asn540Thr substitution in the fibroblast growth factor receptor 3 tyrosine kinase domain causing hypochondroplasia.,http://www.ncbi.nlm.nih.gov/pubmed/9452043
8827,24452392,A novel somatic FGFR3 mutation in primary lung cancer.,http://www.ncbi.nlm.nih.gov/pubmed/24452392
8828,17487277,Mutational analysis of EGFR and related signaling pathway genes in lung adenocarcinomas identifies a novel somatic kinase domain mutation in FGFR4.,http://www.ncbi.nlm.nih.gov/pubmed/17487277
8829,23415752,BRCA1/2 mutation analysis in 41 ovarian cell lines reveals only one functionally deleterious BRCA1 mutation.,http://www.ncbi.nlm.nih.gov/pubmed/23415752
8830,23696849,FGFR4 role in epithelial-mesenchymal transition and its therapeutic value in colorectal cancer.,http://www.ncbi.nlm.nih.gov/pubmed/23696849
8831,19008009,"Fibroblast growth factor receptor 4 regulates proliferation, anti-apoptosis and alpha-fetoprotein secretion during hepatocellular carcinoma progression and represents a potential target for therapeutic intervention.",http://www.ncbi.nlm.nih.gov/pubmed/19008009
8832,24569783,Novel Mutations in Neuroendocrine Carcinoma of the Breast: Possible Therapeutic Targets.,http://www.ncbi.nlm.nih.gov/pubmed/24569783
8833,,"First-in-human study of BLU-554, a potent, highly-selective FGFR4 inhibitor designed for hepatocellular carcinoma (HCC) with FGFR4 pathway activation",http://www.sciencedirect.com/science/article/pii/S0959804916327046?via%3Dihub
8834,26751841,The biology behind interleukin-6 targeted interventions.,http://www.ncbi.nlm.nih.gov/pubmed/26751841
8835,25658637,Interleukin 6 receptor is an independent prognostic factor and a potential therapeutic target of ovarian cancer.,http://www.ncbi.nlm.nih.gov/pubmed/25658637
8836,26824321,Differential regulation of mTOR signaling determines sensitivity to AKT inhibition in diffuse large B cell lymphoma.,http://www.ncbi.nlm.nih.gov/pubmed/26824321
8837,28376212,"Durable Control of Metastatic AKT1-Mutant WHO Grade 1 Meningothelial Meningioma by the AKT Inhibitor, AZD5363.",http://www.ncbi.nlm.nih.gov/pubmed/28376212
8838,15448036,Kinase inhibition with BAY 43-9006 in renal cell carcinoma.,http://www.ncbi.nlm.nih.gov/pubmed/15448036
8839,15466206,BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis.,http://www.ncbi.nlm.nih.gov/pubmed/15466206
8840,18772362,beta-Klotho and FGF-15/19 inhibit the apical sodium-dependent bile acid transporter in enterocytes and cholangiocytes.,http://www.ncbi.nlm.nih.gov/pubmed/18772362
8841,20657013,Metabolic regulator betaKlotho interacts with fibroblast growth factor receptor 4 (FGFR4) to induce apoptosis and inhibit tumor cell proliferation.,http://www.ncbi.nlm.nih.gov/pubmed/20657013
8842,27573985,Clinical significance of α‑ and β‑Klotho in urothelial carcinoma of the bladder.,http://www.ncbi.nlm.nih.gov/pubmed/27573985
8843,22439738,Klotho-beta overexpression as a novel target for suppressing proliferation and fibroblast growth factor receptor-4 signaling in hepatocellular carcinoma.,http://www.ncbi.nlm.nih.gov/pubmed/22439738
8844,24735930,Effects of AKT inhibitor therapy in response and resistance to BRAF inhibition in melanoma.,http://www.ncbi.nlm.nih.gov/pubmed/24735930
8845,25188413,Novel genetic mutations in a sporadic port-wine stain.,http://www.ncbi.nlm.nih.gov/pubmed/25188413
8846,22484628,Exome sequencing of gastric adenocarcinoma identifies recurrent somatic mutations in cell adhesion and chromatin remodeling genes.,http://www.ncbi.nlm.nih.gov/pubmed/22484628
8847,28332364,Potential Antitumor Activity of SIM-89 in Non-Small Cell Lung Cancer Cells.,http://www.ncbi.nlm.nih.gov/pubmed/28332364
8848,20949568,Consistent MYC and FLT4 gene amplification in radiation-induced angiosarcoma but not in other radiation-associated atypical vascular lesions.,http://www.ncbi.nlm.nih.gov/pubmed/20949568
8849,27797976,Genomic Heterogeneity and Exceptional Response to Dual Pathway Inhibition in Anaplastic Thyroid Cancer.,http://www.ncbi.nlm.nih.gov/pubmed/27797976
8850,28247011,"Population pharmacokinetics of ABT-767 in BRCA1 or BRCA2 mutation carriers with advanced solid tumors or in subjects with high grade serous ovarian, primary peritoneal or fallopian tube cancer.",http://www.ncbi.nlm.nih.gov/pubmed/28247011
8851,28151720,Biomarker and Tumor Responses of Oral Cavity Squamous Cell Carcinoma to Trametinib: A Phase II Neoadjuvant Window-of-Opportunity Clinical Trial.,http://www.ncbi.nlm.nih.gov/pubmed/28151720
8852,,Avelumab in patients with metastatic urothelial carcinoma: Pooled results from two cohorts of the phase 1b JAVELIN Solid Tumor trial.,http://meetinglibrary.asco.org/content/178781-197
8853,,BGB-290: A highly potent and specific PARP1/2 inhibitor potentiates anti-tumor activity of chemotherapeutics in patient biopsy derived SCLC models,http://cancerres.aacrjournals.org/content/75/15_Supplement/1653.short
8854,28292941,Preclinical Antitumor Efficacy of BAY 1129980-a Novel Auristatin-Based Anti-C4.4A (LYPD3) Antibody-Drug Conjugate for the Treatment of Non-Small Cell Lung Cancer.,http://www.ncbi.nlm.nih.gov/pubmed/28292941
8855,28450422,Characterization of a Dual Rac/Cdc42 Inhibitor MBQ-167 in Metastatic Cancer.,http://www.ncbi.nlm.nih.gov/pubmed/28450422
8856,28283652,BRCA2 Hypomorphic Missense Variants Confer Moderate Risks of Breast Cancer.,http://www.ncbi.nlm.nih.gov/pubmed/28283652
8857,27816996,"Alisertib demonstrates significant antitumor activity in bevacizumab resistant, patient derived orthotopic models of glioblastoma.",http://www.ncbi.nlm.nih.gov/pubmed/27816996
8858,26798966,"A first-in-human phase I study of the oral Notch inhibitor, LY900009, in patients with advanced cancer.",http://www.ncbi.nlm.nih.gov/pubmed/26798966
8859,19795481,Functional redundancy of exon 12 of BRCA2 revealed by a comprehensive analysis of the c.6853A>G (p.I2285V) variant.,http://www.ncbi.nlm.nih.gov/pubmed/19795481
8860,26439132,"BRCA1 and BRCA2 mutations in Japanese patients with ovarian, fallopian tube, and primary peritoneal cancer.",http://www.ncbi.nlm.nih.gov/pubmed/26439132
8861,,"Phase I study of the safety, pharmacokinetics (PK), and pharmacodynamics (PD) of the poly(ADP-ribose) polymerase (PARP) inhibitor E7016 in combination with temozolomide (TMZ) in patients with advanced solid tumors.",http://mct.aacrjournals.org/content/10/11_Supplement/B185.short
8862,28387926,Overall survival with ponatinib versus allogeneic stem cell transplantation in Philadelphia chromosome-positive leukemias with the T315I mutation.,http://www.ncbi.nlm.nih.gov/pubmed/28387926
8863,28447912,"Targeting RET in Patients With RET-Rearranged Lung Cancers: Results From the Global, Multicenter RET Registry.",http://www.ncbi.nlm.nih.gov/pubmed/28447912
8864,28265006,Characterization of the Anti-PD-1 Antibody REGN2810 and Its Antitumor Activity in Human PD-1 Knock-In Mice.,http://www.ncbi.nlm.nih.gov/pubmed/28265006
8865,,Phase 1 study of the PARP inhibitor E7449 as a single agent in patients with advanced solid tumors or B-cell lymphoma.,http://meetinglibrary.asco.org/content/131248-144
8866,28235199,Multivalent Small-Molecule Pan-RAS Inhibitors.,http://www.ncbi.nlm.nih.gov/pubmed/28235199
8867,,The PARP inhibitor niraparib demonstrates synergy with chemotherapy in treatment of patient derived Ewing's sarcoma tumorGraft models.,http://mct.aacrjournals.org/content/12/11_Supplement/A258.short
8868,27214403,Structural analysis of human KDM5B guides histone demethylase inhibitor development.,http://www.ncbi.nlm.nih.gov/pubmed/27214403
8869,21840268,"The PARP inhibitor PJ34 causes a PARP1-independent, p21 dependent mitotic arrest.",http://www.ncbi.nlm.nih.gov/pubmed/21840268
8870,28138028,Combining Chk1/2 Inhibition with Cetuximab and Radiation Enhances In Vitro and In Vivo Cytotoxicity in Head and Neck Squamous Cell Carcinoma.,http://www.ncbi.nlm.nih.gov/pubmed/28138028
8871,27076630,Myc-Driven Glycolysis Is a Therapeutic Target in Glioblastoma.,http://www.ncbi.nlm.nih.gov/pubmed/27076630
8872,27914241,"ENGOT-ov-6/TRINOVA-2: Randomised, double-blind, phase 3 study of pegylated liposomal doxorubicin plus trebananib or placebo in women with recurrent partially platinum-sensitive or resistant ovarian cancer.",http://www.ncbi.nlm.nih.gov/pubmed/27914241
8873,27856601,Axl Blockade by BGB324 Inhibits BCR-ABL Tyrosine Kinase Inhibitor-Sensitive and -Resistant Chronic Myeloid Leukemia.,http://www.ncbi.nlm.nih.gov/pubmed/27856601
8874,17639584,"In a model of immunoglobulin heavy-chain (IGH)/MYC translocation, the Igh 3' regulatory region induces MYC expression at the immature stage of B cell development.",http://www.ncbi.nlm.nih.gov/pubmed/17639584
8875,27410038,Detection of JAK2 Exon 12 Mutations in JAK2 V617F-Negative Polycythemia Vera Patients by Cloning Technique.,http://www.ncbi.nlm.nih.gov/pubmed/27410038
8876,26361084,Detection of mutations in JAK2 exons 12-15 by Sanger sequencing.,http://www.ncbi.nlm.nih.gov/pubmed/26361084
8877,17984312,Somatic mutations of JAK2 exon 12 in patients with JAK2 (V617F)-negative myeloproliferative disorders.,http://www.ncbi.nlm.nih.gov/pubmed/17984312
8878,22642932,Detection of JAK2 mutations in paraffin marrow biopsies by high resolution melting analysis: identification of L611S alone and in cis with V617F in polycythemia vera.,http://www.ncbi.nlm.nih.gov/pubmed/22642932
8879,19491085,Detection of low allele burden of JAK2 exon 12 mutations using TA-cloning in patients with erythrocytosis.,http://www.ncbi.nlm.nih.gov/pubmed/19491085
8880,17914411,Two novel JAK2 exon 12 mutations in JAK2V617F-negative polycythaemia vera patients.,http://www.ncbi.nlm.nih.gov/pubmed/17914411
8881,27389715,Cooperation of germ line JAK2 mutations E846D and R1063H in hereditary erythrocytosis with megakaryocytic atypia.,http://www.ncbi.nlm.nih.gov/pubmed/27389715
8882,17471559,Patterns of PIK3CA alterations in familial colorectal and endometrial carcinoma.,http://www.ncbi.nlm.nih.gov/pubmed/17471559
8883,28240010,PIK3CA mutations in HER2-positive Breast Cancer Patients; Frequency and Clinicopathological Perspective in Egyptian Patients,http://www.ncbi.nlm.nih.gov/pubmed/28240010
8884,24533074,PIK3CA mutations frequently coexist with EGFR/KRAS mutations in non-small cell lung cancer and suggest poor prognosis in EGFR/KRAS wildtype subgroup.,http://www.ncbi.nlm.nih.gov/pubmed/24533074
8885,26759238,Dual HER2 Targeting with Trastuzumab and Liposomal-Encapsulated Doxorubicin (MM-302) Demonstrates Synergistic Antitumor Activity in Breast and Gastric Cancer.,http://www.ncbi.nlm.nih.gov/pubmed/26759238
8886,27900042,"Antitumor activity of 7RH, a discoidin domain receptor 1 inhibitor, alone or in combination with dasatinib exhibits antitumor effects in nasopharyngeal carcinoma cells.",http://www.ncbi.nlm.nih.gov/pubmed/27900042
8887,26855149,Combined inhibition of DDR1 and Notch signaling is a therapeutic strategy for KRAS-driven lung adenocarcinoma.,http://www.ncbi.nlm.nih.gov/pubmed/26855149
8888,28422713,SEL120-34A is a novel CDK8 inhibitor active in AML cells with high levels of serine phosphorylation of STAT1 and STAT5 transactivation domains.,http://www.ncbi.nlm.nih.gov/pubmed/28422713
8889,27994185,In silico characterization of functional SNP within the oestrogen receptor gene.,http://www.ncbi.nlm.nih.gov/pubmed/27994185
8890,16756500,The structure and function of telomerase reverse transcriptase.,http://www.ncbi.nlm.nih.gov/pubmed/16756500
8891,11103775,Frequent amplification of the telomerase reverse transcriptase gene in human tumors.,http://www.ncbi.nlm.nih.gov/pubmed/11103775
8892,23887589,Frequency of TERT promoter mutations in human cancers.,http://www.ncbi.nlm.nih.gov/pubmed/23887589
8893,26910118,Efficacy of targeted AKT inhibition in genetically engineered mouse models of PTEN-deficient prostate cancer.,http://www.ncbi.nlm.nih.gov/pubmed/26910118
8894,19844788,Phosphatidyl-inositol-3-kinase alpha catalytic subunit mutation and response to neoadjuvant endocrine therapy for estrogen receptor positive breast cancer.,http://www.ncbi.nlm.nih.gov/pubmed/19844788
8895,26479420,Evaluation of 122 advanced-stage cutaneous squamous cell carcinomas by comprehensive genomic profiling opens the door for new routes to targeted therapies.,http://www.ncbi.nlm.nih.gov/pubmed/26479420
8896,22292935,Highly frequent PIK3CA amplification is associated with poor prognosis in gastric cancer.,http://www.ncbi.nlm.nih.gov/pubmed/22292935
8897,23370426,Identification of uncommon PIK3CA mutations in lung cancer by using pyrosequencing.,http://www.ncbi.nlm.nih.gov/pubmed/23370426
8898,19148475,Mutation of PIK3CA: possible risk factor for cervical carcinogenesis in older women.,http://www.ncbi.nlm.nih.gov/pubmed/19148475
8899,23349881,Mutations in the hedgehog pathway genes SMO and PTCH1 in human gastric tumors.,http://www.ncbi.nlm.nih.gov/pubmed/23349881
8900,25395299,PTCH1 mutation is a frequent event in oesophageal basaloid squamous cell carcinoma.,http://www.ncbi.nlm.nih.gov/pubmed/25395299
8901,17252020,JAK3 mutations occur in acute megakaryoblastic leukemia both in Down syndrome children and non-Down syndrome adults.,http://www.ncbi.nlm.nih.gov/pubmed/17252020
8902,15122079,"Phase II trial of flavopiridol, a cyclin dependent kinase inhibitor, in untreated metastatic malignant melanoma.",http://www.ncbi.nlm.nih.gov/pubmed/15122079
8903,,Abstract LB-198: Phase I and molecular correlates study of oral rigosertib in patients with refractory metastatic head and neck cancer and advanced solid tumors.,http://cancerres.aacrjournals.org/content/73/8_Supplement/LB-198.short
8904,26817999,Case Report: Next generation sequencing identifies a NAB2-STAT6 fusion in Glioblastoma.,http://www.ncbi.nlm.nih.gov/pubmed/26817999
8905,24093751,Germline variants in MRE11/RAD50/NBN complex genes in childhood leukemia.,http://www.ncbi.nlm.nih.gov/pubmed/24093751
8906,23270583,The significance of spliceosome mutations in chronic lymphocytic leukemia.,http://www.ncbi.nlm.nih.gov/pubmed/23270583
8907,25605964,Prp40 pre-mRNA processing factor 40 homolog B (PRPF40B) associates with SF1 and U2AF65 and modulates alternative pre-mRNA splicing in vivo.,http://www.ncbi.nlm.nih.gov/pubmed/25605964
8908,24798549,"Oncolytic reovirus preferentially induces apoptosis in KRAS mutant colorectal cancer cells, and synergizes with irinotecan.",http://www.ncbi.nlm.nih.gov/pubmed/24798549
8909,25258342,IPI-145 antagonizes intrinsic and extrinsic survival signals in chronic lymphocytic leukemia cells.,http://www.ncbi.nlm.nih.gov/pubmed/25258342
8910,28480783,"Pharmacogenetics of drug-drug interaction and drug-drug-gene interaction: a systematic review on CYP2C9, CYP2C19 and CYP2D6.",http://www.ncbi.nlm.nih.gov/pubmed/28480783
8911,22994728,Genetic variants of CYP2D6 gene and cancer risk: a HuGE systematic review and meta-analysis.,http://www.ncbi.nlm.nih.gov/pubmed/22994728
8912,16550168,Cytochrome P450 pharmacogenetics and cancer.,http://www.ncbi.nlm.nih.gov/pubmed/16550168
8913,24076587,Mapping the p53 transcriptome universe using p53 natural polymorphs.,http://www.ncbi.nlm.nih.gov/pubmed/24076587
8914,25542057,PACMEL: a phase 1 dose escalation trial of trametinib (GSK1120212) in combination with paclitaxel.,http://www.ncbi.nlm.nih.gov/pubmed/25542057
8915,28346230,Glutaminase and poly(ADP-ribose) polymerase inhibitors suppress pyrimidine synthesis and VHL-deficient renal cancers.,http://www.ncbi.nlm.nih.gov/pubmed/28346230
8916,18312355,Clinical significance of oncogenic KIT and PDGFRA mutations in gastrointestinal stromal tumours.,http://www.ncbi.nlm.nih.gov/pubmed/18312355
8917,28334365,Effect of KIT and PDGFRA Mutations on Survival in Patients With Gastrointestinal Stromal Tumors Treated With Adjuvant Imatinib: An Exploratory Analysis of a Randomized Clinical Trial.,http://www.ncbi.nlm.nih.gov/pubmed/28334365
8918,27918764,"Effect of Fluorouracil, Leucovorin, and Oxaliplatin With or Without Onartuzumab in HER2-Negative, MET-Positive Gastroesophageal Adenocarcinoma: The METGastric Randomized Clinical Trial.",http://www.ncbi.nlm.nih.gov/pubmed/27918764
8919,26826118,Sequential Combination Therapy of CDK Inhibition and Doxorubicin Is Synthetically Lethal in p53-Mutant Triple-Negative Breast Cancer.,http://www.ncbi.nlm.nih.gov/pubmed/26826118
8920,28414062,Novel PIK3CD mutations affecting N-terminal residues of p110δ cause activated PI3Kδ syndrome (APDS) in humans.,http://www.ncbi.nlm.nih.gov/pubmed/28414062
8921,28428270,Mutations in the adaptor-binding domain and associated linker region of p110δ cause Activated PI3K-δ Syndrome 1 (APDS1).,http://www.ncbi.nlm.nih.gov/pubmed/28428270
8922,22801959,Simultaneous inhibition of pan-phosphatidylinositol-3-kinases and MEK as a potential therapeutic strategy in peripheral T-cell lymphomas.,http://www.ncbi.nlm.nih.gov/pubmed/22801959
8923,28029594,Priming Hand Motor Training with Repetitive Stimulation of the Fingertips; Performance Gain and Functional Imaging of Training Effects.,http://www.ncbi.nlm.nih.gov/pubmed/28029594
8924,28089594,Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor-sensitive Exon 19 Insertion and Exon 20 Insertion in Patients With Advanced Non-Small-cell Lung Cancer.,http://www.ncbi.nlm.nih.gov/pubmed/28089594
8925,26634271,Selective Toxicity of Investigational Ixazomib for Human Leukemia Cells Expressing Mutant Cytoplasmic NPM1: Role of Reactive Oxygen Species.,http://www.ncbi.nlm.nih.gov/pubmed/26634271
8926,27810904,"Phase Ib Trial of the Toll-like Receptor 8 Agonist, Motolimod (VTX-2337), Combined with Cetuximab in Patients with Recurrent or Metastatic SCCHN.",http://www.ncbi.nlm.nih.gov/pubmed/27810904
8927,27841872,IAP antagonists induce anti-tumor immunity in multiple myeloma.,http://www.ncbi.nlm.nih.gov/pubmed/27841872
8928,26928463,Substantial interindividual and limited intraindividual genomic diversity among tumors from men with metastatic prostate cancer.,http://www.ncbi.nlm.nih.gov/pubmed/26928463
8929,26082451,Whole-genome sequencing reveals oncogenic mutations in mycosis fungoides.,http://www.ncbi.nlm.nih.gov/pubmed/26082451
8930,21821710,FERM domain mutations induce gain of function in JAK3 in adult T-cell leukemia/lymphoma.,http://www.ncbi.nlm.nih.gov/pubmed/21821710
8931,28235761,High-Throughput Genomic Profiling of Adult Solid Tumors Reveals Novel Insights into Cancer Pathogenesis.,http://www.ncbi.nlm.nih.gov/pubmed/28235761
8932,27942391,Metastatic basal cell carcinoma with amplification of PD-L1: exceptional response to anti-PD1 therapy.,http://www.ncbi.nlm.nih.gov/pubmed/27942391
8933,28487883,Genetic and epigenetic profiling of a solitary Peutz-Jeghers colon polyp.,http://www.ncbi.nlm.nih.gov/pubmed/28487883
8934,24258993,ERBB4 mutation analysis: emerging molecular target for melanoma treatment.,http://www.ncbi.nlm.nih.gov/pubmed/24258993
8935,28212060,Pembrolizumab as Second-Line Therapy for Advanced Urothelial Carcinoma.,http://www.ncbi.nlm.nih.gov/pubmed/28212060
8936,27780859,The Second-Generation Exportin-1 Inhibitor KPT-8602 Demonstrates Potent Activity against Acute Lymphoblastic Leukemia.,http://www.ncbi.nlm.nih.gov/pubmed/27780859
8937,28218735,Aurora kinase A regulates Survivin stability through targeting FBXL7 in gastric cancer drug resistance and prognosis.,http://www.ncbi.nlm.nih.gov/pubmed/28218735
8938,27245312,"Evidence for Clinical Differentiation and Differentiation Syndrome in Patients With Acute Myeloid Leukemia and IDH1 Mutations Treated With the Targeted Mutant IDH1 Inhibitor, AG-120.",http://www.ncbi.nlm.nih.gov/pubmed/27245312
8939,,"62 - ADCT-502, a novel pyrrolobenzodiazepine (PBD)-based antibody–drug conjugate (ADC) targeting low HER2-expressing solid cancers",http://www.sciencedirect.com/science/article/pii/S0959804916326624
8940,,"AGEN1884, an IgG1 anti-CTLA-4 antibody, combines effectively with PD-1 blockade in primary human T cell assays and in a non-human primate pharmacodynamic (PD) model",http://www.abstractsonline.com/pp8/#!/4292/presentation/6300
8941,,Abstract B198: Pharmacological profile of the PGE2 EP4 receptor antagonist E7046,http://mct.aacrjournals.org/content/14/12_Supplement_2/B198.short
8942,,Pharmacodynamic biomarkers for anti-TIGIT treatment and prevalence of TIGIT expression in multiple solid tumor types,http://publications.oncomed.com/Pharmacodynam-biomarkers-anti-TIGIT-treatment-and-expression-solid-tumor-AACR-2017.pdf
8943,28232670,Pan-mutant-IDH1 inhibitor BAY1436032 is highly effective against human IDH1 mutant acute myeloid leukemia in vivo.,http://www.ncbi.nlm.nih.gov/pubmed/28232670
8944,,Abstract B034: Preclinical immune antitumor activity of myeloid-targeting E7046 and Treg depleting E7777,http://cancerimmunolres.aacrjournals.org/content/4/1_Supplement/B034.short
8945,,"SY-1365, a potent and selective CDK7 inhibitor, exhibits promising anti-tumor activity in multiple preclinical models of aggressive solid tumors",https://books.google.com/books?id=4UFUDgAAQBAJ&pg=PT1269&lpg=PT1269&dq=SY-1365+aacr&source=bl&ots=qSIk2T1yGY&sig=KtZ3HYzvtHo8njvplLeHoPoXTFg&hl=en&sa=X&ved=0ahUKEwim2sfivPzTAhUY0GMKHdZ3CxMQ6AEIPjAE#v=
8946,,Combination of a Novel EP4 Antagonist E7046 and Radiation Therapy Promotes Anti-tumor Immune Response and Tumor Rejection in Preclinical Tumor Models,http://www.redjournal.org/article/S0360-3016(16)30638-1/abstract
8947,28492898,Selumetinib Plus Docetaxel Compared With Docetaxel Alone and Progression-Free Survival in Patients With KRAS-Mutant Advanced Non-Small Cell Lung Cancer: The SELECT-1 Randomized Clinical Trial.,http://www.ncbi.nlm.nih.gov/pubmed/28492898
8949,,Preclinical development of MVT-1075 as radioimmunotherapy for pancreatic cancer and other CA19-9 positive malignancies,http://www.aacr.org/Meetings/Pages/MeetingDetail.aspx?EventItemID=105&DetailItemID=539#.WR9AdvMo9Qo
8950,,Exploratory Pharmacokinetic/Pharmacodynamic and Tolerability Study of BCMAxCD3 in Cynomolgus Monkeys,http://www.bloodjournal.org/content/128/22/5668
8951,,"Neratinib + fulvestrant in ERBB2-mutant, HER2–non-amplified, estrogen receptor (ER)-positive, metastatic breast cancer (MBC): Preliminary analysis from the phase II SUMMIT trial",http://cancerres.aacrjournals.org/content/77/4_Supplement/PD2-08.short
8952,28157217,Acute myeloid leukemia targets for bispecific antibodies.,http://www.ncbi.nlm.nih.gov/pubmed/28157217
8953,27189165,Characterization of CD33/CD3 Tetravalent Bispecific Tandem Diabodies (TandAbs) for the Treatment of Acute Myeloid Leukemia.,http://www.ncbi.nlm.nih.gov/pubmed/27189165
8954,,"Immuno-oncologic efficacy of RXDX-106, a selective, TAM family small molecule kinase inhibitor",http://www.sciencedirect.com/science/article/pii/S0959804916326739?via%3Dihub
8955,,"Abstract A73: Antitumor activity of MVT-5873, a monoclonal antibody targeting sialyl Lewisa, alone and in combination with gemcitabine/nab-paclitaxel in a BxPC3 human pancreatic cancer xenograft model",http://cancerres.aacrjournals.org/content/76/24_Supplement/A73.short
8956,22034289,High prevalence of BRCA1 and BRCA2 mutations in unselected Nigerian breast cancer patients.,http://www.ncbi.nlm.nih.gov/pubmed/22034289
8957,15744044,Complete allelic analysis of BRCA1 and BRCA2 variants in young Nigerian breast cancer patients.,http://www.ncbi.nlm.nih.gov/pubmed/15744044
8958,18024013,Common variants of DNA repair genes and malignant melanoma.,http://www.ncbi.nlm.nih.gov/pubmed/18024013
8959,27815358,"Phase I Study of GDC-0425, a Checkpoint Kinase 1 Inhibitor, in Combination with Gemcitabine in Patients with Refractory Solid Tumors.",http://www.ncbi.nlm.nih.gov/pubmed/27815358
8960,,"Abstract B118: A phase 1, open-label multiple dose escalation trial to determine safety and tolerability of once daily OPB-111077 in subjects with advanced cancer",http://mct.aacrjournals.org/content/14/12_Supplement_2/B118.short
8961,25577571,"MGN1703, an immunomodulator and toll-like receptor 9 (TLR-9) agonist: from bench to bedside.",http://www.ncbi.nlm.nih.gov/pubmed/25577571
8962,16168123,Strong evidence that the common variant S384F in BRCA2 has no pathogenic relevance in hereditary breast cancer.,http://www.ncbi.nlm.nih.gov/pubmed/16168123
8963,27787897,Novel TIE-2 inhibitor BAY-826 displays in vivo efficacy in experimental syngeneic murine glioma models.,http://www.ncbi.nlm.nih.gov/pubmed/27787897
8965,,"KO-947, a potent and selective ERK inhibitor with slow dissociation kinetics",http://www.ejcancer.com/article/S0959-8049(16)32974-4/abstract
8966,,Vaccination targeting insulin-like growth factor binding protein-2 (IGFBP-2) in advanced ovarian cancer: Safety and immunogenicity,http://meetinglibrary.asco.org/content/165931-176
8967,,"Adoptive cellular immunotherapy with APN401, autologous Cbl-b-silenced peripheral blood mononuclear cells, in patients with solid tumors.",http://meetinglibrary.asco.org/content/170952-176
8968,26984758,HSP70 Inhibition Limits FAK-Dependent Invasion and Enhances the Response to Melanoma Treatment with BRAF Inhibitors.,http://www.ncbi.nlm.nih.gov/pubmed/26984758
8969,,"Development of AVID100, a novel antibody–drug conjugate for the treatment of EGFR expressing solid tumors",http://www.ejcancer.com/article/S0959-8049%2816%2933037-4/abstract
8970,,338 BM-1252 (APG-1252): a potent dual specific Bcl-2/Bcl-xL inhibitor that achieves complete tumor regression with minimal platelet toxicity,http://www.sciencedirect.com/science/article/pii/S0959804914704642
8971,,544 Preclinical studies of a dual Bcl-2/Bcl-xL inhibitor APG-1252 with strong anti-tumor efficacy and significantly reduced platelet toxicity,http://www.ejcancer.com/article/S0959-8049%2814%2970670-7/abstract
8972,,"Abstract 3912: MM-310, a novel EphA2-targeted docetaxel nanoliposome",http://cancerres.aacrjournals.org/content/76/14_Supplement/3912
8973,26319232,Common and specific effects of TIE2 mutations causing venous malformations.,http://www.ncbi.nlm.nih.gov/pubmed/26319232
8974,,"Abstract 4321: Effect of pretreatment, dose and route of administration of BPM31510 (Coenyzme Q10 containing proprietary formulation) alone or in combination with gemcitabine improves survival in pancreatic cancer",http://cancerres.aacrjournals.org/content/74/19_Supplement/4321.short
8975,,Abstract 208: BPM 31510-induced alteration in Complex II activity is functionally linked to cell death activation pathway in a preclinical model of triple-negative breast cancer,http://cancerres.aacrjournals.org/content/76/14_Supplement/208.short
8976,,Abstract 4889: The highly specific CSF1R inhibitor DCC-3014 exhibits immunomodulatory and anti-invasive activities in cancer models,http://cancerres.aacrjournals.org/content/76/14_Supplement/4889
8977,,A phase 1 trial of TRC102 (methoxyamine HCl) with temozolomide (TMZ) in patients with solid tumors and lymphomas.,http://meetinglibrary.asco.org/content/168775-176
8978,27797168,Dual Inhibition of PDK1 and Aurora Kinase A: An Effective Strategy to Induce Differentiation and Apoptosis of Human Glioblastoma Multiforme Stem Cells.,http://www.ncbi.nlm.nih.gov/pubmed/27797168
8980,,"A Phase I/II Study of MCLA-128, a full length IgG1 Bispecific Antibody Targeting HER2 and HER3, in Patients with Solid Tumors",http://cancerres.aacrjournals.org/content/76/14_Supplement/CT050.short
8981,,Inhibition of NF-kB inducing kinase (NIK) selectively abrogates NIK and TRAF3 mutant multiple myeloma tumor growth,http://www.abstractsonline.com/pp8/#!/4292/presentation/3906
8982,27671527,"Development of a Novel Antibody-Drug Conjugate for the Potential Treatment of Ovarian, Lung, and Renal Cell Carcinoma Expressing TIM-1.",http://www.ncbi.nlm.nih.gov/pubmed/27671527
8983,27413764,Immune Regulation and Antitumor Effect of TIM-1.,http://www.ncbi.nlm.nih.gov/pubmed/27413764
8984,20536563,TIM genes: a family of cell surface phosphatidylserine receptors that regulate innate and adaptive immunity.,http://www.ncbi.nlm.nih.gov/pubmed/20536563
8985,27998968,Drug-sensitive FGFR3 mutations in lung adenocarcinoma.,http://www.ncbi.nlm.nih.gov/pubmed/27998968
8986,12776205,The TIM gene family: emerging roles in immunity and disease.,http://www.ncbi.nlm.nih.gov/pubmed/12776205
8987,23352434,Hepatitis A virus cellular receptor 1/kidney injury molecule-1 is a susceptibility gene for clear cell renal cell carcinoma and hepatitis A virus cellular receptor/kidney injury molecule-1 ectodomain shedding a predictive biomarker of tumour progression.,http://www.ncbi.nlm.nih.gov/pubmed/23352434
8988,24390735,HAVCR/KIM-1 activates the IL-6/STAT-3 pathway in clear cell renal cell carcinoma and determines tumor progression and patient outcome.,http://www.ncbi.nlm.nih.gov/pubmed/24390735
8989,24278394,Integrative analysis of hereditary nonpolyposis colorectal cancer: the contribution of allele-specific expression and other assays to diagnostic algorithms.,http://www.ncbi.nlm.nih.gov/pubmed/24278394
8990,9927034,Neurofibromatosis and early onset of cancers in hMLH1-deficient children.,http://www.ncbi.nlm.nih.gov/pubmed/9927034
8991,28471727,"Safety and Clinical Activity of the Programmed Death-Ligand 1 Inhibitor Durvalumab in Combination With Poly (ADP-Ribose) Polymerase Inhibitor Olaparib or Vascular Endothelial Growth Factor Receptor 1-3 Inhibitor Cediranib in Women's Cancers: A Dose-Escalation, Phase I Study.",http://www.ncbi.nlm.nih.gov/pubmed/28471727
8992,25871441,Evaluation of CADD Scores in Curated Mismatch Repair Gene Variants Yields a Model for Clinical Validation and Prioritization.,http://www.ncbi.nlm.nih.gov/pubmed/25871441
8993,15139004,"HNPCC mutation MLH1 P648S makes the functional protein unstable, and homozygosity predisposes to mild neurofibromatosis type 1.",http://www.ncbi.nlm.nih.gov/pubmed/15139004
8994,16093711,DIRS-1 and the other tyrosine recombinase retrotransposons.,http://www.ncbi.nlm.nih.gov/pubmed/16093711
8995,21404117,Missense variants in hMLH1 identified in patients from the German HNPCC consortium and functional studies.,http://www.ncbi.nlm.nih.gov/pubmed/21404117
8996,15222003,"Association of colonic and endometrial carcinomas in Portuguese families with hereditary nonpolyposis colorectal carcinoma significantly increases the probability of detecting a pathogenic mutation in mismatch repair genes, primarily the MSH2 gene.",http://www.ncbi.nlm.nih.gov/pubmed/15222003
8997,20167975,R659X mutation in the MLH1 gene in hereditary non-polyposis colorectal cancer(HNPCC) in an Indian extended family.,http://www.ncbi.nlm.nih.gov/pubmed/20167975
8998,22252508,Three-dimensional reconstruction of protein networks provides insight into human genetic disease.,http://www.ncbi.nlm.nih.gov/pubmed/22252508
8999,25142776,Comprehensive screening for mutations associated with colorectal cancer in unselected cases reveals penetrant and nonpenetrant mutations.,http://www.ncbi.nlm.nih.gov/pubmed/25142776
9000,24351291,FANCJ localization by mismatch repair is vital to maintain genomic integrity after UV irradiation.,http://www.ncbi.nlm.nih.gov/pubmed/24351291
9001,25894969,Dissecting Genomic Aberrations in Myeloproliferative Neoplasms by Multiplex-PCR and Next Generation Sequencing.,http://www.ncbi.nlm.nih.gov/pubmed/25894969
9002,28338653,Breast ductal carcinoma in situ carry mutational driver events representative of invasive breast cancer.,http://www.ncbi.nlm.nih.gov/pubmed/28338653
9003,23297823,Diverse mechanisms of AKT pathway activation in human malignancy.,http://www.ncbi.nlm.nih.gov/pubmed/23297823
9004,,"SEA-CD40, a sugar engineered non-fucosylated anti-CD40 antibody with improved immune activating capabilities",http://cancerres.aacrjournals.org/content/75/15_Supplement/2472
9005,17611497,A transforming mutation in the pleckstrin homology domain of AKT1 in cancer.,http://www.ncbi.nlm.nih.gov/pubmed/17611497
9006,23277329,The Fc-engineered CD19 antibody MOR208 (XmAb5574) induces natural killer cell-mediated lysis of acute lymphoblastic leukemia cells from pediatric and adult patients.,http://www.ncbi.nlm.nih.gov/pubmed/23277329
9007,,Development of KITE-585: a fully human BCMA CAR T-cell therapy for the treatment of multiple myeloma,http://www.aacr.org/Documents/AACR2017_Proceedings.pdf
9008,23776238,B-cell maturation antigen is modified by a single N-glycan chain that modulates ligand binding and surface retention.,http://www.ncbi.nlm.nih.gov/pubmed/23776238
9009,26370838,Targeting B-cell maturation antigen in multiple myeloma.,http://www.ncbi.nlm.nih.gov/pubmed/26370838
9010,20140688,Exploring the cause of drug resistance by the detrimental missense mutations in KIT receptor: computational approach.,http://www.ncbi.nlm.nih.gov/pubmed/20140688
9011,19333543,Interstitial cells of Cajal do not harbor c-kit or PDGFRA gene mutations in patients with sporadic gastrointestinal stromal tumors.,http://www.ncbi.nlm.nih.gov/pubmed/19333543
9012,25729726,"Incidence, clinical features, and prognostic impact of CALR exon 9 mutations in essential thrombocythemia and primary myelofibrosis: an experience of a single tertiary hospital in Korea.",http://www.ncbi.nlm.nih.gov/pubmed/25729726
9013,24577951,Radiation dosimetry and first therapy results with a (124)I/ (131)I-labeled small molecule (MIP-1095) targeting PSMA for prostate cancer therapy.,http://www.ncbi.nlm.nih.gov/pubmed/24577951
9014,,Preclinical Evaluation of CSL362/JNJ-56022473 Single Agent in in Vitro Assays,http://www.bloodjournal.org/content/126/23/4946?sso-checked=true
9015,,Anti-tumor activity of PEGylated human IL-10 (AM0010) in patients with pancreatic or colorectal cancer.,http://meetinglibrary.asco.org/record/125848/abstract
9016,,"LY3200882, a novel, highly selective TGFbetaRI small molecule inhibitor",http://www.abstractsonline.com/pp8/#!/4292/presentation/7901
9017,,A novel prodrug of indoximod with enhanced pharmacokinetic properties,http://www.abstractsonline.com/pp8/#!/4292/presentation/1270
9018,17234791,"Inhibition of indoleamine 2,3-dioxygenase in dendritic cells by stereoisomers of 1-methyl-tryptophan correlates with antitumor responses.",http://www.ncbi.nlm.nih.gov/pubmed/17234791
9019,25288198,Phase Ib study evaluating a self-adjuvanted mRNA cancer vaccine (RNActive®) combined with local radiation as consolidation and maintenance treatment for patients with stage IV non-small cell lung cancer.,http://www.ncbi.nlm.nih.gov/pubmed/25288198
9020,16625838,Physiology of somatostatin receptors.,http://www.ncbi.nlm.nih.gov/pubmed/16625838
9021,24513123,CD 123 is a membrane biomarker and a therapeutic target in hematologic malignancies.,http://www.ncbi.nlm.nih.gov/pubmed/24513123
9022,14671644,Interleukin-3 receptor in acute leukemia.,http://www.ncbi.nlm.nih.gov/pubmed/14671644
9023,21034425,Somatostatin receptor-targeted anti-cancer therapy.,http://www.ncbi.nlm.nih.gov/pubmed/21034425
9024,7978860,"Expression of somatostatin receptors in normal, inflamed, and neoplastic human gastrointestinal tissues.",http://www.ncbi.nlm.nih.gov/pubmed/7978860
9025,9440032,Somatostatin and somatostatin receptors in the diagnosis and treatment of gliomas.,http://www.ncbi.nlm.nih.gov/pubmed/9440032
9026,20637207,Role of somatostatins in gastroenteropancreatic neuroendocrine tumor development and therapy.,http://www.ncbi.nlm.nih.gov/pubmed/20637207
9027,,"Discovery of PEN-221, an SSTR2-targetign maytansinoid conjugate with potent activity in vitro and in vivo",https://books.google.com/books?id=4UFUDgAAQBAJ&pg=PT48&lpg=PT48&dq=PEN-221+aacr&source=bl&ots=qSIl2V4wHV&sig=dN3Z-YpHN0nqfJevoJVo3FKstS4&hl=en&sa=X&ved=0ahUKEwjnlZ-Dn5rUAhUr6YMKHbuSCMkQ6AEIVzAJ#v=onep
9028,15195113,Mutations in components of the Wnt signaling pathway in adenoid cystic carcinoma.,http://www.ncbi.nlm.nih.gov/pubmed/15195113
9029,28202004,A phase II study to evaluate LY2603618 in combination with gemcitabine in pancreatic cancer patients.,http://www.ncbi.nlm.nih.gov/pubmed/28202004
9030,27829224,Inhibition of Chk1 with the small molecule inhibitor V158411 induces DNA damage and cell death in an unperturbed S-phase.,http://www.ncbi.nlm.nih.gov/pubmed/27829224
9031,,"A phase I study of SAR566658, an anti CA6-antibody drug conjugate (ADC), in patients (Pts) with CA6-positive advanced solid tumors (STs)(NCT01156870).",http://meetinglibrary.asco.org/record/125293/abstract
9032,28498808,Restoration of p53 using the novel MDM2-p53 antagonist APG115 suppresses dedifferentiated papillary thyroid cancer cells.,http://www.ncbi.nlm.nih.gov/pubmed/28498808
9033,22510280,Identification of somatic mutations in non-small cell lung carcinomas using whole-exome sequencing.,http://www.ncbi.nlm.nih.gov/pubmed/22510280
9034,,"ASN003, a highly selective BRAF and PI3K inhibitor: Preclinical and phase 1 clinical data in patients with advanced solid tumors",http://abstracts.asco.org/199/AbstView_199_186123.html
9035,,"Abstract B100: ASN003, a unique B-RAF inhibitor with additional selective activity against PI3K and mTOR kinases, shows strong antitumor activity in multiple xenograft models",http://mct.aacrjournals.org/content/14/12_Supplement_2/B100.short
9036,,Abstract 1770: Viral-based nanoparticles: a new therapeutic approach for anticancer therapy,http://cancerres.aacrjournals.org/content/74/19_Supplement/1770
9037,19656415,Molecular genetics analysis of hereditary breast and ovarian cancer patients in India.,http://www.ncbi.nlm.nih.gov/pubmed/19656415
9038,28149837,Next-Generation EGFR Tyrosine Kinase Inhibitors for Treating EGFR-Mutant Lung Cancer beyond First Line.,http://www.ncbi.nlm.nih.gov/pubmed/28149837
9039,,"Abstract 3204: INCAGN01949: an anti-OX40 agonist antibody with the potential to enhance tumor-specific T-cell responsiveness, while selectively depleting intratumoral regulatory T cells",http://cancerres.aacrjournals.org/content/76/14_Supplement/3204
9040,26424751,Common variants at the CHEK2 gene locus and risk of epithelial ovarian cancer.,http://www.ncbi.nlm.nih.gov/pubmed/26424751
9041,24879340,Identification of two poorly prognosed ovarian carcinoma subtypes associated with CHEK2 germ-line mutation and non-CHEK2 somatic mutation gene signatures.,http://www.ncbi.nlm.nih.gov/pubmed/24879340
9042,24325359,Somatic CALR mutations in myeloproliferative neoplasms with nonmutated JAK2.,http://www.ncbi.nlm.nih.gov/pubmed/24325359
9043,27609087,Casitas B-lineage lymphoma linker helix mutations found in myeloproliferative neoplasms affect conformation.,http://www.ncbi.nlm.nih.gov/pubmed/27609087
9044,20369050,Coexisting with clonal evolution and BCR-ABL mutant in CML patients treated with second-generation tyrosine kinase inhibitors predict the discrepancy of in vitro drug sensitivity.,http://www.ncbi.nlm.nih.gov/pubmed/20369050
9045,17947479,A half-log increase in BCR-ABL RNA predicts a higher risk of relapse in patients with chronic myeloid leukemia with an imatinib-induced complete cytogenetic response.,http://www.ncbi.nlm.nih.gov/pubmed/17947479
9046,28514312,Treatment inferred from mutations identified using massive parallel sequencing leads to clinical benefit in some heavily pretreated cancer patients.,http://www.ncbi.nlm.nih.gov/pubmed/28514312
9047,24618614,Desmoplastic melanoma with sarcomatoid dedifferentiation.,http://www.ncbi.nlm.nih.gov/pubmed/24618614
9048,,XMT-1522 induces tumor regressions in pre-clinical models representing HER2-positive and HER2 low-expressing breast cancer,http://cancerres.aacrjournals.org/content/76/4_Supplement/P4-14-28
9049,21860433,"TG02, a novel oral multi-kinase inhibitor of CDKs, JAK2 and FLT3 with potent anti-leukemic properties.",http://www.ncbi.nlm.nih.gov/pubmed/21860433
9050,23774674,Mutation of the colony-stimulating factor-3 receptor gene is a rare event with poor prognosis in chronic myelomonocytic leukemia.,http://www.ncbi.nlm.nih.gov/pubmed/23774674
9051,28432176,"A Phase I Study of the CDK4/6 Inhibitor Ribociclib (LEE011) in Pediatric Patients with Malignant Rhabdoid Tumors, Neuroblastoma, and Other Solid Tumors.",http://www.ncbi.nlm.nih.gov/pubmed/28432176
9052,27821605,A Phase I/II Multicenter Study of Single-Agent Foretinib as First-Line Therapy in Patients with Advanced Hepatocellular Carcinoma.,http://www.ncbi.nlm.nih.gov/pubmed/27821605
9053,27312238,A cellular reporter to evaluate CRM1 nuclear export activity: functional analysis of the cancer-related mutant E571K.,http://www.ncbi.nlm.nih.gov/pubmed/27312238
9054,28375706,"Impact of Diabetes, Insulin, and Metformin Use on the Outcome of Patients With Human Epidermal Growth Factor Receptor 2-Positive Primary Breast Cancer: Analysis From the ALTTO Phase III Randomized Trial.",http://www.ncbi.nlm.nih.gov/pubmed/28375706
9055,17361096,Apaf1 in chronic myelogenous leukemia (CML) progression: reduced Apaf1 expression is correlated with a H179R p53 mutation during clinical blast crisis.,http://www.ncbi.nlm.nih.gov/pubmed/17361096
9056,18424693,IL-10: the master regulator of immunity to infection.,http://www.ncbi.nlm.nih.gov/pubmed/18424693
9057,24076584,Current status of interleukin-10 and regulatory T-cells in cancer.,http://www.ncbi.nlm.nih.gov/pubmed/24076584
9058,28357727,A Phase Ib Study of the Dual PI3K/mTOR Inhibitor Dactolisib (BEZ235) Combined with Everolimus in Patients with Advanced Solid Malignancies.,http://www.ncbi.nlm.nih.gov/pubmed/28357727
9059,28559560,Immuno-oncology upset in bladder cancer.,http://www.ncbi.nlm.nih.gov/pubmed/28559560
9060,,"A phase Ia study of CC-90003, a selective extracellular signal-regulated kinase (ERK) inhibitor, in patients with relapsed or refractory BRAF or RAS-mutant tumors.",http://abstracts.asco.org/199/AbstView_199_186986.html
9061,,Characterisation of CCS1477: A novel small molecule inhibitor of p300/CBP for the treatment of castration resistant prostate cancer.,http://abstracts.asco.org/199/AbstView_199_189631.html
9062,,"Phase I study of ABBV-399, a c-Met antibody-drug conjugate (ADC), as monotherapy and in combination with erlotinib in patients (pts) with non-small cell lung cancer (NSCLC)",http://abstracts.asco.org/199/AbstView_199_183940.html
9063,28270606,"Functional characterization of CFI-402257, a potent and selective Mps1/TTK kinase inhibitor, for the treatment of cancer.",http://www.ncbi.nlm.nih.gov/pubmed/28270606
9064,,Effect of adenoviral p53 (Ad-p53) tumor suppressor immune gene therapy on checkpoint inhibitor resistance and abscopal therapeutic efficacy,http://abstracts.asco.org/199/AbstView_199_194552.html
9065,,EGFR/CD16A tetravalent bispecific antibody AFM24 to engage NK-cells to kill EGFR expressing tumor cells and safety results in cynomolgus monkey studies,http://abstracts.asco.org/199/AbstView_199_191813.html
9066,,"Discovery of COM701, a therapeutic antibody targeting the novel immune checkpoint PVRIG, for the treatment of cancer.",http://abstracts.asco.org/199/AbstView_199_193132.html
9067,,Abstract PR04: CPI-444: A potent and selective inhibitor of A2AR induces antitumor responses alone and in combination with anti-PD-L1 in preclinical and clinical studies,http://cancerimmunolres.aacrjournals.org/content/4/11_Supplement/PR04
9068,,Overall survival results of ICON6: A trial of chemotherapy and cediranib in relapsed ovarian cancer.,http://meetinglibrary.asco.org/record/147010/abstract
9069,,"Phase 1 open-label, multiple ascending dose trial of AGEN1884, an anti-CTLA-4 monoclonal antibody, in advanced solid malignancies.",http://abstracts.asco.org/199/AbstView_199_193189.html
9070,,Multicenter phase II study of pembrolizumab (P) in advanced soft tissue (STS) and bone sarcomas (BS): Final results of SARC028 and biomarker analyses.,http://meetinglibrary.asco.org/record/145286/abstract
9071,,Phase I trial of a novel stapled peptide ALRN-6924 disrupting MDMX- and MDM2-mediated inhibition of WT p53 in patients with solid tumors and lymphomas,http://abstracts.asco.org/199/AbstView_199_187803.html
9072,,"Safety and clinical activity of adenosine A2a receptor (A2aR) antagonist, CPI-444, in anti-PD1/PDL1 treatment-refractory renal cell (RCC) and non-small cell lung cancer (NSCLC) patients.",http://abstracts.asco.org/199/AbstView_199_186068.html
9073,,Phase 1 study of the p53-MDM2 inhibitor AMG 232 combined with trametinib plus dabrafenib or trametinib in patients (Pts) with TP53 wild type (TP53WT) metastatic cutaneous melanoma (MCM),http://abstracts.asco.org/199/AbstView_199_181299.html
9074,,"Phase 1 study of ARQ 761, a ?-lapachone analog that promotes NQO1-mediated programmed cancer cell necrosis",http://abstracts.asco.org/199/AbstView_199_190411.html
9075,,"Single agent activity of DS-8201a, a HER2-targeting antibody-drug conjugate, in heavily pretreated HER2 expressing solid tumors.",http://abstracts.asco.org/199/AbstView_199_191619.html
9076,,MONARCH 2: Abemaciclib in combination with fulvestrant in patients with HR+/HER2- advanced breast cancer who progressed on endocrine therapy,http://meetinglibrary.asco.org/record/144891/abstract
9077,,In vitro functional analysis of HER2 variants in lung cancers to evaluate their oncogenic activity and predict clinical response to HER2 targeted therapies.,http://abstracts.asco.org/199/AbstView_199_190816.html
9078,,"Preliminary results from a phase 1 trial of M7824 (MSB0011359C), a bifunctional fusion protein targeting PD-L1 and TGF-?, in advanced solid tumors.",http://abstracts.asco.org/199/AbstView_199_187226.html
9079,,First-in-human phase 1 study of ETC-159 an oral PORCN inhbitor in patients with advanced solid tumours,http://abstracts.asco.org/199/AbstView_199_181737.html
9080,,"A phase I study of PF-06647263, a novel EFNA4-ADC, in patients with metastatic triple negative breast cancer.",http://abstracts.asco.org/199/AbstView_199_182473.html
9081,,Atezolizumab (A) + cobimetinib (C) + vemurafenib (V) in BRAFV600-mutant metastatic melanoma (mel): Updated safety and clinical activity.,http://abstracts.asco.org/199/AbstView_199_186773.html
9082,,"A randomized, double-blind, single dose comparison of pharmacokinetics and safety of FKB238 with bevacizumab.",http://abstracts.asco.org/199/AbstView_199_184952.html
9083,18020980,Selective Raf inhibition in cancer therapy.,http://www.ncbi.nlm.nih.gov/pubmed/18020980
9084,27551077,2-Sulfonylpyrimidines: Mild alkylating agents with anticancer activity toward p53-compromised cells.,http://www.ncbi.nlm.nih.gov/pubmed/27551077
9085,,Targeting mutant p53 with PK11007: A new approach for the treatment of patients with triple-negative breast cancer?,http://abstracts.asco.org/199/AbstView_199_189403.html
9086,,A phase Ib dose escalation study of combined inhibition of IDO1 (GDC-0919) and PD-L1 (atezolizumab) in patients (pts) with locally advanced or metastatic solid tumors.,http://abstracts.asco.org/199/AbstView_199_192935.html
9087,,"GCT1021-01, a first-in-human, open-label, dose-escalation trial with expansion cohorts to evaluate safety of Axl-specific antibody-drug conjugate (HuMax-Axl-ADC) in patients with solid tumors (NCT02988817).",http://abstracts.asco.org/199/AbstView_199_184372.html
9088,,"Preclinical efficacy studies using HuMax-Axl-ADC, a novel antibody-drug conjugate targeting Axl-expressing solid cancers.",http://ascopubs.org/doi/abs/10.1200/jco.2015.33.15_suppl.3066
9089,,"Phase 1 results of PTC596, a novel small molecule targeting cancer stem cells (CSCs) by reducing levels of BMI1 protein.",http://abstracts.asco.org/199/AbstView_199_189820.html
9090,28062663,A population-based analysis of germline BAP1 mutations in melanoma.,http://www.ncbi.nlm.nih.gov/pubmed/28062663
9091,,Novel porcupine (PORCN) inhibitor RXC004: Evaluation in models of RNF43 loss of function cancers.,http://abstracts.asco.org/199/AbstView_199_193236.html
9092,,Phase Ib pharmacokinetics of non-hormonal SM88 in patients with non-metastatic recurrent prostate cancer.,http://abstracts.asco.org/199/AbstView_199_182430.html
9093,,"A phase I trial of the oral hedgehog inhibitor taladegib (LY2940680) in combination with weekly paclitaxel in patients with advanced, solid tumours.",http://abstracts.asco.org/199/AbstView_199_183751.html
9094,26416890,The BAP1/ASXL2 Histone H2A Deubiquitinase Complex Regulates Cell Proliferation and Is Disrupted in Cancer.,http://www.ncbi.nlm.nih.gov/pubmed/26416890
9095,,"First-in-human phase I study of an oral HSP90 inhibitor, TAS-116, in advanced solid tumors.",http://abstracts.asco.org/199/AbstView_199_186280.html
9096,,Type II RAF inhibition predicts superior ERK suppression compared to type I RAF inhibition in different BRAF mutant types recurrently found in lung cancer,http://abstracts.asco.org/199/AbstView_199_191661.html
9097,,"A first in human phase I study of AZD8186, a potent and selective inhibitor of PI3K in patients with advanced solid tumours as monotherapy and in combination with the dual mTORC1/2 inhibitor vistusertib (AZD2014) or abiraterone acetate",http://abstracts.asco.org/199/AbstView_199_183406.html
9098,,Phase II randomized trial of neoadjuvant (NA) chemotherapy (CT) with or without bevacizumab (Bev) in advanced epithelial ovarian cancer (EOC)? (GEICO 1205/NOVA TRIAL).,http://abstracts.asco.org/199/AbstView_199_186640.html
9099,,"Preclinical in vitro and in vivo evaluation of antitumor activity of UD-017, a novel selective and orally available CDK7 inhibitor, in colorectal cancer.",http://abstracts.asco.org/199/AbstView_199_194372.html
9100,,Phase I study of the combination of balixafortide (CXCR4 inhibitor) and eribulin in HER2-negative metastatic breast cancer (MBC) patients (pts),http://abstracts.asco.org/199/AbstView_199_185772.html
9101,,OlympiAD: Phase III trial of olaparib monotherapy versus chemotherapy for patients (pts) with HER2-negative metastatic breast cancer (mBC) and a germline BRCA mutation (gBRCAm).,http://abstracts.asco.org/199/AbstView_199_186720.html
9102,26193344,NY-ESO-1-specific TCR-engineered T cells mediate sustained antigen-specific antitumor effects in myeloma.,http://www.ncbi.nlm.nih.gov/pubmed/26193344
9103,,A phase 1b study of the anti-PD-1 monoclonal antibody BGB-A317 (A317) in combination with the PARP inhibitor BGB-290 (290) in advanced solid tumors,http://abstracts.asco.org/199/AbstView_199_191325.html
9104,,"Abstract B79: BI 894999, a novel BET inhibitor: Treatment of hematological malignancies by repression of super-enhancer driven oncogenes",http://mct.aacrjournals.org/content/14/12_Supplement_2/B79.short
9105,,Phase I first-in-man trial of a novel bromodomain and extra-terminal domain (BET) inhibitor (BI 894999) in patients (Pts) with advanced solid tumors,http://abstracts.asco.org/199/AbstView_199_186636.html
9106,,First-line treatment of iNHL or MCL patients with BR or R-CHOP/R-CVP: Results of the BRIGHT 5-year follow-up study.,http://meetinglibrary.asco.org/record/147107/abstract
9107,11309386,In vivo role of NAD(P)H:quinone oxidoreductase 1 (NQO1) in the regulation of intracellular redox state and accumulation of abdominal adipose tissue.,http://www.ncbi.nlm.nih.gov/pubmed/11309386
9108,25885439,High expression of NQO1 is associated with poor prognosis in serous ovarian carcinoma.,http://www.ncbi.nlm.nih.gov/pubmed/25885439
9110,,Novel Mutations in NOTCH and Altered Wnt/?-Catenin Pathway Indicate a Role of Embryonic Signals in the Pathogenesis of T-Cell Prolymphocytic Leukemia,http://www.bloodjournal.org/content/128/22/4103?sso-checked=true
9111,23566281,Genetic variants in the NOTCH4 gene influence the clinical features of migraine.,http://www.ncbi.nlm.nih.gov/pubmed/23566281
9112,,"Gefitinib (G) versus vinorelbine+cisplatin (VP) as adjuvant treatment in stage II-IIIA (N1-N2) non-small-cell lung cancer (NSCLC) with EGFR-activating mutation (ADJUVANT): A randomized, Phase III trial (CTONG 1104).",http://meetinglibrary.asco.org/record/145337/abstract
9113,28193775,Targeting the EED-H3K27me3 Interaction Allosterically Inhibits PRC2.,http://www.ncbi.nlm.nih.gov/pubmed/28193775
9114,,APHINITY trial (BIG 4-11): A randomized comparison of chemotherapy (C) plus trastuzumab (T) plus placebo (Pla) versus chemotherapy plus trastuzumab (T) plus pertuzumab (P) as adjuvant therapy in patients (pts) with HER2-positive early breast cancer (EBC).,http://meetinglibrary.asco.org/record/145538/abstract
9115,28135235,An allosteric PRC2 inhibitor targeting the H3K27me3 binding pocket of EED.,http://www.ncbi.nlm.nih.gov/pubmed/28135235
9116,25159915,Diverse modes of genomic alteration in hepatocellular carcinoma.,http://www.ncbi.nlm.nih.gov/pubmed/25159915
9117,,Augmentation of adoptive T-cell therapy for Merkel cell carcinoma with avelumab.,http://abstracts.asco.org/199/AbstView_199_185408.html
9118,27494029,Whole Exome Sequencing Identifies TSC1/TSC2 Biallelic Loss as the Primary and Sufficient Driver Event for Renal Angiomyolipoma Development.,http://www.ncbi.nlm.nih.gov/pubmed/27494029
9119,23684012,Germline BAP1 mutations predispose to renal cell carcinomas.,http://www.ncbi.nlm.nih.gov/pubmed/23684012
9120,,CALGB/ECOG 100104 (Alliance) study: Lenalidomide vs placebo maintenance  after stem cell transplant for patients with multiple myeloma—Overall survival and progression-free survival adjusted for treatment crossover,http://meetinglibrary.asco.org/record/145449/abstract
9121,,"Clinical efficacy of icotinib in patients with advanced non-small cell lung cancer harboring EGFR exon 18, 20 and 21 uncommon mutations.",http://abstracts.asco.org/199/AbstView_199_186649.html
9122,28135237,The EED protein-protein interaction inhibitor A-395 inactivates the PRC2 complex.,http://www.ncbi.nlm.nih.gov/pubmed/28135237
9123,,Lenalidomide induction and maintenance therapy for transplant eligible myeloma patients: Results of the Myeloma XI study.,http://meetinglibrary.asco.org/record/152934/abstract
9124,,"Evaluation of RAD1901, a novel investigational, selective estrogen receptor degrader (SERD), for the treatment of ER-positive (ER+) advanced breast cancer.",http://abstracts.asco.org/199/AbstView_199_192812.html
9125,28473534,"Elacestrant (RAD1901), a selective estrogen receptor degrader (SERD), has anti-tumor activity in multiple ER+ breast cancer patient-derived xenograft models.",http://www.ncbi.nlm.nih.gov/pubmed/28473534
9126,26762747,Clinicopathological Characteristics of RET Rearranged Lung Cancer in European Patients.,http://www.ncbi.nlm.nih.gov/pubmed/26762747
9127,23597238,Whole-genome sequencing in an autism multiplex family.,http://www.ncbi.nlm.nih.gov/pubmed/23597238
9128,27697534,Emerging roles of the neurotrophin receptor TrkC in synapse organization.,http://www.ncbi.nlm.nih.gov/pubmed/27697534
9129,,TBCRC 022: Phase II trial of neratinib + capecitabine for patients (Pts) with human epidermal growth factor receptor 2 (HER2+) breast cancer brain metastases (BCBM).,http://abstracts.asco.org/199/AbstView_199_186113.html
9130,,LOTUS (NCT02162719): A double-blind placebo (PBO)-controlled randomized phase II trial of first-line ipatasertib (IPAT) + paclitaxel (P) for metastatic triple-negative breast cancer (TNBC).,http://abstracts.asco.org/199/AbstView_199_183382.html
9131,,IRX4204 in combination with erlotinib to target distinct pathways in lung cancer cells.,http://abstracts.asco.org/199/AbstView_199_192863.html
9132,28317872,"Preclinical evaluation of the efficacy, pharmacokinetics and immunogenicity of JS-001, a programmed cell death protein-1 (PD-1) monoclonal antibody.",http://www.ncbi.nlm.nih.gov/pubmed/28317872
9133,,"A phase 1 trial of JS001, a monoclonal antibody targeting programmed death-1 (PD-1) in patients with advanced or recurrent malignancies.",http://abstracts.asco.org/199/AbstView_199_188639.html
9134,,"A phase I study of JS001, a humanized IgG4 mAb against programmed death-1 (PD-1) in patients with advanced solid tumors",http://abstracts.asco.org/199/AbstView_199_189353.html
9135,,A multicenter phase I trial of the DNA-dependent protein kinase (DNA-PK) inhibitor M3814 in patients with solid tumors.,http://abstracts.asco.org/199/AbstView_199_187975.html
9136,,"Phase I/II, first in human trial of the Bruton’s tyrosine kinase inhibitor (BTKi) M7583 in patients with B cell malignancies.",http://abstracts.asco.org/199/AbstView_199_186701.html
9138,16502349,Phase II trial of DNA methyltransferase 1 inhibition with the antisense oligonucleotide MG98 in patients with metastatic renal carcinoma: a National Cancer Institute of Canada Clinical Trials Group investigational new drug study.,http://www.ncbi.nlm.nih.gov/pubmed/16502349
9139,24952746,The genomic landscape of nasopharyngeal carcinoma.,http://www.ncbi.nlm.nih.gov/pubmed/24952746
9140,28341788,"Discovery and Pharmacological Characterization of JNJ-42756493 (Erdafitinib), a Functionally Selective Small-Molecule FGFR Family Inhibitor.",http://www.ncbi.nlm.nih.gov/pubmed/28341788
9141,26831668,"Pre-clinical characterization of 4SC-202, a novel class I HDAC inhibitor, against colorectal cancer cells.",http://www.ncbi.nlm.nih.gov/pubmed/26831668
9142,25427824,Mutational analysis of the tyrosine kinome in serous and clear cell endometrial cancer uncovers rare somatic mutations in TNK2 and DDR1.,http://www.ncbi.nlm.nih.gov/pubmed/25427824
9143,22536950,A small-molecule probe of the histone methyltransferase G9a induces cellular senescence in pancreatic adenocarcinoma.,http://www.ncbi.nlm.nih.gov/pubmed/22536950
9144,23649896,Genetic analysis of inherited leukodystrophies: genotype-phenotype correlations in the CSF1R gene.,http://www.ncbi.nlm.nih.gov/pubmed/23649896
9145,28368437,Phase II randomized study of PM01183 versus topotecan in patients with platinum-resistant/refractory advanced ovarian cancer.,http://www.ncbi.nlm.nih.gov/pubmed/28368437
9146,28327953,Final overall survival analysis for the phase II RECORD-3 study of first-line everolimus followed by sunitinib versus first-line sunitinib followed by everolimus in metastatic RCC.,http://www.ncbi.nlm.nih.gov/pubmed/28327953
9147,28242752,"Phase I, Dose-Escalation, Two-Part Trial of the PARP Inhibitor Talazoparib in Patients with Advanced Germline BRCA1/2 Mutations and Selected Sporadic Cancers.",http://www.ncbi.nlm.nih.gov/pubmed/28242752
9148,20127001,Overexpression of EGFR pathway-related genes in the circulation is highly correlated with EGFR mutations and overexpression in paired cancer tissue from patients with non-small cell lung cancer.,http://www.ncbi.nlm.nih.gov/pubmed/20127001
9149,28363909,A Phase Ib Dose-Escalation Study of Encorafenib and Cetuximab with or without Alpelisib in Metastatic BRAF-Mutant Colorectal Cancer.,http://www.ncbi.nlm.nih.gov/pubmed/28363909
9150,2406720,"FMS mutations in myelodysplastic, leukemic, and normal subjects.",http://www.ncbi.nlm.nih.gov/pubmed/2406720
9151,,"TAS4464, a novel, highly potent, and selective inhibitor of NEDD8 activating enzyme demonstrates sustained target inhibition and antitumor activity in a preclinical model",http://mct.aacrjournals.org/content/14/12_Supplement_2/C176
9152,,"TAS4464, a novel and highly potent NEDD8 activating enzyme (NAE) inhibitor, causes apoptosis of sarcomas via cell cycle dysregulation",http://cancerres.aacrjournals.org/content/76/14_Supplement/3777
9153,,"TAS4464, a novel highly potent NEDD8 activating enzyme inhibitor, demonstrates antitumor activity in multiple myeloma through the inactivation of NF-?B pathways",http://cancerres.aacrjournals.org/content/75/15_Supplement/1730
9154,28108151,A Functional Genetic Screen Identifies the Phosphoinositide 3-kinase Pathway as a Determinant of Resistance to Fibroblast Growth Factor Receptor Inhibitors in FGFR Mutant Urothelial Cell Carcinoma.,http://www.ncbi.nlm.nih.gov/pubmed/28108151
9155,,"TG02, an Oral CDK9-Inhibitor, in Combination with Carfilzomib Demonstrated Objective Responses in Carfilzomib Refractory Multiple Myeloma Patients",http://www.bloodjournal.org/content/126/23/3052?sso-checked=true
9156,28274957,An Acquired HER2(T798I) Gatekeeper Mutation Induces Resistance to Neratinib in a Patient with HER2 Mutant-Driven Breast Cancer.,http://www.ncbi.nlm.nih.gov/pubmed/28274957
9157,26895102,The cancer-testis antigens SPANX-A/C/D and CTAG2 promote breast cancer invasion.,http://www.ncbi.nlm.nih.gov/pubmed/26895102
9158,24457462,"Expression of cancer-testis antigens MAGEA1, MAGEA3, ACRBP, PRAME, SSX2, and CTAG2 in myxoid and round cell liposarcoma.",http://www.ncbi.nlm.nih.gov/pubmed/24457462
9159,15715909,"Cancer/testis antigens and gametogenesis: a review and ""brain-storming"" session.",http://www.ncbi.nlm.nih.gov/pubmed/15715909
9160,22936067,The cancer-testis antigen NY-ESO-1 is highly expressed in myxoid and round cell subset of liposarcomas.,http://www.ncbi.nlm.nih.gov/pubmed/22936067
9161,27439477,Irreversible Inhibition of EGFR: Modeling the Combined Pharmacokinetic-Pharmacodynamic Relationship of Osimertinib and Its Active Metabolite AZ5104.,http://www.ncbi.nlm.nih.gov/pubmed/27439477
9162,,A phase II study of everolimus for advanced melanoma patients with mTOR mutations.,http://ascopubs.org/doi/abs/10.1200/jco.2015.33.15_suppl.e20007
9163,27713405,Molecular analysis of aggressive renal cell carcinoma with unclassified histology reveals distinct subsets.,http://www.ncbi.nlm.nih.gov/pubmed/27713405
9164,24190505,"Exomic analysis of myxoid liposarcomas, synovial sarcomas, and osteosarcomas.",http://www.ncbi.nlm.nih.gov/pubmed/24190505
9165,21936726,"A dual CCR2/CCR5 chemokine antagonist, BMS-813160? Evaluation of WO2011046916.",http://www.ncbi.nlm.nih.gov/pubmed/21936726
9166,26843484,Phase II multicenter study of gene-mediated cytotoxic immunotherapy as adjuvant to surgical resection for newly diagnosed malignant glioma.,http://www.ncbi.nlm.nih.gov/pubmed/26843484
9167,20160034,Evaluation of the proteasome inhibitor MLN9708 in preclinical models of human cancer.,http://www.ncbi.nlm.nih.gov/pubmed/20160034
9168,25098829,Development of asparaginase Erwinia chrysanthemi for the treatment of acute lymphoblastic leukemia.,http://www.ncbi.nlm.nih.gov/pubmed/25098829
9169,26698391,L-asparaginase as a critical component to combat Acute Lymphoblastic Leukaemia (ALL): A novel approach to target ALL.,http://www.ncbi.nlm.nih.gov/pubmed/26698391
9170,27920721,Commentary: Overcoming mTOR resistance mutations with a new-generation mTOR inhibitor.,http://www.ncbi.nlm.nih.gov/pubmed/27920721
9171,28553668,The clinical spectrum of Erdheim-Chester disease: an observational cohort study.,http://www.ncbi.nlm.nih.gov/pubmed/28553668
9172,27903679,The Bruton Tyrosine Kinase (BTK) Inhibitor Acalabrutinib Demonstrates Potent On-Target Effects and Efficacy in Two Mouse Models of Chronic Lymphocytic Leukemia.,http://www.ncbi.nlm.nih.gov/pubmed/27903679
9173,28580882,MONARCH 2: Abemaciclib in Combination With Fulvestrant in Women With HR+/HER2- Advanced Breast Cancer Who Had Progressed While Receiving Endocrine Therapy.,http://www.ncbi.nlm.nih.gov/pubmed/28580882
9174,28383677,"Pazopanib in advanced germ cell tumors after chemotherapy failure: results of the open-label, single-arm, phase 2 Pazotest trial.",http://www.ncbi.nlm.nih.gov/pubmed/28383677
9175,28327907,"A randomized, open-label, phase 2 study of everolimus in combination with pasireotide LAR or everolimus alone in advanced, well-differentiated, progressive pancreatic neuroendocrine tumors: COOPERATE-2 trial.",http://www.ncbi.nlm.nih.gov/pubmed/28327907
9176,27932416,A Phase II Trial of Dovitinib in BCG-Unresponsive Urothelial Carcinoma with FGFR3 Mutations or Overexpression: Hoosier Cancer Research Network Trial HCRN 12-157.,http://www.ncbi.nlm.nih.gov/pubmed/27932416
9177,28327988,"Efficacy and safety of nilotinib in patients with KIT-mutated metastatic or inoperable melanoma: final results from the global, single-arm, phase II TEAM trial.",http://www.ncbi.nlm.nih.gov/pubmed/28327988
9178,28011461,Antitumor Activity of RXDX-105 in Multiple Cancer Types with RET Rearrangements or Mutations.,http://www.ncbi.nlm.nih.gov/pubmed/28011461
9179,,Abiraterone + prednisone (Abi) +/- veliparib (Vel) for patients (pts) with metastatic castration-resistant prostate cancer (CRPC): NCI 9012 updated clinical and genomics data.,http://abstracts.asco.org/199/AbstView_199_182138.html
9180,28615361,"Targeting KRAS-dependent tumors with AZD4785, a high-affinity therapeutic antisense oligonucleotide inhibitor of KRAS.",http://www.ncbi.nlm.nih.gov/pubmed/28615361
9181,28297679,Integrative Genomic Analysis of Cholangiocarcinoma Identifies Distinct IDH-Mutant Molecular Profiles.,http://www.ncbi.nlm.nih.gov/pubmed/28297679
9182,26806567,Microglandular adenosis associated with triple-negative breast cancer is a neoplastic lesion of triple-negative phenotype harbouring TP53 somatic mutations.,http://www.ncbi.nlm.nih.gov/pubmed/26806567
9183,22678283,Chemical genetic discovery of targets and anti-targets for cancer polypharmacology.,http://www.ncbi.nlm.nih.gov/pubmed/22678283
9184,,NTRK1-3 point mutations in poor prognosis thyroid cancers,http://abstracts.asco.org/199/AbstView_199_186788.html
9185,28249155,Pharmacologic Targeting of S6K1 in PTEN-Deficient Neoplasia.,http://www.ncbi.nlm.nih.gov/pubmed/28249155
9186,28615362,Drugging the catalytically inactive state of RET kinase in RET-rearranged tumors.,http://www.ncbi.nlm.nih.gov/pubmed/28615362
9187,28578312,A Next-Generation TRK Kinase Inhibitor Overcomes Acquired Resistance to Prior TRK Kinase Inhibition in Patients with TRK Fusion-Positive Solid Tumors.,http://www.ncbi.nlm.nih.gov/pubmed/28578312
9188,27273450,CRAF R391W is a melanoma driver oncogene.,http://www.ncbi.nlm.nih.gov/pubmed/27273450
9189,20350212,Pseudonegative BCL2 protein expression in a t(14;18) translocation positive lymphoma cell line: a need for an alternative BCL2 antibody.,http://www.ncbi.nlm.nih.gov/pubmed/20350212
9190,25495986,Histone methylases as novel drug targets: developing inhibitors of EZH2.,http://www.ncbi.nlm.nih.gov/pubmed/25495986
9191,27034166,Mutational analysis of single circulating tumor cells by next generation sequencing in metastatic breast cancer.,http://www.ncbi.nlm.nih.gov/pubmed/27034166
9192,22722798,Rare and novel epidermal growth factor receptor mutations in non-small-cell lung cancer and lack of clinical response to gefitinib in two cases.,http://www.ncbi.nlm.nih.gov/pubmed/22722798
9193,27027238,Use of dedicated gene panel sequencing using next generation sequencing to improve the personalized care of lung cancer.,http://www.ncbi.nlm.nih.gov/pubmed/27027238
9194,17409862,Clinicopathologic characteristics of the EGFR gene mutation in non-small cell lung cancer.,http://www.ncbi.nlm.nih.gov/pubmed/17409862
9195,25411647,Single-Tube Mutation Scanning of The Epidermal Growth Factor Receptor Gene Using Multiplex LATE-PCR and Lights-On/Lights-Off Probes.,http://www.ncbi.nlm.nih.gov/pubmed/25411647
9196,22317764,Frequency of driver mutations in lung adenocarcinoma from female never-smokers varies with histologic subtypes and age at diagnosis.,http://www.ncbi.nlm.nih.gov/pubmed/22317764
9197,17094398,Gefitinib efficacy associated with multiple expression of HER family in non-small cell lung cancer.,http://www.ncbi.nlm.nih.gov/pubmed/17094398
9198,24376513,Drug resistance missense mutations in cancer are subject to evolutionary constraints.,http://www.ncbi.nlm.nih.gov/pubmed/24376513
9199,23486275,Two rare exon 21 EGFR mutations in patients treated with gefitinib.,http://www.ncbi.nlm.nih.gov/pubmed/23486275
9200,17409930,Mutation and polymorphism in the EGFR-TK domain associated with lung cancer.,http://www.ncbi.nlm.nih.gov/pubmed/17409930
9201,27123274,Distinct epithelial growth factor receptor mutation profile in non-small-cell lung cancer patients from the Xuanwei area of China.,http://www.ncbi.nlm.nih.gov/pubmed/27123274
9202,24406864,High EGFR gene copy number predicts poor outcome in triple-negative breast cancer.,http://www.ncbi.nlm.nih.gov/pubmed/24406864
9203,18379371,Long-lasting complete remission with tyrosine kinase inhibitor in bronchioloalveolar carcinoma with a so far unknown EGFR mutation.,http://www.ncbi.nlm.nih.gov/pubmed/18379371
9204,25560806,"Pharmacologic inhibition of ATR and ATM offers clinically important distinctions to enhancing platinum or radiation response in ovarian, endometrial, and cervical cancer cells.",http://www.ncbi.nlm.nih.gov/pubmed/25560806
9205,28416490,Preclinical Characterization of BET Family Bromodomain Inhibitor ABBV-075 Suggests Combination Therapeutic Strategies.,http://www.ncbi.nlm.nih.gov/pubmed/28416490
9206,28632865,Effect of First-Line Chemotherapy Combined With Cetuximab or Bevacizumab on Overall Survival in Patients With KRAS Wild-Type Advanced or Metastatic Colorectal Cancer: A Randomized Clinical Trial.,http://www.ncbi.nlm.nih.gov/pubmed/28632865
9207,,Updated survival of patients (pts) with previously treated BRAF V600E–mutant advanced non-small cell lung cancer (NSCLC) who received dabrafenib (D) or D + trametinib (T) in the phase II BRF113928 study.,http://ascopubs.org/doi/abs/10.1200/JCO.2017.35.15_suppl.9075
9208,,Randomized phase III trial of adjuvant pazopanib versus placebo after nephrectomy in patients with locally advanced renal cell carcinoma (RCC) (PROTECT).,http://abstracts.asco.org/199/AbstView_199_186739.html
9209,24240689,Preclinical validation of AXL receptor as a target for antibody-based pancreatic cancer immunotherapy.,http://www.ncbi.nlm.nih.gov/pubmed/24240689
9210,27923843,Therapeutic Activity of Anti-AXL Antibody against Triple-Negative Breast Cancer Patient-Derived Xenografts and Metastasis.,http://www.ncbi.nlm.nih.gov/pubmed/27923843
9211,,Epacadostat plus pembrolizumab in patients with advanced RCC: Preliminary phase I/II results from ECHO-202/KEYNOTE-037.,http://abstracts.asco.org/199/AbstView_199_184165.html
9212,28280273,A pharmacogenomic approach validates AG-221 as an effective and on-target therapy in IDH2 mutant AML.,http://www.ncbi.nlm.nih.gov/pubmed/28280273
9213,,Enasidenib in mutant-IDH2 relapsed or refractory acute myeloid leukemia (R/R AML): Results of a phase I dose-escalation and expansion study.,http://abstracts.asco.org/199/AbstView_199_189549.html
9214,8381544,Housing conditions influence acquisition of sufentanil aerosol self-administration in rats.,http://www.ncbi.nlm.nih.gov/pubmed/8381544
9215,28381544,Modulation of Bax and mTOR for Cancer Therapeutics.,http://www.ncbi.nlm.nih.gov/pubmed/28381544
9216,,Alectinib versus crizotinib in treatment-naive advanced ALK-positive non-small cell lung cancer (NSCLC): Primary results of the global phase III ALEX study.,http://abstracts.asco.org/199/AbstView_199_185951.html
9217,24376688,The Frequency and clinical significance of IDH1 mutations in Chinese acute myeloid leukemia patients.,http://www.ncbi.nlm.nih.gov/pubmed/24376688
9218,28330869,Molecular mechanisms of isocitrate dehydrogenase 1 (IDH1) mutations identified in tumors: The role of size and hydrophobicity at residue 132 on catalytic efficiency.,http://www.ncbi.nlm.nih.gov/pubmed/28330869
9219,25677745,Rationale for targeting fibroblast growth factor receptor signaling in breast cancer.,http://www.ncbi.nlm.nih.gov/pubmed/25677745
9220,28039262,Potential Predictive Value of TP53 and KRAS Mutation Status for Response to PD-1 Blockade Immunotherapy in Lung Adenocarcinoma.,http://www.ncbi.nlm.nih.gov/pubmed/28039262
9221,23063752,Identification of Hedgehog pathway responsive glioblastomas by isocitrate dehydrogenase mutation.,http://www.ncbi.nlm.nih.gov/pubmed/23063752
9222,27979916,Combination Epigenetic Therapy in Advanced Breast Cancer with 5-Azacitidine and Entinostat: A Phase II National Cancer Institute/Stand Up to Cancer Study.,http://www.ncbi.nlm.nih.gov/pubmed/27979916
9223,28476440,"Efficacy and safety of subcutaneous rituximab versus intravenous rituximab for first-line treatment of follicular lymphoma (SABRINA): a randomised, open-label, phase 3 trial.",http://www.ncbi.nlm.nih.gov/pubmed/28476440
9224,28258222,Molecular mechanism and structural basis of gain-of-function of STAT1 caused by pathogenic R274Q mutation.,http://www.ncbi.nlm.nih.gov/pubmed/28258222
9225,15860862,Role of the CDKN2A locus in patients with multiple primary melanomas.,http://www.ncbi.nlm.nih.gov/pubmed/15860862
9226,22368299,CDKN2A is the main susceptibility gene in Italian pancreatic cancer families.,http://www.ncbi.nlm.nih.gov/pubmed/22368299
9227,21771097,Low incidence of EGFR and HRAS mutations in cutaneous squamous cell carcinomas of a German cohort.,http://www.ncbi.nlm.nih.gov/pubmed/21771097
9228,28196074,Clinical applicability and cost of a 46-gene panel for genomic analysis of solid tumours: Retrospective validation and prospective audit in the UK National Health Service.,http://www.ncbi.nlm.nih.gov/pubmed/28196074
9229,19671843,Impact of epidermal growth factor receptor and KRAS mutations on clinical outcomes in previously untreated non-small cell lung cancer patients: results of an online tumor registry of clinical trials.,http://www.ncbi.nlm.nih.gov/pubmed/19671843
9230,20346742,Epidermal growth factor receptor mutation and diverse tumors: case report and concise literature review.,http://www.ncbi.nlm.nih.gov/pubmed/20346742
9231,28404587,CIC-DUX4 Induces Small Round Cell Sarcomas Distinct from Ewing Sarcoma.,http://www.ncbi.nlm.nih.gov/pubmed/28404587
9232,27389054,Mutations in the JAK/STAT and RAS signaling pathways are common in intestinal T-cell lymphomas.,http://www.ncbi.nlm.nih.gov/pubmed/27389054
9233,26918361,Panel sequencing for clinically oriented variant screening and copy number detection in 142 untreated multiple myeloma patients.,http://www.ncbi.nlm.nih.gov/pubmed/26918361
9234,24837465,STAT3 mutations are present in aggressive B-cell lymphomas including a subset of diffuse large B-cell lymphomas with CD30 expression.,http://www.ncbi.nlm.nih.gov/pubmed/24837465
9235,28452926,"KRAS, TP53, CDKN2A, SMAD4, BRCA1, and BRCA2 Mutations in Pancreatic Cancer.",http://www.ncbi.nlm.nih.gov/pubmed/28452926
9236,28067794,The TGF-β/Smad4 Signaling Pathway in Pancreatic Carcinogenesis and Its Clinical Significance.,http://www.ncbi.nlm.nih.gov/pubmed/28067794
9237,28224663,Loss of MLH1 sensitizes colon cancer cells to DNA-PKcs inhibitor KU60648.,http://www.ncbi.nlm.nih.gov/pubmed/28224663
9238,28454461,Prognostic value of MLH1 promoter methylation in male patients with esophageal squamous cell carcinoma.,http://www.ncbi.nlm.nih.gov/pubmed/28454461
9239,27723760,The genomic landscape of schwannoma.,http://www.ncbi.nlm.nih.gov/pubmed/27723760
9240,27758892,E2A-PBX1 Remodels Oncogenic Signaling Networks in B-cell Precursor Acute Lymphoid Leukemia.,http://www.ncbi.nlm.nih.gov/pubmed/27758892
9241,25236161,A-770041 reverses paclitaxel and doxorubicin resistance in osteosarcoma cells.,http://www.ncbi.nlm.nih.gov/pubmed/25236161
9242,28444114,"Efficacy of everolimus plus octreotide LAR in patients with advanced neuroendocrine tumor and carcinoid syndrome: final overall survival from the randomized, placebo-controlled phase 3 RADIANT-2 study.",http://www.ncbi.nlm.nih.gov/pubmed/28444114
9243,28407039,Tumor Immune Microenvironment and Nivolumab Efficacy in EGFR Mutation-Positive Non-Small Cell Lung Cancer Based on T790M Status after Disease Progression During EGFR-TKI Treatment.,http://www.ncbi.nlm.nih.gov/pubmed/28407039
9244,26434885,Metformin Addition to Chemotherapy in Stage IV Non-Small Cell Lung Cancer: an Open Label Randomized Controlled Study.,http://www.ncbi.nlm.nih.gov/pubmed/26434885
9245,23729478,Amplification of the MET receptor drives resistance to anti-EGFR therapies in colorectal cancer.,http://www.ncbi.nlm.nih.gov/pubmed/23729478
9246,26657506,HER2 genomic amplification in circulating tumor DNA from patients with cetuximab-resistant colorectal cancer.,http://www.ncbi.nlm.nih.gov/pubmed/26657506
9247,21900593,Activation of ERBB2 signaling causes resistance to the EGFR-directed therapeutic antibody cetuximab.,http://www.ncbi.nlm.nih.gov/pubmed/21900593
9248,21964340,Inhibition of BET recruitment to chromatin as an effective treatment for MLL-fusion leukaemia.,http://www.ncbi.nlm.nih.gov/pubmed/21964340
9249,28592386,"CT-P6 compared with reference trastuzumab for HER2-positive breast cancer: a randomised, double-blind, active-controlled, phase 3 equivalence trial.",http://www.ncbi.nlm.nih.gov/pubmed/28592386
9250,24332717,"Structure, functional characterization, and evolution of the dihydroorotase domain of human CAD.",http://www.ncbi.nlm.nih.gov/pubmed/24332717
9251,10995463,Retrovirus-mediated gene transfer of MLL-ELL transforms primary myeloid progenitors and causes acute myeloid leukemias in mice.,http://www.ncbi.nlm.nih.gov/pubmed/10995463
9252,26816005,Homologous Transcription Factors DUX4 and DUX4c Associate with Cytoplasmic Proteins during Muscle Differentiation.,http://www.ncbi.nlm.nih.gov/pubmed/26816005
9253,27079694,CIC-DUX4 fusion-positive round-cell sarcomas of soft tissue and bone: a single-institution morphological and molecular analysis of seven cases.,http://www.ncbi.nlm.nih.gov/pubmed/27079694
9254,25667100,Aurora kinase A and B as new treatment targets in aromatase inhibitor-resistant breast cancer cells.,http://www.ncbi.nlm.nih.gov/pubmed/25667100
9255,22586653,"A molecularly annotated platform of patient-derived xenografts (""xenopatients"") identifies HER2 as an effective therapeutic target in cetuximab-resistant colorectal cancer.",http://www.ncbi.nlm.nih.gov/pubmed/22586653
9256,23251566,High DNA methyltransferase DNMT3B levels: a poor prognostic marker in acute myeloid leukemia.,http://www.ncbi.nlm.nih.gov/pubmed/23251566
9257,28512244,Engineering and Functional Characterization of Fusion Genes Identifies Novel Oncogenic Drivers of Cancer.,http://www.ncbi.nlm.nih.gov/pubmed/28512244
9258,,"Efficacy, maximal tolerated dose, and toxicokinetics of TTC-352 in rats and dogs, a partial ER agonist for metastatic ER+ breast cancer.",http://abstracts.asco.org/199/AbstView_199_193693.html
9259,25205655,Novel selective estrogen mimics for the treatment of tamoxifen-resistant breast cancer.,http://www.ncbi.nlm.nih.gov/pubmed/25205655
9260,27027445,Small-molecule inhibition of STAT3 in radioresistant head and neck squamous cell carcinoma.,http://www.ncbi.nlm.nih.gov/pubmed/27027445
9261,28644114,Midostaurin plus Chemotherapy for Acute Myeloid Leukemia with a FLT3 Mutation.,http://www.ncbi.nlm.nih.gov/pubmed/28644114
9262,,ATR inhibitor BAY 1895344 in monotherapy and combination in preclinical tumor models,https://books.google.com/books?id=4UFUDgAAQBAJ&pg=PT918&lpg=PT918&dq=ATR+inhibitor+BAY+1895344+in+monotherapy+and+combination+in+preclinical+tumor+models&source=bl&ots=qSIo1S4wDW&sig=FG2REd6HnsC284nxW
9263,11607843,The actin filament-associated protein AFAP-110 is an adaptor protein that modulates changes in actin filament integrity.,http://www.ncbi.nlm.nih.gov/pubmed/11607843
9264,21236256,Actin filament associated protein mediates c-Src related SRE/AP-1 transcriptional activation.,http://www.ncbi.nlm.nih.gov/pubmed/21236256
9265,25043309,Actin filament-associated protein 1 is required for cSrc activity and secretory activation in the lactating mammary gland.,http://www.ncbi.nlm.nih.gov/pubmed/25043309
9266,17885682,AFAP-110 is overexpressed in prostate cancer and contributes to tumorigenic growth by regulating focal contacts.,http://www.ncbi.nlm.nih.gov/pubmed/17885682
9267,10843801,"Transcription mapping of the 5q- syndrome critical region: cloning of two novel genes and sequencing, expression, and mapping of a further six novel cDNAs.",http://www.ncbi.nlm.nih.gov/pubmed/10843801
9268,27626069,Evolution of a FLT3-TKD mutated subclone at meningeal relapse in acute promyelocytic leukemia.,http://www.ncbi.nlm.nih.gov/pubmed/27626069
9269,16314519,"Disruption of Sept6, a fusion partner gene of MLL, does not affect ontogeny, leukemogenesis induced by MLL-SEPT6, or phenotype induced by the loss of Sept4.",http://www.ncbi.nlm.nih.gov/pubmed/16314519
9270,28522256,"Sporadic Early-Onset Diffuse Gastric Cancers Have High Frequency of Somatic CDH1 Alterations, but Low Frequency of Somatic RHOA Mutations Compared With Late-Onset Cancers.",http://www.ncbi.nlm.nih.gov/pubmed/28522256
9271,27294782,Functional interdependence of BRD4 and DOT1L in MLL leukemia.,http://www.ncbi.nlm.nih.gov/pubmed/27294782
9272,26068201,TCF12 is mutated in anaplastic oligodendroglioma.,http://www.ncbi.nlm.nih.gov/pubmed/26068201
9273,28504649,Activation of tumor suppressor protein PP2A inhibits KRAS-driven tumor growth.,http://www.ncbi.nlm.nih.gov/pubmed/28504649
9274,23915145,Overexpression of CARM1 in breast cancer is correlated with poorly characterized clinicopathologic parameters and molecular subtypes.,http://www.ncbi.nlm.nih.gov/pubmed/23915145
9275,24211191,CARM1 and PRMT1 are dysregulated in lung cancer without hierarchical features.,http://www.ncbi.nlm.nih.gov/pubmed/24211191
9276,27621679,IDH1 and IDH2 mutations as novel therapeutic targets: current perspectives.,http://www.ncbi.nlm.nih.gov/pubmed/27621679
9277,27196317,Gene Expression Analysis Indicates Divergent Mechanisms in DEN-Induced Carcinogenesis in Wild Type and Bid-Deficient Livers.,http://www.ncbi.nlm.nih.gov/pubmed/27196317
9278,28035363,ADAR2 functions as a tumor suppressor via editing IGFBP7 in esophageal squamous cell carcinoma.,http://www.ncbi.nlm.nih.gov/pubmed/28035363
9279,25836588,Clinical and biological implications of ancestral and non-ancestral IDH1 and IDH2 mutations in myeloid neoplasms.,http://www.ncbi.nlm.nih.gov/pubmed/25836588
9280,24344212,Predicting and communicating the risk of recurrence and death in women with early-stage breast cancer: a systematic review of risk prediction models.,http://www.ncbi.nlm.nih.gov/pubmed/24344212
9281,28591738,AGO2 involves the malignant phenotypes and FAK/PI3K/AKT signaling pathway in hypopharyngeal-derived FaDu cells.,http://www.ncbi.nlm.nih.gov/pubmed/28591738
9282,28363999,ATM Deficiency Is Associated with Sensitivity to PARP1- and ATR Inhibitors in Lung Adenocarcinoma.,http://www.ncbi.nlm.nih.gov/pubmed/28363999
9283,21647154,IDH1 and IDH2 mutations in pediatric acute leukemia.,http://www.ncbi.nlm.nih.gov/pubmed/21647154
9284,22215888,IDH2 mutations are frequent in angioimmunoblastic T-cell lymphoma.,http://www.ncbi.nlm.nih.gov/pubmed/22215888
9285,28194436,Real-time genomic profiling of histiocytoses identifies early-kinase domain BRAF alterations while improving treatment outcomes.,http://www.ncbi.nlm.nih.gov/pubmed/28194436
9286,28648147,Functional roles of CTCF in breast cancer.,http://www.ncbi.nlm.nih.gov/pubmed/28648147
9287,27469332,"Clinicopathological effects of protein phosphatase 2, regulatory subunit A, alpha mutations in gastrointestinal stromal tumors.",http://www.ncbi.nlm.nih.gov/pubmed/27469332
9288,26137586,A Hot-spot of In-frame Duplications Activates the Oncoprotein AKT1 in Juvenile Granulosa Cell Tumors.,http://www.ncbi.nlm.nih.gov/pubmed/26137586
9289,24318467,"Mutations in EGFR, BRAF and RAS are rare in triple-negative and basal-like breast cancers from Caucasian women.",http://www.ncbi.nlm.nih.gov/pubmed/24318467
9290,27736729,"KB004, a first in class monoclonal antibody targeting the receptor tyrosine kinase EphA3, in patients with advanced hematologic malignancies: Results from a phase 1 study.",http://www.ncbi.nlm.nih.gov/pubmed/27736729
9291,28377489,Preclinical Activity of the Novel Anti-Prolactin Receptor (PRLR) Antibody-Drug Conjugate REGN2878-DM1 in PRLR-Positive Breast Cancers.,http://www.ncbi.nlm.nih.gov/pubmed/28377489
9292,28428442,Combination of Ibrutinib and ABT-199 in Diffuse Large B-Cell Lymphoma and Follicular Lymphoma.,http://www.ncbi.nlm.nih.gov/pubmed/28428442
9293,28507002,Neuregulin 1 Allosterically Enhances the Antitumor Effects of the Noncompeting Anti-HER3 Antibody 9F7-F11 by Increasing Its Binding to HER3.,http://www.ncbi.nlm.nih.gov/pubmed/28507002
9294,28424227,ONC201 Demonstrates Antitumor Effects in Both Triple-Negative and Non-Triple-Negative Breast Cancers through TRAIL-Dependent and TRAIL-Independent Mechanisms.,http://www.ncbi.nlm.nih.gov/pubmed/28424227
9295,27697994,The Dual Syk/JAK Inhibitor Cerdulatinib Antagonizes B-cell Receptor and Microenvironmental Signaling in Chronic Lymphocytic Leukemia.,http://www.ncbi.nlm.nih.gov/pubmed/27697994
9296,,"Phase 1b/2 trial of ribociclib+binimetinib in metastatic NRAS-mutant melanoma: Safety, efficacy, and recommended phase 2 dose (RP2D).",http://meetinglibrary.asco.org/record/147511/abstract
9297,25259869,Genetic disruption of the sh3pxd2a gene reveals an essential role in mouse development and the existence of a novel isoform of tks5.,http://www.ncbi.nlm.nih.gov/pubmed/25259869
9298,28351928,Ribociclib (LEE011): Mechanism of Action and Clinical Impact of This Selective Cyclin-Dependent Kinase 4/6 Inhibitor in Various Solid Tumors.,http://www.ncbi.nlm.nih.gov/pubmed/28351928
9299,24040176,Serine protease HTRA1 antagonizes transforming growth factor-β signaling by cleaving its receptors and loss of HTRA1 in vivo enhances bone formation.,http://www.ncbi.nlm.nih.gov/pubmed/24040176
9300,26035313,HtrA1: Its future potential as a novel biomarker for cancer.,http://www.ncbi.nlm.nih.gov/pubmed/26035313
9301,,CR rates in relapsed/refractory (R/R) aggressive B-NHL treated with the CD19-directed CAR T-cell product JCAR017 (TRANSCEND NHL 001).,http://abstracts.asco.org/199/AbstView_199_185939.html
9302,,Patient-reported quality of life (QOL) following CTL019 in pediatric and young adult patients (pts) with relapsed/refractory (r/r) b-cell acute lymphoblastic leukemia (B-ALL).,http://abstracts.asco.org/199/AbstView_199_187018.html
9303,22573616,Function of Wnt/β-catenin in counteracting Tcf3 repression through the Tcf3-β-catenin interaction.,http://www.ncbi.nlm.nih.gov/pubmed/22573616
9304,23090119,Control of breast cancer growth and initiation by the stem cell-associated transcription factor TCF3.,http://www.ncbi.nlm.nih.gov/pubmed/23090119
9305,25729575,A (1;19) translocation involving TCF3-PBX1 fusion within the context of a hyperdiploid karyotype in adult B-ALL: a case report and review of the literature.,http://www.ncbi.nlm.nih.gov/pubmed/25729575
9306,25519700,"MLN0128, an ATP-competitive mTOR kinase inhibitor with potent in vitro and in vivo antitumor activity, as potential therapy for bone and soft-tissue sarcoma.",http://www.ncbi.nlm.nih.gov/pubmed/25519700
9307,27002938,"A first in man, dose-finding study of the mTORC1/mTORC2 inhibitor OSI-027 in patients with advanced solid malignancies.",http://www.ncbi.nlm.nih.gov/pubmed/27002938
9308,19561198,Fibroblast growth factor 1 induced during myogenesis by a transcription-translation coupling mechanism.,http://www.ncbi.nlm.nih.gov/pubmed/19561198
9309,26840910,Identification of new FGF1 binding partners-Implications for its intracellular function.,http://www.ncbi.nlm.nih.gov/pubmed/26840910
9310,20094046,Fibroblast growth factor signalling: from development to cancer.,http://www.ncbi.nlm.nih.gov/pubmed/20094046
9311,24463227,Amphiregulin.,http://www.ncbi.nlm.nih.gov/pubmed/24463227
9312,21658434,The multiple roles of amphiregulin in human cancer.,http://www.ncbi.nlm.nih.gov/pubmed/21658434
9313,19577736,Nuclear pore proteins and cancer.,http://www.ncbi.nlm.nih.gov/pubmed/19577736
9314,21948299,NUP98 gene fusions and hematopoietic malignancies: common themes and new biologic insights.,http://www.ncbi.nlm.nih.gov/pubmed/21948299
9315,27889185,NUP98 Fusion Proteins Interact with the NSL and MLL1 Complexes to Drive Leukemogenesis.,http://www.ncbi.nlm.nih.gov/pubmed/27889185
9316,11598623,Expression of fibroblast growth factor (FGF)-10 in human colorectal adenocarcinoma cells.,http://www.ncbi.nlm.nih.gov/pubmed/11598623
9317,18594526,FGF10/FGFR2 signal induces cell migration and invasion in pancreatic cancer.,http://www.ncbi.nlm.nih.gov/pubmed/18594526
9318,26811660,Group II p21-activated kinases as therapeutic targets in gastrointestinal cancer.,http://www.ncbi.nlm.nih.gov/pubmed/26811660
9319,23685956,P21-activated kinase 5 plays essential roles in the proliferation and tumorigenicity of human hepatocellular carcinoma.,http://www.ncbi.nlm.nih.gov/pubmed/23685956
9320,26212009,PAK5-mediated E47 phosphorylation promotes epithelial-mesenchymal transition and metastasis of colon cancer.,http://www.ncbi.nlm.nih.gov/pubmed/26212009
9321,21640373,FOXL2 C402G mutation detection using MALDI-TOF-MS in DNA extracted from Israeli granulosa cell tumors.,http://www.ncbi.nlm.nih.gov/pubmed/21640373
9322,24794443,CTCF haploinsufficiency destabilizes DNA methylation and predisposes to cancer.,http://www.ncbi.nlm.nih.gov/pubmed/24794443
9323,26325035,"Anti-PD-1/PD-L1 therapy of human cancer: past, present, and future.",http://www.ncbi.nlm.nih.gov/pubmed/26325035
9324,26681673,Regulation of PD-L1: a novel role of pro-survival signalling in cancer.,http://www.ncbi.nlm.nih.gov/pubmed/26681673
9325,26320063,Antagonists of PD-1 and PD-L1 in Cancer Treatment.,http://www.ncbi.nlm.nih.gov/pubmed/26320063
9326,21896759,Restraint of angiogenesis by zinc finger transcription factor CTCF-dependent chromatin insulation.,http://www.ncbi.nlm.nih.gov/pubmed/21896759
9327,24403232,PD-1 as a potential target in cancer therapy.,http://www.ncbi.nlm.nih.gov/pubmed/24403232
9328,12917689,CYLD is a deubiquitinating enzyme that negatively regulates NF-kappaB activation by TNFR family members.,http://www.ncbi.nlm.nih.gov/pubmed/12917689
9329,20838385,"An inactivating CYLD mutation promotes skin tumor progression by conferring enhanced proliferative, survival and angiogenic properties to epidermal cancer cells.",http://www.ncbi.nlm.nih.gov/pubmed/20838385
9330,11224527,PD-L2 is a second ligand for PD-1 and inhibits T cell activation.,http://www.ncbi.nlm.nih.gov/pubmed/11224527
9331,28018338,The PD1:PD-L1/2 Pathway from Discovery to Clinical Implementation.,http://www.ncbi.nlm.nih.gov/pubmed/28018338
9332,26432723,Signaling pathway and dysregulation of PD1 and its ligands in lymphoid malignancies.,http://www.ncbi.nlm.nih.gov/pubmed/26432723
9333,28619999,PD-L2 Expression in Human Tumors: Relevance to Anti-PD-1 Therapy in Cancer.,http://www.ncbi.nlm.nih.gov/pubmed/28619999
9334,11782357,Tumor-associated zinc finger mutations in the CTCF transcription factor selectively alter tts DNA-binding specificity.,http://www.ncbi.nlm.nih.gov/pubmed/11782357
9335,23071139,Catenin family genes are not commonly mutated in hereditary diffuse gastric cancer.,http://www.ncbi.nlm.nih.gov/pubmed/23071139
9336,20715154,δ-Catenin dysregulation in cancer: interactions with E-cadherin and beyond.,http://www.ncbi.nlm.nih.gov/pubmed/20715154
9337,23733751,Loss of p120-catenin induces metastatic progression of breast cancer by inducing anoikis resistance and augmenting growth factor receptor signaling.,http://www.ncbi.nlm.nih.gov/pubmed/23733751
9338,18541534,Pyruvate dehydrogenase complex activity controls metabolic and malignant phenotype in cancer cells.,http://www.ncbi.nlm.nih.gov/pubmed/18541534
9339,24904893,Pyruvate dehydrogenase kinase as a potential therapeutic target for malignant gliomas.,http://www.ncbi.nlm.nih.gov/pubmed/24904893
9340,27878287,PDK1 promotes tumor cell proliferation and migration by enhancing the Warburg effect in non-small cell lung cancer.,http://www.ncbi.nlm.nih.gov/pubmed/27878287
9341,28617852,Dicumarol inhibits PDK1 and targets multiple malignant behaviors of ovarian cancer cells.,http://www.ncbi.nlm.nih.gov/pubmed/28617852
9342,28199182,One reporter for in-cell activity profiling of majority of protein kinase oncogenes.,http://www.ncbi.nlm.nih.gov/pubmed/28199182
9343,22939401,Resequencing analysis of the candidate tyrosine kinase and RAS pathway gene families in multiple myeloma.,http://www.ncbi.nlm.nih.gov/pubmed/22939401
9344,28505181,Overexpression of pyruvate dehydrogenase kinase 1 in retinoblastoma: A potential therapeutic opportunity for targeting vitreous seeds and hypoxic regions.,http://www.ncbi.nlm.nih.gov/pubmed/28505181
9345,25868605,The pyruvate dehydrogenase complex in cancer: An old metabolic gatekeeper regulated by new pathways and pharmacological agents.,http://www.ncbi.nlm.nih.gov/pubmed/25868605
9346,21900959,CYLD regulates keratinocyte differentiation and skin cancer progression in humans.,http://www.ncbi.nlm.nih.gov/pubmed/21900959
9347,26982322,Regulation of Oral Squamous Cell Carcinoma Proliferation Through Crosstalk Between SMAD7 and CYLD.,http://www.ncbi.nlm.nih.gov/pubmed/26982322
9348,28572092,CYLD deubiquitinase is necessary for proper ubiquitination and degradation of the epidermal growth factor receptor.,http://www.ncbi.nlm.nih.gov/pubmed/28572092
9349,23954140,Clinicopathologic significance of immunostaining of α-thalassemia/mental retardation syndrome X-linked protein and death domain-associated protein in neuroendocrine tumors.,http://www.ncbi.nlm.nih.gov/pubmed/23954140
9350,27162024,"Study of clinicopathological features, hormone immunoexpression, and loss of ATRX and DAXX expression in pancreatic neuroendocrine tumors.",http://www.ncbi.nlm.nih.gov/pubmed/27162024
9351,26205068,Daxx and TCF4 interaction links to oral squamous cell carcinoma growth by promoting cell cycle progression via induction of cyclin D1 expression.,http://www.ncbi.nlm.nih.gov/pubmed/26205068
9352,23642739,Overexpression of the chromatin remodeler death-domain-associated protein in prostate cancer is an independent predictor of early prostate-specific antigen recurrence.,http://www.ncbi.nlm.nih.gov/pubmed/23642739
9353,15585319,The link between PKCalpha regulation and cellular transformation.,http://www.ncbi.nlm.nih.gov/pubmed/15585319
9354,12417014,Protein kinase C alpha (PKC alpha): regulation and biological function.,http://www.ncbi.nlm.nih.gov/pubmed/12417014
9355,24970481,"Definition of PKC-α, CDK6, and MET as therapeutic targets in triple-negative breast cancer.",http://www.ncbi.nlm.nih.gov/pubmed/24970481
9356,24366551,Protein kinase C-α downregulates estrogen receptor-α by suppressing c-Jun phosphorylation in estrogen receptor-positive breast cancer cells.,http://www.ncbi.nlm.nih.gov/pubmed/24366551
9357,19812598,Somatic mutation of epidermal growth factor receptor in a small subset of cutaneous squamous cell carcinoma.,http://www.ncbi.nlm.nih.gov/pubmed/19812598
9358,28151998,Effects of FGFR2 kinase activation loop dynamics on catalytic activity.,http://www.ncbi.nlm.nih.gov/pubmed/28151998
9359,9554852,"Functional interaction of an axin homolog, conductin, with beta-catenin, APC, and GSK3beta.",http://www.ncbi.nlm.nih.gov/pubmed/9554852
9360,15735151,The links between axin and carcinogenesis.,http://www.ncbi.nlm.nih.gov/pubmed/15735151
9361,28489509,AKT Inhibition in Solid Tumors With AKT1 Mutations.,http://www.ncbi.nlm.nih.gov/pubmed/28489509
9362,17373666,Mutations of the Wnt antagonist AXIN2 (Conductin) result in TCF-dependent transcription in medulloblastomas.,http://www.ncbi.nlm.nih.gov/pubmed/17373666
9363,23838596,A novel AXIN2 germline variant associated with attenuated FAP without signs of oligondontia or ectodermal dysplasia.,http://www.ncbi.nlm.nih.gov/pubmed/23838596
9364,27468715,Investigation of N-cadherin/β-catenin expression in adrenocortical tumors.,http://www.ncbi.nlm.nih.gov/pubmed/27468715
9365,16708370,Mutations within Wnt pathway genes in sporadic colorectal cancers and cell lines.,http://www.ncbi.nlm.nih.gov/pubmed/16708370
9366,21555518,The BTB and CNC homology 1 (BACH1) target genes are involved in the oxidative stress response and in control of the cell cycle.,http://www.ncbi.nlm.nih.gov/pubmed/21555518
9367,24864265,FOXO transcription factors: their clinical significance and regulation.,http://www.ncbi.nlm.nih.gov/pubmed/24864265
9368,25399570,Protein kinase C in cellular transformation: a valid target for therapy?,http://www.ncbi.nlm.nih.gov/pubmed/25399570
9369,12417015,Protein kinase C beta (PKC beta): normal functions and diseases.,http://www.ncbi.nlm.nih.gov/pubmed/12417015
9370,17548205,Classical PKC isoforms in cancer.,http://www.ncbi.nlm.nih.gov/pubmed/17548205
9371,25678856,Evaluating the evidence for targeting FOXO3a in breast cancer: a systematic review.,http://www.ncbi.nlm.nih.gov/pubmed/25678856
9372,28571764,"Protein kinase C (PKC) isoforms in cancer, tumor promotion and tumor suppression.",http://www.ncbi.nlm.nih.gov/pubmed/28571764
9373,17384583,Protein kinase C and other diacylglycerol effectors in cancer.,http://www.ncbi.nlm.nih.gov/pubmed/17384583
9374,27108804,"BACH1, the master regulator gene: A novel candidate target for cancer therapy.",http://www.ncbi.nlm.nih.gov/pubmed/27108804
9375,27855221,Cell Transformation by PTP1B Truncated Mutants Found in Human Colon and Thyroid Tumors.,http://www.ncbi.nlm.nih.gov/pubmed/27855221
9376,19782770,The two faces of PTP1B in cancer.,http://www.ncbi.nlm.nih.gov/pubmed/19782770
9377,16198645,"Involvement of the small protein tyrosine phosphatases TC-PTP and PTP1B in signal transduction and diseases: from diabetes, obesity to cell cycle, and cancer.",http://www.ncbi.nlm.nih.gov/pubmed/16198645
9378,28111468,Deletion of Ptpn1 induces myeloproliferative neoplasm.,http://www.ncbi.nlm.nih.gov/pubmed/28111468
9379,24531327,Recurrent somatic mutations of PTPN1 in primary mediastinal B cell lymphoma and Hodgkin lymphoma.,http://www.ncbi.nlm.nih.gov/pubmed/24531327
9380,25773741,Histone H3 mutations--a special role for H3.3 in tumorigenesis?,http://www.ncbi.nlm.nih.gov/pubmed/25773741
9381,23079654,Hotspot mutations in H3F3A and IDH1 define distinct epigenetic and biological subgroups of glioblastoma.,http://www.ncbi.nlm.nih.gov/pubmed/23079654
9382,24162739,Distinct H3F3A and H3F3B driver mutations define chondroblastoma and giant cell tumor of bone.,http://www.ncbi.nlm.nih.gov/pubmed/24162739
9383,19327386,Rho GTPase function in tumorigenesis.,http://www.ncbi.nlm.nih.gov/pubmed/19327386
9384,24467208,Regulation of RhoA activity by adhesion molecules and mechanotransduction.,http://www.ncbi.nlm.nih.gov/pubmed/24467208
9385,27693615,Variegated RHOA mutations in human cancers.,http://www.ncbi.nlm.nih.gov/pubmed/27693615
9386,26103434,G17V RHOA: Genetic evidence of GTP-unbound RHOA playing a role in tumorigenesis in T cells.,http://www.ncbi.nlm.nih.gov/pubmed/26103434
9387,23697933,The physiological roles of histone deacetylase (HDAC) 1 and 2: complex co-stars with multiple leading parts.,http://www.ncbi.nlm.nih.gov/pubmed/23697933
9388,22328974,Frequent alterations and epigenetic silencing of differentiation pathway genes in structurally rearranged liposarcomas.,http://www.ncbi.nlm.nih.gov/pubmed/22328974
9389,28644771,Biomarker-Based Phase II Trial of Savolitinib in Patients With Advanced Papillary Renal Cell Cancer.,http://www.ncbi.nlm.nih.gov/pubmed/28644771
9390,28039265,"Safety, Tolerability, and Preliminary Activity of LB-100, an Inhibitor of Protein Phosphatase 2A, in Patients with Relapsed Solid Tumors: An Open-Label, Dose Escalation, First-in-Human, Phase I Trial.",http://www.ncbi.nlm.nih.gov/pubmed/28039265
9391,28520527,"Open-Label, Multicenter, Phase II Study of Ceritinib in Patients With Non-Small-Cell Lung Cancer Harboring ROS1 Rearrangement.",http://www.ncbi.nlm.nih.gov/pubmed/28520527
9392,15759019,Enhancement of adenoviral gene transfer to adult rat cardiomyocytes in vivo by immobilization and ultrasound treatment of the heart.,http://www.ncbi.nlm.nih.gov/pubmed/15759019
9393,28331003,"Phase I Dose-Escalation Study of Taselisib, an Oral PI3K Inhibitor, in Patients with Advanced Solid Tumors.",http://www.ncbi.nlm.nih.gov/pubmed/28331003
9394,12476283,Basiliximab is well tolerated and effective in the treatment of steroid-refractory acute graft-versus-host disease after allogeneic stem cell transplantation.,http://www.ncbi.nlm.nih.gov/pubmed/12476283
9395,16098072,Efficacy of the interleukin-2 receptor antagonist basiliximab in steroid-refractory acute graft-versus-host disease.,http://www.ncbi.nlm.nih.gov/pubmed/16098072
9396,20932932,Functions and regulation of the 70kDa ribosomal S6 kinases.,http://www.ncbi.nlm.nih.gov/pubmed/20932932
9397,22168436,Regulation and function of ribosomal protein S6 kinase (S6K) within mTOR signalling networks.,http://www.ncbi.nlm.nih.gov/pubmed/22168436
9398,10922410,Detecting activation of ribosomal protein S6 kinase by complementary DNA and tissue microarray analysis.,http://www.ncbi.nlm.nih.gov/pubmed/10922410
9399,18335499,High-resolution genomic and expression analyses of copy number alterations in breast tumors.,http://www.ncbi.nlm.nih.gov/pubmed/18335499
9400,28455243,The second-generation ALK inhibitor alectinib effectively induces apoptosis in human neuroblastoma cells and inhibits tumor growth in a TH-MYCN transgenic neuroblastoma mouse model.,http://www.ncbi.nlm.nih.gov/pubmed/28455243
9401,27771704,"SGK1, the New Player in the Game of Resistance: Chemo-Radio Molecular Target and Strategy for Inhibition.",http://www.ncbi.nlm.nih.gov/pubmed/27771704
9402,28529581,Expression of serum- and glucocorticoid-regulated kinase 1 and its association with clinicopathological factors and the survival of patients with adenocarcinoma of the esophagogastric junction.,http://www.ncbi.nlm.nih.gov/pubmed/28529581
9403,28236975,SGK1: The Dark Side of PI3K Signaling.,http://www.ncbi.nlm.nih.gov/pubmed/28236975
9404,27993876,Emerging Role of MDM2 as Target for Anti-Cancer Therapy: A Review.,http://www.ncbi.nlm.nih.gov/pubmed/27993876
9405,22416102,Association of age at diagnosis and genetic mutations in patients with neuroblastoma.,http://www.ncbi.nlm.nih.gov/pubmed/22416102
9406,24148618,Loss of DAXX and ATRX are associated with chromosome instability and reduced survival of patients with pancreatic neuroendocrine tumors.,http://www.ncbi.nlm.nih.gov/pubmed/24148618
9407,12673795,Mutational analysis of the ATRX gene by DGGE: a powerful diagnostic approach for the ATRX syndrome.,http://www.ncbi.nlm.nih.gov/pubmed/12673795
9408,25608029,Whole-exome sequencing identifies somatic ATRX mutations in pheochromocytomas and paragangliomas.,http://www.ncbi.nlm.nih.gov/pubmed/25608029
9409,23536011,Blockade of nonhormonal fibroblast growth factors by FP-1039 inhibits growth of multiple types of cancer.,http://www.ncbi.nlm.nih.gov/pubmed/23536011
9410,27223434,"Inhibition of FGF/FGFR autocrine signaling in mesothelioma with the FGF ligand trap, FP-1039/GSK3052230.",http://www.ncbi.nlm.nih.gov/pubmed/27223434
9411,22869205,"Frequent ATRX, CIC, FUBP1 and IDH1 mutations refine the classification of malignant gliomas.",http://www.ncbi.nlm.nih.gov/pubmed/22869205
9412,25743702,Genomic landscape of paediatric adrenocortical tumours.,http://www.ncbi.nlm.nih.gov/pubmed/25743702
9413,22886134,Frequent ATRX mutations and loss of expression in adult diffuse astrocytic tumors carrying IDH1/IDH2 and TP53 mutations.,http://www.ncbi.nlm.nih.gov/pubmed/22886134
9414,16955409,ATRX syndrome in a girl with a heterozygous mutation in the ATRX Zn finger domain and a totally skewed X-inactivation pattern.,http://www.ncbi.nlm.nih.gov/pubmed/16955409
9415,26692951,Targeted next-generation sequencing of cancer genes identified frequent TP53 and ATRX mutations in leiomyosarcoma.,http://www.ncbi.nlm.nih.gov/pubmed/26692951
9416,8358790,"Bcl-2 heterodimerizes in vivo with a conserved homolog, Bax, that accelerates programmed cell death.",http://www.ncbi.nlm.nih.gov/pubmed/8358790
9417,11535832,"Cloning and characterization of a histone deacetylase, HDAC9.",http://www.ncbi.nlm.nih.gov/pubmed/11535832
9418,21435179,Class IIa HDACs: from important roles in differentiation to possible implications in tumourigenesis.,http://www.ncbi.nlm.nih.gov/pubmed/21435179
9419,9032050,Seminars in medicine of the Beth Israel Deaconess Medical Center. Insulin-like growth factors.,http://www.ncbi.nlm.nih.gov/pubmed/9032050
9420,17634542,Low expression of Bax predicts poor prognosis in patients with locally advanced esophageal cancer treated with definitive chemoradiotherapy.,http://www.ncbi.nlm.nih.gov/pubmed/17634542
9421,21861179,"The significance of expression of autophagy-related gene Beclin, Bcl-2, and Bax in breast cancer tissues.",http://www.ncbi.nlm.nih.gov/pubmed/21861179
9422,24574804,Bax protein may influence the invasion of colorectal cancer.,http://www.ncbi.nlm.nih.gov/pubmed/24574804
9423,18074738,Expression of Bax protein in gastric carcinomas. A clinicopathological and immunohistochemical study.,http://www.ncbi.nlm.nih.gov/pubmed/18074738
9424,25906122,Prognostic Significance of Apoptosis-related Markers in Patients With Soft-Tissue Sarcomas of Extremities.,http://www.ncbi.nlm.nih.gov/pubmed/25906122
9425,15229476,Insulin-like growth factors and neoplasia.,http://www.ncbi.nlm.nih.gov/pubmed/15229476
9426,22075983,BCL2A1: the underdog in the BCL2 family.,http://www.ncbi.nlm.nih.gov/pubmed/22075983
9427,18308616,IGF2: epigenetic regulation and role in development and disease.,http://www.ncbi.nlm.nih.gov/pubmed/18308616
9428,24080445,IGF2 and cancer.,http://www.ncbi.nlm.nih.gov/pubmed/24080445
9429,14613034,Targeting Bcl-2 and Bcl-XL with nonpeptidic small-molecule antagonists.,http://www.ncbi.nlm.nih.gov/pubmed/14613034
9430,8358789,"bcl-x, a bcl-2-related gene that functions as a dominant regulator of apoptotic cell death.",http://www.ncbi.nlm.nih.gov/pubmed/8358789
9431,,Pre-Clinical Studies of Anti-CD123 CAR-T Cells for the Treatment of Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN),https://ash.confex.com/ash/2016/webprogram/Paper95092.html
9432,26325082,The BIM deletion polymorphism is a prognostic biomarker of EGFR-TKIs response in NSCLC: A systematic review and meta-analysis.,http://www.ncbi.nlm.nih.gov/pubmed/26325082
9433,26405162,Regulation of Bim in Health and Disease.,http://www.ncbi.nlm.nih.gov/pubmed/26405162
9434,18308615,IkappaB kinase beta (IKKbeta/IKK2/IKBKB)--a key molecule in signaling to the transcription factor NF-kappaB.,http://www.ncbi.nlm.nih.gov/pubmed/18308615
9435,25107905,IκB kinase β (IKBKB) mutations in lymphomas that constitutively activate canonical nuclear factor κB (NFκB) signaling.,http://www.ncbi.nlm.nih.gov/pubmed/25107905
9436,27824842,"CAR-T cells forge ahead, Novartis reorganizes.",http://www.ncbi.nlm.nih.gov/pubmed/27824842
9437,21296109,The pro- and anti-inflammatory properties of the cytokine interleukin-6.,http://www.ncbi.nlm.nih.gov/pubmed/21296109
9438,21156962,Interleukin 6/interleukin 6 receptor interaction and its role as a therapeutic target for treatment of cachexia and cancer.,http://www.ncbi.nlm.nih.gov/pubmed/21156962
9439,20501618,Prostate stem cell antigen: a Jekyll and Hyde molecule?,http://www.ncbi.nlm.nih.gov/pubmed/20501618
9440,24308679,"Prostate stem cell antigen and cancer risk, mechanisms and therapeutic implications.",http://www.ncbi.nlm.nih.gov/pubmed/24308679
9441,23457259,The insulin receptor: both a prototypical and atypical receptor tyrosine kinase.,http://www.ncbi.nlm.nih.gov/pubmed/23457259
9442,24384568,Insulin receptor signaling in normal and insulin-resistant states.,http://www.ncbi.nlm.nih.gov/pubmed/24384568
9443,18785179,Insulin receptor expression by human prostate cancers.,http://www.ncbi.nlm.nih.gov/pubmed/18785179
9444,19074892,Phosphorylated insulin-like growth factor-i/insulin receptor is present in all breast cancer subtypes and is related to poor survival.,http://www.ncbi.nlm.nih.gov/pubmed/19074892
9445,12193537,Functional insulin receptors on human epithelial ovarian carcinoma cells: implications for IGF-II mitogenic signaling.,http://www.ncbi.nlm.nih.gov/pubmed/12193537
9446,,"UCART19, an allogeneic “off-the-shelf” adoptive T-cell immunotherapy against CD19+ B-cell leukemias.",http://meetinglibrary.asco.org/record/110654/abstract
9447,,A NKG2D-based CAR-T therapy in a multinational phase I dose escalation and expansion study targeting multiple solid and hematologic tumor types.,http://abstracts.asco.org/199/AbstView_199_189080.html
9448,24807060,"Interferon regulatory factors: at the crossroads of immunity, metabolism, and disease.",http://www.ncbi.nlm.nih.gov/pubmed/24807060
9449,18469857,"Epigenetic disruption of interferon-gamma response through silencing the tumor suppressor interferon regulatory factor 8 in nasopharyngeal, esophageal and multiple other carcinomas.",http://www.ncbi.nlm.nih.gov/pubmed/18469857
9450,17189268,Interferon regulatory factor-8 is indispensable for the expression of promyelocytic leukemia and the formation of nuclear bodies in myeloid cells.,http://www.ncbi.nlm.nih.gov/pubmed/17189268
9451,21716851,Chimeric Antigen Receptor Therapy for B-cell Malignancies.,http://www.ncbi.nlm.nih.gov/pubmed/21716851
9452,28053021,"First-in-Human Phase I Study of the Oral Inhibitor of Indoleamine 2,3-Dioxygenase-1 Epacadostat (INCB024360) in Patients with Advanced Solid Malignancies.",http://www.ncbi.nlm.nih.gov/pubmed/28053021
9453,27518460,"Establishment and Characterization of a Novel Cell Line, ASAN-PaCa, Derived From Human Adenocarcinoma Arising in Intraductal Papillary Mucinous Neoplasm of the Pancreas.",http://www.ncbi.nlm.nih.gov/pubmed/27518460
9454,27661107,RNF43 and ZNRF3 are commonly altered in serrated pathway colorectal tumorigenesis.,http://www.ncbi.nlm.nih.gov/pubmed/27661107
9455,,Unraveling the oncogenic pathway of serrated polyposis syndrome driven by RNF43 germline mutation,http://cancerres.aacrjournals.org/content/77/13_Supplement/1448
9456,27993143,Marginal zone lymphoma-derived interfollicular diffuse large B-cell lymphoma harboring 20q12 chromosomal deletion and missense mutation of BIRC3 gene: a case report.,http://www.ncbi.nlm.nih.gov/pubmed/27993143
9457,23347099,"The MYSTerious MOZ, a histone acetyltransferase with a key role in haematopoiesis.",http://www.ncbi.nlm.nih.gov/pubmed/23347099
9458,16626284,MOZ fusion proteins in acute myeloid leukaemia.,http://www.ncbi.nlm.nih.gov/pubmed/16626284
9459,10824998,MOZ is fused to p300 in an acute monocytic leukemia with t(8;22).,http://www.ncbi.nlm.nih.gov/pubmed/10824998
9460,12628346,At the acidic edge: emerging functions for lysosomal membrane proteins.,http://www.ncbi.nlm.nih.gov/pubmed/12628346
9461,23826410,Expression of the lysosomal-associated membrane protein-1 (LAMP-1) in astrocytomas.,http://www.ncbi.nlm.nih.gov/pubmed/23826410
9462,27788920,LAMP1 expression is associated with malignant behaviours and predicts unfavourable prognosis in laryngeal squamous cell carcinoma.,http://www.ncbi.nlm.nih.gov/pubmed/27788920
9463,23790005,Inhibitors of apoptotic proteins: new targets for anticancer therapy.,http://www.ncbi.nlm.nih.gov/pubmed/23790005
9464,17692804,Frequent engagement of the classical and alternative NF-kappaB pathways by diverse genetic abnormalities in multiple myeloma.,http://www.ncbi.nlm.nih.gov/pubmed/17692804
9465,21881048,Alteration of BIRC3 and multiple other NF-κB pathway genes in splenic marginal zone lymphoma.,http://www.ncbi.nlm.nih.gov/pubmed/21881048
9466,11084335,"ML-IAP, a novel inhibitor of apoptosis that is preferentially expressed in human melanomas.",http://www.ncbi.nlm.nih.gov/pubmed/11084335
9467,23070005,The inhibitor of apoptosis (IAP) proteins are critical regulators of signaling pathways and targets for anti-cancer therapy.,http://www.ncbi.nlm.nih.gov/pubmed/23070005
9468,20685151,NF-κB inducing kinase: a key regulator in the immune system and in cancer.,http://www.ncbi.nlm.nih.gov/pubmed/20685151
9469,22718757,Structure of the nuclear factor κB-inducing kinase (NIK) kinase domain reveals a constitutively active conformation.,http://www.ncbi.nlm.nih.gov/pubmed/22718757
9470,22469134,Genetic lesions of the TRAF3 and MAP3K14 genes in classical Hodgkin lymphoma.,http://www.ncbi.nlm.nih.gov/pubmed/22469134
9471,22569528,"ERK1/2 MAP kinases: structure, function, and regulation.",http://www.ncbi.nlm.nih.gov/pubmed/22569528
9472,28232778,"Bloom's Syndrome: Clinical Spectrum, Molecular Pathogenesis, and Cancer Predisposition.",http://www.ncbi.nlm.nih.gov/pubmed/28232778
9473,19001847,Function of cyclins in regulating the mitotic and meiotic cell cycles in male germ cells.,http://www.ncbi.nlm.nih.gov/pubmed/19001847
9474,25039670,Cyclin A1 expression predicts progression in pT1 urothelial carcinoma of bladder: a tissue microarray study of 149 patients treated by transurethral resection.,http://www.ncbi.nlm.nih.gov/pubmed/25039670
9475,9639417,Cyclin A1 is predominantly expressed in hematological malignancies with myeloid differentiation.,http://www.ncbi.nlm.nih.gov/pubmed/9639417
9476,27787547,Adjuvant Weekly Girentuximab Following Nephrectomy for High-Risk Renal Cell Carcinoma: The ARISER Randomized Clinical Trial.,http://www.ncbi.nlm.nih.gov/pubmed/27787547
9477,12941272,Cyclin E ablation in the mouse.,http://www.ncbi.nlm.nih.gov/pubmed/12941272
9478,9840927,Cyclin E2: a novel CDK2 partner in the late G1 and S phases of the mammalian cell cycle.,http://www.ncbi.nlm.nih.gov/pubmed/9840927
9479,12466974,Deregulation of cyclin E2 expression and associated kinase activity in primary breast tumors.,http://www.ncbi.nlm.nih.gov/pubmed/12466974
9480,28537669,"E2F2 induces MCM4, CCNE2 and WHSC1 upregulation in ovarian cancer and predicts poor overall survival.",http://www.ncbi.nlm.nih.gov/pubmed/28537669
9481,27034264,Cyclin D1 and cyclin E2 are differentially expressed in gastric cancer.,http://www.ncbi.nlm.nih.gov/pubmed/27034264
9482,28463630,"Safety and Activity of Varlilumab, a Novel and First-in-Class Agonist Anti-CD27 Antibody, in Patients With Advanced Solid Tumors.",http://www.ncbi.nlm.nih.gov/pubmed/28463630
9483,23207919,Restricted leucine zipper dimerization and specificity of DNA recognition of the melanocyte master regulator MITF.,http://www.ncbi.nlm.nih.gov/pubmed/23207919
9484,22012259,A SUMOylation-defective MITF germline mutation predisposes to melanoma and renal carcinoma.,http://www.ncbi.nlm.nih.gov/pubmed/22012259
9485,25433395,MITF in melanoma: mechanisms behind its expression and activity.,http://www.ncbi.nlm.nih.gov/pubmed/25433395
9486,18059271,CD19 is essential for B cell activation by promoting B cell receptor-antigen microcluster formation in response to membrane-bound ligand.,http://www.ncbi.nlm.nih.gov/pubmed/18059271
9487,8528044,CD19 antigen in leukemia and lymphoma diagnosis and immunotherapy.,http://www.ncbi.nlm.nih.gov/pubmed/8528044
9488,28413717,Advances of CD19-directed chimeric antigen receptor-modified T cells in refractory/relapsed acute lymphoblastic leukemia.,http://www.ncbi.nlm.nih.gov/pubmed/28413717
9489,8942985,hMSH2 forms specific mispair-binding complexes with hMSH3 and hMSH6.,http://www.ncbi.nlm.nih.gov/pubmed/8942985
9490,27869803,Genome-wide CRISPR screens reveal a Wnt-FZD5 signaling circuit as a druggable vulnerability of RNF43-mutant pancreatic tumors.,http://www.ncbi.nlm.nih.gov/pubmed/27869803
9491,26980022,Ring finger protein 43 expression is associated with genetic alteration status and poor prognosis among patients with intrahepatic cholangiocarcinoma.,http://www.ncbi.nlm.nih.gov/pubmed/26980022
9492,25966119,Correlation of MSH3 polymorphisms with response and survival in advanced non-small cell lung cancer patients treated with first-line platinum-based chemotherapy.,http://www.ncbi.nlm.nih.gov/pubmed/25966119
9493,23756651,The structural basis of R-spondin recognition by LGR5 and RNF43.,http://www.ncbi.nlm.nih.gov/pubmed/23756651
9494,28542671,FOLFOXIRI Plus Bevacizumab as Conversion Therapy for Patients With Initially Unresectable Metastatic Colorectal Cancer: A Systematic Review and Pooled Analysis.,http://www.ncbi.nlm.nih.gov/pubmed/28542671
9495,24763061,The role of CD22 and Siglec-G in B-cell tolerance and autoimmune disease.,http://www.ncbi.nlm.nih.gov/pubmed/24763061
9496,23696252,Targeting CD22 in B-cell malignancies: current status and clinical outlook.,http://www.ncbi.nlm.nih.gov/pubmed/23696252
9497,28249663,Immunotherapy in Squamous Cell Skin Carcinoma: A Game Changer?,http://www.ncbi.nlm.nih.gov/pubmed/28249663
9498,27824130,Identification of novel MYO18A interaction partners required for myoblast adhesion and muscle integrity.,http://www.ncbi.nlm.nih.gov/pubmed/27824130
9499,19006078,Identification of a MYO18A-PDGFRB fusion gene in an eosinophilia-associated atypical myeloproliferative neoplasm with a t(5;17)(q33-34;q11.2).,http://www.ncbi.nlm.nih.gov/pubmed/19006078
9500,26670045,"Specific Myosins Control Actin Organization, Cell Morphology, and Migration in Prostate Cancer Cells.",http://www.ncbi.nlm.nih.gov/pubmed/26670045
9501,18794343,Hedgehog: functions and mechanisms.,http://www.ncbi.nlm.nih.gov/pubmed/18794343
9502,26727947,Overexpression of sonic hedgehog in the triple negative breast cancer: clinicopathological characteristics of high burden breast cancer patients from Bangladesh.,http://www.ncbi.nlm.nih.gov/pubmed/26727947
9503,14520413,Hedgehog is an early and late mediator of pancreatic cancer tumorigenesis.,http://www.ncbi.nlm.nih.gov/pubmed/14520413
9504,15132968,Hedgehog signaling promotes prostate xenograft tumor growth.,http://www.ncbi.nlm.nih.gov/pubmed/15132968
9505,20180807,Expression and regulation mechanisms of Sonic Hedgehog in breast cancer.,http://www.ncbi.nlm.nih.gov/pubmed/20180807
9506,20532501,Anti-HER2 vaccines: new prospects for breast cancer therapy.,http://www.ncbi.nlm.nih.gov/pubmed/20532501
9507,21245093,Dual IGF-I/II-neutralizing antibody MEDI-573 potently inhibits IGF signaling and tumor growth.,http://www.ncbi.nlm.nih.gov/pubmed/21245093
9508,26776524,Kinase Inhibitor Profiling Reveals Unexpected Opportunities to Inhibit Disease-Associated Mutant Kinases.,http://www.ncbi.nlm.nih.gov/pubmed/26776524
9509,28326306,CD44: A Multifunctional Cell Surface Adhesion Receptor Is a Regulator of Progression and Metastasis of Cancer Cells.,http://www.ncbi.nlm.nih.gov/pubmed/28326306
9510,27200096,The Importance of CD44 as a Stem Cell Biomarker and Therapeutic Target in Cancer.,http://www.ncbi.nlm.nih.gov/pubmed/27200096
9511,26658103,DAB2IP in cancer.,http://www.ncbi.nlm.nih.gov/pubmed/26658103
9512,27858941,"Block one, unleash a hundred. Mechanisms of DAB2IP inactivation in cancer.",http://www.ncbi.nlm.nih.gov/pubmed/27858941
9513,20360384,The output of Hedgehog signaling is controlled by the dynamic association between Suppressor of Fused and the Gli proteins.,http://www.ncbi.nlm.nih.gov/pubmed/20360384
9514,27234298,SCF (Fbxl17) ubiquitylation of Sufu regulates Hedgehog signaling and medulloblastoma development.,http://www.ncbi.nlm.nih.gov/pubmed/27234298
9515,15482598,Activation of the hedgehog pathway in advanced prostate cancer.,http://www.ncbi.nlm.nih.gov/pubmed/15482598
9516,22958902,Loss of SUFU function in familial multiple meningioma.,http://www.ncbi.nlm.nih.gov/pubmed/22958902
9517,19996307,Emerging roles of the EBF family of transcription factors in tumor suppression.,http://www.ncbi.nlm.nih.gov/pubmed/19996307
9518,24246475,A20 in inflammation and autoimmunity.,http://www.ncbi.nlm.nih.gov/pubmed/24246475
9519,23134590,The role of A20 in the pathogenesis of lymphocytic malignancy.,http://www.ncbi.nlm.nih.gov/pubmed/23134590
9520,26085207,"Targeting signaling factors for degradation, an emerging mechanism for TRAF functions.",http://www.ncbi.nlm.nih.gov/pubmed/26085207
9521,9032281,Induction of nuclear factor kappaB by the CD30 receptor is mediated by TRAF1 and TRAF2.,http://www.ncbi.nlm.nih.gov/pubmed/9032281
9522,23904233,CD30-positive malignant lymphomas: time for a change of management?,http://www.ncbi.nlm.nih.gov/pubmed/23904233
9523,15886117,CD27 and CD70 in T cell and B cell activation.,http://www.ncbi.nlm.nih.gov/pubmed/15886117
9524,23264908,Modulating CD27 signaling to treat cancer.,http://www.ncbi.nlm.nih.gov/pubmed/23264908
9525,27427153,Targeting WEE1 Kinase in Cancer.,http://www.ncbi.nlm.nih.gov/pubmed/27427153
9526,15279796,The XRCC genes: expanding roles in DNA double-strand break repair.,http://www.ncbi.nlm.nih.gov/pubmed/15279796
9527,15723711,"The RAD51 gene family, genetic instability and cancer.",http://www.ncbi.nlm.nih.gov/pubmed/15723711
9528,18991789,The role of XRCC4 in carcinogenesis and anticancer drug discovery.,http://www.ncbi.nlm.nih.gov/pubmed/18991789
9529,23098447,"Association between XRCC5, 6 and 7 gene polymorphisms and the risk of breast cancer: a HuGE review and meta-analysis.",http://www.ncbi.nlm.nih.gov/pubmed/23098447
9530,25795425,The structural basis of XRCC1-mediated DNA repair.,http://www.ncbi.nlm.nih.gov/pubmed/25795425
9531,12496039,Polymorphisms in DNA repair genes and associations with cancer risk.,http://www.ncbi.nlm.nih.gov/pubmed/12496039
9532,28194092,Paradoxes of the EphB1 receptor in malignant brain tumors.,http://www.ncbi.nlm.nih.gov/pubmed/28194092
9533,26790531,"Mechanisms of ephrin-Eph signalling in development, physiology and disease.",http://www.ncbi.nlm.nih.gov/pubmed/26790531
9534,27902925,"Targeted inhibition of WRN helicase, replication stress and cancer.",http://www.ncbi.nlm.nih.gov/pubmed/27902925
9535,25620975,RECQL1 and WRN DNA repair helicases: potential therapeutic targets and proliferative markers against cancers.,http://www.ncbi.nlm.nih.gov/pubmed/25620975
9536,16723399,Epigenetic inactivation of the premature aging Werner syndrome gene in human cancer.,http://www.ncbi.nlm.nih.gov/pubmed/16723399
9537,3015991,Functional and structural characteristics of EGF and its receptor and their relationship to transforming proteins.,http://www.ncbi.nlm.nih.gov/pubmed/3015991
9538,21527828,FANCP/SLX4: a Swiss army knife of DNA interstrand crosslink repair.,http://www.ncbi.nlm.nih.gov/pubmed/21527828
9539,21805310,Mutation analysis of the SLX4/FANCP gene in hereditary breast cancer.,http://www.ncbi.nlm.nih.gov/pubmed/21805310
9540,28031425,Phase Ib Study of Safety and Pharmacokinetics of the PI3K Inhibitor SAR245408 with the HER3-Neutralizing Human Antibody SAR256212 in Patients with Solid Tumors.,http://www.ncbi.nlm.nih.gov/pubmed/28031425
9541,26251521,Clinicopathological characteristics of RHOA mutations in a Central European gastric cancer cohort.,http://www.ncbi.nlm.nih.gov/pubmed/26251521
9542,27922598,EphA3 as a target for antibody immunotherapy in acute lymphoblastic leukemia.,http://www.ncbi.nlm.nih.gov/pubmed/27922598
9543,9565577,Determination of interaction sites on the small G protein RhoA for phospholipase D.,http://www.ncbi.nlm.nih.gov/pubmed/9565577
9544,28645776,"Selective inhibition of FLT3 by gilteritinib in relapsed or refractory acute myeloid leukaemia: a multicentre, first-in-human, open-label, phase 1-2 study.",http://www.ncbi.nlm.nih.gov/pubmed/28645776
9545,28364000,Anti-PD-L1 Efficacy Can Be Enhanced by Inhibition of Myeloid-Derived Suppressor Cells with a Selective Inhibitor of PI3Kδ/γ.,http://www.ncbi.nlm.nih.gov/pubmed/28364000
9546,15711920,Anti-apoptotic action of API2-MALT1 fusion protein involved in t(11;18)(q21;q21) MALT lymphoma.,http://www.ncbi.nlm.nih.gov/pubmed/15711920
9547,27535106,Targeting Chromatin Regulators Inhibits Leukemogenic Gene Expression in NPM1 Mutant Leukemia.,http://www.ncbi.nlm.nih.gov/pubmed/27535106
9548,25817203,Pharmacologic inhibition of the Menin-MLL interaction blocks progression of MLL leukemia in vivo.,http://www.ncbi.nlm.nih.gov/pubmed/25817203
9549,26386283,The Paracaspase MALT1.,http://www.ncbi.nlm.nih.gov/pubmed/26386283
9550,26033159,Recurrent DICER1 hotspot mutations in endometrial tumours and their impact on microRNA biogenesis.,http://www.ncbi.nlm.nih.gov/pubmed/26033159
9551,27906793,Multimorbidity and Genetic Characteristics of DICER1 Syndrome Based on Systematic Review.,http://www.ncbi.nlm.nih.gov/pubmed/27906793
9552,25285878,Targeting B-cell lymphomas with inhibitors of the MALT1 paracaspase.,http://www.ncbi.nlm.nih.gov/pubmed/25285878
9553,15286744,MALT lymphoma: from morphology to molecules.,http://www.ncbi.nlm.nih.gov/pubmed/15286744
9554,27249753,Immunotherapy: Beyond Anti-PD-1 and Anti-PD-L1 Therapies.,http://www.ncbi.nlm.nih.gov/pubmed/27249753
9555,26325034,Cytotoxic T lymphocyte antigen-4 and immune checkpoint blockade.,http://www.ncbi.nlm.nih.gov/pubmed/26325034
9556,28213364,Safety and Antitumor Activity of Apalutamide (ARN-509) in Metastatic Castration-Resistant Prostate Cancer with and without Prior Abiraterone Acetate and Prednisone.,http://www.ncbi.nlm.nih.gov/pubmed/28213364
9557,28520362,,http://www.ncbi.nlm.nih.gov/pubmed/28520362
9558,28520364,,http://www.ncbi.nlm.nih.gov/pubmed/28520364
9559,25398397,"T-DM1, a novel antibody-drug conjugate, is highly effective against uterine and ovarian carcinosarcomas overexpressing HER2.",http://www.ncbi.nlm.nih.gov/pubmed/25398397
9560,26260909,Neratinib shows efficacy in the treatment of HER2 amplified carcinosarcoma in vitro and in vivo.,http://www.ncbi.nlm.nih.gov/pubmed/26260909
9561,24367169,Lapatinib: new opportunities for management of breast cancer.,http://www.ncbi.nlm.nih.gov/pubmed/24367169
9562,28662232,Nivolumab for Patients With Advanced Melanoma Treated Beyond Progression: Analysis of 2 Phase 3 Clinical Trials.,http://www.ncbi.nlm.nih.gov/pubmed/28662232
9563,25800760,Human Epidermal Growth Factor Receptor 2 (HER2) -Specific Chimeric Antigen Receptor-Modified T Cells for the Immunotherapy of HER2-Positive Sarcoma.,http://www.ncbi.nlm.nih.gov/pubmed/25800760
9564,25711536,CAR-T Cells Inflict Sequential Killing of Multiple Tumor Target Cells.,http://www.ncbi.nlm.nih.gov/pubmed/25711536
9565,27983647,Critical Function of PRDM2 in the Neoplastic Growth of Testicular Germ Cell Tumors.,http://www.ncbi.nlm.nih.gov/pubmed/27983647
9566,28162974,A UBE2O-AMPKα2 Axis that Promotes Tumor Initiation and Progression Offers Opportunities for Therapy.,http://www.ncbi.nlm.nih.gov/pubmed/28162974
9567,26272043,Myristoylation confers noncanonical AMPK functions in autophagy selectivity and mitochondrial surveillance.,http://www.ncbi.nlm.nih.gov/pubmed/26272043
9568,28260718,"Loss of SETD2, but not H3K36me3, correlates with aggressive clinicopathological features of clear cell renal cell carcinoma patients.",http://www.ncbi.nlm.nih.gov/pubmed/28260718
9569,28159833,SETting the Stage for Cancer Development: SETD2 and the Consequences of Lost Methylation.,http://www.ncbi.nlm.nih.gov/pubmed/28159833
9570,28386724,Shaping the cellular landscape with Set2/SETD2 methylation.,http://www.ncbi.nlm.nih.gov/pubmed/28386724
9571,28202515,Systematic In Vivo Inactivation of Chromatin-Regulating Enzymes Identifies Setd2 as a Potent Tumor Suppressor in Lung Adenocarcinoma.,http://www.ncbi.nlm.nih.gov/pubmed/28202515
9572,27528607,Structure/Function Analysis of Recurrent Mutations in SETD2 Protein Reveals a Critical and Conserved Role for a SET Domain Residue in Maintaining Protein Stability and Histone H3 Lys-36 Trimethylation.,http://www.ncbi.nlm.nih.gov/pubmed/27528607
9573,26338826,SETD2 histone modifier loss in aggressive GI stromal tumours.,http://www.ncbi.nlm.nih.gov/pubmed/26338826
9574,27282254,Genomic disruption of the histone methyltransferase SETD2 in chronic lymphocytic leukaemia.,http://www.ncbi.nlm.nih.gov/pubmed/27282254
9575,26779630,SET7/9 inhibits oncogenic activities through regulation of Gli-1 expression in breast cancer.,http://www.ncbi.nlm.nih.gov/pubmed/26779630
9576,27046831,SETD7 Controls Intestinal Regeneration and Tumorigenesis by Regulating Wnt/β-Catenin and Hippo/YAP Signaling.,http://www.ncbi.nlm.nih.gov/pubmed/27046831
9577,28514182,Aberrant Level of Skp2 and p27KIP1 in Intraductal Proliferative Lesions is Associated with Tumorigenesis.,http://www.ncbi.nlm.nih.gov/pubmed/28514182
9578,28624440,BAG3 promotes proliferation of ovarian cancer cells via post-transcriptional regulation of Skp2 expression.,http://www.ncbi.nlm.nih.gov/pubmed/28624440
9579,27160538,Skp2 Inhibitors: Novel Anticancer Strategies.,http://www.ncbi.nlm.nih.gov/pubmed/27160538
9580,28202352,Amino acid transporter SLC38A3 promotes metastasis of non-small cell lung cancer cells by activating PDK1.,http://www.ncbi.nlm.nih.gov/pubmed/28202352
9581,28639750,Protein lysine methyltransferase SMYD3 is involved in tumorigenesis through regulation of HER2 homodimerization.,http://www.ncbi.nlm.nih.gov/pubmed/28639750
9582,28019723,Therapeutical potential of deregulated lysine methyltransferase SMYD3 as a safe target for novel anticancer agents.,http://www.ncbi.nlm.nih.gov/pubmed/28019723
9583,28123630,SET and MYND domain containing protein 3 in cancer.,http://www.ncbi.nlm.nih.gov/pubmed/28123630
9584,28228755,Dysregulation of SOCS-Mediated Negative Feedback of Cytokine Signaling in Carcinogenesis and Its Significance in Cancer Treatment.,http://www.ncbi.nlm.nih.gov/pubmed/28228755
9585,,Imatinib-induced downregulation of Skp2 inhibits cell growth in human squamous cell ca,http://cancerres.aacrjournals.org/content/77/13_Supplement/2108.short
9586,27077911,Molecular Heterogeneity of Ewing Sarcoma as Detected by Ion Torrent Sequencing.,http://www.ncbi.nlm.nih.gov/pubmed/27077911
9587,28710747,Phase I study of chimeric antigen receptor modified T cells in treating HER2-positive advanced biliary tract cancers and pancreatic cancers.,http://www.ncbi.nlm.nih.gov/pubmed/28710747
9588,28284008,Effective and persistent antitumor activity of HER2-directed CAR-T cells against gastric cancer cells in vitro and xenotransplanted tumors in vivo.,http://www.ncbi.nlm.nih.gov/pubmed/28284008
9589,22187960,Recurrent somatic DICER1 mutations in nonepithelial ovarian cancers.,http://www.ncbi.nlm.nih.gov/pubmed/22187960
9590,23132766,Cancer-associated somatic DICER1 hotspot mutations cause defective miRNA processing and reverse-strand expression bias to predominantly mature 3p strands through loss of 5p strand cleavage.,http://www.ncbi.nlm.nih.gov/pubmed/23132766
9591,26874901,"Neratinib after trastuzumab-based adjuvant therapy in patients with HER2-positive breast cancer (ExteNET): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial.",http://www.ncbi.nlm.nih.gov/pubmed/26874901
9592,28215905,APOBEC2 negatively regulates myoblast differentiation in muscle regeneration.,http://www.ncbi.nlm.nih.gov/pubmed/28215905
9593,26760979,Overexpression of APOBEC3F in tumor tissues is potentially predictive for poor recurrence-free survival from HBV-related hepatocellular carcinoma.,http://www.ncbi.nlm.nih.gov/pubmed/26760979
9594,27249646,APOBEC4 Enhances the Replication of HIV-1.,http://www.ncbi.nlm.nih.gov/pubmed/27249646
9595,25190313,Somatic mutations in DROSHA and DICER1 impair microRNA biogenesis through distinct mechanisms in Wilms tumours.,http://www.ncbi.nlm.nih.gov/pubmed/25190313
9596,28446642,Cotargeting mTORC and EGFR Signaling as a Therapeutic Strategy in HNSCC.,http://www.ncbi.nlm.nih.gov/pubmed/28446642
9597,28539475,The brain microenvironment mediates resistance in luminal breast cancer to PI3K inhibition through HER3 activation.,http://www.ncbi.nlm.nih.gov/pubmed/28539475
9598,27879268,Transcriptional Selectivity of Epigenetic Therapy in Cancer.,http://www.ncbi.nlm.nih.gov/pubmed/27879268
9599,20568732,Structurally designed trans-2-phenylcyclopropylamine derivatives potently inhibit histone demethylase LSD1/KDM1 .,http://www.ncbi.nlm.nih.gov/pubmed/20568732
9600,27914215,Lysine-Specific Demethylase 1 (LSD1) Inhibitor S2101 Induces Autophagy via the AKT/mTOR Pathway in SKOV3 Ovarian Cancer Cells.,http://www.ncbi.nlm.nih.gov/pubmed/27914215
9601,28039268,Therapeutic Small Molecules Target Inhibitor of Apoptosis Proteins in Cancers with Deregulation of Extrinsic and Intrinsic Cell Death Pathways.,http://www.ncbi.nlm.nih.gov/pubmed/28039268
9602,27677741,Pharmacogenomics and chemical library screens reveal a novel SCF(SKP2) inhibitor that overcomes Bortezomib resistance in multiple myeloma.,http://www.ncbi.nlm.nih.gov/pubmed/27677741
9603,,"The dual IAP antagonist, ASTX660, increases the anti-tumor activity of paclitaxel in preclinical models of triple-negative breast cancer in vivo",http://cancerres.aacrjournals.org/content/76/14_Supplement/1287
9604,27149990,Genomic profiling of murine mammary tumors identifies potential personalized drug targets for p53-deficient mammary cancers.,http://www.ncbi.nlm.nih.gov/pubmed/27149990
9605,25644089,Anti-cancer fatty-acid derivative induces autophagic cell death through modulation of PKM isoform expression profile mediated by bcr-abl in chronic myeloid leukemia.,http://www.ncbi.nlm.nih.gov/pubmed/25644089
9606,28427193,Targeting high Aurora kinases expression as an innovative therapy for hepatocellular carcinoma.,http://www.ncbi.nlm.nih.gov/pubmed/28427193
9607,26607903,Perturbation of energy metabolism by fatty-acid derivative AIC-47 and imatinib in BCR-ABL-harboring leukemic cells.,http://www.ncbi.nlm.nih.gov/pubmed/26607903
9608,27390342,Cotargeting HSP90 and Its Client Proteins for Treatment of Prostate Cancer.,http://www.ncbi.nlm.nih.gov/pubmed/27390342
9609,28111925,"Combination of bevacizumab, irinotecan, and temozolomide for refractory or relapsed neuroblastoma: Results of a phase II study.",http://www.ncbi.nlm.nih.gov/pubmed/28111925
9610,28690523,A Case Report Demonstrating the Potential Clinical Benefit of Exhaustive Molecular Profiling in an Aggressive Muscle-Invasive High-Grade Metastatic Urothelial Carcinoma.,http://www.ncbi.nlm.nih.gov/pubmed/28690523
9611,11793469,Polymorphisms and HNPCC: PMS2-MLH1 protein interactions diminished by single nucleotide polymorphisms.,http://www.ncbi.nlm.nih.gov/pubmed/11793469
9612,24390348,Landscape of genomic alterations in cervical carcinomas.,http://www.ncbi.nlm.nih.gov/pubmed/24390348
9613,28476735,Identification of Targetable ALK Rearrangements in Pancreatic Ductal Adenocarcinoma.,http://www.ncbi.nlm.nih.gov/pubmed/28476735
9614,22127019,Redirected antitumor activity of primary human lymphocytes transduced with a fully human anti-mesothelin chimeric receptor.,http://www.ncbi.nlm.nih.gov/pubmed/22127019
9615,28446612,CDK4 protein is degraded by anaphase-promoting complex/cyclosome in mitosis and reaccumulates in early G1 phase to initiate a new cell cycle in HeLa cells.,http://www.ncbi.nlm.nih.gov/pubmed/28446612
9616,28380455,Targeted next generation sequencing of mucosal melanomas identifies frequent NF1 and RAS mutations.,http://www.ncbi.nlm.nih.gov/pubmed/28380455
9617,28678784,Personalized RNA mutanome vaccines mobilize poly-specific therapeutic immunity against cancer.,http://www.ncbi.nlm.nih.gov/pubmed/28678784
9618,18323416,Oncogenic CARD11 mutations in human diffuse large B cell lymphoma.,http://www.ncbi.nlm.nih.gov/pubmed/18323416
9619,27224912,Genetic heterogeneity in primary and relapsed mantle cell lymphomas: Impact of recurrent CARD11 mutations.,http://www.ncbi.nlm.nih.gov/pubmed/27224912
9620,26754925,IER5 generates a novel hypo-phosphorylated active form of HSF1 and contributes to tumorigenesis.,http://www.ncbi.nlm.nih.gov/pubmed/26754925
9621,28370690,"Heat shock transcription factor 1 promotes the proliferation, migration and invasion of osteosarcoma cells.",http://www.ncbi.nlm.nih.gov/pubmed/28370690
9622,28617974,High expression of heat shock proteins and heat shock factor-1 distinguishes an aggressive subset of clear cell renal cell carcinoma.,http://www.ncbi.nlm.nih.gov/pubmed/28617974
9623,28487934,Targeting HSF1 leads to an antitumor effect in human epithelial ovarian cancer.,http://www.ncbi.nlm.nih.gov/pubmed/28487934
9624,28598816,Combined inhibition of AKT and HSF1 suppresses breast cancer stem cells and tumor growth.,http://www.ncbi.nlm.nih.gov/pubmed/28598816
9625,28454329,Overexpression of heat-shock factor 1 is associated with a poor prognosis in esophageal squamous cell carcinoma.,http://www.ncbi.nlm.nih.gov/pubmed/28454329
9626,28669924,Histone H3 lysine 4 methyltransferase KMT2D.,http://www.ncbi.nlm.nih.gov/pubmed/28669924
9627,28007623,Small Cell Lung Cancer Exhibits Frequent Inactivating Mutations in the Histone Methyltransferase KMT2D/MLL2: CALGB 151111 (Alliance).,http://www.ncbi.nlm.nih.gov/pubmed/28007623
9628,27873319,"Lung neuroendocrine tumours: deep sequencing of the four World Health Organization histotypes reveals chromatin-remodelling genes as major players and a prognostic role for TERT, RB1, MEN1 and KMT2D.",http://www.ncbi.nlm.nih.gov/pubmed/27873319
9629,28108315,Essential role of Notch4/STAT3 signaling in epithelial-mesenchymal transition of tamoxifen-resistant human breast cancer.,http://www.ncbi.nlm.nih.gov/pubmed/28108315
9630,27197026,Association of Notch4 with metastasis in human oral squamous cell carcinoma.,http://www.ncbi.nlm.nih.gov/pubmed/27197026
9631,27157043,In vitro and in vivo effects of JAK2 inhibition in chronic myelomonocytic leukemia.,http://www.ncbi.nlm.nih.gov/pubmed/27157043
9632,21078672,KRIBB11 inhibits HSP70 synthesis through inhibition of heat shock factor 1 function by impairing the recruitment of positive transcription elongation factor b to the hsp70 promoter.,http://www.ncbi.nlm.nih.gov/pubmed/21078672
9633,,Molecular Basis of Ibrutinib Resistance in Waldenstrom's Macroglobulinemia,http://www.bloodjournal.org/content/128/22/756?sso-checked=true
9634,28369544,New inhibitor targeting human transcription factor HSF1: effects on the heat shock response and tumor cell survival.,http://www.ncbi.nlm.nih.gov/pubmed/28369544
9635,28235842,Acquired mutations associated with ibrutinib resistance in Waldenström macroglobulinemia.,http://www.ncbi.nlm.nih.gov/pubmed/28235842
9636,27803051,"Up-regulation of mismatch repair genes MSH6, PMS2 and MLH1 parallels development of genetic instability and is linked to tumor aggressiveness and early PSA recurrence in prostate cancer.",http://www.ncbi.nlm.nih.gov/pubmed/27803051
9637,28627627,Stromal antigen 2 functions as a tumor suppressor in bladder cancer cells.,http://www.ncbi.nlm.nih.gov/pubmed/28627627
9638,,"Abstract 3217: MGD013, a bispecific PD-1 x LAG-3 Dual-Affinity Re-Targeting (DART) protein with T-cell immunomodulatory activity for cancer treatment",http://cancerres.aacrjournals.org/content/76/14_Supplement/3217
9639,26701267,Identification of T-cell Receptors Targeting KRAS-Mutated Human Tumors.,http://www.ncbi.nlm.nih.gov/pubmed/26701267
9640,28498454,Identification of SETD2-NF1 fusion gene in a pediatric spindle cell tumor with the chromosomal translocation t(3;17)(p21;q12).,http://www.ncbi.nlm.nih.gov/pubmed/28498454
9641,27595477,Mutational signatures in esophageal adenocarcinoma define etiologically distinct subgroups with therapeutic relevance.,http://www.ncbi.nlm.nih.gov/pubmed/27595477
9642,28302137,Mutations of CREBBP and SOCS1 are independent prognostic factors in diffuse large B cell lymphoma: mutational analysis of the SAKK 38/07 prospective clinical trial cohort.,http://www.ncbi.nlm.nih.gov/pubmed/28302137
9643,27187383,A Tumor-Specific Neo-Antigen Caused by a Frameshift Mutation in BAP1 Is a Potential Personalized Biomarker in Malignant Peritoneal Mesothelioma.,http://www.ncbi.nlm.nih.gov/pubmed/27187383
9644,28616688,Somatic mutations of the coding microsatellites within the beta-2-microglobulin gene in mismatch repair-deficient colorectal cancers and adenomas.,http://www.ncbi.nlm.nih.gov/pubmed/28616688
9645,23147571,The targeted inhibition of mitochondrial Hsp90 overcomes the apoptosis resistance conferred by Bcl-2 in Hep3B cells via necroptosis.,http://www.ncbi.nlm.nih.gov/pubmed/23147571
9646,28194276,A case report of concurrent embryonal rhabdomyosarcoma and diffuse large B-cell lymphoma in an adult without identifiable cancer predisposition.,http://www.ncbi.nlm.nih.gov/pubmed/28194276
9647,28087600,Sunitinib Stimulates Expression of VEGFC by Tumor Cells and Promotes Lymphangiogenesis in Clear Cell Renal Cell Carcinomas.,http://www.ncbi.nlm.nih.gov/pubmed/28087600
9648,28522750,Inhibition of Mitochondrial Matrix Chaperones and Antiapoptotic Bcl-2 Family Proteins Empower Antitumor Therapeutic Responses.,http://www.ncbi.nlm.nih.gov/pubmed/28522750
9649,28466543,Mutation patterns in genes encoding interferon signaling and antigen presentation: A pan-cancer survey with implications for the use of immune checkpoint inhibitors.,http://www.ncbi.nlm.nih.gov/pubmed/28466543
9650,22137796,Combined genetic inactivation of β2-Microglobulin and CD58 reveals frequent escape from immune recognition in diffuse large B cell lymphoma.,http://www.ncbi.nlm.nih.gov/pubmed/22137796
9651,28588020,Enasidenib in mutant-IDH2 relapsed or refractory acute myeloid leukemia.,http://www.ncbi.nlm.nih.gov/pubmed/28588020
9652,26337639,Blinatumomab: a bispecific T cell engager (BiTE) antibody against CD19/CD3 for refractory acute lymphoid leukemia.,http://www.ncbi.nlm.nih.gov/pubmed/26337639
9653,28734759,"Nivolumab in patients with metastatic DNA mismatch repair-deficient or microsatellite instability-high colorectal cancer (CheckMate 142): an open-label, multicentre, phase 2 study.",http://www.ncbi.nlm.nih.gov/pubmed/28734759
9654,27900363,Integration of genomics and histology revises diagnosis and enables effective therapy of refractory cancer of unknown primary with PDL1 amplification.,http://www.ncbi.nlm.nih.gov/pubmed/27900363
9655,28655787,Cytosine deaminase APOBEC3A sensitizes leukemia cells to inhibition of the DNA replication checkpoint.,http://www.ncbi.nlm.nih.gov/pubmed/28655787
9656,28698210,APOBEC3A and 3B activities render cancer cells susceptible to ATR inhibition.,http://www.ncbi.nlm.nih.gov/pubmed/28698210
9657,26929412,"Structural Basis for Substrate Preference of SMYD3, a SET Domain-containing Protein Lysine Methyltransferase.",http://www.ncbi.nlm.nih.gov/pubmed/26929412
9658,26985287,"Novel Oxindole Sulfonamides and Sulfamides: EPZ031686, the First Orally Bioavailable Small Molecule SMYD3 Inhibitor.",http://www.ncbi.nlm.nih.gov/pubmed/26985287
9659,25728514,A SMYD3 Small-Molecule Inhibitor Impairing Cancer Cell Growth.,http://www.ncbi.nlm.nih.gov/pubmed/25728514
9660,28249141,Blinatumomab versus Chemotherapy for Advanced Acute Lymphoblastic Leukemia.,http://www.ncbi.nlm.nih.gov/pubmed/28249141
9661,26951679,Whole-exome sequencing identifies MST1R as a genetic susceptibility gene in nasopharyngeal carcinoma.,http://www.ncbi.nlm.nih.gov/pubmed/26951679
9662,28679775,Detection of Activating Estrogen Receptor Gene (ESR1) Mutations in Single Circulating Tumor Cells.,http://www.ncbi.nlm.nih.gov/pubmed/28679775
9663,26599269,Mutation Profiling of Lung Cancers with Long-Term Response to Gefitinib Therapy.,http://www.ncbi.nlm.nih.gov/pubmed/26599269
9664,25628777,Activation of Keap1/Nrf2 signaling pathway by nuclear epidermal growth factor receptor in cancer cells.,http://www.ncbi.nlm.nih.gov/pubmed/25628777
9665,28523248,The KEAP1-NRF2 System in Cancer.,http://www.ncbi.nlm.nih.gov/pubmed/28523248
9666,28331050,First-in-Human Clinical Trial of Oral ONC201 in Patients with Refractory Solid Tumors.,http://www.ncbi.nlm.nih.gov/pubmed/28331050
9667,28280091,Dual Inhibition of EGFR and c-Src by Cetuximab and Dasatinib Combined with FOLFOX Chemotherapy in Patients with Metastatic Colorectal Cancer.,http://www.ncbi.nlm.nih.gov/pubmed/28280091
9668,28270494,Blockade of Deubiquitylating Enzyme USP1 Inhibits DNA Repair and Triggers Apoptosis in Multiple Myeloma Cells.,http://www.ncbi.nlm.nih.gov/pubmed/28270494
9669,28314788,The PARP Inhibitor Veliparib Can Be Safely Added to Bendamustine and Rituximab and Has Preliminary Evidence of Activity in B-Cell Lymphoma.,http://www.ncbi.nlm.nih.gov/pubmed/28314788
9670,28589492,"A Phase 1 Study of LY2874455, an Oral Selective pan-FGFR Inhibitor, in Patients with Advanced Cancer.",http://www.ncbi.nlm.nih.gov/pubmed/28589492
9671,28351930,Hyperprogressors after Immunotherapy: Analysis of Genomic Alterations Associated with Accelerated Growth Rate.,http://www.ncbi.nlm.nih.gov/pubmed/28351930
9672,28270498,"A Randomized Phase II Neoadjuvant Study of Cisplatin, Paclitaxel With or Without Everolimus in Patients with Stage II/III Triple-Negative Breast Cancer (TNBC): Responses and Long-term Outcome Correlated with Increased Frequency of DNA Damage Response Gene Mutations, TNBC Subtype, AR Status, and Ki67.",http://www.ncbi.nlm.nih.gov/pubmed/28270498
9673,28377480,A Phase II Study of Dovitinib in Patients with Recurrent or Metastatic Adenoid Cystic Carcinoma.,http://www.ncbi.nlm.nih.gov/pubmed/28377480
9674,28702806,Efficacy and Safety of Nintedanib Plus Docetaxel in Patients with Advanced Lung Adenocarcinoma: Complementary and Exploratory Analyses of the Phase III LUME-Lung 1 Study.,http://www.ncbi.nlm.nih.gov/pubmed/28702806
9675,27758824,CK2 inhibitor CX-4945 destabilizes NOTCH1 and synergizes with JQ1 against human T-acute lymphoblastic leukemic cells.,http://www.ncbi.nlm.nih.gov/pubmed/27758824
9676,22267551,CK2 inhibitor CX-4945 suppresses DNA repair response triggered by DNA-targeted anticancer drugs and augments efficacy: mechanistic rationale for drug combination therapy.,http://www.ncbi.nlm.nih.gov/pubmed/22267551
9677,21159648,"CX-4945, an orally bioavailable selective inhibitor of protein kinase CK2, inhibits prosurvival and angiogenic signaling and exhibits antitumor efficacy.",http://www.ncbi.nlm.nih.gov/pubmed/21159648
9678,22017441,Science gone translational: the OX40 agonist story.,http://www.ncbi.nlm.nih.gov/pubmed/22017441
9679,28679771,Neratinib Efficacy and Circulating Tumor DNA Detection of HER2 Mutations in HER2 Non-amplified Metastatic Breast Cancer.,http://www.ncbi.nlm.nih.gov/pubmed/28679771
9680,28526063,Targeting the CXCR4 pathway using a novel anti-CXCR4 IgG1 antibody (PF-06747143) in chronic lymphocytic leukemia.,http://www.ncbi.nlm.nih.gov/pubmed/28526063
9681,28611046,Autocrine BMP-4 Signaling Is a Therapeutic Target in Colorectal Cancer.,http://www.ncbi.nlm.nih.gov/pubmed/28611046
9682,21670081,BMP4 promotes prostate tumor growth in bone through osteogenesis.,http://www.ncbi.nlm.nih.gov/pubmed/21670081
9683,19029982,BMP type I receptor inhibition reduces heterotopic [corrected] ossification.,http://www.ncbi.nlm.nih.gov/pubmed/19029982
9684,28687830,"Effect of the Addition of Cetuximab to Paclitaxel, Cisplatin, and Radiation Therapy for Patients With Esophageal Cancer: The NRG Oncology RTOG 0436 Phase 3 Randomized Clinical Trial.",http://www.ncbi.nlm.nih.gov/pubmed/28687830
9685,28446439,PAX3-FOXO1 Establishes Myogenic Super Enhancers and Confers BET Bromodomain Vulnerability.,http://www.ncbi.nlm.nih.gov/pubmed/28446439
9686,28455392,Biomarker Accessible and Chemically Addressable Mechanistic Subtypes of BRAF Melanoma.,http://www.ncbi.nlm.nih.gov/pubmed/28455392
9687,,A Phase I Study of Enfortumab Vedotin: Updated Analysis of Patients with Metastatic Urothelial Cancer.,http://meetinglibrary.asco.org/record/152459/abstract
9688,26425336,CD19-redirected chimeric antigen receptor-modified T cells: a promising immunotherapy for children and adults with B-cell acute lymphoblastic leukemia (ALL).,http://www.ncbi.nlm.nih.gov/pubmed/26425336
9689,25849745,Inhibition of iNOS as a novel effective targeted therapy against triple-negative breast cancer.,http://www.ncbi.nlm.nih.gov/pubmed/25849745
9690,28586279,Alectinib versus Crizotinib in Untreated ALK-Positive Non-Small-Cell Lung Cancer.,http://www.ncbi.nlm.nih.gov/pubmed/28586279
9691,28678668,Safety and Efficacy of Nivolumab in Combination With Ipilimumab in Metastatic Renal Cell Carcinoma: The CheckMate 016 Study.,http://www.ncbi.nlm.nih.gov/pubmed/28678668
9692,28783719,Tumours with class 3 BRAF mutants are sensitive to the inhibition of activated RAS.,http://www.ncbi.nlm.nih.gov/pubmed/28783719
9693,26181448,"Gastric cancers with microsatellite instability sharing clinical features, chemoresistance and germline MSH6 variants.",http://www.ncbi.nlm.nih.gov/pubmed/26181448
9694,15343278,Switching on kinases: oncogenic activation of BRAF and the PDGFR family.,http://www.ncbi.nlm.nih.gov/pubmed/15343278
9695,26582644,Cooperation of BRAF(F595L) and mutant HRAS in histiocytic sarcoma provides new insights into oncogenic BRAF signaling.,http://www.ncbi.nlm.nih.gov/pubmed/26582644
9696,28783165,TMPRSS2-ERG fusion co-opts master transcription factors and activates NOTCH signaling in primary prostate cancer.,http://www.ncbi.nlm.nih.gov/pubmed/28783165
9697,,"Dacomitinib Versus Gefitinib For The First-Line Treatment of Advanced EGFR Mutation Positive Non-Small Cell Lung Cancer (ARCHER 1050): A Randomized, Open-Label Phase III Trial",http://meetinglibrary.asco.org/record/145472/abstract
9698,26205736,Implementation of a Molecular Tumor Board: The Impact on Treatment Decisions for 35 Patients Evaluated at Dartmouth-Hitchcock Medical Center.,http://www.ncbi.nlm.nih.gov/pubmed/26205736
9699,28381415,HER2-Overexpressing Breast Cancers Amplify FGFR Signaling upon Acquisition of Resistance to Dual Therapeutic Blockade of HER2.,http://www.ncbi.nlm.nih.gov/pubmed/28381415
9700,28753594,The first-in-class alkylating HDAC inhibitor EDO-S101 is highly synergistic with proteasome inhibition against multiple myeloma through activation of multiple pathways.,http://www.ncbi.nlm.nih.gov/pubmed/28753594
9701,25935605,Proteasome inhibitors.,http://www.ncbi.nlm.nih.gov/pubmed/25935605
9702,18057228,"CEP-18770: A novel, orally active proteasome inhibitor with a tumor-selective pharmacologic profile competitive with bortezomib.",http://www.ncbi.nlm.nih.gov/pubmed/18057228
9703,26069288,The novel β2-selective proteasome inhibitor LU-102 synergizes with bortezomib and carfilzomib to overcome proteasome inhibitor resistance of myeloma cells.,http://www.ncbi.nlm.nih.gov/pubmed/26069288
9704,28179288,Aurora B Inhibitor TAK-901 Synergizes with BCL-xL Inhibition by Inducing Active BAX in Cancer Cells.,http://www.ncbi.nlm.nih.gov/pubmed/28179288
9705,24371232,An antibody-drug conjugate that targets tissue factor exhibits potent therapeutic activity against a broad range of solid tumors.,http://www.ncbi.nlm.nih.gov/pubmed/24371232
9706,28529740,Copy-number variation and protein expression of DOT1L in pancreatic adenocarcinoma as a potential drug target.,http://www.ncbi.nlm.nih.gov/pubmed/28529740
9707,,"KO-947, a potent ERK inhibitor with robust preclinical single agent activity in MAPK pathway dysregulated tumors",http://cancerres.aacrjournals.org/content/77/13_Supplement/5168.short
9708,22464749,SARAF inactivates the store operated calcium entry machinery to prevent excess calcium refilling.,http://www.ncbi.nlm.nih.gov/pubmed/22464749
9709,27461012,Transcriptome analysis of paired primary colorectal carcinoma and liver metastases reveals fusion transcripts and similar gene expression profiles in primary carcinoma and liver metastases.,http://www.ncbi.nlm.nih.gov/pubmed/27461012
9710,28489605,Genetic rearrangements result in altered gene expression and novel fusion transcripts in Sézary syndrome.,http://www.ncbi.nlm.nih.gov/pubmed/28489605
9711,10880430,The ErbB signaling network: receptor heterodimerization in development and cancer.,http://www.ncbi.nlm.nih.gov/pubmed/10880430
9712,25501131,Molecular Pathways: Targeting NRG1 Fusions in Lung Cancer.,http://www.ncbi.nlm.nih.gov/pubmed/25501131
9713,28196207,Correlation of Long-term Results of Imatinib in Advanced Gastrointestinal Stromal Tumors With Next-Generation Sequencing Results: Analysis of Phase 3 SWOG Intergroup Trial S0033.,http://www.ncbi.nlm.nih.gov/pubmed/28196207
9714,28428443,Mechanisms of Pinometostat (EPZ-5676) Treatment-Emergent Resistance in MLL-Rearranged Leukemia.,http://www.ncbi.nlm.nih.gov/pubmed/28428443
9715,28753574,,http://www.ncbi.nlm.nih.gov/pubmed/28753574
9716,28785073,Lysine demethylase KDM2A inhibits TET2 to promote DNA methylation and silencing of tumor suppressor genes in breast cancer.,http://www.ncbi.nlm.nih.gov/pubmed/28785073
9717,24482232,Transcriptional repression of histone deacetylase 3 by the histone demethylase KDM2A is coupled to tumorigenicity of lung cancer cells.,http://www.ncbi.nlm.nih.gov/pubmed/24482232
9718,26207617,Integrated genomic and functional analyses of histone demethylases identify oncogenic KDM2A isoform in breast cancer.,http://www.ncbi.nlm.nih.gov/pubmed/26207617
9719,28506929,Inhibition of cell proliferation and induction of autophagy by KDM2B/FBXL10 knockdown in gastric cancer cells.,http://www.ncbi.nlm.nih.gov/pubmed/28506929
9720,28661478,"KDM2B, an H3K36-specific demethylase, regulates apoptotic response of GBM cells to TRAIL.",http://www.ncbi.nlm.nih.gov/pubmed/28661478
9721,28706445,Histone demethylase KDM2B upregulates histone methyltransferase EZH2 expression and contributes to the progression of ovarian cancer in vitro and in vivo.,http://www.ncbi.nlm.nih.gov/pubmed/28706445
9722,27630312,Strong KDM4B and KDM4D Expression Associates with Radioresistance and Aggressive Phenotype in Classical Hodgkin Lymphoma.,http://www.ncbi.nlm.nih.gov/pubmed/27630312
9723,28784858,Targeted MAPK Pathway Inhibitors in Patients With Disseminated Pilocytic Astrocytomas.,http://www.ncbi.nlm.nih.gov/pubmed/28784858
9724,28182364,A Rare Case of ETV6/MECOM Rearrangement in Therapy-Related Acute Myeloid Leukemia with t(3;12) and Monosomy 7.,http://www.ncbi.nlm.nih.gov/pubmed/28182364
9725,28231254,Rapid generation of drug-resistance alleles at endogenous loci using CRISPR-Cas9 indel mutagenesis.,http://www.ncbi.nlm.nih.gov/pubmed/28231254
9726,28784859,Neoadjuvant Treatment With Trastuzumab and FOLFOX Induces a Complete Pathologic Response in a Metastatic ERBB2 (HER2)-Amplified Duodenal Cancer.,http://www.ncbi.nlm.nih.gov/pubmed/28784859
9727,16508002,Regulation and role of Raf-1/B-Raf heterodimerization.,http://www.ncbi.nlm.nih.gov/pubmed/16508002
9728,28424201,PIK3CA Mutations Contribute to Acquired Cetuximab Resistance in Patients with Metastatic Colorectal Cancer.,http://www.ncbi.nlm.nih.gov/pubmed/28424201
9729,23884293,Novel insights into breast cancer genetic variance through RNA sequencing.,http://www.ncbi.nlm.nih.gov/pubmed/23884293
9730,28073943,KDM4B/JMJD2B is a p53 target gene that modulates the amplitude of p53 response after DNA damage.,http://www.ncbi.nlm.nih.gov/pubmed/28073943
9731,26221327,Correlation of APOBEC3 in tumor tissues with clinico-pathological features and survival from hepatocellular carcinoma after curative hepatectomy.,http://www.ncbi.nlm.nih.gov/pubmed/26221327
9732,28590025,APOBEC3G is increasingly expressed on the human uterine cervical intraepithelial neoplasia along with disease progression.,http://www.ncbi.nlm.nih.gov/pubmed/28590025
9733,28426845,HER2-Specific Chimeric Antigen Receptor-Modified Virus-Specific T Cells for Progressive Glioblastoma: A Phase 1 Dose-Escalation Trial.,http://www.ncbi.nlm.nih.gov/pubmed/28426845
9734,25619690,Cancer-associated protein kinase C mutations reveal kinase's role as tumor suppressor.,http://www.ncbi.nlm.nih.gov/pubmed/25619690
9735,17453000,Alteration of the serum levels of the epidermal growth factor receptor and its ligands in patients with non-small cell lung cancer and head and neck carcinoma.,http://www.ncbi.nlm.nih.gov/pubmed/17453000
9736,17393301,The spectrum of ATM missense variants and their contribution to contralateral breast cancer.,http://www.ncbi.nlm.nih.gov/pubmed/17393301
9737,16520463,"Single nucleotide polymorphisms of RecQ1, RAD54L, and ATM genes are associated with reduced survival of pancreatic cancer.",http://www.ncbi.nlm.nih.gov/pubmed/16520463
9738,26548627,A novel somatic MAPK1 mutation in primary ovarian mixed germ cell tumors.,http://www.ncbi.nlm.nih.gov/pubmed/26548627
9739,26744778,The yin-yang of kinase activation and unfolding explains the peculiarity of Val600 in the activation segment of BRAF.,http://www.ncbi.nlm.nih.gov/pubmed/26744778
9740,10871156,Complete sequencing and mRNA expression analysis of the MEN-I gene in adrenal myelolipoma.,http://www.ncbi.nlm.nih.gov/pubmed/10871156
9741,27913610,Whole exome sequencing of thymic neuroendocrine tumor with ectopic ACTH syndrome.,http://www.ncbi.nlm.nih.gov/pubmed/27913610
9742,22290698,Classification of mismatch repair gene missense variants with PON-MMR.,http://www.ncbi.nlm.nih.gov/pubmed/22290698
9743,28203297,Therapeutic approach to treating patients with BRAF-mutant lung cancer: latest evidence and clinical implications.,http://www.ncbi.nlm.nih.gov/pubmed/28203297
9744,28396313,Acquired MET Y1248H and D1246N Mutations Mediate Resistance to MET Inhibitors in Non-Small Cell Lung Cancer.,http://www.ncbi.nlm.nih.gov/pubmed/28396313
9745,22751495,"Autosomal dominant STAT3 deficiency and hyper-IgE syndrome: molecular, cellular, and clinical features from a French national survey.",http://www.ncbi.nlm.nih.gov/pubmed/22751495
9746,24797340,Clinical relevance of sensitive and quantitative STAT3 mutation analysis using next-generation sequencing in T-cell large granular lymphocytic leukemia.,http://www.ncbi.nlm.nih.gov/pubmed/24797340
9747,20859667,Diffuse large B cell lymphoma in hyper-IgE syndrome due to STAT3 mutation.,http://www.ncbi.nlm.nih.gov/pubmed/20859667
9748,18381930,Endoglin (CD105): a marker of tumor vasculature and potential target for therapy.,http://www.ncbi.nlm.nih.gov/pubmed/18381930
9749,28654422,PARP1 expression and its correlation with survival is tumour molecular subtype dependent in glioblastoma.,http://www.ncbi.nlm.nih.gov/pubmed/28654422
9750,27760319,Phenotypic Characterization of a Comprehensive Set of MAPK1/ERK2 Missense Mutants.,http://www.ncbi.nlm.nih.gov/pubmed/27760319
9751,10329598,Detection of translocation t(11;14)(q13;q32) in mantle cell lymphoma by fluorescence in situ hybridization.,http://www.ncbi.nlm.nih.gov/pubmed/10329598
9752,25398436,Oncolytic measles virus expressing the sodium iodide symporter to treat drug-resistant ovarian cancer.,http://www.ncbi.nlm.nih.gov/pubmed/25398436
9753,22185260,Effective radiovirotherapy for malignant gliomas by using oncolytic measles virus strains encoding the sodium iodide symporter (MV-NIS).,http://www.ncbi.nlm.nih.gov/pubmed/22185260
9754,27619395,Lanreotide Depot: An Antineoplastic Treatment of Carcinoid or Neuroendocrine Tumors.,http://www.ncbi.nlm.nih.gov/pubmed/27619395
9755,28465443,Phase I and Preliminary Phase II Study of TRC105 in Combination with Sorafenib in Hepatocellular Carcinoma.,http://www.ncbi.nlm.nih.gov/pubmed/28465443
9756,28420720,"A Phase I Study of ABC294640, a First-in-Class Sphingosine Kinase-2 Inhibitor, in Patients with Advanced Solid Tumors.",http://www.ncbi.nlm.nih.gov/pubmed/28420720
9757,28765324,Glesatinib Exhibits Antitumor Activity in Lung Cancer Models and Patients Harboring MET Exon 14 Mutations and Overcomes Mutation-Mediated Resistance to Type I MET Inhibitors in Nonclinical Models.,http://www.ncbi.nlm.nih.gov/pubmed/28765324
9758,28522754,MET Exon 14 Mutation Encodes an Actionable Therapeutic Target in Lung Adenocarcinoma.,http://www.ncbi.nlm.nih.gov/pubmed/28522754
9759,,Phase I study of the anti-PD-1 antibody SHR-1210 in patients with advanced solid tumors.,http://ascopubs.org/doi/abs/10.1200/JCO.2017.35.15_suppl.e15572
9760,28679395,Ongoing clinical trials of PD-1 and PD-L1 inhibitors for lung cancer in China.,http://www.ncbi.nlm.nih.gov/pubmed/28679395
9761,28280600,Structural basis of a novel PD-L1 nanobody for immune checkpoint blockade.,http://www.ncbi.nlm.nih.gov/pubmed/28280600
9762,27998224,Phase II Study of WEE1 Inhibitor AZD1775 Plus Carboplatin in Patients With TP53-Mutated Ovarian Cancer Refractory or Resistant to First-Line Therapy Within 3 Months.,http://www.ncbi.nlm.nih.gov/pubmed/27998224
9763,28442586,Therapeutic Targeting of PTK7 is Cytotoxic in Atypical Teratoid Rhabdoid Tumors.,http://www.ncbi.nlm.nih.gov/pubmed/28442586
9764,28270495,The Checkpoint Kinase 1 Inhibitor Prexasertib Induces Regression of Preclinical Models of Human Neuroblastoma.,http://www.ncbi.nlm.nih.gov/pubmed/28270495
9765,15494073,Molecular mechanisms of heptaplatin effective against cisplatin-resistant cancer cell lines: less involvement of metallothionein.,http://www.ncbi.nlm.nih.gov/pubmed/15494073
9766,28314790,Selinexor (KPT-330) Induces Tumor Suppression through Nuclear Sequestration of IκB and Downregulation of Survivin.,http://www.ncbi.nlm.nih.gov/pubmed/28314790
9767,28420721,Phase I Study of Fenretinide Delivered Intravenously in Patients with Relapsed or Refractory Hematologic Malignancies: A California Cancer Consortium Trial.,http://www.ncbi.nlm.nih.gov/pubmed/28420721
9768,28410228,Identification of a novel functional JAK1 S646P mutation in acute lymphoblastic leukemia.,http://www.ncbi.nlm.nih.gov/pubmed/28410228
9769,28646019,Functionally Null RAD51D Missense Mutation Associates Strongly with Ovarian Carcinoma.,http://www.ncbi.nlm.nih.gov/pubmed/28646019
9770,27767379,Identification and characterization of PKF118-310 as a KDM4A inhibitor.,http://www.ncbi.nlm.nih.gov/pubmed/27767379
9771,21798997,Interplay between pVHL and mTORC1 pathways in clear-cell renal cell carcinoma.,http://www.ncbi.nlm.nih.gov/pubmed/21798997
9772,28822769,Somatic mutation analysis in melanoma using targeted next generation sequencing.,http://www.ncbi.nlm.nih.gov/pubmed/28822769
9773,28598829,Impaired expression of Drosha in breast cancer.,http://www.ncbi.nlm.nih.gov/pubmed/28598829
9774,27331624,Expression of the SIBLINGs and their MMP partners in human benign and malignant prostate neoplasms.,http://www.ncbi.nlm.nih.gov/pubmed/27331624
9775,27748874,Mechanism of G9a inhibitor BIX‑01294 acting on U251 glioma cells.,http://www.ncbi.nlm.nih.gov/pubmed/27748874
9776,24658378,Immunohistochemistry for histone h3 lysine 9 methyltransferase and demethylase proteins in human melanomas.,http://www.ncbi.nlm.nih.gov/pubmed/24658378
9777,28427223,Isoform expression patterns of EPHA10 protein mediate breast cancer progression by regulating the E-Cadherin and β-catenin complex.,http://www.ncbi.nlm.nih.gov/pubmed/28427223
9778,28453458,Reduced EphB6 protein in gastric carcinoma and associated lymph nodes suggests EphB6 as a gastric tumor and metastasis inhibitor.,http://www.ncbi.nlm.nih.gov/pubmed/28453458
9779,28262839,Loss of the EPH receptor B6 contributes to colorectal cancer metastasis.,http://www.ncbi.nlm.nih.gov/pubmed/28262839
9780,28703335,GATA3 as a putative marker of breast cancer metastasis-A retrospective immunohistochemical study.,http://www.ncbi.nlm.nih.gov/pubmed/28703335
9781,25628771,Molecular diagnosis and comprehensive treatment of multiple endocrine neoplasia type 2 in Southeastern Chinese.,http://www.ncbi.nlm.nih.gov/pubmed/25628771
9782,23849459,Prophylactic thyroidectomy for MEN 2-related medullary thyroid carcinoma based on predictive testing for RET proto-oncogene mutation and basal serum calcitonin in China.,http://www.ncbi.nlm.nih.gov/pubmed/23849459
9783,16849421,RET as a diagnostic and therapeutic target in sporadic and hereditary endocrine tumors.,http://www.ncbi.nlm.nih.gov/pubmed/16849421
9784,15858153,Nine novel germline gene variants in the RET proto-oncogene identified in twelve unrelated cases.,http://www.ncbi.nlm.nih.gov/pubmed/15858153
9785,9160884,A complex nine base pair deletion in RET exon 11 common in sporadic medullary thyroid carcinoma.,http://www.ncbi.nlm.nih.gov/pubmed/9160884
9786,10622534,Somatic mutations in RET exons 12 and 15 in sporadic medullary thyroid carcinomas: different spectrum of mutations in sporadic type from hereditary type.,http://www.ncbi.nlm.nih.gov/pubmed/10622534
9787,23509818,A DSPP mutation causing dentinogenesis imperfecta and characterization of the mutational effect.,http://www.ncbi.nlm.nih.gov/pubmed/23509818
9788,26328274,Clinical next-generation sequencing reveals aggressive cancer biology in adolescent and young adult patients.,http://www.ncbi.nlm.nih.gov/pubmed/26328274
9789,27714650,Molecular Profiling of Synchronous Colon Cancers and Anaplastic Thyroid Cancer in a Patient with Lynch Syndrome.,http://www.ncbi.nlm.nih.gov/pubmed/27714650
9790,11443540,Global analysis of ATM polymorphism reveals significant functional constraint.,http://www.ncbi.nlm.nih.gov/pubmed/11443540
9791,28787259,Targeting ALK With Crizotinib in Pediatric Anaplastic Large Cell Lymphoma and Inflammatory Myofibroblastic Tumor: A Children's Oncology Group Study.,http://www.ncbi.nlm.nih.gov/pubmed/28787259
9792,28099140,Telomerase antagonist imetelstat increases radiation sensitivity in esophageal squamous cell carcinoma.,http://www.ncbi.nlm.nih.gov/pubmed/28099140
9793,28830912,Mapping genetic vulnerabilities reveals BTK as a novel therapeutic target in oesophageal cancer.,http://www.ncbi.nlm.nih.gov/pubmed/28830912
9794,,Preliminary results from a phase 1 study of the antibody-drug conjugate ABBV-221 in patients with solid tumors likely to express EGFR.,http://ascopubs.org/doi/abs/10.1200/JCO.2017.35.15_suppl.2510
9795,27588951,Gain- and Loss-of-Function Mutations in the Breast Cancer Gene GATA3 Result in Differential Drug Sensitivity.,http://www.ncbi.nlm.nih.gov/pubmed/27588951
9796,18823382,The rate of germline mutations and large deletions of SMAD4 and BMPR1A in juvenile polyposis.,http://www.ncbi.nlm.nih.gov/pubmed/18823382
9797,18955974,PI3K/Akt: getting it right matters.,http://www.ncbi.nlm.nih.gov/pubmed/18955974
9798,28800861,"Ipatasertib plus paclitaxel versus placebo plus paclitaxel as first-line therapy for metastatic triple-negative breast cancer (LOTUS): a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial.",http://www.ncbi.nlm.nih.gov/pubmed/28800861
9799,9215690,Identification of the multiple endocrine neoplasia type 1 (MEN1) gene. The European Consortium on MEN1.,http://www.ncbi.nlm.nih.gov/pubmed/9215690
9800,28498781,"Phase I Study and Biomarker Analysis of Pyrotinib, a Novel Irreversible Pan-ErbB Receptor Tyrosine Kinase Inhibitor, in Patients With Human Epidermal Growth Factor Receptor 2-Positive Metastatic Breast Cancer.",http://www.ncbi.nlm.nih.gov/pubmed/28498781
9801,10373409,Signaling pathways activated by oncogenic forms of Abl tyrosine kinase.,http://www.ncbi.nlm.nih.gov/pubmed/10373409
9802,15494376,Bcr (breakpoint cluster region) protein binds to PDZ-domains of scaffold protein PDZK1 and vesicle coat protein Mint3.,http://www.ncbi.nlm.nih.gov/pubmed/15494376
9803,28603720,MET in human cancer: germline and somatic mutations.,http://www.ncbi.nlm.nih.gov/pubmed/28603720
9804,27727468,"Molecular testing for JAK2, MPL, and CALR in myeloproliferative neoplasms.",http://www.ncbi.nlm.nih.gov/pubmed/27727468
9805,18612690,Missense polymorphisms in the adenomatous polyposis coli gene and colorectal cancer risk.,http://www.ncbi.nlm.nih.gov/pubmed/18612690
9806,24790607,Identification of an APC Variant in a Patient with Clinical Attenuated Familial Adenomatous Polyposis.,http://www.ncbi.nlm.nih.gov/pubmed/24790607
9807,20233475,Germline Missense Changes in the APC Gene and Their Relationship to Disease.,http://www.ncbi.nlm.nih.gov/pubmed/20233475
9808,15793561,A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera.,http://www.ncbi.nlm.nih.gov/pubmed/15793561
9809,15837627,"Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis.",http://www.ncbi.nlm.nih.gov/pubmed/15837627
9810,18528423,New mutations of MPL in primitive myelofibrosis: only the MPL W515 mutations promote a G1/S-phase transition.,http://www.ncbi.nlm.nih.gov/pubmed/18528423
9811,24909511,"Androgen receptor: structure, role in prostate cancer and drug discovery.",http://www.ncbi.nlm.nih.gov/pubmed/24909511
9812,21784131,Androgen receptor-mediated gene repression.,http://www.ncbi.nlm.nih.gov/pubmed/21784131
9813,25132836,Toll-Like Receptors and Cancer: MYD88 Mutation and Inflammation.,http://www.ncbi.nlm.nih.gov/pubmed/25132836
9814,28637487,The NF1 somatic mutational landscape in sporadic human cancers.,http://www.ncbi.nlm.nih.gov/pubmed/28637487
9815,16061860,FGFR3 and Tp53 mutations in T1G3 transitional bladder carcinomas: independent distribution and lack of association with prognosis.,http://www.ncbi.nlm.nih.gov/pubmed/16061860
9816,16643430,Spectrum and significance of variants and mutations in the Fanconi anaemia group G gene in children with sporadic acute myeloid leukaemia.,http://www.ncbi.nlm.nih.gov/pubmed/16643430
9817,17010390,Four human FANCG polymorphic variants show normal biological function in hamster CHO cells.,http://www.ncbi.nlm.nih.gov/pubmed/17010390
9818,17555444,Recent advances in the understanding of mastocytosis: the role of KIT mutations.,http://www.ncbi.nlm.nih.gov/pubmed/17555444
9819,28178345,PI3Kδ inhibitor idelalisib in combination with BTK inhibitor ONO/GS-4059 in diffuse large B cell lymphoma with acquired resistance to PI3Kδ and BTK inhibitors.,http://www.ncbi.nlm.nih.gov/pubmed/28178345
9820,10612852,"A new germline mutation, R600Q, within the coding region of RET proto-oncogene: a rare polymorphism or a MEN 2 causing mutation?",http://www.ncbi.nlm.nih.gov/pubmed/10612852
9821,19723893,Activate and resist: L576P-KIT in GIST.,http://www.ncbi.nlm.nih.gov/pubmed/19723893
9822,24393766,NF2/merlin in hereditary neurofibromatosis 2 versus cancer: biologic mechanisms and clinical associations.,http://www.ncbi.nlm.nih.gov/pubmed/24393766
9823,22482125,Merlin: a tumour suppressor with functions at the cell cortex and in the nucleus.,http://www.ncbi.nlm.nih.gov/pubmed/22482125
9824,,Analysis of a Global Registration Trial of the Efficacy and Safety of CTL019 in Pediatric and Young Adults with Relapsed/Refractory Acute Lymphoblastic Leukemia (ALL),http://www.bloodjournal.org/content/128/22/221
9825,19047099,Imatinib targeting of KIT-mutant oncoprotein in melanoma.,http://www.ncbi.nlm.nih.gov/pubmed/19047099
9826,25996639,Exome sequencing identifies rare variants in multiple genes in atrioventricular septal defect.,http://www.ncbi.nlm.nih.gov/pubmed/25996639
9827,20633291,Motesanib inhibits Kit mutations associated with gastrointestinal stromal tumors.,http://www.ncbi.nlm.nih.gov/pubmed/20633291
9828,21037274,Reduced expression by SETBP1 haploinsufficiency causes developmental and expressive language delay indicating a phenotype distinct from Schinzel-Giedion syndrome.,http://www.ncbi.nlm.nih.gov/pubmed/21037274
9829,7623807,Regulation of Raf-1 and Raf-1 mutants by Ras-dependent and Ras-independent mechanisms in vitro.,http://www.ncbi.nlm.nih.gov/pubmed/7623807
9830,15690055,Correlation of KIT and platelet-derived growth factor receptor alpha mutations with gene activation and expression profiles in gastrointestinal stromal tumors.,http://www.ncbi.nlm.nih.gov/pubmed/15690055
9831,15044690,Identification of genes that synergize with Cbfb-MYH11 in the pathogenesis of acute myeloid leukemia.,http://www.ncbi.nlm.nih.gov/pubmed/15044690
9832,26352826,Squamous Change in Basal-Cell Carcinoma with Drug Resistance.,http://www.ncbi.nlm.nih.gov/pubmed/26352826
9833,26496030,Elucidating the cancer-specific genetic alteration spectrum of glioblastoma derived cell lines from whole exome and RNA sequencing.,http://www.ncbi.nlm.nih.gov/pubmed/26496030
9834,27195705,Analysis of Paired Primary-Metastatic Hormone-Receptor Positive Breast Tumors (HRPBC) Uncovers Potential Novel Drivers of Hormonal Resistance.,http://www.ncbi.nlm.nih.gov/pubmed/27195705
9835,14571271,"Mutations in NSD1 are responsible for Sotos syndrome, but are not a frequent finding in other overgrowth phenotypes.",http://www.ncbi.nlm.nih.gov/pubmed/14571271
9836,12464997,NSD1 mutations are the major cause of Sotos syndrome and occur in some cases of Weaver syndrome but are rare in other overgrowth phenotypes.,http://www.ncbi.nlm.nih.gov/pubmed/12464997
9837,26305677,Targeted or whole genome sequencing of formalin fixed tissue samples: potential applications in cancer genomics.,http://www.ncbi.nlm.nih.gov/pubmed/26305677
9838,27664710,"NRAS, NRAS, Which Mutation Is Fairest of Them All?",http://www.ncbi.nlm.nih.gov/pubmed/27664710
9839,27023146,Colorectal Cancer Genetic Heterogeneity Delineated by Multi-Region Sequencing.,http://www.ncbi.nlm.nih.gov/pubmed/27023146
9840,27774772,Touch imprint cytology with massively parallel sequencing (TIC-seq): a simple and rapid method to snapshot genetic alterations in tumors.,http://www.ncbi.nlm.nih.gov/pubmed/27774772
9841,27070703,Single-Cell Phosphoproteomics Resolves Adaptive Signaling Dynamics and Informs Targeted Combination Therapy in Glioblastoma.,http://www.ncbi.nlm.nih.gov/pubmed/27070703
9842,25941399,Oncogenic and RASopathy-associated K-RAS mutations relieve membrane-dependent occlusion of the effector-binding site.,http://www.ncbi.nlm.nih.gov/pubmed/25941399
9843,28666118,RAS Proteins and Their Regulators in Human Disease.,http://www.ncbi.nlm.nih.gov/pubmed/28666118
9844,25339142,Modeling the role of G12V and G13V Ras mutations in the Ras-GAP-catalyzed hydrolysis reaction of guanosine triphosphate.,http://www.ncbi.nlm.nih.gov/pubmed/25339142
9845,16546179,Understanding mutations and protein stability through tripeptides.,http://www.ncbi.nlm.nih.gov/pubmed/16546179
9846,26902995,"The Structural Basis of Oncogenic Mutations G12, G13 and Q61 in Small GTPase K-Ras4B.",http://www.ncbi.nlm.nih.gov/pubmed/26902995
9847,26994145,MultiDimensional ClinOmics for Precision Therapy of Children and Adolescent Young Adults with Relapsed and Refractory Cancer: A Report from the Center for Cancer Research.,http://www.ncbi.nlm.nih.gov/pubmed/26994145
9848,27669306,Novel Immunotherapeutic Approaches for Head and Neck Squamous Cell Carcinoma.,http://www.ncbi.nlm.nih.gov/pubmed/27669306
9849,,"Abstract DDT01-04: Discovery and development of H3B-6545: A novel, oral, selective estrogen receptor covalent antagonist (SERCA) for the treatment of breast cancer",http://cancerres.aacrjournals.org/content/77/13_Supplement/DDT01-04
9850,25065594,Differential in vivo tumorigenicity of diverse KRAS mutations in vertebrate pancreas: A comprehensive survey.,http://www.ncbi.nlm.nih.gov/pubmed/25065594
9851,15270668,Role of TGF-beta in cancer and the potential for therapy and prevention.,http://www.ncbi.nlm.nih.gov/pubmed/15270668
9852,26659273,"A novel, native-format bispecific antibody triggering T-cell killing of B-cells is robustly active in mouse tumor models and cynomolgus monkeys.",http://www.ncbi.nlm.nih.gov/pubmed/26659273
9853,26184075,Interaction of a novel fluorescent GTP analogue with the small G-protein K-Ras.,http://www.ncbi.nlm.nih.gov/pubmed/26184075
9854,28484014,Selective targeting of point-mutated KRAS through artificial microRNAs.,http://www.ncbi.nlm.nih.gov/pubmed/28484014
9855,26398719,Role of the LKB1/AMPK pathway in tumor invasion and metastasis of cancer cells (Review).,http://www.ncbi.nlm.nih.gov/pubmed/26398719
9856,26877140,Energy sensing and cancer: LKB1 function and lessons learnt from Peutz-Jeghers syndrome.,http://www.ncbi.nlm.nih.gov/pubmed/26877140
9857,25209843,Chronic mast cell leukemia (MCL) with KIT S476I: a rare entity defined by leukemic expansion of mature mast cells and absence of organ damage.,http://www.ncbi.nlm.nih.gov/pubmed/25209843
9858,28472820,Clinical value of R-spondins in triple-negative and metaplastic breast cancers.,http://www.ncbi.nlm.nih.gov/pubmed/28472820
9859,,Immunotherapeutic treatment of metastatic colorectal cancer using ETBX-011.,http://ascopubs.org/doi/abs/10.1200/jco.2014.32.15_suppl.3093
9860,28589491,Synthesis and Characterization of Novel BMI1 Inhibitors Targeting Cellular Self-Renewal in Hepatocellular Carcinoma.,http://www.ncbi.nlm.nih.gov/pubmed/28589491
9861,28144789,ProCAID: a phase I clinical trial to combine the AKT inhibitor AZD5363 with docetaxel and prednisolone chemotherapy for metastatic castration resistant prostate cancer.,http://www.ncbi.nlm.nih.gov/pubmed/28144789
9862,19812602,Response to imatinib mesylate depends on the presence of the V559A-mutated KIT oncogene.,http://www.ncbi.nlm.nih.gov/pubmed/19812602
9863,28402581,Akt inhibitor MK-2206 in combination with bendamustine and rituximab in relapsed or refractory chronic lymphocytic leukemia: Results from the N1087 alliance study.,http://www.ncbi.nlm.nih.gov/pubmed/28402581
9864,28750271,"Safety, tolerability and antitumour activity of LY2780301 (p70S6K/AKT inhibitor) in combination with gemcitabine in molecularly selected patients with advanced or metastatic cancer: a phase IB dose escalation study.",http://www.ncbi.nlm.nih.gov/pubmed/28750271
9865,28490463,"A First-in-Human, Phase I, Dose-Escalation Study of TAK-117, a Selective PI3Kα Isoform Inhibitor, in Patients with Advanced Solid Malignancies.",http://www.ncbi.nlm.nih.gov/pubmed/28490463
9866,28533223,"MONARCH 1, A Phase II Study of Abemaciclib, a CDK4 and CDK6 Inhibitor, as a Single Agent, in Patients with Refractory HR(+)/HER2(-) Metastatic Breast Cancer.",http://www.ncbi.nlm.nih.gov/pubmed/28533223
9867,25605849,Phase I dose-escalation trial of checkpoint kinase 1 inhibitor MK-8776 as monotherapy and in combination with gemcitabine in patients with advanced solid tumors.,http://www.ncbi.nlm.nih.gov/pubmed/25605849
9868,25317746,Characterization of S628N: a novel KIT mutation found in a metastatic melanoma.,http://www.ncbi.nlm.nih.gov/pubmed/25317746
9869,28559019,IL6 is associated with response to dasatinib and cetuximab: Phase II clinical trial with mechanistic correlatives in cetuximab-resistant head and neck cancer.,http://www.ncbi.nlm.nih.gov/pubmed/28559019
9870,24114124,Characterization and preclinical development of LY2603618: a selective and potent Chk1 inhibitor.,http://www.ncbi.nlm.nih.gov/pubmed/24114124
9871,28843487,STAT3 mediates Nilotinib response in KIT-altered Melanoma: a Phase II Multicenter Trial of the French Skin Cancer Network.,http://www.ncbi.nlm.nih.gov/pubmed/28843487
9872,27350064,"Phase II evaluation of LY2603618, a first-generation CHK1 inhibitor, in combination with pemetrexed in patients with advanced or metastatic non-small cell lung cancer.",http://www.ncbi.nlm.nih.gov/pubmed/27350064
9873,20013610,New mutations in the RET protooncogene-L881V - associated with medullary thyroid carcinoma and -R770Q - in a patient with mixed medullar/follicular thyroid tumour.,http://www.ncbi.nlm.nih.gov/pubmed/20013610
9874,28652249,WEE1 Kinase Inhibitor AZD1775 Has Preclinical Efficacy in LKB1-Deficient Non-Small Cell Lung Cancer.,http://www.ncbi.nlm.nih.gov/pubmed/28652249
9875,27372520,"USP7 inhibitors, downregulating CCDC6, sensitize lung neuroendocrine cancer cells to PARP-inhibitor drugs.",http://www.ncbi.nlm.nih.gov/pubmed/27372520
9876,28813164,Pembrolizumab in Patients With Extensive-Stage Small-Cell Lung Cancer: Results From the Phase Ib KEYNOTE-028 Study.,http://www.ncbi.nlm.nih.gov/pubmed/28813164
9877,28002797,Targeted exome sequencing reveals distinct pathogenic variants in Iranians with colorectal cancer.,http://www.ncbi.nlm.nih.gov/pubmed/28002797
9878,17392432,Estrogen receptor alpha is a putative substrate for the BRCA1 ubiquitin ligase.,http://www.ncbi.nlm.nih.gov/pubmed/17392432
9879,28830922,Deletion of 11q in neuroblastomas drives sensitivity to PARP inhibition.,http://www.ncbi.nlm.nih.gov/pubmed/28830922
9880,28591191,Reanalysis of BRCA1/2 negative high risk ovarian cancer patients reveals novel germline risk loci and insights into missing heritability.,http://www.ncbi.nlm.nih.gov/pubmed/28591191
9881,27175599,The chronological sequence of somatic mutations in early gastric carcinogenesis inferred from multiregion sequencing of gastric adenomas.,http://www.ncbi.nlm.nih.gov/pubmed/27175599
9882,28834486,Anti-CD19 CAR T Cells in CNS Diffuse Large-B-Cell Lymphoma.,http://www.ncbi.nlm.nih.gov/pubmed/28834486
9883,28588062,Secondary Somatic Mutations Restoring RAD51C and RAD51D Associated with Acquired Resistance to the PARP Inhibitor Rucaparib in High-Grade Ovarian Carcinoma.,http://www.ncbi.nlm.nih.gov/pubmed/28588062
9884,28619751,Synthesis and Profiling of a Novel Potent Selective Inhibitor of CHK1 Kinase Possessing Unusual N-trifluoromethylpyrazole Pharmacophore Resistant to Metabolic N-dealkylation.,http://www.ncbi.nlm.nih.gov/pubmed/28619751
9885,28500235,β-Catenin Inhibitor BC2059 Is Efficacious as Monotherapy or in Combination with Proteasome Inhibitor Bortezomib in Multiple Myeloma.,http://www.ncbi.nlm.nih.gov/pubmed/28500235
9886,28526733,"Discovery and Optimization of HKT288, a Cadherin-6-Targeting ADC for the Treatment of Ovarian and Renal Cancers.",http://www.ncbi.nlm.nih.gov/pubmed/28526733
9887,27958275,ATR inhibitors as a synthetic lethal therapy for tumours deficient in ARID1A.,http://www.ncbi.nlm.nih.gov/pubmed/27958275
9888,28500231,Discovery of a Novel Small-Molecule Inhibitor that Targets PP2A-β-Catenin Signaling and Restricts Tumor Growth and Metastasis.,http://www.ncbi.nlm.nih.gov/pubmed/28500231
9889,23222511,Targeting ATR in vivo using the novel inhibitor VE-822 results in selective sensitization of pancreatic tumors to radiation.,http://www.ncbi.nlm.nih.gov/pubmed/23222511
9890,,"A Phase 1/2 trial of intratumoral (i.t.) IMO-2125 (IMO) in combination
with checkpoint inhibitors (CPI) in PD-(L)1-refractory melanoma",http://www.esmo.org/content/download/117241/2057634/file/ESMO-2017-Abstract-Book.pdf
9892,,Abstract C60: Pre-clinical efficacy of the ATR inhibitor AZD6738 in combination with the PARP inhibitor olaparib,http://mct.aacrjournals.org/content/14/12_Supplement_2/C60
9893,,A Phase 1/2 trial of intratumoral (i.t.) IMO-2125 (IMO) in combination with checkpoint inhibitors (CPI) in PD-(L)1-refractory melanoma,http://www.esmo.org/Conferences/ESMO-2017-Congress/Programme
9894,27537276,Expanding the molecular signature of ossifying fibromyxoid tumors with two novel gene fusions: CREBBP-BCORL1 and KDM2A-WWTR1.,http://www.ncbi.nlm.nih.gov/pubmed/27537276
9895,,"Effects of G1T48, a novel orally bioavailable selective estrogen receptor degrader (SERD), and the CDK4/6 inhibitor, G1T38, on tumor growth in animal models of endocrine resistant breast cancer",http://cancerres.aacrjournals.org/content/77/13_Supplement/5641.short
9896,28145866,KEAP1 loss modulates sensitivity to kinase targeted therapy in lung cancer.,http://www.ncbi.nlm.nih.gov/pubmed/28145866
9897,28802831,Validation of a Targeted RNA Sequencing Assay for Kinase Fusion Detection in Solid Tumors.,http://www.ncbi.nlm.nih.gov/pubmed/28802831
9898,27184972,"Description of Aspergillus flavus growth under the influence of different factors (water activity, incubation temperature, protein and fat concentration, pH, and cinnamon essential oil concentration) by kinetic, probability of growth, and time-to-detection models.",http://www.ncbi.nlm.nih.gov/pubmed/27184972
9899,25961935,Mechanism of action of a WWTR1(TAZ)-CAMTA1 fusion oncoprotein.,http://www.ncbi.nlm.nih.gov/pubmed/25961935
9900,18344018,Kallikrein-related peptidases.,http://www.ncbi.nlm.nih.gov/pubmed/18344018
9901,24809052,Kallikreins as biomarkers for prostate cancer.,http://www.ncbi.nlm.nih.gov/pubmed/24809052
9902,25364714,Olfactomedin proteins: central players in development and disease.,http://www.ncbi.nlm.nih.gov/pubmed/25364714
9903,12399961,Molecular and chromosomal mechanisms of resistance to imatinib (STI571) therapy.,http://www.ncbi.nlm.nih.gov/pubmed/12399961
9904,25424851,Phase II clinical and exploratory biomarker study of dacomitinib in patients with recurrent and/or metastatic squamous cell carcinoma of head and neck.,http://www.ncbi.nlm.nih.gov/pubmed/25424851
9905,26800850,Prediction of functionally significant single nucleotide polymorphisms [SNPs] in PTEN tumor suppressor gene: An in silico approach.,http://www.ncbi.nlm.nih.gov/pubmed/26800850
9906,25256166,Mutational profiling of kinases in glioblastoma.,http://www.ncbi.nlm.nih.gov/pubmed/25256166
9907,24498881,A novel deleterious PTEN mutation in a patient with early-onset bilateral breast cancer.,http://www.ncbi.nlm.nih.gov/pubmed/24498881
9908,16775234,Dasatinib in imatinib-resistant Philadelphia chromosome-positive leukemias.,http://www.ncbi.nlm.nih.gov/pubmed/16775234
9909,17189410,Contribution of ABL kinase domain mutations to imatinib resistance in different subsets of Philadelphia-positive patients: by the GIMEMA Working Party on Chronic Myeloid Leukemia.,http://www.ncbi.nlm.nih.gov/pubmed/17189410
9910,11853795,BCR-ABL gene mutations in relation to clinical resistance of Philadelphia-chromosome-positive leukaemia to STI571: a prospective study.,http://www.ncbi.nlm.nih.gov/pubmed/11853795
9911,22281684,Unresponsiveness of colon cancer to BRAF(V600E) inhibition through feedback activation of EGFR.,http://www.ncbi.nlm.nih.gov/pubmed/22281684
9912,28726812,A patient with germ-line gain-of-function PDGFRB p.N666H mutation and marked clinical response to imatinib.,http://www.ncbi.nlm.nih.gov/pubmed/28726812
9913,24909266,Mutational and expressional analysis of ERBB3 gene in common solid cancers.,http://www.ncbi.nlm.nih.gov/pubmed/24909266
9914,27292784,The Evolving Landscape in the Development of Isocitrate Dehydrogenase Mutant Inhibitors.,http://www.ncbi.nlm.nih.gov/pubmed/27292784
9915,23792568,Off-label use of cetuximab plus sorafenib and panitumumab plus regorafenib to personalize therapy for a patient with V600E BRAF-mutant metastatic colon cancer.,http://www.ncbi.nlm.nih.gov/pubmed/23792568
9916,18573086,Structure-based view of epidermal growth factor receptor regulation.,http://www.ncbi.nlm.nih.gov/pubmed/18573086
9917,28084343,Recurrent GNAQ mutations in anastomosing hemangiomas.,http://www.ncbi.nlm.nih.gov/pubmed/28084343
9918,27770002,Triple Therapy Improves Colorectal Cancer Response.,http://www.ncbi.nlm.nih.gov/pubmed/27770002
9919,26919320,Molecular Diagnostics of Gliomas Using Next Generation Sequencing of a Glioma-Tailored Gene Panel.,http://www.ncbi.nlm.nih.gov/pubmed/26919320
9920,25730880,"Therapeutic antitumor immunity by checkpoint blockade is enhanced by ibrutinib, an inhibitor of both BTK and ITK.",http://www.ncbi.nlm.nih.gov/pubmed/25730880
9921,,Abstract 2321: Ibrutinib enhances antitumor activity in solid tumors when combined with checkpoint inhibitors,http://cancerres.aacrjournals.org/content/76/14_Supplement/2321
9922,11212236,Inhibiting mutations in the transforming growth factor beta type 2 receptor in recurrent human breast cancer.,http://www.ncbi.nlm.nih.gov/pubmed/11212236
9923,21840482,Neuregulin-1-mediated autocrine signaling underlies sensitivity to HER2 kinase inhibitors in a subset of human cancers.,http://www.ncbi.nlm.nih.gov/pubmed/21840482
9924,28649441,Clinical responses to ERK inhibition in BRAF(V600E)-mutant colorectal cancer predicted using a computational model.,http://www.ncbi.nlm.nih.gov/pubmed/28649441
9925,28182693,Molecular modeling and molecular dynamic simulation of the effects of variants in the TGFBR2 kinase domain as a paradigm for interpretation of variants obtained by next generation sequencing.,http://www.ncbi.nlm.nih.gov/pubmed/28182693
9926,26689995,Identification of a novel HER3 activating mutation homologous to EGFR-L858R in lung cancer.,http://www.ncbi.nlm.nih.gov/pubmed/26689995
9927,25953157,Response to dual HER2 blockade in a patient with HER3-mutant metastatic breast cancer.,http://www.ncbi.nlm.nih.gov/pubmed/25953157
9928,28436936,The U2AF1S34F mutation induces lineage-specific splicing alterations in myelodysplastic syndromes.,http://www.ncbi.nlm.nih.gov/pubmed/28436936
9929,28911062,TPF plus cetuximab induction chemotherapy followed by biochemoradiation with weekly cetuximab plus weekly cisplatin or carboplatin: a randomized phase II EORTC trial.,http://www.ncbi.nlm.nih.gov/pubmed/28911062
9930,28633365,"Phase II study of copanlisib, a PI3K inhibitor, in relapsed or refractory, indolent or aggressive lymphoma.",http://www.ncbi.nlm.nih.gov/pubmed/28633365
9931,28539463,BRAF Fusion as a Novel Mechanism of Acquired Resistance to Vemurafenib in BRAF(V600E) Mutant Melanoma.,http://www.ncbi.nlm.nih.gov/pubmed/28539463
9932,28725044,Cord blood NK cells engineered to express IL-15 and a CD19-targeted CAR show long-term persistence and potent antitumor activity.,http://www.ncbi.nlm.nih.gov/pubmed/28725044
9933,,Copanlisib in patients with relapsed or refractory follicular lymphoma.,http://ascopubs.org/doi/abs/10.1200/JCO.2017.35.15_suppl.7535
9934,28611108,Wnt/β-catenin Signaling Contributes to Tumor Malignancy and Is Targetable in Gastrointestinal Stromal Tumor.,http://www.ncbi.nlm.nih.gov/pubmed/28611108
9935,,Phase I study of the checkpoint kinase 1 inhibitor GDC-0575 in combination with gemcitabine (gem) in patients (pts) with refractory solid tumors,http://www.esmo.org/Conferences/ESMO-2017-Congress/Abstracts
9936,27429073,Activation of the Met kinase confers acquired drug resistance in FGFR-targeted lung cancer therapy.,http://www.ncbi.nlm.nih.gov/pubmed/27429073
9937,28424412,FBXW7 missense mutation: a novel negative prognostic factor in metastatic colorectal adenocarcinoma.,http://www.ncbi.nlm.nih.gov/pubmed/28424412
9938,27399335,FBW7 mutations mediate resistance of colorectal cancer to targeted therapies by blocking Mcl-1 degradation.,http://www.ncbi.nlm.nih.gov/pubmed/27399335
9939,,"Discovery of LY3214996, a selective and novel ERK1/2 inhibitor with potent antitumor activities in cancer models with MAPK pathway alterations",http://cancerres.aacrjournals.org/content/77/13_Supplement/4973
9940,28483787,A STING Agonist Given with OX40 Receptor and PD-L1 Modulators Primes Immunity and Reduces Tumor Growth in Tolerized Mice.,http://www.ncbi.nlm.nih.gov/pubmed/28483787
9941,,Phase 1 safety and clinical activity of BLU-554 in advanced hepatocellular carcinoma (HCC),http://www.esmo.org/content/download/117241/2057634/file/ESMO-2017-Abstract-Book.pdf
9942,,"Phase I dose escalation study of M2698, a p70S6K/AKT inhibitor, in patients with advanced cancer",http://www.esmo.org/content/download/117241/2057634/file/ESMO-2017-Abstract-Book.pdf
9943,,"Phase I study of the investigational, oral pan-RAF kinase inhibitor TAK- 580 (MLN2480) in patients with advanced solid tumors (ST) or melanoma (MEL): Final analysis",http://www.esmo.org/Conferences/ESMO-2017-Congress/Abstracts
9944,,Abstract 338: A novel small molecule inhibitor of the Notch transcription activation complex,http://cancerres.aacrjournals.org/content/76/14_Supplement/338
9945,,"Dose escalation/expansion study to investigate the safety, pharmacokinetics, food effect, and antitumor activity of BGB-290 in patients with advanced solid tumors",http://www.esmo.org/content/download/117241/2057634/file/ESMO-2017-Abstract-Book.pdf
9946,,Pharmacological activity of CB-103: An oral pan-NOTCH inhibitor with a novel mode of action,http://www.esmo.org/Conferences/ESMO-2017-Congress/Abstracts
9947,,"A Phase 1 PK/PD Study of ASN003, a novel highly selective BRAF and PI3K inhibitor, in patients with advanced solid tumors",http://www.esmo.org/content/download/117241/2057634/file/ESMO-2017-Abstract-Book.pdf
9948,,"First-in-human (FIH) study of TAS-120, a highly selective covalent oral fibroblast growth factor receptor (FGFR) inhibitor, in patients (pts) with advanced solid tumors",http://www.esmo.org/content/download/117241/2057634/file/ESMO-2017-Abstract-Book.pdf
9949,,"Phase 1 Study of E7046, a PGE2 Receptor EP-4 inhibitor that targets immunosuppressive myeloid cells in the tumor microenvironment",http://www.esmo.org/content/download/117241/2057634/file/ESMO-2017-Abstract-Book.pdf
9950,,"Updated results of phase 1 study of DS-8201a in patients with HER2 expressing non-breast, non-gastric malignancies",http://www.esmo.org/Conferences/ESMO-2017-Congress/Abstracts
9951,,"A first in human phase 1 study of KPT-9274, a first in class dual inhibitor of PAK4 and NAMPT, in patients with advanced solid malignancies or NHL",http://www.esmo.org/content/download/117241/2057634/file/ESMO-2017-Abstract-Book.pdf
9952,,Meta-analysis of the effect of rituximab in the treatment of primary central nervous system lymphoma,http://www.esmo.org/content/download/117241/2057634/file/ESMO-2017-Abstract-Book.pdf
9953,,Benefit of oral monotherapy with pazopanib in metastatic gastroenteropancreatic neuroendocrine tumours,http://www.esmo.org/Conferences/ESMO-2017-Congress/Abstracts
9954,,"Preclinical activity of SL-801, a reversible inhibitor of Exportin-1 (XPO1)/Chromosome Region Maintenance-1 (CRM1) in solid and hematologic cancers",http://ascopubs.org/doi/abs/10.1200/jco.2015.33.15_suppl.e13543
9955,25649741,"A Novel Anti-Cancer Agent, 1-(3,5-Dimethoxyphenyl)-4-[(6-Fluoro-2-Methoxyquinoxalin-3-yl)Aminocarbonyl] Piperazine (RX-5902), Interferes With β-Catenin Function Through Y593 Phospho-p68 RNA Helicase.",http://www.ncbi.nlm.nih.gov/pubmed/25649741
9956,,"Phase 1 study of RX-5902, a novel orally bioavailable inhibitor of phosphorylated P68, which prevents b-catenin translocation in advanced solid tumors",http://www.esmo.org/content/download/117241/2057634/file/ESMO-2017-Abstract-Book.pdf
9957,28829677,BRAF mutation as a novel driver of eosinophilic cystitis.,http://www.ncbi.nlm.nih.gov/pubmed/28829677
9958,24647592,"PTEN mutation, loss of heterozygosity, promoter methylation and expression in colorectal carcinoma: two hits on the gene?",http://www.ncbi.nlm.nih.gov/pubmed/24647592
9959,22586683,Amplification of CRKL induces transformation and epidermal growth factor receptor inhibitor resistance in human non-small cell lung cancers.,http://www.ncbi.nlm.nih.gov/pubmed/22586683
9960,18669439,Multiple tumors in a child with germ-line mutations in TP53 and PTEN.,http://www.ncbi.nlm.nih.gov/pubmed/18669439
9961,28808038,The Phosphatidylinositol 3-kinase Pathway as a Potential Therapeutic Target in Bladder Cancer.,http://www.ncbi.nlm.nih.gov/pubmed/28808038
9962,17531815,Structure of the human MutSalpha DNA lesion recognition complex.,http://www.ncbi.nlm.nih.gov/pubmed/17531815
9963,,A novel mRNA-based patient selection strategy identifies fibroblast growth factor receptor (FGFR) inhibitor-sensitive tumors: Results from rogaratinib Phase-1 study,http://www.esmo.org/Conferences/ESMO-2017-Congress/Abstracts
9964,24468202,Prediction for response duration to epidermal growth factor receptor-tyrosine kinase inhibitors in EGFR mutated never smoker lung adenocarcinoma.,http://www.ncbi.nlm.nih.gov/pubmed/24468202
9965,25185240,Plasma circulating tumor DNA as an alternative to metastatic biopsies for mutational analysis in breast cancer.,http://www.ncbi.nlm.nih.gov/pubmed/25185240
9966,,A phase I dose-escalation study of the novel peptide ALM201 in patients (pts) with advanced solid tumours,http://www.esmo.org/Conferences/ESMO-2017-Congress/Abstracts
9967,,A phase I study of durvalumab (D) in combination with olaparib (O) and cediranib (C) in recurrent women’s cancers,http://www.esmo.org/Conferences/ESMO-2017-Congress/Abstracts
9968,23066114,Utility of PTEN protein dosage in predicting for underlying germline PTEN mutations among patients presenting with thyroid cancer and Cowden-like phenotypes.,http://www.ncbi.nlm.nih.gov/pubmed/23066114
9969,,"Phase I expansion of olaparib (PARP inhibitor) and AZD5363 (AKT inhibitor) in recurrent ovarian, endometrial and triple negative breast cancer",http://www.esmo.org/Conferences/ESMO-2017-Congress/Abstracts
9970,,"DS-1205b, a novel, selective, small-molecule inhibitor of AXL, delays the onset of resistance and overcomes acquired resistance to EGFR- TKIs in a human EGFR-mutant NSCLC (T790M-negative) xenograft model",http://www.poster-submission.com/esmo2017/visitors/eposter/34996
9971,17504928,Methylation of the PTEN promoter defines low-grade gliomas and secondary glioblastoma.,http://www.ncbi.nlm.nih.gov/pubmed/17504928
9972,,"RANGE: a randomized, double-blind, placebo-controlled phase 3 study of docetaxel (DOC) with or without ramucirumab (RAM) in platinum-refractory advanced or metastatic urothelial carcinoma.",http://oncologypro.esmo.org/Meeting-Resources/ESMO-2017-Congress/RANGE-a-randomized-double-blind-placebo-controlled-phase-3-study-of-docetaxel-DOC-with-or-without-ramucirumab-RAM-in-platinum-refractor
9973,17604275,Elevation of cellular NAD levels by nicotinic acid and involvement of nicotinic acid phosphoribosyltransferase in human cells.,http://www.ncbi.nlm.nih.gov/pubmed/17604275
9974,26675378,Extensive regulation of nicotinate phosphoribosyltransferase (NAPRT) expression in human tissues and tumors.,http://www.ncbi.nlm.nih.gov/pubmed/26675378
9975,7984242,A polyadenylation factor subunit is the human homologue of the Drosophila suppressor of forked protein.,http://www.ncbi.nlm.nih.gov/pubmed/7984242
9976,27602501,Specific inhibition of p110α subunit of PI3K: putative therapeutic strategy for KRAS mutant colorectal cancers.,http://www.ncbi.nlm.nih.gov/pubmed/27602501
9977,28607471,Gemtuzumab ozogamicin in acute myeloid leukemia.,http://www.ncbi.nlm.nih.gov/pubmed/28607471
9978,26811524,Gemtuzumab Ozogamicin Versus Best Supportive Care in Older Patients With Newly Diagnosed Acute Myeloid Leukemia Unsuitable for Intensive Chemotherapy: Results of the Randomized Phase III EORTC-GIMEMA AML-19 Trial.,http://www.ncbi.nlm.nih.gov/pubmed/26811524
9979,17051246,High efficacy and safety profile of fractionated doses of Mylotarg as induction therapy in patients with relapsed acute myeloblastic leukemia: a prospective study of the alfa group.,http://www.ncbi.nlm.nih.gov/pubmed/17051246
9980,,"Abstract 4911: Allosteric inhibition of the Receptor Tyrosine Kinases c-MET, RON and VEGFR-2 via the co-receptor CD44v6 by the novel compound AMC303",http://cancerres.aacrjournals.org/content/77/13_Supplement/4911.short
9981,28937020,Unique characteristics of ARID1A mutation and protein level in gastric and colorectal cancer: A meta-analysis.,http://www.ncbi.nlm.nih.gov/pubmed/28937020
9982,28583311,Next-generation Sequencing of Nonmuscle Invasive Bladder Cancer Reveals Potential Biomarkers and Rational Therapeutic Targets.,http://www.ncbi.nlm.nih.gov/pubmed/28583311
9983,,KEYNOTE-059 cohort 1: Efficacy and safety of pembrolizumab (pembro) monotherapy in patients with previously treated advanced gastric cancer.,http://ascopubs.org/doi/abs/10.1200/JCO.2017.35.15_suppl.4003
9984,28891423,Adjuvant Nivolumab versus Ipilimumab in Resected Stage III or IV Melanoma.,http://www.ncbi.nlm.nih.gov/pubmed/28891423
9985,21903282,The receptor tyrosine kinase inhibitor amuvatinib (MP470) sensitizes tumor cells to radio- and chemo-therapies in part by inhibiting homologous recombination.,http://www.ncbi.nlm.nih.gov/pubmed/21903282
9986,28891408,Adjuvant Dabrafenib plus Trametinib in Stage III BRAF-Mutated Melanoma.,http://www.ncbi.nlm.nih.gov/pubmed/28891408
9987,22718863,Regulatory polymorphisms in β-tubulin IIa are associated with paclitaxel-induced peripheral neuropathy.,http://www.ncbi.nlm.nih.gov/pubmed/22718863
9988,26577839,Genetic variants in the mTOR pathway and breast cancer risk in African American women.,http://www.ncbi.nlm.nih.gov/pubmed/26577839
9989,24894543,Conserved recurrent gene mutations correlate with pathway deregulation and clinical outcomes of lung adenocarcinoma in never-smokers.,http://www.ncbi.nlm.nih.gov/pubmed/24894543
9990,21035469,"Genetic variation in RPS6KA1, RPS6KA2, RPS6KB1, RPS6KB2, and PDK1 and risk of colon or rectal cancer.",http://www.ncbi.nlm.nih.gov/pubmed/21035469
9991,20953835,Clinical potential of the mTOR targets S6K1 and S6K2 in breast cancer.,http://www.ncbi.nlm.nih.gov/pubmed/20953835
9992,,"Phase 1 dose-escalation study of single-agent ZW25, a HER2-targeted bispecific antibody, in patients (pts) with HER2-expressing cancers",http://www.esmo.org/content/download/117241/2057634/file/ESMO-2017-Abstract-Book.pdf
9993,28645859,Discovery of a novel pan-RAF inhibitor with potent anti-tumor activity in preclinical models of BRAF(V600E) mutant cancer.,http://www.ncbi.nlm.nih.gov/pubmed/28645859
9994,,"Initial results of a phase 1 dose expansion cohort of M6620 (formerly VX-970), an ATR inhibitor, in combination with cisplatin in patients with advanced triple-negative breast cancer (NCT02157792)",http://www.esmo.org/content/download/117241/2057634/file/ESMO-2017-Abstract-Book.pdf
9995,,"BEECH: A randomised Phase 2 study assessing the efficacy of AKT inhibitor AZD5363 combined with paclitaxel in patients with ER+ve advanced or metastatic breast cancer, and in a PIK3CA mutant sub-population",http://www.esmo.org/content/download/117241/2057634/file/ESMO-2017-Abstract-Book.pdf
9996,,"A phase II trial of pan-HER inhibitor Poziotinib, in patients with HER2-positive metastatic breast cancer who have received at least two prior HER2-directed regimens: The results of NOV120101-203 trial",http://www.esmo.org/content/download/117241/2057634/file/ESMO-2017-Abstract-Book.pdf
9997,,"One-year safety, immunogenicity, and survival results from a phase III study comparing SB3 (a proposed trastuzumab biosimilar) and originator trastuzumab in HER2-positive early breast cancer treated with neoadjuvant-adjuvant treatment",http://www.esmo.org/content/download/117241/2057634/file/ESMO-2017-Abstract-Book.pdf
9998,28783722,Identification of essential genes for cancer immunotherapy.,http://www.ncbi.nlm.nih.gov/pubmed/28783722
9999,,"Double-blind, randomized phase III study to compare the efficacy and safety of trastuzumab and its biosimilar candidate CT-P6 in HER2 positive early breast cancer (EBC)",http://www.esmo.org/content/download/117241/2057634/file/ESMO-2017-Abstract-Book.pdf
10002,,Efficacy and safety of biosimilar ABP 980 compared with trastuzumab in HER2 positive early breast cancer,http://www.esmo.org/content/download/117241/2057634/file/ESMO-2017-Abstract-Book.pdf
10003,28731148,Molecular genetics and targeted therapy of WNT-related human diseases (Review).,http://www.ncbi.nlm.nih.gov/pubmed/28731148
10004,28659148,"PLX8394, a new generation BRAF inhibitor, selectively inhibits BRAF in colonic adenocarcinoma cells and prevents paradoxical MAPK pathway activation.",http://www.ncbi.nlm.nih.gov/pubmed/28659148
10005,23248257,Phase II study of the MEK1/MEK2 inhibitor Trametinib in patients with metastatic BRAF-mutant cutaneous melanoma previously treated with or without a BRAF inhibitor.,http://www.ncbi.nlm.nih.gov/pubmed/23248257
10006,27834212,Preclinical efficacy of a RAF inhibitor that evades paradoxical MAPK pathway activation in protein kinase BRAF-mutant lung cancer.,http://www.ncbi.nlm.nih.gov/pubmed/27834212
10007,23943882,The apelin receptor APJ: journey from an orphan to a multifaceted regulator of homeostasis.,http://www.ncbi.nlm.nih.gov/pubmed/23943882
10008,9140397,Germline and somatic mutations in the tyrosine kinase domain of the MET proto-oncogene in papillary renal carcinomas.,http://www.ncbi.nlm.nih.gov/pubmed/9140397
10009,,Potential biomarkers of response to DKK1 blockade with DKN-01 in combination with paclitaxel in advanced esophagogastric cancer (EGC) patients (pts),http://www.esmo.org/content/download/117241/2057634/file/ESMO-2017-Abstract-Book.pdf
10010,,L-8 as a pharmacodynamic biomarker for TGF-b2 antisense (trabedersen) therapy: Results of a phase II trial,http://www.esmo.org/content/download/117241/2057634/file/ESMO-2017-Abstract-Book.pdf
10011,,"Randomized, double-blind, phase 3 study evaluating efficacy and safety of ABP 215 compared with bevacizumab in patients with non-squamous NSCLC.",http://ascopubs.org/doi/abs/10.1200/JCO.2016.34.15_suppl.9095
10012,,Nivolumab (nivo) in sorafenib (sor)-naive and -experienced pts with advanced hepatocellular carcinoma (HCC): CheckMate 040 study.,http://meetinglibrary.asco.org/record/152902/abstract
10013,28434648,"Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label, non-comparative, phase 1/2 dose escalation and expansion trial.",http://www.ncbi.nlm.nih.gov/pubmed/28434648
10014,26536169,Comprehensive Molecular Characterization of Papillary Renal-Cell Carcinoma.,http://www.ncbi.nlm.nih.gov/pubmed/26536169
10015,28911087,An antisense oligonucleotide targeting TGF-β2 inhibits lung metastasis and induces CD86 expression in tumor-associated macrophages.,http://www.ncbi.nlm.nih.gov/pubmed/28911087
10016,21224104,Randomized intergroup comparison of bacillus calmette-guerin immunotherapy and mitomycin C chemotherapy prophylaxis in superficial transitional cell carcinoma of the bladder a southwest oncology group study.,http://www.ncbi.nlm.nih.gov/pubmed/21224104
10017,,Clinical comparison of ABP 215 and bevacizumab in patients with NSCLC: Pharmacokinetic results and justification for extrapolation across bevacizumab indications.,http://ascopubs.org/doi/abs/10.1200/JCO.2017.35.15_suppl.9050
10018,28832978,Bevacizumab alone or in combination with TRC105 for patients with refractory metastatic renal cell cancer.,http://www.ncbi.nlm.nih.gov/pubmed/28832978
10019,28796588,"Obinutuzumab or Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone in Previously Untreated Diffuse Large B-Cell Lymphoma.",http://www.ncbi.nlm.nih.gov/pubmed/28796588
10020,28531214,Suspected Lynch syndrome associated MSH6 variants: A functional assay to determine their pathogenicity.,http://www.ncbi.nlm.nih.gov/pubmed/28531214
10021,28692054,Modeling cancer driver events in vitro using barrier bypass-clonal expansion assays and massively parallel sequencing.,http://www.ncbi.nlm.nih.gov/pubmed/28692054
10022,,Abstract 5621: Prevalence of GITR expression and pharmacodynamic (PD) biomarkers in syngeneic tumor models treated by a GITR agonist (GITRL-Fc),http://cancerres.aacrjournals.org/content/77/13_Supplement/5621
10023,,IACS-010759 is a novel inhibitor of oxidative phosphorylation that selectively targets AML cells by inducing a metabolic catastrophe,http://mct.aacrjournals.org/content/14/12_Supplement_2/LB-A15
10024,28615371,A Phase Ib Open-Label Multicenter Study of AZD4547 in Patients with Advanced Squamous Cell Lung Cancers.,http://www.ncbi.nlm.nih.gov/pubmed/28615371
10025,27424159,"A first-in-human phase I study to evaluate the MEK1/2 inhibitor, cobimetinib, administered daily in patients with advanced solid tumors.",http://www.ncbi.nlm.nih.gov/pubmed/27424159
10026,28633425,Androgen receptor mutations in patients with castration-resistant prostate cancer treated with apalutamide.,http://www.ncbi.nlm.nih.gov/pubmed/28633425
10027,18689681,Membrane curvature induced by Arf1-GTP is essential for vesicle formation.,http://www.ncbi.nlm.nih.gov/pubmed/18689681
10028,24196838,ARF1 regulates the Rho/MLC pathway to control EGF-dependent breast cancer cell invasion.,http://www.ncbi.nlm.nih.gov/pubmed/24196838
10029,,A phase I/II study to assess the safety and efficacy of pazopanib (PAZ) and pembrolizumab (PEM) in patients (pts) with advanced renal cell carcinoma (aRCC).,http://meetinglibrary.asco.org/record/152938/abstract
10030,,MONARCH 2: Abemaciclib in Combination With Fulvestrant in Women With HR+/HER2- Advanced Breast Cancer Who Had Progressed While Receiving Endocrine Therapy,http://ascopubs.org/doi/abs/10.1200/JCO.2017.73.7585
10031,,"A Novel Bcma-Specific, Centyrin-Based CAR-T Product for the Treatment of Multiple Myeloma",http://www.bloodjournal.org/content/128/22/2127?sso-checked=true
10032,26767191,Preclinical toxicology of oncolytic adenovirus-mediated cytotoxic and interleukin-12 gene therapy for prostate cancer.,http://www.ncbi.nlm.nih.gov/pubmed/26767191
10033,26639348,Targeting BCL2 with Venetoclax in Relapsed Chronic Lymphocytic Leukemia.,http://www.ncbi.nlm.nih.gov/pubmed/26639348
10034,,"NVP-FGF401, a first-in-class highly selective and potent FGFR4 inhibitor for the treatment of HCC",http://cancerres.aacrjournals.org/content/77/13_Supplement/2098.short
10035,28619981,Ibrutinib Unmasks Critical Role of Bruton Tyrosine Kinase in Primary CNS Lymphoma.,http://www.ncbi.nlm.nih.gov/pubmed/28619981
10036,27915469,"MYD88, CD79B, and CARD11 gene mutations in CD5-positive diffuse large B-cell lymphoma.",http://www.ncbi.nlm.nih.gov/pubmed/27915469
10037,28856744,"Frequency of MYD88 and CD79B mutations, and MGMT methylation in primary central nervous system diffuse large B-cell lymphoma.",http://www.ncbi.nlm.nih.gov/pubmed/28856744
10038,,Ph I/II study of FGF401 in adult pts with HCC or solid tumors characterized by FGFR4/KLB expression,http://cancerres.aacrjournals.org/content/77/13_Supplement/CT106.short
10039,,Immune checkpoint inhibitor (ICPI) efficacy and resistance detected by comprehensive genomic profiling (CGP) in non-small cell lung cancer (NSCLC),http://www.esmo.org/content/download/117241/2057634/file/ESMO-2017-Abstract-Book.pdf
10040,25359991,Activation of lymphoma-associated MyD88 mutations via allostery-induced TIR-domain oligomerization.,http://www.ncbi.nlm.nih.gov/pubmed/25359991
10041,27923841,Biological and Clinical Relevance of Associated Genomic Alterations in MYD88 L265P and non-L265P-Mutated Diffuse Large B-Cell Lymphoma: Analysis of 361 Cases.,http://www.ncbi.nlm.nih.gov/pubmed/27923841
10042,,"Identification of SAR439859, an orally bioavailable selective estrogen receptor degrader (SERD) that has strong antitumor activity in wild-type and mutant ER+ breast cancer models",http://cancerres.aacrjournals.org/content/77/4_Supplement/P3-04-05
10043,27102345,Comprehensive genomic profiling of orbital and ocular adnexal lymphomas identifies frequent alterations in MYD88 and chromatin modifiers: new routes to targeted therapies.,http://www.ncbi.nlm.nih.gov/pubmed/27102345
10044,,"Identification of SAR439859, an orally bioavailable selective estrogen receptor degrader (SERD) that has strong antitumor activity in wild-type and mutant ER+ breast cancer models",http://cancerres.aacrjournals.org/content/77/4_Supplement/P3-04-05
10045,27705932,KRAS mutations in blood circulating cell-free DNA: a pancreatic cancer case-control.,http://www.ncbi.nlm.nih.gov/pubmed/27705932
10046,27888800,Multipoint Kras oncogene mutations potentially indicate mucinous carcinoma on the entire spectrum of mucinous ovarian neoplasms.,http://www.ncbi.nlm.nih.gov/pubmed/27888800
10047,25840541,GNAS and KRAS Mutations Define Separate Progression Pathways in Intraductal Papillary Mucinous Neoplasm-Associated Carcinoma.,http://www.ncbi.nlm.nih.gov/pubmed/25840541
10048,12438234,Similarity of the phenotypic patterns associated with BRAF and KRAS mutations in colorectal neoplasia.,http://www.ncbi.nlm.nih.gov/pubmed/12438234
10049,24798001,Genomic portrait of resectable hepatocellular carcinomas: implications of RB1 and FGF19 aberrations for patient stratification.,http://www.ncbi.nlm.nih.gov/pubmed/24798001
10050,20160721,KRAS status analysis and anti-EGFR therapies: is comprehensiveness a biologist's fancy or a clinical necessity?,http://www.ncbi.nlm.nih.gov/pubmed/20160721
10051,16826224,A novel somatic K-Ras mutation in juvenile myelomonocytic leukemia.,http://www.ncbi.nlm.nih.gov/pubmed/16826224
10052,12759240,Mutation of p53 in recurrent hepatocellular carcinoma and its association with the expression of ZBP-89.,http://www.ncbi.nlm.nih.gov/pubmed/12759240
10053,23149933,Oxidized DJ-1 inhibits p53 by sequestering p53 from promoters in a DNA-binding affinity-dependent manner.,http://www.ncbi.nlm.nih.gov/pubmed/23149933
10054,22460905,The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity.,http://www.ncbi.nlm.nih.gov/pubmed/22460905
10055,28120820,DNA copy number changes define spatial patterns of heterogeneity in colorectal cancer.,http://www.ncbi.nlm.nih.gov/pubmed/28120820
10056,21632860,Increased detection sensitivity for KRAS mutations enhances the prediction of anti-EGFR monoclonal antibody resistance in metastatic colorectal cancer.,http://www.ncbi.nlm.nih.gov/pubmed/21632860
10057,16827139,P53 mutants suppress ZBP-89 function.,http://www.ncbi.nlm.nih.gov/pubmed/16827139
10058,10719737,Distinct prognostic values of p53 mutations and loss of estrogen receptor and their cumulative effect in primary breast cancers.,http://www.ncbi.nlm.nih.gov/pubmed/10719737
10059,26876098,Reconstructing the TIR Side of the Myddosome: a Paradigm for TIR-TIR Interactions.,http://www.ncbi.nlm.nih.gov/pubmed/26876098
10060,24667986,Novel insight into mutational landscape of head and neck squamous cell carcinoma.,http://www.ncbi.nlm.nih.gov/pubmed/24667986
10061,24019529,Mutational analysis identifies residues crucial for homodimerization of myeloid differentiation factor 88 (MyD88) and for its function in immune cells.,http://www.ncbi.nlm.nih.gov/pubmed/24019529
10062,16616891,A dominant negative form of p63 inhibits apoptosis in a p53-independent manner.,http://www.ncbi.nlm.nih.gov/pubmed/16616891
10063,8464896,Progression toward tumor cell phenotype is enhanced by overexpression of a mutant p53 tumor-suppressor gene isolated from nasopharyngeal carcinoma.,http://www.ncbi.nlm.nih.gov/pubmed/8464896
10064,8080050,Gain-of-function mutations of the p53 gene induce lymphohematopoietic metastatic potential and tissue invasiveness.,http://www.ncbi.nlm.nih.gov/pubmed/8080050
10065,27813088,Nutlin-3a selects for cells harbouring TP53 mutations.,http://www.ncbi.nlm.nih.gov/pubmed/27813088
10066,26319365,Mutational Analysis of BRAF Inhibitor-Associated Squamoproliferative Lesions.,http://www.ncbi.nlm.nih.gov/pubmed/26319365
10067,,Clinical genomic testing of anaplastic thyroid carcinoma (ATC) and need for integration into future prospective clinical trials.,http://ascopubs.org/doi/abs/10.1200/JCO.2016.34.15_suppl.6085
10068,25220666,"TP53 and PIK3CA gene mutations in adenocarcinoma, squamous cell carcinoma and high-grade intraepithelial neoplasia of the cervix.",http://www.ncbi.nlm.nih.gov/pubmed/25220666
10069,28769798,Molecular Characterization of Somatic Alterations in Dukes' B and C Colorectal Cancers by Targeted Sequencing.,http://www.ncbi.nlm.nih.gov/pubmed/28769798
10070,23897043,Validation of a yeast functional assay for p53 mutations using clonal sequencing.,http://www.ncbi.nlm.nih.gov/pubmed/23897043
10071,,"A detailed analysis of von Hippel Lindau (VHL) mutations in sporadic clear cell renal carcinoma (ccRCC), VHL syndrome, and Chuvash polycythaemia.",http://ascopubs.org/doi/abs/10.1200/jco.2010.28.15_suppl.e15024
10072,28775317,Interaction between von Hippel-Lindau Protein and Fatty Acid Synthase Modulates Hypoxia Target Gene Expression.,http://www.ncbi.nlm.nih.gov/pubmed/28775317
10073,26870154,Whole-Exome Sequencing Identifies Novel Somatic Mutations in Chinese Breast Cancer Patients.,http://www.ncbi.nlm.nih.gov/pubmed/26870154
10074,17530187,The over-expression of p53 H179Y residue mutation causes the increase of cyclin A1 and Cdk4 expression in HELF cells.,http://www.ncbi.nlm.nih.gov/pubmed/17530187
10075,21483000,Mutational status of the TP53 gene as a predictor of response and survival in patients with chronic lymphocytic leukemia: results from the LRF CLL4 trial.,http://www.ncbi.nlm.nih.gov/pubmed/21483000
10076,11307149,"Determination of microsatellite instability, p53 and K-RAS mutations in hepatic metastases from patients with colorectal cancer: relationship with response to 5-fluorouracil and survival.",http://www.ncbi.nlm.nih.gov/pubmed/11307149
10077,20138958,"Iodine induces apoptosis via regulating MAPKs-related p53, p21, and Bcl-xL in thyroid cancer cells.",http://www.ncbi.nlm.nih.gov/pubmed/20138958
10078,9049183,Functional characterization in vivo of mutant p53 molecules derived from squamous cell carcinomas of the head and neck.,http://www.ncbi.nlm.nih.gov/pubmed/9049183
10079,21094160,Association of TP53 mutations with stem cell-like gene expression and survival of patients with hepatocellular carcinoma.,http://www.ncbi.nlm.nih.gov/pubmed/21094160
10080,16000567,Assessment of the transcriptional activity of p53 improves the prediction of recurrence in superficial transitional cell carcinoma of the bladder.,http://www.ncbi.nlm.nih.gov/pubmed/16000567
10081,27273737,Hepatocellular carcinoma cell lines retain the genomic and transcriptomic landscapes of primary human cancers.,http://www.ncbi.nlm.nih.gov/pubmed/27273737
10082,27782820,Comparison between two amplicon-based sequencing panels of different scales in the detection of somatic mutations associated with gastric cancer.,http://www.ncbi.nlm.nih.gov/pubmed/27782820
10083,20008300,Two routes to leukemic transformation after a JAK2 mutation-positive myeloproliferative neoplasm.,http://www.ncbi.nlm.nih.gov/pubmed/20008300
10084,8633021,Dominant-negative p53 mutations selected in yeast hit cancer hot spots.,http://www.ncbi.nlm.nih.gov/pubmed/8633021
10085,19494353,WT1 mutations in T-ALL.,http://www.ncbi.nlm.nih.gov/pubmed/19494353
10086,27499137,The novel PI3K-δ inhibitor TGR-1202 enhances Brentuximab Vedotin-induced Hodgkin lymphoma cell death via mitotic arrest.,http://www.ncbi.nlm.nih.gov/pubmed/27499137
10087,,"TGR-1202, a Novel Once Daily PI3K-Delta Inhibitor, Demonstrates Clinical Activity with a Favorable Safety Profile in Patients with CLL and B-Cell Lymphoma",http://www.bloodjournal.org/content/126/23/4154?sso-checked=true
10088,26596524,Next-Generation Sequencing and Fluorescence in Situ Hybridization Have Comparable Performance Characteristics in the Analysis of Pancreaticobiliary Brushings for Malignancy.,http://www.ncbi.nlm.nih.gov/pubmed/26596524
10089,17704260,Cardio-facio-cutaneous and Noonan syndromes due to mutations in the RAS/MAPK signalling pathway: genotype-phenotype relationships and overlap with Costello syndrome.,http://www.ncbi.nlm.nih.gov/pubmed/17704260
10090,27416986,A review of new agents evaluated against pediatric acute lymphoblastic leukemia by the Pediatric Preclinical Testing Program.,http://www.ncbi.nlm.nih.gov/pubmed/27416986
10091,25972002,Anti-CD20/CD3 T cell-dependent bispecific antibody for the treatment of B cell malignancies.,http://www.ncbi.nlm.nih.gov/pubmed/25972002
10092,22328975,Genomic complexity and AKT dependence in serous ovarian cancer.,http://www.ncbi.nlm.nih.gov/pubmed/22328975
10093,28356789,"Significance of KRAS, NRAS, BRAF and PIK3CA mutations in metastatic colorectal cancer patients receiving Bevacizumab: a single institution experience.",http://www.ncbi.nlm.nih.gov/pubmed/28356789
10094,24549645,KRAS (but not BRAF) mutations in ovarian serous borderline tumour are associated with recurrent low-grade serous carcinoma.,http://www.ncbi.nlm.nih.gov/pubmed/24549645
10095,28911067,Maintenance treatment with capecitabine and bevacizumab versus observation in metastatic colorectal cancer: updated results and molecular subgroup analyses of the phase 3 CAIRO3 study.,http://www.ncbi.nlm.nih.gov/pubmed/28911067
10096,26220040,Impact of PTEN abnormalities on outcome in pediatric patients with T-cell acute lymphoblastic leukemia treated on the MRC UKALL2003 trial.,http://www.ncbi.nlm.nih.gov/pubmed/26220040
10097,23456389,Mutations in specific codons of the KRAS oncogene are associated with variable resistance to neoadjuvant chemoradiation therapy in patients with rectal adenocarcinoma.,http://www.ncbi.nlm.nih.gov/pubmed/23456389
10098,26090869,"Molecular spectrum of BRAF, NRAS and KRAS gene mutations in plasma cell dyscrasias: implication for MEK-ERK pathway activation.",http://www.ncbi.nlm.nih.gov/pubmed/26090869
10099,28798986,"A Phase II Multicentre, Open-Label, Proof-of-Concept Study of Tasquinimod in Hepatocellular, Ovarian, Renal Cell, and Gastric Cancers.",http://www.ncbi.nlm.nih.gov/pubmed/28798986
10100,28679770,"Therapy of Small Cell Lung Cancer (SCLC) with a Topoisomerase-I-inhibiting Antibody-Drug Conjugate (ADC) Targeting Trop-2, Sacituzumab Govitecan.",http://www.ncbi.nlm.nih.gov/pubmed/28679770
10101,28645941,"A First-Time-in-Human Study of GSK2636771, a Phosphoinositide 3 Kinase Beta-Selective Inhibitor, in Patients with Advanced Solid Tumors.",http://www.ncbi.nlm.nih.gov/pubmed/28645941
10102,12725534,Differentially expressed downstream genes in cells with normal or mutated p53.,http://www.ncbi.nlm.nih.gov/pubmed/12725534
10103,28817753,Efficacy and Safety of Durvalumab in Locally Advanced or Metastatic Urothelial Carcinoma: Updated Results From a Phase 1/2 Open-label Study.,http://www.ncbi.nlm.nih.gov/pubmed/28817753
10104,28634283,"Phase Ib Study of Utomilumab (PF-05082566), a 4-1BB/CD137 Agonist, in Combination with Pembrolizumab (MK-3475) in Patients with Advanced Solid Tumors.",http://www.ncbi.nlm.nih.gov/pubmed/28634283
10105,19759556,TP53 mutations in myeloid malignancies are either homozygous or hemizygous due to copy number-neutral loss of heterozygosity or deletion of 17p.,http://www.ncbi.nlm.nih.gov/pubmed/19759556
10106,28460620,"CX-4945, a selective inhibitor of casein kinase 2, synergizes with B cell receptor signaling inhibitors in inducing diffuse large B cell lymphoma cell death.",http://www.ncbi.nlm.nih.gov/pubmed/28460620
10107,26288819,Characterization of Somatic Mutations in Air Pollution-Related Lung Cancer.,http://www.ncbi.nlm.nih.gov/pubmed/26288819
10108,28611198,Phase I Dose-Escalation and -Expansion Study of the BRAF Inhibitor Encorafenib (LGX818) in Metastatic BRAF-Mutant Melanoma.,http://www.ncbi.nlm.nih.gov/pubmed/28611198
10109,28957417,Molecular subtype specific efficacy of MEK inhibitors in pancreatic cancers.,http://www.ncbi.nlm.nih.gov/pubmed/28957417
10110,28600476,Phase Ib Study of Lumretuzumab Plus Cetuximab or Erlotinib in Solid Tumor Patients and Evaluation of HER3 and Heregulin as Potential Biomarkers of Clinical Activity.,http://www.ncbi.nlm.nih.gov/pubmed/28600476
10111,27069690,Molecular Characterization of a Novel Germline VHL Mutation by Extensive In Silico Analysis in an Indian Family with Von Hippel-Lindau Disease.,http://www.ncbi.nlm.nih.gov/pubmed/27069690
10112,,Actionable mutations and mutational burden in renal cell carcinoma,http://cancerres.aacrjournals.org/content/76/14_Supplement/4503
10113,23224817,"A novel missense mutation (N78D) in a family with von Hippel-Lindau disease with central nervous system haemangioblastomas, pancreatic and renal cysts.",http://www.ncbi.nlm.nih.gov/pubmed/23224817
10114,11257211,"Is the P25L a ""real"" VHL mutation?",http://www.ncbi.nlm.nih.gov/pubmed/11257211
10115,18456719,Noonan and cardio-facio-cutaneous syndromes: two clinically and genetically overlapping disorders.,http://www.ncbi.nlm.nih.gov/pubmed/18456719
10116,28961841,Dual MET and ERBB inhibition overcomes intratumor plasticity in osimertinib-resistant-advanced non-small-cell lung cancer (NSCLC).,http://www.ncbi.nlm.nih.gov/pubmed/28961841
10117,,Efficacy of EGFR/HER2 duel-kinase inhibitors in PDX models harboring known and novel HER2-mutations,http://cancerres.aacrjournals.org/content/76/14_Supplement/4760
10118,28655712,BRAF-inhibitor Associated MEK Mutations Increase RAF-Dependent and -Independent Enzymatic Activity.,http://www.ncbi.nlm.nih.gov/pubmed/28655712
10119,,Identification and validation of actionable mutations in solid tumors.,http://meetinglibrary.asco.org/record/95445/abstract
10120,23637631,Breakpoint analysis of transcriptional and genomic profiles uncovers novel gene fusions spanning multiple human cancer types.,http://www.ncbi.nlm.nih.gov/pubmed/23637631
10121,26290145,Distribution of mutations in DNMT3A gene and the suitability of mutations in R882 codon for MRD monitoring in patients with AML.,http://www.ncbi.nlm.nih.gov/pubmed/26290145
10122,27625305,Targeting the kinase activities of ATR and ATM exhibits antitumoral activity in mouse models of MLL-rearranged AML.,http://www.ncbi.nlm.nih.gov/pubmed/27625305
10123,25110197,Hairy cell leukemia: Update on molecular profiling and therapeutic advances.,http://www.ncbi.nlm.nih.gov/pubmed/25110197
10124,23848818,"BRAF V600E mutation-specific antibody, a sensitive diagnostic marker revealing minimal residual disease in hairy cell leukaemia.",http://www.ncbi.nlm.nih.gov/pubmed/23848818
10125,,NCCN Guidelines Version 2.2018 Hairy Cell Leukemia,
10126,17827387,Uniform sensitivity of FLT3 activation loop mutants to the tyrosine kinase inhibitor midostaurin.,http://www.ncbi.nlm.nih.gov/pubmed/17827387
10127,28743916,Analysis of somatic mutations across the kinome reveals loss-of-function mutations in multiple cancer types.,http://www.ncbi.nlm.nih.gov/pubmed/28743916
10128,18676759,Mismatch repair deficiency does not mediate clinical resistance to temozolomide in malignant glioma.,http://www.ncbi.nlm.nih.gov/pubmed/18676759
10129,19250818,"A new strategy to screen MMR genes in Lynch Syndrome: HA-CAE, MLPA and RT-PCR.",http://www.ncbi.nlm.nih.gov/pubmed/19250818
10130,27020089,Phase IB study of cabozantinib in patients with relapsed and/or refractory multiple myeloma.,http://www.ncbi.nlm.nih.gov/pubmed/27020089
10131,25184754,Unambiguous detection of multiple TP53 gene mutations in AAN-associated urothelial cancer in Belgium using laser capture microdissection.,http://www.ncbi.nlm.nih.gov/pubmed/25184754
10132,22718121,"Activated mutant NRas(Q61K) drives aberrant melanocyte signaling, survival, and invasiveness via a Rac1-dependent mechanism.",http://www.ncbi.nlm.nih.gov/pubmed/22718121
